<SEC-DOCUMENT>0001628908-23-000029.txt : 20230224
<SEC-HEADER>0001628908-23-000029.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224170956
ACCESSION NUMBER:		0001628908-23-000029
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		151
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		23668561

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>evh-20221231.htm
<DESCRIPTION>2022 10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5,d:e5cc4f785ce54597a137387a0d3f51e9--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:evh="http://www.evolenthealth.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8xLTEtMS0xLTgyODU4_5d01b876-325f-4c89-ab96-2c45bb26c33d">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8yLTEtMS0xLTgyODU4_b927369e-e7f9-4811-82f6-86cc796c7b38">false</ix:nonNumeric><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8zLTEtMS0xLTgyODU4_60b9fac3-db99-4b5e-b8d3-d785fb030b96">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl80LTEtMS0xLTgyODU4_00609a65-347d-414b-900f-75fe406fab6d">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibc5cc544a61241c5b8328c4af50e52ce_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTAtMS0xLTgyODU4_01dd2877-01d2-4acc-a335-6631e19fc8dd">http://www.evolenthealth.com/20221231#AccountingStandardsUpdate201603Member</ix:nonNumeric><ix:nonNumeric contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTAtMS0xLTg5NjU1_8a6bb333-5720-430e-8abf-edbdd08b7af1">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i63d23082543b457b9daa2ffcb02ded0c_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id8a19c81d5714f6d8f22e6db248a7c11_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfMi0xLTEtMS04Mjg1OA_9d92b872-1173-46e0-a450-e3640a58e476">1</ix:nonNumeric><ix:nonNumeric contextRef="i71c38f21edbe411aa8eb628e23ab4e20_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfMy0xLTEtMS04Mjg1OA_7282440a-a785-4544-949c-f08969bde876">2</ix:nonNumeric><ix:nonNumeric contextRef="i2d354e96c97c42cba45e2df7b64eda05_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfNC0xLTEtMS04Mjg1OA_170d65b1-aa65-488c-8768-2540a7e71535">3</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ic5906257debf420b8d9e2c9abfb9ca3d_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83My9mcmFnOjM3NTY0NGUzNGJiMjQ4MTQ4ZjQ5YWM4NTg5NWE5M2QwL3RleHRyZWdpb246Mzc1NjQ0ZTM0YmIyNDgxNDhmNDlhYzg1ODk1YTkzZDBfNQ_ab7469c2-92c5-445c-9cd5-dc8da96c312e">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i94980624d2f94f11863369dc8080f610_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83My9mcmFnOjM3NTY0NGUzNGJiMjQ4MTQ4ZjQ5YWM4NTg5NWE5M2QwL3RleHRyZWdpb246Mzc1NjQ0ZTM0YmIyNDgxNDhmNDlhYzg1ODk1YTkzZDBfMjE1_8214cb5d-3efd-401f-bd3a-158e58b96004">.0299135</ix:nonFraction><ix:nonNumeric contextRef="ia9c9f5bff0894afd93077c2643b31f4a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTc_a570a6ad-3bd2-47aa-b3bf-a2a19da0786d">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i722177f039a9497595141ed257b0dd95_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwMDg1_e95feb79-e657-48b8-946d-eecdc5e29c31">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i722177f039a9497595141ed257b0dd95_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwODYz_60171b02-aaa9-4bbe-95cb-bb9bb4968182">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i824e8ac2e16d440da74ac31890aacd82_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzcvZnJhZzplNzJhMWQ4ZWNhOTg0OGQyYTcxN2Y0ZmZjNjdkMTI2Ni90YWJsZTpjMjJiOGJhYzM0OTM0MmZhOTZkYjY5NTIzMDUzODA3Yy90YWJsZXJhbmdlOmMyMmI4YmFjMzQ5MzQyZmE5NmRiNjk1MjMwNTM4MDdjXzItMS0xLTEtODI4NTg_3f94f66f-a38d-4c97-9057-3edfd1f36451">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i17ac516448fc45b193467cb1ef2df574_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzcvZnJhZzplNzJhMWQ4ZWNhOTg0OGQyYTcxN2Y0ZmZjNjdkMTI2Ni90YWJsZTpjMjJiOGJhYzM0OTM0MmZhOTZkYjY5NTIzMDUzODA3Yy90YWJsZXJhbmdlOmMyMmI4YmFjMzQ5MzQyZmE5NmRiNjk1MjMwNTM4MDdjXzMtMS0xLTEtODI4NTg_f645bd70-3c19-4c88-91ff-be7a806fd227">0.3333</ix:nonFraction><ix:nonNumeric contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" name="us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017">http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</ix:nonNumeric><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e">http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d672079722445e9903492553b719cd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id530a61ad22641e08d98ced8a800ffda_I20230216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7de54fc5bc4847faa175a8ac09179032_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b6870c04cf45a7a22f92062187c8b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b766a37ca0b47ffb3be346f3d8b2a47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff2679b53d74ef7bc24df5385a2e916_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc16408fdc2f457ca9bf96a6ff0288e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if70bbd87e6c7400684ed1f05186aab79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i211392e628d14c2bb3d3202fadd1e955_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77788cda88584bada7bf9ba9c37f88e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f26637675c489a938b4dd3e4068e67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5cc544a61241c5b8328c4af50e52ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0069b2782a4a49ab67a323fb9055aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29a022394774916af9c2f4fb440db9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dbc8526caa04360a8f7a3aad7061a5e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173c4f55d1a74452b5e44d2cab35ebd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9268d85098487aa9053456186fe226_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b29db4886614e8cb747051097d57a16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic335aec702854b39aad8f2e5e220ae6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a7173b3e1d4ea0bf04dd1bbb81c077_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bbf0d725dd45f3a6c123d36bd2715b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676d4e2a769c4bd1825c4e7a238270d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504d5250f6a74571832f036561396187_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d6a2705b50479eb89edc0845501b62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dcebc8005994a85ac2c4f44251b586b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9e09aed0674d2184d736359fae1f7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d183758c28e42748ea9f0baf38ea61b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c369d6b43ba4b62913e4007fef79e83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006a422e447e45a4a9b4c1c667093316_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5547116dd92544ff88c29dc8b9b6fe3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a03703f143645bf9ba9043225c49c63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce95dfdb9b847c5b2476842c531da54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97488e48877b4c0f9463a34a496911e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace02407fa42475e9b151a58bea5b3d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2738bd3890c14cba841e976265d057fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3a355f9a909459691e4f7374ba9cd65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67118d2408f84f85a9231fcddea5a5e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72141e7136894e7394a041ed0f2a15d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f12b36b156e4f77b72612737e0e8773_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec9777d918a483895645ef1f407025e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a51239b501447b911a29ce59ff5506_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7972290d242a4362ba5061064cb35fb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23bab8ce4c244fd1b411ed8b2d13efb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ebc0071f484c15a790e6c754033f5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6682920acd2443d386cf76a82976b820_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09286a182824949b042732ea31cdf80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if04d6ce7269d40dab417987869d2650e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i14887938c6954e6aa3b47e2ee7ab8115_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71cc310322b745e4b90c41075da7866b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a701948765942b1893beaaa2e66fdd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4400bacf8149dbb4b6b9e8edb38886_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4972904db74d38b50bc19776ed0515_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65bd9571ab84a89b67a22db31fb6851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2acaca954cda497b8eedaf35072199d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dea7b844271441593c0a803a0bbe671_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i854900308f794ba998ae7299645ae028_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29b4590881941c2b0537c0cb5530ec2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90606a7074b43028a72787dec08a3dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>evh:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794b0726c989443ab36cb30e95208a59_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dac60b49c3a4ba89b21c18a1a14925a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d654080ecda47ef9c7d0a2e2dfbaaf3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2eaceac28d48bb9ab95b4c5c5c71ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36ebf6b661340eb9375f2171ebfae85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="option_to_renew_lease"><xbrli:measure>evh:option_to_renew_lease</xbrli:measure></xbrli:unit><xbrli:context id="i63d23082543b457b9daa2ffcb02ded0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec00374a180d419c962d3b3783c65443_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cc2e5de7bd4ce6ba6f437a0abdf186_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11dc640ba4864bd9ab71ea3a5d03e0ce_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3474707099524f5ab5cb8bcdef64f129_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278ee21fa4de4432b9d32268373e0d51_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521ab45bcc9f4828b98cbd32c8324834_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c918a773654828be4d267be661bf92_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e6da47331f49339af7c848e28837a7_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731418333b3f457db87705a22ef20938_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied844aa0a1054ee8a864d50320d0ae98_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20beaec13c36498a8bc039958c7e54dd_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251ae7d7cad040829c7cc296314ee7a5_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f82a39ee182494c9861025f94b259b3_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5790c27f32404bbca49e84b9b60f2d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed01c1956424fc8b203762b2f8ad778_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2addc7fc4c404ba9808eca26ad7144_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba8025aa2b5405cbb56eb40f35c59c9_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adfad20cf7f4a50ab8f54cce2eb1c05_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e5d9baadc74708b8555d95b779a6b4_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee36e9557da420a9bad4cb01fb7b743_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49894ecf0ce44d6aa77bc0c1e9552b6_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3d798217ac414cb2080eebc4cbe42e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b848b407c6a43a98ee8f6b9437139c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i299f85d0abd44211ba11ded9b436d161_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6a62a817d1416b9bad705a714c025f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id27c2948c6044f07921f59caf0304963_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1705bda8a114733924cb513d21573c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb70847d04443d8b6e7ab48773cde8d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a6dbe2c6f2414b90261c99c16aa440_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5bff01d6db40d49a991496b0df8d88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia342dc91eb1f44d4a17bc2df78ae5230_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb97d6ee9d56404985bda4f9b13e5846_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcffd9facc4645f4a013b7bdbb72a431_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a2bb61dae04616b359eba263ce435c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d8936f21714f009331932a8897b732_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3548808ff348918ed362fd31f8088d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee490b62ac543baa9936f426d939efb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60d893faa2748b58fedd3523e6ec66c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab057b320374485bb2001c40a00ce836_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab12224f7bf840829d0a888e32c3dded_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b27104772b4bde9b232264fa371923_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd90e09efa14e17ad4601baa83a3961_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356a26303bb54909842ab7a281dbfe38_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfb19be991146d3a9e26988e59d0c39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954aacf21ddb4d74a25b5f7fea44da70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f54db1c05e74787a89c8997e36036e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60221f52e25e439cb996bb69367033a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a19c81d5714f6d8f22e6db248a7c11_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c38f21edbe411aa8eb628e23ab4e20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d354e96c97c42cba45e2df7b64eda05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312025Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4dd7b111832484390e1d97d1f46453e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee9e7b57f344206982ad42c4f293487_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590b14ec27994ed597799e4952a9046f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934d9414193f4601b5323bf2a681279b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35616843f0a7418d8fc7ad365b3215fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8607bc42763645fbbe43278eec65e305_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c9997d7a05d4993962ccc3338c361fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bd19d50e3f457ba4098eb4c0c152d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8388c7551f94e269587ab5aac659a6d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3355e9dfc324571bb9fba8d6e2175e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b29b57edf8c489f99a4516a6ca5a0b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cd6e53eeb5464e80084e5f32636562_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c2ab305dbd45518a81ed1d65fe5dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71ceeb3c88542a5b9fb0b508980035b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28121c511dcf46e8aeb20910dbcc12be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483d3e1f905c4cde909281c7434e61aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7248538c4a04c15bcc464cd4c0426fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746f0154926c44cc9b1f8fa00aebd8f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c5eb57b4454e3b9de4de900fd38726_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00357009ca34124aea7882662570449_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56205dd981748ccb2ada978c977bd74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6fe725ce94f4628b487593ab6df6f26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c0a14df2764899b90a8c02978cddda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237b041a348240acacdd4c6703d9631c_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2836cea2fd340c28f57a47a9edab8d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb588c9720747cb8e17ec8afc367996_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ea7981a58e4cf1bb90015e38b89007_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a58b613f9cd47b2bef946da4ceb3f68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee356487cda493a86e8c0ec69db8b59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6ad6302d9d4822b4677702de0baca6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85dc77e96282486ab64329e19f4f8975_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b789e0f0774de2bb35c5e8066ddbdd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488bd1b5b44642adb4bec38ca437c356_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f170a61f3e841a696fad5b6a3b357d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a13a56d549482ea13997a959c85f3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5277c572ae949a594d492c3ef91a577_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e29b5293f19416f96f6460860735e67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6669bf057ca644eebe6dffc37bb4b27d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48beabe4144b40898879179f114601ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a310b65ac104a1b98bfe8cb95002a92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc46062bad34e1d9ad09e26a1395bd2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2ad760c97e421385f5a9e39aaac544_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee5d4ede71548928f9a624468ad3e3b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9c6f919ebe4066b86bae9e616abcfd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeedc3e2c6d34ca9b04f0eed321027af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3d5be6458143d680d969951cb1b604_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316c2f9226f948c7a4f01201f54acc48_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f12ae346f44c719a6800ae9ccbebab_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>evh:day</xbrli:measure></xbrli:unit><xbrli:context id="i2b8033c2ed5c404898e4b63272e9b227_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c87170725f741bb95ab4f861ab14a5f_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332b999bfd9a41b4b40e9a3798d29b87_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c23219c9604a849ec11f326a2fa715_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d73991f5a114e408f7f6580f4dd0c39_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307390bb8f1941719453c9b89db584f1_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf042bd30a44a15975073db664b70be_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide70b505dfd6454e9ffca84126ff1890_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01455d65a30b4de88519c6a15c185622_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1f72876d42429a99ca22c58f5f1ecc_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c958236f3a54e838f8aa587bb9a8d31_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1619fddb91d54d6f96208efd4dce37f6_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ae7d691d994f36bcd8595faf8c39ee_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if764124a6770471488243909ab9e256d_D20220811-20220811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb6b9ecd1444687b8479680f813d784_D20220817-20220818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-17</xbrli:startDate><xbrli:endDate>2022-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7bc6c0f93045b9ad4a49e3466404b9_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d60561640304c998ba5ee229f359173_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2804de286fbc48f587c48f683cfa4074_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140bd5a200d14de591a2f882386a3910_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ec033ba9234eb488e9598b782c6c15_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b374313017e499e85ef4cf594469720_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21455ed9e898487f8740230211473db0_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a685a81d42142c896e77b4bc4ca525a_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6f6a273d2b4dbda2d60fcdb292d567_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bef66f774044af386b81c078514f9bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f4dfb899054fdfbad69a92f3ebee35_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a2bfbe33214fceb0357343f7b7e72b_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd78b743e5442379fb00d3420537154_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69ff65edc314e66af837b40573b525f_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aef6137413544e2a1fd7506ce233492_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5650df78c4e4f098ea12cdc3e6d079f_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebd374c7c4724e05ac999f332b4ab82e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf6fc0014354fbe9758d2279614f394_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f5b6436bc448ddb51d297c0f42e141_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6001ba8bbed04b7a829551c60b521a2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2edea02961a848e792c082a2d78f7be9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2bca88869d4c9795e3e92b114eabad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b3ec5f2a0940ddba506d2e9a3d8c0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4776fc60e442c0948db94fbd3d4085_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5906257debf420b8d9e2c9abfb9ca3d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94980624d2f94f11863369dc8080f610_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb561ac225443dbaff96dea400e900b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6788632dc8e44b589e517a3e62e51f4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01dda4dd7b24edd859959507bf961ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f551ff8e8ba4ff3beb6c4b903203199_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>evh:customer</xbrli:measure></xbrli:unit><xbrli:context id="i8421b42e39084ee89ac6a78c380b126b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea705e860864044aca57384b2588af0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e0a630ce154bf89c611d1821c71553_D20220802-20220802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d330e617a348658676375fec5a5db0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09667045f534fb08afb88b78cd4bffd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19460fef358144489558a7d191e376e1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c1626a52334b328a1c7519c6d48da1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f194e0613ef4a9eb4ce0f29bc3e59be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d5358cfd784a34a9c92cf66e6fe24d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3c513620354b04ae269dff1b11efc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0971990c3b524dc2ab01bca9e7047db0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0ca95c4f8d453aa5b952029c52ede5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f79061242845d39ce24ea7ea1e6531_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ef3bafc332487fbfffb51f8c73921e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b1f625f4e94de3bac6f65f975417eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie780f96a5b1646b797b6c069ab760343_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc10e07863c4eb1a63ee717112c9d0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b43f5864a3c456d988a47acf3b9ce95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ffe1b4508e486a9edadc82247bd895_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e84c1fcc7a409eb2d609e87902510a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f31f283eac947978662db9d2181e301_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9b3ff8bd76404884b782de11442494_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia459503de1114b44a6f26fc10d288f5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b3426aba894c62ba3dd99da2cf9a73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a933c8c05464474bc7d7b13541a2e90_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76a99b4e1234159af5825d2a6781f2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a31bc4994b74fc58c2b392809cd688c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5780125dcb45fbb548a97d1af89fdb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd672678d98466986c506543160641f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c53413574a404b9b955fd4063e9fa2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29b0fddbc044c099c98a1f8e946e6ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac01085f2974bffb7e9c05372fce3ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9999816186400782cf19912fe831e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb1199689b9485e9e38c8454c856583_I20130923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b21dc206e94394abb9958199abeb98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb78a01fb022451a868b84564b638dc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fdd473b34824a438f104a82a06cc181_I20150501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49a044638374607bbfbdc97696620c2_I20180613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e202260e1024d14b21b9a333d1e719e_I20210415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cf289eea9b494d912166499c2914fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76c5580ffe1407da7f478f22181effd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490fcda4c6dc4ac48114257dd334a44f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8598bae5e2d4ae6a59a8764c8bc367a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f5c218d62449f4a45332796fafbe3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454730d8be0c4135908d533cc24236ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4ade146df04303ae15516a0f51d6e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168e32227da54d569993ff509ca28512_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i593745b628164db9ad5c5aee03724e76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4f0db782744810b86b3de6bffd9661_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide564d56628c4112b1707eb060bf579b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2688027cbefe476297d030d725212d57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23513d63acc84e1d9329774077f86588_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7c11ea28704ab6b523786a90949ff8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eab875363854633ac2dc697d7c48c89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15eadbd1e3724998b19a496cc3d2b5aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f478bf1b114c2694835b3dc5f160fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia818a57c910f43b6b57bb34ff556565f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1df49b093b4a088aece5a992f943a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i126ccd42807a4cc3b17d8951d96c7aab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb15940b3a94d76ac5798bef87541cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41135afe093644db89a3b87635fe4dc4_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ec3a6efe87f4e2c84e6ce6e8641efac_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74229af73c04802bcf5f1aad8b9d1d1_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ad45c36cfc43c9bc1893539e98ce7f_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1492a0e32c114c64887521b21cadd182_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d882797dafa45e4973fe074ac9e136b_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e040acb0b747928e36b0c44713716f_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e9688f5f7d4228b70c0cb904a39028_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f870a295164c058463681d0e9d876f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8645daae4ccd401babc69a6cbb852628_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777ec06acf834f40a1fa728483007e42_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evh:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c9f5bff0894afd93077c2643b31f4a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9641b95f774ba8a8d7a8d32b4cce92_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c02b94720e4106be78e0e1359efd32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d4a953b2504f45a7692ab718621a5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NewCenturyHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27068971ef7e44f082589f349b94a0f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d4b61188184f9b8043474a605003cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e836072148b4d08a3bb37cfb2e717b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380305502d0f40bf81987e1a5ae4ab46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">evh:TwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722177f039a9497595141ed257b0dd95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9e2e62339c438aa769354df4580b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performance_period"><xbrli:measure>evh:performance_period</xbrli:measure></xbrli:unit><xbrli:context id="iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f26ba9b9cd641d5aec7f9d0359b6769_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824e8ac2e16d440da74ac31890aacd82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ac516448fc45b193467cb1ef2df574_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c16ad239424ec88d83268977b370bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f84cee7ed64c41ad902dcd77f1d4e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a909c5b37546d18248f54d9b4a4151_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de795bc67904a5e85f0decbbd09ab32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997feae046c54b3a9bf17e3433160784_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31a88fa387b4e53a12f438b4b3b5bac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief049904d28f460d998a77dd264865b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8dfb8ced52c4e3cb9c781d4c11d94cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84bf075d368e44968b724f9fa95b7960_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib816cd0b1e5246268d85139debf44ec6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2fe137ef9b94b438227de3ce6b602f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6973c687f47242d48d1ab11cc64f5795_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4265c7d21f1d4b838581fca135d6e78c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">evh:PeriodsPriortoJune2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9836acdd1fb436298594c2019552b35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife27a03e76054f2293b5ac1cb4a4010f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07bcd3c52e24dc1836baafe4f759c78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ddb5f52bed406dacf7038dcf91f94c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab25d9d5a634cb59dbe05457f809563_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a8a373598344ec1894589f6195ded59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if17c85faa0f841b99a3b41d10678e6f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6345c725b74f1185b75d72fe34dc81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922ff0166d094a94bc7b6cb25be53520_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7077a023068e40ef90f4eafdef2ac9d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4b399529244e3a9a265bff227a5cba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9511c01ee7c4db793847be4cc362076_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8ce3db74aa417989fbb9df2f38ad5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae7be454d7b4ccca01d6d258c44d97f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e6659721d84a6a93639ba51c8411c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025995168f8f42fba6c2563b6e8916a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38cc40fb229457c9241d55acdc35d64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fa49659d7d4d6f9e976bf660432df5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4619916bbd2482ab8018d375249be03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0251e2b7f89d4de890ab29fd635ae904_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843d5fcb4df3420485390014398766dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a4f5ce8e6c44d9b8740ae1f7ba19dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375cbb6ae8bf4bf4af4ed3910f4e95fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7bf3dd1e1e42c38fecc74e534c3349_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c76ef785ed6456998aa2837427805d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9903fd78307a4882846df7bd26ed4ca2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2afd02fdc0d43e283e8a6be9bbf3622_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i507c481168c24a8282e6d5446b4557e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a9aeec0e924002bd91990917dd2807_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cb6ba27fa047439559a1ce5bdf570e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af8d3395ca54542b8e581cd46d63e85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea6990f35a04f21953a710e60c32fb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia138a2f2ee96409fbd2de15262bbc9a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d2a17bc955412cbbed83c8fa718cf1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7c08e385554e8cb407ca29ab063d05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d50a01d5910438a928adb7f868c6ed6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16141fafab8e460196d863fb9865d30b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46413fc7149140518ad72598cb806328_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5cf9a41dc0464dadd48964641367bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214e73201d094671bbc005a4978f6737_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a3b9433a4c407da22c8da144e6159f_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25bed0d5f05c47d3835d72e78088845d_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f01c74be814b40a8b3c55316700bd3_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d4b347f77b40ef82561500db57566f_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a86616c8d74739ae6c3edec5552b03_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id784014eb86c4d16a227b2b1b8318c54_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evh:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f63204d749d4153bfe87ae223342e6f_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f3fa6a087c446baded83c2feace046_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evh:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89686cfadfc473caea4541bb62f1bb3_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e686cc2d964acc99bb40a8e562febb_D20230120-20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb6fa070893484684f8ab6a16c9b50a_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a97018288f4cc8b3674c490b0d4fa5_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc785f8e81be428088e0d8326cda1937_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09af4e4b44d0499bb93e05f0108e6e4d_I20230120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac1e2d763d64e7f83a06724d5407c9f_D20230101-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5 id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_7"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY3_22502420-d47b-4c8b-ae53-1177d8f1cbf0">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzUz_9fbddb7a-6f9b-4a74-85b6-24fe17559708">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8xOTY_e67b0883-2385-40d6-adb6-bed6b55212ac"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8xOTY_0c7fb262-0f8b-482f-869f-97346c6ed7da">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU3_6d24f29d-49fe-4223-9d3f-5ea6e488a924">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYy_718d7dad-49eb-4136-b9ff-09b670d02ad1">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU4_dcff24b9-4462-45db-a0c4-085fc3a696a9">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:349.50pt"><tr><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8wLTAtMS0xLTgyODU4_6c97c866-f45a-4986-9e9b-3fea83ad864b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8wLTgtMS0xLTgyODU4_c4813ef8-e021-4502-8e77-350493812644">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTAtMS0xLTgyODU4_8dc8cec1-b4f7-455d-9d5c-e8e8ed6e4934">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTItMS0xLTgyODU4_f3dcb529-32f4-4cf9-ab28-eacfbacde098">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTQtMS0xLTgyODU4_c1fbb72f-b1e1-431a-9be2-94353c16844c">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTYtMS0xLTgyODU4_7ebe18c7-68a2-4e93-b368-8d6f032e0e3d">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTgtMS0xLTgyODU4_1b48a984-453c-432a-b42a-13f7e5dc64db">22203</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU0_798d3ec2-5998-4cd7-a5ad-e4af8a428f9b">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYz_1b124421-3a0a-4517-833e-30e8a80e55af">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTAtMS0xLTgyODU4_666cf63b-b08d-4b0a-a0e0-900ba3d9e5c7">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTEtMS0xLTgyODU4_00fa3c00-aaba-45a8-9e1c-36357d7a3dbf">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTItMS0xLTgyODU4_1ae577b8-883b-4d0c-9438-0861f92b90ca">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY4_cb3ee78e-ce1e-47f9-8266-7a1cd09689f1">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;  <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY0_939c7bc9-e8e9-4e29-9821-3385f423ef6b">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU5_a8256d20-6927-43c5-920a-8cd3e086611a">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY5_bc8bce55-03fc-4633-b2be-e9efbb7138d9">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzcw_ade8b5f5-e105-4f86-a323-0fa6d7781eab">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY1_656c9abd-cce6-4595-885c-a880bd83cc4d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU1_4e9d4ba9-2571-4fc6-9fb5-484d535ec638">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY2_4d0d8fff-22ed-460c-8be1-dd864d7c17a7">S</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8yMTk5MDIzMjU5MzMw_8dda9012-0392-4e65-852f-7f0b06bfad99">S</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (based on the closing price of the shares on the New York Stock Exchange on such date) as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="i59d672079722445e9903492553b719cd_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zMjM2_5fe1a9ae-5137-413f-9a41-183cee48c4af">2.5</ix:nonFraction> billion. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of February&#160;16, 2023, there were <ix:nonFraction unitRef="shares" contextRef="id530a61ad22641e08d98ced8a800ffda_I20230216" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zMjYz_bf9c4920-d306-44c0-84b8-84521df44cce">111,052,414</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="text-align:center"><span><br/></span></div><div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYx_861149f9-af1f-49bb-91e1-935617478347" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;8, 2023, hav</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</span></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_211"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_19">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_220">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_220">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_214">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_214">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_256">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_256">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_268">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_268">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_151">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_151">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_163">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_163">45</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_148">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_259">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_259">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_250">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_250">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_118">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_142">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_142">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_22">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_22">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_199">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_199">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_145">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_145">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_166">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_166">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_223">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_223">123</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_232">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_235">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_235">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_238">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_238">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_241">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_241">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_244">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_244">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_247">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_247">124</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_196">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_169">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_169">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_229">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_229">129</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_202">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_202">130</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on 10-K, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to the business of Evolent Health, Inc. and its consolidated subsidiaries since their respective dates of acquisition, unless otherwise indicated. In October 2021, we acquired Vital Decisions, a leading provider of technology-enabled advance care planning services. In August 2022, we acquired IPG, a leader in providing surgical management solutions for musculoskeletal conditions. In January 2023, we acquired NIA, a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report on Form 10-K:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;ACA&#8221; means the Patient Protection and Affordable Care Act;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;accountable care organizations,&#8221; or &#8220;ACOs,&#8221; means organizations of groups of doctors, hospitals and other health care providers which have come together voluntarily to provide coordinated care to their Medicare patients;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;capitated arrangements&#8221; means health care payment arrangements whereby providers are paid a fixed amount of money per patient during a given period of time rather than on a per-service or per-procedure basis;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;CMS&#8221; means the Centers for Medicare and Medicaid Services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;DGCL&#8221; means General Corporation Law of the State of Delaware;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;EMR&#8221; means electronic medical records;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Evolent Health Holdings&#8221; means Evolent Health Holdings, Inc., the predecessor to Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;EVH Passport&#8221; means Justify Holdings, Inc., a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Evolent Care Partners&#8221; means Evolent Care Partners (&#8220;ECP&#8221;), a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;founders&#8221; means the Advisory Board Company (&#8220;The Advisory Board&#8221;), and the University of Pittsburgh Medical Center (&#8220;UPMC&#8221;);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;FTC&#8221; means the United States Federal Trade Commission;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;GAAP&#8221; means United States of America generally accepted accounting principles;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;HIPAA&#8221; means The Health Insurance Portability and Accountability Act;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;HITECH Act&#8221; means The Health Information Technology for Economic and Clinical Health Act;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;IPG&#8221; means Implantable Provider Group, Inc, a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;IPO&#8221; means our initial public offering of 13.2 million shares of our Class A common stock at a public offering price of $17.00 per share in June 2015;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;New Century Health&#8221; means NCIS Holdings, Inc., a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;NIA&#8221; means National Imaging Associates, Inc., a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;NYSE&#8221; means the New York Stock Exchange;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Offering Reorganization&#8221; means the reorganization undertaken in 2015 prior to our IPO where our predecessor, Evolent Health Holdings, Inc. merged with and into Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;partners&#8221; means our customers, unless we indicate otherwise or the context otherwise implies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;performance-based&#8221; means risk-based contracts with our partners wherein Evolent assumes financial responsibility for the cost of care, which may range from upside and downside gain share to all, or substantially all, of the responsibility for the cost of care within a defined scope subject to Evolent management controls and contractual protections;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;pharmacy benefit management,&#8221; or &#8220;PBM,&#8221; means the administration of prescription drug programs, including developing and maintaining a list of medications that are approved to be prescribed, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers and processing prescription drug claim payments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;population health&#8221; means an approach to health care that seeks to improve the health of an entire human population;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;SEC&#8221; means the Securities and Exchange Commission;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Securities Act&#8221; means the Securities Act of 1933, as amended;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;third-party administration,&#8221; or &#8220;TPA,&#8221; means the processing of insurance claims or the administration of certain aspects of employee benefit plans for a separate entity;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;True Health&#8221; means True Health New Mexico, Inc., a previously wholly-owned subsidiary of Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;TPG&#8221; means TPG Global, LLC and its affiliates including one or both of TPG Growth II BDH, LP and TPG Eagle Holdings, L.P.;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;TRA&#8221; means the Income Tax Receivables Agreement. See &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note 15&#8221; for further details of the Tax Receivables Agreement;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;UHC&#8221; means University Health Care, Inc d/b/a Passport Health Plan;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;UR&#8221; means utilization review;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Valence Health&#8221; means Valence Health, Inc., excluding Cicerone Health Solutions, Inc.;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;value-based care&#8221; means a health care management strategy that is focused on high-quality and cost-effective care with the goals of promoting a healthy lifestyle, enhancing the patient experience and reducing preventable hospital admissions and emergency visits;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;VIE&#8221; means variable interest entities; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Vital Decisions&#8221; means Vital Decisions, LLC, a wholly-owned subsidiary of the Company.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_16"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to efficiently integrate NIA into our operations; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial information of NIA and the pro forma financial information of NIA may not be indicative of future results or our financial condition; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution of the healthcare regulatory and political framework;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners&#8217; needs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisitions of IPG and NIA, which could divert management resources, result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport to Molina Healthcare, Inc. may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including increasing inflationary pressures and economic and business conditions and the impact thereof on the economy resulting from public health emergencies, epidemics, pandemics or contagious diseases such as the COVID-19 pandemic;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships and develop our partner relationships over time;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners could limit or negatively impact our profitability;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets for our services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts in some of our partner and founder contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to managing our offshore operations and cost reduction goals;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation proceedings, government inquiries, reviews, audits or investigations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to legal proceedings related to any alleged infringement, misappropriation or violation of third-party intellectual property rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2025 convertible notes, which, if triggered, could require us to settle the 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interest rate risk under the Credit Agreement and the terms of our Series A Preferred Stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our debt following the NIA acquisition and our ability to meet our obligations; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to service our debt and pay dividends on our Series A Preferred Stock</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale, including those issuable upon conversion of our Series A Preferred Stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our Series A Preferred Stock has rights, preferences and privileges that are not held by and are preferential to the rights of holders of our Class A common stock, and could in the future substantially dilute the ownership interest of holders of our Class A common stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. More information on potential factors that could affect our businesses and financial performance is included in &#8220;Forward Looking Statements - Cautionary Language,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; or similarly captioned sections of this Annual Report and the other period and current filings we make from time to time with the SEC. Moreover, we operate </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this report except to the extent expressly required by law.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Data and Industry Forecasts and Projections</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use market data and industry forecasts and projections throughout this Annual Report on Form 10-K, and in particular in &#8220;Part I - Item 1. - Business.&#8221; We have obtained the market data from certain publicly available sources of information, including publicly available independent industry publications and other third-party sources. Unless otherwise indicated, statements in this Annual Report on Form 10-K concerning our industry and the markets in which we operate, including our general expectations and competitive position, business opportunity and market size, growth and share, are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts), data from our internal research and management estimates. We believe the data that third parties have compiled is reliable, but we have not independently verified the accuracy of this information and there is no assurance that any of the forecasted amounts will be achieved. Any forecasts are based on data (including third-party data), models and experience of various professionals and are based on various assumptions, all of which are subject to change without notice. While we are not aware of any misstatements regarding the industry data presented herein, forecasts, assumptions, expectations, beliefs, estimates and projections involve risks and uncertainties and are subject to change based on various factors, including those described under the heading &#8220;Forward-Looking Statements - Cautionary Language&#8221; and in &#8220;Part I - Item 1A. Risk Factors.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_220"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which leading health systems and physician organizations, which we refer to as providers, as well as health plans, which we refer to as payers, are moving their business models from traditional fee-for-service (&#8220;FFS&#8221;) reimbursement to an increasingly integrated clinical and financial responsibility for populations. We refer to our provider and payer customers as partners. We consider this integration of health care delivery and financial responsibility with the aim of lowering cost, enhancing quality, and improving satisfaction, to be the core of value-based care. We believe the pace of this integration is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and innovation in data and technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. health care market was $4.3 trillion in spending during 2022, accounting for 20% of the United State Gross Domestic Product. As of December 31, 2021, it is estimated that approximately 61% of all health care payments in the United States are tied in some way to quality of care or value, with the remainder based purely on FFS reimbursement. However, the proportion of payments tied to quality and value varies significantly by health plan line of business and the majority of current value-based models remain tied to FFS frameworks. Government agencies and private organizations are focused on goals aimed at accelerating the adoption of risk-based reimbursement models to be the predominant form of health care payment by the end of the current decade. We believe this shift to value-based care is likely to continue accelerating, driven by price pressure in traditional FFS health care, a policy and market environment that is incentivizing value-based care models and innovation in data and technology. We believe that the transition to value-based care is impacting the business models of both providers and payers in all segments of the market, including Medicare, Medicaid, and Commercial lines of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a significant opportunity exists to facilitate the continuing transition from FFS by focusing on improving the cost and quality of care through alignment of the business between payers and providers. Providers are well-positioned to lead this transition to value-based care because of their control over large portions of health care delivery costs, their primary position with consumers, and their strong local brands. Providers operating successfully in value-based arrangements can diversify their revenue streams, capture superior economics, and improve the quality of care they provide.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe payers who successfully evolve their business model from that of FFS reimbursement towards value-based care can gain meaningful competitive advantages. Payers who successfully integrate care delivery and financing with providers stand to gain market advantage as medical expenses for their populations are lowered while quality of care is also improved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transformation of provider and payer business models from FFS to value-based care requires infrastructure that performs two functions: (i) the ability to create clinical value, which is typically defined as lowering the cost of care while maintaining or improving quality, that is superior to FFS, and (ii) an administrative platform to operate an increasingly value-based business. In addition to this infrastructure, we believe that participants in value-based arrangements also need sustainable contractual mechanisms to enable each party to capture clinical value that is created and sufficient lives in value-based arrangements to provide a return on infrastructure investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our History</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent was founded in 2011 by members of our management team, UPMC, an integrated delivery system in Pittsburgh, Pennsylvania, and The Advisory Board Company, to enable providers to pursue a value-based business model and evolve their competitive position and market opportunity. Since that time, we have grown both organically and through acquisitions. During 2016 and 2017 we focused on building out administrative capabilities within value-based care. In October 2018, we acquired New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based arrangements, focused primarily on oncology and cardiovascular care, initiating Evolent&#8217;s current primary strategy to pursue solutions for managing high prevalence, complex specialty care. To add to our capabilities, in October 2021, we acquired Vital Decisions, a leading provider of technology-enabled advance care planning services. In August 2022, we acquired IPG, a leader in providing surgical management solutions for musculoskeletal conditions. In January 2023, we acquired NIA, a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently manages its operations and allocates resources across two reportable segments as follows:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health, Vital Decisions, IPG, NIA and Evolent Care Partners brands; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Evolent Health Services (&#8220;EHS&#8221;), focused on administrative simplification solution and supporting value-based business infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, as a result of the operational success and growth within its Clinical Solutions segment including the acquisition of NIA, as well as Bright Health Group (&#8220;BHG&#8221;), a health plan operating partner of EHS, which accounted for 11.3% of the Company&#8217;s short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable as of December 31, 2022, announced its plans to exit its Individual and Family Plans (&#8220;IFP&#8221;) line of business for 2023 and thus negatively impacting the Company&#8217;s future revenues from such partner, the Company is making organizational changes and business strategy decisions which necessitate re-evaluating its reportable segments, including potentially changing the number of reportable segments. The Company anticipates its focus in the future will be primarily on maximizing the market opportunity it believes it has in the management of complex specialty conditions, which constituted approximately 70% of corporate revenue for the year ended December 31, 2022, prior to the acquisition of NIA which will increase this proportion further.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Solutions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Clinical Solutions segment has two primary solutions: (i) specialty care management services and (ii) total cost of care management. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one, or multiple types of solutions, depending on specific needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Core elements of our total cost of care management services include: (i) population health performance, which supports the delivery of patient-centric cost-effective care and (ii) delivery network alignment, comprising the development of high-performance delivery networks. Our total cost of care solution focuses on primary care providers, who serve as the primary point of contact for populations accessing medical care. Increasingly we are referring to this capability as &#8220;Complex Care,&#8221; within the framework of our focus on specialty care. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialty care management services support a broad range of specialty care delivery stakeholders during their transition from FFS to value-based care, independent of their stage of maturation and specific market dynamics. We focus on the oncology, cardiology and increasingly the musculoskeletal, physical medicine and genetics markets with the objective of helping providers and payers deliver higher quality, more affordable care. In addition, we provide comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services as well as identifying the highest quality, lowest site of care for outpatient orthopedic surgeries. We will build out these capabilities significantly within our service offerings to support additional points in the clinical care process that can positively impact quality and cost of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Care Management Services Solution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation for our specialty care management services solution was derived through our acquisition in 2018 of New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based and technology and services arrangements. Since then, we have continued to invest in the solution to broaden, deepen, and scale its capabilities. We have invested in internal capabilities, as well as the acquisition of assets that expand our ability to provide more value for our clients and align with the evolution of our strategic approach to Clinical Solutions. For example, on August 1, 2022, the Company completed its acquisition of IPG, a leading technology and services company providing surgical management solutions for musculoskeletal conditions, and on January 20, 2023, the Company completed its acquisition of NIA, which provides specialty solutions for complex areas of healthcare including radiology, musculoskeletal, physical medicine and genetics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its founding in 2002, New Century Health traditionally focused on the oncology and cardiology markets, which are the two largest specialties in Medicare Advantage by total expenditures. Using clinical data analytics, predictive modeling and decision support tools, New Century Health has developed proprietary clinical pathways in these markets. Managed through its proprietary specialty care management platform, New Century Health combines high performance networks of specialists and enhanced clinical pathways to deliver higher quality and more affordable care, which we consider to be hallmarks of value-based care, to patients, providers and payers. Historically, New Century Health&#8217;s legacy operations focused on the Medicare market and offered performance-based contracts, as well as technology and services arrangements, primarily to payers in the Medicare HMO segment of the overall Medicare market. More recently, New Century Health has entered into performance-based contracts with Medicaid health plans, the radiology, musculoskeletal, physical medicine and genetics markets through its acquisitions of NIA and IPG and advanced care planning through its acquisition of Vital Decisions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Century Health, through its legacy operations and through Vital Decisions, IPG and NIA, provides a differentiated approach designed to meet market challenges based on (i) networks of high-performance providers, (ii) design of evidence-based clinical pathways and (iii) leveraging our proprietary specialty care management technology.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt;text-decoration:underline">High-performance provider networks</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop high-performance provider networks with tools, capabilities and incentives to align and support physicians. We develop and manage comprehensive specialty networks, provide physician engagement and support and identify provider financial incentive alignment. Key features include:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Direct contracts with specialists </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilitate ease of care.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Comprehensive specialty networks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include multiple downstream subspecialists.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Incentivizes financial payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for quality and cost-efficient utilization.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Minimizes &#8220;buy and bill&#8221; incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through shared savings methodologies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Dedicated provider operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide staff to support practices.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Clinical response team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides clinical education on-site to practice staff.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Dedicated central call center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> facilitates referrals and helps to resolve claims issues.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Provides established system</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of ongoing provider education and training.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Increases the frequency of utilization and value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advance care planning.</span></div><div style="text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt;text-decoration:underline">Design evidence-based clinical pathways</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design high-quality evidence-based clinical pathways to drive provider behavior towards improved quality of care at a lower cost. The transparent pathway development process for our specialty population health focal areas, oncology and cardiology, is designed to achieve the following objectives:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Reduce</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unnecessary clinical variation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Support</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> physician clinical decision making of evidence-based therapies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patient engagement.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Facilitate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> total cost-of-care management.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical pathways are based on national guidelines with independent scientific advisory boards, in-house clinical expertise with original publications and presentations at national congress. We employ a collaborative review process that is not based on denials, which includes customized clinical review based on tier 1-5 drugs and proactive monitoring response to therapy. We employ quality metrics and clinical benchmarking to continually improve our pathways. We incentivize financial payment for quality by minimizing &#8220;buy and bill&#8221; incentives and through a shared savings methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt;text-decoration:underline">Leverage proprietary specialty care management technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legacy NCH business leverages a custom specialty care management workflow platform, CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners. Key attributes include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Decision support portal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivers specialty specific clinical experience based on assigned roles (e.g., cardiologist vs. oncologist).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Custom-built rules engine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows flexibility for multiple specialties and automated decisions based on clinical relevance, considering, for example, rigor levels based on specified payers and providers.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Workflow capability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> facilitates a seamless collaboration within and across organizations, connecting payers and clearing houses for systematic data exchange.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Nurse triage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">system</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> leverages proprietary technology infrastructure.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Overall flexibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enables a new business launch of existing specialty within 60 days.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we completed our acquisition of NIA. NIA is a healthcare management business and is focused on delivering innovative specialty solutions for fast growing, complex areas of healthcare, including radiology, musculoskeletal, physical medicine and genetics. NIA develops innovative solutions that combine advanced analytics, agile technology and clinical excellence aimed to drive better decision making and positively impact members' health outcomes. NIA&#8217;s services can be applied broadly across commercial, Medicaid and Medicare populations, or on a more targeted basis for health plan customers. NIA provides its management services primarily through: (i) risk-based contractual arrangements, where NIA assumes all or a substantial portion of the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsibility for the cost of providing treatment services in exchange for a fixed per member per month (&#8220;PMPM&#8221;) capitation payment, or (ii) ASO contractual arrangements, where NIA provides services such as utilization review, but does not assume full responsibility for the cost of the treatment services, in exchange for an administrative fee and, in some instances, shared savings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Cost of Care Management Solution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or ACO contracts with CMS. This solution seeks to reduce the total cost of care for a given population by identifying and managing high-cost patients with targeted interventions managed and coordinated through primary care physicians. The economic model of our total cost of care management solution is primarily performance-based, which we believe enhances our ability to influence provider behavior by aligning our incentives with our partners. We use, and may continue to use, different go-to-market brand names for various solution packages, depending on the markets we seek to address. These go-to-market brand names include: (i) Value Based Services, wherein we support primarily health systems in their value-based operations and (ii) Evolent Care Partners, wherein we offer physicians the opportunity to join Evolent&#8217;s proprietary payer contracting vehicles, scaled risk pools, and operating model. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the offerings within this solution increasingly as &#8220;Complex Care.&#8221; Core elements of this solution include: (i) population health performance, which supports the delivery of patient-centric cost-effective care and (ii) delivery network alignment, comprising the development of high performance delivery networks. We integrate change management processes and ongoing physician-led transformation into all value-based services to build engagement, integration and alignment within our partners to successfully deliver value-based care and sustain performance. We have standardized the processes described below and are able to leverage our expertise across our partner base. Through the technological and clinical integration, we achieve, our solutions are delivered as engrained components of our partners&#8217; core operations rather than as add-on solutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health Services Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Evolent Health Services segment includes our integrated value-based care platform designed to help our customers manage and administer patient health in a more cost-effective manner. We have invested in our primary platform to facilitate value-based care business models for health plans called Identifi&#174; along with our clinical solutions to offer an integrated value-based care platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive health plan administration services help regional and national payers and providers assemble the infrastructure required to operate, manage and capitalize on a variety of financial and administrative management services, such as health plan services, risk management, analytics and reporting and leadership and management. Historically, the economic model of this solution is primarily fee-based with defined service-level agreements around key operating metrics. The services provided by Evolent Health Services include:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Health plan services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Health plan services is a comprehensive suite of services including third-party administration, enrollment and billing support, medical and utilization management, third-party payment and program integrity support and provider network contracting services. Other health plan related services include sales and marketing, product development, actuarial, and regulatory and compliance.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Pharmacy benefit management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our team of professionals support the prescription drug component of providers&#8217; plan offerings and bring national buying power and dedicated resources that are tightly integrated with the care delivery model. Differentiated from what we consider to be traditional PBMs, our solution is integrated into patient care and engages population health levers including generic utilization, provider management, and utilization management to reduce pharmacy costs.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Risk management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our risk management services provide the capabilities needed to successfully manage risk for payers, including analysis, data and operational integration with payer processes, and ongoing performance management.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Analytics and reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our analytics and reporting services provide the ongoing and ad hoc analytic teams and reports required to measure, inform and improve performance, including population health analytics, market analytics, network evaluation, staffing models, physician effectiveness, clinical delivery optimization and patient engagement.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Leadership and management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our local and national talent assist our partners in effectively managing the performance of their value-based operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifi&#174; is our proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients. Identifi&#174; links our processes with those of our partners and other third parties to create a connected clinical delivery ecosystem, stratify patient populations, standardize clinical workflows and enable high-quality, cost-effective care. The configurable nature and broad capabilities of Identifi&#174; help enhance the benefits our partners receive from our services and increase the effectiveness of our partners&#8217; existing technology architecture. In addition, Identifi&#174; provides support and value to our Clinical Solutions segment in a limited fashion. As part of our integration of NIA and focus on specialty care, we believe there are opportunities to more tightly integrate this technology to provide additional capabilities. From this, we can scale within our Clinical Solutions segment and this will be an area of focus during the NIA integration period. Highlights of the capabilities of Identifi&#174; include the following:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Data and integration services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from disparate sources, such as EMRs, and lab and pharmacy data, is collected, assembled, integrated and maintained to provide health care professionals with a holistic view of the patient.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Clinical and business content:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and business content is applied to the integrated data to create actionable information to optimize clinical and financial performance.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">EMR integration:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data and clinical insights from Identifi&#174; are fed back into partner EMRs to improve both provider and patient satisfaction, create workflow efficiencies, promote clinical documentation and coding and provide clinical support at the point-of-care.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Applications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A suite of cloud-based applications manages the clinical, financial and operational aspects of the value-based model. Our applications scale with the clinical, financial and administrative needs of our provider partners. As additional capabilities are required by our partners, they are often deployed as applications through Identifi&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue is derived from recurring multi-year platform and operations contracts. We believe the recurring, multi-year nature of our platform and operations contracts enables us to have strong visibility into future revenue. The amount of revenue in a given platform and operations contract is typically driven by: (i) the number of members that Evolent is contracted to manage, (ii) the population types being served (e.g., Medicare, Medicaid, Commercial), (iii) the depth and breadth of the services and technology applications that our partners utilize from us. In situations involving clinical solutions, we typically elect to participate alongside or co-own risk-sharing arrangements with our partners whereby we share in a portion of the upside and downside clinical performance, or by owning a portion of the underwriting results through capitation. We believe performance-based contracts align our partners&#8217; incentives with our own and enables us to capture greater value from our contracts. We believe we are in the early stages of capitalizing on these aligned operating partnerships. We believe the current value-based care arrangements of our payer and provider partners represent a relatively small portion of their overall total opportunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model benefits from scale, as we leverage our purpose-built technology-enabled solutions and centralized resources in conjunction with the growth of our partners&#8217; membership base. While our absolute investment in our centralized resources and technologies may increase over time, we expect it will decrease as a percentage of revenue as we are able to scale this investment across a broader group of partners. We expect to grow with current partners as they increase membership in their existing operations, through expanding the number of services we provide to our existing partners, by adding new partners and by capturing value through risk-sharing arrangements.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Significant Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, the Company, through a wholly owned subsidiary, entered into a definitive agreement for the Company to acquire Vital Decisions. On October 1, 2021, we consummated the acquisition of Vital Decisions for $46.5 million in cash and the issuance of 1.8 million shares of Class A common stock. Vital Decisions reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for additional discussion regarding the Vital Decisions transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company, through a wholly owned subsidiary, entered into a definitive agreement for the Company to acquire IPG. On August 1, 2022, we consummated the acquisition of IPG for $256.5 million in cash and the issuance of 3.7 million shares of Class A common stock. IPG reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for additional discussion regarding the IPG transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (&#8220;IPG Closing Date&#8221;), the Company entered into a credit agreement to finance the IPG transaction and fund fees and expenses incurred in connection therewith, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation (&#8220;Ares&#8221;), as administrative agent and collateral agent and revolver agent, together with the Company (the &#8220;2022 Credit Agreement&#8221;), pursuant </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#8220;2022 Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Credit Facilities&#8221;), subject to the satisfaction of specified conditions. Refer to &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional discussion regarding the 2022 Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. Refer to &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional discussion regarding the exchange of 2024 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, Evolent Health LLC, a wholly owned subsidiary of the Company, and the Company entered into a definitive agreement for the Company to acquire NIA (the &#8220;NIA acquisition&#8221;). On January 20, 2023, we consummated the NIA acquisition for $400.0 million in cash, $265.0 million in debt financing provided by Ares Capital Corporation and the issuance of 8.5 million shares of Class A common stock. NIA reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the NIA acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, in connection with the consummation of the NIA acquisition, we entered into Amendment No. 1 (&#8220;Amendment No. 1&#8221;) to the Credit Agreement, dated as of August 1, 2022, that provided new secured debt financing in the form of (i) additional commitments under the Company&#8217;s existing asset-based revolving credit facility in an aggregate principal amount equal to $25.0 million (the &#8220;Priority ABL Incremental Facility&#8221;), and (ii) additional commitments under the Company&#8217;s existing term loan facility in an aggregate principal amount equal to $240.0 million (the &#8220;Term Loan Incremental Facility&#8221; and together with the Priority ABL Incremental Facility, the &#8220;Acquisition Facilities&#8221;), and effected certain amendments to the Existing Credit Agreement. Concurrently with Amendment No. 1, EVH LLC borrowed $25.0 million under the Priority ABL Incremental Facility and $240.0 million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock (as defined below), the cash consideration payable for the NIA acquisition and pay transaction fees and expenses. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the amendment to the Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the NIA acquisition, on January 20, 2023, we entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) pursuant to which the Company offered and sold an aggregate 175,000 shares of our newly created Cumulative Series A Convertible Preferred Shares, par value $0.01 per share (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of $960.00 per share, resulting in total gross proceeds to us of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable for the NIA acquisition and pay transaction fees and expenses. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the sale of Series A Convertible Preferred Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are well-positioned to benefit from the transformations occurring in health care payment and delivery described above. We believe this environment that rewards the better use of information to drive patient outcomes aligns with our business model, recent investments and other competitive strengths.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Innovator</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are an innovator in the delivery of comprehensive value-based care solutions. We were founded in 2011, ahead of the implementation of the ACA and before the rapid expansion of programs, such as Medicare ACOs or Medicare Bundled Payment Initiatives. Since our inception, we have invested a significant amount in expanding our offerings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Differentiated Offering by Performing More Services Utilizing An Integrated Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building off of our strength in oncology and cardiology, we believe the acquisition of NIA will accelerate our market leadership to serve the needs of large scale, national payer organizations to manage the cost and quality of care across large and complex medical specialties. NIA is a specialty benefit management company with a complementary service offering to the Company&#8217;s historic specialties. Based on feedback from our clients, we believe the market for value-based specialty care is large, fragmented and lacking a market leader to provide clinically sophisticated, technology-enabled solutions across the highest cost, highly prevalent and most complex medical specialties.  The acquisitions of NIA and IPG by Evolent are part of our competitive response to this apparent unmet need. We believe our payer clients will benefit from a platform offering a broader set of specialty services in order to avoid the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inefficiencies of vendor fragmentation, and we believe they prefer fewer vendors that may provide more consistent services to their membership over time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive End-to-End Solutions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide end-to-end, built-for-purpose, technology-enabled solutions for our partners to succeed in value-based payment models. We believe that offering comprehensive and integrated solutions which bring together clinical and administrative management allows payers and providers to accelerate their path to adoption of value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depth of Market Experience</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With experience across Medicare, Medicaid and commercial markets, our depth and variety of expertise allows us to serve a variety of customer types in the broad health care marketplace including health systems, providers, physicians, health plans, ACOs, delegated arrangements and other payers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrated proprietary technology, Identifi&#174;, allows us to deliver a connected delivery ecosystem, implement replicable clinical processes, scale our value-based services and capitalize on multiple types of value-based payment relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We leverage a custom specialty care management workflow platform, CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we are creating scaled benefits for our partners in areas such as data analytics, administrative services and care management. We expect Identifi&#174; and CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to enable us to deliver increasing levels of efficiency to our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider-Heritage Brand Identity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our provider-heritage brand identity and origins differentiate us from our competitors in the value-based care services area. We believe our solutions resonate with potential partners seeking proven solutions that work with providers in a manner that attempts to minimize friction and foster a care team approach. Our analytical and clinical solutions are rooted in our experience in growing a provider-led, integrated delivery network over the 15-years prior to the founding of Evolent Health, Inc., and growing to become one of the largest provider-owned health plans in the country. Our unique position allows for the sharing of data across multiple payers and care delivery integration regardless of payer, which we believe is not possible with traditional, payer-siloed solutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership-Driven Business Model</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is predicated on strategic partnerships with leading providers and payers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the provider care delivery and payment work-flow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit. In certain cases, we also agree to participate alongside our partners in risk-sharing or other support arrangements to increase our alignment of interests via performance-based relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proven Leadership Team</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made a significant investment in building an industry-leading management team. Our senior leadership team has extensive experience in the health care industry and a track record of delivering measurable clinical, financial and operational improvement for health care providers and payers. Our Chief Executive Officer, Seth Blackley, had served as our President since August 2011. Prior to co-founding the Company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011. Our President, Dan McCarthy, served as the New Century Health&#8217;s Chief Executive Officer since 2019 and held multiple leadership roles within Evolent since joining the Company in 2014. Prior to joining the Company, Mr. McCarthy was a partner at McKinsey &amp; Company. Our Chief Financial Officer, John Johnson, served as the Chief Financial Officer for New Century Health along with various roles within the Company since 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Opportunities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple Avenues for Growth with Our Existing, Embedded Partner Base</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a multi-year partnership model with multiple drivers of embedded growth through the following avenues:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">growth in lives in existing covered populations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners expanding into new lines of value-based care to capture growth in new profit pools; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cross-selling additional solutions to existing partners; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">capturing value created through a variety of value-based arrangements by participating alongside our partners in upside risk sharing arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stages of a Rapidly Growing Transformational Addressable Market</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing partners represent a small fraction of providers and payers that could benefit from our solutions. The transformation of the care delivery and payment model in the United States has been rapid, but it is still in the early stages. Approximately 20% of health care payments were paid through performance or value-based care programs in 2021 and we believe that this number will continue to grow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a significant market opportunity in our specialty care management services solution. As of December&#160;31, 2022, New Century Health served approximately 3.2 million Medicaid Managed Care and Medicare HMO patients out of total population of approximately 74 million. This represents a market share of roughly 4% of this total population. We believe that the adoption of this solution in oncology and cardiology by payers serving the Medicare HMO market is very low but is likely to increase as the growth in spending in these specialties is higher than the growth in overall health care spending. Furthermore, we believe that our specialty care management solution is scalable to Medicaid and other lines of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalize on Growth in Select Government-Driven Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of people managed by government-driven programs in the United States has seen significant growth since 2016. Specifically, the number of Medicare beneficiaries reached 65 million in 2022, an 10% increase from 2017. The nature of our variable fee economic model enables us to benefit from this growth in government-managed lives. A significant portion of our revenues are attributable to government-driven programs, primarily comprised of Medicaid and, to a less significant extent, Medicare.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ability to Capture Additional Value through Delivering Clinical Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are capturing only a portion of the addressable clinical and administrative dollars in the market through our current solutions. We believe there is a significant opportunity to capture an increasing portion of the medical dollar over time, namely the remainder of the premium dollar which goes to medical expenses, and we have begun to do so in certain performance-based relationships. We believe business models that allow us to participate in the medical savings through a variety of risk-sharing arrangements that align incentives to reduce costs and improve quality outcomes will enable us to grow and differentiate ourselves from other vendors. We anticipate the manner with which we partner and share in risk with health care providers will likely continue to evolve over time given the still nascent and fragmented nature of value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expand Offerings to Meet Evolving Market Needs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple business offerings that our partners may require to operate in a value-based care environment that we do not currently provide, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">physician employment;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">PBM expansion to include additional specialty pharmacy management capabilities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additional specialty lines of business beyond oncology, cardiology and musculoskeletal, including kidney and fetal-maternal medicine care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">on-site or specialty clinic services; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consumer engagement and digital outreach.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selectively Pursue Strategic Acquisitions, Investments and Divestitures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the nature of our competitive landscape provides meaningful acquisition and investment opportunities. Our industry is in the early stages of its life cycle and there are multiple firms attempting to capitalize on the transformation of the care delivery model and the various forms of new profit pools. We believe that our partners will require an end-to-end solution and we believe we are well </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">positioned to meet this demand by expanding the breadth of our offerings through not only organic growth, but also the acquisition of niche vendors and non-core portions of larger enterprises. From time to time, we may also pursue acquisition and investment opportunities of businesses related to services we currently provide or that are complementary to our technical capabilities. For example, we completed the following recent acquisitions which are expected to deepen capabilities of both Evolent and the acquired organizations, allowing cross-sell, an enhanced value proposition to partners and an opportunity to increase the margin profile of the combined organization:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On October 1, 2021, we completed the acquisition of Vital Decisions, a leading provider of technology-enabled advance care planning services. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On August 1, 2022, we completed the acquisition of IPG, a leading technology and services company providing surgical management solutions for musculoskeletal conditions.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On January 20, 2023, we completed the acquisition of NIA (also known as Magellan Specialty Health), the specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As we grow, from time to time, we pursue and consummate opportunities to dispose of non-core businesses and assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell our services to payers and providers throughout the United States. Our sales team works closely with our leadership team and subject matter experts to foster long-term relationships with our partners&#8217; leadership and board of directors given the nature of our partnerships. Our dedicated business development team works closely with our partners to identify additional service opportunities on a continuous basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partner Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is predicated on strategic partnerships with leading payers and providers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the care delivery and payment workflow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought to partner with leading payers and providers in sizable markets, which we believe creates a growth cycle that benefits from the secular transition to value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had contractual relationships with 47 operating partners. We define an operating partner as an individual health plan or provider entity under contract with the Company based on a specific state-level geography and whether a relationship is based on fees for covered lives or capitation per life under management. Certain of our partners operate in a local and highly decentralized manner, requiring negotiation and contracting at a local level to expand into new arrangements and thus may be considered multiple entities under this definition, depending on partner business requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts governing the relationships with our operating partners include key terms which may include the period of performance, revenue rates, advanced billing terms, service level agreements, termination clauses, exclusivity clauses and right of first refusal clauses. Typically, these contracts provide for a monthly payment calculated based on a specified rate multiplied by the number of members that our partners are managing. The specified rate varies depending on which market-facing solutions the partner has adopted and the number of services and technology applications they are utilizing. In some cases, we are responsible for paying for all, or substantially all, of the cost of care for a defined scope of health care services out of the revenue we receive. Some of our contracts allow for advance billing of our partners. In some of our contracts, a defined portion of the revenue is at risk and can be refunded to the partner if certain service levels are not attained. We monitor our compliance with the service levels to determine whether a refund will be provided and record an estimate of these refunds. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. The initial term of New Century Health contracts, including contracts of IPG and Vital Decisions, typically have a multi-year initial term. While they typically contain year-to-year renewal provisions, we cannot assure you any or all of these contracts will be renewed in any particular year. NIA&#8217;s contracts with customers typically have stated terms of one to three years, and in certain cases contain renewal provisions (at the customer&#8217;s option) for successive terms of between one and two years (unless terminated earlier). Substantially all these contracts may be immediately terminated with cause and many of NIA&#8217;s contracts are terminable without cause by the customer or NIA either upon the giving of requisite notice and the passage of a specified period of time (typically between 30 and 180 days) or upon the occurrence of other specified events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the revenue from our contracts is not guaranteed because certain of our contracts are terminable for convenience by our partners after a notice period has passed, certain partners would be required to pay us a termination fee in certain circumstances. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination fees and the related notice period in certain of our contracts are determined based on the scope of the market-facing solutions that the partner has adopted and the duration of the contract. Most of our contracts include cure periods for certain breaches, during which time we may attempt to resolve any issues that would trigger a partner&#8217;s ability to terminate the contract. However, certain of our contracts are also terminable immediately on the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. The loss, termination or renegotiation of any contract could negatively impact our results. In addition, as our partners&#8217; businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, we expect that certain of our partners will, from time to time, seek to restructure their agreements with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts may contain exclusivity or other restrictive provisions which are negotiated on an individual basis and vary depending on many factors, including the term and scope of the contract. The term of these exclusivity and other restrictive provisions typically corresponds to the term of the contract. These exclusivity or other restrictive provisions may apply to specific competitors of our  partners or specific geographic areas, subject to certain exceptions. Accordingly, these exclusivity clauses may prevent us from entering into relationships with certain potential partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts with our partners impose other obligations on us. For example, we typically agree that all services provided under the partner contract and all employees providing such services will comply with our partner&#8217;s policies and procedures. In addition, in most instances, we have agreed to indemnify our partners against certain third-party claims, which may include claims that our services infringe the intellectual property rights of such third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our solutions is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities. Some of our competitors are more established, benefit from greater brand recognition, have larger client bases and have substantially greater financial, technical and marketing resources. The entrance or expansion of these larger companies in the managed healthcare industry (including our customers who have in-sourced or who may choose to in-source healthcare services) could increase the competitive pressures we face and could limit our ability to maintain or increase our rates. Other competitors have proprietary technology that differentiates their product and service offerings from ours. Our competitors are constantly developing products and services that may become more efficient or appealing to our existing partners and potential partners. Additionally, some health care information technology providers have begun to incorporate enhanced analytical tools and functionality into their core product and service offerings used by health care providers. Our partners may also choose to insource solution functions from us in part or in whole. Our services solutions compete based on several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement using products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. We also compete based on price and aligned performance relationships and are subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of health care industry participants, practices of managed care organizations, government action and financial stress experienced by our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to extensive, complex and rapidly changing federal and state laws and regulations. Various federal and state agencies have discretion to issue regulations and interpret and enforce health care laws. While we believe we comply in all material respects with applicable health care and insurance laws and regulations, these regulations can vary significantly from jurisdiction to jurisdiction, and interpretation of existing laws and regulations may change periodically. Federal and state legislatures also may enact various legislative proposals that could materially impact certain aspects of our business. The following are summaries of key federal and state laws and regulations that impact our operations:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governmental Health Care Programs &amp; Health Care Reform</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by both CMS and state agencies with respect to certain services we provide relating to Medicaid and Medicare programs. Medicare is a federal program that provides hospital and medical insurance benefits to persons age 65 and over, as well as certain other individuals. Medicaid programs are jointly funded by federal and state governments and are administered by states under an approved plan that provides hospital and other health care benefits to qualifying individuals. As we increase our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exposure to Medicare and Medicaid businesses through new and existing partners, we increase our exposure to changes in government policy with respect to and regulation of the Medicaid and Medicare programs in which we and our partners participate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because some of our partners are participants in governmental programs, our services have in the past and may again in the future be subject to periodic surveys and audits by governmental entities or contractors for compliance with Medicare and other standards and requirements. As a result of surveys or audits, we may incur fines and penalties, and could be excluded from participating in one or more programs or institute other sanctions against us if we fail to comply with CMS regulations or Medicare and Medicaid contractual requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations and requirements applicable to us and other participants in Medicaid and Medicare programs are complex and subject to change. In particular, prior authorization standards and requirements of Medicaid and Medicare programs have come under increased scrutiny at the state and federal level. Medicare Advantage Organization (&#8220;MAOs&#8221;) utilization management practices have been the focus of a report by the Department of Health and Human Services Office of Inspector General as well as another recent calendar year 2024 proposed rule by CMS (&#8220;CY 2024 Proposed Rule&#8221;). The CY 2024 Proposed Rule would impose several requirements on MAOs with respect to their use of prior authorization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Congress (&#8220;Congress&#8221;) and state and local legislatures and regulators may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes with respect to Medicare and Medicaid programs. Such changes in the law, or new interpretations of existing laws, may have a significant impact on our methods and costs of doing business. Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS, Congress, and state agencies to continue to closely scrutinize each component of the Medicare and Medicaid programs, as well as modify the terms and requirements of the programs. It is not possible to predict the outcome of this congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare, and Medicaid, and exchange programs. We cannot assure you as to the ultimate content, timing, or effect of any changes, nor is it possible at this time to estimate the impact of any such potential legislation or changes. Health care reform has resulted in profound changes to the individual health insurance market and our business, and we expect these changes to continue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraud, Waste and Abuse Laws</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigating and prosecuting healthcare fraud, waste and abuse continues to be a top priority for state and federal law enforcement entities. The focus of these efforts has been directed at Medicare, Medicaid, Health Insurance Marketplace and commercial products. Compliance with these laws may require substantial resources. We are constantly looking for ways to improve our fraud, waste and abuse detection methods. The fraud, waste and abuse laws include federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. The United States federal health care programs&#8217; Anti-Kickback Statute makes it unlawful for individuals or entities knowingly and willfully to solicit, offer, receive or pay any kickback, bribe or other remuneration, directly or indirectly, in exchange for or to induce the referral of an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal health care program or the purchase, lease or order, or arranging for or recommending purchasing, leasing or ordering, any good, facility, service, or item for which payment may be made in whole or in part under a federal health care program. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from federal health care programs. If an arrangement falls outside the safe harbors, it must be evaluated on its specific facts to assess whether regulatory authorities might take the position that one purpose of the arrangement is to induce referrals of federal health care program business. Our business arrangements may implicate the Anti-Kickback Statute, and we evaluate whether investment and compensation arrangements being developed by us on behalf of clients and providers fall within one of the safe harbors or Medicare Shared Savings Program waiver. If not, we consider the factors that regulatory authorities are likely to consider in attempting to identify the intent behind such arrangements. We also design business models that reduce the risk that any such arrangements might be viewed as abusive and trigger Anti-Kickback Statute claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. Our activities relating to the way we sell and market our services, including our risk adjustment solution, may be subject to scrutiny under these laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA health care fraud statute created a class of federal crimes, including health care fraud and false statements relating to health care matters, known as the &#8220;federal health care offenses.&#8221; The HIPAA health care fraud statute prohibits, among other things, executing a scheme to defraud any health care benefit program, while the HIPAA false statements statute prohibits, among other things, concealing a material fact or making a materially false statement in connection with the payment for health care benefits, items or services. Entities that are found to have aided or abetted in a violation of the HIPAA federal health care offenses are deemed by statute to have committed the offense and are punishable as a principal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to federal and state &#8220;self-referral&#8221; laws, which generally prohibit physicians from referring patients for items covered by Medicare or Medicaid to entities with which the physician has a financial relationship, unless that relationship falls within a specified exception. The Stark Law is a strict liability statute and is violated even if the parties did not have an improper intent to induce physician referrals. The Stark Law is relevant to our business because we frequently organize arrangements of various kinds under which (a) physicians and hospitals jointly invest in and own ACOs, clinically integrated networks and other entities that engage in value-based contracting with third-party payers or (b) physicians are paid by hospitals or hospital affiliates for care management, medical or other services related to value-based contracts. We evaluate when these investment and compensation arrangements create financial relationships under the Stark Law and design structures that are intended to satisfy exceptions under the Stark Law or Medicare Shared Savings Program waiver.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The antitrust laws are designed to prevent competitors from jointly fixing prices. However, competitors often work collaboratively to reduce the cost of health care and improve quality. To balance these competing goals, antitrust enforcement agencies have established a regulatory framework under which claims of per se price fixing can be avoided if a network of competitors (such as an ACO or clinically integrated network) is financially or clinically integrated. In this context, we evaluate the tests for financial and clinical integration that would be applied to the provider networks that we are helping to create and support, including the nature and extent of any financial risk that must be assumed to be deemed financially integrated and the types of programs that must be implemented to achieve clinical integration. However, even if a network is integrated, it is still subject to a &#8220;rule of reason&#8221; test to determine whether its activities are, on balance, pro-competitive. The key factors in the rule of reason analysis are market share and exclusivity. We focus on network size, composition and contracting policies to strengthen our partners&#8217; position that their networks meet the rule of reason test.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and Data Security</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal, state and local laws and rules regarding the use, security and disclosure of protected health information, personal information, and other categories of confidential or legally protected data that we handle. Such laws and rules include, without limitation, HIPAA, the Federal Trade Commission Act, the Gramm-Leach-Bliley Financial Modernization Act of 1999 (Gramm-Leach-Bliley Act), and state privacy and security laws such as the California Privacy Rights Act. Privacy and security laws and regulations often change due to new or amended legislation, regulations or administrative interpretation. A variety of state and federal regulators enforce these laws, including but not limited to the U.S. Department of Health and Human Services (HHS), the Federal Trade Commission, state attorneys general and other state regulators. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By processing data on behalf of our partners, we are subject to specific compliance obligations under privacy and data security-related laws, including HIPAA, the HITECH Act and related state laws. We are also subject to federal and state security breach notification laws, as well as state laws regulating the processing of protected personal information, including laws governing the collection, use and disclosure of social security numbers and related identifiers. The regulations that implement HIPAA and the HITECH Act establish uniform standards governing the conduct of certain electronic health care transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by health care providers, health plans and health care clearinghouses, all of which are referred to as &#8220;covered entities,&#8221; and their &#8220;business associates&#8221; (which includes anyone who performs a service on behalf of a covered entity involving the use or disclosure of protected health information and is not a member of the covered entity&#8217;s workforce). Our partners&#8217; health plans generally will be covered entities, and, as their business associate, they require us to contractually comply with certain aspects of these standards by entering into requisite business associate agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal regulations issued under HIPAA, several states have enacted privacy and security statutes or regulations, which we refer to as state privacy laws, that govern the use and disclosure of a person&#8217;s medical information or records and, in some cases, are more stringent than those issued under HIPAA. These state privacy laws include regulation of employers; regulation of organizations that perform certain administrative functions, such as UR, or TPA; issuance of notices of privacy practices; and reporting and providing access to law enforcement authorities. In those cases, it may be necessary to modify our operations and procedures to comply with these more stringent state privacy laws. If we fail to comply with applicable state privacy laws, we could be subject to additional sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state consumer protection laws are being applied increasingly by the FTC, Federal Communications Commission and states&#8217; attorneys general to regulate the collection, use, storage and disclosure of personal or patient information, through websites or otherwise, and to regulate the presentation of website content and to regulate direct marketing, including telemarketing and telephonic communication. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other State Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State insurance laws require licenses for certain health plan administrative activities, including TPA licenses for the processing, handling and adjudication of health insurance claims and UR agent licenses for providing medical management services. Given the nature and scope of services that we provide to certain partners, we are required to maintain TPA and UR agent licenses and ensure that such licenses are in good standing on an annual basis. In addition, laws in many states govern prompt payment obligations for health care services. These laws generally define claims payment processes and set specific time frames for submission, payment, and appeal steps. Failure to meet these requirements and time frames may result in rejection, delay of claims and possible interest and regulatory penalties. The Company has also established a captive insurance company under the laws of the State of Vermont and is subject to the captive insurance laws of that state.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our continued growth and success depend, in part, on our ability to protect our intellectual property and proprietary technology, including our Identifi&#174; software and CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> platform. We primarily protect our intellectual property through a combination of copyrights, trademarks and trade secrets, intellectual property licenses and other contractual rights (including confidentiality, non-disclosure and assignment-of-invention agreements with our employees, independent contractors, consultants and companies with which we conduct business).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, these intellectual property rights and procedures may not prevent others from creating a competitive online presence or otherwise competing with us. We may be unable to obtain, maintain and enforce the intellectual property rights on which our business depends, and assertions by third parties that we violate their intellectual property rights could have a material adverse effect on our business, financial condition and results of operations. For additional information related to our intellectual property position see &#8220;Part I - Item 1A. Risk Factors - Risks relating to our business and industry.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenditures primarily consist of our strategic investment in enhancing the functionality and usability of our software, Identifi&#174; and developing programs and processes to maximize care delivery efficiency and effectiveness. We also capitalize software development costs related to Identifi&#174; and CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our research and development expenditures and capitalized software development costs also include the suite of products developed primarily by New Century Health.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our commitment to and investment in human capital enables our continued efforts to reduce the total cost of care, improve clinical quality and simplify administration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">February&#160;16, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we had approximately 5,100 global employees. None of our employees are represented by a labor union, and we are not a party to any collective bargaining agreements. We focus on the following key measures and objectives in managing our business in order to deploy and develop our human capital strategy:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Compensation and Incentives</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Training and Career Development</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Well Being </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Diversity, Equity and Inclusion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Compensation and Incentives</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to attract and retain the highest caliber of health care talent. We believe in pay for performance and structure our compensation to annually incentivize and reward high performance. We annually conduct market pay equity assessments and compensation reviews, and we continue to actively work to reduce unconscious bias in our sourcing, hiring practices, performance reviews and promotion opportunities that may contribute to pay inequities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Training and Career Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the continued edification and development of our talent is important in continuing to maintain growth as a company as well as the growth of our individual talent. Training programs are available to all employees through our company portal that is managed by our learning and development team. Our learning and development portal enables employees to find on-demand content, view and attend live learning sessions. Additionally, during 2020 we launched our internal mobility initiative. The initiative gives employees the visibility and opportunity to apply for positions within their current teams as well as company-wide. In 2021 and 2022, we enhanced our support for our internal mobility initiative by offering Talent profiles within our human capital management system which allows employees to share skills, education, job history, personal statements and career interests. We believe this initiative will continue to help with transparency of opportunities and talent across the organization, enables employees to develop in areas that align to their career goals as well as focus on increasing the diversity of our senior levels within the company over time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Well-Being</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a responsibility to help maintain the health and well-being of our employees. We provide our employees with comprehensive benefits including: medical insurance, dental, vision, PTO and 401k plan. In addition, we offer 100% paid maternity leave, parental leave, fertility support, bariatric surgery, diabetes and hypertension program offerings. With the on-going COVID-19 pandemic impacting our employees, we have continued to support work from home across our employee population. We continue to offer additional mental health offerings through our insurance provider through Lyra Health, work from home office set-up support, regular employee feedback surveys, personal impact days to promote social improvement engagement, an employee crisis fund, holistic wellness initiatives during the year that include yoga, cooking sessions, meditation and wellness challenges.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Diversity, Equity and Inclusion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent stands firm behind its commitment to diversity, equity and inclusion and overall non-discrimination practices. Evolent is an equal opportunity employer and works to create an environment where diverse perspectives can belong, grow and lead regardless of gender, national origin, ethnicity or other protected class. In 2022, we continue to build on established diversity, equity and inclusion initiatives as we aim to continue to create a more equitable workspace. In 2021, we introduced a new development program focused on top diverse employees across the business and continued that program through 2022. This initiative included additional training for leadership in diversity, equity and inclusion throughout the organization and the hiring of a Head of Diversity, Equity and Inclusion to focus on diversity as well as an internal organization review that focused around pay, rewards, job descriptions, recruiting, career pathing and development. The table below presents certain demographic data based on our latest engagement surveys for each of the respective years below (results are based on self-identification):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gender (global representation)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Men</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Racial and ethnic minorities (U.S. representation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black or African American</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hispanic or Latino</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two or more races</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Indian or Alaska Native</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Native Hawaiian or Other Pacific Islander</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leadership Representation (Managing Director level or above)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee self-identification (U.S. representation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veteran</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disabled Individual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Information about our Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers as of February&#160;24, 2023, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:118.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:334.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seth Blackley</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dan McCarthy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve Tutewohl</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Weinberg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aammaad Shams</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Seth Blackley </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is our co-founder and has served as our Chief Executive Officer since October 2020 and served as our President from August 2011 until his promotion. Prior to co-founding the Company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011. Mr. Blackley began his career as an analyst in the Washington, D.C. office of McKinsey &amp; Company. Mr. Blackley holds a Bachelor of Arts degree in business from The University of North Carolina at Chapel Hill, and a master of business administration from Harvard Business School.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dan McCarthy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our President since September 2022. Prior to his role as President, Mr. McCarthy was the  New Century Health&#8217;s Chief Executive Officer since 2019, and prior to that held multiple leadership roles within Evolent since joining the Company in 2014. Mr. McCarthy came to Evolent from McKinsey &amp; Company, where he was a leader in the firm's health care practice. Mr. McCarthy holds an M.B.A. from Harvard Business School, where he was a Goldsmith Fellow, and received a B.A. from Georgetown University.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Johnson </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer since July 2019. Prior to his role as Chief Financial Officer, Mr. Johnson was acting Chief Financial Officer for New Century Health from March 2019 to June 2019. Prior to his New Century Health role, Mr. Johnson was Senior Vice President, Corporate Performance at Evolent Health from January 2018 to March 2019 and Vice President, Corporate Performance at Evolent Health from April 2016 to December 2017. Prior to joining the Company, Mr. Johnson was the Managing Partner at Riverbend Analytics, LLC from December 2015 until April 2016 and the Vice President of Strategy at PSA Healthcare from February 2013 until November 2015. Mr. Johnson holds a Bachelor of Arts degree in Physics from Cornell University.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Steve Tutewohl </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Operating Officer since June 2020. Mr. Tutewohl has also served as the Chief Executive Officer of Evolent Health Services, since January 2018. Mr. Tutewohl previously served as the Chief Actuary of the Company from January 2017 until December 2017. Prior to the Company&#8217;s acquisition of Valence Health, Mr. Tutewohl was the Strategic Accounts Officer of Valence Health from October 1996 - January 2017. Mr. Tutewohl received his B.S. in risk management, math and actuarial science from the University of Wisconsin.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jonathan Weinberg </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our General Counsel since January 2014. Prior to joining Evolent, Mr. Weinberg was a Senior Vice President and Deputy General Counsel for Coventry Health Care, Inc. (Aetna Inc.) from 1999 to 2013, and oversaw the day-to-day management of the legal department as well as the company&#8217;s risk management department. Prior to joining Coventry, Mr. Weinberg was an associate and then partner at Epstein Becker and Green, P.C. in the firm&#8217;s health care practice, specializing in managed care issues from 1992 to 2002. Mr. Weinberg received his Bachelor of Arts in history and political science from the University of Wisconsin-Madison and his juris doctorate from the Catholic University of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aammaad Shams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Accounting Officer since August 2022. Prior to his current role, Mr. Shams was the Company&#8217;s Controller from June 2020 to August 2022 and Assistant Corporate Controller from January 2020 to June 2020. Mr. Shams also served as Senior Director of Technical Accounting from April 2018 to June 2019 and Senior Director of Accounting from July 2019 until December 2019. Prior to joining the Company, Mr. Shams was a Director in KPMG, LLP&#8217;s Accounting Advisory Services practice from June 2015 until March 2018. Mr. Shams is a Certified Public Accountant in the Commonwealth of Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers are elected annually by our Board of Directors. All executive officers serve until their successors are duly chosen or elected and qualified, except in the case of earlier death, resignation or removal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent began business operations in August 2011. Evolent Health, Inc., the registrant, was incorporated in the State of Delaware in December 2014. We completed our IPO in June 2015 and our Class A common stock is listed on the NYSE under the symbol &#8220;EVH&#8221;. Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries and the financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website to Access Our Reports</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet website address is www.evolenthealth.com. In addition to the information about us and our subsidiaries contained in this Annual Report on Form 10-K, information about us can be found on our website including information on our corporate governance principles and practices. Our Investor Relations website at ir.evolenthealth.com contains a significant amount of information about us, including financial and other information for investors. We use the investor relations page of our website for purposes of compliance with Regulation FD and as a routine channel for distribution of important information, including news releases, investor presentations, financial information and corporate governance practices. We encourage investors to visit our website, as we frequently update and post new information about our company on our website and it is possible that this information could be deemed to be material information. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, free of charge, on or through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_214"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary highlights some of the principal risks that could adversely affect our business, financial condition or results of operations. This summary is not complete and the risks summarized below are not the only risks we face. These risks are discussed more fully further below. These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We may be unable to efficiently integrate NIA into our operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The historical financial information of NIA related to the NIA acquisition may not be a reliable indicator of future results.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We derive a significant portion of our revenues from our largest partners.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The market for value-based health care in the United States is rapidly evolving. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The health care regulatory and political framework is uncertain and evolving.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to offer new and innovative products and services or our products and services fail to keep pace our results of operations may suffer.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have made and entered, and may in the future make and enter acquisitions, investments and alliances and joint ventures, which may be difficult to integrate, result in unanticipated costs or dilute our stockholders.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our revenues and growth rely, in part, on our partners and revenues from our engagements, which are subject to factors outside of our control.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Failure to accurately underwrite performance-based contracts could result in a reduction in profitability for our specialty care management solution.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we fail to effectively manage our growth and costs, our business could be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Public health emergencies such as the COVID-19 pandemic have adversely affected, and could in the future, adversely affect our business and the business of our customers and suppliers.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our offshore support and professional services may prove difficult to manage or may not allow us to realize our cost reduction goals.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we lose key members of our management team or employees or are unable to attract and retain employees, our compensation costs will increase and our business and operating results will be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have recorded a significant amount of goodwill, and we may never realize the full value of our intangible assets, causing us to record impairments that may negatively affect our results of operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We may need to obtain additional financing.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have experienced net losses in the past and we may not achieve profitability in the future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We typically incur significant upfront costs in our partner relationships, and if we are unable to develop or grow these partner relationships over time, we are unlikely to recover these costs and our operating results may suffer.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we do not continue to attract new partners and successfully capture new opportunities, we may not achieve our financial projections, and our results of operations would be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">As we enter into an increasing number and variety of risk sharing arrangements with partners, our revenues and profitability could be limited and negatively impacted.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted and our business would be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Consolidation in the health care industry could have a material adverse effect on us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our offerings could be subject to audits by CMS and other governmental payers and whistleblower claims.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Exclusivity and right of first refusal clauses in some of our partner and founder contracts may prohibit us from partnering with certain other providers in the future, and limit our growth.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Increasing inflationary pressures and consumer costs may have a negative effect on our margins, profitability and results of operations</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are subject to privacy and data protection laws.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Data loss or corruption due to failures or errors in our systems or service disruptions at our data centers may adversely affect our reputation and relationships with existing partners, which could have a negative impact on us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to develop and commercialize technology and products similar to ours, and our ability to commercialize our technology and products may be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on us.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our use of &#8220;open source&#8221; software could adversely affect our ability to offer our services and subject us to possible litigation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary information, the value of our technology and products could be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We do not control the intellectual property rights covering certain technologies and any loss of rights to these technologies or the rights licensed to us could prevent us from developing and/or commercializing our products.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with partners, adversely affecting our brand and our business.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We rely on third-party vendors to host and maintain our technology platform.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we identify material weaknesses in the future, we and our auditor may conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future, and these amounts are expected to be material.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We will not be reimbursed for any payments made under the TRA in the event that any tax benefits are disallowed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units or from the utilization of certain NOLs and from payments made under the TRA.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">In certain cases, payments by us under the TRA may be accelerated or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the TRA.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The agreements between us and certain of our pre-IPO investors were made in the context of an affiliated relationship and may contain different terms than comparable agreements with unaffiliated third parties.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The accounting method for convertible debt securities that may be settled in cash.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are exposed to interest rate risk, which could cause the Company&#8217;s debt service obligations to increase significantly.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our debt following the NIA acquisition is significant and could adversely affect our business and our ability to meet our obligations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We expect that our stock price will be volatile and may fluctuate or decline significantly.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our Series A Preferred Stock has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Class A common stock. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The market price of our Class A common stock could decline due to the large number of shares of Class A common stock issuable upon conversion of our convertible notes or the Series A Preferred Stock, or by sales or issuances of substantial amounts of our Class A common stock.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Some provisions of Delaware law certificate of incorporation  and our by-laws and certain of our contracts may deter third parties from acquiring us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our second amended and restated certificate of incorporation, as amended, and stockholders&#8217; agreement contain provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our certificate of incorporation designates the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operations and financial position are subject to various risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the audited annual financial statements and notes thereto included elsewhere in this Form 10-K, when evaluating your investment in our securities. The risks and uncertainties described below are those that we currently believe may materially affect the Company. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial also may become important factors that affect the Company. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our securities could decline, and you could lose part or all of your investment. Some statements in this Form 10-K, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled &#8220;Forward-Looking Statements - Cautionary Language.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_2460"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks relating to the NIA acquisition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We may be unable to efficiently integrate NIA into our operations.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful integration of the NIA business and operations into those of our own, and our ability to realize the expected synergies and benefits of the NIA acquisition are subject to a number of risks and uncertainties, many of which are outside of our control. We will also be required to devote significant management attention and resources to integrating business practices, cultures and operations of each business. The risks and uncertainties relating to integrating the two businesses, and realizing the anticipated cost synergies, include, among other things:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the challenge of integrating complex organizations, platforms, systems, operating procedures, compliance programs, technology, networks and other assets of NIA&#894;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the difficulties harmonizing differences in the business cultures of our company and NIA&#894;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to combine successfully our respective businesses in a manner that permits us to achieve the cost savings, revenue synergies and other anticipated benefits from the NIA acquisition&#894;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to minimize the diversion of management attention from ongoing business concerns during the process of integrating NIA into our businesses&#894;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to resolve potential conflicts that may arise relating to customer, supplier and other important relationships of our business and NIA&#894; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulties in retaining key management and other key employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial expenses to consummate the NIA acquisition but may not realize the anticipated cost synergies, revenue synergies and other benefits to the extent expected, on the timeline expected, or at all. In addition, even if we are able to integrate the NIA business successfully, the anticipated benefits of the NIA acquisition may not be realized fully, or at all, or may take longer to realize than expected. Moreover, competition may also cause us not to fully realize the anticipated benefits of the NIA acquisition. Given the size and significance of the NIA acquisition, we may encounter difficulties in the integration of the operations of NIA and may fail to realize the full benefits and synergies of the NIA acquisition, which could adversely impact our business, results of operation and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">The historical combined financial information of NIA may not be a reliable indicator of future results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical audited and unaudited financial information of NIA that was included in our Current Report on Form 8-K filed with the SEC on January 23, 2023, was prepared on a carve-out basis from Centene Corporation (&#8220;Centene&#8221;), which required certain assumptions and estimates based on accounting data extracted from accounting data books that were used when preparing the consolidated financial statements of Centene.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the historical combined financial information of NIA in our Current Report on Form 8-K filed with the SEC on January 23, 2023, was derived from the historical accounting records of Centene, and we anticipate that significant changes will occur in NIA&#8217;s cost structure, financing and business operations as a result of our operation of it as part of our larger corporate organization. Such historical financial information may therefore not reflect what NIA&#8217;s results of operations, financial position or cash flows would have been had it been a standalone company during the periods presented, or what they would have been had NIA been operated by us as part of our larger corporate organization during the periods presented, and may not be indicative of what NIA&#8217;s results of operations, financial position or cash flows will be in the future. In addition, our accounting policies may differ from those reflected in the carve-out financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The pro forma financial information related to the NIA acquisition was prepared for informational purposes only and may not be an indication of our financial condition or results of operations in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined financial statements included in our Current Report on Form 8-K filed with the SEC on January 23, 2023, were presented for informational purposes only and are not necessarily indicative of what our actual financial condition or results of operations would have been had the NIA acquisition, Amendment No. 1 to the Credit Agreement and sale of the Series A Preferred Stock been completed on the date indicated. The assumptions used in preparing the pro forma financial information may not prove to be accurate and other factors may affect our financial condition or results of operations. Accordingly, our financial condition and results of operations in the future may not be consistent with, or evident from, such pro forma financial information. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to our business and industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with a significant partner, or multiple partners in the aggregate, could negatively impact our results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have relied on a limited number of partners for a substantial portion of our total revenue. Our largest partner in terms of revenue, Cook County Health and Hospitals System, comprised 22.4% of our revenue for the year ended December 31, 2022. In addition, our partnership with Centene has grown, both as a result of the NIA acquisition and from other partnership opportunities. The loss of Cook County Health and Hospitals System, or any other significant partner, pursuant to a reprocurement process or otherwise, or the non-renewal or renegotiation of any of our significant partner contracts, could adversely affect our results. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we engage in active discussions and renegotiations, and at times we are required to participate in reprocurement or other request for proposal (&#8220;RFP&#8221;) exercises with our partners in respect of the services we provide and the terms of our partner agreements, including our fees. Certain of our customers are subject to Medicaid health plans with state contracts that come up for renewal from time to time and can be subject to an RFP process. If a customer loses its contract or an RFP process it would cause the Company to lose that portion of the customer&#8217;s business. In addition, we may not successfully win new contracts or renewals of existing contracts through competitive market standard reprocurement or RFP processes. As partners&#8217; businesses respond to market dynamics and financial pressures, and as partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our and NIA&#8217;s partners have renegotiated or terminated, or not renewed, and we expect that in the future additional partners will, from time to time, seek to renegotiate or terminate or not renew their agreements with us. For example, in October 2022, BHG, an operating partner of the EHS segment of the Company who accounted for 12.2% of the Company&#8217;s accounts receivable as of September 30, 2022, announced that it plans to exit its IFP line of business in 2023. The Company had previously announced the selection of EHS by BHG as the administrative services provider for this line of business, along with BHG&#8217;s intention to add approximately 700,000 members to our platform beginning January 1, 2023. BHG&#8217;s announcement, other discussions and decisions, and future discussions and decisions, have resulted and could result in reductions to the fees and changes to the scope of services contemplated by our original partner contracts and consequently have and could negatively impact our revenues, financial results (including potential impairments), business and prospects. The impact of these actions have included, and in the future could include making organizational changes across our business as well as other profitability initiatives that may result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a limited number of partners for a significant portion of our revenues, we depend on the creditworthiness of these partners. Our partners are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our partners declines, our credit risk could increase. Should one or more of our significant partners declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, financial results (including potential impairments), the collectability of our accounts receivable and our bad debt reserves and net income (loss).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have long-term contracts with many partners, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of our contracts are terminable for convenience by the partner after a notice period has passed and, in certain cases, the partner has paid a termination fee. Certain contracts are terminable immediately upon the occurrence of certain events. For example, some contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service. Certain contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, the contract with such partner could in effect be terminated. In addition, certain contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any contracts with partners are terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. In addition, certain contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health, including Vital Decisions, typically run for one-year terms. While they typically contain year-to-year renewal provisions, we cannot assure that any or all of these contracts will be renewed in any particular year. We expect that future contracts will contain similar provisions to those described in this paragraph. The market for value-based health care in the United States continues to evolve, which makes it difficult to forecast demand for our products and services.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The market for value-based health care in the United States is rapidly evolving. Our future financial performance will depend in part on growth in this market and on our ability to adapt to emerging demands of this market. It is difficult to predict with any precision the future growth rate and size of our target markets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapidly evolving nature of the markets in which we operate, as well as other factors that are beyond our control, reduce our ability to accurately evaluate our long-term outlook and forecast annual performance. We believe that demand for our products and services has been driven in large part by price pressure in traditional FFS health care, a regulatory environment that is incentivizing value-based care models, a rapid expansion of retail insurance, broader use of the Internet and advances in technology. Widespread acceptance of the value-based care model is critical to our future growth and success. A reduction in demand for our products and services caused by lack of acceptance, technological challenges, competing offerings or other factors would result in a lower revenue growth rate or decreased revenue, either of which could negatively impact our business and results of operations. For example, a large portion of New Century Health&#8217;s and NIA&#8217;s revenue is derived from customers in the managed care industry, including risk bearing providers and national and regional managed care companies. Changes in this industry&#8217;s business practices could negatively impact New Century Health and NIA. For example, if New Century Health&#8217;s and NIA&#8217;s managed care customers seek to provide services directly to their subscribers instead of contracting with New Century Health or NIA for such services, New Century Health and NIA could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The health care regulatory and political framework is uncertain and evolving.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care laws and regulations are rapidly evolving and may change significantly in the future, including as a result of the Biden administration, which could adversely affect our financial condition and results of operations. We are subject to regulation by both CMS and state agencies in respect of certain services we provide relating to Medicaid and Medicare programs. Medicare is a federal program that provides hospital and medical insurance benefits to persons age 65 and over, as well as certain other individuals. Medicaid programs are jointly funded by federal and state governments and are administered by states under an approved plan that provides hospital and other health care benefits to qualifying individuals. As we increase our exposure to Medicare and Medicaid businesses through new and existing partners, we increase our exposure to changes in government policy with respect to and regulation of the Medicaid and Medicare programs in which we and our partners participate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because some of our partners are participants in governmental programs, our services have in the past and may again in the future be subject to periodic surveys and audits by governmental entities or contractors for compliance with Medicare and other standards and requirements. As a result of surveys or audits, we may incur fines and penalties, and could be excluded from participating in one or more programs or institute other sanctions against us if we fail to comply with CMS regulations or Medicare and Medicaid contractual requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations and requirements applicable to us and other participants in Medicaid and Medicare programs are complex and subject to change. In particular, prior authorization standards and requirements of Medicaid and Medicare programs have come under increased scrutiny at the state and federal level. MAO utilization management practices have been the focus of a report by the Department of Health and Human Services Office of Inspector General as well as the recent CY 2024 Proposed Rule. The CY 2024 Proposed Rule would impose several requirements on MAOs with respect to their use of prior authorization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress and state and local legislatures and regulators may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes with respect to Medicare and Medicaid programs. Such changes in the law, or new interpretations of existing laws, may have a significant impact on our methods and costs of doing business. Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS, Congress, and state agencies to continue to closely scrutinize each component of the Medicare and Medicaid programs, as well as modify the terms and requirements of the programs. It is not possible to predict the outcome of this congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, CMS, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare, Medicaid, and exchange programs. In October 2021, the CMS Center for Medicare and Medicaid Innovation (CMMI) published a white paper outlining its new strategic direction. Key themes include an increased focus on health equity, on streamlining the CMMI model portfolio, and on advancing new goals to get &#8220;all Medicare beneficiaries&#8221; and &#8220;the vast majority of Medicaid beneficiaries&#8221; into care relationships with accountability for quality and total cost of care by 2030. We cannot quantify or predict with any certainty the likely impact of this new strategic direction on the availability or functioning of CMMI models, participation in CMS programs or modifications to their rules and regulations, changes in the law, or new interpretations of existing laws, on our methods and costs of doing business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS and Congress to continue to closely scrutinize each component of the Medicare program as well as modify the terms and requirements of the program. It is not possible to predict the outcome of this congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the health care delivery system, including Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in April 2020, Congress enacted the Families First Coronavirus Response Act (the &#8220;FFCRA&#8221;), which requires Medicaid programs to keep individuals continuously enrolled through the end of the month in which the COVID-19 public health emergency (the &#8220;PHE&#8221;) is terminated. The PHE was most recently re-extended on October 13, 2022 through January 11, 2023. On January 30, 2023, President Biden stated that the PHE would terminate on May 11, 2023. Once the PHE extension ends on May 11, 2023, and Medicaid redeterminations resume, millions of Medicaid enrollees could lose their coverage. At such time, we believe that certain of our partners may experience a meaningful decrease of enrolled lives, which may decrease the numbers of lives on our platform and which would impact the revenues derived from such partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example of recent health care legislative changes, the Consolidated Appropriations Act (the &#8220;CAA&#8221;), enacted on December 27, 2020, contains provisions impacting group health plans, including protections for plan participants from surprise medical bills and ensuring health plan price transparency. The CAA prohibits plans from entering into services agreements that directly or indirectly restrict the plans from disclosing provider-specific costs and quality of care information. The CAA will also require certain service providers for health plans to comply with certain ERISA fee disclosure rules. In addition, effective January 1, 2022, the No Surprises Act (enacted as part of the CAA) provides protection against surprise medical bills by prohibiting plans and providers from balance billing patients for emergency care performed by out-of-network providers as well as non-emergency and ancillary services performed by out-of-network providers at in-network facilities, subject to certain notice and consent exceptions for non-emergency and ancillary services. The new law also grants additional patient protections, including requiring providers to send a good faith estimate of the expected charges for furnishing items or services to an insured patient&#8217;s health plan (or directly to an uninsured patient) before such items or services are delivered (including items or services reasonably expected to be provided in conjunction with scheduled items or services or that are reasonably expected to be delivered by another provider). The No Surprises Act also provides a dispute resolution process in the event the actual charges for such items and services are substantially higher than the plan&#8217;s estimate and will prohibit providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to certain exceptions. Several states have also enacted comprehensive surprise billing laws and the CAA defers to existing state requirements with respect to state-established payment amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict how these changes and other health care reform initiatives from new legislation, regulation, judicial action and/or executive action, including the CAA and No Surprises Act and state laws, will ultimately impact the health care industry and what the potential impact may be on our business, financial condition, operating results and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these health care laws and regulations, we are subject to various other laws and regulations, including, among others, other aspects of state insurance laws, the Stark Law relating to self-referrals, the whistleblower provisions of the False Claims Act, anti-kickback laws, antitrust laws and the privacy and data protection laws. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigating and prosecuting healthcare fraud, waste and abuse continues to be a top priority for state and federal law enforcement entities. The focus of these efforts has been directed at Medicare, Medicaid, Health Insurance Marketplace and commercial products. Compliance with these laws may require substantial resources. We are constantly looking for ways to improve our fraud, waste and abuse detection methods. The fraud, waste and abuse laws include In the United States, there are federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. In addition to these health care laws and regulations, we are subject to various other laws and regulations, including, among others, other aspects of state insurance laws, the Stark Law relating to self-referrals, the whistleblower provisions of the False Claims Act, anti-kickback laws, antitrust laws and the privacy and data protection laws. The federal civil False Claims Act imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. Our activities relating to the way we sell and market our services, including our risk adjustment solution, may be subject to scrutiny under these laws. The Stark Law is relevant to our business because we frequently organize arrangements of various kinds under which (a) physicians and hospitals jointly invest in and own ACOs, clinically integrated networks and other entities that engage in value-based contracting with third-party payers or (b) physicians are paid by hospitals or hospital affiliates for care management, medical or other services related to value-based contracts. We evaluate when these investment and compensation arrangements create financial relationships under the Stark Law and design structures that are intended to satisfy exceptions under the Stark Law or Medicare Shared Savings Program waiver. We have identified instances of noncompliance in the past and cannot guarantee that we will not identify other instances in the future, or the outcome of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any regulatory investigation into any non-compliance. If we were to become subject to litigation, liabilities or penalties under these or other laws or as part of a governmental review or audit, our business could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">If we are unable to offer new and innovative products and services or our products and services fail to keep pace with advances in industry standards, technology and our partners&#8217; needs, our partners may terminate or fail to renew their relationships with us and our revenue and results of operations may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success depends on providing high-quality products and services that health care providers use to improve clinical, financial and operational performance. If we cannot adapt to rapidly evolving industry standards, technology and increasingly sophisticated and varied partner needs, our existing technology could become undesirable or obsolete, which could harm our reputation. We must continue to invest significant resources in our personnel and technology in a timely and cost-effective manner in order to enhance our existing products and services and introduce new high-quality products and services that existing partners and potential new partners will want. Our operating results would also suffer if our innovations are not responsive to the needs of our existing partners or potential new partners, are not appropriately timed with market opportunity, are not effectively brought to market or significantly increase our operating costs. If our new or modified product and service innovations are not responsive to partner preferences, emerging industry standards or regulatory changes, are not appropriately timed with market opportunity or are not effectively brought to market, we may lose existing partners or be unable to obtain new partners and our results of operations may suffer. In addition, should any of our partners terminate their relationship with us after implementation has begun, we would not only lose our time, effort and resources invested in that implementation, but we would also have lost the opportunity to leverage those resources to build a relationship with other partners over that same period of time. In some cases, we price our services based on expectations of long-term relationships with our partners. When a partner terminates the relationship earlier than we had expected, we lose the resources invested in that relationship as well as the upside benefits we had anticipated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also engage third-party vendors to develop, maintain and enhance our technology solutions, and our ability to develop and implement new technologies is therefore dependent on our ability to engage suitable vendors. We may also need to license software or technology from third parties in order to maintain, expand or modify our technology-enabled services platform. However, there is no guarantee we will be able to enter into such agreements on acceptable terms or at all. The functionality of our services platforms depends, in part, on our ability to integrate with third-party applications and data management systems that our partners use and from which they obtain data. These third parties may terminate their relationships with us, change the features of their applications and platforms, restrict our access to their applications and platforms or alter the terms governing use of their applications, data management systems and application programming interfaces and access to those applications and platforms in an adverse manner.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In addition to our recent acquisition of NIA we have made and entered into, and may in the future make and enter into acquisitions, investments, alliances and joint ventures, which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As our business continues to grow, we may continue to acquire or invest in companies, businesses, products or technologies that complement our current products and services, enhance our market coverage or technical capabilities or offer growth opportunities. This may include acquiring or investing in companies, businesses, products or technologies that are tangential to our current business and in which we have limited or no prior operating experience. That, and other acquisitions, investments, alliances or joint ventures, have resulted and could result in new, material risks to our results of operations, financial condition, business and prospects. These new risks could include increased variability in revenues and prospects associated with various risk sharing arrangements. In addition, the market price for our Class A common stock could also be affected, following the consummation of any other transaction, by factors that have not historically affected the market price for our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continuously evaluate potential acquisition targets and investments as well as opportunities to divest of non-core assets. However, there can be no assurance that any of these potential acquisitions, investments or divestitures will be consummated. Acquisitions, investments and alliances, including our recent acquisitions of NIA, Vital Decisions, and IPG, could result in numerous risks to our business which could negatively impact our financial condition and results of operations, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty converting platforms or integrating the purchased operations, products or technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial unanticipated integration costs, delays and challenges that may arise in integration;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the loss of key customers who are in turn subject to risks and financial dislocation in their businesses;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the loss of key employees, particularly those of the acquired operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty retaining or developing the acquired business&#8217; customers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adverse effects on our existing business relationships with customers, suppliers, other partners, standing with regulators;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">challenges related to the integration and operation of businesses that operate in new geographic areas and new markets or lines of business;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unanticipated financial losses in the acquired business, including the risk of higher-than-expected health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to realize the potential cost savings or other financial benefits or the strategic benefits of the acquisitions, including failure to consummate any proposed or contemplated transaction; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities, including acquired litigation, and expenses from the acquired businesses for contractual disputes with customers and other third parties, infringement of intellectual property rights, data privacy violations or other claims and failure to obtain indemnification for such liabilities or claims, and distraction of our personnel in connection with any related proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to integrate the operations, products, technologies or personnel gained through acquisitions or investments or integrate or complete any other such transaction without a material adverse effect on our business, financial condition and results of operations. Transaction agreements may impose limitations on our ability, or the ability of the business to be acquired, to conduct business. Events outside our control, including operating changes or regulatory changes, could also adversely affect our ability to realize anticipated revenues, synergies, benefits and cost savings. In addition, revenues of acquired businesses or companies, prior to and after consummation of a transaction, may be less than expected. Counterparties in transactions may have contracts with customers and other business partners which may require consents from these parties in connection with a transaction. If these consents cannot be obtained, the Company may suffer a loss of potential future revenue and may lose rights that are material to its business and the business of any combined company. Any such disruptions could limit our ability to achieve the anticipated benefits of the transaction. Any integration may be unpredictable, or subject to delays or changed circumstances, and we and any targets may not perform in accordance with our expectations. See the risk factor captioned &#8220;We may be unable to efficiently integrate NIA into our operations.&#8221; for additional information concerning integrating NIA into our operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a number of joint ventures. Conflicts or disagreements between us and any joint venture partner may negatively impact the benefits expected to be achieved by the joint venture or may ultimately threaten the ability of such joint venture to continue. We are also subject to additional risks and uncertainties because we may be dependent upon and subject to the liability, losses or reputational damage relating to joint venture partners that are not entirely under our control.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these acquisitions, investments, alliances or joint ventures, we could incur significant costs, debt, amortization expenses related to intangible assets or large and immediate write-offs or other impairments or charges (as was the case with the $47.1 million impairment charge we incurred in connection with our investment in GlobalHealth, Inc. during the year ended December 31, 2020, which represented the total value of our investment), assume liabilities or issue stock (as we have done in prior transactions) that would dilute our current stockholders&#8217; ownership.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Our revenues and the growth of our business rely, in part, on the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with our partners under which a significant portion of our fees are variable, including fees which are dependent upon the number of members that are covered by  partners&#8217; health care plans each month, expansion of partners and the services that we provide, as well as performance-based metrics. The number of members covered by a partner&#8217;s health care plan is often impacted by factors outside of our control, such as the actions of our partner or third parties. In addition, ongoing payment of fees by our partners could be negatively impacted by the general financial condition of partners. Accordingly, revenue under these agreements is unpredictable. If the number of members covered by one or more of our partners&#8217; plans were to be reduced by a material amount, or if member enrollment numbers in new plans are lower than expected, which was the case with our Florida Medicaid partners, such decrease would lead to a decrease in our expected revenue, which could harm our business, financial condition and results of operations. In addition, growth forecasts of our partners are subject to significant uncertainty and are based on assumptions and estimates that may prove to be inaccurate. Even if the markets in which partners compete meet the size estimates and growth forecasted, their health plan membership could fail to grow at similar rates, if at all. In addition, a portion of the revenue under certain of our service contracts is tied to the partners&#8217; continued participation in specified payer programs over which we have no control. If a partner ceases to participate or is disqualified from participation in any such program, this would lead to a decrease in our expected revenue under the relevant contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the transition to value-based care may be challenging for our partners. For example, fully-capitated or other provider risk arrangements have had a history of financial challenges for providers. Our partners may also have difficulty in value-based care if premium pricing is under pressure or if they incur selection bias in the health plans under which they assume risk and in so doing the premium, capitation amount or other risk-sharing arrangement they undertake may not adequately reflect the health status of the membership. Our partners may choose not to continue to capitalize affiliated health plans or subsidize losses to their reimbursement rates. Furthermore, revenue under our partner contracts may differ from our projections because of the termination of the contract for cause or at specified life cycle events, or because of fee reductions that are occasionally agreed to after the contract is initially signed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners derive a substantial portion of their revenue from third-party private and federal and state governmental payers, including Medicaid programs. Revenue under certain of our agreements could be negatively impacted as a result of governmental funding reductions impacting government-sponsored programs, changes in reimbursement rates, and premium pricing reductions, as well as the inability of partners to control and, if necessary, reduce health care costs, all of which are out of our control. We are unable to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predict the impact on the Company&#8217;s operations of future regulations or legislation affecting Medicaid programs, or the healthcare industry in general. For example, our partners may receive less Medicaid-based revenue once the Biden administration terminates the PHE on May 11, 2023 and state Medicaid redeterminations begin. Because certain partners&#8217; revenues are highly reliant on third-party payer reimbursement funding rates and mechanisms, overall reductions of rates from such payers could adversely impact the liquidity of our partners, resulting in their inability to make payments to us on agreed payment terms. These risks may be heightened by the COVID-19 pandemic. See &#8220;Risk factors-The health care regulatory and political framework is uncertain and evolving&#8221; for additional information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The financial benefits we expect to receive as a result of our sale of certain assets of Passport to Molina may not be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;). On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In the event certain conditions are not fulfilled, we may not realize the full economic benefits we expect to derive from the transaction. The amount of cash we ultimately receive in connection with the transactions consummated by the Molina APA, the wind down of EVH Passport and related transactions could be adversely affected by a number of factors outside of our control. As of December&#160;31, 2022, EVH Passport has $36.7 million recorded in cash and cash equivalents on our consolidated balance sheet and we cannot control or predict the timing of such capital return subject to regulatory approval from the Kentucky Department of Insurance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to accurately underwrite performance-based contracts could result in a reduction in profitability for our specialty care management solution.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both New Century Health, the brand name we use for our specialty care management solution, and NIA derive a portion of their revenue from arrangements under which they assume responsibility for a portion of the total cost of treatments (for oncology, cardiology, radiology, musculoskeletal, physical medicine, and genetics patients) in exchange for a fixed fee. These are typically referred to as &#8220;performance-based contracts&#8221;. If the Company is unable to accurately underwrite the health care cost risk for New Century Health and NIA and control associated costs, for example due to changes in the delivery system; changes in utilization patterns; changes in the number of members seeking treatment; unforeseen fluctuations in claims backlogs; unforeseen increases in the costs of the services; the occurrence of catastrophes; regulatory changes; and changes in benefit plan design, the Company&#8217;s profitability could decline. Moreover, costs of providing oncology, cardiology, radiology, musculoskeletal, physical medicine, genetics and other specialties are very hard to predict, in part as a result of rapidly changing utilization of new and existing drugs and changing diagnostic and therapeutic protocols. The competitive environment for New Century Health&#8217;s and NIA&#8217;s performance-based products could result in pricing pressures which could cause New Century Health or NIA to reduce their respective rates. In addition, customer demands or expectations as to margin levels could cause New Century Health or NIA to reduce their respective rates. A reduction in performance-based contract rates which are not accompanied by a reduction in covered services or expected underlying care trend could result in a decrease of New Century Health&#8217;s or NIA&#8217;s operating margins.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">If we fail to effectively manage our growth and cost structure, our business and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded our operations significantly since our inception, organically as well as through acquisitions. If we do not effectively manage our growth and maintain an efficient cost structure as we continue to expand, the quality of our products and services could suffer. Our growth to date has increased the significant demands on our management, our operational and financial systems and infrastructure and other resources. We must also continue to improve our existing systems for operational and financial management, including our reporting systems, procedures and controls. These improvements require significant capital expenditures and place increasing demands on our management. We may not be successful in managing or expanding our operations or in maintaining adequate financial and operating systems and controls. If we do not successfully manage these processes, including the timely processing of claims on behalf of our partners, our business and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Public health emergencies or outbreaks of epidemics, pandemics, or contagious diseases such as the COVID-19 pandemic have adversely affected, and could in the future, adversely affect our business and the business of our customers and suppliers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could significantly disrupt or prevent us from operating our business in the ordinary course for an extended period of time, and thereby, and/or along with any associated economic and/or social instability or distress, have a material adverse impact on our results of operations, cash flows and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, due to the nature of the services we provide, market dynamics in our end markets and with our significant customers, our operations have not been materially affected by the ongoing global COVID-19 pandemic and the resulting volatility and uncertainty it </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has caused in the U.S. and international markets. The extent to which COVID-19 ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Factors that may determine the severity of the impact include the scope, severity and duration of the pandemic, including the resurgence of COVID-19 cases due to more contagious variants emerging such as Omicron, employee mobility and productivity and actions to contain COVID-19 or treat its impact (including federal, state and local directives to remain at home or forced business closures and the effectiveness of vaccines), among others. A prolonged economic downturn or recession resulting from the public health emergencies, outbreak of epidemics, pandemics, or contagious diseases such as the COVID-19 pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations. The Biden administration has announced that the public health emergency that was declared in connection with the COVID-19 pandemic will expire on May 11, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the severity of the COVID-19 pandemic recently appeared to be trending downward, particularly as vaccination rates increased, new variants of COVID-19 continue emerging, including the Omicron variants, spreading throughout the U.S. and globally and have caused and may continue to cause significant disruptions. The global economy, our markets and our business have been, and may continue to be, materially and adversely affected by COVID-19. Though availability of vaccines and reopening of state and local economies has improved the outlook for recovery from COVID-19's impacts, the impact of new, more contagious or lethal variants that may emerge, and the effectiveness of COVID-19 vaccines against new variants and the related responses by governments, including reinstated government-imposed lockdowns or other measures, cannot be predicted at this time. Both the health and economic aspects of the COVID-19 pandemic remain highly fluid and the future course of each is uncertain.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted and may impact our business, financial condition, cash flows, or results of operations in a number of ways, including the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state Medicaid agencies may experience budget pressures as a result of the pandemic which could negatively impact payments to certain of our Medicaid health plan customers and potentially cause us to incur additional bad debt expense;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the pandemic on certain partners could result in delayed or reduced payments to us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">as our employees and our partners&#8217; employees work from home and access our system remotely, we may be subject to heightened security and privacy risks, including the risks of cyberattacks and privacy incidents;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">volatility in the capital markets could have a negative impact on our ability to access those markets on acceptable terms, or at all;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any benefits to our business as a result of increased Medicaid membership or lower utilization may not be sustained in or through future periods; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased Medicaid membership as a result of Medicaid redeterminations in 2023 may reduce certain of our partners&#8217; revenues, which could result in reduced payments to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inherent uncertainty surrounding COVID-19, due in part to rapidly changing governmental directives, public health challenges and progress, and market reactions thereto, also makes it more challenging for our management to estimate the potential impact and the future performance of our business. We cannot predict the ultimate impact of the COVID-19 pandemic, but it could materially adversely affect our business, including our financial position, results of operations and/or cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our offshore support and professional services may prove difficult to manage or may not allow us to realize our cost reduction goals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use certain offshore resources to provide certain support and professional services, which requires technical and logistical coordination. If we are unable to maintain acceptable standards of quality in support and professional services, our attempts to reduce costs and drive growth through margin improvements in technical support and professional services may be negatively impacted, which would adversely affect our results of operations. Our offshore resources, and their ability to provide support and professional services to our domestic operations, are subject to domestic regulation at the federal, state and local levels. In certain cases, those regulations restrict or prohibit us from using our offshore resources. As a result, we may not be able to reduce costs for our domestic operations or fully realize our margin improvement goals, which could adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends largely upon the continued services of our key executive officers and recruitment of additional highly-skilled employees. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. Hiring executives with needed skills or the replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives. In addition, competition for qualified talent in our industry is intense, particularly in the last several years. There has been a dramatic increase in workers leaving their positions throughout our industry that is being referred to as </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the &#8220;great resignation,&#8221; and the market to build, retain and replace talent has become even more highly competitive. Many of the companies with which we compete for personnel have greater financial and other resources than we do. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced and may continue to face difficulties attracting, hiring and retaining highly-skilled personnel with appropriate qualifications and may not be able to fill positions. To attract top talent, we have had to offer, and believe we will need to continue to offer, competitive compensation and benefits packages before we can validate the productivity of those employees. We have increased, and expect to continue to increase, our employee compensation levels in response to our competition, as necessary. In addition, the pressures of inflation have increased our costs of labor and may continue to do so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe our corporate culture has been a key contributor to our success to date. With many of our employees working remotely, we may find it difficult to maintain important aspects of our culture, which could negatively affect our ability to retain and recruit personnel who are essential to our future success and could ultimately have a negative impact on our business and our ability to execute on our strategy. In order to successfully expand our business, we must effectively recruit, integrate and motivate new and retain existing employees, while maintaining the beneficial aspects of our corporate culture. All of our employees are &#8220;at-will&#8221; employees, and their employment can be terminated by us or them at any time, for any reason and without notice. We may not be able to hire new employees quickly enough to meet our needs. If we fail to effectively manage our hiring needs and successfully integrate new employees, our efficiency and ability to meet our forecasts and our employee morale, productivity and retention could suffer, and our business and results of operations could be harmed. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have recorded a significant amount of goodwill, and we may never realize the full value of our intangible assets, causing us to record impairments that may negatively affect our results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units. Our total assets include substantial goodwill. As of December&#160;31, 2022, we had $722.8 million recorded as goodwill on our balance sheet. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our annual goodwill impairment test is conducted annually on October 31, we have processes in place to monitor for interim triggering events. Under GAAP, we review our goodwill for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our goodwill may not be recoverable include macroeconomic conditions, industry and market considerations, our overall financial performance including an analysis of our current and projected cash flows, revenue and earnings, a sustained decrease in our share price and other relevant entity-specific events including changes in strategy, customers or litigation. A detailed discussion of our impairment testing is included in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 9.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an impairment charge of $215.1 million during the three months ended June 30, 2020, as a result of the Kentucky Cabinet for Health and Family Services announcing that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period. When other indications of goodwill impairment exist, we may be required to recognize additional impairments in the future as a result of market conditions or other factors related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may need to obtain additional financing which may not be available or, if it is available, may result in a reduction in the ownership of our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional funds in order to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">finance unanticipated working capital requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop or enhance our technological infrastructure and our existing products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund strategic relationships, including joint ventures and co-investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund additional implementation engagements; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire complementary businesses, technologies, products or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on terms favorable to us, or at all. If adequate funds are unavailable or are unavailable on acceptable terms, our ability to fund our expansion strategy, take advantage of unanticipated opportunities, develop or enhance technology or services or otherwise respond to competitive pressures could be significantly limited. If we raise additional funds by issuing equity or convertible debt securities, the ownership of our then-existing stockholders may be reduced, and holders of these securities may have rights, preferences or privileges senior to those of our then-existing stockholders. In addition, any indebtedness we incur and restrictive covenants contained in the agreements related thereto could:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make it difficult for us to satisfy our obligations, including interest payments on any debt obligations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our ability to obtain additional financing to operate our business;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to dedicate a substantial portion of our cash flow to payments on our debt, reducing our ability to use our cash flow to fund capital expenditures and working capital and other general operational requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our flexibility to plan for and react to changes in our business and the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">place us at a competitive disadvantage relative to our competitors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our ability to pursue acquisitions; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any one of these events could cause a significant decrease in our liquidity and impair our ability to pay amounts due on any indebtedness, and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have experienced net losses in the past and we may not achieve profitability in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in the past and our operating expenses may increase in the future as we continue to invest to grow our business and build relationships with partners, develop our platforms and develop new solutions. These efforts may prove to be more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. In addition, as we continue to increase our partner base, we could incur increased losses due to mis-forecasted underwriting in performance-based contracts or because significant costs associated with entering into partner agreements are generally incurred upfront, while revenue under certain of our partner agreements is recognized each period in the month in which the services are delivered. As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations. We may also fail to improve the gross margins of our business as anticipated. If we are unable to effectively manage these risks and difficulties as we encounter them, our business, financial condition and results of operations may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations in the future, including potential claims against us by our partners, with or without merit. For example, on August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934. Although we have settled this action, some of these matters and claims may result in significant defense costs and potentially significant judgments against us, some of which we are not, or cannot be, insured against. We generally intend to defend ourselves vigorously; however, we cannot be certain of the ultimate outcomes of any claims or other matters that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments or settlements, which, if uninsured, or if the fines, judgments and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby having a material adverse effect on our business, financial condition, results of operations, cash flow and per share trading price of our Class A common stock. Certain litigation, proceedings, government inquiries, reviews, audits or investigations or the resolution of such matters may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured and adversely impact our ability to attract directors and officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We typically incur significant upfront costs in our partner relationships, and if we are unable to develop or grow these partner relationships over time, we are unlikely to recover these costs and our operating results may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We devote significant resources to establish relationships with our partners. Some of our partners undertake a significant and prolonged evaluation process, often to determine whether our products and services meet their unique health system needs, which has in the past resulted in extended periods of time to establish a partner relationship. Our efforts involve educating our partners about the use, technical capabilities and benefits of our products and services. Accordingly, our operating results will depend in substantial part on our ability to deliver a successful partner experience and persuade our partners to grow their relationship with us over time. There is no guarantee that we will be able to successfully convert a customer of our transformation services into a partner of our platform and operations services. If we are unable to sell additional products and services to existing partners, enter into and maintain favorable relationships with new partners or sufficiently grow our partners&#8217; lives on platform, it could have a material adverse effect on our business, financial condition and results of operations. As we grow, our customer acquisition costs could outpace our build-up of recurring revenue, and we may be unable to reduce our total operating costs through economies of scale such that we are unable to achieve profitability. For example, some of our partnerships require significant upfront investment including, in the case of new markets, investments in infrastructure to meet readiness and operating requirements which have outpaced our revenue growth. Under the ASC 606 revenue standard, certain set up costs we incur during the implementation phase may be deferred into the P&amp;O phase, potentially along with associated revenues. If the economics of a partnership change such that we are unlikely to fully recover those costs, we may be required to write off a portion or all of those deferred costs and revenues and our operating results may suffer. In </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, we estimate the costs and timing for completing the transformation phase of relevant partner relationships. These estimates reflect our best judgment. Any increased or unexpected costs or unanticipated delays, including delays caused by factors outside our control, could cause our operating results to suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we do not continue to attract new partners and successfully capture new opportunities, we may not achieve our financial projections, and our results of operations would be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to grow our business, we must continually attract new partners and successfully capture new opportunities. Our ability to do so depends in large part on the success of our sales and marketing efforts. Potential partners may seek out other options. Therefore, we must demonstrate that our products and services provide a viable solution for potential partners. If we fail to provide high-quality solutions and convince individual partners of our value proposition, we may not be able to retain existing partners or attract new partners. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of the market for our products and services due in part to the rapidly evolving nature of the health care and technology industries and the substantial resources available to our existing and potential competitors. If the market for our products and services declines or grows more slowly than we expect, if we fail to successfully convert new growth opportunities or if the number of individual partners that use our solutions declines or fails to increase as we expect, our revenue, results of operations, financial condition, business and prospects could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As we enter into an increasing number and variety of risk sharing arrangements with partners, our revenues and profitability could be limited and negatively impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate certain risk sharing arrangements as part of our contractual arrangements with certain partners, and we expect to enter an increasing number and variety of risk sharing arrangements in the future. As an example, as part of our strategy to support certain partners, we entered into upside and downside risk-sharing arrangements. Through our specialty care management services, we take on members from payers through performance-based arrangements where we assume risks related to pricing of contracts. We may incur losses under these arrangements if we are unable to adjust our rates if faced with increased costs related to patient care or pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the market evolves, we expect to engage in similar and new risk sharing strategies with our partners. As of December 31, 2022, the Company had approximately $10.9 million of restricted cash and restricted investments related to risk-sharing arrangements. These arrangements have included and may include provision of letters of credit, loans, reinsurance arrangements, equity investments and other extensions of capital, where we are and may be at risk of not recovering all or a portion of any such loan or other extension of capital. These and any other potential risk sharing arrangements could limit and negatively impact our revenue, results of operations, financial condition, business and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our failure to agree on satisfactory risk sharing solutions with potential partners could negatively impact our ability to attract new partners. We may also be required to make additional capital contributions as we invest and enter into new joint ventures and strategic alliances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted and our business would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our estimates and forecasts relating to the size and expected growth of the markets for our services may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the market opportunities for our services are based on the assumption that the strategic approaches we offer will be attractive to potential partners. Potential partners may pursue different strategic options, or none at all. In addition, our assumptions could be impacted by changes to health care laws and regulations. If our assumptions prove inaccurate, our business, financial condition and results of operations could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing partners and to our ability to attract new partners. The promotion of our brands may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our partners, or any adverse publicity or litigation involving or surrounding the Company or one of our joint venture partners, investors or strategic alliance partners could make it substantially more difficult for us to attract new partners. Similarly, because our existing partners often act as references for us with prospective new partners, any existing partner that questions the quality of our work or that of our employees could impair our ability to secure additional new partners. Therefore, financial adversity of our partners&#8217; affiliated health plans may adversely affect our reputation. In addition, negative publicity resulting from any adverse government payer audit could injure our reputation. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with partners, which would harm our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many health care industry participants and payers are consolidating to create larger and more integrated health care delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the health care industry in the future. As consolidation accelerates, the economies of scale of our partners&#8217; organizations may grow. If a partner experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as health care providers consolidate to create larger and more integrated health care delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Consolidation may also result in the acquisition or future development by our partners of products and services that compete with our products and services. Finally, if any of our partners were to be acquired or otherwise change ownership, we cannot assure you that the new owner would not seek to renegotiate or terminate their agreements with us. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete on the basis of several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. Some of our competitors are more established, benefit from greater brand recognition, have larger client bases and have substantially greater financial, technical and marketing resources. The entrance or expansion of these larger companies in the managed healthcare industry (including our customers who have in-sourced or who may choose to in-source healthcare services) could increase the competitive pressures we face and could limit our ability to maintain or increase our rates. If this happens, our profitability could be adversely affected. In addition, if we do not adequately respond to these competitive pressures, it could cause us to be unable to maintain our current contracts or obtain new contracts. Other competitors have proprietary technology that differentiates their product and service offerings from ours. Our competitors are constantly developing products and services that may become more efficient or appealing to our existing partners and potential partners. Additionally, some health care information technology providers have begun to incorporate enhanced analytical tools and functionality into their core product and service offerings used by health care providers. As a result of these competitive advantages, our competitors and potential competitors may be able to respond more quickly to market forces, undertake more extensive marketing campaigns for their brands, products and services and make more attractive offers to our existing partners and potential partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete on the basis of price. We are subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of health care industry participants, practices of managed care organizations, government action and financial stress experienced by our partners. If our pricing experiences significant downward pressure, our business will be less profitable and our results of operations will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we will be able to retain our current partners or expand our partner base in this competitive environment. If we do not retain current partners or expand our partner base, or if we have to renegotiate existing contracts, our business, financial condition and results of operations will be harmed. Moreover, we expect that competition will continue to increase as a result of consolidation in both the health care information technology and health care industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our offerings could be subject to audits by CMS and other governmental payers and whistleblower claims under the False Claims Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support provider-sponsored health plans with Medicare Advantage, Medicaid and exchange products, as well as health systems and physician groups participating in payer-delegated risk arrangements or in the CMS Next Generation ACO Model. We anticipate that CMS and other governmental payers will continue to review and audit the results of our services including risk adjustment offerings, with a focus on identifying possible false claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, aspects of our review process and coding procedures could be subject to claims under the False Claims Act or Anti-Kickback Statute. Negative results of any such audit or claim could have a material adverse effect on our business, financial condition, results of operations or prospects and could damage our reputation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusivity and right of first refusal clauses in some of our partner and founder contracts may prohibit us from partnering with certain other providers in the future, and as a result may limit our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partner and founder contracts include exclusivity and right of first refusal clauses. Any founder contracts with exclusivity, right of first refusal or other restrictive provisions may limit our ability to conduct business with certain potential partners, including competitors of our founders. For example, under the UPMC IP Agreement, if we were to conduct business with certain precluded providers, it would result in the loss of the license thereunder. Partner contracts with exclusivity or other restrictive provisions may limit our ability to partner with or provide services to other providers or purchase services from other vendors within certain time periods. These exclusivity or other restrictive provisions often apply to specific competitors of our health system partners or specific geographic areas within a particular state or an entire state. Accordingly, these exclusivity clauses may prevent us from entering into relationships with potential partners and could cause our business, financial condition and results of operations to be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a reseller, services and non-competition agreement with an affiliate of UPMC, pursuant to which we are prohibited from providing products or services to certain third parties and in certain territories. These restrictions could cause our business, financial condition and results of operations to be harmed if we found it advantageous to provide products or services to such third parties or in such territories during the restricted period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Increasing inflationary pressures and consumer costs may have a negative effect on our margins, profitability and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The broader U.S. economy has experienced higher than expected inflationary pressures throughout  2022 related to continued supply chain disruptions, labor shortages and geopolitical instability. Increasing  inflationary pressures may have a negative effect on our profit margins and earnings due to associated costs increases. Additionally, we face an increasingly competitive labor market due to sustained labor shortages in part from the COVID-19 pandemic and are subject to inflationary pressures on employee wages and salaries which may increase labor costs. Failure to retain highly skilled employees due to wage inflation could have a material adverse impact on our business, results of operations or financial condition. See the risk factor captioned &#8220;If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected.&#8221; While we are unable to predict the direction of the economy or if inflation will increase or revert to normal levels, if the current inflationary trends continue for a sustained period of time, our margins, profitability and results of operations could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Data Protection Privacy, Cybersecurity, Intellectual Property and Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to privacy and data protection laws governing the transmission, security and privacy of health information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, we are required to comply with numerous federal and state laws and regulations governing the collection, use, disclosure, storage and transmission of individually identifiable health information that we may obtain or have access to in connection with the provision of our services. These laws and regulations, including their interpretation by governmental agencies, are subject to frequent change and could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA expanded protection of the privacy and security of personal health information and required the adoption of standards for the exchange of electronic health information. Among the standards that the Department of Health and Human Services has adopted pursuant to HIPAA are standards for electronic transactions and code sets, unique identifiers for providers, employers, health plans and individuals, security, electronic signatures, privacy and enforcement. Privacy regulations under HIPAA also provide patients with rights related to understanding and controlling how their protected health information is used and disclosed. As a provider of services to entities subject to HIPAA, we are directly subject to certain provisions of the regulations as a &#8220;Business Associate.&#8221;. If we are </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to properly protect the privacy and security of protected health information entrusted to us, we could be found to have breached our contracts with our customers and be subject to investigation by the U.S. Department of Health and Human Services Office for Civil Rights (&#8220;OCR&#8221;). In the event the OCR finds that we have failed to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties that could have a material adverse effect on us. In addition, OCR performs compliance audits of Business Associates in order to proactively enforce the HIPAA privacy and security standards. OCR has become an increasingly active regulator and has signaled its intention to continue this trend. OCR has the discretion to impose penalties without being required to attempt to resolve violations through informal means; further, OCR may require companies to enter into resolution agreements and corrective action plans which impose ongoing compliance requirements. OCR enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The HITECH Act, enacted as part of the American Recovery and Reinvestment Act of 2009, also known as the &#8220;Stimulus Bill,&#8221; effective February 22, 2010, set forth health information security breach notification requirements and increased penalties for violation of HIPAA. The HITECH Act requires individual notification for all breaches, media notification of breaches for over 500 individuals and at least annual reporting of all breaches to the Department of Health and Human Services. Failure to comply with the HITECH Act could result in fines and penalties that could have a material adverse effect on us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Numerous other federal and state laws may apply that restrict the use and protect the privacy and security of individually identifiable information, as well as employee personal information. These include state medical privacy laws, state social security number protection laws and federal and state consumer protection laws. These various laws in many cases are not preempted by HIPAA and may be subject to varying interpretations by the courts and government agencies, creating complex compliance issues for us and our partners and potentially exposing us to additional expense, adverse publicity and liability, any of which could adversely affect our business.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Federal and state consumer protection laws are increasingly being applied by the FTC and states&#8217; attorneys general to regulate the collection, use, storage and disclosure of personal or individually identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is ongoing concern from privacy advocates, regulators and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws have been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous or pseudonymized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. These discussions may lead to further restrictions on the use of such information. There can be no assurance that these initiatives or future initiatives will not adversely affect our ability to access and use data or to develop or market current or future services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The security measures that we and our third-party vendors and subcontractors have in place to ensure compliance with privacy and data protection laws may not protect our facilities and systems from security breaches, acts of vandalism or theft, computer viruses, misplaced or lost data, programming and human errors or other similar events. Under the HITECH Act, as a business associate we may also be liable for privacy and security breaches and failures of our subcontractors. Even though we provide for protections through our agreements with our subcontractors, we still have limited control over their actions and practices. A breach of privacy or security of individually identifiable health information by a subcontractor may result in an enforcement action, including criminal and civil liability, against us. Our failure to comply may result in criminal and civil liability because the potential for enforcement action against business associates has increased in recent years. Enforcement actions against us could be costly and could interrupt regular operations, which may adversely affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data loss or corruption due to failures or errors in our systems or service disruptions at our data centers may adversely affect our reputation and relationships with existing partners, which could have a negative impact on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the large amount of data that we collect and manage, it is possible that hardware failures or errors in our systems could result in data loss or corruption or cause the information that we collect to be incomplete or contain inaccuracies that our partners regard as significant. Complex software such as ours may contain errors or failures that are not detected until after the software is introduced or updates and new versions are released. We continually introduce new software and updates and enhancements to our existing software. Despite testing by us, we may discover defects or errors in our software. In addition, we may encounter defects or errors in connection with the integration of software and technology we acquire. Any defects or errors could expose us to risk of liability to partners and the government and could cause delays in the introduction of new products and services, result in increased costs and diversion of development resources, require design modifications, decrease market acceptance or partner satisfaction with our products and services or cause harm to our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our partners might use our software together with products from other companies. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when our software does not cause these problems, the existence of these </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">errors might cause us to incur significant costs, divert the attention of our technical personnel from our product development efforts, impact our reputation and lead to significant partner relations problems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services involve the collection, storage and analysis of confidential information, including intellectual property and personal information of employees, health providers and others, as well as protected health information of our partners&#8217; patients. Because of the extreme sensitivity of this information, the security and privacy features of our computer, network, and communications systems infrastructure are very important. In certain cases, we provide such information to third parties, for example, to the service providers who provide hosting services for our technology platform, and we may be unable to control the use of such information or the security and privacy protections employed by such third parties. We may be required to expend significant capital and other resources to protect against security breaches and/or privacy incidents or to alleviate problems caused by security breaches and/or privacy incidents. Despite our implementation of security and privacy measures designed to help ensure data security and compliance with applicable laws and rules, our facilities and systems, and those of our third-party providers, are vulnerable to threats. These threats could include cyber-attacks, the use of harmful malware or ransomware, security breaches, acts of vandalism or theft (including by employees), computer viruses, misplaced or lost data, programming and/or human errors, power outages, protected health information leakage from implementing third-party technology to process and share data, hardware failures or other similar events. Furthermore, our increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic, has heightened these cybersecurity and privacy risks, including risks from cyber-attacks such as phishing, spam emails, hacking, social engineering, and malicious software including harmful malware and ransomware. If an actual or perceived breach of our security occurs, or if we are unable to effectively resolve such breaches in a timely manner, the market perception of the effectiveness of our security and privacy measures could be harmed and we could lose sales and partners, which could have a material adverse effect on our business, operations, and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cyber-attack that bypasses our, or our third-party providers&#8217;, security systems successfully could require us to expend significant resources to remediate any damage, and prevent future occurrences, interrupt our operations, damage our reputation and our relationship with our partners, expose us or other third parties to a risk of loss or misuse of confidential information, reduce demand for our products and services or subject us to significant liability through litigation as well as regulatory action. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks continue to evolve in sophistication and volume and may remain undetected for an extended period. In addition, techniques used to obtain unauthorized access to information or to sabotage information technology systems change frequently. We have seen, and will continue to see, industry-wide vulnerabilities, such as the Log4j vulnerability reported in December 2021, which could in the future affect our or other parties&#8217; systems. We expect to continue to experience such vulnerabilities in the future. The costs of attempting to protect against cybersecurity risks and the costs of responding to cyber-attacks are significant. This could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New data security and privacy laws and regulations are being implemented rapidly and are evolving, and we may not be able to timely comply with such requirements, and such requirements may not be compatible with our current processes. For example, regulators in the United States and globally are also inquiring more about and imposing greater monetary fines for privacy violations. In the last year, the FTC has announced that it will begin enforcing the Health Breach Notification Rule, and entered into a consent order with a $1.5 million fine. The FTC and many states (including California, Utah, Colorado, Virginia and Connecticut) have specific requirements for collecting and processing certain data including data minimization, data de-identification, opt out rights, deletion and sharing. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could subject us to liability for non-compliance. Various events described above have occurred in the past and may occur in the future. Although impacts of past events have been immaterial, the impacts of such events in the future may be material.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to obtain, maintain and enforce intellectual property protection for our technology and products or if the scope of our intellectual property protection is not sufficiently broad, others may be able to develop and commercialize technology and products substantially similar to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on proprietary technology and content, including software, databases, confidential information and know-how, the protection of which is crucial to the success of our business. We rely on a combination of trademark, trade-secret and copyright laws and confidentiality procedures and contractual provisions to protect our intellectual property rights in our proprietary technology and content. We may, over time, increase our investment in protecting our intellectual property through additional trademark, patent and other intellectual property filings that could be expensive and time-consuming. Effective trademark, trade-secret and copyright protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defending our rights. These measures, however, may not be sufficient to offer us meaningful protection. If we are unable to protect our intellectual property and other proprietary rights, our competitive position and our business could be harmed, as third parties may be able to commercialize and use technologies and software products that are substantially the same as ours without incurring the development and licensing costs that we have incurred. Any of our owned or licensed intellectual property rights could be challenged, invalidated, circumvented, infringed or misappropriated, our trade secrets and other confidential information could be disclosed in an unauthorized manner to third parties, or our intellectual property rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide us with competitive advantages, which could result in costly redesign efforts, discontinuance of certain offerings or other competitive harm.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors&#8217; products and services, and may in the future seek to enforce our rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent infringement or misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our technology and products. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our products and services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be required to protect our proprietary technology and content in an increasing number of jurisdictions, a process that is expensive and may not be successful, or which we may not pursue in every location. In addition, effective intellectual property protection may not be available to us in every country, and the laws of some foreign countries may not be as protective of intellectual property rights as those in the United States. Additional uncertainty may result from changes to intellectual property legislation enacted in the United States and elsewhere, and from interpretations of intellectual property laws by applicable courts and agencies. Accordingly, despite our efforts, we may be unable to obtain and maintain the intellectual property rights necessary to provide us with a competitive advantage. Our failure to obtain, maintain and enforce our intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered or unregistered trademarks or trade names that we own or license may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to commercialize our technologies or products in certain relevant countries. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends on our ability to develop and commercialize our services and use our proprietary technology without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. As the market for health care in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our partners, our licensees or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties. Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. It may be necessary for us to initiate litigation to defend ourselves in order to determine the scope, enforceability and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such claims can be time-consuming, divert management&#8217;s attention and financial resources and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our products or technology, obtain licenses, modify our services and technology while we develop non-infringing substitutes or incur substantial damages, settlement costs or face a temporary </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or permanent injunction prohibiting us from marketing or providing the affected products and services. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services. We may also have to redesign our products or services so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology and products may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology on reasonable terms or at all, or obtain similar technology from another source, our revenue and earnings could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have been and may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. We are not currently subject to any claims from third parties asserting infringement of their intellectual property rights. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our Class A common stock. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to offer our services and subject us to possible litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary information, the value of our technology and products could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our trade secrets, know-how and other proprietary information adequately. Although we use reasonable efforts to protect this proprietary information and technology, our employees, consultants and other parties may unintentionally or willfully disclose our information or technology to competitors. Enforcing a claim that a third-party illegally obtained and is using any of our proprietary information or technology is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets, know-how and other proprietary information. We rely, in part, on non-disclosure, confidentiality and invention assignment agreements with our employees, consultants and other parties to protect our trade secrets, know-how and other intellectual property and proprietary information. These agreements may not be self-executing, or they may be breached and we may not have adequate remedies for such breach. Moreover, third parties may independently develop similar or equivalent proprietary information or otherwise gain access to our trade secrets, know-how and other proprietary information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on certain technologies that are licensed to us. We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from developing and/or commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements under which we are granted rights to intellectual property that is important to our business, and we expect that we may need to enter into additional license agreements in the future. We are party to an intellectual property and development services license agreement between Evolent and UPMC, or the UPMC IP Agreement, and a technology license agreement with UPMC, or the UPMC Technology Agreement. Under the UPMC IP Agreement, certain of UPMC&#8217;s proprietary analytics models and know-how are licensed to Evolent on a nonexclusive basis from UPMC; pursuant to the UPMC Technology Agreement, UPMC&#8217;s proprietary technology platform, associated know-how and the Identifi&#174; trademark are licensed to Evolent on an irrevocable, non-exclusive basis from UPMC; in each case, subject to certain ongoing territorial, time and use </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions. Evolent&#8217;s rights to use these technologies and know-how and employ the software claimed in the licensed technologies are subject to the continuation of and our compliance with the terms of those licenses. Our existing license agreements impose, and we expect that future license agreements will impose on us, various exclusivity obligations. If we fail to comply with our obligations under these agreements, the applicable licensor may have the right to terminate our license, in which case we may not be able to develop or commercialize the products or technologies covered by the license.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations with respect to the use of the licensed technology in relation to our services and technologies, and which activities satisfy those obligations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether our activities are in compliance with the restrictions placed upon our rights to use the licensed technology by our licensors; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to obtain equivalent replacement licensing arrangements or to successfully develop and commercialize the affected products and technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we do not have control over the prosecution, maintenance or enforcement of the intellectual property rights that we license, and may not have sufficient ability to consult and input into the prosecution and maintenance process with respect to such intellectual property, and our licensors may fail to take the steps we feel are necessary or desirable in order to obtain, maintain and enforce the licensed intellectual property rights and, as a result, our ability to retain our competitive advantage with respect to our products and technologies may be materially affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon licenses from third parties for some of the technology and data used in our applications, and for some of the technology platforms upon which these applications are built and operate, including under the UPMC IP Agreement and the UPMC Technology Agreement. We expect that we may need to obtain additional licenses from third parties in the future in connection with the development of our products and services. In addition, we obtain a portion of the data that we use from government entities, public records and from our partners for specific partner engagements. We believe that we have all rights necessary to use the data that is incorporated into our products and services. However, we cannot assure you that our licenses for information will allow us to use that information for all potential or contemplated applications and products. In addition, certain of our products depend on maintaining our data and analytics platform, which is populated with data disclosed to us by our partners with their consent. If these partners revoke their consent for us to maintain, use, de-identify and share this data, consistent with applicable law, our data assets could be degraded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, data providers could withdraw their data from us or restrict our usage for any reason, including if there is a competitive reason to do so, if legislation is passed restricting the use of the data or if judicial interpretations are issued restricting use of the data that we currently use in our products and services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide products and services to our partners would be materially adversely impacted, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also integrate into our proprietary applications and use third-party software to maintain and enhance, among other things, content generation and delivery, and to support our technology infrastructure. Some of this software is proprietary and some is open source software. These technologies may not be available to us in the future on commercially reasonable terms or at all and could be difficult to replace once integrated into our own proprietary applications. Most of these licenses can be renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with partners, adversely affecting our brand and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to deliver our products and services, particularly our cloud-based solutions, is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network connection with the necessary speed, data capacity and security for providing reliable Internet access and services and reliable telephone and facsimile services. As a result, our information systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information technology, emerging cybersecurity risks and threats, evolving industry and regulatory standards and changing preferences of our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services are designed to operate without interruption in accordance with our service level commitments. However, we have experienced limited interruptions in these systems in the past, including server failures that temporarily slow down the performance of our services, and we may experience more significant interruptions in the future. We rely on internal systems as well as third-party suppliers, including bandwidth and telecommunications equipment providers, to provide our services. We do not maintain redundant systems or facilities for some of these services. Interruptions in these systems, whether due to system failures, computer viruses, physical or electronic break-ins or other catastrophic events, could affect the security or availability of our services and prevent or inhibit the ability of our partners to access our services. These systems may be at greater risk of interruption as a result of increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could result in substantial costs to remedy those problems or negatively impact our relationship with our partners, our business, results of operations and financial condition. To operate without interruption, both we and our service providers must guard against:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">damage from fire, power loss and other natural disasters;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">telecommunications failures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">software and hardware errors, failures and crashes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">security breaches, computer viruses and similar disruptive problems; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other potential interruptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption in the network access, telecommunications or co-location services provided by third-party providers or any failure of or by third-party providers&#8217; systems or our own systems to handle current or higher volume of use could significantly harm our business. We exercise limited control over our third-party suppliers, which increases our vulnerability to problems with services they provide. Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with partners and adversely affect our business and could expose us to third-party liabilities. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reliability and performance of our Internet connection may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party vendors to host and maintain our technology platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party vendors to host and maintain our technology platform, including Identifi&#174;. Our ability to offer our services and operate our business is therefore dependent on maintaining our relationships with third-party vendors and entering into new relationships to meet the changing needs of our business. Any deterioration in our relationships with such vendors or our failure to enter into agreements with vendors in the future could harm our business, results of operations and financial condition. Despite </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precautions taken at our vendors&#8217; facilities, the occurrence of a natural disaster, a decision to close the facilities without adequate notice or other unanticipated problems, including relating to the COVID-19 pandemic, could result in lengthy interruptions in our service. These service interruption events could cause our platform to be unavailable to our partners and impair our ability to deliver services and to manage our relationships with new and existing partners, which in turn could materially affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our vendors are unable or unwilling to provide the services necessary to support our business, or if our agreements with such vendors are terminated, our operations could be significantly disrupted. Certain vendor agreements may be unilaterally terminated by the licensor for convenience, and if such agreements are terminated, we may not be able to enter into similar relationships in the future on reasonable terms or at all. We may also incur substantial costs, delays and disruptions to our business in transitioning such services to ourselves or other third-party vendors. In addition, third-party vendors may not be able to provide the services required in order to meet the changing needs of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_187"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to internal control over financial reporting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we identify material weaknesses in the future, we and our auditor may conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements, any of which could adversely impact our investors&#8217; confidence and our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting includes policies and procedures that provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to design and implement an effective control environment may not be sufficient to identify or prevent future material weaknesses or significant deficiencies from occurring. Any newly identified material weakness could result in a misstatement of our financial statements or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected. A control system, no matter how well designed and operated, can provide only reasonable assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and all instances of fraud will be detected. In addition, if we identify future material weaknesses in our internal controls over financial reporting or if we are unable to comply with the demands that are placed upon us as a public company, including the requirements of Section 404 of the Sarbanes-Oxley Act, in a timely manner, we may be unable to accurately report our financial results, or report them within the timeframes required by the SEC. We also could become subject to investigations by the NYSE, the SEC or other regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our continuing growth and expansion in dispersed markets, such as our acquisitions of IPG during the third quarter of 2022, NIA in the first quarter of 2023, and other businesses we may acquire in the future, may place significant additional pressure on our system of internal control over financial reporting and require us to update our internal control over financial reporting to integrate such acquisitions.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_184"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to our structure </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future, and these amounts are expected to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an exchange agreement we entered into at the time of our IPO, in connection with our implementation of an &#8220;Up-C&#8221; structure (which was collapsed on December 26, 2019), we granted TPG, The Advisory Board and Ptolemy Capital (together, the &#8220;Investor Stockholders&#8221;) an exchange right that allowed for receipt of newly-issued shares of the Company&#8217;s Class A common stock in exchange (a &#8220;Class B Exchange&#8221;) for an equal number of shares of the Company&#8217;s Class B common stock (which were subsequently canceled) and an equal number of Evolent Health LLC&#8217;s Class B common units. Class B common units received by the Company from relevant Investor Stockholders were simultaneously exchanged for an equivalent number of Class A common units of Evolent Health LLC, and Evolent Health LLC cancelled the Class B common units it received in the Class B Exchanges, resulting in an increase in the Company&#8217;s economic interest in Evolent Health LLC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, all of the Class B common units held by the Investor Stockholders and certain other stockholders had been exchanged (together with an equal number of shares) for our Class A common stock. These exchanges resulted in increases in the tax basis of our share of the assets of Evolent Health LLC that otherwise would not have been available to the Company. In addition, we expect that certain net operating losses (&#8220;NOLs&#8221;) will be available to us as a result of the transactions as described in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 15 - &#8220;Tax Receivables Agreement.&#8221; These increases in tax basis and NOLs may reduce the amount of tax that we may otherwise be required to pay in the future, although the Internal Revenue Service (&#8220;IRS&#8221;) may challenge all or a part of the tax basis increases and NOLs, and a court could sustain such a challenge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the TRA, related to the tax basis step-up of the assets of Evolent Health LLC and certain NOLs of the former members of Evolent Health LLC, with the Investor Stockholders and certain of our other investors (the &#8220;TRA Holders&#8221;). Pursuant to the TRA, we will pay the TRA Holders 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of increases in tax basis resulting from exchanges of Class B common units for shares of our Class A common stock (calculated assuming that any post-IPO transfer of Class B common units (other than the exchanges) had not occurred) as well as certain other benefits attributable to payments under the TRA itself.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRA also requires us to pay 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings and an affiliate of TPG attributable to periods prior to our IPO and the deduction of any imputed interest attributable to our payment obligations under the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments that we make under the TRA could be substantial. Assuming no material changes in relevant tax law and based on our current operating plan and other assumptions, including the tax basis of our assets as of the date of the Offering Reorganization and the tax basis step-ups resulting from each completed exchange, we estimate that the total amount that we would be required to pay under the TRA could be approximately $113.1 million. This estimated amount includes approximately $18.1 million of potential future payments under the TRA related to the future utilization of the pre-IPO NOLs described above and approximately $95.0 million of potential future payments related to the tax basis step-up of the assets of Evolent Health LLC in connection with the exchanges that occurred in connection with our completed secondary offerings and private sales. The actual amount we will be required to pay under the TRA may be materially greater than these hypothetical amounts, as potential future payments will vary as a consequence of our tax position, the relevant tax basis analysis, our ability to generate sufficient future taxable income in order to be able to benefit from the aforementioned tax attributes, the character and timing of our taxable income and the income tax rates applicable at the time we realize cash savings attributable to our recognition and utilization of the aforementioned tax attributes. Payments under the TRA are not conditioned on our existing investors&#8217; continued ownership of any of our equity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will not be reimbursed for any payments made under the TRA in the event that any tax benefits are disallowed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the IRS successfully challenges the tax basis increases resulting from the Class B Exchanges or the existence or amount of the pre-IPO NOLs at any point in the future after payments are made under the TRA, we will not be reimbursed for any payments we had made under the TRA (although future payments under the TRA, if any, would be netted against any unreimbursed payments to reflect the result of any such successful challenge by the IRS). As a result, in certain circumstances, we could be required to make payments under the TRA in excess of our cash tax savings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units for our Class A common stock or from the utilization of NOLs previously held by Evolent Health Holdings and an affiliate of TPG and from payments made under the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to realize the tax benefits that we expect to be available as a result of the increases in tax basis created by the Class B Exchanges and by the payments made pursuant to the TRA, and our ability to utilize the pre-IPO NOLs of Evolent Health Holdings and an affiliate of TPG and the interest deductions imputed under the TRA all depend on a number of assumptions, including that we earn sufficient taxable income each year during the period over which such deductions are available and that there are no adverse changes in applicable law or regulations. If our actual taxable income is insufficient or there are adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our cash flows and stockholders&#8217; equity could be negatively affected. Please refer to the discussion in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 15 - Tax Receivables Agreement&#8221; for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In certain cases, payments by us under the TRA may be accelerated or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRA provides that upon certain changes of control, or if, at any time, we elect an early termination of the TRA or are in material breach of our obligations under the TRA, we would be required to make an immediate payment equal to the present value of the anticipated future tax benefits to certain current or former shareholders. Such payment would be based on certain valuation assumptions and deemed events set forth in the TRA, including the assumption that we have sufficient taxable income to fully utilize </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such tax benefits. The benefits would be payable even though, in certain circumstances, no tax basis step-up deductions and no NOLs are actually used at the time of the accelerated payment under the TRA. Accordingly, payments under the TRA may be made years in advance of the actual realization, if any, of the anticipated future tax benefits and may be significantly greater than the benefits we realize in respect of the tax attributes subject to the TRA. In these situations, our obligations under the TRA could have a substantial negative impact on our liquidity. We may not be able to finance our obligations under the TRA and any indebtedness we incur may limit our subsidiaries&#8217; ability to make distributions to us to pay these obligations. In addition, our obligations under the TRA could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control that could be in the best interests of holders of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The agreements between us and certain of our pre-IPO investors were made in the context of an affiliated relationship and may contain different terms than comparable agreements with unaffiliated third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual agreements that we have with certain of our pre-IPO investors were negotiated in the context of an affiliated relationship in which representatives of such pre-IPO investors and their affiliates comprised a significant portion of our board of directors. As a result, the financial provisions, and the other terms of these agreements, such as covenants, contractual obligations on our part and on the part of such pre-IPO investors and termination and default provisions, may be less favorable to us than terms that we might have obtained in negotiations with unaffiliated third parties in similar circumstances, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Relating to Indebtedness and our Series A Preferred Stock</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;2025 Notes&#8221;). In the event the conditional conversion feature of the 2025 Notes is triggered, holders of such notes will be entitled to convert such notes at any time during specified periods at their option. If one or more holders elect to convert their 2025 Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our Class A common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2025 Notes, as applicable, as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are exposed to interest rate risk under the Credit Agreement and the terms of our Series A Preferred Stock, which could cause the Company&#8217;s debt service obligations to increase significantly.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from changes in interest rates. Interest under all Credit Facilities under our Credit Agreement (including the Acquisition Facilities) and under the terms of our Series A Preferred Stock is based on the Secured Overnight Funding Rate (&#8220;SOFR&#8221;), a floating rate, subject to a minimum rate. The Federal Reserve has raised, and may in the future further raise, interest rates to combat the effects of recent high inflation. Any further increase in the SOFR will increase the Company&#8217;s debt service obligations, which could have a negative impact on the Company&#8217;s cash flow, financial position or operating results, including cash available for servicing the Company&#8217;s indebtedness, or result in increased borrowing costs in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our debt following the NIA acquisition is significant and could adversely affect our business and our ability to meet our obligations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have $421.8 million of principal amount of indebtedness outstanding as of December 31, 2022. In connection with the NIA acquisition, we borrowed an additional $25.0 million under the Priority ABL Incremental Facility and $240.0 million under the Initial Term Loan Incremental Facility.  In addition, we sold 175,000 shares of our Series A Preferred Stock for $960.00 per share, resulting in gross proceeds of $168.0 million in connection with the closing of the NIA acquisition. The proceeds from the sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Initial Term Loan Incremental Facility, to finance the cash consideration payable upon the closing of the NIA acquisition and pay transaction fees and expenses.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This significant amount of debt and other cash needs could have important consequences to us, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requiring a substantial portion of our cash flow from operations to make payments on this debt, thereby limiting the cash we have available to fund future growth opportunities, such as capital expenditures and acquisitions&#894;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">restrictive covenants in our debt arrangements and the arrangements governing our Series A Preferred Stock, which could limit our operations and borrowing&#894;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the risk of a future credit ratings downgrade of our debt, increasing future debt costs and limiting the future availability of debt financing&#894;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">increasing our vulnerability to general adverse economic and industry conditions and limiting our flexibility in planning for, or reacting to, changes in our business and industry, due to the need to use our cash to service our outstanding debt and Series A Preferred Stock&#894;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">placing us at a competitive disadvantage relative to our competitors that are not as highly leveraged and that may therefore be more able to invest in their business or use their available cash to pursue other opportunities, including acquisitions&#894; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to repay all of our outstanding debt as it becomes due and satisfy obligations with respect to our Series A Preferred Stock, and we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, or at all, to refinance our debt or Series A Preferred Stock.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Servicing our debt and paying dividends on our Series A Preferred Stock requires a significant amount of cash, and we may not have sufficient cash flow from our business to service our debt and make necessary capital expenditures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest or dividends on or to refinance our indebtedness or our Series A Preferred Stock depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive to our stockholders. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our obligations and have a material adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictive covenants in our Credit Agreement and in the Investors Rights Agreement we entered into in connection with the closing of the NIA acquisition, on January 20, 2023, with the Purchasers named in Schedule I thereto (the &#8220;Investors Rights Agreement&#8221;)  may interfere with our ability to access the revolving credit facility under the Credit Agreement, or to obtain new financing or to engage in other business activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement and the Investors Rights Agreement impose significant operating and financial restrictions on us. These restrictions limit our ability and/or the ability of certain of our subsidiaries to, among other things:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur or guarantee additional debt;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur certain liens;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">merge or consolidate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">transfer or sell assets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make certain investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pay dividends and make other distributions on, or redeem or repurchase, capital stock; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into transactions with affiliates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to our Credit Agreement and Investors Rights Agreement, we are required to comply with certain financial covenants consisting of a minimum liquidity test, and a total secured leverage test. As a result of these restrictions, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that the Company will be able to maintain compliance with these covenants in the future and, if it fails to do so, that it will be able to obtain waivers from the lenders and/or amend the covenants. The Company&#8217;s failure to comply with the restrictive covenants described above as well as the terms of any future indebtedness could result in an event of default, which, if not cured or waived, could result in it being required to repay these borrowings before their due date and the lenders would be entitled to foreclose on collateral. If the Company is forced to refinance these borrowings on less favorable terms or cannot refinance these borrowings, our results of operations and financial condition could be adversely affected. In addition, we may be unable to access future borrowings under our revolving facility if we are unable to satisfy the applicable conditions precedent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to ownership of our Class A common stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We expect that our stock price will be volatile and may fluctuate or decline significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Class A common stock has been and may continue to be volatile and subject to wide price fluctuations in response to various factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic and political conditions or events;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the broader stock market in general, or in our industry in particular, including as a result of COVID-19 related impacts , inflationary pressures, and an uncertain macroeconomic environment due in part to the conflict between Russia and Ukraine;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated fluctuations in our quarterly financial reports and results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to satisfy our ongoing capital needs and unanticipated cash requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indebtedness incurred in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">introduction of new products and services by us or our competitors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business developments of our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issuance of new or changed securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of large blocks of our stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions or departures of key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">litigation and governmental investigations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These and other factors may cause the market price and demand for our Class A common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of Class A common stock, including any shares of Class A common stock they receive upon conversion of our convertible notes, and may otherwise negatively affect the liquidity of our Class A common stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. We are, and from time to time may become, subject to such litigation, and we could incur substantial costs defending a lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trading market for our Class A common stock will also be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrades our stock, or if our results of operations do not meet their expectations, our stock price could decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Series A Preferred Stock has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Class A common stock, which could adversely affect our liquidity and financial condition, and could in the future substantially dilute the ownership interest of holders of our Class A common stock. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the consummation of the NIA acquisition, we issued 175,000 shares of Series A Preferred Stock to Ares (through one or more of its funds and managed accounts). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Series A Preferred Stock ranks senior to the Company&#8217;s Class A common stock and all future series of the Company&#8217;s preferred stock with respect to dividends and distributions on liquidation. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designation) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.00% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investors Rights Agreement or the Company&#8217;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under various circumstances defined in the Certificate of Designation, (a) holders of shares of the Series A Preferred Stock may be entitled to convert such shares into shares of our Class A common stock, or (b) we may require all holders of such shares to convert such shares to shares of our Class A common stock. In addition, upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares Capital Management LLC, we will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of regular dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025. If the Company undergoes a Change of Control (as defined in the Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The share repurchase obligations could adversely affect our liquidity and reduce the amount of cash available for working capital, capital expenditures, growth opportunities, acquisitions, and other general corporate purposes. Our obligations to the holders of Series A Preferred Stock could also limit our ability to obtain additional financing and increase our borrowing costs, which could have an adverse effect on our financial condition. The preferential rights could also result in divergent interests between the holders of Series A Preferred Stock and holders of shares of our Class A common stock. Any conversion of Series A Preferred Stock into Class A common stock would dilute the ownership interest of existing holders of our Class A common stock, and any sales in the public market of the Class A common stock issuable upon such conversion could adversely affect prevailing market prices of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The market price of our Class A common stock could decline due to the large number of shares of Class A common stock issuable upon conversion of our convertible notes or the Series A Preferred Stock, or by sales or issuances of substantial amounts of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The market price of our Class A common stock could decline as a result of sales of a large number of the shares of our Class A common stock issuable upon the conversion of our convertible notes or the Series A Preferred Stock, or the perception that such conversions and sales could occur. These sales, or the possibility that these sales may occur, may also make it more difficult for us to raise additional capital by selling equity or equity-linked securities in the future, at a time and price that we deem appropriate. As of February&#160;16, 2023, 111,052,414 shares of our Class A common stock were outstanding. Up to a maximum of 13.3 million shares of our Class A common stock is reserved for issuance upon the conversion of our convertible notes and 4,375,000 million shares are reserved for issuance upon the conversion of our Series A Preferred Stock. Similarly, sales or issuances of substantial amounts of our Class A common stock in the public market by us or by our stockholders into the public market could cause the market price of our Class A common stock to decrease significantly. We issued 8,474,576 shares of our Class A common stock to Centene in connection with the closing of the NIA acquisition. Such shares are subject to lock-up obligations, subject to certain exceptions, for a fifteen-month period following the closing; provided, that Magellan Health, Inc. will be permitted to sell one-third of such shares following the nine-month anniversary of the closing of the NIA acquisition and an additional one-third of such shares following the twelve-month anniversary of the closing of the NIA acquisition. In addition, we agreed to provide Magellan Health, Inc. with registration rights. See the risk factor captioned &#8220;We have made and entered, and may in the future make and enter into acquisitions, investments, alliances and joint ventures, which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Some provisions of Delaware law, our second amended and restated certificate of incorporation, as amended and our third amended and restated by-laws and certain of our contracts may deter third parties from acquiring us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among other things, our second amended and restated certificate of incorporation, as amended, and our third amended and restated by-laws:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit stockholder action by written consent;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to increase the number of outstanding shares of capital stock, making a takeover more difficult and expensive;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that special meetings of the stockholders may be called only by or at the direction of the board of directors, the chairman of our board or the chief executive officer; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require advance notice to be given by stockholders for any stockholder proposals or director nominees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the DGCL may affect the ability of an &#8220;interested stockholder&#8221; to engage in certain business combinations, for a period of three years following the time that the stockholder becomes an &#8220;interested stockholder.&#8221; We have elected in our second amended and restated certificate of incorporation, as amended, not to be subject to Section 203 of the DGCL. Nevertheless, our second amended and restated certificate of incorporation, as amended, contains provisions that have the same effect as Section 203 of the DGCL, except that they provide that each of TPG, UPMC and The Advisory Board and their transferees will not be deemed to be &#8220;interested stockholders,&#8221; and accordingly are not subject to such restrictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions could have the effect of discouraging, delaying or preventing a transaction involving a change in control of our company or could make it more difficult for stockholders to elect directors of their choosing or to cause us to take other corporate actions that they desire. Provisions in certain of our contracts may also deter third parties from acquiring us. In addition, certain partners would have the right to terminate if we are acquired by certain competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation, as amended, and stockholders&#8217; agreement contain provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPMC and its affiliates may engage in activities similar to ours or lines of business or have an interest in the same areas of corporate opportunities as we do. Our second amended and restated certificate of incorporation, as amended, and stockholders&#8217; agreement provide that UPMC and its affiliates do not have any duty to refrain from (1) engaging, directly or indirectly, in the same or similar business activities or lines of business as us, including those business activities or lines of business deemed to be competing with us, or (2) doing business with any of our clients, customers or vendors. In the event that UPMC or any of its affiliates acquires knowledge of a potential business opportunity which may be a corporate opportunity for us, they have no duty to communicate or offer such corporate opportunity to us. Our second amended and restated certificate of incorporation, as amended, and stockholders&#8217; agreement also provide that, to the fullest extent permitted by law, UPMC and its affiliates will not be liable to us for breach of any fiduciary duty or otherwise, by reason of directing such corporate opportunity to another person, or otherwise not communicating information regarding such corporate opportunity to us, and we have waived and renounced any claim that such business opportunity constituted a corporate opportunity that should have been presented to us. These potential conflicts of interest could have a material adverse effect on our business, financial condition, results of operations or prospects if attractive business opportunities are allocated by UPMC to itself or its affiliates instead of to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation, as amended, designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation, as amended, provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the DGCL, our second amended and restated certificate of incorporation, as amended, or our third amended and restated by-laws, (d) any action to interpret, apply, enforce or determine the validity of our second amended and restated certificate of incorporation, as amended, or third amended and restated by-laws or (e) any other action asserting a claim against us that is governed by the internal affairs doctrine. We refer to each of these proceedings as a covered proceeding. In addition, our second amended and restated certificate of incorporation, as amended, provides that if any action the subject matter of which is a covered proceeding is filed in a court other than the specified Delaware courts without the approval of our board of directors, which we refer to as a foreign action, the claiming party will be deemed to have consented to (1) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (2) having service of process made upon such claiming party in any such enforcement action by service upon such claiming party&#8217;s counsel in the foreign action as agent for such claiming party. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these provisions. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our second amended and restated certificate of incorporation, as amended, inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We do not anticipate paying any cash dividends on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain our future earnings, if any, for the foreseeable future to fund the development and growth of our business. We do not intend to pay any dividends to holders of our Class A common stock. As a result, capital appreciation in the price of our Class A common stock, if any, will be your only source of gain on an investment in our Class A common stock. See &#8220;Part II - Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities - Dividends&#8221; for a discussion of our dividend policy.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_256"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_268"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our corporate headquarters and executive officers are located in Arlington, Virginia, where we occupy approximately 34,000 square feet of office space. We also lease offices throughout the United States, and in Pune, India and Manila, Philippines. We lease all of our facilities and we do not own any real property. As provided in &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12 - Leases,&#8221; the total rental expense on operating leases, net of sublease income, was $14.6 million for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of legal proceedings included within &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_163"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_148"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_259"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Dividend Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A common stock is traded on the New York Stock Exchange under the symbol &#8220;EVH.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;16, 2023, there were 93 holders of record of our Class A common stock. The number of record holders does not include individuals or entities who beneficially own shares and whose shares are held of record by a broker, bank, or other nominee, but does include each such broker, bank, or other nominee as one record holder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock. We do not anticipate paying any cash dividends on our Class A common stock for the foreseeable future. The timing and amount of future cash dividends on our Class A common stock, if any, is periodically evaluated by our board of directors and would depend on, among other factors, our current and expected earnings, financial condition, projected cash flows and anticipated financing needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Graph</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total stockholder return on our Class A common stock for the 5 years ended December&#160;31, 2022, to the cumulative total returns of the NASDAQ Health Care Index and the NYSE Composite Index over the same period. This graph assumes an investment of $100 at the closing price of the markets on December 31, 2017, in our Class A common stock, the NASDAQ Health Care Index and the NYSE Composite Index, and assumes the reinvestment of dividends, if any. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the following graph are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="evh-20221231_g1.jpg" alt="evh-20221231_g1.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:694px"/></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities, Purchases of Equity Securities by the Issuer or Affiliated Purchases or Other Stockholder Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_250"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes to consolidated financial statements presented in &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data&#8221; as well as &#8220;Part I - Item 1A. Risk Factors.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_121"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models. We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manage our operations and allocate resources across two reportable segments: EHS and Clinical Solutions. The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our specialty care management under the brand name New Century Health, and for our total cost of care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, as a result of the operational success and growth within its Clinical Solutions segment including the acquisition of NIA, as well as BHG, a health plan operating partner of EHS, which accounted for 11.3% of the Company&#8217;s short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable as of December 31, 2022, announced its plans to exit its IFP line of business for 2023 and thus negatively impacting the Company&#8217;s future revenues from such partner, the Company is making organizational changes and business strategy decisions which necessitate re-evaluating its reportable segments, including potentially changing the number of reportable segments. The Company anticipates its focus in the future will be primarily on maximizing the market opportunity it believes it has in the management of complex specialty conditions, which constituted approximately 70% percent of corporate revenue for the year ended December 31, 2022, prior to the acquisition of NIA which will increase this proportion further.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net income during the year ended December&#160;31, 2022. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8 million and 117.4 million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our average contractual relationship with our operating partners was approximately 6.4 years, with an average of 1.3 years of performance remaining per contract. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, BHG, an operating partner of the EHS segment, announced that it plans to exit its IFP line of business for 2023. As a result of this announcement, the Company performed a quantitative assessment of the goodwill impairment test for that specific reporting unit which showed that no goodwill impairment had occurred. Revenue from BHG comprised less than 10% of our consolidated revenue for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Vital Decisions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, and the Company entered into a definitive agreement for the Company to acquire Vital Decisions. On October 1, 2021, we consummated the acquisition of Vital Decisions for $46.5 million in cash and the issuance of 1.8 million shares of Class A common stock. Vital Decisions reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. The transaction closed on October 1, 2021. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of IPG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022, which is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. IPG will report into Evolent&#8217;s specialty care management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for additional discussion regarding the IPG transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ares Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#8220;Evolent&#8221;), Endzone Merger Sub, Inc. (&#8220;Endzone&#8221; or &#8220;Initial Borrower&#8221;), which upon consummation of the transactions contemplated by the Merger Agreement was merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#8220;Implantable&#8221;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#8220;Borrowers&#8221; and each a &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of the (i) 2022 Initial Term Loan Facility, with an aggregate principal amount of $175.0&#160;million and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the 2022 Initial Term Loan Facility, the &#8220;2022 Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the 2022 Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0 million under the Revolving Facility on the Closing Date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of the Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the Closing Date. Refer to &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional discussion regarding the 2022 Credit Facilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2024 Notes Conversion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquisition of NIA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 17, 2022, Evolent Health LLC, a wholly owned subsidiary of the Company, and the Company entered into a definitive agreement for the Company to acquire NIA. On January 20, 2023, we consummated the acquisition of NIA for $400.0 million in cash, $265.0 million in debt financing provided by Ares Capital Corporation and the issuance of 8.5 million shares of Class A common stock. NIA reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the NIA acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Amendment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, in connection with the consummation of the acquisition of NIA, we entered into Amendment No. 1 to the Credit Agreement, dated as of August 1, 2022, that provided new secured debt financing in the form of (i) additional commitments under the Priority ABL Incremental Facility in an aggregate principal amount equal to $25.0 million, and (ii) additional commitments under the Company&#8217;s Term Loan Incremental Facility in an aggregate principal amount equal to $240.0 million, and effected certain </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amendments to the Existing Credit Agreement. Concurrently with Amendment No. 1, EVH LLC borrowed $25.0 million under the Priority ABL Incremental Facility and $240.0 million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock (as defined below), the cash consideration payable for the acquisition of NIA and pay transaction fees and expenses. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the amendment to the Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the acquisition of NIA, on January 20, 2023, we entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) pursuant to which the Company offered and sold an aggregate 175,000 shares of Series A Preferred Stock, at a purchase price of $960.00 per share, resulting in total gross proceeds to us of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable for the acquisition of NIA and pay transaction fees and expenses. Refer to &#8220;Part II - Item 8. Financial Statements - Note 25&#8221; for additional discussion regarding the sale of Series A Preferred Stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repositioning Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.902%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_130"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified the accounting policies below as critical to the understanding of our results of operations and our financial condition. In applying these critical accounting policies in preparing our financial statements, management must use critical assumptions, estimates and judgments concerning future results or other developments, including the likelihood, timing or amount of one or more future events. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our assumptions, estimates and judgments based upon historical experience and various other information that we believe to be reasonable under the circumstances. For a detailed discussion of other significant accounting policies, see &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the EHS reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2022. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts with Multiple Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Principal vs Agent</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract-by-contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We estimate our actual current tax expense, including permanent charges and benefits, and temporary differences resulting from differing treatment of items, such as deferred revenue for tax and book accounting purposes. These temporary differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the likelihood that our deferred tax assets will be recovered from future taxable income by considering both positive and negative evidence relating to their recoverability. If we believe that it is more likely than not that these deferred tax assets will not be recovered, we establish a valuation allowance. To the extent that we increase a valuation allowance in a period, we include an expense in the consolidated statement of operations in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, we considered all available evidence, including recent operating results, projections of future taxable income, our ability to utilize loss and credit carryforwards, and the feasibility of tax planning strategies. A significant piece of objective negative evidence evaluated for jurisdictions in a net deferred tax asset position was cumulative pre-tax losses over the three years ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertainty in income taxes by recognizing a tax position only when it is more likely than not that the tax position, based on its technical merits, will be sustained upon ultimate settlement with the applicable tax authority. The tax benefit to be recognized is the largest amount of tax benefit that is greater than fifty percent likely of being realized upon ultimate settlement with the applicable tax authority that has full knowledge of all relevant information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross unrecognized benefits are $1.6 million as of December 31, 2022. Our evaluation of uncertain tax positions is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, and new audit activity. If actual settlements differ from these estimates, or we adjust these estimates in future periods, we may need to recognize additional tax benefits or charges that could materially impact our financial position and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserve for Claims and Performance-based Arrangements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for performance-based arrangements and claims reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as a change in fair value of contingent consideration and indemnification asset on the Company's consolidated statements of operations and comprehensive income (loss). Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2&#160;million and increased retained earnings by $39.8&#160;million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1&#160;million and $41.3&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_133"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Solutions Lives on Platform in our Performance Suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services Suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. Clinical Solutions Cases are calculated by summing the number of individuals receiving services through our IPG and Vital Decisions programs in a given period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Solutions Performance Suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance Suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance Suite Lives on Platform for the period divided by the number of months in the period. New Century Health Technology and Services Suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services Suite during the period reported divided by the average of the beginning and ending New Century Health Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Clinical Solutions Revenue per Case is calculated by the revenue pertaining to IPG and Vital Decisions divided by the number of cases for a given period.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average PMPM fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services Lives on Platform for the period divided by the number of months in the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform, PMPM fees, cases and revenue per case because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,352,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of assets and consolidation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277.1)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,187,486&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(237,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262,847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.9%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for Years Ended December&#160;31, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $444.1 million, or 48.9%, to $1,352.0 million for the year ended December 31, 2022, as compared to 2021. This increase is primarily due to $79.3 million from our acquisitions of IPG and Vital Decisions and $364.8 million from the addition of new partners and expansion with existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment increased by $97.7 million for the year ended December 31, 2022, as compared to 2021 due to growth with existing customers and new customer additions; one of these new customers has entered winddown as of January 1, 2023, and we do not expect future revenues from this customer to remain at these levels. Revenue from our Clinical Solutions segment increased by $346.4 million for the year ended December 31, 2022 as compared to 2021, primarily due to $79.3 million from our acquisitions of IPG and Vital Decisions, new partner additions, transition to risk based contracts with Medicaid customers and expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform and cases as of December&#160;31, 2022 and 2021 and PMPM fees and revenue per case for the years ended December&#160;31, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform/ Cases during Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees / Revenue per Case </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services Suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment eliminations attributable to EHS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Evolent Health Services revenue includes $9.7 million and $11.2 million of revenue from transformation services for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the year ended December 31, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $377.9 million, or 57.5%, to $1,035.4 million for the year ended December 31, 2022, as compared to 2021, principally as a result of the growth in our revenue. The increase included approximately $253.8 million from higher claims cost in our Clinical Solutions and Evolent Health Services segments from acquisitions and transition from ASO to risk based contracts for certain customers, $33.6 million of higher personnel costs due to increased headcount, employee benefits and bonus accruals for employees primarily in our Clinical Solutions segment, $22.1 million in higher professional fees primarily due to costs incurred for contracts that went live during the year and third-party service fees for existing customers, $40.9 million of surgical management costs at IPG and $12.3 million of severance costs primarily in our Evolent Health Services segment. Approximately $4.4 million and $2.3 million of total personnel costs in costs of revenue was attributable to stock-based compensation expense for the year ended December 31, 2022 and 2021, respectively. Cost of revenue represented 76.6% and 72.4% of total revenue for the year ended December 31, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings with the rapid growth of our Performance Suite products. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the year ended December 31, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $49.8 million, or 22.7%, to $269.3 million for the year ended December 31, 2022, as compared to 2021, principally as a result of acquisitions in our Clinical Solutions segment and employee costs across all business units. The increase was primarily driven by higher personnel fees due to increased headcount and expected benefit accruals to employees of $33.1 million primarily in our Clinical Solutions segment, higher stock compensation of $15.2 million due to the achievement and change in projected achievement of certain performance measurements, technology services due to higher headcount </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $9.1 million, $1.5 million of severance costs and acquisition costs of $7.5 million, offset, in part by lower professional fees from cost savings initiatives of $9.6 million and the termination of certain leases of $3.9 million. Approximately $29.6 million and $14.4 million of total personnel costs were attributable to stock-based compensation expense for the year ended December 31, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $24.9&#160;million and $4.4&#160;million of total selling, general and administrative expenses for the year ended December 31, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.9% and 24.2% of total revenue for the year ended December 31, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as we integrate NIA operations, we expect them to decrease as a percentage of our total revenue over the long-term due to cost saving initiatives completed in the fourth quarter of 2021 and higher operating performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $7.2 million, or 11.9%, to $67.2 million for the year ended December 31, 2022, as compared to 2021 due primarily to amortization of intangible assets acquired through our asset acquisitions and business combinations. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a loss (gain) on change in fair value of contingent consideration of&#160;$(23.5) million&#160;for the year ended December 31, 2022, related to the liabilities acquired as a result of the acquisitions of Vital Decisions in October 2021, and IPG in August 2022, and&#160;$13.3 million for the twelve months ended December 31, 2021, related to liabilities acquired as a result of the acquisition of Vital Decisions in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Comparison of the Results for the Year Ended December 31, 2021 to 2020 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by $16.7 million, or 1.8%, to $908.0 million for the year ended December 31, 2021, as compared to 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment decreased by $72.5 million for the year ended December 31, 2021, as compared to 2020 due to the consolidation and runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $55.9 million for the year ended December 31, 2021 as compared to 2020 due to new partner additions including Florida Blue Medicare, Inc., as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform and cases as of December 31, 2021 and 2020 and PMPM fees and revenue per case for the years ended December 31, 2021 and 2020 (Lives on Platform in thousands):</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform/ Cases during Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees / Revenue per Case </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the year ended December 31, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue decreased by $39.0 million, or 5.6%, to $657.6 million for the year ended December 31, 2021, as compared to 2020. Cost of revenue decreased by approximately $23.2 million due to lower personnel costs, $8.4 million due to lower claims activity in our Clinical Solutions segment, $4.0 million in lower professional fees and $4.1 million in our technology services, TPA fees, brokerage fees and other costs. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for the year ended December 31, 2021 includes approximately $(0.5) million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport&#8217;s claims reserve. Approximately $2.3 million and $1.8 million of total personnel costs was attributable to stock-based compensation expense for the years ended December 31, 2021 and 2020, respectively. Cost of revenue represented 72.4% and 75.3% of total services revenue for the years ended December 31, 2021 and 2020, respectively. Our cost of revenue decreased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the year ended December 31, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $9.1 million, or 4.3%, to $219.5 million for the year ended December 31, 2021, as compared to 2020. Professional fees increased by $14.8 million for the year ended December 31, 2021, as compared to 2020, respectively, primarily due to the Repositioning Plan and shareholder advisory services. During the year ended December 31, 2021, personnel costs decreased by $1.3&#160;million period over period due to a reduction in employee headcount, other expenses decreased by $2.8 million due to the termination of leases at EVH Passport during the third quarter of 2020 and legal fees decreased $2.1 million due to the timing and volume of transactions. Approximately $14.4 million and $12.8 million of total personnel costs were attributable to stock-based compensation expense for the year ended December 31, 2021 and 2020, respectively. Acquisition and severance costs accounted for approximately $4.4&#160;million and $9.2&#160;million of total selling, general and administrative expenses for the year ended December 31, 2021 and 2020, respectively. Selling, general and administrative expenses represented 24.2% and 22.8% of total revenue for the year ended December 31, 2021, as compared to 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $0.8 million, or 1.3%, to $60.0 million for the year ended December 31, 2021, as compared to 2020. The decrease was due primarily to lower amortization on existing technology intangibles of $3.9 million, offset, in part by, an increase in amortization expense for internal-use software of $2.6 million and customer relationships of $0.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss (Gain) on Disposal of Assets and Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the year ended December 31, 2020, the Company sold its interest in the subsidiary and recorded a $6.4 million loss in loss (gain) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina consummated the Molina Closing, and the Passport Medicaid Contract was novated to Molina. As a result, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 and recorded a $5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the two reporting units in the EHS segment was less than the carrying amount. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II - Item 8.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Financial Statements - Note 9&#8221; for further details of the impairment charge to goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration and Indemnification Asset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a gain on change in fair value of contingent consideration and indemnification asset of&#160;$13.3 million&#160;and&#160;$3.9 million for the year ended December 31, 2021 and 2020, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering into the warrant agreements compared to the liabilities acquired as a result of the acquisition of Vital Decisions in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes and 2025 Notes, as well as our 2022 and 2019 Credit Agreements with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $15.6 million, $25.4 million and $28.3 million for the years ended December 31, 2022, 2021 and 2020, respectively. The decrease in interest expense during the year ended December 31, 2022, compared to 2021 is driven primarily by the adoption of ASU 2020-06 and partial conversion of the 2024 Notes offset, in part by interest expense incurred on our 2022 Credit Agreement. The decrease in interest expense during the year ended December 31, 2021, compared to 2020, is driven primarily by the termination of the Ares Credit Agreement in January 2021, offset, in part by, the issuance of the 2024 Notes in August 2020. We expect interest expense to increase during 2023 as a result of the Acquisition Facilities entered into in January 2023. However, we are focused on deleveraging the balance sheet in the long-term thereby decreasing interest expense.  See &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; in this Form 10-K for more information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2020, the Oklahoma Insurance Division (&#8220;OID&#8221;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we have recorded a non-cash impairment charge of approximately $47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $4.6&#160;million, $13.2&#160;million and $10.0&#160;million for the years ended December 31, 2022, 2021 and 2020, respectively. The change in gain from equity method investees for the year ended December 31, 2022, compared to 2021 is driven primarily by the sale of our Florida equity investee&#8217;s membership during the three months ended March 31, 2021. The change in gain from equity method investees for the year ended December 31, 2021, compared to 2020, is driven primarily by the Company&#8217;s investment in Passport during 2020 combined with gains on the sale of our Florida equity investee&#8217;s membership during 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, EVH Passport earned a cash payment from Molina in the amount of $46.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. 50% of the payment was received during the year ended December 31, 2021, and the remaining 50% was received in the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment/Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of  the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment to noteholders of $2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Tax Receivable Agreement Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $46.0 million as of December&#160;31, 2022, which represents 85% of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance. As a result of the NIA acquisition, we expect to record a significant reduction to our valuation allowance paired with a significant increase in our TRA liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax provision for (benefit from) of $(43.4) million, $0.5 million and $(2.4) million was recognized for the years ended December 31, 2022, 2021 and 2020, respectively, which resulted in effective tax rates of 69.9%, (1.6)% and 0.7%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_136"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_139"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported operating gains (losses) of $3.6 million, $(42.4) million and $(262.8) million for the years ended December 31, 2022, 2021 and 2020, respectively. Net cash and restricted cash provided by (used in) operating activities was $(11.6) million, $38.7 million and $(16.2) million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $188.2 million of cash and cash equivalents and $27.0 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies, which may require us to seek sources of financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part II - Item 8. Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $11.6 million for the year ended December 31, 2022 were primarily due to our net loss of $19.2 million, non-cash items including depreciation and amortization expenses of $67.2 million, stock-based compensation expense of $34.0 million, deferred tax benefit of $(45.6) million, amortization of contract cost assets of $23.1 million, loss on extinguishment of debt of $10.2 million, change in fair value of contingent consideration of $(23.5) million and change in our tax receivable liability of $46.0 million. Our operating cash outflows were affected by the timing of our customer and vendor payments primarily driven by increases in accounts receivables from Cook County Health and Hospitals System of approximately $99.2 million, reduction of our accrued liabilities due to a decrease in expected IPG and Vital Decisions contingent consideration payments of $25.7 million and an increase in reserves for  liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services of $28.4 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities of $38.7 million for the year ended December 31, 2021 were primarily due to our net loss of $37.6 million, a loss on the repayment and termination of our Credit Agreement and 2021 Notes of $21.3 million, a gain on the disposal of assets of $6.8 million, gain on the transfer of memberships of $45.9 million, and non-cash items including depreciation and amortization expenses of $60.0 million, stock-based compensation expense of $16.7 million and change in fair value of contingent consideration and indemnification asset of $13.3 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in reserves for claims and performance-based arrangements contributed and accrued liabilities approximately $28.9 million to our cash outflows. Those cash outflows were offset, in part by higher accounts payable and accrued compensation and employee benefits of approximately $10.8 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $16.2 million in the year ended December 31, 2020 were due primarily to our net loss of $334.2 million, partially offset by non-cash items, including an impairment of goodwill of $215.1 million, an impairment of an equity method investment of $47.1 million, depreciation and amortization expenses of $61.5 million, stock-based compensation expense of $14.6 million and a loss on the disposal of assets and consolidation of $0.7 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and decreases in claims reserves contributed approximately $94.5 million to our cash outflows. Those cash outflows were partially offset by an increase in accounts payable, accrued expenses and accrued compensation and employee benefits contributed approximately $23.5 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $259.1 million in the year ended December 31, 2022 were primarily attributable to $248.1 million paid for the acquisition of IPG, $9.2 million paid for a purchase price adjustment related to our disposal of True Health New Mexico and $38.4 million of investments in internal-use software and purchases of property and equipment, offset in part, by $31.0 million from the transfer of membership and release of Passport escrow and $5.6 million from returns from our equity method investments.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $15.8 million in the year ended December 31, 2021 were primarily attributable to cash flows of $46.5 million for the acquisition of Vital Decisions and $25.0 million of investments in internal-use software and purchases of property and equipment offset, in part by, $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $14.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from investing activities of $261.1 million in the year ended December 31, 2020 were primarily attributable to cash flows from the impact of the initial consolidation of EVH Passport of $159.8 million, maturities and sales of investments primarily held by EVH Passport of $143.4 million, offset, in part by investments in internal-use software and purchases of property and equipment of $29.5 million, disposal of non-strategic assets of $2.3 million and purchases of investments of $11.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by financing activities of $131.5 million in the year ended December 31, 2022, were primarily related to $219.7 million received from our 2022 Credit Agreement, offset in part, by $59.4 million of cash outflows related to claims processing services on behalf of partners and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$18.3 million from taxes withheld for restricted stock unit vesting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $29.5 million in the year ended December 31, 2021, were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part, by a $61.2 million increase in net working capital balances held on behalf of our partners for claims processing services and a $13.3 million increase from cash proceeds from stock option exercises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $11.9 million in the year ended December 31, 2020, were primarily related to a $20.0 million redemption of the Sponsors equity in EVH Passport in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement as part of the EVH Passport wind-down and repurchase of our 2021 Notes of $16.6 million, $1.9 million of taxes withheld and paid for vests of restricted stock units and a $6.0 million decrease in working capital balances held on behalf of our partners for claims processing services offset, in part by $30.1 million from proceeds of convertible debt. The change in working capital balances held on behalf of partners for claims processing are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual and Other Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2023. Our estimated contractual obligations (in thousands) as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024-2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026-2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2028+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes interest payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Operating leases for facilities includes $596 thousand and $76 thousand of leases not yet commenced for the 2023 and 2024-2025 time periods, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents the fair value of earn-out consideration related to the IPG and Vital Decisions transactions. See &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for further details of the Company&#8217;s contingent consideration obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $175.0 million of aggregate principal amount in a secured term loan and $50.0 million of aggregate principal amount in a secured revolving credit facility, which were subsequently increased on January 20, 2023, through additional secured term loan borrowings of $240.0 million of aggregate principal amount and secured revolving credit facility of $25.0 million of aggregate principal amount entered into as part of the NIA acquisition. All loans under the Credit Agreement (including loans under the Acquisition Facilities and loans outstanding under the Existing Credit Agreement) (collectively, the &#8220;Loans&#8221;) will mature in 2029. The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on January 20, 2023, we entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company&#8217;s newly created Cumulative Series A Convertible Preferred Shares. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations) plus 6.00%. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the year ended December 31, 2022, accounts receivable, net, increased due primarily to the timing of cash receipts from Florida Blue Medicare, Inc. and Cook County Health and Hospital Systems combined with $34.2 million of receivables acquired as part of the IPG acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $27.0 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $13.8 million, collateral for letters of credit required as security deposits for facility leases of $2.3 million, amounts held with financial institutions for risk-sharing arrangements of $10.9 million as of December&#160;31, 2022. See &#8220;Part II - Item 8. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets are carried at cost and includes prepaid expenses and non-trade accounts receivable. During the year ended December 31, 2022, non-trade accounts receivable decreased $23.0 million primarily due to proceeds from the transfer of EVH Passport membership to Molina and $8.0 million of proceeds from other EVH Passport receivables.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. As part of our acquisition of IPG in August 2022, we added $195.7 million of intangible assets and $296.6 million of goodwill. See &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. Payments under the TRA are due within 100 days of filing the Company&#8217;s annual U.S. Federal income tax return. The Company has recorded a partial TRA liability of $46.0 million as of December 31, 2022. See &#8220;Part II - Item 8. Financial Statements - Note 15&#8221; for further details of the Company&#8217;s TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business, payment of interest on our convertible debt and secured borrowings and payment of preferred dividends. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cash and cash equivalents and restricted cash and restricted investments of $215.2 million, which consisted of bank deposits with FDIC participating banks of $214.4 million and bank deposits in international banks of $0.8 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $196.8 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. In addition, as of December 31, 2022, we had $175.0 million of aggregate principal amount in a secured term loan and $50.0 million of aggregate principal amount in a secured revolving credit facility, which were subsequently increased through additional secured term loan borrowings of $240.0 million aggregate principal amount and secured revolving credit facility of $25.0 million of aggregate principal amount entered into as part of the NIA acquisition. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations) plus 6.00%. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events. All of our secured term loan and secured revolving credit facility and Series A Preferred Stock borrowings are floating rate instruments based on the SOFR and subject to fluctuations in interest rates. For every 1% increase in SOFR, the Company would record additional interest expense of $4.9 million per annum and preferred dividends of $1.8 million per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the discussion in &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have foreign currency risks related to our operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee and the Philippino Peso. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation losses of $0.8 million, $84.0 thousand and $44.0 thousand for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_217">Report of Independent Registered Public Accounting Firm (PCAOB ID No. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMi9mcmFnOmZkNjFkMzdmNGVjMDQxOGM5ZWFiNDA5NTcwYmYyMmY4L3RhYmxlOmVjOTkwZDY0NTg5YzQwOWI5NTA2YWMxZjI0YzNmNWMxL3RhYmxlcmFuZ2U6ZWM5OTBkNjQ1ODljNDA5Yjk1MDZhYzFmMjRjM2Y1YzFfMS0wLTEtMS04MzI0Ni90ZXh0cmVnaW9uOmQzZjQ1MTExM2MxZDRhNjM5M2Y0MjMyMTU3Y2E0NGI0Xzc0_b6f88ef8-5e77-49ab-8bb8-96ddbb70a4cd">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_217">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_217">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_25">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_25">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_28">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_28">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_226">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_226">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_34">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_34">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_37">76</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_217"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the shareholders and the Board of Directors of Evolent Health, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Evolent Health, Inc. and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive income (loss), changes in shareholders' equity (deficit), and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 24, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Emphasis of Matter</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to the financial statements, the accompanying consolidated financial statements have been retrospectively adjusted for discontinued operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Reserve for Claims &#8212; Refer to Note 22 to the financial statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records reserves for the ultimate cost of claims that have been incurred but not reported (IBNR), including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. The liability is primarily calculated using completion factors developed by comparing the claim incurred date to the date claims were paid. Key assumptions include current payment experience, trend factors, and completion factors. Completion factors are impacted by several key items including changes in (1) electronic (auto-adjudication) versus manual claim processing, (2) provider claims submission rates, (3) membership, and (4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is insufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflect expected claim payment patterns and other relevant operational considerations or authorization analysis. For each reporting period, the Company compares key assumptions used to establish the reserves for claims to actual experience. When actual experience differs from these assumptions, reserves for claims are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. The reserve for claims as of December 31, 2022, was $199.7 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the IBNR reserve as a critical audit matter because the development of the IBNR reserve involves significant estimation by management. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our actuarial specialists.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures related to the reserve for claims included the following, among others: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We tested the effectiveness of controls related to the reserve for claims, including management&#8217;s controls over the development and reporting of the IBNR reserve.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We tested the underlying data that served as the basis for the actuarial analysis, including claims lag triangles and membership data, to test that the inputs to the actuarial estimate were complete and accurate.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">With the assistance of our actuarial specialists, we evaluated the reasonableness of the actuarial methods and assumptions used by management to estimate the IBNR reserve by:</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;    Developing an independent estimate of the IBNR reserve and comparing our estimate to management&#8217;s estimates.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;   Comparing management&#8217;s September 30, 2022 assumptions of expected development and ultimate cost of claims to actuals incurred during the fourth quarter of 2022 to identify potential bias in the determination of the reserve for claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Goodwill &#8212; Refer to Note 9 to the financial statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation of goodwill for impairment involves the comparison of the fair value of each of its reporting units to the respective carrying value for each of those reporting units at least annually. In addition to the annual impairment evaluation, the Company evaluates goodwill for impairment if an event occurs or circumstances change during the period that indicates that the fair value of a reporting unit may be below the carrying value. The Company performed its annual goodwill impairment assessment as of October 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill balance was $722.8 million as of December 30, 2022. Due to a health plan operating partner within the EHS segment announcing its plans to exit its Individual and Family Plans line of business, the Company performed a quantitative impairment evaluation of the goodwill in the EHS segment&#8217;s reporting unit by comparing the estimated fair value of the reporting unit to its carrying value. Estimating the fair value of a reporting unit requires the exercise of significant judgment and assumptions including judgments about expected future cash flows, weighted-average cost of capital, discount rates and expected long-term growth rates. The impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to the Company&#8217;s forecasted cash flows due to being unsuccessful in winning certain contracts or certain of the contracts being cancelled or renegotiated by its customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to the Company&#8217;s results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified goodwill for the EHS segment&#8217;s reporting unit as a critical audit matter due to the significant judgments made by management to estimate the fair value, the sensitivity of the assumptions used and the difference between its fair value and carrying value. Performing audit procedures to evaluate the reasonableness of management&#8217;s estimates and assumptions related to the revenue growth rates, operating margins, the discount rates, and the implied control premium required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to management&#8217;s assumptions for the revenue growth rates, operating margins, the discount rates, and the implied control premium for the Company&#8217;s reporting unit in the EHS segment included the following, among others: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over management&#8217;s goodwill impairment evaluations, including controls over management&#8217;s impairment assessment methodology and assumptions related to revenue growth rates, operating margins, selection of the discount rate, and the implied control premium.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated management&#8217;s ability to accurately forecast future revenues and operating margins by comparing actual results to management&#8217;s historical forecasts. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the reasonableness of management&#8217;s revenue and operating margin forecasts by comparing the forecasts to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Historical revenues and operating margins.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Internal communications to management and the Board of Directors.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Forecasted information included in analyst reports as well as certain publicly available peer company information. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the impact of changes in management&#8217;s forecasts from the October 31, 2022 annual measurement date to December 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) discount rate, and (3) implied control premium by:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Testing the source information underlying the determination of the discount rate and the mathematical accuracy of the calculation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Developing a range of independent estimates and comparing those to the discount rate selected by management and the implied control premium.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMTcvZnJhZzo5Zjg5NTg3MWE5ZjU0ZjUxYTIwMTM0MDZmNTlhZmQzYy90ZXh0cmVnaW9uOjlmODk1ODcxYTlmNTRmNTFhMjAxMzQwNmY1OWFmZDNjXzU0OTc1NTg2NTA3OA_9c5b9a9c-7511-436d-a78d-59c93ec675d1">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMTcvZnJhZzo5Zjg5NTg3MWE5ZjU0ZjUxYTIwMTM0MDZmNTlhZmQzYy90ZXh0cmVnaW9uOjlmODk1ODcxYTlmNTRmNTFhMjAxMzQwNmY1OWFmZDNjXzU0OTc1NTg2NTA5Nw_81553df5-29ce-488e-879a-5f5427272b2a">McLean, Virginia</ix:nonNumeric>  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;24, 2023 </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2019.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:325.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMy0xLTEtMS04Mjg1OA_a7507435-e630-478e-aa0f-d93c19a56870">188,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMy0zLTEtMS04Mjg1OA_f7cf586c-a132-43be-8856-7ddd2582c136">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNC0xLTEtMS04Mjg1OA_1ce80cc8-bea6-4164-91b2-d407e05ec74c">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNC0zLTEtMS04Mjg1OA_44e6310e-165f-4390-966c-7df3618944b0">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3">254,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a">130,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1">20,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df">51,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNy0xLTEtMS04Mjg1OA_7b5da6fe-1022-4a59-8230-418246025356">478,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNy0zLTEtMS04Mjg1OA_3803359a-e106-4980-9248-d36d043973fe">523,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOC0xLTEtMS04Mjg1OA_b876ba1d-5840-4d0d-a01c-e2bd92e87529">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOC0zLTEtMS04Mjg1OA_b5ddff1b-f137-48a6-ae54-b54e9ad1eb40">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOS0xLTEtMS04Mjg1OA_4906a986-d1ff-4cd1-8895-f696eea67567">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOS0zLTEtMS04Mjg1OA_2a263043-13b0-4269-a294-aab9e0575a3a">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTAtMS0xLTEtODI4NTg_52626800-5b48-4588-94ca-f918d6e46858">87,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTAtMy0xLTEtODI4NTg_46de5007-ba73-4e5d-acc8-92629ff2f5d3">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTEtMS0xLTEtODI4NTg_d499a331-e2ce-415c-af10-2e13a2b44245">49,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTEtMy0xLTEtODI4NTg_4ba7a2ef-2b4d-428c-b5f3-c340414c6e7c">50,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTMtMS0xLTEtODI4NTg_8ab8b821-8ae2-45d7-bfeb-abe0ac56ffbe">17,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTMtMy0xLTEtODI4NTg_0a3dfce9-7aa2-40be-8364-09e9c99f2c9b">32,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTQtMS0xLTEtODI4NTg_494eb7a8-052d-4913-a0b0-5a6018af86bb">442,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTQtMy0xLTEtODI4NTg_6749275f-c818-4279-aab4-000e354810db">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTUtMS0xLTEtODI4NTg_30dc7ce9-9003-44a9-b4f5-34a920c74493">722,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTUtMy0xLTEtODI4NTg_395d40f5-166a-472d-ad0b-be69414bd0b7">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTYtMS0xLTEtODI4NTg_29405253-3f0f-4d8d-a647-1d4dcd1018b8">1,817,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTYtMy0xLTEtODI4NTg_b9449583-1fa4-480e-8a54-ee8335a8fce0">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716">57,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588">111,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631">107,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjItMS0xLTEtODI4NTg_43036ee2-ee33-45a5-bdc6-67dad5a92ec5">7,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjItMy0xLTEtODI4NTg_b906e3b7-c0a8-42af-a95a-ee031ff46486">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjMtMS0xLTEtODI4NTg_2957877b-7240-4634-99f2-5b5437c031f8">52,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjMtMy0xLTEtODI4NTg_04166145-69c1-495e-a7e2-8ea7d42eca93">51,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjQtMS0xLTEtODI4NTg_95fe4a0f-a499-4bca-bf6f-1c16c726b1c8">5,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjQtMy0xLTEtODI4NTg_bcd330b4-f3f1-4ca8-9251-f33c45cd9de6">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492">199,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjYtMS0xLTEtODI4NTg_c3fff41e-b45e-4a87-bc6a-0c93ccff0ec2">433,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjYtMy0xLTEtODI4NTg_fd33149a-b629-4ec4-ae3c-0d233284d6db">445,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjctMS0xLTEtODI4NTg_fa3aeda2-43ff-4fca-aaba-c0a195ac27a1">412,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjctMy0xLTEtODI4NTg_fe27a078-d634-4baa-9d0f-4939fa6c5261">215,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjgtMS0xLTEtODI4NTg_0ecafdef-0ad8-4957-8154-814910cb1af8">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjgtMy0xLTEtODI4NTg_fa32bf91-e696-41c7-b16b-905149ef9e4d">5,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjktMS0xLTEtODI4NTg_1137602a-d2d3-4960-875c-e13415d32cc1">45,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjktMy0xLTEtODI4NTg_34f13e0f-d1bd-45e0-9ebb-b15b783aa396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzAtMS0xLTEtODI4NTg_6d1899a0-6d3c-417f-b263-9166955f9b3e">56,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzAtMy0xLTEtODI4NTg_387c8b2f-8add-406d-be6d-470ad7ea4f38">57,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzEtMS0xLTEtODI4NTg_5e8ad72b-d257-491e-a29e-373ffa952bc2">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzEtMy0xLTEtODI4NTg_416059a1-adb5-445a-b291-a423de4b1e5a">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzItMS0xLTEtODI4NTg_f06d9498-1563-4d08-a6bc-a760b03c8c93">957,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzItMy0xLTEtODI4NTg_e35c3651-b12f-4e4a-9bbf-6d510ac621f5">725,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzMtMS0xLTEtODI4NTg_a9876273-f011-449f-b5e4-b7fc6d077b53"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzMtMy0xLTEtODI4NTg_69a2a758-b42b-4c69-bfec-2b381e1e0c92"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF8yNw_45114a84-7fc4-4d73-a7b9-5543b3f6a393"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF8yNw_77d73ea8-867a-4af7-8de2-ceeea79ce80c">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF80MQ_1ff52c16-73c8-4bcb-b860-bcbb6f3d690a"><ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF80MQ_bf50a8b7-bc96-4a2a-adbb-946c4d2e5163">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF82Mw_6d0e7b80-9399-4a33-b78d-0117a0b32582">101,500,558</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF83MA_8e4d6fe5-7d17-404b-8b47-56e9dd0d4f36">90,758,318</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMS0xLTEtODI4NTg_4bd7d29d-537b-4388-89f9-619677604721">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMy0xLTEtODI4NTg_366b35da-ed33-49db-8987-3cbe18ad0384">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzYtMS0xLTEtODI4NTg_f5a2bb11-6d6e-41e6-a0e0-5d068001c071">1,486,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzYtMy0xLTEtODI4NTg_672a78ab-ff4c-4276-ab89-13f1dde1ace4">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzctMS0xLTEtODI4NTg_b5855596-c8f0-4b1c-8112-05755454f7de">1,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzctMy0xLTEtODI4NTg_e4b0b036-0505-4148-b7db-fae4de562b4a">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzgtMS0xLTEtODI4NTg_c8380cfd-08e0-4523-8277-4fc9efc368d4">606,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzgtMy0xLTEtODI4NTg_893d071b-dbbd-4d7f-8192-f3cfe817b2a4">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjpkMmRkNzg4YzYyYjA0OGJhOWQxNGQ0NDcxNzQ0MDVkMV8yOQ_b5eb6f37-e5fb-452e-94de-02ff24f5c120"><ix:nonFraction unitRef="shares" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjpkMmRkNzg4YzYyYjA0OGJhOWQxNGQ0NDcxNzQ0MDVkMV8yOQ_c5aa6de5-f0e8-423b-a4d7-aa2a50e29d4f">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMS0xLTEtODI4NTg_0f5af84f-7945-4e2c-8c7f-4a0ccc371133">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMy0xLTEtODI4NTg_92a4f0d9-0b6c-40df-b31e-a286d32a77f6">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDAtMS0xLTEtODI4NTg_b34c35b4-017b-40ee-8538-334e2c28fab7">859,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDAtMy0xLTEtODI4NTg_5df8c348-0df0-40cf-9870-bf4c5127697f">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDEtMS0xLTEtODI4NTg_673e5877-eeeb-4fca-8153-ace79a36477e">1,817,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDEtMy0xLTEtODI4NTg_ec90737d-6de2-4b3e-9b77-f41dcaa48479">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 19 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_28"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:303.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772">1,352,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5">1,035,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d">657,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464">696,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb">269,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d">219,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786">210,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi01LTEtMS04Mjg1OA_da2e6e60-d8c5-4ddc-a592-59908e7b3fff">67,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi03LTEtMS04Mjg1OA_c70f8dee-cc99-4c51-96ed-9cb20b495793">60,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy05LTEtMS04Mzg4OA_31e7a481-7954-43b5-8d90-c8b1e39d6ed4">60,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets and consolidation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC01LTEtMS04MzkwNQ_cf78217b-203b-4cb4-b8c3-f46f397ef641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC03LTEtMS04MzkwNQ_57f9df25-3c63-47fa-b76f-abb9e76fa821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC05LTEtMS04Mzg5NQ_2311addd-8ecc-4492-864b-cdd07055cc0d">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNS0xLTEtODM5MDU_2a87cf44-6632-4eab-ad23-0510a1ced313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNy0xLTEtODM5MDU_b4a9e3c8-b4dd-45a9-90dc-5000be5b90a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtOS0xLTEtODM4OTU_c26863ed-cb86-4074-b5e7-5ae24787ad9e">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy01LTEtMS04Mjg1OA_a530b829-25bb-47c6-97ee-18f8f9829dc4">23,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy03LTEtMS04Mjg1OA_45367148-f350-4855-87c5-4fde31feb7ac">13,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtOS0xLTEtODM4OTU_c8a71e0c-e34a-49d1-bc90-71a07f53298e">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC01LTEtMS04Mjg1OA_d673158b-4907-4035-b502-4b8e7600fdbf">1,348,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC03LTEtMS04Mjg1OA_348071a2-9177-4556-b24f-78c6772a045b">950,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItOS0xLTEtODM4OTU_22b6c05a-6def-4d36-9ac9-1b616b7c2fd2">1,187,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOS01LTEtMS04Mjg1OA_4abb1dc8-3f7b-42b3-9446-079dbe5d587f">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOS03LTEtMS04Mjg1OA_39e8ee52-349e-4343-974d-0e8a4cffbc23">42,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtOS0xLTEtODM4OTU_72cff562-f9c3-4ee4-9b0d-f06c75212cc7">262,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNS0xLTEtODI4NTg_77d3c87c-380e-42d6-ab8b-45ce2eb4e5a1">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNy0xLTEtODI4NTg_3b500807-f461-46fb-9aa0-0febd382e857">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtOS0xLTEtODM5NTc_69d05b00-0dda-4515-b9ea-78b7bc40039f">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtNS0xLTEtODI4NTg_8d6db517-61b7-4e92-87e0-e9e7cf5f2ddb">15,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtNy0xLTEtODI4NTg_b71a8b65-fda2-4902-839c-bf5341bd97ce">25,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtOS0xLTEtODM5NTc_21d7471c-642f-454f-b564-a17fbf4d37ea">28,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNS0xLTEtODM5NjM_c60c466b-acdd-45f5-ad00-7ce996fb12f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNy0xLTEtODM5NjM_649f9708-0d38-44b3-bb14-c1ed5e31a16b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtOS0xLTEtODM5NjM_a0e7f48f-c393-4f18-beda-119a6b251f9d">47,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItNS0xLTEtODI4NTg_9c7c7899-f630-43fa-a818-437a5b2c571a">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItNy0xLTEtODI4NTg_fbcec15b-e344-44e5-8a38-7a79d377b76f">13,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctOS0xLTEtODQwMTY_8f66d080-a696-4f54-8479-9050c6100581">10,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtNS0xLTEtODI4NTg_f885f3c9-0122-4206-bec2-a3580c9ee5d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtNy0xLTEtODI4NTg_4f13f57d-2831-4b8c-8164-4cc8b73fde21">45,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtOS0xLTEtODQwMTY_80b09630-1214-41ab-a796-edc4a40c4ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtNS0xLTEtODI4NTg_57d2fd30-1f8c-4d4a-ae7f-f278cf75f9d5">10,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtNy0xLTEtODI4NTg_3511c764-4862-4f96-932f-2045654e4dcb">21,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktOS0xLTEtODQwMzI_cd13ec90-b12d-42fb-91ea-8c2f07d835bb">4,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtNS0xLTEtODI4NTg_474330d4-dae1-49ca-9466-d7943d23d3d1">45,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtNy0xLTEtODI4NTg_787d69de-9073-4740-86e6-5e160f2f8dba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtOS0xLTEtODQwMzI_4b3300c7-7e7d-41ea-aa47-9b50279fdcd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNS0xLTEtODI4NTg_54587851-39b7-4fa7-a4d1-c10589aef5b7">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNy0xLTEtODI4NTg_e39f8bec-4cec-4b06-bd95-c57c6bae328d">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtOS0xLTEtODQwMzI_cfb0d504-3ecb-4f80-9d0a-0fefc21ce5bb">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctNS0xLTEtODI4NTg_83bdaf92-eff5-479f-b307-5a041ba61f06">62,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctNy0xLTEtODI4NTg_602c1094-a838-41c9-b7d9-f01ebbfa921c">29,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjItOS0xLTEtODQwMzI_68605381-978d-41cb-93d0-19b5b6a6a251">330,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtNS0xLTEtODI4NTg_b2abe7cd-bbfb-4b69-8ad5-4fe2a0a86310">43,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtNy0xLTEtODI4NTg_3235ba29-0efd-4de7-ab1c-10defc2b6e80">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjMtOS0xLTEtODQwMzI_abd6c6f3-f096-4f93-aa20-05c899213db4">2,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktNS0xLTEtODI4NTg_112f45da-4664-48a6-aee7-fbb2f80ad0c5">18,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktNy0xLTEtODI4NTg_9177faf4-f040-4777-bc9f-6ec51ec2d38b">30,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjQtOS0xLTEtODQwMzI_5c2a3b30-13b8-4ea6-a1b7-35e3c8d59d63">328,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNS0xLTEtODI4NTg_d01217a6-5959-4584-b22e-a36764658993"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNS0xLTEtODI4NTg_e5c62161-bcfa-4dd4-b071-60fca703cc7d">19,164</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNy0xLTEtODI4NTg_2a23462b-da52-41dc-ad00-306bbbdf0b76"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNy0xLTEtODI4NTg_e271052a-4a63-4981-a4f3-a7a87f46848b">37,601</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODQwMzI_1d68db10-6ff6-458a-b202-81d13456566c"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODQwMzI_3bbc3d55-ae5c-4322-847b-102357351b6f">334,246</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNS0xLTEtODI4NTg_03631c9b-1fca-482b-bc21-712366fde1c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNS0xLTEtODI4NTg_8e148c6b-2b64-4487-811e-8143fd8a108e">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNy0xLTEtODI4NTg_7d3d737d-bbbb-4e90-95df-f5c070e63d3f"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNy0xLTEtODI4NTg_93c76584-0af4-496c-b18f-ac56307e8f67">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODM4NjQ_0d907ba3-3b25-426d-a58e-d63555f4328d"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODM4NjQ_ef2de908-b81a-4ee6-9705-f0c868576b09">3.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNS0xLTEtODI4NTg_13051571-1486-458a-a693-81f16ec20e3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNS0xLTEtODI4NTg_2e81288a-b6e7-45e1-b2c8-b0e4dc95ecdf">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNy0xLTEtODI4NTg_4e315877-8fcd-418c-ade6-201b86112525"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNy0xLTEtODI4NTg_a2cb81db-574c-4b1a-b6dd-726d8b3656e9">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctOS0xLTEtODM4NjQ_1cc63df2-3264-46da-adfc-81ad817f2e33"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctOS0xLTEtODM4NjQ_4a171798-299d-444d-b4bc-be280c334f63">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNS0xLTEtODI4NTg_e00dc34d-016a-4911-aa17-a9e3f570441a"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNS0xLTEtODI4NTg_fb2f9fff-b3ac-4ab7-bb32-74d9d56181c7">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNy0xLTEtODI4NTg_ceb7521b-3185-4e91-a71c-86273bc538c3"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNy0xLTEtODI4NTg_d80a8583-6a89-4435-b5b4-c4527c5a3bbe">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjgtOS0xLTEtODM4NzI_4a6e219f-944f-4248-83bb-64d123921211"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjgtOS0xLTEtODM4NzI_b4cdb5eb-97ee-43c1-8fa3-5ff79883d395">3.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNS0xLTEtODI4NTg_60410be7-dbdf-4d6e-bb0a-6c398f88c7a8"><ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNS0xLTEtODI4NTg_810b4a96-f715-4a7b-af3a-869e10436860">93,699</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNy0xLTEtODI4NTg_6422c41e-d861-4de3-b5c0-4fe5c75c6f6a"><ix:nonFraction unitRef="shares" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNy0xLTEtODI4NTg_e4501877-9e46-48d9-a574-409f39d2d2b8">86,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzUtOS0xLTEtODM4NzY_045ec5e8-e8da-4501-a2c0-d4f80dcd4fb7"><ix:nonFraction unitRef="shares" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzUtOS0xLTEtODM4NzY_50c47909-94fb-4f4c-b6a5-b5d7bc214d34">84,928</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzgtNS0xLTEtODI4NTg_e02e235a-589d-41f9-be53-cda0c7b2bb3b">19,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzgtNy0xLTEtODI4NTg_7b4ecc2c-082f-4c03-b35b-4ad502f5d8ac">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzktOS0xLTEtODM4NDE_dfe5f93a-f79d-47dc-8bb5-7f23c9bd5b6c">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDAtNS0xLTEtODI4NTg_fb4f11e1-73e8-4640-8840-4449720dad2d">816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDAtNy0xLTEtODI4NTg_1b309c84-fa64-43f8-9dda-4020f0a4341e">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtOS0xLTEtODM4NDE_3496ad2e-b1a3-470f-a2d4-dcd6482818d9">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtNS0xLTEtODI4NTg_9c3727be-de02-4d4d-9088-0b8b0060a6c2">19,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtNy0xLTEtODI4NTg_bc627152-dc87-45ce-a89e-4ec7fc4463fe">37,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDItOS0xLTEtODM4NDE_59fdaee5-c4a3-4fea-a17d-7902ffce4a3b">334,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfMjY5_3e724a0d-d187-4ffc-a50f-e2e675db99dc">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfMzY1_96f98c70-26e2-458d-af35-5bd0ae5400d6">6.8</ix:nonFraction>&#160;million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_226"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="54" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr><td colspan="54" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="54" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to Evolent Health, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32b6870c04cf45a7a22f92062187c8b9_I20191231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTEtMS0xLTgyODU4_de4bfaba-4938-4ed0-949d-42d36d7dda9e">84,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b6870c04cf45a7a22f92062187c8b9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTMtMS0xLTgyODU4_d0a432ef-a472-4cb3-9938-0a63754e6c75">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b766a37ca0b47ffb3be346f3d8b2a47_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTktMS0xLTgyODU4_404ccc86-e6a4-4f8b-be7e-d158fb612f9b">1,173,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibff2679b53d74ef7bc24df5385a2e916_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTExLTEtMS04Mjg1OA_029305e1-7e87-4386-b26e-ffd38864399f">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc16408fdc2f457ca9bf96a6ff0288e9_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTEzLTEtMS04Mjg1OA_be0540f5-0ee2-48a2-aee3-f2edb0480fb4">251,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70bbd87e6c7400684ed1f05186aab79_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE1LTEtMS04Mjg1OA_5dfcff6a-2670-4798-bf2b-718a3fbe0b9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211392e628d14c2bb3d3202fadd1e955_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE3LTEtMS04Mjg1OA_1348f7a3-b6aa-4f20-87b3-545615b1ccab">922,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77788cda88584bada7bf9ba9c37f88e2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE5LTEtMS04Mjg1OA_922f9067-52fd-4e53-a7ac-eacd9cea9f94">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTIxLTEtMS04Mjg1OA_4b34633c-0833-4807-b545-084427eb11dc">929,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTAtMS0xLTgyODU4_01dd2877-01d2-4acc-a335-6631e19fc8dd">Cumulative-effect adjustment from adoption of ASU 2016-03</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0069b2782a4a49ab67a323fb9055aa_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTEzLTEtMS04Mjg1OA_f8aeb662-3f85-4ee5-beb7-1f57c2fdda15">2,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if29a022394774916af9c2f4fb440db9e_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTE3LTEtMS04Mjg1OA_e084779d-a296-40eb-8005-092727d6cd57">2,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dbc8526caa04360a8f7a3aad7061a5e_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTIxLTEtMS04Mjg1OA_eb5628cd-9d5b-4029-b184-0f3f5e35c0df">2,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTktMS0xLTgyODU4_a5ab2af6-e8c5-4cd2-a83d-4dedf248cecc">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTE3LTEtMS04Mjg1OA_9305981a-ac97-43fb-bbb0-11abb7805c14">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTIxLTEtMS04Mjg1OA_605a3ab7-e88e-4bb4-8e5e-51af4cd518a7">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTEtMS0xLTgyODU4_925a940b-5475-4260-a3ba-94f30b722e61">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTMtMS0xLTgyODU4_d9fc9fa6-c6a7-4da0-a333-93c2359a31f8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTktMS0xLTgyODU4_abfb612c-94b3-4601-a0da-7d18b68c72eb">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTE3LTEtMS04Mjg1OA_63fcfaa1-cd19-472b-945b-6384f2a4201b">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTIxLTEtMS04Mjg1OA_4dd35709-75e5-4cac-9eac-3d2a91330c70">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTEtMS0xLTgyODU4_058e6327-faff-415d-8282-ba428e209525">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTMtMS0xLTgyODU4_0ac38be7-43ee-4730-8a75-bddbab48e01c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTktMS0xLTgyODU4_7c9e60e8-b082-4300-83a3-ebc54b640373">1,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTE3LTEtMS04Mjg1OA_5714b4b3-856c-47aa-a959-a400747d7588">1,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTIxLTEtMS04Mjg1OA_2dd635fb-6bc7-41b4-a013-8dd0d1ae3c7b">1,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidation of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i173c4f55d1a74452b5e44d2cab35ebd1_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTE1LTEtMS04Mjg1OA_6a99db2d-dd62-45fe-9352-7d42f3a8e102">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTE3LTEtMS04Mjg1OA_1fe6716e-f095-46b7-bca6-8ed2e986601d">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTIxLTEtMS04Mjg1OA_afc88ccb-029c-443b-9ee5-4af7746a76de">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTEtMS0xLTgyODU4_7d2270a8-cb0c-4009-a2a6-bb6ac76217ca">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTMtMS0xLTgyODU4_8b9d98a3-174d-498e-8a75-57180e2c34b9">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTktMS0xLTgyODU4_43271ded-87a5-4ce1-8222-2e4c8e21f201">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTE3LTEtMS04Mjg1OA_b0c1d5f7-2632-44df-83d8-5164fe95efbc">685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTIxLTEtMS04Mjg1OA_be6508c7-1f73-4506-8c3c-d500d972370f">685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTEtMS0xLTgyODU4_7b98997f-5c79-47ca-81c1-2abfed3e7e4b">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTMtMS0xLTgyODU4_66249e7a-5e22-426d-a4fa-3017708cf05d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTktMS0xLTgyODU4_06408372-f7d8-4adf-8abf-12d43faebf40">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTE3LTEtMS04Mjg1OA_570e36fc-fcc8-478c-b96b-ab45d5cf5133">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTIxLTEtMS04Mjg1OA_6c80a6fc-9b44-4eb1-8a80-d4b797764131">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity component of 2024 Notes, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTktMS0xLTgyODU4_d386b30d-b0db-4117-a0df-477b5875ab85">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTE3LTEtMS04Mjg1OA_fed6af26-e565-430b-9585-7c6badf1c7e5">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTIxLTEtMS04Mjg1OA_69762ffb-21ec-4eac-b11b-bfd07c03de77">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f9268d85098487aa9053456186fe226_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTE5LTEtMS04Mjg1OA_9d04fc24-4f49-47f7-a177-7b76d00e8b6f">6,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTIxLTEtMS04Mjg1OA_5d3c1900-5c41-4339-b3eb-0bea6398edbf">6,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b29db4886614e8cb747051097d57a16_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTExLTEtMS04Mjg1OA_c91d473f-f3e0-42c6-890a-88e97602e193">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTE3LTEtMS04Mjg1OA_58d5a474-2aba-41a6-940c-2e7e4b9974e3">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTIxLTEtMS04Mjg1OA_f8440a6c-10a8-499f-9ef7-2580710d8b38">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic335aec702854b39aad8f2e5e220ae6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTEzLTEtMS04Mjg1OA_bb192798-80b9-4ed6-a726-820af36a4700">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTE3LTEtMS04Mjg1OA_0e8a5c03-92b5-4983-a9de-18005e51380d">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTIxLTEtMS04Mjg1OA_b5ded3cd-50be-48eb-8f73-b89238b3b464">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEtMS0xLTgyODU4_5de9e09e-f203-49f9-818e-8136f17a7214">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTMtMS0xLTgyODU4_0f936133-2475-446d-bd26-ada27c544b3a">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a7173b3e1d4ea0bf04dd1bbb81c077_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTktMS0xLTgyODU4_ef74adf8-157c-4f34-a796-d23bb8521040">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09bbf0d725dd45f3a6c123d36bd2715b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTExLTEtMS04Mjg1OA_8fabebe2-16af-4fb9-ad2c-7ce342f8f61d">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676d4e2a769c4bd1825c4e7a238270d7_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEzLTEtMS04Mjg1OA_b0a8cd22-ac96-47a3-acb2-f5b53ccd99f5">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i504d5250f6a74571832f036561396187_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE1LTEtMS04Mjg1OA_6e0e8da9-ff16-45bf-b7a0-38c381b05c58">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d6a2705b50479eb89edc0845501b62_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE3LTEtMS04Mjg1OA_01ac5a34-75e1-4350-87e2-7858798570fc">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcebc8005994a85ac2c4f44251b586b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE5LTEtMS04Mjg1OA_35832601-6536-4543-bbb8-a63ec4e72f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTIxLTEtMS04Mjg1OA_2dfe1d75-cc91-4942-829e-26e1eb498bf8">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTktMS0xLTgyODU4_7ec8a045-f206-4fc4-92e5-34ff8a6b394a">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTE3LTEtMS04Mjg1OA_2e799fd3-5410-47c7-9ee6-6820cb444e07">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTIxLTEtMS04Mjg1OA_5a960f49-464c-4994-9668-ab01aea2d2e3">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTEtMS0xLTgyODU4_935e92b4-895b-499d-afb7-8a5aaffab1b1">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTMtMS0xLTgyODU4_2b90f8f0-00c3-4648-9e90-2230ac8a5618">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTktMS0xLTgyODU4_7cbf1a8f-f26d-45df-a77a-1a086f9a8d75">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTE3LTEtMS04Mjg1OA_6b55e029-f16d-453a-8266-42ea47063dee">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTIxLTEtMS04Mjg1OA_5775954f-798f-4444-b793-61f7d23e29c0">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTEtMS0xLTgyODU4_cb21ca8c-e0dc-49a4-9da9-22ee7802f300">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTMtMS0xLTgyODU4_12e9f009-daac-4578-ab9d-849f3799b080">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTktMS0xLTgyODU4_47a869d2-0805-4f19-ab4b-12879fcd3006">3,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTE3LTEtMS04Mjg1OA_aeda8bf1-a701-40a8-acd0-5b7e5888a1aa">3,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTIxLTEtMS04Mjg1OA_62a8d0ba-440a-422b-878f-21d83896c6c5">3,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTEtMS0xLTgyODU4_59ce569b-08d2-49aa-a07a-67a31bbdd34c">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTMtMS0xLTgyODU4_3b09f0d9-5c5d-41ed-958e-2fd8e3e48b2f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTktMS0xLTgyODU4_609a5173-3533-4387-bddc-32e1ba1dac55">56,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTE3LTEtMS04Mjg1OA_41a56ec1-c429-4604-b0f6-099714bb9ca8">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTIxLTEtMS04Mjg1OA_7f9aa3ab-37f7-47c8-a565-1322bed48af4">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of 2021 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTEtMS0xLTgyODU4_4bc8dcd0-e2e1-4786-a127-622f174a6d2d">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTMtMS0xLTgyODU4_36184fd4-e879-4095-ba56-0a937e447e10">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTktMS0xLTgyODU4_ca3a18ec-3ca4-4395-8135-ba1b14396728">28,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTE3LTEtMS04Mjg1OA_f3f864c8-ae98-4c3b-9241-0cbb210ab34e">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTIxLTEtMS04Mjg1OA_bab9fe44-b85b-4145-a8ca-25a3c0346a66">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEtMS0xLTgyODU4_227c0887-e137-441d-8023-87395690ed42">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTktMS0xLTgyODU4_1cd67f1a-fe91-436f-b7ac-a44043397221">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE3LTEtMS04Mjg1OA_1226594a-2227-45d3-97ee-51b79875c6a1">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTIxLTEtMS04Mjg1OA_f30faff5-0a29-4368-928b-604e6afeb73f">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a9e09aed0674d2184d736359fae1f7d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTExLTEtMS04Mjg1OA_b07b83d7-3ae1-4e3b-b44d-5f62f09f7897">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTE3LTEtMS04Mjg1OA_41a0eaaf-1709-4063-8f63-172ca6fe3039">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTIxLTEtMS04Mjg1OA_7bdfd6ae-9309-4062-8012-2d3dfbdc6ea9">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d183758c28e42748ea9f0baf38ea61b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTEzLTEtMS04Mjg1OA_2b56660a-3f8f-4a80-b80b-cd47ec9cd821">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTE3LTEtMS04Mjg1OA_8ec5d55a-f5f0-4bb7-bf9c-4d40adec9c92">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTIxLTEtMS04Mjg1OA_7517cb8e-436b-4c9f-9cba-f249dba9155a">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c369d6b43ba4b62913e4007fef79e83_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTEtMS0xLTgyODU4_e7bab56a-2374-4835-9a9a-f451a1a64869">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c369d6b43ba4b62913e4007fef79e83_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTMtMS0xLTgyODU4_43708b2f-39ad-444b-889d-a2c86a3a178c">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i006a422e447e45a4a9b4c1c667093316_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTktMS0xLTgyODU4_70e0b724-51e9-4756-9e32-48e9c7c86cca">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5547116dd92544ff88c29dc8b9b6fe3e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTExLTEtMS04Mjg1OA_a39c9c01-74f3-4781-9581-f187c2592e74">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a03703f143645bf9ba9043225c49c63_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTEzLTEtMS04Mjg1OA_19d8de33-20a3-4d50-a199-72f122407d99">626,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce95dfdb9b847c5b2476842c531da54_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE1LTEtMS04Mjg1OA_7f1fa353-839c-44aa-bbd7-28d50c26ef66">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97488e48877b4c0f9463a34a496911e5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE3LTEtMS04Mjg1OA_d8d25ff0-9664-4ba1-a7ec-99092d4f20ae">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace02407fa42475e9b151a58bea5b3d5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE5LTEtMS04Mjg1OA_1fee3d4d-c226-46c6-b27d-cb840ff3ac35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTIxLTEtMS04Mjg1OA_ba732e45-0014-429f-8a79-03325eee1e6c">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTAtMS0xLTg5NjU1_8a6bb333-5720-430e-8abf-edbdd08b7af1">Cumulative-effect adjustment from adoption of ASC 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2738bd3890c14cba841e976265d057fe_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTktMS0xLTg0MzYz_201e339e-0534-42ac-9e1d-5ae97c88641a">106,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a355f9a909459691e4f7374ba9cd65_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTEzLTEtMS04NDM2Mw_65ad2606-cd1b-404d-8dff-991d0e7a54a1">39,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67118d2408f84f85a9231fcddea5a5e7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTE3LTEtMS04NDM2Mw_e3940d18-60fc-4d6c-b408-716a163e8a20">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72141e7136894e7394a041ed0f2a15d0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTIxLTEtMS04NDM2Mw_251560f6-9b87-4fb4-bb3a-09f8a8124250">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTktMS0xLTg0MzYz_94426557-de09-4c51-9136-4b8902cc3615">33,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTE3LTEtMS04NDM2Mw_86eba9e1-8bf3-4b69-b00b-dec1bcd504dc">33,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTIxLTEtMS04NDM2Mw_8a70d6fc-6afe-48d9-aab2-0343357c63b0">33,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTEtMS0xLTg0MzYz_c695de00-6fb5-443e-83c3-99aa2c221be1">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTMtMS0xLTg0MzYz_136d1ec5-dff2-4c57-9f2f-47f5f6a956e4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTktMS0xLTg0MzYz_e90c676f-0015-4daa-84d0-2e77d222f836">4,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTE3LTEtMS04NDM2Mw_227658ef-eb06-4230-8502-5ece3b29aa27">4,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTIxLTEtMS04NDM2Mw_7640a89d-1501-42e4-bd48-93adf60b235f">4,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEtMS0xLTg0MzYz_992d1071-41d1-4a48-a882-ad61db5bcc2a">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTMtMS0xLTg0MzYz_c807100b-6eab-47a3-852a-fd1d33abf3d7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTktMS0xLTg0MzYz_81419573-47f8-49e2-b521-8a4a883a290d">7,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE3LTEtMS04NDM2Mw_df3365ab-5b21-41a1-81c7-5679c5ab2833">7,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTIxLTEtMS04NDM2Mw_d3ad72c6-a673-42e3-960b-82b7d76a3f38">7,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTEtMS0xLTg0MzYz_05b25042-92d5-4465-b807-1fd480b918cb">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTMtMS0xLTg0MzYz_0029da6f-d915-4d15-8d9f-2894f63f472a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTktMS0xLTg0MzYz_63fee225-61b0-4419-8276-a3facb6f7720">11,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTE3LTEtMS04NDM2Mw_cbebc82d-d935-4814-b1cb-f6511b936f36">11,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTIxLTEtMS04NDM2Mw_3668ba56-340b-44cb-9a38-c8a7c2b929ba">11,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange of 2024 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTEtMS0xLTg0MzYz_57aa91af-ab64-4473-a22e-ee862ac6cc0d">5,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTMtMS0xLTg0MzYz_83d4dd2d-bb31-4bf1-b596-a0bbf68f9e1f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTktMS0xLTg0MzYz_3166be2a-2a50-4b1d-9832-51baa0688cdb">101,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTE3LTEtMS04NDM2Mw_0952f843-30a6-4144-beca-079cb246a35e">101,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTIxLTEtMS04NDM2Mw_04a1df6d-5c8a-424c-a97d-79b3901d9853">101,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTEtMS0xLTg0MzYz_182db4b6-ca7e-46c1-85b0-3308518ed676">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTMtMS0xLTg0MzYz_13255455-e15d-45e2-8b59-e437177557f7">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTktMS0xLTg0MzYz_ef9aac24-7ca4-4477-88a1-937955c44d6d">130,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTE3LTEtMS04NDM2Mw_9b00e697-32f6-4b96-975a-bbb4ec6c4eed">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTIxLTEtMS04NDM2Mw_6e9d24c0-771a-4232-9905-a5b89c1d9f98">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f12b36b156e4f77b72612737e0e8773_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTExLTEtMS04NDM2Mw_0be039f7-51d1-4c95-a98d-ce49a2a5e6bf">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTE3LTEtMS04NDM2Mw_79a5051b-6ee6-411e-b5dd-2b5b670e5568">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTIxLTEtMS04NDM2Mw_845b4bf7-4c71-4181-a597-5864f5ff41f9">816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ec9777d918a483895645ef1f407025e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTEzLTEtMS04NDM2Mw_590c5caa-4771-454a-9011-23d2b83df640">19,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTE3LTEtMS04NDM2Mw_79c5898e-6fcb-4307-9ec7-38c8e3ae3eaa">19,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTIxLTEtMS04NDM2Mw_13b883e0-cfaf-4acf-b118-8db072082e5a">19,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48a51239b501447b911a29ce59ff5506_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEtMS0xLTg0MzYz_b6ca6730-5567-4e7f-8dd2-ce1a3cf458bf">101,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a51239b501447b911a29ce59ff5506_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTMtMS0xLTg0MzYz_b2eaaec1-308c-42c2-bf5c-122ec7287e6c">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7972290d242a4362ba5061064cb35fb0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTktMS0xLTg0MzYz_346a2750-d0f8-4968-8818-42ed488a30fc">1,486,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bab8ce4c244fd1b411ed8b2d13efb2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTExLTEtMS04NDM2Mw_c2978d5c-d99f-4cb4-ac6d-23132f76e3e7">1,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8ebc0071f484c15a790e6c754033f5c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEzLTEtMS04NDM2Mw_aebfe06b-c4a8-4db1-9b69-0cff573a87cf">606,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6682920acd2443d386cf76a82976b820_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE1LTEtMS04NDM2Mw_52166339-6f47-42e8-8d88-b3449ff627a4">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09286a182824949b042732ea31cdf80_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE3LTEtMS04NDM2Mw_782770ca-6058-43ff-bf5a-c671aa4c0e82">859,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04d6ce7269d40dab417987869d2650e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE5LTEtMS04NDM2Mw_f0903d83-2a6a-4c41-80cc-806901d7e95b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTIxLTEtMS04NDM2Mw_14edbf6c-f222-4e93-acee-c3606f40bb2b">859,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy0xLTEtMS04Mjg1OA_d00664c6-f064-4eba-af4f-32195174fa23">19,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy0zLTEtMS04Mjg1OA_e25c6efd-c718-4639-ab4a-380b38636984">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy01LTEtMS04NDU2NQ_2d676619-4cfe-42a6-89d2-ca05ffd20b7d">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS0xLTEtMS04Mjg1OA_313ef0db-d71a-48e6-a67b-52de79b1f8dd">23,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS0zLTEtMS04Mjg1OA_2df495e9-e6ae-44d3-9761-e09ea39a82fb">13,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS01LTEtMS04NDU2NQ_11ea8732-9755-40ec-aec8-d2db63a38b1e">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi0xLTEtMS04Mjg1OA_ae8efbb2-80a2-4779-b984-0ff80440b113">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi0zLTEtMS04Mjg1OA_4e4594be-044c-450a-b310-c9847966125b">6,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi01LTEtMS04NDU3Mw_d50e2657-560f-4fe1-9a17-3f1fe9de252b">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy0xLTEtMS04Mjg1OA_e578c599-30b9-4ada-a682-ec9fe37e974a">4,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy0zLTEtMS04Mjg1OA_2de0600f-1291-4523-aa3e-f012abe63d17">13,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy01LTEtMS04NDU3Mw_d9af58f6-97d9-41e2-b773-4168b181fa71">10,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC0xLTEtMS04Mjg1OA_9e349ebd-da19-4c91-a5ad-099bee792536">67,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC0zLTEtMS04Mjg1OA_abdcb58c-dbb7-44c2-8288-b6d14a6564c8">60,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC01LTEtMS04NDU3Mw_fcdf9ec0-fbb4-49e6-b6b4-5175915b975f">61,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0xLTEtMS05MTU2Mg_a767683a-cf44-4d27-aa7b-58352ab040a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0zLTEtMS05MTU2Mg_7f8bdf79-e4c4-4c80-96b8-bee8eec20dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS01LTEtMS05MTU2Mg_7f401b53-5a6d-45d0-8288-4124ae826791">47,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0xLTEtMS04Mjg1OA_a6ad207f-141e-4dd6-a202-8aa4331118bb">33,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0zLTEtMS04Mjg1OA_70b00e70-fa50-43fa-a3b8-65de7269b6c2">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS01LTEtMS04NDU5MQ_835c2a48-2b8c-4fe0-934a-4e95a8d5c78b">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtMS0xLTEtODI4NTg_5b227b3e-2477-4638-9854-6daefcb2b786">45,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtMy0xLTEtODI4NTg_c7f47aa9-e1ea-412e-90ce-122b83ee8716">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtNS0xLTEtODQ1OTE_32029db9-e552-4417-a694-f91106a6e9c1">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtMS0xLTEtODI4NTg_2a0ff33d-f95b-44a3-a692-2d3ddc26cca6">23,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtMy0xLTEtODI4NTg_f81357b6-c9de-4f33-8c62-965d38c06f4b">13,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtNS0xLTEtODQ1OTE_5c86ffa5-a4ac-4267-ac50-e95e75be8691">21,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItMS0xLTEtODI4NTg_065be73a-b340-472a-a6af-a90fbe5d7c96">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItMy0xLTEtODI4NTg_3f2d5a08-34db-4767-8549-b11d434a74f8">18,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItNS0xLTEtODQ1OTE_9de1e621-7df0-4748-a6c5-d4f1c9c05a26">14,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtMS0xLTEtODI4NTg_91eaec76-0ac3-4603-b746-252404475e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtMy0xLTEtODI4NTg_9a78c7b0-d1f9-4d45-b901-7ca52d5e65c7">45,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtNS0xLTEtODQ1OTk_94c97816-3288-46c4-91f9-84b93475cf75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMS0xLTEtODQ1ODM_94f4d440-219e-481c-90d8-a3ac65f66320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMy0xLTEtODQ1ODM_b8eb171a-9f09-4fc2-9860-4208e7446fac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtNS0xLTEtODQ1ODM_072d9e2e-b157-4de8-9bc7-6fd419106a70">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMS0xLTEtODI4NTg_3a4373d6-0752-444e-a472-8dc81bbc846c">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMy0xLTEtODI4NTg_516b6cec-2b1e-4646-9631-0140495d2b9d">21,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtNS0xLTEtODQ2MDc_43cd53ce-bbd7-4420-9035-c78554c0f5c3">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:IncreaseDecreaseInTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtMS0xLTEtODI4NTg_b6ac90a4-fcba-4a16-a283-4ac5c7117b38">45,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:IncreaseDecreaseInTaxReceivableAgreement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtMy0xLTEtODI4NTg_ee5e8c03-56a0-4e46-a270-ed233fbb4d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:IncreaseDecreaseInTaxReceivableAgreement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtNS0xLTEtODQ2MzM_b3483153-d0a6-4321-a775-a519a551410a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtMS0xLTEtODI4NTg_df96ef37-2e7e-4dae-88d4-294c6d92b8bd">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtMy0xLTEtODI4NTg_d26fba7e-5102-4e55-8f49-7d02564d2681">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTctNS0xLTEtODQ2NDE_e54f24f6-5c0d-4fbe-bfd0-28d797773dcc">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTgtMS0xLTEtODI4NTg_78b150f8-5342-4c82-af14-6dd669b9febf">102,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTgtMy0xLTEtODI4NTg_5ab5e435-436a-41c2-95a2-59c1bfdcdc7b">5,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktNS0xLTEtODQ2NTA_4b440c5b-764c-4741-aa93-96d0cad95281">47,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktMS0xLTEtODI4NTg_26daea35-ec6f-435f-9388-3dc5e2f09805">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktMy0xLTEtODI4NTg_8c9c8167-b8e6-40dd-b040-5a8ceeb4e530">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtNS0xLTEtODQ2NTA_a6eed9af-86c9-4755-bc0b-058500654408">7,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtMS0xLTEtODI4NTg_a0f89318-86d3-465f-aa71-d17aa0cc8269">7,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtMy0xLTEtODI4NTg_c075eed9-c21c-4670-b794-e24b4b713364">18,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtNS0xLTEtODQ2NTA_7c933a94-e60f-4308-9de2-d796acd0eadc">11,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtMS0xLTEtODI4NTg_569128bf-3aec-4f8a-9207-9f4ddd8bd3f4">13,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtMy0xLTEtODI4NTg_0d534192-4094-4076-8e68-47bf0654bb71">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItNS0xLTEtODQ2NTg_bfe4a944-bdf3-46c7-83ba-91582c330750">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItMS0xLTEtODI4NTg_de5796ec-e5a7-4fe0-8f9b-c58654a1c245">28,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItMy0xLTEtODI4NTg_c6430b7d-3d9c-440a-9be6-b50e1651bfd1">324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtNS0xLTEtODQ2NTg_5e3b972f-2467-4373-bdb2-df4b8a1c4d1b">8,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtMS0xLTEtODI4NTg_fa389acd-da0f-4b52-b25f-6c36fd44c928">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtMy0xLTEtODI4NTg_6cfd606d-6d14-49c8-b6d1-0e483cf08f2f">3,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtNS0xLTEtODQ2NTg_c6d0519c-2341-4a7f-85ef-361490857985">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtMS0xLTEtODI4NTg_f63571cd-f5e0-4b95-aa6c-57d6ef98be33">6,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtMy0xLTEtODI4NTg_c97fe1b3-6901-4323-a3a9-9e6cef0f307f">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtNS0xLTEtODQ2NjY_f36eb246-03e7-41de-abcc-96ebc6ffb3ae">8,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtMS0xLTEtODI4NTg_d4beea75-9157-4a22-8ecd-8470281ec319">28,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtMy0xLTEtODI4NTg_7af95c9e-b029-458f-960b-5358b5da6c38">3,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtNS0xLTEtODQ2NjY_ae270ef5-0e33-4fa2-9e27-b02212ae7b6f">36,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtMS0xLTEtODI4NTg_abfa4b4c-10d2-46a9-9cfc-83b5ed4333f1">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtMy0xLTEtODI4NTg_9060c783-f071-4666-85d4-29334f86fd20">8,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctNS0xLTEtODQ2NjY_dc701156-c949-4e26-9623-e259000a4fe9">11,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctMS0xLTEtODI4NTg_2ca2ba3c-645d-4ecb-ae42-fb6a5597029c">2,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctMy0xLTEtODI4NTg_558c5c8b-f8b1-4b3f-85b1-530f0d93f2d3">6,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtNS0xLTEtODQ2NzQ_6a60fd29-d4e0-4d70-ac2e-a8ff37ef6f39">2,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtMS0xLTEtODI4NTg_7027ed6f-d0ae-4d56-b14b-f8a6ba5cbeaf">1,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtMy0xLTEtODI4NTg_877a7127-84e0-4439-a086-2261448aaca7">2,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktNS0xLTEtODQ2NzQ_e1d7f9a0-d53a-4f9e-8764-3cf431219a32">8,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktMS0xLTEtODI4NTg_aefd47ea-9382-4c6f-9411-359abcf007b8">11,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktMy0xLTEtODI4NTg_8bfe1649-ee03-4dad-a499-d875a92cd7f6">38,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzAtNS0xLTEtODQ2NzQ_3b3e5c8c-8735-4fae-825b-aa2cd1ab310b">16,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzEtMS0xLTEtODI4NTg_b8879ad4-dc11-4bf9-82d5-24c144ecc806">248,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzEtMy0xLTEtODI4NTg_2c18aae0-5b6f-4e87-860c-3827a778271a">49,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItNS0xLTEtODQ2ODI_99b609a1-1d83-4c28-8755-48c942ae0662">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan for implementation funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMS0xLTEtODQ3MTc_90f2581d-17d3-4895-a6cc-95fa1bbd573d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMy0xLTEtODQ3MTc_70841a35-0639-4841-9842-4ca43423a5c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtNS0xLTEtODQ3MTc_6b49ffa7-c677-47da-a4b0-cc60f1a915fb">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItMS0xLTEtODI4NTg_f0da7b6c-ee22-4315-a2ed-d1ea7229e067">30,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItMy0xLTEtODI4NTg_4bc561b3-f98e-4f5d-99f4-0e812c979501">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtNS0xLTEtODQ2OTA_0b136ed5-5481-45a7-a8e8-e0c4e89ff0e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMS0xLTEtODI4NTg_de4c7888-b38e-448c-a4d3-448f21bde995">9,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMy0xLTEtODI4NTg_ffd398b0-fc19-434b-8ce6-93efc3a9e5f8">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtNS0xLTEtODQ2OTg_1fd209a8-ca79-4567-8926-ed1be889e97c">2,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtMS0xLTEtODI4NTg_436d90ea-ea13-42d0-b67e-9839588584ba">5,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtMy0xLTEtODI4NTg_fc9b6836-8976-4a84-9096-aa9318a20b23">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtNS0xLTEtODQ3MDY_8d3f3ea0-3876-4f98-9475-831af4ef14ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact to cash and cash equivalents and restricted cash from initial consolidation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMS0xLTEtODQ3NTQ_05bfea16-68ea-48d5-a162-6f67896f81f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMy0xLTEtODQ3NTQ_091a4278-1113-407f-b77e-d7fbacab77c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctNS0xLTEtODQ3NTQ_a21f50fd-d7ea-4a77-aa3e-014be9a02862">159,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtMS0xLTEtODI4NTg_a371afb7-ed6b-41a6-b7c4-cc1267447f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtMy0xLTEtODI4NTg_da83cae1-cdd1-432d-823f-c9f2b42f653b">2,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctNS0xLTEtODQ3MjU_3c56ab37-53a4-4516-9eb5-e60078cfca6c">11,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzYtMS0xLTEtODI4NTg_06b2bea7-533e-4e72-847a-7047533db1b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzYtMy0xLTEtODI4NTg_3332a86c-10e8-406e-a4a9-c3a43fdc814c">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtNS0xLTEtODQ3MjU_d6694bbc-fdc0-4905-b70a-960742dc0d64">143,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMS0xLTEtODI4NTg_5c7de243-5ca8-4cdd-94e7-03fe1e05141e">38,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMy0xLTEtODI4NTg_c6fbfe0d-d274-4842-a11e-a3cd851e45cd">24,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzktNS0xLTEtODQ3MzY_1950063c-3da1-4461-9ea3-9c1eb030b322">29,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMS0xLTEtODQ3NDQ_069a344a-343a-41d9-bdeb-e99f71261506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMy0xLTEtODQ3NDQ_7cbeae4c-2a42-4092-9ac7-f6eab4bcb906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtNS0xLTEtODQ3MzY_db66c833-9f19-4cb3-bffd-5515fdf4a82e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtMS0xLTEtODI4NTg_d849cba4-0cb6-4f9a-bd10-db52b51ea83f">259,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtMy0xLTEtODI4NTg_ce14ac35-a5a4-4afb-a7d8-5cf2a6d85981">15,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtNS0xLTEtODQ3MzY_86b33d55-2772-44b8-8422-762713b89332">261,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMS0xLTEtODI4NTg_258a67d5-042c-4591-be63-824da1157051">59,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMy0xLTEtODI4NTg_45e63acc-7676-478e-85e6-3f34640c584b">61,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtNS0xLTEtODQ3Njc_23357e10-755f-4773-9865-834f9c5d0b1d">6,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Credit Agreement including settlement of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtMS0xLTEtODI4NTg_2780fbab-1bfa-4655-92fc-c2811339ce83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtMy0xLTEtODI4NTg_eb31676c-55f6-46a1-9b6f-6b34026b4218">98,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtNS0xLTEtODQ3NzU_9beabace-97ad-4b37-bfdb-683260809d8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDItMS0xLTEtODI4NTg_00d21b36-cbe2-4c86-9db3-f1634ac58b37">4,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDItMy0xLTEtODI4NTg_f8469c0d-bbdb-4528-bb41-43511cc3fe7f">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtNS0xLTEtODQ3ODM_f0bf8848-d8a0-42de-bfb4-c0ad0b222c57">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDMtMS0xLTEtODI4NTg_6a34c3e5-8ec5-4572-8fa4-b8ede63a3ec2">219,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDMtMy0xLTEtODI4NTg_206df105-695e-4b95-afda-954a4b146913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctNS0xLTEtODQ3OTM_77f03707-7fed-4686-a5a6-776625040b2f">30,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment and repurchase of 2021 Notes and financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMS0xLTEtODQ4MzI_46cd1560-4dc8-45cf-a7f3-d10685d9eca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMy0xLTEtODQ4MzI_7dbb85e4-7e20-4d9e-88cc-3101065b36fd">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtNS0xLTEtODQ4MzI_81ac0d0c-622a-4b64-8787-3ae83da56c37">16,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtMS0xLTEtODI4NTg_a435d6e4-8b02-4310-ae12-0fe3657539b8">14,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtMy0xLTEtODI4NTg_7e9cf86b-ea90-4918-bed6-76e18d35511d">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtNS0xLTEtODQ4MDE_a4a68325-ad66-4d6c-8ab9-3de82c54cf1a">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtMS0xLTEtODI4NTg_956c1dc2-23ac-49c5-8828-0b64c9fec36d">18,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtMy0xLTEtODI4NTg_378720ee-d062-434e-8c1f-4b1374e89273">3,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktNS0xLTEtODQ4MDk_bd8c623d-14d8-4135-a0d6-836071b8ed0b">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtMS0xLTEtODI4NTg_dbae0d76-a675-47f1-b737-25e6bc5f50da">131,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtMy0xLTEtODI4NTg_b4cf6782-da8b-445a-8079-087b77e2bef3">29,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtNS0xLTEtODQ4MTc_1e13c200-a567-490e-a3de-3c1499f36750">11,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctMS0xLTEtODI4NTg_f667b1fc-300f-4a02-87c2-dd93f33acecb">657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctMy0xLTEtODI4NTg_382ae2a9-5c5e-4e36-a8a4-6fa4cc5831b7">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTEtNS0xLTEtODQ4MTc_9ba8ec31-95de-4ec7-861d-f830beeeff2b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMS0xLTEtODI4NTg_948db984-50fb-4660-b2ad-4ed8ac7b858e">139,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMy0xLTEtODI4NTg_70b2ca86-69ed-4684-8db9-44088751a7ad">6,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTItNS0xLTEtODQ4MTc_a196e2a5-4d9e-487a-a30c-dd4a03d19d20">233,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab">215,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a" footnoteRole="http://www.xbrl.org/2003/role/footnote">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80MC9mcmFnOmZjNjY2MjAyN2ZhZjQ2NzliZDA3ZDI4Mzg0MGVlODg3L3RleHRyZWdpb246ZmM2NjYyMDI3ZmFmNDY3OWJkMDdkMjgzODQwZWU4ODdfMTAwNg_4debe02e-a9c4-4e2b-abd1-51beb3d703cf" continuedAt="ifee3396948954cea83e4ca91c73793f4" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifee3396948954cea83e4ca91c73793f4" continuedAt="iad222bded6bc44cbbc566d3644ea7c97"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee-for-service (&#8220;FFS&#8221;) reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80MC9mcmFnOmZjNjY2MjAyN2ZhZjQ2NzliZDA3ZDI4Mzg0MGVlODg3L3RleHRyZWdpb246ZmM2NjYyMDI3ZmFmNDY3OWJkMDdkMjgzODQwZWU4ODdfNDYw_8f4e1a50-cc8a-4f49-bd64-2f9223a480ce">188.2</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad222bded6bc44cbbc566d3644ea7c97">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MjY_5e2ba71e-62f5-4ba7-9b62-8e71207f7490" continuedAt="ibe0c82ee17084ebd857488a01c705901" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibe0c82ee17084ebd857488a01c705901" continuedAt="ie7833f0ba0684599a780e814fbca5891"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA0OA_2a48a199-bf26-41ad-9b0c-af9c27febae2" continuedAt="i4bf8d98bad704081b631a7a7eb27197e" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4bf8d98bad704081b631a7a7eb27197e">The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODg_b09d28a5-5934-4631-8f15-0a26788cb9bc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA0OQ_c44efd29-9ae3-40b3-b101-2dbdff47494b" continuedAt="i1ff5267d837d4205bd49bd52d4294751" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into <ix:nonFraction unitRef="segment" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ3NjE4NA_91720fd5-5904-425f-8645-a29370397f8b">two</ix:nonFraction> segments. The Company&#8217;s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie7833f0ba0684599a780e814fbca5891" continuedAt="i739f465021584a32b71c6c1360f00e93"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ff5267d837d4205bd49bd52d4294751">management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODk_62daf450-7e1b-4c76-b258-ab21dbafc01f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI3MTM4NA_a7bae898-11d0-4c9b-908e-7964e31d421d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODM_75f59d5a-e3e7-4236-bd65-22d5ad9486c4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14887938c6954e6aa3b47e2ee7ab8115_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMS0xLTEtMS04Mjg1OA_b0105b2b-5f46-4fb5-9a24-93bc02ecdbca">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71cc310322b745e4b90c41075da7866b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMS0zLTEtMS04Mjg1OA_61af8c68-6ea7-4dec-b642-037bc743338a">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a701948765942b1893beaaa2e66fdd6_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMi0xLTEtMS04Mjg1OA_6379ee4e-4669-4b0e-8880-bda4b887cd54">10,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4400bacf8149dbb4b6b9e8edb38886_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMi0zLTEtMS04Mjg1OA_f2da12be-b1ee-42d4-899e-c08a6cdc916c">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4972904db74d38b50bc19776ed0515_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMy0xLTEtMS04Mjg1OA_49775ab1-3cce-4127-b30d-16da00aa61b6">13,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65bd9571ab84a89b67a22db31fb6851_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMy0zLTEtMS04Mjg1OA_2d1d6268-acf6-414b-bc44-484205b9837c">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acaca954cda497b8eedaf35072199d5_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNC0xLTEtMS04Mjg1OA_fdf0d328-b19b-46e0-bb72-00cced9cadd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dea7b844271441593c0a803a0bbe671_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNC0zLTEtMS04Mjg1OA_26926199-230f-4c3d-aee4-cfaad08e9ddb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNS0xLTEtMS04Mjg1OA_e683d75a-b0e2-4ce7-87cf-4a05eb838481">26,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNS0zLTEtMS04Mjg1OA_1323f413-8149-449a-8736-6bcb75699916">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNy0xLTEtMS04Mjg1OA_c325e7ef-cc6d-4db4-a8cf-072a07a14e92">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNy0zLTEtMS04Mjg1OA_2acfac63-214c-4613-8fab-f8b680b186cc">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfOC0xLTEtMS04Mjg1OA_11a62342-2ba8-4abd-ab1b-8a04785637f2">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfOC0zLTEtMS04Mjg1OA_706f9ccc-1b5f-4530-83e5-76d94d73d725">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTAtMS0xLTEtODI4NTg_728ac26e-174a-4dfd-87fc-77bace9e3844">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTAtMy0xLTEtODI4NTg_eff5e1ba-bcf6-4894-8f60-e20a9d7a5cbd">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTEtMS0xLTEtODI4NTg_c336b0d4-7873-4738-80b3-7583f3877e7e">12,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTEtMy0xLTEtODI4NTg_7c197d60-d308-4d78-91f4-56964178713b">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4Mjg_f1bf72ca-f334-41b5-9bce-d5ff1da75108" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMi0xLTEtMS04Mjg1OA_362d5224-fd28-4335-a4bf-b9d0f619c635">188,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMi0zLTEtMS04Mjg1OA_889be920-d9d6-4c6a-8d11-2da11b30dfa5">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMy0xLTEtMS04Mjg1OA_a3957fcd-7c4e-4ebe-8e5e-5c800da0a439">26,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMy0zLTEtMS04Mjg1OA_1af36b15-c891-4a84-9ab1-951138eb7387">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfNC0xLTEtMS04Mjg1OA_3524958a-6c1d-4654-b020-7fc1aab0b0ec">215,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfNC0zLTEtMS04Mjg1OA_8f411d46-4f53-4927-9a55-7dd4c5bbc20c">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1MA_22eb88e0-fa2f-4ba1-ac1a-fa2f3565d37e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1MQ_f3e9dd83-9ffe-4ee5-addf-bee3c322f599" continuedAt="i05282005e82f4f898ad1b77dfc106901" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i739f465021584a32b71c6c1360f00e93" continuedAt="iea85b77cadbb4dfe83f7b3f5742a95d6"><ix:continuation id="i05282005e82f4f898ad1b77dfc106901"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2Mw_fcb673aa-4822-434f-b6dc-e05199721741" continuedAt="i7b3c5e6db6074e81accbb97b1a73fa76" escape="true">The following summarizes the estimated useful lives by asset classification:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i7b3c5e6db6074e81accbb97b1a73fa76" continuedAt="i8405303fd64b4d6db3b7d04b48a60a15"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMC0yLTEtMS04NzYyMQ_cc50e08d-3c19-403e-bdfc-5673b83c9646">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i854900308f794ba998ae7299645ae028_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMS0yLTEtMS04NzYyMQ_acbdaccd-c697-4436-88ed-211063255542">1</ix:nonNumeric> year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if29b4590881941c2b0537c0cb5530ec2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMi0yLTEtMS04NTA2OS90ZXh0cmVnaW9uOmE2M2QwYmFiOThiZDQ5YzJiNDFhOWE0ZjI0MTUzYjJjXzQ_c0d5f439-bedf-4d42-82cd-d18b3c7ef17c">3</ix:nonNumeric> - <ix:nonNumeric contextRef="id90606a7074b43028a72787dec08a3dd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMi0yLTEtMS04NTA2OS90ZXh0cmVnaW9uOmE2M2QwYmFiOThiZDQ5YzJiNDFhOWE0ZjI0MTUzYjJjXzk_aa980363-47aa-4dfb-8e7f-94277fade12e">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMy0yLTEtMS04NzYyNA_4d7fa30b-1d39-4231-b728-43dd2dd2176e">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.  See note 8 for additional discussion regarding accounts receivable and allowances.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1Mg_3d02236b-666f-4049-90b7-35f1462cf094" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3OTE_7f65a982-598e-4981-a16c-d24c0b80a91e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1Mw_92d53841-72aa-4c2b-ab99-e4328a5f979e" continuedAt="i77f1b5014dd744529dc0bc4e1fccb0e1" escape="true">Equity Method Investments</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iea85b77cadbb4dfe83f7b3f5742a95d6" continuedAt="i71d0845e28974d57bacb9785c86d0b66"><ix:continuation id="i77f1b5014dd744529dc0bc4e1fccb0e1" continuedAt="ic84fbdf40442454ca4d3212bdb34ff46"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic84fbdf40442454ca4d3212bdb34ff46">The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions.</ix:continuation> Refer to Note 17 for additional discussion regarding impairments on equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NzM_99194d88-23ea-4314-b9c6-fa977b6f2282" continuedAt="i6ea7cb279cac4ad38a9a0017b439f281" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="reporting_unit" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfNzY3MA_b6cf575a-e1b9-4abb-bc0a-a368a84e45c4">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ea7cb279cac4ad38a9a0017b439f281">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</ix:continuation> See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3OTU_11ac5725-d3d0-4eb2-942d-cec9dfa5d259" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NjA_be90ab06-8a3f-45e7-880f-1886812ae39f" continuedAt="i26958b08b6f7463bbc3f42cf8759ce71" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMC0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmQyM2YxNGI2YmZhYjRhNjQ4ZjhkMDJiYjFjNzY2ZDA4XzQ_c7bc2a0d-32ff-4834-8b94-e5d6e05d887e">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i794b0726c989443ab36cb30e95208a59_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMC0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmQyM2YxNGI2YmZhYjRhNjQ4ZjhkMDJiYjFjNzY2ZDA4Xzk_f728a53f-ffc9-4944-86e9-57265d59b77a">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6dac60b49c3a4ba89b21c18a1a14925a_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMS0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOjUyM2E5NDc4ZGQxNjRjOGVhYTEzZWE1Mjg1ZmQ5NWMxXzQ_218ff898-91f4-4f62-b6c4-adc24f730a62">11</ix:nonNumeric> - <ix:nonNumeric contextRef="i2d654080ecda47ef9c7d0a2e2dfbaaf3_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMS0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOjUyM2E5NDc4ZGQxNjRjOGVhYTEzZWE1Mjg1ZmQ5NWMxXzk_3095f197-a3f5-421f-9b3c-9def383ffaa9">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMi0xLTEtMS04Mjg1OA_52adc2f6-bc4f-4499-9709-99723e315eba">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f2eaceac28d48bb9ab95b4c5c5c71ab_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMy0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmI4MGRlZGRhZWQ2MzRiZjdhZGMwMjk4NzZhYmUzMTUyXzQ_469e83c1-e3c7-47c5-bdc7-de83f680d194">3</ix:nonNumeric> - <ix:nonNumeric contextRef="ib36ebf6b661340eb9375f2171ebfae85_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMy0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmI4MGRlZGRhZWQ2MzRiZjdhZGMwMjk4NzZhYmUzMTUyXzk_2055c9ae-4141-4174-b889-99f17ab005d5">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3Nzk_52dd6995-bb27-4cec-82c0-70e72e965f7b" continuedAt="i65f203db9e4c4559ab79d76d5f514a81" escape="true">Research and Development Costs</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i71d0845e28974d57bacb9785c86d0b66" continuedAt="i2a113ae3923c4b298efca47c901f8b43"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i65f203db9e4c4559ab79d76d5f514a81">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3Njk_71461b80-c1b2-435b-bc61-61a8b5d88fa6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NzA_aa22613d-270c-44f7-9233-5a3c95839886" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December&#160;31, 2022 and 2021, approximately <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI0NTM_371437ce-f09c-4846-a787-9c17bffb4957">47</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI0NjA_31f1b133-2399-442f-88fe-c83bc5a91a93">42</ix:nonFraction>%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI2MDM_cc37bdb1-3516-48c5-9961-bd2afcc0c29a">14</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1NQ_e0277e78-eee2-4a98-9c7c-5a7bec533f83" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MjU_f6e78ab2-17c7-468c-b856-5e593bf5c296" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTMxMzk_3ba63abc-e84e-4761-be8a-0b4b7f046418">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2a113ae3923c4b298efca47c901f8b43" continuedAt="i21f5c0f0dccb4f7b9f2ad6b67430f9e2"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MDQ_1492b3f1-cb0e-4837-ba5d-04bae12fb891" continuedAt="i304221e571994a38b97851c26fce22ea" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMzg0ODI5MDczMzk5OQ_7d7bc357-33c2-41bc-9773-9057c61454f1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4Mzg0Nw_b90e80e5-86f2-41ef-9c2e-5d90dad42916" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a">three</span> or <ix:nonNumeric contextRef="iec00374a180d419c962d3b3783c65443_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4MzgzMQ_54f9cc4a-eb69-4e16-8ee4-078c2b3837f9">four-year</ix:nonNumeric> period and stock options expire <ix:nonNumeric contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4MzgzNA_97e352b0-a87b-4d5d-b33a-bb89837506fb">10</ix:nonNumeric> years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1OQ_6eacc79e-f923-4cf3-9a17-96acd710f6eb" continuedAt="i1d172c807f00490aab01c30a50e9666a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21f5c0f0dccb4f7b9f2ad6b67430f9e2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d172c807f00490aab01c30a50e9666a">exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2MA_704bafc9-34e3-4cf6-a5f1-138ee63ad883" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss per Common Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2MQ_53b3cb8b-5f4a-4a7d-8386-55f156cc3bd1" continuedAt="i6563a015b2ae4efe95262918d6c38705" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for further discussion regarding fair value measurement.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMzE4Mg_a109de33-1473-450e-8563-c5b242861141" continuedAt="i13e5253519754d718e16436c7ff98b76" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i13e5253519754d718e16436c7ff98b76"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMzE3OA_cb4d036b-409d-4a49-835a-18c01f1d131e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $<ix:nonFraction unitRef="usd" contextRef="if3cc2e5de7bd4ce6ba6f437a0abdf186_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjIxMQ_c4e1f54c-af46-48dd-9287-7dbfb29991f8">39.8</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i11dc640ba4864bd9ab71ea3a5d03e0ce_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjI1Mw_5fad41b0-402f-44c2-8507-6b21253f4511">106.2</ix:nonFraction>&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $<ix:nonFraction unitRef="usd" contextRef="i3474707099524f5ab5cb8bcdef64f129_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjMyNA_773b118c-137b-4fbf-81f1-9257ac5cec99">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i278ee21fa4de4432b9d32268373e0d51_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjMzMQ_479f4fc1-fcf4-42d7-88a7-35d1279cebc0">41.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_49"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ1Mg_2d85c765-74a4-436f-9bf0-999617686b05" continuedAt="idf35b67b971745f0b2a235a8caff75cd" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idf35b67b971745f0b2a235a8caff75cd" continuedAt="i21b34935f94f4844af1d194bfe75a574"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including <ix:nonFraction unitRef="number" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTkw_1db1d8e4-0151-4ebd-8d00-c6947dd815d6">100</ix:nonFraction>% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ3_0f23b94f-2805-43d1-9f0c-de20f193ba0e">461.7</ix:nonFraction>&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfODg1_b8f01590-5367-44f0-8770-f9d65f28fced">256.5</ix:nonFraction>&#160;million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfOTEx_d9ce62cf-9c17-4a73-93cb-3241fc230889">3.7</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfOTYx_0e3ca226-22e8-4611-8223-e7dd4326ed63">130.2</ix:nonFraction>&#160;million as of August 1, 2022, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTAxMQ_949113b2-f8bc-4aae-bcc0-ceb1c87b0b1e">87.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTAzMA_464b66a8-d2b1-45b5-898d-32f58be75fa4">75.0</ix:nonFraction>&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ2MA_2a05f44d-bb88-4f78-8a03-4921fe18021c" continuedAt="i57f805dc3020419eb6eace603577c8a4" escape="true"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ2MA_81fa556c-939e-45cc-8f58-8beb877fd87c" continuedAt="ica5c35000fdd42caae1dc27f006f9238" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMS0xLTEtMS04Mjg1OA_25359b9c-dd39-49fd-8c51-b6c4363d97bd">256,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMi0xLTEtMS04Mjg1OA_84b895ef-4a21-4ead-b5df-fb348b75dbd0">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMy0xLTEtMS04Mjg1OA_d654c80f-53b5-4d14-87fb-15dc87aaf483">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfNC0xLTEtMS04Mjg1OA_7723a8b4-cada-4140-99a8-85debf136696">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfNy0xLTEtMS04Mjg1OA_41bc26bf-b24f-4d4f-91fd-20c99562215d">34,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfOC0xLTEtMS04Mjg1OA_849701f2-f384-40fe-8243-33d96ddb3b52">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfOS0xLTEtMS04Mjg1OA_990a457a-9b1f-4f56-9dac-44e178ba6317">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTAtMS0xLTEtODI4NTg_aa108b31-d379-4254-91ff-aa38664c45b2">36,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e6da47331f49339af7c848e28837a7_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTMtMS0xLTEtODI4NTg_20a844b8-9d4c-4e39-b834-9125399a2ee4">154,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i731418333b3f457db87705a22ef20938_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTQtMS0xLTEtODI4NTg_aa4d1634-18ed-441d-ace7-b2df043eedce">23,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied844aa0a1054ee8a864d50320d0ae98_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTUtMS0xLTEtODI4NTg_f85d526f-6615-44c3-ac8a-526ccaf169f0">17,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTYtMS0xLTEtODI4NTg_b7f6248d-020c-49fb-882e-cfb255ca8561">195,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTktMS0xLTEtODI4NTg_75379130-b951-4b64-8116-3a9b5f01f42a">7,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjAtMS0xLTEtODI4NTg_08921172-96b3-42e5-ae88-84f9bc533198">8,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjEtMS0xLTEtODI4NTg_2ddaebfc-fc3b-4a51-8469-3313280799ce">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjItMS0xLTEtODI4NTg_ab290372-5b31-42ce-a559-7efd2fef294a">48,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjMtMS0xLTEtODI4NTg_252efff7-4723-4c20-92c6-dd6287a32952">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjQtMS0xLTEtODI4NTg_c9fed61b-d64e-4ec4-befb-08c5e8d2b421">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjUtMS0xLTEtODI4NTg_18a9bdc8-b78f-4bb2-ae1f-5186ba322164">66,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21b34935f94f4844af1d194bfe75a574" continuedAt="i04c66e17d83a466dba6cfee27dc37295"><div><ix:continuation id="i57f805dc3020419eb6eace603577c8a4" continuedAt="ic8340d83f2ef485e9a7191f14e90a18a"><ix:continuation id="ica5c35000fdd42caae1dc27f006f9238" continuedAt="i4f2d9894179848f09d052fa61d597585"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjctMS0xLTEtODI4NTg_dc8f59a9-9287-4805-8440-21ef4a7ac473">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjgtMS0xLTEtODI4NTg_e5ff9e4d-cd9f-4852-92c6-07a0a1e8aa1e">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#8217;s consolidated financial statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i20beaec13c36498a8bc039958c7e54dd_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTc5Mg_f394710f-f60e-4888-9366-0f1d25e08ab4">20</ix:nonNumeric> years, <ix:nonNumeric contextRef="i251ae7d7cad040829c7cc296314ee7a5_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTc5Ng_de94a7c4-ee93-4f0d-94c5-91a39a84c055">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i0f82a39ee182494c9861025f94b259b3_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTgwNA_e1f541a6-1096-48f7-a8f3-f6b8a0743aba">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is <ix:nonFraction unitRef="usd" contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMzQ4Mw_39c8263e-d80f-4a21-a2ec-b04e1840c4df">no</ix:nonFraction>t deductible for tax purposes. Additionally, a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i6f5790c27f32404bbca49e84b9b60f2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMzU1Ng_b33f4ff0-4c38-44c1-a885-9bd0ff567fcb">46.8</ix:nonFraction>&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of December 31, 2022, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including <ix:nonFraction unitRef="number" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDI4Nw_a77137c6-31b3-45ba-8eb8-3adc677ee350">100</ix:nonFraction>% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDg0Nw_3e986b04-bc99-41a5-9198-fe66ea5307d1">117.7</ix:nonFraction> million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The acquisition consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDk4Ng_0fe5c59e-6270-45ac-b84c-538a4f4f4a66">46.5</ix:nonFraction> million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTAxMg_1ce5d074-7081-4784-8d84-3aa2c250ad3e">1.8</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTA2Mg_34ece5a4-e800-4135-b4c7-7528dac54f06">56.6</ix:nonFraction> million as of October 1, 2021, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTExMw_6e3be36f-d6b2-47d9-9416-d08f307f0820">45.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTEzMg_e2345f81-c25e-4c6b-b501-e0ec37b4b78b">14.6</ix:nonFraction> million as of October 1, 2021 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic8340d83f2ef485e9a7191f14e90a18a" continuedAt="i452aa44f0d224333b9faa8945bb8fc69"><ix:continuation id="i4f2d9894179848f09d052fa61d597585" continuedAt="ibe9d5a04df8247c19c64371af8effef2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMS0xLTEtMS04Mjg1OA_050b7af3-1235-41db-a9fe-ca16de76cf4f">46,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMi0xLTEtMS04Mjg1OA_dbf45afd-dc98-4319-8ed5-8baf531c53ae">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMy0xLTEtMS04Mjg1OA_d9af2223-6dbe-49b9-bb7f-3007a06b22b8">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfNC0xLTEtMS04Mjg1OA_0578a054-e3bb-48e9-848c-87f5f5ea864f">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfNy0xLTEtMS04Mjg1OA_567be779-c25e-427b-a31c-d323c50614cb">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i04c66e17d83a466dba6cfee27dc37295"><div><ix:continuation id="i452aa44f0d224333b9faa8945bb8fc69"><ix:continuation id="ibe9d5a04df8247c19c64371af8effef2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfOC0xLTEtMS04Mjg1OA_8f337e33-bb2a-4cc4-92cc-5752951c5fe1">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfOS0xLTEtMS04Mjg1OA_3b8fa321-b707-4e67-b74c-36f4f838d573">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTAtMS0xLTEtODI4NTg_029e49a1-0ec7-4c77-a33f-3863e52a85f0">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTEtMS0xLTEtODI4NTg_9bf5f883-89b1-4d26-8ff2-d72892016cb9">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2addc7fc4c404ba9808eca26ad7144_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTQtMS0xLTEtODI4NTg_30756a72-167f-4433-8348-08e5d7a71bb7">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba8025aa2b5405cbb56eb40f35c59c9_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTUtMS0xLTEtODI4NTg_dfe6656a-5c15-4333-a411-f0976b12c947">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adfad20cf7f4a50ab8f54cce2eb1c05_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTYtMS0xLTEtODI4NTg_5d563e60-4d4b-4d60-8673-5da86894f6ef">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTctMS0xLTEtODI4NTg_a9fe41df-cb6b-4154-857c-d98a7fa6e17b">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjAtMS0xLTEtODI4NTg_035459bf-b9c7-4cf8-a0fa-2d9dcf68240a">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjEtMS0xLTEtODI4NTg_80f8fa70-56fe-4d4f-98c5-a113c7cb269b">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjItMS0xLTEtODI4NTg_3acc0130-289c-4f05-85e3-376d6b084624">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjMtMS0xLTEtODI4NTg_2d19791e-6381-4542-a0e1-f3b31950a92d">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjQtMS0xLTEtODI4NTg_1effc386-97ac-4460-9254-79e90d66f60a">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjUtMS0xLTEtODI4NTg_59616ffd-d018-4069-a2b9-cfe1f290274d">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjYtMS0xLTEtODI4NTg_46e407ba-2935-4695-af9b-181f1216e31f">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjgtMS0xLTEtODI4NTg_4acc121a-d024-4a51-9b72-0e381144bb27">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjktMS0xLTEtODI4NTg_62288879-b076-415f-ba83-778931870029">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the Vital Decisions acquisition as the impact to the Company&#8217;s consolidated financial statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="ia9e5d9baadc74708b8555d95b779a6b4_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTg5NA_3af1d2ac-a7d7-419b-84eb-c2b90adafef2">13</ix:nonNumeric> years, <ix:nonNumeric contextRef="iaee36e9557da420a9bad4cb01fb7b743_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTg5OA_8a42a404-ab8c-4bbf-bc2b-d3d908a59cf6">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="ic49894ecf0ce44d6aa77bc0c1e9552b6_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTkwNg_864797c2-9793-467e-acde-2d13965cf35a">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $<ix:nonFraction unitRef="usd" contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzM3Mg_89ebdfdc-68ae-457d-b630-0b10b8c20225">69.6</ix:nonFraction>&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjI3Ng_c5b4519b-2d0d-45f9-bab4-d19b67d8aad6" continuedAt="ia688a8dd6dbf439a99df4f8742aefce4" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia688a8dd6dbf439a99df4f8742aefce4" continuedAt="ic5ff5b48b3414e5e89bac73a6b7c52cb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic5ff5b48b3414e5e89bac73a6b7c52cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjI3Nw_3497aab1-992f-40f8-893e-f91b9c7bdd57" continuedAt="i1dcd8493e075425f8c341b39aba02590" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3d798217ac414cb2080eebc4cbe42e_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMi0xLTEtMS04Mjg1OA_c7a0ea8b-2e24-4270-a858-08888fe26bad">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b848b407c6a43a98ee8f6b9437139c2_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMi0zLTEtMS04Mjg1OA_aac954f4-2636-4293-9886-d13ba0314c4d">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299f85d0abd44211ba11ded9b436d161_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMy0xLTEtMS04Mjg1OA_70ad7116-b700-4c78-a521-336c2db356ca">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6a62a817d1416b9bad705a714c025f_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMy0zLTEtMS04Mjg1OA_afee6864-4698-4a88-86df-e0013561ceee">117,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNC0xLTEtMS04Mjg1OA_4c68e74c-95d4-4a5c-b3ba-7a3d1852988a">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNC0zLTEtMS04Mjg1OA_d60324c5-3a02-434b-a53a-bbb1daa26627">117,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNy0xLTEtMS04Mjg1OA_eb0983ac-a555-4f66-a540-e95ac91edaa4">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNy0zLTEtMS04Mjg1OA_8c392369-f5c9-491e-b86d-1d67d2d1bc98">18,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOC0xLTEtMS04Mjg1OA_f5552d70-a042-43a3-869a-d809f525bd95">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOC0zLTEtMS04Mjg1OA_943320b7-6e53-45b0-ab37-7a8b9be59198">87,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOS0xLTEtMS04Mjg1OA_6a22e93c-9512-40c2-bc06-e52cfbc4b6e5">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOS0zLTEtMS04Mjg1OA_71af4a5b-4925-4224-a0e1-e23d9c502e1e">18,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTAtMS0xLTEtODI4NTg_6b44805e-f5de-4ac3-beee-53c33c7ec6d6">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTAtMy0xLTEtODI4NTg_8be1169c-b11b-4518-83d3-743156535b64">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTEtMS0xLTEtODI4NTg_ca690b87-1f25-4233-b7af-d496880d5514">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTEtMy0xLTEtODI4NTg_6acc17c8-7dc8-45f0-9322-cfee7c874f7e">125,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTItMS0xLTEtODI4NTg_3cad3d79-8f13-488d-8309-af4fa4421d72">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTItMy0xLTEtODI4NTg_7eecbbbe-6a33-4bbb-bc9a-67541b8f61e1">7,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTMtMS0xLTEtODI4NTg_e92ccf45-cb1b-4889-a66f-8f954377504c">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTMtMy0xLTEtODI4NTg_13cdf2de-90ca-41f4-8453-7b6f5571bb70">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTQtMS0xLTEtODI4NTg_4f05e835-43e7-4484-b1df-6db54566e297">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTQtMy0xLTEtODI4NTg_356f0277-2238-473d-9e4d-99206286c8c0">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTUtMS0xLTEtODI4NTg_a8e044fb-06f9-4361-b5d4-b7df432b8e33">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTUtMy0xLTEtODI4NTg_993b6662-f455-4b8d-b9f6-1693fd7687d2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTYtMS0xLTEtODI4NTg_5846684b-347f-4d84-819b-a59f0b2a1597">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTYtMy0xLTEtODI4NTg_b69bc09a-1ede-45a9-92ff-82f8cac5a6b3">7,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTctMS0xLTEtODI4NTg_d1aaf534-471f-4186-a605-d21c9e5aefdc">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTctMy0xLTEtODI4NTg_fa9017bc-5f28-4cec-829a-4b23f5b29f61">1,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTgtMS0xLTEtODI4NTg_1e3ba5d8-74ee-472f-97f0-2365b3073d02">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTgtMy0xLTEtODI4NTg_86d03260-f7b8-48e8-aad5-ee57d7dcd873">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="id27c2948c6044f07921f59caf0304963_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMTY4NQ_45da922a-b181-47f8-9696-e5d5ebe8d66c">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic1705bda8a114733924cb513d21573c4_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfNTQ5NzU1ODE2MzQ3_35a60f29-979d-4c07-b4f0-d187ed8fb4c9">13.6</ix:nonFraction>&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="id27c2948c6044f07921f59caf0304963_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjA1Mw_502ecbcd-a0bd-4d61-a13a-c4c51976e8aa">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1705bda8a114733924cb513d21573c4_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfNTQ5NzU1ODE2Mzc5_67eddc3d-5f7c-4930-8688-06f7fc77ff40">6.4</ix:nonFraction>&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="i1dcd8493e075425f8c341b39aba02590" continuedAt="i7b41199e7f564994ad159267233ca54d">Cash flows related to the True Health business were as follows:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i7b41199e7f564994ad159267233ca54d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMC0xLTEtMS04Mjg1OA_1af3ca37-6b48-4f7f-811d-f01a7b69a0a8">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMi0zLTEtMS04NTI4MA_b4a322b3-1d29-4648-bb66-feb33cf529a2">6,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMS0xLTEtMS04Mjg1OA_d93ce49b-0bb6-4371-8a1f-75ca787ba12b">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMy0zLTEtMS04NTI4MA_1affccde-74be-4a02-90ce-1fcd175abc7d">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ4MQ_ad62b498-ca99-4d70-846f-ad8352b62f1a" continuedAt="ic3c0493167b44b408c6ff6dc9b8ec379" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i304221e571994a38b97851c26fce22ea" continuedAt="idbe6df9e103f4524bff79bb4fe2f53ca"><ix:continuation id="ic3c0493167b44b408c6ff6dc9b8ec379" continuedAt="ic318ce2a573d4a529442e164668a244e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic318ce2a573d4a529442e164668a244e" continuedAt="i9da11e9ce9be48219c5c45e973d56fa9"><ix:continuation id="idbe6df9e103f4524bff79bb4fe2f53ca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ3Nw_2c103638-39e8-44ba-9124-b5067cf1f24c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:226.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb70847d04443d8b6e7ab48773cde8d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy05LTEtMS04Mjg1OA_095d6515-39e5-4202-ae3d-2bfc79c8b632">238,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a6dbe2c6f2414b90261c99c16aa440_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMS0xLTEtODI4NTg_af843040-f62c-4f6d-a308-c6586f3214a4">215,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5bff01d6db40d49a991496b0df8d88_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMy0xLTEtODUzMTg_7cf31b8b-5b43-4086-a5d1-87ea3ecbfc7c">236,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia342dc91eb1f44d4a17bc2df78ae5230_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMy0xLTEtODI4NTg_d8e1a6e3-31b6-4eb7-a1d3-ec0c5b966771">320,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb97d6ee9d56404985bda4f9b13e5846_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xNS0xLTEtODI4NTg_9f454018-6509-466f-a9e0-f8947b8e6af2">205,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcffd9facc4645f4a013b7bdbb72a431_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xOS0xLTEtODUzMjY_79d348e6-09d1-4a90-a65a-f5fdc12d74a5">274,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a2bb61dae04616b359eba263ce435c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC05LTEtMS04Mjg1OA_56f345f1-7abe-4f71-ba8e-79a68e503532">27,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d8936f21714f009331932a8897b732_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMS0xLTEtODI4NTg_9a3ae3d7-2511-4c25-8ec4-1136202ac330">26,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3548808ff348918ed362fd31f8088d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMy0xLTEtODUzMTg_6b9f0a01-60d7-4d57-9fce-aa07ec4f8366">68,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee490b62ac543baa9936f426d939efb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMy0xLTEtODI4NTg_74b7d815-c522-4a11-aedb-cc3dadeafda4">431,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60d893faa2748b58fedd3523e6ec66c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xNS0xLTEtODI4NTg_46c9b2a4-019e-4979-b565-9d6975cf3591">380,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab057b320374485bb2001c40a00ce836_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xOS0xLTEtODUzMjY_04d43d80-6045-4560-86b3-d37ff376c9e2">258,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab12224f7bf840829d0a888e32c3dded_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS05LTEtMS04Mjg1OA_cf3b24fe-a904-4e50-a327-0cd5d97ebd26">141,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b27104772b4bde9b232264fa371923_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMS0xLTEtODI4NTg_cc48f95c-0360-4e0b-acf8-d84c6a441aac">68,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd90e09efa14e17ad4601baa83a3961_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMy0xLTEtODUzMTg_59fd1625-f5f8-44c3-8591-7fd09af9ec14">77,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356a26303bb54909842ab7a281dbfe38_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMy0xLTEtODI4NTg_d6e27a59-d7f3-4c53-b48e-5b2cb14d9fc8">192,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfb19be991146d3a9e26988e59d0c39_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xNS0xLTEtODI4NTg_d7349767-182c-4ab2-884a-0cc2670517c2">11,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954aacf21ddb4d74a25b5f7fea44da70_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xOS0xLTEtODUzMjY_c6324760-cfa3-4f8f-95c5-fedcd8dc0240">9,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi05LTEtMS04Mjg1OA_d6da51de-4e41-4acc-ba85-6d819aaec7c2">407,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMS0xLTEtODI4NTg_99f5a876-0b4c-4d1a-9001-7f673d947442">309,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f54db1c05e74787a89c8997e36036e3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMy0xLTEtODUzMTg_8f6820d1-4e44-4b08-9946-5b1f713a3897">382,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMy0xLTEtODI4NTg_a6b92237-5d59-4729-9f0c-8f253d87c77c">944,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xNS0xLTEtODI4NTg_421ec707-00e2-434e-acdd-0a80a2cc249a">598,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60221f52e25e439cb996bb69367033a8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xOS0xLTEtODUzMjY_bd21de1b-41f8-4c19-98f0-b6040f2208aa">542,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDMzNw_d3e815eb-6367-42b2-8530-32b725002640">49.6</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="id8a19c81d5714f6d8f22e6db248a7c11_I20221231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk1Ng_a06651e6-a803-454a-bc63-b189de62bd4a">76</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i71c38f21edbe411aa8eb628e23ab4e20_I20221231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk2MA_856c2859-7cdd-4501-abd2-d9f940fbf92c">93</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2d354e96c97c42cba45e2df7b64eda05_I20221231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk2Nw_db3b8717-f020-4fef-b54b-f92a2bbeee04">100</ix:nonFraction>% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9da11e9ce9be48219c5c45e973d56fa9" continuedAt="i4c44f27776684742a4f7eb335a27f26e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ4MA_083f99b8-e05b-4973-852f-e30efd4758d4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMS0xLTEtMS04Mjg1OA_21d372bc-4045-4914-ae22-c2d4b5fa4105">246,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMS0zLTEtMS04Mjg1OA_0e67facd-01d3-48b8-9111-df00ed91afc5">129,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMi0xLTEtMS04Mjg1OA_44af32e8-27b1-4051-bdfa-fc9b80e4affe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMi0zLTEtMS04Mjg1OA_90d62292-3b4c-4ffa-a722-5ef47b04273a">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMy0xLTEtMS04Mjg1OA_208a03c8-e9c9-4136-91d8-c530a92b502c">5,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMy0zLTEtMS04Mjg1OA_debfb871-5123-4d2d-b579-774cad782130">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfNC0xLTEtMS04Mjg1OA_6fd68b82-87b1-45eb-9e99-fce6c4b510c1">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfNC0zLTEtMS04Mjg1OA_573a7461-562b-401e-88aa-95f69eb26e69">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMS0xLTEtMS04Mjg1OA_e9d713e2-f7b6-4960-9a24-b12a2fbc0101">16,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMi0xLTEtMS04Mjg1OA_f64eaa6a-7665-4080-9c9c-a6f4744ce642">11,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMy0xLTEtMS04Mjg1OA_6b537159-8f7f-4c45-9535-06516f313a9a">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfNC0xLTEtMS04Mjg1OA_b94fe6fb-985b-4a83-af00-3f58ca880a06">8,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzE2NQ_c87c3366-b57c-47b7-b0c5-4124f9c3ee68">36.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzE3Mg_900d4cad-5cb8-40d2-8b63-527dd2d082a2">28.3</ix:nonFraction>&#160;million for the years ended December 31, 2022 and 2021, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ie4dd7b111832484390e1d97d1f46453e_I20221231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzgyMg_adf82242-7126-45b9-9788-42a6873e8872">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ee9e7b57f344206982ad42c4f293487_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzgyOQ_cdf92cab-ff31-4dd9-a353-98df2760ddc9">5.2</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $<ix:nonFraction unitRef="usd" contextRef="i590b14ec27994ed597799e4952a9046f_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODA1MA_1dbc75b2-8d68-43c8-825c-29be6fc13833">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i934d9414193f4601b5323bf2a681279b_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODA4Ng_dad56dcf-fd1a-4ec7-8cc4-426067cf3bf1">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i35616843f0a7418d8fc7ad365b3215fb_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNTQ5NzU1ODIzNTg1_0ccee0fd-85f1-4bc0-a8ee-08747fb6c28e">1.9</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Evolent Health Services segment, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8607bc42763645fbbe43278eec65e305_I20221231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODgyOQ_2380d9df-a391-4402-bdae-7dddae04d2c7">14.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c9997d7a05d4993962ccc3338c361fa_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODgzNg_f7901236-c6f6-4c24-ad02-db034c03dd9f">27.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $<ix:nonFraction unitRef="usd" contextRef="i77bd19d50e3f457ba4098eb4c0c152d8_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTE0MA_54530142-99a4-4fb8-b58b-fe652c8ffdfd">20.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if8388c7551f94e269587ab5aac659a6d_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTE3Ng_e0f7d9d5-1b6e-4a80-b398-221e009b58d2">11.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie3355e9dfc324571bb9fba8d6e2175e0_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNTQ5NzU1ODIzODc1_a79dfe76-2a0e-4081-9449-ec0fe2be8beb">13.0</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c44f27776684742a4f7eb335a27f26e">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTM2Mg_8645e6a8-29a8-462e-9ebf-ebbe86fe9bcd">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMzA5MQ_a122fc8c-8047-4b6c-be3e-792c28b8a785" continuedAt="i4440c9e0858c4d3abf829340b6ec6497" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4440c9e0858c4d3abf829340b6ec6497"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2022,&#160;<ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjI4Mg_a3bf6e92-0bca-49ff-9617-66b2ee2fd1a5">67</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="i3b29b57edf8c489f99a4516a6ca5a0b3_I20221231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjI5OQ_5e515825-a931-4853-aa12-cd7c2f3cdc95">21</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i81cd6e53eeb5464e80084e5f32636562_I20221231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjM0MA_c7df34e0-d57b-44c1-adfb-abbf6d5bad14">29</ix:nonFraction>% past due less than 120 days and at December 31, 2021, <ix:nonFraction unitRef="number" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjM5Nw_87913ad0-a852-4928-bf18-9921ed659c0c">90</ix:nonFraction>% was current, <ix:nonFraction unitRef="number" contextRef="i11c2ab305dbd45518a81ed1d65fe5dce_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjQxMw_b1e33a8c-977e-4852-bc77-e4eab744f2a2">2</ix:nonFraction>% was past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="ic71ceeb3c88542a5b9fb0b508980035b_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjQ1Mw_7a414912-b23c-4909-923e-8fa53e3f7b94">3</ix:nonFraction>% past due less than 120 days. As of&#160;December&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjU3Mg_6f0d3eba-9114-45ea-8a2f-0a4b5dfb182e">269.1</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjU3OQ_36524d3a-16fb-4e58-86d9-08e4abb5258e">171.5</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjcxMg_42902abf-0c23-4339-9f62-61135f1e043a">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjcxOQ_7077c36a-3854-446c-83a3-836939568828">3.4</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMzA5Mg_179e68f5-a673-4f58-936f-5f31562d6ce8" continuedAt="i2893feff52034fa296a61edfe32c208b" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i2893feff52034fa296a61edfe32c208b"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMi0xLTEtMS04Mjg1OA_78539938-8240-458b-8b07-826771115241">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMi0zLTEtMS04Mjg1OA_a157e383-05a7-416b-908c-edede48ae62d">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMy0xLTEtMS04Mjg1OA_b4045290-7967-440d-8d64-906b21686521">5,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMy0zLTEtMS04Mjg1OA_b7153e11-036b-47b4-857b-16ee7e93f59d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNC0xLTEtMS04Mjg1OA_a76195ee-b8aa-40ae-a976-fae48fb57eaf">2,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNC0zLTEtMS04Mjg1OA_151a80cd-d906-45db-b872-375dd9892dba">2,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNS0xLTEtMS04Mjg1OA_00dc0298-e5f6-4aa8-b839-63f7a7ca4b85">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNS0zLTEtMS04Mjg1OA_a6478f02-bb4e-48ae-8fca-3dc6fbd53489">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNi0xLTEtMS04Mjg1OA_80e843a3-6ff5-40f4-8cb1-d64f3c200bd7">10,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNi0zLTEtMS04Mjg1OA_467e5a8b-f3c6-4d13-9316-9564bf6c678b">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjgw_5f8710e2-0204-445a-9a3e-4cd98330b3c3" continuedAt="i52556116eb364292b52bf45350a12e0f" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i52556116eb364292b52bf45350a12e0f"><ix:continuation id="i8405303fd64b4d6db3b7d04b48a60a15"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28121c511dcf46e8aeb20910dbcc12be_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMS0xLTEtMS04Mjg1OA_fc1d7be6-8fd4-425b-bc67-42cfb4b67e9f">30,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483d3e1f905c4cde909281c7434e61aa_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMS0zLTEtMS04Mjg1OA_5d0facb5-6a58-4e30-821f-96a4b691f38b">21,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7248538c4a04c15bcc464cd4c0426fc_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMi0xLTEtMS04Mjg1OA_8d1635b5-63d3-4af3-906d-c5540baca6da">4,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746f0154926c44cc9b1f8fa00aebd8f5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMi0zLTEtMS04Mjg1OA_59589e8d-6e23-4d4d-aca9-473a4ca38228">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMy0xLTEtMS04Mjg1OA_98506a56-12c1-49f8-a3bc-0917c55fe144">189,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c5eb57b4454e3b9de4de900fd38726_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMy0zLTEtMS04Mjg1OA_2064f848-021f-4fcc-a499-182dbcb7db08">159,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00357009ca34124aea7882662570449_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNC0xLTEtMS04Mjg1OA_538036fd-9743-42ed-91f4-cc13a730f599">14,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56205dd981748ccb2ada978c977bd74_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNC0zLTEtMS04Mjg1OA_be427003-2cd6-4097-8eec-a1c5c238b6a8">15,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNS0xLTEtMS04Mjg1OA_8cd75189-f47c-4892-8513-2e155c612edd">238,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNS0zLTEtMS04Mjg1OA_3c3cba80-8179-4193-bcb0-2352e3f04f17">200,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNi0xLTEtMS04Mjg1OA_36d17ea7-d0c5-49a3-a78c-be4b0cf9bcf8">150,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNi0zLTEtMS04Mjg1OA_6e0dba71-495c-4e17-be35-2d8febbf45fa">119,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNy0xLTEtMS04Mjg1OA_ab9bcf47-00e5-4c88-82f3-fa1a33a707d0">87,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNy0zLTEtMS04Mjg1OA_d509e69a-7d3a-4ebe-b885-f064306201cc">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMTQ2_ead96d8a-cb9c-433c-8815-fa18f1cdb9cc">29.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie6fe725ce94f4628b487593ab6df6f26_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMTgy_90a28d33-b037-4621-815d-d6e97e6d219e">22.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie4c0a14df2764899b90a8c02978cddda_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0NjIx_7901c2f6-f0dc-4bec-a6b3-b8a1925fda35">24.6</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMzI5_931d3ee1-3a19-449b-a668-1b35b7c0e3ba">73.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69c5eb57b4454e3b9de4de900fd38726_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMzM2_d6a382de-c471-4ced-803a-78890c4a2d32">71.2</ix:nonFraction> million as of December&#160;31, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNDUz_ff4b3235-8689-4dc5-9f0d-96e0710bcf31">32.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNDg5_9942add1-7962-4bf2-8c8c-231a25f6cb34">30.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0NzY1_d7dc776c-bf47-48ef-928f-4b49d6c98e59">28.3</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjE4_87a53031-1e31-44fc-b947-1da1f8efca41">27.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjU0_5d3feffa-5733-4b24-a728-56864691411e">26.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0OTg2_ea1fec14-b7eb-414a-a9b5-a3a1e83bac55">24.3</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjk4Ng_d14b395f-9142-4343-97ea-39de78c53138" continuedAt="i9628f85df0534d76a8048db597f57e6b" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9628f85df0534d76a8048db597f57e6b" continuedAt="iaef8a794e095419d823ba6c4617ca209"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reporting_unit" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzE3_b4300e8f-2087-4356-a2dc-8bc60bce03f1">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaef8a794e095419d823ba6c4617ca209" continuedAt="i24290e844fd4459986e6730b02f72018"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate.  Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i237b041a348240acacdd4c6703d9631c_D20221031-20221031" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzg0ODI5MDcxNTg1Mw_80add303-3c34-489b-bc1a-80d194177def">no</ix:nonFraction> impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2022. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our <ix:nonFraction unitRef="reporting_unit" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMTg4NA_2fbb4a26-3ad3-4f6a-b67c-e5d597ed1e9a">three</ix:nonFraction> reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzAwNA_23e6f1c9-9681-4a5e-807d-2e3777026e69" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi0xLTEtMS04Mjg1OA_3397478a-9fa8-45e5-b723-091280bd81a3">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi0zLTEtMS04Mjg1OA_d13f551c-2579-4bb3-bb3b-601ddb9ad1b2">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi01LTEtMS04Mjg1OA_431cacfa-b9db-4d07-b7f7-e1c220589b33">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0xLTEtMS04NTc5Mw_ab521432-f955-4d08-97fc-eeddc41c9e30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0zLTEtMS04NTc3MA_cacbca0a-ef86-48f1-8ef1-3743e37f84cb">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy01LTEtMS04NTc4MA_db7f9e45-cc0d-4b9b-a446-267a959a4c4c">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0xLTEtMS04Mjg1OA_75af81c6-574b-4ae2-bb87-603c90c4345a">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0zLTEtMS04Mjg1OA_675efddc-8996-4e19-8fdc-c8e860d83f53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy01LTEtMS04Mjg1OA_f35aa7a1-60d7-4dc1-bd10-034d7bee2e77">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC0xLTEtMS04Mjg1OA_08356206-1ac0-44d6-9695-fac64fd73899">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC0zLTEtMS04Mjg1OA_be018962-0fc0-4be6-a362-7683029953d1">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC01LTEtMS04Mjg1OA_e0a9d4ab-78ed-4428-b627-bc0d6e386eb4">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtMS0xLTEtODU4MDM_c1776756-7fce-4c89-9853-08145b20b387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtMy0xLTEtODU4MDM_808d2a51-7548-4f9e-8836-11bee5698bd5">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtNS0xLTEtODU4MDM_ad91af2c-33b1-448a-a619-4ccdd590405f">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtMS0xLTEtODU4MDM_7287a501-828b-4bb6-a4fd-40cf5197f694">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtMy0xLTEtODU4MDM_045da0c5-6ca4-451b-8f79-22346a051c00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtNS0xLTEtODU4MDM_74f1aada-1e87-4b89-bb4b-5ab9e8f346aa">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItMS0xLTEtODU4MDM_cb5a58c5-bc80-4fef-9f78-4818326ab9c0">214,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ea7981a58e4cf1bb90015e38b89007_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItMy0xLTEtODU4MDM_e6f59ad3-eb6f-467a-9aa3-e713e54ddb64">508,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItNS0xLTEtODU4MDM_e6144a74-86dd-4cd7-9589-45a5b08db331">722,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjI0OQ_9f6b2453-9f84-44f7-96f5-cc413ae94990">575.5</ix:nonFraction> million as of December 31, 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i24290e844fd4459986e6730b02f72018"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i26958b08b6f7463bbc3f42cf8759ce71"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a58b613f9cd47b2bef946da4ceb3f68_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xLTEtMS04Mjg1OA_bb55a252-88b9-473d-a9bc-58c03652a3b0">12.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0zLTEtMS04Mjg1OA_50fb3575-7825-4af1-9b3c-10683b398e15">43,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi01LTEtMS04Mjg1OA_6ac09f21-ff17-446e-8e7a-9f86821ac37e">11,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi03LTEtMS04Mjg1OA_98e73955-cf5b-4d40-b50a-06271eb4b431">31,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b6ad6302d9d4822b4677702de0baca6_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi05LTEtMS04Mjg1OA_4b22361e-80ac-488c-a682-79177cc26f93">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xMS0xLTEtODI4NTg_c809a589-144e-45ca-9c5e-0668625381e7">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xMy0xLTEtODI4NTg_66a2ce1c-6d17-445c-8110-620c79be4b90">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xNS0xLTEtODI4NTg_16820f05-8428-419f-a77f-59f39a19ffb5">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9b789e0f0774de2bb35c5e8066ddbdd_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xLTEtMS04Mjg1OA_dd51e4d3-987a-4a47-bb04-a93061e3e930">15.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0zLTEtMS04Mjg1OA_486b6d5c-832d-40b6-8bd7-755a0d696ee0">465,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy01LTEtMS04Mjg1OA_6338e5fe-301b-433e-ad32-b63ceaa63093">92,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy03LTEtMS04Mjg1OA_243a3eb4-7e86-4073-9760-0f1033a370d9">372,259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f170a61f3e841a696fad5b6a3b357d0_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy05LTEtMS04Mjg1OA_ab4aa0b7-c389-4228-9186-b68fccc65703">14.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xMS0xLTEtODI4NTg_e40a9b73-a72a-487b-b350-9f143816a9a8">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xMy0xLTEtODI4NTg_f6d74d2c-93f9-4071-b032-6696666e76de">72,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xNS0xLTEtODI4NTg_18a941d9-4c4d-49f1-a7d0-e9aec56270b3">238,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xLTEtMS04Mjg1OA_c3eb6d71-5a03-4499-8516-b60ad9c53f33">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0zLTEtMS04Mjg1OA_7f1d13ce-158f-449d-91b2-4c7ca1a0b0f0">111,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC01LTEtMS04Mjg1OA_fff00557-0271-43bd-ba15-73256bc6eabe">80,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC03LTEtMS04Mjg1OA_5a9af28b-2135-4856-a69d-eeda94d42010">31,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e29b5293f19416f96f6460860735e67_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC05LTEtMS04Mjg1OA_560ce6ba-ff30-47d5-b090-f30f604e9bcb">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xMS0xLTEtODI4NTg_44095951-a158-4fc7-b0aa-fb1731c5f460">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xMy0xLTEtODI4NTg_24924b6c-2ab9-41bc-b768-592f1789053f">73,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xNS0xLTEtODI4NTg_f0eb7d39-4b4c-43be-b093-a4e0b6c4be74">14,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48beabe4144b40898879179f114601ab_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xLTEtMS04Mjg1OA_15a6ff51-d9f1-4ce5-b669-945d936133ce">0.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0zLTEtMS04Mjg1OA_729bdf1e-0df3-42d6-a6b5-00bfe9268f62">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS01LTEtMS04Mjg1OA_75e1c013-b4c8-4abf-bae5-c6a71300fd25">1,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS03LTEtMS04Mjg1OA_497979b2-d8d8-4bd3-93d5-b010fc209d01">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2cc46062bad34e1d9ad09e26a1395bd2_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS05LTEtMS04Mjg1OA_e5a31293-69ae-45bd-b6d6-87e477596cfe">1.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xMS0xLTEtODI4NTg_6616af54-1691-49b5-8ac9-309253125543">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xMy0xLTEtODI4NTg_8c558707-d3e8-43c4-9307-a5a62a37fd69">950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xNS0xLTEtODI4NTg_15654b6f-b62b-4552-9636-a8acf593aa13">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ee5d4ede71548928f9a624468ad3e3b_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xLTEtMS04Mjg1OA_1cd04051-7022-4b91-b029-4f05d18ef9ab">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0zLTEtMS04Mjg1OA_fe904805-9846-4837-b799-fb28abfd1847">18,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi01LTEtMS04Mjg1OA_9989a14a-b39c-4252-b653-fd19959f68a9">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi03LTEtMS04Mjg1OA_3d74151e-f682-4a2b-9b1f-a15b6e0e36c7">7,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieeedc3e2c6d34ca9b04f0eed321027af_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi05LTEtMS04Mjg1OA_fd6cc53b-9a55-4829-87e7-435305b2195f">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xMS0xLTEtODI4NTg_3ad54fea-c09a-42f9-9e01-92c3eb731583">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xMy0xLTEtODI4NTg_8b048e68-1aaa-4a17-a141-8885aef23c9b">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xNS0xLTEtODI4NTg_b8ccf660-376b-47f4-a37f-60486b220720">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0zLTEtMS04Mjg1OA_f7c73f18-e119-46f9-8dd6-7bc396343108">640,510</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy01LTEtMS04Mjg1OA_7322bf55-f479-4cbf-b0e8-815ce0aacf0c">197,726</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy03LTEtMS04Mjg1OA_80d2a568-4b3e-439a-a9f7-775be78d6137">442,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xMS0xLTEtODI4NTg_1ec1e9cf-7536-44d0-a177-3d1c214356de">442,376</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xMy0xLTEtODI4NTg_6cd27a64-8cf6-49e8-859f-c376d34f3360">162,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xNS0xLTEtODI4NTg_a363efac-90b6-4fe5-b81f-dfc88df9d95e">279,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjU3Nw_c17ea41e-6978-4119-a712-3f35c069472f">35.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjYxMw_a5516e5f-2276-46d7-bde2-bc11f0d8a4b4">29.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfNTQ5NzU1ODE3MjQy_44e60ce1-7bd8-483f-9fd4-259196fd721a">32.3</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, excluding $<ix:nonFraction unitRef="usd" contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzg0ODI5MDcwMDg3OA_d0d43a9d-f7f3-4947-90cd-4aa5cc25d03e">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfNTQ5NzU1ODE3NTM0_4c4cb912-af42-4019-a959-7827bb152d94">0.6</ix:nonFraction>&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzAwMQ_23aed692-7e49-45e6-93f4-0d22d95c5815" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMC0xLTEtMS04Mjg1OA_70480527-8e5f-4586-b165-d499c199ea3a">41,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMS0xLTEtMS04Mjg1OA_a5269fd6-9ffc-455d-8611-75058a5c745d">35,604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMi0xLTEtMS04Mjg1OA_06739578-010d-4497-bfd8-729772c2bfbb">33,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMy0xLTEtMS04Mjg1OA_b4c28f9f-308f-414f-9417-0669723601ae">32,880</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNC0xLTEtMS04Mjg1OA_132bd24a-6990-4141-8404-8db114a97a7c">30,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNS0xLTEtMS04Mjg1OA_3b400321-234c-4c41-8f15-a0f4b359fc52">269,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNi0xLTEtMS04Mjg1OA_23c7a49b-e3ed-4b6d-b774-244e77eb2b8f">442,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2022 that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_70"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjMyNzI_5d2ef0a8-e562-4be2-8a32-e6fc841eb7c6" continuedAt="ie1f6e256894f494dba5512573bb3d2b6" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie1f6e256894f494dba5512573bb3d2b6" continuedAt="i7efcfd84a4cf4bb3b5a67ba618b352cc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the IPG Closing Date, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2022 Initial Term Facility, with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i316c2f9226f948c7a4f01201f54acc48_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjE1_59d8a661-66f8-40ce-bfb3-1debdb71af8f">175.0</ix:nonFraction>&#160;million and (ii) a revolving credit facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i63f12ae346f44c719a6800ae9ccbebab_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzMz_4202e74a-9c7d-4b0f-bb43-b0c233be968d">50.0</ix:nonFraction>&#160;million, to be determined by reference to the lesser of $<ix:nonFraction unitRef="usd" contextRef="i63f12ae346f44c719a6800ae9ccbebab_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzg0_647fcb6b-cf98-4b6c-918f-dccda071a493">50.0</ix:nonFraction>&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the 2022 Initial Term Loan Facility, the &#8220;Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the 2022 Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $<ix:nonFraction unitRef="usd" contextRef="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA5Ng_ae708a5c-eff5-407f-9822-0b9867ce29eb">50.0</ix:nonFraction>&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (<ix:nonFraction unitRef="day" contextRef="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg4MA_f35e415f-31d7-422d-b1de-972fbbb642c6">91</ix:nonFraction>) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="i2b8033c2ed5c404898e4b63272e9b227_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjU4MA_16b54889-4ffb-4e63-bf0f-37e4f4259f15">5.50</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="i4c87170725f741bb95ab4f861ab14a5f_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjYwNg_fc0ff470-bf5e-4186-85cd-9cb59fbb7b8f">4.50</ix:nonFraction>% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="i332b999bfd9a41b4b40e9a3798d29b87_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjY5Mw_795dbe1e-c801-413a-bced-8d852c71537d">3.50</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="i94c23219c9604a849ec11f326a2fa715_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjcxOQ_6c3baf67-17f9-42f0-990b-25d2232a0f30">2.50</ix:nonFraction>%. A commitment fee of (a) <ix:nonFraction unitRef="number" contextRef="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjc0Nw_31424dd8-b205-4bbe-bd32-a6cece8cf034">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) <ix:nonFraction unitRef="number" contextRef="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjg1Ng_3d571881-aaaa-412d-9bc5-b46c71937313">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjk4OA_5645d4a2-efc5-48b9-b586-868326c76de3">7.9</ix:nonFraction>&#160;million in interest expense related to our 2022 Credit Agreement for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) <ix:nonFraction unitRef="number" contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzI4OQ_479962e4-103c-4a8e-b502-18f18f6290f7">3.00</ix:nonFraction>% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) <ix:nonFraction unitRef="number" contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzQwOQ_bd356b62-ca31-45e2-883d-41c2f7df33cc">2.00</ix:nonFraction>% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) <ix:nonFraction unitRef="number" contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzU1NQ_38927073-1140-479f-a163-5b056c6a8542">1.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) <ix:nonFraction unitRef="number" contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzcwNQ_e006a534-abab-4448-ba32-f0879b4029eb">0.00</ix:nonFraction>% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $<ix:nonFraction unitRef="usd" contextRef="i7d73991f5a114e408f7f6580f4dd0c39_I20220801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNDgxNw_a00938fd-f2ea-414c-ba07-5760c2c01d74">5.3</ix:nonFraction>&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTA2Mw_4581d5ec-7668-4c86-966d-9309daae6da4">0.4</ix:nonFraction>&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTIyOA_85b550fd-3051-40df-a7a6-a5b2b854554a">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTI2NQ_8eb17526-22b0-4f9e-9c99-9c9bd95b1668">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ4Mw_c47c9efe-ef64-441e-8aa4-e0cbeab9f8c0">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTU1MQ_94890efc-aac7-499d-bbca-cf4ec486d636">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTY0MA_268338f7-f1f2-4ae8-a783-92c8489ea9c3">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="ide70b505dfd6454e9ffca84126ff1890_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTY1NQ_fabbbc6b-8531-48f0-961a-02f8c599d674">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTczNQ_4eeb945e-dfba-4dca-80db-0d47a011f1f7">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7efcfd84a4cf4bb3b5a67ba618b352cc" continuedAt="ibd737e1f01c24234a1a68c12320ad7f1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjI5MQ_e514c13a-62bf-4061-a9f2-90a0904549db">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjYwNg_a5c0e98f-ebef-4b28-9939-5c2e481e7446">2.7</ix:nonFraction> million,  $<ix:nonFraction unitRef="usd" contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjY0Mg_6e501957-22a0-40b9-bca9-77a854e4395c">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3MjUy_39d70196-2e7f-4231-8b98-175a6113dc83">1.5</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzA1MQ_02585592-2679-4d0d-b19e-d513f32c88d8">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzE2Nw_3be587b1-919a-4ce1-9ba7-15bb5ba7e0d7">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODA4Mg_b84553b8-f452-4280-9c38-7325cedd320b">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODIzMQ_c4814747-7fdc-48f9-92b9-b2c1265269dc">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODMyNg_da7dd618-5b31-4209-aae8-ceb94817d30d">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0d1f72876d42429a99ca22c58f5f1ecc_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODMzMw_ce643eed-0258-4f87-9422-391f5e6f0970">1.3</ix:nonFraction>&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODQ2NQ_e828fead-d668-4d18-a2bb-697d668623e6">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODQ2OQ_e43bf67e-c4f2-4f2d-b23b-97c6cbc98f74">1.7</ix:nonFraction>&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i1c958236f3a54e838f8aa587bb9a8d31_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTE0OA_a793d582-e469-445a-ac9d-71caa6acc49a">38.1</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="i1619fddb91d54d6f96208efd4dce37f6_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTE5Ng_c98303bb-81ae-4959-8f71-e71c87995a0b">1.3</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $<ix:nonFraction unitRef="usd" contextRef="ie0ae7d691d994f36bcd8595faf8c39ee_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTMzNw_bc610d39-c535-47aa-a539-8eda72e52bd7">11.7</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i3474707099524f5ab5cb8bcdef64f129_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTYxOQ_773b118c-137b-4fbf-81f1-9257ac5cec99">25.1</ix:nonFraction>&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAwOTk_8aac15fa-e499-44ab-946d-02fca0aa7f6b">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAxMzU_276642eb-03ab-42a3-a49b-3ff3db35cb5c">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3NDEy_02ebdfc7-766c-420e-aede-6800b622f74a">2.7</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $<ix:nonFraction unitRef="usd" contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM4MDA2_0aa98688-c733-4ad9-b169-1cd81eaedf10">7.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM4MDIw_e33a3844-a3a7-4590-84a4-2f827f1ecb32">2.6</ix:nonFraction>&#160;million for the years ended December 31, 2021 and 2020, respectively,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAzMTY_3917e57d-c312-4288-a5dc-b4b0de24558f">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA3Mzc_5ba4b59b-a4c1-453b-88fb-b8fd2744e7e6">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA3OTI_e7639c6a-d602-415d-99f1-bde8e42106a9">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA4NDg_8eff6f61-224b-4664-a6ff-d97dae5168e1">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTEwODY_50969b4b-ae87-433b-944d-70d1ccd62630">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $<ix:nonFraction unitRef="usd" contextRef="if764124a6770471488243909ab9e256d_D20220811-20220811" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTEzNzM_2ff66afe-7e92-463b-b458-5ba663074561">92.8</ix:nonFraction>&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7fb6b9ecd1444687b8479680f813d784_D20220817-20220818" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTE1NjI_349908b3-e46b-41a8-98a3-723fe13bfefd">5,394,165</ix:nonFraction> shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $<ix:nonFraction unitRef="usd" contextRef="i8a7bc6c0f93045b9ad4a49e3466404b9_D20220801-20220831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTE2OTY_03285295-ed5e-4c1b-9d5d-dd1c44d19967">10.2</ix:nonFraction>&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibd737e1f01c24234a1a68c12320ad7f1" continuedAt="i24b1e253a24f40d18c037edfff609ca6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2019 Initial Term Loan Facility, with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i3d60561640304c998ba5ee229f359173_I20191230" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTIzODA_0dedf027-8840-44dc-877c-4697414013c9">75.0</ix:nonFraction> million and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i2804de286fbc48f587c48f683cfa4074_I20191230" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTI1MTI_18e72e3d-ed65-4eba-9a04-1e1a91f34403">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the 2019 Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the 2019 Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $<ix:nonFraction unitRef="usd" contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2MzE_817ea807-1a28-4c49-b038-8bbb02545a03">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108" decimals="-5" name="evh:PaymentsOfMakeWholePremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2NTA_9643abc7-9720-4317-902c-9441230b68f1">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2OTE_d3e1a727-78a5-483d-b6ae-7d9a3167ea20">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM4MDQ_55f4d370-bdc9-4781-8d85-9e4b1cf3aa1c">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM4NzA_9869769e-93a7-4446-9e07-ced82ea1980e">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM5MDE_66b7c24d-73b8-44e0-b4ed-72ecc4905b77">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i140bd5a200d14de591a2f882386a3910_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQxMzI_37b83d25-040a-4229-8092-87c7729341aa">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i140bd5a200d14de591a2f882386a3910_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQyMDU_5fe90da1-f6a6-4a69-abb5-6ba0eff1baaa">8.05</ix:nonFraction>. The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="i84ec033ba9234eb488e9598b782c6c15_D20191230-20191230" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQyNjc_502da935-d9eb-4ec5-8724-fbfe4e6e42cc">thirty days</ix:nonNumeric> after the maturity of the 2019 Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="i0b374313017e499e85ef4cf594469720_D20210108-20210108" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3MDM_3c72dfbc-b23f-4529-aeeb-b9a019553550">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3NTY_371aa5f9-905f-43f5-89d6-c13be40daefa">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3OTM_512e75b7-3b95-4a86-9a8e-880267df2b38">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUwNjE_79b4c878-d374-47e2-884e-493a2dc1abe6">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i21455ed9e898487f8740230211473db0_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUwNzc_6e42df3e-a0c2-4628-84d7-e7f4f30380ce">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="i2a685a81d42142c896e77b4bc4ca525a_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUxNzg_d830af4d-fd24-437b-bfc2-2025747c75dc">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="i6c6f6a273d2b4dbda2d60fcdb292d567_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUzMDY_efcd5ba2-e5ba-4948-a8d9-f436105f603b">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU2NDY_512e75b7-3b95-4a86-9a8e-880267df2b38">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_0b7ffc12-4692-44a7-b58a-e262592524c4"><ix:nonFraction unitRef="usd" contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_89cfe33d-9e5e-44d2-b469-c123497324b2"><ix:nonFraction unitRef="usd" contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_a9f1733b-a453-48ba-a1b4-a81608c78a39">2.6</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTY2MDc_2e135105-4427-4852-80b9-b18a6fb73947">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTY3MjM_9c2dc441-12e6-4c9c-b0df-074d51506418">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i24b1e253a24f40d18c037edfff609ca6" continuedAt="i268c923ee29f49f6977a64f39ff4497f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc2MzE_1b8f6781-e44d-4bee-be05-d98aae76a548">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc3ODA_eb30a001-8766-416f-901c-f668aaea155f">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc5OTE_11760300-877a-46f4-a4e4-3f0e3e7bc3a2">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70f4dfb899054fdfbad69a92f3ebee35_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc5OTg_802487ef-a54c-4b2a-8fe7-12a3e26ce12a">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTgxMjk_eb30a001-8766-416f-901c-f668aaea155f">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTgxMzM_11760300-877a-46f4-a4e4-3f0e3e7bc3a2">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="ie2a2bfbe33214fceb0357343f7b7e72b_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg4NTk_d39f4871-d43f-4bbc-a70b-36568255a755">71.8</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="i6bd78b743e5442379fb00d3420537154_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg5MDc_49fc43c3-6489-423f-8291-97371eb4f66b">2.5</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ie69ff65edc314e66af837b40573b525f_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTkwNDc_7cf3c809-11c3-4743-8e3b-1edcf0c6fc4e">28.1</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i278ee21fa4de4432b9d32268373e0d51_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTkzMjk_479f4fc1-fcf4-42d7-88a7-35d1279cebc0">41.3</ix:nonFraction>&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTk4MDk_d9e454a5-6fd9-4bd4-864c-85ae31e80462">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTk4NDU_0258cc5f-e35a-47d9-867b-542a8b54607c">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3NjIy_4536ac5c-0c81-4fa8-b265-386d3cb94ebf">9.2</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $<ix:nonFraction unitRef="usd" contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3ODE3_57c2a74e-6b93-4bcf-ac8b-74e464de6cfa">9.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3ODMx_9ac0bdcd-4492-4f3b-9dbf-350049e2999b">8.8</ix:nonFraction>&#160;million for the years ended December 31, 2021 and 2020, respectively,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjAwMjY_d97bc4d5-c2db-4ef1-8ef9-b755dee4a159">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA0MjU_a0f57908-0940-4162-ab92-e16274ea5c65">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA0ODA_c081fe74-5c4e-4b56-8171-950f57832e6f">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA1MzY_f8a5c5cd-8d2f-47ae-b612-229db9a69517">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA3NzQ_40e113d7-bc84-4d47-9934-44f174cf8bf4">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA5NDI_9f867ba2-2a53-41c3-822e-f6b68358411d">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA5Nzk_bbaae372-2f87-46f6-be97-f2ba0c5fa4b8">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if5650df78c4e4f098ea12cdc3e6d079f_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjEyMDI_170eadd1-ad57-4cfe-a460-a02471ffcfb8">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjEyMTg_13cfd577-9f50-46fe-9825-0802656adf7e">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE2MzY_5f4a8584-7e92-4c5e-b8b1-8bfd3c84fc76">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE3MDA_0e82411c-af25-48bd-b2d6-c287ac9c079d">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE4MzM_ea4f249a-0d4d-4171-b476-db8b5f9e45e6">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE5Nzc_d0caf548-8311-405c-a77e-bb3e594282b0">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIwMjA_0bcee426-9ee8-4911-ab23-e57dcb2ebb0c">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIwOTM_bb860161-f0c3-4550-94c1-4c195c85a651">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIxMTk_be929d44-e1f0-48f3-a395-d3db6d297aba">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIyOTM_ead80d33-11fc-4b4a-8b8d-beff3edf6244">26.7</ix:nonFraction>&#160;million were settled, at the option of the holders, by converting $<ix:nonFraction unitRef="usd" contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIzNTQ_0da79533-dbf0-4d8a-b7c3-ad1018f043c6">26.3</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $<ix:nonFraction unitRef="usd" contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjI0Mzc_bce84604-605d-4976-9de2-6fe9c2ff36c2">0.4</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes. </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i268c923ee29f49f6977a64f39ff4497f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjMyNzY_d93bf47d-98ec-4586-990d-ba2d6a53f392" continuedAt="i01bfca6af05940c4b75134f4b402f4be" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2022 and December 31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i01bfca6af05940c4b75134f4b402f4be"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMi0xLTEtMS04Mjg1OA_8308564e-a07a-4add-aaec-bb907328d0a9">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMi0zLTEtMS04Mjg1OA_392ad586-5583-4310-b0fd-9fa0ca3e3e9d">89,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMy0xLTEtMS04Mjg1OA_cf9d0462-6348-4ff6-8bcb-9a72f04a7fc3">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMy0zLTEtMS04Mjg1OA_855e5430-4c1e-4659-ad7a-406dc61949c3">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNC0xLTEtMS04Mjg1OA_25fd0ab6-9df0-4847-a07b-d0741c4db3e2">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNC0zLTEtMS04Mjg1OA_1400a256-8467-4d84-836d-dcaa81d17db3">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNS0xLTEtMS04Mjg1OA_61117fd3-5f1c-4cdd-ac31-5241502f5d6d">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNS0zLTEtMS04Mjg1OA_47d17b1b-f554-4f49-b2be-c1deeb7d2d11">2.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f5b6436bc448ddb51d297c0f42e141_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNi0xLTEtMS04Mjg1OA_45ae83ed-ad60-4e6b-a3d2-64ddff01d821">38,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6001ba8bbed04b7a829551c60b521a2a_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNi0zLTEtMS04Mjg1OA_3c01c752-f384-4ad9-813b-07c5c0896ae5">195,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfOS0xLTEtMS04Mjg1OA_9981d8c2-4ecf-4b1f-aed9-480b3e4c0e30">168,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfOS0zLTEtMS04Mjg1OA_d37e67db-eadf-48be-9c8a-22c4d315f431">126,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTAtMS0xLTEtODI4NTg_3ef7b516-a1f2-4ad0-b23a-6f32263d73ba">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTAtMy0xLTEtODI4NTg_7e3dc559-f9a7-4f75-81ae-057e7e66bbb3">46,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTEtMS0xLTEtODI4NTg_4379895c-55b3-4156-8a19-bdff710c50cd">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTEtMy0xLTEtODI4NTg_18e38326-2199-4caa-9dc2-5672d423d33b">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTItMS0xLTEtODI4NTg_c31868c9-d6b9-492f-9619-dfc4527da10d">2.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTItMy0xLTEtODI4NTg_ef028bb7-4c96-4790-86db-e940d532c4be">3.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b3ec5f2a0940ddba506d2e9a3d8c0a_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTMtMS0xLTEtODI4NTg_c6f6b390-7f90-4226-9e1d-84e197005c2f">185,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4776fc60e442c0948db94fbd3d4085_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTMtMy0xLTEtODI4NTg_ae0d0dfb-03e2-4df7-8c54-c57045b1b408">177,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzE_9bb2f9a0-83f9-46de-b8f9-161ffddecdb4" continuedAt="ic949948aff6140df8b9c3427214fb7b6" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic949948aff6140df8b9c3427214fb7b6" continuedAt="i0e70e174885642c794d7c67dd34d4018"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $<ix:nonFraction unitRef="usd" contextRef="i0bb561ac225443dbaff96dea400e900b_I20221231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTc1_7d8c90a0-87ae-4812-aeff-6da8092c0d01">13.1</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i6788632dc8e44b589e517a3e62e51f4a_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTgy_72774546-5665-47b7-81ec-745e0a944a70">15.4</ix:nonFraction> million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="ic01dda4dd7b24edd859959507bf961ac_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMzAx_9570455a-a07f-4b0b-99dc-e881aac5afa0">13.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5f551ff8e8ba4ff3beb6c4b903203199_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMzA4_7c8f7efd-5ed3-46be-9e2a-ac591226c9c8">15.4</ix:nonFraction> million, respectively, in restricted cash and restricted investments as collateral as of December&#160;31, 2022 and 2021, respectively. The letters of credit have current expiration dates between January 2023 and March 2032 and will automatically extend without amendment for an additional <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="evh:LineOfCreditFacilityAutomaticExtensionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzI_e46b63d8-49ad-4948-b88c-83beb3209e33">one-year</ix:nonNumeric> period and will continue to automatically extend after each <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNjY_3168136d-c7f9-4c3d-9621-d3abf66ab380">one-year</ix:nonNumeric> term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0e70e174885642c794d7c67dd34d4018" continuedAt="i93452414e75646e796d2056f4f1bd775"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2022, 2021 and 2020,  respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of December&#160;31, 2022, there are no outstanding amounts under this reinsurance agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of <ix:nonFraction unitRef="customer" contextRef="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231" decimals="INF" name="evh:NumberOfCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjM4MQ_c75aa40f-1487-41da-9eb9-0b3075b1f08b">20</ix:nonFraction> of the Company&#8217;s customers. Expense associated with the UPMC Reseller Agreement for the years ended December 31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjUyMw_80677b95-c19c-4b44-928d-5e4f1d7ec6d8">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i8421b42e39084ee89ac6a78c380b126b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNTQ5NzU1ODI5ODkx_f503c3a1-860b-4312-b708-3b331826ed25">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5ea705e860864044aca57384b2588af0_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjUzMA_0ab407db-7389-4ebe-bca9-b3b5fc2ec17a">4.7</ix:nonFraction>&#160;million, respectively, and is in wind-down. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i93452414e75646e796d2056f4f1bd775" continuedAt="i56c7c97ad71a4a1288b8405510d40ccd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjgyNw_6d7edc1b-4901-40a6-ae3f-37348d28d58f">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNzI4NA_080980f4-b5fe-43e6-abf9-ec9a08cdbd20">46.0</ix:nonFraction>&#160;million as of December&#160;31, 2022, which represents <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="INF" name="evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNzMzMA_4e0cccca-2fe8-472a-b416-4105a1024e9a">85</ix:nonFraction>% of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the TRA-related deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the TRA may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation was granted final approval at hearing on November 18, 2022. The agreed-upon settlement payment of $<ix:nonFraction unitRef="usd" contextRef="id9e0a630ce154bf89c611d1821c71553_D20220802-20220802" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTAwMjY_f5689bb5-a01e-4b55-9c93-355444337328">23.5</ix:nonFraction>&#160;million was funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we did not incur a significant net loss or cash outflow as a result of the settlement of this matter. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE1Mjg_4bdd70be-d1c5-4994-9c75-5e01de5988f8">99.6</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE1Mzg_265960d3-18e2-4580-882b-471486f278f8">215.2</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE2ODk_a9efa90a-7a01-4691-b697-64b4b538364e">0.4</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i56c7c97ad71a4a1288b8405510d40ccd" continuedAt="i4b52452a5cc04c8294411810109b9fdf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzM_ab3a3b8b-d1bf-4da7-99db-a39969639414" continuedAt="i64d922a7b56d4ff6be4c7985aeaa33be" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i64d922a7b56d4ff6be4c7985aeaa33be" continuedAt="ic45913ad6da0450a9f5f09713efb1342"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05d330e617a348658676375fec5a5db0_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMS0xLTEtMS04Mjg1OA_50b827af-b1f9-4269-9f8e-601947a44ae5">42.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic09667045f534fb08afb88b78cd4bffd_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMi0zLTEtMS04Mjg1OA_fed6acba-1ee1-43ad-8c4d-a3568ce8907a">46.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19460fef358144489558a7d191e376e1_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMy0xLTEtMS04Mjg1OA_3a436621-c6c9-42a2-9181-df0299033852">12.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34c1626a52334b328a1c7519c6d48da1_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMy0zLTEtMS04Mjg1OA_0be70b96-1580-454f-9601-5a97b89f02c1">10.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f194e0613ef4a9eb4ce0f29bc3e59be_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfNC0xLTEtMS04Mjg1OA_1d3b71ca-d773-4192-8da8-5ca35bc83872">11.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic45913ad6da0450a9f5f09713efb1342"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47d5358cfd784a34a9c92cf66e6fe24d_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi01LTEtMS04Mjg1OA_4179bac2-a845-4575-a110-9ccdbff61a3f">22.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a3c513620354b04ae269dff1b11efc4_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi03LTEtMS04Mjg1OA_b8abcd47-c513-4c2e-8d6b-a2bed5222c0b">28.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0971990c3b524dc2ab01bca9e7047db0_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi05LTEtMS04NjIzNg_c5b14543-2f9b-48f1-9fc1-fe1c45b25bca">22.3</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0ca95c4f8d453aa5b952029c52ede5_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMy01LTEtMS04Mjg1OA_1fd038fc-761a-4478-a0bb-158fc62e91bd">11.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17f79061242845d39ce24ea7ea1e6531_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMy03LTEtMS04Mjg1OA_a08ca2fe-255b-4076-933b-2072494f0ef8">14.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37ef3bafc332487fbfffb51f8c73921e_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfNC05LTEtMS04NjI0NQ_61b58eb0-7edc-41bb-a556-33d743419205">19.0</ix:nonFraction>%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $<ix:nonFraction unitRef="usd" contextRef="ia1b1f625f4e94de3bac6f65f975417eb_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDIzNQ_8675d6a1-9249-40a7-89ac-4857801497cc">44.8</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="ie780f96a5b1646b797b6c069ab760343_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDI1MA_6b8cc206-9869-4fba-aeb3-7bc3b1bd04ba">117.4</ix:nonFraction>&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately  <ix:nonFraction unitRef="number" contextRef="i3cc10e07863c4eb1a63ee717112c9d0b_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDI2NA_c8ab690d-0e28-461a-9e1d-149b05248cd1">9.7</ix:nonFraction>% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b52452a5cc04c8294411810109b9fdf">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1NQ_436dcd23-da8a-48ed-84cb-a4102e5326aa" continuedAt="i5101f30ad7074a05926d1843a8bc7713" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5101f30ad7074a05926d1843a8bc7713" continuedAt="i35c0957c65914f16999e52eab9a7c5e4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfNDI2_c3c17810-ae80-48c8-85cd-d81869bcab28">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i35c0957c65914f16999e52eab9a7c5e4" continuedAt="i96e81dce4d334ebb92131c37db53a072"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="i5b43f5864a3c456d988a47acf3b9ce95_I20221231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjY2Mg_7eedcd8e-8d91-4c78-8b1f-4df1e47f0dff">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i84ffe1b4508e486a9edadc82247bd895_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjY2OQ_aa4a1e46-d706-43a5-859a-a83203ff94db">3.8</ix:nonFraction> million in letters of credit as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022 and 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="i5b43f5864a3c456d988a47acf3b9ce95_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjc0NA_84aadf10-f939-4f1f-9cd6-a944dba9718a">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i84ffe1b4508e486a9edadc82247bd895_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjc1MQ_53062ef5-2e09-4ec1-93d2-ddacadcbaff7">3.8</ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1Ng_6154824a-1b01-4bce-bfcd-a26e35871677" continuedAt="i2a194b2f556e4bea95402d063e197422" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS0yLTEtMS04Mjg1OA_2cfdb297-bbaf-48cf-8039-38b8bc72a61d">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS00LTEtMS04Mjg1OA_6a1fe250-5f1a-41d8-af21-d3516a9b3b15">32,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS02LTEtMS04Mjg1OA_823a5755-5462-42d7-acdc-1b49af911642">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi0yLTEtMS04Mjg1OA_7a1e5b4c-d72c-4652-b66b-34a8264f8085">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi00LTEtMS04Mjg1OA_909941ce-5103-4b6e-af1c-fe2afd640d7d">38,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi02LTEtMS04Mjg1OA_9e5e3081-b8aa-4df0-b4f2-4fea8de525b8">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f31f283eac947978662db9d2181e301_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy0yLTEtMS04Mjg1OA_35848ecf-9b0b-47e8-8889-ade9dd07eeba">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f31f283eac947978662db9d2181e301_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy00LTEtMS04Mjg1OA_5797b69e-c187-46ae-a75e-56e871cbe183">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f31f283eac947978662db9d2181e301_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy02LTEtMS04Mjg1OA_e3b7f2c1-891f-4363-89d3-a4d48b76ba87">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC0yLTEtMS04Mjg1OA_b8922817-498b-4794-99a5-6e8c2522502c">2.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC00LTEtMS04Mjg1OA_fddd0ac8-da23-401f-aaff-27002369e2b1">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC02LTEtMS04Mjg1OA_3b408e60-5ec2-45e7-8548-7763de08ca95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS0yLTEtMS04Mjg1OA_8627841c-bbfb-4a81-961b-f78940a61f97">0.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS00LTEtMS04Mjg1OA_51c24287-30b1-4d93-b63a-95f7bb51fb81">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS02LTEtMS04Mjg1OA_a0714b17-f913-4445-a3b5-308788ced2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi0yLTEtMS04Mjg1OA_adc6f887-d766-45bf-8a89-0ae55634acbe">4.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi00LTEtMS04Mjg1OA_e460728f-f7e5-4e11-9eac-d2bac440ff46">4,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi02LTEtMS04Mjg1OA_964c71b8-1280-4023-b585-c171cf6fcf8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1Nw_3ce4e0cb-1595-4908-8b8b-059ddaac813c" continuedAt="i240555531042407b8c6088b58dbaf2b9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.316%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi01LTEtMS04Mjg1OA_116e7419-c1ea-4acb-97aa-df7771bd3518">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi03LTEtMS04Mjg1OA_354c87d2-4b9c-417b-9d64-62e4449f8079">12,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi05LTEtMS04NjMxNw_538e8ef3-9638-4873-a1a1-08a942e79b3a">15,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy01LTEtMS04NjMyNQ_910f90cd-2ec9-40e8-9f78-24dd74f2f3a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy03LTEtMS04NjMyNQ_2e82a0d1-f17c-44a2-9a99-9378a6f76f5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy05LTEtMS04NjMxNw_59681016-7b42-4140-8a97-68d64d5d1f3d">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC01LTEtMS04NjMyNQ_e030a8f7-9711-4c9b-8e82-6d56bd589b00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC03LTEtMS04NjMyNQ_20662c04-95f1-4c73-97e7-4d609063d775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC05LTEtMS04NjMxNw_49ea6831-ae24-453d-b0d6-fd0d1acc4a2b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy01LTEtMS04Mjg1OA_129cc8f4-fe19-4227-b8c3-d3afe68bb367">5,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy03LTEtMS04Mjg1OA_e21f0edf-c307-411c-8f40-63301fac9bae">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNS05LTEtMS04NjMxNw_4147d630-ea3d-44a2-9367-ae238a5b4f7a">5,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC01LTEtMS04Mjg1OA_7e376c50-17dd-4399-b195-e544e48b531f">14,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC03LTEtMS04Mjg1OA_959a5871-43f6-4564-ae64-893646346885">18,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNi05LTEtMS04NjMzMw_d57cdb97-8e35-47a5-93de-54ba39c7e32d">21,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2a194b2f556e4bea95402d063e197422"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMS0xLTEtMS04Mjg1OA_89af04f5-3ac7-441c-b3b0-390b340d2755">10,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMi0xLTEtMS04Mjg1OA_e1214627-4c7c-471a-a767-26fbd7765df0">10,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMy0xLTEtMS04Mjg1OA_db0543ec-7c96-4eed-9b64-46ded6ec16f2">10,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNC0xLTEtMS04Mjg1OA_208354f0-260e-4148-9753-4d25adce18ae">8,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNS0xLTEtMS04Mjg1OA_bf1bc077-3681-44c6-96d8-2e33827e24b5">8,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNi0xLTEtMS04Mjg1OA_8b975418-0f99-4230-85fe-fd3424f7d064">31,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNy0xLTEtMS04Mjg1OA_89bd6a9c-4e15-4747-b1dc-2bdb75b81ea1">80,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfOS0xLTEtMS04Mjg1OA_9951b636-7155-46c3-bb36-208b587d907c">17,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMTAtMS0xLTEtODI4NTg_0ea2e933-4dcd-4011-b93c-379b060f5a78">63,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96e81dce4d334ebb92131c37db53a072"><ix:continuation id="i240555531042407b8c6088b58dbaf2b9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMS0xLTEtMS04Mjg1OA_c13e5e99-c6cc-46e3-9538-96699b89e3f2">6.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi0zLTEtMS04NjQwMQ_726e8442-4a57-44e2-895e-cb4717062b9c">6.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi01LTEtMS04NjQwMQ_df842ea2-ebbb-46ca-a91e-59dbf3a476f5">6.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi0xLTEtMS04Mjg1OA_e4564a24-0d5e-4c97-81dd-f5c90066bb3f">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMy0zLTEtMS04NjQwMQ_f0bd3efc-7e3b-46ec-80a9-b1017ae603d2">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMy01LTEtMS04NjQwMQ_9bb96a1c-f544-4a00-8323-e5172a916238">9.4</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzE0_0af99d93-44b4-4847-a60d-e75dda830dfc" continuedAt="i9d80aa90b6864234919080cdd50400d0" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9d80aa90b6864234919080cdd50400d0"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzEz_7089b370-0ff8-4824-aa19-52efb2b74c24" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi01LTEtMS04Mjg1OA_112f45da-4664-48a6-aee7-fbb2f80ad0c5">18,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi03LTEtMS04Mjg1OA_9177faf4-f040-4777-bc9f-6ec51ec2d38b">30,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi05LTEtMS04NjUwNQ_5c2a3b30-13b8-4ea6-a1b7-35e3c8d59d63">328,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC01LTEtMS04Mjg1OA_c1eec9a1-c762-4774-9cd7-83bc748fe20a"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC01LTEtMS04Mjg1OA_f0000a12-0f69-4c7c-8dd3-db41a773de91">19,164</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC03LTEtMS04Mjg1OA_12bae645-15fb-4b58-bcc8-a8b92cd3f67e"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC03LTEtMS04Mjg1OA_67ab0ff4-87d0-4c6d-ae77-14166e64fbf6">37,601</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC05LTEtMS04NjUwNQ_2dba2787-d143-44cd-afd3-9a456f61ad3a"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC05LTEtMS04NjUwNQ_fe20e9fd-47fb-4716-92c8-72b0abf9cf10">334,246</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi01LTEtMS04Mjg1OA_872d184b-3e76-485e-9889-1c2a9eeaab97"><ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi01LTEtMS04Mjg1OA_d4f7bc56-ce54-4b55-afb6-d2e8092c4846">93,699</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi03LTEtMS04Mjg1OA_6422c41e-d861-4de3-b5c0-4fe5c75c6f6a"><ix:nonFraction unitRef="shares" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi03LTEtMS04Mjg1OA_e4501877-9e46-48d9-a574-409f39d2d2b8">86,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi05LTEtMS04NjUyNw_417b4287-8e1c-4e49-bf8b-947a2a9e0b1e"><ix:nonFraction unitRef="shares" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi05LTEtMS04NjUyNw_b8e91cca-55e5-4b5f-b235-a6bab722af6b">84,928</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNS0xLTEtODI4NTg_03631c9b-1fca-482b-bc21-712366fde1c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNS0xLTEtODI4NTg_8e148c6b-2b64-4487-811e-8143fd8a108e">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNy0xLTEtODI4NTg_7d3d737d-bbbb-4e90-95df-f5c070e63d3f"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNy0xLTEtODI4NTg_93c76584-0af4-496c-b18f-ac56307e8f67">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtOS0xLTEtODY1MzU_0d907ba3-3b25-426d-a58e-d63555f4328d"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtOS0xLTEtODY1MzU_ef2de908-b81a-4ee6-9705-f0c868576b09">3.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNS0xLTEtODI4NTg_13051571-1486-458a-a693-81f16ec20e3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNS0xLTEtODI4NTg_2e81288a-b6e7-45e1-b2c8-b0e4dc95ecdf">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNy0xLTEtODI4NTg_4e315877-8fcd-418c-ade6-201b86112525"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNy0xLTEtODI4NTg_a2cb81db-574c-4b1a-b6dd-726d8b3656e9">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtOS0xLTEtODY1MzU_1cc63df2-3264-46da-adfc-81ad817f2e33"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtOS0xLTEtODY1MzU_4a171798-299d-444d-b4bc-be280c334f63">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNS0xLTEtODI4NTg_e00dc34d-016a-4911-aa17-a9e3f570441a"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNS0xLTEtODI4NTg_fb2f9fff-b3ac-4ab7-bb32-74d9d56181c7">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNy0xLTEtODI4NTg_ceb7521b-3185-4e91-a71c-86273bc538c3"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNy0xLTEtODI4NTg_d80a8583-6a89-4435-b5b4-c4527c5a3bbe">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtOS0xLTEtODY1MzU_4a6e219f-944f-4248-83bb-64d123921211"><ix:nonFraction unitRef="usdPerShare" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtOS0xLTEtODY1MzU_b4cdb5eb-97ee-43c1-8fa3-5ff79883d395">3.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzEw_df284718-a138-47ab-9ca9-7cf3b2b988a8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a933c8c05464474bc7d7b13541a2e90_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi01LTEtMS04Mjg1OA_659c6118-a46d-4d73-85ed-6a9019d56125">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if76a99b4e1234159af5825d2a6781f2e_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi03LTEtMS04Mjg1OA_933cc931-161c-4a44-95de-279149ff3545">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a31bc4994b74fc58c2b392809cd688c_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi05LTEtMS04NjQ3NA_447588cc-bf68-4e33-acf8-d14f976af99d">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf5780125dcb45fbb548a97d1af89fdb_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy01LTEtMS04Mjg1OA_c05da682-15e0-4184-9f6b-53d394a20327">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd672678d98466986c506543160641f_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy03LTEtMS04Mjg1OA_7a357d64-ab6a-4657-9308-e353dfb4a362">2,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c53413574a404b9b955fd4063e9fa2_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy05LTEtMS04NjQ3NA_785fc78d-0a24-4d82-87cd-9442d86b1b79">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia29b0fddbc044c099c98a1f8e946e6ef_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC01LTEtMS04Mjg1OA_2e7ba648-9072-49d1-a4ac-df48ac88f12f">9,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac01085f2974bffb7e9c05372fce3ed_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC03LTEtMS04Mjg1OA_5e2c480e-d390-4a7e-bced-428b187e7476">12,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd9999816186400782cf19912fe831e6_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC05LTEtMS04NjQ3NA_ecbdc898-d426-4393-b4d6-71e4f64804a9">11,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS01LTEtMS04Mjg1OA_45343da5-7955-40e2-8c36-10d0bc2af485">13,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS03LTEtMS04Mjg1OA_5e6e45ca-8471-4bcc-b20f-a0d0453c5a46">16,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS05LTEtMS04NjQ3NA_883e54d9-c82c-48bc-b738-7fea535524e0">13,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_274"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg0_f39aebde-35ee-4b21-9faf-5dfef7a08c75" continuedAt="i406b5dc7f76d41cabb161616f0cc08b0" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i406b5dc7f76d41cabb161616f0cc08b0" continuedAt="i6be77aeba7fa466c8e1206817d087a4b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 and 2015 Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#8220;2015 Plan&#8221;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to <ix:nonFraction unitRef="shares" contextRef="i2fb1199689b9485e9e38c8454c856583_I20130923" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4OQ_648bdc3b-e773-4786-bb27-baceb0c5f844">9.1</ix:nonFraction>&#160;million of the Company&#8217;s common stock. As of December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="id5b21dc206e94394abb9958199abeb98_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MA_a62612f4-77c0-4fe6-b80e-7a265aacdfb1">4.8</ix:nonFraction> million stock options and <ix:nonFraction unitRef="shares" contextRef="icb78a01fb022451a868b84564b638dc6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg2MQ_70adfd13-513f-4984-9e16-c8351ae6e76a">3.8</ix:nonFraction> million shares of restricted stock have been awarded, net of forfeitures, under the 2011 Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6be77aeba7fa466c8e1206817d087a4b" continuedAt="i41564e6659c2432b8ebc469f1ecf1bb6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i1fdd473b34824a438f104a82a06cc181_I20150501" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNzA_d0e8ed9f-11da-4e30-b21a-d0dde931d213">6.0</ix:nonFraction> million shares of the Company&#8217;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018 and April 15, 2021, to increase the number of shares authorized to <ix:nonFraction unitRef="shares" contextRef="ie49a044638374607bbfbdc97696620c2_I20180613" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEzMTk_83520373-d972-4255-acb1-fe5fe1eb649b">10.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i0e202260e1024d14b21b9a333d1e719e_I20210415" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEzMjY_e5123dd8-9354-40c9-8ce3-8eccf8384124">15.4</ix:nonFraction> million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i65cf289eea9b494d912166499c2914fb_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE1OTY_98c9e38d-0000-45b7-bc75-61e55e65ca36">2.8</ix:nonFraction> million of stock options, <ix:nonFraction unitRef="shares" contextRef="ia76c5580ffe1407da7f478f22181effd_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2MTc_8dd6c684-b95f-4a89-a7d5-625cac658b67">5.5</ix:nonFraction> million RSUs, <ix:nonFraction unitRef="shares" contextRef="i490fcda4c6dc4ac48114257dd334a44f_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2MjY_7f02c35f-c019-4e9e-bd92-4e74fd4d4710">1.4</ix:nonFraction> million LSUs and <ix:nonFraction unitRef="shares" contextRef="ie8598bae5e2d4ae6a59a8764c8bc367a_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2Mzg_7bc2aef4-c7f6-4d15-bef8-4cbd966b1ff3">0.8</ix:nonFraction> million PSUs, have been awarded, net of forfeitures, under the 2015 Plan. As of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i34f5c218d62449f4a45332796fafbe3e_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3MzE_db5622de-a633-4c08-9198-e013f0739a79">2.8</ix:nonFraction> million stock options, <ix:nonFraction unitRef="shares" contextRef="i454730d8be0c4135908d533cc24236ff_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3NDk_a116c64d-415c-40ab-b00f-2206caf6aff7">4.5</ix:nonFraction> million RSUs and <ix:nonFraction unitRef="shares" contextRef="ibd4ade146df04303ae15516a0f51d6e0_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3NjE_e8df2f9d-8fb2-4c3b-a4a8-9aa6b33943ab">1.1</ix:nonFraction> million LSUs and <ix:nonFraction unitRef="shares" contextRef="i168e32227da54d569993ff509ca28512_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyNjUwOA_ae835ca6-ecd6-4060-9f5e-e465ac85648e">0.3</ix:nonFraction> million PSUs, have been awarded, net of forfeitures, under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTYy_0e53622e-d7c9-44ba-91cc-c73036a523a3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtMS0xLTEtODI4NTg_822a6a8c-4317-422a-9727-8a4e3b4c933e">416</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtMy0xLTEtODI4NTg_22ae1a82-bff6-444a-b7c1-d3e54785d26a">1,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtNS0xLTEtODI4NTg_781b08be-4e6f-4695-a289-5b70e6a3833b">2,927</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtMS0xLTEtODI4NTg_a93f016b-4c50-4239-83fe-d55490d53ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtMy0xLTEtODI4NTg_eabd0979-a7ba-4072-84ea-1a0154b86ad2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4f0db782744810b86b3de6bffd9661_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtNS0xLTEtODI4NTg_2fd20987-66ec-4243-a0d4-80c4f543b9a3">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtMS0xLTEtODI4NTg_8ceb2643-f96b-438b-a539-9b042f0bcbc4">17,327</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtMy0xLTEtODI4NTg_d672819a-ec8c-4356-b051-ae932f10a04c">9,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtNS0xLTEtODI4NTg_1673d522-bea7-4d70-97c4-18fa7eca9587">7,763</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtMS0xLTEtODI4NTg_bb6d8f73-0f6b-4583-9e71-94100f84730d">14,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtMy0xLTEtODI4NTg_5c81986e-0a58-4c52-a71c-ed38f78c7131">2,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2688027cbefe476297d030d725212d57_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtNS0xLTEtODI4NTg_08a02ab6-2d64-4276-b0d3-d9b9915016f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctMS0xLTEtODI4NTg_66dcbf62-e94c-4771-a68c-2c42e9d5d838">1,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctMy0xLTEtODI4NTg_e46d7ccc-fa65-4705-a3e3-2a087657b125">3,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctNS0xLTEtODI4NTg_015597bd-135c-4bc6-b31a-d901703abf07">3,841</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtMS0xLTEtODI4NTg_827297cf-a19c-489e-9f1a-3d0f5d117349">33,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtMy0xLTEtODI4NTg_0454cfdc-37fb-49a9-a8c2-9ffee15cb8f7">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtNS0xLTEtODI4NTg_ef879958-702e-4526-b5a8-8e4f26d59947">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7c11ea28704ab6b523786a90949ff8_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTEtMS0xLTgyODU4_bc9092a4-ffb4-40c8-83f2-9e180225e3a1">4,387</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eab875363854633ac2dc697d7c48c89_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTMtMS0xLTgyODU4_7747279f-f85f-4b95-951f-142c980495e1">2,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15eadbd1e3724998b19a496cc3d2b5aa_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTUtMS0xLTgyODU4_7fe27949-6e4a-490e-bb70-2e376ef93667">1,811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f478bf1b114c2694835b3dc5f160fb_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTEtMS0xLTgyODU4_81c4aad9-f5d2-4779-b4a6-dbbaa55dbab0">29,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia818a57c910f43b6b57bb34ff556565f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTMtMS0xLTgyODU4_636c2c5c-6519-4a8c-b061-0def36c36926">14,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1df49b093b4a088aece5a992f943a3_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTUtMS0xLTgyODU4_6eab48e7-8771-492e-817b-4f4e27f7d0dd">12,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTEtMS0xLTgyODU4_71f75e2b-3c1b-493c-bd85-6494863554af">33,981</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTMtMS0xLTgyODU4_c752727b-b578-4052-97f0-e0428124335d">16,711</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTUtMS0xLTgyODU4_4f753de8-b41a-48a3-89c1-27d93d603c83">14,606</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_116b7789-ddcf-4a49-9832-00564daa3c1f"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_1341f45c-7fdd-4667-af23-659c1ea75cd1"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_da58b21b-c108-4450-9b17-747396f04007">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTY5_9a4f6de9-69ef-400d-bd23-e944e975c476" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"></td><td style="width:393.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126ccd42807a4cc3b17d8951d96c7aab_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzItMS0xLTEtODI4NTg_d972170e-97de-460a-91fc-062012514d80">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzItMy0xLTEtODI4NTg_5a12df33-6f27-4920-9458-8c736fb54d65">0.29</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzMtMS0xLTEtODI4NTg_4adde784-85dd-4da0-a42e-1987928dfb30">36,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzMtMy0xLTEtODI4NTg_8f35e8c5-a04b-4933-86eb-42145c2f6f30">1.55</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzQtMS0xLTEtODI4NTg_400a6ff0-4cbc-44ad-aeef-a46fe0868d41">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzQtMy0xLTEtODI4NTg_9ded8b41-8d96-4674-8e00-04c2b553e02a">0.61</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzUtMS0xLTEtODI4NTg_069c0070-e434-42dd-8808-ba53bcc5e257">27,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzUtMy0xLTEtODI4NTg_8727fd62-0f80-4fb3-9d08-f8f016dfe66c">2.02</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzYtMS0xLTEtODI4NTg_06844033-f630-4db3-9c6c-badd59a9bd97">64,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a <ix:nonNumeric contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNjAw_b1767286-cdb4-45a9-97f1-896fb9d2116f">four-year</ix:nonNumeric> graded service vesting period where <ix:nonFraction unitRef="number" contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzI4NzQ_7aa1a5ff-fafa-4021-82db-b79be26d5db8">25</ix:nonFraction>% of the award vests after each year of service and have a maximum term of <ix:nonNumeric contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzI5NTA_d0bc8681-e8de-443d-85e0-ec035934fc38">10</ix:nonNumeric> years. Information with respect to our options is presented in the following disclosures. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i41564e6659c2432b8ebc469f1ecf1bb6" continuedAt="iee67dab8edca44f595a4547a350e5b5a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTk0_84493d94-284f-4378-b635-e0ae741b12de" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtMS0xLTEtODI4NTg_71cf805e-61b9-4659-8339-8fc33cd25f0e">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtMy0xLTEtODI4NTg_b33bedc1-4b25-4ff1-b352-3f22af5411ec">9.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtNS0xLTEtODI4NTg_2a066848-1489-4ed0-a253-7d863c8460fb">3.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtNy0xLTEtODI4NTg_2f34a16f-d61f-47ae-b946-a21d8e3aef92">46,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzItMS0xLTEtODI4NTg_efcbb565-5209-4711-b48a-e5b1b019aea2">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzItMy0xLTEtODI4NTg_8fb6d0df-bda6-4b91-b0b5-9b141b175327">6.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzMtMS0xLTEtODI4NTg_9076b025-e600-4e3e-9513-d98383345ef7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzMtMy0xLTEtODI4NTg_bb934d71-93f5-44b4-8389-d00f1807d756">13.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtMS0xLTEtODI4NTg_111f0bd8-404a-449d-a500-7c45603dea32">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtMy0xLTEtODI4NTg_d871474d-d1a1-4cdd-ab83-f4191ed1d858">10.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtNS0xLTEtODI4NTg_42c891ef-9704-438e-8639-90e1836a85d8">3.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtNy0xLTEtODI4NTg_360b082c-b5c5-47d3-b4fe-a8d857447594">33,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtMS0xLTEtODI4NTg_1f3b1c5a-b3df-47f8-b041-c7ec78612cc1">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtMy0xLTEtODI4NTg_bf7856ef-e7ea-46ef-97d3-8181e29e12eb">10.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtNS0xLTEtODI4NTg_c59dc7ce-5386-46f4-9420-fa6d16d998b6">3.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtNy0xLTEtODI4NTg_dae2e02b-c94b-454f-bcc2-c1b727277e51">33,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtMS0xLTEtODI4NTg_d8fa2eaa-99aa-4670-8ef3-4f8d91b4d236">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtMy0xLTEtODI4NTg_3fb094e3-d101-42ae-bdcd-46b4fea76799">10.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtNS0xLTEtODI4NTg_d20b2a53-a552-46c2-bb99-054dc45480a8">3.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtNy0xLTEtODI4NTg_78f28e46-3c7f-4b89-b1b5-7528889606b5">32,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options vested during the years ended December 31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0Nzc_8fdb1fec-6e0e-4fa5-95fd-7f05f0ecb7a7">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0ODE_45b44365-a123-4036-869d-7e44e518d600">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0ODg_624f1c66-3599-4f79-8ceb-b151d8ae3826">3.6</ix:nonFraction> million, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1Nzg_ca178fee-824c-4636-a5fa-ff9673bd4642">16.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1ODI_374182d2-3d30-416d-868c-b58dfd1fc1f0">20.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1ODk_4078ec5f-d6bf-4bbe-9f60-112ee66d0cd0">2.2</ix:nonFraction> million, respectively. We issue new shares to satisfy option exercises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock option awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ3NDU_5d91453a-a201-4320-873f-341e96e04bd4">0.3</ix:nonFraction>&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to market-based vesting, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="i41135afe093644db89a3b87635fe4dc4_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzUxNTk_24f5f3ec-bdfd-4729-bd72-921dd2502434">13.35</ix:nonFraction> per share for a consecutive <ix:nonNumeric contextRef="i8ec3a6efe87f4e2c84e6ce6e8641efac_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTYz_1fde305e-4a59-4dca-8270-afe731118aa2">ninety day</ix:nonNumeric> period;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="if74229af73c04802bcf5f1aad8b9d1d1_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzUzNzM_a1e5cbf3-605a-4095-ae58-6405a1d836ff">16.43</ix:nonFraction> per share for a consecutive <ix:nonNumeric contextRef="i15ad45c36cfc43c9bc1893539e98ce7f_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MDk4MjI_8b4b38b5-1054-4bbb-bedc-2e845d49d7ea">ninety day</ix:nonNumeric> period; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="i1492a0e32c114c64887521b21cadd182_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU1OTE_d559b1b9-4e96-4836-96f9-3fc38bf21877">19.51</ix:nonFraction> per share for a consecutive <ix:nonNumeric contextRef="i0d882797dafa45e4973fe074ac9e136b_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MDk4MjM_b3560ab1-cbb3-47c6-9a41-dc992e49158a">ninety day</ix:nonNumeric> period.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"><ix:nonFraction unitRef="number" contextRef="i80e040acb0b747928e36b0c44713716f_D20160301-20160331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU5MDg_81f9b16c-addb-4660-a641-f946a91818c2">50</ix:nonFraction>% of the shares subject to the option award vested on March 1, 2019, and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"><ix:nonFraction unitRef="number" contextRef="ic8e9688f5f7d4228b70c0cb904a39028_D20160301-20160331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU5ODI_5e9ad0bb-56ef-4865-8271-533114ae1a66">50</ix:nonFraction>% of the shares subject to the option award vested on March 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyMTg_add8b3aa-c4d1-4fb1-a991-1076290ca510">1.83</ix:nonFraction>%, volatility of <ix:nonFraction unitRef="number" contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyMzY_80a6813a-0200-4835-a697-ab487ae80fb7">65</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyNTc_95bbe795-4c6b-40b4-8eaa-5d7137c460a7">ten years</ix:nonNumeric> and dividend yield of <ix:nonFraction unitRef="number" contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyODI_c7d8569f-9983-4531-a265-3e8d50512411">0</ix:nonFraction>% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzY0NTI_cc16d906-fe03-4da6-b3e9-0ae593cf9bfc">6.68</ix:nonFraction>. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee67dab8edca44f595a4547a350e5b5a" continuedAt="i381452535fbf4d3ca49adf7f01b8a915"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg1_892d2c05-89d8-4f37-9d6c-a52a39f0a3b7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67f870a295164c058463681d0e9d876f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtMS0xLTEtODI4NTg_9c9ae336-85c2-4d4a-8eb2-7e43d551d7f8">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67f870a295164c058463681d0e9d876f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtMy0xLTEtODI4NTg_681a57d9-c4c3-4c8d-81fb-c7ef91547e91">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtNS0xLTEtODI4NTg_e4e6bd72-1a72-4b5d-afda-95832b54c999">4.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f870a295164c058463681d0e9d876f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtNy0xLTEtODI4NTg_8b578ef0-91aa-4bdf-be23-355f2f2bc1eb">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItMS0xLTEtODI4NTg_f4ffb969-e284-437d-97f5-50d2dc223407">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItMy0xLTEtODI4NTg_19dae78c-d2fe-4516-94ae-ac0b9f96acb8">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItNS0xLTEtODI4NTg_9bc4bf01-ae0b-4f7c-b005-b7385267c3f0">3.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItNy0xLTEtODI4NTg_80bd5dde-e315-4a0e-999a-fdfc1d715621">5,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtMS0xLTEtODI4NTg_2d9ecad3-f4d2-48aa-ad05-7687268bfeeb">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtMy0xLTEtODI4NTg_f7df01d9-f338-4079-91ef-5c440069be78">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtNS0xLTEtODI4NTg_cde58677-b60c-4a7c-91dc-7b80413f13f4">3.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtNy0xLTEtODI4NTg_13d1dd1e-bab8-4b71-b75c-a56e97140229">5,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a <ix:nonNumeric contextRef="i777ec06acf834f40a1fa728483007e42_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzY5NjE_ec3a4ef9-9d93-4f2d-a777-914d908b0524">one year</ix:nonNumeric> vesting period, RSUs awarded under the incentive compensation plans are generally subject to a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTc_a570a6ad-3bd2-47aa-b3bf-a2a19da0786d">three</span> or <ix:nonNumeric contextRef="iba9641b95f774ba8a8d7a8d32b4cce92_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTk2_6abbec4b-ebc2-4ed9-863e-d3c028a21727">four-year</ix:nonNumeric> graded service vesting period where <ix:nonFraction unitRef="number" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzcxMDM_5e31371d-eefa-4232-8a80-60f1b9fe3da5">25</ix:nonFraction>% of the award vests after each year of service or a <ix:nonNumeric contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTU_27dd9131-fd45-4258-8c7f-517d64720c8e">three-year</ix:nonNumeric> graded service vesting period where <ix:nonFraction unitRef="number" contextRef="ib5c02b94720e4106be78e0e1359efd32_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyOTc1OA_d41c57a2-5bd2-4077-b8b0-7fc93b0ba916">33</ix:nonFraction>% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a <ix:nonNumeric contextRef="i31d4a953b2504f45a7692ab718621a5b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTUz_d62939cd-49ec-48a2-86b2-7464d50b3f53">one-year</ix:nonNumeric> vesting period in conjunction with the New Century Health transaction. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg3_9fd646c5-efc4-49da-9417-83a88a1d3bf6" continuedAt="if8b2e9f638274af290acb36e4adc5d00" escape="true">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="if8b2e9f638274af290acb36e4adc5d00"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:412.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27068971ef7e44f082589f349b94a0f5_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzEtMS0xLTEtODI4NTg_f7306dea-55a2-4177-bf41-9ba0e4e14bfe">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27068971ef7e44f082589f349b94a0f5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzEtMy0xLTEtODI4NTg_61a29be9-42d9-489f-952f-e35b3e07ee89">16.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzItMS0xLTEtODI4NTg_93fffd36-dfea-43a7-8c77-d1460bc42583">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzItMy0xLTEtODI4NTg_2a31532a-c633-4e1f-9caf-708f13b9af30">28.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzMtMS0xLTEtODI4NTg_6dad216f-e483-4b0d-bb6a-5464639c0da8">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzMtMy0xLTEtODI4NTg_1e47266c-62ae-48af-af6f-fd8d868c4ad5">21.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzQtMS0xLTEtODI4NTg_7ca005ef-5e16-410c-9018-a60a882cd3d5">743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzQtMy0xLTEtODI4NTg_bf0c061c-a07c-4fcb-bb75-2c09385bd978">15.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzUtMS0xLTEtODI4NTg_c5512ed2-51bd-45cb-b997-c4731eb81416">2,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzUtMy0xLTEtODI4NTg_a081cbaa-6130-4584-91ee-b10bc3020d7c">22.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we granted RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MDU_2a31532a-c633-4e1f-9caf-708f13b9af30">28.23</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MDk_cac2470d-b95f-4830-ac89-8cb47d230021">21.10</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MTY_b1372a82-71cd-4560-8749-e9c37bdb4201">8.88</ix:nonFraction>, respectively, which represents the weighted-average closing price of our common stock on the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MDQ_2225a3d0-bdd6-46d8-afd2-bcd57bf33cfa">11.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MDg_b5fca1ed-6efd-4ae4-bbfd-1ee175e1f0c5">7.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MTU_bb69745c-7800-4d82-9944-ca95c7dc7a85">6.1</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraged Stock Unit Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc5MDU_937b8730-2670-4ad0-a7d3-3e6cb6cf5406">0.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc5MTI_a9928074-5745-4fb3-8683-b316c438717c">0.7</ix:nonFraction>&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is or was subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgyODA_bc61237e-dc8c-42d6-945c-f8c19ebab2e4">33.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgyODQ_d012e8e6-fc9d-4c52-8a55-cce27eee94be">75</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgzNDc_f1088ee1-d8c3-4382-abdb-6401d665312d">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgzNTE_9096da89-5fff-4cf5-bc63-74224ed94aae">100</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MTQ_55103383-faf8-4524-b5a5-d608015916f9">100</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MTg_f7e1d1c7-d35c-437d-80a3-431c97cfc8b0">150</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i36d4b61188184f9b8043474a605003cb_D20220101-20221231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0ODE_5b1cf1ad-c9b2-4ec0-9cc8-62671df4570d">200</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i36d4b61188184f9b8043474a605003cb_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0ODU_a79ceb73-fb8a-4691-8b31-b333462f0498">200</ix:nonFraction>% of the shares will vest (this is the maximum possible vest amount)</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTcw_5018227c-76f7-4a71-8f89-7892373c3d4a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzItMS0xLTEtODI4NTg_af918682-029d-4040-8aaa-a21ba65441d5">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzItMy0xLTEtODI4NTg_9a33b81f-efe1-4223-9e42-b0aa0d243f1b">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzQtMS0xLTEtODI4NTg_48958735-d822-48d4-93af-57a0570063b3">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzQtMy0xLTEtODI4NTg_6273bda5-f907-490b-a57a-b551b967e248">10</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzUtMS0xLTEtODI4NTg_e8bfafdc-c947-42cd-8f22-4f9eacfa158e">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzUtMy0xLTEtODI4NTg_717ce42d-f7a1-4bfa-be9e-aa0c2fa55dab">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzYtMS0xLTEtODI4NTg_97d4c07f-3aaa-46bd-a653-6433736e900b">0.85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzYtMy0xLTEtODI4NTg_1a9ebc57-de9e-423d-a206-5a2db4036a79">2.54</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzctMS0xLTEtODI4NTg_32142079-9d6f-4fea-9191-3c7aa36d868d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzctMy0xLTEtODI4NTg_55898d76-aee5-4397-8504-0fe5a647ed3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i381452535fbf4d3ca49adf7f01b8a915" continuedAt="i8c2f10ed847c436b99abc95c366fe1a6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTc5_69649f19-b0a9-4635-be97-47fd2efc0ad2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMS0xLTEtOTEwMzE_b5d0e7cc-f329-49bf-baa8-9d28673feed4">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMy0xLTEtOTEwMzE_f5972b8d-327e-4854-bc00-d9578c4ac9dc">11.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNS0xLTEtOTEwMzE_189b04cb-fe18-4fdf-a4bc-bff2dbcb753d">7.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNy0xLTEtOTEwMzE_35d4bd89-5af2-4b3e-b0c2-3d5358671532">17,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzItMS0xLTEtOTEwNDA_79e53331-1532-449b-bcfb-200389730e4f">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzItMy0xLTEtOTMzNDk_f8219b21-b469-44a8-99e7-e98e37268830">12.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMS0xLTEtOTEwNDA_6172f0d2-7c72-42b0-b34e-57e64e26cd42">867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMy0xLTEtOTQxMDU_27cbe228-4acb-4a26-9be8-6535ebd9b389">12.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMS0xLTEtODI4NTg_5eb27080-3c82-48f3-bb24-985835e385ae">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMy0xLTEtODI4NTg_964a0274-0a4e-4c0b-9381-230e7854057c">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNS0xLTEtODI4NTg_83d500a0-350c-45d4-9aee-b71c77e8fd25">7.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNy0xLTEtODI4NTg_c2219462-8c6c-4d7f-9eb5-6fb8f7569125">9,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMS0xLTEtODI4NTg_ba189a28-4b2d-4377-8a51-0525abd0cb1d">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="2" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMy0xLTEtODI4NTg_18c1f69d-460c-4b54-9b43-2092240b0e30">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtNS0xLTEtODI4NTg_367f908b-e400-486e-b29e-49ad235287d9">7.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtNy0xLTEtODI4NTg_5df42773-299d-4cf1-8857-fa199d82a08b">9,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares awarded during fiscal 2022 include <ix:nonFraction unitRef="shares" contextRef="i380305502d0f40bf81987e1a5ae4ab46_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTI1NjQ_fea4f487-8889-468d-b6fd-936eb49350e2">0.3</ix:nonFraction>&#160;million additional shares awarded for the final achievement of the 2019 leveraged stock unit awards which was certified in the first quarter of fiscal 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based RSUs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzk5MDk_fd1b7b07-e558-4168-9b11-897be77c92ae">0.3</ix:nonFraction>&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwMDg1_e95feb79-e657-48b8-946d-eecdc5e29c31">two</span> and <ix:nonNumeric contextRef="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNjA1_c290f470-0db9-4dec-8f77-0d63840e3f06">three-year</ix:nonNumeric> cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If <ix:nonFraction unitRef="number" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNDYw_4aa9b09b-4c8f-4f92-aeac-88f9a4cd640d">100</ix:nonFraction>% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then <ix:nonFraction unitRef="number" contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNTc4_a888681d-cf75-492b-b7b7-70663f005d00">200</ix:nonFraction>% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwODYz_60171b02-aaa9-4bbe-95cb-bb9bb4968182">two</span> and <ix:nonNumeric contextRef="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTgz_bdba609b-7f2f-4c94-8fb9-6e72cf0aac61">three-year</ix:nonNumeric> cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted  if TSR performance is in the bottom quartile and will be adjusted +<ix:nonFraction unitRef="number" contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzExMDkx_89bad9d4-1f5c-4b80-a3d5-6284fdaea577">10</ix:nonFraction>% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the <ix:nonFraction unitRef="performance_period" contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2NDkyNjc0NTk2MjE_39709979-26e9-4c18-9581-c84f601742f5">two</ix:nonFraction> performance periods. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTU1_efb882e0-d488-4788-ac1c-0e6dc840da01" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzEtMS0xLTEtODI4NTg_170d4d1f-d982-4cf0-9c93-00a0bc73f45e">20.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f26ba9b9cd641d5aec7f9d0359b6769_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzEtMy0xLTEtODI4NTg_7643e401-58d5-44fd-a939-f3d0d3b33bc7">20.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzMtMS0xLTEtODI4NTg_9c3c305a-e0e3-4764-88ca-074f8df5b68e">2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzMtMy0xLTEtODI4NTg_6080b622-2118-4e38-a075-5064cd9d8ed8">3</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzQtMS0xLTEtODI4NTg_227c1544-e172-43c3-9a65-a33a776ba74b">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzQtMy0xLTEtODI4NTg_014f3b7f-52ae-4197-b1eb-863706726aaa">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzUtMS0xLTEtODI4NTg_9871d1fe-a9fb-4016-acb5-906b709e6032">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzUtMy0xLTEtODI4NTg_a114706f-b308-4214-b32b-985cea0f424e">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzYtMS0xLTEtODI4NTg_2bf47187-bdc0-42f0-87b1-539016ebe8d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzYtMy0xLTEtODI4NTg_2be52582-cccb-4580-9441-dfe6dcf39049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8c2f10ed847c436b99abc95c366fe1a6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwOTk1MTE2NDA2NjQ_a3fcd677-172f-48c4-af72-c28a52c53257">0.5</ix:nonFraction>&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A <ix:nonNumeric contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTE1MzA_ca6d7d97-5212-4b66-b60e-36906658e39c">three-year</ix:nonNumeric> cliff vesting was approved and began on January 1, 2022. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of company value. Per the agreements, company value is calculated using a formula based on revenue growth and cumulative Adjusted EBITDA, as adjusted for any acquired business during the period. If the minimum performance goal is not achieved, then no performance shares are earned. If <ix:nonFraction unitRef="number" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwOTk1MTE2NDEwODA_4aa9b09b-4c8f-4f92-aeac-88f9a4cd640d">100</ix:nonFraction>% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then <ix:nonFraction unitRef="number" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyOTc4MQ_cecbfe21-0e0e-487e-af17-473fa49c808b">250</ix:nonFraction>% of the targeted shares are earned. If the company value falls between tiers on the sliding scale, the actual company value payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTky_37b54984-0184-4a04-96d4-2baef5f62e21" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"></td><td style="width:280.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMS0xLTEtOTQxMTI_910c4418-9569-45d5-88b2-d4fd4628b5c1">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMy0xLTEtOTQxMTI_b2b9cb36-d8b4-4878-8125-398c5cc770d4">20.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNS0xLTEtOTQxMTQ_cb6ee2b5-9d92-42da-84cd-4c29179004df">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNy0xLTEtOTQxMTQ_bf701bbe-a129-4fab-9a76-f7b7928fb5cb">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzItMS0xLTEtOTQxMTY_4c75e03b-95b0-4620-b7ca-30a57c3ae16c">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzItMy0xLTEtOTM4OTk_91128d6c-6ccc-413c-a36c-5d930ead278c">28.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="-3" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMS0xLTEtOTQxMTY_9857d7e9-132d-4640-8b21-1134e84f4184">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="2" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMy0xLTEtOTQxMTY_d7fb1186-41a8-494a-9352-ceac41e7429a">23.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzQtMS0xLTEtOTQxMTY_95541343-5148-40f1-b27d-8e29e685beca">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzQtMy0xLTEtOTQxMTY_60d06443-f84c-4af0-aca2-2c293d0e97aa">25.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMS0xLTEtODI4NTg_6ef60272-3bb6-4cee-88bb-48cc4b0ff5d7">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMy0xLTEtODI4NTg_238a34d3-8681-436e-8f30-896681a410f5">24.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNS0xLTEtODI4NTg_0e809f01-4adb-4850-96bb-1f7e481513a5">8.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNy0xLTEtODI4NTg_d87f1917-9f5f-42c0-8535-d537d4bc099a">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMS0xLTEtODI4NTg_2f35e3ee-5c29-4564-ab6b-435547a6d745">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="2" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMy0xLTEtODI4NTg_24c84252-9266-4e10-b1ce-33d4660d6156">24.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtNS0xLTEtODI4NTg_2af4d17c-9a49-4d35-bf24-f97a81252788">8.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtNy0xLTEtODI4NTg_eab802ac-690b-4197-a7d8-a0e715186c7a">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_262"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMjc_ce69189f-d93e-4882-844c-4a733651f31c" continuedAt="i134586c880f94b1a81e8a0876bb37cb2" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i134586c880f94b1a81e8a0876bb37cb2" continuedAt="ic600f8bd671f400b9792fee11f83fce1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY0_8c37efeb-8bb1-4b41-8b53-5402d8020b02">43.4</ix:nonFraction>)&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY4_6df29640-b7dd-4699-9b6b-d89329ccc252">0.5</ix:nonFraction>&#160;million, and $(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc2_fba59ebf-1562-487d-9e86-ec2882b71380">2.4</ix:nonFraction>)&#160;million was recognized for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTc_47d7b8fc-c724-4985-ad5f-4f5c78295cd9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItMS0xLTEtODI4NTg_c9eb7323-ec04-4935-bea5-ab580c2e2b3b">66,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItMy0xLTEtODI4NTg_c270e189-ad68-4101-850b-362bc23d3469">32,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItNS0xLTEtODI4NTg_1ac92609-db0c-44f0-aa89-56241d86b50d">332,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtMS0xLTEtODI4NTg_6457ae3c-203c-473b-9858-81cfb1920480">3,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtMy0xLTEtODI4NTg_9ccff614-d5e0-4a58-8f8d-1991073b3e88">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtNS0xLTEtODI4NTg_d79753ea-3b30-4cb9-b99e-b027ce1c41a0">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtMS0xLTEtODI4NTg_05f229b1-b9dd-47cd-8692-af186686301a">62,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtMy0xLTEtODI4NTg_c1228c44-3b83-45e1-9cbe-e7fd8d92ab50">29,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtNS0xLTEtODI4NTg_8179bf0a-0576-4d05-90e6-9c5b560a76a3">330,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic600f8bd671f400b9792fee11f83fce1" continuedAt="icce5004fd7f84e2da93079d375d85e84"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgyOTc_147e636a-761f-4a84-8d33-afbe99006f84" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:370.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtMS0xLTEtODI4NTg_4a059bc6-ae58-490c-ab9b-68c45fc96dc3">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtMy0xLTEtODI4NTg_51e0072d-f52a-4521-b0a6-a89581c6a7c3">1,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtNS0xLTEtODI4NTg_b2835637-769b-4296-86a3-93c41118d3c8">2,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtMS0xLTEtODI4NTg_969d93c7-3a1a-4f63-8ae5-af85e8d41b98">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtMy0xLTEtODI4NTg_a1d9ce02-11b5-4ac9-a3ff-980ad17da323">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtNS0xLTEtODI4NTg_9b73314a-2491-47f3-8f5b-d80095fd117b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtMS0xLTEtODI4NTg_a189cfcd-92db-40e9-8917-249f1d85e9c0">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtMy0xLTEtODI4NTg_5eb3e3c0-6666-426a-84b1-a42dae3364fd">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtNS0xLTEtODI4NTg_0cdbdc99-a3b5-41df-8554-244c169cd620">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtMS0xLTEtODI4NTg_25dcfe70-9ac6-4447-84b2-bbaac00b3a68">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtMy0xLTEtODI4NTg_ea6812db-e339-42b6-bb00-8e511553b0cc">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtNS0xLTEtODI4NTg_eb4d55d5-7e5b-45a3-b4a7-6b2c26c61b78">1,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtMS0xLTEtODI4NTg_08ac4198-92ea-4b61-8491-51b16248fd65">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtMy0xLTEtODI4NTg_ed07e42f-59b6-46cf-8061-c56ee2398bce">5,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtNS0xLTEtODI4NTg_a1448007-3d74-4861-bca2-a46afb308327">38,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktMS0xLTEtODI4NTg_483b344f-4682-46d4-9cb1-e728e39c652e">2,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktMy0xLTEtODI4NTg_716b75df-2505-4fdb-b096-155bd030b57e">4,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktNS0xLTEtODI4NTg_04ac7c04-b8d3-422c-a106-a766c81f3a1a">9,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTEtMS0xLTgyODU4_e7d59489-33cc-4f30-a19d-8e4547351d82">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTMtMS0xLTgyODU4_2038c9e4-dc98-4ee7-8065-6fe6195fa852">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTUtMS0xLTgyODU4_9d570c18-f67d-4d84-9ddd-176663196d30">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTEtMS0xLTgyODU4_08f34644-5dbb-4333-a5e2-ff7ac6d9b74e">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTMtMS0xLTgyODU4_a3b3a48f-f746-4aba-99fa-e6156ee8f2b3">10,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTUtMS0xLTgyODU4_b457d323-78dc-41a5-ae74-3f47168d5348">48,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTEtMS0xLTgyODU4_29d2fad5-b6b9-4adf-b5c8-12eb432eba51">47,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTMtMS0xLTgyODU4_5ff4c168-9b78-4ba8-a872-4860fd985231">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTUtMS0xLTgyODU4_460ff2e5-6829-4111-83c8-8d7c9f455949">47,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTEtMS0xLTgyODU4_70c9ed1a-b1de-4f35-b1d0-f850299d7c22">43,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTMtMS0xLTgyODU4_d626588e-1e31-447a-9f02-3702ae0f2cbb">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTUtMS0xLTgyODU4_29003c2e-71a9-4f2b-a2bc-2c4e2f01e2cd">2,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTQ_33e8d6e7-0d60-4c7d-915b-ad48e43dd69e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItMS0xLTEtODI4NTg_f5b3f339-ef63-4c0c-ae28-294855c792c2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItMy0xLTEtODI4NTg_1b7b3724-eecc-40f5-9e48-75b050254b17">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItNS0xLTEtODI4NTg_8aba9873-12e2-4334-9500-39d4a915f7ff">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtMS0xLTEtODI4NTg_f7418d23-c8b5-418d-846c-259ec27f154e">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtMy0xLTEtODI4NTg_564c815d-8fa1-4465-9924-e165345c7d40">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtNS0xLTEtODI4NTg_c3d816f9-f458-4d53-b94b-6b4503dc60be">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtMS0xLTEtODI4NTg_25876679-d9c6-4284-b15b-2bd5651166b3">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtMy0xLTEtODI4NTg_0b2257f1-1ba6-429d-a8e8-f06684dbbcbe">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtNS0xLTEtODI4NTg_1271c834-4df8-4f23-8b2e-bacd7d9cb6d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtMS0xLTEtODI4NTg_7bb8cc68-817f-4ef9-8e88-afb980c0185a">77.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtMy0xLTEtODI4NTg_cab844c9-9add-4f97-9732-95559f785b6b">33.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtNS0xLTEtODI4NTg_6a6ee555-b115-4436-8045-1a36923ba4ee">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtMS0xLTEtODI4NTg_c1a6db84-ac73-4390-8a79-de444fa6d739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtMy0xLTEtODI4NTg_0bbd7b0e-707d-4e75-9777-0d3b1d718fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtNS0xLTEtODI4NTg_b947929f-8925-4c0e-ae5f-3ad22cbabc3f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctMS0xLTEtODI4NTg_e3469e08-27bd-409b-986b-5b0b50c16c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctMy0xLTEtODI4NTg_0bbd7141-4c76-4c8b-8fc2-daa3b3d73743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctNS0xLTEtODI4NTg_978768b1-3d66-4a5b-b5c8-0d6effcb0282">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible excess compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktMS0xLTEtODI4NTg_70828d55-6d63-4a9b-893e-3ef8e4cedd73">27.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktMy0xLTEtODI4NTg_5529afe8-686e-4364-bb00-064bc31ec667">10.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktNS0xLTEtODI4NTg_5856752d-08fd-4f3c-9196-be8f6b8f5d22">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTEtMS0xLTgyODU4_1f895530-dd3b-42bd-91a0-b5cbd332ef22">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTMtMS0xLTgyODU4_0bc4430d-f38f-45db-8dde-a97e57fabf45">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTUtMS0xLTgyODU4_1004ec2d-b06b-47aa-a47b-fcfa434635f6">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTEtMS0xLTgyODU4_eae99a5f-1de0-43c5-b341-822ebbb06a22">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTMtMS0xLTgyODU4_47c6f67a-0eb3-4f06-a64c-dad6f848e5db">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTUtMS0xLTgyODU4_d9f0a792-21dd-4b77-aefe-2bfad976d10f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTEtMS0xLTgyODU4_c7017bfc-bdc8-4fb0-9972-6e459700a693">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTMtMS0xLTgyODU4_45daca15-feb6-4ffd-b0b7-891a2f3f7f17">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTUtMS0xLTgyODU4_63b26c6a-9a45-4715-bc5b-dba0c7b461a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTEtMS0xLTkyOTQ4_c63458b6-c982-4472-94a0-ba1a73442291">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTMtMS0xLTkyOTQ4_b09e0551-eb84-401c-a6b2-d23d1efc0f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTUtMS0xLTkyOTQ4_c2966601-e6b0-49c4-a35c-5bc24ec6c43d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTEtMS0xLTgyODU4_f0de1e7c-97ff-4be6-9252-f5b858018e99">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTMtMS0xLTgyODU4_ea074938-a624-4e7d-b221-fb23899a2465">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTUtMS0xLTgyODU4_07ea0a3c-fb33-4f16-a0b1-076968696104">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTEtMS0xLTgyODU4_4d109ab1-2637-4e4b-aebc-a754f0b5e7cd">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTMtMS0xLTgyODU4_893d258c-4ae4-435c-b4a3-d6b1e0d1c459">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTUtMS0xLTgyODU4_3a4673ea-b64a-4e22-bbfd-6858335f2330">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTEtMS0xLTgyODU4_9bad426d-ca34-4c5d-81f1-86c41ffb8160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTMtMS0xLTgyODU4_7279e5f0-7526-4b40-b4a2-22a2b1a1bece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTUtMS0xLTgyODU4_509fdf3a-052c-4e33-8ebc-5af30d1f3195">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTEtMS0xLTgyODU4_7b1d0fcd-0e6b-44a7-8361-3df3c8203725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTMtMS0xLTgyODU4_d95193aa-a37b-4555-a81b-750ac99cae4a">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTUtMS0xLTgyODU4_d37225ac-114d-4bd2-a85b-c93ca71f60ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTEtMS0xLTkyOTM4_f595c03a-affb-442b-8b48-9cad7dcc18a9">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTMtMS0xLTkyOTM4_a4e8cbae-78ed-458f-925b-8edfba12dd58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTUtMS0xLTkyOTM4_c15f35e5-c592-40c5-b1d5-c7b70b6f28de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTEtMS0xLTgyODU4_1e5464eb-80b5-4445-9e28-a855c52327fb">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTMtMS0xLTgyODU4_16b2c80c-5f08-4fd9-9bc9-12674b82d3bb">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTUtMS0xLTgyODU4_7f3617fe-6310-466a-8b59-34ff7bd20b07">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTEtMS0xLTgyODU4_16bf0e20-f9ab-43c5-b5b3-d0cd66399149">69.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTMtMS0xLTgyODU4_cb67d903-65b8-4eeb-b1ae-afac84551df3">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTUtMS0xLTgyODU4_08a0bd5f-4362-47bc-bc90-5bc756070118">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icce5004fd7f84e2da93079d375d85e84" continuedAt="ib46f2e33608d436383e860ece5efcdc9"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMjM_32656467-df08-45d0-832b-a0e71cacc418" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:DeferredTaxAssetsStartupandOrganizationalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzMtMS0xLTEtODI4NTg_84414535-0594-4df9-a8d7-6ce77581f7fd">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:DeferredTaxAssetsStartupandOrganizationalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzMtMy0xLTEtODI4NTg_a98d40e8-47a9-4554-8c4f-0cf088870b65">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzQtMS0xLTEtODI4NTg_9c7ab624-7e7d-4a49-8fd1-fb55625447f8">12,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzQtMy0xLTEtODI4NTg_672e74bd-c6a8-430d-bdcf-4417da106f9c">18,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzUtMS0xLTEtODI4NTg_e1a96259-bfcd-493f-bd7e-6350df048790">16,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzUtMy0xLTEtODI4NTg_a8b9ae71-19b4-4092-af30-e7a5376ada2b">15,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzYtMS0xLTEtODI4NTg_b16f937a-f638-49ee-859b-2cc69503dc0e">9,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzYtMy0xLTEtODI4NTg_7a3fbd56-740e-4056-9b2b-79fe8b179a80">10,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzctMS0xLTEtODI4NTg_9fdc3bf7-c880-46c1-8315-474d86478a7a">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzctMy0xLTEtODI4NTg_16e166b8-c893-458f-ae05-1f6b3b264ba8">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzgtMS0xLTEtODI4NTg_5e146b1d-3066-4e70-9fa1-d0623ea5252a">131,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzgtMy0xLTEtODI4NTg_5fd43150-2068-4781-958b-9a61ff996327">130,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzktMS0xLTEtODI4NTg_12c7ce07-3d2d-4adf-bce6-14c02c37b0bc">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzktMy0xLTEtODI4NTg_bda47c49-46e6-41a6-a823-8286c1fdd7ca">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEwLTEtMS0xLTgyODU4_6641b4e4-423f-46f1-9835-ec692b3ec06e">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEwLTMtMS0xLTgyODU4_3c5cff48-f585-48a6-9c4b-dee7ae95b3ca">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzExLTEtMS0xLTgyODU4_63a11692-f2ca-409c-b092-3b22e27174e2">7,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzExLTMtMS0xLTgyODU4_d4993abe-7985-4c37-8819-2ca3be31091a">7,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="evh:DeferredTaxAssetOutsideBasisDifferences" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEyLTEtMS0xLTgyODU4_58b1be46-72fe-43aa-9759-c9101c25acd9">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="evh:DeferredTaxAssetOutsideBasisDifferences" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEyLTMtMS0xLTgyODU4_d954a31f-5317-4288-9f35-26391d84a5c8">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEzLTEtMS0xLTgyODU4_25ded0a5-f2bb-4d33-a639-f32726e500b2">6,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEzLTMtMS0xLTgyODU4_5000a0b3-37a8-4cfb-90b3-777d89976789">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE0LTEtMS0xLTgyODU4_28310828-5475-40a9-96bf-d2bb975c0aae">187,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE0LTMtMS0xLTgyODU4_b87e6c42-91d3-4006-90bd-9a81180bb467">205,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE1LTEtMS0xLTgyODU4_5ad757fd-09c8-4a58-a550-fc67d66d92e1">70,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE1LTMtMS0xLTgyODU4_5ffce3cc-de66-4d6e-b972-89f4bbd7b2df">101,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE2LTEtMS0xLTgyODU4_db52703d-7df1-43df-a4f5-91ec59589147">116,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE2LTMtMS0xLTgyODU4_0138b5a0-a529-4a28-b4f1-79c044884562">104,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE5LTEtMS0xLTgyODU4_479a60a0-20ac-499f-8892-f46f813225ae">11,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE5LTMtMS0xLTgyODU4_b64ece07-09ab-40ae-9ccb-652fb8ca6a72">12,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIwLTEtMS0xLTgyODU4_37199b64-dc71-4389-9f07-041cd9fc313a">89,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIwLTMtMS0xLTgyODU4_c149ed00-62cb-494d-9866-4da82eb6cb82">48,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIxLTEtMS0xLTgyODU4_8daba110-57d2-4bbd-9d75-8d12f769767a">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIxLTMtMS0xLTgyODU4_ff837b62-2835-460d-9828-534f0b6c066c">12,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIyLTEtMS0xLTgyODU4_dc3398a9-6921-42de-8af6-d0f8e1c8d81c">4,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIyLTMtMS0xLTgyODU4_220ae388-722a-4baa-81f7-186799b40033">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIzLTEtMS0xLTgyODU4_33cd7401-94b9-45fc-83f4-eec745c52588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIzLTMtMS0xLTgyODU4_ccd53607-b2ab-475f-88f0-59d6ef46952a">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI0LTEtMS0xLTgyODU4_a0d04977-f375-4c77-9c21-00d6aade3a64">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI0LTMtMS0xLTgyODU4_41e7da4c-faaf-4314-9c1a-f5e050df954a">5,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI1LTEtMS0xLTgyODU4_7011188c-e857-4286-9f7e-5f3e6d35f81c">120,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI1LTMtMS0xLTgyODU4_3e16ae75-c8ca-4478-aa01-c1a4d56a6fdb">104,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI2LTEtMS0xLTgyODU4_05157338-376c-49af-b626-6d361f9fc912">3,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI2LTMtMS0xLTgyODU4_a5f10afb-d4c3-4bda-b763-5e2afe7975a2">658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c16ad239424ec88d83268977b370bf_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzItMS0xLTEtODI4NTg_cd2cd9ac-2d60-40a9-ad31-04c2ae461f06">101,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f84cee7ed64c41ad902dcd77f1d4e2_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzItMy0xLTEtODI4NTg_41417d62-4513-4796-87f9-c7952e3f4307">89,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzMtMS0xLTEtODI4NTg_46a25e3b-0d48-4865-a1f5-a3f0a4e08ba3">47,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzMtMy0xLTEtODI4NTg_bb8835c8-801f-4a59-ad97-3a65ae9f6a2d">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzQtMS0xLTEtODI4NTg_4b0abb0c-5781-45d5-8b5f-1517c4fd983c">17,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzQtMy0xLTEtODI4NTg_c2b98827-7fe1-4d93-aafc-e8ba1acf9fa7">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a909c5b37546d18248f54d9b4a4151_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzUtMS0xLTEtODI4NTg_6cd0dd64-be88-43dd-9e6d-335cf8db8684">70,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c16ad239424ec88d83268977b370bf_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzUtMy0xLTEtODI4NTg_4ceccfb3-7522-4ace-baf9-faa778f2c5b7">101,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:2.94pt">Amounts charged  to other accounts includes $<ix:nonFraction unitRef="usd" contextRef="i2de795bc67904a5e85f0decbbd09ab32_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3Njg_8f368c56-6e7f-4f54-a3d7-a06766f4d772">17.3</ix:nonFraction>&#160;million charged to shareholders&#8217; equity and $<ix:nonFraction unitRef="usd" contextRef="i997feae046c54b3a9bf17e3433160784_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3ODQ_37898dac-7b8f-4c43-bb5b-296b289d1b5a">0.1</ix:nonFraction>&#160;million charged to discontinued operations for the year ended December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="id31a88fa387b4e53a12f438b4b3b5bac_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzk0Mg_38a7c66e-4566-4d07-90a5-22dbf49a09bd">1.8</ix:nonFraction>&#160;million charged to discontinued operations for the year ended December 31, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2022, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNTI0Ng_d291c0ab-422a-4117-accd-1ee2ff014f69">69.9</ix:nonFraction>% and the corresponding tax benefit recorded was $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNTI1Mw_33a24430-525c-4ef7-b77a-ee9e328607c9">43.4</ix:nonFraction>&#160;million. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded by the company in 2022 primarily relates to the $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0Mzc_9ca6101d-1b12-4ebc-a5e0-de3d44fa92e8">46.8</ix:nonFraction>&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the effective tax rate was (<ix:nonFraction unitRef="number" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzEyMDY_1d683934-947d-4979-8e8f-632f39a67c65">1.6</ix:nonFraction>)% and the corresponding tax expense recorded was $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzEyNTY_cc9dbeb0-d751-47fd-9977-0a3b2a14f826">0.5</ix:nonFraction>&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#8217;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDY_52419f8f-009c-446c-8535-b31d6134b23c">0.7</ix:nonFraction>% and the corresponding tax benefit recorded was $<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2OTc_d682fa02-9cec-4dd1-b014-51c554fe2bdd">2.4</ix:nonFraction>&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib46f2e33608d436383e860ece5efcdc9" continuedAt="ia121ada75e9f412fb2f5d8066cefc071"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying back New Century Health&#8217;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, did not have a significant impact on the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ief049904d28f460d998a77dd264865b8_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQwODg_e2dffde5-962d-45b0-92a7-ac871f03a8dd">186.9</ix:nonFraction>&#160;million of federal and $<ix:nonFraction unitRef="usd" contextRef="ib8dfb8ced52c4e3cb9c781d4c11d94cc_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQxMDY_4da5f3e3-59f9-401c-ab77-1ff77ac96e9c">301.8</ix:nonFraction>&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i84bf075d368e44968b724f9fa95b7960_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQyMzE_74d0b4d8-e18c-4364-83db-47e44671ff5f">295.5</ix:nonFraction>&#160;million federal and $<ix:nonFraction unitRef="usd" contextRef="ib816cd0b1e5246268d85139debf44ec6_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQyNDY_9c358cd4-2a5d-4367-a1e3-3e7ffb0eae3a">245.0</ix:nonFraction>&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#8217;s ability to utilize NOLs and could cause U.S. federal and state income taxes to be due sooner than if no such limitations applied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ic2fe137ef9b94b438227de3ce6b602f5_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQ5NTc_94c6b22f-4b59-4065-b979-d54f88361ff8">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6973c687f47242d48d1ab11cc64f5795_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQ5NjQ_592864ad-402f-4f35-b880-193c8f139968">0.3</ix:nonFraction>&#160;million of research and development credits for federal and state income tax purposes, respectively, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a partial valuation allowance against those credits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the President signed into law the Inflation Reduction Act of 2022 which contained provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks, both of which we expect to be immaterial to our financial results, financial position and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTI_64ff1f2d-e210-466e-a2a3-7817f77d5c97" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:402.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItMS0xLTEtODI4NTg_f62de48a-0f78-4704-8366-a2ddb49e6f74">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItMy0xLTEtODI4NTg_116901e7-6913-4f8a-a462-11c6f6739861">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItNS0xLTEtODI4NTg_b360383a-9584-4be1-9564-118bcc97ad16">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMS0xLTEtOTMwMjE_33d09c79-a035-4134-a96f-ce1a45bcc582">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMy0xLTEtOTMwMjE_5f897e25-4472-4df7-8632-4dcc289a7a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtNS0xLTEtOTMwMjE_acc25e8e-0355-46b1-bbb3-7fb1b8b0efa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMS0xLTEtOTMwMzA_a22fa7b4-1683-4ead-ab29-ba4ef0138501">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMy0xLTEtOTMwMzA_bf85df19-9fa1-43fc-b005-ad491ad294a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtNS0xLTEtOTMwMzA_0df23f2b-68e0-44ad-84a8-9a42ef5b8d46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMS0xLTEtODI4NTg_101223e6-7ea7-4dec-a359-83bac1871b51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMy0xLTEtODI4NTg_f06b02d8-cb3a-4e43-9bb7-3a283664a33d">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtNS0xLTEtODI4NTg_b146ebcf-7237-480b-9066-265de0357a57">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMS0xLTEtODI4NTg_fbd8657b-46f0-4e7b-b2fa-71832d47d62e">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMy0xLTEtODI4NTg_f3a271cf-7d9f-4f54-a81a-ec240ec9eddc">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtNS0xLTEtODI4NTg_221b5f34-605b-4079-9a16-50ef58291f6e">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in various jurisdictions in the U.S., India and the Philippines. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2022, are $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU1ODA_2d8b5b81-538f-490f-87d9-8ef50a8d0d4f">0.6</ix:nonFraction>&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#8217;s valuation allowance. The Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNzkzOA_65c34745-4086-4263-b6d4-8e427da0810f">0.3</ix:nonFraction>&#160;million of interest and penalties related to uncertain tax positions as a component of income tax expense for the year ended December 31, 2022. The Company recognized <ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0Mjg_063a44b9-5e96-4bab-bfd1-1369340caf3f">no</ix:nonFraction> interest and penalties related to uncertain tax positions for the year ended December 31, 2021. The Company has accrued interest and penalties related to uncertain tax positions of $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNzk1Mg_078172bf-3a16-42f8-836c-ff8d695f2e1e">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3OTg_d069e9e6-2274-48a7-8518-3a0f6bc130f4">0.0&#160;million</ix:nonFraction> as of December 31, 2022 and 2021, respectively.  The Company had recognized $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU4ODU_7ae254fb-75a7-4482-a7e6-1a7d5d5bca98">1.6</ix:nonFraction>&#160;million of uncertain tax positions as of December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU5Mjk_73028042-1f25-49f5-886a-c32a71e9bbc8">0.6</ix:nonFraction>&#160;million as of December&#160;31, 2021. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#8217;s tangible and intangible assets. These increases in tax basis increase our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders <ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY4MTc_e18bb098-002c-40fd-9d7a-458a58e5bf27">85</ix:nonFraction>% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings <ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc1Njg_560c406f-ba88-421d-b030-a120d18b478a">85</ix:nonFraction>% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $<ix:nonFraction unitRef="usd" contextRef="i4265c7d21f1d4b838581fca135d6e78c_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc4NjA_09f10d0e-a8b5-40cb-ba26-bbd0b72bb735">79.3</ix:nonFraction>&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. The Company has recorded a partial TRA liability of $<ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-5" name="evh:TaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0MDY_2746ce8f-d1d7-4e25-b323-26c3babfdb13">46.0</ix:nonFraction>&#160;million as of December&#160;31, 2022.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia121ada75e9f412fb2f5d8066cefc071">We will benefit from the remaining <ix:nonFraction unitRef="number" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="evh:TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc5OTg_b5645c3f-be2e-49f3-9c63-468334069418">15</ix:nonFraction>% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated. See Note 11 for additional discussion of the implications of the TRA.</ix:continuation></span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_253"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzU5Ng_fdf34090-24df-48c7-aeb5-25e038fe7ccc" continuedAt="i1e2eecf9e73948f593995e49fd9763d7" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i1e2eecf9e73948f593995e49fd9763d7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzM5MA_f795fc4c-1e33-47ed-9c6a-b0bceee2ae14">7.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzM5NA_c6fae005-328c-48b3-a6cb-3aefad42078a">5.4</ix:nonFraction>&#160;million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzQwMQ_a10f6727-1cee-4bb5-bb59-91cb872b543f">6.2</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in contributions to the 401(k) plan for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total contributions for the year ended December 31, 2020, are net of $<ix:nonFraction unitRef="usd" contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzU1OA_b62541ed-75cf-480e-9790-00ae3e031d26">0.2</ix:nonFraction>&#160;million from discontinued operations.</span></ix:continuation></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjE4OA_dcfcca00-e444-4212-a204-b3fb2d95f25a" continuedAt="i8c5bfe77d15048de8257f8fc1054355a" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8c5bfe77d15048de8257f8fc1054355a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="ib9836acdd1fb436298594c2019552b35_I20221231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI0NA_0185b9f4-db1e-4d15-b625-175c3045d9b2">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ife27a03e76054f2293b5ac1cb4a4010f_I20221231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI1MQ_4a0c5fd9-0d7f-4bc0-9815-74260f6413d0">38</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if07bcd3c52e24dc1836baafe4f759c78_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI1OA_89572e94-8085-44de-ae0a-62a9a0d9d974">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI2NQ_2640ec05-99d3-4899-9c9a-73c6bf47d520">39</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="if07bcd3c52e24dc1836baafe4f759c78_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1Mg_b6e6a60a-6a55-4bd0-ae8e-e17903530b21"><ix:nonFraction unitRef="number" contextRef="ib9836acdd1fb436298594c2019552b35_I20221231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1Mg_fbad8d22-c45a-470e-8294-5d60d29d5f8f">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ife27a03e76054f2293b5ac1cb4a4010f_I20221231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1OQ_a5625ab9-b402-46a2-aae2-b6858b00eea6"><ix:nonFraction unitRef="number" contextRef="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1OQ_e8e572bd-d7de-404d-be18-7f95c266b065">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTgwOA_2b765b9d-a470-4022-9025-eb13aea49a2e">4.6</ix:nonFraction> million,  $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTg0NA_7489738b-b4dc-4057-b730-f5d564247049">13.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfNTQ5NzU1ODE2MTk2_99451f6a-a6c6-4fc6-bb10-813033631c08">10.0</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="i08ddb5f52bed406dacf7038dcf91f94c_D20220101-20221231" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjEyNg_4ac3dfbb-57df-4e47-b538-e7c01ccc1384">16.9</ix:nonFraction> million,  $<ix:nonFraction unitRef="usd" contextRef="i5ab25d9d5a634cb59dbe05457f809563_D20210101-20211231" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjE2Mg_a472db18-7d6d-4aeb-bb0e-2afb9e8cca11">15.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a8a373598344ec1894589f6195ded59_D20200101-20201231" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfNTQ5NzU1ODE2MzMw_1e4d1f07-ba72-4916-8771-671cf3167f96">192.8</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:continuation id="i6563a015b2ae4efe95262918d6c38705" continuedAt="i341e70c6eb254e919549a0d4f1e8a17e"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI1Nw_15bd34de-c163-4c1b-8227-2f934828741f" continuedAt="ic48bc16dca8a444f998cb7854bf8eb2d" escape="true">Fair Value Measurement</ix:nonNumeric></ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i341e70c6eb254e919549a0d4f1e8a17e" continuedAt="ibe5a6e92f23d43319edbdace0ce094bc"><ix:continuation id="ic48bc16dca8a444f998cb7854bf8eb2d" continuedAt="i29f32c2f3e1a4ebe8dd2348bdec0dfd6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i29f32c2f3e1a4ebe8dd2348bdec0dfd6" continuedAt="i998ebd6e677248f9852c42f71f941573"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI1OQ_54da63f4-9ab2-4632-b12f-550e034ec66c" continuedAt="i7dde9b33f5d447b8be373d49d12f3380" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i7dde9b33f5d447b8be373d49d12f3380" continuedAt="i346a1e1d2197425c88547444bbd3cf9c"> </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i346a1e1d2197425c88547444bbd3cf9c"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17c85faa0f841b99a3b41d10678e6f9_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy0xLTEtMS04Mjg1OA_5e38d305-0235-43bf-9675-4c5143952ecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6345c725b74f1185b75d72fe34dc81_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy0zLTEtMS04Mjg1OA_2fd5f22f-5b79-4c73-90ce-3e0da125f938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy01LTEtMS04Mjg1OA_d13e1a23-6df0-4b9f-94ce-0f039674edd0">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy03LTEtMS04Mjg1OA_31ef5524-9071-4bd8-a0e2-eabe0b90ed8a">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17c85faa0f841b99a3b41d10678e6f9_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC0xLTEtMS04Mjg1OA_9d8fcdb7-892e-4f40-bf8e-fe9198cebfc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6345c725b74f1185b75d72fe34dc81_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC0zLTEtMS04Mjg1OA_355f2cd7-4ec2-4be4-aac3-83f6ae7c7f85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC01LTEtMS04Mjg1OA_ed9ae7fd-eb61-46a9-b83a-16b2eab72e43">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC03LTEtMS04Mjg1OA_acc30541-c7b4-4438-867b-9157ff8f47bf">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922ff0166d094a94bc7b6cb25be53520_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy0xLTEtMS04Mjg1OA_d52f0642-3438-4a16-8c6e-d00c05bb58ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7077a023068e40ef90f4eafdef2ac9d5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy0zLTEtMS04Mjg1OA_ebb6ee4a-799d-4b87-83e8-b50ddf8000e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy01LTEtMS04Mjg1OA_7af22d7f-255d-4df8-a6ea-853e6a2faaaf">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy03LTEtMS04Mjg1OA_c7c3da13-50b5-4217-985c-d806306e1b25">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922ff0166d094a94bc7b6cb25be53520_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC0xLTEtMS04Mjg1OA_c403958b-8e98-4947-8f26-8919f33cc6ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7077a023068e40ef90f4eafdef2ac9d5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC0zLTEtMS04Mjg1OA_37b23023-1c27-4ecf-8b6a-cb6772b2fc33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC01LTEtMS04Mjg1OA_27170565-fd8c-4ff1-9dee-e9ead8588228">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC03LTEtMS04Mjg1OA_cb499fab-4f19-4358-bea1-439955b4a685">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI2MA_54f2d4dc-ae45-46a2-92a9-b4571ffe0dc8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMi0xLTEtMS04Mjg1OA_15e0f217-48eb-4334-b4c6-5d9c5e3af8eb">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMi0zLTEtMS04Mjg1OA_f111839d-2519-47e3-8d43-dd4ed2ab2e6a">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMy0xLTEtMS04Mjg1OA_f0db3c6c-916c-41ac-b143-2ad8b218456f">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMy0zLTEtMS04Mjg1OA_724ebb1c-fa10-4cf0-bdcb-67735af54a8f">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNC0xLTEtMS04Mjg1OA_3194bb41-9355-410a-af36-724fcd3ae9af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNC0zLTEtMS04Mjg1OA_cc78d3f2-49bb-4fc5-ba51-22c2302c4418">13,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0wLTEtMS04OTYxNQ_18d250a8-ffa3-4981-a373-91017e1f61d8"><ix:nonNumeric contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" name="evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0wLTEtMS04OTYxNQ_5f68097d-06ed-44f1-b5b0-a30919dea20e">Unrealized (gain) loss, net</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0xLTEtMS04Mjg1OA_c0ba3d60-2133-4c68-8cb6-496c04bcedcd">25,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0zLTEtMS04Mjg1OA_ea05268a-1103-49b5-8619-0f540d7b4cf2">14,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNi0xLTEtMS04Mjg1OA_07cd59c2-5ecb-4a96-9216-6fdfb3e6770f">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNi0zLTEtMS04Mjg1OA_c066b171-5407-4fd2-a851-7f5100023cd5">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI2MQ_28931531-ccfa-4cf2-b45f-4c386b63aeaa" continuedAt="iff725be628624a4f8066910504b54e43" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfMy0xLTEtMS04Mjg1OA_2d92b1de-499f-4661-a659-8fe6f613abed">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9511c01ee7c4db793847be4cc362076_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfMy03LTEtMS04Mjg1OA_59d6f668-1899-4344-874a-8c8d059f6d39">77,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa8ce3db74aa417989fbb9df2f38ad5b_I20221231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfNC03LTEtMS04Mjg1OC90ZXh0cmVnaW9uOmEwODM3ZTVlOGVkODRjM2RiYzg4MGFkNTU0MDA0YTgxXzE2NDkyNjc0NDE2ODc_69026719-b1a1-450f-a1c7-f1c494285944">9.85</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iaae7be454d7b4ccca01d6d258c44d97f_I20221231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfNC03LTEtMS04Mjg1OC90ZXh0cmVnaW9uOmEwODM3ZTVlOGVkODRjM2RiYzg4MGFkNTU0MDA0YTgxXzE2NDkyNjc0NDE2OTY_98c941b3-f502-4289-b719-9303009f5753">10.01</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i998ebd6e677248f9852c42f71f941573"><div style="text-align:justify"><ix:continuation id="iff725be628624a4f8066910504b54e43"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfMy0xLTEtMS04Mjg1OA_c42b6963-54e8-4ee6-b48d-f3c67283ae5c">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e6659721d84a6a93639ba51c8411c8_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfMy03LTEtMS04Mjg1OA_6f2b1a6a-8bc3-4671-93b1-257e61424431">30,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i025995168f8f42fba6c2563b6e8916a1_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfNC03LTEtMS04Mjg1OA_ed2c24e1-642e-4b3c-a658-cd212b204a50">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibe5a6e92f23d43319edbdace0ce094bc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90ZXh0cmVnaW9uOmEzZTJkMzcxODYyNzQwN2FiZDRjNjc1NTA2MmY3YzlhXzExNzY_0bb47c61-304a-420b-9555-4e0c4f23e656" continuedAt="i2f4b605f4f4d4cc1981efc99311232fd" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f4b605f4f4d4cc1981efc99311232fd" continuedAt="ie392cb2e29634140bdc48ec2e8989c49"> </ix:continuation></span></div><ix:continuation id="ie392cb2e29634140bdc48ec2e8989c49" continuedAt="id5b99838082b4507b2e0c2d21a289560"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90ZXh0cmVnaW9uOmEzZTJkMzcxODYyNzQwN2FiZDRjNjc1NTA2MmY3YzlhXzExNzM_b0174fba-f695-47d2-b924-81803b40f37e" continuedAt="ib2bd620fbfe1408b955ff52c725d4ef6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzItMS0xLTEtODI4NTg_e79c652c-09ae-4b5f-94f8-21570741cecb">8,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzItMy0xLTEtODI4NTg_e5ed3afd-1ce7-4bc3-b592-479114452f3e">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzMtMS0xLTEtODI4NTg_812d29be-7423-41a2-94a4-7c803b56ebea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzMtMy0xLTEtODI4NTg_94e4737b-c83b-4d1b-b47b-00ae46113deb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzQtMS0xLTEtODI4NTg_00e6391a-df63-419c-964c-2f2b3ab4d338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzQtMy0xLTEtODI4NTg_616a8a3f-eccf-4f7a-8a48-48a0b5f9bc7e">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzctMS0xLTEtODI4NTg_5987a43d-8d25-4e08-96c4-82d62ba2a3b4">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzctMy0xLTEtODI4NTg_42998660-2a95-4290-9c52-879e2bbc230b">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzgtMS0xLTEtODI4NTg_4f1d2272-f914-4576-a56c-aa6fd2d62323">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzgtMy0xLTEtODI4NTg_91678ede-c08b-4bb0-8f61-59a602758cae">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzktMS0xLTEtODI4NTg_ce7d3f08-d134-4e1c-bd2c-4d43fd0e9e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzktMy0xLTEtODI4NTg_3c17f205-b1ad-4fce-ae3d-1a009a931360">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id5b99838082b4507b2e0c2d21a289560"><ix:continuation id="ib2bd620fbfe1408b955ff52c725d4ef6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:367.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4619916bbd2482ab8018d375249be03_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItNS0xLTEtODI4NTg_b52a0e68-2eed-43ed-8c22-3eca18557dd9">154,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0251e2b7f89d4de890ab29fd635ae904_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItNy0xLTEtODI4NTg_cca9d69c-40ac-4859-add4-fdbb722c405f">45,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843d5fcb4df3420485390014398766dd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItOS0xLTEtODcwNDk_5863a74e-e1ad-4660-98d9-794c16188eb1">231,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a4f5ce8e6c44d9b8740ae1f7ba19dc_D20220101-20221231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtNS0xLTEtODI4NTg_7c4ab117-3a8f-4767-915b-150ea794f2d5">128,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375cbb6ae8bf4bf4af4ed3910f4e95fb_D20210101-20211231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtNy0xLTEtODI4NTg_3c418c7f-703e-486c-8b4b-e825f7a314b1">3,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7bf3dd1e1e42c38fecc74e534c3349_D20200101-20201231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtOS0xLTEtODcwNDk_147a90fd-02e0-4c06-bba7-343d317d8267">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c76ef785ed6456998aa2837427805d2_D20220101-20221231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtNS0xLTEtODI4NTg_42a9b210-8f9d-43e0-a58c-e298fd738487">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9903fd78307a4882846df7bd26ed4ca2_D20210101-20211231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtNy0xLTEtODI4NTg_2a37a391-21b6-4853-9981-a7b6de1b824b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2afd02fdc0d43e283e8a6be9bbf3622_D20200101-20201231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtOS0xLTEtODcwNDk_a0066576-a20b-4540-8f2f-b20924fd6641">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90ZXh0cmVnaW9uOjNhODc1YjkzNjE4YTRiNDU5OTA4YTVjYTg0MmQxYmIyXzE0NjQ_9c6191cb-006c-400e-bd14-8077f54a04e9" continuedAt="id4236e3df44645a88e1e05557f3dc440" escape="true">Repositioning and Other Changes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id4236e3df44645a88e1e05557f3dc440"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90ZXh0cmVnaW9uOjNhODc1YjkzNjE4YTRiNDU5OTA4YTVjYTg0MmQxYmIyXzM4NDgyOTA2OTkwMTA_fb4b42af-7e10-48f6-8583-3e4b4d33cb08" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.902%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507c481168c24a8282e6d5446b4557e0_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItMS0xLTEtOTQxNDU_f227a37f-d900-4d94-9262-a29f6656fc40">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a9aeec0e924002bd91990917dd2807_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItMy0xLTEtOTQxNDU_cae28a25-8053-4572-9f1b-d941306ea139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83cb6ba27fa047439559a1ce5bdf570e_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItNS0xLTEtOTQxNDM_e749d2e8-b2ea-4f11-a6eb-0765a701f447">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af8d3395ca54542b8e581cd46d63e85_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtMS0xLTEtOTQxNDU_14c9f2d6-ce3b-44fe-8609-98c49874ba7c">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea6990f35a04f21953a710e60c32fb7_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtMy0xLTEtOTQxNDU_58ce109f-85ed-44ca-b265-6b251c542617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia138a2f2ee96409fbd2de15262bbc9a2_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtNS0xLTEtOTQxNDM_f46c0fdf-77c5-4aa6-914d-fc8ed28a5183">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d2a17bc955412cbbed83c8fa718cf1_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtMS0xLTEtOTQxNDU_fbfbacca-f7dc-4304-bdfb-69afe51e5d2a">4,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7c08e385554e8cb407ca29ab063d05_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtMy0xLTEtOTQxNDU_92469134-616e-46f0-ab51-21cbdda8d124">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d50a01d5910438a928adb7f868c6ed6_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtNS0xLTEtOTQxNDM_87a65680-2dc6-4e11-b937-1186f556489a">5,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtMS0xLTEtOTQxNDU_08ac7e58-ba27-432e-9bca-8656e24277fe">7,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtMy0xLTEtOTQxNDU_419d9daa-842c-4dcb-95bb-7c3953fcccea">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtNS0xLTEtOTQxNDM_6251088a-1b0d-47c5-b3ba-73da0b98adb0">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzY_20f306a3-b607-42ff-9959-5f7e9ce25170" continuedAt="i4ccbc4d7b59442ba8e9eb4a54623ef9c" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4ccbc4d7b59442ba8e9eb4a54623ef9c" continuedAt="i0ce9ed6b7d16467e953382a0ed06eca4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI0Mg_87c7c719-1772-4984-9334-44786f9c73e4">two</ix:nonFraction> reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0ce9ed6b7d16467e953382a0ed06eca4" continuedAt="ifb367ca6faf2476caba86e139f62e92a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision for) benefit from income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on extinguishment/repayment of debt, net, goodwill impairment, gain from equity method investees, loss on disposal of assets, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs and loss from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzM_4f6e6857-0e35-4917-95e1-1986c010810e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMS0xLTEtODI4NTg_ce1e114e-35f2-466e-94d4-60da51d761fa">408,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMy0xLTEtODI4NTg_3cf92d05-a902-4784-90ba-6f9814adc635">944,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16141fafab8e460196d863fb9865d30b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtNS0xLTEtODI4NTg_5f7333e2-6ddf-49fa-9e63-87f9defc6edb">869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtNy0xLTEtODI4NTg_4214a764-8a2c-44a9-bd87-dfa5b75e989c">1,352,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtOS0xLTEtODI4NTg_bb658694-e8a5-4290-9854-0f4b246272a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMTEtMS0xLTgyODU4_aa4c66db-0868-4055-964f-0b339d595934">1,352,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMS0xLTEtODI4NTg_fc9a03f8-659e-4fec-ab51-c3171bb42c36">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMy0xLTEtODI4NTg_48fe23fb-605d-4baf-9e8b-854611e4f226">598,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46413fc7149140518ad72598cb806328_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtNS0xLTEtODI4NTg_886ba342-496f-4568-93d6-b597dcbcd5cd">1,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtNy0xLTEtODI4NTg_40ebb366-8c92-49c2-914d-29ae8ef32e83">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtOS0xLTEtODI4NTg_a21403d6-9325-40d7-928d-f34ae9985af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMTEtMS0xLTgyODU4_b6911f44-267b-486a-abbf-eb931509fd7e">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMS0xLTEtODc3NTU_22cb26b3-fd04-477b-af73-64ed22823787">385,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMy0xLTEtODc3NTU_ef406e50-a9bc-4aaa-84fc-8f7843a8cd94">542,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife5cf9a41dc0464dadd48964641367bd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktNS0xLTEtODc3NTU_30ca2b1f-ae15-4512-b869-4991e1e0ff9d">2,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e73201d094671bbc005a4978f6737_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktNy0xLTEtODc3NTU_bd0da357-0b48-4613-9164-6b3b7f39dd51">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktOS0xLTEtODc3NTU_dc9d42f8-983d-4333-8a4f-485b468d81c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMTEtMS0xLTg3NzU1_6033bdcd-42fc-48c8-86fd-1d26fc42941b">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTEtMS0xLTgyODU4_a48e4782-5b83-4f97-a977-b7ceeeed5b1e">57,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTMtMS0xLTgyODU4_c6d67e31-6d51-46fc-a363-2d9c475a7863">78,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTUtMS0xLTgyODU4_3fe6099f-6117-47d2-9a39-c24c7ec48ef0">136,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTctMS0xLTgyODU4_319dab37-3312-4525-834f-9206a096d072">30,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTktMS0xLTgyODU4_1c60467c-eb25-4b59-ad7b-b53bc330ddb9">106,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTEtMS0xLTgyODU4_fba955c9-b3b8-4587-ad9b-995896c2853a">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTMtMS0xLTgyODU4_cd5a195c-e865-4ba7-826c-fe4063239758">82,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTUtMS0xLTgyODU4_df9784bf-2517-4416-a7c7-4c97f6268cc3">99,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTctMS0xLTgyODU4_5dc5366c-bf90-479b-b9ea-5f23d4871b1a">33,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTktMS0xLTgyODU4_74ccad7a-d5b5-4190-9b56-5586cf1e30a9">66,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTEtMS0xLTg3NzU4_85a5f94c-33e1-4293-82ee-623867f8909e">57,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTMtMS0xLTg3NzU4_d18afc53-403f-4880-87f4-f3665ec48c47">26,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e73201d094671bbc005a4978f6737_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTUtMS0xLTg3NzU4_2b1a37d8-319a-43e6-9b04-7b9c334349af">84,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTctMS0xLTg3NzU4_8b586d5f-6650-4dcc-9673-fa7eab4a0c10">36,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTktMS0xLTg3NzU4_f75ed29a-69b9-4b1b-aaf7-7277a5ffee7a">48,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifb367ca6faf2476caba86e139f62e92a"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzU_2e8ddc46-ca57-4d82-835f-bc1104b40eb7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItNS0xLTEtODI4NTg_51025e15-83d6-4ce4-aa51-d89ac0a06d94">19,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItNy0xLTEtODI4NTg_64aca2a7-e414-4ca7-9622-843c24747b75">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItOS0xLTEtODcxNDg_27aff77e-0448-42c6-b5ce-ddcfe3f47279">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtNS0xLTEtODI4NTg_77d3c87c-380e-42d6-ab8b-45ce2eb4e5a1">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtNy0xLTEtODI4NTg_069cd645-2486-4d02-b881-4fe388de69ad">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtOS0xLTEtODcxNDg_69d05b00-0dda-4515-b9ea-78b7bc40039f">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtNS0xLTEtODI4NTg_8d6db517-61b7-4e92-87e0-e9e7cf5f2ddb">15,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtNy0xLTEtODI4NTg_48067f4a-85d5-4a77-94ce-d74ddcbaa634">25,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtOS0xLTEtODcxNDg_21d7471c-642f-454f-b564-a17fbf4d37ea">28,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtNS0xLTEtODI4NTg_89550962-9294-4d46-934d-56dc56caf52e">43,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtNy0xLTEtODI4NTg_4c614299-9048-49e0-a542-224129562f70">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtOS0xLTEtODcxNDg_551855ea-00e9-453f-9606-0276cb96fd78">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtNS0xLTEtODI4NTg_26ad842d-524d-4c58-966c-195b66aa1724">67,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtNy0xLTEtODI4NTg_e32269d6-e83b-4ab3-9884-a22ac4f54a00">60,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtOS0xLTEtODcxNjI_66fbc295-6d8f-4b7c-aee0-025a34b17e9d">60,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNS0xLTEtODcxOTQ_8d8ea15c-84d2-4a92-8ec5-907e46d46a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNy0xLTEtODcxOTQ_bb7c0991-bf1b-473e-b45c-d3a794087690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktOS0xLTEtODcxOTQ_d760fb58-6971-436c-8a99-766ff8a8c171">47,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNS0xLTEtODI4NTg_f761e3bb-e10b-4cfa-87c5-b5d0d81da565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNy0xLTEtODI4NTg_236c09cd-e9bc-4ba6-aa00-2888ff65e146">45,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTktMS0xLTg3MjIz_3dbd7a8c-4ed6-486d-947d-ad1ec5c1ba33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTUtMS0xLTk3Nzkw_fbce464d-11d3-48e6-a4b8-be22c3313308">45,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTctMS0xLTk3Nzkw_64b96d99-5d64-4e48-9519-84598f6c727e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTktMS0xLTk3Nzkw_c3ccd5dd-0198-4ea7-878f-989e48115308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTUtMS0xLTgyODU4_77d64676-3a64-48f1-aafd-add39e6021e5">10,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTctMS0xLTgyODU4_45f55865-2f25-4c89-9e8e-0c392e8cd80c">21,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTktMS0xLTg3MjAz_49de7963-e920-4908-952e-a23f2102f16b">4,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTUtMS0xLTg3Mzcy_6f852fa2-f6b7-4382-b607-e7145b0e89aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTctMS0xLTg3Mzcy_5866b5bb-9744-4f5f-833f-f163223494d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTktMS0xLTg3Mzcy_ed4f33e0-0ea4-4097-8d67-423337295bf7">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTUtMS0xLTgyODU4_24703dc5-452b-4052-8b92-1801ef669fb4">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTctMS0xLTgyODU4_cdc1c06a-5e06-4336-8982-f9bfc9a2d283">13,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTktMS0xLTg3MzU2_8867d3b0-3919-4c95-998d-e062515af213">10,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTUtMS0xLTg3Mzkz_c34a7a7a-b896-4625-a221-c77ecabbd5ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTctMS0xLTg3Mzkz_d869a3b2-3c47-4d7a-9786-3ac427b77137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTktMS0xLTg3Mzkz_1c7bede6-1bdd-4e15-a23b-367d78f610f5">698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTUtMS0xLTgyODU4_fcab6b90-4d9b-4d5b-b972-92bde3ce4ca0">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTctMS0xLTgyODU4_2b976aa3-2361-48c3-9c39-dda5df992f15">13,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTktMS0xLTg3MzQ4_1965a159-07e1-4f25-89e2-d114cd1d58bc">3,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTUtMS0xLTgyODU4_97e35179-3c94-42e8-919d-7ad051870e46">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTctMS0xLTgyODU4_8fd983c5-302d-4649-823e-6c13a9021c58">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTktMS0xLTg3MzQw_3cfa487b-1346-40b2-829d-0d9a0b8952a1">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTUtMS0xLTgyODU4_4b3cefd9-06ed-42d0-aa6c-ac00eb7a5d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTctMS0xLTgyODU4_bc15e827-ede6-4823-be16-c371bc37993e">7,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTktMS0xLTg3MzQw_053c5758-b041-406b-b8ed-6f370d9d7622">1,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTUtMS0xLTgyODU4_43105990-320a-4324-9039-6be863668bac">33,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTctMS0xLTgyODU4_ba6a8a39-b673-45d1-b90b-7062a5aa78e1">16,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTktMS0xLTg3MzI3_83f95b2d-3884-411a-8781-77db36ffa36a">14,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTUtMS0xLTgyODU4_f0e8388b-88cf-40a2-a8bc-3e05a13330b0">13,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTctMS0xLTgyODU4_7bef8c77-f17f-44cf-8dc8-7d9eae3cc05e">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTktMS0xLTg3MzI3_1d952fd3-3d6b-4f93-97ca-20d0b3a1a03e">8,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTUtMS0xLTgyODU4_30bb1b71-e526-4d98-a4b4-a10e191e1671">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTctMS0xLTgyODU4_0dd24f84-5696-42ba-a58d-90a7f112c99a">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTktMS0xLTg3MzI3_a6e45c5a-7ad8-410c-880b-ec00c33ad6ad">3,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTUtMS0xLTgyODU4_fb9a9bcd-bfa5-4bff-b688-5e5a97fae924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTctMS0xLTgyODU4_f086d0d2-e947-4b36-9436-a873e056aefd">6,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTktMS0xLTg3MjYy_2eb2cd68-ede4-455d-92a5-48bb6ff38b09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTUtMS0xLTgyODU4_b5ecf84b-d30a-4b75-9dcf-c1a60930c17f">11,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTctMS0xLTgyODU4_4c57df29-544f-4cc6-880c-3b87889fda65">4,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTktMS0xLTg3MjU0_df33b606-ac43-42b1-a7e9-67443eeef99c">2,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTUtMS0xLTgyODU4_3a6f70e8-795d-4d07-94b5-062a024f3f14">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTctMS0xLTgyODU4_c86fd325-2fbe-480c-890f-9bea1191d6c6">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTktMS0xLTg3MjM2_3dd583db-b965-45fb-9fb8-6a58fc1fbe5b">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTUtMS0xLTgyODU4_f4c4649c-f64c-4c3f-903b-5753a040fcd2">106,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTctMS0xLTgyODU4_169ac10a-cf59-4670-877a-45cf9a8b4aeb">66,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIyLTktMS0xLTg3MjE0_5c4cdc93-8e85-461a-82c0-51711a2c647c">48,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI4NTg_3e724a0d-d187-4ffc-a50f-e2e675db99dc">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI5MTY_96f98c70-26e2-458d-af35-5bd0ae5400d6">6.8</ix:nonFraction>&#160;million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90ZXh0cmVnaW9uOmFhZWZlZGYzYmRiZTQxNWM4NjFkNjE2MTc2Y2QwNDExXzQ1MDI_76200897-ce17-4e9e-bb97-9b19cccf88f1" continuedAt="i66dbe5ceba574b83bdef727973b750c7" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i66dbe5ceba574b83bdef727973b750c7" continuedAt="i3c79c294d8ee461aaf2ce122d187aa19"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3c79c294d8ee461aaf2ce122d187aa19"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90ZXh0cmVnaW9uOmFhZWZlZGYzYmRiZTQxNWM4NjFkNjE2MTc2Y2QwNDExXzQ1MDQ_10339414-d0cf-42f2-abb3-16f88924dcda" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMS0xLTEtODI4NTg_79e08f39-db5e-47d2-b251-011da96ccc8b">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMy0xLTEtODI4NTg_3d6f6637-5802-494f-aa1c-ad55dd7ef3f2">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtNS0xLTEtODI4NTg_4924d38b-6933-49d3-a9f7-92ac4dba50ac">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtNy0xLTEtODI4NTg_67072d3a-7b62-4edc-a2ae-c8c893027bee">56,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtOS0xLTEtODI4NTg_4efef94e-de07-49be-884a-1401096a587f">122,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMTEtMS0xLTgyODU4_06ab6347-ca4e-4e78-9f9e-4d69425c17f0">178,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMS0xLTEtODI4NTg_62ecc223-6807-4bb9-a25f-dffdba8ce2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMy0xLTEtODI4NTg_4db8b678-b9ed-4498-bbe8-73e8b0ee6617">605,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtNS0xLTEtODI4NTg_f7f43e1c-dc27-4337-ab65-7a3827592d75">605,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtNy0xLTEtODI4NTg_efc47aac-9659-40d3-b14c-6acfab131149">8,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtOS0xLTEtODI4NTg_6beb9342-6219-4ba3-a88c-33fdf82251b6">449,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMTEtMS0xLTgyODU4_b9d52610-7f57-44ec-836f-627dd23541cb">457,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMS0xLTEtODI4NTg_7b0eff11-cecf-4f85-8560-0f3339ca21d3">8,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMy0xLTEtODI4NTg_0b9ec8ea-0732-481e-b97d-67a4abebf2f0">3,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtNS0xLTEtODI4NTg_b499e6a5-b156-4806-a927-b269fcde0b2e">11,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtNy0xLTEtODI4NTg_c4231122-c0c5-4617-ae98-3d6ea20774fe">7,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtOS0xLTEtODI4NTg_8f59d73e-5637-493a-bb97-77aa8d71f3e7">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMTEtMS0xLTgyODU4_4c380011-6b68-45e2-9087-922c481e2587">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMS0xLTEtODI4NTg_7821f9c1-418a-402c-93d2-f19848486238">8,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMy0xLTEtODI4NTg_3b2c2edd-48a7-4434-9d5c-47d25310f01a">602,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctNS0xLTEtODI4NTg_2bda15f2-7779-44e0-94b0-b3493a3b093c">594,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctNy0xLTEtODI4NTg_5b7c8308-3962-4768-8a57-4ea3ef367355">15,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctOS0xLTEtODI4NTg_81709d9a-ef18-4009-866c-c11d4b2bfcf5">449,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMTEtMS0xLTgyODU4_77a7aa92-9f2e-473c-be03-5e1479edfd33">464,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMS0xLTEtODI4NTg_7d599dd1-8db2-4d02-b3ae-1de99dafd56a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMy0xLTEtODI4NTg_5f8a7d94-3f98-4756-9c73-081218938c35">427,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktNS0xLTEtODI4NTg_a71f2cb3-9736-4cc7-b13c-5bd3277a7dbc">427,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktNy0xLTEtODI4NTg_aac16e52-eeee-4d1a-8bb2-1bbbf6ce94d1">20,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktOS0xLTEtODI4NTg_11e320e5-2c78-4907-aebd-c317754c188f">326,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMTEtMS0xLTgyODU4_daacf48b-bb71-4e75-a3f8-5653124ae56a">346,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTEtMS0xLTgyODU4_5d160108-35f5-4f73-9133-af44ac00ba22">12,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTMtMS0xLTgyODU4_739ab76e-97fd-4a62-91cb-0a46c4ac7eb7">124,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTUtMS0xLTgyODU4_8b6cbb05-a8db-4801-b8e7-72e6fec23d53">137,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTctMS0xLTgyODU4_b2a47c8b-ea04-49d9-951d-561193cf2285">25,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTktMS0xLTgyODU4_2048d669-7dce-47bd-9463-46aac5e8779f">100,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTExLTEtMS04Mjg1OA_f9e94d59-fea7-4ab1-8dd7-372457fcdf4c">125,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTEtMS0xLTgyODU4_1e3a5669-a182-4060-ba64-03d42a0d3bce">12,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTMtMS0xLTgyODU4_7364f9d7-3e8c-4da7-a1e0-d4e9e8cb8fec">552,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTUtMS0xLTgyODU4_816af749-b9ae-44e3-a83c-a26bbf19a3c2">565,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTctMS0xLTgyODU4_c6fcb5e4-1c9a-4fd3-ac39-d29da2ced792">46,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTktMS0xLTgyODU4_de1cbedb-b66f-419b-b561-baa52483b178">426,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTExLTEtMS04Mjg1OA_c7c039dd-e2cc-43b8-9312-923755e72d11">472,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTEtMS0xLTgyODU4_d29e02ca-ec02-4763-869c-30e67544c714">4,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ea7981a58e4cf1bb90015e38b89007_I20221231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTMtMS0xLTgyODU4_7e2d4673-ea18-4654-997c-94407fe0c44d">195,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTUtMS0xLTgyODU4_58a3e2ec-58e5-4544-b22a-f6183a7f3b86">199,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTctMS0xLTgyODU4_f2c496bd-4d01-420d-b6e6-9c41fc1c1b86">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTktMS0xLTgyODU4_54fcb113-51a9-4133-b26a-51070a65bd1e">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTExLTEtMS04Mjg1OA_d23be45e-6b0c-4dc6-9c40-e69cf0cd7fe0">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_271"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 23. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90ZXh0cmVnaW9uOmI5Mjc2NzEyMmM5ZjQ5NGFhYTM2MzE5NzYxYjE0ZmU5XzE3NQ_fdb2adf3-8abf-483a-bfa5-b2e82271eac2" continuedAt="i955dad9c62e74315b0a07512c88a3c2c" escape="true">Quarterly Results of Operations (unaudited)</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i955dad9c62e74315b0a07512c88a3c2c" continuedAt="i9387d6f044fc45bfbf517aac0f36eb49"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90ZXh0cmVnaW9uOmI5Mjc2NzEyMmM5ZjQ5NGFhYTM2MzE5NzYxYjE0ZmU5XzE3Ng_8dbc2729-aec4-45dc-9cde-0ddbb6cda92a" continuedAt="i66c6a4c09b054f41bf4e135ebbd7577b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMS0xLTEtODgzOTE_3a6e79bd-aa09-4e13-8f6e-d933d32bf073">382,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMy0xLTEtODc3NjM_c0b03300-02db-46ff-9011-256a6bd9546c">352,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNS0xLTEtODc3NjM_5bcfc47d-1975-415d-9261-5bae3181ccdf">319,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNy0xLTEtODc3NjM_8e9aed0b-21d2-42ca-81a0-7b974bc26edf">297,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODgzOTE_7ce73830-b483-4917-927f-dede24a24bb2"><ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODgzOTE_fb3e8a56-76de-49f2-998d-4f4bcafb6d26">384,310</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMy0xLTEtODc3Njk_717ae2a1-bcd9-4446-91ee-79665732f73b">339,634</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNS0xLTEtODc3Njk_3ba7f107-ca92-4206-8d16-35548091a5a4">324,572</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNy0xLTEtODc3Njk_dd1dd914-27ef-4557-ba81-425ab6cf95c5">299,855</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMS0xLTEtODgzOTE_5a5e5307-e0ae-4e41-9a53-11a0edad4dec">11,349</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMy0xLTEtODc3NzE_926bc695-6361-42ea-b6ba-bd4319a94afd">2,123</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNS0xLTEtODc3NzE_53be3078-d3fa-4f09-8a62-6e93ea83c8c0">4,125</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNy0xLTEtODc3NzE_507dff5c-ba51-485f-94d0-4c72ada99ab5">5,350</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMS0xLTEtODgzOTE_ba022879-b660-4ceb-9da3-54f0a5e9c9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMy0xLTEtODc3NzM_cb92cce9-0d8f-4a08-9c6e-13083f15a418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNS0xLTEtODc3NzM_c0e6d8a2-e619-43b3-948a-b92a770b8b43">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNy0xLTEtODc3NzM_61af0a2f-b917-4eca-a584-2d09bb24f4fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODgzOTE_11819543-dd40-41a0-9947-d9ceef1a8795"><ix:nonFraction unitRef="usd" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODgzOTE_f30114ad-fd2b-45dd-91ff-bc0ec7891981">11,349</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODc3NzU_8cbbf119-d495-4e04-99e0-9bbfe4c3fa1c"><ix:nonFraction unitRef="usd" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODc3NzU_9857544f-6f2a-4eba-b824-a3032b197d21">2,123</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODc3NzU_4042a2b3-825e-4fcc-9d5a-b2c8d4de1c5e"><ix:nonFraction unitRef="usd" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODc3NzU_6a2c2989-29d4-4970-a7cd-788f2ecb87bd">4,588</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODc3NzU_0062eb12-d078-439e-8dc7-f31e208b248c"><ix:nonFraction unitRef="usd" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODc3NzU_8b897b75-2595-47c7-91e0-4413eaed4845">5,350</ix:nonFraction></ix:nonFraction>)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i9387d6f044fc45bfbf517aac0f36eb49"><ix:continuation id="i66c6a4c09b054f41bf4e135ebbd7577b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTg4Mzkz_30824775-11c9-4cb9-b2e4-8c3bb46cdbe6"><ix:nonFraction unitRef="usdPerShare" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTg4Mzkz_5078b798-745c-4e64-8fb7-81b53433e8f6">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTg3Nzgy_4a797f90-ad8d-4f7a-a2b1-2ef399d617b5"><ix:nonFraction unitRef="usdPerShare" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTg3Nzgy_e8639e32-7531-4707-829f-3ccf1d2b2658">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTg3Nzgy_97698986-fb41-4fe8-bb83-7dfdb78cbe10"><ix:nonFraction unitRef="usdPerShare" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTg3Nzgy_b8e5c3cd-9639-4bcb-badb-865124a38f37">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTg3Nzgy_1a7993e8-f79f-477c-ba87-07dba33bc9d6"><ix:nonFraction unitRef="usdPerShare" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTg3Nzgy_3b97dacc-f82f-48fe-aa7d-38200b8a9095">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTk0MTU4_39148552-231a-48f9-9064-8d61b457c52c"><ix:nonFraction unitRef="usdPerShare" contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTk0MTU4_fc6bbd44-bf65-4b63-9c6c-d00ee9eabf32">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTg4Mzk3_2336abb8-35d5-4479-ac53-4699a06204a6"><ix:nonFraction unitRef="usdPerShare" contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTg4Mzk3_883c88d9-4d81-4fc7-9749-bd84ff896f1c">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTg4Mzk3_43983d77-a922-486e-984e-5f57d49b1ff8"><ix:nonFraction unitRef="usdPerShare" contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTg4Mzk3_baab50de-0913-4767-99fc-1aac5b3717ba">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTg4Mzk3_4583e65c-d770-4eac-bc25-2adf9bb9acb6"><ix:nonFraction unitRef="usdPerShare" contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTg4Mzk3_c1799fe6-7687-4c0b-ac6a-991d491d67e1">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMS0xLTEtODI4NTg_27c2bccf-00e4-4206-951b-573e132cf499">248,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMy0xLTEtODI4NTg_163e2720-c1e2-4295-88c7-a4f85f5453c1">222,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNS0xLTEtODI4NTg_8457ff99-f320-4b83-b968-f88aae0c5d78">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNy0xLTEtODI4NTg_14eebbcd-dcf9-4db2-bf0a-1108759d8923">215,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODI4NTg_8a9b7ccb-1530-42e9-ba5d-720b2403f2d4">260,572</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMy0xLTEtODI4NTg_f01bb93b-7752-41e1-9e9f-21c8bf7f0901">229,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNS0xLTEtODI4NTg_9fbc1778-d432-4944-8021-98fd3c570c96">229,728</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNy0xLTEtODI4NTg_c7f5e0b4-cfd2-4bbc-b031-6584c54f3f2e">231,016</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMS0xLTEtODI4NTg_90a2b3aa-0546-4a80-a615-57f42f497571">3,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMy0xLTEtODI4NTg_d7af5833-2fb6-4770-84a5-2f1472b8b5b8">13,040</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNS0xLTEtODI4NTg_29704c09-3961-409c-873a-79be4350b08a">9,107</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNy0xLTEtODI4NTg_8a0fd663-3bd7-4b15-8550-848c9c9ca1f1">11,190</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMS0xLTEtODI4NTg_07be0ce3-d11e-4e7b-82fb-29cae14341d8">8,700</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMy0xLTEtODI4NTg_b5bf83a6-4416-4adf-8a4e-1ceabd1da6ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNS0xLTEtODI4NTg_e9d892a3-d092-4e6f-a2a2-3df59e3325a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNy0xLTEtODI4NTg_df383bf3-a24f-43a8-a6d4-70c58122e78e">1,383</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODI4NTg_422a97f7-59c4-4568-b147-b53a3d81d944"><ix:nonFraction unitRef="usd" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODI4NTg_9047993d-e343-4279-a7bc-9ed190fd7fc3">5,647</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODI4NTg_9f6bc839-b0d7-46f4-847e-f471e60f911b"><ix:nonFraction unitRef="usd" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODI4NTg_fbe7e817-02cd-4fd5-99f4-95c5ffdb2dcb">13,040</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODI4NTg_9d59b18f-06de-4500-8d06-443bd9411f93"><ix:nonFraction unitRef="usd" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODI4NTg_e8821c57-175d-4a4b-8617-fdcf74d43b6c">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODI4NTg_114a80a4-9ea9-445c-be28-0be7844308c8"><ix:nonFraction unitRef="usd" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODI4NTg_660bd444-36a4-4489-a0de-e8c1def0ef5f">9,807</ix:nonFraction></ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTgyODU4_a73a91b9-8411-4cc8-86ca-c6fa80f0fdc4"><ix:nonFraction unitRef="usdPerShare" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTgyODU4_ba505c31-4563-4b37-bba7-48808f064fc6">0.03</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTgyODU4_46043a8c-b95c-4388-ae7a-25af1dd872bd"><ix:nonFraction unitRef="usdPerShare" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTgyODU4_7aeb7df0-671f-40ef-89b2-2b58dd6305ef">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTgyODU4_01c3b654-62ec-483c-8d65-643784c869dc"><ix:nonFraction unitRef="usdPerShare" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTgyODU4_e76ee6e4-5d27-4f5f-a775-280c123935fb">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTgyODU4_89b208fb-0a5b-4a6d-82a2-ef8c7b8b820c"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTgyODU4_fb5cdda1-bc71-4316-af6e-b6031c928785">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTgyODU4_2d293011-f4f0-4c9f-a72b-53f693704b2f"><ix:nonFraction unitRef="usdPerShare" contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTgyODU4_61f282e8-ec9c-471a-bd84-fc91a8a8da3c">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTgyODU4_6719c36d-8fca-45a6-9cd6-8dd4440432e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTgyODU4_8fe05706-3ece-4705-ac8b-1bcc7a523c6e">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTgyODU4_5e26ccfa-0664-4af9-b13c-dcea9da08664"><ix:nonFraction unitRef="usdPerShare" contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTgyODU4_c0a4c8bc-f66f-4821-a5d2-47ed61cf9bde">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTgyODU4_815c058a-df92-4362-af25-ecf65981c210"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTgyODU4_d213f7c0-f389-45b4-ac07-ce73a69c8a05">0.01</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 24. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90ZXh0cmVnaW9uOjU4ZDA2MTE0N2E1NjQwOWI4NWI2NmMzZDAxNGFkYjUxXzEzMw_65473808-c606-4c7b-af5f-579232a12d39" continuedAt="i2c2ba0b4d1ae41fcaf9f6b41fac626a3" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2c2ba0b4d1ae41fcaf9f6b41fac626a3"><ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90ZXh0cmVnaW9uOjU4ZDA2MTE0N2E1NjQwOWI4NWI2NmMzZDAxNGFkYjUxXzEzMg_f51578fd-6633-4113-8784-d9d0c6c34d49" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtMS0xLTEtODI4NTg_0f021507-8ca4-4eed-a161-aa75ed792fe4">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtMy0xLTEtODI4NTg_6c51c37b-8b23-4713-8c72-d62b84ac53c0">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtNS0xLTEtODc1MDY_90f99e1b-e8bd-496f-b26b-7fa069f6304d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODc4MDA_037eb09c-2976-4b7e-9180-0e837d692c8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODc4MDU_8807852f-fef4-4f93-8d22-1c46d6ab7d01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtNS0xLTEtODc4MDU_ca599076-a07d-4b65-a8fb-3640ac371f50">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODc1MzQ_35bccd75-27e8-4f7c-ab4a-7db24bda0d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODc1MzQ_c8bce1ed-80fe-432c-851d-424b7bbe8282">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtNS0xLTEtODc1MzQ_a35cbb36-ede4-4041-bcf5-8da5c3cf387c">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtOTQ1Mjc_d9206462-7be0-4a41-b297-5d2a69940ac8">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtOTQ1Mjc_f15fe9f8-cdfd-4507-82e7-378cb697c3fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtNS0xLTEtOTQ1Mjc_5f0f1c64-3971-4f6a-9e54-6d452e6cd17b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:GainLossFromTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtODc4MTE_1121efcc-2727-49bc-9ef1-380253e17838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossFromTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtODc4MTE_00575aa7-a364-42c1-9dd2-f097ae4b7715">22,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:GainLossFromTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtNS0xLTEtODc4MTE_8812679f-af5e-4246-ad45-d03dce3ebd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODI4NTg_92f6c486-b738-42e1-bac9-3ace9a0686f3">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODI4NTg_ade2b2c0-8a3b-4998-b985-6a4af835b282">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzctNS0xLTEtODc3OTg_606df781-5422-4171-a8de-a89418921d85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzUtMS0xLTEtODI4NTg_867f4309-416a-4ee3-a67f-5f6cbb40c6af">101,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzUtMy0xLTEtODI4NTg_b555ac3a-481f-4524-b29f-a536153785f4">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtNS0xLTEtODc3OTg_9a14c868-8b3f-4032-a0ef-f26f40a64e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMS0xLTEtODc4MTk_ef16556e-037b-47fd-b1b1-70580af67f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMy0xLTEtODc4MjE_ec0b53d9-5bb8-45e2-a665-6bde0a5ca6e0">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktNS0xLTEtODc4MjM_78763a08-b754-4051-8075-fd160c3388ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtODI4NTg_31961b86-7579-4d87-882c-a2da0ce6acb0">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtODI4NTg_818463ae-3689-4155-8440-e4ff8608970d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEwLTUtMS0xLTg3Nzk4_af55a515-1361-4f23-b5a1-53d9856a844c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtMS0xLTEtODI4NTg_bf5abc36-2640-43ea-9137-d6eb6605c15e">14,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtMy0xLTEtODI4NTg_d6c33a73-418f-4656-a85b-493ff9154dac">13,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtNS0xLTEtODc0OTA_7582e606-903c-4f31-a1e6-389e6e10123b">13,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMS0xLTEtODI4NTg_79b63504-e210-449f-abbb-d9bc26906deb">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMy0xLTEtODI4NTg_f1920ca4-73cf-4391-9177-3a58e11b14f4">2,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktNS0xLTEtODc0OTA_05d97616-f97d-4c0d-97ee-938cfe7edba3">2,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTEtMS0xLTgyODU4_d2ea904c-b1a7-4f07-af0e-54c37c045457">6,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTMtMS0xLTgyODU4_c76a453c-8fa7-4b61-a4a6-450e96741731">7,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTUtMS0xLTg3NDk4_c6d3bf83-5f7f-4aba-ae7a-dcb790703a83">13,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTEtMS0xLTgyODU4_afe18122-675a-445f-a9da-8836a335473f">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTMtMS0xLTgyODU4_8b7183ea-9b1f-4a9e-9f0d-215b29adef03">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTUtMS0xLTg3NDk4_5f4a71ef-63b1-40c7-bf69-365e6a3d070d">9,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 25. <ix:nonNumeric contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzg5Mw_8b5e657a-4298-476d-9022-59127e54fce8" continuedAt="i71c1deda526d445db1de688284a9bcf4" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i71c1deda526d445db1de688284a9bcf4" continuedAt="i421a5e0eed7f4b97b1553db6288c6733"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIA Purchase and Ares Debt Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023 (the &#8220;Closing Date&#8221;), Evolent Health, Inc. (the &#8220;Company&#8221;) consummated the transactions (the &#8220;Closing&#8221;) contemplated by the previously announced Stock and Asset Purchase Agreement (the &#8220;Magellan Purchase Agreement&#8221;), dated November 17, 2022, by and among the Company, Evolent Health LLC (&#8220;EVH LLC&#8221;), Magellan Health, Inc. (&#8220;Magellan Parent&#8221;), and Magellan Healthcare, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on the Closing Date, we entered into Amendment No. 1 to the Credit Agreement, dated as of August 1, 2022, by and between the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i421a5e0eed7f4b97b1553db6288c6733" continuedAt="iec8d5636403444ef8a58c97b2dbe4447"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company, as the Parent, each other Guarantor party thereto, Ares, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent (the &#8220;Existing Credit Agreement&#8221;; the Existing Credit Agreement, as amended by Amendment No. 1, the &#8220;Credit Agreement&#8221;) that provided us with new secured debt financing in the form of (i) additional commitments under our existing asset-based revolving credit facility in an aggregate principal amount equal to $<ix:nonFraction unitRef="usd" contextRef="i00a3b9433a4c407da22c8da144e6159f_I20230120" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4Mjk_75a688c1-430f-4773-8d00-ca243118bf6f">25.0</ix:nonFraction>&#160;million (the &#8220;Priority ABL Incremental Facility&#8221;), and (ii) additional commitments under our existing term loan facility in an aggregate principal amount equal to $<ix:nonFraction unitRef="usd" contextRef="i25bed0d5f05c47d3835d72e78088845d_I20230120" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NDQ_ffde7c35-3f0a-4531-b13a-ab558ac55b56">240.0</ix:nonFraction>&#160;million (the &#8220;Term Loan Incremental Facility&#8221; and together with the Priority ABL Incremental Facility, the &#8220;Acquisition Facilities&#8221;), and effected certain amendments to the Existing Credit Agreement. On the Closing Date, we borrowed $<ix:nonFraction unitRef="usd" contextRef="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NjA_eca3c4b3-bbe1-43d4-a036-5875883601f5">25.0</ix:nonFraction>&#160;million under the Priority ABL Incremental Facility and $<ix:nonFraction unitRef="usd" contextRef="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NzU_2f540a85-26ae-4cba-99d3-ef5297cd0197">240.0</ix:nonFraction>&#160;million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable at Closing and pay transaction fees and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All loans under the Credit Agreement (including loans under the Acquisition Facilities and loans outstanding under the Existing Credit Agreement) (collectively, the &#8220;Loans&#8221;) will mature on the date that is the earliest of (a) the sixth anniversary of the Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (<ix:nonFraction unitRef="day" contextRef="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMTQ_6fbb1146-1077-4413-9172-64fa5aa0acb3">91</ix:nonFraction>) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="i33f01c74be814b40a8b3c55316700bd3_D20230120-20230120" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4OTI_553ef499-81a4-4388-ab08-184df1cf8b7e">6.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="ia6d4b347f77b40ef82561500db57566f_D20230120-20230120" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4OTk_0d385b4d-23c0-4d06-ae72-e5b4d37d9846">5.00</ix:nonFraction>% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="ie9a86616c8d74739ae6c3edec5552b03_D20230120-20230120" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MDY_a3710d62-7910-4c8d-9ae1-4db7125e29c2">4.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="id784014eb86c4d16a227b2b1b8318c54_D20230120-20230120" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MTM_85931167-a875-45b4-8b77-bc839f513ba3">3.00</ix:nonFraction>%. We have paid closing fees equal to <ix:nonFraction unitRef="number" contextRef="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MjA_e3204835-8dcd-47ea-8315-d9857d56a9c8">3.00</ix:nonFraction>% of the aggregate commitments provided in respect of the Acquisition Facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Agreement may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) <ix:nonFraction unitRef="number" contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5Mjc_a6667124-5076-4553-b5d2-d9cabf5a003c">3.00</ix:nonFraction>% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) <ix:nonFraction unitRef="number" contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MzQ_1c5e3f6d-6cac-49b5-b0fe-c3f7732c2a6c">2.00</ix:nonFraction>% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) <ix:nonFraction unitRef="number" contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NDE_55301447-ed2b-4e07-bce5-d31a533e9845">1.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) <ix:nonFraction unitRef="number" contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NDg_4f1b4a8c-a562-49c2-b24f-e8fc67264614">0.00</ix:nonFraction>% of the principal amount so prepaid on or after the third anniversary of the Closing Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Acquisition Facilities are subject to the same security and guarantee arrangements and affirmative and negative covenants, mandatory prepayment provisions and events of default as loans outstanding under the Existing Credit Agreement, in each case, subject to certain modifications agreed by the parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Magellan Purchase Agreement and at Closing, EVH LLC acquired all of the issued and outstanding shares of capital stock of National Imaging Associates, Inc. as well as certain assets held by Magellan Parent and/or certain of its subsidiaries that were used in the Magellan Specialty Health Division. At Closing, EVH LLC paid cash consideration to Magellan Parent and certain of its affiliates of approximately $<ix:nonFraction unitRef="usd" contextRef="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5Njc_b4e73fb8-918d-4af1-b9d5-b8425908c365">386.7</ix:nonFraction>&#160;million (which is subject to certain post-Closing adjustments) and issued <ix:nonFraction unitRef="shares" contextRef="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NTY_885c1a02-06e9-4752-9462-4952709e338b">8,474,576</ix:nonFraction> shares of the Company&#8217;s Class A Common Stock (&#8220;Magellan Class A Shares&#8221;) to Magellan Parent. Pursuant to Amendment No. 1 and the Securities Purchase Agreement, Ares and certain of its affiliates, who, along with certain of their affiliates, are currently lenders and agents under our Existing Credit Agreement, have provided funds used in the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the NIA acquisition as the initial accounting for this business combination is incomplete as of the filing date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumulative Series A Convertible Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company offered and sold to the Purchasers an aggregate <ix:nonFraction unitRef="shares" contextRef="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5ODM_e967a179-ddf0-4af7-84ab-c5e856286844">175,000</ix:nonFraction> shares of the Company&#8217;s newly created Series A Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMDE_4e1567ef-fe51-4c93-87bb-b4352ca5e0d9">0.01</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i04f3fa6a087c446baded83c2feace046_I20230120" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5OTI_fa9a5c1b-cb98-4385-ad13-24999d18e44b">960.00</ix:nonFraction> per share, resulting in total gross proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMDg_5f24ca1a-e7b5-4cfe-8c13-96c8fd840771">168.0</ix:nonFraction>&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#8217;s Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMjQ_fe0f9e5a-fc25-4a92-8988-5970901a119e">0.01</ix:nonFraction> per share (the &#8220;Class A Common Stock&#8221;) and all future series of the Company&#8217;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120" decimals="INF" name="us-gaap:PreferredStockLiquidationPreference" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMjY_7827c95e-c8f3-4402-b95b-afa46de4e7a9">1,000</ix:nonFraction> per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus <ix:nonFraction unitRef="number" contextRef="ia89686cfadfc473caea4541bb62f1bb3_I20230120" decimals="4" name="evh:PreferredStockVariableDividendRateBasisSpread" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMzE_69974835-2ab1-4285-9568-3b2b1efe449b">6.00</ix:nonFraction>%. The liquidation preference of the Series A </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec8d5636403444ef8a58c97b2dbe4447" continuedAt="iea879fadad4944799c4dfd557fb5d017"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by <ix:nonFraction unitRef="number" contextRef="i86e686cc2d964acc99bb40a8e562febb_D20230120-20230120" decimals="3" name="evh:PreferredStockDividendRatePercentageAnnualIncreaseInRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMzg_f0d7e45d-b85a-40d7-8483-479543aa031d">2.0</ix:nonFraction>% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#8217;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120" decimals="2" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNDQ_4f9bc7aa-bece-4213-8644-bba8f2e64a6d">40.00</ix:nonFraction> of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="i4cb6fa070893484684f8ab6a16c9b50a_I20230120" decimals="4" name="evh:PreferredStockRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNTI_4cd4eff0-dd57-4276-8105-24bf0dc4d74d">165.00</ix:nonFraction>% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="ie9a97018288f4cc8b3674c490b0d4fa5_I20230120" decimals="4" name="evh:PreferredStockRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNzg_2bd20741-6c56-4a53-82f8-787a25086fa4">150.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to <ix:nonFraction unitRef="number" contextRef="i4cb6fa070893484684f8ab6a16c9b50a_I20230120" decimals="4" name="evh:PreferredStockRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwODc_0fb8e4dd-cccc-43f9-8286-980887dbcbf5">165.00</ix:nonFraction>% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) <ix:nonFraction unitRef="number" contextRef="ibc785f8e81be428088e0d8326cda1937_I20230120" decimals="4" name="evh:PreferredStockRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwOTY_00b800ed-8e12-4742-82f4-afca3a2998e9">150.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and <ix:nonFraction unitRef="number" contextRef="i09af4e4b44d0499bb93e05f0108e6e4d_I20230120" decimals="4" name="evh:PreferredStockRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMDU_32add0e9-3bfe-4904-b970-76a856b3933e">135.00</ix:nonFraction>% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such change of control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Existing Credit Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders  (the &#8220;Ares Registration Rights Agreement&#8221;), which granted certain registration rights to Ares in respect of the shares of the Company&#8217;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment of Contingent Consideration</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea879fadad4944799c4dfd557fb5d017">Subsequent to December 31, 2022, the Company satisfied its contingent consideration obligation for the periods ended December 31, 2022. As a result, it made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i4ac1e2d763d64e7f83a06724d5407c9f_D20230101-20230223" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4MzE_6db30dc7-6fb8-4354-9c5c-51355e155f54">0.3</ix:nonFraction>&#160;million and issued <ix:nonFraction unitRef="shares" contextRef="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4NDU_e6b80d11-d5c6-46fe-bc02-aac96a2a3b55">849,716</ix:nonFraction> shares of its Class A Common Stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4MTY_37693404-1ae7-4489-a11f-ae9b2e6aa71e">26.5</ix:nonFraction>&#160;million. See Note 4 and Note 18 for additional information regarding the IPG acquisition and the fair value determination of the IPG earn-out consideration.</ix:continuation> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_199"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. The Chief Executive Officer (&#8220;CEO&#8221;) and the Chief Financial Officer (&#8220;CFO&#8221;), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by SEC rules, we excluded IPG from our assessment of internal control over financial reporting as of December 31, 2022. This exclusion considers SEC guidance on newly acquired entities which may allow companies to exclude acquired entities from their assessment of internal control over financial reporting during the first year following the acquisition. IPG was acquired during the third quarter of 2022 in a business combination. IPG is a wholly-owned subsidiary whose total assets excluded from management's assessment represent 29.6% of the Company&#8217;s consolidated assets and total revenues excluded from management's assessment represent 4.3% of the Company&#8217;s consolidated revenue as of and for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of our internal control over financial reporting as of December 31, 2022, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the year ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Evolent Health, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Evolent Health, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022, of the Company and our report dated February 24, 2023, expressed an unqualified opinion on those financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management excluded from its assessment the internal control over financial reporting at Implantable Provider Group, which was acquired on August 1, 2022, and whose financial statements constitute 29.6% of total assets and 4.3% of revenue of the consolidated financial statement amounts as of and for the year ended December 31, 2022. Accordingly, our audit did not include the internal control over financial reporting at Implantable Provider Group.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Deloitte &amp; Touche LLP</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McLean, Virginia  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;24, 2023 </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_223"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_232"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_235"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item 10 pertaining to Directors is incorporated herein by reference to Evolent Health, Inc.&#8217;s definitive proxy statement for the Annual Meeting of Shareholders to be held on June 8, 2023, to be filed by Evolent Health, Inc. with the SEC pursuant to Regulation&#160;14A within 120&#160;days after the year ended December&#160;31, 2022&#160;(the &#8220;2023 Proxy Statement&#8221;).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item 10 pertaining to Executive Officers appears in &#8220;Part I - Item 1. Business - Information about our Executive Officers&#8221; in this Annual Report on Form 10-K and our&#160;2023&#160;Proxy Statement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our investor relations website (ir.evolenthealth.com) under &#8220;Corporate Governance.&#8221; We intend to satisfy the SEC&#8217;s disclosure requirements regarding amendments to, or waivers of, the code of ethics by posting such information on our website.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_238"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;11 is incorporated herein by reference to our 2023 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_241"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;12 is incorporated herein by reference to our 2023 Proxy Statement.</span></div><div><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_244"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;13 is incorporated herein by reference to our 2023 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_247"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;14 is incorporated herein by reference to our 2023 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_196"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this report:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The following financial statements of the registrant and report of independent registered public accounting firm are included of Item 8 hereof:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_217">Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_25">Consolidated Balance Sheets</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_28">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_226">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_34">Consolidated Statements of Cash Flows</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie5cc4f785ce54597a137387a0d3f51e9_37">Notes to Consolidated Financial Statements</a></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) All financial statement schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission either have been included in the Financial Statements, are not required under the related instructions, or are not applicable and therefore have been omitted.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The Exhibits listed in the Exhibit Index below are filed with or incorporated by reference into this report</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_172"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">2.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,  filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">2.4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">Agreement and Plan of Merger, dated August 1, 2022, by and among Evolent Health, Inc., Evolent Health LLC, Endzone Merger Sub, Inc, TPG Growth Iceman Parent, Inc. and the Sellers&#8217; Representative, filed as Exhibit 2.4 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit25.htm">2.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit25.htm">Stock and Asset Purchase Agreement by and among Evolent Health, Inc., Evolent Health LLC, Magellan Health, Inc. and Magellan Healthcare, Inc., dated as of November 17, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit26.htm">2.6*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit26.htm">Amendment No. 1 to Stock and Asset Purchase Agreement dated January 20, 2023, by and among Evolent Health, Inc., Evolent Health LLC, and Magellan Health, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit27.htm">2.7*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit27.htm">Amendment No. 2 to Stock and Asset Purchase Agreement dated February 17, 2023, by and among Evolent Health, Inc., Evolent Health LLC, and Magellan Health, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000054/exhibit31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000054/exhibit31.htm">Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., filed as Exhibit 3.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on June 15, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., dated June 10, 2021, filed as Exhibit 3.1 to the Company&#8217;s report on Form 8-K filed with the SEC on June 10, 2021 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001628908/000162890820000143/a20201214form8-kex31.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001628908/000162890820000143/a20201214form8-kex31.htm">Third Amended and Restated By-laws of Evolent Health, Inc., filed as Exhibit 3.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on December 14, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Company, dated as of January 19, 2023, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex41.htm">Form of Class A common stock certificate, filed as Exhibit 4.1 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex41.htm">Registration Rights Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC, The Advisory Board Company and Ptolemy Capital, LLC, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">Indenture dated as of October 22, 2018, between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">Form of 1.50% Convertible Senior Notes due 2025, filed as Exhibit A to the Indenture (Item 4.5 above), which was filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000032/a528198-kexhibit41.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000032/a528198-kexhibit41.htm">Registration Rights Agreement, dated May 24, 2019, by and between Evolent Health, Inc. and Momentum Health Group, LLC, filed as exhibit 4.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on May 28, 2019, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/evh10-kexhibit46.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/evh10-kexhibit46.htm">Description of Registrant&#8217;s Securities, which was filed as Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 23, 2022, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">4.7*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">Indenture, dated as of August 19, 2020, by and between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">4.8*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">Form of 3.50% Convertible Senior Note due 2024 (included as Exhibit A to Exhibit 4.1), filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">Registration Rights Agreement, dated August 1, 2022, by and between Evolent Health, Inc., TPG Growth V Iceman, L.P.,  and the individuals in Schedule I of the agreement, filed as Exhibit 4.1 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex104.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex104.htm">Income Tax Receivables Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health LLC and certain stockholders of Evolent Health, Inc., filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex101.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex101.htm">Stockholders Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC and The Advisory Board Company, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex108.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex108.htm">VPHealth, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">Amendment No. 1 to the Evolent Health, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Exhibit 10.9 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">Amendment to the Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 27, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">Form of Executive Officer Option Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">Form of Executive Officer Restricted Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">Form of Non-Employee Director Restricted Stock Unit Award Agreement under the Evolent Health, Inc., 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">Form of Non-Qualified Stock Option Agreement under the Evolent Health, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.8 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">Amended and Restated HealthPlaNet Technology License Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">Amended and Restated Intellectual Property License and Development Services Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1015.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1015.htm">13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1015.htm">Amended and Restated Intellectual Property License and Data Access Agreement by and between The Advisory Board Company and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1018.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1018.htm">4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1018.htm">Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of July 31, 2012, filed as Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1019.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1019.htm">5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1019.htm">First Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of March 1, 2013, filed as Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1020.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1020.htm">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1020.htm">Second Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of April 1, 2014, filed as Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515199503/d838828dex1020.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515199503/d838828dex1020.htm">7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515199503/d838828dex1020.htm">Form of Director Indemnification Agreement, filed as Exhibit 10.20 to Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 26, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">Form of Executive Officer Performance-Based Option Award Agreement Under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 16, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">19</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">Form of Non-Employee Director Restricted Stock Unit Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2017, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">Form of Leveraged Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 28, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">Asset Purchase Agreement, dated July 16, 2020, by and among Passport Health Plan, Inc., Evolent Health LLC, and Molina Healthcare, Inc., filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q with the SEC on August 7, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312520323903/d12759dex101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312520323903/d12759dex101.htm">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312520323903/d12759dex101.htm">Cooperation Agreement, dated December 21, 2020, by and among Evolent Health, Inc., Engaged Capital Flagship Master Fund, LP, Engaged Capital Co-Invest XI, LP, Engaged Capital Special Situation Fund, LP, Engaged Capital Flagship Fund, LP, Engaged Capital Flagship Fund, Ltd., Engaged Capital LLC, Engaged Capital Holdings, LLC and Glenn W. Welling, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 22, 2020, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Frank Williams, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Seth Blackley, filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. John Johnson, filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Jonathan Weinberg, filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Steve Tutewohl, filed  as Exhibit 10.32 to the Company's Annual Report on Form 10-K filed with the SEC on February 26, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit1028.htm">10.28+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit1028.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Dan McCarthy.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312521145005/d154291ddef14a.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312521145005/d154291ddef14a.htm">Evolent Health, Inc. Amended and Restated 2015 Omnibus Equity Incentive Plan, filed as Appendix D to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 30, 2021, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000054/q12021exhibit102.htm">10.30+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000054/q12021exhibit102.htm">Form of Performance Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q with the SEC on May 6, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/a123121exhibit1031.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/a123121exhibit1031.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/a123121exhibit1031.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/a123121exhibit1031.htm">Form of Executive Officer Restricted Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, which was filed as Exhibit 10.31 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 23, 2022, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit101.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit101.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit101.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit101.htm">Form of Corporate PSU Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2022. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit102.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit102.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000063/a33122exhibit102.htm">Form of Business Unit PSU Award Agreement under the Evolent Health, Inc., 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2022. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">Credit Agreement, by and among Evolent Health, Inc., Evolent Health LLC, certain subsidiaries of Evolent Health, Inc, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as revolving agent and collateral agent, dated as of August 1, 2022, filed as Exhibit 10.1 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">Security Agreement, by and among Evolent Health, Inc., Evolent Health LLC, the other guarantors and ACF Finco I LP, as collateral agent for the benefit of the secured parties, dated as of August 1, 2022, filed as Exhibit 10.2 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex101.htm">Amendment No. 1, dated as of January 20, 2023, to the Credit Agreement, dated as of August 1, 2022, by the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the Company, as the Parent, each other Guarantor party thereto, Ares Capital Corporation, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">Security Agreement, by and among Evolent Health, Inc., Evolent Health LLC, the other guarantors and ACF Finco I LP, as collateral agent for the benefit of the secured parties, dated as of August 1, 2022, filed as Exhibit 10.2 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">Guarantee Agreement, by Evolent Health, Inc. and each of the other guarantors in favor of Ares Capital Corporation, as administrative agent for the lenders, and ACF Finco I LP, as collateral agent for the lenders, dated as of August 1, 2022, filed as Exhibit 10.3 to the Company&#8217;s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex102.htm">10.39</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex102.htm">Securities Purchase Agreement, dated as of January 20, 2023, by and among the Purchasers listed on Schedule I thereto and the Company, filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">40</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex103.htm">Investors Rights Agreement, dated as of January 20, 2023, by and among the Purchasers listed on Schedule I thereto and the Company, filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex104.htm">10.41</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex104.htm">Registration Rights Agreement, dated as of January 20, 2023, by and among the Stockholders named in Schedule I thereto and the Company, filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex105.htm">10.42</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex105.htm">Registration Rights Agreement, dated as of January 20, 2023, by and between Magellan Health, Inc. and the Company, filed as Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex106.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex106.htm">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex106.htm">Lock-Up Agreement, Dated as of January 20, 2023, by and between Magellan Health, Inc. and the Company, filed as Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022exhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022exhibit211.htm">Subsidiaries of Evolent Health, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123122exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">+ Constitutes a management contract or other compensatory plan or arrangement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_229"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ie5cc4f785ce54597a137387a0d3f51e9_202"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.111%"><tr><td style="width:1.0%"></td><td style="width:16.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.865%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  February&#160;24, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:163.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Seth Blackley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Seth Blackley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Controller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Craig Barbarosh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Craig Barbarosh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. Bridget Duffy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">M. Bridget Duffy, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Farner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David Farner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Grua</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Grua</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Diane Holder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diane Holder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kim Keck</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kim Keck</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cheryl Scott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cheryl Scott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Tunde Sotunde</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tunde Sotunde, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Frank Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Frank Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.5
<SEQUENCE>2
<FILENAME>a123122exhibit25.htm
<DESCRIPTION>EX-2.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie7be9b9b35414cc7908357c73bda1109_1"></div><div style="min-height:76.32pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 2.5</font></div><div><font><br></font></div></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STOCK AND ASSET PURCHASE AGREEMENT</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">by and among</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.,</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC,</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAGELLAN HEALTH, INC.,</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAGELLAN HEALTHCARE, INC.</font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dated as of November&#160;17, 2022</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie7be9b9b35414cc7908357c73bda1109_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;I<br>PURCHASE AND SALE</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acquisition</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain Closing Deliveries</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing Payments and Issuances</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Post-Closing Adjustment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Second Post-Closing Adjustment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Excluded Assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assumed Liabilities </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.10</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Retained Liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;II<br>REPRESENTATIONS AND WARRANTIES REGARDING SELLERS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Due Organization and Good Standing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authority&#59; Binding Nature of Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Noncontravention&#59; Consents</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claims&#59; Orders</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brokers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article&#160;III<br>REPRESENTATIONS AND WARRANTIES REGARDING THE ACQUIRED ENTITIES AND THE BUSINESS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Due Organization and Good Standing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalization&#59; Acquired Entities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Statements&#59; Undisclosed Liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Absence of Certain Changes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IP Rights&#59; Privacy&#59; Cybersecurity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Real Property</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Contracts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compliance With Laws&#59; Permits</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claims&#59; Orders</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.10</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.11</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Benefit Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.12</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Labor Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.13</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Environmental Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.14</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Health Care Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.15</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.16</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Customers and Suppliers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.17</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors and Officers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.18</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank Accounts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.19</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Anti-Corruption</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.20</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliate Contracts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.21</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.22</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brokers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.23</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 Relief</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.24</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;IV<br>REPRESENTATIONS AND WARRANTIES OF THE BUYER ENTITIES</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Due Organization and Good Standing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authority&#59; Binding Nature of Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Noncontravention&#59; Consents</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalization</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SEC Documents&#59; Financial Statements&#59; Related-Party Transactions&#59; Undisclosed Liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compliance With Laws</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Absence of Certain Changes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claims&#59; Orders</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Anti-Corruption</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.10</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Solvency</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.11</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.12</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.13</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brokers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.14</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">R&#38;W Insurance Policy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;V<br>COVENANTS AND AGREEMENTS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conduct of Business Prior to the Closing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Access to Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Consents and Filings&#59; Buyer Entities' Actions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Names and Marks&#59; Termination of Rights to IP Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification&#59; Directors' and Officers' Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination of Affiliate Contracts and Intercompany Accounts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Retention and Access to Personnel, Information and Records</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.10</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company Employee Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.11</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Transfer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.12</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.13</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transition</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.14</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exclusivity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.15</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further Assurances</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.16</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Post-Closing Cooperation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.17</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additional Financial Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.18</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain Post-Closing Agreements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.19</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Earnout</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.20</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">R&#38;W Insurance Policy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.21</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidentiality</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.22</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent Shares</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.23</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NIA Pennsylvania</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;VI<br>CONDITIONS TO CLOSING</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conditions to the Obligation of Each Party</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conditions to the Obligations of the Buyer Entities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conditions to Obligation of Sellers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;VII<br>TERMINATION</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effect of Termination</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;VIII<br>TAX MATTERS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preparation and Filing of Tax Returns&#59; Contests</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Straddle Periods</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pre-Closing Tax Refunds</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allocation of Purchase Price</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer Taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tax Sharing Agreements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cooperation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Survival</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exclusivity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;IX<br>Indemnification</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification Procedures</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Indemnification Procedures</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exclusive Remedy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;X<br>OTHER COVENANTS, AGREEMENTS AND ACKNOWLEDGEMENTS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Other Representations and Warranties&#59; Survival&#59; As-Is Sale&#59; <br>Nonreliance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mutual Release</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Retention of Counsel</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Protected Communications</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Waiver of Privilege, Protection From Disclosure or Use</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;XI<br>MISCELLANEOUS PROVISIONS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.1</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amendment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.2</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Waiver</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.3</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Entire Agreement&#59; Counterparts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.4</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Law&#59; Jurisdiction&#59; WAIVER OF JURY TRIAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.5</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Remedies&#59; Specific Performance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.6</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment of Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.7</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assignability&#59; Third-Party Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.8</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.9</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Severability</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.10</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.11</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Publicity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.12</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Construction</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.13</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Definitions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv</font></div></div></div><div id="ie7be9b9b35414cc7908357c73bda1109_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STOCK AND ASSET PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This STOCK AND ASSET PURCHASE AGREEMENT, dated as of November&#160;17, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is by and among Evolent Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;),  Evolent Health LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with the Buyer Parent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Magellan Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Magellan Healthcare, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MHI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with Seller Parent, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sellers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, Sellers together with the Buyer Entities, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Sellers and certain of their respective Subsidiaries own and operate the Business&#59;</font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, on the terms and conditions hereof, Buyer desires to acquire, and Sellers desire to sell to Buyer, the Business, including all of the outstanding Equity Interests (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transferred Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in National Imaging Associates, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Transferred Assets&#59; and</font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, on the terms and conditions hereof, Buyer desires to assume, agree to pay, perform, fulfill and discharge when due all of the Assumed Liabilities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the representations, warranties, covenants and agreements herein, and intending to be legally bound hereby, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br>PURCHASE AND SALE</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On the terms and conditions hereof, at and effective as of the Closing, (a)&#160;MHI shall sell, assign, transfer, convey and deliver (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to Buyer, and Buyer shall (and Buyer Parent shall cause Buyer to) purchase from MHI, all of the Transferred Equity Interests, free and clear of any Lien (other than any Lien created by Buyer or any of its Affiliates), and (b)&#160;Seller Parent shall, and shall cause the applicable members of the Seller Group to, Transfer, and Buyer shall (and Buyer Parent shall cause Buyer to) purchase from such members, the Transferred Assets (the transactions contemplated by the foregoing clauses&#160;(a) and (b), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). On the terms and conditions hereof, at and effective as of the Closing, Buyer shall (and Buyer Parent shall cause Buyer to) assume, agree to pay, perform, fulfill and discharge when due all of the Assumed Liabilities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties shall consummate the Acquisition and the Liabilities Assumption (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by the exchange of required closing deliverables at 8&#58;00&#160;a.m. Eastern time on the third (3) Business Day after the date on which the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are satisfied or waived (except for any such condition that by its nature is to be satisfied at the Closing, but subject to the satisfaction or waiver of any such condition at the Closing), unless Seller Parent and the Buyer Entities agree in writing on another time, date or place&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, if, prior to the Closing, Sellers deliver the Additional Financial Information to the Buyer Entities, then either Seller Parent or the Buyer Entities may request in writing from the other Party that the Closing be delayed for up to forty-five (45) days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Delay </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and, if the other Party agrees in writing to such delay, the Parties shall not be required to consummate the Closing prior to the date specified in the Closing Delay Notice. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which the Closing occurs. In the event the Measurement Time is not 12&#58;01&#160;a.m. on the first day of a calendar month, then the Seller Group shall use commercially reasonable efforts to prepare (or cause to be prepared) and deliver to Buyer Parent (in each case, at Buyer Parent&#8217;s sole cost and expense with respect to reasonable out-of-pocket expenses paid by the Seller Group to third parties in connection therewith (and excluding any internal costs or expenses, including with respect to employees of the Seller Group or their Affiliates)) within twenty (20) days after the Closing Date a standalone closing balance sheet of &#8220;Magellan Specialty Health&#8221; and, following the delivery thereof, shall use commercially reasonable efforts to respond to any reasonable information requests by Buyer Parent or its Representatives with respect to such balance sheet. For the avoidance of doubt, as used in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to the preparation and delivery of such standalone balance sheet, &#8220;commercially reasonable efforts&#8221; will (a)&#160;include identification of and providing data related to the significant and material (materiality as reasonably agreed to by the Parties) account level activity that occurred between the last month-end date prior to close and the actual Closing Date, and (b)&#160;include a roll forward and reconciliation of the material (materiality as reasonably agreed to by the Parties) balance sheet accounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Closing Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;At or prior to the Closing, Sellers shall deliver to the Buyer Entities the following&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;an IRS Form&#160;W-9, duly executed by Seller&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a transition services agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transition Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), duly executed by Seller Parent and an Acquired Entity&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a software license agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Software License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), duly executed by Seller Parent and an Acquired Entity&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a bill of sale and assignment and assumption agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bill of Sale and Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), duly executed by the applicable members of the Seller Group&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;if any Buyer Parent Shares are issued to Seller Parent hereunder, a registration rights agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), if applicable, duly executed by Seller Parent&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;a restrictive covenant agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), duly executed by Seller Parent and MHI&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;if any Buyer Parent Shares are issued to Seller Parent hereunder, a lock-up agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lock-Up Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), duly executed by Seller Parent&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;a certificate of the Secretary or other authorized officer of each Seller, dated as of the Closing Date, certifying as to the resolutions or actions of such Seller&#8217;s board of directors approving the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, and certifying to the incumbency of the officers of such Seller executing this Agreement and any other documents being executed in connection with the consummation of the transactions contemplated hereby&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;a certificate of good standing from such Acquired Entity&#8217;s jurisdiction of formation, each dated within ten (10) Business Days prior to the Closing Date&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;for any Transferred Equity Interests represented by physical certificates, such certificates, duly endorsed in blank or accompanied by transfer powers duly executed by MHI.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;At or prior to the Closing, the Buyer Entities shall deliver to Sellers the following&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Bill of Sale and Assignment Agreement, duly executed by Buyer&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;if any Buyer Parent Shares are issued to Seller Parent hereunder, the Registration Rights Agreement and Lock-Up Agreement, duly executed by Buyer Parent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As promptly as practicable after the date hereof, Sellers or their Affiliates shall use reasonable best efforts to obtain approval of the Contract attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;G-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Florida Company Commercial Agreement Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by the Office of Insurance Regulation of the State of Florida pursuant to Form&#160;D OIR-A1-2117 and Rule&#160;69O-143.047, Florida Administrative Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Form&#160;D Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). As promptly as practicable after receipt of a Form&#160;D Approval of the Florida Company Commercial Agreement Amendment, Sellers shall cause the Company and the applicable Subsidiaries of Ultimate Parent to execute and deliver the Florida Company Commercial Agreement Amendment. Receipt of the Form&#160;D Approval shall not be a condition to the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Immediately after the Closing, Sellers shall deliver to the Buyer Entities the commercial agreements and commercial agreement amendments in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;G-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Florida Commercial Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the Florida Company Commercial Agreement Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Florida Company Commercial Agreement Amendment (to the extent it has not been executed prior to the Closing), duly executed by the applicable Subsidiaries of Ultimate Parent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Immediately after the Closing, the Buyer Entities shall deliver to Sellers the Non-Florida Commercial Agreements and the Florida Company Commercial Agreement Amendment (to the extent it has not been executed prior to the Closing), duly executed by the Company, Buyer Parent, Buyer or the applicable Subsidiary of Buyer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Payments and Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No later than two (2) Business Days prior to the Closing Date, Seller Parent shall deliver a written statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Buyer Entities setting forth, with reasonable supporting information, the following&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Estimated Business Enterprise Value, including a good-faith estimate of (1)&#160;the Closing Date Cash (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Closing Date Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (2)&#160;the Closing Date Indebtedness (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Closing Date Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (3)&#160;the Net Working Capital Adjustment Amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Net Working Capital Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;wiring instructions for the payment contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the allocation of the Estimated Business Enterprise Value between Sellers (each Seller&#8217;s percentage allocation being referred to as its &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Allocation Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Between the delivery of the Payment Statement and the Measurement Time, Seller Parent shall (A)&#160;provide the Buyer Entities and their Representatives with reasonable access, during normal business hours, to the books and records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Business for purposes of their review of the Payment Statement, and (B)&#160;reasonably cooperate with the Buyer Entities and their Representatives in connection with such review, including using commercially reasonable efforts to provide on a timely basis all other information reasonably necessary in connection with the review of the Payment Statement, in each case, as reasonably requested by the Buyer Entities and their Representatives. Notwithstanding anything to the contrary in this Agreement, between the Measurement Time and the Closing, Sellers shall not, and Sellers shall not cause any Acquired Entity to, take any action (or omit to take any action) outside of the ordinary course of business and not contemplated by this Agreement that has the effect of modifying the Estimated Closing Date Cash, Estimated Closing Date Indebtedness, or Estimated Net Working Capital Adjustment Amount in order to increase the amounts payable to the Sellers. Following the delivery of the Payment Statement, Seller Parent shall consider in good faith any comments of the Buyer Entities to the Payment Statement and the calculations set forth therein (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any failure to accept any such comments to the Payment Statement shall not relieve the Buyer Entities of their obligations to consummate the Closing when required hereunder). Seller Parent shall use commercially reasonable efforts to deliver a draft of the Payment Statement to Buyer Parent no later than five (5) Business Days prior to the Closing Date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment and Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;At the Closing, the Buyer Entities shall pay to Sellers an aggregate amount in cash equal to the Cash Consideration Amount, by wire transfer of immediately available funds in accordance with the wiring instructions and allocation in the Payment Statement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;At the Closing, Buyer Parent shall, if applicable, (1)&#160;issue to Seller Parent, in book-entry form, the Buyer Parent Shares and (2)&#160;deliver to Seller Parent a letter, duly executed by Buyer Parent, directing such transfer agent to enter into its book and records the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">number of Buyer Parent Shares in the name of Seller Parent. Promptly after the Closing, Buyer Parent shall deliver to Seller Parent evidence of the entry into the books and records of Buyer Parent&#8217;s transfer agent of the number of Buyer Parent Shares in the name of Seller Parent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At the Closing, all Transaction Expenses payable to third-party Representatives of the Acquired Entities (to the extent not paid by Sellers or the Acquired Entities prior to the Closing) will be fully paid, and such payment will be funded by Buyer Parent. In order to facilitate such payment, prior to the Closing, Sellers shall use commercially reasonable efforts to obtain and deliver to Buyer Parent invoices with respect to such Transaction Expenses.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Post-Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Within one hundred and twenty (120) days after the Closing Date, Buyer Parent shall prepare and deliver to Seller Parent a written statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Adjustment Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) setting forth, in reasonable detail and with reasonable supporting information, Buyer Parent&#8217;s good-faith calculation of the First Adjustment Amount. Buyer Parent shall prepare the First Adjustment Statement in a manner consistent herewith, including this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the definitions herein, and in accordance with the Accounting Principles. Seller Parent shall (i)&#160;provide Buyer Parent and its Representatives with reasonable access during normal business hours to the books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Business to the extent necessary or useful for purposes of Buyer Parent&#8217;s preparation of the First Adjustment Statement, and (ii)&#160;reasonably cooperate with Buyer Parent and its Representatives in connection with such preparation, including using commercially reasonable efforts to provide on a timely basis all other information reasonably necessary in connection with the preparation of the First Adjustment Statement as is requested by Buyer Parent or its Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Seller Parent shall have thirty (30) days from the date on which the First Adjustment Statement is delivered to Seller Parent in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to review the First Adjustment Statement. During such First Review Period, Buyer Parent shall, and shall cause the Acquired Entities to, (i)&#160;provide Seller Parent with reasonable access during normal business hours upon reasonable prior notice to the books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Acquired Entities and to work papers of Buyer Parent&#8217;s and the Acquired Entities&#8217; respective accountants, in each case, for purposes of their review of the First Adjustment Statement and (ii)&#160;reasonably cooperate with all requests of Seller Parent in connection with such review, including timely providing all information in connection with Seller Parent&#8217;s review of the First Adjustment Statement as is requested by Seller.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Unless Seller Parent delivers written notice to Buyer Parent prior to 5&#58;00&#160;p.m. on the last day of the First Review Period that it objects to any item or items shown or reflected in the First Adjustment Statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the First Adjustment Statement shall be deemed accepted by Seller Parent for all purposes hereof. The Dispute Notice shall specify in reasonable detail the item or items to which Seller Parent objects and the reasons therefor (such item or items, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disputed Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If Seller Parent delivers a Dispute Notice at or prior to 5&#58;00&#160;p.m. on the last day of the First Review Period, Seller Parent and Buyer Parent shall attempt in good faith to resolve each Disputed Item, and any resolution agreed by them in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">writing shall be final, binding and conclusive for all purposes of determining the payments in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If, for any reason, Seller Parent and Buyer Parent are unable to resolve in writing each Disputed Item within forty-five (45) Business Days (or such longer period as Buyer Parent and Seller Parent may agree in writing) after the delivery of the Dispute Notice, all unresolved Disputed Items shall be referred to Ernst &#38; Young LLP for resolution acting as an expert and not an arbitrator. If Ernst &#38; Young LLP is unwilling or unable to serve as such expert, Seller Parent and Buyer Parent shall jointly select and retain a nationally recognized accounting firm that is independent and impartial to serve as such expert Ernst &#38; Young LLP or such other accounting firm engaged in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Accountant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If, within ten (10) Business Days after the date Ernst &#38; Young LLP informs Seller Parent and Buyer Parent that it is unable or unwilling to serve as the Independent Accountant and Seller Parent and Buyer Parent cannot mutually agree on an alternate accounting firm to serve as the Independent Accountant, either Seller Parent or Buyer Parent may request the American Arbitration Association to appoint as the Independent Accountant, within fifteen (15) days from the date of such request or as soon as practicable thereafter, a partner in a nationally recognized accounting firm that is not the auditor or independent accounting firm of any of Buyer Parent or any of its Affiliates or Seller Parent or any of its Affiliates, who is a certified public accountant and who is independent of Seller Parent and Buyer Parent and impartial to serve as the Independent Accountant. If any Disputed Item is referred to the Independent Accountant, Buyer Parent on the one hand, and Seller Parent, on the other hand, shall prepare a written report addressing each such Disputed Item and deliver such reports to the Independent Accountant and each other within fifteen (15) Business Days after the date the Independent Accountant is retained. Each of Buyer Parent, on the one hand, and Seller Parent, on the other hand, shall have fifteen (15) Business Days thereafter to deliver a rebuttal submission to the Independent Accountant. Each of Buyer Parent and Seller Parent shall use reasonable efforts to cause the Independent Accountant, as soon as reasonably practicable and in any event within thirty (30) days after receiving such rebuttal submissions, to resolve the Disputed Items&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the dollar amount of each Disputed Item shall be determined within the range of dollar amounts proposed in the First Adjustment Statement and the Dispute Notice, respectively. Buyer Parent and Seller Parent acknowledge and agree that (i)&#160;the review by and determination of the Independent Accountant shall be limited only to the Disputed Items in the reports prepared and submitted to the Independent Accountant by Buyer Parent and Seller Parent and (ii)&#160;the determinations by the Independent Accountant shall be based solely on (1)&#160;such reports and supporting information submitted by Buyer Parent and Seller Parent and (2)&#160;the terms hereof, and not on the basis of an independent review. Neither Buyer Parent nor Seller Parent shall authorize the Independent Accountant to modify or amend any term or provision hereof or modify items previously agreed in writing between Buyer Parent and Seller Parent. If requested by the Independent Accountant, each of Buyer Parent and Seller Parent shall enter into an engagement letter with the Independent Accountant containing customary terms and conditions. There shall be no ex parte communications with the Independent Accountant, and any information or documentation provided by any Party to the Independent Accountant shall be concurrently delivered to the other Party, subject, in the case of independent accountant work papers, to such other Party entering into a customary confidentiality agreement related thereto. Neither Buyer Parent nor Seller Parent shall disclose to the Independent Accountant, and the Independent Accountant shall not consider for any purposes, any discussions, offers or negotiations made by any of the Parties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">related to the compromise of any Disputed Item. The determinations by the Independent Accountant as to the Disputed Items shall be in writing and shall, absent manifest mathematical error promptly corrected by the Independent Accountant, be an expert determination that is final, binding and conclusive for all purposes of determining the adjustments in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if any, and such determination may be entered and enforced in any court of competent jurisdiction. The costs and expenses of the Independent Accountant shall be allocated between Buyer Parent and Seller Parent in inverse proportion to the amounts of Disputed Items decided in their respective favors. As an illustrative example, if Disputed Items asserting that the First Adjustment Amount should be increased by $1,000 are submitted to the Independent Accountant, and the Independent Accountant finally determines that the First Adjustment Amount should be increased by $300, then the costs and expenses of the Independent Accountant shall be allocated 70% (i.e., $700&#47;$1000) to Seller Parent and 30% (i.e., $300&#47;$1,000) to Buyer Parent. The process in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the exclusive remedy for the Parties for any disputes arising from the calculation of the Purchase Price and the First Adjustment Amount (and any components thereof).</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If the First Adjustment Amount, as finally determined under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final First Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), exceeds the Estimated First Adjustment Amount (the amount of any such excess, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Positive First Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, within five (5) Business Days after the determination of the Final First Adjustment Amount, the Buyer Entities shall pay to Sellers an aggregate amount in cash equal to the Positive First Adjustment Amount, by wire transfer of immediately available funds in accordance with the wiring instructions and allocation in the Payment Statement. If the Final First Adjustment Amount is less than the Estimated First Adjustment Amount (the amount of any such difference, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Negative First Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, within five (5) Business Days after the determination of the Final First Adjustment Amount, Sellers shall jointly and severally pay to the Buyer Entities an aggregate amount in cash equal to the Negative First Adjustment Amount, by wire transfer of immediately available funds in accordance with the wiring instructions that the Buyer Entities shall deliver to Sellers prior to the date when such payment is required to be made.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Any payment made under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be treated as an adjustment to the purchase price for the Acquisition for Tax purposes to the maximum extent permitted by applicable Law.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Post-Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Within one hundred and twenty (120) days after the Second Adjustment Date, Buyer Parent shall prepare and deliver to Seller Parent a written statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Adjustment Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) setting forth, in reasonable detail and with reasonable supporting information, Buyer Parent&#8217;s good-faith calculation of the Second Adjustment Amount. Buyer Parent shall prepare the Second Adjustment Statement in a manner consistent herewith, including this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the definitions herein, and in accordance with the Accounting Principles. Seller Parent shall (A)&#160;provide Buyer Parent and its Representatives with reasonable access during normal business hours to the books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Business to the extent reasonably necessary for purposes of Buyer Parent&#8217;s preparation of the Second Adjustment Statement, and (B)&#160;reasonably cooperate with Buyer Parent and its Representatives in connection with such preparation, including using commercially reasonable efforts to provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on a timely basis all other information reasonably necessary in connection with the preparation of the Second Adjustment Statement as is requested by Buyer Parent or its Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Seller Parent shall have thirty (30) days from the date on which the Second Adjustment Statement is delivered to Seller Parent in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to review the Second Adjustment Statement. During such Second Review Period, Buyer Parent shall, and shall cause the Acquired Entities to, (i)&#160;provide Seller Parent with reasonable access during normal business hours upon reasonable prior notice to the books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Acquired Entities and to work papers of Buyer Parent&#8217;s and the Acquired Entities&#8217; respective accountants, in each case, for purposes of their review of the Second Adjustment Statement and (ii)&#160;reasonably cooperate with all requests of Seller Parent in connection with such review, including timely providing all information in connection with Seller Parent&#8217;s review of the Second Adjustment Statement as is requested by Seller.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Unless Seller Parent delivers written Dispute Notice to Buyer Parent prior to 5&#58;00&#160;p.m. on the last day of the Second Review Period that it objects to any item or items shown or reflected in the Second Adjustment Statement, the Second Adjustment Statement shall be deemed accepted by Seller Parent for all purposes hereof. The Dispute Notice shall specify in reasonable detail the Disputed Items and the reasons therefor. If Seller Parent delivers a Dispute Notice at or prior to 5&#58;00&#160;p.m. on the last day of the Second Review Period, Seller Parent and Buyer Parent shall attempt in good faith to resolve each Disputed Item, and any resolution agreed by them in writing shall be final, binding and conclusive for all purposes of determining the payments in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.6(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If, for any reason, Seller Parent and Buyer Parent are unable to resolve in writing each Disputed Item within forty-five (45) Business Days (or such longer period as Buyer Parent and Seller Parent may agree in writing) after the delivery of the Dispute Notice, all unresolved Disputed Items shall be referred to the Independent Accountant for resolution acting as an expert and not an arbitrator and the dispute resolution provisions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply to such dispute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If the Second Adjustment Amount, as finally determined under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Second Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is positive (the amount of any such excess, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Positive Second Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, within five (5) Business Days after the determination of the Final Second Adjustment Amount, the Buyer Entities shall pay to Sellers an aggregate amount in cash equal to the Positive Second Adjustment Amount, by wire transfer of immediately available funds in accordance with the wiring instructions and allocation in the Payment Statement. If the Final Second Adjustment Amount is negative (the amount of any such difference, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Negative Second Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, within five (5) Business Days after the determination of the Final Second Adjustment Amount, Sellers shall jointly and severally pay to the Buyer Entities an aggregate amount in cash equal to the Negative Second Adjustment Amount, by wire transfer of immediately available funds in accordance with the wiring instructions that the Buyer Entities shall deliver to Sellers prior to the date when such payment is required to be made.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Any payment made under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.6(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be treated as an adjustment to the purchase price for the Acquisition for Tax purposes to the maximum extent permitted by applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Asset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, except as otherwise provided herein or in the Ancillary Agreements, any of the following assets (and all title and interest thereto or therein), as existing at the Closing, to the extent owned, leased, held or licensed by any member of the Seller Group (which, for the avoidance of doubt, excludes the Acquired Entities)&#58;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the leases for Business Leased Real Property listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Leases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all Contracts Related to the Business (together with the Transferred Leases, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including the Contracts listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule but excluding any Consent Required Contract&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the employment agreements listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule to the extent the employee a party thereto is a Transferred Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Employment-Related Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;all accounts receivable and notes receivable Related to the Business&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;all expenses that have been prepaid and are Related to the Business&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;all insurance proceeds arising out of or related to damage or destruction of any Transferred Assets (or assets existing as of the date hereof that would have been Transferred Assets but for the occurrence of the event giving rise to the insurance proceeds) to the extent such damage or destruction remains unrepaired or to the extent any asset remains unreplaced at the Closing (such insurance proceeds, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Post-Signing Insurance Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;all documents, instruments, papers, books, records, books of account, files and tangible or electronic embodiments of data, telephone numbers and fax numbers, catalogs, brochures, sales literature, promotional materials, certificates and other documents to the extent Related to the Business and in the possession or control of the Seller Group, other than (i)&#160;Employee Records, (ii)&#160;any documents, instruments, papers, books, records, books of account, files and tangible, electronic embodiments of data (including customer and supplier lists and repair and performance records), telephone numbers and fax numbers, catalogs, brochures, sales literature, promotional materials, certificates and other documents not permitted to be transferred to Buyer by applicable Law and (iii)&#160;any Tax Returns or Tax records (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Seller Group shall be permitted to maintain copies of any Books and Records (1)&#160;as reasonably necessary to comply with applicable Law (including pursuant to a &#8220;litigation hold&#8221;) or professional standards, (2)&#160;for bona fide corporate record keeping purposes pursuant to written policies established by a member of the Seller Group prior to the Closing or (3)&#160;that are in electronic form, including any emails and attachments thereto, to the extent saved or stored by a member of the Seller Group in the ordinary course of business&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;all goodwill Related to the Business&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the domain names listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;other than IT Assets, all tangible assets (including equipment, furniture and furnishings) Related to the Business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;to the extent permitted to be transferred by applicable Law, all files and records that relate to Transferred Employees but only to the extent that such files and records relate to (1)&#160;skill and development training, (2)&#160;biographies, (3)&#160;seniority histories, (4)&#160;salary and benefits, (5)&#160;Occupational, Safety and Health Administration reports (or the equivalent), (6)&#160;active medical restriction forms, (7)&#160;drug testing and background check documentation (including criminal background history, SSN trace and OIG&#47;SAM exclusions, if any), (8)&#160;credential verification (including Form&#160;I-9) and addresses and (9)&#160;fitness for duty, in each case, that are in the possession or under the control of any member of the Seller Group (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, the Employee Records will include all employee data of the Transferred Employees (including employee offers and new hire records, performance records, bonus awards and talent acquisition records) maintained in &#8220;Workday&#8221; by the Seller Group in the ordinary course of business and all employee discipline records of the Transferred Employees for the three (3) year period preceding the Closing Date maintained in &#8220;ServiceNow&#8221; by the Seller Group in the ordinary course of business&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;(i)&#160;all Personal Electronic Devices issued by a member of the Seller Group to a Transferred Employee for individual use in connection with their employment by a member of the Seller Group (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred Business Employee Devices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii)&#160;all IT Assets and Software Related to the Business, including the Software and other IP Rights set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(l)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (together with the Transferred Domain Names and the Transferred Business Employee Devices, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferred IT&#47;IP Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Transfer of such Transferred IT&#47;IP Assets to Buyer shall not grant Buyer or any of its Affiliates, including the Acquired Entities, any right, title or interest in or to any Seller Names&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that none of the foregoing assets or rights shall be Transferred Assets to the extent any such asset or right is an Excluded Asset. A single asset may fall within more than one (1) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections&#160;1.7(a)-(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and such fact does not imply that (A)&#160;such asset shall be Transferred if any provision hereof restricts such Transfer, (B)&#160;such asset shall be Transferred more than once or (C)&#160;any duplication of such asset is required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, the Seller Group shall retain all of its right, title and interest in and to, and shall not, and shall not be required to, Transfer to Buyer, and the Transferred Assets shall not include, any of the following assets or rights to the extent owned, leased, held or licensed by any member of the Seller Group (which, for the avoidance of doubt, excludes the Acquired Entities) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;other than Post-Signing Insurance Proceeds, all cash and cash equivalents of Sellers and their respective Affiliates (other than cash and cash equivalents held in a deposit account the registered owner of which is an Acquired Entity), including all deposits with utilities, insurance companies and other Persons (other than to the extent such amounts constitute prepaid expenses subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and all cash and cash equivalents held in any account the registered owner of which is a member of the Seller Group&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any distribution or dividend from any Acquired Entity that has a record date or record time and paid prior to the Measurement Time&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all accounts receivable that are not Related to the Business and all accounts receivable for which the obligor is a member of the Seller Group&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;all notes receivable (and any similar claims or rights) that are not Related to the Business and all notes receivable that are related to or arise out of the financing of the Business or the transfer of cash to or from the Business&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;all checkbooks, canceled checks, bank deposits, bank accounts, deposit accounts, investment accounts and collateral supporting letters of credit or any other support obligation&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;any Equity Interests of any Person (other than an Acquired Entity)&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;all Contracts that are not Transferred Contracts (including all Contracts related to any Excluded IP Rights or any Excluded IT Assets) and all rights and Claims thereunder, including the Contracts listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;other than any IP Rights included in the Transferred IT&#47;IP Assets, all other IP Rights (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including (i)&#160;the IP Rights listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.8(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule and (ii)&#160;&#8220;Centene,&#8221; &#8220;Magellan&#8221; or any confusingly similar derivative or variant thereof or any name or trademark confusingly similar to or dilutive of any of the foregoing, alone or as part of a combination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;other than any IT Assets included in the Transferred IT&#47;IP Assets, all other IT Assets (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded IT Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including (1)&#160;all Software installed on any Business Employee Hardware and (2)&#160;all IT Assets listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.8(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;any Claims against Third Parties to the extent (i)&#160;not Related to the Business or (ii)&#160;related to the Excluded Assets or the Retained Liabilities&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;any assets or rights privileged under the attorney-client privilege or the attorney work-product doctrine&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;all of the Seller Group&#8217;s books and records that form part of the general ledger of Seller Parent or its Subsidiaries, including any such Person&#8217;s corporate or organizational books and records (including minute books), Tax Returns, financial and other accounting records (including records related to Taxes) necessary for the preparation of financial statements, Tax Returns or government-required Filings&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;other than the Employee Records, all (i)&#160;personnel records and (ii)&#160;other records that (1)&#160;any member of the Seller Group is required by Law to retain in its possession, (2)&#160;cannot be transferred pursuant to applicable Law, or (3)&#160;relate to any present, former or future director, officer or employee (including any Transferred Employee) of any member of the Seller Group (including files and records containing personal identifying information or related to skill and development training, performance, biographies, seniority histories, salary and benefits, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Occupational, Safety and Health Administration reports (or the equivalent), active medical restriction forms, fitness for duty and disciplinary actions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;all emails, instant messages, text messages, recorded voicemails and other electronic communications, of any employee (including any Transferred Employee) of any member of the Seller Group, whether on employee-owned devices or devices owned by MHI or its Subsidiaries to the extent not Related to the Business&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;all Seller Employee Plans and all assets and rights thereunder, together with all funding arrangements thereto (including all trusts, insurance policies and administrative service contracts)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;all Tax assets (including any refunds, rebates or credits or similar benefits) of Seller Parent or its Subsidiaries (the allocation of which among the Parties shall be governed exclusively by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;all confidential or proprietary information in any Transferred Employee&#8217;s possession or control to the extent related to any business of the Seller Group (other than the Business), including (i)&#160;any such confidential or proprietary information obtained inadvertently by such Transferred Employee or contained or stored in such Transferred Employee&#8217;s personal electronic devices (including mobile phones, smartphones, tablets, laptop computers and desktop computers) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Electronic Devices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii)&#160;confidential or proprietary information, including all such information contained or archived in any Transferred Employee&#8217;s emails, that is related to any business of the Seller Group (other than the Business)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;all assets and rights not Related to the Business or set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.8(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assumed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assumed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the following Liabilities of the Seller Group, whether arising prior to, on or after the Closing&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;all trade and other accounts payable and notes payable Related to the Business or otherwise attributed to the Business in the Financial Statements or the notes thereto or in the calculation of the Closing Date Indebtedness or Net Working Capital&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all Liabilities arising under or to the extent related to the Transferred Assets, including all such Liabilities related to credits, prepaid expenses, rebates, deferred charges and prepaid items of any Person (other than the Seller Group), including any deferred revenue), to the extent related to the Transferred Assets&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all Liabilities related to or arising from (i)&#160;the Transferred Employees or the employment thereof, including (1)&#160;all severance or termination payments that are payable on the cessation of employment of any Transferred Employee, and (2)&#160;the Accrued PTO (but excluding any other Liabilities under any Seller Employee Plan (except as contemplated by (ii) or (iii) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)), (ii)&#160;all severance or termination payments that are payable by Seller or its Affiliates on the cessation of employment of any Business Employee who (1)&#160;does not receive a written offer of employment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (2)&#160;who receives a written offer of employment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> but such written offer does not meet the requirements of such Section, and (iii)&#160;the Transferred Employment-Related </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreements to the extent the Business Employee a party thereto is a Transferred Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assumed Employee Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;all Liabilities arising under or related to the Closing Date Indebtedness&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;all Liabilities allocated to Buyer, any Acquired Entity or any of their respective Affiliates (other than any member of the Seller Group) herein or in the Ancillary Agreements, including all Liabilities related to or arising from any Consent Required Contract (including all third-party costs and expenses incurred by Sellers or their respective Affiliates in enforcing any Claims, rights and benefits under any Consent Required Contracts in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;all Liabilities to the extent arising from or related to any action or omission by a Buyer Entity or its Affiliates (including the Acquired Entities) after the Closing with respect to the Business, the Acquired Entities or the Transferred Assets or the other Assumed Liabilities, including any violation of any Law by a Buyer Entity or its Affiliates (including the Acquired Entities) after the Closing&#59; and</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;all Liabilities arising under or related to any Indebtedness or financing arrangement to be incurred or entered into by a Buyer Entity or its Affiliates (including the Acquired Entities) at or in connection with the Closing&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any single Liability may fall within more than one of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections&#160;1.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">1.9(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and such fact does not imply that (1)&#160;such Liability shall be transferred more than once or (2)&#160;any duplication of such Liability is required.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retained Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the Assumed Liabilities, Buyer shall not assume or become obligated with respect to any Liability of the Seller Group of any nature whatsoever (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retained Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Seller Group shall retain and shall pay, discharge and perform all of the Retained Liabilities, including&#58;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;all Liabilities not related to the Business or to the extent arising from or related to the Excluded Assets or any business of the Seller Group (other than the Business)&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all Liabilities to the extent related to or arising out of any Indebtedness of the Seller Group&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all Liabilities of the Seller Group arising or incurred in connection with the negotiation, preparation, investigation and performance of this Agreement, the agreements contemplated hereby and the transactions contemplated hereby and thereby, including fees and expenses of counsel, accountants, consultants, advisers and others&#59;</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;all Tax Liabilities of Seller or its Subsidiaries (the allocation of which among the Parties shall be governed exclusively by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;other than the Assumed Employee Liabilities, all Liabilities of the Seller Group under any Seller Employee Plan or for any present or former employees, officers, directors, retirees, independent contractors or consultants of the Seller Group, including, without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">limitation, any Liabilities associated with any claims for wages or other benefits, bonuses, accrued vacation, workers&#8217; compensation, severance, retention, termination or other payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;all Liabilities allocated to any Seller, any member of the Seller Group or any of their respective Affiliates (other than an Acquired Entity) herein or in the Ancillary Agreements&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;all Liabilities related to any payroll Taxes deferred under the CARES Act&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;all risk-based or administrative services only (ASO) Liabilities under the Centene Customer Agreements (as defined in the Disclosure Schedule) arising prior to the Closing&#59; and</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Liabilities listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.10(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Retained Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no Liability of an Acquired Entity shall be a Retained Liability.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>REPRESENTATIONS AND WARRANTIES REGARDING SELLERS</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as disclosed in the Disclosure Schedule, each Seller represents and warrants to the Buyer Entities as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Due Organization and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Such Seller is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation. Except as would not be material to the Business, such Seller has all Entity power and authority to own, lease and operate its assets and to conduct its businesses in the manner in which its businesses are currently being conducted. Such Seller is not in material breach or material default of any obligation under its Organizational Documents.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority&#59; Binding Nature of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Such Seller has the requisite power and authority to execute and deliver, and to perform its covenants and agreements under, this Agreement. The execution and delivery hereof by such Seller and the performance by such Seller of its covenants and agreements hereunder have been duly and validly authorized by all necessary Entity action on the part of such Seller. This Agreement has been duly and validly executed and delivered by such Seller and, assuming the due authorization, execution and delivery hereof by the other Parties, is a legal, valid and binding obligation of such Seller, enforceable against such Seller in accordance with its terms, subject to (a)&#160;Laws of general application related to bankruptcy, insolvency, reorganization, moratorium and other Laws affecting creditors&#8217; rights generally and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies (such Laws and rules of law, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy and Equity Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Noncontravention&#59; Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Such Seller&#8217;s execution and delivery hereof do not, and the performance of such Seller&#8217;s, each member of the Seller Group&#8217;s and each Acquired Entity&#8217;s covenants and agreements hereunder (or otherwise applicable to such member of the Seller Group or Acquired </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Entity) shall not, (i)&#160;conflict with or violate any of the Organizational Documents of such Seller or any Acquired Entity, (ii)&#160;subject to making or obtaining, as applicable, the Consents and Filings referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, conflict with or violate any Law or (iii) (1)&#160;require any Consent of, or any notice or filing (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to or with, any Person that is not a Governmental Authority under, or (2)&#160;result in any breach of or, with or without notice or lapse of time or both, be a default under or give rise to any right of termination, cancellation, amendment or acceleration of, or result in the creation of a Lien on any asset of such Seller or an Acquired Entity under, any Material Contract.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Such Seller&#8217;s execution and delivery hereof do not, and the performance of such Seller&#8217;s, each member of the Seller Group&#8217;s and each Acquired Entity&#8217;s covenants and agreements hereunder shall not, require such Seller or any Acquired Entity to make any Filing with or to, or to obtain any Consent from, any Governmental Authority, other than the following&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the HSR Act Clearance and Filings under the HSR Act&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Form&#160;D Approval&#59; and</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Filings listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Seller owns the Transferred Equity Interests free and clear of any Lien (other than any restriction on transfer arising under the Organizational Documents of the Company). One or more members of the Seller Group own, license or hold a valid leasehold interest in or to the Transferred Assets, in each case, free and clear of any Lien (other than any Permitted Lien).</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims&#59; Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. There is no, and since the Reference Date, there has not been any, Claim pending or, to Sellers&#8217; Knowledge, being threatened against such Seller, and such Seller is not, and since the Reference Date, has not been subject to any Order, that, in each case, would result in a Seller Material Adverse Effect.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No broker, finder or investment banker is entitled to any brokerage, finder&#8217;s or other similar fee or commission in connection with the transactions contemplated hereby based on arrangements made by or on behalf of such Seller and for which the Buyer Entities or any Acquired Entity would be liable.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>REPRESENTATIONS AND WARRANTIES REGARDING THE ACQUIRED ENTITIES AND THE BUSINESS</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as disclosed in the Disclosure Schedule, each Seller represents and warrants to the Buyer Entities as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Due Organization and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Acquired Entity is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation. Each Acquired Entity has all Entity power and authority to own, lease and operate its assets and to conduct its businesses as they are currently being conducted in all material respects. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Acquired Entity is duly qualified to do business as a foreign Entity, and is in good standing, under the Laws of the jurisdictions where the nature of its businesses or the character of its assets requires such qualification, except where the failure to be so qualified or in good standing is not, and would not reasonably be expected to be, material to such Acquired Entity. None of the Acquired Entities is in material breach or material default of any material obligation under its Organizational Documents.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalization&#59; Acquired Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Transferred Equity Interests are all of the outstanding Equity Interests in the Company.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists all of the Subsidiaries of the Company. No Acquired Entity owns any Equity Interests in any Person, other than Equity Interests in another Acquired Entity. All of the capital stock of, or other Equity Interests in, the Subsidiaries of the Company are owned by an Acquired Entity, free and clear of any Lien (other than any restriction on transfer arising under the Organizational Documents of such Subsidiary). All of the outstanding Equity Interests in the Acquired Entities have been duly authorized and validly issued and are free of preemptive rights. There are no voting agreements or other contracts, agreements, commitments, arrangements, instruments or rights of any kind of nature outstanding or in effect with respect to the any Equity Interests of an Acquired Entity or which restrict the transfer of any Equity Interest of an Acquired Entity.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements&#59; Undisclosed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Sellers have made available to the Buyer Entities (i)&#160;combined unaudited financial statements of &#8220;Magellan Specialty Health&#8221; as of and for the years ended December&#160;31, 2021, and December&#160;31, 2020, and (ii)&#160;combined unaudited financial statements of &#8220;Magellan Specialty Health&#8221; for the nine-month period ended September&#160;30, 2022 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The applicable Financial Statements present fairly, in all material respects, the consolidated financial position of &#8220;Magellan Specialty Health&#8221; as at the respective dates thereof and the consolidated results of operations for the periods then ended in accordance with GAAP (other than the absence of footnotes and normal year-end adjustments). The Acquired Entities and the members of the Seller Group with respect to the Business maintain a system of internal controls and procedures that are sufficient to provide reasonable assurance that transactions are executed only with management&#8217;s authorization, and that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets of the Acquired Entities and the members of the Seller Group with respect to the Business. No Acquired Entity or member of the Seller Group with respect to the Business has identified or been made aware of (i)&#160;any significant deficiency or material weakness in the system of internal accounting controls utilized by any Acquired Entity or member of the Seller Group with respect to the Business, (ii)&#160;any fraud, whether or not material, that involves the management of the any Acquired Entity or member of the Seller Group with respect to the Business who have a role in the preparation of financial statements or the internal accounting controls utilized by any Acquired Entity or member of the Seller Group with respect to the Business or (iii)&#160;any claim or allegation regarding any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;No Acquired Entity or any member of the Seller Group with respect to the Business has any material Liability, other than (i)&#160;Liabilities provided for in the Financial Statements or disclosed in the notes thereto, (ii)&#160;Liabilities that have arisen in the ordinary course of business since September&#160;30, 2022, (iii)&#160;executory obligations under any Contract and (iv)&#160;Liabilities incurred in connection with this Agreement and the transactions contemplated hereby.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;All accounts and notes receivable reflected on the Financial Statements have arisen in the ordinary course of business, and represent legal, valid, binding and enforceable obligations owed to the Acquired Entities or the Business, subject only to consistently recorded reserves for bad debts set forth on the Financial Statements, and are not subject to any material contests, claims, counterclaims or setoffs.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth all Indebtedness of the Acquired Entities and all Indebtedness of the Seller Group with respect to the Transferred Assets, in each case, as of the date hereof. For each item of Indebtedness, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth the debtor, the Contract governing the Indebtedness (if any), the principal amount of the Indebtedness as of the date hereof, the creditor, the maturity date, and the collateral, if any, securing the Indebtedness (and all Contracts governing all related Liens, if any).</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Certain Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Since December&#160;31, 2021, until the date hereof, (a)&#160;other than this Agreement, the negotiation, preparation or execution hereof and the process conducted by Sellers and their Affiliates in connection therewith, Sellers and the Acquired Entities have conducted the Business in all material respects in the ordinary course of business consistent with past practice, (b)&#160;no Material Adverse Effect has occurred, and (c)&#160;none of the Acquired Entities or any member of the Seller Group has taken any action described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, if taken after the date hereof and prior to the Closing without the prior written consent of Buyer Parent, would violate such provision.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IP Rights&#59; Privacy&#59; Cybersecurity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists, for the Owned Intellectual Property, all unexpired (i)&#160;issued Patents and Patent applications (published or unpublished), (ii)&#160;Trademark registrations and applications, (iii)&#160;domain names, (iv)&#160;Copyright registrations and applications, and (v)&#160;material unregistered, common law Trademarks.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Acquired Entities or the applicable member of the Seller Group exclusively own and possess, all right, title and interest in and to all material Owned Intellectual Property, free and clear of all Liens (other than Permitted Liens). All registered or applied for Owned Intellectual Property is subsisting, valid and enforceable, and Seller Parent possesses all rights, privileges, licenses, and consents necessary to provide the Licensed Software (as defined in the Software License Agreement) to the Acquired Entities pursuant to the Software License Agreement.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Since December&#160;31, 2019, (i)&#160;neither the conduct of the Business nor the Owned Intellectual Property has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any material IP Rights owned by any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Person and (ii)&#160;to Sellers&#8217; Knowledge, no Person has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any material Owned Intellectual Property. There is no material Claim pending or, to Sellers&#8217; Knowledge, being threatened by or against any Acquired Entity or a member of the Seller Group with respect to the Business, alleging either of the foregoing clauses&#160;(i) or (ii).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;As of the date hereof, no Acquired Entity or member of the Seller Group with respect to the Business, is subject to any outstanding Order that restricts, in a manner material to the Business, its use, licensing, enforceability or registrability of any Owned Intellectual Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each Acquired Entity and member of the Seller Group with respect to the Business, uses commercially reasonable efforts to protect the confidentiality of its material Trade Secrets. Since December&#160;31, 2019, there has been no disclosure unauthorized by an Acquired Entity or applicable member of the Seller Group with respect to the Business of Trade Secrets owned by any Acquired Entity or applicable member of the Seller Group that has resulted in the loss of trade secrets material to the Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Owned Software is sufficient and operates for its intended purpose as necessary for the needs of the Business as currently conducted, in all material respects. There is no Malicious Code in any of the Owned Software or the IT Assets owned by or under the control of the Acquired Entities or any member of the Seller Group with respect to the Business. The Acquired Entities and members of the Seller Group with respect to the Business take commercially reasonable anti-virus measures, and neither Seller Parent, any member of the Seller Group nor their respective Representatives have introduced or allowed to be introduced any Malicious Code into the Licensed Software as defined in and licensed under the Software License Agreement.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Since December&#160;31, 2019, (i)&#160;no Source Code for any Owned Software has been disclosed or delivered by or on behalf of any Acquired Entity or member of the Seller Group with respect to the Business in any material respect, and (ii)&#160;no Acquired Entity or member of the Seller Group with respect to the Business has a present or contingent duty or obligation to disclose or deliver Source Code for Owned Software, to any escrow agent or other Person, other than vendors and service providers who have a need to access the Source Code for the purpose of hosting, support, or development of the Owned Software on behalf of the Business.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.5(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth a list of all Copyleft Software that has been incorporated into, linked to or integrated with material Owned Software and distributed to third parties. The applicable Acquired Entity or member of the Seller Group is in material compliance with the terms and conditions of all licenses for such Copyleft Software.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Since December&#160;31, 2019, each current and former employee and contractor of any Acquired Entity or member of the Seller Group who have developed or contributed to Owned Intellectual Property (including any Owned Software) material to the Business has entered into a valid, written agreement that protects the confidential information and Trade Secrets of the applicable Acquired Entity or member of the Seller Group and legally assigns to the applicable Acquired Entity or member of the Seller Group exclusive ownership of, including all IP Rights in and to, such Owned Intellectual Property, such that such Acquired </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Entity or member of the Seller Group has thereby obtained exclusive ownership of all IP Rights in such Owned Intellectual Property by operation of law or by valid assignment.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;The Acquired Entities or members of the Seller Group own, lease, license or otherwise have the legal right to use or have operated on its behalf, all material IT Assets and such material IT Assets are sufficient and operate as necessary for the needs of the Business as currently conducted. Since December&#160;31, 2019, (1)&#160;there has not been any material failure, malfunction, or other adverse event with respect to the IT Assets owned by or under the control of any Acquired Entity that has not been remedied or replaced in all material respects&#59; and (2)&#160;each Acquired Entity and member of the Seller Group has taken commercially reasonable actions to protect the security and integrity of the IT Assets and all data stored or contained therein or transmitted thereby (including all Personal Information).</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Neither this Agreement nor the consummation of the transactions contemplated by this Agreement, including the assignment to the Buyer Entities of any Contracts, will result in, to the extent material&#58; (i)&#160;any Acquired Entity granting to any third party any right to or with respect to Owned Intellectual Property&#59; or (ii)&#160;any Acquired Entity or a Buyer Entity being obligated to pay any royalties or other amounts to any Person in excess of those payable by the Acquired Entity prior to the Closing Date.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Each Acquired Entity and member of the Seller Group has maintained and currently maintains data security programs with standards materially consistent with Data Security Requirements with respect to the confidentiality and Processing of Personal Information. Since December&#160;31, 2019, each Acquired Entity has conducted and conducts risk assessments of the IT Assets. Since the Reference Date and except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.5(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule, no material Personal Information has been disclosed in breach or violation of, and each Acquired Entity and member of the Seller Group and the conduct of the Business are, and since December&#160;31, 2019, have been, in compliance with in all material respects, Data Security Requirements. Without limiting the generality of the foregoing, each Acquired Entity and member of the Seller Group with respect to the Business has taken commercially reasonable steps to implement and maintain, at a minimum, such physical, technical, administrative, electronic and procedural safeguards designed to maintain the security, integrity, and confidentiality of Personal Information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;No Acquired Entity nor any member of the Seller Group with respect to the Business distributes marketing communications to any data subject, except in accordance with the Privacy Laws or other Data Security Requirements. Each Acquired Entity has obtained all consents, authorizations, waivers of authorization or other permission pursuant to which any Acquired Entity Processed or Processes Personal Information as required under applicable Privacy Laws, except as would not be material to the Business (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Acquired Entity or member of the Seller Group with respect to the Business has a valid and legal right (whether contractually, by law, or otherwise) in all material respects to Process all Personal Information for the purpose such Personal Information was collected, used, or disclosed in connection with the Business. Neither the execution, delivery or performance of this Agreement, nor the consummation of any of the transactions contemplated by this Agreement, including any direct or indirect transfer of Personal Information resulting from such transactions, will violate any Privacy Policies or Privacy Consents in a material respect. No Acquired Entity or member of the Seller Group with respect to the Business has supplied or provided access to Personal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information Processed by it to a third party for remuneration or other consideration in violation of applicable Privacy Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;Since the Reference Date, no Acquired Entity or member of the Seller Group with respect to the Business has received any material notice, complaint, or inquiry, written or, to Sellers&#8217; Knowledge, oral, from any Governmental Authority or any other Person regarding such Acquired Entity&#8217;s or member of the Seller Group&#8217;s Processing of any Personal Information or its compliance with the Data Security Requirements. Since the Reference Date, (i)&#160;there have been no material security breaches with respect to any Owned Software, IT Assets, Personal Information or related data resulting in the loss of, unauthorized disclosure, access to or acquisition of such information or data, and (ii)&#160;no Acquired Entity or member of the Seller Group with respect to the Business has received any material notices or complaints from any Person concerning the foregoing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;No Acquired Entity owns in fee any real property, and no member of the Seller Group owns in fee any real property Related to the Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists the address of each parcel of real property that, as of the date hereof, is leased, subleased, sub-subleased, licensed or otherwise occupied by a member of the Seller Group pursuant to a Transferred Lease (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Leased Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Business Leased Real Property comprises all of the material real property primarily used in the operation of the Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as is not, and would not reasonably be expected to be, individually or in the aggregate, material to the Business, a member of the Seller Group has a valid leasehold interest in each Business Leased Real Property, free and clear of any Lien (other than Permitted Liens), and (ii) there are no leases, subleases, licenses, occupancy agreements, options, rights or other agreements or arrangements to which any member of the Seller Group or any Acquired Entity is a party granting to any Person the right to use, occupy or otherwise obtain a real property interest in all or any portion of the Business Leased Real Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists each Material Contract in effect on the date hereof. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any of the following Contracts (other than any Employee Plan (except with regard to clause&#160;(viii) below)) (x)&#160;to which any Acquired Entity is a party or by which it is bound or (y)&#160;that is a Transferred Contract&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any Contract for specialty management services with the top twenty-five (25) largest customers of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), measured by the amounts paid to the Business by customers during the twelve (12) month period ended September&#160;30, 2022&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any Contract with a vendor or supplier of the Business, under which the amount paid during the twelve (12) month period ended September&#160;30, 2022 was greater than $200,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(such vendors or suppliers, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any Contract that by its express terms prohibits the Business from engaging in any line of business or competing with any Person or otherwise conducting the Business in any geographic area or during any period of time&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any Contract granting most favored nation pricing, exclusive sales, distribution, marketing or other exclusive rights, rights of refusal, rights of first negotiation or similar rights and&#47;or terms to any Person&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any Contract under which the Business has incurred Indebtedness or is a guarantor with respect to Indebtedness&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any Contract providing for the acquisition or disposition by the Business of any material assets (whether by merger, sale of stock, sale of assets or otherwise) and under which the Business has material continuing obligations after the date hereof (excluding indemnification obligations under which there are no pending claims)&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any Collective Bargaining Agreement or any other Contract with a labor union or organization&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;any Contract for the employment of any individual providing for annual compensation in excess of $100,000 or which is not terminable upon notice of thirty (30) days or less without penalty or an obligation to pay severance or similar payments&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;any Contract with any Governmental Authority&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;any Contract under which marketing, sale, advertising or promotion services are provided to the Business&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;settlement Contracts with respect to any action before or by any Governmental Authority pursuant to which the Business or any Acquired Entity is subject to any outstanding material monetary or other obligations as of the date of this Agreement&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;any Contract that provides for indemnification any Person (other than Contracts entered into in the ordinary course of business)&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;Contracts with respect to any partnership, joint venture, strategic alliance or any sharing of revenues, profits, losses, costs or liabilities or similar arrangement&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;any lease for the Business Leased Real Property&#59;</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;any lease or similar agreement under which (a)&#160;the Business is lessee of, or holds or uses, any material machinery, equipment, vehicle or other material tangible personal property owned by a third party or (b)&#160;the Business is a lessor or sublessor of, or makes available for use by any third party, any material tangible personal property owned or leased by the Business&#59; and</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)&#160;&#160;&#160;&#160;any Contract under which the Business grants, or is granted, a license or right to use material IP Rights, other than (1)&#160;any non-exclusive license for generally </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">commercially available third-party technology or services that has a one-time acquisition cost of $100,000, or an annual fee of $25,000 or less (2)&#160;any nonexclusive license granted to customers, contractors, service providers or other vendors of the Business in the ordinary course of business or (3)&#160;any Contract in which grants of rights to IP are immaterial and incidental to and not the principal purpose of such Contract.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Material Contract is a valid and binding agreement of the Acquired Entity party thereto and each other party thereto and is in full force and effect. The Acquired Entity party to each Material Contract and each other party thereto has performed all material obligations required to be performed by it under such Material Contract, and no Acquired Entity or, to Sellers&#8217; Knowledge, any other party thereto is in breach of any Material Contract. To Sellers&#8217; Knowledge, no event has occurred that would, with or without notice or lapse of time or both, be a default or give rise to a termination right under any Material Contract. No Acquired Entity has given or received written or, to Sellers&#8217; Knowledge, oral notice of (i)&#160;any actual or alleged material breach of or material default under any Material Contract, or (ii)&#160;the intention of any party to a Material Contract to terminate such Material Contract.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Sellers have made available to the Buyer Entities complete and accurate (i)&#160;copies of each Material Contract that is in written form and (ii)&#160;descriptions of each Material Contract that is not in written form, in each case including any and all amendments and modifications thereof.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance With Laws&#59; Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Acquired Entity and member of the Seller Group with respect to the Business is, and since the Reference Date has been, in compliance in all material respects with all applicable Laws. Since the Reference Date, no notice has been received by any Acquired Entity alleging a material violation of, material liability for, material potential responsibility under, or regarding an investigation or audit related to, any Law. No event has occurred, and no condition or circumstance exists, that (with or without notice or lapse of time) constitutes or results directly or indirectly in a violation in any material respect by any Acquired Entity or member of the Seller Group with respect to the Business of any Law.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule contains a complete and accurate listing of all material Permits held by any Acquired Entity. All Permits that are necessary to own and operate the Business are and have been held by the Acquired Entities and are in full force and effect. Each Acquired Entity is, and has been since the Reference Date, in compliance in all material respects with the terms and conditions of such Permits, and no suspension, cancellation, termination, modification, revocation, forfeiture or nonrenewal of any such Permits is pending or, to Sellers&#8217; Knowledge, threatened. No event has occurred, and no condition or circumstance exists, that (with or without notice or lapse of time) would constitute or result directly or indirectly in the suspension, cancellation, termination, modification, revocation, forfeiture or nonrenewal of any such Permits.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims&#59; Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. There is no, and since the Reference Date, there has not been any, Claim pending or, to Sellers&#8217; Knowledge, being threatened against any Acquired Entity or member of the Seller Group with respect to the Business and, to Sellers&#8217; Knowledge, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">no facts or circumstances exist that could reasonably be expected to result in any such Claim pending or threatened against any Acquired Entity or member of the Seller Group with respect to the Business, and no Acquired Entity or member of the Seller Group with respect to the Business is, or since the Reference Date, has been subject to any Order, that, in each case, would, individually or in the aggregate, reasonably be expected to be material to the Business. There is no Claim that is an Assumed Liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For all taxable periods beginning on or after January&#160;1, 2017, for which the period of assessment or collection has not lapsed&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Each Acquired Entity has prepared (or caused to be prepared) and timely filed (taking into account applicable extensions) with the appropriate Governmental Authority all Tax Returns required to be filed by such Person prior to the date hereof, and all such filed Tax Returns are true, complete and accurate in all material respects and have been prepared in compliance in all material respects with applicable Laws.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;All material Taxes of the Acquired Entities due and payable (whether or not shown on any Tax Return) have been timely paid in full to the appropriate Governmental Authority, and where the payment of Tax is not yet due or is being contested in good faith pursuant to appropriate procedures, an adequate accrual in accordance with GAAP has been established in each case for all Taxes reflected in the Financial Statements.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Each Acquired Entity has complied in all material respects with all Laws related to the withholding of Taxes and has duly and properly withheld from amounts paid or owing to any Person, and paid over to appropriate Governmental Authorities, all material amounts required to be so withheld and paid over for all periods, and each Acquired Entity has complied with the associated reporting and recordkeeping requirements (including all IRS Forms&#160;W-2 and 1099 and any corresponding forms for applicable state and local Tax purposes) in all material respects.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;There is no material Tax Contest in progress, pending or, to Sellers&#8217; Knowledge, threatened with respect to any Taxes or Tax Returns of any Acquired Entity. In the past three (3) years, no written claim has been made by any Governmental Authority in a jurisdiction where an Acquired Entity does not file Tax Returns that such Acquired Entity is or may be subject to taxation by that jurisdiction. No Acquired Entity has commenced a voluntary disclosure proceeding in any state or local or non-U.S. jurisdiction that has not been fully resolved or settled.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;There are no Liens for Taxes upon any Transferred Assets or the assets of any Acquired Entity other than Permitted Liens.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No Acquired Entity has any Liability for a material amount of Taxes of any Person under Treasury Regulation Section&#160;1.1502-6 (or any similar provision of state, local or foreign Law), or as a transferee or successor or by contract, other than any Commercial Tax Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each Acquired Entity is and has at all times been resident for Tax purposes in its country of incorporation or formation and is not and has not at any time been a resident in any other country for any Tax purpose (including any arrangement for the avoidance of double taxation). No Acquired Entity is or has been subject to Tax in any country other than the country of its incorporation or formation by virtue of having a branch, permanent establishment, place of control or management or fixed place of business in that jurisdiction.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;No Acquired Entity has participated in, nor are any of them currently participating in, a &#8220;listed transaction&#8221; as defined under Section&#160;6706A(c)(1) of the Code and Treasury Regulations Section&#160;1.6011-4(b), or any transaction requiring disclosure under a corresponding or similar provision of state, local or foreign law.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;No Acquired Entity has consented to or is subject to any extension of time in which any Tax may be assessed or collected by any taxing authority, which extension is in effect as of the date hereof.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;No Acquired Entity has requested or been granted an extension of the time for filing any Tax Return to a date later than the Closing Date other than automatic extensions taken in accordance with past practice.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;No Acquired Entity has been a member of an Affiliated Group (other than a group of which any Acquired Entity or member of the Seller Group is or was the parent).</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;No Acquired Entity is a party to or bound by any Tax indemnity agreement, Tax allocation agreement or Tax sharing agreement, or similar agreement, except for any Commercial Tax Agreement or any agreement exclusively between or among the Acquired Entities.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;No Acquired Entity has requested, been the subject of or entered into any closing agreement, private letter ruling, technical advice memoranda or similar agreements or rulings related to any Taxes, in each case that will have continuing effect after the Closing.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;No Acquired Entity has executed any power of attorney with respect to any Tax, other than powers of attorney that are no longer in force.</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;No Acquired Entity has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution of stock purported or intended to qualify in whole or in part for Tax-free treatment under Sections&#160;355 or 361 of the Code.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;No Acquired Entity is required to include an item of income, or exclude an item of deduction, for any period after the Closing Date as a result of (i)&#160;an installment sale transaction occurring on or before the Closing governed by Section&#160;453 of the Code (or any similar provision of state, local or non-U.S. Law)&#59; (ii)&#160;a transaction occurring on or before the Closing reported as an open transaction for U.S. federal income Tax purposes (or any similar doctrine under state, local, or non-U.S. Law)&#59; (iii)&#160;any prepaid amounts received on or prior to the Closing Date&#59; (iv)&#160;a change in method of accounting with respect to a Pre-Closing Tax Period (or an impermissible method used in a Pre-Closing Tax Period)&#59; (v)&#160;an agreement entered into with any Governmental Authority (including a &#8220;closing agreement&#8221; under Section&#160;7121 of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Code or any &#8220;gain recognition agreements&#8221; entered into under Section&#160;367 of the Code) on or prior to the Closing Date or deferred revenue realized on or prior to the Closing Date&#59; or (vi)&#160;an election pursuant to Section&#160;965(h) of the Code. No Acquired Entity currently uses the cash method of accounting for income Tax purposes. No Acquired Entity has any &#8220;long-term contracts&#8221; that are subject to a method of accounting provided for in Section&#160;460 of the Code or has deferred any income pursuant to IRS Revenue Procedure 2004-34, Section&#160;451(c) of the Code, or any corresponding or similar provisions of Law.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;No Acquired Entity owns an interest in (i)&#160;any entity, plan or arrangement that is treated for income Tax purposes as a partnership, (ii)&#160;a &#8220;controlled foreign corporation&#8221; within the meaning of Section&#160;957 of the Code, or (iii)&#160;a &#8220;passive foreign investment corporation&#8221; within the meaning of Section&#160;1297 of the Code.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;No Acquired Entity has an &#8220;excess loss account&#8221; for U.S. federal or state income Tax purposes with respect to stock owned in any Subsidiary of such Acquired Entity.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;No material property or obligation of any Acquired Entity is currently escheatable to any Governmental Authority under any applicable escheatment or similar Law, and the Acquired Entities have made all filings required under applicable Law in respect thereof.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;No Acquired Entity (i)&#160;has made any election to defer any payroll Taxes under the CARES Act or Notice 2020-65 or (ii)&#160;has claimed any Tax credits under the CARES Act or the Families First Coronavirus Response Act.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;Each Acquired Entity has collected all material Taxes required to be collected in respect of sales of goods or the provision of services, and has remitted on a timely basis such amounts to the appropriate Governmental Authority, or has furnished properly completed exemption certificates and has retained all such records and supporting documents in the manner required by applicable sales and use Tax Laws and has filed all required Tax Returns and any reports related to unclaimed property.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;No Acquired Entity has any net operating loss or other Tax attribute that is currently subject to limitation under Sections&#160;382, 383 or 384 of the Code.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists each Business Benefit Plan and identifies each such Business Benefit Plan as either a Company Employee Plan or a Seller Employee Plan. For each material Seller Employee Plan, such Seller has provided or made available to the Buyer Entities copies of the plan document (including all amendments thereto) with respect to such Seller Employee Plan, or a summary of the material terms of such Seller Employee Plan. For each Company Employee Plan, Sellers have made available to the Buyer Entities copies of each of the following documents, as applicable&#58; (i)&#160;all documents pursuant to which the Company Employee Plan is maintained, funded and administered (including, without limitation, the plan and trust documents, any amendments thereto, and any insurance contracts or service provider agreements and any amendments thereto)&#59; (ii)&#160;a copy of the most recent summary plan description and any current summary of material modifications&#59; (iii)&#160;a copy of the three most recent annual reports and Forms&#160;5500&#59; (iv)&#160;the most recent determination letter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">received from the IRS&#59; (v)&#160;nondiscrimination testing results for the last 3 plan years, (vi)&#160;any correspondence from the IRS, the Department of Labor or the Pension Benefit Guaranty Corporation regarding a Business Benefit Plan&#59; and (vii)&#160;the most recent actuarial report and financial statements related thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;No Business Benefit Plan is (i)&#160;a &#8220;multiemployer plan,&#8221; as such term is defined in Section&#160;3(37) of ERISA, (ii)&#160;a plan that is subject to Title&#160;IV of ERISA, Sections&#160;302 or 303 of ERISA or Sections&#160;412 or 436 of the Code, (iii)&#160;a multiple employer plan as defined in Section&#160;413(c) of the Code, or (iv)&#160;is a &#8220;multiple employer welfare arrangement&#8221; as such term is defined in Section&#160;3(40) of ERISA, and neither any the Acquired Entities, Sellers or any trade or business, whether or not incorporated, that together with Sellers or any Acquired Entities would be deemed a &#8220;single employer&#8221; within the meaning of Section&#160;4001(b) of ERISA have, in the previous six years, maintained, contributed to, or been required to contribute to or otherwise have had any Liability with regards to any Business Benefit Plan or other agreement described in clauses&#160;(i), (ii), (iii) or (iv).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as would not reasonably be expected to result in material liability to the Acquired Entities (taken as a whole) or the Buyer Entities&#58; (i)&#160;each Business Benefit Plan has been operated and administered in accordance with its terms and applicable Law, including ERISA and the Code&#59; (ii)&#160;there are no Claims (other than routine claims for benefits in the ordinary course of business) that are pending, or to Sellers&#8217; Knowledge, threatened against any Company Employee Plan. Sellers have timely paid all contributions, premiums and expenses payable to or in respect of each Business Benefit Plan under the terms thereof and in accordance with applicable legal requirements&#59; and (iii)&#160;neither Sellers nor the Acquired Entities nor, to Sellers&#8217; Knowledge, any other Person, has engaged in any transaction with respect to any Business Benefit Plan that would be reasonably likely to subject the any Acquired Entity or the Buyer Entities to any Tax or penalty (civil or otherwise) imposed by ERISA, the Code or other applicable legal requirements. Each Business Benefit Plan that is a &#8220;nonqualified deferred compensation plan&#8221; (within the meaning of Section&#160;409A(d)(1) of the Code) has been operated in material compliance with Section&#160;409A of the Code, Treasury Regulations issued under Section&#160;409A of the Code, and any subsequent guidance related thereto, and no additional tax under Section&#160;409A(a)(1)(B) of the Code has been or is reasonably expected to be incurred by a Business Employee in respect of any such Business Benefit Plan, and no employee of any Acquired Entity is entitled to any gross-up or otherwise entitled to indemnification by the Acquired Entities or the Sellers for any violation of Section&#160;409A of the Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No material excise tax or penalty under the ACA including Section&#160;4980D and 4980H of the Code, is outstanding, has accrued, has arisen or could arise with respect to any period prior to the Closing, with respect to any Acquired Entities or any Business Benefit Plan nor has the Seller or any Acquired Entity filed or been required to file with the IRS a Form&#160;8928 in order to self-report any health plan violations with respect to Business Benefit Plans which are subject to excise taxes under applicable provisions of the Code, and, to the Sellers&#8217; Knowledge, there are no facts or circumstances that would reasonably be expected to result in the any such Form&#160;8928 with respect to Business Benefit Plans to be filed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each Business Benefit Plan that is intended to be &#8220;qualified&#8221; within the meaning of Section&#160;401(a) of the Code has received a favorable determination letter or opinion </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">letter from the IRS as to its qualification and, to Sellers&#8217; Knowledge, no event has occurred that would reasonably be expected to result in disqualification of such Business Benefit Plan.</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Neither the execution hereof nor the consummation of the transactions contemplated hereby (either alone or together with any other event) shall (i)&#160;entitle any current or former director, manager, officer, or employee of an Acquired Entity or any Business Employee to any compensatory payment or benefit, (ii)&#160;accelerate the time of payment or vesting of any compensation or benefits for any such director, manager, officer or employee of any Acquired Entity or any Business Employee, (iii)&#160;require the funding of any compensation or benefits (through a grantor trust or otherwise) for any such director, manager, officer or employee of any Acquired Entity or any Business Employee, or (iv)&#160;result in the payment of any amount that would, individually or in combination with any other payment, not be deductible as a result of Section&#160;280G of the Code.</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;No Business Benefit Plan that is a &#8220;welfare benefit plan&#8221; within the meaning of Section&#160;3(1) of ERISA provides benefits with respect to Business Employees or any current or former employee, director or officer of any Acquired Entities beyond the end of the month in which a retirement or other termination of service occurs, other than coverage mandated by applicable Law or benefits the full costs of which are borne by the Business Employee or his or her beneficiary.</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.11(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists each Specified Business Employee as of the date hereof who holds any Ultimate Parent equity or equity-based awards (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ultimate Parent Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that, if such Specified Business Employee becomes a Transferred Employee, such Specified Business Employee would receive equity awards of the Buyer Entities in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect thereof and, in respect of each such Ultimate Parent Equity Award held as of the date hereof, (i)&#160;the type of award and number of shares of Ultimate Parent common stock related thereto, (ii)&#160;the date of grant and service-based vesting terms, (iii)&#160;date of retirement eligibility and (iv)&#160;exercise price (as applicable) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Award Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;There are no pending or, to Sellers&#8217; Knowledge, threatened, Claims that have been asserted related to any Business Benefit Plan by any employee or beneficiary covered under any Business Benefit Plan or otherwise involving any Employee Plan (other than routine claims for benefits). No examination, voluntary correction proceeding or audit of any Business Benefit Plan by any Governmental Authority is currently in progress or, to Sellers&#8217; Knowledge, threatened. No Acquired Entity is a party to any agreement or understanding with the Pension Benefit Guaranty Corporation, the IRS or the Department of Labor.</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Labor Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of the date hereof, (i)&#160;none of the Acquired Entities or any member of the Seller Group with respect to the Business is a party to or subject to, or is currently negotiating in connection with entering into, any Collective Bargaining Agreement, and to Sellers&#8217; Knowledge, in the three (3) year period prior to the date hereof, there has not been any organizational campaign, petition or other unionization activity seeking recognition of a collective bargaining unit related to any Business Employee, and (ii) (1)&#160;there is no material </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">labor strike, slowdown, stoppage, picketing, interruption of work or lockout pending or, to Sellers&#8217; Knowledge, threatened in writing against any Acquired Entity or the Business and (2)&#160;there are no unfair labor practice complaints pending or, to Sellers&#8217; Knowledge, threatened in writing against any Acquired Entity before any Governmental Authority.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule lists each Business Employee, setting forth for each such Person as of the Closing Date&#58; name or employee identification number, title, work location, employer, annual salary or hourly rate (or other compensation rate, as applicable), commission, bonus or other incentive-based compensation, vacation or paid time off accrual, hire date and designation as either exempt or non-exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act and applicable state Laws. Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule no current officer or key employee of the Acquired Entities or the Seller Group with respect to the Business has given written or, to Sellers&#8217; Knowledge, oral notice of his or her intent to terminate such employment.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;There have not been any &#8220;employment losses&#8221; within the meaning of the Worker Adjustment and Retraining Notification Act of 1988, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within the past six (6) months impacting the Business Employees. The Acquired Entities and the members of the Seller Group with respect to the Business have not implemented any &#8220;mass layoff&#8221; or &#8220;plant closing&#8221; (as those terms are defined by the WARN Act or any similar applicable state Law) in the past three (3) years, nor is any such action currently planned.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;There are no written or, to Sellers&#8217; Knowledge, oral internal complaints or reports by any current or former employee, consultant, or independent contractor alleging violations of the anti-harassment or equal employment opportunity policies of the Acquired Entities or the Business by any Business Employees that are pending or under investigation, nor have there been any such written or, to Sellers&#8217; Knowledge, oral complaints or reports, or settlements related to any such complaints or reports, in the past three (3) years.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;All Business Employees are working in the United States in compliance in all material respects with all applicable Laws related to immigration and naturalization.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Acquired Entities and the Seller Group with respect to the Business Employees and the Business are and have been at all times during the past three (3) years in compliance in all material respects with all applicable Laws respecting employment, employment practices, terms and conditions of employment, applicant and employee background checks, immigration and verification of employment eligibility (including Form&#160;I-9 and E-Verify requirements), discrimination and retaliation, employee leave, classification of workers as employees and independent contractors, classification of employees as exempt or non-exempt under applicable wage and hour Laws, privacy, employee representation, employee safety and health, overtime, wages and hours, collective negotiations, working time, social security, lending of personnel, temporary and fixed term employment, fair employment practices, reasonable accommodation, disability rights or benefits, payment of compensation, child labor, hiring, promotion and termination of employees, meal and break periods, plant closings or mass layoffs as defined by the WARN Act or any similar state statute, workers&#8217; compensation, the withholding of payroll Taxes and contract termination. There are no material Claims pending or, to the Sellers&#8217; Knowledge, threatened against the Acquired Entities or any member of the Seller </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Group with respect to the Business related to any of the matters described in the previous sentence, nor have there been any such material Claims pending or, to the Sellers&#8217; Knowledge, threatened against the Acquired Entities or any member of the Seller Group with respect to the business in the past three (3) years.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Acquired Entity and member of the Seller Group with respect to the Business is, and since the Reference Date, has been, in compliance in all material respects with all applicable Environmental Laws. Each Acquired Entity and member of the Seller Group with respect to the Business holds all material Environmental Permits necessary for the lawful conduct of the Business as currently being conducted and all such Permits are valid and in full force and effect. There is no, and since the Reference Date, there has not been, any material Environmental Claim pending or, to Sellers&#8217; Knowledge, threatened against any Acquired Entity or any member of the Seller Group with respect to the Business. There has been no material Release of Hazardous Materials by any Acquired Entity or member of the Seller Group with respect to the Business at any of the properties that are currently or formerly owned, leased, operated or used by any Acquired Entity or member of the Seller Group with respect to the Business or at any properties for which any Acquired Entity or member of the Seller Group with respect to the Business has assumed liability for any Release of Hazardous Materials.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Health Care Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule, (i)&#160;each Acquired Entity and member of the Seller Group with respect to the Business is, and has been since the Reference Date, in compliance in all material respects with all Health Care Laws, (ii)&#160;since the Reference Date, the Acquired Entities and members of the Seller Group with respect to the Business have not received any written notice or Claim issued by a Governmental Authority that alleges or asserts that an Acquired Entity or applicable member of the Seller Group has violated any Health Care Laws (iii)&#160;since the Reference Date, the Acquired Entities and members of the Seller Group with respect to the Business have not entered into any written consent decree, judgment, corporate integrity agreement, corrective action plan, deferred prosecution agreement, or other agreement or settlement with any Governmental Authority related to any actual or alleged violation of any Health Care Law and (iv)&#160;since the Reference Date, the Acquired Entities and members of the Seller Group with respect to the Business have made all Filings that they were required to file pursuant to any Health Care Law and all such Filings were correct and in compliance with Health Care Laws when filed (or were timely corrected in or supplemented by a subsequent filing). Neither the Acquired Entities or the members of the Seller Group with respect to the Business, nor to Sellers&#8217; Knowledge, any of their respective Representatives has been charged with, convicted of or entered a plea of guilty or nolo contendere to any criminal or civil offense related to the delivery of any item or service under a Governmental Health Care Program or any other violation of Health Care Laws. No Acquired Entity or member of the Seller Group with respect to the Business is a defendant or named party in any qui tam&#47;False Claims Act litigation.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Neither the Acquired Entities, any member of the Seller Group with respect to the Business, nor any of their respective Representatives are or have been since the Reference Date excluded, precluded, debarred, suspended from or otherwise excluded from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contracting with any Governmental Authority or from participation in, any Governmental Health Care Program or are subject to a Claim, investigation or proceeding by any Governmental Authority that could result in such suspension, exclusion, preclusion or debarment, and no current or former Representative of the Acquired Entities or member of the Seller Group with respect to the Business has been convicted of a criminal offense related to any Health Care Law during their employ or engagement (as applicable) with the Acquired Entities or applicable member of the Seller Group or any of their respective Affiliates in connection with services performed for or on behalf of the Acquired Entities or applicable member of the Seller Group.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Since the Reference Date, neither the Acquired Entities, any member of the Seller Group with respect to the Business nor any of their respective Representatives acting in such capacity (i)&#160;have been assessed a civil monetary penalty under Section&#160;1128A of the Social Security Act, (ii)&#160;have been convicted of any criminal offense related to the delivery of any item or service under any Governmental Health Care Program or (iii)&#160;have knowingly made an untrue or fraudulent statement to any Governmental Authority or agent thereof or knowingly failed to disclose a fact required to be disclosed to a Governmental Authority or agent thereof.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Acquired Entity and member of the Seller Group with respect to the Business has implemented policies and procedures reasonably designed to assure that the Acquired Entity or applicable member of the Seller Group is in compliance in all material respects with all Health Care Laws. Each Acquired Entity and member of the Seller Group has established and maintains a corporate compliance program that reflects the material elements of an effective corporate compliance program as set forth in guidance issued by the U.S. Department of Health and Human Services&#8217; Office of Inspector General.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Neither the Acquired Entities, any member of the Seller Group with respect to the Business nor any of their respective Representatives have, directly or indirectly, made or offered to make, or solicited or received, any contribution, gift, bribe, rebate, payoff, influence payment, kickback or inducement to any Person, or entered into any similar financial arrangement, regardless of form, in each case, in material violation of any applicable Health Care Law.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;No Person with which any Acquired Entity or any member of the Seller Group with respect to the Business has a contract is, or has been since the Reference Date, the subject of an audit, investigation, or material recoupment demand or request by any Governmental Authority related to any contract between such Person and such Acquired Entity or member of the Seller Group, or related to any charges, bills or records submitted which reflect the financial or managerial relationship between such Person and Acquired Entity or member of the Seller Group, or related to the charges made by such Acquired Entity or member of the Seller Group to any such Person.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Acquired Entities and members of the Seller Group with respect to the Business do not directly or indirectly bill, have not billed or indirectly billed, and have not submitted or caused the submission of claims for payment to, any Government Health Care Program or any other health insurance program or plan, including commercial and non-governmental medical insurance plans.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The Acquired Entities and members of the Seller Group with respect to the Business are and at all times since the Reference Date have been in compliance in all material </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respects with the applicable requirements of HIPAA. When acting as a Business Associate (as defined at 45 CFR &#167;&#160;160.103), each Acquired Entity and member of the Seller Group with respect to the Business has in effect with each entity on whose behalf such Acquired Entity or member of the Seller Group receives, creates, or transmits Protected Health Information (as defined at 45 CFR &#167;&#160;160.103) a Business Associate agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Customer BA Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Acquired Entities and applicable members of the Seller Group with respect to the Business are, and have been since the Reference Date, in compliance in all material respects with the Customer BA Agreements. Each Acquired Entity and member of the Seller Group with respect to the Business has in effect with each entity acting as a Business Associate of such Acquired Entity and member of the Seller Group with respect to the Business an agreement that materially satisfies all of the requirements of 45 CFR &#167;&#167;&#160;164.504(e) and 164.314(a). To the extent the Acquired Entities or, with respect to the Business, any member of the Seller Group create, disclose, transfer, sell and&#47;or assign any information derived from Protected Health Information of the Business that has been &#8220;de-identified&#8221; (in accordance with the requirements of 45 C.F.R. &#167;&#160;164.514(b)), each such Acquired Entity or member of the Seller Group has obtained all rights necessary for such creation, disclosure, transfer, sale and&#47;or assignment. The Acquired Entities and members of the Seller Group with respect to the Business have not received any written complaint or notice of investigation from any Governmental Authority regarding an Acquired Entity&#8217;s or member of the Seller Group&#8217;s or any of their respective Business Associates&#8217; uses or disclosures of, or security practices or security incidents regarding, Protected Health Information. There have not been any Security Incidents or Breaches (as these terms are defined in HIPAA) of Protected Health Information involving the Acquired Entities or the members of the Seller Group with respect to the Business and their respective Business Associates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each insurance policy maintained by the Seller Group or any Acquired Entity and under which any of the assets or properties of the Acquired Entities or any of the Transferred Assets are covered is legal, valid, binding and enforceable and in full force and effect, and the Acquired Entities or applicable member of the Seller Group have paid or accrued (to the extent not due and payable) all premiums due, and have otherwise performed in all material respects all of their obligations under such insurance policies and are not in material breach or material default with respect to their obligations under such insurance policies. There are no material claims pending with respect to the Business which are covered under any such insurance policy and no material pending claims have been denied or are subject to an insurer&#8217;s reservation of rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Customers and Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth a complete and accurate list of the Material Customers and Material Suppliers. Since January&#160;1, 2021, no Material Customer or Material Supplier has had any material dispute with any Acquired Entity or member of the Seller Group with respect to the Business, made or threatened to make any indemnification claim against any Acquired Entity or member of the Seller Group with respect to the Business, cancelled, terminated or otherwise materially altered (including any material reduction in the rate or amount of sales or purchases or material increase in the prices charged or paid, as the case may be) or notified any Acquired Entity or member of the Seller Group with respect to the Business of any intention to do any of the foregoing or otherwise threatened in writing to cancel, terminate or materially alter (including any material reduction in the rate or amount of sales or purchases or material increase </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the prices charged or paid, as the case may be) its relationship with any Acquired Entity or member of the Seller Group with respect to the Business.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Directors and Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth a complete and accurate list of the directors and officers of each Acquired Entity as of the date hereof.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bank Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule sets forth the name of each bank, safe deposit company or other financial institution in which any Acquired Entity has an account, lock box or safe deposit box used or held for use in connection with the Business, or in which cash or cash equivalents of any Acquired Entity are otherwise held, in each case, as of the date hereof.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. None of the Acquired Entities, any member of the Seller Group with respect to the Business, any director, officer, agent, employee or representative of the Acquired Entities or any member of the Seller Group with respect to the Business, nor, to Sellers&#8217; Knowledge, any other Person associated with or acting for or on behalf of the Business, has, since the Reference Date&#58; (a)&#160;made, authorized, offered or promised to make any unlawful payment or transfer of anything of value, whether money, property or services, directly or indirectly through a third party, to any officer, employee or representative of a foreign government or any department, agency or instrumentality thereof, political party, political campaign or public international organization, in violation in any material respect of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any applicable Law of similar effect&#59; or (b)&#160;otherwise taken any action which would cause any Acquired Entity or member of the Seller Group with respect to the Business to be in violation in any material respect of the FCPA or any applicable Law of similar effect.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Acquired Entity is a party to any Affiliate Contract. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;any Contract, commitment or transaction between an Acquired Entity, on the one hand, and any member of the Seller Group, or any officer, director, stockholder or Affiliate of a member of the Seller Group, on the other hand, and (ii)&#160;any Transferred Contract that, following the transfer to Buyer Entities or any Acquired Entity, would be between the Buyer Entities or an Acquired Entity, on the one hand, and any member of the Seller Group, or any officer, director, stockholder or affiliate of a member of the Seller Group, on the other hand, other than (A)&#160;employment or service Contracts with employees, individual consultants or individual independent contractors in the ordinary course of business and (B)&#160;any Contract entered into in connection with this Agreement or the transactions contemplated hereby.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Acquired Entities own, license or hold a valid leasehold interest in or to all of their respective material assets, in each case, free and clear of any Lien (other than any Permitted Lien). Except as is not, and would not reasonably be expected to be, individually or in the aggregate, material to the Business, all of the tangible assets of the Acquired Entities and Transferred Assets are in good condition and repair (ordinary wear and tear excepted). Except for the Excluded Assets and any &#8220;Excluded Services&#8221; (as defined in the Transition Services Agreement), the assets of the Acquired Entities and the Transferred Assets, together with the services under the Transition Services Agreement (without regard to any Excluded Services (as defined therein)) and the license under the Software License Agreement, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">collectively constitute all of the material assets, properties, rights, and interests used in the operation of the Business or necessary to enable the Business to conduct its business in all material respects.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No broker, finder or investment banker is entitled to any brokerage, finder&#8217;s or other similar fee or commission in connection with the transactions contemplated hereby based on arrangements made by or on behalf of any Acquired Entity and for which the Buyer Entities or any Acquired Entity would be liable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Acquired Entity or member of the Seller Group has obtained any financial aid or other assistance or relief under, any federal, state or local programs adopted in response to COVID-19, including the CARES Act, the Enhancement Act, the Federal Reserve Main Street Lending Program and any similar non-US Law or program (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Relief Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). With respect to any assistance or relief obtained under any COVID-19 Relief Program, the Acquired Entities and the members of the Seller Group have complied in all material respects with the requirements of the applicable program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;3.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sellers have been advised and understand and acknowledge that the Buyer Parent Shares and Earnout Shares have not been registered in accordance with the Securities Act or the &#8220;blue sky&#8221; Laws of any jurisdiction and may be resold only if registered in accordance with the provisions of the Securities Act or if an exemption from registration is available, unless neither such registration nor such an exemption is required by applicable Law. Sellers have such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of the purchase of the Buyer Parent Shares and Earnout Shares. Sellers are able to bear the economic risk of an investment in the Buyer Parent Shares and Earnout Shares and are able to afford a complete loss of such investment. Each Seller is an &#8220;accredited investor,&#8221; as defined in Rule&#160;501 under the Securities Act.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>REPRESENTATIONS AND WARRANTIES OF THE BUYER ENTITIES</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as disclosed in Buyer Parent&#8217;s (x)&#160;annual report on Form&#160;10-K for the fiscal year ended December&#160;31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Buyer 10-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or (y)&#160;quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K filed from and after the date of the filing of the 2021 Buyer 10-K to the date prior to the date hereof (collectively, with the 2021 Buyer 10-K, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Signing Buyer Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (excluding, in each case, any risk factor disclosure that is contained solely in any &#8220;Risk Factors&#8221; section of any such Pre-Signing Buyer Report or any disclosure in any &#8220;qualitative and quantitative disclosure about market risk&#8221; section, any &#8220;forward-looking statements&#8221; disclaimer or any other disclosure included in any such Pre-Signing Buyer Report that is predictive or forward-looking in nature), the Buyer Entities represent and warrant to Sellers as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Due Organization and Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Buyer Entities is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation and, except as would not result in a Buyer Material Adverse Effect, has all requisite Entity power and authority to own, lease and operate its assets and to conduct its businesses in the manner in which its businesses are currently being conducted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority&#59; Binding Nature of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Buyer Entities has the requisite power and authority to execute and deliver, and to perform its covenants and agreements under, this Agreement. The execution and delivery hereof by the Buyer Entities and the performance by each of the Buyer Entities of their covenants and agreements hereunder have been duly and validly authorized by all necessary Entity action on the part of such Buyer Entity. This Agreement has been duly and validly executed and delivered by the Buyer Entities and, assuming the due authorization, execution and delivery hereof by the other Parties, is a legal, valid and binding obligation of the Buyer Entities, enforceable against the Buyer Entities in accordance with its terms, subject to the Bankruptcy and Equity Exceptions. No Consent of the stockholders of Buyer Parent or the holder of any Equity Interests in any member of the Buyer Group is necessary or required under Buyer&#8217;s Organizational Documents, applicable Law or the rules and regulations of the New York Stock Exchange (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NYSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in order for Buyer Entities to execute and deliver, and to perform its covenants and agreements under, this Agreement.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Noncontravention&#59; Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Buyer Entities&#8217; execution and delivery hereof do not, and the Buyer Entities&#8217; performance of its covenants and agreements hereunder shall not, (i)&#160;materially violate the Organizational Documents of Buyer, (ii)&#160;subject to making or obtaining, as applicable, the Consents and Filings referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, violate any Law or (iii) (1)&#160;require any Consent of, or any Filing to or with, any Person that is not a Governmental Authority under, or (2)&#160;result in any breach of or, with or without notice or lapse of time or both, be a default under or give rise to any right of termination, cancellation, amendment or acceleration of, or result in the creation of a Lien on any asset of a Buyer Entity under, any Contract to which a Buyer Entity is a party or by which a Buyer Entity or its assets are bound, except, in the case of the foregoing clauses&#160;(ii) and (iii), as would not result in a Buyer Material Adverse Effect.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Buyer Entities&#8217; execution and delivery hereof do not, and Buyer Entities&#8217; performance of its covenants and agreements hereunder shall not, require Buyer Entities to make any Filing with or to, or to obtain any Consent from, any Governmental Authority, other than the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the HSR Act Clearance and Filings under the HSR Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Form&#160;D Approval&#59; and</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Required Filings.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The authorized capital stock of Buyer Parent is (a)&#160;50,000,000 shares of preferred stock, par value $0.01 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer Parent Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (b)&#160;850,000,000 shares of common stock, divided into 750,000,000 shares of Class A common stock, par value $0.01 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer Parent Class A Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and 100,000,000 shares of Class B common stock, par value $0.01 per share, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer Parent Class B Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with Class A Common Stock, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer Parent Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). All of the issued and outstanding shares of Buyer Parent Common Stock have been duly authorized and validly issued and are fully paid and nonassessable. As of the date hereof, there are (i)&#160;zero (0) shares of Buyer Parent Preferred Stock issued and outstanding, (ii)&#160;101,302,600 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shares of Buyer Parent Class A Common Stock issued and outstanding, and (iii)&#160;zero (0) shares of Buyer Parent Class B Common Stock issued and outstanding (the foregoing clauses&#160;(ii) and (iii), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outstanding Buyer Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). As of the date hereof, other than the Outstanding Buyer Common Shares, there are no outstanding Equity Interests in Buyer Parent. Buyer is a wholly owned subsidiary of Buyer Parent.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Documents&#59; Financial Statements&#59; Related-Party Transactions&#59; Undisclosed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Buyer Parent has filed with or furnished to the SEC all reports, schedules, forms, statements, registration statements, prospectuses and other documents (including all exhibits and financial statements required to be filed or furnished therewith and any other document or information required to be incorporated therein) required by the Securities Act or the Exchange Act to be filed or furnished by Buyer Parent with the SEC since December&#160;31, 2019 (collectively, together with any documents filed with or furnished to the SEC during such period by Buyer Parent on a voluntary basis, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer SEC Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). As of its respective date, or, if amended prior to the date hereof, as of the date of the last such amendment, each Buyer SEC Document complied when filed or furnished (or, if applicable, when amended) in all material respects with the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, and none of the Buyer SEC Documents when filed or furnished (or, in the case of a registration statement filed under the Securities Act, at the time it was declared effective or subsequently amended) contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. No Subsidiary of Buyer Parent is, or has at any time since December&#160;31, 2019, been, subject to the periodic reporting requirements of the Exchange Act or is or has been otherwise required to file any report, schedule, form, statement, registration statement, prospectus or other document with the SEC.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The consolidated financial statements of Buyer Parent included in the Buyer SEC Documents (including, in each case, any notes or schedules thereto) and all related compilations, reviews and other reports issued by Buyer&#8217;s accountants with respect thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer SEC Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (i)&#160;have been prepared from the books and records of the members of the Buyer Group, which have been maintained in accordance with GAAP, (ii)&#160;were prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto and except, in the case of the unaudited interim financial statements, as may be permitted by Form&#160;10-Q and Regulation&#160;S-X under the Securities Act) and (iii)&#160;present fairly, in all material respects, the Buyer Group&#8217;s consolidated financial position as at the respective dates thereof and the Buyer Group&#8217;s consolidated results of operations and, where included, consolidated stockholders&#8217; equity and consolidated cash flows for the respective periods indicated, in each case, in conformity with GAAP (except as may be indicated in the notes thereto and except, in the case of the unaudited interim financial statements, as may be permitted by Form&#160;10-Q and Regulation&#160;S-X under the Securities Act). Pursuant to Regulation&#160;S-X under the Securities Act, as of the date hereof (except with regard to the transactions contemplated hereby), Buyer Parent is not required and would not be required upon the passage of any grace period or upon completion of any pending transaction to file any financial statements, audited, unaudited, pro forma or otherwise, with the SEC in order for a registration statement filed by Buyer Parent to be declared effective. Except as required by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAAP and disclosed in the Buyer SEC Documents, between December&#160;31, 2019, and the date hereof, Buyer Parent has not made or adopted any material change in its accounting methods, practices or policies.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Buyer Parent is, and since December&#160;31, 2019, has been, in compliance in all material respects with the applicable (i)&#160;provisions of the Sarbanes-Oxley Act and (ii)&#160;listing and corporate governance rules and regulations of NYSE. The Buyer Parent Class A Common Stock is listed on the NYSE.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Buyer Parent has established and maintains a system of internal control over financial reporting (within the meaning of Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that is designed to provide reasonable assurance about the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures that&#160;(i)&#160;require the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Buyer Group, (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Buyer Group are being made only in accordance with appropriate authorizations of Buyer&#8217;s management and Buyer&#8217;s board of directors and (iii)&#160;provide reasonable assurance about prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Buyer Group. Buyer Parent has established and maintains a system of disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed by Buyer Parent in the Buyer SEC Documents is recorded and reported within the time periods specified in the SEC&#8217;s rules and forms and that all such information is communicated to Buyer&#8217;s management as appropriate to allow timely decisions about required disclosure and to make the certifications required pursuant to&#160;Sections&#160;302 and&#160;906 of the Sarbanes-Oxley Act. Buyer Parent has disclosed to Buyer&#8217;s outside auditors and the audit committee of Buyer&#8217;s board of directors&#160;any (1)&#160;significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting (as defined in Rule&#160;13a-15(f) under the Exchange Act) which are reasonably likely to adversely affect Buyer&#8217;s ability to record, process, summarize and report financial information and (2)&#160;any fraud, whether or not material, that involves Buyer&#8217;s management or other employees who have a significant role in Buyer&#8217;s internal control over financial reporting. As of the date hereof, there are no material outstanding or unresolved comments in comment letters received from the SEC&#8217;s staff related to any Buyer SEC Documents. As of the date hereof, to Buyer&#8217;s Knowledge, none of the Buyer SEC Documents is the subject of ongoing SEC review, and there are no formal internal investigations, any formal SEC inquiries or investigations or other inquiries or investigations by Governmental Authorities that are pending or threatened, in each case under this sentence, related to any accounting practices of any member of the Buyer Group.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;No member of the Buyer Group has any Liability, except (i)&#160;as reflected or specifically reserved against in the most recent audited balance sheet included in the Buyer SEC Financial Statements, (ii)&#160;for any liability incurred in the ordinary course of business since the date of the most recent audited balance sheet included in the Buyer SEC Financial Statements, (iii)&#160;liabilities or obligations arising out of this Agreement or the transactions contemplated hereby and (iv)&#160;for any liability that is not and would not reasonably be expected to result in, individually or in the aggregate, a Buyer Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance With Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each member of the Buyer Group is, and since December&#160;31, 2019, has been, in compliance with all applicable Laws except for instances of noncompliance that, individually and in the aggregate, have not had and would not reasonably be expected to have a Buyer Material Adverse Effect.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Certain Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Since December&#160;31, 2021, until the date hereof, (a)&#160;other than this Agreement, the negotiation, preparation or execution hereof, the Buyer Group has conducted their respective businesses in all material respects in the ordinary course of business and (b)&#160;no Buyer Material Adverse Effect has occurred.</font></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims&#59; Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. There is no Claim pending or, to Buyer&#8217;s actual knowledge, being threatened against any member of the Buyer Group, and no member of the Buyer Group is subject to any Order, that, in each case, would, individually or in the aggregate, reasonably be expected to have a Buyer Material Adverse Effect.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. None of the members of the Buyer Group, any director, officer, agent, employee or representative of any member of the Buyer Group, nor, to Buyer&#8217;s actual knowledge, any other Person associated with or acting for or on behalf of the Buyer Group, has, since December&#160;31, 2019&#58; (a)&#160;made, authorized, offered or promised to make any unlawful payment or transfer of anything of value, whether money, property or services, directly or indirectly through a third party, to any officer, employee or representative of a foreign government or any department, agency or instrumentality thereof, political party, political campaign or public international organization, in violation in any material respect of the FCPA or any applicable Law of similar effect&#59; or (b)&#160;otherwise taken any action which would cause any member of the Buyer Group to be in violation in any material respect of the FCPA or any applicable Law of similar effect.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Immediately after giving effect to the Acquisition and the Liabilities Assumption (including any financings to be undertaken in connection therewith) and assuming the accuracy of Sellers&#8217; representations and warranties set forth in this Agreement, each Acquired Entity shall be Solvent. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for any Person and as of any date of determination, that (a)&#160;the amount of the &#8220;present fair saleable value&#8221; of the assets of such Person shall, as of such date, exceed the amount of all &#8220;liabilities of such Person, contingent or otherwise,&#8221; as of such date, as such quoted terms are generally determined in accordance with applicable federal Laws governing determinations of the insolvency of debtors, (b)&#160;the present fair saleable value of the assets of such Person shall, as of such date, be greater than the amount that shall be required to pay the liability of such Person on its indebtedness as its indebtedness becomes absolute and matured, (c)&#160;such Person shall not have, as of such date, an unreasonably small amount of capital with which to conduct its businesses and (d)&#160;such Person shall be able to pay its indebtedness as it matures. For purposes of the foregoing definition only, &#8220;indebtedness&#8221; means a liability in connection with another Person&#8217;s (i)&#160;right to payment, whether or not such a right is reduced to judgment, liquidated, unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured or unsecured or (ii)&#160;right to any equitable remedy for breach of performance if such breach gives rise to a right of payment, whether or not such right to an equitable remedy is reduced to judgment, fixed, contingent, matured, unmatured, disputed, undisputed, secured or unsecured. No transfer of property is being made and no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obligation is being incurred in connection with the transactions contemplated hereby with the intent to hinder, delay or defraud either present or future creditors of any Acquired Entity.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Buyer Entities have delivered to Sellers true, correct and complete copies of (i)&#160;a duly executed preferred equity commitment letter, dated as of the date hereof, among Buyer Parent and the Financing Sources party thereto (including all exhibits, schedules, term sheets, amendments, supplements, modifications and annexes thereto, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as may be amended, modified or replaced in accordance with the terms hereof, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Equity Commitment Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the preferred equity financing contemplated therein the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Equity Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii)&#160;a duly executed debt commitment letter, dated as of the date hereof, among Buyer and the Financing Sources party thereto (including all exhibits, schedules, term sheets, amendments, supplements, modifications and annexes thereto, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as may be amended, modified or replaced in accordance with the terms hereof, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Commitment Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the Preferred Equity Commitment Letter, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commitment Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and any other agreements related thereto, pursuant to which the Financing Sources party thereto have committed, subject to the terms and conditions set forth therein, to lend the amounts set forth therein to the Buyer Entities (together with any Alternate Debt Financing, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together with the Preferred Equity Financing, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of funding the transactions contemplated hereby. The Buyer Entities have also delivered to Sellers a true, correct and complete copy of any fee letter (which may be redacted in a customary manner solely with respect to the fee amounts (but not covenants or other terms), none of which affects conditionality, enforceability, termination or aggregate principal amount of the Financing) in connection with the Debt Commitment Letter (any such letter, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together with the Commitment Letters, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of the date hereof, the Financing Letters have not been modified, amended, supplemented or altered in any respect and none of the respective commitments or obligations thereunder have been terminated, reduced, withdrawn, rescinded or otherwise repudiated in any respect, and, to Buyer&#8217;s knowledge, no termination, reduction, withdrawal, rescission or other repudiation thereof is contemplated. As of the date hereof, no modification, amendment, supplement or alteration to any of the Financing Letters is currently contemplated. As of the date hereof, there are no other contracts, side letters or arrangements to which the Buyer Entities or any of its Affiliates is a party related to the Financing Letters or the Financing. No Fee Letter contains any &#8220;flex&#8221; provisions.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Financing, when funded in accordance with the Financing Letters shall provide the Buyer Entities with cash proceeds on the Closing Date sufficient and available to (i)&#160;satisfy all obligations of the Buyer Entities and the Company under this Agreement and the Financing Letters due and owing on the Closing Date and (ii)&#160;pay (1)&#160;the aggregate cash consideration required to be paid by Buyer hereunder at the Closing, (2)&#160;any and all fees and expenses, including Transaction Expenses, required to be paid by Buyer on the Closing Date in connection with the transactions contemplated hereby and (3)&#160;any and all amounts in connection with the refinancing or repayment of any outstanding indebtedness of the Company or its Subsidiaries required by this Agreement or the Financing Letters (clauses&#160;(i) and (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each of the Buyer Entities and, to Buyer&#8217;s actual knowledge, the other parties to the Financing Letters has the requisite power and authority to execute and deliver, and to perform its covenants and agreements under, the Financing Letters. The execution and delivery hereof by the Buyer Entities and, to Buyer&#8217;s knowledge, the other parties to the Financing Letters, and the performance by each of Buyer Entity and, to Buyer&#8217;s knowledge, the other parties to the Financing Letters of their respective covenants and agreements thereunder have been duly and validly authorized by all necessary Entity action on the part of Buyer and such parties. The Financing Letters have been duly and validly executed and delivered by the Buyer Entities and, to Buyer&#8217;s knowledge, the other parties to the Financing Letters and are legal, valid and binding obligations of the Buyer Entities and, to Buyer&#8217;s knowledge, such other parties, enforceable against the Buyer Entities and such other parties in accordance with their respective terms, subject to the Bankruptcy and Equity Exceptions.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Other than as expressly set forth in the Financing Letters, there are no conditions precedent or other contingencies related to the funding of the full proceeds of the Financing pursuant to any agreement related to the Financing to which the Buyer Entities or any of its Affiliates is a party. The Buyer Entities are not, nor are, to Buyer&#8217;s actual knowledge, any other parties to any Financing Letter, in default in the performance, observation or fulfillment of any obligation, covenant or condition contained in any Financing Letter, and, as of the date hereof and to Buyer&#8217;s actual Knowledge, no event has occurred or circumstance exists which, with or without notice, lapse of time or both, could be expected to (i)&#160;constitute or result in a default under or breach on the part of the Buyer Entities or on the part of any other party under any Financing Letter, (ii)&#160;constitute or result in a failure by the Buyer Entities or any other party to any Financing Letter to satisfy, or any delay in satisfaction, of any condition or other contingency to the funding of the Financing in the Required Amount, (iii)&#160;make any assumptions or any of the statements set forth in any Financing Letter inaccurate in any material respect or (iv)&#160;otherwise result in the Required Amount of the Financing being unavailable on a timely basis, and in any event, not later than the Closing. As of the date hereof, the Buyer Entities have no reason to believe that any term or condition of closing of the Financing contained in the Financing Letters will be unable to be satisfied on a timely basis (and in any event, not later than the Closing) or that the Required Amount committed pursuant to the Financing Letters will not be available at the Closing. As of the date hereof, the Buyer Entities have not incurred any obligation, commitment, restriction or liability of any kind, and is not contemplating or aware of any obligation, commitment, restriction or liability of any kind, in either case which could be expected to delay, impair or adversely affect the parties to the Financing Letters. The Buyer Entities have paid in full any and all commitment or other fees required to be paid on or prior to the date of this Agreement pursuant to the terms of the Financing Letters, and will pay in full any such amounts due on or before the Closing Date.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;As of the date hereof, each of the Financing Letters is in full force and effect, and none of the Financing Letters has been withdrawn, rescinded or terminated or otherwise amended or modified in any respect, and, to the knowledge of Buyer, no such withdrawal, rescission, termination, amendment or modification is contemplated. As of the date hereof, no Financing Source has notified the Buyer Entities, the Company or any of their respective Affiliates or Representatives of its intention to terminate any of the Financing Letters or not to provide its portion of the Financing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Buyer Entities hereby acknowledge and agrees that its obligations hereunder are not subject to any conditions regarding its or any other Person&#8217;s ability to obtain financing for the consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Buyer is acquiring the Transferred Equity Interests for its own account and not with a view to distribution in violation of any securities Laws. Buyer has been advised and understands and acknowledges that the Transferred Equity Interests have not been registered in accordance with the Securities Act or the &#8220;blue sky&#8221; Laws of any jurisdiction and may be resold only if registered in accordance with the provisions of the Securities Act or if an exemption from registration is available, unless neither such registration nor such an exemption is required by applicable Law. Buyer has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of the Transferred Equity Interests. Buyer is able to bear the economic risk of an investment in the Transferred Equity Interests and is able to afford a complete loss of such investment. Buyer is an &#8220;accredited investor,&#8221; as defined in Rule&#160;501 under the Securities Act.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No broker, finder or investment banker is entitled to any brokerage, finder&#8217;s or other similar fee or commission that could be payable by Sellers in connection with the Acquisition or the Liabilities Assumption based on arrangements made by or on behalf of the Buyer Entities.</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;4.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R&#38;W Insurance Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Buyer Entities have delivered to Sellers the binder agreement, dated as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Binder Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), between the Buyer Entities and QBE Specialty Insurance Co. (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Underwriter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with respect to the buyer-side representation and warranty insurance policy attached thereto, naming the Buyer Entities and&#47;or an Affiliate thereof as the &#8220;named insured&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R&#38;W Insurance Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The R&#38;W Insurance Policy does not include an entitlement to subrogation rights of recovery against Sellers, except in the case of Fraud. As of the date hereof, the Binder Agreement is in full force and effect and has not been amended, restated or otherwise modified or waived, and the respective commitments in the Binder Agreement have not been withdrawn, modified or rescinded in any respect. The Binder Agreement includes all of the conditions precedent to the issuance of the final R&#38;W Insurance Policy. The Binder Agreement has been duly and validly executed and delivered by Buyer Entities and Underwriter and is a legal, valid and binding obligation of Buyer Entities and Underwriter enforceable against Buyer Entities and Underwriter in accordance with its terms, subject to the Bankruptcy and Equity Exceptions. As of the date hereof, Buyer Entities has no reason to believe that any of the conditions precedent to the issuance of the final R&#38;W Insurance Policy on the terms therein will not be satisfied. Each of Buyer Entities and Underwriter has the requisite power and authority to execute and deliver, and to perform its covenants, agreements and obligations under, the Binder Agreement. The execution and delivery of the Binder Agreement by Buyer Entities and Underwriter and the performance by each of Buyer Entities and Underwriter of their respective covenants and agreements thereunder have been duly and validly authorized by all necessary entity action on the part of Buyer Entities and, to the Buyer Entities&#8217; knowledge, Underwriter, respectively. As of the date hereof, no event has occurred that, with or without notice or lapse of time or both, would or would reasonably be expected to constitute a breach or default of any provision of the Binder Agreement by Buyer Entities, constitute or result in a failure to satisfy a condition precedent to or other contingency to be satisfied set forth in the Binder Agreement or otherwise cause the final R&#38;W Insurance Policy to be unavailable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE&#160;V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>COVENANTS AND AGREEMENTS</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conduct of Business Prior to the Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Prior to the Closing, except (i)&#160;as required by this Agreement, (ii)&#160;as required by applicable Law, (iii)&#160;for any actions taken, or omitted, that Sellers reasonably determine are necessary in response to COVID-19 or COVID-19 Measures, (iv)&#160;as disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule or (v)&#160;with the prior written consent of Buyer Parent (which shall not be unreasonably withheld, conditioned or delayed), Sellers shall cause the Seller Group and the Acquired Entities to use commercially reasonable efforts to (1)&#160;cause the Business to preserve intact its present business organization and its relationships with material customers, material suppliers, employees and others to whom it has material contractual obligations or material business dealings or relations, and (2)&#160;conduct Business in the ordinary course of business in all material respects.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Prior to the Closing, except (v) as required by this Agreement, (w)&#160;as required by applicable Law or (x)&#160;any actions taken, or omitted, that Sellers reasonably determine are necessary in response to COVID-19 or COVID-19 Measures, (y)&#160;as disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule or (z)&#160;with the prior written consent of Buyer Parent (which shall not be unreasonably withheld, conditioned or delayed), Sellers shall not permit&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any Acquired Entity to amend or otherwise change its Organizational Documents&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any Acquired Entity to adjust, split, combine, amend the terms of or reclassify any shares of its capital stock&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any Acquired Entity to declare, set aside or pay any dividend or distribution (other than any dividend or distribution payable solely in cash prior to the Closing) on any of its Equity Interests or propose or authorize the issuance of any other securities for, in lieu of or in substitution for any of its Equity Interests&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any Acquired Entity to merge or consolidate with any other Person or restructure, reorganize, recapitalize or completely or partially liquidate (or adopt a plan of liquidation)&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any Acquired Entity to acquire (including by merger or consolidation or otherwise) any Equity Interest in any other Entity or any material asset from any other Person (other than another Acquired Entity)&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any member of the Seller Group or any Acquired Entity to issue, sell, pledge or transfer any Equity Interests in any Acquired Entity to any Person (other than any Acquired Entity)&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any member of the Seller Group or any Acquired Entity to sell, transfer, lease, sublease or license to any Person (other than any Acquired Entity) any material assets, other than (1)&#160;nonexclusive licenses or other grants of rights to IP Rights in the ordinary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">course of business or (2)&#160;in the case of any member of the Seller Group, any asset that is not Related to the Business&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;any Acquired Entity to repurchase, redeem or otherwise acquire any of its Equity Interests&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;any member of the Seller Group or any Acquired Entity to, except as required by (1)&#160;the terms of any Business Benefit Plan or (2)&#160;for which any Seller and its Affiliates (other than the Acquired Entities) shall be solely obligated to pay and as would not result in a Liability to the Buyer Entities or any Acquired Entity, (A)&#160;adopt, amend or terminate any Company Employee Plan, (B)&#160;materially increase the cash compensation or fringe benefits of any director, manager officer, employee, consultant or other natural person service provider of any Acquired Entity, other than (x)&#160;base salary increases in the ordinary course of business not to exceed 3.5% in the aggregate over the base salary levels in effect as of the date hereof or (y)&#160;in connection with promotions or responses to competing offers of employment, in each case, in the ordinary course of business, or (C)&#160;other than in the ordinary course of business, hire, engage or terminate any employee or individual independent contractor of an Acquired Entity or a member of the Seller Group with respect to the Business other than non-physician employees at the level of director or above who have an annual base salary in excess of $200,000&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;any member of the Seller Group or any Acquired Entity to enter into, terminate, or modify or amend in any material respect any Material Contract, other than expirations of Material Contracts in accordance with their terms&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not prohibit the entry into customer and vendor agreements in the ordinary course of business with pricing and other material terms that are consistent in all material respects with past practice of the Acquired Entities&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;any Acquired Entity (1)&#160;to settle, cancel or compromise any Claim (or series of related Claims) against such Acquired Entity, other than (A)&#160;customer payment reconciliations made in the ordinary course of business and (B)&#160;any other settlement, cancelation or compromise (x)&#160;involving only monetary payments where the amount paid by an Acquired Entity is less than $3,000,000,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">individually or in the aggregate, in excess of available insurance proceeds for such settlement, cancelation or compromise or (y)&#160;that would not result in a Liability to any Acquired Entity after the Closing, or (2)&#160;to intentionally waive or release any material rights&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;any Acquired Entity to authorize, or make any commitment with respect to, capital expenditures that are, in the aggregate, in excess of $1,500,000&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;any Acquired Entity to change any annual accounting period for GAAP or adopt or change any material accounting method used by it for GAAP or adopt any material accounting method, except, in each case, as required by GAAP or any Governmental Authority with jurisdiction over the business of any such Acquired Entity&#59;</font></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;any Acquired Entity to (1)&#160;make or change any material Tax election or method of accounting for U.S. federal income tax purposes, except in the ordinary course of business, (2)&#160;settle or compromise any audit, dispute or Claim in respect of any claim or assessment with respect to any material amount of Taxes, (3)&#160;consent to any extension or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">waiver of the limitation period applicable to any claim or assessment for any material amount of Taxes, (4)&#160;file any amended Tax Return or (5)&#160;enter into any Contract in respect of Taxes with any Governmental Authority&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;any Acquired Entity to assume or incur any Borrowed Money Indebtedness or to assume or guarantee any liability of a member of the Seller Group&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)&#160;&#160;&#160;&#160;any Acquired Entity to assume, incur, endorse or guarantee or otherwise become liable or responsible for any obligations of another Person (other than an Acquired Entity), whether directly, contingently or otherwise&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvii)&#160;&#160;&#160;&#160;any Acquired Entity to incur any Lien on any of its material assets (whether tangible or intangible), other than Permitted Liens&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xviii)&#160;&#160;&#160;&#160;any member of the Seller Group to incur any Lien on any of the Transferred Assets, other than Permitted Liens&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xix)&#160;&#160;&#160;&#160;any Acquired Entity to make any material loans, advances, capital contributions to or investments in any other Person (other than an Acquired Entity)&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xx)&#160;&#160;&#160;&#160;any Acquired Entity or any member of the Seller Group to enter into any Affiliate Contract&#59;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxi)&#160;&#160;&#160;&#160;any member of the Seller Group (with respect to the Business) or any Acquired Entity to make any material changes in their respective policies with respect to terms, systems, policies or procedures of accounts payable and accounts receivable&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxii)&#160;&#160;&#160;&#160;any member of the Seller Group or any Acquired Entity to enter into any Contract or understanding to do any of the foregoing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;(i)&#160;Nothing herein, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, shall give the Buyer Entities or any of its Representatives, directly or indirectly, the right to control or direct the operations of any member of the Seller Group or any Acquired Entity prior to the Closing, and (ii)&#160;prior to the Closing, the Seller Group and the Acquired Entities shall exercise complete control and supervision over their respective businesses and operations. Notwithstanding anything herein to the contrary, (1)&#160;the Seller Group shall have complete control over the Excluded Assets and the Retained Liabilities, and nothing herein shall restrict, limit or prohibit the Seller Group from taking any action, or omitting to take any action, in the Seller Group&#8217;s sole discretion, with respect to the Excluded Assets or the Retained Liabilities, (2)&#160;any action expressly permitted by an exception to a subsection of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and the Acquired Entities&#8217; failure to take any action prohibited by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, shall not be a breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (3)&#160;prior to the Closing, Sellers and their respective Affiliates shall be permitted to use all available cash and cash equivalents for dividends or distributions, to repay any Indebtedness or for any other purpose.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, prior to or at the Closing, the Seller Group shall be permitted to assign to the Company any Contract that would be a Transferred Contract absent such assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that any such Contract shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">considered a Transferred Contract for all purposes hereof (except for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> and the Bill of Sale and Assignment Agreement).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Access to Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Upon reasonable advance notice from the Buyer Entities, Sellers shall cause the Seller Group and the Acquired Entities to provide the Buyer Entities and their Representatives reasonable access, during normal business hours throughout the period prior to the Closing, to the Seller Group&#8217;s (but solely to the extent Related to the Business) and the Acquired Entities&#8217; respective properties and books and records (other than records related to skill and development training, performance, active medical restriction forms, fitness for duty and disciplinary actions), and during such period, Sellers shall furnish or make available to the Buyer Entities and their Representatives all readily available information Related to the Business as the Buyer Entities may reasonably request&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Sellers shall not be required to permit any such access, or to disclose any information, that in the reasonable, good-faith judgment of Sellers would (a)&#160;result in the disclosure of any trade secrets of any Person (other than the Acquired Entities or the Seller Group to the extent Related to the Business) or violate any applicable Law or (b)&#160;jeopardize protections afforded any Acquired Entity under the attorney-client privilege or the attorney work product doctrine&#59; provide that Sellers shall use commercially reasonable efforts to provide such information in a format or manner that would not disclose trade secrets or violate any applicable Law or jeopardize protections afforded any Acquired Entity under the attorney-client privilege or the attorney work product doctrine. All information obtained by the Buyer Entities and their Representatives under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall be treated as &#8220;Confidential Information&#8221; (as defined in the Confidentiality Agreement) for purposes of the Confidentiality Agreement, and any such information may be designated Clean Team Information in accordance with the Clean Team Confidentiality Agreement. Centene Corporation, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Ultimate Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), is an express third-party beneficiary of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> to the extent related to the Buyer Entities&#8217; obligations under the Confidentiality Agreement. Notwithstanding anything in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> to the contrary, neither Seller nor any of their respective Affiliates shall be required to provide Buyer Entities or their Representatives with any access to properties or books and records, or furnish the Buyer Entities or their Representatives with any information, to the extent any such properties, books, records or information are related to the Excluded Assets or the Retained Liabilities or the disclosure of which would be in violation of applicable Privacy Laws.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Consents and Filings&#59; Buyer Entities&#8217; Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Each Party shall use reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to cause the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> to be satisfied as soon as reasonably practicable after the date hereof and in any event no later than the date that is two (2) Business Days prior to the Outside Date, including using reasonable best efforts to prepare and make all Filings with, and obtain all Consents of, Governmental Authorities that are necessary, proper or advisable to consummate the Closing, including the HSR Act Clearance and the Required Filings (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, for the avoidance of doubt, the foregoing will not require any Party to waive any condition to Closing). Promptly following the date hereof, Sellers shall use commercially reasonable efforts to obtain all Consents and provide all notices under the Contracts listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;2.3(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule in connection with the transactions contemplated hereby&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that (i)&#160;none of Sellers or any of their respective Affiliates shall be required to make, or commit or agree to make, any concession or payment to, or incur any Liability to, any such Person and (ii)&#160;the inability or failure to obtain any such Consents, and any consequences to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">extent arising out of or related to such inability or failure, including the termination of any such Contract to the extent related to the Closing or the transactions contemplated hereby shall in no event (1)&#160;be deemed a breach of, or failure to perform or comply with, a covenant or agreement hereunder or (2)&#160;grant any Buyer Entity any right to terminate this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> or fail to consummate the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;In furtherance, and without limiting the generality, of Section&#160;5.3(a), each Party shall, and shall cause its Representatives to, (i)&#160;make or cause to be made the initial Filings of such Party or its Representatives required by the HSR Act related to the transactions contemplated hereby within five (5) Business Days after the date hereof and, if available, shall request early termination of the waiting period under the HSR Act applicable to the transactions contemplated hereby, (ii)&#160;make or cause to be made all other Filings with Governmental Authorities required of such Party or its Affiliates that are necessary, proper or advisable to consummate the Closing or to obtain all Consents of Governmental Authorities that are necessary, proper or advisable to consummate the Closing, in each case, as soon as reasonably practicable after the date hereof (including the Required Filings), (iii)&#160;provide as soon as reasonably practicable all information required by applicable Law to be provided to any Governmental Authority in connection with any such Filings or Consents and comply at the earliest reasonably practicable date with any request from a Governmental Authority for additional information, documents or other materials received by such Party or its Representatives related to such Filings or the transactions contemplated hereby and (iv)&#160;act in good faith and reasonably cooperate with the other Parties in connection with any such Filings and in obtaining any Consent of a Governmental Authority that is necessary to consummate the Closing. To the extent not prohibited by applicable Law, each Party shall use reasonable best efforts to furnish to each other all information required for any Filing to be made to a Governmental Authority by applicable Law in connection with the transactions contemplated hereby. Each of the Buyer Entities and Sellers shall give the other reasonable prior notice of any communication with, and any proposed understanding, undertaking or agreement with, any Governmental Authority regarding any such Filing or Consent and shall not independently participate in any meeting, or engage in any substantive conversation, discussion or negotiation, with any Governmental Authority related to any such Filing or Consent, or related to any Claims by such Governmental Authority related to the transactions contemplated hereby, without giving the other (1)&#160;prior written notice of such meeting, conversation, discussion or negotiation and (2)&#160;unless prohibited by such Governmental Authority, the opportunity to attend or participate therein. Each of the Buyer Entities and Sellers shall consult and cooperate with the other in good faith in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of such Party in connection with any Claim by a Governmental Authority related to such Filings or the transactions contemplated hereby. Without limiting the foregoing, each Party shall not, and shall cause their respective Representatives not to, enter into any agreement with any Governmental Authority not to consummate the transactions contemplated hereby. All filing fees payable by any of the Buyer Entities, Sellers, the Acquired Entities or any of their respective Representatives in connection with any such Filings or Consents shall be borne and payable by the Buyer Entities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;In furtherance, and without limiting any, of the Buyer Entities&#8217; covenants and agreements under Section&#160;5.3(a) and Section&#160;5.3(b), as soon as possible after the date hereof, the Buyer Entities shall, and shall cause their Representatives to, take all actions necessary, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">proper or advisable to (i)&#160;avoid or eliminate each and every impediment that may be asserted by a Governmental Authority related to any Filings or Consents contemplated by this Section&#160;5.3, the Acquisition, the Liabilities Assumption or the other transactions contemplated hereby as soon as possible and (ii)&#160;to enable the Closing to occur as soon as possible after the date hereof, in each case, which actions shall include (1)&#160;defending through litigation on the merits, including appeals, any Claim asserted in any court or other proceeding by any Person, including any Governmental Authority, that seeks to or could prevent or prohibit or impede, interfere with or delay the consummation of the Closing, (2)&#160;proposing, negotiating, committing and effecting, by consent decree, hold separate order, settlement or otherwise, the sale, divestiture, licensing or disposition of any assets or businesses of (A)&#160;a Buyer Entity, its Affiliates or the Acquired Entities or (B)&#160;the Transferred Assets, (3)&#160;terminating existing relationships, contractual rights or obligations of a Buyer Entity, its Affiliates or the Acquired Entities or the Transferred Assets, (4)&#160;agreeing to any limitation, restriction, prohibition, undertaking, covenant, revision, obligation (contractual or otherwise) or requirement on the conduct (including contractual, business or service performance) of (A)&#160;a Buyer Entity, its Affiliates or any of their respective businesses, (B)&#160;the Acquired Entities, (C)&#160;the Transferred Assets or (D)&#160;the Business (5)&#160;taking any other action as may be required by a Governmental Authority in order to obtain any Consent thereof that is necessary, appropriate or advisable to consummate the Closing or avoiding the entry of, or having vacated, lifted, dissolved, reversed or overturned any Order, in each case, as soon as possible and in any event prior to the Outside Date (each of the actions described in the foregoing clauses&#160;(2)&#8211;(5), a &#8220;Regulatory Concession&#8221;) and (6)&#160;not acquiring any asset (including any business, Equity Interests or Entity) (by way of merger, consolidation, share exchange, investment, other business combination, asset, stock or equity purchase, or otherwise), that could reasonably be expected to adversely affect obtaining or making any Consent or Filing contemplated by this Section&#160;5.3 or the timely receipt thereof or that would or would be reasonably likely to impair, interfere with, hinder, delay or prevent the Closing. Notwithstanding anything in this Section&#160;5.3(c) to the contrary, no member of the Buyer Group shall be required to take, propose or agree to any Regulatory Concession that, individually or in the aggregate with all Regulatory Concessions, would or would reasonably be expected to result in a material adverse effect on the business, financial condition or results of operations of (A)&#160;the Buyer Group, taken as a whole, (B)&#160;the Acquired Entities and the Business, taken as a whole, or (C)&#160;Buyer and its Subsidiaries (including the Acquired Entities and the Business), taken as a whole after giving effect to the transactions contemplated hereby (provided that, for purposes of the foregoing clauses&#160;(A) and (C), the Buyer Group, taken as a whole, and Buyer and its Subsidiaries (including the Acquired Entities and the Business), taken as a whole after giving effect to the transactions contemplated hereby, shall be deemed to be of the size, scope and scale of the Acquired Entities and the Business, taken as a whole.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, (A)&#160;the Seller Group shall not be required to make, or commit or agree to make, any Regulatory Concession or incur any Liability in connection with such Filings or Consents (other than Liabilities incidental to the making of such Filings or Consents), (B)&#160;the Acquired Entities shall not be required to make, or commit or agree to make, any Regulatory Concession or incur any Liability (I)&#160;that is not conditioned on the consummation of the transactions contemplated hereby or (II)&#160;related to any business or assets of the Seller Group (other than the Business, the Acquired Entities or the Transferred Assets) and (C)&#160;no Regulatory Concession, individually or in the aggregate, shall have any effect on, or be reflected in the calculation of, the Estimated First Adjustment Amount or the First Adjustment Amount.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Section&#160;5.4&#160;&#160;&#160;&#160;Employee Matters.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(a)&#160;&#160;&#160;&#160;No later than thirty (30) days prior to the Closing Date, Buyer shall, or shall cause one of its Affiliates to, offer employment in writing to each Business Employee providing for employment (assuming that the Business Employee accepts such employment) commencing at midnight local time on the Closing Date (or to the extent such Business Employee is on a leave of absence as of the Closing Date, commencing on the date on which such Business Employee returns to active service provided such return occurs within six (6) months following the Closing Date) on the terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">. Buyer and its Affiliates, as applicable, shall employ those Transferred Employees who are foreign nationals working in the United States under terms and conditions such that Buyer and its Affiliates, as applicable, qualify as a &#8220;successor employer&#8221; under applicable United States immigration laws effective as of the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(b)&#160;&#160;&#160;&#160;Subject, and in addition, to any requirements imposed by applicable Law&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(i)&#160;&#160;&#160;&#160;for a period of one (1) year immediately following the Closing Date (or if shorter, during the period of employment) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Continuation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;), Buyer shall provide, or shall cause to be provided, to each Business Employee who accepts an offer of employment provided under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> to be employed by Buyer or one of its Affiliates following the Closing (each such Business Employee, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Transferred Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;) with (1)&#160;an annual base salary or wage rate, (2)&#160;target annual cash incentive opportunities (excluding equity-based incentive opportunities), and (3)&#160;employee benefits (excluding benefits under any defined benefit plan, retiree health plan, equity plan, severance payments and severance benefits) that are in the aggregate substantially similar to those provided by Sellers or any of their Affiliates (including the Acquired Entities) to such Transferred Employee immediately prior to the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> that notwithstanding the foregoing, each Transferred Employee shall be provided with an annual base salary or wage rate that is no less favorable than the annual base salary or wage rate provided to such Transferred Employee immediately prior to the Closing Date&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(ii)&#160;&#160;&#160;&#160;Buyer shall provide, or shall cause to be provided, to each Transferred Employee severance payments and benefits that are no less favorable than the severance payments and benefits provided to similarly situated employees of Buyer and its Affiliates&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(iii)&#160;&#160;&#160;&#160;for eligibility and vesting purposes only under the employee benefit plans of Buyer and its Affiliates, if any, that are offered and provide benefits to Transferred Employees after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Buyer Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;), each Transferred Employee shall be credited with his or her years of service or comparable experience with Sellers or their Affiliates (including the Acquired Entities) prior to the Closing Date to the same extent as such employee was entitled prior to the Closing Date to credit for such service under any similar Business Benefit Plan, except to the extent such credit would result in a duplication of benefits (and excluding, for the avoidance of doubt, the sabbatical program maintained by Buyer and its Affiliates)&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(iv)&#160;&#160;&#160;&#160;for purposes of each Buyer Plan, providing medical, dental, pharmaceutical or vision benefits to any Transferred Employee, to the extent such Transferred Employee satisfied participation requirements and waiting period requirements under a comparable Business Benefit Plan, Buyer shall use reasonable best efforts to obtain the consent of any applicable insurer to, or if insurer consent is not required, cause all pre-existing condition </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">exclusions and actively-at-work requirements of such Buyer Plan to be waived for such Transferred Employee and his or her covered dependents, and all eligible expenses incurred by such Transferred Employee and his or her covered dependents under the comparable Business Benefit Plans during the portion of the plan year ending on the date of such Transferred Employee&#8217;s participation in the corresponding Buyer Plan begins shall be considered under such Buyer Plan for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and his or her covered dependents for the applicable plan year as if such amounts had been paid in accordance with such Buyer Plan subject to all applicable terms and conditions related to such benefits or amounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Effective as of the Closing Date, Buyer Parent shall, or shall cause one of its Affiliates to, grant to the individuals set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Business Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) a cash or equity incentive award (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in respect of any Ultimate Parent Equity Awards that are outstanding on the date hereof and that are forfeited in accordance with their terms by such Specified Business Employee as of the Closing. Each Replacement Award shall equal the value of any Ultimate Parent Equity Award (using the Replacement Award VWAP) and shall have the same terms, conditions and vesting schedule as applied to such Ultimate Parent Equity Awards immediately prior to the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such Replacement Awards shall (i)&#160;be subject to solely service-based vesting conditions but shall otherwise remain subject to the same terms and conditions as applied prior to the Closing Date (except as otherwise provided herein), (ii)&#160;to the extent that such Ultimate Parent Equity Awards are stock options, (1)&#160;have a value determined in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> equal to the Aggregate Spread Value and (2)&#160;shall be vest and paid to the Specified Business Employee on the applicable service-based vesting schedule and (iii)&#160;vest and be paid upon the termination of employment (absent for cause termination) of the applicable Specified Business Employee by Buyer, or an Affiliate thereof, on or following the Closing Date. Prior to the Closing, Seller Parent shall use commercially reasonable efforts to deliver an updated Equity Award Schedule containing the applicable information in respect of each Specified Business Employee as of the Business Day prior to the Closing Date.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Effective as of the Closing Date, the Transferred Employees shall no longer actively participate in the Magellan Health, Inc. Retirement Savings Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Seller 401(k) Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Sellers shall, and shall cause their respective Affiliates to, take all actions required to fully vest the Transferred Employees in their accounts under the Seller 401(K) Plan. Buyer shall designate a tax-qualified defined contribution plan of Buyer (such plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer Savings Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that either (i)&#160;currently provides for the receipt from the Transferred Employees of &#8220;eligible rollover distributions&#8221; (as such term is defined in Section&#160;401(a)(31) of the Internal Revenue Code, including notes representing plan loans) or (ii)&#160;shall be amended effective as of the Closing Date to provide for the receipt from the Transferred Employees of eligible rollover distributions. Sellers, the Buyer Entities and their respective Affiliates shall cooperate in good faith to work with the recordkeepers of Seller 401(k) Plan and Buyer Savings Plan to develop a process and procedure for effecting the in-kind direct rollover of promissory notes evidencing participant loans from the Seller 401(k) Plan to the Buyer Savings Plan and voluntary rollovers of account balances to the Seller 401(k) Plan. In the event that a process and procedure acceptable to the recordkeepers of Seller 401(k) Plan and Buyer Savings Plan for effecting the in-kind rollover of loan promissory notes is agreed upon, the Seller and Buyer shall take any and all commercially reasonable actions needed to permit each Transferred Employee with an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">outstanding loan balance under the Seller 401(k) Plan as of the Closing to continue to make scheduled loan payments to the Seller 401(k) Plan after the Closing, pending the distribution and in-kind rollover of the promissory notes evidencing such loans from the Seller 401(k) Plan to the Buyer Savings Plan so as to prevent, to the extent reasonably possible, a deemed distribution or loan offset with respect to such outstanding loans. Sellers shall, and shall cause their respective Affiliates to, use commercially reasonable efforts to provide Buyer year to date employee contributions and cumulative balances for the Transferred Employees under the Seller 401(k) Plan for purposes of compliance with applicable statutory limitations.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Sellers shall timely advise Buyer of the amount of all accrued and unused vacation time and other paid time off as of the Closing Date held by such Transferred Employee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Buyer shall assume and credit each Transferred Employee with their Accrued PTO to the extent included in Net Working Capital as finally determined and shall cooperate in good faith with all Transferred Employees with respect to vacation and paid time off commitments purchased or reserved by such Transferred Employee prior to the Closing Date in respect of periods occurring on or subsequent to the Closing Date.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Buyer shall not, and shall cause its Affiliates not to, cause any of the Transferred Employees to suffer an &#8220;employment loss&#8221; under the WARN Act on or in the ninety (90) days following the Closing Date which would reasonably be expected to create any Liability for Sellers or any of their Affiliates under the WARN Act.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The obligation of Seller and its Affiliates (other than the Acquired Entities) to provide benefits under Seller Employee Plans shall cease effective as of the Effective Time with respect to the Transferred Employees. With respect to periods on and following the Effective Time, each Transferred Employee shall be eligible to commence participation in the Buyer Plans that provide health and welfare benefits. Seller and its Affiliates (other than the Acquired Entities) shall be responsible for all liabilities with respect to claims incurred by Transferred Employees (and their beneficiaries and covered dependents) prior to the Effective Time under those Seller Employee Plans that provide medical, dental, vision and prescription drug coverage, life, accidental death and dismemberment and business travel accident insurance and disability coverage. Buyer and its Affiliates shall be responsible for all liabilities with respect to claims incurred by Transferred Employees (and their beneficiaries and covered dependents) on and after the Effective Time under Buyer Plans that provide medical, dental, vision and prescription drug coverage, life, accidental death and dismemberment and business travel accident insurance and disability coverage. For purposes of this Section, the following claims shall be deemed to be incurred as follows&#58; (A)&#160;with respect to short-term disability, long-term disability, life and accidental death and dismemberment benefits, upon the event giving rise to such benefits, and (B)&#160;with respect to medical, dental, vision care, prescription and health-related benefits, upon provision of medical, dental, vision, prescription and health-related services, materials or supplies.</font></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Sellers and Buyer or their respective Affiliates shall take all actions necessary or appropriate, consistent with &#8220;Situation 2&#8221; of Revenue Ruling 2002-32, including  adopting the amendments described in such Revenue Ruling to the health and dependent care flexible spending account plans of Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Seller FSAs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Buyer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Buyer FSAs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), so that, effective as of the Closing Date, (i)&#160;the account balances (whether positive or negative) of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Transferred Employees who are participants in the Seller FSAs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FSA Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be transferred to the Buyer FSAs&#59; (ii)&#160;the elections, contribution levels and coverage levels of the FSA Participants shall apply under Buyer FSAs in the same manner as under Seller FSAs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Seller has provided to Buyer all data necessary to reflect such application&#59; and (iii)&#160;the FSA Participants shall be reimbursed from the Buyer FSAs for claims (A)&#160;incurred at any time during the plan year of the Seller FSAs during which the Closing Date occurs (or during any grace period or extended grace period applicable to the Seller FSAs), and (B)&#160;submitted to Buyer FSAs from and after the Closing Date, substantially on the same basis, terms and conditions as under Seller FSAs. As soon as reasonably practicable following the Closing Date, (i)&#160;if the aggregate benefits paid by the Seller FSA to the Transferred Employees prior to the Closing Date exceed the aggregate payroll deductions for the Seller FSAs made in respect of the Transferred Employees at or prior to the Closing Date, then Buyer shall reimburse Seller for the amount of such excess or (ii)&#160;if the aggregate payroll deductions for the Seller FSAs made in respect of the Transferred Employees at or prior to the Closing Date exceed the aggregate benefits paid by the Seller FSAs to the Transferred Employees prior to the Closing, then Seller shall reimburse Buyer for the amount of such excess. The parties hereto agree to make reasonable, good faith efforts to implement the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, taking into account the complexity of transferring flexible spending accounts.</font></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be treated as an amendment of, an undertaking to amend or terminate, or a limitation on the ability of Buyer or its Affiliates to amend or terminate any Employee Plans. Nothing herein shall require Buyer to continue to employ the services of any particular individual after the Closing Date. No provision hereof shall create any third-party beneficiary rights in any employee (including any Business Employee or Transferred Employee) or any other natural person service provider of any Acquired Entity or any beneficiary or dependents thereof for any specific compensation, terms and conditions of employment or benefits.</font></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section&#160;5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Names and Marks&#59; Termination of Rights to IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;From and after the Closing (but subject to the one hundred eighty (180) day transition period referenced in the following sentence), Buyer and its Affiliates shall have no right, title or interest in or to, and Buyer shall not use, shall not permit any of its Affiliates or any third party to use, and shall cause the Acquired Entities to cease to use, the Seller Names, in whole or in part, as the name or mark of or otherwise in connection with the Acquired Entities, the Business, the Transferred Assets, the business of Buyer or any of its Affiliates or otherwise. As soon as reasonably practicable, and in any event within one hundred and eighty (180) days after the Closing Date, Buyer shall use commercially reasonable efforts to (i)&#160;remove, strike over or otherwise obliterate all Seller Names from all existing physical items, content and materials (tangible or intangible), including signage, vehicles, facilities, business cards, schedules, stationery, packaging materials, displays, promotional materials, manuals, forms, software, email, social media, online identifiers and properties, and other items, content and materials, and (ii)&#160;change the name of each Acquired Entity (and any other entity, if applicable) to remove any Seller Name, including causing its Organizational Documents to be amended to remove any references thereto. Buyer shall have no rights during such time to make any new use of any Seller Name. For the avoidance of doubt, nothing herein shall require Buyer or any Acquired Entity to amend any Contract to remove any Seller Name.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Other than such rights as may be expressly granted to an Acquired Entity pursuant to the Transition Services Agreement or the Software License Agreement, any licenses, rights and access to proprietary IP Rights, data, software or other technology that may have been granted by Sellers and their Affiliates (excluding, for clarity, the Acquired Entities) to the Acquired Entities prior to the Closing, whether expressly or impliedly, shall terminate as of immediately prior to the Closing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification&#59; Directors&#8217; and Officers&#8217; Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;From and after the Closing, Buyer shall cause the Acquired Entities to fulfill and honor the obligations of each Acquired Entity under any indemnification provision, exculpation provision or advancement-of-expense provision in the Organizational Documents of any Acquired Entity as in effect as of the Closing. Buyer shall not permit any such provision to be amended, repealed or otherwise modified after the Closing in any manner that would adversely affect the rights thereunder of any Pre-Closing Indemnified Person, unless any such amendment, repeal or modification is required by applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Without limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and solely to the extent covered by the Tail Policy, from and after the Closing, Buyer shall, and shall cause the Acquired Entities (each of Buyer and the Acquired Entities, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to, to the fullest extent permitted by applicable Law, (i)&#160;indemnify and hold harmless and exculpate (and release from any liability to Buyer or the Acquired Entities) the Pre-Closing Indemnified Persons against all D&#38;O Expenses and all Losses (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising from or related to any threatened, pending or completed claim or investigation, whether criminal, civil, administrative or investigative or otherwise, related to acts or omissions occurring on or prior to the Closing (including for acts or omissions in connection with this Agreement and the transactions contemplated thereby) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Indemnifiable Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii)&#160;advance to such Pre-Closing Indemnified Persons all D&#38;O Expenses incurred in connection with any D&#38;O Indemnifiable Claim (including in circumstances where the Pre-Closing Indemnified Person has assumed the defense of such claim) promptly after receipt of reasonably detailed statements therefor. Subject to the terms of the Tail Policy, the rights of any Pre-Closing Indemnified Person related to any D&#38;O Indemnifiable Claims shall continue until such D&#38;O Indemnifiable Claim is finally disposed (with no liability or potential liability of, and at no cost to, such Pre-Closing Indemnified Person) or all judgments, orders, decrees or other rulings in connection with such D&#38;O Indemnifiable Claim are fully satisfied (with no liability or potential liability of, and at no cost to, such Pre-Closing Indemnified Person). For the purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;D&#38;O Expenses&#8221; shall include attorneys&#8217; fees and all other costs, charges and expenses paid or incurred in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to defend, to be a witness in or participate in any D&#38;O Indemnifiable Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;At the Closing, Buyer shall obtain, at its sole cost and expense, a prepaid &#8220;tail&#8221; insurance policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tail Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that provides the Pre-Closing Indemnified Persons with directors&#8217; and officers&#8217; liability insurance up to an aggregate policies limit of $10,000,000, for a period ending no earlier than the sixth (6th) anniversary of the Closing Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Buyer acknowledges (on behalf of itself and its Representatives, including, after the Closing, the Acquired Entities) that the Pre-Closing Indemnified Persons may have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">certain rights to indemnification, advancement of expenses and&#47;or insurance provided by current direct or indirect equity holders, members or other Affiliates of Sellers or their Representatives (other than the Acquired Entities) or their respective direct or indirect equity holders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) separate from the obligations of Buyer and the Acquired Entities hereunder or under their respective Organizational Documents. From and after the Closing, (i)&#160;the D&#38;O Indemnifying Parties shall be the indemnitors of first resort (i.e., their obligations to the Pre-Closing Indemnified Persons are primary and any obligation of any Indemnitee Affiliate to advance expenses or to provide indemnification or insurance for the same D&#38;O Expenses or D&#38;O Costs incurred by the Pre-Closing Indemnified Persons is secondary), (ii)&#160;the D&#38;O Indemnifying Parties shall advance the full amount of D&#38;O Expenses required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and shall be liable for the full amount of D&#38;O Costs to the extent provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, without regard to any rights the Pre-Closing Indemnified Persons may have against any Indemnitee Affiliate and (iii)&#160;the D&#38;O Indemnifying Parties (on behalf of themselves and their respective Subsidiaries) irrevocably waive, relinquish and release the Indemnitee Affiliates from all claims against the Indemnitee Affiliates for contribution, subrogation or any other recovery of any kind in respect thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Pre-Closing Indemnified Persons are intended third-party beneficiaries of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with full rights of enforcement of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as if a party hereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;For purposes hereof, each Person who is or was an officer, manager or director of an Acquired Entity at or at any time prior to the Closing shall be deemed to be a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Closing Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;If Buyer or any of its respective successors or assigns (i)&#160;consolidates with or merges into any other Entity and is not the continuing or surviving Entity of such consolidation or merger or (ii)&#160;transfers or conveys all or substantially all of its assets to any Person, then Buyer or its applicable successor or assign shall cause its applicable successors or assigns to assume all of the obligations thereof in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Termination of Affiliate Contracts and Intercompany Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Other than as listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule, (a)&#160;all of the Acquired Entities&#8217; rights, remedies and Liabilities under the Affiliate Contracts shall be terminated as of immediately prior to the Measurement Time, (b)&#160;all rights, remedies, and Liabilities of any member of the Seller Group under the Affiliate Contracts shall be terminated as of immediately prior to the Measurement Time, and (c)&#160;all accounts (payables and receivables) between any member of the Seller Group, on the one hand, and any Acquired Entity, on the other hand, shall be terminated or settled immediately prior to the Measurement Time. Buyer acknowledges and agrees that, from and after the Closing, other than the specific services to be provided to Buyer under, and on the terms and conditions of, the Transition Services Agreement and the Software License Agreement, neither Buyer nor any Acquired Entity shall have any right, Claim or cause of action in or with respect to any Shared Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retention and Access to Personnel, Information and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;From and after the Closing Date through the date that is seven (7) years after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Preservation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), Buyer shall, and shall cause the Acquired Entities to, preserve, keep and maintain the Books and Records and all books, records, data and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">information of the Acquired Entities related to the Business, the Transferred Assets or the Assumed Liabilities, in each case, in their possession following the Closing as a result of the Acquisition with respect to periods or occurrences prior to the Closing Date. From and after the Closing Date through the Preservation Date, Buyer shall, and shall cause the Acquired Entities to, provide Sellers and their Representatives, upon Sellers&#8217; or their Representatives&#8217; reasonable request, access to or copies of such Books and Records and such other books, records, data and information and access to the personnel of Buyer and the Acquired Entities to the extent necessary for tax purposes or otherwise to comply with applicable Law or for any other legitimate business purpose.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;From and after the Closing Date through the Preservation Date, Sellers shall, and shall cause the Seller Group to, preserve, keep and maintain all books, records, data and information of related to the Business, in each case, in their possession following the Closing and not otherwise transferred in connection with the Acquisition with respect to periods or occurrences prior to the Closing Date. From and after the Closing Date through the Preservation Date, Sellers shall, and shall cause the Seller Group to, provide Buyer and its Representatives, upon Buyer&#8217;s or its Representatives&#8217; reasonable request, access to or copies of such books, records, data and information and access to the personnel of Seller and the Seller Group to the extent necessary for tax purposes or otherwise to comply with applicable Law or for any other legitimate business purpose.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. From and after the Closing, the Acquired Entities, the Business, the Transferred Assets and the Assumed Liabilities shall cease to be insured by, have access or availability to, or be entitled to make claims on, claim benefits from or seek coverage under any insurance policy maintained by Sellers or any of their Affiliates (other than the Acquired Entities), including any insurance policy maintained by Sellers under which any Acquired Entity is a beneficiary or the Business, the Transferred Assets or the Assumed Liabilities are covered. Sellers or any of their respective Affiliates shall be permitted to amend, effective as of the Closing, any insurance policy in a manner they deem appropriate to give effect to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Company Employee Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Promptly after the Closing, Buyer shall instruct each Transferred Employee (a)&#160;to at all times maintain the confidentiality of all confidential or proprietary information in such Transferred Employee&#8217;s possession or control that is related to any business of the Seller Group (other than the Business), including any such confidential or proprietary information obtained inadvertently by such Transferred Employee or contained or stored in such Transferred Employee&#8217;s Personal Electronic Devices and (b)&#160;not to use, or disclose or make available to any third party, any confidential or proprietary information, including all such information contained or archived in such Transferred Employee&#8217;s emails, that is related to any business of the Seller Group (other than the Business) for any purpose at any time during or after such Transferred Employee&#8217;s employment by Buyer or any of its Affiliates.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;This Agreement shall not constitute an agreement to Transfer, and no member of the Seller Group shall be required to Transfer to Buyer or any Acquired Entity any Transferred Contract for which the Consent of the counterparty thereto is required pursuant to the terms thereof in connection with the transactions contemplated hereby and for which consent is not obtained prior to the Closing (any such Contract, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Consent Required Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;With respect to any Consent Required Contract, Sellers and Buyer shall enter into, as of the Closing, a mutually agreeable arrangement under which (i)&#160;Buyer would obtain, through a subcontracting, sublicensing or subleasing arrangement or otherwise, the Claims, rights and benefits of the applicable member of the Seller Group under such Consent Required Contract, (ii)&#160;Buyer would assume all Liabilities of the Seller Group under such Consent Required Contract to the same extent as an Assumed Liability and agree to perform and discharge all such Liabilities, (iii)&#160;Sellers would enforce, at Buyer&#8217;s sole cost and expense and at the reasonable request of and for the benefit of Buyer, all Claims, rights and benefits of the Seller Group against any third party thereto arising from any such Consent Required Contract and (iv)&#160;Sellers would be liable for a breach of such Consent Required Contract to the extent caused by the Seller Group. Sellers shall and cause the Seller Group to, as applicable, promptly pay to Buyer, when received, all monies received by the Seller Group under any such Consent Required Contract as a result of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. If and when the legal or contractual impediments the presence of which caused the deferral of transfer of any Consent Required Contract pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> are obtained, the Transfer of the applicable Consent Required Contract shall be effected in accordance with the terms hereof and, upon such Transfer, such Consent Required Contract shall be a Transferred Asset and no longer considered a Consent Required Contract for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. For the avoidance of doubt, in no event shall the non-existence of any Consent Required Contract be a condition to the Closing, and there shall be no adjustment to the purchase price or other consideration payable hereunder as a result of any Contract being a Consent Required Contract. Any such mutually agreeable arrangement shall terminate on the earlier of (1)&#160;the expiration of the Consent Required Contract in accordance with is terms and (2)&#160;the date that the applicable Consent Required Contract becomes a Transferred Asset pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;From and after the Closing until the earlier of the expiration of the Consent Required Contract in accordance with its terms and the date that the applicable Consent Required Contract becomes a Transferred Asset, Sellers shall, at their sole cost and expense, use their commercially reasonable efforts to obtain the written Consent of each third party that is a party to any Consent Required Contract in order for Sellers to assign each such Consent Required Contract to Buyer&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Sellers shall not be required to expend money (other than reasonable fees of, and payments to, Sellers&#8217; legal and other professional advisors and internal costs and expenses), incur any liability, commence any litigation or offer or grant any accommodation (financial or otherwise) to any such third party or any other Person. Buyer shall use its commercially reasonable efforts to assist Sellers in obtaining each such Consent. Promptly after receipt of any such Consent, Sellers and Buyer shall enter into a customary written assignment and assumption agreement assigning the applicable Consent Required Contract to Buyer.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Financing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;The Buyer Entities shall, and shall cause its Subsidiaries and each of their respective Representatives and Affiliates to take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to arrange and consummate the Financing at the Closing on the terms and subject only to the conditions set forth in the Commitment Letters, including&#58; (1)&#160;complying with and maintaining (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the Buyer Entities shall not be required to commence litigation to enforce its rights under the Commitment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Letters) the Commitment Letters in full force and effect in accordance with the terms and subject only to the conditions thereof, (2)&#160;using reasonable best efforts to negotiate and enter into definitive agreements with respect thereto on the terms and subject only to the conditions set forth in the Commitment Letters, (3)&#160;complying with and performing the obligations applicable to it pursuant to the Commitment Letters, (4)&#160;drawing down on and consummating the Financing at or prior to the Closing, including by enforcing their respective rights under the Commitment Letter and causing the Financing Sources to fund the Financing at the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the Buyer Entities shall not be required to commence litigation to enforce such rights under the Commitment Letters, and (5)&#160;satisfying on a timely basis all conditions in such definitive agreements to the extent within the Buyer Entities&#8217; any of their Subsidiaries&#8217; or any of their respective Representatives&#8217; or Affiliates&#8217; control and assist in the satisfaction of all other conditions. If the Required Amount of the Financing expires or terminates or otherwise becomes (or could be expected to become) unavailable in the manner contemplated by the Debt Commitment Letter, the Buyer Entities shall immediately notify Sellers in writing thereof and use its reasonable best efforts to arrange for and obtain as promptly as practicable following the occurrence of any such event alternative debt financing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Alternate Debt Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) in the Required Amount on terms and conditions that are not less favorable or more onerous (including imposition of new conditions or expansion of existing conditions), in the aggregate, than those set forth in the Debt Commitment Letter and that would not, and could not be expected to, prevent, delay or impair the ability of the Buyer Entities to obtain the Financing or consummate the transactions contemplated hereby. In the event Buyer obtains any Alternate Debt Financing, Buyer shall promptly deliver an executed debt commitment letter to Sellers with respect to such Alternate Debt Financing, including all exhibits, schedules, term sheets, amendments, supplements, modifications and annexes thereto and true, correct and complete copies of any related executed fee letters, engagement letters and other agreements, it being understood that any such fee letters may be redacted only in the same manner as the Fee Letters. Buyer shall be subject to the same obligations with respect to any Alternate Debt Financing as set forth in this Agreement with respect to the Financing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Buyer Entities shall not withdraw, rescind, terminate, replace, amend or waive any Financing Letter or any provision thereof without Sellers&#8217; prior written consent if (in the case of any such replacement, amendment or waiver) such replacement, amendment or waiver would, or could be expected to, when taken together with all such amendments, modifications, and waivers&#58; (1)&#160;delay or prevent the Closing, (2)&#160;make the funding of the Financing (or satisfaction of the conditions to obtaining the Financing) materially less likely to occur, (3)&#160;adversely impact the ability of the Buyer Entities to enforce their rights against the other parties to the Financing Letters or the definitive agreements with respect thereto, the ability of the Buyer Entities to consummate the transactions contemplated hereby at the Closing or the likelihood of the consummation of the transactions contemplated hereby to be consummated at the Closing, (4)&#160;reduce (or have the effect of reducing) the aggregate amount of the Financing below the Required Amount or (5)&#160;impose new conditions or adversely expand, amend or modify any of the existing conditions to the receipt of the Financing, or otherwise add, expand, amend or modify any other provision of the Financing Letters, in a manner that could be expected to delay or prevent the funding of the Financing (or satisfaction of the conditions to the Financing) at the Closing. The Buyer Entities shall promptly deliver a copy of any amendment, supplement, modification or replacement of any Financing Letter to Sellers. Upon any permitted amendment, supplement, modification or replacement of any Financing Letter (including with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respect to any Alternate Debt Financing) in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the term &#8220;Financing Letters&#8221; shall mean the Financing Letters as so amended, supplemented, modified or replaced, and references to &#8220;Preferred Equity Financing,&#8221; &#8220;Debt Financing&#8221; &#8220;Financing&#8221; and&#47;or &#8220;Alternate Debt Financing&#8221; shall include the financing contemplated by the Financing Letters as so amended, supplemented, modified or replaced.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;The Buyer Entities shall provide Sellers prompt (but in any event, within two (2) Business Days) written notice (1)&#160;upon becoming aware of any (A)&#160;actual or threatened material breach, default, repudiation, cancellation or termination (or any event or circumstance that, with or without notice, lapse of time or both, could be expected to give rise to any such breach, default, repudiation, cancellation or termination) by any party to any Financing Letter or such other agreements or documents (including any definitive agreements) related to the Financing or (B)&#160;any amendment, supplement, waiver, other modification or termination of any Financing Letter or such other agreements or documents (including any definitive agreements) related to the Financing, (2)&#160;upon receipt by the Buyer Entities or any of their Affiliates or Representatives of any written notice or other written communication of any such breach, default, repudiation, cancellation or termination, (3)&#160;of any dispute or disagreement between or among the parties to any of the Financing Letters or the definitive documents related to any of the Financing with respect to the obligation to fund the Financing or the amount thereof to be funded at the Closing and (4)&#160;if for any reason Buyer Entities believe in good faith that will not be able to obtain the Required Amount of the Financing on the terms, in the manner or from the sources contemplated by the Financing Letters or the definitive documents related to the Financing in any manner which could be expected to impair, delay or prevent the consummation of the transactions contemplated hereby. As soon as reasonably practicable, but in any event within two (2) Business Days after the date Sellers deliver to Buyer Entities a written request, Buyer Entities shall provide any information reasonably requested by Sellers related to any circumstance referred to in clause&#160;(1), (2), (3) or (4) of the immediately preceding sentence. In addition, the Buyer Entities shall keep Sellers informed on a reasonably current basis and in reasonable detail of the status of their efforts to obtain and finalize the Financing and provide to Sellers copies of all definitive documents related to the Financing, including by providing Sellers with drafts of such definitive documents related to the Financing a reasonable period of time prior to their execution or use.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Financing Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;Prior to the Closing and subject to the limitations in this Agreement, Sellers and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts (at Buyer&#8217;s sole cost and expense)&#160;to cause the appropriate officers and employees of the Company and its Subsidiaries to, provide such cooperation as is necessary, customary and reasonably requested by the Buyer Entities upon reasonable prior notice to assist the Buyer Entities solely in connection with causing the conditions to the Financing to be satisfied or as is otherwise reasonably requested by the Buyer Entities in connection with the Buyer Entities&#8217; efforts to obtain the Financing (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that any such requests are timely made so as not to delay the Closing beyond the date on which it would otherwise occur), which cooperation may include (1)&#160;participating in a reasonable number of meetings and due diligence sessions with providers or potential providers of the Financing (which shall be limited to teleconference or virtual meeting platforms)&#160;during normal business hours and at mutually agreed locations and times (2)&#160;reasonably assisting the Buyer Entities in the preparation of materials reasonably and customarily requested to be used in connection with obtaining the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Financing, in each case, solely with respect to information related to the Company (to the extent related to its business)&#160;and its Subsidiaries, (3)&#160;providing reasonably promptly to the Buyer Entities such financial and other pertinent information regarding the Company and its Subsidiaries that is readily available or within the Company&#8217;s possession, in each case, as is required to satisfy the conditions set forth in paragraph&#160;6 of Exhibit&#160;C to the Debt Commitment Letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Required Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), (4)&#160;executing and delivering customary authorization letters (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that, such customary authorization letters, or the bank information memoranda in which such letters are included, shall include language that exculpates the Company, each of its Subsidiaries and its Representatives and Affiliates from any liability in connection with the unauthorized use or misuse by the recipients thereof of the information set forth in any such bank information memoranda or similar memoranda or report distributed in connection therewith)&#160;and other reasonable and customary certificates, management representation letters and other documentation required by the Financing Sources and the definitive documentation related to the Financing, in each case (other than with respect to such authorization letters), subject to the occurrence of the Closing and (5)&#160;delivering information and documentation related to the Company and its Subsidiaries required and reasonably requested in writing by the Financing Sources at least ten (10)&#160;Business Days prior to the Closing Date with respect to compliance under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the USA PATRIOT Act.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, none of Sellers, the Company, their respective Subsidiaries or any officer, employee or Representative of any of the foregoing, shall be required to (1)&#160;provide or prepare, and the Buyer Entities shall be solely responsible for, the preparation of pro forma financial information, including pro forma costs savings, synergies, capitalization or other pro forma adjustments desired to be incorporated into any pro forma financing information, (2)&#160;pay any fee, (3)&#160;provide Regulation&#160;S-X compliant financial statements or any financial data other than the Required Information, (4)&#160;approve any document or other matter related to the Financing or incur or reimburse any costs or expenses or incur any other liability or obligation of any kind or give any indemnities in connection with the Financing (unless given by the Company or any of its continuing officers at or after the Closing), (5)&#160;enter into, approve or perform any agreement or commitment in connection with the Financing or modify any agreement or commitment or provide any certification (in each case, unless by the Company or any of its continuing officers and effective only at or after the Closing, excluding any customary authorization letters described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)(i)(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), (6)&#160;provide any legal opinion or reliance letters or any certificate, comfort letter or opinion of any of its Representatives, (7)&#160;provide access to or disclose any information to the Buyer Entities or their Representatives to the extent such disclosure would violate the attorney-client privilege, attorney work product protections or similar protections or violate any applicable Law or contract, (8)&#160;take any action that could (A)&#160;unreasonably interfere with the day-to-day operations of the Company or any of its Subsidiaries, (B)&#160;cause any representation or warranty in this Agreement to be breached or cause any condition to Closing to fail to be satisfied or otherwise cause any breach of this Agreement, (C)&#160;result in any director, officer, employee or other Representative of the Company, the Sellers or any of their respective Subsidiaries incurring any personal liability, (D)&#160;conflict with the Organizational Documents of the Company or any of its Subsidiaries or any Law, (E)&#160;result in the contravention, violation or breach of, or a default under, any material contract, (9)&#160;prepare separate financial statements for the Company or any of its Subsidiaries or change any fiscal period (except with regard to the Audited Financial Statements), or (10)&#160;adopt any resolutions, execute any consents or otherwise take any corporate or similar action (in each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">case, unless by the Company or any of its continuing directors or officers and effective only at or after the Closing). Any use of the Company&#8217;s and its Subsidiaries&#8217; logos in connection with the Financing shall require the Company&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;The Buyer Entities expressly acknowledge and agrees that neither the availability, the terms nor the obtaining of the Financing or any other financing is in any manner a condition to the Closing or the obligations of the Buyer Entities to consummate the transactions contemplated hereby. Sellers, the Company and each of their respective Subsidiaries will be deemed to be in compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, and the Buyer Entities shall not allege that any of Sellers, the Company or any of their respective Subsidiaries is or has not been in compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, unless the Buyer Entities provide prompt written notice of the alleged failure to comply specifying in reasonable detail specific steps to cure such alleged failure in a commercially reasonable and practical manner consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, which alleged failure to comply has not been cured within ten (10) Business Days from receipt of such written notice.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;Neither Sellers, the Company nor any of their respective Affiliates or Subsidiaries (or any of their respective Representatives) shall have any liability to the Buyer Entities in respect of any financial statements, other financial information or data or other information provided pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in each case, other than, with respect to the Financial Statements, liability for Fraud or the exercise of the Buyer Entities rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as and if applicable. None of Sellers, the Company or any of their respective Affiliates or Subsidiaries (or any of their respective Representatives) shall have any liability or incur any losses, damages or penalties with respect to the Financing or any marketing materials, presentations or disclosure documents in connection therewith in the event the Closing does not occur. All non-public or other confidential information provided by or behalf of Sellers or the Company to the Buyer Entities or its Affiliates or any of their respective Representatives pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be kept confidential in accordance with the terms of the Confidentiality Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;The Buyer Entities shall indemnify and hold harmless Sellers, Company, each of their respective Subsidiaries and their respective Representatives and Affiliates from and against all losses suffered or incurred by any of them in connection with the obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the Financing or any information used in connection with the Financing, except for any of the foregoing to the extent the same is the result of a material breach of this Agreement, gross negligence, willful misconduct or Fraud committed by or on behalf of Sellers or the Company in connection with this Agreement or the transactions contemplated hereby, and then limited only to the extent of such material breach, gross negligence, willful misconduct or Fraud. The Buyer Entities shall promptly (and in any event within two (2) Business Days of delivery of documentation evidencing the applicable cost or expense), upon request by Sellers or the Company, reimburse Sellers or the Company or any of their respective Subsidiaries or Affiliates, as the case may be, for all reasonable and documented out-of-pocket costs and expenses (including reasonable outside attorneys&#8217; fees and disbursements) incurred thereby in connection with the cooperation contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Transition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Prior to the Closing, the Buyer Entities and Sellers shall use commercially reasonable efforts to develop, and, if and when developed, begin implementing, a mutually acceptable transition plan for the migration and integration of the Business out of the businesses of the Seller Group and into the business of Buyer, in each case, in compliance with applicable Law and subject to the other terms and conditions hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. From the execution of this Agreement until the Closing or earlier termination of this Agreement in accordance with its terms, Sellers will not, and will cause each of their respective Affiliates and Representatives, not to, directly or indirectly, (a)&#160;solicit, initiate or knowingly encourage any inquiry, proposal, offer or contact from any Person (other than the Buyer Entities and their Representatives) related to any transaction involving (i)&#160;the sale of the outstanding equity or consolidated assets (other than in the ordinary course of business) of any Acquired Entity, the Transferred Assets or the Business, (ii)&#160;any acquisition, divestiture, merger, equity exchange, consolidation, redemption or business combination transaction involving any Acquired Entity, the Transferred Assets or the Business or (iii)&#160;any similar transaction or business combination involving any Acquired Entity, the Transferred Assets or the Business (in each case, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Acquisition Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), or (b)&#160;participate in any discussion or negotiation regarding, or furnish any information with respect to, or assist or facilitate in any manner, any Acquisition Proposal or any attempt to make an Acquisition Proposal. The Seller Group shall immediately cease, and cause to be terminated, any and all contacts, discussions and negotiations with third parties regarding any of the foregoing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. From and after the Closing, each of Sellers and the Buyer Entities shall use commercially reasonable efforts from time to time to execute and deliver, or cause to be executed and delivered by its respective Affiliates, at the reasonable request of the other Party such additional documents and instruments, including any assignment or assumption agreements, bills of sale, instruments of assignment, consents and other similar instruments in addition to those required by this Agreement, as may be reasonably required to give effect to this Agreement and the transactions contemplated hereby and to provide any documents or other evidence of ownership as may be reasonably requested by the Buyer Entities to confirm Buyer&#8217;s ownership of the Transferred Equity Interests and the Transferred Assets and the assumption of the Assumed Liabilities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Post-Closing Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Other than with respect to any Consent Required Contract, which is subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, from and after the Closing, if Sellers or any of their Affiliates receives or collects any funds in respect of any accounts receivable or notes receivable or any credits, prepaid expenses, rebates, deferred charges or prepaid items of any Person that are Transferred Assets in accordance hereof or otherwise belong to an Acquired Entity, Sellers or their applicable Affiliates shall remit such funds to Buyer promptly after receipt thereof. From and after the Closing, if Buyer or any of its Affiliate receives or collects any funds related to any Excluded Asset, Buyer or its Affiliate shall remit any such funds to Sellers promptly after its receipt thereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Additional Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Prior to the Closing, Seller Parent shall use commercially reasonable efforts to cause to be prepared, at Buyer Parent&#8217;s cost and expense (not to exceed $500,000 or, in the event the 2022 Audited Financial Statements are included in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">the definition of Additional Financial Information, $900,000), (i)&#160;the audited combined balance sheets of the Business as of December&#160;31, 2021, and December&#160;31, 2020, and the respective related audited combined statements of income, parent investment, and cash flows of the Business for the fiscal years ended December&#160;31, 2021, and December&#160;31, 2020, and (ii)&#160;the unaudited combined balance sheets of the Business as of September&#160;30, 2022, and September&#160;30, 2021, and the respective related unaudited combined statements of income, parent investment and cash flows for the Business for the nine months ended September&#160;30, 2022 and September&#160;30, 2021, including the notes thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Additional Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;). If any of the Additional Financial Information has not been completed as of the Closing, Seller Parent and Buyer shall cooperate in good faith for Buyer to be assigned the engagement with the auditor conducting the audits thereof with respect to such Additional Financial Information, and Buyer Parent shall use reasonable best efforts to cause the Additional Financial Information to be completed as promptly as practicable after the Closing. The failure of any Additional Financial Information to be completed, or any differences between the Additional Financial Information and the Financial Statements, shall in no event (a)&#160;be a breach of, or failure to comply with, any provision hereof or (b)&#160;grant the Buyer Entities any right to terminate this Agreement or fail to consummate the Closing. Buyer shall, promptly upon request by Seller Parent, reimburse Seller Parent for all documented out-of-pocket costs incurred by Seller Parent or its Representatives in connection with the Additional Financial Information. Buyer shall be responsible, at its sole cost and expense, for procuring any comfort letter from the auditor of the Additional Financial Information, and Sellers shall not be required to provide any legal opinion or reliance letters or any certificate, comfort letter or opinion of any of its Representatives with respect to the Additional Financial Information. Notwithstanding anything to the contrary herein, if the Closing has not occurred prior to January&#160;15, 2023, the definition of &#8220;Additional Financial Information&#8221; shall also include the audited combined balance sheets of the Business as of December&#160;31, 2022, and the respective related audited combined statements of income, parent investment, and cash flows of the Business for the fiscal years ended December&#160;31, 2022 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2022 Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Certain Post-Closing Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Following the Closing, the Buyer Entities, as applicable, shall take the actions listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;5.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Earnout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Buyer Parent shall pay to Seller Parent the cash amounts, and, if applicable, Buyer Parent shall issue to Seller Parent the shares of Buyer Class A Common Stock, in each case, as provided in, and on and subject to the terms, conditions, procedures and definitions set forth in, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (such shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Earnout Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; and such cash payment together with the Earnout Shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Earnout Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), and the Parties hereby agree to such terms, conditions, procedures and definitions. As set forth in more detail on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, the Earnout Amount, will be payable, if at all, based on the achievement of certain metrics, or the occurrence of certain events, in calendar year 2023 and will in no event exceed $150,000,000. As set forth in more detail on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, the Earnout Amount will be payable 50% in cash and 50% in Earnout Shares (based upon the volume weighted average of the sale prices per share of Buyer Parent Class A Common Stock on NYSE for the twenty (20) full consecutive trading days ending on the trading day that is two (2) Business Days prior to the date on which such shares of Buyer Parent Class A Common Stock are required to be issued)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that, Buyer Parent may increase the cash amount (and correspondingly decrease the number of Earnout Shares) upon two Business Days&#8217; prior written notice to Seller Parent prior to the payment of the Earnout Amount. In the event of any conflict between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;5.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R&#38;W Insurance Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Buyer Entities shall not permit the Binder Agreement or the R&#38;W Insurance Policy to be amended in any manner adverse to Sellers. The Buyer Entities shall take all actions necessary to cause the final R&#38;W Insurance Policy to be issued in accordance with the Binder Agreement as promptly as practicable on or after the Closing Date. Prior to the Closing, Sellers shall provide the Buyer Entities with access and information (including participating in diligence calls as reasonably requested by the Buyer Entities) pursuant to, and subject to the terms and conditions of, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the extent reasonably requested by the Buyer Entities for the Buyer Entities to seek to limit or eliminate any exclusions from coverage under the R&#38;W Insurance Policy.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the period commencing on the date hereof and ending on the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) anniversary of the Closing Date, Sellers agree to hold all Buyer Confidential Information confidential and shall not, and shall cause their respective Representatives not to, directly or indirectly, (a)&#160;use any Buyer Confidential Information or (b)&#160;disclose any Buyer Confidential Information to any third Person (other than Buyer and its Affiliates), in each case, other than to perform its obligations, or exercise or enforce its rights, under the Purchase Agreement, any Ancillary Agreement, any Affiliate Contract that survives the Closing or any Contract between Buyer or its Affiliates, on the one hand, and any Seller or its Affiliates, on the other hand. Notwithstanding anything herein to the contrary, (i)&#160;Buyer Confidential Information may be disclosed to any of Sellers&#8217; respective Representatives if such Representative has a need to know such Buyer Confidential Information or is otherwise already in possession of the Buyer Confidential Information on the date hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that Sellers shall be liable for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> by any of their respective Representatives, (ii)&#160;Sellers and their respective Representatives may disclose Buyer Confidential Information to the extent such disclosure is, on the advice of Sellers&#8217; legal counsel, required by applicable Law or the rules of any applicable stock exchange or the terms of a subpoena, Order or similar legal process pursuant to applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that such Seller or such Representative give Buyer prompt notice of any and all such requests for disclosure, to the extent reasonably practicable and permissible, and uses commercially reasonable efforts to cooperate with Buyer, at Buyer&#8217;s sole expense, so that Buyer has may take all legally available actions to avoid disclosure&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that, if despite such notice and cooperation and Buyer&#8217;s attempt to avoid disclosure any Seller or such Representative is nonetheless obligated to disclose the Buyer Confidential Information, such Seller or such Representative shall disclose only that portion of the Buyer Confidential Information which, on the advice of its legal counsel, such Seller or Representative is required to disclose, and (iii)&#160;Sellers and their respective Representatives may disclose Buyer Confidential Information to any Governmental Authority or securities exchange to which any Seller or any such Representative is subject in the course of any routine, non-targeted audit, examination, investigation or review by such Governmental Authority without providing notice thereof to Buyer or any other Person or otherwise complying with the foregoing clause&#160;(B). For purposes hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all confidential, proprietary or trade secret information of the Buyer Group provided by the Buyer Group to any member of the Seller Group prior to the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Buyer Confidential Information shall not include any information that (1)&#160;is or becomes generally available to the public prior to, on or after the Closing Date (other than as a result of a disclosure by Sellers, any of their Affiliates or any of their respective Representatives), or (2)&#160;becomes available to Sellers, their Affiliates, or their respective Representatives on a non-confidential basis after the Closing Date from a source </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">other than Buyer or any of its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that such source was not known by Sellers, Sellers&#8217; Affiliates, or their respective Representatives to be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation of confidentiality to, Buyer or any of its Affiliates.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Parent Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If applicable, Buyer Parent shall use reasonable best efforts to cause the Buyer Parent Shares to be issued to Seller Parent hereunder to be listed on the NYSE, subject to official notice of issuance, prior to the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;5.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">NIA Pennsylvania</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In the event that National Imaging Associates of Pennsylvania, LLC, a Pennsylvania limited liability company and Subsidiary of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">NIA Pennsylvania</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), is not dissolved prior to the Closing, Sellers shall cause ownership of NIA Pennsylvania to be transferred to a member of the Seller Group prior to the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"><br>CONDITIONS TO CLOSING</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conditions to the Obligation of Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The respective obligations of the Buyer Entities and Sellers to consummate the Acquisition and the Liabilities Assumption shall be subject to the satisfaction (or waiver by the Buyer Entities, on the one hand, and Sellers, on the other hand) at or prior to the Closing of the following conditions&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;The waiting period (and any extension of such period) under the HSR Act applicable to the transactions contemplated hereby shall have expired or otherwise been terminated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">HSR Act Clearance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;No Order issued after the date hereof, whether preliminary, temporary or permanent, shall be in effect that prohibits the consummation of the Acquisition (any such Law, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Legal Restraint</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;All Required Filings shall have been made.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conditions to the Obligations of the Buyer Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The obligation of Buyer Entities to consummate the Acquisition and the Liabilities Assumption is further subject to the satisfaction (or waiver by the Buyer Entities) prior to the Closing of the following conditions&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;(i)&#160;Each Sell-Side Fundamental Representation shall be accurate (read, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> only, without giving effect to any qualifier as to materiality, &#8220;in all material respects,&#8221; &#8220;material,&#8221; Seller Material Adverse Effect or Material Adverse Effect) in all material respects as of the Closing Date as if made as of the Closing Date (except to the extent any such representation or warranty expressly speaks as of a specific date, in which case such representation or warranty shall have been accurate in all material respects as of such date), (ii)&#160;each representation and warranty in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (other than any Sell-Side Fundamental Representations) shall be accurate (read, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> only, without giving effect to any qualifier as to materiality, &#8220;in all material respects,&#8221; &#8220;material,&#8221; Seller Material Adverse Effect or Material Adverse Effect) as of the Closing Date as if made as of the Closing Date (except to the extent any such representation or warranty expressly speaks as of a specific date, in which case such representation or warranty shall have been accurate as of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">date), other than any failure of any such representation or warranty to be accurate as of the Closing Date as if made on the Closing Date (or express earlier date) that would not result in a Seller Material Adverse Effect, and (iii)&#160;each representation and warranty in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (other than any Sell-Side Fundamental Representation) shall be accurate (read, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> only, without giving effect to any qualifier as to materiality, &#8220;in all material respects,&#8221; &#8220;material&#8221; or Material Adverse Effect) as of the Closing Date as if made as of the Closing Date (except to the extent any such representation or warranty expressly speaks as of a specific date, in which case such representation or warranty shall have been accurate as of such date), other than any failure of any such representation or warranty to be accurate as of the Closing Date as if made on the Closing Date (or express earlier date) that would not result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;None of Sellers shall have materially breached any covenant or agreement hereunder (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) that is required to be performed or complied with prior to the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;The Buyer Entities shall have received a certificate, dated as of the Closing Date and duly executed on behalf of Sellers, confirming the satisfaction of the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Since the date of this Agreement, there shall not have occurred any Material Adverse Effect or Seller Material Adverse Effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conditions to Obligation of Sellers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The obligation of Sellers to consummate the Acquisition and the Liabilities Assumption is further subject to the satisfaction (or waiver by the Buyer Entities) prior to the Closing of the following conditions&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Each representation and warranty in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be accurate (read, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> only, without giving effect to any qualifier as to materiality, &#8220;in all material respects,&#8221; &#8220;material&#8221; or Buyer Material Adverse Effect) as of the Closing Date as if made as of the Closing Date (except to the extent any such representation or warranty expressly speaks as of a specific date, in which case such representation or warranty shall have been accurate as of such date), other than any failure of any such representation or warranty to be accurate as of the Closing Date as if made on the Closing Date (or express earlier date) that would not result in a Buyer Material Adverse Effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;The Buyer Entities shall not have materially breached any covenant or agreement hereunder that is required to be performed or complied with prior to the Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Sellers shall have received a certificate, dated as of the Closing Date and duly executed on behalf of the Buyer Entities, confirming the satisfaction of the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;(i)&#160;Since the date of this Agreement, there shall not have occurred any Buyer Material Adverse Effect, and (ii)&#160;if Buyer Parent Shares are to be issued hereunder, such Buyer Parent Shares shall have been approved for listing on the NYSE, subject to official notice of issuance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE&#160;VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"><br>TERMINATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination by Mutual Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Seller Parent (on behalf of Sellers) and Buyer Parent (on behalf of the Buyer Entities) shall have the right to terminate this Agreement at any time prior to the Closing by mutual written agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination by Either Seller Parent or the Buyer Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each of Seller Parent (on behalf of Sellers) and Buyer Parent (on behalf of the Buyer Entities) shall have the right to terminate this Agreement at any time prior to the Closing if&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;the Closing does not occur prior to 5&#58;00&#160;p.m. on August&#160;17, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that, if the condition in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not have been satisfied as of 5&#58;00&#160;p.m. on the day immediately preceding the Outside Date, then the Outside Date shall be extended automatically to November&#160;17, 2023 (and, in the case of such extension, any reference to the Outside Date in any other provision hereof shall be a reference to the Outside Date, as extended)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not be available to a Party if the failure of the Closing to have occurred prior to 5&#58;00&#160;p.m. on the Outside Date was caused by such Party&#8217;s breach of any of its covenants or agreements hereunder&#59; or</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;a Legal Restraint is in effect that has become final and nonappealable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not be available to a Party if the existence of such Legal Restraint was caused by such Party&#8217;s breach of any of its covenants or agreements hereunder.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination by Buyer Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Buyer Parent, on behalf of the Buyer Entities, shall have the right to terminate this Agreement if a Seller breaches any of its covenants or agreements hereunder, or any of such Seller&#8217;s representations or warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is inaccurate, which breach or inaccuracy (1)&#160;would give rise to the failure of a condition in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable, to be satisfied and (2)&#160;cannot be cured by such Seller by the Outside Date or, if capable of being so cured, is not cured by such Seller within thirty (30) days after Buyer Parent delivers written notice of such breach or inaccuracy to Seller Parent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Buyer Parent shall not have the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> if a Buyer Entity has breached any of its respective covenants or agreements hereunder, or any of the Buyer Entities&#8217; representations or warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is inaccurate, which breach or inaccuracy would give rise to the failure of a condition in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination by Seller Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Seller Parent, on behalf of Sellers, shall have the right to terminate this Agreement at any time prior to the Closing if&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;a Buyer Entity breaches any of its covenants or agreements hereunder, or any of the Buyer Entities&#8217; representations or warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is inaccurate, which breach or inaccuracy (A)&#160;would give rise to the failure of a condition in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable, to be satisfied and (B)&#160;cannot be cured by such Buyer Entity by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Outside Date or, if so capable of being cured, is not cured by such Buyer Entity within thirty (30) days after Seller Parent delivers written notice of such breach or inaccuracy to Buyer Parent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Seller Parent shall not have the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> if a Seller breaches any of its covenants or agreements hereunder, or any of Sellers&#8217; representations or warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is inaccurate, which breach or inaccuracy would give rise to the failure of a condition in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable&#59; or</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;(1)&#160;all of the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> have been satisfied (other than any such condition that by its nature is to be satisfied at the Closing, any such condition that has been waived by Buyer Parent and any such condition the failure of which to be satisfied has been caused by or results from a breach by a Buyer Entity of any of its covenants or agreements hereunder), (2)&#160;Seller Parent has irrevocably confirmed in writing at least three (3) Business Days prior to such termination that Sellers stand ready, willing and able to consummate the Closing, and (3)&#160;the Buyer Entities have failed (for any reason) to consummate the Closing on or prior to the date on which the Buyer Entities were required to consummate the Closing under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and within three (3) Business Days after receipt by Buyer Parent of the written confirmation referred to in clause&#160;(2) of this sentence (the occurrence of the foregoing, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Closing Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;This Agreement may be terminated only under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In order to terminate this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (other than under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), the Party desiring to terminate this Agreement shall give written notice of such termination to the other Parties, specifying the subsection of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> under which such Party is terminating this Agreement. If this Agreement is terminated under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, this Agreement shall immediately become void and of no effect, and no Party shall have any further Liability, whether arising before, at or after such termination, that may be based on this Agreement, arising out of this Agreement or related hereto or the negotiation, execution, performance or subject matter hereof, except that (a)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, this Section&#160;7.2, the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, and the Parties&#8217; Liabilities thereunder, shall survive such termination and remain in full force and effect in accordance with their terms, (b)&#160;Buyer Parent&#8217;s Liability under the Confidentiality Agreement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall survive such termination and remain in full force and effect and (c)&#160;subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, no such termination shall relieve any Party from liability for (i)&#160;any material breach of a covenant or agreement hereunder occurring prior to such termination (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that a Buyer Closing Failure shall be a covenant or agreement hereof occurring prior to the termination hereof) or (ii)&#160;any Fraud.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;In the event that this Agreement is validly terminated by Seller Parent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (other than a termination under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as a result of a breach of a representation or warranty giving rise to the failure of the condition to Closing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> under clause&#160;(ii) of the definition of Buyer Material Adverse Effect (if applicable)), then Buyer Parent shall pay to Seller Parent an amount in cash by wire transfer of immediately available funds equal to $52,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) within two (2) Business Days after the date of such termination. In no event shall Buyer Parent be required to pay the Termination Fee on more than one (1) occasion or at different times. If Buyer Parent fails </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to pay the Termination Fee when required to be made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Buyer Parent shall also pay to Seller Parent interest on the Termination Fee from the date such payment was required to be made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> until the date of payment at the prime lending rate as published in The Wall Street Journal in effect on the date such payment was required to be made, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> five hundred (500) basis points (such interest, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination Fee Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). In addition, if Buyer Parent fails to pay the Termination Fee when required to be made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and Seller Parent commences a Claim that results in a final, non-appealable Order against Buyer Parent for payment of the Termination Fee (or any portion thereof), Buyer Parent shall also pay to Seller Parent an amount equal to Seller Parent&#8217;s and its Affiliates&#8217; reasonable and documented out-of-pocket costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such Claim (such costs and expenses, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination Fee Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and, together with the Termination Fee and Termination Fee Interest, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Termination Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein, if this Agreement is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (other than a termination under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.1(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as a result of a breach of a representation or warranty giving rise to the failure of the condition to Closing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> under clause&#160;(ii) of the definition of Buyer Material Adverse Effect (if applicable)), the exclusive remedy of Sellers and their respective Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company Related Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) against the Buyer Entities and any of their Representatives (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Related Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) for any Claim (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) that may be based on, arise out of or relate to this Agreement or the Ancillary Agreements (including the negotiation, execution, performance or subject matter hereof or thereof) or the transactions contemplated hereby or thereby shall be payment of the Termination Payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, and, upon Buyer Parent&#8217;s payment of the Termination Payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, none of the Buyer Related Persons shall have any further liability or obligation relating to or arising his Agreement or the Ancillary Agreements (including the negotiation, execution, performance or subject matter hereof or thereof) or the transactions contemplated hereby or thereby.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"><br>TAX MATTERS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Preparation and Filing of Tax Returns&#59; Contests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Seller Parent shall prepare and timely file (or cause to be prepared and timely filed) (i)&#160;all Tax Returns in respect of Seller Consolidated Taxes, (ii)&#160;all other Income Tax Returns required to be filed with respect to any Acquired Entity for any Pre-Closing Tax Period (excluding any Straddle Period), and (iii)&#160;all other Tax Returns of the Acquired Entities and with respect to the Transferred Assets that are filed prior to the Closing (those Tax Returns described in clauses&#160;(i) to (iii), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Seller Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). In each case, Seller Parent shall timely remit (or cause to be timely remitted) to the applicable Governmental Authority (or, in the case of any Seller Tax Return described in clause&#160;(ii) above that is required to be filed after Closing, to Buyer for remittance to the applicable Governmental Authority) any Taxes shown as due on such Seller Tax Returns. To the extent any such Seller Tax Return relates to the Acquired Entities or to the Transferred Assets, (x)&#160;Seller Parent shall prepare such Seller Tax Returns in accordance with past practices of the Acquired Entities (or the applicable owner of the Transferred Asset </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">prior to Closing), and (y)&#160;completed drafts of any such Seller Tax Returns filed after the Closing Date shall be submitted to Buyer not later than thirty (30) days prior to the due date (taking into account applicable extensions) for filing such Seller Tax Return (or, if such due date is within forty-five (45) days following the Closing Date, as promptly as practicable following the Closing Date) for Buyer&#8217;s review and comment, the resolution of which shall be determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that with respect to any Tax Return regarding Seller Consolidated Taxes, Seller Parent shall provide only pro forma statements (including the relevant data used to create such pro forma statements, excluding data that may disclose information about the operations of any member of the Seller Group other than an Acquired Entity) reporting the operations of the Acquired Entities on a separate return basis.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Buyer shall prepare and timely file (or cause to be prepared and timely filed) all Tax Returns of the Acquired Entities and with respect to the Transferred Assets that are due (after taking into account applicable extensions validly obtained) after the Closing Date, other than Seller Tax Returns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Buyer shall prepare any Buyer Tax Return for a Pre-Closing Tax Period (including any Straddle Period) in accordance with existing procedures and practices and accounting methods of the applicable Acquired Entity (or, if applicable, the applicable owner of the Transferred Asset prior to Closing). Seller Parent shall remit Seller Parent&#8217;s share of any Taxes shown as due on any Buyer Tax Return with respect to any Straddle Period to Buyer within three Business Days following demand from Buyer therefor and, without limiting the obligations of Seller Parent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Buyer shall timely remit, or cause to be timely remitted, all Taxes shown as due in respect of such Buyer Tax Returns&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that for the avoidance of doubt, Buyer&#8217;s obligation to pay such Taxes shall not affect the calculation of the Closing Date Cash for purposes of the Final First Adjustment Amount. Buyer shall provide Seller Parent with a copy of each Buyer Tax Return that includes any Accrued Taxes or any Taxes for which Buyer may claim indemnification from Sellers at least twenty (20) days prior to the due date (taking into account applicable extensions) of such Tax Return for Seller Parent&#8217;s review and comment. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> with respect to any disputed comments provided by Seller Parent to Buyer at least ten (10) days prior to the due date (taking into account applicable extensions validly obtained) for filing such Buyer Tax Return, Buyer shall timely file each Buyer Tax Return with the appropriate Governmental Authority.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;To the extent permitted by Law, each of the Acquired Entities shall elect to close each of its respective taxable periods as of or prior to the Closing Date. Any Tax Return of any Acquired Entity or of any member of the Seller Group with respect to the Transferred Assets for a Straddle Period shall, to the extent permitted by Law, be filed on the basis that the relevant taxable period ended as of the close of business on the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Buyer and Seller Parent shall use good faith efforts to resolve any dispute regarding the preparation of Seller Tax Returns and Buyer Tax Returns. In the event of any such dispute that cannot be resolved, such dispute shall be resolved by the Independent Accountant and any determination by the Independent Accountant with respect to such dispute shall be final. The fees and expenses of the Independent Accountant shall be borne equally by Buyer and Seller Parent. If the Independent Accountant does not resolve any differences between Buyer and Seller Parent with respect to such Tax Return at least five (5) days prior to the due date therefor, such Tax Return shall be filed as prepared by the Party responsible for preparing such Tax Return and amended to reflect the Independent Accountant&#8217;s resolution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;None of Buyer or any of its Affiliates (including the Acquired Entities) shall (or shall cause or permit any other Person to) (i)&#160;except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, amend, re-file, or otherwise modify any Tax Return or Tax election related in whole or in part to the Acquired Entities or the Transferred Assets with respect to any Pre-Closing Tax Period or any Pre-Closing Straddle Period, (ii)&#160;agree to any waiver or extension of the statute of limitations related in whole or in part to Taxes or Tax Returns of the Acquired Entities or the Transferred Assets for any Pre-Closing Tax Period, (iii)&#160;file any ruling or request with any Taxing Authority related in whole or in part to any Taxes or Tax Returns of the Acquired Entities or the Transferred Assets for a Pre-Closing Tax Period or any Pre-Closing Straddle Period, or (iv)&#160;enter into or initiate any voluntary disclosure agreement with any Taxing Authority related in whole or in part to any Taxes or Tax Returns of the Acquired Entities or the Transferred Assets for any Pre-Closing Tax Period, in each case, without the prior written consent of Sellers (which consent shall not be unreasonably withheld, conditioned, or delayed). Sellers and Buyer, as applicable, shall not make or permit to be made any election under Section&#160;336(e) or Section&#160;338 of the Code with respect to the disposition of shares of the Acquired Entities hereunder.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;Sellers shall have the right to initiate any Claim for Pre-Closing Tax Refunds and amend any Pre-Closing Tax Return.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Straddle Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Where it is necessary for purposes hereof to apportion Taxes between the Seller Group and Buyer with respect to the Acquired Entities or the Transferred Assets for a Straddle Period, such Taxes shall be apportioned between the period deemed to end on the Closing Date and the period deemed to begin at the beginning of the day following the Closing Date on the basis of an interim closing of the books, except that (a)&#160;exemptions, allowances, and deductions that are calculated on an annual basis and (b)&#160;Taxes (such as real or personal property Taxes) that are imposed on a periodic basis, shall, in each case, be allocated ratably across the entire Straddle Period on a per diem basis.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Pre-Closing Tax Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any refund of Taxes of the Acquired Entities or with respect to the Transferred Assets for any Pre-Closing Tax Period or any Pre-Closing Straddle Period (including any interest in respect thereof) paid by the Acquired Entities on or before the Closing Date that is specifically identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Disclosure Schedule and that is received by Buyer or its Affiliates (including the Acquired Entities) after the Closing Date (any such refund, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Pre-Closing Tax Refund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), shall be for the account of the Seller Group to the extent such Pre-Closing Tax Refund was not taken into account in determining Net Working Capital or Accrued Taxes. Buyer shall pay over to Sellers any such Pre-Closing Tax Refund within three (3) days after receipt thereof, net of (i)&#160;any Taxes that the Acquired Entities, Buyer or any of their respective Affiliates incur with respect to the receipt of such refund, and (ii)&#160;any reasonable expenses that the Acquired Entities, Buyer, or any of their respective Affiliates incur in obtaining such Pre-Closing Tax Refund. Buyer shall reasonably cooperate with Sellers in obtaining such Pre-Closing Tax Refund and Buyer shall and shall cause the Acquired Entities to request refunds (rather than credits against future Taxes) with respect to such Pre-Closing Tax Refunds. Any refunds or credits of Taxes of the Acquired Entities or with respect to the Transferred Assets for any Straddle Period shall be apportioned between Buyer and Sellers in accordance with the principles set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If, as a result of a final determination (within the meaning of Code Section&#160;1313(a)), the amount of any such refund or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">credit for which the Seller Group received a payment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Seller shall repay to Buyer an amount equal to any such reduction, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> any penalties or interest required to be repaid to the applicable Governmental Body in connection with such determination.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Allocation of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Within thirty (30) days following the determination of the Final First Adjustment Amount pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Buyer shall prepare and deliver to Seller Parent a draft allocation of the Purchase Price (and any other amounts treated as consideration for U.S. federal income Tax purposes) among the Transferred Equity Interests and the Transferred Assets (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Purchase Price Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in accordance with Section&#160;1060 of the Code and the Treasury Regulations promulgated thereunder. If, within ten (10) Business Days of receiving the Purchase Price Allocation, Seller Parent has not objected to such allocation in writing, the Purchase Price Allocation shall become final and binding on the Parties. If, within ten (10) Business Days of receiving the Purchase Price Allocation, Seller Parent notifies Buyer in writing of its objection to the Purchase Price Allocation, Buyer and Seller Parent shall cooperate in good faith to resolve any disputed items. If Buyer and Seller Parent cannot resolve any disputed items with respect to the Purchase Price Allocation within thirty (30) Business Days of Seller Parent&#8217;s delivery of its written objection (or such longer period as Buyer and Seller Parent may agree in writing), neither Party shall have any further obligation pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In the event Buyer and Seller Parent agree on the Purchase Price Allocation, Seller Parent, Buyer and their respective Affiliates shall not take any position inconsistent with such Purchase Price Allocation on any Tax Return or in any Tax Proceeding or otherwise, in each case, except to the extent otherwise required pursuant to a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code (or any similar provision of applicable state, local or non-U.S. Law).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. All transfer, documentary, sales, use, value added, goods and services, stamp, registration and similar Taxes, and all conveyance fees and recording charges (including any penalties and interest), arising in connection with or as a result of the transactions contemplated hereby (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall be borne and paid equally by Buyer, on the one hand, and Seller Parent, on the other hand. The Party required to do so under applicable Law shall prepare and timely file (or cause to be prepared and timely filed) all Tax Returns with respect to such Transfer Taxes.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Tax Sharing Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Sellers shall cause all Tax sharing agreements involving any of the Acquired Entities, on the one hand, and any member of the Seller Group, on the other hand, to terminate as of the Closing Date, and shall ensure that such agreements are of no further force and effect as to the Acquired Entities on and after the Closing Date and that there shall be no present or future liabilities or obligations imposed on the Acquired Entities under any such agreements.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each of Buyer and the members of the Seller Group shall cooperate, as reasonably requested by another of them, with respect to (a)&#160;preparing and filing any Tax Return, amended Tax Return, or claim for refund, (b)&#160;determining a liability for Taxes under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, or a right to refund of Taxes and (c)&#160;any audit, examination, assessment, litigation, or other proceeding with respect to Taxes. Such cooperation shall include the retention and (upon another such party&#8217;s request) the provision of records and information that are reasonably relevant to any such audit, litigation, or other proceeding, and making employees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Buyer shall cause the Company to retain all books and records with respect to Tax matters pertinent to the Acquired Entities related to any taxable period beginning before the Closing Date until the expiration of the applicable statute of limitations (and, to the extent notified by Sellers, any extensions thereof), and to abide by all record retention agreements entered into with any Taxing Authority. Buyer shall cause the Company to furnish any Tax information reasonably requested by Seller Parent for any taxable period of the Acquired Entities, the Transferred Assets or the Assumed Liabilities that includes the Closing Date. Notwithstanding anything herein to the contrary, (i)&#160;Sellers shall not be required to provide Buyer with any Tax Returns or other information with respect to Seller Consolidated Taxes (other than pro forma Tax Returns of any Acquired Entity), and (ii)&#160;Buyer shall not be required to provide Seller Parent with any Tax Returns or other information with respect to Buyer Consolidated Taxes (other than pro forma Tax Returns of any Acquired Entity).</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary in this Agreement, the covenants and agreements of the Parties in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall survive the Closing Date until thirty (30) days after the expiration of the applicable statutory periods of limitation (including any extensions or waivers thereof).</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary in this Agreement, in the event of a conflict or inconsistency between the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and any other provisions hereof, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall govern.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"><br>INDEMNIFICATION</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, from and after the Closing, Sellers shall jointly and severally indemnify the Buyer Entities for, and defend and hold harmless the Buyer Entities and their Representatives (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Buyer Indemnified Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) from and against, any Losses incurred or suffered by the Buyer Indemnified Persons (including arising from a Third-Party Claim or otherwise) arising from or related to any of the following&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;any breach by Sellers of any covenant or agreement herein that is required to be performed or complied with at or after the Closing&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;any Excluded Asset&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;any Retained Liability (other than Tax Liabilities and Specified Retained Liabilities)&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;any D&#38;O Costs not covered by the Tail Policy&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v)&#160;&#160;&#160;&#160;any Closing Date Indebtedness to the extent not taken into account in the calculation of the First Adjustment Amount&#59;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vi)&#160;&#160;&#160;&#160;any Pre-Closing Taxes&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vii)&#160;&#160;&#160;&#160;the matters listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Disclosure Schedule.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, from and after the Closing, the Buyer Entities shall jointly and severally indemnify Sellers for, and defend and hold harmless Sellers and their respective Representatives (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Seller Indemnified Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) from and against, any Losses incurred or suffered by the Seller Indemnified Persons (including arising from a Third-Party Claim or otherwise) arising from or related to any of the following&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;any breach by the Buyer Entities after the Closing of any covenant or agreement herein that is required to be performed or complied with at or after the Closing&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;any Transferred Asset&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;any Assumed Liability.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, no amounts payable under an Affiliate Contract that survives the Closing or any Contract entered into at or after the Closing between Buyer or its Affiliates (including the Acquired Entities), on the one hand, and Seller or its Affiliates, on the other hand, shall be considered Losses.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;As a condition to making an indemnification Claim under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, any Party seeking indemnification under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall assert any Claim for indemnification, including any Third-Party Claim, by delivering written notice thereof (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to the Party from which indemnification is sought pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) promptly upon becoming aware of any fact or circumstance that may give rise to an indemnification Claim under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the failure to give such prompt written notice shall not relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party is materially prejudiced by such failure. Each Claim Notice shall describe in reasonable detail the nature of the Claim and reference the Sections under which the Claim is asserted and attach copies of all material written evidence thereof that the Indemnified Party has received from any Person that is not a Party or an Affiliate of a Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The date of the delivery of such Claim Notice is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Claim Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.&#8221; If the Indemnifying Party objects to any Claim within such Claim Notice, such objection must be made in writing delivered to the Indemnified Party within thirty (30) days after the Claim Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Objection Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Prior to the institution of any Claim under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the Indemnified Party and the Indemnifying Party shall attempt to resolve any dispute for a period of thirty (30) days from the date of the delivery of the Objection Notice to the Indemnified Party and thereafter. If a Claim Notice was delivered to the Indemnifying Party and the Indemnifying Party does not deliver an Objection Notice to the Indemnified Party within thirty (30) days after the Claim Date, the Indemnifying Party shall be deemed to have irrevocably agreed to pay the Losses at issue in the Claim Notice, subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Following receipt by an Indemnifying Party of a Claim Notice in respect of a Claim brought by a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), the Indemnifying Party shall be entitled to assume and have sole control over the defense and investigation of, and negotiate and enter into a settlement or compromise of, or consent to the entry of an Order with respect to, such Third-Party Claim at its sole cost and expense and with counsel of its own choosing if it gives </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">notice of its intention to do so to the Indemnified Party within thirty (30) days after the Claim Date. The Indemnified Party shall have the right to participate in the defense of any Third-Party Claim with counsel selected by it subject to the Indemnifying Party&#8217;s right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, if in the reasonable opinion of counsel to the Indemnified Party, (i)&#160;there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party or (ii)&#160;there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. Notwithstanding the foregoing, the Indemnifying Party shall not consent to any settlement, compromise or consent of such Third-Party Claim without the prior written consent of such Indemnified Party (whether or not such Indemnified Party is an actual or potential party to such Third-Party Claim), which consent shall not be unreasonably withheld, conditioned or delayed, unless such settlement, compromise or consent includes a full release by the applicable Third Party of the Indemnified Party or its applicable Representatives for all Losses with respect to such Third-Party Claim. In connection with any Third-Party Claim, the Indemnified Party and the Indemnifying Party and their applicable Representatives shall reasonably cooperate with one another and use their commercially reasonable efforts to make available to the other all relevant information in their possession or under their control and shall take such other steps as are reasonably necessary to enable the Indemnifying Party and&#47;or Indemnified Party to conduct such defense.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.3(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to the contrary, the Indemnifying Party shall not be entitled to assume and control the defense or investigation of any Third-Party Claim that (i)&#160;seeks an injunction or other equitable relief against an Indemnified Party (other than an injunction or other equitable relief that is immaterial and is incidental to monetary remedies) or (ii)&#160;involves an allegation that an Indemnified Party committed a criminal violation of Law. If, within thirty (30) days after the Claim Date with respect to a Third-Party Claim, the Indemnifying Party (1)&#160;notifies such Indemnified Party in writing that the Indemnifying Party does not elect to defend and investigate such Third-Party Claim or (2)&#160;fails to deliver to the Indemnified Party a written election to assume the defense and investigation of such Third-Party Claim or (3)&#160;is not entitled to assume the defense or investigation of such Third-Party Claim, then (A)&#160;such Indemnified Party may, at its option, defend, investigate, settle or compromise, or consent to an entry of an Order with respect to, such Third-Party Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any such settlement, compromise or consent shall be permitted only with the written consent of the Indemnifying Party (whether or not the Indemnifying Party is an actual or potential party to such Third-Party Claim), which consent shall not be unreasonably withheld, conditioned or delayed and (B)&#160;the Indemnifying Party may participate in (but not control) any such defense and investigation at its sole cost and expense.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Other Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, Sellers&#8217; aggregate liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not exceed an amount equal to the sum of (i)&#160;the Business Enterprise Value, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (ii)&#160;the First Adjustment Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (iii)&#160;the Second Adjustment Amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (1)&#160;Sellers&#8217; aggregate liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not exceed the RWI Retention Amount and (2)&#160;Sellers&#8217; aggregate liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(except as otherwise set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.1(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Disclosure Schedule) shall not exceed $65,000,000.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, the Buyer Entities hereby acknowledge and agree that the R&#38;W Insurance Policy shall be the initial source for satisfaction for all claims by the Buyer Indemnified Persons that might otherwise be brought under this Agreement and the Buyer Indemnified Persons shall seek recovery first pursuant to the R&#38;W Insurance Policy in accordance with the terms thereof, unless such claim is excluded under the terms of the R&#38;W Insurance Policy or such claim is for less than the remaining retention under the R&#38;W Insurance Policy. If such claim is rejected by the policy provider or such claim is not covered, or only partially covered, by the R&#38;W Insurance Policy (including on account of the exclusions and policy limits of the R&#38;W Insurance Policy), then the Buyer Entities may seek recovery from Sellers to the extent of such lack of coverage and to the extent available hereunder, and subject to the limitations and conditions in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;The amount of indemnifiable Losses that an Indemnifying Party is required to pay to any Indemnified Party pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be reduced (retroactively, if necessary) by any insurance proceeds (net of reasonable and documented out-of-pocket recovery costs), that are actually received by or on behalf of such Indemnified Party or its Affiliates in respect of such indemnifiable Losses. If an Indemnified Party shall have received the payment required hereby from the Indemnifying Party in respect of indemnifiable Losses and shall subsequently receive (or any of its Affiliates shall subsequently receive) any insurance proceeds in respect of such indemnifiable Losses, then such Indemnified Party shall promptly repay, or cause to be repaid, to the Indemnifying Party a sum equal to the amount of such insurance proceeds actually received.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Without limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;9.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, each Indemnified Party and its Representatives, to the extent required by applicable Law, shall, in connection with any Claim for indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, use commercially reasonable efforts to mitigate indemnifiable Losses upon and after becoming aware of any fact or circumstance that may give rise to such indemnifiable Losses.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;All indemnifiable Losses under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be determined without duplication of recovery under other provisions hereof (including that no Liability to the extent reflected in the First Adjustment Amount shall be an indemnifiable Loss under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) or of any Ancillary Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;Neither Party shall have any right to off-set or set-off any payment due pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;The Parties agree to treat, and to cause their respective Affiliates to treat, for all Tax purposes, any payment made under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the maximum extent permitted by applicable Law, as an adjustment to the purchase price.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. From and after the Closing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the provisions of the Transition Services Agreement, the Software License Agreement and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Commercial Agreements (and, subject to the terms and conditions of the Transition Services Agreement, Software License Agreement and Commercial Agreements, remedies for any breach thereof) or any other Ancillary Agreement shall be the sole and exclusive remedy for any Claim by any Party or any other Person (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) that may be based on, arise out of or relate to this Agreement or the Ancillary Agreements (including the negotiation, execution, performance or subject matter hereof or thereof) or the transactions contemplated hereby or thereby or any Losses alleged to be suffered by any Party as a result of the actions or failure to act by any Buyer Indemnified Person or Seller Indemnified Person in connection herewith or the transactions contemplated hereby and thereby, including for any breach of any covenant, agreement or obligation set forth herein or therein. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including the limits imposed on each Party&#8217;s rights and remedies with respect to the foregoing Claims, were specifically bargained for between sophisticated Persons and were specifically taken into account in the determination of the amounts to be paid to Sellers hereunder. No Person may avoid the limitations on liability set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by seeking Losses for breach of contract, tort or pursuant to any other theory of liability. Notwithstanding the foregoing, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not limit any Party&#8217;s liability for Fraud.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE&#160;X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>OTHER COVENANTS, AGREEMENTS AND ACKNOWLEDGEMENTS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Representations and Warranties&#59; Survival&#59; As-Is Sale&#59; Nonreliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;None of the representations or warranties of any Party herein shall survive, and all such representations and warranties, including any Claim arising from or related thereto, shall terminate automatically upon, the Closing. None of the covenants and agreements of the Parties herein shall survive, and all such covenants and agreements, including any Claim arising from or related thereto, shall terminate automatically upon, the Closing, except that any covenant or agreement that, by its terms, is required to be performed or complied with, in whole or in part, at or after the Closing shall survive the Closing in accordance with its terms solely to the extent such covenant or agreement, by its terms, requires performance or compliance, in whole or in part, at or after the Closing. The Parties shall have no rights, Claims or causes of action (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity), based on or related to any inaccuracy in, or breach of, any representation or warranty in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or any covenant or agreement hereunder that does not survive the Closing, except prior to the Closing, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Other than the representations and warranties expressly in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or made by the Buyer Entities in the Ancillary Agreements, each Seller acknowledges and agrees that none of the Buyer Entities or any of their Representatives or direct or indirect equity holders make, or have made, any other express or implied representation or warranty whatsoever (whether at law (including at common law or by statute) or in equity) in connection with or related to the transactions contemplated hereby or by the Ancillary Agreements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Other than the representations and warranties expressly in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or made by Sellers or any Affiliate of Sellers in the Ancillary Agreements (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sell-Side Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Sellers (on behalf of themselves and their respective Affiliates) disclaim (i) any other express or implied representation or warranty whatsoever (whether at law (including at common law or by statute) or in equity) in connection with or related to the transactions contemplated hereby or by any Ancillary Agreement, including related to (1)&#160;the Seller Group, the Acquired Entities or any of their respective businesses (including the Business), assets (including the Transferred Assets), employees, Permits, Liabilities (including the Assumed Liabilities), operations, prospects or condition (financial or otherwise), including the condition, value, quality, risks, incidents or prospects of the Transferred Assets or (2)&#160;any opinion, projection, forecast, statement (including any forward-looking statement), budget, estimate, advice or other similar information (including information related to the future revenues, earnings, results or operations (or any component thereof)), cash flows, financial condition (or any component thereof) or the future business and operations, as well as any other business plan and cost-related plan information of or related to the foregoing (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, (A)&#160;with respect to the Seller Group, the Acquired Entities or any of their respective businesses (including the Business), assets (including the Transferred Assets), employees, Permits, liabilities (including the Assumed Liabilities), operations, prospects or condition (financial or otherwise), (B)&#160;whether made, communicated or furnished (orally or in writing), or to be made, communicated or furnished (orally or in writing), to the Buyer Entities or any of their Representatives and (C)&#160;whether made by Sellers, any Acquired Entity or any of their respective Representatives or direct or indirect equity holders or any other Person and (ii) all liability for any such other representation or warranty or any Projection.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Other than the Sell-Side Representations, the Buyer Entities (i) (1)&#160;acknowledge and agree that none of Sellers, any Acquired Entity or any of their respective Representatives or direct or indirect equity holders or any other Person make, or have made, any other express or implied representation or warranty whatsoever (whether at law (including at common law or by statute) or in equity) in connection with or related to the transactions contemplated hereby or by the Ancillary Agreements, including related to the Seller Group, the Acquired Entities or their respective businesses (including the Business), assets (including the Transferred Assets), employees, Permits, Liabilities (including the Assumed Liabilities), operations, prospects, condition (financial or otherwise) or any Projection, and (2)&#160;irrevocably and unconditionally waives and relinquishes all rights, Claims or causes of action (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law or in equity, or based on contract, tort or otherwise) based on or related to any such other representation or warranty or any Projection, (ii)&#160;acknowledges and agrees to Sellers&#8217; disclaimer of any such other representation or warranty or any Projection and of all liability and responsibility for any such other representation or warranty or any Projection, (iii)&#160;irrevocably and unconditionally waives and relinquishes all rights, Claims and causes of action (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law or in equity, or based on contract, tort or otherwise) against (1)&#160;Sellers or any Acquired Entity in connection with the accuracy, completeness or materiality of any Projection and (2)&#160;any Representative or direct or indirect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">equity holder of Sellers or any Acquired Entity for any such other representation or warranty and (iv)&#160;acknowledges and agrees that none of Sellers, any Acquired Entity or any of their respective Representatives or direct or indirect equity holders shall have any liability for any alleged nondisclosure or misrepresentation made by any such Person or in connection with the accuracy, completeness or materiality of any Projection. The Buyer Entities acknowledge and agree that (A)&#160;it has conducted to its satisfaction its own independent investigation of the transactions contemplated hereby (including, as applicable, related to the Seller Group, the Acquired Entities and their respective businesses (including the Business), assets, employees, Permits, liabilities, operations, prospects, condition (financial or otherwise) and any Projection), including reviewing all information and documents accessible by it or its Representatives in the Data Room, and, in making its determination to enter into this Agreement and proceed with the transactions contemplated hereby and the transactions contemplated by the Ancillary Agreements, has relied solely on the results of such independent investigation and the Sell-Side Representations and (B)&#160;except the Sell-Side Representations, it has not relied on, or been induced by, any representation, warranty or other statement of or by Sellers, any Acquired Entity, any of their respective Representatives or direct or indirect equity holders or any other Person, including any Projection, in making its determination to enter into this Agreement and proceed with the transactions contemplated hereby and the transactions contemplated by the Ancillary Agreements.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e)&#160;&#160;&#160;&#160;Other than the representations and warranties expressly in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">ARTICLE&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> or made by the Buyer Entities or any Affiliate of the Buyer Entities in the Ancillary Agreements (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buy-Side Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), each Buyer Entity (on behalf of itself and its Affiliates) disclaims (i)&#160;any other express or implied representation or warranty whatsoever (whether at law (including at common law or by statute) or in equity) in connection with or related to the transactions contemplated hereby or by any Ancillary Agreement, including related to (1)&#160;the Buyer Group or any of their respective businesses, assets, employees, Permits, Liabilities, operations, prospects or condition (financial or otherwise), or (2)&#160;any Projections, in each case, (A)&#160;with respect to the Buyer Group or any of their respective businesses, assets, employees, Permits, liabilities, operations, prospects or condition (financial or otherwise), (B)&#160;whether made, communicated or furnished (orally or in writing), or to be made, communicated or furnished (orally or in writing), to Sellers or any of their Representatives and (C)&#160;whether made by the Buyer Group or any of their respective Representatives or direct or indirect equity holders or any other Person and (ii)&#160;all liability for any such other representation or warranty or any Projection.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;Other than the Buy-Side Representations, Sellers (i) (1)&#160;acknowledge and agree that none of the Buyer Group or any of their respective Representatives or direct or indirect equity holders or any other Person make, or have made, any other express or implied representation or warranty whatsoever (whether at law (including at common law or by statute) or in equity) in connection with or related to the transactions contemplated hereby or by the Ancillary Agreements, including related to the Buyer Group or their respective businesses, assets, employees, Permits, Liabilities, operations, prospects, condition (financial or otherwise) or any Projection, and (2)&#160;irrevocably and unconditionally waives and relinquishes all rights, Claims or causes of action (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law or in equity, or based on contract, tort or otherwise) based on or related to any such other representation or warranty or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">any Projection, (ii)&#160;acknowledges and agree to the Buyer Entities&#8217; disclaimer of any such other representation or warranty or any Projection and of all liability and responsibility for any such other representation or warranty or any Projection, (iii)&#160;irrevocably and unconditionally waives and relinquishes all rights, Claims and causes of action (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law or in equity, or based on contract, tort or otherwise)&#160;against (1)&#160;the Buyer Entities in connection with the accuracy, completeness or materiality of any Projection and (2)&#160;any Representative or direct or indirect equity holder of the Buyer Entities for any such other representation or warranty and (iv)&#160;acknowledges and agrees that none of the Buyer Group or any of their respective Representatives or direct or indirect equity holders shall have any liability for any alleged nondisclosure or misrepresentation made by any such Person or in connection with the accuracy, completeness or materiality of any Projection. Each Seller acknowledges and agrees that (A)&#160;it has conducted to its satisfaction its own independent investigation of the transactions contemplated hereby (including, as applicable, related to the Buyer Group and their respective businesses, assets, employees, Permits, liabilities, operations, prospects, condition (financial or otherwise)&#160;and any Projection), and, in making its determination to enter into this Agreement and proceed with the transactions contemplated hereby and the transactions contemplated by the Ancillary Agreements, has relied solely on the results of such independent investigation and the Buy-Side Representations and (B)&#160;except the Buy-Side Representations, it has not relied on, or been induced by, any representation, warranty or other statement of or by the Buyer Group, any of their respective Representatives or direct or indirect equity holders or any other Person, including any Projection, in making its determination to enter into this Agreement and proceed with the transactions contemplated hereby and the transactions contemplated by the Ancillary Agreements.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall not limit any Party&#8217;s liability for Fraud.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Mutual Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Effective as of the Closing, other than (i)&#160;any Claims of Fraud, or (ii)&#160;any rights or remedies arising under the Ancillary Agreements or under the covenants and agreements hereunder that survive the Closing under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;10.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">), each Buyer Entity, on behalf of itself and its Subsidiaries (including the Acquired Entities)&#160;and its and their respective past, present and future officers, directors, employees, agents, general or limited partners, managers, management companies, members, advisors, direct or indirect equity holders, controlling Persons, other representatives or Affiliates and any heir, executor, administrator, successor or assign of any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Releasing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), hereby irrevocably and unconditionally releases and forever discharges Sellers and their respective Affiliates (excluding the Acquired Entities), and Sellers&#8217; and such Affiliates&#8217; respective past, present and future officers, directors, employees, agents, general or limited partners, managers, management companies, members, advisors, direct or indirect equity holders, controlling Persons, other representatives or Affiliates, and any heir, executor, administrator, successor or assign of any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#160;of and from, and irrevocably and unconditionally waives and relinquishes any rights, claims or remedies arising from or related to, all Claims, causes of action, Orders, assessments, damages, deficiencies, losses, fines, interest, liabilities (including any indebtedness), obligations, penalties, executions and covenants whatsoever (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">or in equity, or based on contract, tort or otherwise)&#160;that any Buyer Releasing Party may have against any of the Buyer Released Parties, now or in the future, in each case related to (a)&#160;the Transferred Equity Interests, (b)&#160;the Business, the Transferred Assets, the Assumed Liabilities or the ownership or operation thereof, (c)&#160;this Agreement, or (d)&#160;any other cause, matter or thing related to the Acquired Entities or the transactions contemplated hereby, including any claim for breach of contract, breach of representation or warranty or negligent misrepresentation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Effective as of the Closing, other than (i)&#160;any Claims of Fraud, or (ii)&#160;any rights or remedies arising under the Ancillary Agreements or under the covenants and agreements hereunder that survive the Closing under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;10.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">), Sellers, on behalf of themselves and their respective Subsidiaries (excluding the Acquired Entities)&#160;and their and their respective past, present and future officers, directors, employees, agents, general or limited partners, managers, management companies, members, advisors, direct or indirect equity holders, controlling Persons, other representatives or Affiliates and any heir, executor, administrator, successor or assign of any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Releasing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), hereby irrevocably and unconditionally release and forever discharge the Buyer Entities and their Affiliates (including the Acquired Entities), and the Buyer Entities&#8217; and such Affiliates&#8217; respective past, present and future officers, directors, employees, agents, general or limited partners, managers, management companies, members, advisors, direct or indirect equity holders, controlling Persons, other representatives or Affiliates, and any heir, executor, administrator, successor or assign of any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#160;of and from, and irrevocably and unconditionally waives and relinquishes any rights, claims or remedies arising from or related to, all Claims, causes of action, Orders, assessments, damages, deficiencies, losses, fines, interest, liabilities (including any indebtedness), obligations, penalties, executions and covenants whatsoever (in each case, whether accrued, absolute, contingent or otherwise, known or unknown, or due or to become due, express or implied, in law or in equity, or based on contract, tort or otherwise)&#160;that any Seller Releasing Party may have against any of the Seller Released Parties, now or in the future, in each case related to (a)&#160;the Transferred Equity Interests, (b)&#160;the Business, the Transferred Assets, the Assumed Liabilities or the ownership or operation thereof, (c)&#160;this Agreement, or (d)&#160;any other cause, matter or thing related to the Acquired Entities or the transactions contemplated hereby, including any claim for breach of contract, breach of representation or warranty or negligent misrepresentation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Each of the Buyer Entities, on behalf of the Buyer Releasing Parties, and Sellers, on behalf of the Seller Releasing Parties, understands that the Buyer Releasing Parties or Seller Releasing Parties, as applicable, currently have sustained, or currently have or are subject to, or may in the future sustain or have or be subject to, as applicable, Claims, causes of action, Orders, assessments, damages, deficiencies, losses, fines, interest, liabilities (including any indebtedness), obligations, penalties, executions and covenants for which they might otherwise have made a claim, or sought a right or remedy, that are presently unknown or unsuspected. Each of the Buyer Entities, on behalf of the Buyer Releasing Parties, and Sellers, on behalf of the Seller Releasing Parties, acknowledges that the releases and waivers in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> have been agreed upon and given in light of such facts and that the releases and waivers are intended to apply to all Claims, causes of action, Orders, assessments, damages, deficiencies, losses, fines, interest, liabilities (including any indebtedness), obligations, penalties, executions and covenants. IN THIS CONNECTION, EACH OF THE BUYER ENTITIES, ON BEHALF OF THE BUYER RELEASING PARTIES, AND SELLERS, ON BEHALF OF THE SELLER RELEASING PARTIES, UNDERSTANDS AND AGREES AS PART OF THE INDUCEMENT FOR THE CONSIDERATION GIVEN FOR SUCH RELEASES AND WAIVERS THAT THE BUYER </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ENTITIES, ON BEHALF OF THE BUYER RELEASING PARTIES, AND SELLERS, ON BEHALF OF THE SELLER RELEASING PARTIES, WAIVES THE PROVISIONS OF SECTION&#160;1542 OF THE CALIFORNIA CIVIL CODE, WHICH SECTION READS AS FOLLOWS, AND ANY OTHER STATE, FEDERAL, PROVINCIAL OR FOREIGN STATUTE OR COMMON LAW PRINCIPLE OF SIMILAR EFFECT&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(d)&#160;&#160;&#160;&#160;The Buyer Released Parties and Seller Released Parties are intended third-party beneficiaries of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, with full rights of enforcement of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> as if a party hereto.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Section&#160;10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Retention of Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">. In any dispute or proceeding arising under or in connection with this Agreement after the Closing, (a)&#160;Sellers shall have the right, at their election, to retain Skadden, Arps, Slate, Meagher &#38; Flom LLP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Skadden</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;)&#160;to represent it in such matter, even if such representation shall be adverse to the Buyer Entities or the Acquired Entities, (b)&#160;each Buyer Entity, for itself and its Representatives (including the Acquired Entities), successors and assigns, hereby irrevocably consent to any such representation in any such matter and (c)&#160;each Buyer Entity, for itself and for its Representatives (including the Acquired Entities), successors and assigns, hereby irrevocably waive any actual or potential conflict arising from any such representation in the event of (i)&#160;any adversity between the interests of Sellers or its direct or indirect equity holders, on the one hand, and the Buyer Entities or the Acquired Entities, on the other hand, in any such matter or (ii)&#160;any Protected Communication.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Section&#160;10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Protected Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">. The Parties agree that, immediately prior to the Closing, without the need for any further action, (a)&#160;all right, title and interest of any Acquired Entity in and to all Protected Communications shall thereupon transfer to and be vested solely in Sellers, and (b)&#160;all expectations of client confidence and protections from disclosure, including attorney&#8211;client privileges and work product protections, associated with or arising from any Protected Communications that would have been exercisable by any Acquired Entity shall thereupon be vested exclusively in Sellers and shall be exercised or waived solely as directed by Sellers. From and after the Closing, neither the Buyer Entities nor the Acquired Entities shall, or shall have any right to, use or access the Protected Communications. Notwithstanding the foregoing, if a dispute arises between any Buyer Entity and any Acquired Entity, on the one hand, and any other Person (other than Sellers or any of their Representatives), on the other hand, such Buyer Entity and Acquired Entity may exercise all protections from disclosure, including attorney&#8211;client privileges and work product protections, associated with or arising from any Protected Communications&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> that none of the Buyer Entities, any Acquired Entity or any Person acting on any of their behalf, shall, without the prior written consent of Sellers, waive or attempt to waive, or take any action that could result in a waiver of, any such protection against disclosure, including the attorney-client privileges or work product protection of, or provide to such Person or its Representatives, any Protected Communication.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Section&#160;10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">No Waiver of Privilege, Protection From Disclosure or Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">. The Parties understand and agree that nothing herein, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Section&#160;10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, shall be deemed to be a waiver of any applicable attorney&#8211;client privilege or other protection from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">disclosure or use related to any Protected Communication. Each Party understands and agrees that it has undertaken reasonable efforts to prevent the disclosure of Protected Communications. Notwithstanding those efforts, the Parties understand and agree that the consummation of the transactions contemplated hereby could result in the inadvertent disclosure of Protected Communications. The Parties further understand and agree that any disclosure of any Protected Communications shall not waive or otherwise prejudice any claim of confidentiality, privilege or protection from disclosure.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE&#160;XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"><br>MISCELLANEOUS PROVISIONS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement may be amended, supplemented or changed only by a written instrument signed by the Buyer Entities and Seller Parent (on behalf of Sellers)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that notwithstanding anything to the contrary set forth herein, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (and any related definitions to the extent an amendment, supplement or change of such definitions would modify the substance of any of the foregoing provisions) may not be amended, supplemented or changed in a manner that is in any material respect adverse to the Financing Sources without the prior written consent of the Financing Sources then party to the Commitment Letters.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No failure on the part of any Party to exercise any power, right, privilege or remedy hereunder, and no delay on the part of any Party in exercising any power, right, privilege or remedy hereunder, shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed to have waived any claim or cause of action arising out hereof, or any power, right, privilege or remedy hereunder, unless the waiver of such claim, cause of action, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered by the waiving Party, and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement&#59; Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement, the Confidentiality Agreement and the Ancillary Agreements are the entire agreement, and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties related to the subject matter hereof and thereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall be one and the same instrument. Delivery of an executed counterpart hereof by electronic transmission (including email or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall be effective as delivery of an original counterpart hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Applicable Law&#59; Jurisdiction&#59; WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement, and all claims, disputes and causes of action (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) that may be based on, arise out of or relate hereto or the negotiation, execution, performance or subject matter hereof, shall be governed by the Laws of the State of Delaware applicable to agreements made and to be performed solely therein, without giving effect to principles of conflicts of law. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, with respect to any such claim, dispute or cause of action, each Party (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the U.S. District Court for the District of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware, (b)&#160;agrees that all such claims, disputes and causes of action shall be heard and determined exclusively in the courts identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">clause&#160;(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (c)&#160;waives any objection to laying venue in any such claim, dispute or cause of action in such courts, (d)&#160;waives any objection that any such court is an inconvenient forum or does not have jurisdiction over any Party and (e)&#160;agrees that service of process upon such Party in any such claim, dispute or cause of action shall be effective if such process is given as a notice under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EACH PARTY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY CLAIM, DISPUTE OR CAUSE OF ACTION that may be based on, arise out of or relate HERETO or the negotiation, execution, performance or subject matter hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies&#59; Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Except as otherwise provided herein, prior to the Closing, all remedies herein expressly conferred upon a Party shall be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy shall not preclude the exercise of any other remedy.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;The Parties acknowledge and agree that irreparable damage would occur if any of the provisions hereof were not performed in accordance with their specific terms or were otherwise breached and that monetary damages, even if available, would not be an adequate remedy therefor. Accordingly, the Parties shall be entitled to equitable relief (including an injunction or injunctions) to prevent breaches or threatened breaches hereof and to enforce specifically the performance of terms and provisions hereof, including that each Party shall be entitled to equitable relief (including an injunction or injunctions) to cause each other Party to consummate the Acquisition, the Liabilities Assumption and the other transactions contemplated hereby in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in each case, in any court referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, without proof of actual damages (and each Party waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at law or in equity. No Party shall assert (i)&#160;that a remedy of specific enforcement is unenforceable, invalid, contrary to Law or inequitable for any reason or (ii)&#160;that a remedy of monetary damages would provide an adequate remedy for any such breach. If any Party brings any Claim to enforce specifically the performance of the terms of provisions hereof, then, notwithstanding anything to the contrary herein, the Outside Date shall automatically be extended by (1) the period of time between the commencement of such Claim and the date on which such Claim is fully and finally resolved, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> twenty (20) Business Days, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (b) any such other time period as finally determined by the court presiding over such Claim.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, it is expressly agreed that Sellers will be entitled to specific performance of Buyer&#8217;s obligation to consummate the Acquisition and Liabilities Assumption only in the event that (i)&#160;a Buyer Closing Failure has occurred and (ii)&#160;provided that Buyer has complied with its covenants and agreements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the Debt Financing has been funded or will be funded at the Closing in accordance with the Debt Commitment Letters (or definitive agreements related thereto). For the avoidance of doubt, under no circumstance shall the Sellers be permitted or entitled to receive both a grant of specific </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">performance pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and, if the Closing occurs, payment of the Termination Payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Payment of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as provided herein, whether or not the Closing occurs, each Party shall pay its own expenses incident to preparing for, entering into and carrying out this Agreement and the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignability&#59; Third-Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned or delegated, in whole or in part, by any Party without the prior written consent of the other Parties, and any such assignment without such prior written consent shall be null and void&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (a)&#160;the Buyer Entities may transfer or assign their rights and obligations to any Financing Source as collateral security for the Financing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Buyer Entities shall not be released from any of its Liabilities hereunder by reason of such transfer or assignment, and (b)&#160;each Seller may assign any of their rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit&#160;K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> without the prior written consent of the Buyer Entities. This Agreement shall be binding upon, and shall be enforceable by and inure to the benefit of, the Parties and their respective successors and permitted assigns. Except as provided herein (including in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;5.6(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), nothing herein is intended to or shall confer upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. All notices and other communications hereunder shall be in writing and shall be deemed given (a)&#160;when delivered personally by hand (with written confirmation of receipt by nonautomatic means, whether electronic or otherwise), (b)&#160;when sent by email (with written confirmation of transmission) or (c)&#160;one (1) Business Day after the day sent by an internationally recognized overnight courier (with written confirmation of receipt), in each case, at the following addresses and email addresses (or to such other address or email address as a Party may have specified by notice given to the other Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">if to Sellers, as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">c&#47;o Centene Corporation<br>7700 Forsyth Boulevard<br>St. Louis, MO 63105<br>Email&#58;&#160;&#160;&#160;&#160;christopher.a.koster&#64;centene.com<br>Attention&#58; &#160;&#160;&#160;&#160;Christopher Koster</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">with copies (which shall not be notice) to&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Skadden, Arps, Slate, Meagher &#38; Flom LLP<br>1440 New York Avenue, NW<br>Washington, DC 20005<br>Attention&#58;&#160;&#160;&#160;&#160;Jeremy London<br>&#160;&#160;&#160;&#160;Micah Kegley<br>Email&#58;&#160;&#160;&#160;&#160;jeremy.london&#64;skadden.com<br>&#160;&#160;&#160;&#160;micah.kegley&#64;skadden.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">if to the Buyer Entities, as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Evolent Health, Inc.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">800 N.&#160;Glebe Road, Suite 500</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Arlington, Virginia 22203<br>Attention&#58; &#160;&#160;&#160;&#160;Jonathan Weinberg, General Counsel<br>Email&#58;&#160;&#160;&#160;&#160;jweinberg&#64;evolenthealth.com</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">with a copy (which shall not be notice) to&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Bass, Berry &#38; Sims PLC<br>150 Third Ave. South, Suite 2800<br>Nashville, Tennessee 37201<br>Attention&#58; &#160;&#160;&#160;&#160;Angela Humphreys&#59; Price Wilson<br>Email&#58;&#160;&#160;&#160;&#160;ahumphreys&#64;bassberry.com&#59; pwilson&#64;bassberry.com</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any term or provision hereof that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Notwithstanding anything in this Agreement to the contrary, each Party, on behalf of itself and each of its Affiliates, hereby (a)&#160;agrees that it will not bring or support any action, cause of action, claim, cross-claim or third-party claim or any proceeding, whether in law or in equity, whether in contract or in tort or otherwise, involving the Financing Sources, arising out of or related to, this Agreement, the Financing or any of the agreements (including the Commitment Letters and each Fee Letter) entered into in connection with the Financing or any of the transactions contemplated hereby or thereby or the performance of any services thereunder in any forum other than exclusively in the Supreme Court of the State of New York, County of New York, or, if under applicable law exclusive jurisdiction is vested in the federal courts, the United States District Court for the Southern District of New York (and appellate courts thereof) and irrevocably submits itself and its property with respect to any such proceeding to the exclusive jurisdiction of such courts, (b)&#160;agrees that any such proceeding shall be governed by the laws of the State of New York (without giving effect to any conflicts of law principles that would result in the application of the laws of another state), (c)&#160;agrees that service of process upon such Person in any such proceeding shall be effective if notice is given in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (d)&#160;knowingly, intentionally and voluntarily waives, to the fullest extent permitted by applicable law, trial by jury in any proceeding brought against any Financing Source in any way arising out of or related to, this Agreement, the Financing, the Commitment Letters, any Fee Letter or any of the transactions contemplated hereby or thereby or the performance of any services thereunder, (e)&#160;agrees that notwithstanding anything to the contrary contained herein, none of Sellers, Company, any of their respective Affiliates nor any of their respective stockholders, partners, members, officers, directors, employees, controlling persons, agents and representatives shall have any rights or claims against any Financing Source related to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or arising out of this Agreement, the Financing, the Commitment Letters, any Fee Letter or any of the transactions contemplated hereby or thereby or the performance of any services thereunder, whether at law or equity, in contract, in tort or otherwise, (f)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW TRIAL BY JURY IN ANY PROCEEDING BROUGHT AGAINST ANY FINANCING SOURCE IN ANY WAY ARISING OUT OF OR RELATED TO, THIS AGREEMENT, THE FINANCING, THE COMMITMENT LETTERS, ANY FEE LETTER OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY OR THE PERFORMANCE OF ANY SERVICES THEREUNDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and (g)&#160;agrees that the Financing Sources are express third-party beneficiaries of, and may enforce, any of the provisions herein reflecting the foregoing agreements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not limit the rights of the parties to the Financing under the Commitment Letters or any other definitive agreement in respect of the Financing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Without the prior written consent of the other Parties, no Party shall issue any press release or make any other public announcement related hereto or the transactions contemplated hereby, except (a)&#160;to the extent required by applicable Law or the rules of any securities exchange on which such Party&#8217;s or such Party&#8217;s Affiliates securities are listed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, in each case, the disclosing Party provides the other Parties with a reasonable opportunity to review and comment on such disclosure and (b)&#160;for any communication by Sellers, any Acquired Entity or any of their respective Representatives to the employees, members or other business relations of the Acquired Entities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section&#160;11.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Parties have been represented by counsel during the negotiation and execution hereof and, therefore, waive the application of any applicable Law, holding or rule of construction providing that ambiguities in a Contract or other document shall be construed against the Party drafting such Contract or document. Each Party has participated in the drafting and negotiation hereof. If an ambiguity or question of intent or interpretation arises, this Agreement must be construed as if it is drafted by all the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of authorship of any of the provisions hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. When calculating the period of time prior to which, within which or after which any act is to be done or step taken pursuant hereto, (i)&#160;the date that is the reference date in calculating such period shall be excluded and (ii)&#160;if the last day of such period is not a Business Day, the period in question shall end on the next succeeding Business Day. Unless specified otherwise herein, any reference herein to a specific time shall be to such time in the North American Central Time Zone.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Unless otherwise specifically indicated, any reference herein to &#8220;$&#8221; means U.S. dollars.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Gender and Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any reference herein to gender shall include all genders, and words imparting the singular number only shall include the plural and vice versa.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Articles, Sections and Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. When a reference is made herein to an Article or a Section, such reference shall be to an Article or a Section hereof unless otherwise indicated. The table of contents and headings herein are for reference purposes only and shall not affect in any way the meaning or interpretation hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used herein, they shall be deemed to be followed by the words &#8220;without limitation.&#8221;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The words &#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;hereby,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used herein shall refer to this Agreement as a whole and not to any particular provision hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Extent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase shall not mean simply &#8220;if.&#8221;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Contracts&#59; Employee Plans&#59; Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. (i)&#160;Any Contract or Employee Plan referred to herein or in the Disclosure Schedule means such Contract or Employee Plan as from time to time amended, modified or supplemented (including by a statement of work or similar agreement) prior to the Closing Date, and (ii)&#160;any Law defined or referred to herein means such Law as from time to time amended, modified or supplemented prior to the date hereof, and includes all rules and regulations promulgated under such Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. References to a person are also to its successors and permitted assigns.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibits and Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Exhibits hereto and the Disclosure Schedule are incorporated and made a part hereof and are an integral part hereof. The Disclosure Schedule shall be organized into sections that correspond to the Sections hereof. Any item set forth in any section of the Disclosure Schedule that corresponds to a Section shall apply to and qualify&#160;such Section and any other Section if such item&#8217;s relevance to such other Section is reasonably apparent on its face. Each capitalized term used in any Exhibit or in the Disclosure Schedule but not otherwise defined therein has the meaning given to such term herein. The Disclosure Schedule may include items that are not material in order to avoid any misunderstanding, and such inclusion, or any references to dollar amounts herein or in the Disclosure Schedule, shall not be deemed to be an acknowledgement or representation that such items are material, to establish any standard of materiality or to define further the meaning of such terms for purposes hereof or otherwise. The inclusion of any information, item or other disclosure in the Disclosure Schedule shall not be construed as (i)&#160;an admission of any liability or obligation of Sellers with respect to any third Person, (ii)&#160;an admission against the interest of Sellers to any third Person or (iii)&#160;a basis for establishing any standard for what is or is not in the ordinary course of business or defining any other term or establishing any other standard set forth in this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assets&#59; Ownership of Equity Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Unless the context otherwise requires, (i)&#160;any reference herein to &#8220;assets&#8221; shall include tangible assets (including real property) and intangible assets and (ii)&#160;any reference herein to the ownership of Equity Interests shall refer to both record ownership and beneficial ownership of such Equity Interests.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Made Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. A document or information shall be deemed to have been &#8220;made available&#8221; or otherwise delivered to Buyer if such document or information is accessible by Buyer or any of its Representatives in the Data Room or otherwise has been delivered (by email or otherwise) to Buyer or its Representatives at least one (1) Business Day prior to the date hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section&#160;11.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;As used herein, each of the following underlined terms has the meaning specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;11.13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; mean </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit&#160;H.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Accrued Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the sum of the amounts of obligations for Income Taxes of the Acquired Entities for Pre-Closing Straddle Periods (regardless of whether or not then due) as to which taxable period or portion thereof the relevant Tax Return has not yet been filed as of the Closing Date, calculated as of the end of the day on the Closing Date after giving effect to the transactions contemplated hereby and in a manner consistent with the principles of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that Accrued Taxes shall be calculated in accordance with the past practices (including reporting positions, jurisdictions, elections and accounting methods) of the Acquired Entities in preparing Tax Returns unless otherwise required by applicable Law (determined consistent with the principles of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">), and for the avoidance of doubt, by excluding any item of income, gain, loss, deduction, or credit includible with respect to Seller Consolidated Taxes for which no Acquired Entity has primary Liability.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Acquired Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Company and its Subsidiaries (other than NIA Pennsylvania).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means, for any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that, for purposes of the immediately preceding clause, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), for any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, from and after the Closing, no member of the Seller Group shall be an Affiliate of the Buyer Entities or the Acquired Entities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Affiliated Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an affiliated group as defined in Section&#160;1504 of the Code (or any analogous combined, consolidated or unitary group defined under state, local or foreign Income Tax Law) of which any Acquired Entity is or has been a member.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Aggregate Spread Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means, in respect of each Ultimate Parent Equity Award that is a stock option, an amount equal to (i)&#160;the number of shares of Ultimate Parent common stock subject to such stock option, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the difference, if any, of (1)&#160;the Replacement Award VWAP, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> over (2)&#160;the per-share exercise price for such stock option.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Ancillary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Bill of Sale and Assignment Agreement, the Transition Services Agreement, the Software License Agreement, the Commercial Agreements, the Registration Rights Agreement, the Lock-Up Agreement and the Restrictive Covenant Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Base Business Enterprise Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means $650,000,000.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Borrowed Money Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means, with respect to any Person at any date, without duplication&#58; (i)&#160;all obligations of such Person for borrowed money (excluding any trade payables, accounts payable, and any other current liabilities)&#59; and (ii)&#160;any accrued interest and fees related to any of the foregoing</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the research, development, implementation, customization, marketing, testing, maintenance, provision, support, licensing, commercialization, promotion, distribution, sale and offering for sale of the following specialty healthcare management services, in each case as conducted by (A)&#160;the Acquired Entities and (B)&#160;the Acquired Entities and the Seller Group solely with respect to the Transferred Assets as of the date hereof&#58; (i)&#160;prior, retrospective, and concurrent authorization services and specialty-matched medical necessity reviews for&#58; (1)&#160;advanced radiology imaging, (2)&#160;diagnostic cardiac imaging and interventional cardiac procedures, (3)&#160;interventional pain management procedures and musculoskeletal surgeries, (4)&#160;physical medicine services including physical, occupational and speech therapy and chiropractic services, (5)&#160;radiation oncology therapies, (6)&#160;genetic testing and (7)&#160;sleep management&#59; (ii)&#160;the provision of genetic testing payment integrity services&#59; (iii)&#160;the provision of analytic tools related to the foregoing&#59; (iv)&#160;clinical guideline development and maintenance only related to the foregoing&#59; (v)&#160;limited physical medicine network development and oversight only related to the foregoing&#59; and (vi)&#160;DecisionPoint, the Business&#8217;s automated prior authorization solution&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that the Business shall not include (x)&#160;any behavioral health services provided by any member of the Seller Group or (y)&#160;any of Ultimate Parent&#8217;s (through one or more of its Subsidiaries) population health, utilization management (other than to the extent expressly included in the items&#160;(i) through (vi) above) or health plan services&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that the Business shall include the Transferred Assets.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Business Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means each Seller Employee Plan and each Company Employee Plan.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means a day, other than a Saturday, a Sunday or other day on which commercial banks in New York, New York, are authorized or required by Law to close.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Business Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means each employee of (i)&#160;an Acquired Entity, or (ii)&#160;a member of the Seller Group who is listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;11.13(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Consolidated Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means Taxes of (i)&#160;any member of an affiliated group as defined in Section&#160;1504 of the Code that has filed a consolidated return for U.S. federal income Tax purposes, or (ii)&#160;any consolidated, combined or unitary group (or member thereof) under state, local, or non-U.S. Law, of which any of the Acquired Entities (or any successor) is or was a member following to the Closing Date, including pursuant to Treasury Regulation Section&#160;1.1502-6 or any analogous or similar U.S., state or local, or non-U.S. Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means Buyer Parent and its Subsidiaries.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;any event, change, effect, development or occurrence that would prevent, materially delay or materially impede a Buyer Entity&#8217;s consummation of the transactions contemplated hereby or (ii)&#160;any event, change, effect, development or occurrence that, individually or in the aggregate with any other event, change, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">effect, development or occurrence, has, or would reasonably be expected to have, a material adverse effect on the businesses, financial condition or results of operations of the Buyer Group, taken as a whole&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, solely for purposes of this clause&#160;(ii), none of the following (or any change, effect, development or occurrence related to the following) shall be a Buyer Material Adverse Effect or be considered in determining whether a Buyer Material Adverse Effect has occurred&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;changes in general economic conditions, including changes in exchange rates, interest rates or monetary policy, or the credit, financial, currency, securities or capital markets&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;changes in general conditions in the industry in which Buyer Group operates&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;any natural (including weather-related) or man-made disaster, disease or virus (including COVID-19), pandemic (including the COVID-19 pandemic), epidemic, act of terrorism, sabotage, cyberattack, military action or war, or any escalation or worsening thereof&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;changes in general legal, regulatory or political conditions after the date hereof&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;changes in Law, GAAP, or any accounting requirements applicable to the industry in which the Buyer Group operates or the interpretation of any of the foregoing after the date hereof&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;any action or omission required to be taken or omitted by Buyer pursuant to this Agreement or which is otherwise taken or omitted at the written consent or request of Sellers&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;any breach hereunder by a Seller or any action taken by a Seller or any of its Representatives&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;any failure by the Buyer Group to meet any internal or published projection for any period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the underlying cause of any such failure may be, or be considered in determining, a Buyer Material Adverse Effect to the extent not otherwise excluded under the foregoing clauses&#160;(1)&#8211;(8))&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, with respect to clauses&#160;(1), (2), (3), (4), or (5), any such event, change, effect, development or occurrence shall be taken into account if it is disproportionately adverse to the Buyer Group, taken as a whole, when compared to other, similarly situated Persons operating in the industry in which the Buyer Group operates&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if no Buyer Parent Shares are to be issued hereunder, then (ii) of the definition of Buyer Material Adverse Effect shall be deemed deleted and of no further force or effect for purposes of this Agreement including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Parent Per Share Proceeds Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means $29.50 (or a lesser amount if requested by Buyer Parent in writing and consented to in writing by Seller Parent in its sole and absolute discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that, for the avoidance of doubt, if Seller Parent does not consent in writing to any such lesser amount, the Buyer Parent Per Share Proceeds Amount shall be $29.50).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Parent Share Proceeds Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the product of (i)&#160;the aggregate number of shares of Buyer Parent Class A Common Stock sold in Offerings (not to exceed 8,474,576), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the Buyer Parent Per Share Proceeds Amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the Buyer Parent Share Proceeds Amount shall not be less than $0.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Buyer Parent Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the difference of (i)&#160;8,474,576 shares of Buyer Parent Class A Common Stock </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the aggregate number of shares of Buyer Parent Class A Common Stock sold in Offerings, if any&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the Buyer Parent Shares shall not be less than 0.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Coronavirus, Aid, Relief and Economic Security Act (H.R. 748) (together with all amendments thereto and the statutes, rules and regulations promulgated thereunder) and any successor to such statutes, rules or regulations.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Cash Consideration Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to the (i)&#160;the Estimated Business Enterprise Value, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) $250,000,000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (iii)&#160;the Buyer Parent Share Proceeds Amount.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any arbitration, criminal charge, claim, lawsuit, other legal proceeding, action, order, writ, injunction, demand, charge, complaint, grievance, demand, notice of violation, litigation, proceeding, mediation, audit, inquiry, dispute, criminal prosecution, citation, summons, subpoena or investigation of any nature by or before any Governmental Authority, whether civil, criminal, administrative, judicial, investigative, regulatory or otherwise, whether at law or in equity, whether formal or informal, whether public or private.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Closing Date Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to all cash and cash equivalents (including marketable securities and short-term investments held in bank accounts or investment accounts the registered owner of which is an Acquired Entity), taken as a whole, and determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that Closing Date Cash shall (i)&#160;include the amount of any checks and drafts made out to any of the Acquired Entities that have been received by any such Acquired Entity but not yet cleared and any wires and deposits transmitted to any such account and in transit, and (ii)&#160;exclude the amount of any checks and drafts made out by any of the Acquired Entities that have been sent by any such Acquired Entity but not yet cleared and any wires and deposits transmitted by any such account and in transit, in each case, as of the Measurement Time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Closing Date Cash shall not include any Restricted Cash.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Closing Date Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to the sum of the Indebtedness of the Acquired Entities and the Transaction Expenses, without double counting and outstanding as of immediately prior to Closing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Internal Revenue Code of 1986.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Collective Bargaining Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any collective bargaining agreement or any other labor-related agreement or arrangement with any labor union, trade union or labor organization.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Tax Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any contract entered into the ordinary course of business the principal subject matter of which is not Tax (such as financing agreements with Tax gross-up obligations or leases with Tax escalation provisions).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Employee Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each Employee Plan that is sponsored or maintained by an Acquired Entity.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, (i)&#160;that certain letter agreement, dated July&#160;7, 2022, by and between Ultimate Parent and Buyer, and (ii)&#160;that certain letter agreement, dated August&#160;24, 2022, by and between Ultimate Parent and Buyer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clean Team Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any consent, approval, authorization, permission or waiver of, or registration, declaration, waiting period expiration or other exemption.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any agreement, deed, bond, mortgage, lease, license, instrument, indenture, note, commitment, undertaking, arrangement or contract or other instrument or obligation that is legally binding, in each case, whether written or oral.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Copyleft Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Software licensed or distributed as &#8220;free&#8221; or &#8220;open source&#8221; Software (e.g., Linux) as defined by the Free Software Foundation or the Open Source Initiative, as applicable, that require as a condition of use, modification, or distribution of such open source Software that other Software incorporated into or with, derived from, or distributed with such open source Software, be (A)&#160;disclosed or distributed in source code form, (B)&#160;licensed to a third party for the purpose of making derivatives, or (C)&#160;redistributable by such third party at no charge, which includes Software licensed or distributed under any of the following licenses or distribution models, or licenses or distribution models substantially equivalent to any of the following&#58; GNU&#8217;s General Public License (GPL) or Lesser&#47;Library GPL (LGPL), the Sun Community Source License (SCSL), and the Sun Industry Source License (SISL).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; social distancing, shut down, closure, sequester, safety, vaccine or similar Law, directive, guidelines or recommendations promulgated by any Governmental Authority or quasi-governmental organization, including the Centers for Disease Control and Prevention, the World Health Organization and the Occupational Safety and Health Administration, in each case, in connection with or in response to COVID-19.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the &#8220;Minuet&#8221; electronic data room folders hosted by Datasite.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Data Security Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, collectively, all of the following to the extent governing Processing of Personal Information, or otherwise as related to privacy or breach notification requirements with respect to Personal Information and applicable to the Acquired Entities and to the conduct of its Business&#58; (i)&#160;each Acquired Entity&#8217;s published and internal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">written policies to the extent relating to Personal Information&#59; (ii)&#160;all applicable Privacy Laws&#59; and (iii)&#160;any Contracts between such Acquired Entity, on the one hand, and its vendors, marketing affiliates, customers, business partners, or other Persons, on the other hand, to the extent governing use and disclosure of Personal Information, including any consents, authorizations, waivers of authorization, or other permission or third-party terms pursuant to which any Acquired Entity Processed or Processes Personal Information.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the disclosure schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;A.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employee Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means each (i)&#160;&#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA (whether or not subject to ERISA), (ii)&#160;other material benefit and compensation plan, policy, program, practice, arrangement or agreement, including pension, profit-sharing, savings, termination, executive compensation, phantom stock, change-in-control, retention, salary continuation, vacation, sick leave, disability, death benefit, insurance, hospitalization, medical, dental, life, employee loan, educational assistance, fringe benefit, deferred compensation, retirement or post-retirement, severance, equity or equity-based, incentive and bonus plan, contract, policy, program, practice, arrangement or agreement, and (iii)&#160;other material employment, consulting or other individual agreement, plan, practice, policy, contract, program, and arrangement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enhancement Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Paycheck Protection Program and Health Care Enhancement Act (H.R. 266) (together with all amendments thereto and the statutes, rules and regulations promulgated thereunder) and any successor to such statutes, rules or regulations.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any corporation (including any nonprofit corporation), general partnership, limited partnership, limited liability partnership, estate, trust, company (including any company limited by shares, limited liability company or joint stock company) or other association, organization or entity (including any Governmental Authority).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Claim related to any Environmental Law or Environmental Permit, including those related to an actual or alleged Release of, or human exposure to, any Hazardous Materials or violation of any Environmental Law or Environmental Permit.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all Laws related to pollution or protection of the environment or human health and safety, including laws related to releases or threatened releases of Hazardous Materials into the indoor or outdoor environment (including air, surface water, groundwater, land, surface and subsurface strata) or otherwise related to the manufacture, processing, distribution, use, treatment, storage, Release, transport or handling of Hazardous Materials and all Laws related to endangered or threatened species of fish, wildlife and plants, and the management or use of natural resources.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Permit issued under any applicable Environmental Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means, for any Person, any (i)&#160;shares or units of capital stock or voting securities, membership or limited liability company interests or units, partnership interests or other ownership interests (whether voting or nonvoting) in such Person, (ii)&#160;other interest or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">participation (including phantom shares, units or interests or stock appreciation rights) in such Person that confers on the holder thereof the right to receive a share of the profits and losses of, or distribution of assets of, such Person, (iii)&#160;subscriptions, calls, warrants, options or commitments of any kind or character related to, or entitling any Person or entity to purchase or otherwise acquire any of the interests in the foregoing clauses&#160;(i) and (ii), or (iv) securities convertible into or exercisable or exchangeable for any of the interests in the foregoing clauses&#160;(i)&#8211;(iii).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Employee Retirement Income Security Act of 1974.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Estimated Business Enterprise Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to the solution of (i)&#160;the Base Business Enterprise Value, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the Estimated First Adjustment Amount.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Estimated First Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to the solution of (i)&#160;the Estimated Closing Date Cash, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the Estimated Net Working Capital Adjustment Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (iii)&#160;the Estimated Closing Date Indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the Estimated First Adjustment Amount may be positive or negative.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Final Specified Customer Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Specified Customer Net Working Capital determined in accordance with the Accounting Principles.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Financing Sources</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the entities that have committed to arrange or provide or otherwise entered into agreements in connection with all or any portion of the Financing or other financings in connection with the transactions contemplated hereby, including the parties to the Commitment Letters and parties to any joinder agreements, note purchase agreements, indentures or credit agreements entered into pursuant thereto or related thereto and, in each case, their respective successors and assigns.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">First Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an amount equal to the solution of (i)&#160;the Closing Date Cash, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (ii)&#160;the Net Working Capital Adjustment Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (iii)&#160;the Closing Date Indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the First Adjustment Amount may be positive or negative.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Fraud</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;a knowing and deliberate common law fraud under the Laws of the State of Delaware in the making of a materially false representation or warranty expressly set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article&#160;IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that Fraud does not include any fraud based on negligence, gross negligence or recklessness or (ii)&#160;any action or omission that constitutes a material breach of any covenant or agreement herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that such action or omission was taken (1)&#160;with the knowledge that it was a breach of a covenant or agreement herein and (2)&#160;with the intent to commit a material breach hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means U.S. generally accepted accounting principles in effect as of the date hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any government, court, regulatory or administrative agency, commission or authority or other governmental instrumentality, whether federal, state or local, domestic, foreign or multinational, or any contractor acting on behalf of such agency, commission, authority or governmental instrumentality.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Governmental Health Care Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;the Medicare program established under and governed by the applicable provisions of Title&#160;XVIII of the Social Security Act, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;the Medicaid program governed by the applicable provisions of Title&#160;XIX of the Social Security Act and any state&#8217;s applicable Laws implementing the Medicaid program and (iii)&#160;any other federal health care program as defined in 42 U.S.C. 1320a-7b, and any similar or successor programs with, paid for by, or for the benefit of any Governmental Authority.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;any petrochemical or petroleum products, radioactive materials, asbestos in any form that is or could become friable, urea formaldehyde foam insulation, transformers or other equipment that contain dielectric fluid containing polychlorinated biphenyls and radon gas, (ii)&#160;any chemicals, materials or substances defined as or included in the definition of &#8220;hazardous substances,&#8221; &#8220;hazardous wastes,&#8221; &#8220;hazardous materials,&#8221; &#8220;restricted hazardous materials,&#8221; &#8220;extremely hazardous substances,&#8221; &#8220;toxic substances,&#8221; &#8220;contaminants&#8221; or &#8220;pollutants&#8221; or words of similar meaning and regulatory effect or (iii)&#160;any other chemical, material or substance, exposure to which is prohibited, limited or regulated by any applicable Environmental Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means all Laws related to the provision of health care services or health care regulatory matters, in each case, to the extent applicable to the Business, including the following&#58; (i) any Law prohibiting or regulating fraud and abuse or the referral of health care items or services (including the following statutes&#58; the federal Anti-Kickback Statute (42 U.S.C. &#167;&#160;1320a-7b(b))&#59; the civil False Claims Act (31 U.S.C. &#167;&#160;3729 et seq.)&#59; Sections&#160;1320a-7, 1320a-7a and 1320a-7b of Title&#160;42 of the United States Code&#59; (commonly referred to as the &#8220;Federal Exclusion Statutes&#8221; (and including the Federal Anti-Kickback Statute))&#59; the Federal Civil Monetary Penalties Law (42 U.S.C. &#167;&#160;1320a-7a), the Federal physician self-referral law (42 U.S.C. &#167;&#160;1395nn), the Federal Program Fraud Civil Remedies Act (31 U.S.C. &#167;&#160;3801 et seq.) and the Federal Health Care Fraud Law (18 U.S.C. &#167;&#160;1347))&#59; (ii) Laws related to Governmental Health Care Programs&#59; (iii) the Patient Protection and Affordable Care Act (Pub. L.&#160;111-148), as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L.&#160;111-152) and the regulations promulgated thereunder&#59; (iv) any state health care professional licensure Laws&#59; (v)&#160;any Laws related to billing or claims for reimbursement for health care services, including Laws related to patient charges, timely repayment of overpayments, and submissions to any payor&#59; (vi) HIPAA&#59; (vii) all Laws relating to utilization review, payors, third party administrators, preferred provider networks, and risk bearing organizations as applicable to the Business&#59; and (viii) any similar federal, state or local Laws.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations set forth at 45 C.F.R. Parts&#160;160, 162 and 164.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Income Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any U.S. federal, state, local or non-U.S. Tax determined by reference to income, gains, net worth, gross receipts, or any Taxes imposed in lieu of such a Tax.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for any Person, (i)&#160;the principal amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> any related accrued and unpaid interest and fees or prepayment premiums or penalties, of all indebtedness for borrowed money of such Person incurred under a loan agreement or evidenced by any note, bond, debenture or other debt security, (ii)&#160;all obligations of such Person in respect of letters of credit, surety bonds, performance bonds, bankers&#8217; acceptances, or similar obligations to the extent drawn upon, (iii)&#160;obligations of a lessee under leases that are required to be recorded as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">capital leases in accordance with the Accounting Principles (excluding any obligations for operating leases or leases for real property), (iv)&#160;any monetary obligations of a Person secured by a Lien (other than Permitted Liens) against the assets of such Person (other than trade payables entered into in the ordinary course of business), (v)&#160;Accrued Taxes, (vi)&#160;obligations under foreign exchange contracts, interest rate and currency swap arrangements or any other arrangements designed to provide protection against fluctuations in interest or currency rates, (vii)&#160;obligations to pay any potential future earnout, purchase price adjustment or release of &#8220;holdback&#8221; (assuming the maximum amount thereof) in connection with a prior acquisition, but excluding trade payables incurred in the ordinary course of business), (viii)&#160;obligations for the employer portion of any payroll Taxes deferred under the CARES Act&#59; (ix) Liabilities for earned but unpaid 401(k), deferred compensation, profit sharing, matching contribution or claim, premium or other costs associated with a Business Benefit Plan&#59; (x) Liabilities related to any underfunded liability under any Business Benefit Plan that is a nonqualified deferred compensation plan, defined benefit pension plan or retiree health or welfare plan that is sponsored or maintained by such Person&#59; (xii) any guarantees of such Person (including the incurrence of a Lien) with respect to any of the foregoing obligations in clauses&#160;(i) through (xii) of any other Person&#59; and (xii) any accrued interest and fees (including prepayment penalties, premiums, breakage costs, fees and other costs and expenses associated with repayment) related to any of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Indebtedness of an Acquired Entity shall not include any liabilities or obligations solely between or among any of the Acquired Entities.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all intellectual property and&#47;or proprietary rights throughout the world, including all U.S. and foreign, state, provincial and federal (a)&#160;issued patents and pending patent applications, and any and all divisions, continuations, continuations in part, reissues, continuing patent applications, reexaminations, and extensions thereof, any counterparts claiming priority therefrom, utility models, patents of importation&#47;confirmation, certificates of invention, certificates of registration and like rights&#59; inventions, invention disclosures, discoveries and improvements, whether or not patentable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (b)&#160;trademarks, service marks, trade names, designs, logos and slogans, all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (c)&#160;registered and unregistered copyrights in any work of authorship (including mask works, databases and Software) and all registrations and applications to register the same (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (d)&#160;trade secrets (including those trade secrets defined in the United States Uniform Trade Secrets Act and under corresponding foreign Law), including in formulas, compositions, processes, techniques, business and technical information, know-how, and non-public information (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (e)&#160;Internet domain names and social media accounts.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Service or any successor agency.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IT Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means computer and other information technology systems and assets, including hardware (including desktop computers, laptop computers, tablets, servers, cellular telephones, &#8220;smart phones,&#8221; communications equipment and related devices) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Hardware</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Software, and documentation and reference materials owned or controlled by the Business or a member of the Seller Group for use in the operation of the Business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any laws (statutory, common or otherwise), constitutions, treaties, conventions, ordinances, codes, rules, regulations, guidance, manual, Orders or other similar requirements enacted, adopted, promulgated or applied by a Governmental Authority.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any liability or obligation (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether incurred or consequential and whether due or to become due).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any mortgage, lien, pledge, charge, security interest or other security agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Lien does not include any restriction on transfer arising under an applicable securities Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means all losses, Liabilities, damages, Taxes, penalties, fines, assessments, judgments, damages, settlement amounts, forfeitures, fees, costs and expenses (including the reasonable and documented fees and expenses of counsel and experts and their staffs)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Losses shall not include any punitive or exemplary damages except to the extent awarded in a Third-Party Claim.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Malicious Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any virus, Trojan horse, worm, or other software routines or hardware components designed to permit unauthorized access, disablement, erasure or otherwise designed to harm Software, hardware or data.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any event, change, effect, development or occurrence that, individually or in the aggregate with any other event, change, effect, development or occurrence, has, or would reasonably be expected to have, a material adverse effect on the businesses, financial condition or results of operations of the Business, taken as a whole&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that none of the following (or any change, effect, development or occurrence related to the following) shall be a Material Adverse Effect or be considered in determining whether a Material Adverse Effect has occurred&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;changes in general economic conditions, including changes in exchange rates, interest rates or monetary policy, or the credit, financial, currency, securities or capital markets&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;changes in general conditions in the industry in which the Acquired Entities and the Business operate&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;any natural (including weather-related) or man-made disaster, disease or virus (including COVID-19), pandemic (including the COVID-19 pandemic), epidemic, act of terrorism, sabotage, cyberattack, military action or war, or any escalation or worsening thereof&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;changes in general legal, regulatory or political conditions after the date hereof&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;changes in Law, GAAP, or any accounting requirements applicable to the industry in which the Acquired Entities and the Business operate or the interpretation of any of the foregoing after the date hereof&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the announcement, pendency or anticipated consummation of the Acquisition, the Liabilities Assumption or any of the other transactions contemplated hereby, the negotiation, execution or performance hereof, the identity of the Buyer Entities or any facts or circumstances related to the Buyer Entities or the announcement or other disclosure of the Buyer Entities&#8217; plans or intentions for the conduct of any of the Business, the Transferred Assets, the Assumed Liabilities or the Acquired Entities after the Closing, including the effect of any of the foregoing on the relationships, contractual or otherwise, of or any Acquired Entity, the Business, the Transferred Assets or the Assumed Liabilities with clients, customers, employees, suppliers, vendors, service providers or Governmental Authorities&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any action or omission required to be taken or omitted by Sellers, any Acquired Entity or the Business pursuant to this Agreement or which is otherwise taken or omitted at the written consent or request of a Buyer Entity&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;any breach hereunder by a Buyer Entity or any action taken by a Buyer Entity or any of its Representatives&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;any failure by an Acquired Entity or the Business to meet any internal or published Projection for any period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the underlying cause of any such failure may be, or be considered in determining, a Material Adverse Effect to the extent not otherwise excluded under the foregoing clauses&#160;(i)&#8211;(viii))&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, with respect to clauses&#160;(i), (ii), (iii), (iv), or (v), any such event, change, effect, development or occurrence shall be taken into account if it is disproportionately adverse to the Business, taken as a whole, when compared to other, similarly situated Persons operating in the industry in which the Acquired Entities and the Business operate.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Measurement Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means 12&#58;01&#160;a.m. on the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, if the Closing occurs on the first Business Day of a calendar month, then the Measurement Time shall be 12&#58;01&#160;a.m. on the first day of the calendar month in which the Closing occurs and the Closing shall be effective for tax and accounting purposes as of such Measurement Time.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount equal to the difference of (i)&#160;the aggregate value of the current assets that are owned by the Acquired Entities or that are Transferred Assets, in each case, in the balance sheet accounts listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii)&#160;the aggregate value of the current liabilities of Acquired Entities or that are Assumed Liabilities, in each case, in the balance sheet accounts listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case under the forgoing clauses&#160;(i) and (ii), calculated without double counting as of the Measurement Time and determined in accordance with the Accounting Principles&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Net Working Capital shall exclude all Closing Date Cash, Restricted Cash, Closing Date Indebtedness, Income Tax assets (including deferred Income Tax assets), Income Tax liabilities (including deferred Income Tax liabilities), Post-Signing Insurance Proceeds, operating lease obligations, right of use assets and capitalized development costs that are classified as short-term assets, in each case, regardless of whether any such items are current assets or current liabilities of the Acquired Entities under GAAP. For </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">illustrative purposes only, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth the calculation of Net Working Capital assuming that the Closing Date was June&#160;30, 2022.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Net Working Capital Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount equal to the difference of (i)&#160;the Net Working Capital, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii)&#160;the Target Net Working Capital&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Net Working Capital Adjustment Amount may be positive or negative.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the sale following the date hereof and prior to the Closing Date by Buyer Parent of shares of Buyer Parent Class A Common Stock pursuant to an effective Registration Statement (other than Form&#160;S-4 or Form&#160;S-8 or any similar or successor form) filed under the Securities Act.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any judgment, decree, injunction, rule, order, decision, decree, ruling or assessment of any arbitrator or Governmental Authority.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Organizational Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any corporate, partnership or limited liability organizational documents, including certificates or articles of incorporation, bylaws, certificates of formation, operating agreements (including limited liability company agreements and agreements of limited partnership), certificates of limited partnership, partnership agreements, shareholder agreements and certificates of existence, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all IP Rights that are owned or purported to be owned by any Acquired Entity or any member of the Seller Group to the extent included in the Transferred Assets, including all Owned Software.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Owned Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Software owned or purported to be owned by any Acquired Entity or any member of the Seller Group to the extent included in the Transferred Assets.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any permit, license, registration, certificate, franchise, qualification, waiver, authorization, provider or supplier number, clearance or similar rights issued, granted or obtained by or from any Governmental Authority.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;mechanics&#8217;, carriers&#8217;, materialmens&#8217;, workers&#8217;, repairers&#8217;, landlords&#8217; and similar Liens, (ii)&#160;Liens related to any amounts not yet delinquent or are being contested in good faith, and in each case for which adequate accruals or reserves have been established, (iii)&#160;Liens for Taxes not yet due and payable or the amount of which is being contested in good faith, and for which appropriate reserves have been established in accordance with GAAP, (iv)&#160;Liens on real property (including easements, rights of way, covenants, conditions, licenses, reservations, zoning ordinances, encroachments, servitudes, and similar restrictions) affecting the underlying fee interest of any real property, (v)&#160;zoning, entitlement, building codes, permits, utility easements, rights of way, environmental and other land use laws regulating the use or occupancy of real property and improvements or the activities conducted thereon that are imposed by any Governmental Authority having jurisdiction over such real property that are not violated by the current use or occupancy of such real property or the operation of the businesses of the Acquired Entities as currently conducted, (vi)&#160;public roads and highways or title to any portion of the real property lying within the right of way or boundary of any public road or private road that do not materially impair the occupancy, use or value of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">real property, (vii)&#160;to the extent terminated in connection with the Closing, Liens securing payment, or any other obligations, of the Acquired Entities for Indebtedness, (viii)&#160;licenses of, or other grants of rights or interests with respect to, or obligations related to, IP Rights, (ix) Liens arising under worker&#8217;s compensation, unemployment insurance, social security, retirement or similar laws, (x) Liens that are not material to the Business and (xi) Liens listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;11.13(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any individual or Entity.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means information that identifies a specific natural person or when used in combination with other data elements is capable of identifying a specific natural person, the use, disclosure, transmission, receipt, collection, processing or maintenance of or access to which is regulated by one or more Laws, including, without limitation, &#8220;Protected Health Information&#8221; and &#8220;Electronic Protected Health Information&#8221; (as those terms are defined in 45 CFR &#167;&#160;160.103).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Pre-Closing Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the portion of any Straddle Period ending on the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Pre-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any taxable period ending on or before the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Pre-Closing Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;any Taxes of or with respect to an Acquired Entity or the owner of any Transferred Asset for any Pre-Closing Tax Period (including, for the avoidance of doubt, the Pre-Closing Straddle Period), (ii)&#160;any Taxes that any Acquired Entity is liable for, including under U.S. Treasury Regulation Section&#160;1.1502-6 (or under any similar provision of state, local or non-U.S. Law) as a result of being a member of (or leaving) any Affiliated Group on or before the Closing Date, as a transferee or successor, by Contract (other than a Commercial Tax Agreement) or otherwise by operation of Law, which Taxes relate to a Pre-Closing Tax Period or an event or transaction occurring or relationship existing on or prior to the Closing, or (iii)&#160;any payroll, unemployment, social security or Medicare Taxes deferred pursuant to Section&#160;2302 of the CARES Act or similar legislation, orders or guidance for any Pre-Closing Tax Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that &#8220;Pre-Closing Taxes&#8221; shall not include (1)&#160;any Taxes included in the Estimated Business Enterprise Value or (without duplication) the Final First Adjustment Amount, (2)&#160;the portion of any Transfer Taxes payable by Buyer pursuant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, or (3)&#160;any Taxes arising as a result of transactions entered into on the Closing Date after the Closing outside of the ordinary course of business and not contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Preliminary Specified Customer Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Specified Customer Net Working Capital, set forth in the First Adjustment Amount as finally determined.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means HIPAA, the Payment Card Industry Data Security Standards (PCI-DSS), and any Laws governing the Processing of Personal Information, in each case to the extent applicable to any Acquired Entity.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Processing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the creation, collection, use, storage, processing, distribution, transfer (including cross-border transfers), import, export, safeguarding, disposal, access, transmission or disclosure or other activity regarding data (whether electronically or in any other form or medium) of Personal Information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protected Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, at any time on or prior to the Closing, all communications in whatever form, whether written, oral, video, electronic or otherwise, that shall have occurred between or among any of Sellers, an Acquired Entity or any of their respective equity holders or Representatives and attorneys (including Skadden) related to or in connection with this Agreement, the events and negotiations leading to this Agreement, any of the transactions contemplated herein or any other potential sale or transfer of control transaction involving an Acquired Entity.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount equal to the sum of (i)&#160;the Base Business Enterprise Value, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii)&#160;the First Adjustment Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iii)&#160;the Second Adjustment Amount.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reference Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date that is five (5) years preceding the date hereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a registration statement of Buyer Parent under the Securities Act which covers Buyer Parent Class A Common Stock.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Related to the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means exclusively related to the ownership and operation of the Business.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any release, spill, emission, leaking, pumping, emitting, depositing, discharging, injecting, escaping, leaching, dispersing, dumping, pouring, disposing or migrating into, onto or through the environment (including air, surface water, ground water, land surface or subsurface strata).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement Award VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $82.8735.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for any Person, such Person&#8217;s officers, directors, managers, employees, contractors, consultants, agents, financial advisors, attorneys, accountants, other advisors, Affiliates and other representatives.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any cash or cash equivalents owned by any Acquired Entity that are not freely useable by such Acquired Entity because of any restriction on use or distribution in any Contract, including (a)&#160;deposits (including collateral deposits, security deposits and escrow amounts) with third parties and (b)&#160;cash collateral under any letter of credit.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RWI Retention Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $4,875,000, in the aggregate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that to the extent the Retention (as defined in the RWI Policy) is greater than $3,250,000 on the 12-month anniversary of the Closing Date, the RWI Retention Amount shall be reduced to $3,250,000 in the aggregate, on such date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Adjustment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount equal to the difference of (i)&#160;the Final Specific Customer Net Working Capital, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii)&#160;Preliminary Specified Customer Net Working Capital&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Second Adjustment Amount may be positive or negative.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Second Adjustment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the earlier of (i)&#160;the final settlement of all contract reconciliations between the Specified Customers and the Company for contract years ending prior to January 1, 2023 or (ii)&#160;December&#160;31, 2023.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Securities Act of 1933, as amended, and any successor statute thereto and the rules and regulations of the SEC promulgated thereunder.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Sell-Side Fundamental Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the representations and warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Sections&#160;2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (other than the last sentence thereof) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">3.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Consolidated Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means Taxes of (i)&#160;any member of an affiliated group as defined in Section&#160;1504 of the Code that has filed a consolidated return for U.S. federal income Tax purposes, or (ii)&#160;any consolidated, combined or unitary group (or member thereof) under state, local, or non-U.S. Law, of which any of the Acquired Entities (or any predecessor) is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulation Section&#160;1.1502-6 or any analogous or similar U.S., state or local, or non-U.S. Law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Employee Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means each Employee Plan that is sponsored or maintained by Sellers or any of their Affiliates (other than any Acquired Entity) that covers or otherwise provides for the payment or provision of compensation or benefits to any Business Employee or their respective beneficiaries or dependents.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means, collectively, Seller Parent and its Subsidiaries (other than the Acquired Entities).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Seller Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means any event, change, effect, development or occurrence that, individually or in the aggregate with any other event, change, effect, development or occurrence, prevents, materially delays or materially impedes, or would reasonably be expected to prevent, materially delay or materially impede, Sellers&#8217; consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Sellers&#8217; Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the actual knowledge, after reasonable inquiry, of the individuals listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;11.13(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Shared Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means (i)&#160;all Contracts of Sellers or any of their Subsidiaries (other than an Acquired Entity) as of the Closing Date under which goods, services or other rights are made available to any Acquired Entity, on the one hand, and Sellers or any of their Subsidiaries (other than an Acquired Entity), on the other hand, and (ii)&#160;all services and benefits provided by Sellers or any of their Subsidiaries (other than an Acquired Entity) as of the Closing Date to any Acquired Entity.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means all computer software, programs, operating systems, databases, and sets of statements or instructions, in all forms (including Source Code) and other items and documentation related thereto.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Source Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any collection of code and instructions in a form that is readily suitable for review and edit by computer programmers, including related programmer comments and documentation embedded therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Material Customers set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;11.13(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Disclosure Schedule.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Customer Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the net amounts due from related contract reconciliations with each Specified Customer. For illustrative purposes only, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth the calculation of Specified Customer Net Working Capital assuming that the Closing Date was June&#160;30, 2022.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Straddle Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any taxable period that includes (but does not end on) the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any Person means any Entity (i)&#160;of which 50% or more of the outstanding share capital, voting securities or other voting equity interests are owned, directly or indirectly, by such Person, (ii)&#160;of which such Person is entitled to elect, directly or indirectly, at least 50% of the board of directors (or managers) or similar governing body of such Entity or (iii)&#160;if such Entity is a limited partnership or limited liability company, of which such Person or one of its Subsidiaries is a general partner or managing member or has the power to direct the policies, management or affairs.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $31,265,000.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Contest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any audit, assessment, action, suit or proceeding or other contest with respect to Taxes.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any return, form, declaration, report, claim for refund or information return, certificate, bill, statement or other written information filed or submitted or required to be filed or submitted with any Taxing Authority related to Taxes, including any supplement, schedule or attachment thereto, and including any amendment thereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any U.S. or non-U.S. federal, state, county, local, provincial or other income, gross receipts, ad valorem, franchise, profits, sales or use, transfer, registration, excise, utility, environmental, communications, real or personal property, any penalties or assessable payments under Section&#160;4980H of the Code, capital unit, license, payroll, wage or other withholding, employment, social security (or similar), severance, stamp, occupation, premium, windfall profits, customs duties, unemployment, disability, value added, healthcare, unclaimed property, escheat, alternative or add on minimum, estimated and other taxes of any kind whatsoever and any fee, custom, impost, assessment, obligation, levy, tariff, charge or duty in the nature of a tax (including deficiencies, penalties, interest, additions to tax, additional amounts and other charges or fees attributable thereto).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxing Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the IRS and any other Governmental Authority responsible for the administration, imposition, regulation, determination or collection of any Tax.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;all fees, costs and expenses incurred prior to or at the Closing and payable by the Acquired Entities to accountants, attorneys, financial advisors, investment banks and other professional advisors in connection with the preparation and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">negotiation of this Agreement or the Ancillary Agreements or the consummation of the transactions contemplated hereby or thereby, in each case, to the extent not paid as of immediately prior to the Closing and (b)&#160;the amount of any change-in-control payments, transaction bonuses, retention payments or other similar payments payable by any of the Acquired Entities solely as a result of the Closing to any current or former director, manager, officer, employee or individual independent contractor of the Seller Group (including the Business Employees) from or incurred in connection with this Agreement or the transactions contemplated hereby and the employer portion of payroll, social security, unemployment or similar Taxes arising therefrom.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Treasury Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the regulations of the United States Department of the Treasury promulgated under the Code, as amended.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In addition to the terms defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;11.13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as used herein, each capitalized term listed below has the meaning identified in the Section set forth opposite such term below.</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2021 Buyer 10-K&#160;&#160;&#160;&#160;Article&#160;IV</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2022 Audited Financial Statements&#160;&#160;&#160;&#160;Section&#160;5.17</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accrued PTO&#160;&#160;&#160;&#160;Section&#160;5.4(e)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acquisition&#160;&#160;&#160;&#160;Section&#160;1.1</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acquisition Proposal&#160;&#160;&#160;&#160;Section&#160;5.14</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additional Financial Information&#160;&#160;&#160;&#160;Section&#160;5.17</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliate Contract&#160;&#160;&#160;&#160;Section&#160;3.20</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allocation Percentage&#160;&#160;&#160;&#160;Section&#160;1.4(a)(iii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alternate Debt Financing&#160;&#160;&#160;&#160;Section&#160;5.12(a)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assumed Employee Liabilities&#160;&#160;&#160;&#160;Section&#160;1.9(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assumed Liabilities&#160;&#160;&#160;&#160;Section&#160;1.9</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bankruptcy and Equity Exceptions&#160;&#160;&#160;&#160;Section&#160;2.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bill of Sale and Assignment Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(iv)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Binder Agreement&#160;&#160;&#160;&#160;Section&#160;4.14</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Books and Records&#160;&#160;&#160;&#160;Section&#160;1.7(g)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Business Leased Real Property&#160;&#160;&#160;&#160;Section&#160;3.6(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Closing Failure&#160;&#160;&#160;&#160;Section&#160;7.1(d)(ii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Confidential Information&#160;&#160;&#160;&#160;Section&#160;5.21</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Entities&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer FSAs&#160;&#160;&#160;&#160;Section&#160;5.4(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Indemnified Persons&#160;&#160;&#160;&#160;Section&#160;9.1(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent Class A Common Stock&#160;&#160;&#160;&#160;Section&#160;4.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent Class B Common Stock&#160;&#160;&#160;&#160;Section&#160;4.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent Common Stock&#160;&#160;&#160;&#160;Section&#160;4.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Parent Preferred Stock&#160;&#160;&#160;&#160;Section&#160;4.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Plans&#160;&#160;&#160;&#160;Section&#160;5.4(b)(iii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Related Persons&#160;&#160;&#160;&#160;Section&#160;7.2(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Released Parties&#160;&#160;&#160;&#160;Section&#160;10.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Releasing Parties&#160;&#160;&#160;&#160;Section&#160;10.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer Savings Plan&#160;&#160;&#160;&#160;Section&#160;5.4(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.12pt;text-indent:-0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Buyer SEC Documents&#160;&#160;&#160;&#160;Section&#160;4.5(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Buyer SEC Financial Statements&#160;&#160;&#160;&#160;Section&#160;4.5(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Buyer Tax Returns&#160;&#160;&#160;&#160;Section&#160;8.1(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Buy-Side Representations&#160;&#160;&#160;&#160;Section&#160;10.1(e)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Claim Date&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Claim Notice&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Closing&#160;&#160;&#160;&#160;Section&#160;1.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Closing Date&#160;&#160;&#160;&#160;Section&#160;1.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Closing Delay Notice&#160;&#160;&#160;&#160;Section&#160;1.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Commercial Agreements&#160;&#160;&#160;&#160;Section&#160;1.3(e)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Commitment Letters&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Company&#160;&#160;&#160;&#160;Recitals</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Company Related Persons&#160;&#160;&#160;&#160;Section&#160;7.2(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Consent Required Contracts&#160;&#160;&#160;&#160;Section&#160;5.11(a)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Continuation Period&#160;&#160;&#160;&#160;Section&#160;5.4(b)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">COVID-19 Relief Programs&#160;&#160;&#160;&#160;Section&#160;3.23</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Customer BA Agreement&#160;&#160;&#160;&#160;Section&#160;3.14(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">D&#38;O Costs&#160;&#160;&#160;&#160;Section&#160;5.6(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">D&#38;O Indemnifiable Claim&#160;&#160;&#160;&#160;Section&#160;5.6(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">D&#38;O Indemnifying Party&#160;&#160;&#160;&#160;Section&#160;5.6(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Debt Commitment Letter&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Debt Financing&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Dispute Notice&#160;&#160;&#160;&#160;Section&#160;1.5(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Disputed Items&#160;&#160;&#160;&#160;Section&#160;1.5(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Earnout Amount&#160;&#160;&#160;&#160;Section&#160;5.19</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Earnout Shares&#160;&#160;&#160;&#160;Section&#160;5.19</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Employee Records&#160;&#160;&#160;&#160;Section&#160;1.7(k)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Equity Award Schedule&#160;&#160;&#160;&#160;Section&#160;3.11(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Estimated Closing Date Cash&#160;&#160;&#160;&#160;Section&#160;1.4(a)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Estimated Closing Date Indebtedness&#160;&#160;&#160;&#160;Section&#160;1.4(a)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Estimated Net Working Capital Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.4(a)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Excluded Assets&#160;&#160;&#160;&#160;Section&#160;1.8</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Excluded IP Rights&#160;&#160;&#160;&#160;Section&#160;1.8(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Excluded IT Assets&#160;&#160;&#160;&#160;Section&#160;1.8(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">FCPA&#160;&#160;&#160;&#160;Section&#160;3.19</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Fee Letter&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Filing&#160;&#160;&#160;&#160;Section&#160;2.3(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Final First Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.5(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Final Second Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.6(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Financial Statements&#160;&#160;&#160;&#160;Section&#160;3.3(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Financing&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Financing Letters&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">First Adjustment Statement&#160;&#160;&#160;&#160;Section&#160;1.5(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">First Review Period&#160;&#160;&#160;&#160;Section&#160;1.5(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Florida Company Commercial Agreement Amendment&#160;&#160;&#160;&#160;Section&#160;1.3(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Form&#160;D Approval&#160;&#160;&#160;&#160;Section&#160;1.3(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.12pt;text-indent:-0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">FSA Participants&#160;&#160;&#160;&#160;Section&#160;5.4(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">HSR Act Clearance&#160;&#160;&#160;&#160;Section&#160;6.1(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indemnified Party&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indemnifying Party&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indemnitee Affiliates&#160;&#160;&#160;&#160;Section&#160;5.6(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Independent Accountant&#160;&#160;&#160;&#160;Section&#160;1.5(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Legal Restraint&#160;&#160;&#160;&#160;Section&#160;6.1(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Liabilities Assumption&#160;&#160;&#160;&#160;Section&#160;1.1</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Lock-Up Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(vii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Material Contract&#160;&#160;&#160;&#160;Section&#160;3.7(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Material Customers&#160;&#160;&#160;&#160;Section&#160;3.7(a)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Material Suppliers&#160;&#160;&#160;&#160;Section&#160;3.7(a)(ii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">MHI&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Negative First Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.5(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Negative Second Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.6(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">NIA Pennsylvania&#160;&#160;&#160;&#160;Section&#160;5.23</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Non-Florida Commercial Agreements&#160;&#160;&#160;&#160;Section&#160;1.3(e)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">NYSE&#160;&#160;&#160;&#160;Section&#160;4.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Objection Notice&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Outside Date&#160;&#160;&#160;&#160;Section&#160;7.1(b)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Outstanding Buyer Common Shares&#160;&#160;&#160;&#160;Section&#160;4.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Parties&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Payment Statement&#160;&#160;&#160;&#160;Section&#160;1.4(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Personal Electronic Devices&#160;&#160;&#160;&#160;Section&#160;1.8(q)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Positive First Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.5(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Positive Second Adjustment Amount&#160;&#160;&#160;&#160;Section&#160;1.6(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Post-Signing Insurance Proceeds&#160;&#160;&#160;&#160;Section&#160;1.7(f)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Pre-Closing Indemnified Person&#160;&#160;&#160;&#160;Section&#160;5.6(f)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Pre-Closing Tax Refund&#160;&#160;&#160;&#160;Section&#160;8.3</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Preferred Equity Commitment Letter&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Preferred Equity Financing&#160;&#160;&#160;&#160;Section&#160;4.11(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Preservation Date&#160;&#160;&#160;&#160;Section&#160;5.8(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Pre-Signing Buyer Reports&#160;&#160;&#160;&#160;Article&#160;IV</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Privacy Consents&#160;&#160;&#160;&#160;Section&#160;3.5(m)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Projections&#160;&#160;&#160;&#160;Section&#160;10.1(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Purchase Price Allocation&#160;&#160;&#160;&#160;Section&#160;8.4</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">R&#38;W Insurance Policy&#160;&#160;&#160;&#160;Section&#160;4.14</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Registration Rights Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(v)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Regulatory Concession&#160;&#160;&#160;&#160;Section&#160;5.3(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Replacement Award&#160;&#160;&#160;&#160;Section&#160;5.4(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Required Amount&#160;&#160;&#160;&#160;Section&#160;4.11(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Required Filings&#160;&#160;&#160;&#160;Section&#160;2.3(b)(iii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Required Information&#160;&#160;&#160;&#160;Section&#160;5.12(b)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Restrictive Covenant Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(vi)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Retained Liabilities&#160;&#160;&#160;&#160;Section&#160;1.10</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Second Adjustment Statement&#160;&#160;&#160;&#160;Section&#160;1.6(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.12pt;text-indent:-0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Second Review Period&#160;&#160;&#160;&#160;Section&#160;1.6(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller 401(k) Plan&#160;&#160;&#160;&#160;Section&#160;5.4(d)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller FSAs&#160;&#160;&#160;&#160;Section&#160;5.4(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller Indemnified Persons&#160;&#160;&#160;&#160;Section&#160;9.1(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller Names&#160;&#160;&#160;&#160;Section&#160;1.8(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller Parent&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Seller Released Parties&#160;&#160;&#160;&#160;Section&#160;10.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller Releasing Parties&#160;&#160;&#160;&#160;Section&#160;10.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller Tax Returns&#160;&#160;&#160;&#160;Section&#160;8.1(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sellers&#160;&#160;&#160;&#160;Preamble</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sell-Side Representations&#160;&#160;&#160;&#160;Section&#160;10.1(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Skadden&#160;&#160;&#160;&#160;Section&#160;10.3</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Software License Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(iii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Solvent&#160;&#160;&#160;&#160;Section&#160;4.10</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified Business Employees&#160;&#160;&#160;&#160;Section&#160;5.4(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified Retained Liabilities&#160;&#160;&#160;&#160;Section&#160;1.10(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tail Policy&#160;&#160;&#160;&#160;Section&#160;5.6(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Fee&#160;&#160;&#160;&#160;Section&#160;7.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Fee Expenses&#160;&#160;&#160;&#160;Section&#160;7.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Fee Interest&#160;&#160;&#160;&#160;Section&#160;7.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Payments&#160;&#160;&#160;&#160;Section&#160;7.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Third Party&#160;&#160;&#160;&#160;Section&#160;9.2(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Third-Party Claim&#160;&#160;&#160;&#160;Section&#160;9.2(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer&#160;&#160;&#160;&#160;Section&#160;1.1</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer Taxes&#160;&#160;&#160;&#160;Section&#160;8.5</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Asset&#160;&#160;&#160;&#160;Section&#160;1.7</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Business Employee Devices&#160;&#160;&#160;&#160;Section&#160;1.7(l)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Contracts&#160;&#160;&#160;&#160;Section&#160;1.7(b)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Domain Names&#160;&#160;&#160;&#160;Section&#160;1.7(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Employee&#160;&#160;&#160;&#160;Section&#160;5.4(b)(i)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Employment-Related Agreements&#160;&#160;&#160;&#160;Section&#160;1.7(c)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Equity Interests&#160;&#160;&#160;&#160;Recitals</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred IT&#47;IP Assets&#160;&#160;&#160;&#160;Section&#160;1.7(l)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transferred Leases&#160;&#160;&#160;&#160;Section&#160;1.7(a)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transition Services Agreement&#160;&#160;&#160;&#160;Section&#160;1.3(a)(ii)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ultimate Parent&#160;&#160;&#160;&#160;Section&#160;5.2</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ultimate Parent Equity Awards&#160;&#160;&#160;&#160;Section&#160;3.11(h)</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Underwriter&#160;&#160;&#160;&#160;Section&#160;4.14</font></div><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WARN Act&#160;&#160;&#160;&#160;Section&#160;3.12(c)</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature Pages Follow&#93;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">105</font></div></div></div><div id="ie7be9b9b35414cc7908357c73bda1109_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the undersigned has caused this Agreement to be executed and delivered as of the first date written above.</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC. <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief  Executive Officer</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief  Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Stock and Asset Purchase Agreement&#93;</font></div><div><font><br></font></div></div></div><div id="ie7be9b9b35414cc7908357c73bda1109_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the undersigned has caused this Agreement to be executed and delivered as of the first date written above.</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAGELLAN HEALTH, INC.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derrick Duke </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Derrick Duke  </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President and CEO</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                                                            MAGELLAN HEALTHCARE, INC.</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derrick Duke </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Derrick Duke  </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President and CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Stock and Asset Purchase Agreement&#93;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.6
<SEQUENCE>3
<FILENAME>a123122exhibit26.htm
<DESCRIPTION>EX-2.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i99ffe5a684604c5da8dc012136ead293_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 2.6</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO STOCK AND ASSET PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This AMENDMENT NO. 1, dated as of January 20, 2023 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is by and among Evolent Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Evolent Health LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, together with Buyer Parent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Magellan Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each capitalized term used but not defined in this Amendment has the meaning given to it in the Stock and Asset Purchase agreement, dated as of November 17, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and among Buyer Parent, Buyer, Seller Parent and Magellan Healthcare, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Section 11.1 of the Purchase Agreement provides that the Purchase Agreement may be amended only by a written instrument signed by the Buyer Entities and Seller Parent (on behalf of Sellers)&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Buyer Entities and Seller Parent desire to amend the Purchase Agreement as set forth in this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the foregoing and covenants and agreements herein, and intending to be legally bound hereby, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment to Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Annex D to the Disclosure Schedule is amended and restated to be in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Except to the extent specifically amended in or supplemented by this Amendment, the Purchase Agreement remains unchanged and in full force and effect, and this Amendment shall be governed by and subject to the terms of the Purchase Agreement, as amended by this Amendment. Each reference in the Purchase Agreement to &#8220;hereof,&#8221; &#8220;hereunder&#8221; or words of similar import, and all references to the Purchase Agreement in any and all agreements, instruments, documents, notes, certificates and other writings of every kind or nature (other than in this Amendment or as otherwise expressly provided) shall be deemed to mean the Purchase Agreement as amended by this Amendment regardless of whether this Amendment is expressly referenced therein.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The provisions of Sections 11.1, 11.2, 11.4, 11.5, 11.7, 11.9 and 11.11 of the Purchase Agreement are incorporated into this Amendment by reference and shall apply to this Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature Pages Follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i99ffe5a684604c5da8dc012136ead293_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the undersigned has caused this Agreement to be executed and delivered as of the first date written above.</font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EVOLENT HEALTH, INC.<br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief Executive Officer</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EVOLENT HEALTH LLC&#160;&#160;&#160;&#160;<br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief Executive Officer</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MAGELLAN HEALTH, INC.<br><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derrick Duke </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Derrick Duke  </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President and CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.7
<SEQUENCE>4
<FILENAME>a123122exhibit27.htm
<DESCRIPTION>EX-2.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4a61e876b6a745c3841c1d183b469756_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 2.7</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO STOCK AND ASSET PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This AMENDMENT NO. 2, dated as of February 17, 2023 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is by and among Evolent Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Evolent Health LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with Buyer Parent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Magellan Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each capitalized term used but not defined in this Amendment has the meaning given to it in the Stock and Asset Purchase agreement, dated as of November 17, 2022, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and among Buyer Parent, Buyer, Seller Parent and Magellan Healthcare, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Section 11.1 of the Purchase Agreement provides that the Purchase Agreement may be amended only by a written instrument signed by the Buyer Entities and Seller Parent (on behalf of Sellers)&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Buyer Entities and Seller Parent desire to amend the Purchase Agreement as set forth in this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and covenants and agreements herein, and intending to be legally bound hereby, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments to Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The definition of Net Working Capital in Section 11.13(a) of the Purchase Agreement is amended and restated to be as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an amount equal to the difference of (i) the aggregate value of the current assets that are owned by the Acquired Entities or that are Transferred Assets, in each case, in the balance sheet accounts listed in Exhibit I, minus (ii) the aggregate value of the current liabilities of Acquired Entities or that are Assumed Liabilities, in each case, in the balance sheet accounts listed in Exhibit I, in each case under the forgoing clauses (i) and (ii), calculated without double counting as of the Measurement Time and determined in accordance with the Accounting Principles&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Net Working Capital shall exclude all Closing Date Cash, Restricted Cash, Closing Date Indebtedness, Income Tax assets (including deferred Income Tax assets), Income Tax liabilities (including deferred Income Tax liabilities), Post-Signing Insurance Proceeds, operating lease obligations, right of use assets, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">accrued and unused vacation time and other paid time off as of the Closing Date of any Transferred Employee listed in Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and capitalized development costs that are classified as short-term assets, in each case, regardless of whether any such items are current assets or current liabilities of the Acquired Entities under GAAP. For illustrative purposes only, Exhibit I sets forth the calculation of Net Working Capital assuming that the Closing Date was June 30, 2022.&#8221; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Purchase Agreement is amended by adding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto as Schedule I to the Purchase Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment to Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Annex D to the Disclosure Schedule is amended and restated to be in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Amendment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Except to the extent specifically amended in or supplemented by this Amendment, the Purchase Agreement remains unchanged and in full force and effect, and this Amendment shall be governed by and subject to the terms of the Purchase Agreement, as amended by this Amendment. Each reference in the Purchase Agreement to &#8220;hereof,&#8221; &#8220;hereunder&#8221; or words of similar import, and all references to the Purchase Agreement in any and all agreements, instruments, documents, notes, certificates and other writings of every kind or nature (other than in this Amendment or as otherwise expressly provided) shall be deemed to mean the Purchase Agreement as amended by this Amendment regardless of whether this Amendment is expressly referenced therein.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The provisions of Sections 11.1, 11.2, 11.4, 11.5, 11.7, 11.9 and 11.11 of the Purchase Agreement are incorporated into this Amendment by reference and shall apply to this Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature Pages Follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div><div id="i4a61e876b6a745c3841c1d183b469756_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the undersigned has caused this Agreement to be executed and delivered as of the first date written above.</font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVOLENT HEALTH, INC.<br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief Executive Officer</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVOLNT HEALTH LLC&#160;&#160;&#160;&#160;<br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Seth Blackley </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief Executive Officer</font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="margin-top:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MAGELLAN HEALTH, INC.<br><br></font></div><div style="margin-top:24pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derrick Duke </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Derrick Duke  </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President and C</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>5
<FILENAME>a123122exhibit1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibad74c744edd467484951c04c1db3a14_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEVERANCE AND </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHANGE-IN-CONTROL AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of January 27, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Dan McCarthy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of a termination of employment or the occurrence of a Change in Control (as defined below) of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#8217;s employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board further believes that it is imperative to provide Executive with certain severance benefits upon termination of Executive&#8217;s employment and with certain additional benefits upon a termination of employment in connection with a Change in Control of the Company to provide Executive with enhanced financial security and incentive to remain with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the promises, agreements and conditions contained in this Agreement, the Company and Executive agree as follows&#58;  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION I<br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purposes of this Agreement the following definitions shall apply&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any unpaid Base Salary through the Date of Termination, payable within 30 days following the Date of Termination, or on such earlier date as may be required by applicable law&#59; (b) any Annual Bonus for a prior year earned but unpaid, payable at the time such bonuses would have been paid if Executive was still employed with the Company&#59; (c) reimbursement for any unreimbursed business expenses incurred through the Date of Termination, payable in accordance with the Company&#8217;s policy&#59; and (d) all vested benefits under the Company&#8217;s retirement, health and welfare and equity-based employee benefit plans to which Executive is entitled, payable in accordance with the terms of such plan or program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity controlled by, controlling, or under common control with, the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s annual bonus under the Company&#8217;s or an Affiliate&#8217;s annual executive bonus program, as in effect from time to time, under which Executive is covered.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s annual base salary, exclusive of any bonus pay, commissions or other additional compensation, in effect on the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive&#8217;s failure to perform any of Executive&#8217;s material duties to the Company, including, without limitation, a breach of the Company&#8217;s code of ethics, conflict of interest or employment policies&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive&#8217;s misappropriation of a material business opportunity of the Company, including securing or attempting to secure any personal profit in connection with any transaction entered into on behalf of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Executive&#8217;s misappropriation (or attempted misappropriation) of any Company funds or property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Executive&#8217;s conviction of, indictment for (or its procedural equivalent), or entering of a guilty plea or plea of no contest with respect to (or its procedural equivalent), a felony or any other crime involving dishonesty or theft of property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Executive&#8217;s commission of one or more acts of sexual harassment in violation of applicable federal, state or local laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Executive&#8217;s use of illegal drugs, abuse of controlled substances, or abuse or excessive use of alcohol, which (in the case of alcohol use) interferes with or affects Executive&#8217;s responsibilities to the Company or which reflects negatively upon the integrity or reputation of the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Executive&#8217;s breach of the terms of this Agreement, any other employment agreement, any confidentiality agreement, non-competition agreement or non-solicitation agreement or any other material agreement between Executive and the Company, after giving effect to the notification provisions, if any, and the mechanisms to remedy or cure such breach as described in any such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall determine whether conduct constituting &#8220;Cause&#8221; has occurred for purposes of this Agreement. For purposes of this definition, (i) &#8220;Company&#8221; includes any Subsidiary or Affiliate and (ii) &#8220;Cause&#8221; is not limited to events that have occurred before a termination of Executive&#8217;s employment or services with the Company, nor is it necessary that the Company&#8217;s finding of &#8220;Cause&#8221; occur prior to termination of such employment or services with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;During any period of twenty-four (24) consecutive calendar months, individuals who were directors of the Company on the first day of such period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incumbent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) cease for any reason to constitute a majority of the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that any individual becoming a director subsequent to the first day of such period, whose election, or nomination for election by the Company&#8217;s stockholders, was made pursuant to the Stockholders Agreement by and among the Company, the Advisory Board, TPG Growth II BDH, L.P., TPG Eagle Holdings L.P. and UPMC, dated as of June 4, 2015 or was approved by a vote of at least a majority of the Incumbent Directors shall be considered as though such individual were an Incumbent Director, but excluding, for purposes of this proviso, any such individual whose initial assumption of office occurs as a result of an actual or threatened proxy contest with respect to election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a &#8220;person&#8221; (as used in Section 13(d) of the Securities Exchange Act of 1934, as amended) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case other than the Board&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The consummation of (i) a merger, consolidation, statutory share exchange or similar form of corporate transaction involving (A) the Company or (B) any of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subsidiaries, but in the case of this clause (B) only if Company Voting Securities (as defined below) are issued or issuable (each of the events referred to in this clause (i) being hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reorganization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) the sale or other disposition of all or substantially all the assets of the Company to an entity that is not an Affiliate (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case, if such Reorganization or Sale requires the approval of the Company&#8217;s stockholders under the law of the Company&#8217;s jurisdiction of organization (whether such approval is required for such Reorganization or Sale or for the issuance of securities of the Company in such Reorganization or Sale), unless, immediately following such Reorganization or Sale, (1) all or substantially all the Persons who were the &#8220;beneficial owners&#8221; (as used in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (or a successor rule thereto)) of the securities eligible to vote for the election of the Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) outstanding immediately prior to the consummation of such Reorganization or Sale continue to beneficially own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation or other entity resulting from such Reorganization or Sale (including a corporation or other entity that, as a result of such transaction, owns the Company or all or substantially all the Company&#8217;s assets either directly or through one or more subsidiaries) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continuing Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in substantially the same proportions as their ownership, immediately prior to the consummation of such Reorganization or Sale, of the outstanding Company Voting Securities (excluding, for such purposes, any outstanding voting securities of the Continuing Company that such beneficial owners hold immediately following the consummation of the Reorganization or Sale as a result of their ownership prior to such consummation of voting securities of any corporation or other entity involved in or forming part of such Reorganization or Sale other than the Company), (2) no Person (excluding any employee benefit plan (or related trust) sponsored or maintained by the Continuing Company or any entity controlled by the Continuing Company) beneficially owns, directly or indirectly, fifty percent (50%) or more of the combined voting power of the then outstanding voting securities of the Continuing Company and (3) at least fifty percent (50%) of the members of the board of directors of the Continuing Company were Incumbent Directors at the time of the execution of the definitive agreement providing for such Reorganization or Sale or, in the absence of such an agreement, at the time at which approval of the Board was obtained for such Reorganization or Sale&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The stockholders of the Company approve a plan of complete liquidation or dissolution of the Company unless such liquidation or dissolution is part of a transaction or series of transactions described in paragraph (b) above that does not otherwise constitute a Change of Control&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Any Person, corporation or other entity or &#8220;group&#8221; (as used in Section 13(d) of the Securities Exchange Act of 1934, as amended) (other than (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or an Affiliate or (iii) any entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of the voting power of the Company Voting Securities) becomes the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company Voting Securities&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that for purposes of this subparagraph (d), the following acquisitions shall not constitute a Change of Control&#58; (A) any acquisition directly from the Company, (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or an Affiliate, (C) any acquisition by an underwriter temporarily holding such Company Voting Securities pursuant to an offering of such securities or any acquisition by a pledgee of Company Voting Securities holding such securities as collateral or temporarily holding such securities upon foreclosure of the underlying obligation or (D) any acquisition pursuant to a Reorganization or Sale that does not constitute a Change of Control for purposes of subparagraph (b) above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary, to the extent that nonqualified deferred compensation as defined in and subject to Section 409A is payable under this Agreement upon a Change in Control, an event shall not be considered to be a Change in Control with respect to such nonqualified deferred compensation unless such event is also a &#8220;change in ownership,&#8221; a &#8220;change in effective control&#8221; or a &#8220;change in the ownership of a substantial portion of the assets&#8221; of the Company within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing thirty (30) days prior to a Change in Control and ending twenty-four (24) months after a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the regulations issued thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the effective date of Executive&#8217;s termination of employment and service with the Company and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence, without Executive&#8217;s written consent, of any of the events or circumstances set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;a material reduction in Executive&#8217;s annual Base Salary or Target Bonus, as the same may be increased from time to time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the assignment of duties to Executive inconsistent in any material respect with Executive&#8217;s position, authority or responsibilities with the Company, or any other action or omission by the Company which results in a material diminution of such position, authority or responsibilities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;a relocation of Executive&#8217;s principal work location by more than fifty (50) miles from such location as of immediately prior to the Date of Termination&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;a material diminution of the authority, duties or responsibilities of the supervisor to whom Executive reports&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;any material breach of this Agreement by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Good Reason shall not exist unless Executive gives the Company notice of the event giving rise to Good Reason within sixty (60) days of the date Executive has knowledge of such event. Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within ninety (90) days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) after such notice is given in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If such breach is not so cured (or is not curable), Executive may resign for Good Reason within three (3) months following the end of the Cure Period. If such breach is cured within the Cure Period or if such breach is not cured but Executive does not resign for Good Reason within three (3) months following the end of the Cure Period, Good Reason shall not exist hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section 409A of the Code and any regulations or other formal guidance promulgated thereunder.&#8195;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity in which the Company, directly or indirectly, possesses fifty percent (50%) or more of the total combined voting power of all classes of its stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s target Annual Bonus under the Company&#8217;s or Affiliate&#8217;s annual bonus program, as in effect from time to time, under which Executive is covered. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION II<br>SEVERANCE PAYMENTS AND BENEFITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, during a Change in Control Protection Period, the Company terminates Executive&#8217;s employment without Cause or Executive terminates employment for Good Reason, then the Company shall pay or provide the following amounts and benefits to Executive, in addition to the Accrued Obligations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be paid an amount equal to one and one-half (1.5) times the sum of Executive&#8217;s Annual Salary and Target Bonus in effect immediately prior to the Date of Termination.  Such severance shall be paid in a lump sum within sixty (60) days following the Date of Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus for Year of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;If the Date of Termination occurs during the first six (6) months of the year, Executive will be paid  a pro-rata portion of the Target Bonus in effect on the Date of Termination, determined by multiplying the amount of the Target Bonus by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If the Date of Termination occurs during the last six (6) months of the year, Executive will be paid a pro-rata portion of the Annual Bonus based on actual performance for such year, determined by multiplying the amount of the Annual Bonus that would be due for the full year by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Such pro-rated Target Bonus or Annual Bonus shall be paid in a lump sum at the same time the Annual Bonus would have been paid if Executive continued to be employed by the Company, but in any event in the calendar year following the year during which the Date of Termination occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive timely elects coverage under COBRA under any group health plan of the Company or an Affiliate, the Company will pay Executive a taxable monthly amount that, after applicable federal, state and local tax withholdings, is equal to the portion of the cost of coverage that is subsidized by the Company for active employees as in effect from time to time until the earlier of&#58; (i) eighteen (18)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months following the Date of Termination and (ii) the expiration of the Executive&#8217;s COBRA coverage.   The first monthly payment shall be paid to Executive within sixty (60) days following the Date of Termination and, thereafter, each subsequent monthly payment shall be paid on the first payroll date in each month following the Date of Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or Executive&#8217;s award agreement thereunder, any and all outstanding equity awards granted to Executive under any equity plan of the Company or its Affiliates will be treated as follows&#58; (i) all time-based vesting conditions applicable to such awards will be treated as satisfied in full and shall lapse on the Date of Termination, and (ii) any performance-based vesting conditions applicable to such awards shall be deemed to have been </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfied at the greater of target and actual performance through the Date of Termination.   Such awards will be settled in accordance with, and otherwise be subject to, the terms of the equity plan of the Company or its Affiliates or Executive&#8217;s award agreement thereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that any vested restricted stock units shall be settled upon Executive within sixty (60) days following the Date of Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Outside of Change in Control Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company terminates Executive&#8217;s employment without Cause, or Executive terminates employment for Good Reason, in either case other than during a Change in Control Protection Period, then the Company shall pay or provide the following amounts and benefits to Executive, in addition to the Accrued Obligations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be paid an amount equal to one (1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times the sum of Executive&#8217;s Annual Salary in effect immediately prior to the Date of Termination, payable for a period of twelve (12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months following the Date of Termination in accordance with the Company&#8217;s normal payroll practices and commencing within sixty (60) days following the Date of Termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that any payments that would otherwise be payable during the period following the Date of Termination until the payment commencement date shall be accumulated without interest and paid on such commencement date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus for Year of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;If the Date of Termination occurs during the first six (6) months of the year, Executive will be paid  a pro-rata portion of the Target Bonus in effect on the Date of Termination, determined by multiplying the amount of the Target Bonus by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If the Date of Termination occurs during the last six (6) months of the year, Executive will be paid a pro-rata portion of the Annual Bonus based on actual performance for such year, determined by multiplying the amount of the Annual Bonus that would be due for the full year by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Such pro-rated Target Bonus or Annual Bonus shall be paid in a lump sum at the same time the Annual Bonus would have been paid had Executive continued to be employed by the Company, but in any event in the calendar year following the year during which the Date of Termination occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive timely elects coverage under COBRA under any group health plan of the Company or an Affiliate, the Company will pay Executive a taxable monthly amount that, after applicable federal, state and local tax withholdings, is equal to that portion of the cost of coverage that is subsidized by the Company for active employees as in effect from time to time until the earlier  of&#58; (i) twelve (12) months following the Date of Termination and (ii) the expiration of the Executive&#8217;s COBRA coverage.   The first monthly payment shall be paid to Executive within sixty (60) days following the Date of Termination and thereafter each subsequent monthly payment shall be paid on the first payroll date in each month following the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or Executive&#8217;s award agreement thereunder, any and all outstanding equity awards granted to Executive under any equity plan of the Company or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliates shall be treated as follows&#58; (i) for purposes of any time-based vesting conditions applicable to such awards, Executive shall be deemed to have completed an additional twelve (12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months of employment following the Date of Termination, and (ii) satisfaction of any performance-based vesting conditions applicable to such awards shall be determined at the end of the applicable performance period based on actual performance through the end of the performance period , and pro-rated based on (A) the number of days Executive was employed by the Company during the vesting measurement period through the Date of Termination plus twelve (12) months</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(but not to exceed the performance period)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">over (B) the number of days in the performance period.  Such awards will be settled in accordance with, and otherwise be subject to, the terms of the equity plan of the Company or its Affiliates or Executive&#8217;s award agreement thereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Any Other Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment  and service with the Company and its Affiliates is terminated for any reason other than by the Company without Cause or by Executive for Good Reason, including due to Executive&#8217;s retirement, death or disability, no amounts or benefits will be payable or provided under this Agreement, except the Accrued Amounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained in this Agreement to the contrary, the Company shall not be obligated to provide any payments or benefits to Executive under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof other than the Accrued Obligations unless Executive executes  and delivers to the Company a general release of claims in favor of the Company and its Affiliates and their respective employees, officers and directors in such form as is reasonably requested by the Company, and such release becomes irrevocable by its terms, no later than sixty (60) days after the Date of Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Duplication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In no event shall payments and benefits provided in accordance with this Agreement be made in respect of more than one of Section 2.1 or 2.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of this Section II, the Company&#8217;s obligation to make the severance payments and benefits described herein shall be reduced by any amounts owed by Executive to the Company and its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that offsets of amounts owed by Executive that are nonqualified deferred compensation (within the meaning of Section 409A) shall only be made in accordance with Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Award Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or in any award agreement thereunder, any requirement of an equity award held by Executive that Executive remain an employee of the Company or an Affiliate or a member of the Board through an applicable vesting date shall be deemed satisfied if Executive remains an employee of, or provides services as a consultant to, the Company or an Affiliate, or continues as a member of the Board, through such vesting date. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION III<br>TAX INFORMATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall deduct from payments to be paid to Executive or any beneficiary all federal, state and local withholding and other taxes and charges required to be deducted under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The intent of the parties is that payments and benefits under this Agreement shall comply with or be exempt from Section 409A and  this Agreement shall be interpreted in accordance with such intentions. Notwithstanding the foregoing, neither the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company, its Affiliates nor their respective directors, officers, employees or advisers shall be held liable for any taxes, interest, penalties or other monetary amounts owed by Executive (or any other individual claiming a benefit through Executive) as a result of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and references to the &#8220;Date of Termination,&#8221; a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service,&#8221; within the meaning of Section 409A, from the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company.  In the event the payment period under this Agreement commences in one calendar year and ends in a second calendar year, the payments shall not be paid (or installments commenced) until the second calendar year.  For purposes of Section 409A, Executive&#8217;s right to receive installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;If Executive is deemed on the Date of Termination to be a &#8220;specified employee&#8221; within the meaning of that term under Section 409A(a)(2)(B), then with regard to any payment or benefit subject to Section 409A that is payable on account of a &#8220;separation from service,&#8221; such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such &#8220;separation from service&#8221; of Executive, and (ii) the date of Executive&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this section (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid to Executive in a lump sum without interest, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION IV<br>RESTRICTIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive acknowledges that the Company and its Affiliates continually develop Confidential Information (as defined below), that Executive may develop Confidential Information for the Company or its Affiliates and that Executive may learn of Confidential Information during the course of Executive&#8217;s employment.  Executive will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by applicable law or for the proper performance of Executive&#8217;s duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by Executive incident to Executive&#8217;s employment or other association with the Company or any of its Affiliates. Executive understands that this restriction shall continue to apply after Executive&#8217;s employment terminates, regardless of the reason for such termination. The confidentiality obligation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to information which is generally known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of Executive or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whether or not prepared by Executive, shall be the sole and exclusive property of the Company and its Affiliates. Executive shall safeguard all Documents and shall surrender to the Company at the time Executive&#8217;s employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in Executive&#8217;s possession or control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business and any and all information, publicly known in whole or in part or not, which, if disclosed by the Company or any of its Affiliates would assist in competition against them. Confidential Information includes without limitation such information relating to (i) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (ii) the products and services of the Company and its Affiliates, (iii) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates, (iv) the identity and special needs of the customers of the Company and its Affiliates and (v) the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships. Confidential Information also includes any  information that the Company or any of its Affiliates has received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive agrees and acknowledges that the business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which Executive or was involved on or prior to the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive agrees that, except as the Company expressly agrees in writing, during the Restricted Period (defined below), Executive shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever of or for any person or entity (other than for the Company)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (i) the Business or (ii) if Executive has provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the Restricted Period, such customer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive may accept employment with a Competitor whose business is diversified, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that (A) such employment is with a portion of the Competitor&#8217;s business that does not provide products or services that are the same as, are similar to, or compete with the Company&#8217;s products or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competing Products or Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (B) prior to Executive&#8217;s acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from Executive that Executive will not provide any Competing Products or Services&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, with whom Executive had material Business-related contact and&#47;or about which Executive had access to and&#47;or knowledge of Confidential Information, for a purpose that is competitive with the Business&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;solicit (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the six (6)-month period prior to the Date of Termination had been, employed or engaged by the Company, or induce or take any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period of time beginning on the Effective Date and ending on the date that is (i) eighteen (18) months following the Date of Termination where </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  applies because the termination occurs during a Change in Control Protection Period or (ii) twelve (12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months following the Date of Termination where </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> applies because the termination occurs other than during a Change in Control Protection Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States of America (including the following states&#58; Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, as well as the District of Columbia) and any other country or territory with respect to which Executive has been materially engaged in Business-related activities on behalf of the Company and&#47;or about which Executive has had access to and&#47;or knowledge of Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, Executive is permitted to own, individually, as a passive investor (with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;Executive shall disclose in writing all of Executive&#8217;s relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or any other business entity, to the Company until the end of the Restricted Period. Executive shall not disparage the Company or any of its officers, directors, or employees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not prohibit or constrain truthful testimony by Executive compelled by any valid legal process or valid legal dispute resolution process. Notwithstanding anything herein to the contrary, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall prevent either party hereto from enforcing such party&#8217;s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;During the Restricted Period, Executive shall notify in writing any prospective new employer or entity otherwise seeking to engage Executive that the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section IV </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exist prior to accepting employment or such other engagement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;The terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and necessary in light of Executive&#8217;s position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the parties hereto.  In addition, any breach of the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> would cause irreparable harm to the Company, its Subsidiaries and Affiliates and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach.  In the event of a breach or threatened breach by Executive of any of the provisions of this Agreement, Executive hereby consents and agrees that money damages would not afford an adequate remedy and that the Company shall be entitled to seek a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages, and without the necessity of posting any bond or other security, where permissible under applicable law.  Any equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages, or other available relief.  Notwithstanding the foregoing, this Agreement is not intended to, and shall be interpreted in a manner that does not, limit or restrict Executive from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Securities Exchange Act of 1934).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival of Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon termination of Executive&#8217;s employment for any reason whatsoever, the obligations of Executive pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive and remain in effect for the periods described herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Waiver of Legal Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The restrictions in this Agreement are in addition to and not in lieu of any other obligation of Executive to protect confidential information and trade secrets and any rights and remedies which the Company may have at law or in equity.  Nothing in this Agreement is intended to or should be interpreted as diminishing any rights and remedies the Company has.  Enforcement of rights and remedies pursuant to this Agreement by the Company and&#47;or any other entity shall not be construed as a waiver of any other rights or remedies at law or equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, nothing contained in this Agreement limits Executive&#8217;s ability to file a charge or complaint with the Securities and Exchange Commission or any other federal, state or local government agency or commission (collectively, &#8220;Government Agencies&#8221;), or prevents Executive from providing truthful testimony in response to a lawfully-issued subpoena or court order.  Further, this Agreement does not limit Executive&#8217;s ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing non-privileged documents or other information, without notice to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive is hereby notified that under the Defend Trade Secrets Act&#58; (a) no individual will be held criminally or civilly liable under federal or state trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is&#58; (i) made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law, or (ii) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal&#59; and (b) an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION V<br>DISPUTES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the District of Delaware and (ii) the courts of the State of Delaware for the purposes of any suit, action or other proceeding arising out of this Agreement.  Executive and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the District of Delaware or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Delaware with jurisdiction over New Castle County.  Executive and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party&#8217;s address set forth below shall be effective service of process for any action, suit or proceeding in Delaware with respect to any matters to which Executive has submitted to jurisdiction in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or in (A) the United States District Court for the District of Delaware  or (B) the courts of the State of Delaware, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Jury Trial.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of Executive may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive hereby agrees to keep confidential the existence of, and any information concerning, a dispute described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that Executive may disclose information concerning such dispute to the court that is considering such dispute or to Executive&#8217;s legal counsel (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION VI<br>SUCCESSORS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;In addition to any obligations imposed by law upon any successor to the Company, the Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall continue to apply to each subsequent employer of Executive bound by this Agreement in the event of any merger, consolidation or transfer of all or substantially all of the business or assets of that subsequent employer.  This Agreement shall inure to the benefit of the Company, such successors and any assigns.  The term &#8220;the Company&#8221; as used herein shall include such successors, and any assigns. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION VII<br>NOTICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing (including email, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such email states that it is a notice delivered pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and shall be given at the address or email address set forth below (or to such other address or email address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or email address shall be effective only upon actual receipt).  All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5&#58;00 p.m. on a business day in the place of receipt. Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding business day in the place of receipt.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the Company&#58;  &#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800 N. Glebe Road, Suite 500</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arlington, VA 22203</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; JWeinberg&#64;evolenthealth.com</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To Executive&#58; At Executive&#8217;s most recent mailing address in the records of the Company, or at Executive&#8217;s employee email address (during employment).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION VIII<br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Any compensation paid or payable to Executive pursuant to this Agreement which is subject to recovery under any law, government regulation, order or stock exchange listing requirement, or under any policy of the Company adopted from time to time, will be subject to such deductions and clawback (recovery) as may be required to be made pursuant to such law, government regulation, order, stock exchange listing requirement or policy of the Company. Executive specifically authorizes the Company to withhold from future salary or wages any amounts that may become due under this provision.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;This Agreement embodies the entire agreement of the Company and Executive relating to separation or severance pay and, except as specifically provided herein, no provisions of any employee manual, personnel policies, corporate directives or other agreement or document shall be deemed to modify the terms of this Agreement.  Except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, no amendment or modification of this Agreement shall be valid or binding upon Executive or the Company unless made in writing and signed by the Company and Executive.  This Agreement supersedes all prior understandings and agreements addressing severance or separation pay to which Executive and the Company or an Affiliate are or were parties, including any previous change in control agreement, severance plan, offer letter provisions, or other employment agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;This Agreement shall not modify the &#8220;at will&#8221; nature of Executive&#8217;s employment, nor shall it confer upon Executive any right to continue employment or service with the Company or its affiliates, nor shall this Agreement interfere in any way with the right of the Company or its affiliates to terminate Executive&#8217;s employment or service at any time.&#8195;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in full force and effect.  If a judicial determination is made that any provision of this Agreement constitutes an unreasonable or otherwise unenforceable restriction against Executive, such provision shall be rendered void only to the extent that such judicial determination finds the provision to be unreasonable or otherwise unenforceable with respect to Executive.  In this regard, Executive hereby agrees that any judicial authority construing this Agreement shall be empowered to reform any portion of this Agreement, including without limitation the scope of the Business, the Territory, and the Restricted Period, in order to make the covenants herein binding and enforceable with respect to Executive, and to apply the provisions of this Agreement and to enforce against Executive the remaining portion of such provisions as the judicial authority determines to be reasonable and enforceable.  All of the covenants contained in this Agreement shall be construed as an agreement independent of any other provisions in this Agreement, and the existence of any claim or cause of action Executive may have against the Company and&#47;or its affiliates (other than in connection with a material breach of this Agreement by the Company) shall not constitute a defense to the enforcement by the Company and&#47;or its affiliates of such covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;The Agreement </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be construed, administered and governed in all respects under and by the applicable laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.  Delivery of an executed counterpart of a signature page to this Agreement by &#8220;.pdf&#8221; format or scanned pages shall be effective as delivery of a manually executed counterpart to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%">&#91;Remainder of page left intentionally blank.&#93;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have signed this Agreement to be effective as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:144pt;padding-right:-36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</font></div><div style="padding-left:264.95pt;text-align:justify;text-indent:-48.95pt"><font><br></font></div><div style="padding-left:264.95pt;text-align:justify;text-indent:-48.95pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#47;s&#47; Jonathan Weinberg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58; Jonathan Weinberg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Title&#58; General Counsel</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">       EXECUTIVE</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.717%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;  Dan McCarthy</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Dan McCarthy</font></td></tr></table></div><div style="padding-left:216pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="padding-left:270pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>a2022exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if8e04b40f4ff497090158c501d9b7594_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiaries</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Legal Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCIS Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCH Management Systems, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Assurance Solutions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vermont</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EH Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Justify Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kentucky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health International Private Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners of Texas, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Accountable Care Organization Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners of North Carolina, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">North Carolina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MTS III Vital Decisions Blocker Corp </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vital Decisions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Endzone Merger Sub, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EVH Growth Iceman Intermediate, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Implantable Provider Group, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Surgical Collections Group, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health International Philippines, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Philippines</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>a123122exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icde6ace834b243d28d2a217c2602c29e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statement Nos. 333-212709 and 333-266495 on Form S-3 and Registration Statement Nos. 333-204785, 333-225714, and 333-257118 on Form S-8 of our reports dated February 24, 2023, relating to the financial statements of Evolent Health, Inc. and subsidiaries (the &#8220;Company&#8221;) and the effectiveness of the Company&#8217;s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#47;s&#47; Deloitte &#38; Touche LLP </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">McLean, Virginia </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">February 24, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>a123122exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4145a818249f4f19bb3a71750ddcb932_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>a123122exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6be8f64060a740059899346e9cb23242_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>a123122exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8c94ec3ad47e44669ba66ab4a8fe389d_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>a123122exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib96a89f42c4c4e9e88715266bed44f54_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>evh-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolenthealth.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.evolenthealth.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>0000009 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>0000010 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>0000011 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>0000012 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>0000013 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>0000014 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>0000015 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>0000016 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000017 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>0000018 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>0000020 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperCommonShare" roleURI="http://www.evolenthealth.com/role/LossperCommonShare">
        <link:definition>0000021 - Disclosure - Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>0000022 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlans">
        <link:definition>0000024 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>0000025 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>0000026 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>0000027 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>0000028 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>0000029 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>0000030 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunaudited" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited">
        <link:definition>0000031 - Disclosure - Quarterly Results of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>0000032 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolenthealth.com/role/SubsequentEvents">
        <link:definition>0000033 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>0000034 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>0000035 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>0000036 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>0000037 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>0000038 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>0000039 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000040 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>0000041 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>0000042 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000043 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>0000044 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperCommonShareTables" roleURI="http://www.evolenthealth.com/role/LossperCommonShareTables">
        <link:definition>0000045 - Disclosure - Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompensationRelatedCostsShareBasedPaymentsTables" roleURI="http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables">
        <link:definition>0000046 - Disclosure - Compensation Related Costs, Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolenthealth.com/role/IncomeTaxesTables">
        <link:definition>0000047 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>0000048 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>0000049 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>0000050 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>0000051 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>0000052 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunauditedTables" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables">
        <link:definition>0000053 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>0000054 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>0000055 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>0000056 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails">
        <link:definition>0000058 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>0000059 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails">
        <link:definition>0000060 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>0000061 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsNarrativeDetails" roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails">
        <link:definition>0000062 - Disclosure - Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsAllocationofAcquisitionCostDetails" roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails">
        <link:definition>0000063 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>0000064 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>0000065 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000066 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>0000067 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>0000067 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>0000068 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>0000069 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>0000070 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>0000071 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000072 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>0000073 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>0000074 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>0000075 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>0000076 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2022CreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails">
        <link:definition>0000077 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>0000078 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2019CreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails">
        <link:definition>0000079 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>0000080 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>0000081 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>0000082 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>0000083 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000084 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>0000085 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>0000086 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>0000087 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000088 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>0000089 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>0000089 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>0000090 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails">
        <link:definition>0000091 - Disclosure - Loss per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>0000092 - Disclosure - Loss per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation2011and2015EquityIncentivePlansDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails">
        <link:definition>0000093 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>0000094 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>0000095 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationUnrecognizedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails">
        <link:definition>0000096 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails">
        <link:definition>0000097 - Disclosure - Stock-based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails">
        <link:definition>0000098 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedStockOptionAwardsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails">
        <link:definition>0000099 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails">
        <link:definition>0000100 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationLeveragedStockUnitsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails">
        <link:definition>0000101 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationLeveragedStockUnitsActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails">
        <link:definition>0000102 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedRSUsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails">
        <link:definition>0000103 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedRSUActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails">
        <link:definition>0000104 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000105 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails">
        <link:definition>0000106 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseBenefitDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
        <link:definition>0000107 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails">
        <link:definition>0000108 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000109 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesinValuationAllowanceDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails">
        <link:definition>0000110 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails">
        <link:definition>0000111 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000112 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>0000113 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>0000114 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>0000115 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>0000116 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>0000117 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>0000118 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>0000119 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>0000120 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>0000121 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>0000122 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>0000123 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunauditedDetails" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails">
        <link:definition>0000124 - Disclosure - Quarterly Results of Operations (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>0000125 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails">
        <link:definition>0000126 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_FinitelivedTaxCreditCarryforwardMember" abstract="true" name="FinitelivedTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LineOfCreditFacilityAutomaticExtensionPeriod" abstract="false" name="LineOfCreditFacilityAutomaticExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_DeferredFinancingFeesMember" abstract="true" name="DeferredFinancingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodTwoMember" abstract="true" name="PreferredStockRedemptionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodDomain" abstract="true" name="PreferredStockRedemptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumRevenueMember" abstract="true" name="PremiumRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DeferredTaxAssetOutsideBasisDifferences" abstract="false" name="DeferredTaxAssetOutsideBasisDifferences" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodValueEarnOuts" abstract="false" name="StockIssuedDuringPeriodValueEarnOuts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_StockIssuedInConnectionWithDebtRepayment" abstract="false" name="StockIssuedInConnectionWithDebtRepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_December312024Member" abstract="true" name="December312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AccountingStandardsUpdate201603Member" abstract="true" name="AccountingStandardsUpdate201603Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" abstract="true" name="TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" abstract="false" name="TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SharebasedCompensationAwardSubTrancheOneMember" abstract="true" name="SharebasedCompensationAwardSubTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" abstract="false" name="TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_WeightedAverageRemainingContractualTermAbstract" abstract="true" name="WeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" abstract="false" name="TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxAssetsOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_PreferredStockVariableDividendRateBasisSpread" abstract="false" name="PreferredStockVariableDividendRateBasisSpread" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_NumberOfOptionsToRenewLeases" abstract="false" name="NumberOfOptionsToRenewLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPricePercentage" abstract="false" name="PreferredStockRedemptionPricePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" abstract="false" name="LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_WeightedAverageCommonSharesOutstandingAbstract" abstract="true" name="WeightedAverageCommonSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_PeriodsPriortoJune2015Member" abstract="true" name="PeriodsPriortoJune2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NonEmployeeDirectorsMember" abstract="true" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ChangesInTaxReceivablesAgreementLiability" abstract="false" name="ChangesInTaxReceivablesAgreementLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" abstract="true" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evh_GainLossOnRepaymentOfDebt" abstract="false" name="GainLossOnRepaymentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BrightHealthManagementIncMember" abstract="true" name="BrightHealthManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NewCenturyHealthMember" abstract="true" name="NewCenturyHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementLiability" abstract="false" name="TaxReceivableAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" abstract="false" name="AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementLiability" abstract="false" name="TaxReceivablesAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_UPMCResellerAgreementMember" abstract="true" name="UPMCResellerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodOnePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_December312025Member" abstract="true" name="December312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" abstract="false" name="DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossFromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ImplantableProviderGroupIMPMember" abstract="true" name="ImplantableProviderGroupIMPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInTaxReceivableAgreement" abstract="false" name="IncreaseDecreaseInTaxReceivableAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationAwardSubTrancheTwoMember" abstract="true" name="SharebasedCompensationAwardSubTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodValue" abstract="false" name="StockVestedAndRetiredDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DeferredTaxAssetsStartupandOrganizationalCosts" abstract="false" name="DeferredTaxAssetsStartupandOrganizationalCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TwoThousandNineteenMember" abstract="true" name="TwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodThreeMember" abstract="true" name="PreferredStockRedemptionPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodOneMember" abstract="true" name="PreferredStockRedemptionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodSharesEarnOuts" abstract="false" name="StockIssuedDuringPeriodSharesEarnOuts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_GainLossFromTransferOfMembership" abstract="false" name="GainLossFromTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_VitalDecisionsMember" abstract="true" name="VitalDecisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodAxis" abstract="true" name="PreferredStockRedemptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" abstract="false" name="EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" abstract="false" name="PreferredStockDividendRatePercentageAnnualIncreaseInRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_December312023Member" abstract="true" name="December312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_UniversityHealthCaredbaPassportHealthPlanMember" abstract="true" name="UniversityHealthCaredbaPassportHealthPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PreferredStockRedemptionPeriodFourMember" abstract="true" name="PreferredStockRedemptionPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" abstract="false" name="EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodShares" abstract="false" name="StockVestedAndRetiredDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_TwoThousandElevenEquityIncentivePlanMember" abstract="true" name="TwoThousandElevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IndefinitelivedTaxCreditCarryforwardMember" abstract="true" name="IndefinitelivedTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareholderClassActionComplaintMember" abstract="true" name="ShareholderClassActionComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EquityComponentOfLongTermDebtMember" abstract="true" name="EquityComponentOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NationalImagingAssociatesMember" abstract="true" name="NationalImagingAssociatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SharebasedPaymentArrangementTrancheFourMember" abstract="true" name="SharebasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_A2022CreditFacilitiesMember" abstract="true" name="A2022CreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>evh-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_12e17a63-6ab6-4e3d-86f4-d93abaec3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:to="loc_us-gaap_AdditionalPaidInCapital_12e17a63-6ab6-4e3d-86f4-d93abaec3e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd40610f-dccc-41cf-a0ea-953a94dc8544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd40610f-dccc-41cf-a0ea-953a94dc8544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a8a3ead-132a-4ce2-9ab2-6b45563e57eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a8a3ead-132a-4ce2-9ab2-6b45563e57eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3d261c6e-8e67-40ea-bac2-611822700f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:to="loc_us-gaap_CommonStockValue_3d261c6e-8e67-40ea-bac2-611822700f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_23a4ede4-63b6-4b02-ab9d-b690c445623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3115d4d9-f3e1-442d-979b-b08b980218ce" xlink:to="loc_us-gaap_TreasuryStockCommonValue_23a4ede4-63b6-4b02-ab9d-b690c445623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_242901fa-9d98-42e8-b085-517aca8d6213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15e0effa-a5ab-4f8b-a08a-37f947f06081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242901fa-9d98-42e8-b085-517aca8d6213" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15e0effa-a5ab-4f8b-a08a-37f947f06081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b59fe41b-1f38-408e-bae0-cfa9505d294f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242901fa-9d98-42e8-b085-517aca8d6213" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b59fe41b-1f38-408e-bae0-cfa9505d294f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b83836f7-a252-44f1-b6b3-b1fc972658b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242901fa-9d98-42e8-b085-517aca8d6213" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b83836f7-a252-44f1-b6b3-b1fc972658b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2a5337ac-91a7-430a-8ad5-1274f3de614e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_242901fa-9d98-42e8-b085-517aca8d6213" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2a5337ac-91a7-430a-8ad5-1274f3de614e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de285b6f-58f8-4517-b28f-5585af2abf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e34dd583-7ef4-4b72-aa47-71642fb3c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de285b6f-58f8-4517-b28f-5585af2abf54" xlink:to="loc_us-gaap_Liabilities_e34dd583-7ef4-4b72-aa47-71642fb3c8ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2f30b585-0d85-42bf-83b8-6b1169f32b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de285b6f-58f8-4517-b28f-5585af2abf54" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2f30b585-0d85-42bf-83b8-6b1169f32b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bad77207-527a-4ba6-ac1e-e39cddc3ae28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de285b6f-58f8-4517-b28f-5585af2abf54" xlink:to="loc_us-gaap_StockholdersEquity_bad77207-527a-4ba6-ac1e-e39cddc3ae28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1e18c5ce-ce70-4b45-b36b-1d61c06bdac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_us-gaap_LiabilitiesCurrent_1e18c5ce-ce70-4b45-b36b-1d61c06bdac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cb66a256-65f6-4a1b-8e4c-9fd5020d8544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cb66a256-65f6-4a1b-8e4c-9fd5020d8544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c012a3ce-3db9-453f-bcb4-32a3b3d827f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c012a3ce-3db9-453f-bcb4-32a3b3d827f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_89ffced7-fd22-40b0-808b-fb6b5119968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_89ffced7-fd22-40b0-808b-fb6b5119968a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_42ac53f9-666c-4cc0-bbcf-75a1a90af5d8" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_evh_TaxReceivableAgreementLiability_42ac53f9-666c-4cc0-bbcf-75a1a90af5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2fc6fd23-e39a-43e1-83fc-016683996f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c47aec33-d17a-453f-bf3b-9ecf51ce98cf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2fc6fd23-e39a-43e1-83fc-016683996f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_70dda1c1-aaf6-471a-9290-887df8824949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_70dda1c1-aaf6-471a-9290-887df8824949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1de0f051-8cb4-46ce-a79d-33347872f557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_AssetsCurrent_1de0f051-8cb4-46ce-a79d-33347872f557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b5bfd9d-7853-44f7-940b-669da59f4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b5bfd9d-7853-44f7-940b-669da59f4da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_56b8d22f-9520-43f3-bd06-7cb7f2e99f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_56b8d22f-9520-43f3-bd06-7cb7f2e99f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_8ea1b3bd-2fff-4c78-81db-860265050bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_8ea1b3bd-2fff-4c78-81db-860265050bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0b39fc07-0c00-4f58-8232-be5eb1c38bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0b39fc07-0c00-4f58-8232-be5eb1c38bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ffd0215b-1aaa-4144-957c-7a180661742f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ffd0215b-1aaa-4144-957c-7a180661742f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c57329a0-6c72-42ed-b4f7-0cbd318a1d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_Goodwill_c57329a0-6c72-42ed-b4f7-0cbd318a1d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_298f226e-7b40-4a49-b903-035f0f93f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58c18327-7db3-4975-b73d-376215c56033" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_298f226e-7b40-4a49-b903-035f0f93f6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fa112834-f4b6-41aa-a6bc-00b85b607223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_us-gaap_AccountsPayableCurrent_fa112834-f4b6-41aa-a6bc-00b85b607223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6dd179af-7edc-422e-bb45-a9d51038be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6dd179af-7edc-422e-bb45-a9d51038be4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_bc01ed64-f173-4454-874e-f43ca4484bbd" xlink:href="evh-20221231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_bc01ed64-f173-4454-874e-f43ca4484bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_992cf0f4-634a-4500-bada-cb0289546ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_992cf0f4-634a-4500-bada-cb0289546ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_55ef4d69-f983-42e0-b021-05954fae98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_55ef4d69-f983-42e0-b021-05954fae98a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f7038653-4e5f-45ce-a7b9-a5f3fb0990e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ac8528d-f00b-4105-876b-e946e21078dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f7038653-4e5f-45ce-a7b9-a5f3fb0990e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c67e79b6-509a-4d6c-b09c-20e3b94f3e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_94569bfe-15c7-4ccd-8c60-47af3ed06306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c67e79b6-509a-4d6c-b09c-20e3b94f3e7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_94569bfe-15c7-4ccd-8c60-47af3ed06306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8e181990-96e9-471b-81a4-39e6b1e3a149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c67e79b6-509a-4d6c-b09c-20e3b94f3e7c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8e181990-96e9-471b-81a4-39e6b1e3a149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_25728a79-147c-44ba-86df-c8db40b945ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa78c709-f134-48fc-a815-179f341f91e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_25728a79-147c-44ba-86df-c8db40b945ca" xlink:to="loc_us-gaap_NetIncomeLoss_aa78c709-f134-48fc-a815-179f341f91e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_96ad4bdf-daa8-416a-a332-46de6e2beb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_25728a79-147c-44ba-86df-c8db40b945ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_96ad4bdf-daa8-416a-a332-46de6e2beb65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e9298547-04ac-4978-908e-137cd46e04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e9298547-04ac-4978-908e-137cd46e04cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_55f3ce5b-315d-4ad4-9374-c38086201c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_55f3ce5b-315d-4ad4-9374-c38086201c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61e0e560-97a6-48f9-a66e-a55a0ecbf8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61e0e560-97a6-48f9-a66e-a55a0ecbf8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f380f1a9-d74e-4c70-9df3-8ea96ab19825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f380f1a9-d74e-4c70-9df3-8ea96ab19825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_28aaf710-7966-4040-8b9f-8de93149274d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_DepreciationAndAmortization_28aaf710-7966-4040-8b9f-8de93149274d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0afdc53b-0e50-49e7-a18d-2afd3be1ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e87c8be7-bac4-4e08-8548-7f6cc32f6c62" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0afdc53b-0e50-49e7-a18d-2afd3be1ecab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_249ac081-52ca-4f2f-a4f1-27a0103ea696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b971581b-e9ab-42e1-a69e-af7a691b2cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_249ac081-52ca-4f2f-a4f1-27a0103ea696" xlink:to="loc_us-gaap_CostsAndExpenses_b971581b-e9ab-42e1-a69e-af7a691b2cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0f76869-6b01-427e-9d66-e1de44901b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_249ac081-52ca-4f2f-a4f1-27a0103ea696" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0f76869-6b01-427e-9d66-e1de44901b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_20246d0e-36d3-4ad1-820c-5742c506d685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6ed316b6-2425-47f5-b3ce-446e92815b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_20246d0e-36d3-4ad1-820c-5742c506d685" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6ed316b6-2425-47f5-b3ce-446e92815b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8657b850-1426-47f5-ad4b-668ec5e38208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_20246d0e-36d3-4ad1-820c-5742c506d685" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8657b850-1426-47f5-ad4b-668ec5e38208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_11516cc9-12f6-4ffc-ba55-c9097812efa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_01cb93e4-94d7-45ee-8c95-5237be9f5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_11516cc9-12f6-4ffc-ba55-c9097812efa2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_01cb93e4-94d7-45ee-8c95-5237be9f5b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2319c9f3-1b6a-4921-a47d-ffd9796f335c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_11516cc9-12f6-4ffc-ba55-c9097812efa2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2319c9f3-1b6a-4921-a47d-ffd9796f335c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f1559c33-4266-497d-8ff6-ffec78205d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e978e792-b170-4387-8c7d-a7f71b5abaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f1559c33-4266-497d-8ff6-ffec78205d1d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e978e792-b170-4387-8c7d-a7f71b5abaf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e10d4a84-f9ce-4515-80be-de4137cb08d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f1559c33-4266-497d-8ff6-ffec78205d1d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e10d4a84-f9ce-4515-80be-de4137cb08d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_e285df84-ca8b-4927-984b-0223f68bb61d" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_evh_GainOnTransferOfMembership_e285df84-ca8b-4927-984b-0223f68bb61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_e06568e8-f99b-41f0-ade8-7ffc7672d775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_e06568e8-f99b-41f0-ade8-7ffc7672d775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d7d716e-f860-413d-a911-152b3d36c137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d7d716e-f860-413d-a911-152b3d36c137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_66a6199b-b092-4d13-b282-857074837182" xlink:href="evh-20221231.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_66a6199b-b092-4d13-b282-857074837182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f7ade4ee-4cfb-4307-a341-edf766215c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f7ade4ee-4cfb-4307-a341-edf766215c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d3b962dc-bdcf-4c06-b8a5-2b57f550c508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d3b962dc-bdcf-4c06-b8a5-2b57f550c508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_7277463a-4866-4ee8-937f-8123043d241c" xlink:href="evh-20221231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_7277463a-4866-4ee8-937f-8123043d241c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2e829d4d-5fb1-43bb-ab50-64ef514e9553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_InterestExpense_2e829d4d-5fb1-43bb-ab50-64ef514e9553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f27fd516-3416-4be2-8440-8c5cca10389e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ad2407d-e5ad-41f4-b633-5b6e5dfc3a3e" xlink:to="loc_us-gaap_OperatingIncomeLoss_f27fd516-3416-4be2-8440-8c5cca10389e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_fb2c08a3-b513-48da-8e55-837ae2778db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38099c73-c48a-4daa-b5e9-cd300e82c57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_fb2c08a3-b513-48da-8e55-837ae2778db1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38099c73-c48a-4daa-b5e9-cd300e82c57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c18394a6-995c-4afe-8fc0-416802d02749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_fb2c08a3-b513-48da-8e55-837ae2778db1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c18394a6-995c-4afe-8fc0-416802d02749" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44465b0e-ed5b-4578-a0ad-21e4b5389091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bdbff8ca-3dbd-42cb-8394-2e2eee4f1d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44465b0e-ed5b-4578-a0ad-21e4b5389091" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bdbff8ca-3dbd-42cb-8394-2e2eee4f1d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0283e8b-e6b1-48f9-9d19-f1462c9be1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44465b0e-ed5b-4578-a0ad-21e4b5389091" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0283e8b-e6b1-48f9-9d19-f1462c9be1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_230a9a56-7dcd-42ea-b7a4-22196f2b947d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44465b0e-ed5b-4578-a0ad-21e4b5389091" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_230a9a56-7dcd-42ea-b7a4-22196f2b947d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e616fa17-99ab-42b2-9993-29c8d66ff5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44465b0e-ed5b-4578-a0ad-21e4b5389091" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e616fa17-99ab-42b2-9993-29c8d66ff5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1b049132-cd9b-4590-a360-e92e5e45351d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_1b049132-cd9b-4590-a360-e92e5e45351d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_97d22dbf-8d10-4bc1-8b81-77e8a0aff8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_97d22dbf-8d10-4bc1-8b81-77e8a0aff8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0df4290a-d916-434c-9752-0327b50ea160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0df4290a-d916-434c-9752-0327b50ea160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_c206edd1-49f0-4bf8-809b-a30cca60515d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_c206edd1-49f0-4bf8-809b-a30cca60515d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_003659f6-fb04-4066-aad3-408a9fc3ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_003659f6-fb04-4066-aad3-408a9fc3ee53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6a0e504a-0335-433d-96e3-144825a212a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6a0e504a-0335-433d-96e3-144825a212a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_d1f1fd05-658d-4371-8758-cdd4493b413d" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6c7ddfd-885c-4951-96a6-813b9d94a105" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_d1f1fd05-658d-4371-8758-cdd4493b413d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_88b9c398-5d3a-4605-ac28-96e2a1e42198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_88b9c398-5d3a-4605-ac28-96e2a1e42198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_82f4eb6b-b432-46ba-a61f-92072677e873" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_82f4eb6b-b432-46ba-a61f-92072677e873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_60837bd3-a6ab-4980-89ee-0e978b133664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_60837bd3-a6ab-4980-89ee-0e978b133664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0cd472d2-96c7-4f32-84c6-518230e45845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0cd472d2-96c7-4f32-84c6-518230e45845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_685f9bee-895f-4500-98f6-6cce685b71a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_685f9bee-895f-4500-98f6-6cce685b71a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_d6a5a565-5229-4a60-94a0-bfc4320ecb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_d6a5a565-5229-4a60-94a0-bfc4320ecb89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_3b0816a5-1b92-412a-a22c-906f3b00cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_3b0816a5-1b92-412a-a22c-906f3b00cabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_41222e79-4a5d-47c5-9cb1-efc824dd4f07" xlink:href="evh-20221231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_41222e79-4a5d-47c5-9cb1-efc824dd4f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_7e1b76bc-816e-4d2e-a85b-da3ce28853fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_7e1b76bc-816e-4d2e-a85b-da3ce28853fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3e754c4-9e89-432b-93be-4972626ca2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b94dd94d-06f4-4058-856d-36f508c16f2b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3e754c4-9e89-432b-93be-4972626ca2de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e83b7c80-ff01-45ca-9807-0722089143fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e83b7c80-ff01-45ca-9807-0722089143fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ab6adf02-fafa-44eb-9cb1-ce2886decae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_ShareBasedCompensation_ab6adf02-fafa-44eb-9cb1-ce2886decae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f9d25ca6-2831-4f55-9edc-8b427a3bd6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f9d25ca6-2831-4f55-9edc-8b427a3bd6d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c63fe914-392e-4fa9-bbe0-31d69f42a5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c63fe914-392e-4fa9-bbe0-31d69f42a5f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_33da67f9-0741-4eae-90bb-370c827c669a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_33da67f9-0741-4eae-90bb-370c827c669a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_85c7f7a6-faa6-4302-b386-f62d9734f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_85c7f7a6-faa6-4302-b386-f62d9734f14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_de3026af-2a74-4472-a6a2-f9f2e3a2bbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_de3026af-2a74-4472-a6a2-f9f2e3a2bbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ae4cfce-96d7-4ad0-9084-e93f327120a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ae4cfce-96d7-4ad0-9084-e93f327120a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_7944e347-52c4-496a-a1b8-ed520187f9bb" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_GainOnTransferOfMembership_7944e347-52c4-496a-a1b8-ed520187f9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_89abf1ad-1043-4085-ba75-055c3909ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_89abf1ad-1043-4085-ba75-055c3909ef93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ff4299a4-e3ca-45e7-aa09-942af1a7da1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ff4299a4-e3ca-45e7-aa09-942af1a7da1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7854b7c6-580a-4de7-8df6-bdf1e5f84d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7854b7c6-580a-4de7-8df6-bdf1e5f84d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_cf259ae7-b824-438f-8dc0-206cfded2cc3" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_cf259ae7-b824-438f-8dc0-206cfded2cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c451bddb-9c29-4a3f-8148-36fbbb4ed1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c451bddb-9c29-4a3f-8148-36fbbb4ed1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9aee85a4-e1b2-4aa2-ab05-efb32515cc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9aee85a4-e1b2-4aa2-ab05-efb32515cc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d857b6e-e605-4990-8ea3-39db05d2691b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_NetIncomeLoss_7d857b6e-e605-4990-8ea3-39db05d2691b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b2cbdee4-3d2d-4c45-b33f-cbd52c24ef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b2cbdee4-3d2d-4c45-b33f-cbd52c24ef4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_edc57fee-b0be-4efe-882a-6d835538ccdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_edc57fee-b0be-4efe-882a-6d835538ccdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_dbc7a673-33ef-49f4-b9f5-4e825abd44ac" xlink:href="evh-20221231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_dbc7a673-33ef-49f4-b9f5-4e825abd44ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_086be86b-671d-4a74-9abb-ffbd82736819" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_086be86b-671d-4a74-9abb-ffbd82736819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c49de72d-4f0b-468d-8776-9ca20a7bde21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c49de72d-4f0b-468d-8776-9ca20a7bde21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_826e1880-333d-415f-a441-0ddb4a6a7e05" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_826e1880-333d-415f-a441-0ddb4a6a7e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c1486b9c-dfe2-4cf3-9abd-d228f7ee802f" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c1486b9c-dfe2-4cf3-9abd-d228f7ee802f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2f004f1e-db37-40fb-8224-a2beb0af97e4" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2f004f1e-db37-40fb-8224-a2beb0af97e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_62a296e7-64d9-415d-8054-6bd44eeee79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="25" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_62a296e7-64d9-415d-8054-6bd44eeee79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_84a84b74-7de5-42db-b48b-eb1e0b100a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0774a5bd-302d-4fc7-a926-01483f759c21" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_84a84b74-7de5-42db-b48b-eb1e0b100a9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c1da09c-9e7a-40f8-bd0f-754619da92e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_d6a07f5c-9c61-4c10-aaa7-6aa39be6b7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c1da09c-9e7a-40f8-bd0f-754619da92e2" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_d6a07f5c-9c61-4c10-aaa7-6aa39be6b7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_03ff90b3-f746-49e6-82dc-e9a80f93821c" xlink:href="evh-20221231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c1da09c-9e7a-40f8-bd0f-754619da92e2" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_03ff90b3-f746-49e6-82dc-e9a80f93821c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_4e586eb5-b6b2-478c-9970-9a30a19996d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_78437340-2fa2-4cc1-a662-81a172c6d142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_4e586eb5-b6b2-478c-9970-9a30a19996d5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_78437340-2fa2-4cc1-a662-81a172c6d142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f777705d-e675-4304-ab5a-2ffe903c33aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9de56c6b-c0f7-4e6d-8745-8262bd7a50c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f777705d-e675-4304-ab5a-2ffe903c33aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9de56c6b-c0f7-4e6d-8745-8262bd7a50c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21276264-f718-4ddf-ae9b-aa5df732af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_fbe82849-0006-435f-a77a-36c64098ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21276264-f718-4ddf-ae9b-aa5df732af0b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_fbe82849-0006-435f-a77a-36c64098ab7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_67622d1b-93c5-4df2-9850-9e50c188919f" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21276264-f718-4ddf-ae9b-aa5df732af0b" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_67622d1b-93c5-4df2-9850-9e50c188919f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_100f0999-26d0-4569-ba48-5149e27aab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21276264-f718-4ddf-ae9b-aa5df732af0b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_100f0999-26d0-4569-ba48-5149e27aab06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95366899-ac5f-40bc-a897-e20fa4f4f48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21276264-f718-4ddf-ae9b-aa5df732af0b" xlink:to="loc_us-gaap_Goodwill_95366899-ac5f-40bc-a897-e20fa4f4f48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9375404a-a1c6-438c-b120-b79ffc40f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4fb3c40a-6dbc-40f8-8b1c-a3c5026666ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9375404a-a1c6-438c-b120-b79ffc40f52d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4fb3c40a-6dbc-40f8-8b1c-a3c5026666ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_543e1fdc-553f-4f31-a994-af3bafc14dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9375404a-a1c6-438c-b120-b79ffc40f52d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_543e1fdc-553f-4f31-a994-af3bafc14dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d6368332-2650-4c68-a316-4ee6f81a5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9375404a-a1c6-438c-b120-b79ffc40f52d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d6368332-2650-4c68-a316-4ee6f81a5c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f2fd10a7-c6ec-4432-9341-dc6d492d8350" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_f2fd10a7-c6ec-4432-9341-dc6d492d8350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d0177545-8b08-4976-8465-12dd5134b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d0177545-8b08-4976-8465-12dd5134b2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_664a8de5-4cb4-4264-a80e-905e4ec4746f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_664a8de5-4cb4-4264-a80e-905e4ec4746f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_289db679-ae01-40b5-b5f0-6da306e1215f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_289db679-ae01-40b5-b5f0-6da306e1215f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_0bcb2fdf-ef2c-4bd0-9229-102ed2eee43d" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_0bcb2fdf-ef2c-4bd0-9229-102ed2eee43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_982c5f24-eea6-4c80-951c-d212e7eed2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8b8f5bdb-71c1-488b-b79f-9b82a5dbe98c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_982c5f24-eea6-4c80-951c-d212e7eed2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_486fa1c2-6935-4cca-8aa8-e4dbc024f1a5" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5a5e1119-7173-4f7d-8f74-19f52d8a086f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_486fa1c2-6935-4cca-8aa8-e4dbc024f1a5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5a5e1119-7173-4f7d-8f74-19f52d8a086f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5db2f948-4e3f-414b-afa8-ada636572e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_486fa1c2-6935-4cca-8aa8-e4dbc024f1a5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5db2f948-4e3f-414b-afa8-ada636572e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a1fb58f0-314a-4585-8271-a57f9062016a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_486fa1c2-6935-4cca-8aa8-e4dbc024f1a5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a1fb58f0-314a-4585-8271-a57f9062016a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40eee5fd-fd17-406c-b99b-b6d477623524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_486fa1c2-6935-4cca-8aa8-e4dbc024f1a5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40eee5fd-fd17-406c-b99b-b6d477623524" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_06133205-6d26-4744-b247-abbe6acd5ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_16de98da-8e48-4226-ab8e-438274e4b871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_06133205-6d26-4744-b247-abbe6acd5ac4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_16de98da-8e48-4226-ab8e-438274e4b871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_63e86822-c0cb-44d9-845a-287f1d2bfe38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_06133205-6d26-4744-b247-abbe6acd5ac4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_63e86822-c0cb-44d9-845a-287f1d2bfe38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f5fe0d99-d453-43f6-91e2-48ae759e57f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_aac80054-0bde-4662-8323-2705d4d3b343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f5fe0d99-d453-43f6-91e2-48ae759e57f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_aac80054-0bde-4662-8323-2705d4d3b343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_515219e8-2254-4339-8ba1-76487a3ba793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f5fe0d99-d453-43f6-91e2-48ae759e57f2" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_515219e8-2254-4339-8ba1-76487a3ba793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_55fe859a-52f3-4b0a-81e4-f49d2bddf05c" xlink:href="evh-20221231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f5fe0d99-d453-43f6-91e2-48ae759e57f2" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_55fe859a-52f3-4b0a-81e4-f49d2bddf05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_017c6141-7013-41c7-8afb-8fd534624df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f5fe0d99-d453-43f6-91e2-48ae759e57f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_017c6141-7013-41c7-8afb-8fd534624df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_996d432c-8d69-4a2a-809d-b24318947386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_6d89eafc-0fbd-4298-adf1-7f3e8024d962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_996d432c-8d69-4a2a-809d-b24318947386" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_6d89eafc-0fbd-4298-adf1-7f3e8024d962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_5fc72f09-6807-4901-b1b9-af0f56b36789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_996d432c-8d69-4a2a-809d-b24318947386" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_5fc72f09-6807-4901-b1b9-af0f56b36789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_2e08680c-7866-4265-a904-df3771e2ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_996d432c-8d69-4a2a-809d-b24318947386" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_2e08680c-7866-4265-a904-df3771e2ba1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_52d7215e-2899-4e53-b6e3-4d069467bcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_996d432c-8d69-4a2a-809d-b24318947386" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_52d7215e-2899-4e53-b6e3-4d069467bcd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6166866b-8c76-4e72-a9e6-09917b980812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_21b4c5ff-63b8-4fe0-a9d8-fb9842a034ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6166866b-8c76-4e72-a9e6-09917b980812" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_21b4c5ff-63b8-4fe0-a9d8-fb9842a034ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_189dd120-15d4-4fee-a36a-f9fc3db9705d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6166866b-8c76-4e72-a9e6-09917b980812" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_189dd120-15d4-4fee-a36a-f9fc3db9705d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f1bf349a-7f24-4a4d-9894-c6d6ea54072b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f9500c30-4bb6-4a89-bdfb-8e3eaa895f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f1bf349a-7f24-4a4d-9894-c6d6ea54072b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f9500c30-4bb6-4a89-bdfb-8e3eaa895f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c5d33349-70b8-460b-aa34-392cbca11415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f1bf349a-7f24-4a4d-9894-c6d6ea54072b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c5d33349-70b8-460b-aa34-392cbca11415" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef35faf9-769a-4f03-b38d-f7d00937490d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_75487754-347e-4b75-85df-99de6f671c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef35faf9-769a-4f03-b38d-f7d00937490d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_75487754-347e-4b75-85df-99de6f671c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b7d426ff-f18b-4313-9a4f-1d72d47b58bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef35faf9-769a-4f03-b38d-f7d00937490d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b7d426ff-f18b-4313-9a4f-1d72d47b58bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e77f9c7b-fcff-4a39-b20f-6978115c1123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e77f9c7b-fcff-4a39-b20f-6978115c1123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a04bf647-8ad9-457e-a970-b6e67274f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a04bf647-8ad9-457e-a970-b6e67274f704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1663d388-e76f-4102-831d-e62a10228cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1663d388-e76f-4102-831d-e62a10228cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_348ca914-4e22-4d1c-bd1b-f38686bfedd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_348ca914-4e22-4d1c-bd1b-f38686bfedd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b98ca435-0093-44a8-8709-d96ceff5d36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b98ca435-0093-44a8-8709-d96ceff5d36d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_406acb52-7bc2-46ed-9f77-7eaf377d751b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cbf6c6ba-f7d6-4a19-bd47-3340cdc62316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_406acb52-7bc2-46ed-9f77-7eaf377d751b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4916f576-fc83-4b1f-87f5-088f86b47550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_664331dc-22ca-4285-b35d-5e041bc12993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_4916f576-fc83-4b1f-87f5-088f86b47550" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_664331dc-22ca-4285-b35d-5e041bc12993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7a1fa1da-c832-4fe3-8886-51a2dcb6999c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_4916f576-fc83-4b1f-87f5-088f86b47550" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7a1fa1da-c832-4fe3-8886-51a2dcb6999c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e727e54b-4aef-4697-bd2c-fb78e4f64308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9afbd041-9c68-459e-a4ee-e9d871f7f738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e727e54b-4aef-4697-bd2c-fb78e4f64308" xlink:to="loc_us-gaap_VariableLeaseCost_9afbd041-9c68-459e-a4ee-e9d871f7f738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9edb28d1-a2cf-47f7-a6b7-fffd2f9cde89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e727e54b-4aef-4697-bd2c-fb78e4f64308" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9edb28d1-a2cf-47f7-a6b7-fffd2f9cde89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_43ebb6ee-f8b2-457e-8dc9-12d2eb19328c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e727e54b-4aef-4697-bd2c-fb78e4f64308" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_43ebb6ee-f8b2-457e-8dc9-12d2eb19328c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_99703a0a-c2d0-4c01-8ec8-0dc5dc8728f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e727e54b-4aef-4697-bd2c-fb78e4f64308" xlink:to="loc_us-gaap_OperatingLeaseCost_99703a0a-c2d0-4c01-8ec8-0dc5dc8728f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_500a04b0-f97b-49ce-9c4c-98d2f6f3511e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_500a04b0-f97b-49ce-9c4c-98d2f6f3511e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_70e3a794-7ce0-4c4f-8dcc-878086431068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_70e3a794-7ce0-4c4f-8dcc-878086431068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4c7be35a-164c-4a5f-8d7e-a2c75137b2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4c7be35a-164c-4a5f-8d7e-a2c75137b2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18c792d4-4fdf-4523-883c-5e9b1b6fcdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18c792d4-4fdf-4523-883c-5e9b1b6fcdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_232d8ad6-c777-4a45-92c0-d8b1ee96100b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_232d8ad6-c777-4a45-92c0-d8b1ee96100b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee0445e9-be18-43e2-a68d-1dd263eccf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca841fe0-d2ff-45e4-87fb-a83d8d08aaeb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee0445e9-be18-43e2-a68d-1dd263eccf7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5fd1296b-beba-4f34-a328-0f9b42c605ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f189d584-8306-410b-85b3-7f37f0e08899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5fd1296b-beba-4f34-a328-0f9b42c605ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f189d584-8306-410b-85b3-7f37f0e08899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6f1b7be3-aec3-45d4-a498-b1698da7d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5fd1296b-beba-4f34-a328-0f9b42c605ba" xlink:to="loc_us-gaap_OperatingLeaseLiability_6f1b7be3-aec3-45d4-a498-b1698da7d8e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_72d0a905-231b-4a9d-9515-a33a988cdd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee457f8c-ffb6-4f0c-84d2-7283c070153a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_72d0a905-231b-4a9d-9515-a33a988cdd6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ee457f8c-ffb6-4f0c-84d2-7283c070153a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8312de86-df32-4216-b157-3635d0a958e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_72d0a905-231b-4a9d-9515-a33a988cdd6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8312de86-df32-4216-b157-3635d0a958e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2ec4a071-5d96-478d-a4de-3085378c45b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c1a7c75d-878c-4f36-86e9-c623948d5a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2ec4a071-5d96-478d-a4de-3085378c45b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c1a7c75d-878c-4f36-86e9-c623948d5a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e1f1c86a-e5f9-4143-a1e8-0790ea5008e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2ec4a071-5d96-478d-a4de-3085378c45b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e1f1c86a-e5f9-4143-a1e8-0790ea5008e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b012abd4-c9e6-4bea-b64f-7d0063a836c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cd906140-4dc8-445c-8002-fe864da614a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b012abd4-c9e6-4bea-b64f-7d0063a836c7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cd906140-4dc8-445c-8002-fe864da614a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8303497a-c1a4-49ee-beb9-e8f69bd3b03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b012abd4-c9e6-4bea-b64f-7d0063a836c7" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8303497a-c1a4-49ee-beb9-e8f69bd3b03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1e92d74a-e8a3-451c-b715-23ad6c3c20e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b012abd4-c9e6-4bea-b64f-7d0063a836c7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1e92d74a-e8a3-451c-b715-23ad6c3c20e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aca7a8fd-fdf1-4e59-bd78-94b75ac092bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4402cdf-10ec-49a3-8285-28949900ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_aca7a8fd-fdf1-4e59-bd78-94b75ac092bb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4402cdf-10ec-49a3-8285-28949900ffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0b9962aa-4ff5-46b0-9aa7-83f34a25bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_aca7a8fd-fdf1-4e59-bd78-94b75ac092bb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0b9962aa-4ff5-46b0-9aa7-83f34a25bcd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_a4cf4ace-3a63-45e0-8577-8ace5348cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_aca7a8fd-fdf1-4e59-bd78-94b75ac092bb" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_a4cf4ace-3a63-45e0-8577-8ace5348cadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c9297b-9cda-40d5-976f-cb904e768032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4bdbe78a-9704-427a-bba8-061edcee1511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c9297b-9cda-40d5-976f-cb904e768032" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4bdbe78a-9704-427a-bba8-061edcee1511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7ecdb8af-713d-4ee2-a0fe-ee6d963f66ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c9297b-9cda-40d5-976f-cb904e768032" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7ecdb8af-713d-4ee2-a0fe-ee6d963f66ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3bd60160-1cce-4ac1-a16b-ae45a5b6e1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c9297b-9cda-40d5-976f-cb904e768032" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3bd60160-1cce-4ac1-a16b-ae45a5b6e1c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_a863f8a8-5748-4ce9-aebc-6b5b9406f030" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_a863f8a8-5748-4ce9-aebc-6b5b9406f030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_213dabf9-e1b4-48bf-bfad-3d4c9e33caa6" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_213dabf9-e1b4-48bf-bfad-3d4c9e33caa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_51e2d4e1-c2da-420e-97c1-d13834747356" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_51e2d4e1-c2da-420e-97c1-d13834747356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c1c87832-cacf-48d2-b6e1-cc8cfc557afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c1c87832-cacf-48d2-b6e1-cc8cfc557afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_95cbf562-786b-4838-b616-71769e4830f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_95cbf562-786b-4838-b616-71769e4830f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4493d7e0-bcc9-465a-84c2-6f135f187c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4493d7e0-bcc9-465a-84c2-6f135f187c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_72a357c5-fd6b-4ed7-b8d8-1ca75b3de7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_72a357c5-fd6b-4ed7-b8d8-1ca75b3de7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0e54d15-9c0d-47f0-b0cd-5b0314ae8732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0e54d15-9c0d-47f0-b0cd-5b0314ae8732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_59482fc3-099e-40ee-b4a0-39a4e167d126" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_59482fc3-099e-40ee-b4a0-39a4e167d126" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_178bd0d6-2279-4b9a-aa92-4e6253c99cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_178bd0d6-2279-4b9a-aa92-4e6253c99cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ad7f6fa4-503a-4814-ba4a-34a0564bc534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ad7f6fa4-503a-4814-ba4a-34a0564bc534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_382257ef-d3ad-4c17-8cef-c2547e30996b" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_382257ef-d3ad-4c17-8cef-c2547e30996b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ae58fbf0-13ea-4131-99ee-6e76944f34bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ae58fbf0-13ea-4131-99ee-6e76944f34bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_38a700f4-a648-4133-9918-3ebf5a158da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_38a700f4-a648-4133-9918-3ebf5a158da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_478eea8d-ea64-444c-91e9-7a747c7aeaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_478eea8d-ea64-444c-91e9-7a747c7aeaf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_05681061-917d-4461-8723-c234dc696e75" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_05681061-917d-4461-8723-c234dc696e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_c98ef413-d3fc-495f-9f1d-95fd4cd49e96" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf439f42-ec35-4299-a463-255fa78f6d06" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_c98ef413-d3fc-495f-9f1d-95fd4cd49e96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_08cff9af-e72e-4565-92e4-f6672f36e1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4dbfdc55-11f0-4e6b-b07e-9d76f214509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_08cff9af-e72e-4565-92e4-f6672f36e1b0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4dbfdc55-11f0-4e6b-b07e-9d76f214509a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0dbf1ad5-07fb-452e-9e94-350de2dc87ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_08cff9af-e72e-4565-92e4-f6672f36e1b0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0dbf1ad5-07fb-452e-9e94-350de2dc87ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2b958382-cd8c-42a1-aa86-49ec3cec4baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c8a73819-da46-4bf3-b436-2fc578de8e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2b958382-cd8c-42a1-aa86-49ec3cec4baa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c8a73819-da46-4bf3-b436-2fc578de8e1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c605af74-30a4-47c2-82da-09d0449b0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2b958382-cd8c-42a1-aa86-49ec3cec4baa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c605af74-30a4-47c2-82da-09d0449b0ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_06c01368-31fb-4820-a7fe-94cfa9b43615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_06c01368-31fb-4820-a7fe-94cfa9b43615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_21fa7d60-198e-43da-b1fc-05f3c293f677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_21fa7d60-198e-43da-b1fc-05f3c293f677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_6fe33939-85fa-4cc7-994b-439639dae054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_6fe33939-85fa-4cc7-994b-439639dae054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_83538928-be85-47d6-8300-887a1f4980f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_83538928-be85-47d6-8300-887a1f4980f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1b47859e-49d8-4491-b61c-6e706d6799f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1b47859e-49d8-4491-b61c-6e706d6799f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_acdde046-5359-42bc-98c5-fe30b2e2973b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c3642803-ef5c-461d-b468-dc305d408743" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_acdde046-5359-42bc-98c5-fe30b2e2973b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de2d0c8a-fa0c-4d9d-b98f-422679c26906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de2d0c8a-fa0c-4d9d-b98f-422679c26906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_d9e6f2b8-2347-4208-a39b-746e668b43ae" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_d9e6f2b8-2347-4208-a39b-746e668b43ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8af4baea-33db-4072-8aad-e3ba40585513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8af4baea-33db-4072-8aad-e3ba40585513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_74f3d94f-eaa9-49f7-a503-e2c9abbdb7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_74f3d94f-eaa9-49f7-a503-e2c9abbdb7e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_54e3f20f-27f9-4db2-845b-605e130212c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_54e3f20f-27f9-4db2-845b-605e130212c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_c5abdfac-5f4a-413f-bdc3-c5fe58468a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_c5abdfac-5f4a-413f-bdc3-c5fe58468a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_eb4b6676-ab8f-4378-9711-8c45c08ad907" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_eb4b6676-ab8f-4378-9711-8c45c08ad907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_49862cec-6728-4345-88af-1797f1c8a63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_49862cec-6728-4345-88af-1797f1c8a63f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9e16ed1b-5f34-4497-a901-2bbe4224fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9e16ed1b-5f34-4497-a901-2bbe4224fd5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences_be129bdf-aecc-44ef-a41e-a2235f9367fc" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_evh_DeferredTaxAssetOutsideBasisDifferences_be129bdf-aecc-44ef-a41e-a2235f9367fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_0f2d8628-b7a7-47b6-bcb4-0a5b190aa0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e706da41-b226-479a-ae06-d98cb539dad4" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_0f2d8628-b7a7-47b6-bcb4-0a5b190aa0b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fe023158-2d4c-426d-bd4e-d33286e9e303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a41a5b5d-0d02-40ef-9752-971e9517a92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_fe023158-2d4c-426d-bd4e-d33286e9e303" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a41a5b5d-0d02-40ef-9752-971e9517a92c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_251e1b4b-2991-43ab-9053-18457a51cdbe" xlink:href="evh-20221231.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_251e1b4b-2991-43ab-9053-18457a51cdbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_0f5415dc-340d-49ed-ae0e-87f5dd80a0df" xlink:href="evh-20221231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_0f5415dc-340d-49ed-ae0e-87f5dd80a0df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_742fbbf9-3de5-421e-b466-de6cb9c90f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_742fbbf9-3de5-421e-b466-de6cb9c90f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a859c9e8-0ed3-45dd-8374-37c5e999453d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a859c9e8-0ed3-45dd-8374-37c5e999453d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9e205ecb-abf8-48b1-a410-29fa9a1f65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_InterestExpense_9e205ecb-abf8-48b1-a410-29fa9a1f65d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5d6cb69c-5356-4b8a-bf0e-9ecf9dd49d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_DepreciationAndAmortization_5d6cb69c-5356-4b8a-bf0e-9ecf9dd49d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_211811a1-ae94-4c96-8e27-6b2ff8e0d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_SeveranceCosts1_211811a1-ae94-4c96-8e27-6b2ff8e0d527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c5569144-5a0c-4d50-8e23-e38ddda7a9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c5569144-5a0c-4d50-8e23-e38ddda7a9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_7cc4ba6f-9afa-48d6-b290-8099b7be5489" xlink:href="evh-20221231.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_7cc4ba6f-9afa-48d6-b290-8099b7be5489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_1243c41f-670a-4677-8634-347aa8f4144d" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_GainOnTransferOfMembership_1243c41f-670a-4677-8634-347aa8f4144d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c955e13c-3a49-4d0f-9835-d974d6977687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_RestructuringCharges_c955e13c-3a49-4d0f-9835-d974d6977687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a7caa811-0081-4644-9769-4bd79a7aa8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a7caa811-0081-4644-9769-4bd79a7aa8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_124678a0-411b-4ac9-a86a-1a2159d5b220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_124678a0-411b-4ac9-a86a-1a2159d5b220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_fda3ffb4-78bd-4692-bf61-7d3d36486e46" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_fda3ffb4-78bd-4692-bf61-7d3d36486e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fd5cf486-a340-4d49-b0aa-6edd5c9a23e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fd5cf486-a340-4d49-b0aa-6edd5c9a23e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_216f6b82-173d-4624-8a8e-b10650e6dbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_216f6b82-173d-4624-8a8e-b10650e6dbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a0468fe1-338a-46a4-b16f-46fe3bdb41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a0468fe1-338a-46a4-b16f-46fe3bdb41a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_e2e0b8a1-11a3-48c8-a450-49960613d84e" xlink:href="evh-20221231.xsd#evh_TransactionCosts"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_TransactionCosts_e2e0b8a1-11a3-48c8-a450-49960613d84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_baa0f8b3-661e-4909-a1b0-bb66202e88f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_baa0f8b3-661e-4909-a1b0-bb66202e88f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a3dec3ca-7d80-4ccc-914e-4a9a6304f998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a3dec3ca-7d80-4ccc-914e-4a9a6304f998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_03045718-2b42-4fc4-b60f-d496837d2386" xlink:href="evh-20221231.xsd#evh_ShareholderAdvisoryServices"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f90f7193-3ae6-4b56-bf58-374e9cec019d" xlink:to="loc_evh_ShareholderAdvisoryServices_03045718-2b42-4fc4-b60f-d496837d2386" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_4b4548ad-79e9-4252-b950-63f27083cad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ba815125-0d04-4ee7-a855-6b2069d02e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_4b4548ad-79e9-4252-b950-63f27083cad9" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ba815125-0d04-4ee7-a855-6b2069d02e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_9bf358f8-f386-4cec-aa61-fba702c00a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_4b4548ad-79e9-4252-b950-63f27083cad9" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_9bf358f8-f386-4cec-aa61-fba702c00a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_95fa49c8-fc4d-4cb5-8f59-3ae8c0a91fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_abf8a7ba-fb7d-4ba9-a234-1a81e431963e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_95fa49c8-fc4d-4cb5-8f59-3ae8c0a91fe0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_abf8a7ba-fb7d-4ba9-a234-1a81e431963e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f08ceaca-9308-452b-abed-e2234a2a74eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_95fa49c8-fc4d-4cb5-8f59-3ae8c0a91fe0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f08ceaca-9308-452b-abed-e2234a2a74eb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>evh-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="ib43bb1a0de8443828768103027c8435f_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_af257ead-e0fc-47ef-a97e-bf1a69374b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_SharesIssued_af257ead-e0fc-47ef-a97e-bf1a69374b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e76004a2-8af5-4cc8-ae1a-714315ad129c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockholdersEquity_e76004a2-8af5-4cc8-ae1a-714315ad129c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a0bbb4-8543-4a03-b9de-df7d93cc6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a0bbb4-8543-4a03-b9de-df7d93cc6231" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53c21ffc-1b9b-4c87-a0a9-0735da1c7054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53c21ffc-1b9b-4c87-a0a9-0735da1c7054" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66dcb828-73b2-41b4-94d5-a8e8f9cf1b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66dcb828-73b2-41b4-94d5-a8e8f9cf1b6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4c4a1145-ed9e-4651-bbb7-3acd9721c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4c4a1145-ed9e-4651-bbb7-3acd9721c13b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3dc3b355-006d-44de-b64d-3263dbe159af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3dc3b355-006d-44de-b64d-3263dbe159af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_20ab69de-040e-4d23-96fd-06739677b7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_20ab69de-040e-4d23-96fd-06739677b7d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_24a4a72c-866d-4527-896d-8cae7bae105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_24a4a72c-866d-4527-896d-8cae7bae105c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_16b2c3b6-d8bb-4387-9590-e76174e9bdeb" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_16b2c3b6-d8bb-4387-9590-e76174e9bdeb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_0234af27-17b7-45a0-ac18-74e882f70e78" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_0234af27-17b7-45a0-ac18-74e882f70e78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_38bfd306-3a4e-440d-ae78-bdc07a3ee617" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_38bfd306-3a4e-440d-ae78-bdc07a3ee617" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_25fb9c35-04e0-46f2-94b8-662dc61b7bd3" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_25fb9c35-04e0-46f2-94b8-662dc61b7bd3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_386b0992-ec52-40a1-8bd6-379addbe80a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_386b0992-ec52-40a1-8bd6-379addbe80a0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f906b47-7d8d-4068-a1ef-b85c862482c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f906b47-7d8d-4068-a1ef-b85c862482c9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2001b47e-c3d7-41b4-9dac-342f194ada52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2001b47e-c3d7-41b4-9dac-342f194ada52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_386ea21d-24c6-4689-b907-1295c5f0ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_386ea21d-24c6-4689-b907-1295c5f0ea3d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6a7b429e-42a4-4a6a-b636-3192bc0988d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6a7b429e-42a4-4a6a-b636-3192bc0988d7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d7e3d9ce-b846-4ea3-ae5e-cce73be7b9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d7e3d9ce-b846-4ea3-ae5e-cce73be7b9e3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_933ba4ea-51ba-44f7-946b-f14166783944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_933ba4ea-51ba-44f7-946b-f14166783944" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_f3396608-37f1-4434-86ad-0283534a7d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_f3396608-37f1-4434-86ad-0283534a7d2c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4448b1ca-03dd-41d9-9509-daeeeeb34cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4448b1ca-03dd-41d9-9509-daeeeeb34cb4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bea74865-1077-46f7-a4de-428e5d44ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_NetIncomeLoss_bea74865-1077-46f7-a4de-428e5d44ba55" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_77004c3e-737f-4e9f-bd1e-0036ec402496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b4ddee0-54ea-4176-b7e3-88611569a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:to="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2ec60f3-db81-4fda-93e9-2e64bb610022_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:to="loc_us-gaap_EquityComponentDomain_e2ec60f3-db81-4fda-93e9-2e64bb610022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:to="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:to="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f62a71c-be51-4cd1-9359-c333ba65e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_CommonStockMember_8f62a71c-be51-4cd1-9359-c333ba65e6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_941b9638-fc74-43ce-88f6-a8759931166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_941b9638-fc74-43ce-88f6-a8759931166f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3ffda805-9ea1-43a3-9dfd-f3e3756a2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3ffda805-9ea1-43a3-9dfd-f3e3756a2e30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9b6f01df-2d76-40d6-aa98-ed347098da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_RetainedEarningsMember_9b6f01df-2d76-40d6-aa98-ed347098da3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0328c0d7-4475-45a9-b9c9-c3626e7dc148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_TreasuryStockMember_0328c0d7-4475-45a9-b9c9-c3626e7dc148" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fad2e788-9a70-4c66-9ac0-417becf2b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fad2e788-9a70-4c66-9ac0-417becf2b82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_17e0eb9a-a8dd-45d0-82aa-492868740688_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_17e0eb9a-a8dd-45d0-82aa-492868740688_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8eccb847-7d68-46c0-bd6a-676d5e8c18bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8eccb847-7d68-46c0-bd6a-676d5e8c18bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0ba1c45c-ce57-40b4-9d9a-44c886390be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:to="loc_us-gaap_ClassOfStockDomain_0ba1c45c-ce57-40b4-9d9a-44c886390be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:to="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0feb0886-da72-4ae8-8225-ddd673f58d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:to="loc_us-gaap_CommonClassAMember_0feb0886-da72-4ae8-8225-ddd673f58d00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="i7ef8aa2c2f8d47128874170781911aa7_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_998ea3ea-dd11-4c71-bffc-2a8e357c9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_998ea3ea-dd11-4c71-bffc-2a8e357c9fec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ba926533-e070-40b3-9f79-0712e1467809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ba926533-e070-40b3-9f79-0712e1467809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_be78f6e0-1888-41e0-bb38-0f1d20262318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_be78f6e0-1888-41e0-bb38-0f1d20262318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3002910-eafa-491b-a407-37621035443f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3002910-eafa-491b-a407-37621035443f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c7156b26-2575-4d2f-8f15-5949eacd3450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c7156b26-2575-4d2f-8f15-5949eacd3450" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_7a650f31-bd46-47c7-9acf-ad26dc30ef89" xlink:href="evh-20221231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_7a650f31-bd46-47c7-9acf-ad26dc30ef89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_62c543b9-122c-4ef8-a2da-ba12c1b8c4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_62c543b9-122c-4ef8-a2da-ba12c1b8c4aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc5ba0c0-9791-4121-a19e-02c2ca40ff33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc5ba0c0-9791-4121-a19e-02c2ca40ff33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_256fa155-cfe8-4315-8ef0-deff320291cc" xlink:href="evh-20221231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_256fa155-cfe8-4315-8ef0-deff320291cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_82dfcbb3-7ec6-46fa-b7e9-7efe84aeb778" xlink:href="evh-20221231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_82dfcbb3-7ec6-46fa-b7e9-7efe84aeb778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_22c3ff8a-bedf-426b-b551-b5968d4a195d" xlink:href="evh-20221231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_22c3ff8a-bedf-426b-b551-b5968d4a195d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_2c04cbc9-b3d9-4524-946d-5636aec6ed42" xlink:href="evh-20221231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_2c04cbc9-b3d9-4524-946d-5636aec6ed42" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="extended" id="ied4c0f1fccf547d6b11e54ebc7368ea3_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_dcfa06d3-9e9f-4526-93e5-a8a9e33016b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_dcfa06d3-9e9f-4526-93e5-a8a9e33016b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:to="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23657cd2-4a6a-4934-9bf2-3580e88520aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:to="loc_srt_RangeMember_23657cd2-4a6a-4934-9bf2-3580e88520aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:to="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd13df72-0a06-44fe-b560-b50d76708b80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:to="loc_srt_MinimumMember_fd13df72-0a06-44fe-b560-b50d76708b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d33aef24-f60c-4724-bbcc-596d8f62e41e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:to="loc_srt_MaximumMember_d33aef24-f60c-4724-bbcc-596d8f62e41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_983d2b75-11d4-42a6-97b8-70c430c53ae5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_983d2b75-11d4-42a6-97b8-70c430c53ae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8c0bb428-326e-4e54-a351-6241338d5cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_ComputerEquipmentMember_8c0bb428-326e-4e54-a351-6241338d5cc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a3efa42-11e6-4402-bc42-5519ef5f1f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a3efa42-11e6-4402-bc42-5519ef5f1f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37a60225-d2e5-45c1-8df7-2e2aec87a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37a60225-d2e5-45c1-8df7-2e2aec87a07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_977c81aa-cf45-4d0a-884b-61e1040f7bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_977c81aa-cf45-4d0a-884b-61e1040f7bf6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="iece0a245c53e49008b8d09c7bfc7cc66_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4dbbae19-2022-4b98-b62e-cceb40a338eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4dbbae19-2022-4b98-b62e-cceb40a338eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e99d3c46-f7c0-4046-ba20-4b781905c6e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e99d3c46-f7c0-4046-ba20-4b781905c6e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3190e235-ffa9-480b-bf67-d7ecdfa99436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_TradeNamesMember_3190e235-ffa9-480b-bf67-d7ecdfa99436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_197a6866-5888-4fed-9b77-a5d28b52f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_CustomerRelationshipsMember_197a6866-5888-4fed-9b77-a5d28b52f6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4cc5a496-810f-4e95-b394-7f9146d6ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4cc5a496-810f-4e95-b394-7f9146d6ae9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_e278a0fc-cebd-4d4c-8380-b621089c510b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_e278a0fc-cebd-4d4c-8380-b621089c510b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:to="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:to="loc_srt_RangeMember_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:to="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be6608d6-57ab-4980-9790-65f083fabeb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:to="loc_srt_MinimumMember_be6608d6-57ab-4980-9790-65f083fabeb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10475940-caf7-4d1e-9558-5c06e834ea6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:to="loc_srt_MaximumMember_10475940-caf7-4d1e-9558-5c06e834ea6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="extended" id="i64d7bf7e68574bd69a9970411d3bc977_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c7f717-0163-4005-85ef-1d90437d2d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c7f717-0163-4005-85ef-1d90437d2d30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ca45032-78f4-4974-8cda-badb4e0b1576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ca45032-78f4-4974-8cda-badb4e0b1576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:to="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a40999b2-1fee-4f1a-b938-10addc1884ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a40999b2-1fee-4f1a-b938-10addc1884ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88819565-6b67-43d2-ac86-a045612731ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88819565-6b67-43d2-ac86-a045612731ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:to="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d93604a-c4ae-4611-9f28-1335099d1738_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:to="loc_srt_RangeMember_0d93604a-c4ae-4611-9f28-1335099d1738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:to="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54f39d79-a98a-41a0-bd3c-f4e810a96659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:to="loc_srt_MinimumMember_54f39d79-a98a-41a0-bd3c-f4e810a96659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd165c2e-2821-467a-aef3-d9ea6411ab53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:to="loc_srt_MaximumMember_cd165c2e-2821-467a-aef3-d9ea6411ab53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="i0b2642099d214d20a4c402c8ced04d8d_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_317d9b3f-a87f-4f6d-9e69-3936dbd6088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:to="loc_us-gaap_StockholdersEquity_317d9b3f-a87f-4f6d-9e69-3936dbd6088f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bf565854-a446-47ac-b871-896ca5964202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:to="loc_us-gaap_LongTermDebt_bf565854-a446-47ac-b871-896ca5964202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_69f923cb-a929-4cdb-aa70-2a4fb7e573a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_69f923cb-a929-4cdb-aa70-2a4fb7e573a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a8674763-f412-40b9-aad0-bf1c661a4ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a8674763-f412-40b9-aad0-bf1c661a4ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_701a4b9a-5db1-4210-ac53-e1fd2453d6c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:to="loc_us-gaap_EquityComponentDomain_701a4b9a-5db1-4210-ac53-e1fd2453d6c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:to="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba94fa52-4496-4644-9c50-86bae31ef480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:to="loc_us-gaap_RetainedEarningsMember_ba94fa52-4496-4644-9c50-86bae31ef480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8506261-a246-46ce-984c-241090f93837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8506261-a246-46ce-984c-241090f93837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_68d47401-7821-4bac-9349-20215a0becac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_68d47401-7821-4bac-9349-20215a0becac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8df1bacd-1bda-4003-a067-181ed926136a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8df1bacd-1bda-4003-a067-181ed926136a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4604b522-d2b4-4e8a-9251-fdb76d3b7d48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4604b522-d2b4-4e8a-9251-fdb76d3b7d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_bc13daf6-0711-4a47-b869-cc9271d91ff6" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_bc13daf6-0711-4a47-b869-cc9271d91ff6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6cc1e24f-8eca-46aa-a25a-962dfe0b47c3" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6cc1e24f-8eca-46aa-a25a-962dfe0b47c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_71d0604a-c56e-434c-9e19-7130bdf406eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_71d0604a-c56e-434c-9e19-7130bdf406eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ef3c38df-00c5-4b79-99de-3efac46a5d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:to="loc_us-gaap_SeniorNotesMember_ef3c38df-00c5-4b79-99de-3efac46a5d95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended" id="i549a4ada933a4315a87ed7e7ce008893_TransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_46267576-1b97-49d3-a1e5-89b526d3efbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_46267576-1b97-49d3-a1e5-89b526d3efbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1e721a3-45a6-492f-b7f7-fe2074410ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1e721a3-45a6-492f-b7f7-fe2074410ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_14fde574-c232-4e7b-bc26-31d1a271cbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_14fde574-c232-4e7b-bc26-31d1a271cbec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_309ed0c9-d547-4c1b-973d-e7d5b85358be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_309ed0c9-d547-4c1b-973d-e7d5b85358be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f99dda7-1116-484c-9e2e-51b58e92a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f99dda7-1116-484c-9e2e-51b58e92a3a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_8209975f-ab72-49e7-81ca-4f16cbc8db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_8209975f-ab72-49e7-81ca-4f16cbc8db8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f0de2a88-1864-4784-8c63-e6a583aa1eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f0de2a88-1864-4784-8c63-e6a583aa1eac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_97de414f-ccdd-419e-a791-2c0170d10d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_97de414f-ccdd-419e-a791-2c0170d10d29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a50c0189-fa2d-4899-9dda-3c63f94a9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a50c0189-fa2d-4899-9dda-3c63f94a9eba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20c63316-aabc-467b-9544-18e1b15293b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20c63316-aabc-467b-9544-18e1b15293b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_928a4749-f3f9-497b-bcee-5fc7b45479e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_928a4749-f3f9-497b-bcee-5fc7b45479e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_eedec1aa-3d64-4b9e-91e8-57ba18b85830" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_eedec1aa-3d64-4b9e-91e8-57ba18b85830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_d73b82f9-6099-4726-80f6-d1929795d96f" xlink:href="evh-20221231.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:to="loc_evh_VitalDecisionsMember_d73b82f9-6099-4726-80f6-d1929795d96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3430f3b-8894-4cdf-80dd-ca12c4451836_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3430f3b-8894-4cdf-80dd-ca12c4451836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4693ae12-ffdb-4bb0-a3a7-eac65bba20b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4693ae12-ffdb-4bb0-a3a7-eac65bba20b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_71c67e05-bcaa-4880-8855-acf1e4ad9094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_71c67e05-bcaa-4880-8855-acf1e4ad9094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4bf2087f-52e0-4c4c-9f63-f53a3b223ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_TradeNamesMember_4bf2087f-52e0-4c4c-9f63-f53a3b223ebc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended" id="i235287775be449408d197fa28b1da8dc_TransactionsAllocationofAcquisitionCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e7717dfa-dda3-42c9-b050-7a989c40e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e7717dfa-dda3-42c9-b050-7a989c40e1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c63e4d3-48a4-46d9-ba6d-0a7945e2009c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c63e4d3-48a4-46d9-ba6d-0a7945e2009c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_18667839-6d46-4b55-920e-0806efdd759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_18667839-6d46-4b55-920e-0806efdd759f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5355b3d0-8a00-4e7a-92b3-3ef84bab21f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5355b3d0-8a00-4e7a-92b3-3ef84bab21f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ad43f7da-bd21-4d38-af1e-0d2519973e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ad43f7da-bd21-4d38-af1e-0d2519973e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_09368f22-0771-48b8-ac96-6d2bf459dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_09368f22-0771-48b8-ac96-6d2bf459dcb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_42e86f0d-cd95-4fee-9a9d-d3f449d0569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_42e86f0d-cd95-4fee-9a9d-d3f449d0569a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b11e1624-b117-4cc3-b1a7-4fbcba524347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b11e1624-b117-4cc3-b1a7-4fbcba524347" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_2c0603f0-09ca-4828-bf79-6af34cf317f0" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_2c0603f0-09ca-4828-bf79-6af34cf317f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8e02b97a-15bd-486a-bc49-51e96488069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8e02b97a-15bd-486a-bc49-51e96488069a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a685dc0-55b5-467e-be11-d52971fa3e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a685dc0-55b5-467e-be11-d52971fa3e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_86d13bf3-0bc9-4e1f-ac2f-e43fade47794" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_86d13bf3-0bc9-4e1f-ac2f-e43fade47794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_e7a4bacd-5b84-413e-b003-0be350c155c0" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_e7a4bacd-5b84-413e-b003-0be350c155c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8c636f50-caeb-4b7a-8200-26682f8dd3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8c636f50-caeb-4b7a-8200-26682f8dd3a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ebe55932-7da6-48bc-b284-e123fee8654e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ebe55932-7da6-48bc-b284-e123fee8654e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_75cdbef2-2598-4b69-8907-5c9dc8e365d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_75cdbef2-2598-4b69-8907-5c9dc8e365d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8a00d776-48ec-42c3-bde4-465ef42f6d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8a00d776-48ec-42c3-bde4-465ef42f6d61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e7a7efe9-66a6-40f1-b9d6-6f1dcfe9d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_Goodwill_e7a7efe9-66a6-40f1-b9d6-6f1dcfe9d5f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_74bb6d3c-84c7-425c-bafb-eede863133c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_74bb6d3c-84c7-425c-bafb-eede863133c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaed41ef-7ca6-4ba2-ba71-573c340842ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaed41ef-7ca6-4ba2-ba71-573c340842ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_3c2f9182-4db4-46f8-9207-59cc1fbf6321" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_3c2f9182-4db4-46f8-9207-59cc1fbf6321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_dfcc8771-842a-4dc3-9c17-b1bb4bc6c0eb" xlink:href="evh-20221231.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:to="loc_evh_VitalDecisionsMember_dfcc8771-842a-4dc3-9c17-b1bb4bc6c0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f3b7a79-8977-444f-9688-f89c242683cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f3b7a79-8977-444f-9688-f89c242683cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0ab6a7f9-7977-48cf-bfe2-87f02e9c08c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0ab6a7f9-7977-48cf-bfe2-87f02e9c08c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_19e284a3-7962-4dd3-b9e5-30f10247512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_19e284a3-7962-4dd3-b9e5-30f10247512e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_42cc2788-aa25-4928-92fd-5dd427c6acad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_TradeNamesMember_42cc2788-aa25-4928-92fd-5dd427c6acad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i1fe2bc3ec4d74c4c8352b8c6dab2755b_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e971acdf-8073-4891-8267-fd7114d66de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e971acdf-8073-4891-8267-fd7114d66de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8d9d74b-ca5e-4bc6-9b51-057ce4f48303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8d9d74b-ca5e-4bc6-9b51-057ce4f48303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_69520c2c-48cb-4e65-a58c-28fbe637e7bf" xlink:href="evh-20221231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_69520c2c-48cb-4e65-a58c-28fbe637e7bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_37cdc940-e09b-4742-aa18-86469e9603c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_37cdc940-e09b-4742-aa18-86469e9603c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d101008e-8f71-4ad9-b0b1-b59de149480f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d101008e-8f71-4ad9-b0b1-b59de149480f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_88d4eb76-eee9-450d-a725-5898733c0179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_88d4eb76-eee9-450d-a725-5898733c0179" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d34d2a39-d037-4ba7-b3b5-6aee374bfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d34d2a39-d037-4ba7-b3b5-6aee374bfe23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1991dbec-53e6-43b6-9065-330382111d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1991dbec-53e6-43b6-9065-330382111d78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_0352a2bc-a4dc-46d4-a675-1ca48ba2b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_0352a2bc-a4dc-46d4-a675-1ca48ba2b7f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_23e4abbe-8019-4984-b13d-620819369923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_23e4abbe-8019-4984-b13d-620819369923" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e1013ac-50d5-4877-8701-a492bb2165d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e1013ac-50d5-4877-8701-a492bb2165d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_e147ba09-f197-4256-ac0f-0f7ced9c6d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_e147ba09-f197-4256-ac0f-0f7ced9c6d03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35e65c41-896c-4bbc-ad9b-d4f73be03a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35e65c41-896c-4bbc-ad9b-d4f73be03a78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2f4b5b43-b02f-4b58-a053-3c4595b943f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2f4b5b43-b02f-4b58-a053-3c4595b943f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e0a7aada-cbf5-4e4b-8bb0-601816e8060c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e0a7aada-cbf5-4e4b-8bb0-601816e8060c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7ea07f-1505-467b-8ab4-631365cf509b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af7ea07f-1505-467b-8ab4-631365cf509b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_910a823a-382c-4bec-9823-fc9c1ebe66c2" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:to="loc_evh_TrueHealthMember_910a823a-382c-4bec-9823-fc9c1ebe66c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95a84f3d-78e3-45f9-99dd-0f43f916012b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:to="loc_srt_ProductsAndServicesDomain_95a84f3d-78e3-45f9-99dd-0f43f916012b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:to="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_8db5a967-0aa8-44f7-a29d-88f3aa929388" xlink:href="evh-20221231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_8db5a967-0aa8-44f7-a29d-88f3aa929388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_fd6b80bf-960b-4322-b7d4-799298cc7054" xlink:href="evh-20221231.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_PremiumsRevenueMember_fd6b80bf-960b-4322-b7d4-799298cc7054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_a274e16d-d3ce-46f0-98da-5393857cc5d3" xlink:href="evh-20221231.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_ServicesAgreementsMember_a274e16d-d3ce-46f0-98da-5393857cc5d3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="i49bb1caa92634f6a9ae29c68fd411e47_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_46aded79-5627-4571-8a68-a19fd07fdb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_46aded79-5627-4571-8a68-a19fd07fdb87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60b1067b-caec-4f99-ac4e-0952de2b8ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60b1067b-caec-4f99-ac4e-0952de2b8ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0bfe89a8-e732-4570-8b22-205ef73009c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0bfe89a8-e732-4570-8b22-205ef73009c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_2fb37124-e48d-448e-9c66-5367d1f5f35d" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:to="loc_evh_TrueHealthMember_2fb37124-e48d-448e-9c66-5367d1f5f35d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a68091ad-425b-4361-a19f-e74abd74681a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a68091ad-425b-4361-a19f-e74abd74681a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f6e7a127-ff36-4208-aafa-8f229675ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f6e7a127-ff36-4208-aafa-8f229675ad6b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i7559d323c28a49e9afbbaf8b22bd877f_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c858c461-1969-4fbd-9aeb-573b645c8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c858c461-1969-4fbd-9aeb-573b645c8a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:to="loc_us-gaap_SegmentDomain_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:to="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_a3c19ea2-f1e3-4c5d-be39-68a50227ee8f" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_a3c19ea2-f1e3-4c5d-be39-68a50227ee8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_f38c93a5-d81a-4261-8b6b-475f820b6f75" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_f38c93a5-d81a-4261-8b6b-475f820b6f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:to="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1c640e05-6d1c-4b5e-ae5b-9dea9064841c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:to="loc_srt_NameOfMajorCustomerDomain_1c640e05-6d1c-4b5e-ae5b-9dea9064841c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:to="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_39c2c59a-7d64-454a-b454-996dea202507" xlink:href="evh-20221231.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_MedicaidCustomersMember_39c2c59a-7d64-454a-b454-996dea202507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_217fb591-9310-412f-9b4e-62acbdf84681" xlink:href="evh-20221231.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_MedicareCustomersMember_217fb591-9310-412f-9b4e-62acbdf84681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_74095789-05dd-49a5-a7bf-c693960bc845" xlink:href="evh-20221231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_CommercialAndOtherCustomersMember_74095789-05dd-49a5-a7bf-c693960bc845" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="ia66455bf6e2e475f9ed811b63b3e1968_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6f048698-4c1d-49f3-bba6-1ef1c38b87b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6f048698-4c1d-49f3-bba6-1ef1c38b87b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_034a9b0a-5624-4569-9e76-4c53570b45c9_default" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_034a9b0a-5624-4569-9e76-4c53570b45c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:href="evh-20221231.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:href="evh-20221231.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:href="evh-20221231.xsd#evh_December312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="ibf3793a4a3794b6388fbac487b8be2b4_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_034a9b0a-5624-4569-9e76-4c53570b45c9_default" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_034a9b0a-5624-4569-9e76-4c53570b45c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:href="evh-20221231.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:href="evh-20221231.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:href="evh-20221231.xsd#evh_December312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="ic13d56dfc50c484380c47dbffb720123_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_38903d14-302a-4533-adb6-1ce26f13530e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostNet_38903d14-302a-4533-adb6-1ce26f13530e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_30b4a36e-3cb9-4ccd-a77a-a4e8385fc5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_30b4a36e-3cb9-4ccd-a77a-a4e8385fc5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_d6fc7f0e-311b-4355-8bc1-869bd355c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_d6fc7f0e-311b-4355-8bc1-869bd355c174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_28a881da-ba98-451e-adfe-f21f62498ca0" xlink:href="evh-20221231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:to="loc_evh_BonusesAndCommissionsMember_28a881da-ba98-451e-adfe-f21f62498ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_ddfd8eac-67d1-44a5-b81c-1c3eee453992" xlink:href="evh-20221231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:to="loc_evh_ContractFulfillmentCostsMember_ddfd8eac-67d1-44a5-b81c-1c3eee453992" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="i138c3b2e392d466b8bfddfd690988913_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_c94686b0-42c3-4dc9-b717-0e97eeccf474" xlink:href="evh-20221231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_c94686b0-42c3-4dc9-b717-0e97eeccf474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_f7514967-4234-4341-86ee-cbdfcd679d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_f7514967-4234-4341-86ee-cbdfcd679d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d5298b36-2367-4e42-9af8-f97e8a992732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_AccountsReceivableNet_d5298b36-2367-4e42-9af8-f97e8a992732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53895e6e-5c00-4dc7-8a47-4fd8ec70b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53895e6e-5c00-4dc7-8a47-4fd8ec70b6b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_d6118aad-ef36-4dab-b797-207ff506be08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_d6118aad-ef36-4dab-b797-207ff506be08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_f2636171-ffd6-484d-874e-7ae683efaac8" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_f2636171-ffd6-484d-874e-7ae683efaac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_13666c5a-742a-43fc-993e-e9921e0f292d" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_13666c5a-742a-43fc-993e-e9921e0f292d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i6ee24c0bd9784b63b60203de0fc5ab30_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8be0cd21-c0b1-42c9-bc1c-9612e879c8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8be0cd21-c0b1-42c9-bc1c-9612e879c8d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64f8f8d3-c239-45a4-9b40-125eba72daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64f8f8d3-c239-45a4-9b40-125eba72daeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca091fb9-3b76-43b5-bc83-323ef11b0860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca091fb9-3b76-43b5-bc83-323ef11b0860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_d0bdaf5a-af2d-4ceb-a854-e37ca653f867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_d0bdaf5a-af2d-4ceb-a854-e37ca653f867" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6c1bea2c-6d1c-42c4-b0e6-d2191f205272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_Depreciation_6c1bea2c-6d1c-42c4-b0e6-d2191f205272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_cea6f8da-7403-4c51-ad7a-e0c34e04ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_cea6f8da-7403-4c51-ad7a-e0c34e04ea0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f59c7b-9b73-4bc0-877f-d3e439553560_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f59c7b-9b73-4bc0-877f-d3e439553560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7b0e8dd4-b2cc-4898-9427-ed55b0c23528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_ComputerEquipmentMember_7b0e8dd4-b2cc-4898-9427-ed55b0c23528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8ae91764-32eb-40cb-bfbc-706abf78b37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8ae91764-32eb-40cb-bfbc-706abf78b37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_e358909d-9d3a-4677-9d1d-6f698e3ecd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_e358909d-9d3a-4677-9d1d-6f698e3ecd6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0e0233b0-4b42-4c9a-825b-98d0956c46a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0e0233b0-4b42-4c9a-825b-98d0956c46a8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="i0d12dd986310432091f0743b5ace7390_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:to="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b67cc33a-eeab-4136-bc56-034e52362dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_Goodwill_b67cc33a-eeab-4136-bc56-034e52362dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b70f00ed-60db-4785-baea-eb41ffbf52df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b70f00ed-60db-4785-baea-eb41ffbf52df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_04d4bb5e-4604-4869-bf9e-329a13da927e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_04d4bb5e-4604-4869-bf9e-329a13da927e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7ae57886-1add-4d22-81ab-7d9601cf55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5ff82710-0742-4d58-9a03-b5ef7f2df609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5ff82710-0742-4d58-9a03-b5ef7f2df609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de3aad43-4d08-4ed1-9419-fbf056dc59ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:to="loc_us-gaap_SegmentDomain_de3aad43-4d08-4ed1-9419-fbf056dc59ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:to="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_657d8faa-4c3f-4b2c-aeca-88974cab7a86" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_657d8faa-4c3f-4b2c-aeca-88974cab7a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_4406abfa-fd05-4308-8d34-29fca4457880" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_4406abfa-fd05-4308-8d34-29fca4457880" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="i97ae06f1e95948feaa016b33fc1ebfba_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9829b3f0-b730-4faf-9c76-e5daea40cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9829b3f0-b730-4faf-9c76-e5daea40cb85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e765d490-1ea5-4785-8806-b671a6ae0070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e765d490-1ea5-4785-8806-b671a6ae0070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1c48a407-0f75-4305-89d5-cbd3412c1ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1c48a407-0f75-4305-89d5-cbd3412c1ffc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cebd058-e9e9-4450-bed9-c2be3eaa9190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cebd058-e9e9-4450-bed9-c2be3eaa9190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d494b1df-9bfb-405a-9cda-006784e65070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d494b1df-9bfb-405a-9cda-006784e65070" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1406526-d44b-450a-b30f-969c0cf6642d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1406526-d44b-450a-b30f-969c0cf6642d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7899177f-052a-41da-ba8f-b51519e39cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_TradeNamesMember_7899177f-052a-41da-ba8f-b51519e39cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4b47576a-8473-4f67-b7fe-352772e3e2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4b47576a-8473-4f67-b7fe-352772e3e2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5db05ee7-3e31-4ec9-aeed-d0c04391a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5db05ee7-3e31-4ec9-aeed-d0c04391a918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_6ca48607-88e0-4d27-8887-50c5c4964223" xlink:href="evh-20221231.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_evh_BelowMarketLeasesMember_6ca48607-88e0-4d27-8887-50c5c4964223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_0878c130-6686-4412-8127-ea2b919539a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_0878c130-6686-4412-8127-ea2b919539a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e36bf7fa-8530-4731-a76f-091a8d43a6e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e36bf7fa-8530-4731-a76f-091a8d43a6e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2ca58520-f7e3-47df-b334-0ba63c954948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2ca58520-f7e3-47df-b334-0ba63c954948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_773b5b55-366e-460c-8ad7-762af6e0378d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_773b5b55-366e-460c-8ad7-762af6e0378d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_d89213c0-84b2-4839-acbd-e9a818c12fb7" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:to="loc_evh_TrueHealthMember_d89213c0-84b2-4839-acbd-e9a818c12fb7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended" id="ic195472b558a41f0a3b57e9fe44bf6dc_LongtermDebt2022CreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58f25131-31ea-4a46-9568-ce00e2354f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58f25131-31ea-4a46-9568-ce00e2354f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1326933d-c70f-4082-a9be-c0c9da65c0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1326933d-c70f-4082-a9be-c0c9da65c0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_c7c5d18e-b3fb-4a1e-8abe-a571dba08c27" xlink:href="evh-20221231.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_c7c5d18e-b3fb-4a1e-8abe-a571dba08c27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_31a47b53-792f-41d7-a7e1-8c71a774bb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_31a47b53-792f-41d7-a7e1-8c71a774bb9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7f765d38-8f16-4944-96d6-8cdc3d2c6bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7f765d38-8f16-4944-96d6-8cdc3d2c6bb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a450ebc8-392e-435c-a64a-0b81ebce1859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_InterestExpenseDebt_a450ebc8-392e-435c-a64a-0b81ebce1859" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_fcb811fd-fe5d-4992-aace-529cf3f6d7d0" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_fcb811fd-fe5d-4992-aace-529cf3f6d7d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_c0b0c920-63ea-4684-abcc-5ac75e2db270" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_c0b0c920-63ea-4684-abcc-5ac75e2db270" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_863067fc-142d-4346-b0e5-d6fa2dd64558" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_863067fc-142d-4346-b0e5-d6fa2dd64558" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_07cc7c32-fb0e-4a55-b971-01cb55689cad" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_07cc7c32-fb0e-4a55-b971-01cb55689cad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_20b274f4-660e-438a-bb9a-25841ced5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_20b274f4-660e-438a-bb9a-25841ced5f75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8776526e-5fc6-4bbf-a789-c9460617bdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8776526e-5fc6-4bbf-a789-c9460617bdc7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0ac1bb-e18e-4638-b8e9-29cf4cc4ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0ac1bb-e18e-4638-b8e9-29cf4cc4ab1e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_37752982-b355-40fa-be71-cb8578a852fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:to="loc_us-gaap_CreditFacilityDomain_37752982-b355-40fa-be71-cb8578a852fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:to="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b7df02ae-9e73-464f-b2f0-5ede22427b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_us-gaap_SecuredDebtMember_b7df02ae-9e73-464f-b2f0-5ede22427b69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f3fdea2c-b6da-45e9-b4e8-76de09f17748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f3fdea2c-b6da-45e9-b4e8-76de09f17748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_63157fbc-5a9a-4b26-af43-3e2f4496c546" xlink:href="evh-20221231.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_evh_A2022CreditFacilitiesMember_63157fbc-5a9a-4b26-af43-3e2f4496c546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_afd2f00f-eaee-41b8-aa9b-5be1f02c6372_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_afd2f00f-eaee-41b8-aa9b-5be1f02c6372_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e71f93b5-a14a-4f3d-951c-e468fe7b648c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:to="loc_us-gaap_LineOfCreditMember_e71f93b5-a14a-4f3d-951c-e468fe7b648c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0df5318c-58d0-4902-be9b-b79e280bb9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:to="loc_us-gaap_SecuredDebtMember_0df5318c-58d0-4902-be9b-b79e280bb9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_07c7b74e-cafa-429c-8791-adfcbd8778a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:to="loc_us-gaap_VariableRateDomain_07c7b74e-cafa-429c-8791-adfcbd8778a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:to="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_ccb0c49f-5058-4605-8cae-2cd7d2d51e9c" xlink:href="evh-20221231.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_ccb0c49f-5058-4605-8cae-2cd7d2d51e9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d900fb70-b034-41d2-9421-dfea2c611897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:to="loc_us-gaap_BaseRateMember_d900fb70-b034-41d2-9421-dfea2c611897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29ea1f22-19bf-4be2-8ee1-f325b89217c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29ea1f22-19bf-4be2-8ee1-f325b89217c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_3ba8c75a-8037-4a47-ba6f-fe1169e55578" xlink:href="evh-20221231.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:to="loc_evh_A2022CreditFacilitiesMember_3ba8c75a-8037-4a47-ba6f-fe1169e55578" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i3c81e47d17bf4d699e572f36ebeee1dc_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2a62b7dd-18db-4c4c-9127-5a67bc923a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2a62b7dd-18db-4c4c-9127-5a67bc923a20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7aaed49-c5cb-4e6d-9aa0-d75a431a7e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7aaed49-c5cb-4e6d-9aa0-d75a431a7e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_83c23736-e33a-4160-a695-d4757a5a53ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_83c23736-e33a-4160-a695-d4757a5a53ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_30d8929c-e603-46b7-9c73-21eb34cc997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_30d8929c-e603-46b7-9c73-21eb34cc997c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b780941-b34c-4a3c-aba1-2653767885f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b780941-b34c-4a3c-aba1-2653767885f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_728665ac-321d-4aca-9acc-2dc860c13d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_728665ac-321d-4aca-9acc-2dc860c13d80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3f22b4ec-7565-4bce-9555-5d945b9ed5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_InterestExpenseDebt_3f22b4ec-7565-4bce-9555-5d945b9ed5ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_caae84f8-1ed1-4fd9-be4f-14f52d1b01f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_caae84f8-1ed1-4fd9-be4f-14f52d1b01f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_406df81e-b76d-42f6-915c-1ea143f403e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_406df81e-b76d-42f6-915c-1ea143f403e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_81c6f105-1d70-4782-b867-132263178c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_81c6f105-1d70-4782-b867-132263178c07" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c1ecc71-d53e-4969-a385-ee71a05159dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_LongTermDebt_5c1ecc71-d53e-4969-a385-ee71a05159dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_4cdd9776-3171-4cde-89d9-6d466639cb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_4cdd9776-3171-4cde-89d9-6d466639cb7f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_0a742062-3b2c-4764-87e2-bb1621357aa6" xlink:href="evh-20221231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_0a742062-3b2c-4764-87e2-bb1621357aa6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c03fd24-e29a-47d1-84f4-0684b81bfbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_StockholdersEquity_7c03fd24-e29a-47d1-84f4-0684b81bfbd0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_50146d0a-b1cf-45a8-b3e2-ea902d41a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_50146d0a-b1cf-45a8-b3e2-ea902d41a81f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_612e9955-0cab-4728-8188-cc3e3ccf39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_612e9955-0cab-4728-8188-cc3e3ccf39a5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_e5feb20c-f720-4afc-aade-9a011d34613e" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_e5feb20c-f720-4afc-aade-9a011d34613e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ad5ef9c6-fda9-4378-88f8-63e92cef7a46" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ad5ef9c6-fda9-4378-88f8-63e92cef7a46" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_39bfd6f2-d9a1-41f0-bced-1c62691e5241" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_39bfd6f2-d9a1-41f0-bced-1c62691e5241" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_85eed19b-c976-4430-9aaf-af5b37a1224a" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_85eed19b-c976-4430-9aaf-af5b37a1224a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_da31d51e-46cf-467f-b8f1-fed805c78117" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_da31d51e-46cf-467f-b8f1-fed805c78117" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f6b8fd31-f65d-465b-9afc-d7a43d97b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f6b8fd31-f65d-465b-9afc-d7a43d97b4c3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce4109c6-eb7d-4857-bd84-7b5c7c55f453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce4109c6-eb7d-4857-bd84-7b5c7c55f453" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_112f44fd-5540-4465-95c3-f7d6f087cbf2" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_112f44fd-5540-4465-95c3-f7d6f087cbf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_f7dd0a76-6a5c-452e-ba3a-024d3cd64842" xlink:href="evh-20221231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_f7dd0a76-6a5c-452e-ba3a-024d3cd64842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_8f492442-f2b1-4edb-82d0-e174a26b7b16" xlink:href="evh-20221231.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_NewNotesMember_8f492442-f2b1-4edb-82d0-e174a26b7b16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0b44dbb8-285f-46d6-a43c-19dadc0e644f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0b44dbb8-285f-46d6-a43c-19dadc0e644f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e8312a50-a281-4c47-9dc3-fda6f31748dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:to="loc_us-gaap_SeniorNotesMember_e8312a50-a281-4c47-9dc3-fda6f31748dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:to="loc_us-gaap_EquityComponentDomain_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:to="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ad2995a-2be7-47c7-91a8-16856465578a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_CommonStockMember_4ad2995a-2be7-47c7-91a8-16856465578a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_abccf633-6529-4bde-bb84-4941c1803c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_abccf633-6529-4bde-bb84-4941c1803c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_92849f16-d387-4bd2-8e43-09cfc048f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_RetainedEarningsMember_92849f16-d387-4bd2-8e43-09cfc048f70e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9a9fc55-67e0-44ed-9ed3-5d0333d65438_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9a9fc55-67e0-44ed-9ed3-5d0333d65438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e9be39d8-6f19-4ceb-91e0-352fcf6d4991" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e9be39d8-6f19-4ceb-91e0-352fcf6d4991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_198a4ebb-8ea5-40fc-a7f0-073921685369_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:to="loc_us-gaap_TypeOfAdoptionMember_198a4ebb-8ea5-40fc-a7f0-073921685369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_15286cfd-1ced-43b5-8da3-07385d8b7231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_15286cfd-1ced-43b5-8da3-07385d8b7231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_736b2041-09c5-4c31-b0c3-fd0358fb6753_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_736b2041-09c5-4c31-b0c3-fd0358fb6753_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_5dc1eb7d-3bf9-45f0-86f3-618466b9a2b8" xlink:href="evh-20221231.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_5dc1eb7d-3bf9-45f0-86f3-618466b9a2b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_639642c4-43a5-44ab-99a3-6c314e1bd938" xlink:href="evh-20221231.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:to="loc_evh_DeferredFinancingFeesMember_639642c4-43a5-44ab-99a3-6c314e1bd938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a141af6e-0f33-4c2f-8155-4bb3cd2e1418_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:to="loc_us-gaap_ClassOfStockDomain_a141af6e-0f33-4c2f-8155-4bb3cd2e1418_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:to="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d67367d3-7460-4c5d-bc2c-dcbf93c5d005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:to="loc_us-gaap_CommonClassAMember_d67367d3-7460-4c5d-bc2c-dcbf93c5d005" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2019CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="extended" id="if1a080c9ab84481db014b211a80d7642_LongtermDebt2019CreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7998afe8-3ba7-4a23-8ce3-2ab72b8a497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7998afe8-3ba7-4a23-8ce3-2ab72b8a497d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae01ecb9-251f-4875-b264-4d62b53430f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae01ecb9-251f-4875-b264-4d62b53430f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b73ae9d0-348a-47d3-87cd-983f61a8af26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b73ae9d0-348a-47d3-87cd-983f61a8af26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_ebc788e6-8a62-45b5-bf2d-95f9487e5b26" xlink:href="evh-20221231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_evh_PaymentsOfMakeWholePremium_ebc788e6-8a62-45b5-bf2d-95f9487e5b26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9983b614-9a6d-4bb7-ad2a-7505408e375f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_InterestPaidNet_9983b614-9a6d-4bb7-ad2a-7505408e375f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8f5235a-fff0-4aaa-9234-bd86b1818f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8f5235a-fff0-4aaa-9234-bd86b1818f19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_451ff0d1-1e47-4be7-888c-ae9c86eff71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_451ff0d1-1e47-4be7-888c-ae9c86eff71c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_456ab907-6135-40cc-84d1-676f8f6c672e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_LegalFees_456ab907-6135-40cc-84d1-676f8f6c672e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90260529-7a39-472d-9d4b-69e5004b9d8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90260529-7a39-472d-9d4b-69e5004b9d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_fcd0f71f-cbb9-4ec0-b0f4-29e697d77b35" xlink:href="evh-20221231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_InitialTermLoanFacilityMember_fcd0f71f-cbb9-4ec0-b0f4-29e697d77b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_73c505a3-88d6-4cf6-94be-ad6fd0dd2e69" xlink:href="evh-20221231.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_CreditAgreementMember_73c505a3-88d6-4cf6-94be-ad6fd0dd2e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_d58952ea-bffd-4228-9f88-8e0a1f135f90" xlink:href="evh-20221231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_SeniorCreditFacilitiesMember_d58952ea-bffd-4228-9f88-8e0a1f135f90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d0e35b17-d421-4fb6-877c-50eb8bc9ce97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d0e35b17-d421-4fb6-877c-50eb8bc9ce97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ce4640bc-0931-4a14-aeb5-97dda52bd052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:to="loc_us-gaap_SecuredDebtMember_ce4640bc-0931-4a14-aeb5-97dda52bd052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2c603ce8-7361-4745-9210-3375233dc309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:to="loc_us-gaap_LineOfCreditMember_2c603ce8-7361-4745-9210-3375233dc309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5681352b-ee95-420a-8fbe-e30d1bde6e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:to="loc_us-gaap_CreditFacilityDomain_5681352b-ee95-420a-8fbe-e30d1bde6e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:to="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_10baa2ee-fb70-4bcd-bef9-b7a8a7521fdc" xlink:href="evh-20221231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_10baa2ee-fb70-4bcd-bef9-b7a8a7521fdc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="i7f9969ac010d4f74acf07616ada512ba_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_f1d4eac8-5aa0-4995-8bc3-3a636c22413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_f1d4eac8-5aa0-4995-8bc3-3a636c22413d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac37ba46-8293-4f9e-bd17-f960c35be5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac37ba46-8293-4f9e-bd17-f960c35be5c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_85cddafd-c699-448c-abdb-fc85b9e02510" xlink:href="evh-20221231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_85cddafd-c699-448c-abdb-fc85b9e02510" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8a1b5cc8-1fc9-42fa-8045-81772c963cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8a1b5cc8-1fc9-42fa-8045-81772c963cfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9c3bba46-1d0f-420a-bd85-63abf94cc24b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9c3bba46-1d0f-420a-bd85-63abf94cc24b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_64d0c6f2-41a0-4e87-8bc3-bdb75b7a33b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:to="loc_us-gaap_CommonClassAMember_64d0c6f2-41a0-4e87-8bc3-bdb75b7a33b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="ie2456d9c98b148d2a458664fdfda73cc_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_58f09039-bdd7-49d0-8ecf-6767af78e89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_58f09039-bdd7-49d0-8ecf-6767af78e89c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_67498d62-aca7-4745-9dad-d35a723771c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_67498d62-aca7-4745-9dad-d35a723771c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2300a6fd-d2f4-4f1e-a02c-5c7466f67018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_InterestExpenseDebt_2300a6fd-d2f4-4f1e-a02c-5c7466f67018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4cf4de9f-08fd-41e4-bd0f-f82917dea0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4cf4de9f-08fd-41e4-bd0f-f82917dea0e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4d2c8b6d-f00d-4edf-9c0c-26ab7afb5e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4d2c8b6d-f00d-4edf-9c0c-26ab7afb5e45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_503571da-03ec-4987-b6a9-cbbfa428d930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_503571da-03ec-4987-b6a9-cbbfa428d930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7cee9385-e1a9-4cc5-bb4e-856c1ffc91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_LongTermDebt_7cee9385-e1a9-4cc5-bb4e-856c1ffc91a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0b3b7b23-6d90-4af9-b5eb-a088d1358ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0b3b7b23-6d90-4af9-b5eb-a088d1358ee4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1557415f-5e13-412a-9ee9-7b3165780013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1557415f-5e13-412a-9ee9-7b3165780013" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b36a4da1-272c-4d17-a37b-8cf8cbf56ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_StockholdersEquity_b36a4da1-272c-4d17-a37b-8cf8cbf56ef9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ed254ae0-22ff-4e63-a244-36f4d824b17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ed254ae0-22ff-4e63-a244-36f4d824b17a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e2ce543b-6137-4a16-8384-fa37ac9c6344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e2ce543b-6137-4a16-8384-fa37ac9c6344" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dd860b4f-b552-43a8-8caa-2cebb20bdbb1" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dd860b4f-b552-43a8-8caa-2cebb20bdbb1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_6a81220d-118d-46bc-b8cb-b9310148542e" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_6a81220d-118d-46bc-b8cb-b9310148542e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_5a73641c-6faa-48f7-a530-843d2ff54c1a" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_5a73641c-6faa-48f7-a530-843d2ff54c1a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b4ed3356-d4d2-4fc2-bbc6-a246ca955a6f" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b4ed3356-d4d2-4fc2-bbc6-a246ca955a6f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_84e8c21e-6ff0-4a50-a5ee-9e1edfc919ef" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_84e8c21e-6ff0-4a50-a5ee-9e1edfc919ef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_22a44d54-4489-4112-8ebb-0b8431884019_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_22a44d54-4489-4112-8ebb-0b8431884019_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_22719266-2e71-4d23-b10a-0fcce11be7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:to="loc_us-gaap_SeniorNotesMember_22719266-2e71-4d23-b10a-0fcce11be7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_776a32b7-42dd-4cd9-b777-2dc2a605553a" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_776a32b7-42dd-4cd9-b777-2dc2a605553a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bcba0acb-995c-45cd-85c5-32c6185d2e13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:to="loc_us-gaap_EquityComponentDomain_bcba0acb-995c-45cd-85c5-32c6185d2e13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:to="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97150526-82a8-4deb-af90-807606bc713e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_CommonStockMember_97150526-82a8-4deb-af90-807606bc713e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ab4a61ed-ebe9-4702-9655-190d53145668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ab4a61ed-ebe9-4702-9655-190d53145668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6b025b2a-e850-4cd7-a360-7497347b915c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_RetainedEarningsMember_6b025b2a-e850-4cd7-a360-7497347b915c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_72c14550-fe84-401c-9a48-1c8a7343da0f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_72c14550-fe84-401c-9a48-1c8a7343da0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c377dfb5-86ef-411a-85d8-b094717f02b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c377dfb5-86ef-411a-85d8-b094717f02b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_227e0d05-e739-4e66-9a36-bab5522389b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_227e0d05-e739-4e66-9a36-bab5522389b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_90041e0c-872d-4082-9f01-52645bf3cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_90041e0c-872d-4082-9f01-52645bf3cd76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_d42f7485-9410-4074-8ecf-1d7558ca4b2b" xlink:href="evh-20221231.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_d42f7485-9410-4074-8ecf-1d7558ca4b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_e31054b8-8b73-4022-b37f-dc1aa2048262" xlink:href="evh-20221231.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:to="loc_evh_DeferredFinancingFeesMember_e31054b8-8b73-4022-b37f-dc1aa2048262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:to="loc_us-gaap_ClassOfStockDomain_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:to="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_cee08375-8aff-4f87-b825-aa1eed2f76f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:to="loc_us-gaap_CommonClassAMember_cee08375-8aff-4f87-b825-aa1eed2f76f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i23b2e39c2afd4b2585455983cf039146_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_82eca846-49e1-4a6b-8030-61b68134ce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_82eca846-49e1-4a6b-8030-61b68134ce4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13e7b77a-3577-4aa8-82e5-c1bb109dc9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13e7b77a-3577-4aa8-82e5-c1bb109dc9e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_addda271-0c3c-4c74-9db5-20cdef15994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_addda271-0c3c-4c74-9db5-20cdef15994d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1ae850bf-33ac-4745-92c0-ddce5a19bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1ae850bf-33ac-4745-92c0-ddce5a19bbf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_de24804e-6b93-4322-9685-5a5d141087f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_de24804e-6b93-4322-9685-5a5d141087f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_cb08ec15-73de-4f6f-94eb-202985c9685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_cb08ec15-73de-4f6f-94eb-202985c9685a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_773dc642-bb08-4b33-a8c1-63d19ccec81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_773dc642-bb08-4b33-a8c1-63d19ccec81b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_65ceb9d3-fa84-4901-8100-498d695e2414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_65ceb9d3-fa84-4901-8100-498d695e2414" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_df580ee3-1d90-4082-a099-0cae9daf4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_df580ee3-1d90-4082-a099-0cae9daf4ebe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_6cd8519c-6503-409a-a528-cb63c54cc43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_6cd8519c-6503-409a-a528-cb63c54cc43a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98ec4038-02b4-4ec8-9abf-9f67c17fc78a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98ec4038-02b4-4ec8-9abf-9f67c17fc78a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_55345bfa-bec3-4b59-9f24-c34fde17f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:to="loc_us-gaap_SeniorNotesMember_55345bfa-bec3-4b59-9f24-c34fde17f56d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b044ed5-2bc4-4cff-b6e0-847f12844296_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b044ed5-2bc4-4cff-b6e0-847f12844296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_ebd7ab16-84a9-4e1a-90b0-be87bf0c4b58" xlink:href="evh-20221231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_ebd7ab16-84a9-4e1a-90b0-be87bf0c4b58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_49f27a3c-7e6d-4c3a-91f8-a4a66bfc9e0a" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_49f27a3c-7e6d-4c3a-91f8-a4a66bfc9e0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="i5d7e6b8d20ef46bb82fdf346807004e4_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_eef9bbae-e7c8-43eb-83d6-7484cefecaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_ConvertibleDebt_eef9bbae-e7c8-43eb-83d6-7484cefecaa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dcb228f9-2a73-45d8-8643-14e0fba2a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dcb228f9-2a73-45d8-8643-14e0fba2a461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_97c424b9-dd87-4b33-aa7c-e8595986b028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_97c424b9-dd87-4b33-aa7c-e8595986b028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_65d1b88b-1401-4b99-b6b9-35b9d835c867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_65d1b88b-1401-4b99-b6b9-35b9d835c867" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_886cde57-2683-405b-ba85-555e5c8bff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_LongTermDebtFairValue_886cde57-2683-405b-ba85-555e5c8bff0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02043bf4-b196-4081-a527-c6adb6aac1cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02043bf4-b196-4081-a527-c6adb6aac1cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_335468d5-0270-414b-a740-b61128c8cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:to="loc_us-gaap_SeniorNotesMember_335468d5-0270-414b-a740-b61128c8cc99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_00d3e166-b874-4ed9-9764-5f4672562ffa" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_00d3e166-b874-4ed9-9764-5f4672562ffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_173e399f-29a8-40a0-9f3d-4c3d099daaea" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_173e399f-29a8-40a0-9f3d-4c3d099daaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_657690c5-b442-435d-b119-d442fe6e8bb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_657690c5-b442-435d-b119-d442fe6e8bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7ee42917-d9eb-4bb8-8c09-fd3454d16ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7ee42917-d9eb-4bb8-8c09-fd3454d16ff0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i24d5a58f5bf64ea4b896606dac562fb4_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_89d5f5a9-e2c2-43fd-a40a-37c109c7b6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_89d5f5a9-e2c2-43fd-a40a-37c109c7b6e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_616263ef-1d1c-4201-812c-7550a711fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_616263ef-1d1c-4201-812c-7550a711fe18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_c3bf72d8-b5bd-4e6d-babf-bcf631aae18a" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_c3bf72d8-b5bd-4e6d-babf-bcf631aae18a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_60033f86-0c23-455f-89b3-00c1343faf03" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_60033f86-0c23-455f-89b3-00c1343faf03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_f51eee20-7343-43a3-9d2f-b64b31af3178" xlink:href="evh-20221231.xsd#evh_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_NumberOfCustomers_f51eee20-7343-43a3-9d2f-b64b31af3178" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92f27606-3591-4723-a48c-38c57d929498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_Revenues_92f27606-3591-4723-a48c-38c57d929498" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_751a95b2-a0b7-4a53-94bb-25d898fe6c1c" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_751a95b2-a0b7-4a53-94bb-25d898fe6c1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_f0a449c4-277e-4c75-8ee3-86e570cdbb28" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_TaxReceivableAgreementLiability_f0a449c4-277e-4c75-8ee3-86e570cdbb28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e683bc89-5e7d-4e22-b06a-2b4dea6e96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e683bc89-5e7d-4e22-b06a-2b4dea6e96c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ddeed37f-fbad-491a-99a6-7443c8034905_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:to="loc_us-gaap_CreditFacilityDomain_ddeed37f-fbad-491a-99a6-7443c8034905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:to="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_75373255-14da-4496-a733-37d982addb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:to="loc_us-gaap_LetterOfCreditMember_75373255-14da-4496-a733-37d982addb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01c1d493-aed8-4dbd-bf79-4dc06be22782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01c1d493-aed8-4dbd-bf79-4dc06be22782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9ddfc3a0-3c5e-4847-94ba-3233d15bbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:to="loc_us-gaap_LineOfCreditMember_9ddfc3a0-3c5e-4847-94ba-3233d15bbd95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f7c07e37-a54f-4a5c-9723-32f19aaf8e23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f7c07e37-a54f-4a5c-9723-32f19aaf8e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_64061ef6-24a3-48b6-9b33-bbc5a9396386" xlink:href="evh-20221231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_64061ef6-24a3-48b6-9b33-bbc5a9396386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:to="loc_srt_LitigationCaseTypeDomain_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:to="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_7d3c763d-b978-4e4a-b105-4c5ab2dcc7a0" xlink:href="evh-20221231.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:to="loc_evh_ShareholderClassActionComplaintMember_7d3c763d-b978-4e4a-b105-4c5ab2dcc7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3834fb71-7baf-4817-9413-9f55ac1ad85b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3834fb71-7baf-4817-9413-9f55ac1ad85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_5e26ca2d-68b1-48fd-8aac-f7a71d6c1c49" xlink:href="evh-20221231.xsd#evh_UPMCResellerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:to="loc_evh_UPMCResellerAgreementMember_5e26ca2d-68b1-48fd-8aac-f7a71d6c1c49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="ib3ef499e2a0040e6916601c1effe3655_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_e1dd93d7-8a9e-49e9-bb54-3eb576ed135e" xlink:href="evh-20221231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_e1dd93d7-8a9e-49e9-bb54-3eb576ed135e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b86620ff-39ac-483b-b6c3-c9a0d07a6fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b86620ff-39ac-483b-b6c3-c9a0d07a6fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_81ce10c4-575b-41d5-800b-c32fd9bf85c6" xlink:href="evh-20221231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_81ce10c4-575b-41d5-800b-c32fd9bf85c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b8d60456-d1e8-4ba3-bf3e-9ded518bc308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b8d60456-d1e8-4ba3-bf3e-9ded518bc308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_940367cc-07ad-497e-a0aa-18169373159d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_940367cc-07ad-497e-a0aa-18169373159d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78dad284-5d78-447a-89b2-8d85f0b86c0b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:to="loc_srt_NameOfMajorCustomerDomain_78dad284-5d78-447a-89b2-8d85f0b86c0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:to="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_b5880dad-d156-437f-8be0-fc6bc033198d" xlink:href="evh-20221231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_b5880dad-d156-437f-8be0-fc6bc033198d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_28b9ac94-7fa0-4592-9635-1f575b03bac9" xlink:href="evh-20221231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_FloridaBlueMedicareIncMember_28b9ac94-7fa0-4592-9635-1f575b03bac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_c299cc29-b2a7-4dea-94ff-442594789ad1" xlink:href="evh-20221231.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_MolinaHealthcareMember_c299cc29-b2a7-4dea-94ff-442594789ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_4f1f3911-4e1f-4cfd-be2c-d67cce2403b7" xlink:href="evh-20221231.xsd#evh_BrightHealthManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_BrightHealthManagementIncMember_4f1f3911-4e1f-4cfd-be2c-d67cce2403b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_4cc28a77-1fec-4fe1-93fc-b520ed746335" xlink:href="evh-20221231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_4cc28a77-1fec-4fe1-93fc-b520ed746335" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_329551b3-c889-404d-987f-46fc16600e69" xlink:href="evh-20221231.xsd#evh_NewCenturyHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_NewCenturyHealthMember_329551b3-c889-404d-987f-46fc16600e69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_45ecf292-1dc6-4c79-b127-6d46f4c6a241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_45ecf292-1dc6-4c79-b127-6d46f4c6a241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a9ff1b9-728c-4f2d-8060-6f0424a10975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a9ff1b9-728c-4f2d-8060-6f0424a10975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc23d18e-fb0d-4f95-87df-b1027c2f293c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc23d18e-fb0d-4f95-87df-b1027c2f293c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_38ea2de0-991b-40d8-89f5-263d69dedb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:to="loc_us-gaap_AccountsReceivableMember_38ea2de0-991b-40d8-89f5-263d69dedb30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_4d3ec250-15a2-4ae5-81ff-3efed22cbffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_4d3ec250-15a2-4ae5-81ff-3efed22cbffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_87654e7b-bbb9-426a-8107-9797e38ed141_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:to="loc_us-gaap_ReceivableTypeDomain_87654e7b-bbb9-426a-8107-9797e38ed141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:to="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_6813375e-9b82-487e-a81f-d6dd1b132cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_6813375e-9b82-487e-a81f-d6dd1b132cc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ebe51a80-503b-4d72-8e1d-5f9f21227251_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:to="loc_srt_ProductsAndServicesDomain_ebe51a80-503b-4d72-8e1d-5f9f21227251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:to="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumRevenueMember_9be719c5-e814-4a41-bc37-cae3c96d2e2d" xlink:href="evh-20221231.xsd#evh_PremiumRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:to="loc_evh_PremiumRevenueMember_9be719c5-e814-4a41-bc37-cae3c96d2e2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd381133-7dfc-4842-abfb-e8998b1f3ca2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd381133-7dfc-4842-abfb-e8998b1f3ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0324fe59-1ffe-4433-9e3c-527021b32cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0324fe59-1ffe-4433-9e3c-527021b32cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e892c56b-372c-4dfd-85df-85270ce12499_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e892c56b-372c-4dfd-85df-85270ce12499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_7db97246-6fd8-4dd6-9b58-b080c5a8d74f" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:to="loc_evh_TrueHealthMember_7db97246-6fd8-4dd6-9b58-b080c5a8d74f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i673749018ad54b0887228cc9d1d70676_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_a6e95871-a0c8-4c0a-b6a6-088a6fd131b6" xlink:href="evh-20221231.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_a6e95871-a0c8-4c0a-b6a6-088a6fd131b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_74fcf73b-827e-40ba-b52e-45ce8936ad0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_74fcf73b-827e-40ba-b52e-45ce8936ad0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_103e293e-ee50-49a2-bca8-951f89a7c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_103e293e-ee50-49a2-bca8-951f89a7c3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:to="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_66cf2f44-e380-46fe-9666-18b2a80350d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:to="loc_us-gaap_LeaseAgreementsMember_66cf2f44-e380-46fe-9666-18b2a80350d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="i436a21dc248f496f9dcfb944e32cca6e_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e506c547-1843-4ac9-98b0-a25b46ef380d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e506c547-1843-4ac9-98b0-a25b46ef380d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f119a83-3eac-4e06-99b5-26da9c6c9872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f119a83-3eac-4e06-99b5-26da9c6c9872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_3c19e576-cef8-47a3-91be-34471b8e3086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_3c19e576-cef8-47a3-91be-34471b8e3086" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:to="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8dac3ae8-5c3e-44f2-a35d-820651628a1d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:to="loc_srt_SegmentGeographicalDomain_8dac3ae8-5c3e-44f2-a35d-820651628a1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:to="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_7d55fa0f-c85f-4b08-8569-b9de94aa73d6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_VA_7d55fa0f-c85f-4b08-8569-b9de94aa73d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_debfa239-6522-4d52-9e4b-f3309abd978f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_IL_debfa239-6522-4d52-9e4b-f3309abd978f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_ea2e4ee5-934a-4ff3-ae3e-c7c96345abf1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_NJ_ea2e4ee5-934a-4ff3-ae3e-c7c96345abf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_f1b1090a-c333-4fd9-a5b7-741506b8f098" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_country_IN_f1b1090a-c333-4fd9-a5b7-741506b8f098" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_ba322b40-c7fa-4743-8e10-645295d36252" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_CA_ba322b40-c7fa-4743-8e10-645295d36252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_98316f35-5dec-488d-99c1-d2f7fc059d27" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_GA_98316f35-5dec-488d-99c1-d2f7fc059d27" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LossperCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i1db7fb4b233249d6af1c19c0957efb38_LossperCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64791000-f019-41c8-894f-933fbe07121f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64791000-f019-41c8-894f-933fbe07121f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3d64adc4-d758-402e-bb48-adfbe09b99c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3d64adc4-d758-402e-bb48-adfbe09b99c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_dee8cd6b-aac4-4962-a2b3-ebd029e973b8" xlink:href="evh-20221231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_dee8cd6b-aac4-4962-a2b3-ebd029e973b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c865fa2-1a0c-40f7-9d3d-a372c08bae39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c865fa2-1a0c-40f7-9d3d-a372c08bae39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d405eb49-693a-44ce-b383-a5f34bb6cba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_us-gaap_ConvertibleDebtMember_d405eb49-693a-44ce-b383-a5f34bb6cba0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensation2011and2015EquityIncentivePlansDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="extended" id="idd27dd6a440943d19e2d42c97108db8c_StockbasedCompensation2011and2015EquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f29a9163-5536-4c1e-8ad2-2e1671210461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f29a9163-5536-4c1e-8ad2-2e1671210461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4cb18f9-b7f5-4c04-8e6e-0d341eaf3b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4cb18f9-b7f5-4c04-8e6e-0d341eaf3b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94bbbdd7-862e-469e-a65a-41ec2cd3f525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94bbbdd7-862e-469e-a65a-41ec2cd3f525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d619b0d9-79e7-4483-9731-378e7bbf1a16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:to="loc_us-gaap_PlanNameDomain_d619b0d9-79e7-4483-9731-378e7bbf1a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:to="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember_e22171cf-9e6d-4407-aee8-b4d7ae9f1bd8" xlink:href="evh-20221231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:to="loc_evh_TwoThousandElevenEquityIncentivePlanMember_e22171cf-9e6d-4407-aee8-b4d7ae9f1bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_7fb802a5-8860-4077-8f7b-9da0810e7884" xlink:href="evh-20221231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:to="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_7fb802a5-8860-4077-8f7b-9da0810e7884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:to="loc_us-gaap_ClassOfStockDomain_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:to="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_34847193-ea13-42ca-838e-c82424a05ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:to="loc_us-gaap_CommonClassAMember_34847193-ea13-42ca-838e-c82424a05ccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_870321f4-f105-44ec-a63d-5ee15497a26f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_870321f4-f105-44ec-a63d-5ee15497a26f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_08477a0a-16bf-41bf-a636-c10e8b64ea50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_us-gaap_RestrictedStockMember_08477a0a-16bf-41bf-a636-c10e8b64ea50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e073f44b-3c9e-4976-bb48-bc9d37e7ac7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e073f44b-3c9e-4976-bb48-bc9d37e7ac7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_95d8ba47-9ea0-4b3f-a338-07a406f1306f" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_95d8ba47-9ea0-4b3f-a338-07a406f1306f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3661a2ad-1621-46e3-9519-6821ab4172f9" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3661a2ad-1621-46e3-9519-6821ab4172f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i7d4ed24d03b94c768787408fc8c772ee_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3ff176ad-dbfa-42c5-9c25-301f088ec421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3ff176ad-dbfa-42c5-9c25-301f088ec421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:to="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45b93f21-b184-4c79-8caf-2d0fd2be042c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45b93f21-b184-4c79-8caf-2d0fd2be042c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1273a44a-f44b-41df-8a44-0a85a530d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1273a44a-f44b-41df-8a44-0a85a530d6dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6c63ab1c-ad79-446f-b29b-1240966a0c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_PerformanceSharesMember_6c63ab1c-ad79-446f-b29b-1240966a0c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_94ae24bb-d1e0-45d7-9865-2521920ced58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_94ae24bb-d1e0-45d7-9865-2521920ced58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9336af34-7df8-40d7-8c9a-43767650cba7" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9336af34-7df8-40d7-8c9a-43767650cba7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_34546508-392d-4190-af31-1789c5c17ccb" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_34546508-392d-4190-af31-1789c5c17ccb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e95ad78a-1910-4037-bce6-8a0d0344e929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e95ad78a-1910-4037-bce6-8a0d0344e929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d3cc66fc-8b17-46f6-b9c8-8802ea013272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:to="loc_us-gaap_CostOfSalesMember_d3cc66fc-8b17-46f6-b9c8-8802ea013272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9930af03-0f7d-46aa-9f58-313b029ff60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9930af03-0f7d-46aa-9f58-313b029ff60f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended" id="i4c6055a9138044bc8527a24584be345f_StockbasedCompensationUnrecognizedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_995196fc-e156-4254-8557-bf9782bdff04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_995196fc-e156-4254-8557-bf9782bdff04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8844a848-9082-4e72-bb71-6d454f48d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8844a848-9082-4e72-bb71-6d454f48d39b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0f6adefa-a584-445b-af50-cc7ea0a58b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0f6adefa-a584-445b-af50-cc7ea0a58b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2d172f0-6256-4f2a-b6e7-2936895ddf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2d172f0-6256-4f2a-b6e7-2936895ddf5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:to="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_849989b1-9330-42d8-85ef-735bfee3391e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_849989b1-9330-42d8-85ef-735bfee3391e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2697e4e-efe2-4687-92d5-91da84ddccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2697e4e-efe2-4687-92d5-91da84ddccc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_51382ef5-9337-4103-89f6-cd24a8b9d269" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_51382ef5-9337-4103-89f6-cd24a8b9d269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ad3bcc0a-cc7b-431f-9c6d-cbbcf3decb27" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ad3bcc0a-cc7b-431f-9c6d-cbbcf3decb27" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="extended" id="i33674f601e624c6cb62729447b0ae72d_StockbasedCompensationStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2ff2c7a6-2f1f-4f35-9d0e-6f982f8b81b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2ff2c7a6-2f1f-4f35-9d0e-6f982f8b81b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1fadf9e2-d925-4fa0-9213-77ea473dfa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1fadf9e2-d925-4fa0-9213-77ea473dfa65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ea2cf07b-96b9-4db3-937c-26a3e75162d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ea2cf07b-96b9-4db3-937c-26a3e75162d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_da79398d-a23c-461d-b30b-939017382715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_da79398d-a23c-461d-b30b-939017382715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f49479ea-23b7-4639-a1d4-a982c377b9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f49479ea-23b7-4639-a1d4-a982c377b9b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:to="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c85a83d1-b486-4d5f-bad8-3e8688b84662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c85a83d1-b486-4d5f-bad8-3e8688b84662" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="extended" id="icd086e1759804ad2904fd82350c4647a_StockbasedCompensationPerformancebasedStockOptionAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06872682-d98f-46b0-8967-1d52e9357498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06872682-d98f-46b0-8967-1d52e9357498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_78f660c3-501b-4416-b6a1-b37d99da9ac3" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_78f660c3-501b-4416-b6a1-b37d99da9ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_8e2da69a-e801-40bb-a501-accd55d4b8ee" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_8e2da69a-e801-40bb-a501-accd55d4b8ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc09b7f9-e9c2-416f-8e77-8965aee3114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc09b7f9-e9c2-416f-8e77-8965aee3114d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_428d2e8a-cf07-440c-b33f-7459c66d4b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_428d2e8a-cf07-440c-b33f-7459c66d4b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3f19ab74-615f-44f7-a8db-0b481d7b6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3f19ab74-615f-44f7-a8db-0b481d7b6250" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_937b4ecc-384b-471d-a2ee-3cca3492ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_937b4ecc-384b-471d-a2ee-3cca3492ad62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6ebe9f4a-93ce-4836-a813-59d8fd795fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6ebe9f4a-93ce-4836-a813-59d8fd795fbc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29f70da3-ce7d-4a7b-8fcc-3a6514da9ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29f70da3-ce7d-4a7b-8fcc-3a6514da9ecf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d17d9bc-d94c-4f49-974f-e4e788ee2518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d17d9bc-d94c-4f49-974f-e4e788ee2518" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_827eeb77-d0db-46a5-b0a0-c2d4633f6646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_827eeb77-d0db-46a5-b0a0-c2d4633f6646" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_397c6f02-efde-442c-b5b9-e80065d0c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_397c6f02-efde-442c-b5b9-e80065d0c0de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d324707e-8f1b-4c6d-bb2b-e49b8f7ad5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d324707e-8f1b-4c6d-bb2b-e49b8f7ad5f0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:href="evh-20221231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee60cbe3-60ff-4e9d-90aa-5e83d197ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee60cbe3-60ff-4e9d-90aa-5e83d197ef59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0450e7f-f17d-4fe1-bc9e-83184a46caae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0450e7f-f17d-4fe1-bc9e-83184a46caae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:href="evh-20221231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e7a2025a-7fb8-4479-bd41-81e59b7ba717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e7a2025a-7fb8-4479-bd41-81e59b7ba717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f95b36de-dc98-4d72-bb14-9b22f4bf8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f95b36de-dc98-4d72-bb14-9b22f4bf8ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_161761ba-13fa-4450-b01d-ec93f3937258_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_161761ba-13fa-4450-b01d-ec93f3937258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f56b8b48-db05-4b07-9edd-1b9ef1674259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:to="loc_us-gaap_PerformanceSharesMember_f56b8b48-db05-4b07-9edd-1b9ef1674259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d896cad1-0d22-4616-b28a-79e18b265ce4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:to="loc_us-gaap_ClassOfStockDomain_d896cad1-0d22-4616-b28a-79e18b265ce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:to="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5c6feb98-cf15-4e67-982a-528a498dda9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:to="loc_us-gaap_CommonClassAMember_5c6feb98-cf15-4e67-982a-528a498dda9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:to="loc_us-gaap_VestingDomain_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:to="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b81109b7-0cfd-4aeb-b190-76803499d894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b81109b7-0cfd-4aeb-b190-76803499d894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebd3b9d2-7600-4f46-ba46-8a676de03b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebd3b9d2-7600-4f46-ba46-8a676de03b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c8ba5b71-8aea-4774-9f23-02a3868877ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c8ba5b71-8aea-4774-9f23-02a3868877ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_aeb99914-1e6f-44ef-aedb-a91e472ed382" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_aeb99914-1e6f-44ef-aedb-a91e472ed382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_d271f915-be6c-4eb7-9534-1ef3e2689d2d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_d271f915-be6c-4eb7-9534-1ef3e2689d2d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="ib8f333fd56034895b9466343b4690813_StockbasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_937b895a-6b3a-4304-96c2-ad404c11249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_937b895a-6b3a-4304-96c2-ad404c11249a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0c994fb3-747b-475a-86ab-f6fd7425e41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0c994fb3-747b-475a-86ab-f6fd7425e41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_883fd7e7-f04d-4cb0-8f3e-45ee234f50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_883fd7e7-f04d-4cb0-8f3e-45ee234f50ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad1f53df-dd92-4f25-b916-2711933660d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad1f53df-dd92-4f25-b916-2711933660d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ab279c11-fd2a-4a61-901e-3d528b0edd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ab279c11-fd2a-4a61-901e-3d528b0edd38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3f9d14b6-de99-4570-a742-068bd2260222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3f9d14b6-de99-4570-a742-068bd2260222" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d433fef3-56b3-4e75-80fa-ce53b53fa02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d433fef3-56b3-4e75-80fa-ce53b53fa02d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3162d0-f15e-480b-87d7-4dd9bd8e4036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6953505-88e3-4a05-b0c7-425a641f0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6953505-88e3-4a05-b0c7-425a641f0ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_49595991-cff3-485d-a402-dfbb8f684add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_49595991-cff3-485d-a402-dfbb8f684add" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9669e100-e58e-4ee6-9d10-83d2a7f1efd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9669e100-e58e-4ee6-9d10-83d2a7f1efd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e7e6b01-b217-44f4-abb6-c1be7ade7f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e7e6b01-b217-44f4-abb6-c1be7ade7f2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fd13f5ba-7884-4607-9cba-b8e63433b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_18a00bfb-3743-4fa3-8ed4-f3dcae600718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_18a00bfb-3743-4fa3-8ed4-f3dcae600718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af00113d-2e04-4663-b59e-22dcf48b3d90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af00113d-2e04-4663-b59e-22dcf48b3d90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bef5e85a-db9a-4f9b-988a-87c84d0a0001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bef5e85a-db9a-4f9b-988a-87c84d0a0001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_86fa2ae7-a937-4e65-a70e-5917c6e71842_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:to="loc_us-gaap_RelatedPartyDomain_86fa2ae7-a937-4e65-a70e-5917c6e71842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:to="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember_75857eb1-bd64-410e-b929-c1f65ac3d77a" xlink:href="evh-20221231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:to="loc_evh_NonEmployeeDirectorsMember_75857eb1-bd64-410e-b929-c1f65ac3d77a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17326fd6-284a-42e4-9b7b-f1deb0aac143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17326fd6-284a-42e4-9b7b-f1deb0aac143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_7dcc4357-e06e-43ef-a8ac-8c256a2da48f" xlink:href="evh-20221231.xsd#evh_NewCenturyHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:to="loc_evh_NewCenturyHealthMember_7dcc4357-e06e-43ef-a8ac-8c256a2da48f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb507d65-53ed-4e87-a4d4-c847d6940865_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:to="loc_srt_RangeMember_cb507d65-53ed-4e87-a4d4-c847d6940865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:to="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7d617e9-3787-4977-acd1-b872fd159406" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:to="loc_srt_MinimumMember_c7d617e9-3787-4977-acd1-b872fd159406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b651067-3a84-4e4a-999d-6dbf7662a91d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:to="loc_srt_MaximumMember_2b651067-3a84-4e4a-999d-6dbf7662a91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_81318be5-cc08-4196-a4d8-03b31e052b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:to="loc_us-gaap_VestingDomain_81318be5-cc08-4196-a4d8-03b31e052b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:to="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_45d19768-5ff2-45b0-bd85-aa8bfea4a883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_45d19768-5ff2-45b0-bd85-aa8bfea4a883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ab39273a-9e93-4cfb-b18c-a7c1ad9b786c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ab39273a-9e93-4cfb-b18c-a7c1ad9b786c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e12abd7f-787d-4f31-8517-028f92f44b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e12abd7f-787d-4f31-8517-028f92f44b44" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationLeveragedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="extended" id="ieda96e3b998b4beebf4b5deb21a93de1_StockbasedCompensationLeveragedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c435795-e118-4867-891f-5222f7faecd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c435795-e118-4867-891f-5222f7faecd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_6b02bcec-5000-4509-8e47-20fd8bd3a9dd" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_6b02bcec-5000-4509-8e47-20fd8bd3a9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7aa5f46-b667-4dd8-a93c-47bb98b97125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7aa5f46-b667-4dd8-a93c-47bb98b97125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36eda4ba-81c5-498a-afa1-9afeec00562a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36eda4ba-81c5-498a-afa1-9afeec00562a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3b985d88-8845-42c3-a678-611a1824a596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3b985d88-8845-42c3-a678-611a1824a596" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3864c032-b073-4e47-b88b-1c3041af0320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3864c032-b073-4e47-b88b-1c3041af0320" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e0e9b6d-c492-493e-8af9-af6d2dff5dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e0e9b6d-c492-493e-8af9-af6d2dff5dd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6142864-d75a-4b67-bb57-d80f1d07a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6142864-d75a-4b67-bb57-d80f1d07a13f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f07f4993-df23-4e3d-9d8f-9aa30429f772_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f07f4993-df23-4e3d-9d8f-9aa30429f772_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_43e608be-78d0-47b8-9246-babcc2b3f123" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_43e608be-78d0-47b8-9246-babcc2b3f123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7ee0db99-ec02-4f8f-9904-d52f4cfcc859_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:to="loc_us-gaap_VestingDomain_7ee0db99-ec02-4f8f-9904-d52f4cfcc859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:to="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3eb27ea6-cac3-46ba-bf15-237540a131d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3eb27ea6-cac3-46ba-bf15-237540a131d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a851c001-0bec-42da-bcc3-dc8d93c04c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a851c001-0bec-42da-bcc3-dc8d93c04c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_539daa31-7f60-42e2-ab64-d8e7da9e4966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_539daa31-7f60-42e2-ab64-d8e7da9e4966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember_f7fdc656-8f26-4b97-8529-a09db059a175" xlink:href="evh-20221231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_evh_SharebasedPaymentArrangementTrancheFourMember_f7fdc656-8f26-4b97-8529-a09db059a175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_37e49dba-8c88-4548-9ada-494877df905b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:to="loc_us-gaap_AwardDateDomain_37e49dba-8c88-4548-9ada-494877df905b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:to="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandNineteenMember_5c586fc6-d1a6-4924-aab1-aae4c89fd42b" xlink:href="evh-20221231.xsd#evh_TwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:to="loc_evh_TwoThousandNineteenMember_5c586fc6-d1a6-4924-aab1-aae4c89fd42b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationLeveragedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="extended" id="idc6b20021359439b88d2b46033e831ad_StockbasedCompensationLeveragedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24f2acbf-8935-4683-8304-fab05155f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24f2acbf-8935-4683-8304-fab05155f06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51261c7f-d7ac-4f68-9eb7-e8681c0c463f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51261c7f-d7ac-4f68-9eb7-e8681c0c463f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b5d9900-cf08-444c-ab3d-27abc115fbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b5d9900-cf08-444c-ab3d-27abc115fbfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5a8162fe-db62-4a86-ae4c-ed235a249472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0eefd243-20b5-4c75-ae68-6dc52677b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0eefd243-20b5-4c75-ae68-6dc52677b01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb734d7-f3fb-4355-be19-049d9b0da118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb734d7-f3fb-4355-be19-049d9b0da118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e1a3af8-6acf-4031-8082-eeb2d7c3f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e1a3af8-6acf-4031-8082-eeb2d7c3f919" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ed358d2-dc2b-4fac-8c2f-3cc97cee9158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d40ecba1-4875-4243-b0b5-50c14b4c4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d40ecba1-4875-4243-b0b5-50c14b4c4ce4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e2152ce8-3525-46d4-a3da-294051182975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e2152ce8-3525-46d4-a3da-294051182975" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_5a4c04c7-f6a1-4789-b6c9-fa3a80406767" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_5a4c04c7-f6a1-4789-b6c9-fa3a80406767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_4a06877c-fa79-4aec-bba0-af52cb284178" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_4a06877c-fa79-4aec-bba0-af52cb284178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_e6170a01-93ad-4667-a108-32b4db102333" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_e6170a01-93ad-4667-a108-32b4db102333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_4b3e7574-37bd-44e4-b363-c59c6fee2512" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_4b3e7574-37bd-44e4-b363-c59c6fee2512" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:to="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5142c3d-d732-4e05-8578-f39f2a1a48f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5142c3d-d732-4e05-8578-f39f2a1a48f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_69bdd30e-81ff-45fa-ad6d-3aee4b3c4995" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_69bdd30e-81ff-45fa-ad6d-3aee4b3c4995" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="extended" id="ia1ac889581c84e43b461bcf17f22d07c_StockbasedCompensationPerformancebasedRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f5a28b-0c5b-47fd-b352-009cb2bda827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f5a28b-0c5b-47fd-b352-009cb2bda827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_35970779-20c5-46ca-a426-3640451d700f" xlink:href="evh-20221231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_35970779-20c5-46ca-a426-3640451d700f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_213a6e19-013b-450c-93b7-5796ac7c3627" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_213a6e19-013b-450c-93b7-5796ac7c3627" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_41e1c88b-6674-4b82-881c-484c8a5c7079" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_41e1c88b-6674-4b82-881c-484c8a5c7079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_2032956b-3ad8-4268-9bea-a284c906f778" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_2032956b-3ad8-4268-9bea-a284c906f778" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_7dc6febe-66bf-4850-a0ee-7f2c5703d290" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_7dc6febe-66bf-4850-a0ee-7f2c5703d290" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f73fce6-44a5-4fed-9a58-312cdfaed6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f73fce6-44a5-4fed-9a58-312cdfaed6df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_269231d2-e45c-4759-92d5-5207dc48fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_269231d2-e45c-4759-92d5-5207dc48fc25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1522e3af-7338-404f-a5c8-7186b7ecca88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1522e3af-7338-404f-a5c8-7186b7ecca88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1aa372c1-2828-47a6-ae76-9ba2fd13971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1aa372c1-2828-47a6-ae76-9ba2fd13971f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9f03471-58f2-4353-87ee-33c5994cc1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9f03471-58f2-4353-87ee-33c5994cc1a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f66ae4e3-736d-4578-920b-3b1cd161e645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f66ae4e3-736d-4578-920b-3b1cd161e645" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca8dff83-7bf1-4544-97d2-81919d38c188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca8dff83-7bf1-4544-97d2-81919d38c188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60673ae7-a142-4541-9666-afa280895565" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60673ae7-a142-4541-9666-afa280895565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:to="loc_us-gaap_VestingDomain_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:to="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5f04282d-78a0-4e26-9981-cb47ecd843ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5f04282d-78a0-4e26-9981-cb47ecd843ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e1719546-0cae-40f2-b7f8-70b7daf7a4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e1719546-0cae-40f2-b7f8-70b7daf7a4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:to="loc_srt_RangeMember_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:to="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf9eaea-50b7-409c-b6b1-47e39a6a1a67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:to="loc_srt_MinimumMember_7cf9eaea-50b7-409c-b6b1-47e39a6a1a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c384075-26c4-4b26-90b7-b30628617275" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:to="loc_srt_MaximumMember_3c384075-26c4-4b26-90b7-b30628617275" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="extended" id="i705478cc57094a138651d82326bfdd21_StockbasedCompensationPerformancebasedRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3318af3-0d00-4755-b030-232c4e522dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3318af3-0d00-4755-b030-232c4e522dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e8eaefd-7eed-4d57-94c2-a20af6e17db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e8eaefd-7eed-4d57-94c2-a20af6e17db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_b3fdbc03-150c-4356-8197-85baa2c9ed62" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_b3fdbc03-150c-4356-8197-85baa2c9ed62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c176de7-5991-4f84-b24a-c0fdd8bf4383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c176de7-5991-4f84-b24a-c0fdd8bf4383" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a14d7869-eab4-4ef3-a764-5fb85c0127d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_93eb9e0b-aa24-449b-af69-61a32099d441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_93eb9e0b-aa24-449b-af69-61a32099d441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d93a04b4-3bed-4661-b7b4-9f23b0eeb6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d93a04b4-3bed-4661-b7b4-9f23b0eeb6c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_3e807c8a-6da8-4f2a-ab2b-b8d4a20edf54" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_3e807c8a-6da8-4f2a-ab2b-b8d4a20edf54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec741f20-ea04-4993-b878-72754477b2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec741f20-ea04-4993-b878-72754477b2a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b68f80b-e76d-4a95-8bc2-0fcd6fa8c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d617bd20-800d-42e9-aa56-9e11e0c4b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d617bd20-800d-42e9-aa56-9e11e0c4b16c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d3c282c0-7b59-4c2f-ba14-23e638a8f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5684a171-0b29-49cb-8890-5397b3e1a431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5684a171-0b29-49cb-8890-5397b3e1a431" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9c65a3b6-24d0-4070-9255-78e7a9645d95" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9c65a3b6-24d0-4070-9255-78e7a9645d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_298abf12-b21a-4e2f-b936-5c8c0305478d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_298abf12-b21a-4e2f-b936-5c8c0305478d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_ab3ded77-3dc7-4e9b-adf8-88c37a32be19" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_ab3ded77-3dc7-4e9b-adf8-88c37a32be19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_7828636b-0f4a-4ed9-ba04-bf3d23c061c4" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_7828636b-0f4a-4ed9-ba04-bf3d23c061c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:to="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e02c877-6edf-4ddd-bf54-7853a881a849_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e02c877-6edf-4ddd-bf54-7853a881a849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_fb6bfb92-784b-47dc-9ac7-3f0019b8ce50" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_fb6bfb92-784b-47dc-9ac7-3f0019b8ce50" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="idb83c9e514f04207b778a41843879fb9_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_637ee9e4-fb33-42ff-8c93-618e6f2e7acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_637ee9e4-fb33-42ff-8c93-618e6f2e7acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_362bcc48-f4dd-4149-a45b-553752a96012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_362bcc48-f4dd-4149-a45b-553752a96012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e379b0c2-66c6-43fd-90b5-324fb40a2dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e379b0c2-66c6-43fd-90b5-324fb40a2dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_41259a47-5d8d-4d48-96d8-b7eab296aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_41259a47-5d8d-4d48-96d8-b7eab296aa18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2a67c4c3-ae51-49cc-9c3c-7bd797ce6d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2a67c4c3-ae51-49cc-9c3c-7bd797ce6d0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_f82bc851-b714-4d26-94e9-1b4bc75dbeda" xlink:href="evh-20221231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_f82bc851-b714-4d26-94e9-1b4bc75dbeda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_39a23d06-8b59-4502-851b-3c26b580a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_39a23d06-8b59-4502-851b-3c26b580a7e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3527ccba-c378-4be3-a811-67e912d56dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3527ccba-c378-4be3-a811-67e912d56dfa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fb56a00f-309b-4c37-a893-1eceac204763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fb56a00f-309b-4c37-a893-1eceac204763" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_34f2074c-7102-4546-a982-bd2ebe2b1f1a" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_34f2074c-7102-4546-a982-bd2ebe2b1f1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementLiability_ba0c4489-ee9f-49cc-a6c2-145d4577f175" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivablesAgreementLiability_ba0c4489-ee9f-49cc-a6c2-145d4577f175" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_a0b3d1b7-359a-44fc-8edd-ac377ee55d16" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_a0b3d1b7-359a-44fc-8edd-ac377ee55d16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_af5e7d4e-5048-4a8f-9309-ae597bca6968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_af5e7d4e-5048-4a8f-9309-ae597bca6968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9d66f4c0-26f9-4f9f-b54a-ea49573222cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:to="loc_us-gaap_DomesticCountryMember_9d66f4c0-26f9-4f9f-b54a-ea49573222cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bedeb8dd-d268-45cd-82df-fb6e8ea9f9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bedeb8dd-d268-45cd-82df-fb6e8ea9f9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ed3e9ff8-628f-4f2c-91af-8f11bc61514a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ed3e9ff8-628f-4f2c-91af-8f11bc61514a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember_cceb5756-509f-4da4-896f-0d551d058774" xlink:href="evh-20221231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:to="loc_evh_FinitelivedTaxCreditCarryforwardMember_cceb5756-509f-4da4-896f-0d551d058774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_4d003dbc-f3de-4c34-8fe5-746e7d98c968" xlink:href="evh-20221231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:to="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_4d003dbc-f3de-4c34-8fe5-746e7d98c968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:to="loc_us-gaap_TaxPeriodDomain_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:to="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member_9abd9283-1fce-4928-a5e8-908de192a344" xlink:href="evh-20221231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:to="loc_evh_PeriodsPriortoJune2015Member_9abd9283-1fce-4928-a5e8-908de192a344" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended" id="i72932d1604c94faaa8ede67999279045_IncomeTaxesChangesinValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a0f9009e-204f-4675-b43c-0a7a18c3e6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a0f9009e-204f-4675-b43c-0a7a18c3e6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_826df6f1-484d-4c5e-bc04-3470668c5fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_826df6f1-484d-4c5e-bc04-3470668c5fcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b8c3782-0cc2-4bd4-8a14-4f83168a44f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b8c3782-0cc2-4bd4-8a14-4f83168a44f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_06ba0598-b70c-4df2-a86b-9a558bd59da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e3e341fd-e058-4ec9-9f40-aad713ea4952_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e3e341fd-e058-4ec9-9f40-aad713ea4952_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_5c839444-b8e9-4df4-9059-800b38d34d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_5c839444-b8e9-4df4-9059-800b38d34d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d51e0da1-73a0-4ae9-9c18-889e2e78b297_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:to="loc_us-gaap_EquityComponentDomain_d51e0da1-73a0-4ae9-9c18-889e2e78b297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:to="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cd88175e-61cb-435f-bf6c-7702331c4203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:to="loc_us-gaap_RetainedEarningsMember_cd88175e-61cb-435f-bf6c-7702331c4203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_cef58be5-00e5-4530-85fb-1e4a81edc074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_cef58be5-00e5-4530-85fb-1e4a81edc074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_bd1b9d89-a649-498a-8e49-362ed37cf178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_bd1b9d89-a649-498a-8e49-362ed37cf178" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="ic7671a8a6fdf41749a8758519a5d50ac_EmployeeBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_628cf580-0cd8-4247-9b36-7fe20dd8116d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_628cf580-0cd8-4247-9b36-7fe20dd8116d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_69ced6c7-0c58-444e-9308-75dfcee16dc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_69ced6c7-0c58-444e-9308-75dfcee16dc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dacce77b-0bd5-4686-816e-427a7e478088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dacce77b-0bd5-4686-816e-427a7e478088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fd210a96-8437-4179-b200-bf0aff4465d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fd210a96-8437-4179-b200-bf0aff4465d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_eda6ba22-3a1d-4e9d-b44c-d7ae9a2fb6a4" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:to="loc_evh_TrueHealthMember_eda6ba22-3a1d-4e9d-b44c-d7ae9a2fb6a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="i2e724d7a3b6b4cb3992b6bae7eff3582_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_5b50c2b4-4596-4383-8de2-181490a93aa1" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_5b50c2b4-4596-4383-8de2-181490a93aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_9fa993e9-541e-4e6b-acc0-d52bf809dc82" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_9fa993e9-541e-4e6b-acc0-d52bf809dc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b6cc826-1644-4bcf-9e73-49783eb8db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b6cc826-1644-4bcf-9e73-49783eb8db1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_eb43a9a6-6301-4554-9a16-167df9ebf273" xlink:href="evh-20221231.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_eb43a9a6-6301-4554-9a16-167df9ebf273" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c4609fa-2b42-4769-b17b-e7e736af7cd7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:to="loc_srt_RangeMember_2c4609fa-2b42-4769-b17b-e7e736af7cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:to="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0b076f29-bc00-4f66-9d19-bac991a5bbfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:to="loc_srt_MinimumMember_0b076f29-bc00-4f66-9d19-bac991a5bbfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_707e4ce7-fff5-4434-863f-12c6e20c6e61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:to="loc_srt_MaximumMember_707e4ce7-fff5-4434-863f-12c6e20c6e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e7c4dbb3-f68b-4675-af45-2e7150decfa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:to="loc_us-gaap_RelatedPartyDomain_e7c4dbb3-f68b-4675-af45-2e7150decfa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:to="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_2e7803f8-a5ba-4bb6-90b2-1295bcd9da0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_2e7803f8-a5ba-4bb6-90b2-1295bcd9da0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_6367f82c-5749-46f7-8244-6f67ede4a80d" xlink:href="evh-20221231.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:to="loc_evh_ServicesAgreementsMember_6367f82c-5749-46f7-8244-6f67ede4a80d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="ib89cc650e1cc4def92171553e2725b10_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5292234c-55d6-4c02-99be-00f4d56d9a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5292234c-55d6-4c02-99be-00f4d56d9a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aa90a097-8286-410e-b176-45285ed67a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aa90a097-8286-410e-b176-45285ed67a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ad788b5a-88ba-4231-8448-2394b586e066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ad788b5a-88ba-4231-8448-2394b586e066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6628f8e8-b43f-4b63-85e0-be846fdd1c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6628f8e8-b43f-4b63-85e0-be846fdd1c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc9d2438-c041-462a-a755-0fd2fad90b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc9d2438-c041-462a-a755-0fd2fad90b9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fe259e2-74d2-4192-a00c-225a3017a441_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fe259e2-74d2-4192-a00c-225a3017a441_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b7a7b09c-0abe-4931-8552-39a56e68c38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b7a7b09c-0abe-4931-8552-39a56e68c38c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i700807ec53304572a7c1d20e814c3a2f_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb53a7e1-26c8-49b0-8ea8-788a49de782e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb53a7e1-26c8-49b0-8ea8-788a49de782e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2e52bd57-4bec-4ce4-85b2-a0b5b2b05163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2e52bd57-4bec-4ce4-85b2-a0b5b2b05163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_334ccc20-2e12-46ae-94a0-65870ac4de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_334ccc20-2e12-46ae-94a0-65870ac4de1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_29ec9d3d-bfb4-4f34-98be-45c6c606e115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_29ec9d3d-bfb4-4f34-98be-45c6c606e115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2163bc21-5ec5-4be2-9bbe-6d115aa8b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2163bc21-5ec5-4be2-9bbe-6d115aa8b6d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_230c1b00-9329-4e32-b4b6-c023b3e4e105_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_230c1b00-9329-4e32-b4b6-c023b3e4e105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fd620663-1764-4e44-a0b5-2c77ff622db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fd620663-1764-4e44-a0b5-2c77ff622db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8ac9a57d-dd44-4d00-bdec-6bc5504bafce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8ac9a57d-dd44-4d00-bdec-6bc5504bafce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_772241a5-8a6b-4fe2-ba14-7c13290780c1" xlink:href="evh-20221231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_772241a5-8a6b-4fe2-ba14-7c13290780c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a80217cd-037e-47de-9b6e-8b6e8df74808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a80217cd-037e-47de-9b6e-8b6e8df74808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a546f13-63a3-460a-82c7-6bd2a72bf234_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:to="loc_srt_RangeMember_1a546f13-63a3-460a-82c7-6bd2a72bf234_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:to="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_661722b9-fd50-41c3-b52f-fa624936e52b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:to="loc_srt_MinimumMember_661722b9-fd50-41c3-b52f-fa624936e52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_959069a7-cc21-414f-a096-78be4bc6aee7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:to="loc_srt_MaximumMember_959069a7-cc21-414f-a096-78be4bc6aee7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="i0a27dfaeea814b94ad737bb7e3670b88_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:to="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d7071873-6f60-47f1-8719-d1e62afa2a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d7071873-6f60-47f1-8719-d1e62afa2a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6973f002-1caa-4bda-87c3-a93fb34ffab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6973f002-1caa-4bda-87c3-a93fb34ffab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_49312a4a-d992-465e-b46b-30ca0c19f11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_49312a4a-d992-465e-b46b-30ca0c19f11c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:to="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c26bb373-7dce-45e1-b204-faa778dda54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_AccountsPayableCurrent_c26bb373-7dce-45e1-b204-faa778dda54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_606b3130-b795-4a30-a49d-f9b206778433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_606b3130-b795-4a30-a49d-f9b206778433" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5de6f5f5-1fb9-4436-9fd8-408e65748815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5de6f5f5-1fb9-4436-9fd8-408e65748815" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:to="loc_us-gaap_RelatedPartyDomain_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:to="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5c722824-cd42-4130-bf8f-cf5edd8bdade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:to="loc_srt_AffiliatedEntityMember_5c722824-cd42-4130-bf8f-cf5edd8bdade" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="i482c17d52c084492b09781a62294b5a3_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_99e3d99c-eca0-4a38-908e-f50f9ac23156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:to="loc_us-gaap_RevenueFromRelatedParties_99e3d99c-eca0-4a38-908e-f50f9ac23156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1f20e0d4-72c6-43e2-bb9b-e84e1f041af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1f20e0d4-72c6-43e2-bb9b-e84e1f041af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_273df83f-4745-4cb3-a771-e316478a14c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:to="loc_us-gaap_RelatedPartyDomain_273df83f-4745-4cb3-a771-e316478a14c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:to="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d6de08c4-e959-450f-b5bd-dc9f5f99c84e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:to="loc_srt_AffiliatedEntityMember_d6de08c4-e959-450f-b5bd-dc9f5f99c84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4bdeb9eb-5e05-440c-a1c3-5135710afbbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4bdeb9eb-5e05-440c-a1c3-5135710afbbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_166d6d90-c62c-4fb2-9ad8-da54f8a6fd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:to="loc_us-gaap_CostOfSalesMember_166d6d90-c62c-4fb2-9ad8-da54f8a6fd47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4e21cfa-dbb5-427b-9c6a-163c46ddb601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4e21cfa-dbb5-427b-9c6a-163c46ddb601" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="i6b0e654aec3f41eab1f6e39c5b7be3bb_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_331ccfe0-fca0-4339-be1e-24ee3e77367d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_331ccfe0-fca0-4339-be1e-24ee3e77367d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_74be0f64-0645-403a-9252-5dc9dc0b8ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:to="loc_us-gaap_RestructuringCharges_74be0f64-0645-403a-9252-5dc9dc0b8ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b08ccb4b-9b90-40d2-8add-4563368bfcf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b08ccb4b-9b90-40d2-8add-4563368bfcf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_d3d49d5c-9d28-45cb-b13b-47b9a2b016f5" xlink:href="evh-20221231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_d3d49d5c-9d28-45cb-b13b-47b9a2b016f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_320f0bd0-9763-4cf5-8600-8c9c08a47b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_us-gaap_FacilityClosingMember_320f0bd0-9763-4cf5-8600-8c9c08a47b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_81c3b0b1-ef99-483b-8a7d-2bd63ae1d79f" xlink:href="evh-20221231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_81c3b0b1-ef99-483b-8a7d-2bd63ae1d79f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="i231fdfdb0aad49e6b8dcceb07456092a_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77bc13c5-9d31-464c-b1c6-691b37dca25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77bc13c5-9d31-464c-b1c6-691b37dca25f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_8d95d611-3659-47b0-a4e7-0b1a550673ef" xlink:href="evh-20221231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_8d95d611-3659-47b0-a4e7-0b1a550673ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:to="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:to="loc_srt_ConsolidationItemsDomain_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:to="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b7135d2f-2b99-4be1-b6ff-87d6a606326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b7135d2f-2b99-4be1-b6ff-87d6a606326b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cdded813-e9c2-4a58-be8f-bf0ab70c1031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_OperatingSegmentsMember_cdded813-e9c2-4a58-be8f-bf0ab70c1031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1ed79d16-41a5-42b0-8bd3-edc5599cdf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1ed79d16-41a5-42b0-8bd3-edc5599cdf7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8f0742aa-b777-4401-aff9-88918df07789_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:to="loc_us-gaap_SegmentDomain_8f0742aa-b777-4401-aff9-88918df07789_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:to="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_f60b3102-7808-4576-aa29-8cab57b66a5b" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_f60b3102-7808-4576-aa29-8cab57b66a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_5a51140a-1db5-48b3-b5ce-8b6a761d6e8c" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_5a51140a-1db5-48b3-b5ce-8b6a761d6e8c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="i4992240eb2d143508325a080ec10a718_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_88654d85-82aa-4f44-b7f2-b3f0ce29dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_88654d85-82aa-4f44-b7f2-b3f0ce29dbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5fc77982-b30d-444a-a191-d9d6173c009c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5fc77982-b30d-444a-a191-d9d6173c009c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_b7509950-1b86-4e15-8bc6-f10d5f07b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_b7509950-1b86-4e15-8bc6-f10d5f07b001" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8981dcc2-f4ff-4aaa-a77f-bc231586eef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8981dcc2-f4ff-4aaa-a77f-bc231586eef3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48b2cd80-c3f7-4db6-a1f9-9166027e16c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48b2cd80-c3f7-4db6-a1f9-9166027e16c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_dd5efef4-0a6b-4326-8e04-dbdaf9bb0ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_dd5efef4-0a6b-4326-8e04-dbdaf9bb0ce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_24b909af-3ee9-439a-9d6e-eb58d6d26ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_24b909af-3ee9-439a-9d6e-eb58d6d26ba3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6daff726-c30a-4f70-b6ee-49277ac4b3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:to="loc_us-gaap_SegmentDomain_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:to="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_3041b6ec-201f-4a7b-9e0f-3b57ca4a4809" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_3041b6ec-201f-4a7b-9e0f-3b57ca4a4809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cc5537ce-b7f0-4fd0-a57e-bad1ef523e2e" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cc5537ce-b7f0-4fd0-a57e-bad1ef523e2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended" id="ic2d59dcb2899475c9c907635998548f3_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6eb51af-fe26-40ae-a72a-cc178ba07171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6eb51af-fe26-40ae-a72a-cc178ba07171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_148fe77f-29ea-4816-aa9e-026842355aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_148fe77f-29ea-4816-aa9e-026842355aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_ec3f7c80-5aa3-4ec9-80c5-a212367d4a61" xlink:href="evh-20221231.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_ec3f7c80-5aa3-4ec9-80c5-a212367d4a61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32245f9e-0100-4dfc-9547-31600fc6b463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32245f9e-0100-4dfc-9547-31600fc6b463" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9a6e2294-c8a5-4e0e-b2f6-85d35dabd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9a6e2294-c8a5-4e0e-b2f6-85d35dabd7fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_695dac9a-f14e-448b-ab93-3c1d54c39a32" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_695dac9a-f14e-448b-ab93-3c1d54c39a32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_5933ab7f-7261-42fc-b6ee-3d41ef14cd12" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_5933ab7f-7261-42fc-b6ee-3d41ef14cd12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_df3977f2-86bb-4579-8bbc-d03c249ec854" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_df3977f2-86bb-4579-8bbc-d03c249ec854" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_5192d600-d0be-49c5-b3ea-2b7fdca1af69" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_5192d600-d0be-49c5-b3ea-2b7fdca1af69" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be67221c-d3ca-431d-bd03-f0c46b303274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be67221c-d3ca-431d-bd03-f0c46b303274" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0fcb6da4-bea8-4c87-92b3-18be8512d982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0fcb6da4-bea8-4c87-92b3-18be8512d982" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e557e9e-d700-4dd4-9f88-899ab089efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e557e9e-d700-4dd4-9f88-899ab089efa0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39132915-52c9-496d-89ed-3249e775d9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39132915-52c9-496d-89ed-3249e775d9b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ec7faadd-f10a-4579-abaf-0015bf07cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ec7faadd-f10a-4579-abaf-0015bf07cacf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f96b4ce4-ef74-4bd5-8ed9-4b9476ead471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f96b4ce4-ef74-4bd5-8ed9-4b9476ead471" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_43b2a14a-1aab-4b54-a2fc-048413e64f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_43b2a14a-1aab-4b54-a2fc-048413e64f58" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_f66b232e-c923-4489-a77a-d037a2c01332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_f66b232e-c923-4489-a77a-d037a2c01332" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockVariableDividendRateBasisSpread_3f2cf407-795a-405b-a9c4-ee30a6cc9b5e" xlink:href="evh-20221231.xsd#evh_PreferredStockVariableDividendRateBasisSpread"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockVariableDividendRateBasisSpread_3f2cf407-795a-405b-a9c4-ee30a6cc9b5e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_8c63756f-2627-4fd4-8506-37d0d6b33b61" xlink:href="evh-20221231.xsd#evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_8c63756f-2627-4fd4-8506-37d0d6b33b61" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_cd75f92a-2148-4eb6-9325-d463dfbe581b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_cd75f92a-2148-4eb6-9325-d463dfbe581b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPricePercentage_557698db-4612-4fdf-9ced-6c6027d708f7" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockRedemptionPricePercentage_557698db-4612-4fdf-9ced-6c6027d708f7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_09e2fa91-1992-4735-b901-6945c7df6cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_09e2fa91-1992-4735-b901-6945c7df6cf5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_819c3feb-cb66-4fdc-bb61-a4fcbd6669f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_819c3feb-cb66-4fdc-bb61-a4fcbd6669f3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_928f1596-66de-4d97-8b50-9ecd225fe2c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:to="loc_us-gaap_CreditFacilityDomain_928f1596-66de-4d97-8b50-9ecd225fe2c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:to="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a56959ba-6fb6-4989-9488-0de800843a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:to="loc_us-gaap_SecuredDebtMember_a56959ba-6fb6-4989-9488-0de800843a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f18f208-b312-4ef7-a966-2546ca2d794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f18f208-b312-4ef7-a966-2546ca2d794a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_00cb1bf4-8507-4196-9cfd-778cfb1520ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:to="loc_us-gaap_LineOfCreditMember_00cb1bf4-8507-4196-9cfd-778cfb1520ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_87e579a1-8620-4d5f-8179-14deafeb6e7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:to="loc_us-gaap_VariableRateDomain_87e579a1-8620-4d5f-8179-14deafeb6e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:to="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_b5e3c067-1bc5-4679-919e-a2e93a92a2f5" xlink:href="evh-20221231.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_b5e3c067-1bc5-4679-919e-a2e93a92a2f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c9df56b3-6d78-494e-8121-e2aee8580ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:to="loc_us-gaap_BaseRateMember_c9df56b3-6d78-494e-8121-e2aee8580ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dba025eb-e6b1-4eea-90c3-de0bfe9d7356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:to="loc_us-gaap_SubsequentEventMember_dba025eb-e6b1-4eea-90c3-de0bfe9d7356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuritiesPurchaseAgreementMember_f78ef3a3-4bd2-4eef-9b3b-c403dd292d28" xlink:href="evh-20221231.xsd#evh_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:to="loc_evh_SecuritiesPurchaseAgreementMember_f78ef3a3-4bd2-4eef-9b3b-c403dd292d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:to="loc_us-gaap_ClassOfStockDomain_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:to="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bfca0456-8d84-43fd-a472-26f1a5a66d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bfca0456-8d84-43fd-a472-26f1a5a66d45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_040b3a96-4f91-42a9-ad20-bdae1afc97f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:to="loc_us-gaap_CommonClassAMember_040b3a96-4f91-42a9-ad20-bdae1afc97f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodDomain_684a2cbf-66f4-46bd-92f4-66f0c34b7c88_default" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:to="loc_evh_PreferredStockRedemptionPeriodDomain_684a2cbf-66f4-46bd-92f4-66f0c34b7c88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:to="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodOneMember_13195ebd-db21-49ee-a9be-d949b909f500" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodOneMember_13195ebd-db21-49ee-a9be-d949b909f500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodTwoMember_7141b742-7da5-4d71-9952-96619bb1648f" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodTwoMember_7141b742-7da5-4d71-9952-96619bb1648f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodThreeMember_57425f09-b146-440c-9327-f4458094fd5d" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodThreeMember_57425f09-b146-440c-9327-f4458094fd5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodFourMember_630889a0-7c4d-4d47-acde-de2f56a0688a" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodFourMember_630889a0-7c4d-4d47-acde-de2f56a0688a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_061eaf5e-4693-4e79-82e4-67320a3f38ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_061eaf5e-4693-4e79-82e4-67320a3f38ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesMember_32e0352c-ce34-4e91-aa14-54a4e5723d5e" xlink:href="evh-20221231.xsd#evh_NationalImagingAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:to="loc_evh_NationalImagingAssociatesMember_32e0352c-ce34-4e91-aa14-54a4e5723d5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_2e5dde45-0773-4727-893c-77faf7537b52" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_2e5dde45-0773-4727-893c-77faf7537b52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountingStandardsUpdate201603Member_953f99d4-6b46-4715-8bdb-99ba32488908" xlink:href="evh-20221231.xsd#evh_AccountingStandardsUpdate201603Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_evh_AccountingStandardsUpdate201603Member_953f99d4-6b46-4715-8bdb-99ba32488908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>evh-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7d5f9dd7-f1e2-4ac2-ad0e-25204ed23a98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_56db6bd1-d730-428b-93d5-81e6bbf453e4_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_20180e5a-a73b-46b8-b867-395e8fd6ad9e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8ef2083c-cd65-4dcd-bcb7-ff234ed3e470_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_c97252e4-692c-4f65-98be-e87936996ea3_verboseLabel_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to services agreements</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20221231.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_620a4e14-6959-4e43-a1a8-c3a91b9bb527_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_890dfe85-e9c5-405f-a194-c09f2216cc5a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_069ea787-51c7-4d68-90c8-40d4202a3eda_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_75b38c95-a398-437e-9278-a510b7dde677_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7bf2cd3f-c7cf-447e-926d-38be6644b8b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c340b1ed-2505-4724-8609-70601923e3c9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_355186ed-c20c-428f-804f-d84d29b1db8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity in Claims Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2075318d-4343-41fa-8264-fdcf986d8da3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c759b7c4-89d8-4231-b20e-3e8bdf5720cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_e450dce9-e32d-49c7-8f47-3e30618f34f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible goodwill impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_af8988b7-e456-4d33-ba68-7eb64afd943b_terseLabel_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="evh-20221231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_6fdda48a-b15f-4e95-9503-0dce7c2099cd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8562ec35-d6f8-41e6-aa51-0b51d6f2e515_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d063b474-b21d-4709-a2e4-5d658572cd1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b27f86af-5b54-444a-b2ee-6543a9653db9_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_b6cfa02a-6007-42ea-95b8-0024c4fc5069_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_c007294b-b318-4c03-9bc0-7548d52050df_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_01537355-e052-43c0-b3f9-4c8eb0cca9d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9c1ac32f-5b44-40e2-9b85-e02dddc50bca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4b5551c7-e9a3-43c0-9299-6c7d4d0f0161_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_40a02a44-bc56-4d87-8789-fca982699232_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5231f5e7-1abf-4afc-bd90-737bad6227d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1c0dfa3c-b8e0-4b0a-b76a-031eefeb95d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_088e8525-a060-4513-bc2f-d5c6f168db99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0d5e23a3-7f18-47b7-af9f-d4654ec3ec6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_a8cd493d-289d-476e-9443-9dfb22ea60d1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Payables Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4792ffd6-2e77-4b51-813d-9860e32abf6c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_aa02dfa2-bf24-4442-a488-f7e658fb8227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash inflows (outflows), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8298e94c-6685-4f1b-9358-d468ad017c04_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f1446acd-d576-4086-b491-a683a4bc0e39_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_85e63cce-4036-42fd-8bda-4d51f0147494_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_6c44d856-0038-4db4-be00-93ab7d873fa6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11178f6a-35e4-490f-afaf-715d4b028681_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_260bf74a-42d4-47eb-8eea-4a3a3c910c4f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c9894dd7-d68d-47b0-ba7d-b05312010683_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dbd7d39f-50ce-493d-bea7-11e54346ae32_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c2101976-aba5-47b9-ac29-76980d376f1c_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7f55e50a-ebab-41cb-b34b-eb54dc849546_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AuditInformationAbstract_label_en-US" xlink:label="lab_evh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_evh_AuditInformationAbstract_documentation_en-US" xlink:label="lab_evh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AuditInformationAbstract" xlink:href="evh-20221231.xsd#evh_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AuditInformationAbstract" xlink:to="lab_evh_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d669f2e2-577d-4ead-878d-8c86dd900304_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9a497567-69ba-4d93-91a0-9afa84ebae7c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_0940e7e7-c131-421d-9189-c8adc9f3dd0f_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_682900cf-bbd4-47ae-89f3-b9789394027d_terseLabel_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_label_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:href="evh-20221231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:to="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9579bb63-4995-4ad9-aa9f-b693b02188bb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - tax positions in current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b1f5266c-5f33-44f2-9c23-d23211868403_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_4213e49f-1b46-46d2-8002-4d62886dd4f7_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b9ed991d-5764-43fa-a5a6-5e0e7ac9ca8e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_45afa256-5d6b-4cf5-a32b-9339f1c372eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_82fe6df4-cc04-444a-9abc-4c1c2c9710c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0df2234b-9cf3-4653-ab73-ad46147f8992_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6f42d5c7-387c-4edd-a91c-ef56c218dd2b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d92079d5-cbc3-42c9-88fd-b81edb5d5c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_11d6c629-152a-4af4-b6ca-ce39294dadaa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for asset acquisition or business combinations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_75ffef2d-01f2-4fb1-841e-2bf24e3e5e10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8ef20efa-cade-4af3-9063-b5b8112046e7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_1c65e96e-3cce-4d9b-9061-9a08c7c71537_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_60735b0f-cab9-45c9-88ff-0d9b7773f89b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of 2024 Notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_782a71ab-d297-48bf-ab09-0d3349941fa2_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20221231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5804778f-16c6-4ec0-92f3-e58dda7dd3d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b2ec8d1d-098e-499d-81e5-d6ee3159f1a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a538d815-07a0-40b8-a7ff-c89a799f128d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_5856e0a7-cb73-475c-bd10-43f8e343734c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_3054cfb9-dc09-41ad-a87a-cd27fb18b333_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20221231.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fb2f2424-cf43-4120-b41d-63470b1e7f9e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f3570560-7f9e-40d9-87a8-20e61b26ddff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_62c4c1cc-289e-4284-96e7-9bf1aaab1c50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51997847-dedb-4000-ab6c-dea5db9a9fba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_a7a68558-e7a0-41f2-8fa2-860bb5994c11_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20221231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_d9679b61-2b02-47aa-b44c-55bd0b23d248_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ea56ae1b-bbd8-4e18-83b0-78927d9aef60_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_a9d446f2-c701-4b37-b9cd-cc1e033f0519_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_da3edeb4-6cab-486e-8fe7-99a1dee4e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_d17e5092-95a7-4d44-9aba-b9fd4632243f_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20221231.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_ef5dced1-0152-41ef-8f71-f9212180366a_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_d8f58730-b2d0-447f-ac7f-6b51a6ccdcc8_terseLabel_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_label_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eleven Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eleven Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:href="evh-20221231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:to="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c0eda367-de42-4f56-a474-e03a68eee749_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_496bb641-3d78-432b-a4ed-1b2cd5aa3b27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_35232cd4-77df-40b7-90e4-9640675d47b3_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41883888-1138-480c-b849-b0bed9d8c2f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_40c4df99-0944-4251-aa09-108026203761_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_4060df91-33a5-4cd2-93e1-b6f326fd3d0b_terseLabel_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="evh-20221231.xsd#evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b5116814-f9ad-4842-94f0-ddf577aed19b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2d1709e-6830-4956-a07a-2e8403154958_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_0a382b65-10d2-407e-8487-3804cf562c07_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowances</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_f2e8c545-fa7d-4c44-8a44-ab3eb8b00cd4_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in indefinite reinvestment assertion for domestic subsidiaries</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1a76d805-88ed-4718-9ea1-6fd0b44fb53d_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a39174ee-0584-4c3e-bda0-c21d14e91e0c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b610634a-64a1-486f-bcba-075106eed859_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b94149e8-2a88-4e08-93dc-f4e27504238b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_90db4aec-ff5a-4307-92ef-93c2a0b5d271_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3a13a6dd-5d30-4b33-a9ea-92ee5e1f0383_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_26a738a0-963f-4dee-a8ba-acd656c0c142_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb4a5622-e441-4211-964b-8259991e9112_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_1f1e446c-47c2-42ae-a9a0-f3a484483712_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be9878bc-77d8-4bd2-adcc-41739f2ce7aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b97fa806-52e9-4f89-8b99-954442e7e00e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9c027c20-fee3-4ad0-8506-c5b11710fcaa_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_7454a30a-71cc-4881-a827-9d5905e2b0de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_d9cef99b-11d0-43df-9a27-44e404871c7b_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4bc78bb7-7cf3-4d1e-b05b-05579d368352_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c7b55504-3a32-47b3-a6b1-9cb2355ce842_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d6950391-94aa-432b-8d83-78a907f03360_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1st Tranche</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_7dd5d0a8-cda4-46fc-a973-b566f25a4eca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_5e2ed74a-b88c-4e50-9c50-abdb86421c00_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_27f94c4c-6a11-493b-be0c-c61cea099563_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_49e734fc-7573-4ca4-8b2a-bc4ee5654cd5_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_19b26518-f022-45e9-9b64-eee74de07c07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_42b998ba-19d0-4c6a-aeda-6b8d1563c649_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in achievement (in dollars per share)</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_17023c92-8b42-4451-bd22-5e7ab0f5eca9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12ddbcff-48cb-4148-8aed-d95d0239ac0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3rd Tranche</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_775cb63d-c9fe-4911-b663-229abe8c161b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e05b38aa-ac3b-415c-bfc0-b2c70ffb8286_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_93431779-e111-4b51-8675-b85ac78f9889_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1f78d00-8e6a-4d72-8452-d48a6418e24a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_54d37ae7-2962-49c6-a7c6-89d20425cba6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_63c084ee-6a90-46e0-b2b5-6d6dc0fd729d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_8e5fb716-127b-4a13-b679-0bbf4ee54a95_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_88cda98f-90ce-4ad6-ae73-bafc50ecbd48_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_2268cda1-a499-4c83-b18f-f3bdd47f4e26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312023Member_1cac83d9-9283-4b59-9f40-d3035d7a4017_terseLabel_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_evh_December312023Member_label_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023 [Member]</link:label>
    <link:label id="lab_evh_December312023Member_documentation_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member" xlink:href="evh-20221231.xsd#evh_December312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312023Member" xlink:to="lab_evh_December312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0b0e97d-81e3-44a3-8df3-22dc07f5c0b1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a2842ef8-e70e-4065-8af4-b0c27d6ed9c0_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_af71e213-1970-4421-bbbd-f2618e1f4822_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings at other than U.S. rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_54ea734b-e0ce-492f-8954-0619ac7f1ab9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_270500e6-3663-4ed5-be37-f50b1bd24ec0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a4447128-a2c7-467b-abdc-7ed77940debe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Price Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_626dacf0-2a3a-44d0-a737-f427ded05177_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_3fdf1cf4-ca89-43d7-98cd-d195eed449c4_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20221231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_ec559dc6-16f2-4b9b-b9ba-3855faebfec6_terseLabel_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_label_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt [Member]</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_documentation_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember" xlink:href="evh-20221231.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityComponentOfLongTermDebtMember" xlink:to="lab_evh_EquityComponentOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d6ff1b6a-3cb8-4e49-b2f6-796538e88617_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d7fb54a9-6d5a-420d-b1ea-daae3449580b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9890033e-c7ff-4f6b-9393-7c1e95928a5d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ac3f887d-b980-43ea-8f91-07559be9fb1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d250c74-6ac4-47fc-aa09-9ca798343dc4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_91146089-d21f-43b3-8017-e3178c0618d1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ca216eb7-fdb4-4e5c-9443-21a66a03e5ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e749dfab-ae4b-471c-8ebf-e1dc9f6ffb75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_72f33bbf-dedc-48fc-a8ef-75340715beca_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_c6649d44-7aad-4693-99cd-c4a117b24a87_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible excess compensation</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_79facb0f-56f3-48ca-a915-424383fd68cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_747f9a48-3a81-4f63-903e-7cde3f973f8c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_c8d5e1ac-0124-4058-b978-3200bd61e01b_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_65a2864a-925b-4118-98ed-b52d79fb2351_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_20be4f66-5af3-473f-a113-0ecf0ef3e7ce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_b617636c-bbef-4948-b6b5-a98aaf25afee_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement (in shares)</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8e5d01cd-3f37-49d8-8248-6434907b2dcb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_a37bae00-cbd2-4c8d-9ab1-19e80263d131_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_64e4a794-e5b6-43d0-9f4e-5b219ce18044_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_483d8fa4-e403-422b-9b1b-d6d7d399cc45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b52568bb-1365-4a7e-ae3e-c415b930ddd0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1bf733ff-23bb-477d-b12c-641901e36980_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6ea3004b-f682-4248-a244-bf665e1459b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromLoansReceivable_29d4b58d-1d4c-47b5-af5a-84a2ec21e99e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan for implementation funding</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromLoansReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Loans Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:to="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ab85eb3c-00d6-4371-bcbd-f066f0bd82ab_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9bec92f0-be26-48f9-acba-3bea480915ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_a74f7425-c1fc-4c76-8bc7-2e8c4f5f80ba_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Tax Receivable Agreement</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Tax Receivable Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:to="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c9b17628-981a-4bca-893c-6e9138da4571_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_d1fafe0e-c925-4014-90a1-644902f96996_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_24a8e6cf-8dfc-4b15-8d53-ce28e94cfb9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UPMCResellerAgreementMember_474e3e54-cb22-4a2e-b300-2d228c1ace59_terseLabel_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_label_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement [Member]</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_documentation_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember" xlink:href="evh-20221231.xsd#evh_UPMCResellerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UPMCResellerAgreementMember" xlink:to="lab_evh_UPMCResellerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef764aaa-18b6-4eca-a4c0-c44cc3809f82_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_25434778-3e44-4d84-9c75-d9807336ae73_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d041ff55-b7f3-4efa-94af-2f35645550c0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_adc34d2e-f2d4-49b7-91f2-4648baca44da_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d16728a7-4800-4265-b9ba-8c5ad6c4ab1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt extinguishment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_8651033b-6cd4-4e72-a722-97d56e23a225_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_88635153-fd13-4789-9115-73f21696bddd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5f7b51f5-82f1-4019-9bba-d671b2f8de6b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61fa5e44-192c-4e2c-92b0-cc134da55c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eedd7609-ffcf-4d9e-8687-708e6fd18e96_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in achievement</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33180600-460c-482f-ba54-d7b9f6461edc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b2438a38-e4f5-41ff-adc9-6ad6e3d45b2a_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312024Member_4a57529d-cd8e-4402-9978-8d88d870fb5d_terseLabel_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_evh_December312024Member_label_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024 [Member]</link:label>
    <link:label id="lab_evh_December312024Member_documentation_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member" xlink:href="evh-20221231.xsd#evh_December312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312024Member" xlink:to="lab_evh_December312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f0889fa0-005c-45b4-a5cd-85c2626c7c96_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6b4dbbaa-5423-4d2c-9633-fe61ecca4f29_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_97985af5-456c-4054-b004-fc4ee29e2056_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2506eca5-720c-4f09-91f9-4adbd4c1a34b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfCustomers_8d952549-26f9-4da4-a681-1cc899ebf754_terseLabel_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_label_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_documentation_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers" xlink:href="evh-20221231.xsd#evh_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfCustomers" xlink:to="lab_evh_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3ce3d53f-87ea-44c2-8c5b-ed9eb72198c6_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_bfa68487-3a28-42c0-b9bd-6925f4f3382a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a686fd45-1750-4294-961c-07297bd05875_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47e84cf1-bb46-46a9-b463-c40599b6af94_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fb5006ef-aadc-4a13-9fec-65c66684002d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_0e9ba870-f4b7-4ced-9823-4ad413482152_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3d6a38b3-a1fd-4e60-a669-9d87fb3b6af8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount Incurred through December 31, 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_523eb9bf-b0e6-420c-bcaa-04c414c12242_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_81a15880-1fc4-47b2-aae3-1338e35a5343_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_9679e95f-8084-4b91-b3ed-ad017c482a2b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d27b36cd-2cb7-4560-980b-7f3f928fd774_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f10e5fb1-78d6-43ce-83b1-2a9c0e51a0ed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1397440e-2bd0-4afc-a5e7-121567fe84b1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a1c5ef0b-112d-41e2-beb6-4728f29ef265_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1c989ac2-8aa7-4174-b8fd-802b9b1b95c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period for vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b182fbbb-0cc8-4186-9ece-53fd8bd71526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5fc0fc82-9bd8-4652-9555-9c7d7612dfc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_744b82e8-7b07-47ea-91cb-b0a47cf25e83_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_c3e41c91-8aed-4ec1-8e20-3533fa0c4cfb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_36e147b2-2e75-41f5-a4f9-a544d8d06b51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_3a2a7eb7-8d79-495c-9417-4d910c90fc76_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_40bfab20-97f6-415b-b547-11258cb0515f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64495678-8ddf-492a-8d3d-8c5055b5a5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_2ad57229-acde-41e3-8787-1373d169cfee_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20221231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_b6db361e-d399-4799-97c7-3f292063ade2_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="evh-20221231.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c2559ed6-01bc-4aa9-a3f7-05321aab395c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_50cf6b69-bfb6-4f23-bd2c-8a97ca943ed9_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_891aad89-198a-4e74-9db6-5e6eae56125e_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20221231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_df4c86af-9e1c-4edc-b315-263fdd3cf0d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodTwoMember_fc9c54f5-1a60-4655-82b5-f9f51b9c5fc3_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 20, 2030</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Two [Member]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodTwoMember_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodTwoMember" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodTwoMember" xlink:to="lab_evh_PreferredStockRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_179fd210-b063-4ca0-9fb4-be79f4dce93f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f0e250e-469d-424e-8d20-913f79777ed2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VitalDecisionsMember_01ffe21d-d089-46fc-a488-37540f9f9efa_terseLabel_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_label_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions [Member]</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_documentation_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember" xlink:href="evh-20221231.xsd#evh_VitalDecisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VitalDecisionsMember" xlink:to="lab_evh_VitalDecisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_b3dfc86f-747d-49ce-b300-e573ea2eb1b5_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f67f7969-24c6-49ad-a5ca-ad0c5f5d6eff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_295803c9-dcee-462e-8097-85b564a99686_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5f4a1294-778f-4b0b-9277-28cf8e0c04c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3757f0af-b4e3-4c0a-88e2-9ce9a7308722_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_95c332f0-4ca3-43a9-b1a9-a16961c5b547_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_ee3861ca-37a3-46b4-be2b-4188132b60e5_terseLabel_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA, goal period</link:label>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_label_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</link:label>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_documentation_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:href="evh-20221231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:to="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_b6570656-f8a7-40c9-8fcd-b101090cb2ce_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum performance achieved, percentage of targeted shares earned</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_816c0816-7052-4c6f-9422-b2b6c3a11d05_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8e690896-192d-4dac-84e9-d73bed9ca789_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4eb58147-4ac7-4c4e-974a-af5a63fa5586_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodOneMember_1425df28-1377-4643-83a6-3248908040d5_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to January 20, 2025</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodOneMember_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period One [Member]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodOneMember_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodOneMember" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodOneMember" xlink:to="lab_evh_PreferredStockRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_863d113f-2648-4974-881b-12d36d3b26a0_verboseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2bdfeab2-38e6-4d7b-b9f9-d6dab8bb1d59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e50e8646-966d-43e1-948c-b747ed37ae30_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_09eff04c-5e91-4ff5-86f5-8eb149f96124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8ea249e6-f342-42bc-9d58-5cf878ac5b69_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_e3c3aed6-f9f3-4483-bae1-43c6ab2681f9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5775d66b-ebc9-4f1d-a8d2-28469f1cbbf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a9ab6ff0-b6ea-40d0-b867-c88717242aa5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodDomain_d56ff993-a694-4fb6-97bf-ee3efd0ae5ae_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Domain]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodDomain_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Domain]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodDomain_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodDomain" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain" xlink:to="lab_evh_PreferredStockRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e5ac414d-f49f-42c3-a4c5-3b1ed0bbc304_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_1f379259-da40-4eec-9842-d8a52349ea76_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20221231.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_85245aad-f113-40f6-b07c-82ea57b659bf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5dcede52-04af-4d39-b39e-d2a8c9f1a773_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_505e0869-2c94-411d-8f08-0ec0316cf1d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_c58b165c-7dda-4246-bf86-e0939f82d946_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings not paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Not Paid To Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Not Paid To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_3bc831a5-736e-447a-9aad-e939a4f89540_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_90b71dda-b1f8-4b78-89f1-efaccd8c0e84_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1f0a8141-1c39-4897-b5b0-3743cfb206b9_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_d14bd17e-6e36-4065-9e61-667e159f5109_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20221231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_f6c48bde-1d92-4816-bbc6-4273dbfe186b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_116df46f-4284-43e4-88b9-2199ba2e6d50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_42bcdeda-7c2d-47f2-8716-ab364f851754_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_21dc1878-6edb-4930-aa26-2fdc150effa9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_d34fce2d-adb9-4091-9967-d87e19b65f67_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20221231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_40c8846e-3df8-4ed2-bcde-8a130773efc4_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_6338c39d-d0e2-4831-99a1-1447b6851559_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20221231.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_39fd861d-7d2e-41e7-b504-d49c09be1df0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits (shortfalls) on stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_c34e58ef-e47b-4761-a9ef-f5b745ecf62f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_62a67b82-8c0f-4f11-ae43-bdc9f28fe226_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion issued (in share)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0daa9cd8-78fa-458d-ae99-f8bc71a1bf41_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9768c4f7-de75-4040-9a93-7ebc8d539650_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_7a7b55a4-bdce-41b8-8347-bbd671358bc9_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_779cf2b1-e4a1-4ba9-bf6c-02f16b0700b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_97316b87-8e65-4b1d-a4c0-eab7da9c0bcb_terseLabel_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward</link:label>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember" xlink:href="evh-20221231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinitelivedTaxCreditCarryforwardMember" xlink:to="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44f1ced9-45ff-42ab-818e-cf8fa14f58ed_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_f55ee40f-bd2c-4313-b7f7-517d42110f05_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bdddff64-8047-4436-b0f0-b060336794a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_02901324-17af-4b97-87f9-aa17032112ec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e1b8f681-e7db-422b-8443-428b28125bd0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from (provision for) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_eeb34079-7589-461d-b20f-3ee3e9706bf9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f6f1c0bc-5ea8-4fa8-a5f2-a0893ab046cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_140899e1-f043-4dd0-a7ff-7634337c1c82_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ec4aa739-63f7-4d42-b26b-9cb14cb805a4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredFinancingFeesMember_d7d15a27-0d0a-4589-815e-d3d355aff0f1_terseLabel_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_label_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees [Member]</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_documentation_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember" xlink:href="evh-20221231.xsd#evh_DeferredFinancingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredFinancingFeesMember" xlink:to="lab_evh_DeferredFinancingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2cd65a48-0aca-4fbe-a39e-7bc3b99c1023_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_5a9d2457-4372-4124-872f-90991618deaf_terseLabel_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4th Tranche</link:label>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:href="evh-20221231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:to="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c6a82f6-14be-4192-8a6e-64530a66d489_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_8401e2d8-b323-4133-b528-15f698a9c66a_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_86d59833-7c29-4a64-b6ea-d7f6cc02f7e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_c3d07f80-e5aa-4386-aaf3-4cd6ae98ce44_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20221231.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_8b19ba47-b0dc-46b7-b6b6-58be87145d35_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development Costs</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_7bfa4b70-b2e8-4748-89a6-c8987a510d87_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20221231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dfd53321-0e4f-4d49-bded-b65ecc032311_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_91de5905-6db9-44ac-a624-dbb23967bae0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d6a61480-0361-4812-8999-21e22f9a8d8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4bc05615-0dcb-4dd6-b488-cec7ce54e9a7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1c32d5cb-0575-4d70-b20b-35703fa9a100_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8b0edf87-9687-4993-86ef-f411944d9334_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_25330960-2f9d-47b9-92fc-91fade9c8439_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_9a30a621-cdef-4a7d-b800-3c8954f1fce7_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_6d29abad-f28c-4373-85fb-ab862f9de0f0_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_45338300-dcee-4361-b055-2b979d28074f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (credited) to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_643a368f-157e-448b-8ef9-dbba8eb37d95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_09c4f905-b0c0-4faa-8d7f-2a4fd2a4c09d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1173e3f-3ce7-4336-8aa6-f177ffa31772_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3b652d8-0585-4c22-9271-0354dc65ca49_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09f93a85-2b8b-4caa-a31f-85d6369f104d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9353f204-c75a-4ef3-8322-b28937b1edd2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_43dbabbf-ce46-47e5-bdb7-0c1db983756e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_03497b69-beb7-4b55-a9c9-25731794f8cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPricePercentage_28e26325-2265-44f9-bdcc-225d6a220772_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPricePercentage_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption Price Percentage</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPricePercentage_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption Price Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPricePercentage" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPricePercentage" xlink:to="lab_evh_PreferredStockRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TwoThousandNineteenMember_90d4c265-0000-4ea3-8c2c-0fe6eae23596_terseLabel_en-US" xlink:label="lab_evh_TwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_evh_TwoThousandNineteenMember_label_en-US" xlink:label="lab_evh_TwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_evh_TwoThousandNineteenMember_documentation_en-US" xlink:label="lab_evh_TwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandNineteenMember" xlink:href="evh-20221231.xsd#evh_TwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TwoThousandNineteenMember" xlink:to="lab_evh_TwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7d8fea69-1803-4564-b30a-be82cfa6a123_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4e58f33e-76dd-4fa1-ad90-f3da1f404fd9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7ea4dfe6-12a4-4204-be73-41d0d8e668ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a51f23e9-0b3e-45b6-9e0a-5331f3224a27_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8896e56e-89b5-41d5-983d-a338d344b03d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8f660c94-8991-4c68-95ea-9f2083a42bc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_f68385de-3cf5-45f4-9cd3-d946910c2b9a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_72fc7ff1-7e8c-464a-ad60-b34a2b28bca8_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_630ab3bd-dd40-43f7-8dd3-111f34e020ae_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Receivable Agreement</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Receivable Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_08670ca4-7534-498e-90da-981ca7da711b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ab26c902-15a8-4db1-8a69-040e846268f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_53553801-ab3c-4ffc-98a1-74d3083ee866_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_174834ea-9d9b-4b88-9091-5bb8457c3d0a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_66eb9bcc-2ae1-485a-80c3-7235ab0febf6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3eb264c4-558a-47d2-abf2-a9d7c29f9458_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_9bf5a870-0c4e-473a-9955-ad1e04806914_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_7c05e47b-b7bf-49c8-a98b-459389b4b2b2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d2045db9-b5a5-4370-96cf-60d366c3bb1d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c9c86d2-4a9e-48c4-a80b-6b1c188b9365_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_65fffacf-d434-4f5d-84c6-5fc581f90a04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d926440c-3f52-4b74-b055-387afae84195_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_5952e547-8bb4-40dd-9689-266c696e1c69_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims paid related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_fb98bd9d-21e9-4e78-b3bc-79e7195f7d3c_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_80b36266-6289-4dff-9ef8-0e39498a5bb8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_1b9a036a-58e5-45ba-95df-c5aceea8345c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_00f03539-b148-4c03-8f30-075200771e08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_332eeaa7-14cd-4d2a-96a2-a4f38e58a58e_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20221231.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_23addc6f-be70-4cee-b6c1-e7f755adc172_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_4fa67721-e1d7-473e-9fff-f033b41eef07_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e5acdd48-4112-47f4-bd99-d8a00ced4267_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_55166a66-05e6-46ad-b78c-492dcca3ff11_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_72d662d9-52ea-4831-9145-b0659ba36a1c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_118d3b0f-484c-4a47-b174-fd21c6276a35_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4e39d88d-fa61-45ed-85e4-4c73f90113f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9e82347b-3aa7-4b2d-b369-d0ad1d079df0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c52c152-54ef-474b-aba1-ff2a53a0f7e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_d786cc29-da1a-4907-a684-97c1bd39042e_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20221231.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8bcb1043-9527-45fc-ac90-ce70c4bac80e_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_fa167e60-be27-4920-8d57-2976a15e6763_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8bcffe43-92e2-4636-80e9-c1d7b9b57a87_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_deadd794-eeea-41f7-8b52-7bd1dbc64071_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2bac551e-3cbd-46e3-8209-86578c5f072a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_ce4f8eba-e4c5-42a7-9913-1d2309487534_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest deduction limitation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_aecf2192-ff70-4329-b398-a9f967a3d837_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_d31e4f83-9b15-4fe4-8c9e-6604045d770c_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days prior to any junior debt maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_label_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_documentation_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:href="evh-20221231.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:to="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_28529d6e-ca88-4fa0-b375-48370626e75d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_c92fabe3-6f4a-4067-b679-06aedccb1741_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_fb5a61aa-d45f-460a-9510-80212752e739_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_12d521f5-dd04-4cbb-80d4-303884c6886c_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_2e7dd02d-3242-4120-8695-67ecc0b8eddc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_5553ec18-dbb2-4529-953c-5a8a4a139318_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_55279684-a85b-40d4-839b-abdfed7d8492_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c033d254-dd65-44ee-a986-19a857f72f96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_359647e0-1fb2-4954-8f48-68575ecab5db_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0dfac71d-14c0-44de-a1e4-ecf6b7e2a8df_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fe9bf1a-4efe-4d2e-80c1-465dd0672319_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_fae703e1-45eb-4bec-a725-0724358b671b_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20221231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c4d7ceba-e139-4b65-a08e-5a7a2b1b37df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_555e5ddb-794d-414d-a80c-fe1459d0d0f1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_fe7894bc-a4a8-4924-9d20-fe0d66bacd2a_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d08504e7-7ace-409c-be21-21101cc60a57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_2d68f300-9a71-4ec3-aca5-e6e3f47c1a9f_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_65b71898-cb8b-4f85-9704-25764dd40ec7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_ff9154fa-e676-4e9e-85f6-ce7233e38ccf_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_ec827d0c-c306-487a-bb2e-4266f58e2056_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on discontinued operations</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20221231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_acfe9736-1e7e-49d7-bc87-ad56e03d04e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_5932c041-cf1a-4f81-8aca-01963257d716_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_6b7d0b5f-bedc-40ba-a6c4-b09f2916f294_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e761443-5a8a-4136-b02b-ac4e2f7ac096_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ee409d00-ee28-434b-8d91-0eaa3080fc73_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_baec5341-5236-491b-a882-8e42904982c4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_51f63b08-1daa-4af7-9cdc-2a130b7a6136_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f59e2e13-b4c6-453c-b425-3418133f719a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5a982b7c-aac2-4dfc-a323-2f47a2c81efe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_0c1a9421-cb1b-4342-a669-0d2ccf2631d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f6ec84de-675d-4c6f-9342-9d5466214b77_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d75e5540-a1f2-48b8-8b57-40647d0f6334_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementLiability_732b4116-0443-4cca-9f70-6cfcd0c54901_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRA liability</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementLiability_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement Liability</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementLiability_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementLiability" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementLiability" xlink:to="lab_evh_TaxReceivablesAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_dfe207ca-eca9-4be8-bc3e-1cd3908dc8c9_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20221231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_98a8b46d-15be-4e4b-b8bc-373d29ef6a83_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4bd10d8-ed92-49be-94e6-51d8af9ca0f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d05256d-7a62-4158-b103-27f10123c062_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e542efe2-e0ea-4fe6-923d-da271d64e5d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9e7b0ff4-a930-4496-914a-7dd30669f5a9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2225f2fc-1f85-4dc0-9ad1-a62c4d4d6e7a_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ec4cb4b9-d031-4c30-9646-8d8944d67df5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_03ebc7ff-2388-4a89-b626-584abfa95ee4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_69d3c3d8-a80c-420e-9a1d-58b8cfa839b7_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_44de7ba2-7e64-47b9-b75c-0a3d6fbc03a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b7984215-51ba-4da4-ae45-782684833312_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e1426c98-2278-4b0f-8c35-391438d98921_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8436e673-9cc5-4d7a-b309-8a55b0f9fc12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodThreeMember_06030427-994a-4210-9627-5be969924881_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to January 20, 2025</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Three [Member]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodThreeMember_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodThreeMember" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodThreeMember" xlink:to="lab_evh_PreferredStockRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_ce4f8d87-6921-43f1-b3d7-e31775d1593c_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_63e05a4e-d4a2-4eff-a17a-2f508a9526b3_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (in shares)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_6c476c97-1edc-4261-9391-32b26a5a3484_verboseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Stock Units (in shares)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73426d0a-04c1-4365-a15c-1fe0d5a7963e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16709131-e22d-4593-8809-cfa751d1e49c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_081efcdf-b29b-4e4e-90f3-c792354cc42a_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20221231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0ba4c34e-0582-4993-be4e-ae3be93acd71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_502c644c-c7fc-454c-847c-d1f02a85689c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e39fd997-7e1a-43ab-9bf4-a3343629c9b2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_beb18d3f-a97c-4a81-a7de-61d10ef2936c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_28b292b2-22bd-49a9-92e8-ad9a39c5d6fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets and consolidation</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_ea7b92f6-b2f3-4887-acb7-a550035309f3_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_c93d4dba-4645-4176-8cc1-b995246e28b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_9b6a5214-03d1-4bbf-8192-da9418cbfa15_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_752fac73-4608-4e2e-b42f-368638521f2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9c34b757-7c8f-4631-a013-057fc6497826_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8846abca-d1d2-466a-afa6-3329fa89c3b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_bc34466b-22e5-4ae0-858f-c7a2aac306d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_48ef8327-3e77-4ef3-8fa9-75a756826b19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16616051-906b-44cc-8e80-91aa38e50efc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_b88b0d67-a370-40f2-a884-d75f1dfad6ab_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance period</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Performance Periods</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Performance Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_b9b1f16e-5206-40b3-b9d6-5ac09e5b2a66_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f35b3b3b-1025-45c2-ac7a-2da1c97375e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9cc06329-cdc1-46ae-9382-43c20d7bc650_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_961fe8d5-2988-4871-aa8c-1ad2ceea04da_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_bd229042-7465-41cc-ae3e-1b95e3075046_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_39ee7ea5-93a2-42f2-927d-9d96c48dccdb_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8749fd87-d02f-4c1b-9c1e-02c9a3f0ae01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d2f4ce43-d25b-45e2-bc69-f56d26bb9be7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_fc44cdf3-cceb-42e3-85dc-3d7187b851e7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_0df18b0d-0bf0-41eb-b1ef-aaf58d33e8eb_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_763edb6b-657b-45b2-a5f4-1d79dd16df22_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_196b9470-b0b1-4b41-80cb-7b7293db655f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6840e7e-34a3-44ab-9cc9-3262aacf2c5e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_63c424d8-5821-4d3c-bfe2-643d228bad11_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7a24432f-758d-4c8c-916d-2a0a61fa9a0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a1783a7a-36ed-4be6-9e20-e1d8467a7d5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0b4f1bcf-0d05-4358-a460-2aeb6e0be724_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BrightHealthManagementIncMember_e34975ab-f876-4f7c-beca-4ad18fa37205_terseLabel_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc.</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_label_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc [Member]</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_documentation_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember" xlink:href="evh-20221231.xsd#evh_BrightHealthManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BrightHealthManagementIncMember" xlink:to="lab_evh_BrightHealthManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_1f99b7c3-96a6-4f6e-94ec-c9628e04dae7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_09c0a0e5-6a21-4822-a0ca-26aa233675fc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4c6dc674-39fc-42e9-aa66-77c51ee35797_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7a453b9c-7ff9-4e8a-a87e-44c8e0593af7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e29563ca-cb47-4a1c-a1f5-50933dee8ef0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2nd Tranche</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_74bbbbcd-0788-4079-829b-5b89e5e4bc1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_743a6878-a135-4c53-9d5d-fd9e8bb28eb8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f3467bf5-749f-4245-818c-9a474a4290c5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_557e0b41-74f8-40e9-8846-ab793a4a2ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d10a1b54-9410-4273-be7e-96169b90196e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_5067604d-dbe7-469e-a2c8-7c8d43e107f8_verboseLabel_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:href="evh-20221231.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_01669953-be69-4c57-8500-67c7d4328009_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_dff4ef18-af19-46e3-9e03-4517c60f4333_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_bb5e6baa-3978-4608-990c-3192131d6533_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_73047749-e474-41f6-bc77-3e138254aeaf_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit of net operating loss carryback provision</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_deef32a7-49f5-4a01-bbaa-66a1d2a4c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e09b97fd-5950-4b89-a8d2-808d4dfd419f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_06510860-f629-4433-9504-bd18e0c7165f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b9df0033-b6f6-48c7-8430-2bb4b99c8733_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_46a37eb7-554d-4209-8efa-700d830d9593_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_45cee09f-509f-4c59-954f-068d1fd06ce9_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, share price threshold (in dollars per share)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:to="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_27516803-f082-4fcf-9275-694190aad034_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_91312f2f-affe-44a9-a994-63a4b86debde_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside basis differences</link:label>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_label_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Outside Basis Differences</link:label>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Outside Basis Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:to="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_068fd486-af15-4f85-9bec-0c9abd440233_terseLabel_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from transfer of membership</link:label>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_label_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Transfer of Membership</link:label>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Transfer of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossFromTransferOfMembership" xlink:href="evh-20221231.xsd#evh_GainLossFromTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossFromTransferOfMembership" xlink:to="lab_evh_GainLossFromTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_99c5dec5-5881-48f0-9a91-e5ae33c65be0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_c31c186f-7319-48f9-bfbb-821f39cc9ea5_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ebfdd9e8-e7a4-4aac-867f-bb86251bf675_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_29602eff-04af-4b2c-b6ce-dfe95534b12d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_2fc4ae44-315f-4835-995a-809fc0509d93_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20221231.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ee0c0c97-770e-4a0e-ac8e-5f389798aafd_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_d70ba4f6-fdbb-4926-aae3-ee0000470518_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_deb1dd56-16d1-4217-a944-f39b543a9ece_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_541cd1c3-6395-46b3-991e-c96ff1b3d615_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_78a3495e-3688-4cdb-bef6-799000b7896e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fdeb892c-72de-4831-a8f3-132520fcd106_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_d917a0cf-01b3-43eb-8202-1c3529c05a2f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5fe9d38e-ebc7-4b7e-bc34-bfa8f3d92f9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the U.S. Statutory Tax Rate to our Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38e82d98-7069-44c3-af4d-0d4591564c81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_45ab675e-c0e2-4406-a8d2-10cf8f3f4e6c_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20221231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_148ad222-9ece-4e33-be70-347e1853cb63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Costs Associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c9fb31ba-746a-4d51-810f-cd9984a1751b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or input ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_adf26ba4-6708-4aab-b541-d5f09304ae58_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_6d823ecf-9624-439e-8e53-5619703037e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_25726980-0e21-4306-924b-4d381bb582df_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_27653675-e43f-473e-98bb-a1585ec6432e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_bee7c01d-5e2e-4a61-aa38-e6f650e1cb8a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c067323-b929-4e98-b3e3-235aecf0abc2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7aebac-469a-43ee-b375-caafed9435c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_77104f7f-2266-4f8c-8b26-266e9f531f99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2d6e9c4c-e7e1-465a-8e7f-1c5fe6789dba_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_eb0a8f49-9871-4532-871c-54947ccca5e3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_99e36920-fddb-4a86-9ad2-56f146cf8ab9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c626b69d-dce7-4602-8879-d7a31469f4ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_67554ea3-a879-4e37-a334-beb8a7f8e9b0_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4f839955-1c6f-49e0-a991-b27a1d54cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b5d1996f-1c35-400f-bc90-0b7163c8c980_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_9e1eed01-8ee9-44fb-b3c0-3144653511e1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued net working capital adjustment with business combinations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_b6626821-aa9f-4855-ba41-1590a0cf612c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_37faf290-3de3-45d9-b560-92dbc84107b3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_1b1b333f-a084-4459-adb8-86427b1954db_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a38b6306-869e-4f16-a029-3a21c4cf4524_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_83cebea1-615d-42f8-8414-54e38f005933_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense_08bef6ca-33c0-45fb-bbdd-1aeb5eb22406_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract fulfillment costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33f7aa2e-e0f8-4142-80cc-a4c10314925b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_075eed8b-dc8d-4689-8fd0-1949068014a2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_e06a0e57-89cc-4907-80ff-5cf808dc658a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and repurchase of 2021 Notes and financing fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_7b1c97af-d052-4885-bb70-6c91edf2c2d7_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and repurchase of 2021 Notes and financing fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3450ccb1-5d0a-40e8-ae5e-f17c3aa63c34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_ca7b7010-08d1-4cae-a31c-02773520cbe4_terseLabel_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015</link:label>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_label_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015 [Member]</link:label>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_documentation_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member" xlink:href="evh-20221231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PeriodsPriortoJune2015Member" xlink:to="lab_evh_PeriodsPriortoJune2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2d44551f-6ec1-4901-b5db-f76cb14d2d4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_227a97fe-434b-44ae-a8fb-5de3d5718858_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d224c813-8a00-430f-a5c2-b5a6b824d034_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_b2c9d269-9e6d-4a5c-b8c3-5af943e8ed06_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a478e2d9-32a8-439a-b621-ca99f9586cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b027218a-5191-4e1a-a912-26d33f96dfcf_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_fbc541d7-985d-480d-baf4-9db78aabea6b_terseLabel_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with debt repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_label_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_documentation_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:href="evh-20221231.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:to="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_36b1b9dc-de0f-49c6-bd5d-8a50198f79a8_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax benefit percent</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_8fdb48fc-f820-41a3-a822-f304f6e2c68e_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible transaction costs</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Cost, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Cost, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4ad09f1a-bcd5-4661-99a1-e59f238d917e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_721f9b12-e9a2-419b-9063-1fe4df3fd421_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_4ca871c2-5746-448d-8c67-41fb507bb219_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2cacf052-552d-4cf5-b650-ddcb0954be74_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6fa7bef-084c-4abd-9791-c3c6a668569d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be4c808d-3c97-45cf-bdc6-d4833d1ed047_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_c708ca98-29f2-45e4-ba87-ea2e3fbdbd95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Information Of Performance Based Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bc6031ea-1d4b-46c4-b4cd-b9aec07db5df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_81e790e4-00d4-42e4-b425-e958e6ca8b99_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0bc5cf34-3ed8-4dbb-8c28-355582ed6465_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_654d1327-96f8-4f96-98f5-98bef515fbc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0dac9eca-cb69-40db-8091-28695c284053_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_12a4918e-6d85-4b89-bb99-72745f3cfa6a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_388ecf25-5caf-4712-a669-c4ec786601a4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b5f7c6f2-4942-4154-8b71-95ec92ba0756_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_282ff923-9765-48d8-a554-ff18bd3fd50d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_507bb29e-5eaa-4297-bfde-8d205637a159_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_65f45542-9c32-4a36-86c7-98577ec1370c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_18bd5986-080e-4532-9dd2-673870ef37c2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_ae598d77-40ca-4dfb-862a-4be25c0a36e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5defba91-bc76-4d18-bb11-9c88f558a154_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f183962d-0392-4f94-a2ca-0d20cb128527_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_d1ab5c6f-9af8-4fa9-8441-0275106e783e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76105c93-8d1f-461e-804b-74e9f46e4477_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2db9c598-5ff9-45f7-97ab-7d9e83ba8048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e3475be4-1538-4802-826c-0e254d8c7722_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7001a867-2e3b-44b1-a5bf-898ba9998adf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Purchase Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_21d55cc2-cb4a-439b-9ea7-99e4d4ffcd02_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c3fadeeb-b886-4519-ac08-101bb4113b8d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_666bbbe1-95c6-4602-949e-831a3c0ed873_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1be3c43-8db4-4642-9f13-e2992cc5330d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e2e64558-a486-4d0d-aba1-9f3f4e362cc2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_960eea32-5bbd-4f02-9f76-176397c6297f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_50c905af-620d-4f80-be43-684947709b5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_7dc78406-401c-4dc6-9d68-0357013fd52a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_f2526a9c-1e63-443d-a2c1-f4ff5ffaaf1f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_a2b221b7-aa81-4110-b2a7-fdb272b924df_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in achievement (in shares)</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_008f3002-06fe-40e7-bb07-61ad89c9c72c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_4b6c0bf2-79dc-4539-b374-feb1a9b8e304_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_82291cf0-97c7-4d6a-8e76-c8e658d7dba9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_92770622-d436-42fb-9934-033695b3301e_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_09184ed8-6ce2-4392-84bb-62d4dac8adb2_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_9385000d-ba4c-4711-a5bc-6db2fd0483d6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_89c05ab9-5856-413b-827c-bbf00e590e16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2cb8d89a-95b4-4e3c-b130-a031cb9a5fcd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockVariableDividendRateBasisSpread_ee796851-db27-4b6d-9a81-f0eee7de76f5_terseLabel_en-US" xlink:label="lab_evh_PreferredStockVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of preferred dividends in arrears</link:label>
    <link:label id="lab_evh_PreferredStockVariableDividendRateBasisSpread_label_en-US" xlink:label="lab_evh_PreferredStockVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Variable Dividend Rate, Basis Spread</link:label>
    <link:label id="lab_evh_PreferredStockVariableDividendRateBasisSpread_documentation_en-US" xlink:label="lab_evh_PreferredStockVariableDividendRateBasisSpread" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Variable Dividend Rate, Basis Spread</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockVariableDividendRateBasisSpread" xlink:href="evh-20221231.xsd#evh_PreferredStockVariableDividendRateBasisSpread"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockVariableDividendRateBasisSpread" xlink:to="lab_evh_PreferredStockVariableDividendRateBasisSpread" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_cff07538-2108-4654-835f-281c95fa6043_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d787e741-2833-496f-8c8e-0e0cea8beb86_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax sharing settlement</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e8339697-07e4-44de-ac0c-13a1f3f706a4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_84bc7049-a817-4366-9049-b89c83227d6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3181b33f-8009-4f3d-a550-441549b1e6fa_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_6197fd29-a282-4231-9ead-a81e2218d26e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0d8d27e2-1f62-48e8-a0ad-a954236e121b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5a4c7bf8-9a30-4b73-bd3d-a88616c38f09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_53814d27-5b47-4069-9f98-9a9d78d6bf69_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_c23adbe4-d17a-48d1-96a7-c352d8b8ffdf_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20221231.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_6048e989-d326-4740-9687-4d0fe2d2064f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2a4964d8-3e75-436f-951f-67edb5ceadf0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcc8499e-4d03-4b74-ba7e-880a8d3f17f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ec13ab01-58cf-4dda-8416-8dbe992ed0d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e86d1936-fe85-41cf-9727-1f247cad47a1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6087e1e4-506e-4a7c-98a1-5f312e3f5a7c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_9a6c7685-8e26-4f82-ad1f-8da9b5444789_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c786596f-cf34-46ec-b525-64088895eb95_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_fce1c272-a0a6-401d-9cdf-fb46b0306c2b_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest on March 1, 2020</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_label_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche Two [Member]</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:to="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4728c16e-40d5-42e8-9644-eb3ec212be6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1d3fb2f0-1eaf-4633-ad57-936c90c1e85c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_92ed3d9e-5cb4-4fd3-8497-044105171e6b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_31bcd5d3-fe9f-497e-857a-b25b6309e6a3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_284742ba-3862-439a-a897-5209bbb4da1f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_042487ac-c9e3-42e8-bede-52ef7433124b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fb5395e0-ffaf-4e9d-823c-41433c13cc80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_578ea0bb-40cd-4c09-a0c1-5ee5710f8211_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_fe40e0db-0a77-49c0-bbc3-0db3afb340da_terseLabel_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_label_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint [Member]</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_documentation_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember" xlink:href="evh-20221231.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderClassActionComplaintMember" xlink:to="lab_evh_ShareholderClassActionComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1ed88871-6f63-4bc3-afc3-031d433173e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f573c85e-5c1f-4dda-a17f-0c87102e07dc_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_5152351d-8ab4-4a64-ab11-7642d389b756_terseLabel_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Price Assumptions for Performance Based Stock Units</link:label>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:href="evh-20221231.xsd#evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:to="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_e2be94ca-3c6a-42d0-9e13-f50161acb6c0_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_1b88a818-ba79-438a-9124-f496b6d69922_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7f081e66-dc94-4214-a7b0-b8969d1c9b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_446769d9-0166-4aaf-9edd-6f14d64dceed_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cb2818e6-7c8c-4b31-a9ab-ea874765114f_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_76e45e7e-5596-4389-8d05-53b2959262de_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_36b3e849-4a89-4134-a933-396528238859_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_f0f8244a-8ea3-4f3d-85d9-e014e66047aa_terseLabel_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward</link:label>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:href="evh-20221231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:to="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_18183347-71d0-4b4b-90e9-ac1ea4026413_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a51bf01e-7878-47f5-b6cb-290a2a19a0c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_47c4cf09-6091-40e9-aad7-e4839f0b1ac5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5d477c70-449e-43eb-b459-2c26ea2d3fca_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_eafa7687-f617-47ef-a589-0e55cd38cdcb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_56e37b5b-6ff2-4875-8831-05e5aa4cba3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_10d1c3bb-5f37-4949-99ae-c8122d43c875_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d02a580-33d5-4a6f-b7fa-eab8796543e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3585aed8-0125-400d-bf33-5b10689881cb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_5700cc2e-a6ad-4748-aa9f-4e4a68816402_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract" xlink:href="evh-20221231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract" xlink:to="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_bd6e8ff7-55f2-4a3a-aee4-9b4831a89ac6_terseLabel_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors</link:label>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_label_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors [Member]</link:label>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember" xlink:href="evh-20221231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NonEmployeeDirectorsMember" xlink:to="lab_evh_NonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_5f7ea2d4-3956-4e35-b98e-99174fefb589_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty prior to first anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_5e4159eb-67d8-4e9f-b2fc-2934357f6855_terseLabel_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/decrease to goodwill from measurement period adjustments/business combinations</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_label_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Measurement Period Adjustment</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_documentation_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:href="evh-20221231.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:to="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_edb2f28b-12e0-49c3-961c-b24c3b591fab_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_8bdb9490-0759-41a6-a01e-7d2de7e997c4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2866ffdc-5fcd-467c-b217-66a75d7ae49a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_326efaa5-2479-469e-8986-0e1dd8704b73_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c849def7-c386-42db-b9fc-5d9a507ffff9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_821e37d2-61b3-4a59-a985-574150681924_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_89039bd9-a6ae-45d3-a49a-2e6b8cacf4d0_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_d3dac157-3bb6-4b7c-b49c-0b38dd06fd2b_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_65388c13-d455-4948-928f-00a1561c98e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6b8a6a13-8f58-45db-9bb8-55d79a07d787_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_81d46389-b994-436d-b25e-6457507d38f2_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_503395bb-ee46-4a17-9cd1-091dfb1f0a0a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_8813f0e5-0230-4586-bb5f-9d54d5db4459_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_5797ccc5-5f38-4c57-a12f-6900d6f13aa5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a2eeaa3c-72e4-486e-a221-f88aa7259f97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_4145da32-77b4-4691-8a25-80323448cf64_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_3310532d-b490-4491-90fb-6e0bd75d524e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_81d8e3d5-28c6-4572-8e1d-62439f6d9b84_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, stock price increase, percentage</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d5059e4-850e-4140-88b0-eefaa1f43a26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ac3fb6b7-45c1-4f67-aaff-7b3d59516db4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ed7ee9d7-c1a1-41fc-b43e-a71ca33987e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_883f75b0-6d34-49c8-8fee-8558394d1168_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_9a903213-6fb6-495a-ba09-9660e5c115de_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1de1ced9-1d1d-4ab6-88a0-787b37bf1a71_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0d7262ce-55a7-4d67-95fb-202459d6466c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_c42d532f-6654-4948-ae8e-593dbe138378_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_716bead9-d5c6-4e73-b912-8d7ecfcc80df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_f483afd5-a320-4c80-87db-3dc1bd0b6470_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20221231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_02c7a808-8a69-4039-be66-022ed3ee162c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of the debt discount and the issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_66ca7d4a-b9a9-4eb1-9d22-400e9c816f0f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_030162c7-68ca-44db-8498-5416f08384f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_cc498240-b858-4f42-8388-58a44ab0fbad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccdab39b-63c1-4235-88bd-9f3c839492e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_75425459-e2a6-474c-9472-8d840152873a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ca66aff6-4df8-4b77-92ee-29b97f68b294_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_66b24b7f-c760-4a0c-96a9-4312f9ff3dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_389cf312-b0d5-4b94-a0eb-4791c7e9097d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_3b2c6e80-2ee5-4dd0-b895-ec776a74e92b_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_1e405f28-28d7-4410-b71b-8e1eb5c0b9da_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_50b55e35-b190-4ffb-b6ab-8e3378989cdc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_390300da-894c-4b1b-8ab6-307aaec476d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7efca279-f879-42b8-86ab-56ccb83d64f1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_d181ef0e-bcd4-4097-9354-4a283f471e8f_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_94856794-b80e-4693-a9ac-12106dacbaee_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_e2205043-cb5f-46ac-b914-bb4ae91fc215_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_39aefc4d-3dd6-4375-9323-87f686975ea1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_4d509694-4e4b-4705-89a8-0bdb043ebe26_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e82ad5c3-6b00-4800-9333-6924522d0a47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_75094fd1-caed-47ce-9bb5-9dc02f645d5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of assets</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b4b6af0e-4657-428b-aee8-634a22886a1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b2b48949-d13c-4595-a2e7-5826264abe0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_1c739555-0d8b-4e4b-aa12-6de4e0159a0e_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ddfd4a13-4694-446d-9b4f-5006f9ad2e10_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_15733597-7ccc-4345-8b16-018a686d587c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_b3a47aaf-2f4a-49c7-8b0a-d3fd7cd01068_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_51e54da5-4493-45a4-9069-bd1b43fbb2a8_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_191f8800-ac13-415f-aa95-798f4ac16317_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_e9281dfa-5bd3-413e-9076-f063713eba2d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_69a39cc3-271f-4324-ae8a-7a67a2dc7906_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_4de777e1-c7a3-444c-8ad4-8e8eb18796c8_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_239a3d5c-7c10-4f06-a560-ea1e1a8fe93f_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20221231.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_7dc6c725-9bb8-445b-a2a1-258d5b71efcb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares issued</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ce1b1548-c6e7-4496-a76c-580864dfd709_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d84fca72-0907-4a90-b287-618e457b43cb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - tax positions in prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_44b6439c-1522-4c63-b54b-c480794ed921_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_36e7efb1-afeb-40eb-a667-dbb1b49ee5e0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c661111c-68ab-433a-bb7c-298fcab4b86e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_d82a38b1-e031-4ef1-9dd0-c1826cbc4172_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs (in shares)</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c2fa2b20-2799-43a2-923a-dcbbb9e4210a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_ec35f277-dc61-490c-942b-4c138c509043_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance goal threshold</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5bbc91c4-a459-4409-97ed-58449be3e192_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_e56de77f-6566-4be2-bbef-59c5fc8efde8_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage adjustment of shares earned, total shareholder return in top quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6484887e-f827-4ab7-94b7-01684c69998a_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_22f21b78-96d1-496b-ae46-6009bc3e3b81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_99288773-c9e6-40c9-a72c-2490a4a271d7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_a0beaab4-0cce-42e4-8fa0-f4bf10fd31c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_d02ad168-bbb0-4817-a3c4-665c12e5d5d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Credit Agreement including settlement of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_832ef652-622f-427c-88e9-4825fcd9c802_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2d62d955-28a5-4ffd-b59a-629a6dce6c70_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d3f95324-8c19-4adf-9f71-ce5efdb5ca98_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4bfa06a7-10fa-4fce-a0e8-17db2131c9af_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_18753537-d131-447d-b2c7-4c0b14a83a84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_39f97017-6bf0-4b65-ad41-9cc5871f1c92_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty on or after third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_3604d241-6f80-4e9b-a6ec-ee204f3b72b2_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80fc0ebe-9fb7-4a23-8880-751f6640af60_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_d76d28f5-bd97-4f6d-97a8-c4ee82588b1c_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6999c895-9577-405d-b1d2-0c4f727fbe88_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_024d3fb0-a04e-4af6-aeff-65410e779ab0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7e1c1b90-5016-4b76-9c33-952c25b99ae6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4aba543f-dffc-43a0-95fe-e6457dd974b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7fef91a6-f81d-4e46-b324-4d1cd9941473_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5c99043b-032f-4c5c-a0ae-5b4752142e31_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b9c7914b-d80e-4d54-81a3-f58025c8fd08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f0a0e032-b962-45bc-8a59-2050eb92d421_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_780fc381-5e74-4e90-a61b-9b9f3cf74103_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_de3cd1bb-e6eb-418b-b19a-837fc7d2d3a7_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20221231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_aad7bae3-7d7b-4cea-98af-e692eddea38f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_45af8b6d-f4b1-48f8-994c-72e691b73cae_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_52b04341-0fec-4dad-9a9e-b091b85a1780_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a96fb65d-7a84-4bbc-aa62-fd556887b6ec_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_08a1ed41-5ce5-45b1-9522-cdfec1d87eae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d8fcd8b1-a6b3-4360-bfc7-45e23379d1e7_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_d8014755-950d-4fdd-bb43-7b04e0e76a18_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a365ddd4-b61a-4cd8-85e0-579ca7d14110_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8d348e89-4037-4911-8957-da302ec7f3d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contingent Consideration Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_88b636ad-40d5-4b87-b971-0dba35700dd6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7a276133-73c6-4725-8b84-df1d4ff5e8a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d26eeab4-e693-48b0-86e5-8f6ac5b6680f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ad9b3dea-4cfb-4128-99a9-023f095b09de_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c89a71e5-745a-4c0a-aa3a-912fdcedfa76_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d3202732-b0f4-41f9-9e38-d2d94ed48e7a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_43877515-80f5-4a90-a544-8ab23429cd7a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0fbd838b-6029-411d-af20-ab0e9d4e1e8b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_de112e0b-a948-431a-acd3-f72a4bd2d68e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_0e6573f7-fb51-4b02-bddf-755f48c30f7d_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_12fc960d-92e7-4ee4-89b6-9c1d410cd88b_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_374cb91e-0be0-47d4-8845-2508d871bb2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6f45e8e4-b972-4206-ac45-7ddc1b749fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_720b765b-4181-42ad-b41b-fe7477a1b445_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_384accf5-dcd0-46f1-890f-22a5317d1da5_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_999ac20e-0635-40cc-9491-5bbd3192f649_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_69fc6bfe-96ac-4e08-a9ad-1b36aa573897_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_88face7b-23d3-4e48-854b-db4b78851b19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state research tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_c535607f-49a6-4ec4-813e-e8b8d7a60723_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20221231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_6b9a0370-983e-4ac8-b28a-760a07ca0d6a_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20221231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3145878d-d759-4775-9ce4-ca17dc82cb69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Techniques and Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_d1f12ce5-7e35-436f-bcec-b4a9f35e3242_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_aa0adcd6-6fe0-4ab9-8e59-fb2d84439720_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_f7d600ae-00a1-44ee-ab41-053488277384_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2ada9293-cdaa-4507-81db-2dec3d4f2140_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_301ca8ae-bf65-48af-81b9-ce78b5c60b90_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest on March 1, 2019</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_label_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche One [Member]</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:to="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ace54a5-7c82-4d9e-9147-67272e2a3e74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9b2eac35-799b-4168-80d3-0671e05bb2a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_90f8088c-161a-44e5-9705-251dc7754406_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_149e6cf4-bb64-426d-a14c-825b5bc4bbba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_be7bdd99-97e9-47ac-802e-bb26b7b3460b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewCenturyHealthMember_21fe543a-0b6c-4aef-b938-48ebe5946c60_terseLabel_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health</link:label>
    <link:label id="lab_evh_NewCenturyHealthMember_label_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health [Member]</link:label>
    <link:label id="lab_evh_NewCenturyHealthMember_documentation_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember" xlink:href="evh-20221231.xsd#evh_NewCenturyHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewCenturyHealthMember" xlink:to="lab_evh_NewCenturyHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_42033b84-4809-4fd3-ab6b-488e5941509e_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:to="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2716f317-fc5b-4cb5-af04-ff6fcf6cebce_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_2b99c7d5-b969-4e76-af5a-eb9a2253d546_terseLabel_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_label_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_documentation_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:href="evh-20221231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:to="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2ceaa25b-daea-4783-ab55-2d0d596a63a6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5001fcdd-2800-4986-816e-ef63619d1cfd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cab72194-84f1-4b92-93d3-588842f3249d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c6b5dfd-d7ab-41e5-8822-9d6b4a389fbe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b83dc4fe-127b-4f85-8c9d-8788cab8a1f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a2448dba-8cc2-4467-91d1-a16f000149d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ebddcd24-1cc6-4e15-8c5a-630eeeb93a78_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_4d8ffbcb-a261-4060-9101-09b8bdd3e2b8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_968d13d6-1818-418f-bb9d-fd1efc95e42c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8ce17923-c158-4b53-b4d8-7a0d679b2f74_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b816b963-91e8-4cd7-b6f6-7e867e993fd1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c85e95c5-b687-42c6-99d7-44c1b942a2cd_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_24c563c6-4eef-4b42-bdae-6aee4cedbfa1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d4c604f2-65b2-417e-9008-af0e443227f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_993f5724-f798-40bc-a03a-a259586adcc5_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_582ea5bb-f193-472c-a957-34386b58f623_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_2ff24c3e-ce55-49c6-b6ec-8ceef9f63185_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension after each period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:to="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_fe60df63-c703-4b89-bf25-1285d03fc910_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0c7be8c1-9ac1-404a-a33b-ba5a863fe490_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodFourMember_99019fed-3a6c-4a06-b217-c78cb37a21f2_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 20, 2025</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodFourMember_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Four [Member]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodFourMember_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodFourMember" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodFourMember" xlink:to="lab_evh_PreferredStockRedemptionPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_e14e63ac-ac39-4381-a1d1-bc4d2ac13a6d_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b69c2418-092e-406f-ad07-0f9487837e4e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_51c9f33e-edb0-4fa5-9908-546108093a43_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dcb4cb06-c582-4fad-a26c-15cc5b561704_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cd2dd721-9a8e-4b8a-8b5f-20ac41093975_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_1c60c87d-d333-42d7-92d1-ad7547546d68_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20221231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e57f1fe4-4b01-4448-9121-af2d4d962b04_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_5a55c1ca-d7d7-4125-88ab-0e7620c9c16b_negatedTerseLabel_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPG acquisition</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_label_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_documentation_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:href="evh-20221231.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:to="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dc90347a-abc2-4f90-ab43-bde89c1c2d82_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a50cee19-2f03-42cc-bec5-d9360cc86e2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2020f83a-40cc-4a35-945e-5787548c6622_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3cdeea80-e031-42ca-9347-042c6fb2800f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_afd5932f-3b6e-456c-8537-9d25134098fe_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_923952e5-cc4a-41cb-8e13-5c4d8fcf40b5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SecuritiesPurchaseAgreementMember_fde9daab-e85f-422d-b044-3cb0362c0ba9_terseLabel_en-US" xlink:label="lab_evh_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_evh_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_evh_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_evh_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_evh_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuritiesPurchaseAgreementMember" xlink:href="evh-20221231.xsd#evh_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SecuritiesPurchaseAgreementMember" xlink:to="lab_evh_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_8e8bb806-d3de-4fbe-8c15-1e6b7809bf1a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc2e482c-be46-45b9-b46a-c52ea18528a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a3951433-e808-45eb-8eb0-192ffb18b58b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8b7faef3-7591-4cf8-a625-f116ab975c0a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a6fad5cd-ca63-465d-b535-1281f5c0cc36_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5edf4aa1-45c0-4a2b-ab83-0f163d817404_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f7bf1316-888f-47ab-93f4-9c4302823bd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d958ee99-f463-4bb6-9ee5-73cc1915b69b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_b89d8960-110c-4e47-9286-49cbdaf405e6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f2c1f254-b2a4-4a78-8012-05698d758196_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_20565c34-20f0-4315-8a26-26583a069e19_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_40892b25-35c6-4819-8d3a-95208d0ddd9c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_96146fd8-4ccb-486d-8ce7-98da355d2f26_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_121450ea-d11f-4813-b6ab-6d7f9a1b2ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_c0c74051-0f23-42ed-982d-887856329506_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20221231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_9a043472-b556-430e-a9b1-96c9ffe9487a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumRevenueMember_b4c0de57-e5f3-45ec-8bbf-04d58d8596b7_terseLabel_en-US" xlink:label="lab_evh_PremiumRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue</link:label>
    <link:label id="lab_evh_PremiumRevenueMember_label_en-US" xlink:label="lab_evh_PremiumRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumRevenueMember" xlink:href="evh-20221231.xsd#evh_PremiumRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumRevenueMember" xlink:to="lab_evh_PremiumRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_27ecca46-288c-4973-bd67-9b9cf40d8e30_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fd184173-1f2f-4369-a5d6-56df6553a95e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_18360d27-7c4b-43e0-b8ae-1c4d9e2b727c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1b76eb0-3e73-4098-af4b-79cae079a413_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_634296c3-f620-452d-be20-7a8bb62fff46_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_bb7c84ac-dc65-41c6-a651-a4b4d01b04e4_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20221231.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_be8805ff-6c4b-4538-912d-ad7e149bf2fa_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_48542a4b-5de0-4c08-b459-8f5749338f38_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_9eade695-a6da-4e09-8b15-d509e67e637d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc5c13a6-69b4-445d-abeb-8263d3665aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_c294f654-aaca-445c-b007-7f17a3e799c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_b8579ebe-3a60-44ff-a713-2e45a0704587_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_9707acb2-5c69-4452-b9bf-85459ae47ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_f2899135-af7f-4dca-b1b1-093e185ba768_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20221231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50887603-c068-44c3-98c4-0819b55aefff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_f55d18c8-f3fc-49b1-9e35-0fc611032c78_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1d6fc7f7-4062-4fb4-bc94-d30d44f4e175_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fde5f4a7-4979-4213-9698-883f4e5f25c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e46cc15f-eb6c-4e8b-bfa3-70465cedbf55_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2e153c83-7fa0-4acb-b04c-36a6cd6b2896_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7c179653-e886-426b-8984-d2ac035bd7f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_96f92979-276c-4d8f-bcef-93cd8752e7c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Option Awards Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_05bb6864-04d2-42e8-a5b3-a26e51304ce4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_acee153f-0782-43bf-9af6-7fa7aab90498_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_5adfd625-f3ae-4872-a2d0-b954138206ad_terseLabel_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_label_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember" xlink:href="evh-20221231.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_A2022CreditFacilitiesMember" xlink:to="lab_evh_A2022CreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7ac69a0f-17e3-431c-814b-a95448200b40_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_04e7d0e5-08b6-48aa-9a39-ea645cb7c9ed_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_7f46c9e3-491d-42cb-9751-9b9db9f42fc1_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20221231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a5603eaa-2b21-4a17-a9f5-ac3a360b3441_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_0ac43f6b-ea15-4946-8340-806968df228f_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6ab3eacb-cdd7-4990-b971-a782fb17857b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f4baa21f-32dd-47a9-8515-62624a39a759_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2af37743-e937-41fc-9772-fa6de665977b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_4c14349f-d91f-4fb9-9b0c-6a15a259722a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_de6ce2cf-5f17-48fc-a7d2-c39457724d2a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_40628569-2780-482c-95d3-355f5a2d5a12_terseLabel_en-US" xlink:label="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in dividend rate</link:label>
    <link:label id="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_label_en-US" xlink:label="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage, Annual Increase In Rate</link:label>
    <link:label id="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_documentation_en-US" xlink:label="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage, Annual Increase In Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:href="evh-20221231.xsd#evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:to="lab_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_93311903-369c-4073-b602-3afbaca52d1a_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Total</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ec8e6aef-7f9c-4b07-9e3c-39e3d01721ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_d5fb0c41-02be-417f-bb93-7aacb82fd7db_terseLabel_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPG</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_label_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP") [Member]</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_documentation_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ImplantableProviderGroupIMPMember" xlink:to="lab_evh_ImplantableProviderGroupIMPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_6d78642d-44ed-4f31-8245-7a7a127d4416_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_6eef21bf-8b14-4fe6-bcc6-b58e9c0d30b7_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20221231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_80179658-b621-4172-b0c3-c5d3a043b8c4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_b0078b16-0297-4b09-801a-8e1fb97c0e29_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20221231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1f705f26-dee9-4a64-8354-eec6f95c42e0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c65305cb-506d-462d-86fc-7c0a5ef2a0bd_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_b8d88471-89d4-4018-a5f7-5cfe2628a870_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (credited) to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_90055d81-dacc-4f0c-a73c-11f094f35992_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bee2dbb7-4e27-413d-afd6-bc73669026a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_7a729b98-06ff-4e6b-836d-8d8bb5df4391_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3efb1e61-deef-4851-a0c0-f6770068791f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8176b19-fcb1-45d9-b950-270e25b8cb8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd2e7103-fb88-4122-b4fa-043e4414f469_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_87648bda-d1e9-4207-bdae-f5cccc41496e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_98106641-d4f5-43fa-90be-85fba9413c5e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. state income taxes, net of U.S. federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_3aed66e8-8171-4dca-a834-753f597a2634_terseLabel_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_label_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]</link:label>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_documentation_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:href="evh-20221231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:to="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ac1a769c-90ce-447b-866a-2c5560b51d01_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fb6faae-3b43-42c8-ab1d-f0a25489723d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b14ca389-65d3-42d0-989c-d9fc325b8155_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c85337fa-2c50-4cb0-a378-7dacb880ffbb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1739a53f-c8be-4946-a82a-1199667cb718_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2292418a-26dd-41d1-a30a-f350bfee7070_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_f72c2db5-9679-4bcb-a0f0-b7d3647673f7_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Results of Operations (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_78090f84-e7e9-4b44-94cf-9d67090a7eec_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9f516908-36e6-45c2-8d14-0c59dd2ebd4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_d2ee98e0-8d74-4d21-8e7e-a87799c0501b_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_db17a76d-fed6-43ba-b5c1-7c23b3b5fcac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited / Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94e2a383-d903-4209-a746-60a7e9bd0a3a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d2f44376-e70f-4c85-81a4-15525a7880ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_3c312817-6889-4f0c-a607-86f26a280bde_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c8c6dc5d-7577-4ef0-a958-95b04164525d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_00c8ac45-0081-4a1e-b361-332ac500b378_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_de4a09d3-ab31-498e-9e0c-256298fbbf06_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bc9c8445-be66-4d12-a849-b40079fc5686_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fd47f226-db74-474c-aef1-ee44c27b3f39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_44bc36b7-f041-44e3-9539-f5a031c5c28c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1418b237-d366-4353-9928-d6599b528d6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_7e71a2af-34a8-4abf-99a1-56e886ed4c7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_50e5453c-d51b-4fa8-9ffd-f336ad5eeddf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_b691ce19-47b4-44d6-81f4-50185bf100a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Restricted Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8a2cd18a-fec9-4e2f-9828-febeb30296de_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7126e5c1-14d9-4ad5-9258-05a082e0ee11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e659da0a-d242-436d-bdf5-048b0fc8bb0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0af68fe9-85e2-42e0-8062-b4a3f157e92e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_e178bbe7-c5d8-4ecc-9e3e-903ea6c4bc82_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20221231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312025Member_39c98460-910d-4503-ae6b-71d5f735f166_terseLabel_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_evh_December312025Member_label_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025 [Member]</link:label>
    <link:label id="lab_evh_December312025Member_documentation_en-US" xlink:label="lab_evh_December312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member" xlink:href="evh-20221231.xsd#evh_December312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312025Member" xlink:to="lab_evh_December312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_ebf9a2f4-dc8d-4ab2-9ade-b2cb5d233caf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6a590bba-b6c5-44ee-a159-3b17226b2cc1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_7e20d1cc-cb48-439d-901a-540fda1996c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ce2222f7-cbcd-48f0-b75f-cd004c08ef2c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_f12ad6c9-8ab1-423c-acc9-0c3bd6dc0bad_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1ee28f66-e296-4060-829d-3c8729a848ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8872d0c3-cdda-48cc-b181-0a7325cc9107_totalLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_4f4be604-d61e-4e08-8da8-3e963d77c813_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e342768c-02eb-4b49-ba7c-ec97cda49d09_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e6f5e162-5ee2-4553-bf10-36ec086c32b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9e233537-7017-4c56-80fc-fa623e8d3ae5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9aeb1177-5f58-4240-bf2e-083e1441316c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_855c0357-9631-4947-aaf2-495fc9c979b1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1ad63f00-a298-4191-b866-5dbeaab8b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab34bd30-22fe-4656-86fe-32c517f51054_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_38ce3d77-4384-4d51-a471-81cfc16f9f9e_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20221231.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_61fa06eb-c53c-4737-8e05-9bf8e8fcff1a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1571efda-3ec7-4502-809e-30e0981ef573_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_b7ecc421-0c89-4d14-b04c-73422750b7de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_25d90806-c2a5-4972-a32d-55590c193200_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d48f60e-7983-459f-9ff4-b9ecca61439c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0e1385bf-32b7-4ebb-a6f4-c9175c0b2d9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_eae3cf0f-0a15-4b34-a65e-f8269afee5ac_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3e69e52e-72a8-447c-b0c5-bdd2b4c0e90a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_65a52ab3-9adf-4f5f-ba8d-aa9e9e2a6696_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning-of-year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_d99d5cd3-2952-4f7b-aa1c-9cb1744372e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end-of-year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6b195246-16e9-4121-b4ef-536c4d014659_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_90a73212-fe41-48d2-8c68-2f1c6a5492af_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_20daacf3-1c2a-4c21-abc0-34fae6aae18a_terseLabel_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:href="evh-20221231.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_808fc72c-8237-4f2c-9788-c0a3bb194292_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_23bf45ee-de84-4b6f-97a5-d7bba780b8ab_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up and organizational costs</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_label_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up and Organizational Costs</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up and Organizational Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:to="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_1163e827-3635-4f7a-aad7-3a21ddad597f_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20221231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_5a747edb-00d3-4e2f-82ab-13c6793273e1_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20221231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_9f585700-6ee6-48ad-90aa-ba0a2a0a2aba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d55e5069-af99-4cbc-a494-d8e5624ea0c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_442f5c83-5db9-407a-89f3-d69c84c1b876_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_6b85e2e2-f33e-4b55-b4da-476028aa8199_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_30039faa-b39f-49e4-ba37-6e9cf258937d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_46af599f-fd0f-4143-9ae5-0615ffed0f6c_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_52371513-306e-4d1e-92de-4e5c94717c13_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8e0618b5-5225-44a4-99d9-61c19c2e6851_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c7ebf73f-3975-4020-8627-f9affeb289e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_358b6034-f63b-4026-be0c-b45e8cd2cea5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_4464e4e6-f4ea-47b7-adb1-42f9bc0493d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_75fb0151-8b13-4040-bd78-250ab71ba6a0_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20221231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0982f06f-46d7-4ad9-bfb4-19f1c87b5ba3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d61a9b45-3553-4567-9a11-6ae152336b9b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_676c2bc6-f353-4749-80cf-177d30d1719c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note $11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b06191c0-3ad9-4372-987d-e637a0759ee3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fb2adbd-bb90-4a44-a404-c565b1a69aa2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28ff032b-a40b-4679-9d04-10d92b9ee097_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5436e4e-500c-463f-b09a-fb8f5766f7f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_85c48580-9d8d-4311-bc38-e220d506819d_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7c1eb257-de29-45ba-86fa-b6c8857e08fd_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_3703841e-b702-438a-b14b-2bbed58a8747_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20221231.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_17c4f7d6-d0ac-4b82-b46c-4cf4eef8d3a1_negatedTerseLabel_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_label_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_documentation_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:href="evh-20221231.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:to="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_56b2115f-5515-4a32-bb29-b0f5f5c3f72d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with business combinations</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ad3cfff2-0b04-4022-b11f-32f5196e06af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_9a28829c-4659-417c-a658-af32264ebdbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited consolidated quarterly results of operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_b5f7ae6d-a3a0-4893-a189-add401051b73_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_66d32fc3-f765-49a1-9680-417019ed2812_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_632995da-7a2f-4e99-b33c-35dd2c0dc85a_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3d33789a-2ac9-41ea-bed0-98f6f7998f41_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c273ef52-bab5-47d6-8829-24217cc81817_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97d8bb05-0bea-4ffa-bb92-cb3aa60747df_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b52208d3-d66e-439a-acfe-32f6ea81ec7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_63b3f4e8-bfb2-4c71-8088-1a743633d658_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5163ed1f-261c-4498-8484-ffa205a7406b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_520fb222-fc82-4533-a7a7-c938b748147a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_55edc14a-e40f-4269-92a7-5ca41b8b9159_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4a7de35b-8e78-4b95-b224-e67895a9a17c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2c06a1f9-f853-4e9c-9599-90dd1eeefe13_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_14e707f1-7249-4770-9072-eb18185659ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_1447d073-62b2-4a8b-baf4-cc514453a325_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_db025fff-6a35-4ccc-ae14-a1329af502e7_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0fe68bc6-ed2d-42df-ab08-7fa163c9ed1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_8a821469-3ba6-4318-aae5-aafd1eafe5ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_d9ee96c3-c842-4aae-b59a-557d15736bf5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_0d6ded78-d903-47ef-927a-db74be7cd17c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact to cash and cash equivalents and restricted cash from initial consolidation</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_7d97531c-a2a0-4a3d-ac6c-eb9ea88a9481_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred health care costs:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_096548f5-e1e5-41c8-8718-faed87d8253f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_361a78ce-e58b-41f7-89e7-fef859671511_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5204a182-587b-45bf-8f27-d4939dd517ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5871f77d-a7af-4108-8dba-bb0062d8f195_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e7f7d598-2b21-40d3-b479-b1181b766b27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_fd1db596-5f6e-4221-a073-aa1ac896a6e7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_83d41b2e-abc5-4556-9014-0a7ffdb25869_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_92962d8e-e3a3-4440-8dfe-f14d484e811b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d50a14f6-b6ea-481a-8ad6-959af7723ad4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NationalImagingAssociatesMember_20340284-ede4-4d47-95e5-39155c9dda34_terseLabel_en-US" xlink:label="lab_evh_NationalImagingAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Imaging Associates</link:label>
    <link:label id="lab_evh_NationalImagingAssociatesMember_label_en-US" xlink:label="lab_evh_NationalImagingAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Imaging Associates [Member]</link:label>
    <link:label id="lab_evh_NationalImagingAssociatesMember_documentation_en-US" xlink:label="lab_evh_NationalImagingAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Imaging Associates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesMember" xlink:href="evh-20221231.xsd#evh_NationalImagingAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NationalImagingAssociatesMember" xlink:to="lab_evh_NationalImagingAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_e06b4141-05fa-4826-9f35-d8b8730b7da2_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20221231.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_bd67c921-b760-4366-993f-f9152fe3e4a5_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementLiability" xlink:to="lab_evh_TaxReceivableAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_69109a78-06a8-4850-acd1-570aac8b6bda_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b4809cba-937f-4f88-bd39-fa290eed265d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Before Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_318389af-7613-4543-8974-f4bbf27b69ce_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20221231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9656a75c-5f6c-48fd-98d2-d4b024bca9fd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_bb0685b5-398a-4d1b-89e9-2e283e2f3276_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Adjusted EBITDA to Net Loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_674195e9-f68d-4a3a-8c46-6c60e54cbb04_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e1939dcd-5981-4f02-a3e1-18a5521bb0ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_e787bb35-8569-4e9f-8b31-c9bf31aa5865_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_58f073c7-9ba0-4686-ba0b-bb9b20f48496_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ec14aa1b-eae3-4bf0-ac2a-cc22a5987f3a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f3bf782e-dade-493c-8fdc-816d68a53bd4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_08139a51-c586-4e82-b8fb-7a35ae185dec_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_a22c8d93-7b63-4664-b6a7-df4aa4ef6cd2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_edde9852-c3ae-4876-8149-49cf989acdad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e2455565-3ed0-4e30-bfc7-1302da888413_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_33f57960-fa72-4bd8-93ae-2d335e0ae3f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c25c5440-681d-4c83-8c65-cf705670cec9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_f050e1cc-2582-41ad-9ed0-15f6bd0cb340_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_16630f65-9c01-4e16-9f9f-64f96b303cbd_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_5e608869-118c-4094-a224-8170e8a7cc8c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cc399209-ea1c-44e0-b219-1a2182c6610e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3df78199-b8fd-4b4c-ac07-19f7592ebf66_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning-of-year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9257189e-8d3b-4bc7-af56-cc94c6f206ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end-of-year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4d899068-8c89-4f67-a885-acaf9082d093_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0ff80bf3-d442-44d7-a31b-4d44fb482c0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d3d07757-1542-4c3b-a518-0852d457c42e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_53eb3a80-9dd4-407e-b0b9-52bf4c8a383d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_d5e5d42a-198e-4ec9-82f4-8e86cc5c59b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_b1aef803-fb0b-44ee-b237-2292610f22f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Allowance for Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_54ae0c46-bc61-4958-bc6a-f33040b2c767_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9fdca779-2edd-4889-9896-edbbfafad6f1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_557b630e-868c-4e51-8bae-71f2982ffa36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e2d5e7ca-1aab-4d54-af7a-a23a60e38670_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Primary Office Leases and Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ab4d5dff-4512-45df-b535-c881626f2b5f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f8bcbfb8-c4b8-49a8-8023-4d7752590988_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_227bfe8b-dbcd-432d-8d92-c150d157870f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_14768864-ee4a-4774-a70e-3e887cc9849e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_46f449c5-fee7-4072-8e66-878e09f950ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_92f8a829-cfc0-4fc3-be94-2553aa7d752a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_fc58dd14-9dda-4f81-9847-e7eb0310a48f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ff083fa5-b396-435d-84a6-a3ec362d3c07_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ef49be95-98ce-44dc-b3a3-bc1e3ff9d445_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2a2eda19-1d35-4995-9086-a6206d882d7a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0f817b48-4e53-428f-be5b-00d18a319b76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_cc3edd82-b3db-442e-855a-5056d6a48e2a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_ab90ce81-a449-4934-b40a-076ba87ad4ef_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Impairment of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_5e573437-9de8-4c5d-8246-c7a20f073849_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20221231.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_f5de5ca9-8a46-41a9-ab93-0e67f92772d2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_988fb22e-3d7d-4504-bae1-a5eae87a3fc8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_6e73b126-be92-45dc-b612-c481782cfb60_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - Operating</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f4e0037b-b599-4a1f-9a17-74482061f19c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6088c8cd-69c8-4c1d-8f5c-1a7689fe4109_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_85d6af71-6734-4b8e-85a3-4b6861267659_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0e81c545-5fc3-4df9-a0ac-6480f65300a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodAxis_b56c095c-81ce-4932-86f3-43c641e5fefb_terseLabel_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Axis]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodAxis_label_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period [Axis]</link:label>
    <link:label id="lab_evh_PreferredStockRedemptionPeriodAxis_documentation_en-US" xlink:label="lab_evh_PreferredStockRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Redemption Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodAxis" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PreferredStockRedemptionPeriodAxis" xlink:to="lab_evh_PreferredStockRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5b475038-1fb6-49a0-8cb1-c3ed2a6cab53_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_790c0ef2-9315-4450-996c-272d94fc8b73_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_7e3af82d-b2ee-480c-a441-c31db2743c4f_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_31ae0b0e-d717-41b5-83e6-4348c582ba39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_26c77922-8574-46b1-83c3-269409b1a078_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:to="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c380496b-a3ad-489b-b876-63526f2d02c1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_bb552c8b-c459-4de3-abbf-72a32e3bbb40_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20221231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1ccfb933-f3e8-4a30-acf6-be5efe01b283_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fa415512-a9f9-4c42-9a93-3a66a46dd1ee_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c39de565-d7ae-4d80-a416-2e87ca341195_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_8bca0650-814d-4cee-a5cc-8fd4b3764c21_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_4ac18d72-5a25-433b-b8c7-3f4ef797b4c9_terseLabel_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract" xlink:href="evh-20221231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AggregateIntrinsicValueAbstract" xlink:to="lab_evh_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_c4faa9a2-7543-42bf-858d-65f49c16fcee_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8b3422bb-fcb2-4fba-b2a5-c813c8f88f1f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ce641501-3603-4e42-b5a5-b2ccd488bb14_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2fe245ac-17ca-4372-98c1-4ca00e442243_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_72c473a3-0d5b-4858-80d9-0a49b7991eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_ea769088-72d5-42cc-a968-f05d95c8581b_terseLabel_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases option</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_label_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_documentation_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases" xlink:href="evh-20221231.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfOptionsToRenewLeases" xlink:to="lab_evh_NumberOfOptionsToRenewLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_98bffb85-ac02-4557-9e3b-b8738e3cacb9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a7f323c0-d48e-4738-bbff-c40f02d1805e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_d9ece057-1856-43ba-995b-33cbc720cca3_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_29f7d674-8262-4378-8907-14713de37b73_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_e3010f2a-fc0b-4f0e-8970-59c2ef43ac8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of equity method investment</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_c6c5eafd-d5f7-4143-92eb-9ea7b19869c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_916673db-53bb-4884-8d8b-28edd300f5a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c9b74930-b665-447e-9454-dfed2da5770c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_ade60572-5748-4830-883a-d31e8defec12_terseLabel_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_label_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Repayment Of Debt</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_documentation_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Repayment Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt" xlink:href="evh-20221231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnRepaymentOfDebt" xlink:to="lab_evh_GainLossOnRepaymentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_79acd60e-7c1d-43b6-9162-35f5e1c24a35_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_929c8f89-023d-4d64-a520-e241a93b66d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_6b54bfcd-50cc-4782-9be0-3098ed0a00d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccountingStandardsUpdate201603Member_label_en-US" xlink:label="lab_evh_AccountingStandardsUpdate201603Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-03 [Member]</link:label>
    <link:label id="lab_evh_AccountingStandardsUpdate201603Member_documentation_en-US" xlink:label="lab_evh_AccountingStandardsUpdate201603Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-03</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountingStandardsUpdate201603Member" xlink:href="evh-20221231.xsd#evh_AccountingStandardsUpdate201603Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccountingStandardsUpdate201603Member" xlink:to="lab_evh_AccountingStandardsUpdate201603Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>evh-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7115f8c9-673f-4852-9658-eb14dd751c5c,g:b477b36f-79f2-421d-ab66-c6e4dbe5edd5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Cover" xlink:type="simple" xlink:href="evh-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_021e4797-1953-48f0-87d1-422abd7b4188" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentType_021e4797-1953-48f0-87d1-422abd7b4188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_775dabe6-2eb3-4fca-b905-c0fcbd9a95a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentAnnualReport_775dabe6-2eb3-4fca-b905-c0fcbd9a95a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_735459c0-6d33-4c67-a436-703b9798e957" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentPeriodEndDate_735459c0-6d33-4c67-a436-703b9798e957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_527b870c-2430-4635-92c9-d4b6bd2a5dc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_CurrentFiscalYearEndDate_527b870c-2430-4635-92c9-d4b6bd2a5dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ba627ab0-8b35-4050-89d8-bf5678e737b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentTransitionReport_ba627ab0-8b35-4050-89d8-bf5678e737b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d65bfa25-79b2-4dfb-a4d7-3b75af6f7bae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityFileNumber_d65bfa25-79b2-4dfb-a4d7-3b75af6f7bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5b72862-ae2c-45e3-b357-d692fd1e7e1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityRegistrantName_a5b72862-ae2c-45e3-b357-d692fd1e7e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2995dfc1-1ff7-404e-9570-011fdf06ee13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2995dfc1-1ff7-404e-9570-011fdf06ee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_262a795a-293e-4e7e-859a-e75107d6f7c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityTaxIdentificationNumber_262a795a-293e-4e7e-859a-e75107d6f7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0c21975c-4141-4ada-a220-658797da1799" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityAddressAddressLine1_0c21975c-4141-4ada-a220-658797da1799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_cec2cca9-e0a9-4557-8958-00809779450b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityAddressAddressLine2_cec2cca9-e0a9-4557-8958-00809779450b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_506871cc-f0c6-470d-a645-f98d7dc8a119" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityAddressCityOrTown_506871cc-f0c6-470d-a645-f98d7dc8a119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0f536d11-753b-4a4a-ab53-cf4077f7b235" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityAddressStateOrProvince_0f536d11-753b-4a4a-ab53-cf4077f7b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_993eeacd-5081-457f-b4ff-df3e74d13c09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityAddressPostalZipCode_993eeacd-5081-457f-b4ff-df3e74d13c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5e71db0f-8d4a-4d9d-92b0-3fc886e0c09f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_CityAreaCode_5e71db0f-8d4a-4d9d-92b0-3fc886e0c09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_27a35f07-4f57-4548-97a8-755e485a492b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_LocalPhoneNumber_27a35f07-4f57-4548-97a8-755e485a492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_357d7647-7efc-4cbb-89ec-efdfe4b4409d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_Security12bTitle_357d7647-7efc-4cbb-89ec-efdfe4b4409d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2fa0c0d3-f217-4787-9588-ebcc8ed0fcbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_TradingSymbol_2fa0c0d3-f217-4787-9588-ebcc8ed0fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_74c4f951-dff0-4955-8285-66106b629914" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_SecurityExchangeName_74c4f951-dff0-4955-8285-66106b629914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_532bac85-d42a-4bdd-ad67-c691183a1373" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_532bac85-d42a-4bdd-ad67-c691183a1373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3da42441-5e2b-48e9-9fc0-f6130587c62c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityVoluntaryFilers_3da42441-5e2b-48e9-9fc0-f6130587c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_586e57de-3d41-46fe-90ef-621054291e41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityCurrentReportingStatus_586e57de-3d41-46fe-90ef-621054291e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5d95441b-1581-4e8d-8ee8-e22d2223b821" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityInteractiveDataCurrent_5d95441b-1581-4e8d-8ee8-e22d2223b821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_404bcc0e-5e7d-4ff9-9c35-f3892e52b89b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityFilerCategory_404bcc0e-5e7d-4ff9-9c35-f3892e52b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_aa95185f-9173-4f76-97f0-1798fc6b5a3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntitySmallBusiness_aa95185f-9173-4f76-97f0-1798fc6b5a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b920e55c-b795-4d43-9ac4-abac9dc75290" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityEmergingGrowthCompany_b920e55c-b795-4d43-9ac4-abac9dc75290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ac1d179c-7d11-4aef-b02f-572e71eece91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ac1d179c-7d11-4aef-b02f-572e71eece91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_24f4d8e0-dafe-4084-8574-e708a5447b55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityShellCompany_24f4d8e0-dafe-4084-8574-e708a5447b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f390cea6-707e-4437-b21d-41fe9d0b0ae3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityPublicFloat_f390cea6-707e-4437-b21d-41fe9d0b0ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4d40ad4d-08a3-4938-87ca-4073cac4cf12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4d40ad4d-08a3-4938-87ca-4073cac4cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_00a98853-0bc5-443a-bebd-d79ef3c28afa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_00a98853-0bc5-443a-bebd-d79ef3c28afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fc514fa4-e03f-4f15-9cf0-479fbf8a37e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_EntityCentralIndexKey_fc514fa4-e03f-4f15-9cf0-479fbf8a37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_11ebae0b-bb34-4dfe-9cea-d5469fe77a3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_AmendmentFlag_11ebae0b-bb34-4dfe-9cea-d5469fe77a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1df8af07-f3e7-4ca7-b474-3393385ef89a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentFiscalYearFocus_1df8af07-f3e7-4ca7-b474-3393385ef89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6ec1a12a-b089-4028-b102-5c3fe23cd9b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3f51e89-cf8b-441f-b12d-c9c55db4e9c3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6ec1a12a-b089-4028-b102-5c3fe23cd9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/AuditInformation" xlink:type="simple" xlink:href="evh-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_evh_AuditInformationAbstract_c977bd09-82ad-453c-8e20-c145edb7301d" xlink:href="evh-20221231.xsd#evh_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e646ab8f-e3b4-4257-80fb-6db9f2b6fc08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c977bd09-82ad-453c-8e20-c145edb7301d" xlink:to="loc_dei_AuditorFirmId_e646ab8f-e3b4-4257-80fb-6db9f2b6fc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6b5b9c09-3fac-4f1a-bdf6-c198f6fa0cc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c977bd09-82ad-453c-8e20-c145edb7301d" xlink:to="loc_dei_AuditorName_6b5b9c09-3fac-4f1a-bdf6-c198f6fa0cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6a5dfcce-ba5a-4eb0-8da2-1cebb85cbcc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c977bd09-82ad-453c-8e20-c145edb7301d" xlink:to="loc_dei_AuditorLocation_6a5dfcce-ba5a-4eb0-8da2-1cebb85cbcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_687459e1-2f90-4fef-af1a-b625a69504d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_687459e1-2f90-4fef-af1a-b625a69504d4" xlink:to="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0ac8b74-7971-41f7-96f6-27c06bf0b517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0ac8b74-7971-41f7-96f6-27c06bf0b517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_952173b1-ef2c-4025-b565-ffcacd93a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_952173b1-ef2c-4025-b565-ffcacd93a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f30b3e04-5b2c-450d-919e-1d9c8fde7503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f30b3e04-5b2c-450d-919e-1d9c8fde7503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45e571d4-9fc2-4a4e-9109-b4629ab9a396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45e571d4-9fc2-4a4e-9109-b4629ab9a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bfdb26fa-754d-4693-8bcd-6147101a5b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4f26ffbe-c403-4a1c-ba4d-39bd190bde9d" xlink:to="loc_us-gaap_AssetsCurrent_bfdb26fa-754d-4693-8bcd-6147101a5b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_766008c3-28e3-4e50-8437-e6ed84796f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_766008c3-28e3-4e50-8437-e6ed84796f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_56bc98fb-5e3f-4db9-9e99-4908e18221f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_56bc98fb-5e3f-4db9-9e99-4908e18221f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_af4c61cb-f4c2-4b4e-b0c4-cc8dabca4fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_af4c61cb-f4c2-4b4e-b0c4-cc8dabca4fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_445d9dcf-caa7-4f25-957a-2253d3233f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_445d9dcf-caa7-4f25-957a-2253d3233f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5f0e2409-901d-4c50-9c7c-751caef3c7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5f0e2409-901d-4c50-9c7c-751caef3c7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_72c175da-0960-4bbf-aabf-7cd24024e01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_72c175da-0960-4bbf-aabf-7cd24024e01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4be9928b-24ca-4128-93d0-dbb371b84346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4be9928b-24ca-4128-93d0-dbb371b84346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2390cf66-344c-4ba4-957c-136cec10ac19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_Goodwill_2390cf66-344c-4ba4-957c-136cec10ac19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3d169a4b-1028-4def-bdad-f44a5d86e71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035a114a-40c3-4cc7-8711-0b639c1c0c0f" xlink:to="loc_us-gaap_Assets_3d169a4b-1028-4def-bdad-f44a5d86e71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_687459e1-2f90-4fef-af1a-b625a69504d4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:to="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9460d0c1-9e05-4934-a999-7472bc03ea8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_AccountsPayableCurrent_9460d0c1-9e05-4934-a999-7472bc03ea8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1bf3df6f-8c44-4ad7-8d63-fd6cdb671f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1bf3df6f-8c44-4ad7-8d63-fd6cdb671f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32c2aaf-fb37-46fe-8a4a-4d137a9f395e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32c2aaf-fb37-46fe-8a4a-4d137a9f395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3d92a15e-9bef-4557-9461-158ac6a549cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3d92a15e-9bef-4557-9461-158ac6a549cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e6aaac18-f675-4b7a-8722-84e4d8549d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e6aaac18-f675-4b7a-8722-84e4d8549d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_aa15ccd9-9c29-4f52-9580-108f997d6516" xlink:href="evh-20221231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_aa15ccd9-9c29-4f52-9580-108f997d6516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ab3aec3-c0f8-4bf9-8d82-b636c770115e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ea57088b-32df-47c7-80c5-b3c87935d7c9" xlink:to="loc_us-gaap_LiabilitiesCurrent_9ab3aec3-c0f8-4bf9-8d82-b636c770115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f1b6a0b3-4819-4e71-a7a0-6c08eb3fdbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f1b6a0b3-4819-4e71-a7a0-6c08eb3fdbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_444e1443-12ce-4dbb-8530-e4409f0711ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_444e1443-12ce-4dbb-8530-e4409f0711ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_63176f71-b416-40c3-9b5a-ac1b6d19ed09" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_evh_TaxReceivableAgreementLiability_63176f71-b416-40c3-9b5a-ac1b6d19ed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97552e06-0a73-45e5-84eb-69fb6e2a054f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97552e06-0a73-45e5-84eb-69fb6e2a054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a7b78b33-ba7f-4132-8588-20f2ce4a2dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a7b78b33-ba7f-4132-8588-20f2ce4a2dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4066ddce-1ce0-48e3-90e4-0398cbc19a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a2e6b41-ba2c-4c24-8baa-97442ddd0fad" xlink:to="loc_us-gaap_Liabilities_4066ddce-1ce0-48e3-90e4-0398cbc19a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91ee37d0-2104-4b38-a3f2-7a3fae8ca05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91ee37d0-2104-4b38-a3f2-7a3fae8ca05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_914621e6-1eb0-4956-9dfe-666cbb3fbb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_CommonStockValue_914621e6-1eb0-4956-9dfe-666cbb3fbb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_86b82b31-a456-49d2-8167-74869b2be2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_86b82b31-a456-49d2-8167-74869b2be2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_317a1939-5f60-4af4-825a-732c3b86af74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_317a1939-5f60-4af4-825a-732c3b86af74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_633e9cdd-e88d-4f87-9800-e250731c7d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_633e9cdd-e88d-4f87-9800-e250731c7d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_3d82e334-4b93-42fb-a058-75591605d60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_TreasuryStockCommonValue_3d82e334-4b93-42fb-a058-75591605d60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0370926b-857f-4184-a0eb-7da750339163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94e53f9-50a1-4ae7-a264-cf081f711acd" xlink:to="loc_us-gaap_StockholdersEquity_0370926b-857f-4184-a0eb-7da750339163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3c27b6a5-aa23-4061-92c3-d543575bb551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd96f6af-ba6a-4ec3-870d-00f01d70c40c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3c27b6a5-aa23-4061-92c3-d543575bb551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33067f15-613f-4338-b5f4-6e1ba26d6c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_122ce89d-4c6d-4f6b-b4a9-0893c197f736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33067f15-613f-4338-b5f4-6e1ba26d6c3d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_122ce89d-4c6d-4f6b-b4a9-0893c197f736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_540641cf-c389-4034-9041-373f44c8483d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33067f15-613f-4338-b5f4-6e1ba26d6c3d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_540641cf-c389-4034-9041-373f44c8483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_673c5af1-3eab-4c20-b6d0-e1dd1095d159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33067f15-613f-4338-b5f4-6e1ba26d6c3d" xlink:to="loc_us-gaap_CommonStockSharesIssued_673c5af1-3eab-4c20-b6d0-e1dd1095d159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_53f10bb3-9068-4b0c-8bb5-2b30d1a88e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33067f15-613f-4338-b5f4-6e1ba26d6c3d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_53f10bb3-9068-4b0c-8bb5-2b30d1a88e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78899549-9eb5-4004-9930-302b2fa952b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78899549-9eb5-4004-9930-302b2fa952b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_99ca8ca6-ef3f-4e72-b854-c824811bedcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_99ca8ca6-ef3f-4e72-b854-c824811bedcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e7e817db-0f56-4e2c-a09f-2bb9fc392233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e7e817db-0f56-4e2c-a09f-2bb9fc392233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d46325d-6989-45f2-8ed0-d60529bfba67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d46325d-6989-45f2-8ed0-d60529bfba67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6fc5a88b-cffa-4ed0-ac07-06fbad2ea9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6fc5a88b-cffa-4ed0-ac07-06fbad2ea9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d6b105b4-84f8-424f-b5dd-d51ff61a64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d6b105b4-84f8-424f-b5dd-d51ff61a64d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_347c4d26-27f7-46d5-bc7a-7c71aaa529bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_347c4d26-27f7-46d5-bc7a-7c71aaa529bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_067f243e-2a8c-464b-abaa-2c67f3404ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_558e66a5-93c1-41b2-948f-1943da3b6e67" xlink:to="loc_us-gaap_CostsAndExpenses_067f243e-2a8c-464b-abaa-2c67f3404ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_30fd5501-7c72-4cd1-96b8-6eacaea6793d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_30fd5501-7c72-4cd1-96b8-6eacaea6793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd94978f-b533-42d2-9d4f-d0e9195f6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd94978f-b533-42d2-9d4f-d0e9195f6bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0c8a93ca-e277-4bb4-8660-27be4f8e2981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_InterestExpense_0c8a93ca-e277-4bb4-8660-27be4f8e2981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a09b3b73-7e3f-4105-b3b0-82c174fd5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a09b3b73-7e3f-4105-b3b0-82c174fd5b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_492fa273-3189-4059-9e7a-8c0be2a6f617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_492fa273-3189-4059-9e7a-8c0be2a6f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_21fc6243-bcb0-4685-9c5f-322ffadedea8" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_evh_GainOnTransferOfMembership_21fc6243-bcb0-4685-9c5f-322ffadedea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_51cd5b3b-7aea-4a3f-beb0-3af924c6b438" xlink:href="evh-20221231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_51cd5b3b-7aea-4a3f-beb0-3af924c6b438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_36fdc933-b123-4b1a-8d6c-e6f96e0c84ba" xlink:href="evh-20221231.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_36fdc933-b123-4b1a-8d6c-e6f96e0c84ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9091b8d0-6431-4da2-ae40-6556d7c9a991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9091b8d0-6431-4da2-ae40-6556d7c9a991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2238df41-186b-4f43-a0a5-06cfc4fd3581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2238df41-186b-4f43-a0a5-06cfc4fd3581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_86bd0908-b020-4f3a-a394-b0d0b8bf988e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_86bd0908-b020-4f3a-a394-b0d0b8bf988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_af9643be-9e6c-4304-b280-fd6b5f8f93cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_af9643be-9e6c-4304-b280-fd6b5f8f93cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cbbfa2ec-28d1-49b5-b700-e1b0d28a9a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cbbfa2ec-28d1-49b5-b700-e1b0d28a9a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_38b0959e-ab74-4001-bb1c-63d3d66ab91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_38b0959e-ab74-4001-bb1c-63d3d66ab91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c1c41986-b752-4ecb-a741-40498326f915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c1c41986-b752-4ecb-a741-40498326f915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_59c67898-8a43-40ac-b74a-fef26daa4a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_EarningsPerShareAbstract_59c67898-8a43-40ac-b74a-fef26daa4a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59c67898-8a43-40ac-b74a-fef26daa4a54" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bb6d5d35-8fd0-4374-b247-eeb827ab3a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bb6d5d35-8fd0-4374-b247-eeb827ab3a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0d12008f-58d8-42de-a673-a999dec43adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0d12008f-58d8-42de-a673-a999dec43adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bafe965b-3b54-4552-9080-bc58b4c25f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bafe965b-3b54-4552-9080-bc58b4c25f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_523f9b10-6676-492b-bdd9-25c406b9c915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_523f9b10-6676-492b-bdd9-25c406b9c915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d161e5c4-c4e4-42e4-afb1-c6d72cc4c336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_EarningsPerShareBasic_d161e5c4-c4e4-42e4-afb1-c6d72cc4c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f48eaa8d-f40f-4075-9c80-c4dec5de4ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e665468b-88fa-4cfb-a786-3f7fd15a9580" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f48eaa8d-f40f-4075-9c80-c4dec5de4ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_74844d48-23a8-466a-9487-da9924499b97" xlink:href="evh-20221231.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_74844d48-23a8-466a-9487-da9924499b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99c4efc7-4d7e-4928-a10a-2c4c49cfdf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_74844d48-23a8-466a-9487-da9924499b97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99c4efc7-4d7e-4928-a10a-2c4c49cfdf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec1a0baa-06ae-4413-9540-13f083748ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_74844d48-23a8-466a-9487-da9924499b97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec1a0baa-06ae-4413-9540-13f083748ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_1242ebdc-c164-41d0-864f-3ae6d6130322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a28caa3-e8dd-4252-b272-2dbbed14a9bb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_1242ebdc-c164-41d0-864f-3ae6d6130322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_528dbb37-629d-4990-b899-5cdea03d12c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_1242ebdc-c164-41d0-864f-3ae6d6130322" xlink:to="loc_us-gaap_NetIncomeLoss_528dbb37-629d-4990-b899-5cdea03d12c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0cffec7a-c143-47a7-a12b-56c4a6e9cb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_1242ebdc-c164-41d0-864f-3ae6d6130322" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0cffec7a-c143-47a7-a12b-56c4a6e9cb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a52e7c5e-844d-4ed2-bc20-61f735d6ce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0cffec7a-c143-47a7-a12b-56c4a6e9cb63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a52e7c5e-844d-4ed2-bc20-61f735d6ce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_512d19b2-a098-462c-b28e-3d01809a721d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_1242ebdc-c164-41d0-864f-3ae6d6130322" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_512d19b2-a098-462c-b28e-3d01809a721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b84f3159-f0c0-46d7-9ba5-4e8ecf7dbc37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_225f247e-b380-462d-83fd-977bda40f000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b84f3159-f0c0-46d7-9ba5-4e8ecf7dbc37" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_225f247e-b380-462d-83fd-977bda40f000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_519936e3-5c64-4300-8488-c488833b4b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_519936e3-5c64-4300-8488-c488833b4b0a" xlink:to="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2ec60f3-db81-4fda-93e9-2e64bb610022" xlink:to="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:to="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f62a71c-be51-4cd1-9359-c333ba65e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_CommonStockMember_8f62a71c-be51-4cd1-9359-c333ba65e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_941b9638-fc74-43ce-88f6-a8759931166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_941b9638-fc74-43ce-88f6-a8759931166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3ffda805-9ea1-43a3-9dfd-f3e3756a2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3ffda805-9ea1-43a3-9dfd-f3e3756a2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9b6f01df-2d76-40d6-aa98-ed347098da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_RetainedEarningsMember_9b6f01df-2d76-40d6-aa98-ed347098da3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0328c0d7-4475-45a9-b9c9-c3626e7dc148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_eac32079-1a25-49a0-89fa-6015a7df385a" xlink:to="loc_us-gaap_TreasuryStockMember_0328c0d7-4475-45a9-b9c9-c3626e7dc148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fad2e788-9a70-4c66-9ac0-417becf2b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1bbf5bdc-0f26-4e02-8d6b-5aa7bb58ba5c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fad2e788-9a70-4c66-9ac0-417becf2b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_17e0eb9a-a8dd-45d0-82aa-492868740688" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8eccb847-7d68-46c0-bd6a-676d5e8c18bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4a919bef-ae11-4997-8e75-ea61d06524bb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8eccb847-7d68-46c0-bd6a-676d5e8c18bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0ba1c45c-ce57-40b4-9d9a-44c886390be2" xlink:to="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0feb0886-da72-4ae8-8225-ddd673f58d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b23c55f0-d1d7-4a62-9989-0a9ff9ea5473" xlink:to="loc_us-gaap_CommonClassAMember_0feb0886-da72-4ae8-8225-ddd673f58d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a203c8e7-a8f5-4af9-accf-574335640e07" xlink:to="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_478af42e-f45d-4476-93ea-540611f6f70a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_af257ead-e0fc-47ef-a97e-bf1a69374b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_SharesIssued_af257ead-e0fc-47ef-a97e-bf1a69374b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e76004a2-8af5-4cc8-ae1a-714315ad129c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockholdersEquity_e76004a2-8af5-4cc8-ae1a-714315ad129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a0bbb4-8543-4a03-b9de-df7d93cc6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a0bbb4-8543-4a03-b9de-df7d93cc6231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53c21ffc-1b9b-4c87-a0a9-0735da1c7054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53c21ffc-1b9b-4c87-a0a9-0735da1c7054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66dcb828-73b2-41b4-94d5-a8e8f9cf1b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66dcb828-73b2-41b4-94d5-a8e8f9cf1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4c4a1145-ed9e-4651-bbb7-3acd9721c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4c4a1145-ed9e-4651-bbb7-3acd9721c13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3dc3b355-006d-44de-b64d-3263dbe159af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3dc3b355-006d-44de-b64d-3263dbe159af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_20ab69de-040e-4d23-96fd-06739677b7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_20ab69de-040e-4d23-96fd-06739677b7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_24a4a72c-866d-4527-896d-8cae7bae105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_24a4a72c-866d-4527-896d-8cae7bae105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_16b2c3b6-d8bb-4387-9590-e76174e9bdeb" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_16b2c3b6-d8bb-4387-9590-e76174e9bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_0234af27-17b7-45a0-ac18-74e882f70e78" xlink:href="evh-20221231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_0234af27-17b7-45a0-ac18-74e882f70e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_38bfd306-3a4e-440d-ae78-bdc07a3ee617" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_38bfd306-3a4e-440d-ae78-bdc07a3ee617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_25fb9c35-04e0-46f2-94b8-662dc61b7bd3" xlink:href="evh-20221231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_25fb9c35-04e0-46f2-94b8-662dc61b7bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_386b0992-ec52-40a1-8bd6-379addbe80a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_386b0992-ec52-40a1-8bd6-379addbe80a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f906b47-7d8d-4068-a1ef-b85c862482c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f906b47-7d8d-4068-a1ef-b85c862482c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2001b47e-c3d7-41b4-9dac-342f194ada52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2001b47e-c3d7-41b4-9dac-342f194ada52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_386ea21d-24c6-4689-b907-1295c5f0ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_386ea21d-24c6-4689-b907-1295c5f0ea3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6a7b429e-42a4-4a6a-b636-3192bc0988d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6a7b429e-42a4-4a6a-b636-3192bc0988d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d7e3d9ce-b846-4ea3-ae5e-cce73be7b9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d7e3d9ce-b846-4ea3-ae5e-cce73be7b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_933ba4ea-51ba-44f7-946b-f14166783944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_933ba4ea-51ba-44f7-946b-f14166783944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_f3396608-37f1-4434-86ad-0283534a7d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_f3396608-37f1-4434-86ad-0283534a7d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4448b1ca-03dd-41d9-9509-daeeeeb34cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4448b1ca-03dd-41d9-9509-daeeeeb34cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bea74865-1077-46f7-a4de-428e5d44ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_NetIncomeLoss_bea74865-1077-46f7-a4de-428e5d44ba55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_77004c3e-737f-4e9f-bd1e-0036ec402496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_SharesIssued_77004c3e-737f-4e9f-bd1e-0036ec402496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b4ddee0-54ea-4176-b7e3-88611569a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe37cc98-358f-40ac-b8f6-e4894cc3fd17" xlink:to="loc_us-gaap_StockholdersEquity_3b4ddee0-54ea-4176-b7e3-88611569a48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2746b5fa-706a-4ae8-98e3-1bc333ebb937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2746b5fa-706a-4ae8-98e3-1bc333ebb937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6e288ad-3d3c-46ce-a794-6b1b093b466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2746b5fa-706a-4ae8-98e3-1bc333ebb937" xlink:to="loc_us-gaap_NetIncomeLoss_a6e288ad-3d3c-46ce-a794-6b1b093b466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2746b5fa-706a-4ae8-98e3-1bc333ebb937" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b1eb78d5-aa67-4827-9890-f6cd9fd65510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b1eb78d5-aa67-4827-9890-f6cd9fd65510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_54a1018b-456c-425f-a1dc-c45956aa6fd8" xlink:href="evh-20221231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_54a1018b-456c-425f-a1dc-c45956aa6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc7e8f29-fb33-4808-bc44-b8bb52ff627d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc7e8f29-fb33-4808-bc44-b8bb52ff627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_715596ad-e378-45b3-8fa6-3717ad5db50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_715596ad-e378-45b3-8fa6-3717ad5db50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_256b39fd-8f30-435c-9f1c-2f069acf9a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_256b39fd-8f30-435c-9f1c-2f069acf9a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ebae6b1-a958-423e-9235-b908f68023b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_ShareBasedCompensation_1ebae6b1-a958-423e-9235-b908f68023b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d58fe10b-af1c-4162-b6cb-ffbec3b9a6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d58fe10b-af1c-4162-b6cb-ffbec3b9a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_be8af049-47d4-4862-8dc0-9e63c4dbe24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_be8af049-47d4-4862-8dc0-9e63c4dbe24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7356ae67-8dcf-4518-a66f-d5f4ca31e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7356ae67-8dcf-4518-a66f-d5f4ca31e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_3dd3f46e-774a-4432-a212-f2092a453882" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_evh_GainOnTransferOfMembership_3dd3f46e-774a-4432-a212-f2092a453882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_33d93004-6c1a-4b9c-8746-76f0e5f77e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_33d93004-6c1a-4b9c-8746-76f0e5f77e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09be8a75-ce6a-4b49-9de8-3758f5359914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09be8a75-ce6a-4b49-9de8-3758f5359914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_833895d6-01af-4399-a761-4fe0dbf6ef66" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_833895d6-01af-4399-a761-4fe0dbf6ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bf5bc09c-2663-48e5-98a4-41fa6ce5c690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bf5bc09c-2663-48e5-98a4-41fa6ce5c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_6d7387e6-b607-4074-9849-c286665c23ca" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_6d7387e6-b607-4074-9849-c286665c23ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c424d7c1-bf59-4745-ac61-e2f5ffbe03b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c424d7c1-bf59-4745-ac61-e2f5ffbe03b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_9e7490c4-465a-43ec-b878-2633a2839120" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_9e7490c4-465a-43ec-b878-2633a2839120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2ee8487-f78a-46e8-aed6-1b6175d3a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2ee8487-f78a-46e8-aed6-1b6175d3a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d1d94887-6c75-4b78-bba9-ae986f095897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d1d94887-6c75-4b78-bba9-ae986f095897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d4ab195e-dc8c-4f4f-8ab3-ee7b0c258a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d4ab195e-dc8c-4f4f-8ab3-ee7b0c258a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f5dcf786-8562-4465-9878-8de4de3aa3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f5dcf786-8562-4465-9878-8de4de3aa3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_ea8f2135-00bd-4f03-bd6b-74d4badcb70e" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_ea8f2135-00bd-4f03-bd6b-74d4badcb70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0ba5c757-3e4d-4882-8a62-1b64136e21d0" xlink:href="evh-20221231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0ba5c757-3e4d-4882-8a62-1b64136e21d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48678b61-861b-4ebe-8c94-4f9eb34bb48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48678b61-861b-4ebe-8c94-4f9eb34bb48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_71eda293-5a21-4d69-a2b8-adf1b343edde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_902454c1-3468-4691-8581-b0f99fca9f5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_71eda293-5a21-4d69-a2b8-adf1b343edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ce530b7-7991-4f0d-a093-eb6117e8c370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_889caba2-efd8-4622-83b9-e809be93e1ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ce530b7-7991-4f0d-a093-eb6117e8c370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_387b63fe-4efb-433b-a558-001146d81e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_387b63fe-4efb-433b-a558-001146d81e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_760132ab-76c7-41bb-ad62-a12b82f31707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_760132ab-76c7-41bb-ad62-a12b82f31707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_b2cbe79a-4a03-43fd-a617-5b156a73b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_b2cbe79a-4a03-43fd-a617-5b156a73b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_b8b5a23c-ce5b-4fb2-945a-ec3dc6d9b183" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_b8b5a23c-ce5b-4fb2-945a-ec3dc6d9b183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4d3d8bbb-c7ff-4270-bc76-4e2e9b9afea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4d3d8bbb-c7ff-4270-bc76-4e2e9b9afea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_786e6888-404c-4242-aa05-101615354e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_786e6888-404c-4242-aa05-101615354e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_adf30ff1-bf85-4578-8718-f9bd39436106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_adf30ff1-bf85-4578-8718-f9bd39436106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_f61ea0fb-5928-4230-b135-de1fc0ca3f7d" xlink:href="evh-20221231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_f61ea0fb-5928-4230-b135-de1fc0ca3f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2cce0300-bdb7-4eaf-b37f-32fb1de55f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2cce0300-bdb7-4eaf-b37f-32fb1de55f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e7deb01b-1c90-4a23-a9c4-7c97b97703a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e7deb01b-1c90-4a23-a9c4-7c97b97703a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fa3c2ca2-4eae-420c-826c-82287b8810aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80a35c09-3edf-4f0b-b86a-bb3e30a8a1b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fa3c2ca2-4eae-420c-826c-82287b8810aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_af163f8e-0865-4370-bbe8-8d079075be00" xlink:href="evh-20221231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_af163f8e-0865-4370-bbe8-8d079075be00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4954cbbe-43c0-4555-9dee-6208529b0611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4954cbbe-43c0-4555-9dee-6208529b0611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_04ffb459-1813-48b0-b0a8-1647bb83f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_04ffb459-1813-48b0-b0a8-1647bb83f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9edb202-1d3b-4e16-b473-7737c6e50adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9edb202-1d3b-4e16-b473-7737c6e50adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_c06a48a5-8544-4f6c-b45d-d98290c7181b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_c06a48a5-8544-4f6c-b45d-d98290c7181b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_3a29d661-e23c-4d64-955e-2101de233332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_3a29d661-e23c-4d64-955e-2101de233332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f887c09c-f860-453b-8f68-78fcd6aa9a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f887c09c-f860-453b-8f68-78fcd6aa9a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a09e239-a578-4693-ac05-471bb20c800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4a3641c-a4b0-4658-b352-decfbaea62e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a09e239-a578-4693-ac05-471bb20c800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a1db484-9f63-4633-9c88-992ec792c5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a1db484-9f63-4633-9c88-992ec792c5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a773bc4-bd23-4af1-9732-fa93a2607103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a773bc4-bd23-4af1-9732-fa93a2607103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cda653bd-04f5-4152-af97-aef2900a69f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cda653bd-04f5-4152-af97-aef2900a69f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84d21052-d375-4d87-909c-25432bf2596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ec481fbc-26c5-4dfb-a121-2e4484f463a3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84d21052-d375-4d87-909c-25432bf2596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d93cb02e-1886-4b02-89a1-8bc754297950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a7512bc4-ee49-44c3-8fe1-b22981888bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d93cb02e-1886-4b02-89a1-8bc754297950" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a7512bc4-ee49-44c3-8fe1-b22981888bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a19e3439-441c-4db7-987f-8372354980b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d3c231a7-c829-4710-9fdd-6b60b3907675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a19e3439-441c-4db7-987f-8372354980b4" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d3c231a7-c829-4710-9fdd-6b60b3907675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20221231.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3cf9c596-55b9-407e-9821-4bd2ac5cb154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b3fa4615-64b9-4f6d-940e-277f744a3649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3cf9c596-55b9-407e-9821-4bd2ac5cb154" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b3fa4615-64b9-4f6d-940e-277f744a3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20221231.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_46f39703-b485-4736-83e5-d99d06c09cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c4be8af9-556a-45fd-9f78-31215e64020b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_46f39703-b485-4736-83e5-d99d06c09cf2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c4be8af9-556a-45fd-9f78-31215e64020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c4612071-f657-482a-b37a-aa217a472596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_dd9a27c3-b5c4-4773-963e-6798762c7ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c4612071-f657-482a-b37a-aa217a472596" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_dd9a27c3-b5c4-4773-963e-6798762c7ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6b30522a-92b5-4d05-b49c-69edae2e97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0765ae25-0a2c-432c-8172-4e920acec1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6b30522a-92b5-4d05-b49c-69edae2e97ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0765ae25-0a2c-432c-8172-4e920acec1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20221231.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_e1f1a5d8-3cfe-4310-8950-ada0b30d66aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_5b06027f-59bb-4992-9fea-f8cb3238185d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_e1f1a5d8-3cfe-4310-8950-ada0b30d66aa" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_5b06027f-59bb-4992-9fea-f8cb3238185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_edd27273-08fd-49a7-8033-395a4e0edba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e36a75ed-5abc-4bfd-ba3a-92dcf3eeccec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_edd27273-08fd-49a7-8033-395a4e0edba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e36a75ed-5abc-4bfd-ba3a-92dcf3eeccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7ec7df60-3e9c-4523-9fae-ee4477ea49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_13490cf3-ece5-47fe-9fd2-d2fda4f6b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7ec7df60-3e9c-4523-9fae-ee4477ea49f6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_13490cf3-ece5-47fe-9fd2-d2fda4f6b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_822e5755-74cb-473c-8322-4c9417af5b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cdeeaf6d-5519-4fc3-a6b3-bea5d3ead306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_822e5755-74cb-473c-8322-4c9417af5b54" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cdeeaf6d-5519-4fc3-a6b3-bea5d3ead306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54471ceb-89f9-40fd-a8c5-f450bc0bcc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40a7fbea-f3c2-4b2a-9cec-d5ab70e767a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54471ceb-89f9-40fd-a8c5-f450bc0bcc2a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40a7fbea-f3c2-4b2a-9cec-d5ab70e767a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b86739f1-4439-4150-83df-8887ffcbaf75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_875dd981-14b4-4441-a775-e064c879865d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86739f1-4439-4150-83df-8887ffcbaf75" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_875dd981-14b4-4441-a775-e064c879865d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossperCommonShare" xlink:type="simple" xlink:href="evh-20221231.xsd#LossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57da28cd-9b53-433e-a9cc-b548faf6f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3f682278-a439-4848-a524-769649930136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57da28cd-9b53-433e-a9cc-b548faf6f95e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3f682278-a439-4848-a524-769649930136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f847a6fa-5968-44d1-adbf-6cf6b0bbc388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fa31880d-6913-41aa-a6e2-5f669df22401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f847a6fa-5968-44d1-adbf-6cf6b0bbc388" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fa31880d-6913-41aa-a6e2-5f669df22401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8dabe03a-05e8-4af9-8e36-96ffc6e2ab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e057d62a-6d20-41a1-ba4c-3cfa730d19f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8dabe03a-05e8-4af9-8e36-96ffc6e2ab8f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e057d62a-6d20-41a1-ba4c-3cfa730d19f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="evh-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9fa926e7-2728-42e9-838a-67fa53e6dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0e48c307-628f-4898-ae59-98e9a43cff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9fa926e7-2728-42e9-838a-67fa53e6dda7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0e48c307-628f-4898-ae59-98e9a43cff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20221231.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12b416e9-33f3-4e6c-b65f-106a9d1ad7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_35782892-f3d8-43f6-a068-6273004b6c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12b416e9-33f3-4e6c-b65f-106a9d1ad7b4" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_35782892-f3d8-43f6-a068-6273004b6c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ae9d11fa-9a58-42a7-86fd-798c7d523cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_25d6a64c-3bec-47a2-aa8a-1ede3e702cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ae9d11fa-9a58-42a7-86fd-798c7d523cf3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_25d6a64c-3bec-47a2-aa8a-1ede3e702cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ca8c3677-0e2d-4707-a33e-bb98577d3765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_30b44909-58d0-4eec-9e6e-4e6907fa15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ca8c3677-0e2d-4707-a33e-bb98577d3765" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_30b44909-58d0-4eec-9e6e-4e6907fa15b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20221231.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c70b1496-f0b7-494e-877f-3cf2d6cd06ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_93a0d87c-fc50-4d70-8795-aa93abb8b620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c70b1496-f0b7-494e-877f-3cf2d6cd06ca" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_93a0d87c-fc50-4d70-8795-aa93abb8b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4c6f02f2-82b5-44f7-8097-c1fbd54285c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5b2da060-ce79-4a5e-a573-b18d122c5e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4c6f02f2-82b5-44f7-8097-c1fbd54285c5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5b2da060-ce79-4a5e-a573-b18d122c5e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20221231.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_61b5b176-6302-48fd-85ae-eda46f6eab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_2163027f-245f-4ebf-a71b-f776c2c0ba94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_61b5b176-6302-48fd-85ae-eda46f6eab6f" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_2163027f-245f-4ebf-a71b-f776c2c0ba94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited" xlink:type="simple" xlink:href="evh-20221231.xsd#QuarterlyResultsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_05fe02c4-b54e-4a2f-95db-c3ac256b2587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4d406f3f-6549-499b-8c23-ee0e71c6ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_05fe02c4-b54e-4a2f-95db-c3ac256b2587" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4d406f3f-6549-499b-8c23-ee0e71c6ef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20221231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_5d0bf1c7-3be1-49f5-9655-34d3c5f07f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_107eedd5-882f-4006-b635-aeee62a72448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_5d0bf1c7-3be1-49f5-9655-34d3c5f07f27" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_107eedd5-882f-4006-b635-aeee62a72448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="evh-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_afbfa970-c68c-45e9-9aab-e0a2baf6ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_491d32da-3236-4150-9bc3-083c571c2bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_afbfa970-c68c-45e9-9aab-e0a2baf6ca5d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_491d32da-3236-4150-9bc3-083c571c2bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f9df59dd-f72d-4d6a-9410-ab88d1e3f442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f9df59dd-f72d-4d6a-9410-ab88d1e3f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c690d775-1005-417a-976b-bbfeebad060c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_UseOfEstimates_c690d775-1005-417a-976b-bbfeebad060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f5d400ad-c62a-48ad-b3eb-4990feb78d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f5d400ad-c62a-48ad-b3eb-4990feb78d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_bb3eb111-be12-4e57-b69e-2b0cee0d4183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_bb3eb111-be12-4e57-b69e-2b0cee0d4183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cf8c8f3c-faf8-4494-93ad-8aa6c1868b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cf8c8f3c-faf8-4494-93ad-8aa6c1868b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_72ffbd72-d0b1-429b-b773-a18a8a4f18d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_72ffbd72-d0b1-429b-b773-a18a8a4f18d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_24d051c2-fa64-4693-a251-d2115edcab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_24d051c2-fa64-4693-a251-d2115edcab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_0bd6c787-cf6c-4b60-97bd-2b5775b5c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_0bd6c787-cf6c-4b60-97bd-2b5775b5c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_000a5225-48d8-4058-8c62-3bf73bacf13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_000a5225-48d8-4058-8c62-3bf73bacf13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0e60a9a7-5e91-4de2-a88a-2422f1403093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_0e60a9a7-5e91-4de2-a88a-2422f1403093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a3a3aa2c-c6c2-4029-90ea-b9bea59a10b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a3a3aa2c-c6c2-4029-90ea-b9bea59a10b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_99d9e9e8-afe6-4a35-8beb-8babc3b90e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_99d9e9e8-afe6-4a35-8beb-8babc3b90e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_21008ccd-efac-4ff4-8c57-4931070fbe30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_21008ccd-efac-4ff4-8c57-4931070fbe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_5a361888-b63f-4b72-acf5-e102eae23321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_5a361888-b63f-4b72-acf5-e102eae23321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_ed8aa519-780c-4ec6-8b23-5351df9a4a45" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_ed8aa519-780c-4ec6-8b23-5351df9a4a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_882af9e3-016b-48ac-8aae-daffda79e892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_DebtPolicyTextBlock_882af9e3-016b-48ac-8aae-daffda79e892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5b06c9ce-3fca-4e00-b6f4-c65308bfc166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5b06c9ce-3fca-4e00-b6f4-c65308bfc166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c5649f69-7343-4043-b002-dd56144c760c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c5649f69-7343-4043-b002-dd56144c760c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_22576f9b-0cc2-4d63-9804-dae1a7284d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_22576f9b-0cc2-4d63-9804-dae1a7284d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8f78ad16-1f21-4720-909c-7fa998cd3673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8f78ad16-1f21-4720-909c-7fa998cd3673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d6101e49-832a-45d4-9073-f25416a1e156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d6101e49-832a-45d4-9073-f25416a1e156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_36acfeaa-4749-45de-b170-b1111f9813e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_36acfeaa-4749-45de-b170-b1111f9813e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4a97bff3-6f98-4330-a1c5-7bbf3b41664b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4a97bff3-6f98-4330-a1c5-7bbf3b41664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd4d6e9c-d6a3-4e56-bd4f-7f526470dd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350c8d47-03f4-4234-8cd9-ef3f1f6c803b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd4d6e9c-d6a3-4e56-bd4f-7f526470dd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5946aa1a-6150-4317-9fab-21b2fa8241bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_18ad4e99-10c9-4a9c-a0fd-e0357a356f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5946aa1a-6150-4317-9fab-21b2fa8241bc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_18ad4e99-10c9-4a9c-a0fd-e0357a356f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7f598aee-44ad-49e4-a3ac-3aec4123763b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5946aa1a-6150-4317-9fab-21b2fa8241bc" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7f598aee-44ad-49e4-a3ac-3aec4123763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_aa611cbe-1615-411a-ac93-aba149e8345b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5946aa1a-6150-4317-9fab-21b2fa8241bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_aa611cbe-1615-411a-ac93-aba149e8345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4e0833af-47c2-456f-8915-18702a7908eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5946aa1a-6150-4317-9fab-21b2fa8241bc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4e0833af-47c2-456f-8915-18702a7908eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a36e9ec8-7240-4c30-acf6-8539db195b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_91e6b173-b5e4-4f5b-8212-ee27ef65e959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a36e9ec8-7240-4c30-acf6-8539db195b5f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_91e6b173-b5e4-4f5b-8212-ee27ef65e959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d0ba2596-f675-41e7-98e4-106d08428419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a36e9ec8-7240-4c30-acf6-8539db195b5f" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d0ba2596-f675-41e7-98e4-106d08428419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c92f01e5-dab9-4d9f-87b8-c0415683ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_87796d64-01cc-42a7-b3ec-18c628d667a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c92f01e5-dab9-4d9f-87b8-c0415683ad11" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_87796d64-01cc-42a7-b3ec-18c628d667a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_944fc574-ae0b-4870-8a92-2bab13b31c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_463653bc-6354-40c7-9999-bdc85453ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_944fc574-ae0b-4870-8a92-2bab13b31c75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_463653bc-6354-40c7-9999-bdc85453ec21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f6042f92-4d03-4a7a-9c32-993b2ab350d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_944fc574-ae0b-4870-8a92-2bab13b31c75" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f6042f92-4d03-4a7a-9c32-993b2ab350d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_fd62d912-e7f1-444e-9c3f-bc47283c5be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_60869ba5-2b1d-4e9d-a063-b9d6db01f496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_fd62d912-e7f1-444e-9c3f-bc47283c5be2" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_60869ba5-2b1d-4e9d-a063-b9d6db01f496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_899fec5f-d833-4577-b9e1-061fdbdafa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bc774619-3b1d-47c4-86c1-becae25a5473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_899fec5f-d833-4577-b9e1-061fdbdafa18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bc774619-3b1d-47c4-86c1-becae25a5473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_677d1452-b718-45ad-baec-a57e37567fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0608c87a-728e-4514-87eb-345d69c5497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_677d1452-b718-45ad-baec-a57e37567fc2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0608c87a-728e-4514-87eb-345d69c5497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_292029d4-c4c7-4143-97ad-e2b0c717daa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_677d1452-b718-45ad-baec-a57e37567fc2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_292029d4-c4c7-4143-97ad-e2b0c717daa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_64609c6e-f985-4ead-9613-8f9108a45864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_677d1452-b718-45ad-baec-a57e37567fc2" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_64609c6e-f985-4ead-9613-8f9108a45864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d21df3d6-49f0-42af-8368-c1c9a21e3db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_e9b17220-a12c-4e08-ae7d-583f5bb2e296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d21df3d6-49f0-42af-8368-c1c9a21e3db0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_e9b17220-a12c-4e08-ae7d-583f5bb2e296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df76de93-982e-4a6f-be70-c9e025e3573e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ef987a8c-15dc-4138-888a-a9b6703a06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df76de93-982e-4a6f-be70-c9e025e3573e" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ef987a8c-15dc-4138-888a-a9b6703a06d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4c890dde-c6a9-4aa1-9df7-d9ad7d123258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_12fda906-b88b-4c41-bf7b-0106012e1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c890dde-c6a9-4aa1-9df7-d9ad7d123258" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_12fda906-b88b-4c41-bf7b-0106012e1993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5e38ea1e-5b78-4b79-a46e-8c91ebafb9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c890dde-c6a9-4aa1-9df7-d9ad7d123258" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5e38ea1e-5b78-4b79-a46e-8c91ebafb9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossperCommonShareTables" xlink:type="simple" xlink:href="evh-20221231.xsd#LossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cc4e6557-0e5d-4cea-bcf9-dcb417ec96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b5657c02-ecd3-4203-9fde-922e12b1342f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc4e6557-0e5d-4cea-bcf9-dcb417ec96f5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b5657c02-ecd3-4203-9fde-922e12b1342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_409f6442-074f-4edc-92b6-010478b7a228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc4e6557-0e5d-4cea-bcf9-dcb417ec96f5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_409f6442-074f-4edc-92b6-010478b7a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables" xlink:type="simple" xlink:href="evh-20221231.xsd#CompensationRelatedCostsShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74a3311d-9f03-45dd-befa-73b793463baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74a3311d-9f03-45dd-befa-73b793463baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_a11bb5cc-f0b6-4da1-a02f-5c857203a420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_a11bb5cc-f0b6-4da1-a02f-5c857203a420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d708d51-01f2-4cf4-9d16-2513d468b6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d708d51-01f2-4cf4-9d16-2513d468b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_308c8d6b-f86a-43d3-8149-3e0451f51166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_308c8d6b-f86a-43d3-8149-3e0451f51166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_759511da-6832-4ac6-a508-682de9b936c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_759511da-6832-4ac6-a508-682de9b936c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_cb0efc0d-1d00-42dc-9421-ebba1b8512ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_cb0efc0d-1d00-42dc-9421-ebba1b8512ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_2fd8d9eb-c6e3-4561-b22e-e4ab0a7b6574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_2fd8d9eb-c6e3-4561-b22e-e4ab0a7b6574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_6db029e7-999c-4c66-933c-ddd52d1ed205" xlink:href="evh-20221231.xsd#evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_6db029e7-999c-4c66-933c-ddd52d1ed205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_a60a4bc2-1c77-4ed3-ad3c-d381fb797035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e3f0848-bfbe-43d5-a1e2-16e0f226e029" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_a60a4bc2-1c77-4ed3-ad3c-d381fb797035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_53fe106e-8c7a-4e01-a5f4-f22f8927e419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_53fe106e-8c7a-4e01-a5f4-f22f8927e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dad636b2-f110-40ad-b90f-4fb61c7f8c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dad636b2-f110-40ad-b90f-4fb61c7f8c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c2f041f4-146b-4905-b3bc-51c36da9e50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c2f041f4-146b-4905-b3bc-51c36da9e50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_114891c7-9076-4d2b-8f71-9a925f094352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_114891c7-9076-4d2b-8f71-9a925f094352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_631c73f3-6420-42e1-9440-a34f82e0996a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcc71769-897b-4ff2-91aa-8ea1da3646ee" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_631c73f3-6420-42e1-9440-a34f82e0996a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_10bf5990-4a80-4a7e-af24-6d5b172afd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_3441effa-b600-40b9-9363-e684bbf5f1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10bf5990-4a80-4a7e-af24-6d5b172afd44" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_3441effa-b600-40b9-9363-e684bbf5f1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d6981deb-2b3d-430d-8baf-090cfc180f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10bf5990-4a80-4a7e-af24-6d5b172afd44" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d6981deb-2b3d-430d-8baf-090cfc180f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cd92c8d2-94ad-449a-bec3-b1672418608e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10bf5990-4a80-4a7e-af24-6d5b172afd44" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cd92c8d2-94ad-449a-bec3-b1672418608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_85000c5d-2819-4d20-9056-68971fd6f8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_e5d7e483-8dcc-4028-be5a-8f9a372f36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_85000c5d-2819-4d20-9056-68971fd6f8d9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_e5d7e483-8dcc-4028-be5a-8f9a372f36fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20221231.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a7a59f54-84ea-4d0e-89a4-d725b63ee746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7b52f782-843e-4e5f-b5be-c7261795d691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a7a59f54-84ea-4d0e-89a4-d725b63ee746" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7b52f782-843e-4e5f-b5be-c7261795d691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_39883917-d8c3-497c-9dbb-914e26e79847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_75257e99-d64b-408b-904c-4da0b1f733d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_39883917-d8c3-497c-9dbb-914e26e79847" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_75257e99-d64b-408b-904c-4da0b1f733d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c8461187-53c4-44ef-8293-78d3f0f9a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_39883917-d8c3-497c-9dbb-914e26e79847" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c8461187-53c4-44ef-8293-78d3f0f9a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20221231.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_4a76f469-4786-432e-ab83-21cbccd74e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6a4a4005-2036-4078-9fe6-38cd88182d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_4a76f469-4786-432e-ab83-21cbccd74e21" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6a4a4005-2036-4078-9fe6-38cd88182d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables" xlink:type="simple" xlink:href="evh-20221231.xsd#QuarterlyResultsofOperationsunauditedTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_4f5a7a13-3d9b-41b0-b653-fac177e398d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a5a040d2-813a-461b-994c-cd1a26715868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_4f5a7a13-3d9b-41b0-b653-fac177e398d7" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a5a040d2-813a-461b-994c-cd1a26715868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20221231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1e00f271-d4ce-4be3-bab5-b25db5a65348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c26d92c1-2bda-4a65-8d51-41dd1c4c1960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1e00f271-d4ce-4be3-bab5-b25db5a65348" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c26d92c1-2bda-4a65-8d51-41dd1c4c1960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f72a1fc6-976f-45a1-9247-5c19c717ddb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7df52c9d-cf45-495e-8186-aa87bec3f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f72a1fc6-976f-45a1-9247-5c19c717ddb1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7df52c9d-cf45-495e-8186-aa87bec3f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_496efb91-f144-4e82-b67e-667a246fc3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_496efb91-f144-4e82-b67e-667a246fc3c9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_2a62f5cf-421f-4d97-8ccc-dc807c60d0aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_256fa155-cfe8-4315-8ef0-deff320291cc" xlink:href="evh-20221231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_256fa155-cfe8-4315-8ef0-deff320291cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_82dfcbb3-7ec6-46fa-b7e9-7efe84aeb778" xlink:href="evh-20221231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_82dfcbb3-7ec6-46fa-b7e9-7efe84aeb778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_22c3ff8a-bedf-426b-b551-b5968d4a195d" xlink:href="evh-20221231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_22c3ff8a-bedf-426b-b551-b5968d4a195d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_2c04cbc9-b3d9-4524-946d-5636aec6ed42" xlink:href="evh-20221231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_385fde02-dc4e-41ad-8620-2f5a671d0acd" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_2c04cbc9-b3d9-4524-946d-5636aec6ed42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_1da1a254-6675-417b-b0b0-b17a04e3bc16" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_998ea3ea-dd11-4c71-bffc-2a8e357c9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_998ea3ea-dd11-4c71-bffc-2a8e357c9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ba926533-e070-40b3-9f79-0712e1467809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ba926533-e070-40b3-9f79-0712e1467809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_be78f6e0-1888-41e0-bb38-0f1d20262318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_be78f6e0-1888-41e0-bb38-0f1d20262318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3002910-eafa-491b-a407-37621035443f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3002910-eafa-491b-a407-37621035443f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c7156b26-2575-4d2f-8f15-5949eacd3450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c7156b26-2575-4d2f-8f15-5949eacd3450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_7a650f31-bd46-47c7-9acf-ad26dc30ef89" xlink:href="evh-20221231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_7a650f31-bd46-47c7-9acf-ad26dc30ef89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_62c543b9-122c-4ef8-a2da-ba12c1b8c4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_62c543b9-122c-4ef8-a2da-ba12c1b8c4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc5ba0c0-9791-4121-a19e-02c2ca40ff33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9dfe8694-1cc5-479b-9c5c-ef248a1eb499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc5ba0c0-9791-4121-a19e-02c2ca40ff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8ba84cc1-c032-4d29-a19d-ce8a4ea87bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8ba84cc1-c032-4d29-a19d-ce8a4ea87bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_38371ae4-f13a-44ac-a8a3-4db23caf2814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:to="loc_us-gaap_NumberOfReportingUnits_38371ae4-f13a-44ac-a8a3-4db23caf2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_b7c74cf8-ec9c-4753-a345-a1eb24a61b29" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_b7c74cf8-ec9c-4753-a345-a1eb24a61b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_b64b42ac-4cf5-41b4-830e-a3505949126b" xlink:href="evh-20221231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_b64b42ac-4cf5-41b4-830e-a3505949126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_9dc76d71-2e35-480e-8f2e-fa1133107a0d" xlink:href="evh-20221231.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cae82a52-1b39-4199-8807-140b8e1249eb" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_9dc76d71-2e35-480e-8f2e-fa1133107a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc9854ad-a435-4fdb-a004-1adeeb5ea2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc9854ad-a435-4fdb-a004-1adeeb5ea2de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:to="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_23657cd2-4a6a-4934-9bf2-3580e88520aa" xlink:to="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd13df72-0a06-44fe-b560-b50d76708b80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:to="loc_srt_MinimumMember_fd13df72-0a06-44fe-b560-b50d76708b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d33aef24-f60c-4724-bbcc-596d8f62e41e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb11973a-7882-4746-a0ae-ea59f40a05e9" xlink:to="loc_srt_MaximumMember_d33aef24-f60c-4724-bbcc-596d8f62e41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_983d2b75-11d4-42a6-97b8-70c430c53ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8c0bb428-326e-4e54-a351-6241338d5cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_ComputerEquipmentMember_8c0bb428-326e-4e54-a351-6241338d5cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a3efa42-11e6-4402-bc42-5519ef5f1f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a3efa42-11e6-4402-bc42-5519ef5f1f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37a60225-d2e5-45c1-8df7-2e2aec87a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37a60225-d2e5-45c1-8df7-2e2aec87a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_977c81aa-cf45-4d0a-884b-61e1040f7bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_971cbc5b-4418-444c-a953-e5a78103c882" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_977c81aa-cf45-4d0a-884b-61e1040f7bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b52c3655-8a0e-4512-8a24-19b74e27e6c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_dcfa06d3-9e9f-4526-93e5-a8a9e33016b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2007827d-e865-49b2-89fb-51553b99853c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_dcfa06d3-9e9f-4526-93e5-a8a9e33016b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6258ef3d-f2fd-48f9-b56d-55999f1e75e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6258ef3d-f2fd-48f9-b56d-55999f1e75e6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e99d3c46-f7c0-4046-ba20-4b781905c6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3190e235-ffa9-480b-bf67-d7ecdfa99436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_TradeNamesMember_3190e235-ffa9-480b-bf67-d7ecdfa99436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_197a6866-5888-4fed-9b77-a5d28b52f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_CustomerRelationshipsMember_197a6866-5888-4fed-9b77-a5d28b52f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4cc5a496-810f-4e95-b394-7f9146d6ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4cc5a496-810f-4e95-b394-7f9146d6ae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_e278a0fc-cebd-4d4c-8380-b621089c510b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5227afc7-9391-4ddd-8594-11f118442007" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_e278a0fc-cebd-4d4c-8380-b621089c510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:to="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5f2b8c88-ec16-4c7e-b1c0-baaf52fe8419" xlink:to="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be6608d6-57ab-4980-9790-65f083fabeb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:to="loc_srt_MinimumMember_be6608d6-57ab-4980-9790-65f083fabeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10475940-caf7-4d1e-9558-5c06e834ea6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc60a6a2-2385-43af-9c8a-44d9a25f8b73" xlink:to="loc_srt_MaximumMember_10475940-caf7-4d1e-9558-5c06e834ea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1b096c72-becc-4640-88ff-bf627490ad48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4dbbae19-2022-4b98-b62e-cceb40a338eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_066773a4-8c6c-4ca1-be7a-35f4e1e97375" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4dbbae19-2022-4b98-b62e-cceb40a338eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc6fb574-72ec-47e6-927d-47be1ee74096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc6fb574-72ec-47e6-927d-47be1ee74096" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:to="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a40999b2-1fee-4f1a-b938-10addc1884ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88819565-6b67-43d2-ac86-a045612731ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe73e761-7146-4ac1-af71-df749959f69d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88819565-6b67-43d2-ac86-a045612731ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:to="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0d93604a-c4ae-4611-9f28-1335099d1738" xlink:to="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54f39d79-a98a-41a0-bd3c-f4e810a96659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:to="loc_srt_MinimumMember_54f39d79-a98a-41a0-bd3c-f4e810a96659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd165c2e-2821-467a-aef3-d9ea6411ab53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_160ca30c-1738-4cb3-81f0-8249625f2c3f" xlink:to="loc_srt_MaximumMember_cd165c2e-2821-467a-aef3-d9ea6411ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466d07a5-8b3d-4b4a-b13c-ac94883c7719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c7f717-0163-4005-85ef-1d90437d2d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c7f717-0163-4005-85ef-1d90437d2d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ca45032-78f4-4974-8cda-badb4e0b1576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6d0684d-b1c6-4c45-b517-75ce3621fb2c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ca45032-78f4-4974-8cda-badb4e0b1576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa683eb2-9f38-4e25-b365-3b95690bfd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa683eb2-9f38-4e25-b365-3b95690bfd39" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_69f923cb-a929-4cdb-aa70-2a4fb7e573a8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a8674763-f412-40b9-aad0-bf1c661a4ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ce1260e8-beac-4c86-bcd8-90f11047f0d3" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a8674763-f412-40b9-aad0-bf1c661a4ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_701a4b9a-5db1-4210-ac53-e1fd2453d6c7" xlink:to="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba94fa52-4496-4644-9c50-86bae31ef480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:to="loc_us-gaap_RetainedEarningsMember_ba94fa52-4496-4644-9c50-86bae31ef480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8506261-a246-46ce-984c-241090f93837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd38a6e8-5b35-42af-8228-c712cd5fb9ba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8506261-a246-46ce-984c-241090f93837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68d47401-7821-4bac-9349-20215a0becac" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8df1bacd-1bda-4003-a067-181ed926136a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_084da692-0584-4ae4-9963-389ebbc2ef82" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8df1bacd-1bda-4003-a067-181ed926136a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4604b522-d2b4-4e8a-9251-fdb76d3b7d48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_bc13daf6-0711-4a47-b869-cc9271d91ff6" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_bc13daf6-0711-4a47-b869-cc9271d91ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6cc1e24f-8eca-46aa-a25a-962dfe0b47c3" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e1a2008-26f5-4cef-ad22-079ecd63ec56" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6cc1e24f-8eca-46aa-a25a-962dfe0b47c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71d0604a-c56e-434c-9e19-7130bdf406eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ef3c38df-00c5-4b79-99de-3efac46a5d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e926cde2-c6ee-4b27-9c00-2af415545c8a" xlink:to="loc_us-gaap_SeniorNotesMember_ef3c38df-00c5-4b79-99de-3efac46a5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49b1442f-6df7-457c-bd31-997c29c2a1b4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_317d9b3f-a87f-4f6d-9e69-3936dbd6088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:to="loc_us-gaap_StockholdersEquity_317d9b3f-a87f-4f6d-9e69-3936dbd6088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bf565854-a446-47ac-b871-896ca5964202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6e7d5121-cde2-460b-89cb-d476d709d051" xlink:to="loc_us-gaap_LongTermDebt_bf565854-a446-47ac-b871-896ca5964202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4507d6d8-8eb5-4ce3-8b11-5ccf28ad62ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4507d6d8-8eb5-4ce3-8b11-5ccf28ad62ff" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928a4749-f3f9-497b-bcee-5fc7b45479e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_eedec1aa-3d64-4b9e-91e8-57ba18b85830" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_eedec1aa-3d64-4b9e-91e8-57ba18b85830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_d73b82f9-6099-4726-80f6-d1929795d96f" xlink:href="evh-20221231.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4fab920-cdf5-4594-bed1-d290644ebecf" xlink:to="loc_evh_VitalDecisionsMember_d73b82f9-6099-4726-80f6-d1929795d96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3430f3b-8894-4cdf-80dd-ca12c4451836" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4693ae12-ffdb-4bb0-a3a7-eac65bba20b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4693ae12-ffdb-4bb0-a3a7-eac65bba20b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_71c67e05-bcaa-4880-8855-acf1e4ad9094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_71c67e05-bcaa-4880-8855-acf1e4ad9094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4bf2087f-52e0-4c4c-9f63-f53a3b223ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_454c1952-26e3-4a97-ac01-5d6dac374b07" xlink:to="loc_us-gaap_TradeNamesMember_4bf2087f-52e0-4c4c-9f63-f53a3b223ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_436c6da4-97f6-49ae-b963-ccc1b87cead6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_46267576-1b97-49d3-a1e5-89b526d3efbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_46267576-1b97-49d3-a1e5-89b526d3efbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1e721a3-45a6-492f-b7f7-fe2074410ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a1e721a3-45a6-492f-b7f7-fe2074410ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_14fde574-c232-4e7b-bc26-31d1a271cbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_14fde574-c232-4e7b-bc26-31d1a271cbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_309ed0c9-d547-4c1b-973d-e7d5b85358be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_309ed0c9-d547-4c1b-973d-e7d5b85358be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f99dda7-1116-484c-9e2e-51b58e92a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f99dda7-1116-484c-9e2e-51b58e92a3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_8209975f-ab72-49e7-81ca-4f16cbc8db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_8209975f-ab72-49e7-81ca-4f16cbc8db8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f0de2a88-1864-4784-8c63-e6a583aa1eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f0de2a88-1864-4784-8c63-e6a583aa1eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_97de414f-ccdd-419e-a791-2c0170d10d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_97de414f-ccdd-419e-a791-2c0170d10d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a50c0189-fa2d-4899-9dda-3c63f94a9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a50c0189-fa2d-4899-9dda-3c63f94a9eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20c63316-aabc-467b-9544-18e1b15293b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b8c7830-7639-4698-bb27-3fec70ac403b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20c63316-aabc-467b-9544-18e1b15293b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_08044757-0d1a-4607-9cd5-5b201cd999e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_08044757-0d1a-4607-9cd5-5b201cd999e5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aaed41ef-7ca6-4ba2-ba71-573c340842ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_3c2f9182-4db4-46f8-9207-59cc1fbf6321" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_3c2f9182-4db4-46f8-9207-59cc1fbf6321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_dfcc8771-842a-4dc3-9c17-b1bb4bc6c0eb" xlink:href="evh-20221231.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6384bf9-ebe3-46af-95b1-7102fce2c327" xlink:to="loc_evh_VitalDecisionsMember_dfcc8771-842a-4dc3-9c17-b1bb4bc6c0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f3b7a79-8977-444f-9688-f89c242683cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0ab6a7f9-7977-48cf-bfe2-87f02e9c08c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0ab6a7f9-7977-48cf-bfe2-87f02e9c08c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_19e284a3-7962-4dd3-b9e5-30f10247512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_19e284a3-7962-4dd3-b9e5-30f10247512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_42cc2788-aa25-4928-92fd-5dd427c6acad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b79fa09f-da3d-460b-9d36-024d321a9122" xlink:to="loc_us-gaap_TradeNamesMember_42cc2788-aa25-4928-92fd-5dd427c6acad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebb325e6-0ade-4ec6-a9b4-ae0ba08bf814" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e7717dfa-dda3-42c9-b050-7a989c40e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e7717dfa-dda3-42c9-b050-7a989c40e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c63e4d3-48a4-46d9-ba6d-0a7945e2009c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c63e4d3-48a4-46d9-ba6d-0a7945e2009c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_18667839-6d46-4b55-920e-0806efdd759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_18667839-6d46-4b55-920e-0806efdd759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5355b3d0-8a00-4e7a-92b3-3ef84bab21f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_308ac34e-ac83-43d5-a7f5-36f08e8c447f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5355b3d0-8a00-4e7a-92b3-3ef84bab21f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ad43f7da-bd21-4d38-af1e-0d2519973e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ad43f7da-bd21-4d38-af1e-0d2519973e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_09368f22-0771-48b8-ac96-6d2bf459dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_09368f22-0771-48b8-ac96-6d2bf459dcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_42e86f0d-cd95-4fee-9a9d-d3f449d0569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_42e86f0d-cd95-4fee-9a9d-d3f449d0569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b11e1624-b117-4cc3-b1a7-4fbcba524347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b11e1624-b117-4cc3-b1a7-4fbcba524347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_2c0603f0-09ca-4828-bf79-6af34cf317f0" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_782ab3e3-da78-4b98-96d6-c214176734c1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_2c0603f0-09ca-4828-bf79-6af34cf317f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8e02b97a-15bd-486a-bc49-51e96488069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_5bd4807a-bf8b-4d94-b4c9-ff1cbad3901a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8e02b97a-15bd-486a-bc49-51e96488069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a685dc0-55b5-467e-be11-d52971fa3e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a685dc0-55b5-467e-be11-d52971fa3e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_86d13bf3-0bc9-4e1f-ac2f-e43fade47794" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_86d13bf3-0bc9-4e1f-ac2f-e43fade47794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_e7a4bacd-5b84-413e-b003-0be350c155c0" xlink:href="evh-20221231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_e7a4bacd-5b84-413e-b003-0be350c155c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8c636f50-caeb-4b7a-8200-26682f8dd3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8c636f50-caeb-4b7a-8200-26682f8dd3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ebe55932-7da6-48bc-b284-e123fee8654e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ebe55932-7da6-48bc-b284-e123fee8654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_75cdbef2-2598-4b69-8907-5c9dc8e365d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_75cdbef2-2598-4b69-8907-5c9dc8e365d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8a00d776-48ec-42c3-bde4-465ef42f6d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_401230f8-cbd0-4b7d-9eca-cbd5a29eaf3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8a00d776-48ec-42c3-bde4-465ef42f6d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e7a7efe9-66a6-40f1-b9d6-6f1dcfe9d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_Goodwill_e7a7efe9-66a6-40f1-b9d6-6f1dcfe9d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_74bb6d3c-84c7-425c-bafb-eede863133c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ebacb93b-9867-4b4c-999d-eb9a7f4f2909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_74bb6d3c-84c7-425c-bafb-eede863133c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2fe51388-f606-4203-b009-7ce101199346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2fe51388-f606-4203-b009-7ce101199346" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2f4b5b43-b02f-4b58-a053-3c4595b943f1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e0a7aada-cbf5-4e4b-8bb0-601816e8060c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8d68041a-e6e6-4e10-a40b-6b3f5371f9a9" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e0a7aada-cbf5-4e4b-8bb0-601816e8060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_af7ea07f-1505-467b-8ab4-631365cf509b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_910a823a-382c-4bec-9823-fc9c1ebe66c2" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4b91a763-6a35-4448-8e72-f27fe60cb607" xlink:to="loc_evh_TrueHealthMember_910a823a-382c-4bec-9823-fc9c1ebe66c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_95a84f3d-78e3-45f9-99dd-0f43f916012b" xlink:to="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_8db5a967-0aa8-44f7-a29d-88f3aa929388" xlink:href="evh-20221231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_8db5a967-0aa8-44f7-a29d-88f3aa929388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_fd6b80bf-960b-4322-b7d4-799298cc7054" xlink:href="evh-20221231.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_PremiumsRevenueMember_fd6b80bf-960b-4322-b7d4-799298cc7054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_a274e16d-d3ce-46f0-98da-5393857cc5d3" xlink:href="evh-20221231.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc7acb24-c0e2-41b5-92d8-67b673250efc" xlink:to="loc_evh_ServicesAgreementsMember_a274e16d-d3ce-46f0-98da-5393857cc5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_450e7a39-9221-42e6-8436-6cd423e3c8c5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e971acdf-8073-4891-8267-fd7114d66de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_136e5d82-b3f6-44ea-bf83-1afce6c7d751" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e971acdf-8073-4891-8267-fd7114d66de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8d9d74b-ca5e-4bc6-9b51-057ce4f48303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_a8d9d74b-ca5e-4bc6-9b51-057ce4f48303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_69520c2c-48cb-4e65-a58c-28fbe637e7bf" xlink:href="evh-20221231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_69520c2c-48cb-4e65-a58c-28fbe637e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_37cdc940-e09b-4742-aa18-86469e9603c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_37cdc940-e09b-4742-aa18-86469e9603c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d101008e-8f71-4ad9-b0b1-b59de149480f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d101008e-8f71-4ad9-b0b1-b59de149480f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_88d4eb76-eee9-450d-a725-5898733c0179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc6c5f61-0660-4c4d-8765-420f14efd15b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_88d4eb76-eee9-450d-a725-5898733c0179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d34d2a39-d037-4ba7-b3b5-6aee374bfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d34d2a39-d037-4ba7-b3b5-6aee374bfe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1991dbec-53e6-43b6-9065-330382111d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1991dbec-53e6-43b6-9065-330382111d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_0352a2bc-a4dc-46d4-a675-1ca48ba2b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_0352a2bc-a4dc-46d4-a675-1ca48ba2b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_23e4abbe-8019-4984-b13d-620819369923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_23e4abbe-8019-4984-b13d-620819369923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e1013ac-50d5-4877-8701-a492bb2165d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9e1013ac-50d5-4877-8701-a492bb2165d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_e147ba09-f197-4256-ac0f-0f7ced9c6d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_e147ba09-f197-4256-ac0f-0f7ced9c6d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35e65c41-896c-4bbc-ad9b-d4f73be03a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51895224-7f0f-48bb-b897-26c1bd405484" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35e65c41-896c-4bbc-ad9b-d4f73be03a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b59c65e3-7826-40b0-bd79-eab43564dd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b59c65e3-7826-40b0-bd79-eab43564dd13" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0bfe89a8-e732-4570-8b22-205ef73009c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_2fb37124-e48d-448e-9c66-5367d1f5f35d" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb0c5763-7e2f-427d-ba00-fd780fca893b" xlink:to="loc_evh_TrueHealthMember_2fb37124-e48d-448e-9c66-5367d1f5f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a68091ad-425b-4361-a19f-e74abd74681a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f6e7a127-ff36-4208-aafa-8f229675ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3bff716f-159e-4cac-953e-80bdf859b571" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f6e7a127-ff36-4208-aafa-8f229675ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0cf5c5d6-08b2-4d04-b413-44b7e63bdeb3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_46aded79-5627-4571-8a68-a19fd07fdb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_46aded79-5627-4571-8a68-a19fd07fdb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60b1067b-caec-4f99-ac4e-0952de2b8ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51f5f2cc-7095-4345-b14c-cc12feda2156" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60b1067b-caec-4f99-ac4e-0952de2b8ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba30ebbe-59cc-4407-ad20-26b13b3ff18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba30ebbe-59cc-4407-ad20-26b13b3ff18c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78f4c5cc-c0a9-4736-aa6c-561af44dc7ef" xlink:to="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_a3c19ea2-f1e3-4c5d-be39-68a50227ee8f" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_a3c19ea2-f1e3-4c5d-be39-68a50227ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_f38c93a5-d81a-4261-8b6b-475f820b6f75" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_db29c016-3959-42bf-bb7a-a7d5147b380b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_f38c93a5-d81a-4261-8b6b-475f820b6f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:to="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1c640e05-6d1c-4b5e-ae5b-9dea9064841c" xlink:to="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_39c2c59a-7d64-454a-b454-996dea202507" xlink:href="evh-20221231.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_MedicaidCustomersMember_39c2c59a-7d64-454a-b454-996dea202507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_217fb591-9310-412f-9b4e-62acbdf84681" xlink:href="evh-20221231.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_MedicareCustomersMember_217fb591-9310-412f-9b4e-62acbdf84681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_74095789-05dd-49a5-a7bf-c693960bc845" xlink:href="evh-20221231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b16a5c46-fd59-41d5-88ce-e74d18601086" xlink:to="loc_evh_CommercialAndOtherCustomersMember_74095789-05dd-49a5-a7bf-c693960bc845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51b612c5-5f57-4b9e-8fb3-fe3ede0842f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c858c461-1969-4fbd-9aeb-573b645c8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7f38ee5-caea-4fbd-80be-cafe28542f9e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c858c461-1969-4fbd-9aeb-573b645c8a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2be7cb29-c62d-45f2-9925-34ad6af219b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_74567bc0-6695-473b-b936-fa72846e5335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2be7cb29-c62d-45f2-9925-34ad6af219b0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_74567bc0-6695-473b-b936-fa72846e5335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2be7cb29-c62d-45f2-9925-34ad6af219b0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6f048698-4c1d-49f3-bba6-1ef1c38b87b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6f048698-4c1d-49f3-bba6-1ef1c38b87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:href="evh-20221231.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_034a9b0a-5624-4569-9e76-4c53570b45c9" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:href="evh-20221231.xsd#evh_December312023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312023Member_ec3b8130-4289-41f2-843b-aff2cacfb583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:href="evh-20221231.xsd#evh_December312024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312024Member_d693ae1d-d798-4332-a7e1-7868c9a0aa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:href="evh-20221231.xsd#evh_December312025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_3881e39f-5062-4f80-8113-39a39afda84c" xlink:to="loc_evh_December312025Member_00d59431-89cb-4fb9-9394-711fff3d7496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4db2cf75-a10d-4cb9-b163-0eb3ed91d7c3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5b0c28ff-9fb4-4919-ba83-39608c8a9fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0c9325ef-fda2-4d9f-8e81-9c66c3430269" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f02b6b13-f38d-4802-9d3a-5c5dc645560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_e29802d5-89be-45b2-a5b2-a7a663b25cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_e29802d5-89be-45b2-a5b2-a7a663b25cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_0e8d47a3-5bb8-4739-bc74-d4302108faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_0e8d47a3-5bb8-4739-bc74-d4302108faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a04b63d-aa5c-4ba1-b5a9-bad5dc8f6e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a04b63d-aa5c-4ba1-b5a9-bad5dc8f6e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fbf44e9-0113-4c15-93e7-ec3209b8d463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8fbf44e9-0113-4c15-93e7-ec3209b8d463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:href="evh-20221231.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_55e32571-2390-4fd7-8330-c8e1bc9e3710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:to="loc_us-gaap_ContractWithCustomerLiability_55e32571-2390-4fd7-8330-c8e1bc9e3710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e442ba7e-f68e-4d82-9121-a39edd4ab674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e442ba7e-f68e-4d82-9121-a39edd4ab674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_99e3a684-ed52-49fe-a9a8-d2f1e9aec742" xlink:href="evh-20221231.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_99e3a684-ed52-49fe-a9a8-d2f1e9aec742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_996114f2-c3c1-4b80-a324-fea087455aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7d34c4e2-252c-4e15-8181-ea719fee4365" xlink:to="loc_us-gaap_ContractWithCustomerLiability_996114f2-c3c1-4b80-a324-fea087455aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_44b8385e-a15b-4fde-bbf6-b90dd05b73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0344c0a2-7a3c-4551-bfb3-e31dd6363377" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_44b8385e-a15b-4fde-bbf6-b90dd05b73d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9acca240-b7e2-4ceb-b36f-2f8026996353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9acca240-b7e2-4ceb-b36f-2f8026996353" xlink:to="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_8ce0a377-6e0e-4e7d-9547-6bc78a76e1fd" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_28a881da-ba98-451e-adfe-f21f62498ca0" xlink:href="evh-20221231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:to="loc_evh_BonusesAndCommissionsMember_28a881da-ba98-451e-adfe-f21f62498ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_ddfd8eac-67d1-44a5-b81c-1c3eee453992" xlink:href="evh-20221231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_f9de470e-aa15-4b0b-8f52-67312a6b09ba" xlink:to="loc_evh_ContractFulfillmentCostsMember_ddfd8eac-67d1-44a5-b81c-1c3eee453992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_f9d697d6-2181-4894-a25d-c24d4dabf1a1" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_38903d14-302a-4533-adb6-1ce26f13530e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostNet_38903d14-302a-4533-adb6-1ce26f13530e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_30b4a36e-3cb9-4ccd-a77a-a4e8385fc5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_30b4a36e-3cb9-4ccd-a77a-a4e8385fc5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_d6fc7f0e-311b-4355-8bc1-869bd355c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_384a5d31-0f5d-4149-a0d1-2a0bae72ee1a" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_d6fc7f0e-311b-4355-8bc1-869bd355c174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_b11819ba-cfea-4427-85eb-fc8feb15155e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_b11819ba-cfea-4427-85eb-fc8feb15155e" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_d6118aad-ef36-4dab-b797-207ff506be08" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_f2636171-ffd6-484d-874e-7ae683efaac8" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_f2636171-ffd6-484d-874e-7ae683efaac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_13666c5a-742a-43fc-993e-e9921e0f292d" xlink:href="evh-20221231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_497fc9ec-9b42-4720-bd6c-baa991230069" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_13666c5a-742a-43fc-993e-e9921e0f292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_b0a4d6b1-821b-42ba-9fed-74b44fec9620" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_c94686b0-42c3-4dc9-b717-0e97eeccf474" xlink:href="evh-20221231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_c94686b0-42c3-4dc9-b717-0e97eeccf474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_f7514967-4234-4341-86ee-cbdfcd679d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_f7514967-4234-4341-86ee-cbdfcd679d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d5298b36-2367-4e42-9af8-f97e8a992732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_AccountsReceivableNet_d5298b36-2367-4e42-9af8-f97e8a992732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53895e6e-5c00-4dc7-8a47-4fd8ec70b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_46c0408b-d04f-4dae-bfa9-a75aff21f42f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53895e6e-5c00-4dc7-8a47-4fd8ec70b6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_c118d09b-c9b1-4c8b-ade0-e7e74c0ab470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_c118d09b-c9b1-4c8b-ade0-e7e74c0ab470" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9769e9ff-8a94-4f8e-bb8d-e1f4ddade434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9769e9ff-8a94-4f8e-bb8d-e1f4ddade434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_d7f76c9c-971a-418e-b0f7-8f6ca0d695ae" xlink:href="evh-20221231.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:to="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_d7f76c9c-971a-418e-b0f7-8f6ca0d695ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7c305b76-b7a6-4b33-815e-de7d76bc5160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7c305b76-b7a6-4b33-815e-de7d76bc5160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_3aa73e9a-d3dd-402e-a7a4-4be43e363dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_3aa73e9a-d3dd-402e-a7a4-4be43e363dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f603474a-4161-457f-a2bf-0cb6c6504d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_58b0ec4b-3a0b-4c75-b3a9-2c370720eea4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f603474a-4161-457f-a2bf-0cb6c6504d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97b9aef3-d29a-4dba-8754-b52166902f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97b9aef3-d29a-4dba-8754-b52166902f1d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f59c7b-9b73-4bc0-877f-d3e439553560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7b0e8dd4-b2cc-4898-9427-ed55b0c23528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_ComputerEquipmentMember_7b0e8dd4-b2cc-4898-9427-ed55b0c23528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8ae91764-32eb-40cb-bfbc-706abf78b37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8ae91764-32eb-40cb-bfbc-706abf78b37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_e358909d-9d3a-4677-9d1d-6f698e3ecd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_e358909d-9d3a-4677-9d1d-6f698e3ecd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0e0233b0-4b42-4c9a-825b-98d0956c46a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39fd8cf8-2f78-4e38-a59e-2a54176d6ac9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0e0233b0-4b42-4c9a-825b-98d0956c46a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fc34d8e7-631a-469f-bf30-c411c96396c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8be0cd21-c0b1-42c9-bc1c-9612e879c8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8be0cd21-c0b1-42c9-bc1c-9612e879c8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64f8f8d3-c239-45a4-9b40-125eba72daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64f8f8d3-c239-45a4-9b40-125eba72daeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca091fb9-3b76-43b5-bc83-323ef11b0860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca091fb9-3b76-43b5-bc83-323ef11b0860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_d0bdaf5a-af2d-4ceb-a854-e37ca653f867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_d0bdaf5a-af2d-4ceb-a854-e37ca653f867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6c1bea2c-6d1c-42c4-b0e6-d2191f205272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_Depreciation_6c1bea2c-6d1c-42c4-b0e6-d2191f205272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_cea6f8da-7403-4c51-ad7a-e0c34e04ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2d462967-e02f-416f-987f-33e4e0d4ba34" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_cea6f8da-7403-4c51-ad7a-e0c34e04ea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56a04ba3-d46d-43c3-8e68-e4f40c54b578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_45e8d01b-2a30-4a88-ab92-56a9c3eb2e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56a04ba3-d46d-43c3-8e68-e4f40c54b578" xlink:to="loc_us-gaap_NumberOfReportingUnits_45e8d01b-2a30-4a88-ab92-56a9c3eb2e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bfec7de0-f8b1-4967-99bb-89bc15298e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56a04ba3-d46d-43c3-8e68-e4f40c54b578" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bfec7de0-f8b1-4967-99bb-89bc15298e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5740aa3f-5c51-482e-bbd6-2b3b0994b41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_c8e695a8-0786-4f0e-b959-1de3dea8fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5740aa3f-5c51-482e-bbd6-2b3b0994b41d" xlink:to="loc_us-gaap_NumberOfReportingUnits_c8e695a8-0786-4f0e-b959-1de3dea8fa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5740aa3f-5c51-482e-bbd6-2b3b0994b41d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3aad43-4d08-4ed1-9419-fbf056dc59ce" xlink:to="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_657d8faa-4c3f-4b2c-aeca-88974cab7a86" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_657d8faa-4c3f-4b2c-aeca-88974cab7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_4406abfa-fd05-4308-8d34-29fca4457880" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_964b49c0-e21c-427a-8a69-8c448877dde4" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_4406abfa-fd05-4308-8d34-29fca4457880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a8d9e61a-5d67-4855-8e01-10ca3aadefb0" xlink:to="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:to="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b67cc33a-eeab-4136-bc56-034e52362dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_Goodwill_b67cc33a-eeab-4136-bc56-034e52362dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b70f00ed-60db-4785-baea-eb41ffbf52df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b70f00ed-60db-4785-baea-eb41ffbf52df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_04d4bb5e-4604-4869-bf9e-329a13da927e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_04d4bb5e-4604-4869-bf9e-329a13da927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7ae57886-1add-4d22-81ab-7d9601cf55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d0ebc52b-80ee-4f0d-b66a-28cc8b09fb09" xlink:to="loc_us-gaap_Goodwill_7ae57886-1add-4d22-81ab-7d9601cf55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5ff82710-0742-4d58-9a03-b5ef7f2df609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0ff5304b-b8ce-40cc-af8e-ee692eb8722b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5ff82710-0742-4d58-9a03-b5ef7f2df609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_905b65cc-15c2-47db-b411-42b9967a137f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_905b65cc-15c2-47db-b411-42b9967a137f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1406526-d44b-450a-b30f-969c0cf6642d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7899177f-052a-41da-ba8f-b51519e39cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_TradeNamesMember_7899177f-052a-41da-ba8f-b51519e39cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4b47576a-8473-4f67-b7fe-352772e3e2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4b47576a-8473-4f67-b7fe-352772e3e2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5db05ee7-3e31-4ec9-aeed-d0c04391a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5db05ee7-3e31-4ec9-aeed-d0c04391a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_6ca48607-88e0-4d27-8887-50c5c4964223" xlink:href="evh-20221231.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_evh_BelowMarketLeasesMember_6ca48607-88e0-4d27-8887-50c5c4964223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_0878c130-6686-4412-8127-ea2b919539a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bc92062-e7ce-43bc-85e6-5fd8ca413153" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_0878c130-6686-4412-8127-ea2b919539a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e36bf7fa-8530-4731-a76f-091a8d43a6e3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2ca58520-f7e3-47df-b334-0ba63c954948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dabaa52d-0e57-4eb5-82ec-620fef6a82a7" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2ca58520-f7e3-47df-b334-0ba63c954948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_773b5b55-366e-460c-8ad7-762af6e0378d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_d89213c0-84b2-4839-acbd-e9a818c12fb7" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c2c692d-10db-4b2e-aaf2-bee519a4e0eb" xlink:to="loc_evh_TrueHealthMember_d89213c0-84b2-4839-acbd-e9a818c12fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1924dd6e-b478-458e-bb14-f4c7b954648d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9829b3f0-b730-4faf-9c76-e5daea40cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9829b3f0-b730-4faf-9c76-e5daea40cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e765d490-1ea5-4785-8806-b671a6ae0070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e765d490-1ea5-4785-8806-b671a6ae0070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1c48a407-0f75-4305-89d5-cbd3412c1ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1c48a407-0f75-4305-89d5-cbd3412c1ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cebd058-e9e9-4450-bed9-c2be3eaa9190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cebd058-e9e9-4450-bed9-c2be3eaa9190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d494b1df-9bfb-405a-9cda-006784e65070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590ade0d-455e-467e-bf2c-3d49dcda04e8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d494b1df-9bfb-405a-9cda-006784e65070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b4baefe0-123c-471e-9e9e-887d1035400b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b4baefe0-123c-471e-9e9e-887d1035400b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_693c7b2a-2c4c-4391-aeb4-0ff1c316dcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_693c7b2a-2c4c-4391-aeb4-0ff1c316dcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_23d5fb64-5ff6-4d94-8b37-557be70f69fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_23d5fb64-5ff6-4d94-8b37-557be70f69fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a074a4ff-30f8-4126-9b69-c7d12e13e99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a074a4ff-30f8-4126-9b69-c7d12e13e99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f9be9a7f-e161-4bc1-93db-77c4e2c427d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f9be9a7f-e161-4bc1-93db-77c4e2c427d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d40bc83c-7fb4-4408-a744-5e2c448fd578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d40bc83c-7fb4-4408-a744-5e2c448fd578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5390a8b-3566-4de5-b94d-5f86bd55df92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f533dcfb-ad2e-4646-805f-506ffc69f8c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5390a8b-3566-4de5-b94d-5f86bd55df92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3330a22e-86da-47fd-bbad-5eca412ada7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3330a22e-86da-47fd-bbad-5eca412ada7d" xlink:to="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_37752982-b355-40fa-be71-cb8578a852fc" xlink:to="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b7df02ae-9e73-464f-b2f0-5ede22427b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_us-gaap_SecuredDebtMember_b7df02ae-9e73-464f-b2f0-5ede22427b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f3fdea2c-b6da-45e9-b4e8-76de09f17748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f3fdea2c-b6da-45e9-b4e8-76de09f17748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_63157fbc-5a9a-4b26-af43-3e2f4496c546" xlink:href="evh-20221231.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7dad3994-6ab6-4c07-9838-23378b81fad5" xlink:to="loc_evh_A2022CreditFacilitiesMember_63157fbc-5a9a-4b26-af43-3e2f4496c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afd2f00f-eaee-41b8-aa9b-5be1f02c6372" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e71f93b5-a14a-4f3d-951c-e468fe7b648c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:to="loc_us-gaap_LineOfCreditMember_e71f93b5-a14a-4f3d-951c-e468fe7b648c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0df5318c-58d0-4902-be9b-b79e280bb9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1dcab17-7166-482e-b3ff-c38e02c9fe79" xlink:to="loc_us-gaap_SecuredDebtMember_0df5318c-58d0-4902-be9b-b79e280bb9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_07c7b74e-cafa-429c-8791-adfcbd8778a3" xlink:to="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_ccb0c49f-5058-4605-8cae-2cd7d2d51e9c" xlink:href="evh-20221231.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_ccb0c49f-5058-4605-8cae-2cd7d2d51e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d900fb70-b034-41d2-9421-dfea2c611897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8aff512c-9e59-4a3e-8edb-548860760d78" xlink:to="loc_us-gaap_BaseRateMember_d900fb70-b034-41d2-9421-dfea2c611897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_29ea1f22-19bf-4be2-8ee1-f325b89217c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_3ba8c75a-8037-4a47-ba6f-fe1169e55578" xlink:href="evh-20221231.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7dadf512-217a-411c-ab18-6efe3f805135" xlink:to="loc_evh_A2022CreditFacilitiesMember_3ba8c75a-8037-4a47-ba6f-fe1169e55578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_32995653-01a1-424c-a981-fabec4e27b59" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58f25131-31ea-4a46-9568-ce00e2354f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58f25131-31ea-4a46-9568-ce00e2354f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1326933d-c70f-4082-a9be-c0c9da65c0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1326933d-c70f-4082-a9be-c0c9da65c0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_c7c5d18e-b3fb-4a1e-8abe-a571dba08c27" xlink:href="evh-20221231.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_c7c5d18e-b3fb-4a1e-8abe-a571dba08c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_31a47b53-792f-41d7-a7e1-8c71a774bb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_31a47b53-792f-41d7-a7e1-8c71a774bb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7f765d38-8f16-4944-96d6-8cdc3d2c6bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7f765d38-8f16-4944-96d6-8cdc3d2c6bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a450ebc8-392e-435c-a64a-0b81ebce1859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_InterestExpenseDebt_a450ebc8-392e-435c-a64a-0b81ebce1859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_fcb811fd-fe5d-4992-aace-529cf3f6d7d0" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_fcb811fd-fe5d-4992-aace-529cf3f6d7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_c0b0c920-63ea-4684-abcc-5ac75e2db270" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_c0b0c920-63ea-4684-abcc-5ac75e2db270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_863067fc-142d-4346-b0e5-d6fa2dd64558" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_863067fc-142d-4346-b0e5-d6fa2dd64558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_07cc7c32-fb0e-4a55-b971-01cb55689cad" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_07cc7c32-fb0e-4a55-b971-01cb55689cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_20b274f4-660e-438a-bb9a-25841ced5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_20b274f4-660e-438a-bb9a-25841ced5f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8776526e-5fc6-4bbf-a789-c9460617bdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8776526e-5fc6-4bbf-a789-c9460617bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0ac1bb-e18e-4638-b8e9-29cf4cc4ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b85de908-da64-43a3-a024-a0b25d4b3060" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0ac1bb-e18e-4638-b8e9-29cf4cc4ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d05712e6-53b9-4283-ae5d-1331a7ad3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d05712e6-53b9-4283-ae5d-1331a7ad3e5e" xlink:to="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3bfebf16-596b-41bb-8ef0-b7d1a2cca6cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_112f44fd-5540-4465-95c3-f7d6f087cbf2" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_112f44fd-5540-4465-95c3-f7d6f087cbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_f7dd0a76-6a5c-452e-ba3a-024d3cd64842" xlink:href="evh-20221231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_f7dd0a76-6a5c-452e-ba3a-024d3cd64842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_8f492442-f2b1-4edb-82d0-e174a26b7b16" xlink:href="evh-20221231.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ebb891-8eda-4ab9-839d-a8de1f09d156" xlink:to="loc_evh_NewNotesMember_8f492442-f2b1-4edb-82d0-e174a26b7b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0b44dbb8-285f-46d6-a43c-19dadc0e644f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e8312a50-a281-4c47-9dc3-fda6f31748dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00588485-83ad-4ea5-851a-2d7e42f381fd" xlink:to="loc_us-gaap_SeniorNotesMember_e8312a50-a281-4c47-9dc3-fda6f31748dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_41a1a46f-d0ef-48be-8b5b-8da57a3c6e2e" xlink:to="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ad2995a-2be7-47c7-91a8-16856465578a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_CommonStockMember_4ad2995a-2be7-47c7-91a8-16856465578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_abccf633-6529-4bde-bb84-4941c1803c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_abccf633-6529-4bde-bb84-4941c1803c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_92849f16-d387-4bd2-8e43-09cfc048f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb432342-1b21-41cc-a8b9-57454762af53" xlink:to="loc_us-gaap_RetainedEarningsMember_92849f16-d387-4bd2-8e43-09cfc048f70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e9a9fc55-67e0-44ed-9ed3-5d0333d65438" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e9be39d8-6f19-4ceb-91e0-352fcf6d4991" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_723965e0-4e36-4713-81cc-0720acad6969" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e9be39d8-6f19-4ceb-91e0-352fcf6d4991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_198a4ebb-8ea5-40fc-a7f0-073921685369" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_15286cfd-1ced-43b5-8da3-07385d8b7231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d3f3a92f-3534-491c-a3c0-0a074d9fcced" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_15286cfd-1ced-43b5-8da3-07385d8b7231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_736b2041-09c5-4c31-b0c3-fd0358fb6753" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_5dc1eb7d-3bf9-45f0-86f3-618466b9a2b8" xlink:href="evh-20221231.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_5dc1eb7d-3bf9-45f0-86f3-618466b9a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_639642c4-43a5-44ab-99a3-6c314e1bd938" xlink:href="evh-20221231.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_23ae66b1-f652-4777-95c0-65ec7370dae6" xlink:to="loc_evh_DeferredFinancingFeesMember_639642c4-43a5-44ab-99a3-6c314e1bd938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a141af6e-0f33-4c2f-8155-4bb3cd2e1418" xlink:to="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d67367d3-7460-4c5d-bc2c-dcbf93c5d005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fb90e6db-ad66-4c0d-8a3f-fbcc107d52a9" xlink:to="loc_us-gaap_CommonClassAMember_d67367d3-7460-4c5d-bc2c-dcbf93c5d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_56b0a8b0-2574-4887-b48e-11673800d7d1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2a62b7dd-18db-4c4c-9127-5a67bc923a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2a62b7dd-18db-4c4c-9127-5a67bc923a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7aaed49-c5cb-4e6d-9aa0-d75a431a7e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7aaed49-c5cb-4e6d-9aa0-d75a431a7e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_83c23736-e33a-4160-a695-d4757a5a53ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_83c23736-e33a-4160-a695-d4757a5a53ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_30d8929c-e603-46b7-9c73-21eb34cc997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_30d8929c-e603-46b7-9c73-21eb34cc997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b780941-b34c-4a3c-aba1-2653767885f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b780941-b34c-4a3c-aba1-2653767885f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_728665ac-321d-4aca-9acc-2dc860c13d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_728665ac-321d-4aca-9acc-2dc860c13d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3f22b4ec-7565-4bce-9555-5d945b9ed5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_InterestExpenseDebt_3f22b4ec-7565-4bce-9555-5d945b9ed5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_caae84f8-1ed1-4fd9-be4f-14f52d1b01f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_caae84f8-1ed1-4fd9-be4f-14f52d1b01f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_406df81e-b76d-42f6-915c-1ea143f403e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_406df81e-b76d-42f6-915c-1ea143f403e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_81c6f105-1d70-4782-b867-132263178c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_81c6f105-1d70-4782-b867-132263178c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c1ecc71-d53e-4969-a385-ee71a05159dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_LongTermDebt_5c1ecc71-d53e-4969-a385-ee71a05159dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_4cdd9776-3171-4cde-89d9-6d466639cb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_4cdd9776-3171-4cde-89d9-6d466639cb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_0a742062-3b2c-4764-87e2-bb1621357aa6" xlink:href="evh-20221231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_0a742062-3b2c-4764-87e2-bb1621357aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c03fd24-e29a-47d1-84f4-0684b81bfbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_StockholdersEquity_7c03fd24-e29a-47d1-84f4-0684b81bfbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_50146d0a-b1cf-45a8-b3e2-ea902d41a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_50146d0a-b1cf-45a8-b3e2-ea902d41a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_612e9955-0cab-4728-8188-cc3e3ccf39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_612e9955-0cab-4728-8188-cc3e3ccf39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_e5feb20c-f720-4afc-aade-9a011d34613e" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_e5feb20c-f720-4afc-aade-9a011d34613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ad5ef9c6-fda9-4378-88f8-63e92cef7a46" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ad5ef9c6-fda9-4378-88f8-63e92cef7a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_39bfd6f2-d9a1-41f0-bced-1c62691e5241" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_39bfd6f2-d9a1-41f0-bced-1c62691e5241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_85eed19b-c976-4430-9aaf-af5b37a1224a" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_85eed19b-c976-4430-9aaf-af5b37a1224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_da31d51e-46cf-467f-b8f1-fed805c78117" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_da31d51e-46cf-467f-b8f1-fed805c78117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f6b8fd31-f65d-465b-9afc-d7a43d97b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f6b8fd31-f65d-465b-9afc-d7a43d97b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce4109c6-eb7d-4857-bd84-7b5c7c55f453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6175ef53-c52a-4b62-a865-123642df6f97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce4109c6-eb7d-4857-bd84-7b5c7c55f453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2019CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2656db20-19dd-4872-90e6-ec481d68d366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2656db20-19dd-4872-90e6-ec481d68d366" xlink:to="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_90260529-7a39-472d-9d4b-69e5004b9d8b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_fcd0f71f-cbb9-4ec0-b0f4-29e697d77b35" xlink:href="evh-20221231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_InitialTermLoanFacilityMember_fcd0f71f-cbb9-4ec0-b0f4-29e697d77b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_73c505a3-88d6-4cf6-94be-ad6fd0dd2e69" xlink:href="evh-20221231.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_CreditAgreementMember_73c505a3-88d6-4cf6-94be-ad6fd0dd2e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_d58952ea-bffd-4228-9f88-8e0a1f135f90" xlink:href="evh-20221231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60dd05b9-9d6e-4645-ad1c-6f7507957c4d" xlink:to="loc_evh_SeniorCreditFacilitiesMember_d58952ea-bffd-4228-9f88-8e0a1f135f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0e35b17-d421-4fb6-877c-50eb8bc9ce97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ce4640bc-0931-4a14-aeb5-97dda52bd052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:to="loc_us-gaap_SecuredDebtMember_ce4640bc-0931-4a14-aeb5-97dda52bd052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2c603ce8-7361-4745-9210-3375233dc309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c15294ea-6c07-4d12-bbcc-30ead29dd313" xlink:to="loc_us-gaap_LineOfCreditMember_2c603ce8-7361-4745-9210-3375233dc309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5681352b-ee95-420a-8fbe-e30d1bde6e53" xlink:to="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_10baa2ee-fb70-4bcd-bef9-b7a8a7521fdc" xlink:href="evh-20221231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_26b2561f-97d4-4efd-b330-f78bb2fff915" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_10baa2ee-fb70-4bcd-bef9-b7a8a7521fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cdfa61c5-69eb-4653-af6c-5296ce09e43e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7998afe8-3ba7-4a23-8ce3-2ab72b8a497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7998afe8-3ba7-4a23-8ce3-2ab72b8a497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae01ecb9-251f-4875-b264-4d62b53430f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ae01ecb9-251f-4875-b264-4d62b53430f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b73ae9d0-348a-47d3-87cd-983f61a8af26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b73ae9d0-348a-47d3-87cd-983f61a8af26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_ebc788e6-8a62-45b5-bf2d-95f9487e5b26" xlink:href="evh-20221231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_evh_PaymentsOfMakeWholePremium_ebc788e6-8a62-45b5-bf2d-95f9487e5b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9983b614-9a6d-4bb7-ad2a-7505408e375f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_InterestPaidNet_9983b614-9a6d-4bb7-ad2a-7505408e375f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8f5235a-fff0-4aaa-9234-bd86b1818f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8f5235a-fff0-4aaa-9234-bd86b1818f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_451ff0d1-1e47-4be7-888c-ae9c86eff71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_451ff0d1-1e47-4be7-888c-ae9c86eff71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_456ab907-6135-40cc-84d1-676f8f6c672e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_875840d2-4425-43dd-a410-78bb7291eb67" xlink:to="loc_us-gaap_LegalFees_456ab907-6135-40cc-84d1-676f8f6c672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_99afbc59-6063-41c1-8e3e-1443635e7db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_99afbc59-6063-41c1-8e3e-1443635e7db0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9c3bba46-1d0f-420a-bd85-63abf94cc24b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_64d0c6f2-41a0-4e87-8bc3-bdb75b7a33b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7932b828-55ad-4cb4-be28-a0f4b1e001ec" xlink:to="loc_us-gaap_CommonClassAMember_64d0c6f2-41a0-4e87-8bc3-bdb75b7a33b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6f4f79d0-cece-44f4-9918-d31d38413e24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_f1d4eac8-5aa0-4995-8bc3-3a636c22413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_f1d4eac8-5aa0-4995-8bc3-3a636c22413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac37ba46-8293-4f9e-bd17-f960c35be5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac37ba46-8293-4f9e-bd17-f960c35be5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_85cddafd-c699-448c-abdb-fc85b9e02510" xlink:href="evh-20221231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_85cddafd-c699-448c-abdb-fc85b9e02510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8a1b5cc8-1fc9-42fa-8045-81772c963cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67a11df9-71f3-40c1-8971-873408b24f62" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8a1b5cc8-1fc9-42fa-8045-81772c963cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ac43dfb9-640e-44cd-8b80-a5efec0c5bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac43dfb9-640e-44cd-8b80-a5efec0c5bf6" xlink:to="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_22a44d54-4489-4112-8ebb-0b8431884019" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_22719266-2e71-4d23-b10a-0fcce11be7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_70e32a80-1f5e-48fa-96a3-c8d2eff45e89" xlink:to="loc_us-gaap_SeniorNotesMember_22719266-2e71-4d23-b10a-0fcce11be7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5c4aa1d-06ba-4c5f-8d3d-f3a86e03773d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_776a32b7-42dd-4cd9-b777-2dc2a605553a" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e70948f-dffe-4baf-b1b4-d5de98395982" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_776a32b7-42dd-4cd9-b777-2dc2a605553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bcba0acb-995c-45cd-85c5-32c6185d2e13" xlink:to="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97150526-82a8-4deb-af90-807606bc713e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_CommonStockMember_97150526-82a8-4deb-af90-807606bc713e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ab4a61ed-ebe9-4702-9655-190d53145668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ab4a61ed-ebe9-4702-9655-190d53145668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6b025b2a-e850-4cd7-a360-7497347b915c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ff0350bf-7f3a-43ec-b5d9-72441e74c5fd" xlink:to="loc_us-gaap_RetainedEarningsMember_6b025b2a-e850-4cd7-a360-7497347b915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_72c14550-fe84-401c-9a48-1c8a7343da0f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c377dfb5-86ef-411a-85d8-b094717f02b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_585847eb-2548-43e3-af1c-ff5260b933d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c377dfb5-86ef-411a-85d8-b094717f02b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_227e0d05-e739-4e66-9a36-bab5522389b0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_90041e0c-872d-4082-9f01-52645bf3cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ca38249-b2a1-480c-a4a9-f25c3b602f3f" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_90041e0c-872d-4082-9f01-52645bf3cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2832fc87-fbc0-4f33-a4bc-7e489e7cddfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_d42f7485-9410-4074-8ecf-1d7558ca4b2b" xlink:href="evh-20221231.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_d42f7485-9410-4074-8ecf-1d7558ca4b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_e31054b8-8b73-4022-b37f-dc1aa2048262" xlink:href="evh-20221231.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fe1d12d-58f5-4876-b16b-282aed0ad7d3" xlink:to="loc_evh_DeferredFinancingFeesMember_e31054b8-8b73-4022-b37f-dc1aa2048262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6e7ba2c-6caf-4e6b-960b-a81b5d87f619" xlink:to="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_cee08375-8aff-4f87-b825-aa1eed2f76f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f288bbd7-6c61-4fb8-9987-b3c2d63502fd" xlink:to="loc_us-gaap_CommonClassAMember_cee08375-8aff-4f87-b825-aa1eed2f76f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64eccf69-4fb0-49a2-a5a6-e3cac47166ec" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_58f09039-bdd7-49d0-8ecf-6767af78e89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_58f09039-bdd7-49d0-8ecf-6767af78e89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_67498d62-aca7-4745-9dad-d35a723771c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_67498d62-aca7-4745-9dad-d35a723771c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2300a6fd-d2f4-4f1e-a02c-5c7466f67018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_InterestExpenseDebt_2300a6fd-d2f4-4f1e-a02c-5c7466f67018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4cf4de9f-08fd-41e4-bd0f-f82917dea0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4cf4de9f-08fd-41e4-bd0f-f82917dea0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4d2c8b6d-f00d-4edf-9c0c-26ab7afb5e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4d2c8b6d-f00d-4edf-9c0c-26ab7afb5e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_503571da-03ec-4987-b6a9-cbbfa428d930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_503571da-03ec-4987-b6a9-cbbfa428d930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7cee9385-e1a9-4cc5-bb4e-856c1ffc91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_LongTermDebt_7cee9385-e1a9-4cc5-bb4e-856c1ffc91a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0b3b7b23-6d90-4af9-b5eb-a088d1358ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0b3b7b23-6d90-4af9-b5eb-a088d1358ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1557415f-5e13-412a-9ee9-7b3165780013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1557415f-5e13-412a-9ee9-7b3165780013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b36a4da1-272c-4d17-a37b-8cf8cbf56ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_StockholdersEquity_b36a4da1-272c-4d17-a37b-8cf8cbf56ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ed254ae0-22ff-4e63-a244-36f4d824b17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ed254ae0-22ff-4e63-a244-36f4d824b17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e2ce543b-6137-4a16-8384-fa37ac9c6344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e2ce543b-6137-4a16-8384-fa37ac9c6344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dd860b4f-b552-43a8-8caa-2cebb20bdbb1" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_dd860b4f-b552-43a8-8caa-2cebb20bdbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_6a81220d-118d-46bc-b8cb-b9310148542e" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_6a81220d-118d-46bc-b8cb-b9310148542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_5a73641c-6faa-48f7-a530-843d2ff54c1a" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_5a73641c-6faa-48f7-a530-843d2ff54c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b4ed3356-d4d2-4fc2-bbc6-a246ca955a6f" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b4ed3356-d4d2-4fc2-bbc6-a246ca955a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_84e8c21e-6ff0-4a50-a5ee-9e1edfc919ef" xlink:href="evh-20221231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d53d9ca-9c94-405d-bd97-d97420b40291" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_84e8c21e-6ff0-4a50-a5ee-9e1edfc919ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_60b81b25-60b3-4c4f-bee9-e51754b165ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_60b81b25-60b3-4c4f-bee9-e51754b165ba" xlink:to="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98ec4038-02b4-4ec8-9abf-9f67c17fc78a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_55345bfa-bec3-4b59-9f24-c34fde17f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_542810bf-93fe-45b5-b8f7-9c0c9f08716c" xlink:to="loc_us-gaap_SeniorNotesMember_55345bfa-bec3-4b59-9f24-c34fde17f56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b044ed5-2bc4-4cff-b6e0-847f12844296" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_ebd7ab16-84a9-4e1a-90b0-be87bf0c4b58" xlink:href="evh-20221231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_ebd7ab16-84a9-4e1a-90b0-be87bf0c4b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_49f27a3c-7e6d-4c3a-91f8-a4a66bfc9e0a" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a50b721-dfc5-4217-a02a-4821e50ad966" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_49f27a3c-7e6d-4c3a-91f8-a4a66bfc9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f761deda-80bf-461f-a08e-806c62705877" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_82eca846-49e1-4a6b-8030-61b68134ce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_82eca846-49e1-4a6b-8030-61b68134ce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13e7b77a-3577-4aa8-82e5-c1bb109dc9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13e7b77a-3577-4aa8-82e5-c1bb109dc9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_addda271-0c3c-4c74-9db5-20cdef15994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_addda271-0c3c-4c74-9db5-20cdef15994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1ae850bf-33ac-4745-92c0-ddce5a19bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1ae850bf-33ac-4745-92c0-ddce5a19bbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_de24804e-6b93-4322-9685-5a5d141087f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_de24804e-6b93-4322-9685-5a5d141087f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_cb08ec15-73de-4f6f-94eb-202985c9685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_cb08ec15-73de-4f6f-94eb-202985c9685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_773dc642-bb08-4b33-a8c1-63d19ccec81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_773dc642-bb08-4b33-a8c1-63d19ccec81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_65ceb9d3-fa84-4901-8100-498d695e2414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_65ceb9d3-fa84-4901-8100-498d695e2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_df580ee3-1d90-4082-a099-0cae9daf4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_df580ee3-1d90-4082-a099-0cae9daf4ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_6cd8519c-6503-409a-a528-cb63c54cc43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3437ed-b39e-4091-9961-4358b1698a0e" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_6cd8519c-6503-409a-a528-cb63c54cc43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67d990f8-4ddf-49ea-b27f-f5e10af9ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67d990f8-4ddf-49ea-b27f-f5e10af9ec5e" xlink:to="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02043bf4-b196-4081-a527-c6adb6aac1cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_335468d5-0270-414b-a740-b61128c8cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33fda448-fa8a-4440-bf8f-3a330cc2128e" xlink:to="loc_us-gaap_SeniorNotesMember_335468d5-0270-414b-a740-b61128c8cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39f822d2-d17c-4b19-ac0f-dbc3ad9d88c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_00d3e166-b874-4ed9-9764-5f4672562ffa" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_00d3e166-b874-4ed9-9764-5f4672562ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_173e399f-29a8-40a0-9f3d-4c3d099daaea" xlink:href="evh-20221231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1223473a-f83d-4a34-9f64-33dc10bc9e8d" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_173e399f-29a8-40a0-9f3d-4c3d099daaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_657690c5-b442-435d-b119-d442fe6e8bb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7ee42917-d9eb-4bb8-8c09-fd3454d16ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39750f81-db66-4e53-a8b5-193343e70858" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7ee42917-d9eb-4bb8-8c09-fd3454d16ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30752cdf-05c5-4e0e-9970-80a876cb1e01" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_eef9bbae-e7c8-43eb-83d6-7484cefecaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_ConvertibleDebt_eef9bbae-e7c8-43eb-83d6-7484cefecaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dcb228f9-2a73-45d8-8643-14e0fba2a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dcb228f9-2a73-45d8-8643-14e0fba2a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_97c424b9-dd87-4b33-aa7c-e8595986b028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_97c424b9-dd87-4b33-aa7c-e8595986b028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_65d1b88b-1401-4b99-b6b9-35b9d835c867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_65d1b88b-1401-4b99-b6b9-35b9d835c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_886cde57-2683-405b-ba85-555e5c8bff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d6bf6da3-d73d-4d8e-86f5-00c650bb6904" xlink:to="loc_us-gaap_LongTermDebtFairValue_886cde57-2683-405b-ba85-555e5c8bff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b94d060-3eaa-4192-b4d3-5806f04adbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b94d060-3eaa-4192-b4d3-5806f04adbd4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ddeed37f-fbad-491a-99a6-7443c8034905" xlink:to="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_75373255-14da-4496-a733-37d982addb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6427aa05-843f-4f93-a82c-bea1e28044dc" xlink:to="loc_us-gaap_LetterOfCreditMember_75373255-14da-4496-a733-37d982addb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01c1d493-aed8-4dbd-bf79-4dc06be22782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9ddfc3a0-3c5e-4847-94ba-3233d15bbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_93ced6c4-93e5-4630-9dce-1fb7a2b874f4" xlink:to="loc_us-gaap_LineOfCreditMember_9ddfc3a0-3c5e-4847-94ba-3233d15bbd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f7c07e37-a54f-4a5c-9723-32f19aaf8e23" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_64061ef6-24a3-48b6-9b33-bbc5a9396386" xlink:href="evh-20221231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b19dc747-8869-45c9-be56-a22a1b0634cc" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_64061ef6-24a3-48b6-9b33-bbc5a9396386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f9686aa1-b9cf-47ed-9894-7f91c9a35f1d" xlink:to="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_7d3c763d-b978-4e4a-b105-4c5ab2dcc7a0" xlink:href="evh-20221231.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8aaf0a7c-8de4-4a2d-ac8d-bac2b945ee88" xlink:to="loc_evh_ShareholderClassActionComplaintMember_7d3c763d-b978-4e4a-b105-4c5ab2dcc7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3834fb71-7baf-4817-9413-9f55ac1ad85b" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_5e26ca2d-68b1-48fd-8aac-f7a71d6c1c49" xlink:href="evh-20221231.xsd#evh_UPMCResellerAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4f17fb17-1685-4659-8f7b-56e61db6ff39" xlink:to="loc_evh_UPMCResellerAgreementMember_5e26ca2d-68b1-48fd-8aac-f7a71d6c1c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7e9063d0-d308-472a-b6b7-686eab86efb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_89d5f5a9-e2c2-43fd-a40a-37c109c7b6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_89d5f5a9-e2c2-43fd-a40a-37c109c7b6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_616263ef-1d1c-4201-812c-7550a711fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_616263ef-1d1c-4201-812c-7550a711fe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_c3bf72d8-b5bd-4e6d-babf-bcf631aae18a" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_c3bf72d8-b5bd-4e6d-babf-bcf631aae18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_60033f86-0c23-455f-89b3-00c1343faf03" xlink:href="evh-20221231.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_60033f86-0c23-455f-89b3-00c1343faf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_f51eee20-7343-43a3-9d2f-b64b31af3178" xlink:href="evh-20221231.xsd#evh_NumberOfCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_NumberOfCustomers_f51eee20-7343-43a3-9d2f-b64b31af3178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92f27606-3591-4723-a48c-38c57d929498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_Revenues_92f27606-3591-4723-a48c-38c57d929498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_751a95b2-a0b7-4a53-94bb-25d898fe6c1c" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_751a95b2-a0b7-4a53-94bb-25d898fe6c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_f0a449c4-277e-4c75-8ee3-86e570cdbb28" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_evh_TaxReceivableAgreementLiability_f0a449c4-277e-4c75-8ee3-86e570cdbb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e683bc89-5e7d-4e22-b06a-2b4dea6e96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_99b8b8b6-4fe9-493f-8179-cb7b0bec28ab" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e683bc89-5e7d-4e22-b06a-2b4dea6e96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bcbb84bb-1e86-4290-9e58-f2963c2c9789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bcbb84bb-1e86-4290-9e58-f2963c2c9789" xlink:to="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_78dad284-5d78-447a-89b2-8d85f0b86c0b" xlink:to="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_b5880dad-d156-437f-8be0-fc6bc033198d" xlink:href="evh-20221231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_b5880dad-d156-437f-8be0-fc6bc033198d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_28b9ac94-7fa0-4592-9635-1f575b03bac9" xlink:href="evh-20221231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_FloridaBlueMedicareIncMember_28b9ac94-7fa0-4592-9635-1f575b03bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_c299cc29-b2a7-4dea-94ff-442594789ad1" xlink:href="evh-20221231.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_MolinaHealthcareMember_c299cc29-b2a7-4dea-94ff-442594789ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_4f1f3911-4e1f-4cfd-be2c-d67cce2403b7" xlink:href="evh-20221231.xsd#evh_BrightHealthManagementIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_BrightHealthManagementIncMember_4f1f3911-4e1f-4cfd-be2c-d67cce2403b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_4cc28a77-1fec-4fe1-93fc-b520ed746335" xlink:href="evh-20221231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_4cc28a77-1fec-4fe1-93fc-b520ed746335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_329551b3-c889-404d-987f-46fc16600e69" xlink:href="evh-20221231.xsd#evh_NewCenturyHealthMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4ba6ec08-2991-458a-b04e-4603d8a995a3" xlink:to="loc_evh_NewCenturyHealthMember_329551b3-c889-404d-987f-46fc16600e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_45ecf292-1dc6-4c79-b127-6d46f4c6a241" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a9ff1b9-728c-4f2d-8060-6f0424a10975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66ec7842-87dd-4bc2-92f8-488f510b98fb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a9ff1b9-728c-4f2d-8060-6f0424a10975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc23d18e-fb0d-4f95-87df-b1027c2f293c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_38ea2de0-991b-40d8-89f5-263d69dedb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:to="loc_us-gaap_AccountsReceivableMember_38ea2de0-991b-40d8-89f5-263d69dedb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_4d3ec250-15a2-4ae5-81ff-3efed22cbffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08a8d114-1057-4311-a766-4eca9f373bee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_4d3ec250-15a2-4ae5-81ff-3efed22cbffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_87654e7b-bbb9-426a-8107-9797e38ed141" xlink:to="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_6813375e-9b82-487e-a81f-d6dd1b132cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_2b518dd1-15bd-438c-93f5-66af372cde61" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_6813375e-9b82-487e-a81f-d6dd1b132cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ebe51a80-503b-4d72-8e1d-5f9f21227251" xlink:to="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumRevenueMember_9be719c5-e814-4a41-bc37-cae3c96d2e2d" xlink:href="evh-20221231.xsd#evh_PremiumRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_678696ec-d971-4bb5-8f4b-f83f2594b709" xlink:to="loc_evh_PremiumRevenueMember_9be719c5-e814-4a41-bc37-cae3c96d2e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd381133-7dfc-4842-abfb-e8998b1f3ca2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0324fe59-1ffe-4433-9e3c-527021b32cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6c7c421a-e62b-498a-913e-ea67606ccebd" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0324fe59-1ffe-4433-9e3c-527021b32cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e892c56b-372c-4dfd-85df-85270ce12499" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_7db97246-6fd8-4dd6-9b58-b080c5a8d74f" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8add645f-08d1-4013-8dbc-793a7b63a13d" xlink:to="loc_evh_TrueHealthMember_7db97246-6fd8-4dd6-9b58-b080c5a8d74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a973acb0-5ba6-4788-9e44-fd724e45df4d" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_e1dd93d7-8a9e-49e9-bb54-3eb576ed135e" xlink:href="evh-20221231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_e1dd93d7-8a9e-49e9-bb54-3eb576ed135e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b86620ff-39ac-483b-b6c3-c9a0d07a6fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b86620ff-39ac-483b-b6c3-c9a0d07a6fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_81ce10c4-575b-41d5-800b-c32fd9bf85c6" xlink:href="evh-20221231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_81ce10c4-575b-41d5-800b-c32fd9bf85c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b8d60456-d1e8-4ba3-bf3e-9ded518bc308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b8d60456-d1e8-4ba3-bf3e-9ded518bc308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_940367cc-07ad-497e-a0aa-18169373159d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_28a63a88-5f96-41f5-be98-844dab175c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_940367cc-07ad-497e-a0aa-18169373159d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b2ac0ff1-5d00-4d7d-b850-5a98de8a809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2ac0ff1-5d00-4d7d-b850-5a98de8a809f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:to="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_f3a3bbed-e176-4a21-a794-ba9ba0b0b06e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_66cf2f44-e380-46fe-9666-18b2a80350d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0ef38410-4348-4f24-a59f-9ffd925430dd" xlink:to="loc_us-gaap_LeaseAgreementsMember_66cf2f44-e380-46fe-9666-18b2a80350d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0c14a444-2459-4b85-ae41-5ab030ff5a82" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_a6e95871-a0c8-4c0a-b6a6-088a6fd131b6" xlink:href="evh-20221231.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_a6e95871-a0c8-4c0a-b6a6-088a6fd131b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_74fcf73b-827e-40ba-b52e-45ce8936ad0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_74fcf73b-827e-40ba-b52e-45ce8936ad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_103e293e-ee50-49a2-bca8-951f89a7c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1e35c7b8-4169-4c9b-9596-0a809b7ceb18" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_103e293e-ee50-49a2-bca8-951f89a7c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_060f5735-d6a3-45d6-8972-957ce90e756c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_060f5735-d6a3-45d6-8972-957ce90e756c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:to="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8dac3ae8-5c3e-44f2-a35d-820651628a1d" xlink:to="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_7d55fa0f-c85f-4b08-8569-b9de94aa73d6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_VA_7d55fa0f-c85f-4b08-8569-b9de94aa73d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_debfa239-6522-4d52-9e4b-f3309abd978f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_IL_debfa239-6522-4d52-9e4b-f3309abd978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_ea2e4ee5-934a-4ff3-ae3e-c7c96345abf1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_NJ_ea2e4ee5-934a-4ff3-ae3e-c7c96345abf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_f1b1090a-c333-4fd9-a5b7-741506b8f098" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_country_IN_f1b1090a-c333-4fd9-a5b7-741506b8f098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_ba322b40-c7fa-4743-8e10-645295d36252" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_CA_ba322b40-c7fa-4743-8e10-645295d36252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_98316f35-5dec-488d-99c1-d2f7fc059d27" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_270d73f2-4438-47f2-8265-59a1633c53df" xlink:to="loc_stpr_GA_98316f35-5dec-488d-99c1-d2f7fc059d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_31166e9d-8a19-47e1-aa29-02bb8b18cd8c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e506c547-1843-4ac9-98b0-a25b46ef380d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e506c547-1843-4ac9-98b0-a25b46ef380d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f119a83-3eac-4e06-99b5-26da9c6c9872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f119a83-3eac-4e06-99b5-26da9c6c9872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_3c19e576-cef8-47a3-91be-34471b8e3086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d3a65356-8071-4b4a-a83a-97b3200497f5" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_3c19e576-cef8-47a3-91be-34471b8e3086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_29f09f3b-af1d-4e7f-82c7-b8297735acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:to="loc_us-gaap_OperatingLeaseCost_29f09f3b-af1d-4e7f-82c7-b8297735acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3724122e-84e4-4db7-a171-07860a6289ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3724122e-84e4-4db7-a171-07860a6289ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_55ba4efc-5bf1-4690-8115-22b3ed0061f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_55ba4efc-5bf1-4690-8115-22b3ed0061f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_4c627242-fa20-457c-8f34-1a27fc760dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:to="loc_us-gaap_VariableLeaseCost_4c627242-fa20-457c-8f34-1a27fc760dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b776942f-3f6c-469c-9d86-e3353b279efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f056dda1-17b2-43b3-ba49-c131ee692e2e" xlink:to="loc_us-gaap_LeaseCost_b776942f-3f6c-469c-9d86-e3353b279efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76000671-5445-4dbe-a377-710561de93ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76000671-5445-4dbe-a377-710561de93ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2da78fd3-7ccc-4158-abcb-010f5a8dcc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2da78fd3-7ccc-4158-abcb-010f5a8dcc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37c9c19b-1937-4d53-af70-42acca2435d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37c9c19b-1937-4d53-af70-42acca2435d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8cc9f24b-4277-4863-96a1-37472b8b48ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8cc9f24b-4277-4863-96a1-37472b8b48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2badf447-432a-4b85-a74f-f03524c70a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2badf447-432a-4b85-a74f-f03524c70a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_28753ed0-8521-461a-ac9f-1b04847d1980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_28753ed0-8521-461a-ac9f-1b04847d1980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e72fcff-00cb-431d-a82b-49b1f5bf763b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e72fcff-00cb-431d-a82b-49b1f5bf763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_a08af2f2-9211-4d3f-99c1-81a5dbc6c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_a08af2f2-9211-4d3f-99c1-81a5dbc6c8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf2b01e4-7e5e-40d0-bd9a-7041526d14aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_a08af2f2-9211-4d3f-99c1-81a5dbc6c8c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf2b01e4-7e5e-40d0-bd9a-7041526d14aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_121881a5-8195-4a49-97ea-46c13ea19ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6f93965-4940-4a50-aa2e-84ff593f83f8" xlink:to="loc_us-gaap_OperatingLeaseLiability_121881a5-8195-4a49-97ea-46c13ea19ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c75c5d3e-1b4e-4b2d-ac24-daff5484f31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8cbc8d5e-e204-4135-8236-56d32848a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c75c5d3e-1b4e-4b2d-ac24-daff5484f31e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8cbc8d5e-e204-4135-8236-56d32848a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_35f2f6aa-4179-42d0-a1a1-e6d3fb0fb641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c75c5d3e-1b4e-4b2d-ac24-daff5484f31e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_35f2f6aa-4179-42d0-a1a1-e6d3fb0fb641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LossperCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_217033bb-b45d-453a-bee3-dc49f4dd5a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_217033bb-b45d-453a-bee3-dc49f4dd5a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1dbb4114-4570-4a21-84ca-a4344768d77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1dbb4114-4570-4a21-84ca-a4344768d77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_47668f17-b4f1-4214-bbde-6222319d220d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_47668f17-b4f1-4214-bbde-6222319d220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e7f00cfa-11e3-44e0-8575-372166351c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e7f00cfa-11e3-44e0-8575-372166351c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_83c743c2-511b-4b9e-8c3c-4d5a87d00317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_83c743c2-511b-4b9e-8c3c-4d5a87d00317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3994fa16-6b54-4fd8-be8e-47977d82afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3994fa16-6b54-4fd8-be8e-47977d82afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract_7d25e9c8-3289-4491-af26-8307b9a26997" xlink:href="evh-20221231.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3452ea0d-1418-422e-9f33-188ebae577be" xlink:to="loc_evh_BasicAndDilutedEarningsPerShareAbstract_7d25e9c8-3289-4491-af26-8307b9a26997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_7d25e9c8-3289-4491-af26-8307b9a26997" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4b565dc2-90f9-4720-ac80-195327666f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4b565dc2-90f9-4720-ac80-195327666f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ba13b637-6309-47aa-ba42-d77113a87c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ba13b637-6309-47aa-ba42-d77113a87c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_39950fd6-603e-4524-affa-37014d494a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_39950fd6-603e-4524-affa-37014d494a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1b006873-2fa6-4a6d-9af5-8cbdc1815655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1b006873-2fa6-4a6d-9af5-8cbdc1815655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a5fdb50-514f-4cdc-86f1-e198c1e5f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a5fdb50-514f-4cdc-86f1-e198c1e5f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3df63f0d-4c3e-4628-825c-cc28ee07c8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b291e9b-54d9-40a0-bab7-68f0988c859b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3df63f0d-4c3e-4628-825c-cc28ee07c8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#LossperCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_54a0cd05-a24c-4232-98e2-2c4301fcce12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_54a0cd05-a24c-4232-98e2-2c4301fcce12" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d64adc4-d758-402e-bb48-adfbe09b99c5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_dee8cd6b-aac4-4962-a2b3-ebd029e973b8" xlink:href="evh-20221231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_dee8cd6b-aac4-4962-a2b3-ebd029e973b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c865fa2-1a0c-40f7-9d3d-a372c08bae39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c865fa2-1a0c-40f7-9d3d-a372c08bae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d405eb49-693a-44ce-b383-a5f34bb6cba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_29907983-7840-4564-b46d-cdf50335c721" xlink:to="loc_us-gaap_ConvertibleDebtMember_d405eb49-693a-44ce-b383-a5f34bb6cba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_edd9fe23-58d0-401e-afe3-32b566bfbbcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64791000-f019-41c8-894f-933fbe07121f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7ceaac8-fcc0-4f96-a9ca-54f69e80ea09" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64791000-f019-41c8-894f-933fbe07121f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensation2011and2015EquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6dee9d0-b8d3-4e13-b8d5-ad88f83bffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6dee9d0-b8d3-4e13-b8d5-ad88f83bffc3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d619b0d9-79e7-4483-9731-378e7bbf1a16" xlink:to="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember_e22171cf-9e6d-4407-aee8-b4d7ae9f1bd8" xlink:href="evh-20221231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:to="loc_evh_TwoThousandElevenEquityIncentivePlanMember_e22171cf-9e6d-4407-aee8-b4d7ae9f1bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_7fb802a5-8860-4077-8f7b-9da0810e7884" xlink:href="evh-20221231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8602b409-6d03-454e-a9ba-bafd2b01692d" xlink:to="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_7fb802a5-8860-4077-8f7b-9da0810e7884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b719ad9c-eb8e-4e3d-9347-d4ba08a1a7af" xlink:to="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_34847193-ea13-42ca-838e-c82424a05ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c227375c-45c5-46a6-92d1-635c89b0b47e" xlink:to="loc_us-gaap_CommonClassAMember_34847193-ea13-42ca-838e-c82424a05ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_870321f4-f105-44ec-a63d-5ee15497a26f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_08477a0a-16bf-41bf-a636-c10e8b64ea50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_us-gaap_RestrictedStockMember_08477a0a-16bf-41bf-a636-c10e8b64ea50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e073f44b-3c9e-4976-bb48-bc9d37e7ac7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e073f44b-3c9e-4976-bb48-bc9d37e7ac7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_95d8ba47-9ea0-4b3f-a338-07a406f1306f" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_95d8ba47-9ea0-4b3f-a338-07a406f1306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3661a2ad-1621-46e3-9519-6821ab4172f9" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18373a00-b790-46d8-9218-33fa3014f97c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3661a2ad-1621-46e3-9519-6821ab4172f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fe494e4-68de-47ad-9d17-d13384efb44a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f29a9163-5536-4c1e-8ad2-2e1671210461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f29a9163-5536-4c1e-8ad2-2e1671210461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4cb18f9-b7f5-4c04-8e6e-0d341eaf3b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4cb18f9-b7f5-4c04-8e6e-0d341eaf3b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94bbbdd7-862e-469e-a65a-41ec2cd3f525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2aa1ce76-0edc-46e6-9a07-551988dfebe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94bbbdd7-862e-469e-a65a-41ec2cd3f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc6555eb-0728-4a1c-9057-532bc8eb9fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc6555eb-0728-4a1c-9057-532bc8eb9fcf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:to="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_45b93f21-b184-4c79-8caf-2d0fd2be042c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1273a44a-f44b-41df-8a44-0a85a530d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1273a44a-f44b-41df-8a44-0a85a530d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6c63ab1c-ad79-446f-b29b-1240966a0c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_PerformanceSharesMember_6c63ab1c-ad79-446f-b29b-1240966a0c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_94ae24bb-d1e0-45d7-9865-2521920ced58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_94ae24bb-d1e0-45d7-9865-2521920ced58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9336af34-7df8-40d7-8c9a-43767650cba7" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_9336af34-7df8-40d7-8c9a-43767650cba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_34546508-392d-4190-af31-1789c5c17ccb" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_971a31ca-68a8-4a1b-8ea5-05425e8cf17d" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_34546508-392d-4190-af31-1789c5c17ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e95ad78a-1910-4037-bce6-8a0d0344e929" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d3cc66fc-8b17-46f6-b9c8-8802ea013272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:to="loc_us-gaap_CostOfSalesMember_d3cc66fc-8b17-46f6-b9c8-8802ea013272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9930af03-0f7d-46aa-9f58-313b029ff60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33b56d89-a5b9-44c3-a203-e55ce1058d93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9930af03-0f7d-46aa-9f58-313b029ff60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b0e6314c-0d12-453b-bcf0-fa12bcfb158b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3ff176ad-dbfa-42c5-9c25-301f088ec421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d0fa2473-a69e-4172-a572-dbc505eef97f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3ff176ad-dbfa-42c5-9c25-301f088ec421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70d10664-6583-423a-a7e1-09af87b0a81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4244329b-b13a-4a87-8045-a95e9e4a6463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70d10664-6583-423a-a7e1-09af87b0a81d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4244329b-b13a-4a87-8045-a95e9e4a6463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa8e290b-4994-4a36-97db-f6cafa9fc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa8e290b-4994-4a36-97db-f6cafa9fc6c5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:to="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6afc279b-7936-4a8d-a2d2-6e55f03e9ad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_849989b1-9330-42d8-85ef-735bfee3391e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_849989b1-9330-42d8-85ef-735bfee3391e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2697e4e-efe2-4687-92d5-91da84ddccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2697e4e-efe2-4687-92d5-91da84ddccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_51382ef5-9337-4103-89f6-cd24a8b9d269" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_51382ef5-9337-4103-89f6-cd24a8b9d269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ad3bcc0a-cc7b-431f-9c6d-cbbcf3decb27" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c481ed9e-9ee1-418e-bc21-2dd94086872c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ad3bcc0a-cc7b-431f-9c6d-cbbcf3decb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2fbad0b4-71cb-4536-a518-ef61a731f4ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_995196fc-e156-4254-8557-bf9782bdff04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_995196fc-e156-4254-8557-bf9782bdff04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8844a848-9082-4e72-bb71-6d454f48d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8844a848-9082-4e72-bb71-6d454f48d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0f6adefa-a584-445b-af50-cc7ea0a58b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0f6adefa-a584-445b-af50-cc7ea0a58b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2d172f0-6256-4f2a-b6e7-2936895ddf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0fc90eec-cbf3-42e2-b462-720ab3f869fd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2d172f0-6256-4f2a-b6e7-2936895ddf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8739d8c-4c0f-41e9-b415-1f1934ccc5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8739d8c-4c0f-41e9-b415-1f1934ccc5c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:to="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0fde5e1d-66ee-45d1-b2c2-c9cc398cf3be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c85a83d1-b486-4d5f-bad8-3e8688b84662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcc7e17-89fa-4d40-a3d5-8ccede6945e2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c85a83d1-b486-4d5f-bad8-3e8688b84662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3eff634-822c-49b3-968a-9a9fe87bb815" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2ff2c7a6-2f1f-4f35-9d0e-6f982f8b81b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2ff2c7a6-2f1f-4f35-9d0e-6f982f8b81b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1fadf9e2-d925-4fa0-9213-77ea473dfa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1fadf9e2-d925-4fa0-9213-77ea473dfa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ea2cf07b-96b9-4db3-937c-26a3e75162d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ea2cf07b-96b9-4db3-937c-26a3e75162d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_da79398d-a23c-461d-b30b-939017382715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_da79398d-a23c-461d-b30b-939017382715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f49479ea-23b7-4639-a1d4-a982c377b9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc62cc56-7b0c-4cb0-b789-327b297c6985" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f49479ea-23b7-4639-a1d4-a982c377b9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fadb68f2-f854-4ea1-90f5-4c2404115802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fadb68f2-f854-4ea1-90f5-4c2404115802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_df76328e-cef3-425d-9e69-abe6a807020a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_df76328e-cef3-425d-9e69-abe6a807020a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_33dee032-d852-43bb-9ab2-fbc64ef87720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_33dee032-d852-43bb-9ab2-fbc64ef87720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ed6ec384-5da8-4ea2-8218-952bdbd32a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24803e32-d95a-4424-ac83-3c0c75a1512e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ed6ec384-5da8-4ea2-8218-952bdbd32a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_47257cb1-c998-47c8-becf-4ff4e57f8521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_47257cb1-c998-47c8-becf-4ff4e57f8521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4ad4e567-b605-48dc-969a-3c0eebf6e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4ad4e567-b605-48dc-969a-3c0eebf6e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a61169e1-3d2c-4036-a39e-d359f61d5437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a61169e1-3d2c-4036-a39e-d359f61d5437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be42b450-ac59-4fad-b1d0-12622623620a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be42b450-ac59-4fad-b1d0-12622623620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ada143b-faf9-4364-89a2-1f4a776998c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ada143b-faf9-4364-89a2-1f4a776998c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9caa2930-537a-426e-9ab2-1960e15d605e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbf8e408-7b73-473f-95d0-df50a4629b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9caa2930-537a-426e-9ab2-1960e15d605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_493e71c9-6251-476e-ab5c-3d2ba9862a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_493e71c9-6251-476e-ab5c-3d2ba9862a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9ffd1ce5-3ed3-4111-a8c2-38fa68027876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9ffd1ce5-3ed3-4111-a8c2-38fa68027876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_1c9e3737-63cb-4cdc-9776-71f19d03078a" xlink:href="evh-20221231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_1c9e3737-63cb-4cdc-9776-71f19d03078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60600d5d-c7a0-438d-bcf7-335fc5e06226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_1c9e3737-63cb-4cdc-9776-71f19d03078a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60600d5d-c7a0-438d-bcf7-335fc5e06226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7ee84967-71fa-45a2-886e-a47234ae7532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_1c9e3737-63cb-4cdc-9776-71f19d03078a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7ee84967-71fa-45a2-886e-a47234ae7532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5142a8b3-43e0-4806-9df1-73e8863e2116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_1c9e3737-63cb-4cdc-9776-71f19d03078a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5142a8b3-43e0-4806-9df1-73e8863e2116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_fbcf1a42-e369-44b1-a719-85387b30b143" xlink:href="evh-20221231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd4f08b-fab6-47b1-9b15-158f0f7cb7d8" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_fbcf1a42-e369-44b1-a719-85387b30b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_33d8349b-e170-4025-8c41-2749123ffe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_fbcf1a42-e369-44b1-a719-85387b30b143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_33d8349b-e170-4025-8c41-2749123ffe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f69b386-76f4-499a-9e4d-669e9caa50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_fbcf1a42-e369-44b1-a719-85387b30b143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f69b386-76f4-499a-9e4d-669e9caa50aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d43ecd80-8975-4881-856e-80ed70fd26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_fbcf1a42-e369-44b1-a719-85387b30b143" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d43ecd80-8975-4881-856e-80ed70fd26ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3022584-02a8-4ca8-84d7-9d13a3b4e144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3022584-02a8-4ca8-84d7-9d13a3b4e144" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_161761ba-13fa-4450-b01d-ec93f3937258" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f56b8b48-db05-4b07-9edd-1b9ef1674259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea8c2036-730a-4fe6-b170-a223cc968385" xlink:to="loc_us-gaap_PerformanceSharesMember_f56b8b48-db05-4b07-9edd-1b9ef1674259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d896cad1-0d22-4616-b28a-79e18b265ce4" xlink:to="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5c6feb98-cf15-4e67-982a-528a498dda9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a02c6e4-c942-4f55-ae68-b7dc4a43e9d7" xlink:to="loc_us-gaap_CommonClassAMember_5c6feb98-cf15-4e67-982a-528a498dda9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_e71f5ce0-7175-43f5-aa3e-f13d9dade1ae" xlink:to="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b81109b7-0cfd-4aeb-b190-76803499d894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b81109b7-0cfd-4aeb-b190-76803499d894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebd3b9d2-7600-4f46-ba46-8a676de03b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebd3b9d2-7600-4f46-ba46-8a676de03b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c8ba5b71-8aea-4774-9f23-02a3868877ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c8ba5b71-8aea-4774-9f23-02a3868877ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_aeb99914-1e6f-44ef-aedb-a91e472ed382" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_aeb99914-1e6f-44ef-aedb-a91e472ed382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_d271f915-be6c-4eb7-9534-1ef3e2689d2d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e84e0d9-7474-44c4-a80f-98bae936b4a6" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_d271f915-be6c-4eb7-9534-1ef3e2689d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be0c83dd-6e10-4f90-8b86-317f117e413a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06872682-d98f-46b0-8967-1d52e9357498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_06872682-d98f-46b0-8967-1d52e9357498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_78f660c3-501b-4416-b6a1-b37d99da9ac3" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_78f660c3-501b-4416-b6a1-b37d99da9ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_8e2da69a-e801-40bb-a501-accd55d4b8ee" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_8e2da69a-e801-40bb-a501-accd55d4b8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc09b7f9-e9c2-416f-8e77-8965aee3114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc09b7f9-e9c2-416f-8e77-8965aee3114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_428d2e8a-cf07-440c-b33f-7459c66d4b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_428d2e8a-cf07-440c-b33f-7459c66d4b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3f19ab74-615f-44f7-a8db-0b481d7b6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3f19ab74-615f-44f7-a8db-0b481d7b6250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_937b4ecc-384b-471d-a2ee-3cca3492ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_937b4ecc-384b-471d-a2ee-3cca3492ad62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6ebe9f4a-93ce-4836-a813-59d8fd795fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6ebe9f4a-93ce-4836-a813-59d8fd795fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29f70da3-ce7d-4a7b-8fcc-3a6514da9ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29f70da3-ce7d-4a7b-8fcc-3a6514da9ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d17d9bc-d94c-4f49-974f-e4e788ee2518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d17d9bc-d94c-4f49-974f-e4e788ee2518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_827eeb77-d0db-46a5-b0a0-c2d4633f6646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_827eeb77-d0db-46a5-b0a0-c2d4633f6646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_397c6f02-efde-442c-b5b9-e80065d0c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_397c6f02-efde-442c-b5b9-e80065d0c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d324707e-8f1b-4c6d-bb2b-e49b8f7ad5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d324707e-8f1b-4c6d-bb2b-e49b8f7ad5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:href="evh-20221231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee60cbe3-60ff-4e9d-90aa-5e83d197ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee60cbe3-60ff-4e9d-90aa-5e83d197ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0450e7f-f17d-4fe1-bc9e-83184a46caae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_733411a8-16e9-49cb-bed9-07abc362e883" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0450e7f-f17d-4fe1-bc9e-83184a46caae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:href="evh-20221231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b19a213d-fafa-4004-b604-502aa440634f" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e7a2025a-7fb8-4479-bd41-81e59b7ba717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e7a2025a-7fb8-4479-bd41-81e59b7ba717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f95b36de-dc98-4d72-bb14-9b22f4bf8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5b29090d-2f13-49cb-9133-e5a154445e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f95b36de-dc98-4d72-bb14-9b22f4bf8ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d23d2e7-41c8-4285-8abf-40845319bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d23d2e7-41c8-4285-8abf-40845319bb96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_af00113d-2e04-4663-b59e-22dcf48b3d90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bef5e85a-db9a-4f9b-988a-87c84d0a0001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d9d76c-06a7-4732-a827-229c94a6fd88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bef5e85a-db9a-4f9b-988a-87c84d0a0001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86fa2ae7-a937-4e65-a70e-5917c6e71842" xlink:to="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember_75857eb1-bd64-410e-b929-c1f65ac3d77a" xlink:href="evh-20221231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6fd6cadc-43ec-4d20-8299-564ff65cb5a4" xlink:to="loc_evh_NonEmployeeDirectorsMember_75857eb1-bd64-410e-b929-c1f65ac3d77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17326fd6-284a-42e4-9b7b-f1deb0aac143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_7dcc4357-e06e-43ef-a8ac-8c256a2da48f" xlink:href="evh-20221231.xsd#evh_NewCenturyHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99175ef3-795f-4ff6-afd6-3133d1572dab" xlink:to="loc_evh_NewCenturyHealthMember_7dcc4357-e06e-43ef-a8ac-8c256a2da48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb507d65-53ed-4e87-a4d4-c847d6940865" xlink:to="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7d617e9-3787-4977-acd1-b872fd159406" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:to="loc_srt_MinimumMember_c7d617e9-3787-4977-acd1-b872fd159406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b651067-3a84-4e4a-999d-6dbf7662a91d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d74921fc-cb12-4b8c-b22d-144bd5abd27e" xlink:to="loc_srt_MaximumMember_2b651067-3a84-4e4a-999d-6dbf7662a91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_81318be5-cc08-4196-a4d8-03b31e052b68" xlink:to="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_45d19768-5ff2-45b0-bd85-aa8bfea4a883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_45d19768-5ff2-45b0-bd85-aa8bfea4a883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ab39273a-9e93-4cfb-b18c-a7c1ad9b786c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ab39273a-9e93-4cfb-b18c-a7c1ad9b786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e12abd7f-787d-4f31-8517-028f92f44b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_239b0b67-cbed-4ad8-9eef-23581b4da080" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e12abd7f-787d-4f31-8517-028f92f44b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f62628a-10fb-4c9e-bf98-c7c7ed8059b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_937b895a-6b3a-4304-96c2-ad404c11249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_937b895a-6b3a-4304-96c2-ad404c11249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0c994fb3-747b-475a-86ab-f6fd7425e41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0c994fb3-747b-475a-86ab-f6fd7425e41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_883fd7e7-f04d-4cb0-8f3e-45ee234f50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_883fd7e7-f04d-4cb0-8f3e-45ee234f50ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad1f53df-dd92-4f25-b916-2711933660d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad1f53df-dd92-4f25-b916-2711933660d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ab279c11-fd2a-4a61-901e-3d528b0edd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ab279c11-fd2a-4a61-901e-3d528b0edd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3f9d14b6-de99-4570-a742-068bd2260222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3f9d14b6-de99-4570-a742-068bd2260222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d433fef3-56b3-4e75-80fa-ce53b53fa02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d433fef3-56b3-4e75-80fa-ce53b53fa02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3162d0-f15e-480b-87d7-4dd9bd8e4036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd60685d-e180-405c-bbc0-644e72719fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3162d0-f15e-480b-87d7-4dd9bd8e4036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6953505-88e3-4a05-b0c7-425a641f0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6953505-88e3-4a05-b0c7-425a641f0ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_49595991-cff3-485d-a402-dfbb8f684add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_49595991-cff3-485d-a402-dfbb8f684add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9669e100-e58e-4ee6-9d10-83d2a7f1efd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9669e100-e58e-4ee6-9d10-83d2a7f1efd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e7e6b01-b217-44f4-abb6-c1be7ade7f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e7e6b01-b217-44f4-abb6-c1be7ade7f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fd13f5ba-7884-4607-9cba-b8e63433b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_900959bb-c8e1-4169-92de-06fe7ae1b3c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fd13f5ba-7884-4607-9cba-b8e63433b7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_18a00bfb-3743-4fa3-8ed4-f3dcae600718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad4133d-d277-4317-a3eb-d5dcc7677139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_18a00bfb-3743-4fa3-8ed4-f3dcae600718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationLeveragedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6833a62-ab5d-41f3-b457-67c932b32f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6833a62-ab5d-41f3-b457-67c932b32f0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f07f4993-df23-4e3d-9d8f-9aa30429f772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_43e608be-78d0-47b8-9246-babcc2b3f123" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcc67d60-7041-4940-8d4b-6bbe0f4b22aa" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_43e608be-78d0-47b8-9246-babcc2b3f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7ee0db99-ec02-4f8f-9904-d52f4cfcc859" xlink:to="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3eb27ea6-cac3-46ba-bf15-237540a131d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3eb27ea6-cac3-46ba-bf15-237540a131d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a851c001-0bec-42da-bcc3-dc8d93c04c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a851c001-0bec-42da-bcc3-dc8d93c04c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_539daa31-7f60-42e2-ab64-d8e7da9e4966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_539daa31-7f60-42e2-ab64-d8e7da9e4966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember_f7fdc656-8f26-4b97-8529-a09db059a175" xlink:href="evh-20221231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9f237dad-49d3-4f1b-b7b5-6f2d7c23e684" xlink:to="loc_evh_SharebasedPaymentArrangementTrancheFourMember_f7fdc656-8f26-4b97-8529-a09db059a175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_37e49dba-8c88-4548-9ada-494877df905b" xlink:to="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandNineteenMember_5c586fc6-d1a6-4924-aab1-aae4c89fd42b" xlink:href="evh-20221231.xsd#evh_TwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_f9d767e1-a507-4eee-bac6-42ce3b9f3ed3" xlink:to="loc_evh_TwoThousandNineteenMember_5c586fc6-d1a6-4924-aab1-aae4c89fd42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c09724bc-cc21-49cc-a750-3c22f884f253" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c435795-e118-4867-891f-5222f7faecd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c435795-e118-4867-891f-5222f7faecd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_6b02bcec-5000-4509-8e47-20fd8bd3a9dd" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_6b02bcec-5000-4509-8e47-20fd8bd3a9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7aa5f46-b667-4dd8-a93c-47bb98b97125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7aa5f46-b667-4dd8-a93c-47bb98b97125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36eda4ba-81c5-498a-afa1-9afeec00562a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36eda4ba-81c5-498a-afa1-9afeec00562a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3b985d88-8845-42c3-a678-611a1824a596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3b985d88-8845-42c3-a678-611a1824a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3864c032-b073-4e47-b88b-1c3041af0320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3864c032-b073-4e47-b88b-1c3041af0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e0e9b6d-c492-493e-8af9-af6d2dff5dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e0e9b6d-c492-493e-8af9-af6d2dff5dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6142864-d75a-4b67-bb57-d80f1d07a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627d4f53-3831-4c83-8618-d8f3db6b14fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6142864-d75a-4b67-bb57-d80f1d07a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationLeveragedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24eb13b1-0427-4ac8-a0e3-0120a52d60fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24eb13b1-0427-4ac8-a0e3-0120a52d60fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:to="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c5142c3d-d732-4e05-8578-f39f2a1a48f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_69bdd30e-81ff-45fa-ad6d-3aee4b3c4995" xlink:href="evh-20221231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d56f652-0752-48b6-b008-d8ffb3e0ff4f" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_69bdd30e-81ff-45fa-ad6d-3aee4b3c4995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e88c28c8-04f7-42eb-9a6d-3f91933eeb7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24f2acbf-8935-4683-8304-fab05155f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24f2acbf-8935-4683-8304-fab05155f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51261c7f-d7ac-4f68-9eb7-e8681c0c463f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51261c7f-d7ac-4f68-9eb7-e8681c0c463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b5d9900-cf08-444c-ab3d-27abc115fbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b5d9900-cf08-444c-ab3d-27abc115fbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5a8162fe-db62-4a86-ae4c-ed235a249472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c8394fa3-02f5-401d-8e21-9bda0492caed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5a8162fe-db62-4a86-ae4c-ed235a249472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0eefd243-20b5-4c75-ae68-6dc52677b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0eefd243-20b5-4c75-ae68-6dc52677b01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb734d7-f3fb-4355-be19-049d9b0da118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb734d7-f3fb-4355-be19-049d9b0da118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e1a3af8-6acf-4031-8082-eeb2d7c3f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e1a3af8-6acf-4031-8082-eeb2d7c3f919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ed358d2-dc2b-4fac-8c2f-3cc97cee9158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d081ed10-bfac-47df-adaf-6af5bbf5f778" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ed358d2-dc2b-4fac-8c2f-3cc97cee9158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d40ecba1-4875-4243-b0b5-50c14b4c4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d40ecba1-4875-4243-b0b5-50c14b4c4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e2152ce8-3525-46d4-a3da-294051182975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e2152ce8-3525-46d4-a3da-294051182975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5461ac-b954-42df-8910-6d3bd26bf711" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_5a4c04c7-f6a1-4789-b6c9-fa3a80406767" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_5a4c04c7-f6a1-4789-b6c9-fa3a80406767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_4a06877c-fa79-4aec-bba0-af52cb284178" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_4a06877c-fa79-4aec-bba0-af52cb284178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_e6170a01-93ad-4667-a108-32b4db102333" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_e6170a01-93ad-4667-a108-32b4db102333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_4b3e7574-37bd-44e4-b363-c59c6fee2512" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_5c90763e-ecd0-40db-b3da-6a6871e8236a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_4b3e7574-37bd-44e4-b363-c59c6fee2512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_106d66c5-982b-4309-a16c-97a0745bec79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_106d66c5-982b-4309-a16c-97a0745bec79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ca8dff83-7bf1-4544-97d2-81919d38c188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60673ae7-a142-4541-9666-afa280895565" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723a0a5c-408e-43b7-8ab1-68af44ab0596" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_60673ae7-a142-4541-9666-afa280895565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_eed22bc6-cbc0-47bc-ab24-dfd8481d8b04" xlink:to="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5f04282d-78a0-4e26-9981-cb47ecd843ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5f04282d-78a0-4e26-9981-cb47ecd843ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e1719546-0cae-40f2-b7f8-70b7daf7a4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_632506fc-4fc1-4b00-84b0-04d78d508265" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e1719546-0cae-40f2-b7f8-70b7daf7a4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e39e545-dfb4-4ccd-93d4-1b70ad8f8251" xlink:to="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf9eaea-50b7-409c-b6b1-47e39a6a1a67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:to="loc_srt_MinimumMember_7cf9eaea-50b7-409c-b6b1-47e39a6a1a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c384075-26c4-4b26-90b7-b30628617275" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83219d57-d330-40de-834f-7e5ef8bb1afe" xlink:to="loc_srt_MaximumMember_3c384075-26c4-4b26-90b7-b30628617275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906645c5-f9f7-46e4-82c4-985e657bf4a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f5a28b-0c5b-47fd-b352-009cb2bda827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75f5a28b-0c5b-47fd-b352-009cb2bda827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_35970779-20c5-46ca-a426-3640451d700f" xlink:href="evh-20221231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_35970779-20c5-46ca-a426-3640451d700f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_213a6e19-013b-450c-93b7-5796ac7c3627" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_213a6e19-013b-450c-93b7-5796ac7c3627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_41e1c88b-6674-4b82-881c-484c8a5c7079" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_41e1c88b-6674-4b82-881c-484c8a5c7079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_2032956b-3ad8-4268-9bea-a284c906f778" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_2032956b-3ad8-4268-9bea-a284c906f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_7dc6febe-66bf-4850-a0ee-7f2c5703d290" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods_7dc6febe-66bf-4850-a0ee-7f2c5703d290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f73fce6-44a5-4fed-9a58-312cdfaed6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f73fce6-44a5-4fed-9a58-312cdfaed6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc774ce-2357-40af-bd26-1916224fce13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_269231d2-e45c-4759-92d5-5207dc48fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_269231d2-e45c-4759-92d5-5207dc48fc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1522e3af-7338-404f-a5c8-7186b7ecca88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1522e3af-7338-404f-a5c8-7186b7ecca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1aa372c1-2828-47a6-ae76-9ba2fd13971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1aa372c1-2828-47a6-ae76-9ba2fd13971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9f03471-58f2-4353-87ee-33c5994cc1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9f03471-58f2-4353-87ee-33c5994cc1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f66ae4e3-736d-4578-920b-3b1cd161e645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ca597357-a885-4321-a8db-3848d2c808fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f66ae4e3-736d-4578-920b-3b1cd161e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#StockbasedCompensationPerformancebasedRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4361830-063a-4fcf-a94d-d2a1b3cd2c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4361830-063a-4fcf-a94d-d2a1b3cd2c04" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:to="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e02c877-6edf-4ddd-bf54-7853a881a849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_fb6bfb92-784b-47dc-9ac7-3f0019b8ce50" xlink:href="evh-20221231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_061f0bf0-55d3-485f-97ef-04b20c4c09b6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_fb6bfb92-784b-47dc-9ac7-3f0019b8ce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e375d0a-1a00-4f95-adce-a9feb30e1110" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3318af3-0d00-4755-b030-232c4e522dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3318af3-0d00-4755-b030-232c4e522dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e8eaefd-7eed-4d57-94c2-a20af6e17db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e8eaefd-7eed-4d57-94c2-a20af6e17db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_b3fdbc03-150c-4356-8197-85baa2c9ed62" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement_b3fdbc03-150c-4356-8197-85baa2c9ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c176de7-5991-4f84-b24a-c0fdd8bf4383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c176de7-5991-4f84-b24a-c0fdd8bf4383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a14d7869-eab4-4ef3-a764-5fb85c0127d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3756078-e69b-4332-8247-7001174b8c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a14d7869-eab4-4ef3-a764-5fb85c0127d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_93eb9e0b-aa24-449b-af69-61a32099d441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_93eb9e0b-aa24-449b-af69-61a32099d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d93a04b4-3bed-4661-b7b4-9f23b0eeb6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d93a04b4-3bed-4661-b7b4-9f23b0eeb6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_3e807c8a-6da8-4f2a-ab2b-b8d4a20edf54" xlink:href="evh-20221231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue_3e807c8a-6da8-4f2a-ab2b-b8d4a20edf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec741f20-ea04-4993-b878-72754477b2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ec741f20-ea04-4993-b878-72754477b2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b68f80b-e76d-4a95-8bc2-0fcd6fa8c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03fd6686-941b-4ff2-84c6-f01ce8ca06ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b68f80b-e76d-4a95-8bc2-0fcd6fa8c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d617bd20-800d-42e9-aa56-9e11e0c4b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d617bd20-800d-42e9-aa56-9e11e0c4b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d3c282c0-7b59-4c2f-ba14-23e638a8f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d3c282c0-7b59-4c2f-ba14-23e638a8f7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5684a171-0b29-49cb-8890-5397b3e1a431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_5684a171-0b29-49cb-8890-5397b3e1a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8de1b3d4-25c9-4544-a088-b382ca94d9ec" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9c65a3b6-24d0-4070-9255-78e7a9645d95" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9c65a3b6-24d0-4070-9255-78e7a9645d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_298abf12-b21a-4e2f-b936-5c8c0305478d" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_298abf12-b21a-4e2f-b936-5c8c0305478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_ab3ded77-3dc7-4e9b-adf8-88c37a32be19" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_ab3ded77-3dc7-4e9b-adf8-88c37a32be19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_7828636b-0f4a-4ed9-ba04-bf3d23c061c4" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_00ac5468-8c38-4fc0-80cf-f1afb319c83d" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_7828636b-0f4a-4ed9-ba04-bf3d23c061c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c080ec67-992d-4763-b5a6-853d8946af14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c080ec67-992d-4763-b5a6-853d8946af14" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_af5e7d4e-5048-4a8f-9309-ae597bca6968" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9d66f4c0-26f9-4f9f-b54a-ea49573222cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:to="loc_us-gaap_DomesticCountryMember_9d66f4c0-26f9-4f9f-b54a-ea49573222cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bedeb8dd-d268-45cd-82df-fb6e8ea9f9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_eb9e507a-36f4-4b53-9699-fe091f30f7da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bedeb8dd-d268-45cd-82df-fb6e8ea9f9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed3e9ff8-628f-4f2c-91af-8f11bc61514a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember_cceb5756-509f-4da4-896f-0d551d058774" xlink:href="evh-20221231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:to="loc_evh_FinitelivedTaxCreditCarryforwardMember_cceb5756-509f-4da4-896f-0d551d058774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_4d003dbc-f3de-4c34-8fe5-746e7d98c968" xlink:href="evh-20221231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ebe7de8-88aa-4b3a-8770-3f448602c57f" xlink:to="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_4d003dbc-f3de-4c34-8fe5-746e7d98c968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_59d5e62f-5b09-4a0c-a340-1e1f7d7f66ba" xlink:to="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member_9abd9283-1fce-4928-a5e8-908de192a344" xlink:href="evh-20221231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_86046e55-8cdf-4fbd-b554-3e848f680588" xlink:to="loc_evh_PeriodsPriortoJune2015Member_9abd9283-1fce-4928-a5e8-908de192a344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1facab6f-3384-4d5e-9d75-cd098a112d73" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_637ee9e4-fb33-42ff-8c93-618e6f2e7acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_637ee9e4-fb33-42ff-8c93-618e6f2e7acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_362bcc48-f4dd-4149-a45b-553752a96012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_362bcc48-f4dd-4149-a45b-553752a96012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e379b0c2-66c6-43fd-90b5-324fb40a2dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e379b0c2-66c6-43fd-90b5-324fb40a2dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_41259a47-5d8d-4d48-96d8-b7eab296aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_41259a47-5d8d-4d48-96d8-b7eab296aa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2a67c4c3-ae51-49cc-9c3c-7bd797ce6d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2a67c4c3-ae51-49cc-9c3c-7bd797ce6d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_f82bc851-b714-4d26-94e9-1b4bc75dbeda" xlink:href="evh-20221231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_f82bc851-b714-4d26-94e9-1b4bc75dbeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_39a23d06-8b59-4502-851b-3c26b580a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_39a23d06-8b59-4502-851b-3c26b580a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3527ccba-c378-4be3-a811-67e912d56dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3527ccba-c378-4be3-a811-67e912d56dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fb56a00f-309b-4c37-a893-1eceac204763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fb56a00f-309b-4c37-a893-1eceac204763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_34f2074c-7102-4546-a982-bd2ebe2b1f1a" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_34f2074c-7102-4546-a982-bd2ebe2b1f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementLiability_ba0c4489-ee9f-49cc-a6c2-145d4577f175" xlink:href="evh-20221231.xsd#evh_TaxReceivablesAgreementLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivablesAgreementLiability_ba0c4489-ee9f-49cc-a6c2-145d4577f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_a0b3d1b7-359a-44fc-8edd-ac377ee55d16" xlink:href="evh-20221231.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_adcde53b-dcb6-4dfe-afdc-c2865c432aa6" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders_a0b3d1b7-359a-44fc-8edd-ac377ee55d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_528e1ba1-069e-48c0-acab-40d51649cc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7918541c-156f-455b-934a-64cdb5fefb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_528e1ba1-069e-48c0-acab-40d51649cc80" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7918541c-156f-455b-934a-64cdb5fefb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3a527060-73e7-4734-b0d8-10513a03d2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7918541c-156f-455b-934a-64cdb5fefb9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3a527060-73e7-4734-b0d8-10513a03d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b4271ace-fa36-4766-b885-e24086398125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7918541c-156f-455b-934a-64cdb5fefb9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b4271ace-fa36-4766-b885-e24086398125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_90f5d7f0-aa3a-428f-beaa-167646ed3800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7918541c-156f-455b-934a-64cdb5fefb9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_90f5d7f0-aa3a-428f-beaa-167646ed3800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7dffdfb-dadc-43d2-af4b-a47fea9e7209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7dffdfb-dadc-43d2-af4b-a47fea9e7209" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_922b6787-2fad-4d19-ac94-d2a3a1756ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_922b6787-2fad-4d19-ac94-d2a3a1756ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d2af5d21-d8d2-4fe6-8379-268fe7473f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d2af5d21-d8d2-4fe6-8379-268fe7473f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7a2273ac-1c69-4568-a0ce-75311349e941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7a2273ac-1c69-4568-a0ce-75311349e941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8db90686-ded1-4cd2-94cd-6608b5abfd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_17644fb7-3f70-4556-801e-293c1f54932a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8db90686-ded1-4cd2-94cd-6608b5abfd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7dffdfb-dadc-43d2-af4b-a47fea9e7209" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4dbb8e62-7600-4237-94e3-b163c30bde5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4dbb8e62-7600-4237-94e3-b163c30bde5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8476ad8d-bf0d-46bc-b78b-d0a29e682cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8476ad8d-bf0d-46bc-b78b-d0a29e682cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d0b0416a-d792-449a-b965-fd6c190193ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d0b0416a-d792-449a-b965-fd6c190193ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_191c76bb-cae4-4510-8478-0bb5b01232df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_74185019-4aa3-444f-8118-879601076949" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_191c76bb-cae4-4510-8478-0bb5b01232df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_98e89bee-8731-4806-bbe8-0c255afe8a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7dffdfb-dadc-43d2-af4b-a47fea9e7209" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_98e89bee-8731-4806-bbe8-0c255afe8a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7f76b462-bf08-4e1b-96fa-5adb0f030d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7dffdfb-dadc-43d2-af4b-a47fea9e7209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7f76b462-bf08-4e1b-96fa-5adb0f030d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_371538af-bb17-4ba7-8ac0-a4b67fe0e76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_371538af-bb17-4ba7-8ac0-a4b67fe0e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_222febec-108e-4bb4-bb96-2e43185c7e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_222febec-108e-4bb4-bb96-2e43185c7e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_77021691-8637-4668-a253-25da4586858c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_77021691-8637-4668-a253-25da4586858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6615a746-553e-45cc-b8aa-899e4c277e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6615a746-553e-45cc-b8aa-899e4c277e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_5344fe2d-dce6-4842-bb62-0560925023df" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_5344fe2d-dce6-4842-bb62-0560925023df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_7e2617ad-bd40-4d95-9b34-15eff6f3d3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_7e2617ad-bd40-4d95-9b34-15eff6f3d3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_5345638e-e9f6-46b2-a868-657513d28374" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_5345638e-e9f6-46b2-a868-657513d28374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_17eb805f-e95c-41d0-9b4e-f879dc304591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_17eb805f-e95c-41d0-9b4e-f879dc304591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ddcb6d98-84d6-4452-b1ef-768a2f63acea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ddcb6d98-84d6-4452-b1ef-768a2f63acea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_99a52b4a-50f4-4a04-9895-168c82c6e21d" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_99a52b4a-50f4-4a04-9895-168c82c6e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_afd51898-c219-431b-b89f-1fe7ba9d8d0e" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent_afd51898-c219-431b-b89f-1fe7ba9d8d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_40440174-489d-4dff-ad06-015b5be0ff54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_40440174-489d-4dff-ad06-015b5be0ff54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_278a3e45-8342-41b4-b2b9-e2b365cc9c23" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_278a3e45-8342-41b4-b2b9-e2b365cc9c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_e4b75376-2d9d-4220-a834-c5107586b7b6" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_e4b75376-2d9d-4220-a834-c5107586b7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f54f27e6-ac3f-4c32-b702-43d613ccf50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f54f27e6-ac3f-4c32-b702-43d613ccf50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_dc3575dd-bf16-4fb5-a5c2-6f2c38326110" xlink:href="evh-20221231.xsd#evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement_dc3575dd-bf16-4fb5-a5c2-6f2c38326110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c6807941-7abe-4ecb-998e-cd09726f968f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c6807941-7abe-4ecb-998e-cd09726f968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7d77d250-1553-48d6-83f2-7716440c3de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73e631c0-4d59-477e-b0ad-531b41487114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7d77d250-1553-48d6-83f2-7716440c3de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ee02b0e-d1f3-4130-b4ee-8ba12e7b20f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ee02b0e-d1f3-4130-b4ee-8ba12e7b20f8" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_0276c45b-21ab-4c6d-9472-97ec8c6692ff" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_0276c45b-21ab-4c6d-9472-97ec8c6692ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1a0fbc91-8e3d-4452-94f5-b82bc4f81227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1a0fbc91-8e3d-4452-94f5-b82bc4f81227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_2d4ff8fd-9e96-440d-8422-ffc183a83de3" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_2d4ff8fd-9e96-440d-8422-ffc183a83de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_187aec7d-a4b7-4664-bfc1-230f3d354ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_187aec7d-a4b7-4664-bfc1-230f3d354ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_d757622b-07c4-42e1-bcce-148d56f83944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_d757622b-07c4-42e1-bcce-148d56f83944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_431db496-298b-49aa-81d4-51c7ba6972d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_431db496-298b-49aa-81d4-51c7ba6972d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_960f45e1-37d6-439b-8130-c3e05c39bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_960f45e1-37d6-439b-8130-c3e05c39bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_be8bacdd-fb22-4387-a934-1f644d09a842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_be8bacdd-fb22-4387-a934-1f644d09a842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_56e3f6db-7e9b-460b-a5c4-3dd0e20a8393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_56e3f6db-7e9b-460b-a5c4-3dd0e20a8393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences_c09dfcf0-972b-4904-b86e-6af2a8b3a5a4" xlink:href="evh-20221231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_evh_DeferredTaxAssetOutsideBasisDifferences_c09dfcf0-972b-4904-b86e-6af2a8b3a5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ed472ed5-84ef-4a18-a558-60cbdd21ed51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ed472ed5-84ef-4a18-a558-60cbdd21ed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d9beacd9-7f54-4ab7-8dd7-881839675430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d9beacd9-7f54-4ab7-8dd7-881839675430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7f4503ce-c033-4c04-9231-3d0977c3175e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7f4503ce-c033-4c04-9231-3d0977c3175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4c5d0b4c-dd73-41bf-aed1-17ad78dac4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6af1f908-9f7b-4798-a5c1-6af39c874342" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4c5d0b4c-dd73-41bf-aed1-17ad78dac4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ee02b0e-d1f3-4130-b4ee-8ba12e7b20f8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_ce9f2264-e06c-4821-b661-4b3b67aa7c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_ce9f2264-e06c-4821-b661-4b3b67aa7c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a6fa646b-638b-4fa7-a654-ef3001bc8633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a6fa646b-638b-4fa7-a654-ef3001bc8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_dfc9ab81-7c62-4441-897b-1efa74ef9769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_dfc9ab81-7c62-4441-897b-1efa74ef9769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_1fdc60eb-0535-4fb6-9a26-29422382d113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_1fdc60eb-0535-4fb6-9a26-29422382d113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_ee1e01bf-cbbc-408c-84cd-42e9ca9f503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_ee1e01bf-cbbc-408c-84cd-42e9ca9f503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_732c9083-05ce-4e4b-b90b-c13944ff972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_732c9083-05ce-4e4b-b90b-c13944ff972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_409c65ac-3697-4c41-94c7-0d5d038e3855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e9196f3a-70b5-4084-8c4b-b45ad5af30de" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_409c65ac-3697-4c41-94c7-0d5d038e3855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9029ac10-b7e6-4e7a-a2ec-84c8cabad2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ee02b0e-d1f3-4130-b4ee-8ba12e7b20f8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_9029ac10-b7e6-4e7a-a2ec-84c8cabad2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6827e17-fa3b-4790-828e-8020c0018098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6827e17-fa3b-4790-828e-8020c0018098" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3e341fd-e058-4ec9-9f40-aad713ea4952" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_5c839444-b8e9-4df4-9059-800b38d34d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5cf216b-e92a-4c47-b2b4-bcd77b0e6602" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_5c839444-b8e9-4df4-9059-800b38d34d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d51e0da1-73a0-4ae9-9c18-889e2e78b297" xlink:to="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cd88175e-61cb-435f-bf6c-7702331c4203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc65f9c9-0f46-44ec-a595-1258fb046a09" xlink:to="loc_us-gaap_RetainedEarningsMember_cd88175e-61cb-435f-bf6c-7702331c4203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cef58be5-00e5-4530-85fb-1e4a81edc074" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_bd1b9d89-a649-498a-8e49-362ed37cf178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_04a75a60-ced9-4431-9659-eaa67c5d45f5" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_bd1b9d89-a649-498a-8e49-362ed37cf178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d598dfb3-587d-4f77-ab41-633f18e40180" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_610fe56c-e1ac-410a-9d1c-ae947551731b" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a0f9009e-204f-4675-b43c-0a7a18c3e6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a0f9009e-204f-4675-b43c-0a7a18c3e6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_826df6f1-484d-4c5e-bc04-3470668c5fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_826df6f1-484d-4c5e-bc04-3470668c5fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b8c3782-0cc2-4bd4-8a14-4f83168a44f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b8c3782-0cc2-4bd4-8a14-4f83168a44f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_06ba0598-b70c-4df2-a86b-9a558bd59da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_15370949-6ee2-4bbb-a38b-e85b7e143b1a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_06ba0598-b70c-4df2-a86b-9a558bd59da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b0f2d090-d6be-4817-871f-4930dc9d3c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b0f2d090-d6be-4817-871f-4930dc9d3c97" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cfccefdf-39c8-4184-9dba-eefd94ced55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cfccefdf-39c8-4184-9dba-eefd94ced55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3090b4c6-8564-4b4e-8cd3-b37da81a6665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3090b4c6-8564-4b4e-8cd3-b37da81a6665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a15b2b0c-cd9d-4256-9af1-0132f9b993e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a15b2b0c-cd9d-4256-9af1-0132f9b993e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_7588285b-bdbc-4a07-867d-4dd457f59308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_7588285b-bdbc-4a07-867d-4dd457f59308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e6e2a1f3-fa63-43f5-b59f-d26833f676fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d554c0e9-1acd-4715-9db3-2a26fc013edb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e6e2a1f3-fa63-43f5-b59f-d26833f676fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_92adb5ea-4952-49e4-865c-7a8a2ca60040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_92adb5ea-4952-49e4-865c-7a8a2ca60040" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69ced6c7-0c58-444e-9308-75dfcee16dc8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dacce77b-0bd5-4686-816e-427a7e478088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_798d5c21-37f4-41e5-8391-27c8f50dd7f6" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dacce77b-0bd5-4686-816e-427a7e478088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd210a96-8437-4179-b200-bf0aff4465d2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_eda6ba22-3a1d-4e9d-b44c-d7ae9a2fb6a4" xlink:href="evh-20221231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_158a0186-7585-437b-abcc-e5be4e458038" xlink:to="loc_evh_TrueHealthMember_eda6ba22-3a1d-4e9d-b44c-d7ae9a2fb6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07bc5b79-932c-4713-9643-989124fb9ad6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_628cf580-0cd8-4247-9b36-7fe20dd8116d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_297d18ca-d24a-4c19-935f-170199f11858" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_628cf580-0cd8-4247-9b36-7fe20dd8116d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8096d37e-ba10-40d1-89d7-7bdabf7858c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8096d37e-ba10-40d1-89d7-7bdabf7858c1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2c4609fa-2b42-4769-b17b-e7e736af7cd7" xlink:to="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0b076f29-bc00-4f66-9d19-bac991a5bbfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:to="loc_srt_MinimumMember_0b076f29-bc00-4f66-9d19-bac991a5bbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_707e4ce7-fff5-4434-863f-12c6e20c6e61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f810a3ce-e01e-42db-80d7-4fcd6d255f33" xlink:to="loc_srt_MaximumMember_707e4ce7-fff5-4434-863f-12c6e20c6e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e7c4dbb3-f68b-4675-af45-2e7150decfa9" xlink:to="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_2e7803f8-a5ba-4bb6-90b2-1295bcd9da0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a9b86f20-54d7-4b5a-b3c3-9a7598659f70" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_2e7803f8-a5ba-4bb6-90b2-1295bcd9da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0e7ca825-2aa5-4fe3-832c-ee6e2b5f531d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_6367f82c-5749-46f7-8244-6f67ede4a80d" xlink:href="evh-20221231.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9e17d09a-1419-4926-8d62-ade75524ec59" xlink:to="loc_evh_ServicesAgreementsMember_6367f82c-5749-46f7-8244-6f67ede4a80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49ca4b8a-8d20-4f2b-a9dc-2034ef383edf" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_5b50c2b4-4596-4383-8de2-181490a93aa1" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_5b50c2b4-4596-4383-8de2-181490a93aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_9fa993e9-541e-4e6b-acc0-d52bf809dc82" xlink:href="evh-20221231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_9fa993e9-541e-4e6b-acc0-d52bf809dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b6cc826-1644-4bcf-9e73-49783eb8db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b6cc826-1644-4bcf-9e73-49783eb8db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_eb43a9a6-6301-4554-9a16-167df9ebf273" xlink:href="evh-20221231.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c09adecb-3f32-4461-ac09-b6a3f131025e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_eb43a9a6-6301-4554-9a16-167df9ebf273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_022d84dd-57f1-42d0-8490-7439fc83bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_022d84dd-57f1-42d0-8490-7439fc83bb05" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e06a8a4a-cdbf-4a9c-9a5a-0a38a9a941bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ad788b5a-88ba-4231-8448-2394b586e066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ad788b5a-88ba-4231-8448-2394b586e066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6628f8e8-b43f-4b63-85e0-be846fdd1c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6628f8e8-b43f-4b63-85e0-be846fdd1c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc9d2438-c041-462a-a755-0fd2fad90b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc2a015c-b3f8-458e-9fdb-e914f30cc12a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc9d2438-c041-462a-a755-0fd2fad90b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fe259e2-74d2-4192-a00c-225a3017a441" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b7a7b09c-0abe-4931-8552-39a56e68c38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4fe57073-53a2-4cd1-96d4-0fb4499fe07c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b7a7b09c-0abe-4931-8552-39a56e68c38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b4ece860-732c-45f0-b983-fc9e61c412f1" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93e07acd-9a22-46a2-8e3f-07b570f56738" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5292234c-55d6-4c02-99be-00f4d56d9a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5292234c-55d6-4c02-99be-00f4d56d9a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aa90a097-8286-410e-b176-45285ed67a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_983f2f06-02c7-4778-8fcb-c30079b145e3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aa90a097-8286-410e-b176-45285ed67a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_62b65468-7d5c-4c55-828e-4f409e87ab24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62b65468-7d5c-4c55-828e-4f409e87ab24" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd430b57-e478-423a-9ac4-d5f2b6d9e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd430b57-e478-423a-9ac4-d5f2b6d9e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_80a87cd9-440e-4c1b-bced-d30f9bc2c380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_80a87cd9-440e-4c1b-bced-d30f9bc2c380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b9e91a8c-7910-4f9d-a2c2-f2cca3e4fd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b9e91a8c-7910-4f9d-a2c2-f2cca3e4fd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_d5015f7a-fe95-4cf7-b43b-620071b7e801" xlink:href="evh-20221231.xsd#evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_d5015f7a-fe95-4cf7-b43b-620071b7e801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e13fe08d-9043-4034-8984-494f16ca63bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e13fe08d-9043-4034-8984-494f16ca63bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bdab608c-fe6d-4813-8f26-4ab161e265bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d000647f-55da-4c3b-82af-0d996c86fe0a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bdab608c-fe6d-4813-8f26-4ab161e265bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c233dc46-ae08-45c3-a552-090c8ab45acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c233dc46-ae08-45c3-a552-090c8ab45acd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29ec9d3d-bfb4-4f34-98be-45c6c606e115" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2163bc21-5ec5-4be2-9bbe-6d115aa8b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b7d06d6b-d194-4877-8c6f-3cd918d1fa98" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2163bc21-5ec5-4be2-9bbe-6d115aa8b6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_230c1b00-9329-4e32-b4b6-c023b3e4e105" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fd620663-1764-4e44-a0b5-2c77ff622db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f2173e5-6080-481e-b9af-0ca6732f4596" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fd620663-1764-4e44-a0b5-2c77ff622db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8ac9a57d-dd44-4d00-bdec-6bc5504bafce" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_772241a5-8a6b-4fe2-ba14-7c13290780c1" xlink:href="evh-20221231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_772241a5-8a6b-4fe2-ba14-7c13290780c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a80217cd-037e-47de-9b6e-8b6e8df74808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a04fc51-500c-414b-9fdc-e7859afd1229" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a80217cd-037e-47de-9b6e-8b6e8df74808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1a546f13-63a3-460a-82c7-6bd2a72bf234" xlink:to="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_661722b9-fd50-41c3-b52f-fa624936e52b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:to="loc_srt_MinimumMember_661722b9-fd50-41c3-b52f-fa624936e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_959069a7-cc21-414f-a096-78be4bc6aee7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c078228f-075d-48a0-a73e-5304eabeae2f" xlink:to="loc_srt_MaximumMember_959069a7-cc21-414f-a096-78be4bc6aee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_36e9e794-2188-4629-81aa-23d6bfc43311" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb53a7e1-26c8-49b0-8ea8-788a49de782e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb53a7e1-26c8-49b0-8ea8-788a49de782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2e52bd57-4bec-4ce4-85b2-a0b5b2b05163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2e52bd57-4bec-4ce4-85b2-a0b5b2b05163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_334ccc20-2e12-46ae-94a0-65870ac4de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_efb4cb66-781a-49f9-bf80-64192dbeda41" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_334ccc20-2e12-46ae-94a0-65870ac4de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8b5b1ba4-5154-4db4-a90d-e23d3a34e16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8b5b1ba4-5154-4db4-a90d-e23d3a34e16e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ca7dc97-7f8b-4e6d-ba94-fa60823afb7b" xlink:to="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5c722824-cd42-4130-bf8f-cf5edd8bdade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6b1089b4-57a2-4299-b1d8-2d5dbd44143f" xlink:to="loc_srt_AffiliatedEntityMember_5c722824-cd42-4130-bf8f-cf5edd8bdade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_90c56749-427b-416b-946e-270c53a6e77b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:to="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d7071873-6f60-47f1-8719-d1e62afa2a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d7071873-6f60-47f1-8719-d1e62afa2a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6973f002-1caa-4bda-87c3-a93fb34ffab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6973f002-1caa-4bda-87c3-a93fb34ffab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_49312a4a-d992-465e-b46b-30ca0c19f11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4690e638-650e-4b0e-bab1-98da697fd7ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_49312a4a-d992-465e-b46b-30ca0c19f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_60742147-8aca-43ae-98de-0b5302dbaa2f" xlink:to="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c26bb373-7dce-45e1-b204-faa778dda54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_AccountsPayableCurrent_c26bb373-7dce-45e1-b204-faa778dda54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_606b3130-b795-4a30-a49d-f9b206778433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_606b3130-b795-4a30-a49d-f9b206778433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5de6f5f5-1fb9-4436-9fd8-408e65748815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_17853447-33ac-4b9c-a6fd-82e1ba82fabc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5de6f5f5-1fb9-4436-9fd8-408e65748815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6651f5b5-c6c8-4722-848e-d2d4b3a61d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6651f5b5-c6c8-4722-848e-d2d4b3a61d56" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_273df83f-4745-4cb3-a771-e316478a14c8" xlink:to="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d6de08c4-e959-450f-b5bd-dc9f5f99c84e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_fe286530-1235-41ce-9212-42148b9fca8d" xlink:to="loc_srt_AffiliatedEntityMember_d6de08c4-e959-450f-b5bd-dc9f5f99c84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bdeb9eb-5e05-440c-a1c3-5135710afbbe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_166d6d90-c62c-4fb2-9ad8-da54f8a6fd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:to="loc_us-gaap_CostOfSalesMember_166d6d90-c62c-4fb2-9ad8-da54f8a6fd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4e21cfa-dbb5-427b-9c6a-163c46ddb601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db668618-ee65-4773-8dfc-b658319167cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4e21cfa-dbb5-427b-9c6a-163c46ddb601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b6fb967d-02ad-4a40-900d-8f35c519abca" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_99e3d99c-eca0-4a38-908e-f50f9ac23156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:to="loc_us-gaap_RevenueFromRelatedParties_99e3d99c-eca0-4a38-908e-f50f9ac23156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1f20e0d4-72c6-43e2-bb9b-e84e1f041af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fe0ceba6-bdbc-482f-8bd0-a19cb2b7cb88" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1f20e0d4-72c6-43e2-bb9b-e84e1f041af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_51e37a0f-f835-450d-a45d-b86dd6cee358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_51e37a0f-f835-450d-a45d-b86dd6cee358" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b08ccb4b-9b90-40d2-8add-4563368bfcf8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_d3d49d5c-9d28-45cb-b13b-47b9a2b016f5" xlink:href="evh-20221231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_d3d49d5c-9d28-45cb-b13b-47b9a2b016f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_320f0bd0-9763-4cf5-8600-8c9c08a47b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_us-gaap_FacilityClosingMember_320f0bd0-9763-4cf5-8600-8c9c08a47b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_81c3b0b1-ef99-483b-8a7d-2bd63ae1d79f" xlink:href="evh-20221231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9b50e81f-c980-4546-afd2-4f9386323729" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_81c3b0b1-ef99-483b-8a7d-2bd63ae1d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9e618da7-2210-473d-88d6-bbcf96c302db" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_331ccfe0-fca0-4339-be1e-24ee3e77367d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_331ccfe0-fca0-4339-be1e-24ee3e77367d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_74be0f64-0645-403a-9252-5dc9dc0b8ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d1e61d50-ac4a-4c69-993e-21b1d4bde650" xlink:to="loc_us-gaap_RestructuringCharges_74be0f64-0645-403a-9252-5dc9dc0b8ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_188ea0d8-e73d-4e83-8b30-672eafc62d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_87607054-552a-4c85-8638-ab4e0b6b093e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_188ea0d8-e73d-4e83-8b30-672eafc62d33" xlink:to="loc_us-gaap_NumberOfOperatingSegments_87607054-552a-4c85-8638-ab4e0b6b093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_39499be4-dea5-4c08-bf93-85ab286ec514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_39499be4-dea5-4c08-bf93-85ab286ec514" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:to="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8f2ea5b1-08d3-4c06-88a2-bcc4d7936273" xlink:to="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b7135d2f-2b99-4be1-b6ff-87d6a606326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b7135d2f-2b99-4be1-b6ff-87d6a606326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cdded813-e9c2-4a58-be8f-bf0ab70c1031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_OperatingSegmentsMember_cdded813-e9c2-4a58-be8f-bf0ab70c1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1ed79d16-41a5-42b0-8bd3-edc5599cdf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2de2ff08-0da8-41e1-b858-9219df10c791" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1ed79d16-41a5-42b0-8bd3-edc5599cdf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8f0742aa-b777-4401-aff9-88918df07789" xlink:to="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_f60b3102-7808-4576-aa29-8cab57b66a5b" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_f60b3102-7808-4576-aa29-8cab57b66a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_5a51140a-1db5-48b3-b5ce-8b6a761d6e8c" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae106b7e-2f8c-4f48-b124-8bf8f0c69a47" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_5a51140a-1db5-48b3-b5ce-8b6a761d6e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b516a205-00ed-43b0-8327-21b15d15effb" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77bc13c5-9d31-464c-b1c6-691b37dca25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77bc13c5-9d31-464c-b1c6-691b37dca25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_8d95d611-3659-47b0-a4e7-0b1a550673ef" xlink:href="evh-20221231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9e532c3b-2c58-4d90-9348-79af990fc658" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_8d95d611-3659-47b0-a4e7-0b1a550673ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f035587-18f4-4386-adff-2ba367cfe6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_NetIncomeLoss_4f035587-18f4-4386-adff-2ba367cfe6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_68c6d1ab-7611-4710-8586-b288bcbaa02c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_InvestmentIncomeInterest_68c6d1ab-7611-4710-8586-b288bcbaa02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_50ab1d2d-d384-4012-a50e-c9b55a54260d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_InterestExpense_50ab1d2d-d384-4012-a50e-c9b55a54260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58a8d93c-8317-490e-86f3-2fa6fd2bc7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58a8d93c-8317-490e-86f3-2fa6fd2bc7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8a9eb10d-589d-40a7-a2c4-cb76abb90106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_DepreciationAndAmortization_8a9eb10d-589d-40a7-a2c4-cb76abb90106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_081b026b-8281-495f-be80-2b5d4dd8c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_081b026b-8281-495f-be80-2b5d4dd8c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_d00a6e26-d1c2-4643-bce2-49d4f5ccbfce" xlink:href="evh-20221231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_GainOnTransferOfMembership_d00a6e26-d1c2-4643-bce2-49d4f5ccbfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_4055ea0f-cf30-4ce2-aa43-432c4174602f" xlink:href="evh-20221231.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_4055ea0f-cf30-4ce2-aa43-432c4174602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_41a00d9c-99ff-4c0b-b37a-d9093f7475f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_41a00d9c-99ff-4c0b-b37a-d9093f7475f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_199fd2c7-8e9d-43d7-af71-be248d1897af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_199fd2c7-8e9d-43d7-af71-be248d1897af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02522434-6c30-41cd-a3f9-4040012c3280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02522434-6c30-41cd-a3f9-4040012c3280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_42f6032a-5563-4acd-a19f-796beb02cde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_42f6032a-5563-4acd-a19f-796beb02cde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_27d660f8-233a-44f0-9a1e-24cfd0ee4273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_27d660f8-233a-44f0-9a1e-24cfd0ee4273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_009a3a29-7b39-45b9-a8e2-61935efd9d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_009a3a29-7b39-45b9-a8e2-61935efd9d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8feed5ab-8d35-469a-b607-1fc8edcd5325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_RestructuringCharges_8feed5ab-8d35-469a-b607-1fc8edcd5325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_33d0d269-9b01-43fa-89f0-a0be2c8083f6" xlink:href="evh-20221231.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_33d0d269-9b01-43fa-89f0-a0be2c8083f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4aa5a736-d09e-464e-90bc-f7f42283b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_SeveranceCosts1_4aa5a736-d09e-464e-90bc-f7f42283b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_4976ca59-693f-48bb-b89c-6d2784959d93" xlink:href="evh-20221231.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_4976ca59-693f-48bb-b89c-6d2784959d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_d8c4441f-7b69-4ac6-912f-fb01dab2e184" xlink:href="evh-20221231.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_ShareholderAdvisoryServices_d8c4441f-7b69-4ac6-912f-fb01dab2e184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_9bc8cc00-063c-407f-b954-b2da3dced0b3" xlink:href="evh-20221231.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_TransactionCosts_9bc8cc00-063c-407f-b954-b2da3dced0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0da126d0-bd11-41c2-889c-fa4f2fd58509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0da126d0-bd11-41c2-889c-fa4f2fd58509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_fc88b920-27da-44f8-aeae-a50af9acc7a8" xlink:href="evh-20221231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_fc88b920-27da-44f8-aeae-a50af9acc7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_4908dc91-8393-46d9-94c4-1db3cf100b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_4908dc91-8393-46d9-94c4-1db3cf100b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_76787a40-104b-4b0b-9957-a698b6f08b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b67aac-02fd-4263-8c2a-6994c72fe164" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_76787a40-104b-4b0b-9957-a698b6f08b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_3dbaf77e-b862-415a-8e25-179860760a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_3dbaf77e-b862-415a-8e25-179860760a5c" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25712ab5-1bb1-4f70-a5e5-95bdcf17ad0b" xlink:to="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_3041b6ec-201f-4a7b-9e0f-3b57ca4a4809" xlink:href="evh-20221231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_3041b6ec-201f-4a7b-9e0f-3b57ca4a4809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cc5537ce-b7f0-4fd0-a57e-bad1ef523e2e" xlink:href="evh-20221231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_138f5943-2993-4083-b28d-4229caabea9b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cc5537ce-b7f0-4fd0-a57e-bad1ef523e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_408b4868-82d5-44b1-99af-76a1828e31dc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f494b6ae-8649-46c4-bedb-039d3c66924e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_88654d85-82aa-4f44-b7f2-b3f0ce29dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_88654d85-82aa-4f44-b7f2-b3f0ce29dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5fc77982-b30d-444a-a191-d9d6173c009c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5fc77982-b30d-444a-a191-d9d6173c009c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_b7509950-1b86-4e15-8bc6-f10d5f07b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_b7509950-1b86-4e15-8bc6-f10d5f07b001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8981dcc2-f4ff-4aaa-a77f-bc231586eef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0323a680-e011-4bbe-b7a5-99d9211a7b29" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8981dcc2-f4ff-4aaa-a77f-bc231586eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48b2cd80-c3f7-4db6-a1f9-9166027e16c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48b2cd80-c3f7-4db6-a1f9-9166027e16c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_dd5efef4-0a6b-4326-8e04-dbdaf9bb0ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_dd5efef4-0a6b-4326-8e04-dbdaf9bb0ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_24b909af-3ee9-439a-9d6e-eb58d6d26ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_f8e5de0f-1883-4f76-83de-619a6d21c5ea" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_24b909af-3ee9-439a-9d6e-eb58d6d26ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6daff726-c30a-4f70-b6ee-49277ac4b3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18ae2b2f-999e-4f77-93d5-fe43e93cfe92" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6daff726-c30a-4f70-b6ee-49277ac4b3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#QuarterlyResultsofOperationsunauditedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3e1ec811-e9d7-4b3f-9342-384f97015f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_Revenues_3e1ec811-e9d7-4b3f-9342-384f97015f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_21832301-87b9-496a-908f-c892eac0380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_OperatingExpenses_21832301-87b9-496a-908f-c892eac0380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6634fd38-e636-4d4a-8f79-dd2f920fb5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6634fd38-e636-4d4a-8f79-dd2f920fb5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eaab8984-2efc-43fb-8ed3-27e34d30a0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eaab8984-2efc-43fb-8ed3-27e34d30a0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b76a3e39-982f-4ca3-8bd6-0c76ed9cb535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b76a3e39-982f-4ca3-8bd6-0c76ed9cb535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b48fc64d-34f8-4de2-b824-8ecac3e99805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b48fc64d-34f8-4de2-b824-8ecac3e99805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_7732d8fe-b4bb-4460-ad02-0218711299af" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f463c07e-cbff-4ab6-8fe4-ff917a68830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f463c07e-cbff-4ab6-8fe4-ff917a68830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ff2927f6-296c-4d32-9199-69b0415f3f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ff2927f6-296c-4d32-9199-69b0415f3f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_dfa58eb7-1885-4040-900d-d978bafc9f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_dfa58eb7-1885-4040-900d-d978bafc9f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5670137d-3105-4e06-83ed-7c0f718e99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d68e9214-3b51-4ff9-9a08-7989ad7a4406" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5670137d-3105-4e06-83ed-7c0f718e99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_4c7a5db6-b3ac-4086-9f2e-409872ccbe16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4c7a5db6-b3ac-4086-9f2e-409872ccbe16" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b3e4e63c-b459-4c21-bcb2-5a6506d3bc63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b3e4e63c-b459-4c21-bcb2-5a6506d3bc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_5cf9f2d3-5905-495d-95ba-7ddebdae4a6f" xlink:href="evh-20221231.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_5cf9f2d3-5905-495d-95ba-7ddebdae4a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_ecb69b03-d0d4-45d6-b792-1bd28e4dfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_ecb69b03-d0d4-45d6-b792-1bd28e4dfb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8468bb40-cbd2-4fd9-a357-a2579ddfaadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8468bb40-cbd2-4fd9-a357-a2579ddfaadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossFromTransferOfMembership_3cc8c222-be18-4303-a504-e6910765e9d9" xlink:href="evh-20221231.xsd#evh_GainLossFromTransferOfMembership"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_evh_GainLossFromTransferOfMembership_3cc8c222-be18-4303-a504-e6910765e9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_0c4ffe0d-1a06-4923-9bb5-fe5d9e952418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_StockIssued1_0c4ffe0d-1a06-4923-9bb5-fe5d9e952418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment_efad3b06-447b-40af-80bf-0664596a6815" xlink:href="evh-20221231.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_evh_StockIssuedInConnectionWithDebtRepayment_efad3b06-447b-40af-80bf-0664596a6815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2eb9009f-dff9-43ea-bafe-1c1eeb32addf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2eb9009f-dff9-43ea-bafe-1c1eeb32addf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0bbe0462-9fe2-4287-a001-9d57ce342599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a2ae34d-e534-491f-8179-154628cafed2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0bbe0462-9fe2-4287-a001-9d57ce342599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_574ce2d9-34f4-4c6e-8cd9-3ad2c6c55bd3" xlink:href="evh-20221231.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4c7a5db6-b3ac-4086-9f2e-409872ccbe16" xlink:to="loc_evh_CashFlowLesseeAbstract_574ce2d9-34f4-4c6e-8cd9-3ad2c6c55bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_c064a011-d75d-4757-9d4a-1cf9c140d62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_574ce2d9-34f4-4c6e-8cd9-3ad2c6c55bd3" xlink:to="loc_us-gaap_OperatingLeasePayments_c064a011-d75d-4757-9d4a-1cf9c140d62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4f260daf-1206-47f4-8133-8b2f0758ddee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_574ce2d9-34f4-4c6e-8cd9-3ad2c6c55bd3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4f260daf-1206-47f4-8133-8b2f0758ddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_5556393c-bb81-4cea-be05-a476c5d8d78e" xlink:href="evh-20221231.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_574ce2d9-34f4-4c6e-8cd9-3ad2c6c55bd3" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_5556393c-bb81-4cea-be05-a476c5d8d78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ad7ae0f7-d054-4d5d-9fe0-44294356cb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4c7a5db6-b3ac-4086-9f2e-409872ccbe16" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ad7ae0f7-d054-4d5d-9fe0-44294356cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b9d43988-df51-4d1e-80da-c56ae6eb0146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ad7ae0f7-d054-4d5d-9fe0-44294356cb38" xlink:to="loc_us-gaap_InterestPaidNet_b9d43988-df51-4d1e-80da-c56ae6eb0146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_28f04cc9-1a6b-4958-9e7b-478936f16cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ad7ae0f7-d054-4d5d-9fe0-44294356cb38" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_28f04cc9-1a6b-4958-9e7b-478936f16cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_54effde9-9a07-4938-bb0c-df4a222b058e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_54effde9-9a07-4938-bb0c-df4a222b058e" xlink:to="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_928f1596-66de-4d97-8b50-9ecd225fe2c5" xlink:to="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a56959ba-6fb6-4989-9488-0de800843a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:to="loc_us-gaap_SecuredDebtMember_a56959ba-6fb6-4989-9488-0de800843a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f18f208-b312-4ef7-a966-2546ca2d794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_24e5fb18-a6f6-4ceb-a193-7c9d20671a20" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f18f208-b312-4ef7-a966-2546ca2d794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bf08b4e-4ded-4d7a-a79b-69da96cb8edc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_00cb1bf4-8507-4196-9cfd-778cfb1520ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0bfce16e-08e4-4254-bd38-38084626c46d" xlink:to="loc_us-gaap_LineOfCreditMember_00cb1bf4-8507-4196-9cfd-778cfb1520ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_87e579a1-8620-4d5f-8179-14deafeb6e7d" xlink:to="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_b5e3c067-1bc5-4679-919e-a2e93a92a2f5" xlink:href="evh-20221231.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_b5e3c067-1bc5-4679-919e-a2e93a92a2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c9df56b3-6d78-494e-8121-e2aee8580ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7cad412a-5567-4f55-92c5-64a10f8af0c2" xlink:to="loc_us-gaap_BaseRateMember_c9df56b3-6d78-494e-8121-e2aee8580ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7d434cf-96c1-43c5-8216-1bc6a0f44b7c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dba025eb-e6b1-4eea-90c3-de0bfe9d7356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_83c1a532-ee88-419b-9dbe-37b2d3aaedc8" xlink:to="loc_us-gaap_SubsequentEventMember_dba025eb-e6b1-4eea-90c3-de0bfe9d7356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a90394b4-3dc2-4f9f-ac45-7fb76f5c6e24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuritiesPurchaseAgreementMember_f78ef3a3-4bd2-4eef-9b3b-c403dd292d28" xlink:href="evh-20221231.xsd#evh_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b80c7bb8-22aa-4e07-9734-af6910323855" xlink:to="loc_evh_SecuritiesPurchaseAgreementMember_f78ef3a3-4bd2-4eef-9b3b-c403dd292d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd62a0bf-f1a6-48b9-81e5-8f060c742ed2" xlink:to="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bfca0456-8d84-43fd-a472-26f1a5a66d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bfca0456-8d84-43fd-a472-26f1a5a66d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_040b3a96-4f91-42a9-ad20-bdae1afc97f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d833c23f-e49a-4dd8-aa53-8a948ba67f21" xlink:to="loc_us-gaap_CommonClassAMember_040b3a96-4f91-42a9-ad20-bdae1afc97f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_PreferredStockRedemptionPeriodAxis_684a2cbf-66f4-46bd-92f4-66f0c34b7c88" xlink:to="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodOneMember_13195ebd-db21-49ee-a9be-d949b909f500" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodOneMember_13195ebd-db21-49ee-a9be-d949b909f500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodTwoMember_7141b742-7da5-4d71-9952-96619bb1648f" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodTwoMember_7141b742-7da5-4d71-9952-96619bb1648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodThreeMember_57425f09-b146-440c-9327-f4458094fd5d" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodThreeMember_57425f09-b146-440c-9327-f4458094fd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPeriodFourMember_630889a0-7c4d-4d47-acde-de2f56a0688a" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_PreferredStockRedemptionPeriodDomain_d72ee45d-81a0-42d3-93dc-dca000d177ae" xlink:to="loc_evh_PreferredStockRedemptionPeriodFourMember_630889a0-7c4d-4d47-acde-de2f56a0688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061eaf5e-4693-4e79-82e4-67320a3f38ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NationalImagingAssociatesMember_32e0352c-ce34-4e91-aa14-54a4e5723d5e" xlink:href="evh-20221231.xsd#evh_NationalImagingAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:to="loc_evh_NationalImagingAssociatesMember_32e0352c-ce34-4e91-aa14-54a4e5723d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_2e5dde45-0773-4727-893c-77faf7537b52" xlink:href="evh-20221231.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9edd9c28-f00f-4ea2-a311-8b61b2441afe" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_2e5dde45-0773-4727-893c-77faf7537b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_256eacb5-9058-4e4a-978a-0a586d39a6e2" xlink:to="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6eb51af-fe26-40ae-a72a-cc178ba07171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6eb51af-fe26-40ae-a72a-cc178ba07171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_148fe77f-29ea-4816-aa9e-026842355aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_148fe77f-29ea-4816-aa9e-026842355aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_ec3f7c80-5aa3-4ec9-80c5-a212367d4a61" xlink:href="evh-20221231.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_ec3f7c80-5aa3-4ec9-80c5-a212367d4a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32245f9e-0100-4dfc-9547-31600fc6b463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32245f9e-0100-4dfc-9547-31600fc6b463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9a6e2294-c8a5-4e0e-b2f6-85d35dabd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9a6e2294-c8a5-4e0e-b2f6-85d35dabd7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_695dac9a-f14e-448b-ab93-3c1d54c39a32" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_695dac9a-f14e-448b-ab93-3c1d54c39a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_5933ab7f-7261-42fc-b6ee-3d41ef14cd12" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_5933ab7f-7261-42fc-b6ee-3d41ef14cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_df3977f2-86bb-4579-8bbc-d03c249ec854" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_df3977f2-86bb-4579-8bbc-d03c249ec854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_5192d600-d0be-49c5-b3ea-2b7fdca1af69" xlink:href="evh-20221231.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_5192d600-d0be-49c5-b3ea-2b7fdca1af69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be67221c-d3ca-431d-bd03-f0c46b303274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be67221c-d3ca-431d-bd03-f0c46b303274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0fcb6da4-bea8-4c87-92b3-18be8512d982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0fcb6da4-bea8-4c87-92b3-18be8512d982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e557e9e-d700-4dd4-9f88-899ab089efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e557e9e-d700-4dd4-9f88-899ab089efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39132915-52c9-496d-89ed-3249e775d9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39132915-52c9-496d-89ed-3249e775d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ec7faadd-f10a-4579-abaf-0015bf07cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ec7faadd-f10a-4579-abaf-0015bf07cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f96b4ce4-ef74-4bd5-8ed9-4b9476ead471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f96b4ce4-ef74-4bd5-8ed9-4b9476ead471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_43b2a14a-1aab-4b54-a2fc-048413e64f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_43b2a14a-1aab-4b54-a2fc-048413e64f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_f66b232e-c923-4489-a77a-d037a2c01332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_f66b232e-c923-4489-a77a-d037a2c01332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockVariableDividendRateBasisSpread_3f2cf407-795a-405b-a9c4-ee30a6cc9b5e" xlink:href="evh-20221231.xsd#evh_PreferredStockVariableDividendRateBasisSpread"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockVariableDividendRateBasisSpread_3f2cf407-795a-405b-a9c4-ee30a6cc9b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_8c63756f-2627-4fd4-8506-37d0d6b33b61" xlink:href="evh-20221231.xsd#evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate_8c63756f-2627-4fd4-8506-37d0d6b33b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_cd75f92a-2148-4eb6-9325-d463dfbe581b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_cd75f92a-2148-4eb6-9325-d463dfbe581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PreferredStockRedemptionPricePercentage_557698db-4612-4fdf-9ced-6c6027d708f7" xlink:href="evh-20221231.xsd#evh_PreferredStockRedemptionPricePercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_evh_PreferredStockRedemptionPricePercentage_557698db-4612-4fdf-9ced-6c6027d708f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_09e2fa91-1992-4735-b901-6945c7df6cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_09e2fa91-1992-4735-b901-6945c7df6cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_819c3feb-cb66-4fdc-bb61-a4fcbd6669f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_181ff22f-c50b-4ec4-8b1d-18ca434dcfeb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_819c3feb-cb66-4fdc-bb61-a4fcbd6669f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>evh-20221231_g1.jpg
<TEXT>
begin 644 evh-20221231_g1.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X
MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;
M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*
MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_
M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)
M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_
M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*
MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y
M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@
MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?
M])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27
M;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\
MJ&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AK
MG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\
M>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_
M?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^H
MH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /
MP!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?
M^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$
MV_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^
M"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9
M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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MXPVWQH^R#Q)X9T:QN;.YT*\AD,5K,M]IX+2)) T@9$38)3'EU530!^NO[/\
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M>WU.UEFCD@>"1@T_DOF/YXTR3O)>O$?@+_P55_X*.?$__@V?^,7_  4$U_\
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MM('GG:W)MY4DD$:.=CF,';PV< _D-_P9!?\ )&/VA/\ L;M#_P#2:[K]4/\
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M %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444
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M5S]LN5BU:(VLC)JFV%\ZA"P9R$VQR_,&"J_[=44 ?DI_P00_X)B_MI_LS_\
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MB3XGZ[=:O?ZCX!FTOX@:W)<F6?4-0OK9DOY?-;)<!I72,L3MCCC7HHK\V?\
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M%MOK&C7W_"2Z1J-O=1"U2!H_]!O)G212F?G55(888GBOU1HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OX0OVL/\ DZ;XE_\ 90-9_P#2Z:O[O:_A"_:P_P"3
MIOB7_P!E UG_ -+IJ /V_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG
M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OX0OVL/\
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M>*]3US0O!6EZ9XW^$5]K>HRWE[9Z%?1P"[TR2>9FDEAM;N=$@9V=Q')L+81
M/NV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K^$+]K#_DZ;XE_]E UG_P!+IJ_N]K^$+]K#_DZ;XE_]
ME UG_P!+IJ /V_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?_;Q_
MZ?)Z_?Z@#XG_ ."RW[,'[(/[>G[&/Q)\.?$[PKI^M^(OA?.MO8ZY:HT6I>%M
M4E@LKH>1/@$%K:[M963YHG#IO5BN%X3_ ()!?$[]L3X!_M=?%S_@D5^UC\6I
M/BI:?"?PWI7B#X=_%&[C(U"YT6\)2.SU DL7F3C:S,S_ +N7YG3R]OM?[5/_
M  2Z\(_&S6/B+\2_@Y\;O'/PZ\8_$VPLH/&$NBZ\L^E:R]I##;V\MQ87D5Q
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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MSK;PW8R^)+G26N;KRHK='4BZ;.2>>]=36/9?\CO>_P#7E%_,T '_  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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MS>_^!;5G>&_#=CJU@]S=7-T&6XD0;+I@, X'>NIK'\#_ /((E_Z_9O\ T*@
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:L[PWX;L=6L'N;JYN@RW$B#9=,!@' [UU-8_@?_D$2_P#7[-_Z
M%0 ?\(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_
MP@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M7CW[8GQT\*?LQ^"(;BR6>^\1
M:L731K"6\?8-N-\TF#G8N1P,%B0 1R1[S7YL_P#!2SQ'J6M?M5:GI5Y(QATC
M3+*UM%/0(T*SG'_ YFK\P\7>+<;P=P;/%8)VK5)1IQEORN2DW+U48NWG9Z['
MS_$N95<KRMU*7Q2:BGVO=W^Y.WF>3^/?C'\4/B=?O?\ CCQQJ-_O8E8)+EA#
M'[)&#M4?04> OC'\4/AC?I?^!_'&HV&Q@6@CN6,,GL\9.UA]17,T5_!G]LYO
M]?\ KOUB?MKWY^>7/?OS7O?YGX]]:Q/MO:\[Y^]W?[]S]*_V._CIX4_:<\$3
M7%ZL]CXBTDHFLV$5X^P[L[)H\G.QL'@Y*D$$G@GV'_A!](_Y^;W_ ,"VK\\?
M^":?B/4M%_:JTS2K.1A#J^F7MK=J.A186G&?^!PK7Z35_>?A%Q;C>,>#88K&
MN]:G*5.4MN9Q46I>KC)7\[O38_8>&LRJYIE:J5?BBW%OO:SO]S5_,Q_^$'TC
M_GYO?_ MJ/\ A!](_P"?F]_\"VK8HK]//H#'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VK8HH Q_^$'TC_GYO?\ P+:IO"M_<:AIC27+ F.=XU('\*G K2K'
M\#_\@B7_ *_9O_0J -BOX0OVL/\ DZ;XE_\ 90-9_P#2Z:O[O:_A"_:P_P"3
MIOB7_P!E UG_ -+IJ /V_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG
M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@#P7]KG_DN'P,_['N7
M_P!$5[U7@O[7/_)</@9_V/<O_HBO>J "BBB@ HHHH **** ,?Q+_ ,A?1_\
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M_P#7[-_Z%0!L4444 %%%% !1110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\
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M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+0 >)?^0OH_\ U^G_ -!-;%<IKFN:C/J.FR2>&[F,
MQW)9$9ES(=O05I_\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
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MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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MNC+@$MT_"@#JZ*Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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M>_\ ?2T?\)+J_P#T*%[_ -]+0!L5C^!_^01+_P!?LW_H5'_"2ZO_ -"A>_\
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M#]FOXT7WQ7\*7.C>-+$:?XP\-7/]G^*]+. 8[A>!,H[QR ;E(XZ@$@9/8?\
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MZ*[VMT/;:*\=T7]N+X*-J":%\18];\#ZF_ L?%^CR6N3W(D 9,>Y85ZIX?\
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MR_Y'>]_Z\HOYFMB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO?\
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M5F^,?^18O?\ K@: +FG?\@^#_KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1110
M5C^)?^0OH_\ U^G_ -!-;%8_B7_D+Z/_ -?I_P#030!L4444 %%%% !1110
M5C^)?^0OH_\ U^G_ -!-;%8_B7_D+Z/_ -?I_P#030!L4444 %%%% !1110
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MPOH+BWY=O=\"OF']O;]IKXQ>,)+7X'>.?!">%)-/*W&MV%IK"7:7SL T+;D
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M "")?^OV;_T*MBL?P/\ \@B7_K]F_P#0J^B.TV*_A"_:P_Y.F^)?_90-9_\
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MW"KY\T]Q=O#$Y+,\YG8.6+G/T=\,?B1XO_8I_P"";?PVU']IN34?$'COP_\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@ \2_\A?1_P#K]/\ Z":V*Y37/"NG6NHZ;#'/<D3W)5RUPQ(&WMZ5I_\
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MP2"V#G:JJSGIG;C(R#7YG^*O%?B3QOKUQXG\6ZU<:A?W3[I[JYD+,Q[#V Z
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MB7_K]F_]"K8KE/"OA73M0TZ2::>Y!%S(H"7#*,!JT_\ A!](_P"?F]_\"VH
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MKX5TZ3Q3=6#3W.R.VC92+AMV23U- '5T5C_\(/I'_/S>_P#@6U'_  @^D?\
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MVMW.B0,[.XCDV%L(@'W;0 4444 >"_M<_P#)</@9_P!CW+_Z(KWJO!?VN?\
MDN'P,_['N7_T17O5 !1110 4444 %%%% &/XE_Y"^C_]?I_]!-;%8_B7_D+Z
M/_U^G_T$UL4 %%%% !1110 4444 8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%
M_,UL4 %%%% !116?XK\4Z!X(\-WWB[Q3J4=GIVG6S3WES*>$11DGW/8 <DD
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M&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\ D'P?]<5_D*FH **** "BBB@
MK-\8_P#(L7O_ %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KB
MO\A4U !1110 4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T
M;%%%% !1110 4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T
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M*EI\)_#>E>(/AW\4;N,C4+G1;PE([/4"2Q>9.-K,S/\ NY?F=/+V^U_M4_\
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M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!RFN6OBE=1TU;K5+9W:Y(@98" K;>I]:T_L7C?_ *#=E_X#'_&CQ+_R
M%]'_ .OT_P#H)K8H Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L
M7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW
M_P"@W9?^ Q_QK8HH Y2UM?%)\4W4<>J6PN!;1F20P':5R< "M/[%XW_Z#=E_
MX#'_ !HLO^1WO?\ KRB_F:V* ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QKP;Q)%XJ_:^^*EQ\-[75H)O '@S4$;Q#=
MQQ$0ZSJ*'*V8(/SQQGE^Q/\ P!J[#]I?XF^*KO4]/_9Q^#=WM\7^*8B;F^3D
M:)IV<2W;D?=;&53H<]#G:#Z!\*_AEX5^#W@+3OAYX.L_*LM/AVAFQOF<\O*Y
M[NS$L3[\8  KXO,'_K1F<LLAKA:+7MWTG/1QH+NEI*MY<M/7FFEY5?\ X4,0
M\.OX<?C\WNH>G67R75VGCT[QG#&L,.KV*(B@*JVA  '0 4[[%XW_ .@W9?\
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MQO\ ]!NR_P# 8_XUL44P.4M;7Q2?%-U''JEL+@6T9DD,!VE<G  K3^Q>-_\
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M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M?,1+<@D>QKIJS?&/_(L7O_7 T 5+*S\:&SB,6LV87REV@VQR!CZU+]B\;_\
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M#C[WRGKFI_VC[FY^./Q0T/\ 9.T*X<:?($UGQ]/"Q'EZ?&X,5L2.C2R!>.H
M4\@FO<;6VMK*VCL[.!(H84"111J%5% P  .@ XQ7Q]/_ (7^)'5WH8-N,>TJ
M[5I/S5*#Y5_?G-;P/+C_ +9C^;[%+1><VM7_ -NIV]6^J,K[%XW_ .@W9?\
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ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
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M0OH__7Z?_036Q6/XE_Y"^C_]?I_]!-;% !1110 4444 %%%% &/9?\CO>_\
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M1117V!Z9CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S-;% !1110 4444 %%%%
M&/X'_P"01+_U^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %%%% &/X'
M_P"01+_U^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %%%% &/X'_P"0
M1+_U^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %9OC'_D6+W_K@:TJS
M?&/_ "+%[_UP- %S3O\ D'P?]<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "
MLWQC_P BQ>_]<#6E6;XQ_P"18O?^N!H N:=_R#X/^N*_R%35#IW_ "#X/^N*
M_P A4U !1110 4444 %9OC'_ )%B]_ZX&M*LWQC_ ,BQ>_\ 7 T 7-._Y!\'
M_7%?Y"IJAT[_ )!\'_7%?Y"IJ "BBB@ HHHH *Q_$O\ R%]'_P"OT_\ H)K8
MK'\2_P#(7T?_ *_3_P"@F@#8HHHH **** "BBB@ K'\2_P#(7T?_ *_3_P"@
MFMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH **** "L>R_Y'>]_Z\HOYFMB
ML>R_Y'>]_P"O*+^9H V**** "BBB@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'
M>]_Z\HOYF@#8K ^*7Q&\/_"3X>ZM\1O$\NVSTFT:9U!PTK=$C7_:=BJCW85O
MUX1\2?\ C(_]H_3O@O;?OO"O@-XM8\8,.8[J_.3:V9[$ 9=AR"-P."HKP>(\
MSKY;@%'"I/$56J=)/9SE>S?]V"3J3_NQ?4X\=B)T*-J?QR?+'U?7T2NWY)F_
M^R7\.?$'A_PA??%3XBQ?\5=X[NQJNM%AS;1D?Z/:C/(6.,@;3T+$=A7K%%%=
MF4990R;+:>#I-M06K>\I/64I=Y2DW*3ZMLUPV'AA:$:4>G7N^K?FWJ_,****
M](W"L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F: -BBBB@ HHHH **** "L?
MP/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH **** "BBB@ K'\#_
M /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH *Q_ _P#R
M")?^OV;_ -"K8K'\#_\ ((E_Z_9O_0J -BBBB@ HHHH **** ,WQC_R+%[_U
MP-7-._Y!\'_7%?Y"J?C'_D6+W_K@:N:=_P @^#_KBO\ (4 34444 %%%% !1
M110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%?PA?M8?\G3?$O_
M +*!K/\ Z735_=[7\(7[6'_)TWQ+_P"R@:S_ .ETU '[?_\ !IM_RE,_:[_[
M>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0!\K_MD?\ !3&P^ WB?Q?\
M%_@+\)=0^(OQ \$>$[7Q#XMM+>ZM[73/#EG<R^7:_;KB65&\Z?:[1P0K)(50
MNP1,,WI7[-?[6B?'SQOXT^$?BKX(^+OA_P",_ ']GOXAT'Q3':R1RP7RSFUN
M[.ZM)YH;JWD^S3C<&5E:-D=$92H_.O\ X+7?L??MJ_LN?&GXD?\ !4C]B*6S
M\7>%_B#X+T[1OC_\+M0;;=7%M8>7';:CI[9&Z6.-$38,NI+$),)65/N+_@G'
M^W_^R)_P4I\!ZC^TA^SC/);^(H[>TT7QYX=UF#[/K.@RV[W,D-E>0Y. KW%T
M4D7*/ODPQ*LJ@">,_P#@IM\(?"'_  4)\ _\$XI/AKXX;Q9X^L=4O;+Q!>>'
M9++1XH;"UGGE\N>XV-=,3#L!A1X_G!,G0'T?]JW]JGX9?L>_"@?%;XFQ:C>+
M>:U8Z)X>T'1+=9M0UW5[V=8+/3[2-W17GFE8*-SHBC<SLJJS#XW_ &W0/^(B
M;]B%L<GP-\1,G_N%&O6_^"W'[-7@K]I+]@+7SXI^/UM\+-2^'^KV/C3P;\0K
MYV$&B:WI\A:TDD5 SN':0PA8U:3=,I1)'"HP!VLO[<^I_#;XO^ _@_\ M3?
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MMB@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
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M_P#SXP_]^A4U%?IY] 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 87@NRLY=*D:6TB8_;)1EHP>-U:_P#9VG_\
M^,/_ 'Z%9O@?_D$2_P#7[-_Z%6Q0!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!A>"[*SETJ1I;2)C]LE&6C!XW5K_V=I_\ SXP_]^A6;X'_ .01
M+_U^S?\ H5;% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
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M7;>XW?3RW.:Z2OXWK4*^'GR58N+[--/\3^UJ->AB(<]*:DNZ::_ A_L[3_\
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M,/\ WZ%']G:?_P ^,/\ WZ%344 9'BZQLH_#5X\=G$K"$X*Q@$5;T_3[!K"
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M01+_ -?LW_H5 &Q7\(7[6'_)TWQ+_P"R@:S_ .ETU?W>U_"%^UA_R=-\2_\
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M-3&J^,O$<XO/%.M-R99CTA0]HHP=J@8'4X&0!Z-6/_P@^D?\_-[_ .!;4?\
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M9^FM%?FC_P /P-(_Z-7O?_#C-_\ (-?1?[ ?[8ND?MR?\)9_Q;"]\+_\(O\
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M_P#NZJ<'_!!WSM;GT;_AJG'DPK)YG_"#=<]L?;J_O7_B,GAO_P!!W_E*M_\
M*S^-?^(*^)O_ $ ?^5:/_P L/SUK]H?^"3?_ "C^\ ?]Q7_TZWE?.G_#@?\
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MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJ )O&/\ R+%[_P!<#5S3O^0?!_UQ7^0KG_$OA+3+'0;J
M[AN+HM'$2 ]RQ'XBK-EX+TJ6SBE:YO,M$I.+IL=* -VBL?\ X0?2/^?F]_\
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M-_Z%6Q6/X'_Y!$O_ %^S?^A5L4 %%%% !1110 5F^,?^18O?^N!K2K-\8_\
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MO3<02%C7W8C.#C."*^>-3_X*P:!J.NV<P^"EXEI:7._S?[<0R,,8^YY. ?\
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M5TM?5V1MAZ%7%5HTJ:O)Z+5+\[(]_K'LO^1WO?\ KRB_F:_,/_B)H_ZLG_\
M,D?_ 'MJG!_P<I>3K<^L_P##%V?.A6/R_P#A8W3'?/\ 9U>]_JAQ%_SX_P#)
MH?\ R1[/^J^>_P#/G_R:/_R1^L%%?FM\#O\ @X'\8?M ?%_PY\%O 7[#GFZM
MXDU6*RM,_$<E8]Q^:5\:;PB(&=CV5">U?I37E9AE6/RJ<88J'*WJE=/3Y-GG
M8[+L9ETU'$1Y6]5JG^384445YYPA7PC_ ,%Z?V>OB1\2/V=-*^/'PXULJ_PT
M:[GU?25LED:YLKIK99)U8D[?)\A6(VG*,[9&S#?=U5->T/1_$^AWOAKQ#IT5
MYI^HVDEM?6DZ;HYX9%*.C#NK*2"/0UZF2YMB\BS2ECL-)QG![IV=FG&23Z7B
MVK^9G5PN7XR*I8ZA"M2;3E"<5*,K-.SC)-/5)ZK=)G\P/_"T/'/_ $'/_):+
M_P")H_X6AXY_Z#G_ )+1?_$UZ!^W=^RYJO['?[4?BCX'7@D>PLKS[3X?NY>3
M<Z=-\]NY/=@IV-_MQN.U>05_1]#B/-L31C5IXJHXR2:]^6S^9^AT?#7PQKTH
MU(9+A&I*Z_V:CU_[</=OV*/A%\9?VT/VB]"^ _A;Q2;%+]GGU;5CIL<JZ=91
M+NEG90%W=E4;EW.Z+D9S7]%.LZ+HWB/2I]"\0Z3;7]C=1F.ZL[V!98ID/561
M@0P]B*_-;_@@7X+_ &>?@I\&-6^-/C?XR>#+?QGXTN#!#IMQXEM%N].TR!R%
MC>,R;XVEE#2,I'*K":_271_$OASQ%'YWA_Q!97R8SNL[M)1CZJ37XUQYQ#FF
M<9G&G6J3E&A=1<FW:3MS--Z[I+Y7ZGQ69Y#PUE&85:>4X"EAX-*,O94H4U.U
M_B48I2MS-*]^O<^?_$/[ TGPZUJX\>?L5?%;4/AGJTTGFW.@+F[T&_?TEM)"
M1&3TWI]P'Y5S5>Q_;@^(?P-O8O#/[=/P8N?"BM((H?'WAE)+_0+IB< LR@RV
MI)Z*X8]2=HKZ5J*_L+'5+*73=3LHKFWGC,<]O/&'21",%64\$$=C7EPXF>-B
MJ><4EB%MSWY:R7E52;E;HJBJ)=$CXF?"ZP,G5R6L\-+?DMS49/SI-I1OU=)T
MV^K91\(>,_"/Q \/V_BOP+XGL-8TRZ7=;W^F7:3PR#V="0?IVKS_ /:9_;5_
M9F_8[BT6?]HWXDGPZGB%KA=(;^Q;V\$Y@\OS1_HL,FS'FQ_>QG=QG!QQ7B__
M ()_:%X9\07'Q&_9"^(VI?"CQ',WF3VVCJ)M&OV':>P<^7CL-F O)VDU\)_\
M%F+O]I?QOH7@;X?_ +3OPZT33M2TE=5;2?$OAS4#)8ZUO^QY=(G_ 'D#(8UW
M!^OG#  Z^[PYP7E?%&<4Z& Q?-"2FW"5J=9.,)222?-&:<DE>#D[7E*,5MPX
M[C.?#-&-7B#"RA34Z<95*;YZ7+*I&$I<UN:#C&3ERU().W+&<FT?97_#[3_@
MF+_T<S_Y9FM?_(=9OA7_ (+2?\$T--TZ2"]_:4V.US(X'_"':R>"V0>+.OP5
MEBD@E:"9"KHQ5U/4$=13:]9\ 90G9SJ??'_Y _H:'!V45(J4:DVGJFG'7_R4
M_H B_P""U_\ P3)GE6"']I8L[L%11X+UK))Z#_CSKZHK^87X1^'/[2UEM;N(
M\PV?^KR.#(>GY#G\J_IZKP.,N$*'#67X/%4I2:KNII*VU/DLU9+=R?W'Y;CL
MSR?_ %LQF28&3E+"QI.HVT[3J\[Y-$OAC&+?^*W1A1117P)L%%%% !6/X'_Y
M!$O_ %^S?^A5L5C^!_\ D$2_]?LW_H5 &Q1110 4444 %%%% &;XQ_Y%B]_Z
MX&KFG?\ (/@_ZXK_ "%4_&/_ "+%[_UP-7-._P"0?!_UQ7^0H FHHHH ****
M "BBB@ K'\#_ /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"H V*_A"_:P_Y.F^
M)?\ V4#6?_2Z:O[O:_A"_:P_Y.F^)?\ V4#6?_2Z:@#]O_\ @TV_Y2F?M=_]
MO'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HK\]/VV/^"@7QV\=_M"?'
M7]C/]F?XB:3\/Y?@?\.]&U[Q1XCNM,:\U?5KO4W1X8-/0S1QV]O#"T9FG996
M9YTC58\%V^G?V8O%?[7%G\8?B#\$/VH;OPMKMGX<T_1M3\&>./"^ASZ;_:]I
M?-?QR0W5M)/.D=S!)988Q/L=)8WV1[MH /;J*^*?C5^W/^US\-/^"RGP*_89
MO?"/@>R^&7Q/T+Q+J3ZE9W-S>:O='3K"XE17:1(HK4;_ "&*(LI/(\S&0?=O
MVQ/B+^TWX7\):5X"_8W\"Z!J_P 0_%=^]MIVI>,7G71/#]I'&9+C4K[R/WLJ
M)^[B2",AY)KB(95!(Z@'L%%?FS\*_P!NC_@J!^QE_P %&?AI^P[_ ,%-E^'7
MCKPI\<X;Z+X<_$OX<Z1/I[V6IVD(EEL[JWD8@K@QJ,#/[]'\Q@)$3W'XL?MF
M?%3XL_\ !1'_ (=J?LJ^(M*T#4/"W@,>+OBQX]U'2?[0?1X)I4BL=+L[=G1#
M=S;Q.TDNZ.. <([N-@!]:T5\O_L-_MM>,OBK^T'\8OV$_P!H=-+7XI?!34[)
MKK5-%M&MK/Q-H5_ MQ8:I% [N89-C>5<1!W5)0"K8D"+]04 %%%% '@O[7/_
M "7#X&?]CW+_ .B*]ZKP7]KG_DN'P,_['N7_ -$5[U0 4444 %%%% !117FG
MQ^_:R^#O[.5ND7CC6)9]3GCWVVBZ;&)+F1>FX@D+&N>[$9P<9P17!F>:9=DV
M"EB\=5C2IQWE)V7_  [Z):OH8XC$4,+2=2M)1BNK.S\2_P#(7T?_ *_3_P"@
MFMBOBW4_^"L&@:CKEG,/@I>):6ESO,O]N(9&7&/N>5@'_@5>H?\ #P_X1^*?
MAS+K'PRMKR_\5W,\=EI'A"ZMREU-=RY$>=I*M&""696. ,'!8"OC,%XK>'V8
M\ZP^/BW!-V:G%NW2*E%.;[*-V^B/*I<19+7OR5DVO)IOTNE=^2N='^T;\6/%
M<VM6?[.OP2N ?&?B*$M<WZ\IH5ATDNY".C8X0=<G/7:&[CX0?"?PI\%/ -E\
M/_!]N1;VJEI[B3F6[F;EYI#_ !.QY/H, 8  KG?V<O@A>?"S1;WQ1XXU(:KX
MU\2S"[\4:PW.Z3'RP1^D48^50,#C. , >DU[&1Y?B\3B99QF,>6M-6A!_P#+
MFF]>3MSRLI56MVE%-Q@F^K"4:LZCQ5=6F]$OY8]O5[R??39(****^J/1"BBB
M@#'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** /.OC]^UE^S
M_P#LO?V3_P +T\?_ -A_VYY_]E_\2J[N?/\ )\OS?^/>*3;CS8_O8SNXS@X\
MY_X>R?\ !/[_ *+[_P"6KJO_ ,BU\Z?\%^/^:3_]Q[_W'5^=-?TEP!X.\,\5
M<)8;-,76K1J5.>ZA*"C[M24%9.G)[15]7K?T/YC\0_&CBGA+C#$Y5@Z-&5.G
MR6<XS<O>IPF[M5(K>3M9+2WJ?L?:_P#!57]@F/Q3=:D_QXQ#);(B/_PB^J<D
M$Y&/LN:TO^'LG_!/[_HOO_EJZK_\BU^+U%?8_P#$OG!G_01B/_ Z?_RH^+_X
MF+XV_P"@?#_^ 5/_ )<?T64445_'A_: 4444 %%%% &/9?\ ([WO_7E%_,UL
M5CV7_([WO_7E%_,UL4 %%%% 'S_XOAE_8]^+TGQ.TR)E^''C._5/%5K&N4T3
M47.%O5 ^[%(>'QT/K\BU[]#-%<1+<6\JO&ZAD=&R&!Y!!'453\3>&M"\9>'K
MWPIXFTV*\T_4+9X+RUF&5DC88(]OJ.0>17C/P#\2Z[\"_'[?LG?$K4I;BU\I
M[CX=ZY<G_C^L1R;-V_Y[0CC'=1P  N?BJ/\ QBF:K#O3!XB7N=J5:3NX>4*K
MNX=(U&X;3@EY4?\ A.Q/)_RZF]/[LGT]);KM*ZZH]THHHK[4]4Q_ _\ R")?
M^OV;_P!"K8K'\#_\@B7_ *_9O_0JV* "BBB@ HHHH **** ,?P/_ ,@B7_K]
MF_\ 0JV*Q_ __((E_P"OV;_T*MB@ HHHH **** "BBB@#'\#_P#((E_Z_9O_
M $*MBL?P/_R")?\ K]F_]"K8H **** "BBB@#XO_ &LO^"O7_#+W[0&O_ O_
M (9Z_MS^P_LO_$T_X2S[-Y_G6D-Q_JOLDFW'F[?O'.W/&<#S#6/^"\_]K:7/
MIO\ PRIY?G)MW_\ "<YQ^'V&OGW_ (*R?\I ?'__ '"O_359U\Z5_9O"WA1P
M!F/#.!Q>(P?-4J4:4Y/VE57E*$6W9325VWHDEV1_$O%?B[XAY;Q3C\'AL;RT
MZ=:K"*]G1=HQG)15W3;=DDKMM]V?HG;_ /!?+[/;QP?\,H9V(%S_ ,)WUP,?
M\^->D_LF_P#!7K_AJ']H#0/@7_PSU_8?]N?:O^)I_P )9]I\CR;2:X_U7V2/
M=GRMOWAC=GG&#^4=?1?_  2;_P"4@/@#_N*_^FJ\HXI\*. ,NX9QV+P^#Y:E
M.C5G%^TJNTHPDT[.;3LTM&FNZ#A3Q=\0\RXIP&#Q.-YJ=2M2A)>SHJ\93BI*
MZIIJZ;5TT^S/VAHHHK^,C^V@HHHH *S?&/\ R+%[_P!<#6E6;XQ_Y%B]_P"N
M!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0 4444 %5-=U[1/#&CW/B'Q)K%
MKI]A9PM+=WM[.L44$8&2SNQ 4#U)KS;]HK]KSX8?L[FU\.7Z7?B#Q?JN%T'P
M3X?B^T:C?N<[?D7/EQY!^=L# . Q&*\WT+]EKXR?M4ZQ;?$3]NK54MM%AF6X
MT7X0Z%=G[!:D'*/?RJ<W<H[J#L!Z'#,E?1X'($\-''9E4]AAWL[7G4MTI0NN
M;LY-Q@NLKZ/YK'\0M8J6!RRG[?$+=7M"G?K5G9\O=02E4?2-KM?C?17Z+?\
M#@?_ *NQ_P#+$_\ NZJVL?\ !!C^R=+GU+_AJOS/)3=L_P"$&QG\?MU?V/\
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M/S*HKZ,_:)_X)S_%GX4)'KWP]2X\7:68%-VUA9[;JWEP-_[A22R$Y(*9P.&
MQN/S^?#OB :C_8YT*\^UEMHM?LK^9NSC&W&<U_GEGO"^?\-8YX3,</*G/I=7
M3_PR5XR7HWVW/Q/&9?C<!6]G7@XO\_1[/Y%.OU0_8C\.:EX5_95\&:5JT;),
M^F/=;7ZA)YI)T_\ ')%KY*_9._X)[>/OB'XAM/&'QG\/W.B>&[:196L+U#'=
M:C@Y$>PX:*,_Q,V"1PO7<OZ#PPPV\*6]O$L<:*%1$7 4#@  =!7],_1_X'S?
M*:M?/,?3=)5(>SIQDK2<7)2E)IZI7C%1OOJ]K-_>\&93B<-*>+K1<>9<J3W:
MNFW;Y*W<=1117].'WX5ROQQT/XG^)/A!XCT7X*^-?^$=\6S:5+_PCFL&T@G6
MWO -T6])T>-D9@$;*G"L2,$ CJJ*J$W":DE>VNNJ^:ZE0DX34NW?5'X&:]_P
M67_X*I>&-<O?#7B']HB6SU#3KN2VOK2?P3HJR031L4=&'V/AE8$$>HK.3_@M
M)_P4OCOGU)/VE,32($=_^$.T;D#H,?8\5ZW_ ,%^OV/?^%._M#6G[2GA#2_+
MT#XA[O[4\I,);ZQ&H\S..!YT>V4=V=9C7P!7[CEF$R+,\#3Q,,-3]Y?R1T?5
M;=&?KV7X;)\PP<*\*$/>7\L='U6W1GUKH/\ P67_ ."J7B?7++PUX>_:(EO-
M0U&[CMK&T@\$Z*TD\TC!$11]CY9F( 'J:_<GX':'\3_#?P@\.:+\:O&O_"1>
M+8=*B_X2/6!:00+<7A&Z78D")&J*Q*+A1E5!.223^$G_  28\4?LL_"K]I>+
MX\?M3^/8],L_"5OY_AC2DTJYO9M0U1\K&RQV\3D")=SY;;^\\H@G!Q^K/_#U
M/1O%G[OX'?L7_'3QKO\ ]5?V?@-K2Q;TS/.Z[<^ZU\?Q=@%+$0H8/#*,8ZN2
MBHIM].;1:+?7=^1\OQ-@N:M&CA<.HI:N2BHIM]+Z+1>?7R/JRBOE/_AI7_@J
M)X^^7X>_\$\="\*P./W.H>//B5;RY]VM[1?,3Z$T#X9?\%A?B!SXI_:=^$7P
M]1Q_S)7@NXU9XQ_W$&"DC\LU\?\ V9*/\6K3C_V\I?\ I',?+_V?*/\ $J0C
M_P!O)_\ I',?5E5=9UW1/#EBVJ>(=9M;"V3[]Q>7"Q1K]68@"OET?\$XOC1X
MTPWQP_X*6_&?6-W^N@\)7UOX>@E]04@1_E]L_C5O1O\ @CI^P9;WRZSXU^&V
ML>,M17_F(>,/%U_>R-ZY7SEC.?=:/J^60^.NW_A@W_Z4X?D'L,OA\=9O_#%O
M_P!*<?R/A#_@O[H'[-?C?QYX=_:"^"_QI\&ZSXCN(_[(\7:)H?B&VN;EEC4M
M;731Q.Q&%#1,3S@0CH#7YSU_1[XD_P""=W[&6L_"W7?A5HG[.7@W1+;7=)FL
M9M0TGPU;17<.]"%E68)OWHV'4EN"HK\%_P#ACWXO_P##7W_#%O\ 9?\ Q5G_
M  E?]B?</E_?_P"/KU\GROW^[_GGS7Z=PGG&$K8&6'4G^Z5[RM?E[Z=%MY*Q
M^@\-9IA:N#=!-_NUO*WP_+HMON/I#_@BA\7?V+/V:?B1KWQV_:@^+5OH?B!+
M,:=X/L;C1+ZX"1R<W-UYD,#QJQ 6)<L&P9<C!!/ZA:-_P53_ .">.O;?L/[6
M'A:/=T^VS2VWY^<BXKU+X,?!+P)\#O@UX=^!OA#2HCHOAS2HK*VCGB4^;M7Y
MI7&,%W8L['NSL>]3:S\#?@GXCW?\)#\'O"U_N^]]M\/VTN>O7<A]3^=?!9MF
MN6YMCI5ZL)ZZ*TXVLMK+DT[VN]7N?&YGF6 S+&2K5(3[*TE:RVTY=.^[U.2T
M7]NO]BCQ#M72/VN?AK*[?=B/C>Q5ST_A:4-W':NKT7X[?!#Q)M_X1WXR>%+_
M 'XV_8O$5M+G.,8VN?4?F*Y;6OV%_P!BKQ"&.L?LC_#69FSF7_A"+%7[_P :
MQ!NY[UR>M?\ !*__ ()YZ]N^W?LG^%8]V<_8K>2V]>GDNN.O;V]!7FVR>76H
MOE%_JC@ME3ZS7RB_U1[W9WUCJ, NM/O(IXFZ20R!E/?J*YKXX_![P?\ M ?"
M#Q'\%O'MKYND^)-*ELKO"@M'N'RRIGHZ.%=3V9 >U>"7G_!%[_@G!/.;S3?@
M#-IEP>EQIGB_5H6'.> +K:.>>G85%_PZ _9GL/\ D4/B1\6/#^/N?V-\2;U-
MGIC>7]OR%7"&60FIPKS36JO36C^51CA#+XS4H5I)K57@OTFS\*_CC\'O&'[/
M_P 7_$?P6\>VOE:MX;U66RN\*0LFT_+*F>J.A5U/=7![URM?HK_P69_X)?VW
M[.7@O2OVF/A[\1O''BZVFOUT[Q;=>-M:&HW-KN55M)%E\M&\KY6B.\M@M$!C
M.*^%/@=\'O&'[0'Q?\.?!;P%:^;JWB358K*TRI*Q[C\TKXZ(B!G8]E0GM7[7
MEN9X?'Y<L4I727O/:S6^G3OZ'ZW@,PH8S K$*6B6KVLUOZ=_0_1O_@W]_9F\
M,>$-.U[]NGXOWUAI=HOF:)X.NM6N4@C'3[9=*TA _NPJP/\ SW%?=GQ$_P""
MG7[ /PNWKXI_:M\(R/']^+1+XZFZGT*V:RG/MC-<3\-/^"+/_!/SP!IEA!K7
MPCN/%5[8VR1"_P#$VN7<X; ^8^0)%A4%LMM"8&:]W^'?[-?[._PCV-\+?@5X
M0\//']V;1O#EM;R9]2Z(&)]R<U^2YQF.5YEF$\3-SE?96C%)+97?/^2UZ'YG
MFF.R['XV5>;G*^RTC9+97][\EKT/"?\ A[+\./%_[KX _LP?&GXBE_\ 47OA
M[P!-%9'T+S7#)L7W*T?\-*?\%0OB-\OPS_X)\Z#X1MW_ -3J?Q$^(D,F?=K6
MT7S4QZ$FOJRBO,^N8&G_  \.O^WI2E^3BOP//^M82'P4%_V\Y/\ )Q7X'RG_
M ,*7_P""N'Q'.?'/[9/PX^'L<G^L@^'W@)M3('=5?46!![;NHZTG_#KJZ\:?
MO?C_ /MT?&_QEN_UVG1>+AIFG2>N;:W3C\&Z5]6T4?VMBX_P^6'^&,4_OM?\
M0_M/%1_A\L?\,8I_?:_XGY<?\%9_^"1/P)^%7[*LGQJ_9:^']SIVJ^$;S[7X
MG$FK7=[+J.GR8265C/(_S1-LD^7: AE)' Q^?W["'[+6L?MC?M1>&/@A8I*N
MGW=W]I\17<76UTV'#W#Y_A8K^[4GC?(@[U_1[KVAZ/XGT.]\->(=.BO-/U&T
MDMKZTG3='/#(I1T8=U9201Z&ODO_ ()8_P#!.31/V);_ .(GBZ[N8K[4-?\
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M%SU)4\^WT%?TEU_-_K'@[P_K;^?=V 2?.5N8#LD!]<CK^.:_2?6-;_X+%_\
M!/(F:_O[3X\> +3K<W\4DFH00CNTR?Z0C8'+RB:-1WKX_P 9<@Q^/I9;A(2I
M1E3550CS<KJ+]TK14M.967N\S;OILS\U\(,\X;S+,LWS>&(JJIB)4YU57BFH
M2;JO^-3]UQ=W[TZ=&,>6SZ'Z,T5\=?L]_P#!;3]D7XMO;Z%\5Y=0^&.MS,(S
M!XJ0'3WDP"1'?1CR\ 'K*(OI7UWHFN:)XETFWU[PYK%KJ%C=1B2UO;*X66*9
M#T9'4D,/<&OYJQ^69AE=9TL72E"2Z-6/Z Y&Z4:L;.$M8R33C)=XR5TUYIM%
MJBBBN$@*Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0J -BBBB@ HHHH *
M*** ,WQC_P BQ>_]<#5S3O\ D'P?]<5_D*I^,?\ D6+W_K@:N:=_R#X/^N*_
MR% $U%%% !1110 5\7_M9?\ !7K_ (9>_: U_P"!?_#/7]N?V']E_P")I_PE
MGV;S_.M(;C_5?9)-N/-V_>.=N>,X'VA7X0?\%R/#G_&P'QSXFMH_^@3%<X'_
M %"K/:W]/RK]#\-LJRK-<VQ"S#"_6*=.C*?+SRA9J=./->&KLI/3:UWT1\WQ
M%2QN-J8++\)F7U"IB*RIQJ>RA63;IU)*#C.44N=Q24D[\UHV]YGV3_P_X_ZM
M._\ +[_^X:IZ'_P7B_L:T:U_X96\S=,\F[_A.<8W'./^/$U^/-%?JO\ 8OAO
M_P!"?_RXK?YG?_Q!OQ-_Z*S_ ,L*/_RP_=C]DW_@KU_PU#^T!H'P+_X9Z_L/
M^W/M7_$T_P"$L^T^1Y-I-<?ZK[)'NSY6W[PQNSSC!_D2_:P_Y.F^)?\ V4#6
M?_2Z:OW>_P""&_AS_C8#X&\37,?_ $%HK;(_ZA5YN;^GYU^$/[6'_)TWQ+_[
M*!K/_I=-7Y5XDY5E659MAUE^%^KTZE&,^7GE.[<ZD>:\]5=16FUK/JS@X=I8
MW!5,;E^+S+Z_4P]9TY5/90HI-4Z<G!1A*2?(Y-.3=^:\;>ZC]O\ _@TV_P"4
MIG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J_/#Z0_-;_@O'_P2
MA\/_ !S\*ZG_ ,%#/V=?B?J7PW^-W@OPZMH^LZ:Y^P^*=.$J[=/U*('YTR0!
M)AOE&UTE58PGJW_!*3_@I=\8/VI_%?CK]C;]MOX)CX=_M#?"!+7_ (3;1K)_
M,TW6;.<?N=4L7W-^Z?Y24W,!YD95V#E4A_;+_9L_;]TR/XZZQ\ ];\%^/?!W
MQ6.GZA;^ ]>-YIFJ:#?V^GV&GR_9+N%+F.ZBE2QCE,3Q0[&+X;DEO2/V3OV(
MO%WPU_:<^)/[=7[0WB_2-8^*'Q,T_3](:R\-6LD6E>&]%LE/D:?;/,?-NG9R
M99KB0)O?:$BB5<$ ^?OVW?\ E8E_8A_[$?XB?^FHU^B5?&7[3'[#/[5_Q?\
M^"G7P;_;W\%:_P##ZUT;X,Z3KFG6/A?5+^^^TZW'J=L]O+))/';E;5E4J54)
M,,J<L=W'=?\ !3/X _MR_M.?!>T^#G[&GQT\'_#U-4NC_P )KJOB/3KNYGO+
M$;#]A@-NR&*.;YTF<$.4^5"NYC0!R>C?#&R_;R_X*#^$OVQ[FW67X9?L_P!C
MK&F?#"^QE?$WB6_5+;4M3B[/96L,/V6&3I+.]Q(AV11O)X%_P3+L]0L?^#AG
M]OQ/%X8:K+9>"Y=.,H^9K$Z?\A7U4)]G''H!VKTCX2_LB?\ !;^Q\4^$/"GQ
M<_;_ /A)9?#71]4L/[<T#X;_  Q;2KVXTJV="=/MIB2+5)$00EHPK(C'85(%
M>M_&7]B;QUH_[;VG?\%$OV4]2\/V_CBX\%2>$/'OA?Q3//;:;XITH3+/;2&Y
MMXY7M+NWE0;9O)F#Q,8BJ@*P /E[X KJ=]_P=@?'2\T<,=-L/V7=+MM:9/N"
M\>\TJ2 -C^+RA(1GL#7Z=5\]?L5_L/S_ +._Q(^*7[3WQ9\56/B3XM?&G7;7
M4/&VM:;9M!965I:0"VT_2K-)&9_L]M"-OF.=\SEG8+E43Z%H *\O^*WQY^)7
MP^\7/X<\+_LR^*/%-HL"2#5M)GA6%F8<IASG([UZA10!\>_&3XV?$+X@?';X
M.1^)_P!G;Q)X6%GXT+P/JLT+"Z+1[2J;#U4?,<]J^JO^$EU?_H4+W_OI:\=_
M:Y_Y+A\#/^Q[E_\ 1%>]4 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 <+\6?C)<?"SX;:U\0M
M1\(W/EZ5I\DRK+(H5Y,81"1T#.57\:_*CQGXQ\2?$'Q5?>-/%VJ27NI:E<--
M=W$IY9CV'H ,  <   <"OT%_;X^-OP@NO@+XE^%5O\1=/G\07\4(MM+L)3<2
M[H[B.5E<1!O+^5&^_MK\YZ_C7Z1.?O'9]ALOH5E.E3AS-1DFE4<I)J23TDHJ
M-D]4I/N?EW&^-]MC*="$DXQ5VD_M-O?SLE]_F%:?@WQAXB\ >*;#QIX2U.2S
MU+3;E9[2XC/*L/4=P1D$'@@D'@UF45_/-*K5H58U:<G&46FFM&FM4T^C3V/B
MHRE"2E%V:/UJ^$WQDN?BG\-=%^(6G>$;GR]5T^.9EBD4JDF,2(">H5PR_A71
M?\)+J_\ T*%[_P!]+7!_L1^'-2\+?LJ^"]*U6-EF?3'N@K]0D\TDZ?\ CDBU
MZI7^F_#N*Q6.X?P>)Q2M4J4J<I?XI03E^+9^^8&I4K8*E4J?$XQ;]6E<Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBBO9.HQ_P#A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI:\,_P""LG_*/[Q__P!PK_TZV=?B]7[%X?>$_P#KWDM3'_7/
M8\M1T^7V?/>T82O?VD?YK6MTWU/Q?Q&\7O\ 4#.Z>7_4O;<]-5.;VG):\IQM
M;V<_Y+WOUVTU_H!M=<U%?%-U=+X;N6=[:-6@#+N4 GDUI_\ "2ZO_P!"A>_]
M]+7\]=%?=?\ $N7_ %-/_*'_ -V/@?\ B9;_ *E7_E?_ .XG]"G_  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+7AG_!)L@?\ !/[P"2?^@K_Z=;RNU^*_[;_[
M*7P6D>S\>?&[14O4;:=+TZ<WMWNZ!3#;AW4D\?, *_ \=P[F%'/\3E6$A*O*
MC4G#W8-N7))QORKFM>U[7=N[/Z$P'$F7UN'<-FV,G&A"M3A4]^:2CSQ4K<SY
M4[7M>ROV1WW_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+7@__#:GQV^*1\C]
MF7]BSQ9J5O)Q'X@\<S1Z'98_YZHLA9YT]EVFC_A1?[?OQ>_>?&/]JK2? ]A+
M_K=#^%^BGS=I[?;;K][&P'=01G\*Z?\ 56OAM<QQ%+#^4I\\_P#P724YI_XU
M'U1S?ZV4,5IEN&JXCSC#DAZ^TJNG!KS@Y>C/FW_@O%J=WJ)^%8NM(FM-G]N;
M?.(.[/\ 9_3'IC]:_/6OL#_@LA^S_P#"7]DZ'X=:IIOB;Q)J6I>(VU9=8U[Q
M1J\^H75X8/L9C#-C:N/.D/RJN=QSG Q\0?\ "T/ W_0<_P#):7_XFOZ]\+\P
MR# <"X.A#%Q:7M-9\M.3_>S;]UR;2O>VNJL[*]E_)_B3P7X@\0\;XO'4,HKS
MC+V>M*G5K0TI05E4C32;T]Y+:5U=VN]^BL#_ (6AX&_Z#G_DM+_\33HOB5X*
MGE6"'62SNP5%%K+DD]!]VOOEGF2MV6)I_P#@<?\ ,^%EX9>)$(N4LEQ:2W?U
M:M_\@?T8_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+7SV/VDOVI/V5S]@_
M:_\ AG_PE?A>'@?$[P#:%_)0?QWUB/FB]6=,(.BAC7O/PN^+_P ,/C7X7C\9
M_"CQSIVO:;)@?:-/N WEMC.R1?O1OZJX##N*_P ]LRX?S'+:*Q#2J47HJD'S
M4V^W,OAE_=FHR76*/[XRSB++<SK/#ING72NZ51<M1+OROXH_WH.4'TDRW_PD
MNK_]"A>_]]+1_P )+J__ $*%[_WTM;%%>(>Z8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 <I:ZYJ*^*;JZ7PW<L[VT:M &7<H!/)K3_X275_^A0O
M?^^EHLO^1WO?^O*+^9K8H Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_
M (275_\ H4+W_OI:X7]H#X<S_&_P,=$3P_?:=K.GSK>^'-:A91+I]ZG*2 @Y
MVDC##N#Z@$>I45QX_ 83-,%4PF)CS4YJS7EZ[IK=-:IV:U1E6HT\12=.HKIZ
M,_.+]N'_ (*0?M,?#;P_X,\/>!?$;>#_ !=9S:G9>/+!M)M+@33Q"T\F9!<1
M/LC8/*R[< [B,L%!KY[_ .'LG_!0'_HOO_EJZ5_\BU[U_P %Z_"GA_3O$WPV
M\86.F1Q:CJEMJT%_<H,&=(#9F+=ZE?-<9ZX('0#'Y]5_8_@CP=D]?POR^6;X
M:CB,0O:IU94H.4U&O4C!R;C=RY%'FZ<U[65D?Q'XJ<4<791QYC,'0S"M"$/9
MI*%6<8V=*#ORJ22;O>5EK)M]3Z%L?^"JO[>VFPF"R^/&Q&<N1_PB^EGDG)/-
MK4W_  ]D_P""@/\ T7W_ ,M72O\ Y%KYTHK]6_U)X,_Z%N'_ /!-/_Y$_/?]
M>N-O^AIB/_!]3_Y(_H4_X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6M@$$9!R#T
M-%?YW'^D9C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!\4?M1_P#!8.;]
MFGXZZ[\$Y_V;GU5]%^RYOY/%HMC+YUK%/_JQ:2;<>;M^\<XSQG X#_A_Q_U:
M=_Y??_W#7SI_P5D_Y2 ^/_\ N%?^FJSKYTK^S>%O"C@#,>&<#B\1@^:I4HTI
MR?M*JO*4(MNRFDKMO1)+LC^)>*_%WQ#RWBG'X/#8WEITZU6$5[.B[1C.2BKN
MFV[))7;;[L_0K0_^"\7]C6C6O_#*WF;IGDW?\)SC&XYQ_P >)KTO]EW_ (+!
MS?M+?'70O@G!^S<^E/K7VK%_'XM%R8O)M99_]6;2/=GRMOWAC.><8/Y55]%_
M\$F_^4@/@#_N*_\ IJO*.*?"C@#+N&<=B\/@^6I3HU9Q?M*KM*,)-.SFT[-+
M1IKN@X4\7?$/,N*<!@\3C>:G4K4H27LZ*O&4XJ2NJ::NFU=-/LS]B?\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6MBBOXR/[:,?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** .4\*ZYJ
M-KITD</ANYG!N9&+HRX!+=/PK3_X275_^A0O?^^EH\#_ /((E_Z_9O\ T*MB
M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8H) &2: ,?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EKRCXK?M^_ KP!XA/P\\#RZC\0?&#$K%X5\"VAOY
MPPX/FR)^[B .-VYMRCG;Q7+?\(+^WS^TW^\^)/C>T^"WA6?KH'A&=;S79XS_
M  RWI^2W..C1#(Z%:^EP_"^-5&.(Q\HX:D]5*I=2DN\*:3J3\FH\O>2/F,1Q
M5@76EA\OA+%55HXTK.,7VG4;5.'FG+FMM%GYM?\ !6OX@>'=._X*!>/8-<GD
MLK@KI3-;R0.Q _LNT .54@]*^<?^%H>!O^@Y_P"2TO\ \37JW_!6#X">%OA#
M^U'XL\%^ S?2VF@_8")M2O&N+B<36%M-+))(W+L99'<]AN. !@5\F5_5&"XJ
MS;(,FP.&HQA.E["BX2E&2<H>SC9M*;2?=7=F?%\)> _AOXH4L9F^(Q&)IXI8
MBO"O3A5I.,*JJ2;46\/=Q::E%O6SL]4SUW_A:'@;_H.?^2TO_P 37NO_  33
M_:"^%'P\_;5\&>-/%'BN&UT^Q.H"ZN;B-XXX_,T^YA4LS+A07D09/'-?%M?9
MW_!%OX?:'JO[:7@J/Q=H5IJ%MJR:JDUE?VRRQ20C2[P@,C@A@2,X(["EC>+<
MVSO)<=0KTX^R5"LZCBFI<BIRORMR:4GLFTTF[M-(.+? 3PW\,Z6#S7#8O$2Q
M4L10A0C4G2<)595(VYU&C&3A%)RDHRBVERJ2;3/VQ\+_ !2TOQOHT7B/P7:I
MJ^GSC,-]IE]%/#)_NNC%3^=:/_"2ZO\ ]"A>_P#?2UXIXH_X)P?!*+69?&/P
M&U_Q'\*]>D.XWW@;5GM[>4]A):L3$R?["A :S_M__!23X"\:AI7A;XV:'#_R
MWLV71-;VCJ2AS;O@=ERS'ZU_+O\ 8>4X_7+<;&_\E9*E+Y2;E2?JZD6_Y>WU
M_P#;V;Y?IF>"ER_ST&ZT?G!*-9>BIS2_F[^]_P#"2ZO_ -"A>_\ ?2T?\)+J
M_P#T*%[_ -]+7C?@K_@HY^SUJNMQ^"_BP=:^&?B)N&T?XA:6^GY/0E9VS"5S
MT8LN00<5[KIFJ:9K>GQ:MHVHP7=K<('@N;699(Y%/=64D$>XKR,QR;-<HDEC
M*,H7V;6DO.,MI+S3:/8RW.LISB+E@J\:EMTGK'RE'XHORDDS._X275_^A0O?
M^^EJCXEU[4[G0;J";PQ=0JT1!E=EPON:_(3_ (>R?\% ?^B^_P#EJZ5_\BU%
M>?\ !5C]OC4+5[*[^/.^*1<.O_"+Z4,CZBUK]B_XE\XS_P"@C#_^!U/_ )4?
MBW_$Q?!/_0/B/_ *?_RX_8FR\1ZJEG$B^$KQ@(E 8,N#QUJ7_A)=7_Z%"]_[
MZ6OQUC_X*P?M_11K%'\?,*J@*/\ A%M*X _[=:^B?V%/^"J?Q!O=&\9/^TSX
MQU+QGKC3:9;^ _"^A^'K9;W4)Y/M7G)$MM"@(^6#<SY"C&.6PWF9QX'\8Y/E
MT\6YTJO+R^[3E-R?-)1T3IQ5E>\FVDHIM['JY+X[\%YUF4,'&%6DY<WO5(P4
M5RQ<M6JDG=VM%*+;DTEN??&L>/?^$>TJXUS7]$DL;*TA:6ZO+NYCCBAC49+N
M[$!5 Y))Q7SKKO[6WQU_:IN;CP1^P]X1DLM%CF:WU?XKZS:;K2W(.'6PB;'V
MF4?WC\H/4 %7J[H_[,OQN_:VU6W\>?MPZD-+\-Q3+<:/\']!O6^RQD'*/J,Z
M$&YD'!V*=H/3 +)7TIHFAZ+X:TBV\/\ AS2+:PL+.%8K2RLX%BBAC48"(B@!
M0!V KXS_ (1N'/Y<5BE_V]0IO_W-)?\ @I/_ )^(^V_X6^)MN;"X5_\ ;M>H
MO_<,7_X-:_Y]/?Q[]G7]FKP+^SJ+K7]+\'ZOKWBS5<OK_C7Q!<+<:EJ$AY;,
MC$^6F0/D7 X&=Q&:]3_X275_^A0O?^^EK8HKYS'8_&YGB98C%5'.;W;_  2[
M);)*R2T2L?38#+\#E>%CAL)34(+9+\6^[>[;NV]6VS'_ .$EU?\ Z%"]_P"^
MEJCXEU[4[G0;J";PQ=0JT1!E=EPON:Z:LWQC_P BQ>_]<#7&=A4LO$>JI9Q(
MOA*\8")0&#+@\=:E_P"$EU?_ *%"]_[Z6M+3O^0?!_UQ7^0J:@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6LS7-<U&?4=-DD\-W,9CN2R(S+F0[>@KJZQ_
M$O\ R%]'_P"OT_\ H)H /^$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^
M$EU?_H4+W_OI:P/B/\=/#7PD\-2>+?B':2:98QG:LD\J[I7QD(BCEV/]T G\
M!6%\7_VFK#PAXA'PK^%7AZ3Q?XYN%_=:'8./*LA_SUNY?NPH,@X)R<C[H(:J
M7PT_9EO[KQ3#\8?VC?$,?BSQ>OS64&PC3=%&<A+6$\$@X_>,,D@'@Y8_*8S/
M\1B\5+ Y+!5:L7:=1W]E2?:36LYK_GU!W_GE!-,\ZKC)U*CHX5<TENW\,?5]
M7_=6O=HY"_B^.O[6LB2^*?#^L^#?AQ+\RZ+;.(]4UN/MY[_\L(F'\ Y()ZY5
MAW/C_P"!WPZ\??L_:U^S3/\ "9['POK.CRV#VEFB#R=X^69<]95<+('.3O4$
MDFO5Z*[\FR.CE&(>,E-U<5*W-5E;FT=[12TA!/50BDNKO*\GO@\*L)4]MS.5
M3^9[_+LNR6GJ]3^7_P"-?PB\8? 3XL^(/@WX^L6M]7\.ZG)9W:,I ?:?ED7/
M5'4JZGNK ]ZY>OU _P"#C']G3P7IOB?PM^TYX=UK2[?6=10:/XDT@WD:W5TJ
M*S6UVL1.]PJJ\3L < 0CM7Y?U_3F39BLTRVGB.K6OJM'_P #R/W7*L<LQP$*
M_5K7U6YU'P4^$7C#X]_%GP_\&_ -BUQJ_B+4X[.T15)";C\TC8Z(BAG8]E4G
MM7]'OP.\!Z-^S_\ "#PY\%O 7@6]BTGPWI45E:9*!I-H^:5\=7=RSL>[.3WK
M\E?^".G[%G[:.OS3_M:? "]\":!;NMSH^F:_XUL[BZGCY43SV5O&-C'K$7D8
M#_6*!]['Z ?\._?VG/B1\_[1O_!3#XE:C')_K=/^'ME:^&8<?\\R8 [.O8DX
M)'I7PO&.*H8W%QP[KQC"GNO>;<NNB5M%IJUU/C^*<31Q>)C1=:,8PW6K?-Z)
M6T7=KJ>]^-/C7X4^&VF_VS\1+RRT"S )-WK6K6]K'QU^:5E'ZUX;XQ_X+#?L
M/>$]2&@V'Q,_X234W)$&F^#[275))B.R-;HT9_[[%:'@O_@D;^P3X4U+_A(-
M:^"Y\6:LQ!FU7QMK-UJDDQ_VTGD,1_[X[U[OX&^&'PT^&&G_ -D_#7X>:%X>
MM< ?9M#TF&TCQZ;8E45\9_PCTOYY_P#@,%_[>_R/E/\ A+I_SS^Z"_\ ;_T/
MF@?\%%?VD/B(NW]G?_@F9\4-623_ %-_XXF@\.6[#^^#/O+KWXP3[54N+[_@
MLK\46Q(?A7\++"3[IL+"XUO4H?KYK"W;'MBOK^BCZ_0I_P &A!>;O)_^3/E_
M\E#Z[1A_"HQ7F[R?XNW_ )*? _Q]_P""77QR_:.^%6K:-\>OVQOB5XWUQ+26
MYT"P-M9:7HJZDL;B&26SB5P5!8KE65@&.#VK\9/^$'\7_P#";_\ "MO^$<N_
M[?\ [5_LS^R/)/G_ &SS?*\C9UW^9\N/7BOZDZ^-8/\ @F1X,E_X*M3_ +9!
MM[7^PXM'75O[)P,_\)$?W7G[>FS9F?/7S_FKZ?A[BN6"A6AB6FK7BDDES+[*
M222O^A]#D?$DL)"K#$/2UXI))772R26OZ'I/["/[,>A?L;?LZ^&_A;IOPW1]
M=MK 2^(]9A@B$MY?2_/,QD^\R!CL3)X1$':O:?\ A)=7_P"A0O?^^EK8HKXO
M$5ZN)K2JU'>4G=_,^3K5JF(JRJ5'=MW9C_\ "2ZO_P!"A>_]]+1_PDNK_P#0
MH7O_ 'TM;%%8F1C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DN
MK_\ 0H7O_?2UX_!^S5\.#^VI/^V/_P (-<MXK'A%='\D*FU,MC[4?^FOE#R=
MW_//BO>*Q[+_ )'>]_Z\HOYFM:=:K1YN25KII^:>Z-*=6I2OR.UU9^:?0/\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBBLC,Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EK8HH \\^./@
M/1OV@/A!XC^"WCWP+>RZ3XDTJ6RN\%"T>X?+*F>CHX5U/9D![5\!?\$6OV O
M&_[._P ;/'GQ<^,G@>X?6?#=[<>&_#<;1;0<,/M%]'NZHZ;$C<=5>4=Z_4"L
M>R_Y'>]_Z\HOYFO2PV:XK"8"MA(/W:EK^5M[>JT?D>AA\RQ.&P=7#0?NSM?_
M ('KLP_X275_^A0O?^^EH_X275_^A0O?^^EK8HKS3SS'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6LSPKKFHVNG21P^&[F<&YD8NC+@$MT_"NKK'\#_\@B7_
M *_9O_0J #_A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[
MZ6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6O.?C]^SE\%?VH?[)
M_P"%Z?!&]US^P_/_ ++_ .)O<VWD>=Y?F_\ 'O-'NSY4?WLXV\8R<^O45U8+
M'8W+L3'$82K*G4C>TH2<9*Z:=FFFKIM/79M'+C<#@<RPLL-C*4:E.5KQG%2B
M[--7BTT[-)JZW29\N?\ #L#]A7_HU*]_\*S4_P#Y+K.\-_\ !+S]A)+.9U_9
M=N)S)=2,\D7BG4U!.>AQ==?>OK2L?P/_ ,@B7_K]F_\ 0J]Q\:<8MIO,L1=?
M]/JG_P D>''@K@V$)0CEN'2E:Z]C3L[;77+K;H?.G_#L#]A7_HU*]_\ "LU/
M_P"2Z^B_^$EU?_H4+W_OI:V**\W,L[SK.>7Z_B:E;EOR^TG*=KVO;F;M>RO;
M>R['HY9D629+S_V?A:='GMS>SA&'-:]K\J5[7=K[7?<^;OVE/V"/V=_VF%NM
M5\0?!VZT37KE6\S7] $4,LQ/7SXR#%< G&?,4L0,!A7R!J'["O[:G[$6JW/B
M[]G7Q5XML]+$IFEO_ ,8GC?G)>\T&X9H9S@8'DLJJ,D^E?JA17M9;QGFN#H+
M"XI+$4%IR5/>LNT9?%'R5^2^\683R..'K2Q&65986K)WDZ=N2;_Z>4I)TJGK
M*//;:2/S_P#@1_P5@_:%LM.D3XQ_ 2W^(FG6 /\ :'B3X2.S:A9JO!:[T:XQ
M<1X_CD7$0(.W=7P9_P %=_VC_@5^UO\ M!1_%[X':$85M=,M[#5]2DF9)-3(
MC5DDDMGB1X9(BTENQ)<,(H\8 Y_9OXZ_L6? /X^WZ>*/$?AJ72/$T!#V7C#P
MS<&QU2W<# <31_?(["0,!V K\>?^"C?P3G\+?M:>,/!'Q \9S^*]5L_L0D\3
MW=HD%U<J]A;O&9 APSJC(A8YWE"QY8U^F>'V4\-\39O6EED7"LJ4G[.;DK>]
M!<RE'W9K6WO1AOI3;]^/AYQXDX[P^JX3'9U1Y:?M8QE5PW*XU(N,[QG0JOF@
MW;F3IU&DXIW_ .7<OC6BK&JZ;<Z1J,VF7:XD@D*M[^_T/6HK>%KB=84!RQ_A
M4D@=S@=:]Z5*I"JZ<E:2=K>>UC^JJ.-PF(P4<72FI4I14U):IQ:NFO)K4^X_
M^"#.J^'O"7[8=GJ&K_#M]8U77-.O-/\ #]^+X1_V9LMI9YYEC,9\UW6$1 [T
MVJ\GWLXK]JO^$EU?_H4+W_OI:_$'_@E?\9O@K\+?VS? 6M^,?B#IF@Z/IJZA
M'<ZCK5P+6&$OIMU&I>23"KN=U&2<9:OVY\$_%'X9?$NT^W_#CXBZ%X@@V[O/
MT35X;M,>N8F88K\\\6LKP>79WAUA7SIT(.<D^:+GSU$];M*R2T5N[5VV_P";
M.'N(.*.*JN89AF^&J4%]8G&C"I3=.4:"A3Y-'%-W;E)MW]YM)V22E_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6MBBORH^A,?_ (275_\ H4+W_OI:\;^*O_!2
M;]EKX(^/K_X8?%#QC<:5KNF>5]NL&TB\E,7F1)*GSQ0LARDB-P3C.#SD5[Y7
MX5?\%L=>\7^&O^"AOCF[TG5"EI.NE+M\B-MCC2K/(R5)Y'/YU]QP%D.3\09G
M6I9G[7V5.FY_NN7FOSPBK\Z:Y?>UZWMTN>#GKXCJO#83(ZF'AB:U3DC]9]HH
M-*G4FXKV:<N>T+J^C2:WL?I;KG_!6O\ 8>U729].C^*LJ--'M#-X?U# _P#)
M>I[;_@KM^PY!;1P'XI3$H@4D>']0YP/^O>OP7_X6AXY_Z#G_ )+1?_$T?\+0
M\<_]!S_R6B_^)K]._P!0?#'_ )^8S[Z/_P B8?ZE_2!_GRO[\7_\B?T&_"K_
M (*3?LM?&[Q]8?##X7^,;C5==U/S?L-@ND7D1E\N)Y7^>6%4&$C=N2,XP.<"
MO9/^$EU?_H4+W_OI:_#?_@C5X[U,?M[^#?%/CKQ=:V6C:?'JAN;J^,,$*L=*
MNP"TA "@9]1R1ZU^LOC#_@I-^RQH.K-X8\$>)=3\>ZT,^7HWP_T>74Y9/]UT
M B;GT>OA.+.!XX;-:5'A^A7JTITU-N:3:?/.+;<$HQC[J^+S=[6.+"9YB\B6
M(PO%6+PL<32J<C5"4^76G3FHVJVG*?OZJ*:LTMTSV/\ X275_P#H4+W_ +Z6
MC_A)=7_Z%"]_[Z6OD?XT?\%'/C?X3M6EO? G@/X16;IN@O\ XO>+U-_*AYW)
MI=GFYW =L,,XKPYOCE^T1^U2S0^ =7^.7QB@G/[K_A"](B\#^%Y ?^6;7]PI
MDF3OAXT8C'->50X*KPA[3'8FG2CY2]H_OA>FGY3J1/2HYQF691YLKR^M5C_/
M.*H4OG*LX2:\XPEWV/O+XH_M;_!GX*(Q^*OC#3-$E5<_9+W5(1<,/]F$$R-^
M"FOQZ_X*.?%3X??M!?M1>-/B5X7OG;0-;CL5M;B\A: LL=A;PE]L@4@;HR5)
M R,'O7V5\*_^"9O[6.L2K?WUU\+?@Q:2-O/_  C&@/XFU\@G)#WVI,RPR$_\
MM+<@#L.U?$W[?W[/&C?"?]L+Q;X*UWQWXE\;75A_9[2Z_P",M4-W>7+R:?;2
ML78!00"Y55Q\J*J\XS7ZUX183(</Q%7HY9)UZKHR4G-J$.3GIW]R,9ZWMM5E
MI?U7Y?XNT\7A,@PV,SW&1H1IXB$H1PL)5JJJ*%1Q_>U)T()+5W4'9V>MK/X^
MNX!:W4EL)DD$;E1)&V5;!Z@^E2:5IMSJ^HPZ9:+F2>0*OM[_ $'6NS^+GA.W
MM(8->TNT2*-<13I$@4#^ZV!^7Y4_X-^'/];XFN8_6*VR/^^F_I^=?80X7Q/^
MLBRV>U[MK;DWNOR]3]RQ/C?D_P#Q!N?&6'?O\KIQA*U_K'PJ,DM-_P!X[?\
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MU./[)AF-S>D]A]GA#2<GC)4#WKS;_AD#]I7XR?O_ -J?]KW5_L4O^M\)_#6
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M5ZH-WUS<FC_AUI^R;%_QX6'BNTS][[/XUOQN],YE/3^M>KZS^TA^SOX<W?\
M"0_'OP78;?O?;?%-I%CKUW2#T/Y5RFM?\% _V&- W#4?VOOAON7.Y+;QC9SL
M,9XQ'(QSQT_QK^<X<5<=U-L;B)>LZDOS;.F/A[PK/X,KI?\ ;M&*_*)R?_#L
MKX'Q?\>'Q,^)UIG[WV?Q]<C=Z9SGI_6C_AV_X1B_Y!_[4_QRM,_>^S?$>0;O
M3.8CTI=9_P""M/\ P3GT'=]N_:K\/R;<Y^Q075SZ]/)B;/3^7J*P'_X+1?\
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M%8F[!T^Y68B:4%$*QEV&1\Q0J.2*^7K*SNM0NDLK.!I)9#A$09)KZX_X)O\
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MX=J:K_P\V_X8S^V3?\(S_;']H?VWD_\ (NY\WSMV/]9Y?[C/3S^*_=C0=4\
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MNOM1]5V_O*Z[VV'4P2G!U<,^>*W7VH^J[>:NN]MC\[_^'3?_  4!_P"B!?\
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M@KX$> [9_O?VKJ6I:I>1C_9\@"(GZ\5],_\ "8^&/^@U!_WU7$_&[]IGP/\
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M_P"R@:S_ .ETU '[?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
MMX_]/D]?O]0 5S?QD/Q$'PA\5'X0A3XL_P"$;OO^$7#^5@ZC]G?[-GSOW>/-
MV??^7^]QFNDHH _.#XQ_M7^(?CG\1/!GACXM_P#!/3XI7OCC6/V<_'VAZ]\'
M]4\%L]K?ZC=7OA16@74B3ISV)>*0-=FX"QHT9<(\D:-[;_P3;^"&O_\ !+'_
M ()A_"C]FSXW3Z[XG\0>%]'FAU0>#O#5_K3?;+FYN+UK:,6L,C"*(SF!99 D
M9$:Y*Y KZKDTW3I=1BUB73X&NX()(8+IH@9(XY"C.BMC(5C'&2!P3&I/W1B>
M@#XO^&G['7Q?_:S_ &]-%_X*.?MH>$3X9TOX;Z;=:=\ OA)=7<-S<Z,;D!;K
M7=4>%WA%_.JJJ6\3ND$:1Y=I5RN7XG_9W\<_L7?\%;_%'_!0KP;\.]?\3_#G
MXV_#ZTT/XF6WA+2)=1U'0M>TTQK8ZA]C@#3W%K+:H8&$$<CQR@.PV,2/N2B@
M#XN_8"_9)^(]W^W9\>?^"H_QS\$WGA?5?BLNF>'OA[X1U4I]OTGPSI]O%&)K
MM49A%->31)<&#<6A54#X<LB?:-%% !67JW@CP7KUX=0USPAI=[<%0IGN]/CD
M<@=!N92<5J44 ?.?[4G@[PCH7QR^"#:'X5TVR,WCF02FTL8X]X$.0#M SS7T
M-_9VG_\ /C#_ -^A7A?[7/\ R7#X&?\ 8]R_^B*]ZH A_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHH X[Q'\/O \?Q)TGXAIX5L1KC6YTUM4%NOG&T
MW&7R"W]S?\V/6NK_ +.T_P#Y\8?^_0K-\2_\A?1_^OT_^@FMBFY2ENQMM[D/
M]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344A$/]G:?_SXP_\ ?H4?V=I__/C#
M_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% ''V?@'P4WQDO/'I\+
M6)UE=!CT]=2^SKYHM3+YGD[O[N_YL>M=5_9VG_\ /C#_ -^A6;9?\CO>_P#7
ME%_,UL4W*4MV-MO<A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHI"(?[.T__GQA
M_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* ,*
MSLK,^,[V(VD6T6<9"^6, Y-:_P#9VG_\^,/_ 'Z%9ME_R.][_P!>47\S6Q0!
M#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!\X_M[_\ !/NW_;=_X13R/BBGA3_A&/MV=GA\7GVK[3]G])XM
MFWR/]K._MCGX#_X*$?\ !%+Q/\!?V>=4^/\ X0^,?_"63>&-DNJ:6GA@VCBQ
M+8DF5Q<R[O+)5RNT?)O;/RX/[%54U[0]'\3Z'>^&O$.G17FGZC:26U]:3INC
MGAD4HZ,.ZLI((]#7VN6>('%&6973RJ%:^%@_X?)#9R<W[W+SZMMWYM/30\+
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M[3_^?&'_ +]"IJ* ,+P796<NE2-+:1,?MDHRT8/&ZM?^SM/_ .?&'_OT*S?
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M2(!KPA@(QR-IK=K'\2_\A?1_^OT_^@F@#2_L[3_^?&'_ +]"C^SM/_Y\8?\
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A61X+LK.72I&EM(F/VR49:,'C=6[6/X'_Y!$O_ %^S?^A4 :7]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U%
M $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% &1XNL;*/PU>/'9Q*PA."L8!%6
M]/T^P:P@)LH23"N28QZ"H?&/_(L7O_7 U<T[_D'P?]<5_D* #^SM/_Y\8?\
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MC_\ 7Z?_ $$T ;%%%% !1110 4444 %8]E_R.][_ ->47\S6Q6/9?\CO>_\
M7E%_,T ;%%%% !1110 4444 %8]E_P CO>_]>47\S6Q6/9?\CO>_]>47\S0!
ML4444 %%%% !1110 5CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S0!L4444
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MQ1^VGX(\60M%/\1/!GA/QCX5DE&#>Z;%$;:>1,]5CNI3"2.-T= 'H7_!/O\
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M9DD,!VE<G  K3^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\
MH-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW
M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: "R_Y'>]_Z\HOYFMBN4M;7Q2?%-U''
MJEL+@6T9DD,!VE<G  K3^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
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M_P"-?W'_ *I4,9KFU>IBO[LGRTO3V4.6$E_U\YWYGZW_ &;"KKB9NIY/2/\
MX"K)_P#;URK\/OA'\,?A58?V=\.O NF:1&5VNUG:JLD@_P!N3[SGW8DUT58_
MV+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XU]-AL+AL'15'#P4(+91227HEHCO
MITZ=*"C!))=%HC0U?2-*U_2[C1-<TZ"\L[J)HKFUN8@\<J$8*LIX(([&OEGX
MQ?\ !+OX1:E]K\2_#WQ9J7AX &1M/>(7=NOLFYE=1]7;\*^EOL7C?_H-V7_@
M,?\ &J/B6T\6IH-T]]JUJ\0B/F(EN02/8UX?$/"/#?%=*-/-<-&KR[-W4EZ2
MBU))]4G9G)C<MP&8Q2Q--2MMW7S6I\^_"W_@EA\(O#]Y;ZW\0?&&I>) H5Q8
MK"+.W?C.'"LSL/HZ_C7TU;^&?#EIX?7PG;:#9II:6WV==.6V7R!#C'E[,;=N
M.,8Q5"RL_&ALXC%K-F%\I=H-L<@8^M2_8O&__0;LO_ 8_P"-+(.#^&>%J,J6
M5X6-)2^)J[<EV<I-R:\F[!@LLP&7P<</34;[]WZMW9Y%K/[/?Q'^!&JS^-_V
M2M4C%E+(9M4^'6JSG[#=$_>:U<G_ $:0]AG:>.0 %/9?!C]I/P-\8;B?PT8+
MG0?%-AQJOA36D\J\MV'4J#CS4_VE[$$A<@5U?V+QO_T&[+_P&/\ C7"_&/\
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M %Q7^0J:L*RL_&ALXC%K-F%\I=H-L<@8^M2_8O&__0;LO_ 8_P"- &Q16/\
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ME_X#'_&C[%XW_P"@W9?^ Q_QK^ZC]>-BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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MY'>]_P"O*+^9H^Q>-_\ H-V7_@,?\:S+6U\4GQ3=1QZI;"X%M&9)# =I7)P
M* .KHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
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M!_\ D$2_]?LW_H5;% !1110 4444 %%%% &/X'_Y!$O_ %^S?^A5L5C^!_\
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M ;%%%% !1110 4444 %8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\
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M'32U^*7P4U.R:ZU31;1K:S\3:%?P+<6&J10.[F&38WE7$0=U24 JV) B_4%
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M -<#6E6;XQ_Y%B]_ZX&@"YIW_(/@_P"N*_R%35#IW_(/@_ZXK_(5-0 4444
M%%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444 %%%% !11
M10 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444
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M?CY^Q/\ M._\$,_VW--_:)_X)0Z/=?$/X=:GX(\6^)/%/[/6OWSF/1M)AOM
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MX6\7:!X0;2;_ ,'MIT4MY#ID<333LELTDI=@TTAF+M*64P[#:_X)EV>H6/\
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M ($P5[U10!X+_P -<_'#_HQGQW_X$P4?\-<_'#_HQGQW_P"!,%>]44 >"_\
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M_8]ZS_Z4FO=* /!?^&N?CA_T8SX[_P# F"C_ (:Y^.'_ $8SX[_\"8*]ZHH
M\%_X:Y^.'_1C/CO_ ,"8*/\ AKGXX?\ 1C/CO_P)@KWJB@#P7_AKGXX?]&,^
M._\ P)@H_P"&N?CA_P!&,^.__ F"O>J* /F#X6?MN?$SQ1X=GU#PM^QUXOU.
MW34[B%[BRO86194?#H20/F4\&NE_X:Y^.'_1C/CO_P "8*F_X)[_ /)$]6_[
M'O6?_2DU[I0!X+_PUS\</^C&?'?_ ($P4?\ #7/QP_Z,9\=_^!,%>]44 >"_
M\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\
M@3!1_P -<_'#_HQGQW_X$P5[U10!\P?"S]MSXF>*/#L^H>%OV.O%^IVZ:G<0
MO<65["R+*CX="2!\RG@UTO\ PUS\</\ HQGQW_X$P5-_P3W_ .2)ZM_V/>L_
M^E)KW2@#P7_AKGXX?]&,^.__  )@H_X:Y^.'_1C/CO\ \"8*]ZHH \%_X:Y^
M.'_1C/CO_P "8*/^&N?CA_T8SX[_ / F"O>J* /!?^&N?CA_T8SX[_\  F"L
M/XD_MJ?%7PYX$U/7/$G[&/C+3[&VM2]S>W=Y"L4*Y'S,0"0/PKZ6KRC]N?\
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M.'_1C/CO_P "8*P_B3^VI\5?#G@34]<\2?L8^,M/L;:U+W-[=WD*Q0KD?,Q
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M\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\
M@3!1_P -<_'#_HQGQW_X$P5[U10!X+_PUS\</^C&?'?_ ($P5S7CC]MSXF:)
MXB\-Z?K?['7B^SN-1U-H=.M[F]A#W<H0DI& #EL<\XKZ?KPO]K#_ )+9\#_^
MQ[E_])FH A_X:Y^.'_1C/CO_ ,"8*/\ AKGXX?\ 1C/CO_P)@KWJB@#P7_AK
MGXX?]&,^._\ P)@H_P"&N?CA_P!&,^.__ F"O>J* /!?^&N?CA_T8SX[_P#
MF"C_ (:Y^.'_ $8SX[_\"8*]ZHH \%_X:Y^.'_1C/CO_ ,"8*YK2_P!MSXF7
M7Q2U3PO:_L=>+Y-4M=,@FNM-2]A,T,3$[788P%/;FOI^O"_ /_*03Q__ -B)
MI7_HQJ (?^&N?CA_T8SX[_\  F"C_AKGXX?]&,^._P#P)@KWJB@#P7_AKGXX
M?]&,^.__  )@H_X:Y^.'_1C/CO\ \"8*]ZHH \%_X:Y^.'_1C/CO_P "8*/^
M&N?CA_T8SX[_ / F"O>J* /!?^&N?CA_T8SX[_\  F"N:TO]MSXF77Q2U3PO
M:_L=>+Y-4M=,@FNM-2]A,T,3$[788P%/;FOI^O"_ /\ RD$\?_\ 8B:5_P"C
M&H A_P"&N?CA_P!&,^.__ F"C_AKGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_
M $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X
M:Y^.'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"N:TO]MSXF77Q2U3P
MO:_L=>+Y-4M=,@FNM-2]A,T,3$[788P%/;FOI^O"_ /_ "D$\?\ _8B:5_Z,
M:@"'_AKGXX?]&,^._P#P)@H_X:Y^.'_1C/CO_P "8*]ZHH \%_X:Y^.'_1C/
MCO\ \"8*/^&N?CA_T8SX[_\  F"O>J* /!?^&N?CA_T8SX[_ / F"C_AKGXX
M?]&,^.__  )@KWJB@#P7_AKGXX?]&,^._P#P)@KFOA9^VY\3/%'AV?4/"W['
M7B_4[=-3N(7N+*]A9%E1\.A) ^93P:^GZ\+_ .">_P#R1/5O^Q[UG_TI- $/
M_#7/QP_Z,9\=_P#@3!1_PUS\</\ HQGQW_X$P5[U10!X+_PUS\</^C&?'?\
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M6EHW[87QGO-'M+RS_8A\<30RVT;Q2QW4!5U*@AA[$<UUO[<__)H_CW_L O\
M^AK7=?"[_DF?AW_L!6G_ *)2@#R+_AKGXX?]&,^._P#P)@H_X:Y^.'_1C/CO
M_P "8*]ZHH \%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\  F"O>J* /!?^
M&N?CA_T8SX[_ / F"C_AKGXX?]&,^.__  )@KWJB@#P7_AKGXX?]&,^._P#P
M)@KM?V8?BM9_&/X<3^+;/0[C3A'KEY:26MRZLZO%)M;E>.M>BUX7_P $]_\
MDB>K?]CWK/\ Z4F@#W2OX0OVL/\ DZ;XE_\ 90-9_P#2Z:O[O:_A"_:P_P"3
MIOB7_P!E UG_ -+IJ /V_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG
M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BF75U;6-M)>WMQ'###&7E
MEE<*J*!DL2>  .237RW^Q_\ \%@_V-OVZ/VK_'W[*7[.'BNYUV[\!Z3'>_\
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M0DU:+3H%NY8PDMTL*B1U'12V,D#TJ>BB@ HHHH **** "BO,_P!I#]K7X/\
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M2:BEEX>U+5!IB2_ZI[QK"WF6R5QDJTYC# $C(YKU#X+?'+X._M'?#?3OB_\
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M)XUDAFA<,DB$9#*1P00001UH =%%%!$L$$:HB*%1$& H'0 =A3J** "BBB@
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M'V% &O4$>EZ9%J$FK1:= MW+&$ENEA42.HZ*6QD@>E5/!OC'PI\0_"6F>/?
MGB.RUC1-:L(;[2-5TZX6:WO+:5 \<T;J2'1E8,&'!!%:5 !1110 4444 %%%
M4=<\3>&_#$5M-XE\06.G)>7T-E9O?7:0B>YE8)%"A<C=([$*J#)8G !- %ZH
M(]+TR+4)-6BTZ!;N6,)+=+"HD=1T4MC) ]*GHH **** "BBB@ HHK$\:_$CX
M?_#<:4WQ \:Z7HHUW6H-(T9M4OD@%[J$^[R;6(N1OE?:VU!\S$8 - &W4$>E
MZ9%J$FK1:= MW+&$ENEA42.HZ*6QD@>E3T4 %%%% !1110 445R?Q3^.OP>^
M"$WAJ#XN_$;2O#K>,/$T'AWPR=5NA$-1U2=)'AM(R>#(ZQ2;0<9*X') (!UE
M0:?I>F:1 ;;2M.@M8VD9VCMX512Q.2V !R3U-3T4 %%%% !1110 445YE\?/
MVT_V0?V5]1TS1_VEOVH/ /@&\UGG2K3Q?XMM-/ENESM+HD\BED!X+XV@\$B@
M#TVH-/TO3-(@-MI6G06L;2,[1V\*HI8G);  Y)ZFFZ+K6C>)-'M?$/AW5K:_
MT^_MDN+&^LIUEAN(74,DB.I*NK*00P)!!!%6: "BBB@ HHHH ***\)_:?_X*
M<_\ !/\ _8O\96'P[_:B_:R\'>#=>U.)9;71M4U+-T(F.%EDBC#-#&2#B20*
MIVG!X. #W:H-/TO3-(@-MI6G06L;2,[1V\*HI8G);  Y)ZFJOA'Q=X4\?^%]
M/\<>!?$MAK.BZO9QW>E:MI5XEQ;7EO(H9)8I8R5D1E((9200<BM&@ HHHH *
M*** "BBOEG]KS_@M;_P3!_83^*T'P/\ VG_VL-)T#Q7*L;W&B6FE7VI36*2
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MA\#?A;X[\:_'[4OVS/C+\,(O!6NWW@JV\*Z#X5DU&WO;^RTY+J6[E>^GMF>
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MIYI8;6=78GS8D,<9CD#,ICN516*Q*3[[\>/^""W_  2]_:+_ &B;S]J/Q_\
ML_3VWBS5Y"_B67PYXGO]*MM=9B"YO(+6:-)2Y&9" IE))D+YJU\&?V?_  Q'
M_P %@?'GQW^&OAZSTWPYX'_9X\-_#=XM-MEAM4U ZC>:D;.-$ 53;6)TTE0
M%2\A X&  ?7=%%% !1110!%?W]CI=C-J>IWD5M;6T32W%Q/($2)%&69F/"J
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MQMIFLOJ5[=:5<Z:+.PDT^1V^R-]J-Q))<"!]UI @B8,S( ?8E%%% !117/\
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M5- 'K&E?MG?L@:[\9YOV<=$_:H^'-Y\0;>1HY_ ]KXUL9-721<ED-HLIF#J
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MX":M:17T'Q2\-S:=>RV^F2@-!JL^EK<"YAL9(V$PE/SK$RF2.-B$KJOV(O\
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M&6E?!^V^"'Q-^+?Q#U;1VUH> ?A'X4?5M0L-(60QMJ-T RK!;[T=%8DEF0\
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M:7'8W;:)HL#;3=3+<VZ":4D1A01D*Z-+^BG[$/AOQM9_LP-^SG\;M(U66\\
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M4#6?_2Z:@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
MI\GK]_J "BBB@ KQ[]LKXN^.?@!X5\)?&K0M2CC\+Z)X]TZ+XE6TELC[]!O-
M]A)<!V&8A:W-U:7LCJ1^YM)E.0U?&GQ6_:L_X+G?MC?$GQYXC_X)8_#[X.>%
M_A;\-O&&I>&K'5?BQ-=/J7CS4M-G>VOC:)$C1PVJW,4D",[1;C&6\T?,L?T1
M^P9^TK9_\%4?V$=:M?VB_@W_ ,(QXAEGUKX?_&?X?S,2NG:K &M;^U4L2?+>
M.59%!+%5F +,1N(!T _9 ^%'P8_8X^*?P>N_A5'XYL_&NH^+M>\2:';:8KW/
MB>YU:]N[OR)-Q_>3%9XK<2NP"B)#E$0;?B?]E7]K[_@M#_P3MB^$WPZ_X*??
MLE_#N/X'WO\ 8G@B/QG\-]4DN+_P9<.L-A82:H&N9EEA>7RDDE0!%:4L),[(
MG^\?V OB-XO\:?L[6G@KXIZL][XW^'&J77@KQQ=2_P"LN]0TUQ"M\P[?;+;[
M-?J/[EZG3I7EGQ<\??'3]N7XUZ_^Q)8?L?>+?"GPP\-^)]-F\=?%OQW$EI::
M[!9W<%Z+/0[8%I+T7$D*1-=$QQPQ^:PS)Y:D [S_ (*>_L+^#/\ @HG^QQXG
M_9H\3Z%I\VHZFL<OA76[V1HW\.ZHK8AU2)T!?? &9_+4KYRAH2Z+*S#T']F+
MX#W/[./P=TGX8ZK\7_%_CW4K*TB75?%_C?6'O+_4YTB2,RMD[(@0@Q'&%7JQ
MW.SNWH-% !1110 5XO\ MI_$_P =? C0/!?QWT+Q \'A;PWX]L8_B5I_E(4N
M-"O0^GR7#,5W1K:3W5M?.RD?NK28$'(Q\9_M ?'/_@O=\:!X[_:S_85F^%7A
MSX8_#[Q%K-AX5^&?BK29+O6O'UMI%W-:W=S+-LQ;>?-;3BWB1X6*;=S D.WW
M'X&\5_"C]N7]EB*/7;&SO-$^(G@*%?$WAP7J3/:VVIV :2TFV\JWES,IR >^
M* .7UO\ 99\+_"/]AGQ[^SKX"^&L/C2+6],\32#PY)%##_;MWJUQ=W#PSM*P
MCR\EUM>9V QES@<#XG_9Z^+_ /P7&_X)FZ_\+M#_ ."CND?"?QY\"]<U'1O!
M=[K?PR\];_P%/<O%8:=-<^;##YUL9G@BD?;+@OGS =JR_<W[ /Q%\7^,OV=K
M7P/\4M6>]\;_  VU6Z\$^-[N;_67=_IK"%;YAV^V6WV6_4?W+U.G2O-/%NI?
MM<?MK?'[5_V=?&W[)TGP[^"/@KQK87VI>/?$OB""XO\ QVVFWL-[:V^G6, /
MV:U>XMX'DN)W):'=$L:R.S1 'H/_  4B_8?\#?\ !1']D;Q)^ROXZTW33'KS
M0'3]8OXF:30KE)!MU&VV\FXA4NR+N59"3&["-WKO/V<_@#X4_9H^$VE_";PI
MXD\2:XEA!&MWX@\8^()]4U75)EC2,W%U=3L7DD*QH,#"(JJB*B*JCN:* "BB
MB@"MJNLZ/H5LEYK>JVUG#)<PV\<MU.L:M-+(L448+$ N\CHBKU9F &20*\8_
M;;\>^,O@AIW@3]HK1O$MW;>&_"/CJTB^(VFQRD076@Z@&T^6YE'I9SW-K?%_
MX8K2<8^:O.?B-\;=$\3?\%A_#W[.WCK7K:UT#X:?L\WWQ+CM[V=8[<:A=:K_
M &6M_*S$ ?9;6&\16) 4:A(QYVD.^'G_  5._P""2O\ P45\0>)/V)/AQ^UA
MX2\9ZGXDT>_T?4_# %Q;_P!K6TL+Q7$5K)<1)'>9B,A_<-)\H+#Y030!Z'X\
M_9BM_ ?[!7B[]E;X(>";'7FU#PAK.E:/I&LS1P6MW<:CY^XW;XP(C)<L\S!6
M<KO*H[D*WP]\+K'_ (+4_P#!.#Q9X T?_@H1\:_AW^T!^S]XWUG2_ 7BZTT;
MPK;V5QX-?4I8]-LI=JVL(NK%IYH+>3S?,)67E%)W'[F_8 ^(GB[QC^SO;>!/
MBCJ[WOC?X:ZK=>"?&UW-_K+N_P!-81)?,.WVRU-K?J/[EZG3I7GS^'?VZ?VN
M/VB]2\#?M"? ?PY\-?@5X#\=VNJ:%*/$\6KZW\0YM-O$NM,N=L'[O2[(7,$%
MT\4FZX8PQQ$*C2$@'(_"/_@C!IW['GQ.UKQ;_P $Z_VP?'?P8\*>*;QKKQ'\
M+X+"QUSP^)V&&GL8+^-VL)NGS*SKA44H44(/J_X&?!?P5^SS\*-&^#OP^CN?
M[,T:!PL]],);B[GDD>:>ZG< !YIII)9I&  9Y&( SBNLHH ***YGXU?%7PW\
M"?@WXM^.'C))VT?P;X9O]<U5;9 TAMK2WDN)0@.,MLC; ]: .FKYB_:XTKQ5
M\7/BKXD_8=^(GBO[+X#^/7P6U32/"]PEJH.G:U:^:NH0,Z;7E^U6-]#*L9;A
M=+NL%=U>1_&W4O\ @N$GP7TK]L_]E'XT_"GQI->:';Z[/\ ;OP(\=K<V<L0G
M^RV6L+=>?<7*QL%$CK%',XWA(@1%47@?]NSP=_P56_X)O6G[<7[.'@Z_T_XB
M_!GQ3%XCN_ -RV[4=*US2E)U'1LX7?\ ;-.FO+2.3"[DO@2$9710#T'_ (*M
M_ /XP^*OV;_ 'AG]AC]G3PQKWQ+\#?$/0M6^%R:Q EKH_A;[!('>XF97B\JW
M%LCVWDQ-N?ST"HP5MOSMX;M/CI_P47U77/\ @D-_P7__ &2/"NE^(=:\.S>*
M?A=\0/AK>.-.U9+1XX;B6RFD>5[74+4W,;%3@/%*P>$1D>=^D-G\5/#.O?!^
M+XW>!HKOQ)HU[X:77-'308/.GU2U>W^T1"W0D>8\J%=BDC)8#(S7SO\ LH:U
M\??VU?B]H'[9GQ]_9;U?X.:%X.T74].^'7@SQA<H_B&^EOVMQ<ZE?PQC;8*L
M5LL,5L6=V\Z9Y-H$.0#@OAI_P3;_ &^_#GP&UK]@[XO_ +?.A?$?X):YHTVA
M7&L>)O DX\:1:#-&89],%['>BWE9H&>%;R6)Y$#E@APBK]R6%A9:580:7IMJ
MD%O;0K%;PQ+A8T4 *H'8  "IJ* "BBO.?VO?VA],_9+_ &7/'_[3&K^'+G68
M? WA.]U@:/9G$M_)#$SQVZG!VF1PJ;L'&[.#B@#T:OE_]J'PSJ?Q3^/NL?L<
M_&+Q-++\.?CK\+9K/P]!+;1M'8:QID[/?6IP%,HO+*[BE$;$_+IEU\P! 'QO
M\7/&W_!S1^RO\-G_ ."B7Q3^*OPH\7^%M"MAKWC[]FS0/#$<4FE:,!YES%:Z
MAY!GFN8(=S,3.RAHV*^> $?[<_;!N'^-O['>A?M7? .RFU;6?!1TSXG?#Z.!
M,3ZC'!"9YK-!V:]TR>\LNO'VWKQ0!@?\%7/@'^U'\=/@MX(\)_L.^%O"47Q'
M\/?$33==\+^*_&11-+\)_9$EW7;J$DDD9D<P+%'$^1,Q8!5-<'_P3O\ VG/^
M"E7@/]IB]_8$_P""K_ASP=J7BF_\*7'B;X:?%3X?1M'I?B>RM9H(;ZTDC9(_
M+NH&NK=\"*,%'/RX"O)]>GXK:9K_ ,$?^%X?"G2;CQA9WOA7^W?#=AHTL:RZ
MW$]M]HMXX&E9(PTP**A=E7+C<0,FO"OV0])_:L_:0^)>G?MF?MF_ '3_ (3W
MNB^'K_1?A[\,HO$*:M?Z?;WTUK)>7^HW4:)%Y\OV&U2*WB7]Q&)=[NTNV( 9
M^V[_ ,$OOA5^V]^TA\(/C_XJUO5?"VJ_"J_N[K_A)_!6MW.EZ[J-O)'L72OM
M=LR216;L[R2,K^8,,D903RO7TQHFBZ3X:T6T\.Z#I\5I8V%K';65K NU(8D4
M*B*.P"@ #VJU10 445YQ^UY\:/$_[._[,7CGXU^!_!7_  DFN^'O#MQ<Z#H!
MEV+J%_MVVT#O_ C3-&&;^%23VH ]'KY@^/WA-_&G[5-Y^S+\9?$%]>_#KXV>
M!X)= LKB4/#8:[H=VMQ=6B*X*XO+2:"7R\8(TNZ8_>KYJTL?\%DO^"?WQ\^'
M'[1/[<?_  4(\"?$;X2^.O$R:)\5_##>$K/0;#P+)=02FVNK*]8AI+:&=$B:
M25HRP<;XV+&2/ZF_;"UCP[\>OV4H?VEOV6O%>D>-]6^&.MV_CCP3>^$]5AOH
MM3GT[>;NPAFA9D9KNPDOK#AN/MAY% &7_P %4?V;OVMOVHOA?X)\$_L7>-/#
MG@SQIH?C^V\06WQ&\36D5U'X;2WMKB)I+>V>*7S[J07)C52@0(9BSHP0/YU_
MP3L^+G_!2WX)?M0ZG_P3_P#^"GWC+P[\0[_4O!USXL^%GQ@\,Z7'8IK=E:7-
MM;7]A=V\<<:1W,#7MFXVH,I*<O(<$?6]_P#%2X\2? *;XV_ /P['XYEU#P@V
MN>"])M]3CLT\0-):^?9PK<2_) )\QJ)7^5!)N/ ->._L<?#K]KOXC^-(?VO?
MV^?!OA?PCXUC\.W.A>#_ (<>$M1.H0^%M-NI[>XO/M-]G;>7EQ)9V>\Q 0QI
M:1JFXO(Q '?MB?\ !,C]GO\ ;B_:!^%?QQ^-^C"23X4W%Y=:8-,DDM;S49)U
M51:W%S$ZL;)<,[6X_P!8[ %EC\V.;Z)TO2],T/3+?1=%TZ"SL[.!(+2TM85C
MB@B10JHBJ %4    8 &!4]% !117._%[XCZ1\'?A/XH^+OB"%I+#PKX=O=8O
M8T.&:&V@>9P#V.U#0!T603@'IUKY8^'W@N]_:8^-'_"&_M&ZK;:IXH_9Q^.-
M_K^DQW>FQ^5J>F:CIEZVB7BQJ%17MX-2-L)MI/GZ7.P 8AQ2_8Z_:G^ WP4_
MX)^_#+]J_P#;!_:)\%^$-6^,WA[3_&/B+Q%XO\2VVG17^J:G:179MH7N)%WI
M;Q21VT4:D^7!;1KT7-;'Q$\=^"/"W[4OPC_;-^&'C+2M;\$_%&Q_X5WXFU[0
M]1BNK&Z\YY+O0+T3Q,R2(EZ+RQ0J2"^MKZ9 !XQ_P47^$G_!4&/]N71?V@?^
M"4GP3^&D6O0?#&70O'WC?XG.T=MJD+7\5U::? D4BR2R1>3*6E9?+5;L*) P
M8+Y_H?[,>C?\%P/ L7Q8_:"\&:]^S/\ MC_L]>*SX>U7Q7X(N%:ZT6^2*.Z@
M>,ERM_IEQ#<K-&C2$@22JDQ1G>7[Q_;!_:'\;?LQ_!J7XE?#K]F?QK\6M:?4
MK>QL/!_@2WB>[E>9B!-(TK*L,"8^>4[MN02,9(R/V-OA5\4_#UGXM^/7[07A
MC2M"^(/Q3UFWU?Q!X;T74/MEOH$$%E!9V>FBYVJ+J2**'?+,%"M-/,$_=K'0
M!QOP?_9._:Y\4>+_ (?^+/V]OVA? _CV3X5:K/JOA)O!G@";1I-1U62QN=/7
M4K\RWD\>]+6\NP(((XHQ)-YF3L15^FZ** "BBO#_ -N#]H+Q#\&-+^'/PY\$
M^*;+P_X@^+WQ+M/!.B>)M1M%N(M'EELKV^>X$+D++,8K"6&%&.PSSPEE=0R,
M >X5\N_ ?PC=_%_XW7GAKX^:_)J_C;]G;XHZQ=Z!>7MM&6O](UJRFDTR\ 4
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MO%\WA^\3PKJ&I6PFMK;4C XMI)8R1OC67867(R 17B?[*W@GX;_M(_$S3/\
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MH_AN]\3W5WHWA"QNKHW"Z5IL4I *1_(K7+H)9G5Y"(Q(8Q]5444 %%%?+O\
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MQ\5_#W[.WQ!^*5^NH6]E9>$/AIH7V_4KB69]JR%"RB*!.LDK'"+R<T >>_\
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MZW<UW':B)[2Y%O:1&7'FDI*7EDVH5 9O1]2^,GP\U'XX? O_ (*$?!_7TO\
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M_P#;Q_Z?)Z_?Z@"#4]3T[1=-N-9U>^BM;2T@>:ZN9Y B11J"S.S'@* "23T
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M?M_VG/V8[V\2V\=3S>$+'3?%?@R*1PBSL+&.&TOK;+#):%"6(1C$")&^E/\
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M33E 9MR6L,J6R-QF.!,@'->@T44 %%%% 'S[^T'^T%\9M5_:7TK]B?\ 9?\
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MWYU26Z^'_@_Q-J:KH'@=9(VC)L+&%5B:X$;O$+J0-*(V8 AF=G^AZ "BBB@
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M@4[(P?XG9W;Z1H **** "O!?V@_VB?B\?VB-%_8W_9AG\'6GCK4_ M_XPO\
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M]#T^&QTC2["$1PVEM$@2.)%'"JJJ ![5J444 %%%% !1110 5X!^V)_P3?\
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M'Y4$;+:06]O!#$A8)#!#'&#)(^TO)([>C44 %%%% !1110 4444 ?./[5?\
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M='_#_C_@C;_TD)^'_P#X%S?_ !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\
MC='_  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N
M;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^'_'_  1M_P"DA/P__P#
MN;_XW1_P_P"/^"-O_20GX?\ _@7-_P#&Z /K^BOD#_A_Q_P1M_Z2$_#_ /\
M N;_ .-T?\/^/^"-O_20GX?_ /@7-_\ &Z /K^BOD#_A_P ?\$;?^DA/P_\
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M$;?^DA/P_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X%S?_ !N@#Z_HKY _X?\
M'_!&W_I(3\/_ /P+F_\ C='_  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^
M'_'_  1M_P"DA/P__P# N;_XW1_P_P"/^"-O_20GX?\ _@7-_P#&Z /K^BOD
M#_A_Q_P1M_Z2$_#_ /\  N;_ .-T?\/^/^"-O_20GX?_ /@7-_\ &Z /K^BO
MD#_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^
MOZ*^0/\ A_Q_P1M_Z2$_#_\ \"YO_C='_#_C_@C;_P!)"?A__P"!<W_QN@#Z
M_HKY _X?\?\ !&W_ *2$_#__ ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;H
M ^OZ*^0/^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;
MH ^OZ*^0/^'_ !_P1M_Z2$_#_P#\"YO_ (W1_P /^/\ @C;_ -)"?A__ .!<
MW_QN@#Z_HKY _P"'_'_!&W_I(3\/_P#P+F_^-T?\/^/^"-O_ $D)^'__ (%S
M?_&Z /K^BOD#_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%
MS?\ QN@#Z_HKY _X?\?\$;?^DA/P_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X
M%S?_ !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\ C='_  _X_P""-O\ TD)^
M'_\ X%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX
M?_\ @7-_\;H ^OZ*^0/^'_'_  1M_P"DA/P__P# N;_XW1_P_P"/^"-O_20G
MX?\ _@7-_P#&Z /K^BOD#_A_Q_P1M_Z2$_#_ /\  N;_ .-T?\/^/^"-O_20
MGX?_ /@7-_\ &Z /K^BOD#_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V
M_P#20GX?_P#@7-_\;H ^OZ*^0/\ A_Q_P1M_Z2$_#_\ \"YO_C='_#_C_@C;
M_P!)"?A__P"!<W_QN@#Z_HKY _X?\?\ !&W_ *2$_#__ ,"YO_C='_#_ (_X
M(V_])"?A_P#^!<W_ ,;H ^OZ*^0/^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_
MX(V_])"?A_\ ^!<W_P ;H ^OZ*^0/^'_ !_P1M_Z2$_#_P#\"YO_ (W1_P /
M^/\ @C;_ -)"?A__ .!<W_QN@#Z_HKY _P"'_'_!&W_I(3\/_P#P+F_^-T?\
M/^/^"-O_ $D)^'__ (%S?_&Z /K^BOD#_A_Q_P $;?\ I(3\/_\ P+F_^-T?
M\/\ C_@C;_TD)^'_ /X%S?\ QN@#Z_HKY _X?\?\$;?^DA/P_P#_  +F_P#C
M='_#_C_@C;_TD)^'_P#X%S?_ !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\
MC='_  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N
M;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^'_'_  1M_P"DA/P__P#
MN;_XW1_P_P"/^"-O_20GX?\ _@7-_P#&Z /K^BOD#_A_Q_P1M_Z2$_#_ /\
M N;_ .-T?\/^/^"-O_20GX?_ /@7-_\ &Z /K^BOD#_A_P ?\$;?^DA/P_\
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M$;?^DA/P_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X%S?_ !N@#Z_HKY _X?\
M'_!&W_I(3\/_ /P+F_\ C='_  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^
M'_'_  1M_P"DA/P__P# N;_XW7J?[+'_  4;_8=_;<U_5?"W[*'[2OAOQUJ&
MAV:76K6FASNSVL+OL5VW*."W% 'ME%%% !1110 4444 %%%% !1110 4444
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MCN*_?Z@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBC_B$._X(V_]"5\0/_"[F_\
MB*_3ZB@#\P?^(0[_ ((V_P#0E?$#_P +N;_XBOBO_@S_ /"&C?#[_@HQ^U)X
M"\.)(NGZ'I?]GV"S2;W$,.KRQH&;N=JC)[U_0E7X _\ !IM_RE,_:[_[>/\
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MXNSZ<UXGA6^\*ZP]HK8,XMO#]_,4![9V8_&@#].J*_(?P%^R)^UE_P %/?\
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M?Z;_ &AY\VD^$KBZMV\S4+F5=DJ#:WRN <="".U>T_\ #SG]G_\ Z$KXC?\
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M^.8Y9=,\(:!<:E/:VXS-=O&A,=M$.=TLLFR)% )9Y% Y-?(/_!/#]N3X%_\
M!13]M^7]J7]G[7/M&CZW^S/H27VG3NOVK1[Y->U;S[&Y4'Y)HV(![,I1U)1U
M8]+_ ,%%_C1I_B/]J+X1_LJ3?#KQGXK\/Z'J,/Q(^)VG>"/"\^K3"WL9G&A6
ML\<(.V.?5(C= MP1HS+_ !4 ;G_!%?\ X*&:[_P4D_8>TWXR?$G2;?2OB#H&
MNW_AOXDZ%;P&$:?J]K+ROEL=R;X'@DVG[K.R_P -6_\ @I/^W-XX_9E\8_!;
M]FGX+2>'K'Q_\?/';^'/#OB/QA!)-I>A00Q++=7DD,<D;74^'BC@M_,C$DLR
MY<!2K?$G['?QOTW]B[_@X.\;?#:V^'/C3P9\+OVQ=*;7O#MGXX\+7&D>5XRL
ME:2[6)9P PFWSNQ7[TEY;I_"!7W/_P %2/\ @F]^S9_P5)^#5C^S?\:O%%SH
M'B2RGEU[P#XDT6Y1-4T>ZM_+CDNH4)'G0@SPI*AP#YD?S(XC=0#E/C3XA_X*
MA?LM>+?AO>Q?&3P/\4? ?B?XH>'] \<W]]X#;2=:\/6E[J$-N;B!K>Z:VN(9
M&=8"'B62(SHX:09V<5_P5K_;D_;C_9 _:B_9Q^#?[.'C+X=1:3\?/B)_PB=Q
M-XP\"W>H3:'(7M$6Y0P:C;"X7_2')C.P_* 'YX^8_"7[<'_!5?\ X(=_%;P;
M^S[_ ,%;5L/C9^S]XE\26NB>%_C[8@O?Z/,7#0&^W_/(R;/-9)PTN$=XKB?R
MME>M_P#!?#_D_?\ X)W?]G*1?^C].H ]R_:F^('_  6+_9(^&&H?'CP.?@W\
M>])\-VCW_B3P+I7@?5/"NN7%G$"TIL+@ZIJ$,TH0%A$\(9MI"%V*H?8O^"??
M[=_P0_X*0_LM>'OVK/@'>7']D:T'AOM+OPHN])OHB%GLYU4D"1"0<@X=&1UR
MK@U[1/-#;0O<7,RQQQJ6DD=@%50,DDGH*_(O_@T7L+F7X'_M'>+?",3Q_#[5
MOV@+]O!*HNV!D6"/>\0Z%?*:T7(X^3'8@ 'TI_P6M_X*TR_\$M_"WPTUCP_X
M4?7)]>\;V=SXWBALVG.E>#X+NV@U*^.W_5N9;RSMHF;"F2Y &2,'[9T76M)\
M2:-:>(M U*&\L+^UCN;*\MI \<\+J&21&'#*RD$$=0:_,?Q1XI^%7[>0_:9\
M0?&+]GOXN>)/#GQ4TV;X<?#K7?"_PRO-3L;?PUIOFI'J-K.B['>;5Y+R\5EX
M9(++)/EC'7?\&T/[5OC+XQ_L$3?LK?&^&[LOB9^SGK\O@/Q9I6IQ/%=16L!8
M6#R1N R 0HUL P!)LG)'- 'I?Q3_ ."@GQ8^-?[>.I_\$U_V"+?PZOB3P5H<
M6K_&+XG>*["6^TSPA#-M^SV%O9PRPF^U&4.'"M-'%$H);S&5XUQOVR?VC?V[
M_P#@EQ\-/^&L_B;XZT7XY?"71+VV3XE:5;>#4T7Q'H5E-,D/]I6,D$[6]W'&
M\BE[:6)&V_,)U 8CYN_X-UVU'2_^"F'_  49\/?$$,GBUOC=#<W(N,^9+9-J
M&N&!DSR8MKJ5QP%D3L17W3_P5WD\-Q?\$K/VCW\6&+[%_P *0\4#][T,ITNX
M$('^UYNS;_M8H ]K^%GQ/\!_&SX::!\8?A;XDM]8\-^*-'MM5T+5;4GR[NTG
MC62*09 (RK X(!'0@$8KXH_X+2_MU?MG_L'Z]\$KO]FWQ'X!DT_XL?%O3? U
M[9>,/!]U>R:>]V/ENXY8+^#>%VOF-EYR,,,<W_\ @VNTKQQHW_!$;X#VGQ!C
MG2]?1M4GM5N0=_V&76+Z2S//\)MGA*]MA6O&_P#@Y_@U^YT']D6V\)ZG9V6J
MR?M:>'%TV\U&Q>ZMX+@I,(Y)84EB:9%;!:-9(RP! ="=P /O3]I?7/CM\-?V
M4?%?CGX>>/\ 0$\8^%_"M_JL>HZMX8DGL+R6WMI9A&ULEU&Z(Q51D3$@#O7C
M?_!$C]KC]I3]OO\ X)_^#?VS?VDM7\)KJ/C=M2:UT/PCX=GLH-/CM=2NK(!G
MFNIVF9OLV\GY -^,'&2S]JKX>_\ !3:#]E_XD3>(/VN_@1=6"> M8:]MK/\
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MO^%'_#X']F+_ *)]\5?_  VU[_A7SG]CYI_SYE]QX7]EYC_SZE]Q]55\!_\
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M_A=?Z_X2\=^%_#<^F7>JW<.H:?;R6]Y;R7,Z12P)<@DPL(Y1<HVU"I1?'_\
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M%X^.Y/%EEIMCJ=_:?V-<X=%M7D:UD\^/8R@RA48%"=AWX3S_ /9A_P"">_\
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MZ]^*'B.#4;34?"S7D4VD6-I:PVMCH_ESQ[98(D6>7S0R,9KF9C'^\^7Z1HH
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MMI'\/^/[! GE0WIA(EL[J/RHA'>QB0J(E5XI%R*^18?VI/C)_P %G/VC=?\
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MV/\ P3)_96/[)^A>-G\0:/IOC#6-0T"_GCVSBPNKIIH(I\ !ID1@C,H"L5W
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M/_\ PC;'_P"-4?\ #)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&\_LL_P#1CWQ
M_P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A7Z__P##)_[+/_1M7P__ /"-L?\
MXU1_PR?^RS_T;5\/_P#PC;'_ .-4 ?D!_P 1O/[+/_1CWQ _\**Q_P */^(W
MG]EG_HQ[X@?^%%8_X5^O_P#PR?\ LL_]&U?#_P#\(VQ_^-4?\,G_ ++/_1M7
MP_\ _"-L?_C5 'Y ?\1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/
M^%?K_P#\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5
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M@?\ A16/^%?K_P#\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\
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M ?D!_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X5^O_P#PR?\
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M4?\ #)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&\_LL_P#1CWQ _P#"BL?\*/\
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M $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^%?K_ /\ #)_[+/\ T;5\/_\
MPC;'_P"-4?\ #)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&\_LL_P#1CWQ _P#"
MBL?\*/\ B-Y_99_Z,>^('_A16/\ A7Z__P##)_[+/_1M7P__ /"-L?\ XU1_
MPR?^RS_T;5\/_P#PC;'_ .-4 ?D!_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG
M_HQ[X@?^%%8_X5^O_P#PR?\ LL_]&U?#_P#\(VQ_^-4?\,G_ ++/_1M7P_\
M_"-L?_C5 'Y ?\1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^%?K
M_P#\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5 'Y ?
M\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^%?K_ /\ #)_[+/\
MT;5\/_\ PC;'_P"-4?\ #)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&\_LL_P#1
MCWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A7Z__P##)_[+/_1M7P__ /"-
ML?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-4 ?D!_P 1O/[+/_1CWQ _\**Q_P *
M/^(WG]EG_HQ[X@?^%%8_X5^O_P#PR?\ LL_]&U?#_P#\(VQ_^-4?\,G_ ++/
M_1M7P_\ _"-L?_C5 'Y ?\1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^%?K_P#\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?
M_C5 'Y ?\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^%?K_ /\
M#)_[+/\ T;5\/_\ PC;'_P"-4?\ #)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&
M\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A7Z__P##)_[+/_1M
M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-4 ?D!_P 1O/[+/_1CWQ _
M\**Q_P */^(WG]EG_HQ[X@?^%%8_X5^O_P#PR?\ LL_]&U?#_P#\(VQ_^-4?
M\,G_ ++/_1M7P_\ _"-L?_C5 'Y ?\1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
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M('_A16/^%?K_ /\ #)_[+/\ T;5\/_\ PC;'_P"-4?\ #)_[+/\ T;5\/_\
MPC;'_P"-4 ?D!_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\
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M_99_Z,>^('_A16/^%?K_ /\ #)_[+/\ T;5\/_\ PC;'_P"-4?\ #)_[+/\
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M'_"C_B-Y_99_Z,>^('_A16/^%?K_ /\ #)_[+/\ T;5\/_\ PC;'_P"-4?\
M#)_[+/\ T;5\/_\ PC;'_P"-4 ?D!_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_
M99_Z,>^('_A16/\ A7Z__P##)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/
M_P#PC;'_ .-4 ?D!_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_
MX5^O_P#PR?\ LL_]&U?#_P#\(VQ_^-4?\,G_ ++/_1M7P_\ _"-L?_C5 'Y
M?\1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^%?K_P#\,G_LL_\
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M^'__ (%S?_&Z_D!_:P_Y.F^)?_90-9_]+IJX"@#^SW_A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA
M/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\
MI(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W
M_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW
M_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ*
M/[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*
MB@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\
M;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_
M\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%
MS?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\
M^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#2
M0GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
M20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C
M;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_
MX(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\
M#_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW
M1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_
M^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "
MYO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA
M/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\
MI(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W
M_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW
M_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ*
M/[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*
MB@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\
M;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_
M\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%
MS?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\
M^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#2
M0GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
M20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C
M;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_
MX(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\
M#_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW
M1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_
M^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "
MYO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA
M/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\
MI(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W
M_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW
M_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ*
M/[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*
MB@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\
M;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_
M\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%
MS?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\
M^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#2
M0GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
M20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C
M;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_
MX(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\
M#_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW
M1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_
M^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "
MYO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA
M/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\
MI(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W
M_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_
M (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW
M_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ*
M/[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*
MB@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\
M;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_
M\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%
MS?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\
M^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#2
M0GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
M20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C
M;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_
MX(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\
M#_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW
M1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_
M^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "
MYO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\
M_ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA
M/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\
MI(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W
M_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_
M (?\?\$;?^DA/P__ / N;_XW7\>W[1^OZ-XL_:'\>^*?#FHQW>GZGXTU2ZL+
4N(_)-#)=RNCK[%2"/K7%T4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770644592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,052,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;8, 2023, hav</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774483264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">McLean, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770662256">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188,200<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,492<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">254,684<span></span>
</td>
<td class="nump">130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,678<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">478,054<span></span>
</td>
<td class="nump">523,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,466<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,475<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,874<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,027<span></span>
</td>
<td class="nump">50,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,461<span></span>
</td>
<td class="nump">32,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">442,784<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">722,774<span></span>
</td>
<td class="nump">426,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,817,293<span></span>
</td>
<td class="nump">1,419,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,174<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">111,198<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,122<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,460<span></span>
</td>
<td class="nump">51,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,758<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">199,730<span></span>
</td>
<td class="nump">171,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">433,442<span></span>
</td>
<td class="nump">445,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">412,986<span></span>
</td>
<td class="nump">215,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">5,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,950<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,010<span></span>
</td>
<td class="nump">57,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">957,876<span></span>
</td>
<td class="nump">725,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note $11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,486,857<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(606,154)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">859,417<span></span>
</td>
<td class="nump">693,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,817,293<span></span>
</td>
<td class="nump">$ 1,419,458<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770603376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">101,500,558<span></span>
</td>
<td class="nump">90,758,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares issued</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772394752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,352,013,000<span></span>
</td>
<td class="nump">$ 907,957,000<span></span>
</td>
<td class="nump">$ 924,639,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,429,000<span></span>
</td>
<td class="nump">657,551,000<span></span>
</td>
<td class="nump">696,581,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,269,000<span></span>
</td>
<td class="nump">219,499,000<span></span>
</td>
<td class="nump">210,412,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,195,000<span></span>
</td>
<td class="nump">60,037,000<span></span>
</td>
<td class="nump">60,835,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets and consolidation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,522,000)<span></span>
</td>
<td class="nump">13,281,000<span></span>
</td>
<td class="nump">3,860,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 384,310,000<span></span>
</td>
<td class="nump">1,348,371,000<span></span>
</td>
<td class="nump">950,368,000<span></span>
</td>
<td class="nump">1,187,486,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642,000<span></span>
</td>
<td class="num">(42,411,000)<span></span>
</td>
<td class="num">(262,847,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">2,633,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,572,000)<span></span>
</td>
<td class="num">(25,425,000)<span></span>
</td>
<td class="num">(28,325,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,569,000<span></span>
</td>
<td class="nump">13,179,000<span></span>
</td>
<td class="nump">10,039,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,938,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainLossOnRepaymentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,192,000)<span></span>
</td>
<td class="num">(21,343,000)<span></span>
</td>
<td class="num">(4,789,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,950,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="num">(146,000)<span></span>
</td>
<td class="num">(118,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,077,000)<span></span>
</td>
<td class="num">(29,801,000)<span></span>
</td>
<td class="num">(330,540,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,376,000)<span></span>
</td>
<td class="nump">483,000<span></span>
</td>
<td class="num">(2,368,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,701,000)<span></span>
</td>
<td class="num">(30,284,000)<span></span>
</td>
<td class="num">(328,172,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(463,000)<span></span>
</td>
<td class="num">(7,317,000)<span></span>
</td>
<td class="num">(6,074,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,349,000)<span></span>
</td>
<td class="num">(19,164,000)<span></span>
</td>
<td class="num">(37,601,000)<span></span>
</td>
<td class="num">(334,246,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (11,349,000)<span></span>
</td>
<td class="num">$ (19,164,000)<span></span>
</td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.20)<span></span>
</td>
<td class="num">(0.35)<span></span>
</td>
<td class="num">(3.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20)<span></span>
</td>
<td class="num">(0.44)<span></span>
</td>
<td class="num">(3.94)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageCommonSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,699<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,699<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,164,000)<span></span>
</td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(816,000)<span></span>
</td>
<td class="num">(84,000)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,980,000)<span></span>
</td>
<td class="num">$ (37,685,000)<span></span>
</td>
<td class="num">$ (334,290,000)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $0.5&#160;million and $6.8&#160;million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Repayment Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageCommonSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageCommonSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774409120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">(Loss) gain on disposal of discontinued operations</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (6.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766004160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Parent</div></th>
<th class="th">
<div>Parent </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non-controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 929,047<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 922,358<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 1,173,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (234)<span></span>
</td>
<td class="num">$ (251,962)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(1,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(1,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Consolidation of equity method investment</a></td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodShares', window );">Share retirement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodValue', window );">Share retirement</a></td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of 2024 Notes, net of issuance costs</a></td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Disposal of assets</a></td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">13,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">13,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(3,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(3,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="nump">28,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">28,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">56,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 33,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">4,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(7,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(7,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="nump">101,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(11,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 859,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,486,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,178)<span></span>
</td>
<td class="num">$ (606,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodSharesEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodSharesEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodValueEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodValueEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770428816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 19,164,000<span></span>
</td>
<td class="nump">$ 37,601,000<span></span>
</td>
<td class="nump">$ 334,246,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,522,000)<span></span>
</td>
<td class="nump">13,281,000<span></span>
</td>
<td class="nump">3,860,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">Loss on discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463,000<span></span>
</td>
<td class="nump">6,786,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,569,000)<span></span>
</td>
<td class="num">(13,179,000)<span></span>
</td>
<td class="num">(10,039,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,195,000<span></span>
</td>
<td class="nump">60,037,000<span></span>
</td>
<td class="nump">61,475,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,981,000<span></span>
</td>
<td class="nump">16,711,000<span></span>
</td>
<td class="nump">14,606,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,608,000)<span></span>
</td>
<td class="num">(526,000)<span></span>
</td>
<td class="num">(1,132,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,056,000<span></span>
</td>
<td class="nump">13,041,000<span></span>
</td>
<td class="nump">21,195,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,302,000<span></span>
</td>
<td class="nump">18,045,000<span></span>
</td>
<td class="nump">14,780,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45,938,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,192,000<span></span>
</td>
<td class="nump">21,343,000<span></span>
</td>
<td class="nump">4,789,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInTaxReceivableAgreement', window );">Change in tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,950,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash inflows (outflows), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,612,000<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(102,980,000)<span></span>
</td>
<td class="num">(5,779,000)<span></span>
</td>
<td class="num">(47,017,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,673,000<span></span>
</td>
<td class="nump">5,599,000<span></span>
</td>
<td class="nump">7,340,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,693,000)<span></span>
</td>
<td class="num">(18,979,000)<span></span>
</td>
<td class="num">(11,400,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,165,000<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">3,547,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,791,000)<span></span>
</td>
<td class="num">(324,000)<span></span>
</td>
<td class="nump">8,801,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447,000<span></span>
</td>
<td class="nump">3,538,000<span></span>
</td>
<td class="nump">11,143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,508,000)<span></span>
</td>
<td class="num">(739,000)<span></span>
</td>
<td class="num">(8,943,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,436,000<span></span>
</td>
<td class="num">(3,799,000)<span></span>
</td>
<td class="num">(36,108,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">8,844,000<span></span>
</td>
<td class="nump">11,934,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,983,000)<span></span>
</td>
<td class="num">(6,522,000)<span></span>
</td>
<td class="num">(2,782,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,707,000)<span></span>
</td>
<td class="num">(2,734,000)<span></span>
</td>
<td class="nump">8,166,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash provided by (used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,553,000)<span></span>
</td>
<td class="nump">38,747,000<span></span>
</td>
<td class="num">(16,225,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(248,111,000)<span></span>
</td>
<td class="num">(49,012,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromLoansReceivable', window );">Loan for implementation funding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,969,000<span></span>
</td>
<td class="nump">42,996,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,164,000)<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
<td class="num">(2,287,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,552,000<span></span>
</td>
<td class="nump">14,218,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Impact to cash and cash equivalents and restricted cash from initial consolidation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,995,000)<span></span>
</td>
<td class="num">(11,170,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">143,441,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,361,000)<span></span>
</td>
<td class="num">(24,983,000)<span></span>
</td>
<td class="num">(29,473,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(259,115,000)<span></span>
</td>
<td class="num">(15,786,000)<span></span>
</td>
<td class="nump">261,072,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59,449,000)<span></span>
</td>
<td class="nump">61,162,000<span></span>
</td>
<td class="num">(6,044,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment of Credit Agreement including settlement of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,420,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,452,000<span></span>
</td>
<td class="nump">13,289,000<span></span>
</td>
<td class="nump">2,577,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,740,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,062,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment and repurchase of 2021 Notes and financing fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(429,000)<span></span>
</td>
<td class="num">(16,606,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,884,000)<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,318,000)<span></span>
</td>
<td class="num">(3,850,000)<span></span>
</td>
<td class="num">(1,851,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash provided by (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131,541,000<span></span>
</td>
<td class="num">(29,548,000)<span></span>
</td>
<td class="num">(11,862,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(657,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(139,784,000)<span></span>
</td>
<td class="num">(6,639,000)<span></span>
</td>
<td class="nump">233,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">354,942,000<span></span>
</td>
<td class="nump">361,581,000<span></span>
</td>
<td class="nump">128,531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 215,158,000<span></span>
</td>
<td class="nump">$ 354,942,000<span></span>
</td>
<td class="nump">$ 361,581,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInTaxReceivableAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Tax Receivable Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInTaxReceivableAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776503792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee-for-service (&#8220;FFS&#8221;) reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $188.2 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776584512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.  See note 8 for additional discussion regarding accounts receivable and allowances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December&#160;31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December&#160;31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a">three</span> or four-year period and stock options expire 10 years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss per Common Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for further discussion regarding fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770641232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770641360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#8217;s consolidated financial statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of December 31, 2022, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total acquisition consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The acquisition consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the Vital Decisions acquisition as the impact to the Company&#8217;s consolidated financial statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776731920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,733&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million and $13.6&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774056592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:226.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $49.6 million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 76%, 93% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $36.3&#160;million and $28.3&#160;million for the years ended December 31, 2022 and 2021, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $3.4 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $3.0 million, $1.9 million and $1.9 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Evolent Health Services segment, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $14.1 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $20.1 million, $11.1 million and $13.0 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div>These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770612928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2022,&#160;67% were current, 21%&#160;were past due less than 60 days, with 29% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;December&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$269.1 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$10.2 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628858968208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $29.5 million, $22.5 million and $24.6 million for the years ended December 31, 2022, 2021 and 2020, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $73.7 million and $71.2 million as of December&#160;31, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $32.0 million, $30.6 million and $28.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $27.0 million, $26.5 million and $24.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776534224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#8217;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate.  Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#8217;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2022. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $35.2 million, $29.4 million and $32.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, excluding $0.2&#160;million and $0.6&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2022 that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776814464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the IPG Closing Date, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2022 Initial Term Facility, with an aggregate principal amount of $175.0&#160;million and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the 2022 Initial Term Loan Facility, the &#8220;Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the 2022 Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $7.9&#160;million in interest expense related to our 2022 Credit Agreement for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $5.3&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.4&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $2.7 million,  $4.1 million and $1.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.6 million, $7.9 million and $2.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $7.6&#160;million and $2.6&#160;million for the years ended December 31, 2021 and 2020, respectively,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2019 Initial Term Loan Facility, with an aggregate principal amount of $75.0 million and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the 2019 Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the 2019 Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $1.3 million, $10.0 million and $9.2 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $9.5&#160;million and $8.8&#160;million for the years ended December 31, 2021 and 2020, respectively,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628858954064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of December&#160;31, 2022 and 2021, respectively. The letters of credit have current expiration dates between January 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2022, 2021 and 2020,  respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of December&#160;31, 2022, there are no outstanding amounts under this reinsurance agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers. Expense associated with the UPMC Reseller Agreement for the years ended December 31, 2022, 2021 and 2020 was $1.2&#160;million, $2.4&#160;million and $4.7&#160;million, respectively, and is in wind-down. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $46.0&#160;million as of December&#160;31, 2022, which represents 85% of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the TRA-related deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the TRA may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation was granted final approval at hearing on November 18, 2022. The agreed-upon settlement payment of $23.5&#160;million was funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we did not incur a significant net loss or cash outflow as a result of the settlement of this matter. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2022, approximately 99.6% of our $215.2 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million and 117.4&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately  9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628858968208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022 and 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.316%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776935504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770568672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 and 2015 Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#8220;2015 Plan&#8221;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1&#160;million of the Company&#8217;s common stock. As of December&#160;31, 2022 and 2021, 4.8 million stock options and 3.8 million shares of restricted stock have been awarded, net of forfeitures, under the 2011 Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company&#8217;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018 and April 15, 2021, to increase the number of shares authorized to 10.5 million and 15.4 million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2022, 2.8 million of stock options, 5.5 million RSUs, 1.4 million LSUs and 0.8 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan. As of December 31, 2021, 2.8 million stock options, 4.5 million RSUs and 1.1 million LSUs and 0.3 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"/><td style="width:393.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"/><td style="width:283.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options vested during the years ended December 31, 2022, 2021 and 2020, was $2.6 million, $4.9 million and $3.6 million, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was $16.3 million, $20.8 million and $2.2 million, respectively. We issue new shares to satisfy option exercises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock option awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company granted approximately 0.3&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to market-based vesting, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $13.35 per share for a consecutive ninety day period;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $16.43 per share for a consecutive ninety day period; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $19.51 per share for a consecutive ninety day period.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">50% of the shares subject to the option award vested on March 1, 2019, and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">50% of the shares subject to the option award vested on March 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTc_a570a6ad-3bd2-47aa-b3bf-a2a19da0786d">three</span> or four-year graded service vesting period where 25% of the award vests after each year of service or a three-year graded service vesting period where 33% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:412.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we granted RSUs with a weighted-average grant date fair value of $28.23, $21.10 and $8.88, respectively, which represents the weighted-average closing price of our common stock on the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $11.6&#160;million, $7.3&#160;million and $6.1&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraged Stock Unit Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company granted 0.5&#160;million and 0.7&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is or was subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 33.3%, 75% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 50%, 100% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 100%, 150% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares awarded during fiscal 2022 include 0.3&#160;million additional shares awarded for the final achievement of the 2019 leveraged stock unit awards which was certified in the first quarter of fiscal 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based RSUs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted 0.3&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwMDg1_e95feb79-e657-48b8-946d-eecdc5e29c31">two</span> and three-year cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 200% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwODYz_60171b02-aaa9-4bbe-95cb-bb9bb4968182">two</span> and three-year cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted  if TSR performance is in the bottom quartile and will be adjusted +10% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the two performance periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022, the Company granted 0.5&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A three-year cliff vesting was approved and began on January 1, 2022. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of company value. Per the agreements, company value is calculated using a formula based on revenue growth and cumulative Adjusted EBITDA, as adjusted for any acquired business during the period. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 250% of the targeted shares are earned. If the company value falls between tiers on the sliding scale, the actual company value payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"/><td style="width:280.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628775726992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $(43.4)&#160;million, $0.5&#160;million, and $(2.4)&#160;million was recognized for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,055)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,719)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:370.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,380)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,376)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible excess compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,810)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:2.94pt">Amounts charged  to other accounts includes $17.3&#160;million charged to shareholders&#8217; equity and $0.1&#160;million charged to discontinued operations for the year ended December 31, 2022 and $1.8&#160;million charged to discontinued operations for the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2022, the effective tax rate was 69.9% and the corresponding tax benefit recorded was $43.4&#160;million. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded by the company in 2022 primarily relates to the $46.8&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the effective tax rate was (1.6)% and the corresponding tax expense recorded was $0.5&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#8217;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the effective tax rate was 0.7% and the corresponding tax benefit recorded was $2.4&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying back New Century Health&#8217;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, did not have a significant impact on the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $186.9&#160;million of federal and $301.8&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2023, respectively, and $295.5&#160;million federal and $245.0&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#8217;s ability to utilize NOLs and could cause U.S. federal and state income taxes to be due sooner than if no such limitations applied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $2.1&#160;million and $0.3&#160;million of research and development credits for federal and state income tax purposes, respectively, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a partial valuation allowance against those credits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the President signed into law the Inflation Reduction Act of 2022 which contained provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks, both of which we expect to be immaterial to our financial results, financial position and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:402.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in various jurisdictions in the U.S., India and the Philippines. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2022, are $0.6&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#8217;s valuation allowance. The Company has recognized $0.3&#160;million of interest and penalties related to uncertain tax positions as a component of income tax expense for the year ended December 31, 2022. The Company recognized no interest and penalties related to uncertain tax positions for the year ended December 31, 2021. The Company has accrued interest and penalties related to uncertain tax positions of $0.4&#160;million and $0.0&#160;million as of December 31, 2022 and 2021, respectively.  The Company had recognized $1.6&#160;million of uncertain tax positions as of December&#160;31, 2022, and $0.6&#160;million as of December&#160;31, 2021. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#8217;s tangible and intangible assets. These increases in tax basis increase our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. The Company has recorded a partial TRA liability of $46.0&#160;million as of December&#160;31, 2022.</span></div>We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated. See Note 11 for additional discussion of the implications of the TRA.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628858165536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $7.4&#160;million, $5.4&#160;million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in contributions to the 401(k) plan for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total contributions for the year ended December 31, 2020, are net of $0.2&#160;million from discontinued operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628858968208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $4.6 million,  $13.2 million and $10.0 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $16.9 million,  $15.9 million and $192.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776841232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.85% - 10.01%</span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774196752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:367.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770588768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.902%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776843072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision for) benefit from income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on extinguishment/repayment of debt, net, goodwill impairment, gain from equity method investees, loss on disposal of assets, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs and loss from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,022)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,981)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $0.5&#160;million and $6.8&#160;million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776760096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565,809)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,346)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776592304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Results of Operations (unaudited)</a></td>
<td class="text">Quarterly Results of Operations (unaudited)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,310</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,855</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,349)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,125)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,349)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,728</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,700)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI https://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776498080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776630848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIA Purchase and Ares Debt Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023 (the &#8220;Closing Date&#8221;), Evolent Health, Inc. (the &#8220;Company&#8221;) consummated the transactions (the &#8220;Closing&#8221;) contemplated by the previously announced Stock and Asset Purchase Agreement (the &#8220;Magellan Purchase Agreement&#8221;), dated November 17, 2022, by and among the Company, Evolent Health LLC (&#8220;EVH LLC&#8221;), Magellan Health, Inc. (&#8220;Magellan Parent&#8221;), and Magellan Healthcare, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on the Closing Date, we entered into Amendment No. 1 to the Credit Agreement, dated as of August 1, 2022, by and between the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company, as the Parent, each other Guarantor party thereto, Ares, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent (the &#8220;Existing Credit Agreement&#8221;; the Existing Credit Agreement, as amended by Amendment No. 1, the &#8220;Credit Agreement&#8221;) that provided us with new secured debt financing in the form of (i) additional commitments under our existing asset-based revolving credit facility in an aggregate principal amount equal to $25.0&#160;million (the &#8220;Priority ABL Incremental Facility&#8221;), and (ii) additional commitments under our existing term loan facility in an aggregate principal amount equal to $240.0&#160;million (the &#8220;Term Loan Incremental Facility&#8221; and together with the Priority ABL Incremental Facility, the &#8220;Acquisition Facilities&#8221;), and effected certain amendments to the Existing Credit Agreement. On the Closing Date, we borrowed $25.0&#160;million under the Priority ABL Incremental Facility and $240.0&#160;million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable at Closing and pay transaction fees and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All loans under the Credit Agreement (including loans under the Acquisition Facilities and loans outstanding under the Existing Credit Agreement) (collectively, the &#8220;Loans&#8221;) will mature on the date that is the earliest of (a) the sixth anniversary of the Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. We have paid closing fees equal to 3.00% of the aggregate commitments provided in respect of the Acquisition Facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Agreement may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Acquisition Facilities are subject to the same security and guarantee arrangements and affirmative and negative covenants, mandatory prepayment provisions and events of default as loans outstanding under the Existing Credit Agreement, in each case, subject to certain modifications agreed by the parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Magellan Purchase Agreement and at Closing, EVH LLC acquired all of the issued and outstanding shares of capital stock of National Imaging Associates, Inc. as well as certain assets held by Magellan Parent and/or certain of its subsidiaries that were used in the Magellan Specialty Health Division. At Closing, EVH LLC paid cash consideration to Magellan Parent and certain of its affiliates of approximately $386.7&#160;million (which is subject to certain post-Closing adjustments) and issued 8,474,576 shares of the Company&#8217;s Class A Common Stock (&#8220;Magellan Class A Shares&#8221;) to Magellan Parent. Pursuant to Amendment No. 1 and the Securities Purchase Agreement, Ares and certain of its affiliates, who, along with certain of their affiliates, are currently lenders and agents under our Existing Credit Agreement, have provided funds used in the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pro forma financial information has not been presented for the NIA acquisition as the initial accounting for this business combination is incomplete as of the filing date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumulative Series A Convertible Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company&#8217;s newly created Series A Preferred Stock, par value $0.01 per share, at a purchase price of $960.00 per share, resulting in total gross proceeds to the Company of $168.0&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#8217;s Class A common stock, par value $0.01 per share (the &#8220;Class A Common Stock&#8221;) and all future series of the Company&#8217;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000 per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#8217;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such change of control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Existing Credit Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders  (the &#8220;Ares Registration Rights Agreement&#8221;), which granted certain registration rights to Ares in respect of the shares of the Company&#8217;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment of Contingent Consideration</span></div>Subsequent to December 31, 2022, the Company satisfied its contingent consideration obligation for the periods ended December 31, 2022. As a result, it made cash payments of $0.3&#160;million and issued 849,716 shares of its Class A Common Stock with a fair value of $26.5&#160;million. See Note 4 and Note 18 for additional information regarding the IPG acquisition and the fair value determination of the IPG earn-out consideration.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628769797088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care </span></div>management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Restricted Investments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.  See note 8 for additional discussion regarding accounts receivable and allowances.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Software Development Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments and Impairment of Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div>The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div>Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December&#160;31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December&#160;31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, general and administrative expenses</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a">three</span> or four-year period and stock options expire 10 years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax </span></div>exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss per Common Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div>Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774554800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text">The following summarizes the estimated useful lives by asset classification:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776764272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Allocation of Purchase Price</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776568576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,733&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million and $13.6&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4&#160;million for the years ended December 31, 2021 and 2020, respectively.</span></div>Cash flows related to the True Health business were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772256384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:226.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776788496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Changes in Allowance for Accounts Receivable</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770515952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">The following summarizes the estimated useful lives by asset classification:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628775771232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,726&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776760096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2022 and December 31, 2021 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776565344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million and 117.4&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately  9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770746144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Primary Office Leases and Maturity of Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.316%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773280880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628759135072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Compensation Related Costs, Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule Of Unrecognized Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"/><td style="width:393.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Option Price Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"/><td style="width:283.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Performance-Based Stock Option Awards Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Units Information</a></td>
<td class="text">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:412.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Leveraged Stock Units Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock', window );">Schedule of Price Assumptions for Performance Based Stock Units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule Of Information Of Performance Based Stock Units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"/><td style="width:280.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628769586736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Provision for Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,055)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,719)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:370.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,380)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,376)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the U.S. Statutory Tax Rate to our Effective Tax Rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible excess compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,810)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:2.94pt">Amounts charged  to other accounts includes $17.3&#160;million charged to shareholders&#8217; equity and $0.1&#160;million charged to discontinued operations for the year ended December 31, 2022 and $1.8&#160;million charged to discontinued operations for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Changes in Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:402.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776601184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets and Liabilities on Recurring Basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration Measured at Fair Value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Valuation Techniques and Significant Unobservable Inputs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.85% - 10.01%</span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776604320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:367.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776760096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Costs Associated with the Repositioning Plan</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.902%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628759188944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Schedule of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,022)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Adjusted EBITDA to Net Loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,981)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $0.5&#160;million and $6.8&#160;million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776498080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Activity in Claims Reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565,809)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,346)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776604320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Unaudited consolidated quarterly results of operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,310</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,855</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,349)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,125)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,349)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,728</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,700)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776596032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770612928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 188,200<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772539360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,492<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,492<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,466<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,466<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,200<span></span>
</td>
<td class="nump">266,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,958<span></span>
</td>
<td class="nump">88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">215,158<span></span>
</td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,777<span></span>
</td>
<td class="nump">73,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765978400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>reporting_unit </div>
<div>segment </div>
<div>option_to_renew_lease</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Accounts receivable netted against claims payable</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Accounts receivable, net eligible for net basis settlement</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option | option_to_renew_lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772491408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772153040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771993760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628767065104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 859,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 929,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="num">(606,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(251,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,486,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,173,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771515696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Narrative (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,111,000<span></span>
</td>
<td class="nump">$ 49,012,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,376,000)<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="num">$ (2,368,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 9 months 18 days<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 461,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 256,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">$ 130,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="nump">87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,726,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,626,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766862096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Allocation of Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,111<span></span>
</td>
<td class="nump">$ 49,012<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,774<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 256,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">34,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">36,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">195,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">7,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">8,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">48,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">66,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">296,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">23,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766576016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (463)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,700)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="num">$ (463)<span></span>
</td>
<td class="num">$ (7,317)<span></span>
</td>
<td class="num">$ (6,074)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
<td class="nump">117,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
<td class="nump">18,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
<td class="nump">87,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
<td class="nump">18,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
<td class="nump">125,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="num">(7,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes and non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="num">(7,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="num">(6,074)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
<td class="nump">117,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776903776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
<td class="nump">$ 6,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows (used in) provided by investing activities</a></td>
<td class="num">$ (2,494)<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765964432">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,352,013<span></span>
</td>
<td class="nump">$ 907,957<span></span>
</td>
<td class="nump">$ 924,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">407,502<span></span>
</td>
<td class="nump">309,813<span></span>
</td>
<td class="nump">382,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">238,504<span></span>
</td>
<td class="nump">215,236<span></span>
</td>
<td class="nump">236,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,092<span></span>
</td>
<td class="nump">26,358<span></span>
</td>
<td class="nump">68,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141,906<span></span>
</td>
<td class="nump">68,219<span></span>
</td>
<td class="nump">77,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">944,511<span></span>
</td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320,858<span></span>
</td>
<td class="nump">205,833<span></span>
</td>
<td class="nump">274,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431,321<span></span>
</td>
<td class="nump">380,973<span></span>
</td>
<td class="nump">258,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 192,332<span></span>
</td>
<td class="nump">$ 11,338<span></span>
</td>
<td class="nump">$ 9,346<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765938496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 49.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766942400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 246,209<span></span>
</td>
<td class="nump">$ 129,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">5,758<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="nump">16,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="num">(11,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">8,291<span></span>
</td>
<td class="nump">16,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772151968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 23,056<span></span>
</td>
<td class="nump">$ 13,041<span></span>
</td>
<td class="nump">$ 21,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766901264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 269,100<span></span>
</td>
<td class="nump">$ 171,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 10,180<span></span>
</td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771017984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="num">$ (7,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod', window );">IPG acquisition</a></td>
<td class="num">(5,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(2,740)<span></span>
</td>
<td class="num">(2,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Charge-offs</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">6,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">$ (10,180)<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Acquired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766955840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 238,351<span></span>
</td>
<td class="nump">$ 200,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(150,477)<span></span>
</td>
<td class="num">(119,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">87,874<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">26,500<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">30,092<span></span>
</td>
<td class="nump">21,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">189,119<span></span>
</td>
<td class="nump">159,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">73,700<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">29,500<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">$ 24,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 14,926<span></span>
</td>
<td class="nump">$ 15,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770528464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770471632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">296,597<span></span>
</td>
<td class="nump">77,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">722,774<span></span>
</td>
<td class="nump">426,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">214,334<span></span>
</td>
<td class="nump">214,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">214,214<span></span>
</td>
<td class="nump">214,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">211,963<span></span>
</td>
<td class="nump">134,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">296,597<span></span>
</td>
<td class="nump">77,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">$ 508,560<span></span>
</td>
<td class="nump">$ 211,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772170464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 640,510<span></span>
</td>
<td class="nump">$ 442,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">197,726<span></span>
</td>
<td class="nump">162,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">442,784<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 35,200<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 43,600<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,726<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 31,874<span></span>
</td>
<td class="nump">$ 18,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">15 years 9 months 18 days<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 465,019<span></span>
</td>
<td class="nump">$ 311,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">92,760<span></span>
</td>
<td class="nump">72,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 372,259<span></span>
</td>
<td class="nump">$ 238,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 111,822<span></span>
</td>
<td class="nump">$ 87,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">80,255<span></span>
</td>
<td class="nump">73,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 31,567<span></span>
</td>
<td class="nump">$ 14,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 18,851<span></span>
</td>
<td class="nump">$ 16,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 7,017<span></span>
</td>
<td class="nump">$ 8,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772581504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 41,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">35,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">33,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">32,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">30,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">269,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 442,784<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772230432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2022 Credit Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of the debt discount and the issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember', window );">2022 Credit Facilities | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent', window );">Prepayment penalty prior to first anniversary of closing date (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent', window );">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent', window );">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent', window );">Prepayment penalty on or after third anniversary of closing date (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Four, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period One, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Three, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Two, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628762900784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (859,417,000)<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (929,047,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302,000<span></span>
</td>
<td class="nump">18,045,000<span></span>
</td>
<td class="nump">14,780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,192,000<span></span>
</td>
<td class="nump">21,343,000<span></span>
</td>
<td class="nump">4,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,015,000)<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(846,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,486,857,000)<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173,708,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,154,000<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,962,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,281,000<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,800,000<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion issued (in share) | shares</a></td>
<td class="nump">5,394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771965248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2019 Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,269<span></span>
</td>
<td class="nump">$ 7,113<span></span>
</td>
<td class="nump">$ 13,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
<td class="nump">$ 21,343<span></span>
</td>
<td class="nump">$ 4,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770528592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628762004784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (859,417,000)<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (929,047,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302,000<span></span>
</td>
<td class="nump">18,045,000<span></span>
</td>
<td class="nump">14,780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,015,000)<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(846,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,486,857,000)<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173,708,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,154,000<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628761251264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment and repurchase of 2021 Notes and financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="nump">$ 16,606,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">$ 92,800,000<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment and repurchase of 2021 Notes and financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772290928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">$ 23,925,000<span></span>
</td>
<td class="nump">$ 89,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">356,000<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 195,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">168,885,000<span></span>
</td>
<td class="nump">126,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">3,615,000<span></span>
</td>
<td class="nump">46,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 185,546,000<span></span>
</td>
<td class="nump">$ 177,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628762711120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod', window );">Automatic extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension', window );">Automatic extension after each period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,432<span></span>
</td>
<td class="nump">$ 352,585<span></span>
</td>
<td class="nump">$ 319,939<span></span>
</td>
<td class="nump">$ 297,057<span></span>
</td>
<td class="nump">248,358<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid', window );">Percent of tax savings to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,950<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember', window );">UPMC Reseller Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfCustomers', window );">Number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember', window );">Shareholder Class Action Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement payment</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Automatic Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityAutomaticExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Period Before Each Automatic Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771372336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 215,158<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
<td class="nump">117,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PremiumRevenueMember', window );">Premium Revenue | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 117,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember', window );">Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628769555232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>option_to_renew_lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option | option_to_renew_lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770437536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 80,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 32,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 38,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 4,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_GA', window );">GEORGIA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773703744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 8,956<span></span>
</td>
<td class="nump">$ 12,991<span></span>
</td>
<td class="nump">$ 15,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">5,682<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="nump">5,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 14,638<span></span>
</td>
<td class="nump">$ 18,027<span></span>
</td>
<td class="nump">$ 21,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774389536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 10,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">10,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">8,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">8,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">31,692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">80,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">17,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 63,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770515184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.36%<span></span>
</td>
<td class="nump">6.38%<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766452656">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Loss per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,701)<span></span>
</td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="num">$ (328,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(7,317)<span></span>
</td>
<td class="num">(6,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (11,349)<span></span>
</td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
<td class="num">(19,164)<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (11,349)<span></span>
</td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
<td class="num">$ (19,164)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
<td class="num">$ (334,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,699<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,699<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.20)<span></span>
</td>
<td class="num">(0.35)<span></span>
</td>
<td class="num">(3.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20)<span></span>
</td>
<td class="num">(0.44)<span></span>
</td>
<td class="num">(3.94)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $0.5&#160;million and $6.8&#160;million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765937248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">13,147<span></span>
</td>
<td class="nump">16,445<span></span>
</td>
<td class="nump">13,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">2,036<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">9,574<span></span>
</td>
<td class="nump">12,602<span></span>
</td>
<td class="nump">11,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628767026352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Jun. 13, 2018</div></th>
<th class="th"><div>May 01, 2015</div></th>
<th class="th"><div>Sep. 23, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628775874096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 33,981<span></span>
</td>
<td class="nump">$ 16,711<span></span>
</td>
<td class="nump">$ 14,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">29,594<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
<td class="nump">12,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">17,327<span></span>
</td>
<td class="nump">9,606<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">14,308<span></span>
</td>
<td class="nump">2,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="nump">$ 3,297<span></span>
</td>
<td class="nump">$ 3,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628775710912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773708320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Unrecognized Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 64,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">3 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 36,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">1 year 6 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">7 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 27,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">2 years 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628774082160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Options (Details) - Stock options - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772177824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">6.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">13.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">10.40<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">10.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 33,503<span></span>
</td>
<td class="nump">$ 46,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">33,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 32,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771405344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based Stock Option Awards (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,503<span></span>
</td>
<td class="nump">$ 46,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 6.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,730<span></span>
</td>
<td class="nump">$ 5,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Vest on March 1, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Vest on March 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 13.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 16.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | 3rd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628762780128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Total RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited / Canceled (in shares)</a></td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 16.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">28.23<span></span>
</td>
<td class="nump">$ 21.10<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">21.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 22.09<span></span>
</td>
<td class="nump">$ 16.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 3rd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period for vesting</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period for vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | New Century Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Non-Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NewCenturyHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NewCenturyHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evh_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evh_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766873632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Leveraged Stock Units (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">303,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 12.85<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.10%<span></span>
</td>
<td class="nump">51.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">254.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 3rd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 4th Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=evh_TwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=evh_TwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771335600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Leveraged Stock Units Activity (Details) - LSUs - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Leveraged Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Change in achievement</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 9,846<span></span>
</td>
<td class="nump">$ 17,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Leveraged Stock Units (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 9,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771485680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based RSUs (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>performance_period </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold', window );">Performance goal threshold</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned', window );">Maximum performance achieved, percentage of targeted shares earned</a></td>
<td class="nump">250.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile', window );">Percentage adjustment of shares earned, total shareholder return in top quartile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods', window );">Number of performance period | performance_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 28.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod', window );">EBITDA, goal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod', window );">EBITDA, goal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">89.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">77.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Performance Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628771897984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based RSU Activity (Details) - PSUs - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Based Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement', window );">Change in achievement (in shares)</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 20.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">28.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue', window );">Change in achievement (in dollars per share)</a></td>
<td class="nump">23.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">25.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 24.30<span></span>
</td>
<td class="nump">$ 20.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,274<span></span>
</td>
<td class="nump">$ 2,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Performance Based Stock Units (in shares)</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 24.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628759149536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">69.90%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (43,376,000)<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="num">$ (2,368,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance</a></td>
<td class="nump">46,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">1,828,000<span></span>
</td>
<td class="nump">1,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to uncertain tax positions</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to uncertain tax positions</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,624,000<span></span>
</td>
<td class="nump">$ 609,000<span></span>
</td>
<td class="nump">$ 678,000<span></span>
</td>
<td class="nump">$ 753,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders', window );">Amount of tax benefit percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivablesAgreementLiability', window );">TRA liability</a></td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders', window );">Tax receivable agreement, percent of cash savings not paid to shareholders</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member', window );">Periods Prior to June 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 79,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Finite-lived Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Indefinite-lived Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">295,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Finite-lived Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">301,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Indefinite-lived Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 245,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent Of Cash Savings Not Paid To Shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772258944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (66,055)<span></span>
</td>
<td class="num">$ (32,719)<span></span>
</td>
<td class="num">$ (332,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">$ (62,077)<span></span>
</td>
<td class="num">$ (29,801)<span></span>
</td>
<td class="num">$ (330,540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628762777776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (875)<span></span>
</td>
<td class="num">$ (1,469)<span></span>
</td>
<td class="num">$ (2,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense (benefit)</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="num">(1,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">5,055<span></span>
</td>
<td class="num">(5,866)<span></span>
</td>
<td class="num">(38,258)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(2,790)<span></span>
</td>
<td class="num">(4,021)<span></span>
</td>
<td class="num">(9,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="nump">2,357<span></span>
</td>
<td class="num">(10,380)<span></span>
</td>
<td class="num">(48,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Change in valuation allowance</a></td>
<td class="num">(47,964)<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
<td class="nump">47,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense (benefit)</a></td>
<td class="num">$ (43,376)<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="num">$ (2,368)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773667296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. state income taxes, net of U.S. federal tax benefit</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings at other than U.S. rates</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">77.30%<span></span>
</td>
<td class="num">(33.10%)<span></span>
</td>
<td class="num">(14.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent', window );">Benefit of net operating loss carryback provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible goodwill impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent', window );">Non-deductible excess compensation</a></td>
<td class="num">(27.80%)<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Excess tax benefits (shortfalls) on stock-based compensation</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Convertible debt extinguishment</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent', window );">Nondeductible transaction costs</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in state rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent', window );">Return to provision</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException', window );">Change in indefinite reinvestment assertion for domestic subsidiaries</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax sharing settlement</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement', window );">Tax receivable agreement</a></td>
<td class="num">(9.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">69.90%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Cost, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Receivable Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765813568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DeferredTaxAssetsStartupandOrganizationalCosts', window );">Start-up and organizational costs</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Goodwill</a></td>
<td class="nump">12,281<span></span>
</td>
<td class="nump">18,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset', window );">Operating lease liabilities</a></td>
<td class="nump">16,362<span></span>
</td>
<td class="nump">15,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">9,326<span></span>
</td>
<td class="nump">10,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">8,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">131,317<span></span>
</td>
<td class="nump">130,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest deduction limitation</a></td>
<td class="nump">7,089<span></span>
</td>
<td class="nump">7,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DeferredTaxAssetOutsideBasisDifferences', window );">Outside basis differences</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">9,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">187,270<span></span>
</td>
<td class="nump">205,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(70,790)<span></span>
</td>
<td class="num">(101,345)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">116,480<span></span>
</td>
<td class="nump">104,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware', window );">Internally developed software costs</a></td>
<td class="nump">11,173<span></span>
</td>
<td class="nump">12,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">89,784<span></span>
</td>
<td class="nump">48,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets - Operating</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">12,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Contract fulfillment costs</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="nump">8,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">5,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">120,290<span></span>
</td>
<td class="nump">104,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (3,810)<span></span>
</td>
<td class="num">$ (658)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetOutsideBasisDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Outside Basis Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetOutsideBasisDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetsStartupandOrganizationalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start-up and Organizational Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetsStartupandOrganizationalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766456736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning-of-year</a></td>
<td class="nump">$ 101,345<span></span>
</td>
<td class="nump">$ 89,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (credited) to costs and expenses</a></td>
<td class="num">(47,964)<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (credited) to other accounts</a></td>
<td class="nump">17,409<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end-of-year</a></td>
<td class="nump">70,790<span></span>
</td>
<td class="nump">101,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (credited) to other accounts</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (credited) to other accounts</a></td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770761952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes In Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning-of-year</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases - tax positions in prior period</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases - tax positions in current period</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end-of-year</a></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766463632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773730240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">$ 4,569<span></span>
</td>
<td class="nump">$ 13,179<span></span>
</td>
<td class="nump">$ 10,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement', window );">Revenue related to services agreements</a></td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="nump">$ 192,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772527520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">78,000<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">78,000<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628765829984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (13,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</a></td>
<td class="text">Unrealized (gain) loss, net<span></span>
</td>
<td class="text">Unrealized (gain) loss, net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gains) losses, net</a></td>
<td class="num">$ (25,700)<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773664976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">77,946<span></span>
</td>
<td class="nump">30,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">0.0985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">0.1001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766997184">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 254,684<span></span>
</td>
<td class="nump">$ 130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,678<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,174<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">111,198<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,787<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">192<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770446640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue</a></td>
<td class="nump">$ 154,591<span></span>
</td>
<td class="nump">$ 45,082<span></span>
</td>
<td class="nump">$ 231,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">128,308<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628767013840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,318<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,391<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772402640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628766540080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,352,013<span></span>
</td>
<td class="nump">$ 907,957<span></span>
</td>
<td class="nump">$ 924,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,331<span></span>
</td>
<td class="nump">66,317<span></span>
</td>
<td class="nump">48,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">407,502<span></span>
</td>
<td class="nump">309,813<span></span>
</td>
<td class="nump">382,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">944,511<span></span>
</td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(869)<span></span>
</td>
<td class="num">(1,814)<span></span>
</td>
<td class="num">(2,774)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,352,013<span></span>
</td>
<td class="nump">907,957<span></span>
</td>
<td class="nump">924,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,575<span></span>
</td>
<td class="nump">99,983<span></span>
</td>
<td class="nump">84,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">408,371<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">385,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,936<span></span>
</td>
<td class="nump">17,063<span></span>
</td>
<td class="nump">57,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">944,511<span></span>
</td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,639<span></span>
</td>
<td class="nump">82,920<span></span>
</td>
<td class="nump">26,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (30,244)<span></span>
</td>
<td class="num">$ (33,666)<span></span>
</td>
<td class="num">$ (36,022)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628767078768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,164,000)<span></span>
</td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">2,633,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,572,000)<span></span>
</td>
<td class="num">(25,425,000)<span></span>
</td>
<td class="num">(28,325,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from (provision for) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,376,000<span></span>
</td>
<td class="num">(483,000)<span></span>
</td>
<td class="nump">2,368,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,195,000)<span></span>
</td>
<td class="num">(60,037,000)<span></span>
</td>
<td class="num">(60,835,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(47,133,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,938,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,950,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,192,000)<span></span>
</td>
<td class="num">(21,343,000)<span></span>
</td>
<td class="num">(4,789,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,569,000<span></span>
</td>
<td class="nump">13,179,000<span></span>
</td>
<td class="nump">10,039,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(698,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522,000<span></span>
</td>
<td class="num">(13,281,000)<span></span>
</td>
<td class="num">(3,860,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="num">(146,000)<span></span>
</td>
<td class="num">(118,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,318,000)<span></span>
</td>
<td class="num">(1,275,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,981,000)<span></span>
</td>
<td class="num">(16,711,000)<span></span>
</td>
<td class="num">(14,606,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,265,000)<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="num">(8,986,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,000)<span></span>
</td>
<td class="num">(476,000)<span></span>
</td>
<td class="num">(3,944,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,513,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,671,000)<span></span>
</td>
<td class="num">(4,194,000)<span></span>
</td>
<td class="num">(2,116,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (463,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,700,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,383,000<span></span>
</td>
<td class="num">(463,000)<span></span>
</td>
<td class="num">(7,317,000)<span></span>
</td>
<td class="num">(6,074,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,331,000<span></span>
</td>
<td class="nump">66,317,000<span></span>
</td>
<td class="nump">$ 48,573,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">(Loss) gain on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500,000)<span></span>
</td>
<td class="num">$ (6,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loss from discontinued operations, net of tax<span></span>
</td>
<td class="text">Loss from discontinued operations, net of tax<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628772198528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">$ 171,294<span></span>
</td>
<td class="nump">$ 178,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">605,757<span></span>
</td>
<td class="nump">457,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(11,512)<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="nump">594,245<span></span>
</td>
<td class="nump">464,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="num">(427,994)<span></span>
</td>
<td class="num">(346,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(137,815)<span></span>
</td>
<td class="num">(125,619)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(565,809)<span></span>
</td>
<td class="num">(472,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">199,730<span></span>
</td>
<td class="nump">171,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">25,618<span></span>
</td>
<td class="nump">56,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(8,176)<span></span>
</td>
<td class="nump">7,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="num">(8,176)<span></span>
</td>
<td class="nump">15,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(12,911)<span></span>
</td>
<td class="num">(25,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(12,911)<span></span>
</td>
<td class="num">(46,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">4,531<span></span>
</td>
<td class="nump">25,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">145,676<span></span>
</td>
<td class="nump">122,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">605,757<span></span>
</td>
<td class="nump">449,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(3,336)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="nump">602,421<span></span>
</td>
<td class="nump">449,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="num">(427,994)<span></span>
</td>
<td class="num">(326,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(124,904)<span></span>
</td>
<td class="num">(100,075)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(552,898)<span></span>
</td>
<td class="num">(426,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">$ 195,199<span></span>
</td>
<td class="nump">$ 145,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628770483680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 382,432<span></span>
</td>
<td class="nump">$ 352,585<span></span>
</td>
<td class="nump">$ 319,939<span></span>
</td>
<td class="nump">$ 297,057<span></span>
</td>
<td class="nump">$ 248,358<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">384,310<span></span>
</td>
<td class="nump">339,634<span></span>
</td>
<td class="nump">324,572<span></span>
</td>
<td class="nump">299,855<span></span>
</td>
<td class="nump">260,572<span></span>
</td>
<td class="nump">229,052<span></span>
</td>
<td class="nump">229,728<span></span>
</td>
<td class="nump">231,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(11,349)<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="num">(4,125)<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(11,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="num">$ (463)<span></span>
</td>
<td class="num">$ (7,317)<span></span>
</td>
<td class="num">$ (6,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc - Basic</a></td>
<td class="num">(11,349)<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="num">(4,588)<span></span>
</td>
<td class="num">(5,350)<span></span>
</td>
<td class="num">(5,647)<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
<td class="num">(19,164)<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="num">$ (11,349)<span></span>
</td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (5,350)<span></span>
</td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
<td class="num">$ (19,164)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
<td class="num">$ (334,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="num">(0.11)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.20)<span></span>
</td>
<td class="num">(0.35)<span></span>
</td>
<td class="num">(3.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628773383552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment', window );">Increase/decrease to goodwill from measurement period adjustments/business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrued deferred financing costs</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainLossFromTransferOfMembership', window );">Gain from transfer of membership</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,969)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Class A common stock issued in connection with business combinations</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="nump">56,626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedInConnectionWithDebtRepayment', window );">Class A common stock issued in connection with debt repayment</a></td>
<td class="nump">101,999<span></span>
</td>
<td class="nump">28,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Consideration for asset acquisition or business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Accrued net working capital adjustment with business combinations</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">14,087<span></span>
</td>
<td class="nump">13,845<span></span>
</td>
<td class="nump">13,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="nump">4,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,583)<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,269<span></span>
</td>
<td class="nump">7,113<span></span>
</td>
<td class="nump">13,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes, net</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 9,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossFromTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) from Transfer of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossFromTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Measurement Period Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedInConnectionWithDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued in Connection with Debt Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedInConnectionWithDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628760588112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2023 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>day </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,111<span></span>
</td>
<td class="nump">$ 49,012<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | National Imaging Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">$ 386,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares) | shares</a></td>
<td class="nump">8,474,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payment for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate', window );">Annual increase in dividend rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series A Preferred Stock | Prior to January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series A Preferred Stock | After January 20, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series A Preferred Stock | Prior to January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series A Preferred Stock | After January 20, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockRedemptionPricePercentage', window );">Redemption price percentage</a></td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Class A Common Stock | IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Securities Purchase Agreement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 960.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember', window );">Secured Overnight Financing Rate (SOFR) | Subsequent event | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PreferredStockVariableDividendRateBasisSpread', window );">Percentage of preferred dividends in arrears</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent', window );">Prepayment penalty prior to first anniversary of closing date (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent', window );">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent', window );">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent', window );">Prepayment penalty on or after third anniversary of closing date (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR) | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Base Rate | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of offering costs</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Base Rate | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Four, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period One, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Three, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Two, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Dividend Rate, Percentage, Annual Increase In Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Redemption Price Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockVariableDividendRateBasisSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Variable Dividend Rate, Basis Spread</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockVariableDividendRateBasisSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NationalImagingAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PreferredStockRedemptionPeriodAxis=evh_PreferredStockRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evh_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evh_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139628776824464">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2016-03 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>evh-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:evh="http://www.evolenthealth.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20221231.xsd" xlink:type="simple"/>
    <context id="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59d672079722445e9903492553b719cd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id530a61ad22641e08d98ced8a800ffda_I20230216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="i7de54fc5bc4847faa175a8ac09179032_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32b6870c04cf45a7a22f92062187c8b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b766a37ca0b47ffb3be346f3d8b2a47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibff2679b53d74ef7bc24df5385a2e916_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc16408fdc2f457ca9bf96a6ff0288e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if70bbd87e6c7400684ed1f05186aab79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i211392e628d14c2bb3d3202fadd1e955_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77788cda88584bada7bf9ba9c37f88e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5f26637675c489a938b4dd3e4068e67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc5cc544a61241c5b8328c4af50e52ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e0069b2782a4a49ab67a323fb9055aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if29a022394774916af9c2f4fb440db9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0dbc8526caa04360a8f7a3aad7061a5e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i173c4f55d1a74452b5e44d2cab35ebd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f9268d85098487aa9053456186fe226_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b29db4886614e8cb747051097d57a16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic335aec702854b39aad8f2e5e220ae6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9a7173b3e1d4ea0bf04dd1bbb81c077_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09bbf0d725dd45f3a6c123d36bd2715b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i676d4e2a769c4bd1825c4e7a238270d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i504d5250f6a74571832f036561396187_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16d6a2705b50479eb89edc0845501b62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dcebc8005994a85ac2c4f44251b586b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ecd37c0c42545c0976d2fd1ee487164_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a9e09aed0674d2184d736359fae1f7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d183758c28e42748ea9f0baf38ea61b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c369d6b43ba4b62913e4007fef79e83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i006a422e447e45a4a9b4c1c667093316_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5547116dd92544ff88c29dc8b9b6fe3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a03703f143645bf9ba9043225c49c63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ce95dfdb9b847c5b2476842c531da54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97488e48877b4c0f9463a34a496911e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iace02407fa42475e9b151a58bea5b3d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2738bd3890c14cba841e976265d057fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3a355f9a909459691e4f7374ba9cd65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67118d2408f84f85a9231fcddea5a5e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72141e7136894e7394a041ed0f2a15d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f12b36b156e4f77b72612737e0e8773_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ec9777d918a483895645ef1f407025e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48a51239b501447b911a29ce59ff5506_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7972290d242a4362ba5061064cb35fb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23bab8ce4c244fd1b411ed8b2d13efb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8ebc0071f484c15a790e6c754033f5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6682920acd2443d386cf76a82976b820_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic09286a182824949b042732ea31cdf80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if04d6ce7269d40dab417987869d2650e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14887938c6954e6aa3b47e2ee7ab8115_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71cc310322b745e4b90c41075da7866b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a701948765942b1893beaaa2e66fdd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad4400bacf8149dbb4b6b9e8edb38886_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f4972904db74d38b50bc19776ed0515_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie65bd9571ab84a89b67a22db31fb6851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2acaca954cda497b8eedaf35072199d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2dea7b844271441593c0a803a0bbe671_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i854900308f794ba998ae7299645ae028_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if29b4590881941c2b0537c0cb5530ec2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id90606a7074b43028a72787dec08a3dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i794b0726c989443ab36cb30e95208a59_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6dac60b49c3a4ba89b21c18a1a14925a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d654080ecda47ef9c7d0a2e2dfbaaf3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f2eaceac28d48bb9ab95b4c5c5c71ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib36ebf6b661340eb9375f2171ebfae85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63d23082543b457b9daa2ffcb02ded0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec00374a180d419c962d3b3783c65443_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3cc2e5de7bd4ce6ba6f437a0abdf186_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i11dc640ba4864bd9ab71ea3a5d03e0ce_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i3474707099524f5ab5cb8bcdef64f129_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i278ee21fa4de4432b9d32268373e0d51_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i521ab45bcc9f4828b98cbd32c8324834_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="id2c918a773654828be4d267be661bf92_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ic6e6da47331f49339af7c848e28837a7_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i731418333b3f457db87705a22ef20938_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="ied844aa0a1054ee8a864d50320d0ae98_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i20beaec13c36498a8bc039958c7e54dd_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i251ae7d7cad040829c7cc296314ee7a5_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i0f82a39ee182494c9861025f94b259b3_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i6f5790c27f32404bbca49e84b9b60f2d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifed01c1956424fc8b203762b2f8ad778_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ice2addc7fc4c404ba9808eca26ad7144_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i1ba8025aa2b5405cbb56eb40f35c59c9_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i4adfad20cf7f4a50ab8f54cce2eb1c05_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ia9e5d9baadc74708b8555d95b779a6b4_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaee36e9557da420a9bad4cb01fb7b743_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic49894ecf0ce44d6aa77bc0c1e9552b6_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibd3d798217ac414cb2080eebc4cbe42e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b848b407c6a43a98ee8f6b9437139c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i299f85d0abd44211ba11ded9b436d161_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b6a62a817d1416b9bad705a714c025f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id27c2948c6044f07921f59caf0304963_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1705bda8a114733924cb513d21573c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9eb70847d04443d8b6e7ab48773cde8d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08a6dbe2c6f2414b90261c99c16aa440_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c5bff01d6db40d49a991496b0df8d88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia342dc91eb1f44d4a17bc2df78ae5230_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb97d6ee9d56404985bda4f9b13e5846_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcffd9facc4645f4a013b7bdbb72a431_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6a2bb61dae04616b359eba263ce435c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74d8936f21714f009331932a8897b732_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c3548808ff348918ed362fd31f8088d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ee490b62ac543baa9936f426d939efb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if60d893faa2748b58fedd3523e6ec66c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab057b320374485bb2001c40a00ce836_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab12224f7bf840829d0a888e32c3dded_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i70b27104772b4bde9b232264fa371923_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcd90e09efa14e17ad4601baa83a3961_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i356a26303bb54909842ab7a281dbfe38_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbfb19be991146d3a9e26988e59d0c39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i954aacf21ddb4d74a25b5f7fea44da70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9571070c288405895ac0648fd0b1fad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f54db1c05e74787a89c8997e36036e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60221f52e25e439cb996bb69367033a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8a19c81d5714f6d8f22e6db248a7c11_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71c38f21edbe411aa8eb628e23ab4e20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d354e96c97c42cba45e2df7b64eda05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4dd7b111832484390e1d97d1f46453e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ee9e7b57f344206982ad42c4f293487_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i590b14ec27994ed597799e4952a9046f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i934d9414193f4601b5323bf2a681279b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35616843f0a7418d8fc7ad365b3215fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8607bc42763645fbbe43278eec65e305_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c9997d7a05d4993962ccc3338c361fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77bd19d50e3f457ba4098eb4c0c152d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8388c7551f94e269587ab5aac659a6d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie3355e9dfc324571bb9fba8d6e2175e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b29b57edf8c489f99a4516a6ca5a0b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81cd6e53eeb5464e80084e5f32636562_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11c2ab305dbd45518a81ed1d65fe5dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic71ceeb3c88542a5b9fb0b508980035b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28121c511dcf46e8aeb20910dbcc12be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i483d3e1f905c4cde909281c7434e61aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7248538c4a04c15bcc464cd4c0426fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i746f0154926c44cc9b1f8fa00aebd8f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69c5eb57b4454e3b9de4de900fd38726_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib00357009ca34124aea7882662570449_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie56205dd981748ccb2ada978c977bd74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6fe725ce94f4628b487593ab6df6f26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4c0a14df2764899b90a8c02978cddda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i237b041a348240acacdd4c6703d9631c_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2836cea2fd340c28f57a47a9edab8d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb588c9720747cb8e17ec8afc367996_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33ea7981a58e4cf1bb90015e38b89007_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a58b613f9cd47b2bef946da4ceb3f68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ee356487cda493a86e8c0ec69db8b59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b6ad6302d9d4822b4677702de0baca6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85dc77e96282486ab64329e19f4f8975_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9b789e0f0774de2bb35c5e8066ddbdd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i488bd1b5b44642adb4bec38ca437c356_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f170a61f3e841a696fad5b6a3b357d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67a13a56d549482ea13997a959c85f3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5277c572ae949a594d492c3ef91a577_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e29b5293f19416f96f6460860735e67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6669bf057ca644eebe6dffc37bb4b27d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48beabe4144b40898879179f114601ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a310b65ac104a1b98bfe8cb95002a92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2cc46062bad34e1d9ad09e26a1395bd2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb2ad760c97e421385f5a9e39aaac544_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ee5d4ede71548928f9a624468ad3e3b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied9c6f919ebe4066b86bae9e616abcfd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieeedc3e2c6d34ca9b04f0eed321027af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a3d5be6458143d680d969951cb1b604_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i316c2f9226f948c7a4f01201f54acc48_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i63f12ae346f44c719a6800ae9ccbebab_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i2b8033c2ed5c404898e4b63272e9b227_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i4c87170725f741bb95ab4f861ab14a5f_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i332b999bfd9a41b4b40e9a3798d29b87_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i94c23219c9604a849ec11f326a2fa715_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i7d73991f5a114e408f7f6580f4dd0c39_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i307390bb8f1941719453c9b89db584f1_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i1bf042bd30a44a15975073db664b70be_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ide70b505dfd6454e9ffca84126ff1890_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i01455d65a30b4de88519c6a15c185622_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i0d1f72876d42429a99ca22c58f5f1ecc_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i1c958236f3a54e838f8aa587bb9a8d31_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i1619fddb91d54d6f96208efd4dce37f6_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie0ae7d691d994f36bcd8595faf8c39ee_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if764124a6770471488243909ab9e256d_D20220811-20220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="i7fb6b9ecd1444687b8479680f813d784_D20220817-20220818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="i8a7bc6c0f93045b9ad4a49e3466404b9_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i3d60561640304c998ba5ee229f359173_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i2804de286fbc48f587c48f683cfa4074_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i140bd5a200d14de591a2f882386a3910_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i84ec033ba9234eb488e9598b782c6c15_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i0b374313017e499e85ef4cf594469720_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i21455ed9e898487f8740230211473db0_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i2a685a81d42142c896e77b4bc4ca525a_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="i6c6f6a273d2b4dbda2d60fcdb292d567_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bef66f774044af386b81c078514f9bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i70f4dfb899054fdfbad69a92f3ebee35_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ie2a2bfbe33214fceb0357343f7b7e72b_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i6bd78b743e5442379fb00d3420537154_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie69ff65edc314e66af837b40573b525f_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i6aef6137413544e2a1fd7506ce233492_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="if5650df78c4e4f098ea12cdc3e6d079f_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="iebd374c7c4724e05ac999f332b4ab82e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadf6fc0014354fbe9758d2279614f394_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04f5b6436bc448ddb51d297c0f42e141_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6001ba8bbed04b7a829551c60b521a2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2edea02961a848e792c082a2d78f7be9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf2bca88869d4c9795e3e92b114eabad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88b3ec5f2a0940ddba506d2e9a3d8c0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d4776fc60e442c0948db94fbd3d4085_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5906257debf420b8d9e2c9abfb9ca3d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i94980624d2f94f11863369dc8080f610_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i0bb561ac225443dbaff96dea400e900b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6788632dc8e44b589e517a3e62e51f4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01dda4dd7b24edd859959507bf961ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f551ff8e8ba4ff3beb6c4b903203199_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8421b42e39084ee89ac6a78c380b126b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ea705e860864044aca57384b2588af0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9e0a630ce154bf89c611d1821c71553_D20220802-20220802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="i05d330e617a348658676375fec5a5db0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic09667045f534fb08afb88b78cd4bffd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19460fef358144489558a7d191e376e1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34c1626a52334b328a1c7519c6d48da1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f194e0613ef4a9eb4ce0f29bc3e59be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47d5358cfd784a34a9c92cf66e6fe24d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5a3c513620354b04ae269dff1b11efc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0971990c3b524dc2ab01bca9e7047db0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b0ca95c4f8d453aa5b952029c52ede5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17f79061242845d39ce24ea7ea1e6531_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37ef3bafc332487fbfffb51f8c73921e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1b1f625f4e94de3bac6f65f975417eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie780f96a5b1646b797b6c069ab760343_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cc10e07863c4eb1a63ee717112c9d0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b43f5864a3c456d988a47acf3b9ce95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84ffe1b4508e486a9edadc82247bd895_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20e84c1fcc7a409eb2d609e87902510a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f31f283eac947978662db9d2181e301_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d9b3ff8bd76404884b782de11442494_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia459503de1114b44a6f26fc10d288f5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2b3426aba894c62ba3dd99da2cf9a73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a933c8c05464474bc7d7b13541a2e90_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if76a99b4e1234159af5825d2a6781f2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a31bc4994b74fc58c2b392809cd688c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf5780125dcb45fbb548a97d1af89fdb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6dd672678d98466986c506543160641f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03c53413574a404b9b955fd4063e9fa2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia29b0fddbc044c099c98a1f8e946e6ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ac01085f2974bffb7e9c05372fce3ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd9999816186400782cf19912fe831e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2fb1199689b9485e9e38c8454c856583_I20130923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-23</instant>
        </period>
    </context>
    <context id="id5b21dc206e94394abb9958199abeb98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb78a01fb022451a868b84564b638dc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fdd473b34824a438f104a82a06cc181_I20150501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-01</instant>
        </period>
    </context>
    <context id="ie49a044638374607bbfbdc97696620c2_I20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-13</instant>
        </period>
    </context>
    <context id="i0e202260e1024d14b21b9a333d1e719e_I20210415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-15</instant>
        </period>
    </context>
    <context id="i65cf289eea9b494d912166499c2914fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia76c5580ffe1407da7f478f22181effd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i490fcda4c6dc4ac48114257dd334a44f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8598bae5e2d4ae6a59a8764c8bc367a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34f5c218d62449f4a45332796fafbe3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i454730d8be0c4135908d533cc24236ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd4ade146df04303ae15516a0f51d6e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i168e32227da54d569993ff509ca28512_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i593745b628164db9ad5c5aee03724e76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a4f0db782744810b86b3de6bffd9661_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide564d56628c4112b1707eb060bf579b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2688027cbefe476297d030d725212d57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23513d63acc84e1d9329774077f86588_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d7c11ea28704ab6b523786a90949ff8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5eab875363854633ac2dc697d7c48c89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15eadbd1e3724998b19a496cc3d2b5aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9f478bf1b114c2694835b3dc5f160fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia818a57c910f43b6b57bb34ff556565f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c1df49b093b4a088aece5a992f943a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i126ccd42807a4cc3b17d8951d96c7aab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bb15940b3a94d76ac5798bef87541cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2258e21bec464cc5ae9efad5062cb9c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i41135afe093644db89a3b87635fe4dc4_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i8ec3a6efe87f4e2c84e6ce6e8641efac_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="if74229af73c04802bcf5f1aad8b9d1d1_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i15ad45c36cfc43c9bc1893539e98ce7f_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i1492a0e32c114c64887521b21cadd182_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i0d882797dafa45e4973fe074ac9e136b_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i80e040acb0b747928e36b0c44713716f_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ic8e9688f5f7d4228b70c0cb904a39028_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i67f870a295164c058463681d0e9d876f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8645daae4ccd401babc69a6cbb852628_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i777ec06acf834f40a1fa728483007e42_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evh:NonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9c9f5bff0894afd93077c2643b31f4a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba9641b95f774ba8a8d7a8d32b4cce92_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5c02b94720e4106be78e0e1359efd32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31d4a953b2504f45a7692ab718621a5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NewCenturyHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27068971ef7e44f082589f349b94a0f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36d4b61188184f9b8043474a605003cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e836072148b4d08a3bb37cfb2e717b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i380305502d0f40bf81987e1a5ae4ab46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">evh:TwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i722177f039a9497595141ed257b0dd95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b9e2e62339c438aa769354df4580b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f26ba9b9cd641d5aec7f9d0359b6769_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i824e8ac2e16d440da74ac31890aacd82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17ac516448fc45b193467cb1ef2df574_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2c16ad239424ec88d83268977b370bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2f84cee7ed64c41ad902dcd77f1d4e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00a909c5b37546d18248f54d9b4a4151_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2de795bc67904a5e85f0decbbd09ab32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i997feae046c54b3a9bf17e3433160784_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id31a88fa387b4e53a12f438b4b3b5bac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief049904d28f460d998a77dd264865b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8dfb8ced52c4e3cb9c781d4c11d94cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84bf075d368e44968b724f9fa95b7960_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib816cd0b1e5246268d85139debf44ec6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2fe137ef9b94b438227de3ce6b602f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6973c687f47242d48d1ab11cc64f5795_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4265c7d21f1d4b838581fca135d6e78c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">evh:PeriodsPriortoJune2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9836acdd1fb436298594c2019552b35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife27a03e76054f2293b5ac1cb4a4010f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if07bcd3c52e24dc1836baafe4f759c78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08ddb5f52bed406dacf7038dcf91f94c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ab25d9d5a634cb59dbe05457f809563_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a8a373598344ec1894589f6195ded59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if17c85faa0f841b99a3b41d10678e6f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d6345c725b74f1185b75d72fe34dc81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i922ff0166d094a94bc7b6cb25be53520_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7077a023068e40ef90f4eafdef2ac9d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa4b399529244e3a9a265bff227a5cba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9511c01ee7c4db793847be4cc362076_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa8ce3db74aa417989fbb9df2f38ad5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaae7be454d7b4ccca01d6d258c44d97f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84e6659721d84a6a93639ba51c8411c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i025995168f8f42fba6c2563b6e8916a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie38cc40fb229457c9241d55acdc35d64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27fa49659d7d4d6f9e976bf660432df5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4619916bbd2482ab8018d375249be03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0251e2b7f89d4de890ab29fd635ae904_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i843d5fcb4df3420485390014398766dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48a4f5ce8e6c44d9b8740ae1f7ba19dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i375cbb6ae8bf4bf4af4ed3910f4e95fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b7bf3dd1e1e42c38fecc74e534c3349_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c76ef785ed6456998aa2837427805d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9903fd78307a4882846df7bd26ed4ca2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2afd02fdc0d43e283e8a6be9bbf3622_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i507c481168c24a8282e6d5446b4557e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91a9aeec0e924002bd91990917dd2807_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83cb6ba27fa047439559a1ce5bdf570e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6af8d3395ca54542b8e581cd46d63e85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ea6990f35a04f21953a710e60c32fb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia138a2f2ee96409fbd2de15262bbc9a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4d2a17bc955412cbbed83c8fa718cf1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc7c08e385554e8cb407ca29ab063d05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d50a01d5910438a928adb7f868c6ed6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16141fafab8e460196d863fb9865d30b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46413fc7149140518ad72598cb806328_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife5cf9a41dc0464dadd48964641367bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i214e73201d094671bbc005a4978f6737_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00104c8c47c0426591c253e73ef11658_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60147b063f994be48a84d5d80558ad21_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i892f30e439ed468c872cd62441fadd53_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00a3b9433a4c407da22c8da144e6159f_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i25bed0d5f05c47d3835d72e78088845d_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i33f01c74be814b40a8b3c55316700bd3_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ia6d4b347f77b40ef82561500db57566f_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ie9a86616c8d74739ae6c3edec5552b03_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="id784014eb86c4d16a227b2b1b8318c54_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NationalImagingAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evh:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i2f63204d749d4153bfe87ae223342e6f_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i04f3fa6a087c446baded83c2feace046_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evh:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="ia89686cfadfc473caea4541bb62f1bb3_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i86e686cc2d964acc99bb40a8e562febb_D20230120-20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="i4cb6fa070893484684f8ab6a16c9b50a_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="ie9a97018288f4cc8b3674c490b0d4fa5_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="ibc785f8e81be428088e0d8326cda1937_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i09af4e4b44d0499bb93e05f0108e6e4d_I20230120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="evh:PreferredStockRedemptionPeriodAxis">evh:PreferredStockRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-20</instant>
        </period>
    </context>
    <context id="i4ac1e2d763d64e7f83a06724d5407c9f_D20230101-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>evh:reporting_unit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="option_to_renew_lease">
        <measure>evh:option_to_renew_lease</measure>
    </unit>
    <unit id="day">
        <measure>evh:day</measure>
    </unit>
    <unit id="customer">
        <measure>evh:customer</measure>
    </unit>
    <unit id="performance_period">
        <measure>evh:performance_period</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8xLTEtMS0xLTgyODU4_5d01b876-325f-4c89-ab96-2c45bb26c33d">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8yLTEtMS0xLTgyODU4_b927369e-e7f9-4811-82f6-86cc796c7b38">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl8zLTEtMS0xLTgyODU4_60b9fac3-db99-4b5e-b8d3-d785fb030b96">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80L2ZyYWc6NGZkOTY3NTIxYzM4NDQ2MDk4OThkZDc4ZjIxNjFhNTUvdGFibGU6NDUzNmM3MzNjODgzNDMyYTg1MWNlMTNkOTBmMTdjYjYvdGFibGVyYW5nZTo0NTM2YzczM2M4ODM0MzJhODUxY2UxM2Q5MGYxN2NiNl80LTEtMS0xLTgyODU4_00609a65-347d-414b-900f-75fe406fab6d">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ibc5cc544a61241c5b8328c4af50e52ce_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTAtMS0xLTgyODU4_01dd2877-01d2-4acc-a335-6631e19fc8dd">http://www.evolenthealth.com/20221231#AccountingStandardsUpdate201603Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTAtMS0xLTg5NjU1_8a6bb333-5720-430e-8abf-edbdd08b7af1">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i63d23082543b457b9daa2ffcb02ded0c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="id8a19c81d5714f6d8f22e6db248a7c11_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfMi0xLTEtMS04Mjg1OA_9d92b872-1173-46e0-a450-e3640a58e476">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i71c38f21edbe411aa8eb628e23ab4e20_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfMy0xLTEtMS04Mjg1OA_7282440a-a785-4544-949c-f08969bde876">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i2d354e96c97c42cba45e2df7b64eda05_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81OC9mcmFnOjJkYjhkZTU5YWNhMzRkZGVhNTliM2FlOGUxMmYwNWEyL3RhYmxlOjY0YjRhYjI0MjA1ZDQ4NTE5MTcxZmUwM2Q0NDI5NjUyL3RhYmxlcmFuZ2U6NjRiNGFiMjQyMDVkNDg1MTkxNzFmZTAzZDQ0Mjk2NTJfNC0xLTEtMS04Mjg1OA_170d65b1-aa65-488c-8768-2540a7e71535">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ic5906257debf420b8d9e2c9abfb9ca3d_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83My9mcmFnOjM3NTY0NGUzNGJiMjQ4MTQ4ZjQ5YWM4NTg5NWE5M2QwL3RleHRyZWdpb246Mzc1NjQ0ZTM0YmIyNDgxNDhmNDlhYzg1ODk1YTkzZDBfNQ_ab7469c2-92c5-445c-9cd5-dc8da96c312e"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i94980624d2f94f11863369dc8080f610_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83My9mcmFnOjM3NTY0NGUzNGJiMjQ4MTQ4ZjQ5YWM4NTg5NWE5M2QwL3RleHRyZWdpb246Mzc1NjQ0ZTM0YmIyNDgxNDhmNDlhYzg1ODk1YTkzZDBfMjE1_8214cb5d-3efd-401f-bd3a-158e58b96004"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia9c9f5bff0894afd93077c2643b31f4a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTc_a570a6ad-3bd2-47aa-b3bf-a2a19da0786d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i722177f039a9497595141ed257b0dd95_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwMDg1_e95feb79-e657-48b8-946d-eecdc5e29c31">P2Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i722177f039a9497595141ed257b0dd95_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwODYz_60171b02-aaa9-4bbe-95cb-bb9bb4968182">P2Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i824e8ac2e16d440da74ac31890aacd82_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzcvZnJhZzplNzJhMWQ4ZWNhOTg0OGQyYTcxN2Y0ZmZjNjdkMTI2Ni90YWJsZTpjMjJiOGJhYzM0OTM0MmZhOTZkYjY5NTIzMDUzODA3Yy90YWJsZXJhbmdlOmMyMmI4YmFjMzQ5MzQyZmE5NmRiNjk1MjMwNTM4MDdjXzItMS0xLTEtODI4NTg_3f94f66f-a38d-4c97-9057-3edfd1f36451"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i17ac516448fc45b193467cb1ef2df574_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzcvZnJhZzplNzJhMWQ4ZWNhOTg0OGQyYTcxN2Y0ZmZjNjdkMTI2Ni90YWJsZTpjMjJiOGJhYzM0OTM0MmZhOTZkYjY5NTIzMDUzODA3Yy90YWJsZXJhbmdlOmMyMmI4YmFjMzQ5MzQyZmE5NmRiNjk1MjMwNTM4MDdjXzMtMS0xLTEtODI4NTg_f645bd70-3c19-4c88-91ff-be7a806fd227"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017">http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e">http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY3_22502420-d47b-4c8b-ae53-1177d8f1cbf0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzUz_9fbddb7a-6f9b-4a74-85b6-24fe17559708">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8xOTY_e67b0883-2385-40d6-adb6-bed6b55212ac">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8xOTY_0c7fb262-0f8b-482f-869f-97346c6ed7da">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU3_6d24f29d-49fe-4223-9d3f-5ea6e488a924">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYy_718d7dad-49eb-4136-b9ff-09b670d02ad1">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU4_dcff24b9-4462-45db-a0c4-085fc3a696a9">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8wLTAtMS0xLTgyODU4_6c97c866-f45a-4986-9e9b-3fea83ad864b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8wLTgtMS0xLTgyODU4_c4813ef8-e021-4502-8e77-350493812644">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTAtMS0xLTgyODU4_8dc8cec1-b4f7-455d-9d5c-e8e8ed6e4934">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTItMS0xLTgyODU4_f3dcb529-32f4-4cf9-ab28-eacfbacde098">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTQtMS0xLTgyODU4_c1fbb72f-b1e1-431a-9be2-94353c16844c">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTYtMS0xLTgyODU4_7ebe18c7-68a2-4e93-b368-8d6f032e0e3d">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6NDI3ZDI2OThlNDgyNGIwYWIxYWQ0ZGUxZDA2MGE0NzgvdGFibGVyYW5nZTo0MjdkMjY5OGU0ODI0YjBhYjFhZDRkZTFkMDYwYTQ3OF8zLTgtMS0xLTgyODU4_1b48a984-453c-432a-b42a-13f7e5dc64db">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU0_798d3ec2-5998-4cd7-a5ad-e4af8a428f9b">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYz_1b124421-3a0a-4517-833e-30e8a80e55af">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTAtMS0xLTgyODU4_666cf63b-b08d-4b0a-a0e0-900ba3d9e5c7">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTEtMS0xLTgyODU4_00fa3c00-aaba-45a8-9e1c-36357d7a3dbf">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGFibGU6ZDFmYmJkYzc2ZmQ2NGUxZDhhMjk4ZTJkZDUzOGRiNWUvdGFibGVyYW5nZTpkMWZiYmRjNzZmZDY0ZTFkOGEyOThlMmRkNTM4ZGI1ZV8xLTItMS0xLTgyODU4_1ae577b8-883b-4d0c-9438-0861f92b90ca">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY4_cb3ee78e-ce1e-47f9-8266-7a1cd09689f1">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY0_939c7bc9-e8e9-4e29-9821-3385f423ef6b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU5_a8256d20-6927-43c5-920a-8cd3e086611a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY5_bc8bce55-03fc-4633-b2be-e9efbb7138d9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzcw_ade8b5f5-e105-4f86-a323-0fa6d7781eab">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY1_656c9abd-cce6-4595-885c-a880bd83cc4d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzU1_4e9d4ba9-2571-4fc6-9fb5-484d535ec638">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzY2_4d0d8fff-22ed-460c-8be1-dd864d7c17a7">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8yMTk5MDIzMjU5MzMw_8dda9012-0392-4e65-852f-7f0b06bfad99">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i59d672079722445e9903492553b719cd_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zMjM2_5fe1a9ae-5137-413f-9a41-183cee48c4af"
      unitRef="usd">2500000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id530a61ad22641e08d98ced8a800ffda_I20230216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zMjYz_bf9c4920-d306-44c0-84b8-84521df44cce"
      unitRef="shares">111052414</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83L2ZyYWc6YzJmOTJlNWJhMThiNDUzMzhkMmM5YzE2MWZiZGI4NzIvdGV4dHJlZ2lvbjpjMmY5MmU1YmExOGI0NTMzOGQyYzljMTYxZmJkYjg3Ml8zNzYx_861149f9-af1f-49bb-91e1-935617478347">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; June&#160;8, 2023, hav&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2022.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMi9mcmFnOmZkNjFkMzdmNGVjMDQxOGM5ZWFiNDA5NTcwYmYyMmY4L3RhYmxlOmVjOTkwZDY0NTg5YzQwOWI5NTA2YWMxZjI0YzNmNWMxL3RhYmxlcmFuZ2U6ZWM5OTBkNjQ1ODljNDA5Yjk1MDZhYzFmMjRjM2Y1YzFfMS0wLTEtMS04MzI0Ni90ZXh0cmVnaW9uOmQzZjQ1MTExM2MxZDRhNjM5M2Y0MjMyMTU3Y2E0NGI0Xzc0_b6f88ef8-5e77-49ab-8bb8-96ddbb70a4cd">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMTcvZnJhZzo5Zjg5NTg3MWE5ZjU0ZjUxYTIwMTM0MDZmNTlhZmQzYy90ZXh0cmVnaW9uOjlmODk1ODcxYTlmNTRmNTFhMjAxMzQwNmY1OWFmZDNjXzU0OTc1NTg2NTA3OA_9c5b9a9c-7511-436d-a78d-59c93ec675d1">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMTcvZnJhZzo5Zjg5NTg3MWE5ZjU0ZjUxYTIwMTM0MDZmNTlhZmQzYy90ZXh0cmVnaW9uOjlmODk1ODcxYTlmNTRmNTFhMjAxMzQwNmY1OWFmZDNjXzU0OTc1NTg2NTA5Nw_81553df5-29ce-488e-879a-5f5427272b2a">McLean, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMy0xLTEtMS04Mjg1OA_a7507435-e630-478e-aa0f-d93c19a56870"
      unitRef="usd">188200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMy0zLTEtMS04Mjg1OA_f7cf586c-a132-43be-8856-7ddd2582c136"
      unitRef="usd">266280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNC0xLTEtMS04Mjg1OA_1ce80cc8-bea6-4164-91b2-d407e05ec74c"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNC0zLTEtMS04Mjg1OA_44e6310e-165f-4390-966c-7df3618944b0"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3"
      unitRef="usd">254684000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a"
      unitRef="usd">130604000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1"
      unitRef="usd">20678000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df"
      unitRef="usd">51391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNy0xLTEtMS04Mjg1OA_7b5da6fe-1022-4a59-8230-418246025356"
      unitRef="usd">478054000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNy0zLTEtMS04Mjg1OA_3803359a-e106-4980-9248-d36d043973fe"
      unitRef="usd">523960000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOC0xLTEtMS04Mjg1OA_b876ba1d-5840-4d0d-a01c-e2bd92e87529"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOC0zLTEtMS04Mjg1OA_b5ddff1b-f137-48a6-ae54-b54e9ad1eb40"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOS0xLTEtMS04Mjg1OA_4906a986-d1ff-4cd1-8895-f696eea67567"
      unitRef="usd">4475000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfOS0zLTEtMS04Mjg1OA_2a263043-13b0-4269-a294-aab9e0575a3a"
      unitRef="usd">5458000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTAtMS0xLTEtODI4NTg_52626800-5b48-4588-94ca-f918d6e46858"
      unitRef="usd">87874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTAtMy0xLTEtODI4NTg_46de5007-ba73-4e5d-acc8-92629ff2f5d3"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTEtMS0xLTEtODI4NTg_d499a331-e2ce-415c-af10-2e13a2b44245"
      unitRef="usd">49027000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTEtMy0xLTEtODI4NTg_4ba7a2ef-2b4d-428c-b5f3-c340414c6e7c"
      unitRef="usd">50203000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d"
      unitRef="usd">2378000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186"
      unitRef="usd">6790000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTMtMS0xLTEtODI4NTg_8ab8b821-8ae2-45d7-bfeb-abe0ac56ffbe"
      unitRef="usd">17461000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTMtMy0xLTEtODI4NTg_0a3dfce9-7aa2-40be-8364-09e9c99f2c9b"
      unitRef="usd">32624000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTQtMS0xLTEtODI4NTg_494eb7a8-052d-4913-a0b0-5a6018af86bb"
      unitRef="usd">442784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTQtMy0xLTEtODI4NTg_6749275f-c818-4279-aab4-000e354810db"
      unitRef="usd">279784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTUtMS0xLTEtODI4NTg_30dc7ce9-9003-44a9-b4f5-34a920c74493"
      unitRef="usd">722774000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTUtMy0xLTEtODI4NTg_395d40f5-166a-472d-ad0b-be69414bd0b7"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTYtMS0xLTEtODI4NTg_29405253-3f0f-4d8d-a647-1d4dcd1018b8"
      unitRef="usd">1817293000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTYtMy0xLTEtODI4NTg_b9449583-1fa4-480e-8a54-ee8335a8fce0"
      unitRef="usd">1419458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716"
      unitRef="usd">57174000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2"
      unitRef="usd">96084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588"
      unitRef="usd">111198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631"
      unitRef="usd">107241000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjItMS0xLTEtODI4NTg_43036ee2-ee33-45a5-bdc6-67dad5a92ec5"
      unitRef="usd">7122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjItMy0xLTEtODI4NTg_b906e3b7-c0a8-42af-a95a-ee031ff46486"
      unitRef="usd">7069000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjMtMS0xLTEtODI4NTg_2957877b-7240-4634-99f2-5b5437c031f8"
      unitRef="usd">52460000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjMtMy0xLTEtODI4NTg_04166145-69c1-495e-a7e2-8ea7d42eca93"
      unitRef="usd">51861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjQtMS0xLTEtODI4NTg_95fe4a0f-a499-4bca-bf6f-1c16c726b1c8"
      unitRef="usd">5758000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjQtMy0xLTEtODI4NTg_bcd330b4-f3f1-4ca8-9251-f33c45cd9de6"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492"
      unitRef="usd">199730000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7"
      unitRef="usd">171294000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjYtMS0xLTEtODI4NTg_c3fff41e-b45e-4a87-bc6a-0c93ccff0ec2"
      unitRef="usd">433442000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjYtMy0xLTEtODI4NTg_fd33149a-b629-4ec4-ae3c-0d233284d6db"
      unitRef="usd">445493000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjctMS0xLTEtODI4NTg_fa3aeda2-43ff-4fca-aaba-c0a195ac27a1"
      unitRef="usd">412986000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjctMy0xLTEtODI4NTg_fe27a078-d634-4baa-9d0f-4939fa6c5261"
      unitRef="usd">215676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjgtMS0xLTEtODI4NTg_0ecafdef-0ad8-4957-8154-814910cb1af8"
      unitRef="usd">4744000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjgtMy0xLTEtODI4NTg_fa32bf91-e696-41c7-b16b-905149ef9e4d"
      unitRef="usd">5531000</us-gaap:OtherLiabilitiesNoncurrent>
    <evh:TaxReceivableAgreementLiability
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjktMS0xLTEtODI4NTg_1137602a-d2d3-4960-875c-e13415d32cc1"
      unitRef="usd">45950000</evh:TaxReceivableAgreementLiability>
    <evh:TaxReceivableAgreementLiability
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjktMy0xLTEtODI4NTg_34f13e0f-d1bd-45e0-9ebb-b15b783aa396"
      unitRef="usd">0</evh:TaxReceivableAgreementLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzAtMS0xLTEtODI4NTg_6d1899a0-6d3c-417f-b263-9166955f9b3e"
      unitRef="usd">56010000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzAtMy0xLTEtODI4NTg_387c8b2f-8add-406d-be6d-470ad7ea4f38"
      unitRef="usd">57722000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzEtMS0xLTEtODI4NTg_5e8ad72b-d257-491e-a29e-373ffa952bc2"
      unitRef="usd">4744000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzEtMy0xLTEtODI4NTg_416059a1-adb5-445a-b291-a423de4b1e5a"
      unitRef="usd">1403000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzItMS0xLTEtODI4NTg_f06d9498-1563-4d08-a6bc-a760b03c8c93"
      unitRef="usd">957876000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzItMy0xLTEtODI4NTg_e35c3651-b12f-4e4a-9bbf-6d510ac621f5"
      unitRef="usd">725825000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzMtMS0xLTEtODI4NTg_a9876273-f011-449f-b5e4-b7fc6d077b53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzMtMy0xLTEtODI4NTg_69a2a758-b42b-4c69-bfec-2b381e1e0c92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF8yNw_45114a84-7fc4-4d73-a7b9-5543b3f6a393"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF8yNw_77d73ea8-867a-4af7-8de2-ceeea79ce80c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF80MQ_1ff52c16-73c8-4bcb-b860-bcbb6f3d690a"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF80MQ_bf50a8b7-bc96-4a2a-adbb-946c4d2e5163"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF82Mw_6d0e7b80-9399-4a33-b78d-0117a0b32582"
      unitRef="shares">101500558</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjozZWM1MGNmMWEwYTI0NzhlOGM0NzY1MWM5YWEzZjY5NF83MA_8e4d6fe5-7d17-404b-8b47-56e9dd0d4f36"
      unitRef="shares">90758318</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMS0xLTEtODI4NTg_4bd7d29d-537b-4388-89f9-619677604721"
      unitRef="usd">1015000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzUtMy0xLTEtODI4NTg_366b35da-ed33-49db-8987-3cbe18ad0384"
      unitRef="usd">908000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzYtMS0xLTEtODI4NTg_f5a2bb11-6d6e-41e6-a0e0-5d068001c071"
      unitRef="usd">1486857000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzYtMy0xLTEtODI4NTg_672a78ab-ff4c-4276-ab89-13f1dde1ace4"
      unitRef="usd">1340989000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzctMS0xLTEtODI4NTg_b5855596-c8f0-4b1c-8112-05755454f7de"
      unitRef="usd">-1178000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzctMy0xLTEtODI4NTg_e4b0b036-0505-4148-b7db-fae4de562b4a"
      unitRef="usd">-362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzgtMS0xLTEtODI4NTg_c8380cfd-08e0-4523-8277-4fc9efc368d4"
      unitRef="usd">-606154000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzgtMy0xLTEtODI4NTg_893d071b-dbbd-4d7f-8192-f3cfe817b2a4"
      unitRef="usd">-626779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjpkMmRkNzg4YzYyYjA0OGJhOWQxNGQ0NDcxNzQ0MDVkMV8yOQ_b5eb6f37-e5fb-452e-94de-02ff24f5c120"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMC0xLTEtODI4NTgvdGV4dHJlZ2lvbjpkMmRkNzg4YzYyYjA0OGJhOWQxNGQ0NDcxNzQ0MDVkMV8yOQ_c5aa6de5-f0e8-423b-a4d7-aa2a50e29d4f"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMS0xLTEtODI4NTg_0f5af84f-7945-4e2c-8c7f-4a0ccc371133"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMzktMy0xLTEtODI4NTg_92a4f0d9-0b6c-40df-b31e-a286d32a77f6"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDAtMS0xLTEtODI4NTg_b34c35b4-017b-40ee-8538-334e2c28fab7"
      unitRef="usd">859417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDAtMy0xLTEtODI4NTg_5df8c348-0df0-40cf-9870-bf4c5127697f"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDEtMS0xLTEtODI4NTg_673e5877-eeeb-4fca-8153-ace79a36477e"
      unitRef="usd">1817293000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNDEtMy0xLTEtODI4NTg_ec90737d-6de2-4b3e-9b77-f41dcaa48479"
      unitRef="usd">1419458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772"
      unitRef="usd">1352013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc"
      unitRef="usd">907957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3"
      unitRef="usd">924639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5"
      unitRef="usd">1035429000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d"
      unitRef="usd">657551000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464"
      unitRef="usd">696581000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb"
      unitRef="usd">269269000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d"
      unitRef="usd">219499000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786"
      unitRef="usd">210412000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi01LTEtMS04Mjg1OA_da2e6e60-d8c5-4ddc-a592-59908e7b3fff"
      unitRef="usd">67195000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi03LTEtMS04Mjg1OA_c70f8dee-cc99-4c51-96ed-9cb20b495793"
      unitRef="usd">60037000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy05LTEtMS04Mzg4OA_31e7a481-7954-43b5-8d90-c8b1e39d6ed4"
      unitRef="usd">60835000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC01LTEtMS04MzkwNQ_cf78217b-203b-4cb4-b8c3-f46f397ef641"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC03LTEtMS04MzkwNQ_57f9df25-3c63-47fa-b76f-abb9e76fa821"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC05LTEtMS04Mzg5NQ_2311addd-8ecc-4492-864b-cdd07055cc0d"
      unitRef="usd">-698000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNS0xLTEtODM5MDU_2a87cf44-6632-4eab-ad23-0510a1ced313"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNy0xLTEtODM5MDU_b4a9e3c8-b4dd-45a9-90dc-5000be5b90a6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtOS0xLTEtODM4OTU_c26863ed-cb86-4074-b5e7-5ae24787ad9e"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy01LTEtMS04Mjg1OA_a530b829-25bb-47c6-97ee-18f8f9829dc4"
      unitRef="usd">-23522000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNy03LTEtMS04Mjg1OA_45367148-f350-4855-87c5-4fde31feb7ac"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtOS0xLTEtODM4OTU_c8a71e0c-e34a-49d1-bc90-71a07f53298e"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC01LTEtMS04Mjg1OA_d673158b-4907-4035-b502-4b8e7600fdbf"
      unitRef="usd">1348371000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOC03LTEtMS04Mjg1OA_348071a2-9177-4556-b24f-78c6772a045b"
      unitRef="usd">950368000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItOS0xLTEtODM4OTU_22b6c05a-6def-4d36-9ac9-1b616b7c2fd2"
      unitRef="usd">1187486000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOS01LTEtMS04Mjg1OA_4abb1dc8-3f7b-42b3-9446-079dbe5d587f"
      unitRef="usd">3642000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfOS03LTEtMS04Mjg1OA_39e8ee52-349e-4343-974d-0e8a4cffbc23"
      unitRef="usd">-42411000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtOS0xLTEtODM4OTU_72cff562-f9c3-4ee4-9b0d-f06c75212cc7"
      unitRef="usd">-262847000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNS0xLTEtODI4NTg_77d3c87c-380e-42d6-ab8b-45ce2eb4e5a1"
      unitRef="usd">1369000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTAtNy0xLTEtODI4NTg_3b500807-f461-46fb-9aa0-0febd382e857"
      unitRef="usd">407000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtOS0xLTEtODM5NTc_69d05b00-0dda-4515-b9ea-78b7bc40039f"
      unitRef="usd">2633000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtNS0xLTEtODI4NTg_8d6db517-61b7-4e92-87e0-e9e7cf5f2ddb"
      unitRef="usd">15572000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTEtNy0xLTEtODI4NTg_b71a8b65-fda2-4902-839c-bf5341bd97ce"
      unitRef="usd">25425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtOS0xLTEtODM5NTc_21d7471c-642f-454f-b564-a17fbf4d37ea"
      unitRef="usd">28325000</us-gaap:InterestExpense>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNS0xLTEtODM5NjM_c60c466b-acdd-45f5-ad00-7ce996fb12f6"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNy0xLTEtODM5NjM_649f9708-0d38-44b3-bb14-c1ed5e31a16b"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtOS0xLTEtODM5NjM_a0e7f48f-c393-4f18-beda-119a6b251f9d"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItNS0xLTEtODI4NTg_9c7c7899-f630-43fa-a818-437a5b2c571a"
      unitRef="usd">4569000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTItNy0xLTEtODI4NTg_fbcec15b-e344-44e5-8a38-7a79d377b76f"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctOS0xLTEtODQwMTY_8f66d080-a696-4f54-8479-9050c6100581"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtNS0xLTEtODI4NTg_f885f3c9-0122-4206-bec2-a3580c9ee5d7"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTMtNy0xLTEtODI4NTg_4f13f57d-2831-4b8c-8164-4cc8b73fde21"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtOS0xLTEtODQwMTY_80b09630-1214-41ab-a796-edc4a40c4ef7"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtNS0xLTEtODI4NTg_57d2fd30-1f8c-4d4a-ae7f-f278cf75f9d5"
      unitRef="usd">-10192000</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTQtNy0xLTEtODI4NTg_3511c764-4862-4f96-932f-2045654e4dcb"
      unitRef="usd">-21343000</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktOS0xLTEtODQwMzI_cd13ec90-b12d-42fb-91ea-8c2f07d835bb"
      unitRef="usd">-4789000</evh:GainLossOnRepaymentOfDebt>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtNS0xLTEtODI4NTg_474330d4-dae1-49ca-9466-d7943d23d3d1"
      unitRef="usd">45950000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTUtNy0xLTEtODI4NTg_787d69de-9073-4740-86e6-5e160f2f8dba"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtOS0xLTEtODQwMzI_4b3300c7-7e7d-41ea-aa47-9b50279fdcd1"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNS0xLTEtODI4NTg_54587851-39b7-4fa7-a4d1-c10589aef5b7"
      unitRef="usd">57000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTYtNy0xLTEtODI4NTg_e39f8bec-4cec-4b06-bd95-c57c6bae328d"
      unitRef="usd">-146000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtOS0xLTEtODQwMzI_cfb0d504-3ecb-4f80-9d0a-0fefc21ce5bb"
      unitRef="usd">-118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctNS0xLTEtODI4NTg_83bdaf92-eff5-479f-b307-5a041ba61f06"
      unitRef="usd">-62077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTctNy0xLTEtODI4NTg_602c1094-a838-41c9-b7d9-f01ebbfa921c"
      unitRef="usd">-29801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjItOS0xLTEtODQwMzI_68605381-978d-41cb-93d0-19b5b6a6a251"
      unitRef="usd">-330540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtNS0xLTEtODI4NTg_b2abe7cd-bbfb-4b69-8ad5-4fe2a0a86310"
      unitRef="usd">-43376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTgtNy0xLTEtODI4NTg_3235ba29-0efd-4de7-ab1c-10defc2b6e80"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjMtOS0xLTEtODQwMzI_abd6c6f3-f096-4f93-aa20-05c899213db4"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktNS0xLTEtODI4NTg_112f45da-4664-48a6-aee7-fbb2f80ad0c5"
      unitRef="usd">-18701000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMTktNy0xLTEtODI4NTg_9177faf4-f040-4777-bc9f-6ec51ec2d38b"
      unitRef="usd">-30284000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjQtOS0xLTEtODQwMzI_5c2a3b30-13b8-4ea6-a1b7-35e3c8d59d63"
      unitRef="usd">-328172000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNS0xLTEtODI4NTg_d01217a6-5959-4584-b22e-a36764658993"
      unitRef="usd">-19164000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNS0xLTEtODI4NTg_e5c62161-bcfa-4dd4-b071-60fca703cc7d"
      unitRef="usd">-19164000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNy0xLTEtODI4NTg_2a23462b-da52-41dc-ad00-306bbbdf0b76"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjEtNy0xLTEtODI4NTg_e271052a-4a63-4981-a4f3-a7a87f46848b"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODQwMzI_1d68db10-6ff6-458a-b202-81d13456566c"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODQwMzI_3bbc3d55-ae5c-4322-847b-102357351b6f"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNS0xLTEtODI4NTg_03631c9b-1fca-482b-bc21-712366fde1c0"
      unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNS0xLTEtODI4NTg_8e148c6b-2b64-4487-811e-8143fd8a108e"
      unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNy0xLTEtODI4NTg_7d3d737d-bbbb-4e90-95df-f5c070e63d3f"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtNy0xLTEtODI4NTg_93c76584-0af4-496c-b18f-ac56307e8f67"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODM4NjQ_0d907ba3-3b25-426d-a58e-d63555f4328d"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtOS0xLTEtODM4NjQ_ef2de908-b81a-4ee6-9705-f0c868576b09"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNS0xLTEtODI4NTg_13051571-1486-458a-a693-81f16ec20e3c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNS0xLTEtODI4NTg_2e81288a-b6e7-45e1-b2c8-b0e4dc95ecdf"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNy0xLTEtODI4NTg_4e315877-8fcd-418c-ade6-201b86112525"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjYtNy0xLTEtODI4NTg_a2cb81db-574c-4b1a-b6dd-726d8b3656e9"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctOS0xLTEtODM4NjQ_1cc63df2-3264-46da-adfc-81ad817f2e33"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctOS0xLTEtODM4NjQ_4a171798-299d-444d-b4bc-be280c334f63"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNS0xLTEtODI4NTg_e00dc34d-016a-4911-aa17-a9e3f570441a"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNS0xLTEtODI4NTg_fb2f9fff-b3ac-4ab7-bb32-74d9d56181c7"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNy0xLTEtODI4NTg_ceb7521b-3185-4e91-a71c-86273bc538c3"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjctNy0xLTEtODI4NTg_d80a8583-6a89-4435-b5b4-c4527c5a3bbe"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjgtOS0xLTEtODM4NzI_4a6e219f-944f-4248-83bb-64d123921211"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjgtOS0xLTEtODM4NzI_b4cdb5eb-97ee-43c1-8fa3-5ff79883d395"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNS0xLTEtODI4NTg_60410be7-dbdf-4d6e-bb0a-6c398f88c7a8"
      unitRef="shares">93699000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNS0xLTEtODI4NTg_810b4a96-f715-4a7b-af3a-869e10436860"
      unitRef="shares">93699000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNy0xLTEtODI4NTg_6422c41e-d861-4de3-b5c0-4fe5c75c6f6a"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzQtNy0xLTEtODI4NTg_e4501877-9e46-48d9-a574-409f39d2d2b8"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzUtOS0xLTEtODM4NzY_045ec5e8-e8da-4501-a2c0-d4f80dcd4fb7"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzUtOS0xLTEtODM4NzY_50c47909-94fb-4f4c-b6a5-b5d7bc214d34"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzgtNS0xLTEtODI4NTg_e02e235a-589d-41f9-be53-cda0c7b2bb3b"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzgtNy0xLTEtODI4NTg_7b4ecc2c-082f-4c03-b35b-4ad502f5d8ac"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMzktOS0xLTEtODM4NDE_dfe5f93a-f79d-47dc-8bb5-7f23c9bd5b6c"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDAtNS0xLTEtODI4NTg_fb4f11e1-73e8-4640-8840-4449720dad2d"
      unitRef="usd">-816000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDAtNy0xLTEtODI4NTg_1b309c84-fa64-43f8-9dda-4020f0a4341e"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtOS0xLTEtODM4NDE_3496ad2e-b1a3-470f-a2d4-dcd6482818d9"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtNS0xLTEtODI4NTg_9c3727be-de02-4d4d-9088-0b8b0060a6c2"
      unitRef="usd">-19980000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDEtNy0xLTEtODI4NTg_bc627152-dc87-45ce-a89e-4ec7fc4463fe"
      unitRef="usd">-37685000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNDItOS0xLTEtODM4NDE_59fdaee5-c4a3-4fea-a17d-7902ffce4a3b"
      unitRef="usd">-334290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfMjY5_3e724a0d-d187-4ffc-a50f-e2e675db99dc"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfMzY1_96f98c70-26e2-458d-af35-5bd0ae5400d6"
      unitRef="usd">-6800000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i32b6870c04cf45a7a22f92062187c8b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTEtMS0xLTgyODU4_de4bfaba-4938-4ed0-949d-42d36d7dda9e"
      unitRef="shares">84589000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i32b6870c04cf45a7a22f92062187c8b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTMtMS0xLTgyODU4_d0a432ef-a472-4cb3-9938-0a63754e6c75"
      unitRef="usd">846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b766a37ca0b47ffb3be346f3d8b2a47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTktMS0xLTgyODU4_404ccc86-e6a4-4f8b-be7e-d158fb612f9b"
      unitRef="usd">1173708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibff2679b53d74ef7bc24df5385a2e916_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTExLTEtMS04Mjg1OA_029305e1-7e87-4386-b26e-ffd38864399f"
      unitRef="usd">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc16408fdc2f457ca9bf96a6ff0288e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTEzLTEtMS04Mjg1OA_be0540f5-0ee2-48a2-aee3-f2edb0480fb4"
      unitRef="usd">-251962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if70bbd87e6c7400684ed1f05186aab79_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE1LTEtMS04Mjg1OA_5dfcff6a-2670-4798-bf2b-718a3fbe0b9f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i211392e628d14c2bb3d3202fadd1e955_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE3LTEtMS04Mjg1OA_1348f7a3-b6aa-4f20-87b3-545615b1ccab"
      unitRef="usd">922358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77788cda88584bada7bf9ba9c37f88e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTE5LTEtMS04Mjg1OA_922f9067-52fd-4e53-a7ac-eacd9cea9f94"
      unitRef="usd">6689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzE5LTIxLTEtMS04Mjg1OA_4b34633c-0833-4807-b545-084427eb11dc"
      unitRef="usd">929047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e0069b2782a4a49ab67a323fb9055aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTEzLTEtMS04Mjg1OA_f8aeb662-3f85-4ee5-beb7-1f57c2fdda15"
      unitRef="usd">-2970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if29a022394774916af9c2f4fb440db9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTE3LTEtMS04Mjg1OA_e084779d-a296-40eb-8005-092727d6cd57"
      unitRef="usd">-2970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0dbc8526caa04360a8f7a3aad7061a5e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIwLTIxLTEtMS04Mjg1OA_eb5628cd-9d5b-4029-b184-0f3f5e35c0df"
      unitRef="usd">-2970000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTktMS0xLTgyODU4_a5ab2af6-e8c5-4cd2-a83d-4dedf248cecc"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTE3LTEtMS04Mjg1OA_9305981a-ac97-43fb-bbb0-11abb7805c14"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIxLTIxLTEtMS04Mjg1OA_605a3ab7-e88e-4bb4-8e5e-51af4cd518a7"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTEtMS0xLTgyODU4_925a940b-5475-4260-a3ba-94f30b722e61"
      unitRef="shares">416000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTMtMS0xLTgyODU4_d9fc9fa6-c6a7-4da0-a333-93c2359a31f8"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTktMS0xLTgyODU4_abfb612c-94b3-4601-a0da-7d18b68c72eb"
      unitRef="usd">2573000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTE3LTEtMS04Mjg1OA_63fcfaa1-cd19-472b-945b-6384f2a4201b"
      unitRef="usd">2577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIyLTIxLTEtMS04Mjg1OA_4dd35709-75e5-4cac-9eac-3d2a91330c70"
      unitRef="usd">2577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTEtMS0xLTgyODU4_058e6327-faff-415d-8282-ba428e209525"
      unitRef="shares">462000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTMtMS0xLTgyODU4_0ac38be7-43ee-4730-8a75-bddbab48e01c"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTktMS0xLTgyODU4_7c9e60e8-b082-4300-83a3-ebc54b640373"
      unitRef="usd">-1856000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTE3LTEtMS04Mjg1OA_5714b4b3-856c-47aa-a959-a400747d7588"
      unitRef="usd">-1851000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzIzLTIxLTEtMS04Mjg1OA_2dd635fb-6bc7-41b4-a013-8dd0d1ae3c7b"
      unitRef="usd">-1851000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i173c4f55d1a74452b5e44d2cab35ebd1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTE1LTEtMS04Mjg1OA_6a99db2d-dd62-45fe-9352-7d42f3a8e102"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTE3LTEtMS04Mjg1OA_1fe6716e-f095-46b7-bca6-8ed2e986601d"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI0LTIxLTEtMS04Mjg1OA_afc88ccb-029c-443b-9ee5-4af7746a76de"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <evh:StockVestedAndRetiredDuringPeriodShares
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTEtMS0xLTgyODU4_7d2270a8-cb0c-4009-a2a6-bb6ac76217ca"
      unitRef="shares">188000</evh:StockVestedAndRetiredDuringPeriodShares>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTMtMS0xLTgyODU4_8b9d98a3-174d-498e-8a75-57180e2c34b9"
      unitRef="usd">2000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTktMS0xLTgyODU4_43271ded-87a5-4ce1-8222-2e4c8e21f201"
      unitRef="usd">683000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTE3LTEtMS04Mjg1OA_b0c1d5f7-2632-44df-83d8-5164fe95efbc"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI1LTIxLTEtMS04Mjg1OA_be6508c7-1f73-4506-8c3c-d500d972370f"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTEtMS0xLTgyODU4_7b98997f-5c79-47ca-81c1-2abfed3e7e4b"
      unitRef="shares">616000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i4c4676d7140a4a6099f0d8a8de12877b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTMtMS0xLTgyODU4_66249e7a-5e22-426d-a4fa-3017708cf05d"
      unitRef="usd">6000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTktMS0xLTgyODU4_06408372-f7d8-4adf-8abf-12d43faebf40"
      unitRef="usd">4179000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTE3LTEtMS04Mjg1OA_570e36fc-fcc8-478c-b96b-ab45d5cf5133"
      unitRef="usd">4185000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI2LTIxLTEtMS04Mjg1OA_6c80a6fc-9b44-4eb1-8a80-d4b797764131"
      unitRef="usd">4185000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i5871678b7d244aa5aeb2ef7fb2ed2073_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTktMS0xLTgyODU4_d386b30d-b0db-4117-a0df-477b5875ab85"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTE3LTEtMS04Mjg1OA_fed6af26-e565-430b-9585-7c6badf1c7e5"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI3LTIxLTEtMS04Mjg1OA_69762ffb-21ec-4eac-b11b-bfd07c03de77"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i1f9268d85098487aa9053456186fe226_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTE5LTEtMS04Mjg1OA_9d04fc24-4f49-47f7-a177-7b76d00e8b6f"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTIxLTEtMS04Mjg1OA_5d3c1900-5c41-4339-b3eb-0bea6398edbf"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4b29db4886614e8cb747051097d57a16_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTExLTEtMS04Mjg1OA_c91d473f-f3e0-42c6-890a-88e97602e193"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTE3LTEtMS04Mjg1OA_58d5a474-2aba-41a6-940c-2e7e4b9974e3"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTIxLTEtMS04Mjg1OA_f8440a6c-10a8-499f-9ef7-2580710d8b38"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic335aec702854b39aad8f2e5e220ae6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTEzLTEtMS04Mjg1OA_bb192798-80b9-4ed6-a726-820af36a4700"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ida57b4105ad14d17a77710ca838cc6bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTE3LTEtMS04Mjg1OA_0e8a5c03-92b5-4983-a9de-18005e51380d"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTIxLTEtMS04Mjg1OA_b5ded3cd-50be-48eb-8f73-b89238b3b464"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEtMS0xLTgyODU4_5de9e09e-f203-49f9-818e-8136f17a7214"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ia4d5f28622f44d8db67b5f93e0d7bc7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTMtMS0xLTgyODU4_0f936133-2475-446d-bd26-ada27c544b3a"
      unitRef="usd">859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9a7173b3e1d4ea0bf04dd1bbb81c077_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTktMS0xLTgyODU4_ef74adf8-157c-4f34-a796-d23bb8521040"
      unitRef="usd">1229320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09bbf0d725dd45f3a6c123d36bd2715b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTExLTEtMS04Mjg1OA_8fabebe2-16af-4fb9-ad2c-7ce342f8f61d"
      unitRef="usd">-278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i676d4e2a769c4bd1825c4e7a238270d7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEzLTEtMS04Mjg1OA_b0a8cd22-ac96-47a3-acb2-f5b53ccd99f5"
      unitRef="usd">-589178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i504d5250f6a74571832f036561396187_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE1LTEtMS04Mjg1OA_6e0e8da9-ff16-45bf-b7a0-38c381b05c58"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16d6a2705b50479eb89edc0845501b62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE3LTEtMS04Mjg1OA_01ac5a34-75e1-4350-87e2-7858798570fc"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dcebc8005994a85ac2c4f44251b586b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE5LTEtMS04Mjg1OA_35832601-6536-4543-bbb8-a63ec4e72f30"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTIxLTEtMS04Mjg1OA_2dfe1d75-cc91-4942-829e-26e1eb498bf8"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTktMS0xLTgyODU4_7ec8a045-f206-4fc4-92e5-34ff8a6b394a"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTE3LTEtMS04Mjg1OA_2e799fd3-5410-47c7-9ee6-6820cb444e07"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTIxLTEtMS04Mjg1OA_5a960f49-464c-4994-9668-ab01aea2d2e3"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTEtMS0xLTgyODU4_935e92b4-895b-499d-afb7-8a5aaffab1b1"
      unitRef="shares">1490000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTMtMS0xLTgyODU4_2b90f8f0-00c3-4648-9e90-2230ac8a5618"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTktMS0xLTgyODU4_7cbf1a8f-f26d-45df-a77a-1a086f9a8d75"
      unitRef="usd">13274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTE3LTEtMS04Mjg1OA_6b55e029-f16d-453a-8266-42ea47063dee"
      unitRef="usd">13289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTIxLTEtMS04Mjg1OA_5775954f-798f-4444-b793-61f7d23e29c0"
      unitRef="usd">13289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTEtMS0xLTgyODU4_cb21ca8c-e0dc-49a4-9da9-22ee7802f300"
      unitRef="shares">492000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTMtMS0xLTgyODU4_12e9f009-daac-4578-ab9d-849f3799b080"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTktMS0xLTgyODU4_47a869d2-0805-4f19-ab4b-12879fcd3006"
      unitRef="usd">-3855000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTE3LTEtMS04Mjg1OA_aeda8bf1-a701-40a8-acd0-5b7e5888a1aa"
      unitRef="usd">-3850000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTIxLTEtMS04Mjg1OA_62a8d0ba-440a-422b-878f-21d83896c6c5"
      unitRef="usd">-3850000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTEtMS0xLTgyODU4_59ce569b-08d2-49aa-a07a-67a31bbdd34c"
      unitRef="shares">1771000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTMtMS0xLTgyODU4_3b09f0d9-5c5d-41ed-958e-2fd8e3e48b2f"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTktMS0xLTgyODU4_609a5173-3533-4387-bddc-32e1ba1dac55"
      unitRef="usd">56608000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTE3LTEtMS04Mjg1OA_41a56ec1-c429-4604-b0f6-099714bb9ca8"
      unitRef="usd">56626000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTIxLTEtMS04Mjg1OA_7f9aa3ab-37f7-47c8-a565-1322bed48af4"
      unitRef="usd">56626000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTEtMS0xLTgyODU4_4bc8dcd0-e2e1-4786-a127-622f174a6d2d"
      unitRef="shares">1095000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTMtMS0xLTgyODU4_36184fd4-e879-4095-ba56-0a937e447e10"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTktMS0xLTgyODU4_ca3a18ec-3ca4-4395-8135-ba1b14396728"
      unitRef="usd">28481000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTE3LTEtMS04Mjg1OA_f3f864c8-ae98-4c3b-9241-0cbb210ab34e"
      unitRef="usd">28492000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTIxLTEtMS04Mjg1OA_bab9fe44-b85b-4145-a8ca-25a3c0346a66"
      unitRef="usd">28492000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="i69472ad58fe84508a35e9125896f59ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEtMS0xLTgyODU4_227c0887-e137-441d-8023-87395690ed42"
      unitRef="shares">16000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ib628e4bb8ca248c69b6807d4d017724a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTktMS0xLTgyODU4_1cd67f1a-fe91-436f-b7ac-a44043397221"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE3LTEtMS04Mjg1OA_1226594a-2227-45d3-97ee-51b79875c6a1"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTIxLTEtMS04Mjg1OA_f30faff5-0a29-4368-928b-604e6afeb73f"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9a9e09aed0674d2184d736359fae1f7d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTExLTEtMS04Mjg1OA_b07b83d7-3ae1-4e3b-b44d-5f62f09f7897"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTE3LTEtMS04Mjg1OA_41a0eaaf-1709-4063-8f63-172ca6fe3039"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM4LTIxLTEtMS04Mjg1OA_7bdfd6ae-9309-4062-8012-2d3dfbdc6ea9"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i8d183758c28e42748ea9f0baf38ea61b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTEzLTEtMS04Mjg1OA_2b56660a-3f8f-4a80-b80b-cd47ec9cd821"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i70ba438dc7d6406eadcfbc2e0fb64ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTE3LTEtMS04Mjg1OA_8ec5d55a-f5f0-4bb7-bf9c-4d40adec9c92"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM5LTIxLTEtMS04Mjg1OA_7517cb8e-436b-4c9f-9cba-f249dba9155a"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0c369d6b43ba4b62913e4007fef79e83_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTEtMS0xLTgyODU4_e7bab56a-2374-4835-9a9a-f451a1a64869"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0c369d6b43ba4b62913e4007fef79e83_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTMtMS0xLTgyODU4_43708b2f-39ad-444b-889d-a2c86a3a178c"
      unitRef="usd">908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i006a422e447e45a4a9b4c1c667093316_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTktMS0xLTgyODU4_70e0b724-51e9-4756-9e32-48e9c7c86cca"
      unitRef="usd">1340989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5547116dd92544ff88c29dc8b9b6fe3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTExLTEtMS04Mjg1OA_a39c9c01-74f3-4781-9581-f187c2592e74"
      unitRef="usd">-362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a03703f143645bf9ba9043225c49c63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTEzLTEtMS04Mjg1OA_19d8de33-20a3-4d50-a199-72f122407d99"
      unitRef="usd">-626779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ce95dfdb9b847c5b2476842c531da54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE1LTEtMS04Mjg1OA_7f1fa353-839c-44aa-bbd7-28d50c26ef66"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97488e48877b4c0f9463a34a496911e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE3LTEtMS04Mjg1OA_d8d25ff0-9664-4ba1-a7ec-99092d4f20ae"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iace02407fa42475e9b151a58bea5b3d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTE5LTEtMS04Mjg1OA_1fee3d4d-c226-46c6-b27d-cb840ff3ac35"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzQwLTIxLTEtMS04Mjg1OA_ba732e45-0014-429f-8a79-03325eee1e6c"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2738bd3890c14cba841e976265d057fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTktMS0xLTg0MzYz_201e339e-0534-42ac-9e1d-5ae97c88641a"
      unitRef="usd">-106172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3a355f9a909459691e4f7374ba9cd65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTEzLTEtMS04NDM2Mw_65ad2606-cd1b-404d-8dff-991d0e7a54a1"
      unitRef="usd">39789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67118d2408f84f85a9231fcddea5a5e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTE3LTEtMS04NDM2Mw_e3940d18-60fc-4d6c-b408-716a163e8a20"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72141e7136894e7394a041ed0f2a15d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI4LTIxLTEtMS04NDM2Mw_251560f6-9b87-4fb4-bb3a-09f8a8124250"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTktMS0xLTg0MzYz_94426557-de09-4c51-9136-4b8902cc3615"
      unitRef="usd">33981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTE3LTEtMS04NDM2Mw_86eba9e1-8bf3-4b69-b00b-dec1bcd504dc"
      unitRef="usd">33981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzI5LTIxLTEtMS04NDM2Mw_8a70d6fc-6afe-48d9-aab2-0343357c63b0"
      unitRef="usd">33981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTEtMS0xLTg0MzYz_c695de00-6fb5-443e-83c3-99aa2c221be1"
      unitRef="shares">651000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTMtMS0xLTg0MzYz_136d1ec5-dff2-4c57-9f2f-47f5f6a956e4"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTktMS0xLTg0MzYz_e90c676f-0015-4daa-84d0-2e77d222f836"
      unitRef="usd">4446000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTE3LTEtMS04NDM2Mw_227658ef-eb06-4230-8502-5ece3b29aa27"
      unitRef="usd">4452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMwLTIxLTEtMS04NDM2Mw_7640a89d-1501-42e4-bd48-93adf60b235f"
      unitRef="usd">4452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTEtMS0xLTg0MzYz_992d1071-41d1-4a48-a882-ad61db5bcc2a"
      unitRef="shares">496000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibdddf560f41e4538a739c422bd8253ff_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTMtMS0xLTg0MzYz_c807100b-6eab-47a3-852a-fd1d33abf3d7"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTktMS0xLTg0MzYz_81419573-47f8-49e2-b521-8a4a883a290d"
      unitRef="usd">-7091000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTE3LTEtMS04NDM2Mw_df3365ab-5b21-41a1-81c7-5679c5ab2833"
      unitRef="usd">-7086000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMxLTIxLTEtMS04NDM2Mw_d3ad72c6-a673-42e3-960b-82b7d76a3f38"
      unitRef="usd">-7086000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTEtMS0xLTg0MzYz_05b25042-92d5-4465-b807-1fd480b918cb"
      unitRef="shares">459000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTMtMS0xLTg0MzYz_0029da6f-d915-4d15-8d9f-2894f63f472a"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTktMS0xLTg0MzYz_63fee225-61b0-4419-8276-a3facb6f7720"
      unitRef="usd">-11237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTE3LTEtMS04NDM2Mw_cbebc82d-d935-4814-b1cb-f6511b936f36"
      unitRef="usd">-11232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMyLTIxLTEtMS04NDM2Mw_3668ba56-340b-44cb-9a38-c8a7c2b929ba"
      unitRef="usd">-11232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTEtMS0xLTg0MzYz_57aa91af-ab64-4473-a22e-ee862ac6cc0d"
      unitRef="shares">5394000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTMtMS0xLTg0MzYz_83d4dd2d-bb31-4bf1-b596-a0bbf68f9e1f"
      unitRef="usd">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTktMS0xLTg0MzYz_3166be2a-2a50-4b1d-9832-51baa0688cdb"
      unitRef="usd">101803000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTE3LTEtMS04NDM2Mw_0952f843-30a6-4144-beca-079cb246a35e"
      unitRef="usd">101857000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzMzLTIxLTEtMS04NDM2Mw_04a1df6d-5c8a-424c-a97d-79b3901d9853"
      unitRef="usd">101857000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTEtMS0xLTg0MzYz_182db4b6-ca7e-46c1-85b0-3308518ed676"
      unitRef="shares">3742000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ie7be35f401024c5c8321a3df2cac53d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTMtMS0xLTg0MzYz_13255455-e15d-45e2-8b59-e437177557f7"
      unitRef="usd">37000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="if5d42307930e4664b1d6a3f1c6d31f70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTktMS0xLTg0MzYz_ef9aac24-7ca4-4477-88a1-937955c44d6d"
      unitRef="usd">130138000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTE3LTEtMS04NDM2Mw_9b00e697-32f6-4b96-975a-bbb4ec6c4eed"
      unitRef="usd">130175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM0LTIxLTEtMS04NDM2Mw_6e9d24c0-771a-4232-9905-a5b89c1d9f98"
      unitRef="usd">130175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8f12b36b156e4f77b72612737e0e8773_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTExLTEtMS04NDM2Mw_0be039f7-51d1-4c95-a98d-ce49a2a5e6bf"
      unitRef="usd">-816000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTE3LTEtMS04NDM2Mw_79a5051b-6ee6-411e-b5dd-2b5b670e5568"
      unitRef="usd">-816000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM1LTIxLTEtMS04NDM2Mw_845b4bf7-4c71-4181-a597-5864f5ff41f9"
      unitRef="usd">-816000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i0ec9777d918a483895645ef1f407025e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTEzLTEtMS04NDM2Mw_590c5caa-4771-454a-9011-23d2b83df640"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i547810714ee04d1e984798b4777b9f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTE3LTEtMS04NDM2Mw_79c5898e-6fcb-4307-9ec7-38c8e3ae3eaa"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM2LTIxLTEtMS04NDM2Mw_13b883e0-cfaf-4acf-b118-8db072082e5a"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i48a51239b501447b911a29ce59ff5506_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEtMS0xLTg0MzYz_b6ca6730-5567-4e7f-8dd2-ce1a3cf458bf"
      unitRef="shares">101501000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i48a51239b501447b911a29ce59ff5506_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTMtMS0xLTg0MzYz_b2eaaec1-308c-42c2-bf5c-122ec7287e6c"
      unitRef="usd">1015000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7972290d242a4362ba5061064cb35fb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTktMS0xLTg0MzYz_346a2750-d0f8-4968-8818-42ed488a30fc"
      unitRef="usd">1486857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23bab8ce4c244fd1b411ed8b2d13efb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTExLTEtMS04NDM2Mw_c2978d5c-d99f-4cb4-ac6d-23132f76e3e7"
      unitRef="usd">-1178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8ebc0071f484c15a790e6c754033f5c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTEzLTEtMS04NDM2Mw_aebfe06b-c4a8-4db1-9b69-0cff573a87cf"
      unitRef="usd">-606154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6682920acd2443d386cf76a82976b820_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE1LTEtMS04NDM2Mw_52166339-6f47-42e8-8d88-b3449ff627a4"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic09286a182824949b042732ea31cdf80_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE3LTEtMS04NDM2Mw_782770ca-6058-43ff-bf5a-c671aa4c0e82"
      unitRef="usd">859417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if04d6ce7269d40dab417987869d2650e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTE5LTEtMS04NDM2Mw_f0903d83-2a6a-4c41-80cc-806901d7e95b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yMjYvZnJhZzplOTBkYjE1NzU1ZGM0MmM0OGZiODM2ZGE4NTljMGUwOS90YWJsZTo0ZDc5NDY3ZmJiYTU0MmU2ODBhMDRkZTY1NDU0ZTZhNC90YWJsZXJhbmdlOjRkNzk0NjdmYmJhNTQyZTY4MGEwNGRlNjU0NTRlNmE0XzM3LTIxLTEtMS04NDM2Mw_14edbf6c-f222-4e93-acee-c3606f40bb2b"
      unitRef="usd">859417000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy0xLTEtMS04Mjg1OA_d00664c6-f064-4eba-af4f-32195174fa23"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy0zLTEtMS04Mjg1OA_e25c6efd-c718-4639-ab4a-380b38636984"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMy01LTEtMS04NDU2NQ_2d676619-4cfe-42a6-89d2-ca05ffd20b7d"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS0xLTEtMS04Mjg1OA_313ef0db-d71a-48e6-a67b-52de79b1f8dd"
      unitRef="usd">-23522000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS0zLTEtMS04Mjg1OA_2df495e9-e6ae-44d3-9761-e09ea39a82fb"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNS01LTEtMS04NDU2NQ_11ea8732-9755-40ec-aec8-d2db63a38b1e"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi0xLTEtMS04Mjg1OA_ae8efbb2-80a2-4779-b984-0ff80440b113"
      unitRef="usd">-463000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi0zLTEtMS04Mjg1OA_4e4594be-044c-450a-b310-c9847966125b"
      unitRef="usd">-6786000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNi01LTEtMS04NDU3Mw_d50e2657-560f-4fe1-9a17-3f1fe9de252b"
      unitRef="usd">-698000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy0xLTEtMS04Mjg1OA_e578c599-30b9-4ada-a682-ec9fe37e974a"
      unitRef="usd">4569000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy0zLTEtMS04Mjg1OA_2de0600f-1291-4523-aa3e-f012abe63d17"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNy01LTEtMS04NDU3Mw_d9af58f6-97d9-41e2-b773-4168b181fa71"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC0xLTEtMS04Mjg1OA_9e349ebd-da19-4c91-a5ad-099bee792536"
      unitRef="usd">67195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC0zLTEtMS04Mjg1OA_abdcb58c-dbb7-44c2-8288-b6d14a6564c8"
      unitRef="usd">60037000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOC01LTEtMS04NDU3Mw_fcdf9ec0-fbb4-49e6-b6b4-5175915b975f"
      unitRef="usd">61475000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0xLTEtMS05MTU2Mg_a767683a-cf44-4d27-aa7b-58352ab040a0"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0zLTEtMS05MTU2Mg_7f8bdf79-e4c4-4c80-96b8-bee8eec20dfc"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS01LTEtMS05MTU2Mg_7f401b53-5a6d-45d0-8288-4124ae826791"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:ShareBasedCompensation
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0xLTEtMS04Mjg1OA_a6ad207f-141e-4dd6-a202-8aa4331118bb"
      unitRef="usd">33981000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS0zLTEtMS04Mjg1OA_70b00e70-fa50-43fa-a3b8-65de7269b6c2"
      unitRef="usd">16711000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfOS01LTEtMS04NDU5MQ_835c2a48-2b8c-4fe0-934a-4e95a8d5c78b"
      unitRef="usd">14606000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtMS0xLTEtODI4NTg_5b227b3e-2477-4638-9854-6daefcb2b786"
      unitRef="usd">-45608000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtMy0xLTEtODI4NTg_c7f47aa9-e1ea-412e-90ce-122b83ee8716"
      unitRef="usd">-526000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTAtNS0xLTEtODQ1OTE_32029db9-e552-4417-a694-f91106a6e9c1"
      unitRef="usd">-1132000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtMS0xLTEtODI4NTg_2a0ff33d-f95b-44a3-a692-2d3ddc26cca6"
      unitRef="usd">23056000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtMy0xLTEtODI4NTg_f81357b6-c9de-4f33-8c62-965d38c06f4b"
      unitRef="usd">13041000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTEtNS0xLTEtODQ1OTE_5c86ffa5-a4ac-4267-ac50-e95e75be8691"
      unitRef="usd">21195000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItMS0xLTEtODI4NTg_065be73a-b340-472a-a6af-a90fbe5d7c96"
      unitRef="usd">2302000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItMy0xLTEtODI4NTg_3f2d5a08-34db-4767-8549-b11d434a74f8"
      unitRef="usd">18045000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTItNS0xLTEtODQ1OTE_9de1e621-7df0-4748-a6c5-d4f1c9c05a26"
      unitRef="usd">14780000</us-gaap:AmortizationOfFinancingCosts>
    <evh:GainOnTransferOfMembership
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtMS0xLTEtODI4NTg_91eaec76-0ac3-4603-b746-252404475e45"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtMy0xLTEtODI4NTg_9a78c7b0-d1f9-4d45-b901-7ca52d5e65c7"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTMtNS0xLTEtODQ1OTk_94c97816-3288-46c4-91f9-84b93475cf75"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMS0xLTEtODQ1ODM_94f4d440-219e-481c-90d8-a3ac65f66320"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMy0xLTEtODQ1ODM_b8eb171a-9f09-4fc2-9860-4208e7446fac"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtNS0xLTEtODQ1ODM_072d9e2e-b157-4de8-9bc7-6fd419106a70"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMS0xLTEtODI4NTg_3a4373d6-0752-444e-a472-8dc81bbc846c"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTQtMy0xLTEtODI4NTg_516b6cec-2b1e-4646-9631-0140495d2b9d"
      unitRef="usd">-21343000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtNS0xLTEtODQ2MDc_43cd53ce-bbd7-4420-9035-c78554c0f5c3"
      unitRef="usd">-4789000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <evh:IncreaseDecreaseInTaxReceivableAgreement
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtMS0xLTEtODI4NTg_b6ac90a4-fcba-4a16-a283-4ac5c7117b38"
      unitRef="usd">45950000</evh:IncreaseDecreaseInTaxReceivableAgreement>
    <evh:IncreaseDecreaseInTaxReceivableAgreement
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTUtMy0xLTEtODI4NTg_ee5e8c03-56a0-4e46-a270-ed233fbb4d34"
      unitRef="usd">0</evh:IncreaseDecreaseInTaxReceivableAgreement>
    <evh:IncreaseDecreaseInTaxReceivableAgreement
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtNS0xLTEtODQ2MzM_b3483153-d0a6-4321-a775-a519a551410a"
      unitRef="usd">0</evh:IncreaseDecreaseInTaxReceivableAgreement>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtMS0xLTEtODI4NTg_df96ef37-2e7e-4dae-88d4-294c6d92b8bd"
      unitRef="usd">-2612000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTYtMy0xLTEtODI4NTg_d26fba7e-5102-4e55-8f49-7d02564d2681"
      unitRef="usd">-392000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTctNS0xLTEtODQ2NDE_e54f24f6-5c0d-4fbe-bfd0-28d797773dcc"
      unitRef="usd">-875000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTgtMS0xLTEtODI4NTg_78b150f8-5342-4c82-af14-6dd669b9febf"
      unitRef="usd">102980000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTgtMy0xLTEtODI4NTg_5ab5e435-436a-41c2-95a2-59c1bfdcdc7b"
      unitRef="usd">5779000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktNS0xLTEtODQ2NTA_4b440c5b-764c-4741-aa93-96d0cad95281"
      unitRef="usd">47017000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktMS0xLTEtODI4NTg_26daea35-ec6f-435f-9388-3dc5e2f09805"
      unitRef="usd">-1673000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMTktMy0xLTEtODI4NTg_8c9c8167-b8e6-40dd-b040-5a8ceeb4e530"
      unitRef="usd">-5599000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtNS0xLTEtODQ2NTA_a6eed9af-86c9-4755-bc0b-058500654408"
      unitRef="usd">-7340000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtMS0xLTEtODI4NTg_a0f89318-86d3-465f-aa71-d17aa0cc8269"
      unitRef="usd">7693000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjAtMy0xLTEtODI4NTg_c075eed9-c21c-4670-b794-e24b4b713364"
      unitRef="usd">18979000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtNS0xLTEtODQ2NTA_7c933a94-e60f-4308-9de2-d796acd0eadc"
      unitRef="usd">11400000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtMS0xLTEtODI4NTg_569128bf-3aec-4f8a-9207-9f4ddd8bd3f4"
      unitRef="usd">13165000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjEtMy0xLTEtODI4NTg_0d534192-4094-4076-8e68-47bf0654bb71"
      unitRef="usd">7250000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItNS0xLTEtODQ2NTg_bfe4a944-bdf3-46c7-83ba-91582c330750"
      unitRef="usd">3547000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItMS0xLTEtODI4NTg_de5796ec-e5a7-4fe0-8f9b-c58654a1c245"
      unitRef="usd">-28791000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjItMy0xLTEtODI4NTg_c6430b7d-3d9c-440a-9be6-b50e1651bfd1"
      unitRef="usd">-324000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtNS0xLTEtODQ2NTg_5e3b972f-2467-4373-bdb2-df4b8a1c4d1b"
      unitRef="usd">8801000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtMS0xLTEtODI4NTg_fa389acd-da0f-4b52-b25f-6c36fd44c928"
      unitRef="usd">447000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjMtMy0xLTEtODI4NTg_6cfd606d-6d14-49c8-b6d1-0e483cf08f2f"
      unitRef="usd">3538000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtNS0xLTEtODQ2NTg_c6d0519c-2341-4a7f-85ef-361490857985"
      unitRef="usd">11143000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtMS0xLTEtODI4NTg_f63571cd-f5e0-4b95-aa6c-57d6ef98be33"
      unitRef="usd">-6508000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjQtMy0xLTEtODI4NTg_c97fe1b3-6901-4323-a3a9-9e6cef0f307f"
      unitRef="usd">-739000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtNS0xLTEtODQ2NjY_f36eb246-03e7-41de-abcc-96ebc6ffb3ae"
      unitRef="usd">-8943000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtMS0xLTEtODI4NTg_d4beea75-9157-4a22-8ecd-8470281ec319"
      unitRef="usd">28436000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjUtMy0xLTEtODI4NTg_7af95c9e-b029-458f-960b-5358b5da6c38"
      unitRef="usd">-3799000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtNS0xLTEtODQ2NjY_ae270ef5-0e33-4fa2-9e27-b02212ae7b6f"
      unitRef="usd">-36108000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtMS0xLTEtODI4NTg_abfa4b4c-10d2-46a9-9cfc-83b5ed4333f1"
      unitRef="usd">-2500000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjYtMy0xLTEtODI4NTg_9060c783-f071-4666-85d4-29334f86fd20"
      unitRef="usd">-8844000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctNS0xLTEtODQ2NjY_dc701156-c949-4e26-9623-e259000a4fe9"
      unitRef="usd">-11934000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctMS0xLTEtODI4NTg_2ca2ba3c-645d-4ecb-ae42-fb6a5597029c"
      unitRef="usd">-2983000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjctMy0xLTEtODI4NTg_558c5c8b-f8b1-4b3f-85b1-530f0d93f2d3"
      unitRef="usd">-6522000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtNS0xLTEtODQ2NzQ_6a60fd29-d4e0-4d70-ac2e-a8ff37ef6f39"
      unitRef="usd">-2782000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtMS0xLTEtODI4NTg_7027ed6f-d0ae-4d56-b14b-f8a6ba5cbeaf"
      unitRef="usd">-1707000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjgtMy0xLTEtODI4NTg_877a7127-84e0-4439-a086-2261448aaca7"
      unitRef="usd">-2734000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktNS0xLTEtODQ2NzQ_e1d7f9a0-d53a-4f9e-8764-3cf431219a32"
      unitRef="usd">8166000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktMS0xLTEtODI4NTg_aefd47ea-9382-4c6f-9411-359abcf007b8"
      unitRef="usd">-11553000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMjktMy0xLTEtODI4NTg_8bfe1649-ee03-4dad-a499-d875a92cd7f6"
      unitRef="usd">38747000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzAtNS0xLTEtODQ2NzQ_3b3e5c8c-8735-4fae-825b-aa2cd1ab310b"
      unitRef="usd">-16225000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzEtMS0xLTEtODI4NTg_b8879ad4-dc11-4bf9-82d5-24c144ecc806"
      unitRef="usd">248111000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzEtMy0xLTEtODI4NTg_2c18aae0-5b6f-4e87-860c-3827a778271a"
      unitRef="usd">49012000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItNS0xLTEtODQ2ODI_99b609a1-1d83-4c28-8755-48c942ae0662"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMS0xLTEtODQ3MTc_90f2581d-17d3-4895-a6cc-95fa1bbd573d"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMy0xLTEtODQ3MTc_70841a35-0639-4841-9842-4ca43423a5c8"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtNS0xLTEtODQ3MTc_6b49ffa7-c677-47da-a4b0-cc60f1a915fb"
      unitRef="usd">-1000000</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItMS0xLTEtODI4NTg_f0da7b6c-ee22-4315-a2ed-d1ea7229e067"
      unitRef="usd">30969000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzItMy0xLTEtODI4NTg_4bc561b3-f98e-4f5d-99f4-0e812c979501"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtNS0xLTEtODQ2OTA_0b136ed5-5481-45a7-a8e8-e0c4e89ff0e4"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMS0xLTEtODI4NTg_de4c7888-b38e-448c-a4d3-448f21bde995"
      unitRef="usd">9164000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzMtMy0xLTEtODI4NTg_ffd398b0-fc19-434b-8ce6-93efc3a9e5f8"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtNS0xLTEtODQ2OTg_1fd209a8-ca79-4567-8926-ed1be889e97c"
      unitRef="usd">2287000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtMS0xLTEtODI4NTg_436d90ea-ea13-42d0-b67e-9839588584ba"
      unitRef="usd">5552000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzQtMy0xLTEtODI4NTg_fc9b6836-8976-4a84-9096-aa9318a20b23"
      unitRef="usd">14218000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtNS0xLTEtODQ3MDY_8d3f3ea0-3876-4f98-9475-831af4ef14ac"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMS0xLTEtODQ3NTQ_05bfea16-68ea-48d5-a162-6f67896f81f7"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMy0xLTEtODQ3NTQ_091a4278-1113-407f-b77e-d7fbacab77c0"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctNS0xLTEtODQ3NTQ_a21f50fd-d7ea-4a77-aa3e-014be9a02862"
      unitRef="usd">159755000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtMS0xLTEtODI4NTg_a371afb7-ed6b-41a6-b7c4-cc1267447f99"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzUtMy0xLTEtODI4NTg_da83cae1-cdd1-432d-823f-c9f2b42f653b"
      unitRef="usd">2995000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctNS0xLTEtODQ3MjU_3c56ab37-53a4-4516-9eb5-e60078cfca6c"
      unitRef="usd">11170000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzYtMS0xLTEtODI4NTg_06b2bea7-533e-4e72-847a-7047533db1b1"
      unitRef="usd">0</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzYtMy0xLTEtODI4NTg_3332a86c-10e8-406e-a4a9-c3a43fdc814c"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtNS0xLTEtODQ3MjU_d6694bbc-fdc0-4905-b70a-960742dc0d64"
      unitRef="usd">143441000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMS0xLTEtODI4NTg_5c7de243-5ca8-4cdd-94e7-03fe1e05141e"
      unitRef="usd">38361000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzctMy0xLTEtODI4NTg_c6fbfe0d-d274-4842-a11e-a3cd851e45cd"
      unitRef="usd">24983000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzktNS0xLTEtODQ3MzY_1950063c-3da1-4461-9ea3-9c1eb030b322"
      unitRef="usd">29473000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMS0xLTEtODQ3NDQ_069a344a-343a-41d9-bdeb-e99f71261506"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMy0xLTEtODQ3NDQ_7cbeae4c-2a42-4092-9ac7-f6eab4bcb906"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtNS0xLTEtODQ3MzY_db66c833-9f19-4cb3-bffd-5515fdf4a82e"
      unitRef="usd">-106000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtMS0xLTEtODI4NTg_d849cba4-0cb6-4f9a-bd10-db52b51ea83f"
      unitRef="usd">-259115000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfMzgtMy0xLTEtODI4NTg_ce14ac35-a5a4-4afb-a7d8-5cf2a6d85981"
      unitRef="usd">-15786000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtNS0xLTEtODQ3MzY_86b33d55-2772-44b8-8422-762713b89332"
      unitRef="usd">261072000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMS0xLTEtODI4NTg_258a67d5-042c-4591-be63-824da1157051"
      unitRef="usd">59449000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDAtMy0xLTEtODI4NTg_45e63acc-7676-478e-85e6-3f34640c584b"
      unitRef="usd">-61162000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtNS0xLTEtODQ3Njc_23357e10-755f-4773-9865-834f9c5d0b1d"
      unitRef="usd">6044000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtMS0xLTEtODI4NTg_2780fbab-1bfa-4655-92fc-c2811339ce83"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDEtMy0xLTEtODI4NTg_eb31676c-55f6-46a1-9b6f-6b34026b4218"
      unitRef="usd">98420000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtNS0xLTEtODQ3NzU_9beabace-97ad-4b37-bfdb-683260809d8a"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDItMS0xLTEtODI4NTg_00d21b36-cbe2-4c86-9db3-f1634ac58b37"
      unitRef="usd">4452000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDItMy0xLTEtODI4NTg_f8469c0d-bbdb-4528-bb41-43511cc3fe7f"
      unitRef="usd">13289000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtNS0xLTEtODQ3ODM_f0bf8848-d8a0-42de-bfb4-c0ad0b222c57"
      unitRef="usd">2577000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDMtMS0xLTEtODI4NTg_6a34c3e5-8ec5-4572-8fa4-b8ede63a3ec2"
      unitRef="usd">219740000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDMtMy0xLTEtODI4NTg_206df105-695e-4b95-afda-954a4b146913"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctNS0xLTEtODQ3OTM_77f03707-7fed-4686-a5a6-776625040b2f"
      unitRef="usd">30062000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMS0xLTEtODQ4MzI_46cd1560-4dc8-45cf-a7f3-d10685d9eca2"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMy0xLTEtODQ4MzI_7dbb85e4-7e20-4d9e-88cc-3101065b36fd"
      unitRef="usd">429000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtNS0xLTEtODQ4MzI_81ac0d0c-622a-4b64-8787-3ae83da56c37"
      unitRef="usd">16606000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtMS0xLTEtODI4NTg_a435d6e4-8b02-4310-ae12-0fe3657539b8"
      unitRef="usd">14884000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDQtMy0xLTEtODI4NTg_7e9cf86b-ea90-4918-bed6-76e18d35511d"
      unitRef="usd">1300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtNS0xLTEtODQ4MDE_a4a68325-ad66-4d6c-8ab9-3de82c54cf1a"
      unitRef="usd">20000000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtMS0xLTEtODI4NTg_956c1dc2-23ac-49c5-8828-0b64c9fec36d"
      unitRef="usd">18318000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDUtMy0xLTEtODI4NTg_378720ee-d062-434e-8c1f-4b1374e89273"
      unitRef="usd">3850000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktNS0xLTEtODQ4MDk_bd8c623d-14d8-4135-a0d6-836071b8ed0b"
      unitRef="usd">1851000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtMS0xLTEtODI4NTg_dbae0d76-a675-47f1-b737-25e6bc5f50da"
      unitRef="usd">131541000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDYtMy0xLTEtODI4NTg_b4cf6782-da8b-445a-8079-087b77e2bef3"
      unitRef="usd">-29548000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtNS0xLTEtODQ4MTc_1e13c200-a567-490e-a3de-3c1499f36750"
      unitRef="usd">-11862000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctMS0xLTEtODI4NTg_f667b1fc-300f-4a02-87c2-dd93f33acecb"
      unitRef="usd">-657000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDctMy0xLTEtODI4NTg_382ae2a9-5c5e-4e36-a8a4-6fa4cc5831b7"
      unitRef="usd">-52000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTEtNS0xLTEtODQ4MTc_9ba8ec31-95de-4ec7-861d-f830beeeff2b"
      unitRef="usd">65000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMS0xLTEtODI4NTg_948db984-50fb-4660-b2ad-4ed8ac7b858e"
      unitRef="usd">-139784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDgtMy0xLTEtODI4NTg_70b2ca86-69ed-4684-8db9-44088751a7ad"
      unitRef="usd">-6639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTItNS0xLTEtODQ4MTc_a196e2a5-4d9e-487a-a30c-dd4a03d19d20"
      unitRef="usd">233050000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799"
      unitRef="usd">128531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab"
      unitRef="usd">215158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80MC9mcmFnOmZjNjY2MjAyN2ZhZjQ2NzliZDA3ZDI4Mzg0MGVlODg3L3RleHRyZWdpb246ZmM2NjYyMDI3ZmFmNDY3OWJkMDdkMjgzODQwZWU4ODdfMTAwNg_4debe02e-a9c4-4e2b-abd1-51beb3d703cf">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee-for-service (&#x201c;FFS&#x201d;) reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had unrestricted cash and cash equivalents of $188.2 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80MC9mcmFnOmZjNjY2MjAyN2ZhZjQ2NzliZDA3ZDI4Mzg0MGVlODg3L3RleHRyZWdpb246ZmM2NjYyMDI3ZmFmNDY3OWJkMDdkMjgzODQwZWU4ODdfNDYw_8f4e1a50-cc8a-4f49-bd64-2f9223a480ce"
      unitRef="usd">188200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MjY_5e2ba71e-62f5-4ba7-9b62-8e71207f7490">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#x201c;CODM&#x201d;) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#x2019;s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.  See note 8 for additional discussion regarding accounts receivable and allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#x2013; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December&#160;31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December&#160;31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenue (Exclusive of Depreciation and Amortization)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a"&gt;three&lt;/span&gt; or four-year period and stock options expire 10 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 for further discussion regarding fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA0OA_2a48a199-bf26-41ad-9b0c-af9c27febae2">Basis of PresentationThe consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODg_b09d28a5-5934-4631-8f15-0a26788cb9bc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA0OQ_c44efd29-9ae3-40b3-b101-2dbdff47494b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#x201c;CODM&#x201d;) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#x2019;s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care &lt;/span&gt;&lt;/div&gt;management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ3NjE4NA_91720fd5-5904-425f-8645-a29370397f8b"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODk_62daf450-7e1b-4c76-b258-ab21dbafc01f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI3MTM4NA_a7bae898-11d0-4c9b-908e-7964e31d421d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3ODM_75f59d5a-e3e7-4236-bd65-22d5ad9486c4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i14887938c6954e6aa3b47e2ee7ab8115_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMS0xLTEtMS04Mjg1OA_b0105b2b-5f46-4fb5-9a24-93bc02ecdbca"
      unitRef="usd">2269000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i71cc310322b745e4b90c41075da7866b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMS0zLTEtMS04Mjg1OA_61af8c68-6ea7-4dec-b642-037bc743338a"
      unitRef="usd">3769000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2a701948765942b1893beaaa2e66fdd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMi0xLTEtMS04Mjg1OA_6379ee4e-4669-4b0e-8880-bda4b887cd54"
      unitRef="usd">10912000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iad4400bacf8149dbb4b6b9e8edb38886_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMi0zLTEtMS04Mjg1OA_f2da12be-b1ee-42d4-899e-c08a6cdc916c"
      unitRef="usd">11662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1f4972904db74d38b50bc19776ed0515_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMy0xLTEtMS04Mjg1OA_49775ab1-3cce-4127-b30d-16da00aa61b6"
      unitRef="usd">13777000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie65bd9571ab84a89b67a22db31fb6851_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMy0zLTEtMS04Mjg1OA_2d1d6268-acf6-414b-bc44-484205b9837c"
      unitRef="usd">73226000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2acaca954cda497b8eedaf35072199d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNC0xLTEtMS04Mjg1OA_fdf0d328-b19b-46e0-bb72-00cced9cadd8"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2dea7b844271441593c0a803a0bbe671_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNC0zLTEtMS04Mjg1OA_26926199-230f-4c3d-aee4-cfaad08e9ddb"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNS0xLTEtMS04Mjg1OA_e683d75a-b0e2-4ce7-87cf-4a05eb838481"
      unitRef="usd">26958000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNS0zLTEtMS04Mjg1OA_1323f413-8149-449a-8736-6bcb75699916"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNy0xLTEtMS04Mjg1OA_c325e7ef-cc6d-4db4-a8cf-072a07a14e92"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfNy0zLTEtMS04Mjg1OA_2acfac63-214c-4613-8fab-f8b680b186cc"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfOC0xLTEtMS04Mjg1OA_11a62342-2ba8-4abd-ab1b-8a04785637f2"
      unitRef="usd">14492000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfOC0zLTEtMS04Mjg1OA_706f9ccc-1b5f-4530-83e5-76d94d73d725"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTAtMS0xLTEtODI4NTg_728ac26e-174a-4dfd-87fc-77bace9e3844"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTAtMy0xLTEtODI4NTg_eff5e1ba-bcf6-4894-8f60-e20a9d7a5cbd"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTEtMS0xLTEtODI4NTg_c336b0d4-7873-4738-80b3-7583f3877e7e"
      unitRef="usd">12466000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjhjOTI0ZDU5ZWUwZjQyMzA5NGE4MTAwZDg0ZGQzNTIxL3RhYmxlcmFuZ2U6OGM5MjRkNTllZTBmNDIzMDk0YTgxMDBkODRkZDM1MjFfMTEtMy0xLTEtODI4NTg_7c197d60-d308-4d78-91f4-56964178713b"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4Mjg_f1bf72ca-f334-41b5-9bce-d5ff1da75108">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMi0xLTEtMS04Mjg1OA_362d5224-fd28-4335-a4bf-b9d0f619c635"
      unitRef="usd">188200000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMi0zLTEtMS04Mjg1OA_889be920-d9d6-4c6a-8d11-2da11b30dfa5"
      unitRef="usd">266280000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMy0xLTEtMS04Mjg1OA_a3957fcd-7c4e-4ebe-8e5e-5c800da0a439"
      unitRef="usd">26958000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfMy0zLTEtMS04Mjg1OA_1af36b15-c891-4a84-9ab1-951138eb7387"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfNC0xLTEtMS04Mjg1OA_3524958a-6c1d-4654-b020-7fc1aab0b0ec"
      unitRef="usd">215158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOjU3YTMyOTc3NmY0ZDQ0MmE4MDI2MWM5ZTNiMzZmZTUwL3RhYmxlcmFuZ2U6NTdhMzI5Nzc2ZjRkNDQyYTgwMjYxYzllM2IzNmZlNTBfNC0zLTEtMS04Mjg1OA_8f411d46-4f53-4927-9a55-7dd4c5bbc20c"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1MA_22eb88e0-fa2f-4ba1-ac1a-fa2f3565d37e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1MQ_f3e9dd83-9ffe-4ee5-addf-bee3c322f599">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.  See note 8 for additional discussion regarding accounts receivable and allowances.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2Mw_fcb673aa-4822-434f-b6dc-e05199721741">The following summarizes the estimated useful lives by asset classification:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMC0yLTEtMS04NzYyMQ_cc50e08d-3c19-403e-bdfc-5673b83c9646">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i854900308f794ba998ae7299645ae028_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMS0yLTEtMS04NzYyMQ_acbdaccd-c697-4436-88ed-211063255542">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if29b4590881941c2b0537c0cb5530ec2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMi0yLTEtMS04NTA2OS90ZXh0cmVnaW9uOmE2M2QwYmFiOThiZDQ5YzJiNDFhOWE0ZjI0MTUzYjJjXzQ_c0d5f439-bedf-4d42-82cd-d18b3c7ef17c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id90606a7074b43028a72787dec08a3dd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMi0yLTEtMS04NTA2OS90ZXh0cmVnaW9uOmE2M2QwYmFiOThiZDQ5YzJiNDFhOWE0ZjI0MTUzYjJjXzk_aa980363-47aa-4dfb-8e7f-94277fade12e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmJiNjhhZDg5MmI0MjRkZDc5MDNkNmM2Mzc2ZjMxMTBmL3RhYmxlcmFuZ2U6YmI2OGFkODkyYjQyNGRkNzkwM2Q2YzYzNzZmMzExMGZfMy0yLTEtMS04NzYyNA_4d7fa30b-1d39-4231-b728-43dd2dd2176e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1Mg_3d02236b-666f-4049-90b7-35f1462cf094">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#x2013; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3OTE_7f65a982-598e-4981-a16c-d24c0b80a91e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1Mw_92d53841-72aa-4c2b-ab99-e4328a5f979e">Equity Method Investments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Equity Method Investments&lt;/span&gt;&lt;/div&gt;The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NzM_99194d88-23ea-4314-b9c6-fa977b6f2282">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfNzY3MA_b6cf575a-e1b9-4abb-bc0a-a368a84e45c4"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3OTU_11ac5725-d3d0-4eb2-942d-cec9dfa5d259">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NjA_be90ab06-8a3f-45e7-880f-1886812ae39f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMC0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmQyM2YxNGI2YmZhYjRhNjQ4ZjhkMDJiYjFjNzY2ZDA4XzQ_c7bc2a0d-32ff-4834-8b94-e5d6e05d887e">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i794b0726c989443ab36cb30e95208a59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMC0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmQyM2YxNGI2YmZhYjRhNjQ4ZjhkMDJiYjFjNzY2ZDA4Xzk_f728a53f-ffc9-4944-86e9-57265d59b77a">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6dac60b49c3a4ba89b21c18a1a14925a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMS0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOjUyM2E5NDc4ZGQxNjRjOGVhYTEzZWE1Mjg1ZmQ5NWMxXzQ_218ff898-91f4-4f62-b6c4-adc24f730a62">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2d654080ecda47ef9c7d0a2e2dfbaaf3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMS0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOjUyM2E5NDc4ZGQxNjRjOGVhYTEzZWE1Mjg1ZmQ5NWMxXzk_3095f197-a3f5-421f-9b3c-9def383ffaa9">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMi0xLTEtMS04Mjg1OA_52adc2f6-bc4f-4499-9709-99723e315eba">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2f2eaceac28d48bb9ab95b4c5c5c71ab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMy0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmI4MGRlZGRhZWQ2MzRiZjdhZGMwMjk4NzZhYmUzMTUyXzQ_469e83c1-e3c7-47c5-bdc7-de83f680d194">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib36ebf6b661340eb9375f2171ebfae85_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RhYmxlOmNmOTRiYTI1ODAzYzRlN2RiMjdhYTFlZGU2YzdiNGVlL3RhYmxlcmFuZ2U6Y2Y5NGJhMjU4MDNjNGU3ZGIyN2FhMWVkZTZjN2I0ZWVfMy0xLTEtMS04Mjg1OC90ZXh0cmVnaW9uOmI4MGRlZGRhZWQ2MzRiZjdhZGMwMjk4NzZhYmUzMTUyXzk_2055c9ae-4141-4174-b889-99f17ab005d5">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3Nzk_52dd6995-bb27-4cec-82c0-70e72e965f7b">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3Njk_71461b80-c1b2-435b-bc61-61a8b5d88fa6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU3NzA_aa22613d-270c-44f7-9233-5a3c95839886">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December&#160;31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December&#160;31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI0NTM_371437ce-f09c-4846-a787-9c17bffb4957"
      unitRef="number">0.47</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI0NjA_31f1b133-2399-442f-88fe-c83bc5a91a93"
      unitRef="number">0.42</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTI2MDM_cc37bdb1-3516-48c5-9961-bd2afcc0c29a"
      unitRef="number">0.14</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1NQ_e0277e78-eee2-4a98-9c7c-5a7bec533f83">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MjU_f6e78ab2-17c7-468c-b856-5e593bf5c296">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTMxMzk_3ba63abc-e84e-4761-be8a-0b4b7f046418"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTU4MDQ_1492b3f1-cb0e-4837-ba5d-04bae12fb891">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenue (Exclusive of Depreciation and Amortization)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMzg0ODI5MDczMzk5OQ_7d7bc357-33c2-41bc-9773-9057c61454f1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4Mzg0Nw_b90e80e5-86f2-41ef-9c2e-5d90dad42916">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfODI0NjMzNzI0NTA0MA_f017e09f-c751-4a13-bdbb-0186d2d4035a"&gt;three&lt;/span&gt; or four-year period and stock options expire 10 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iec00374a180d419c962d3b3783c65443_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4MzgzMQ_54f9cc4a-eb69-4e16-8ee4-078c2b3837f9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMTY0OTI2NzQ4MzgzNA_97e352b0-a87b-4d5d-b33a-bb89837506fb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA1OQ_6eacc79e-f923-4cf3-9a17-96acd710f6eb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax &lt;/span&gt;&lt;/div&gt;exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2MA_704bafc9-34e3-4cf6-a5f1-138ee63ad883">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80My9mcmFnOmU3ZTBkNTdjMThhNzQ4OWY4MWMzMjNlZTdkOGY5M2UxL3RleHRyZWdpb246ZTdlMGQ1N2MxOGE3NDg5ZjgxYzMyM2VlN2Q4ZjkzZTFfMjE5OTAyMzI5MDA2MQ_53b3cb8b-5f4a-4a7d-8386-55f156cc3bd1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.&lt;/span&gt;&lt;/div&gt;Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMzE4Mg_a109de33-1473-450e-8563-c5b242861141">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMzE3OA_cb4d036b-409d-4a49-835a-18c01f1d131e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="if3cc2e5de7bd4ce6ba6f437a0abdf186_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjIxMQ_c4e1f54c-af46-48dd-9287-7dbfb29991f8"
      unitRef="usd">39800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11dc640ba4864bd9ab71ea3a5d03e0ce_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjI1Mw_5fad41b0-402f-44c2-8507-6b21253f4511"
      unitRef="usd">106200000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i3474707099524f5ab5cb8bcdef64f129_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjMyNA_773b118c-137b-4fbf-81f1-9257ac5cec99"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i278ee21fa4de4432b9d32268373e0d51_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80Ni9mcmFnOmRlNmEwYzFjOGUyMzQ3NDQ4ZjE0ZDRmMDA0OTdmMTc0L3RleHRyZWdpb246ZGU2YTBjMWM4ZTIzNDc0NDhmMTRkNGYwMDQ5N2YxNzRfMjMzMQ_479f4fc1-fcf4-42d7-88a7-35d1279cebc0"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ1Mg_2d85c765-74a4-436f-9bf0-999617686b05">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Implantable Provider Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#x2019;s Class A Common Stock, at the Company&#x2019;s option. See Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company&#x2019;s consolidated financial statements was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of December 31, 2022, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vital Decisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total acquisition consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on October 1, 2021. The acquisition consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021 is payable in cash and/or shares of the Company&#x2019;s Class A Common Stock, at the Company&#x2019;s option. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pro forma financial information has not been presented for the Vital Decisions acquisition as the impact to the Company&#x2019;s consolidated financial statements was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTkw_1db1d8e4-0151-4ebd-8d00-c6947dd815d6"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ3_0f23b94f-2805-43d1-9f0c-de20f193ba0e"
      unitRef="usd">461700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfODg1_b8f01590-5367-44f0-8770-f9d65f28fced"
      unitRef="usd">256500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfOTEx_d9ce62cf-9c17-4a73-93cb-3241fc230889"
      unitRef="shares">3700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfOTYx_0e3ca226-22e8-4611-8223-e7dd4326ed63"
      unitRef="usd">130200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTAxMQ_949113b2-f8bc-4aae-bcc0-ceb1c87b0b1e"
      unitRef="usd">87000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTAzMA_464b66a8-d2b1-45b5-898d-32f58be75fa4"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ2MA_2a05f44d-bb88-4f78-8a03-4921fe18021c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzQ2MA_81fa556c-939e-45cc-8f58-8beb877fd87c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMS0xLTEtMS04Mjg1OA_25359b9c-dd39-49fd-8c51-b6c4363d97bd"
      unitRef="usd">256488000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMi0xLTEtMS04Mjg1OA_84b895ef-4a21-4ead-b5df-fb348b75dbd0"
      unitRef="usd">130175000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMy0xLTEtMS04Mjg1OA_d654c80f-53b5-4d14-87fb-15dc87aaf483"
      unitRef="usd">75000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id2c918a773654828be4d267be661bf92_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfNC0xLTEtMS04Mjg1OA_7723a8b4-cada-4140-99a8-85debf136696"
      unitRef="usd">461663000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfNy0xLTEtMS04Mjg1OA_41bc26bf-b24f-4d4f-91fd-20c99562215d"
      unitRef="usd">34155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfOC0xLTEtMS04Mjg1OA_849701f2-f384-40fe-8243-33d96ddb3b52"
      unitRef="usd">636000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfOS0xLTEtMS04Mjg1OA_990a457a-9b1f-4f56-9dac-44e178ba6317"
      unitRef="usd">1393000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTAtMS0xLTEtODI4NTg_aa108b31-d379-4254-91ff-aa38664c45b2"
      unitRef="usd">36184000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic6e6da47331f49339af7c848e28837a7_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTMtMS0xLTEtODI4NTg_20a844b8-9d4c-4e39-b834-9125399a2ee4"
      unitRef="usd">154000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i731418333b3f457db87705a22ef20938_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTQtMS0xLTEtODI4NTg_aa4d1634-18ed-441d-ace7-b2df043eedce"
      unitRef="usd">23900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ied844aa0a1054ee8a864d50320d0ae98_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTUtMS0xLTEtODI4NTg_f85d526f-6615-44c3-ac8a-526ccaf169f0"
      unitRef="usd">17800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTYtMS0xLTEtODI4NTg_b7f6248d-020c-49fb-882e-cfb255ca8561"
      unitRef="usd">195700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMTktMS0xLTEtODI4NTg_75379130-b951-4b64-8116-3a9b5f01f42a"
      unitRef="usd">7997000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjAtMS0xLTEtODI4NTg_08921172-96b3-42e5-ae88-84f9bc533198"
      unitRef="usd">8083000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjEtMS0xLTEtODI4NTg_2ddaebfc-fc3b-4a51-8469-3313280799ce"
      unitRef="usd">423000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjItMS0xLTEtODI4NTg_ab290372-5b31-42ce-a559-7efd2fef294a"
      unitRef="usd">48671000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjMtMS0xLTEtODI4NTg_252efff7-4723-4c20-92c6-dd6287a32952"
      unitRef="usd">321000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjQtMS0xLTEtODI4NTg_c9fed61b-d64e-4ec4-befb-08c5e8d2b421"
      unitRef="usd">1323000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjUtMS0xLTEtODI4NTg_18a9bdc8-b78f-4bb2-ae1f-5186ba322164"
      unitRef="usd">66818000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjctMS0xLTEtODI4NTg_dc8f59a9-9287-4805-8440-21ef4a7ac473"
      unitRef="usd">296597000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjg5ODM5NDFlODFhYzRiYzc5NGZiYjk1NWVjNDRhYTk3L3RhYmxlcmFuZ2U6ODk4Mzk0MWU4MWFjNGJjNzk0ZmJiOTU1ZWM0NGFhOTdfMjgtMS0xLTEtODI4NTg_e5ff9e4d-cd9f-4852-92c6-07a0a1e8aa1e"
      unitRef="usd">461663000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i20beaec13c36498a8bc039958c7e54dd_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTc5Mg_f394710f-f60e-4888-9366-0f1d25e08ab4">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i251ae7d7cad040829c7cc296314ee7a5_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTc5Ng_de94a7c4-ee93-4f0d-94c5-91a39a84c055">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0f82a39ee182494c9861025f94b259b3_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMTgwNA_e1f541a6-1096-48f7-a8f3-f6b8a0743aba">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i521ab45bcc9f4828b98cbd32c8324834_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMzQ4Mw_39c8263e-d80f-4a21-a2ec-b04e1840c4df"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6f5790c27f32404bbca49e84b9b60f2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfMzU1Ng_b33f4ff0-4c38-44c1-a885-9bd0ff567fcb"
      unitRef="usd">46800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDI4Nw_a77137c6-31b3-45ba-8eb8-3adc677ee350"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDg0Nw_3e986b04-bc99-41a5-9198-fe66ea5307d1"
      unitRef="usd">117700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNDk4Ng_0fe5c59e-6270-45ac-b84c-538a4f4f4a66"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTAxMg_1ce5d074-7081-4784-8d84-3aa2c250ad3e"
      unitRef="shares">1800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTA2Mg_34ece5a4-e800-4135-b4c7-7528dac54f06"
      unitRef="usd">56600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTExMw_6e3be36f-d6b2-47d9-9416-d08f307f0820"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTEzMg_e2345f81-c25e-4c6b-b501-e0ec37b4b78b"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMS0xLTEtMS04Mjg1OA_050b7af3-1235-41db-a9fe-ca16de76cf4f"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMi0xLTEtMS04Mjg1OA_dbf45afd-dc98-4319-8ed5-8baf531c53ae"
      unitRef="usd">56626000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMy0xLTEtMS04Mjg1OA_d9af2223-6dbe-49b9-bb7f-3007a06b22b8"
      unitRef="usd">14600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9f9c5cc346264042aac84e4c4e05747a_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfNC0xLTEtMS04Mjg1OA_0578a054-e3bb-48e9-848c-87f5f5ea864f"
      unitRef="usd">117726000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfNy0xLTEtMS04Mjg1OA_567be779-c25e-427b-a31c-d323c50614cb"
      unitRef="usd">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfOC0xLTEtMS04Mjg1OA_8f337e33-bb2a-4cc4-92cc-5752951c5fe1"
      unitRef="usd">3301000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfOS0xLTEtMS04Mjg1OA_3b8fa321-b707-4e67-b74c-36f4f838d573"
      unitRef="usd">78000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTAtMS0xLTEtODI4NTg_029e49a1-0ec7-4c77-a33f-3863e52a85f0"
      unitRef="usd">2564000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTEtMS0xLTEtODI4NTg_9bf5f883-89b1-4d26-8ff2-d72892016cb9"
      unitRef="usd">7373000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ice2addc7fc4c404ba9808eca26ad7144_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTQtMS0xLTEtODI4NTg_30756a72-167f-4433-8348-08e5d7a71bb7"
      unitRef="usd">32500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1ba8025aa2b5405cbb56eb40f35c59c9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTUtMS0xLTEtODI4NTg_dfe6656a-5c15-4333-a411-f0976b12c947"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4adfad20cf7f4a50ab8f54cce2eb1c05_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTYtMS0xLTEtODI4NTg_5d563e60-4d4b-4d60-8673-5da86894f6ef"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMTctMS0xLTEtODI4NTg_a9fe41df-cb6b-4154-857c-d98a7fa6e17b"
      unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjAtMS0xLTEtODI4NTg_035459bf-b9c7-4cf8-a0fa-2d9dcf68240a"
      unitRef="usd">93000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjEtMS0xLTEtODI4NTg_80f8fa70-56fe-4d4f-98c5-a113c7cb269b"
      unitRef="usd">661000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjItMS0xLTEtODI4NTg_3acc0130-289c-4f05-85e3-376d6b084624"
      unitRef="usd">970000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjMtMS0xLTEtODI4NTg_2d19791e-6381-4542-a0e1-f3b31950a92d"
      unitRef="usd">499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjQtMS0xLTEtODI4NTg_1effc386-97ac-4460-9254-79e90d66f60a"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjUtMS0xLTEtODI4NTg_59616ffd-d018-4069-a2b9-cfe1f290274d"
      unitRef="usd">2712000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjYtMS0xLTEtODI4NTg_46e407ba-2935-4695-af9b-181f1216e31f"
      unitRef="usd">6935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjgtMS0xLTEtODI4NTg_4acc121a-d024-4a51-9b72-0e381144bb27"
      unitRef="usd">77288000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RhYmxlOjQ3NDEzYzE1OTA4ZDQ2MzViODc0ZDVmN2JhNWMyODgyL3RhYmxlcmFuZ2U6NDc0MTNjMTU5MDhkNDYzNWI4NzRkNWY3YmE1YzI4ODJfMjktMS0xLTEtODI4NTg_62288879-b076-415f-ba83-778931870029"
      unitRef="usd">117726000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia9e5d9baadc74708b8555d95b779a6b4_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTg5NA_3af1d2ac-a7d7-419b-84eb-c2b90adafef2">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iaee36e9557da420a9bad4cb01fb7b743_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTg5OA_8a42a404-ab8c-4bbf-bc2b-d3d908a59cf6">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic49894ecf0ce44d6aa77bc0c1e9552b6_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNTkwNg_864797c2-9793-467e-acde-2d13965cf35a">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ifed01c1956424fc8b203762b2f8ad778_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV80OS9mcmFnOmIwYmY2YmIyNWRlZDQwMDU4Y2RmZjczM2JiZDY2NjI0L3RleHRyZWdpb246YjBiZjZiYjI1ZGVkNDAwNThjZGZmNzMzYmJkNjY2MjRfNzM3Mg_89ebdfdc-68ae-457d-b630-0b10b8c20225"
      unitRef="usd">69600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjI3Ng_c5b4519b-2d0d-45f9-bab4-d19b67d8aad6">Discontinued Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million and $13.6&#160;million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4&#160;million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows (used in) provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjI3Nw_3497aab1-992f-40f8-893e-f91b9c7bdd57">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million and $13.6&#160;million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4&#160;million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows (used in) provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ibd3d798217ac414cb2080eebc4cbe42e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMi0xLTEtMS04Mjg1OA_c7a0ea8b-2e24-4270-a858-08888fe26bad"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1b848b407c6a43a98ee8f6b9437139c2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMi0zLTEtMS04Mjg1OA_aac954f4-2636-4293-9886-d13ba0314c4d"
      unitRef="usd">356000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i299f85d0abd44211ba11ded9b436d161_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMy0xLTEtMS04Mjg1OA_70ad7116-b700-4c78-a521-336c2db356ca"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1b6a62a817d1416b9bad705a714c025f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMy0zLTEtMS04Mjg1OA_afee6864-4698-4a88-86df-e0013561ceee"
      unitRef="usd">117377000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNC0xLTEtMS04Mjg1OA_4c68e74c-95d4-4a5c-b3ba-7a3d1852988a"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNC0zLTEtMS04Mjg1OA_d60324c5-3a02-434b-a53a-bbb1daa26627"
      unitRef="usd">117733000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNy0xLTEtMS04Mjg1OA_eb0983ac-a555-4f66-a540-e95ac91edaa4"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfNy0zLTEtMS04Mjg1OA_8c392369-f5c9-491e-b86d-1d67d2d1bc98"
      unitRef="usd">18343000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOC0xLTEtMS04Mjg1OA_f5552d70-a042-43a3-869a-d809f525bd95"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOC0zLTEtMS04Mjg1OA_943320b7-6e53-45b0-ab37-7a8b9be59198"
      unitRef="usd">87951000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOS0xLTEtMS04Mjg1OA_6a22e93c-9512-40c2-bc06-e52cfbc4b6e5"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfOS0zLTEtMS04Mjg1OA_71af4a5b-4925-4224-a0e1-e23d9c502e1e"
      unitRef="usd">18576000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTAtMS0xLTEtODI4NTg_6b44805e-f5de-4ac3-beee-53c33c7ec6d6"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTAtMy0xLTEtODI4NTg_8be1169c-b11b-4518-83d3-743156535b64"
      unitRef="usd">640000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTEtMS0xLTEtODI4NTg_ca690b87-1f25-4233-b7af-d496880d5514"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTEtMy0xLTEtODI4NTg_6acc17c8-7dc8-45f0-9322-cfee7c874f7e"
      unitRef="usd">125510000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTItMS0xLTEtODI4NTg_3cad3d79-8f13-488d-8309-af4fa4421d72"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTItMy0xLTEtODI4NTg_7eecbbbe-6a33-4bbb-bc9a-67541b8f61e1"
      unitRef="usd">-7777000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTMtMS0xLTEtODI4NTg_e92ccf45-cb1b-4889-a66f-8f954377504c"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTMtMy0xLTEtODI4NTg_13cdf2de-90ca-41f4-8453-7b6f5571bb70"
      unitRef="usd">531000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTQtMS0xLTEtODI4NTg_4f05e835-43e7-4484-b1df-6db54566e297"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTQtMy0xLTEtODI4NTg_356f0277-2238-473d-9e4d-99206286c8c0"
      unitRef="usd">12000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTUtMS0xLTEtODI4NTg_a8e044fb-06f9-4361-b5d4-b7df432b8e33"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTUtMy0xLTEtODI4NTg_993b6662-f455-4b8d-b9f6-1693fd7687d2"
      unitRef="usd">1000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTYtMS0xLTEtODI4NTg_5846684b-347f-4d84-819b-a59f0b2a1597"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTYtMy0xLTEtODI4NTg_b69bc09a-1ede-45a9-92ff-82f8cac5a6b3"
      unitRef="usd">-7259000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTctMS0xLTEtODI4NTg_d1aaf534-471f-4186-a605-d21c9e5aefdc"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTctMy0xLTEtODI4NTg_fa9017bc-5f28-4cec-829a-4b23f5b29f61"
      unitRef="usd">-1185000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTgtMS0xLTEtODI4NTg_1e3ba5d8-74ee-472f-97f0-2365b3073d02"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOjhjYWMwY2Q2MzhiOTRlNTZiY2I2NDlmZDI4NTJmN2M1L3RhYmxlcmFuZ2U6OGNhYzBjZDYzOGI5NGU1NmJjYjY0OWZkMjg1MmY3YzVfMTgtMy0xLTEtODI4NTg_86d03260-f7b8-48e8-aad5-ee57d7dcd873"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="id27c2948c6044f07921f59caf0304963_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMTY4NQ_45da922a-b181-47f8-9696-e5d5ebe8d66c"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ic1705bda8a114733924cb513d21573c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfNTQ5NzU1ODE2MzQ3_35a60f29-979d-4c07-b4f0-d187ed8fb4c9"
      unitRef="usd">13600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="id27c2948c6044f07921f59caf0304963_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfMjA1Mw_502ecbcd-a0bd-4d61-a13a-c4c51976e8aa"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ic1705bda8a114733924cb513d21573c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RleHRyZWdpb246ZGJhMDdlNGM1NWJlNDc4ODhlNTA0OTAyNDFlZTJkYWRfNTQ5NzU1ODE2Mzc5_67eddc3d-5f7c-4930-8688-06f7fc77ff40"
      unitRef="usd">6400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMC0xLTEtMS04Mjg1OA_1af3ca37-6b48-4f7f-811d-f01a7b69a0a8"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMi0zLTEtMS04NTI4MA_b4a322b3-1d29-4648-bb66-feb33cf529a2"
      unitRef="usd">6852000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMS0xLTEtMS04Mjg1OA_d93ce49b-0bb6-4371-8a1f-75ca787ba12b"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81Mi9mcmFnOmRiYTA3ZTRjNTViZTQ3ODg4ZTUwNDkwMjQxZWUyZGFkL3RhYmxlOmZjZmM1ZWJlZWE0NzQ3ZGI4ZTU4ODIyMjMzOGIxZWIxL3RhYmxlcmFuZ2U6ZmNmYzVlYmVlYTQ3NDdkYjhlNTg4MjIyMzM4YjFlYjFfMy0zLTEtMS04NTI4MA_1affccde-74be-4a02-90ce-1fcd175abc7d"
      unitRef="usd">2636000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ4MQ_ad62b498-ca99-4d70-846f-ad8352b62f1a">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $49.6 million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 76%, 93% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $36.3&#160;million and $28.3&#160;million for the years ended December 31, 2022 and 2021, respectively, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $3.4 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of $3.0 million, $1.9 million and $1.9 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Evolent Health Services segment, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2022 and 2021, the Company had $14.1 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $20.1 million, $11.1 million and $13.0 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ3Nw_2c103638-39e8-44ba-9124-b5067cf1f24c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eb70847d04443d8b6e7ab48773cde8d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy05LTEtMS04Mjg1OA_095d6515-39e5-4202-ae3d-2bfc79c8b632"
      unitRef="usd">238504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a6dbe2c6f2414b90261c99c16aa440_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMS0xLTEtODI4NTg_af843040-f62c-4f6d-a308-c6586f3214a4"
      unitRef="usd">215236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5bff01d6db40d49a991496b0df8d88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMy0xLTEtODUzMTg_7cf31b8b-5b43-4086-a5d1-87ea3ecbfc7c"
      unitRef="usd">236634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia342dc91eb1f44d4a17bc2df78ae5230_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xMy0xLTEtODI4NTg_d8e1a6e3-31b6-4eb7-a1d3-ec0c5b966771"
      unitRef="usd">320858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb97d6ee9d56404985bda4f9b13e5846_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xNS0xLTEtODI4NTg_9f454018-6509-466f-a9e0-f8947b8e6af2"
      unitRef="usd">205833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcffd9facc4645f4a013b7bdbb72a431_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfMy0xOS0xLTEtODUzMjY_79d348e6-09d1-4a90-a65a-f5fdc12d74a5"
      unitRef="usd">274028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a2bb61dae04616b359eba263ce435c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC05LTEtMS04Mjg1OA_56f345f1-7abe-4f71-ba8e-79a68e503532"
      unitRef="usd">27092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74d8936f21714f009331932a8897b732_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMS0xLTEtODI4NTg_9a3ae3d7-2511-4c25-8ec4-1136202ac330"
      unitRef="usd">26358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c3548808ff348918ed362fd31f8088d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMy0xLTEtODUzMTg_6b9f0a01-60d7-4d57-9fce-aa07ec4f8366"
      unitRef="usd">68505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ee490b62ac543baa9936f426d939efb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xMy0xLTEtODI4NTg_74b7d815-c522-4a11-aedb-cc3dadeafda4"
      unitRef="usd">431321000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if60d893faa2748b58fedd3523e6ec66c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xNS0xLTEtODI4NTg_46c9b2a4-019e-4979-b565-9d6975cf3591"
      unitRef="usd">380973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab057b320374485bb2001c40a00ce836_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNC0xOS0xLTEtODUzMjY_04d43d80-6045-4560-86b3-d37ff376c9e2"
      unitRef="usd">258905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab12224f7bf840829d0a888e32c3dded_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS05LTEtMS04Mjg1OA_cf3b24fe-a904-4e50-a327-0cd5d97ebd26"
      unitRef="usd">141906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70b27104772b4bde9b232264fa371923_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMS0xLTEtODI4NTg_cc48f95c-0360-4e0b-acf8-d84c6a441aac"
      unitRef="usd">68219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd90e09efa14e17ad4601baa83a3961_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMy0xLTEtODUzMTg_59fd1625-f5f8-44c3-8591-7fd09af9ec14"
      unitRef="usd">77221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356a26303bb54909842ab7a281dbfe38_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xMy0xLTEtODI4NTg_d6e27a59-d7f3-4c53-b48e-5b2cb14d9fc8"
      unitRef="usd">192332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbfb19be991146d3a9e26988e59d0c39_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xNS0xLTEtODI4NTg_d7349767-182c-4ab2-884a-0cc2670517c2"
      unitRef="usd">11338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i954aacf21ddb4d74a25b5f7fea44da70_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNS0xOS0xLTEtODUzMjY_c6324760-cfa3-4f8f-95c5-fedcd8dc0240"
      unitRef="usd">9346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi05LTEtMS04Mjg1OA_d6da51de-4e41-4acc-ba85-6d819aaec7c2"
      unitRef="usd">407502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMS0xLTEtODI4NTg_99f5a876-0b4c-4d1a-9001-7f673d947442"
      unitRef="usd">309813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f54db1c05e74787a89c8997e36036e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMy0xLTEtODUzMTg_8f6820d1-4e44-4b08-9946-5b1f713a3897"
      unitRef="usd">382360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xMy0xLTEtODI4NTg_a6b92237-5d59-4729-9f0c-8f253d87c77c"
      unitRef="usd">944511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xNS0xLTEtODI4NTg_421ec707-00e2-434e-acdd-0a80a2cc249a"
      unitRef="usd">598144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60221f52e25e439cb996bb69367033a8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOjUwOGQyZTM0N2M1MzRjYzQ4NmJmYTQxOGE2NTZmYTI1L3RhYmxlcmFuZ2U6NTA4ZDJlMzQ3YzUzNGNjNDg2YmZhNDE4YTY1NmZhMjVfNi0xOS0xLTEtODUzMjY_bd21de1b-41f8-4c19-98f0-b6040f2208aa"
      unitRef="usd">542279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDMzNw_d3e815eb-6367-42b2-8530-32b725002640"
      unitRef="usd">49600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="id8a19c81d5714f6d8f22e6db248a7c11_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk1Ng_a06651e6-a803-454a-bc63-b189de62bd4a"
      unitRef="number">0.76</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i71c38f21edbe411aa8eb628e23ab4e20_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk2MA_856c2859-7cdd-4501-abd2-d9f940fbf92c"
      unitRef="number">0.93</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i2d354e96c97c42cba45e2df7b64eda05_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNDk2Nw_db3b8717-f020-4fef-b54b-f92a2bbeee04"
      unitRef="number">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTQ4MA_083f99b8-e05b-4973-852f-e30efd4758d4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMS0xLTEtMS04Mjg1OA_21d372bc-4045-4914-ae22-c2d4b5fa4105"
      unitRef="usd">246209000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMS0zLTEtMS04Mjg1OA_0e67facd-01d3-48b8-9111-df00ed91afc5"
      unitRef="usd">129012000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMi0xLTEtMS04Mjg1OA_44af32e8-27b1-4051-bdfa-fc9b80e4affe"
      unitRef="usd">0</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMi0zLTEtMS04Mjg1OA_90d62292-3b4c-4ffa-a722-5ef47b04273a"
      unitRef="usd">4877000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMy0xLTEtMS04Mjg1OA_208a03c8-e9c9-4136-91d8-c530a92b502c"
      unitRef="usd">5758000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfMy0zLTEtMS04Mjg1OA_debfb871-5123-4d2d-b579-774cad782130"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfNC0xLTEtMS04Mjg1OA_6fd68b82-87b1-45eb-9e99-fce6c4b510c1"
      unitRef="usd">2533000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmJiMWE0MTU0NzJlNjQ1MzBhMmJhZjM2MzkzN2FhODQwL3RhYmxlcmFuZ2U6YmIxYTQxNTQ3MmU2NDUzMGEyYmFmMzYzOTM3YWE4NDBfNC0zLTEtMS04Mjg1OA_573a7461-562b-401e-88aa-95f69eb26e69"
      unitRef="usd">4437000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMS0xLTEtMS04Mjg1OA_e9d713e2-f7b6-4960-9a24-b12a2fbc0101"
      unitRef="usd">16381000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMi0xLTEtMS04Mjg1OA_f64eaa6a-7665-4080-9c9c-a6f4744ce642"
      unitRef="usd">11901000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfMy0xLTEtMS04Mjg1OA_6b537159-8f7f-4c45-9535-06516f313a9a"
      unitRef="usd">3811000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RhYmxlOmNhNDg0MGJjMTZjYjRkMzNhNzExYzRhZDU5ZjY5MDFkL3RhYmxlcmFuZ2U6Y2E0ODQwYmMxNmNiNGQzM2E3MTFjNGFkNTlmNjkwMWRfNC0xLTEtMS04Mjg1OA_b94fe6fb-985b-4a83-af00-3f58ca880a06"
      unitRef="usd">8291000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzE2NQ_c87c3366-b57c-47b7-b0c5-4124f9c3ee68"
      unitRef="usd">36300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzE3Mg_900d4cad-5cb8-40d2-8b63-527dd2d082a2"
      unitRef="usd">28300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="ie4dd7b111832484390e1d97d1f46453e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzgyMg_adf82242-7126-45b9-9788-42a6873e8872"
      unitRef="usd">3400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i0ee9e7b57f344206982ad42c4f293487_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNzgyOQ_cdf92cab-ff31-4dd9-a353-98df2760ddc9"
      unitRef="usd">5200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i590b14ec27994ed597799e4952a9046f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODA1MA_1dbc75b2-8d68-43c8-825c-29be6fc13833"
      unitRef="usd">3000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i934d9414193f4601b5323bf2a681279b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODA4Ng_dad56dcf-fd1a-4ec7-8cc4-426067cf3bf1"
      unitRef="usd">1900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i35616843f0a7418d8fc7ad365b3215fb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNTQ5NzU1ODIzNTg1_0ccee0fd-85f1-4bc0-a8ee-08747fb6c28e"
      unitRef="usd">1900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i8607bc42763645fbbe43278eec65e305_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODgyOQ_2380d9df-a391-4402-bdae-7dddae04d2c7"
      unitRef="usd">14100000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i6c9997d7a05d4993962ccc3338c361fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfODgzNg_f7901236-c6f6-4c24-ad02-db034c03dd9f"
      unitRef="usd">27400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i77bd19d50e3f457ba4098eb4c0c152d8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTE0MA_54530142-99a4-4fb8-b58b-fe652c8ffdfd"
      unitRef="usd">20100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if8388c7551f94e269587ab5aac659a6d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTE3Ng_e0f7d9d5-1b6e-4a80-b398-221e009b58d2"
      unitRef="usd">11100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ie3355e9dfc324571bb9fba8d6e2175e0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfNTQ5NzU1ODIzODc1_a79dfe76-2a0e-4081-9449-ec0fe2be8beb"
      unitRef="usd">13000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV81NS9mcmFnOjc5YzI4MmI5YjQ4NTQxOWViODk5Mzg3NGFhZmRjNGNiL3RleHRyZWdpb246NzljMjgyYjliNDg1NDE5ZWI4OTkzODc0YWFmZGM0Y2JfOTM2Mg_8645e6a8-29a8-462e-9ebf-ebbe86fe9bcd">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMzA5MQ_a122fc8c-8047-4b6c-be3e-792c28b8a785">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2022,&#160;67% were current, 21%&#160;were past due less than 60 days, with 29% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;December&#160;31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$269.1 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of&#160;$10.2 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPG acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjI4Mg_a3bf6e92-0bca-49ff-9617-66b2ee2fd1a5"
      unitRef="number">0.67</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i3b29b57edf8c489f99a4516a6ca5a0b3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjI5OQ_5e515825-a931-4853-aa12-cd7c2f3cdc95"
      unitRef="number">0.21</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i81cd6e53eeb5464e80084e5f32636562_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjM0MA_c7df34e0-d57b-44c1-adfb-abbf6d5bad14"
      unitRef="number">0.29</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjM5Nw_87913ad0-a852-4928-bf18-9921ed659c0c"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i11c2ab305dbd45518a81ed1d65fe5dce_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjQxMw_b1e33a8c-977e-4852-bc77-e4eab744f2a2"
      unitRef="number">0.02</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="ic71ceeb3c88542a5b9fb0b508980035b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjQ1Mw_7a414912-b23c-4909-923e-8fa53e3f7b94"
      unitRef="number">0.03</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjU3Mg_6f0d3eba-9114-45ea-8a2f-0a4b5dfb182e"
      unitRef="usd">269100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjU3OQ_36524d3a-16fb-4e58-86d9-08e4abb5258e"
      unitRef="usd">171500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjcxMg_42902abf-0c23-4339-9f62-61135f1e043a"
      unitRef="usd">10200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMjcxOQ_7077c36a-3854-446c-83a3-836939568828"
      unitRef="usd">3400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RleHRyZWdpb246MzM4NGViMTkwODEzNGMzY2I2ZWJhOThlNjMzYzdhYmNfMzA5Mg_179e68f5-a673-4f58-936f-5f31562d6ce8">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPG acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMi0xLTEtMS04Mjg1OA_78539938-8240-458b-8b07-826771115241"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMi0zLTEtMS04Mjg1OA_a157e383-05a7-416b-908c-edede48ae62d"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMy0xLTEtMS04Mjg1OA_b4045290-7967-440d-8d64-906b21686521"
      unitRef="usd">5269000</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfMy0zLTEtMS04Mjg1OA_b7153e11-036b-47b4-857b-16ee7e93f59d"
      unitRef="usd">0</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNC0xLTEtMS04Mjg1OA_a76195ee-b8aa-40ae-a976-fae48fb57eaf"
      unitRef="usd">2740000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNC0zLTEtMS04Mjg1OA_151a80cd-d906-45db-b872-375dd9892dba"
      unitRef="usd">2411000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNS0xLTEtMS04Mjg1OA_00dc0298-e5f6-4aa8-b839-63f7a7ca4b85"
      unitRef="usd">1203000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNS0zLTEtMS04Mjg1OA_a6478f02-bb4e-48ae-8fca-3dc6fbd53489"
      unitRef="usd">6093000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNi0xLTEtMS04Mjg1OA_80e843a3-6ff5-40f4-8cb1-d64f3c200bd7"
      unitRef="usd">10180000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82MS9mcmFnOjMzODRlYjE5MDgxMzRjM2NiNmViYTk4ZTYzM2M3YWJjL3RhYmxlOjc4MGFhYWIyOTIwNjQ4N2VhMzE5NzUyODdiNmEyNjAwL3RhYmxlcmFuZ2U6NzgwYWFhYjI5MjA2NDg3ZWEzMTk3NTI4N2I2YTI2MDBfNi0zLTEtMS04Mjg1OA_467e5a8b-f3c6-4d13-9316-9564bf6c678b"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjgw_5f8710e2-0204-445a-9a3e-4cd98330b3c3">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $29.5 million, $22.5 million and $24.6 million for the years ended December 31, 2022, 2021 and 2020, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $73.7 million and $71.2 million as of December&#160;31, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $32.0 million, $30.6 million and $28.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $27.0 million, $26.5 million and $24.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i28121c511dcf46e8aeb20910dbcc12be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMS0xLTEtMS04Mjg1OA_fc1d7be6-8fd4-425b-bc67-42cfb4b67e9f"
      unitRef="usd">30092000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i483d3e1f905c4cde909281c7434e61aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMS0zLTEtMS04Mjg1OA_5d0facb5-6a58-4e30-821f-96a4b691f38b"
      unitRef="usd">21970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7248538c4a04c15bcc464cd4c0426fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMi0xLTEtMS04Mjg1OA_8d1635b5-63d3-4af3-906d-c5540baca6da"
      unitRef="usd">4214000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i746f0154926c44cc9b1f8fa00aebd8f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMi0zLTEtMS04Mjg1OA_59589e8d-6e23-4d4d-aca9-473a4ca38228"
      unitRef="usd">3581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMy0xLTEtMS04Mjg1OA_98506a56-12c1-49f8-a3bc-0917c55fe144"
      unitRef="usd">189119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i69c5eb57b4454e3b9de4de900fd38726_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfMy0zLTEtMS04Mjg1OA_2064f848-021f-4fcc-a499-182dbcb7db08"
      unitRef="usd">159587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib00357009ca34124aea7882662570449_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNC0xLTEtMS04Mjg1OA_538036fd-9743-42ed-91f4-cc13a730f599"
      unitRef="usd">14926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie56205dd981748ccb2ada978c977bd74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNC0zLTEtMS04Mjg1OA_be427003-2cd6-4097-8eec-a1c5c238b6a8"
      unitRef="usd">15325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNS0xLTEtMS04Mjg1OA_8cd75189-f47c-4892-8513-2e155c612edd"
      unitRef="usd">238351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNS0zLTEtMS04Mjg1OA_3c3cba80-8179-4193-bcb0-2352e3f04f17"
      unitRef="usd">200463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNi0xLTEtMS04Mjg1OA_36d17ea7-d0c5-49a3-a78c-be4b0cf9bcf8"
      unitRef="usd">150477000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNi0zLTEtMS04Mjg1OA_6e0dba71-495c-4e17-be35-2d8febbf45fa"
      unitRef="usd">119098000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNy0xLTEtMS04Mjg1OA_ab9bcf47-00e5-4c88-82f3-fa1a33a707d0"
      unitRef="usd">87874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RhYmxlOmRjYjYwZWNkMmJmNjQxMDM5YjJhM2ZhY2JjMTBjMWIxL3RhYmxlcmFuZ2U6ZGNiNjBlY2QyYmY2NDEwMzliMmEzZmFjYmMxMGMxYjFfNy0zLTEtMS04Mjg1OA_d509e69a-7d3a-4ebe-b885-f064306201cc"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i0573ff9ad81642ec8c214acbc7897d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMTQ2_ead96d8a-cb9c-433c-8815-fa18f1cdb9cc"
      unitRef="usd">29500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ie6fe725ce94f4628b487593ab6df6f26_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMTgy_90a28d33-b037-4621-815d-d6e97e6d219e"
      unitRef="usd">22500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ie4c0a14df2764899b90a8c02978cddda_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0NjIx_7901c2f6-f0dc-4bec-a6b3-b8a1925fda35"
      unitRef="usd">24600000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i51b7226f6b524e9c81d9c7dcd41d01b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMzI5_931d3ee1-3a19-449b-a668-1b35b7c0e3ba"
      unitRef="usd">73700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i69c5eb57b4454e3b9de4de900fd38726_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfMzM2_d6a382de-c471-4ced-803a-78890c4a2d32"
      unitRef="usd">71200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNDUz_ff4b3235-8689-4dc5-9f0d-96e0710bcf31"
      unitRef="usd">32000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNDg5_9942add1-7962-4bf2-8c8c-231a25f6cb34"
      unitRef="usd">30600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0NzY1_d7dc776c-bf47-48ef-928f-4b49d6c98e59"
      unitRef="usd">28300000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjE4_87a53031-1e31-44fc-b947-1da1f8efca41"
      unitRef="usd">27000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNjU0_5d3feffa-5733-4b24-a728-56864691411e"
      unitRef="usd">26500000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82NC9mcmFnOmZjYjUwYjg0OGE2NjQ4MWVhZTE4Y2RiNjI0MThkM2M5L3RleHRyZWdpb246ZmNiNTBiODQ4YTY2NDgxZWFlMThjZGI2MjQxOGQzYzlfNTQ5NzU1ODE0OTg2_ea1fec14-b7eb-414a-a9b5-a3a1e83bac55"
      unitRef="usd">24300000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjk4Ng_d14b395f-9142-4343-97ea-39de78c53138">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company&#x2019;s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate.  Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management&#x2019;s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit&#x2019;s carrying amounts that would require an interim impairment assessment after October 31, 2022. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets was $35.2 million, $29.4 million and $32.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, excluding $0.2&#160;million and $0.6&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2022 that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzE3_b4300e8f-2087-4356-a2dc-8bc60bce03f1"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i237b041a348240acacdd4c6703d9631c_D20221031-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzg0ODI5MDcxNTg1Mw_80add303-3c34-489b-bc1a-80d194177def"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMTg4NA_2fbb4a26-3ad3-4f6a-b67c-e5d597ed1e9a"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzAwNA_23e6f1c9-9681-4a5e-807d-2e3777026e69">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi0xLTEtMS04Mjg1OA_3397478a-9fa8-45e5-b723-091280bd81a3"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi0zLTEtMS04Mjg1OA_d13f551c-2579-4bb3-bb3b-601ddb9ad1b2"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNi01LTEtMS04Mjg1OA_431cacfa-b9db-4d07-b7f7-e1c220589b33"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0xLTEtMS04NTc5Mw_ab521432-f955-4d08-97fc-eeddc41c9e30"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0zLTEtMS04NTc3MA_cacbca0a-ef86-48f1-8ef1-3743e37f84cb"
      unitRef="usd">77288000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy01LTEtMS04NTc4MA_db7f9e45-cc0d-4b9b-a446-267a959a4c4c"
      unitRef="usd">77288000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0xLTEtMS04Mjg1OA_75af81c6-574b-4ae2-bb87-603c90c4345a"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy0zLTEtMS04Mjg1OA_675efddc-8996-4e19-8fdc-c8e860d83f53"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfNy01LTEtMS04Mjg1OA_f35aa7a1-60d7-4dc1-bd10-034d7bee2e77"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC0xLTEtMS04Mjg1OA_08356206-1ac0-44d6-9695-fac64fd73899"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC0zLTEtMS04Mjg1OA_be018962-0fc0-4be6-a362-7683029953d1"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfOC01LTEtMS04Mjg1OA_e0a9d4ab-78ed-4428-b627-bc0d6e386eb4"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtMS0xLTEtODU4MDM_c1776756-7fce-4c89-9853-08145b20b387"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtMy0xLTEtODU4MDM_808d2a51-7548-4f9e-8836-11bee5698bd5"
      unitRef="usd">296597000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTAtNS0xLTEtODU4MDM_ad91af2c-33b1-448a-a619-4ccdd590405f"
      unitRef="usd">296597000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtMS0xLTEtODU4MDM_7287a501-828b-4bb6-a4fd-40cf5197f694"
      unitRef="usd">-120000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtMy0xLTEtODU4MDM_045da0c5-6ca4-451b-8f79-22346a051c00"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTEtNS0xLTEtODU4MDM_74f1aada-1e87-4b89-bb4b-5ab9e8f346aa"
      unitRef="usd">-120000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItMS0xLTEtODU4MDM_cb5a58c5-bc80-4fef-9f78-4818326ab9c0"
      unitRef="usd">214214000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i33ea7981a58e4cf1bb90015e38b89007_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItMy0xLTEtODU4MDM_e6f59ad3-eb6f-467a-9aa3-e713e54ddb64"
      unitRef="usd">508560000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOmE4MTc0ZDBkYWUzNDQ0ZGU5MmIyZTNlODRlNWJlN2Y5L3RhYmxlcmFuZ2U6YTgxNzRkMGRhZTM0NDRkZTkyYjJlM2U4NGU1YmU3ZjlfMTItNS0xLTEtODU4MDM_e6144a74-86dd-4cd7-9589-45a5b08db331"
      unitRef="usd">722774000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjI0OQ_9f6b2453-9f84-44f7-96f5-cc413ae94990"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9a58b613f9cd47b2bef946da4ceb3f68_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xLTEtMS04Mjg1OA_bb55a252-88b9-473d-a9bc-58c03652a3b0">P12Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0zLTEtMS04Mjg1OA_50fb3575-7825-4af1-9b3c-10683b398e15"
      unitRef="usd">43600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi01LTEtMS04Mjg1OA_6ac09f21-ff17-446e-8e7a-9f86821ac37e"
      unitRef="usd">11726000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ee356487cda493a86e8c0ec69db8b59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi03LTEtMS04Mjg1OA_98e73955-cf5b-4d40-b50a-06271eb4b431"
      unitRef="usd">31874000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4b6ad6302d9d4822b4677702de0baca6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi05LTEtMS04Mjg1OA_4b22361e-80ac-488c-a682-79177cc26f93">P12Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xMS0xLTEtODI4NTg_c809a589-144e-45ca-9c5e-0668625381e7"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xMy0xLTEtODI4NTg_66a2ce1c-6d17-445c-8110-620c79be4b90"
      unitRef="usd">7693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i85dc77e96282486ab64329e19f4f8975_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMi0xNS0xLTEtODI4NTg_16820f05-8428-419f-a77f-59f39a19ffb5"
      unitRef="usd">18107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib9b789e0f0774de2bb35c5e8066ddbdd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xLTEtMS04Mjg1OA_dd51e4d3-987a-4a47-bb04-a93061e3e930">P15Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0zLTEtMS04Mjg1OA_486b6d5c-832d-40b6-8bd7-755a0d696ee0"
      unitRef="usd">465019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy01LTEtMS04Mjg1OA_6338e5fe-301b-433e-ad32-b63ceaa63093"
      unitRef="usd">92760000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i488bd1b5b44642adb4bec38ca437c356_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy03LTEtMS04Mjg1OA_243a3eb4-7e86-4073-9760-0f1033a370d9"
      unitRef="usd">372259000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8f170a61f3e841a696fad5b6a3b357d0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy05LTEtMS04Mjg1OA_ab4aa0b7-c389-4228-9186-b68fccc65703">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xMS0xLTEtODI4NTg_e40a9b73-a72a-487b-b350-9f143816a9a8"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xMy0xLTEtODI4NTg_f6d74d2c-93f9-4071-b032-6696666e76de"
      unitRef="usd">72697000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i67a13a56d549482ea13997a959c85f3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfMy0xNS0xLTEtODI4NTg_18a941d9-4c4d-49f1-a7d0-e9aec56270b3"
      unitRef="usd">238322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i48ce0f49254a4eeb9403c54e2bc03a05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xLTEtMS04Mjg1OA_c3eb6d71-5a03-4499-8516-b60ad9c53f33">P2Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0zLTEtMS04Mjg1OA_7f1d13ce-158f-449d-91b2-4c7ca1a0b0f0"
      unitRef="usd">111822000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC01LTEtMS04Mjg1OA_fff00557-0271-43bd-ba15-73256bc6eabe"
      unitRef="usd">80255000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib5277c572ae949a594d492c3ef91a577_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC03LTEtMS04Mjg1OA_5a9af28b-2135-4856-a69d-eeda94d42010"
      unitRef="usd">31567000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7e29b5293f19416f96f6460860735e67_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC05LTEtMS04Mjg1OA_560ce6ba-ff30-47d5-b090-f30f604e9bcb">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xMS0xLTEtODI4NTg_44095951-a158-4fc7-b0aa-fb1731c5f460"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xMy0xLTEtODI4NTg_24924b6c-2ab9-41bc-b768-592f1789053f"
      unitRef="usd">73378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6669bf057ca644eebe6dffc37bb4b27d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNC0xNS0xLTEtODI4NTg_f0eb7d39-4b4c-43be-b093-a4e0b6c4be74"
      unitRef="usd">14544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i48beabe4144b40898879179f114601ab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xLTEtMS04Mjg1OA_15a6ff51-d9f1-4ce5-b669-945d936133ce">P0Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0zLTEtMS04Mjg1OA_729bdf1e-0df3-42d6-a6b5-00bfe9268f62"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS01LTEtMS04Mjg1OA_75e1c013-b4c8-4abf-bae5-c6a71300fd25"
      unitRef="usd">1151000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8a310b65ac104a1b98bfe8cb95002a92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS03LTEtMS04Mjg1OA_497979b2-d8d8-4bd3-93d5-b010fc209d01"
      unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2cc46062bad34e1d9ad09e26a1395bd2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS05LTEtMS04Mjg1OA_e5a31293-69ae-45bd-b6d6-87e477596cfe">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xMS0xLTEtODI4NTg_6616af54-1691-49b5-8ac9-309253125543"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xMy0xLTEtODI4NTg_8c558707-d3e8-43c4-9307-a5a62a37fd69"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icb2ad760c97e421385f5a9e39aaac544_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNS0xNS0xLTEtODI4NTg_15654b6f-b62b-4552-9636-a8acf593aa13"
      unitRef="usd">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4ee5d4ede71548928f9a624468ad3e3b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xLTEtMS04Mjg1OA_1cd04051-7022-4b91-b029-4f05d18ef9ab">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0zLTEtMS04Mjg1OA_fe904805-9846-4837-b799-fb28abfd1847"
      unitRef="usd">18851000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi01LTEtMS04Mjg1OA_9989a14a-b39c-4252-b653-fd19959f68a9"
      unitRef="usd">11834000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ied9c6f919ebe4066b86bae9e616abcfd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi03LTEtMS04Mjg1OA_3d74151e-f682-4a2b-9b1f-a15b6e0e36c7"
      unitRef="usd">7017000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ieeedc3e2c6d34ca9b04f0eed321027af_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi05LTEtMS04Mjg1OA_fd6cc53b-9a55-4829-87e7-435305b2195f">P2Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xMS0xLTEtODI4NTg_3ad54fea-c09a-42f9-9e01-92c3eb731583"
      unitRef="usd">16417000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xMy0xLTEtODI4NTg_8b048e68-1aaa-4a17-a141-8885aef23c9b"
      unitRef="usd">7874000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1a3d5be6458143d680d969951cb1b604_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNi0xNS0xLTEtODI4NTg_b8ccf660-376b-47f4-a37f-60486b220720"
      unitRef="usd">8543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0zLTEtMS04Mjg1OA_f7c73f18-e119-46f9-8dd6-7bc396343108"
      unitRef="usd">640510000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy01LTEtMS04Mjg1OA_7322bf55-f479-4cbf-b0e8-815ce0aacf0c"
      unitRef="usd">197726000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy03LTEtMS04Mjg1OA_80d2a568-4b3e-439a-a9f7-775be78d6137"
      unitRef="usd">442784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xMS0xLTEtODI4NTg_1ec1e9cf-7536-44d0-a177-3d1c214356de"
      unitRef="usd">442376000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xMy0xLTEtODI4NTg_6cd27a64-8cf6-49e8-859f-c376d34f3360"
      unitRef="usd">162592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjhmOTdlOWZjNzg4MDQ1ZmE5OTYyMmNlMWViOTY0MTYyL3RhYmxlcmFuZ2U6OGY5N2U5ZmM3ODgwNDVmYTk5NjIyY2UxZWI5NjQxNjJfNy0xNS0xLTEtODI4NTg_a363efac-90b6-4fe5-b81f-dfc88df9d95e"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjU3Nw_c17ea41e-6978-4119-a712-3f35c069472f"
      unitRef="usd">35200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMjYxMw_a5516e5f-2276-46d7-bde2-bc11f0d8a4b4"
      unitRef="usd">29400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfNTQ5NzU1ODE3MjQy_44e60ce1-7bd8-483f-9fd4-259196fd721a"
      unitRef="usd">32300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7f4faacf6f0445328725694f5418ffff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzg0ODI5MDcwMDg3OA_d0d43a9d-f7f3-4947-90cd-4aa5cc25d03e"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfNTQ5NzU1ODE3NTM0_4c4cb912-af42-4019-a959-7827bb152d94"
      unitRef="usd">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RleHRyZWdpb246ZTRhZDE3NTQwZWUyNGI5N2ExZDE2YmY1NWFlM2Y0ZjRfMzAwMQ_23aed692-7e49-45e6-93f4-0d22d95c5815">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMC0xLTEtMS04Mjg1OA_70480527-8e5f-4586-b165-d499c199ea3a"
      unitRef="usd">41488000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMS0xLTEtMS04Mjg1OA_a5269fd6-9ffc-455d-8611-75058a5c745d"
      unitRef="usd">35604000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMi0xLTEtMS04Mjg1OA_06739578-010d-4497-bfd8-729772c2bfbb"
      unitRef="usd">33057000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfMy0xLTEtMS04Mjg1OA_b4c28f9f-308f-414f-9417-0669723601ae"
      unitRef="usd">32880000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNC0xLTEtMS04Mjg1OA_132bd24a-6990-4141-8404-8db114a97a7c"
      unitRef="usd">30138000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNS0xLTEtMS04Mjg1OA_3b400321-234c-4c41-8f15-a0f4b359fc52"
      unitRef="usd">269617000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV82Ny9mcmFnOmU0YWQxNzU0MGVlMjRiOTdhMWQxNmJmNTVhZTNmNGY0L3RhYmxlOjI5NjQ4OTg3OTkxZDRhYzZiZTcyMGE1YTI5YzVlMmM2L3RhYmxlcmFuZ2U6Mjk2NDg5ODc5OTFkNGFjNmJlNzIwYTVhMjljNWUyYzZfNi0xLTEtMS04Mjg1OA_23c7a49b-e3ed-4b6d-b774-244e77eb2b8f"
      unitRef="usd">442784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjMyNzI_5d2ef0a8-e562-4be2-8a32-e6fc841eb7c6">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the IPG Closing Date, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#x201c;2022 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2022 Initial Term Facility, with an aggregate principal amount of $175.0&#160;million and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#x201c;Revolving Facility&#x201d; and, together with the 2022 Initial Term Loan Facility, the &#x201c;Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the 2022 Initial Term Loan Facility on August 1, 2022 (the &#x201c;Initial Term Loan&#x201d;), and also borrowed $50.0&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $7.9&#160;million in interest expense related to our 2022 Credit Agreement for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $5.3&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.4&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $2.7 million,  $4.1 million and $1.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.6 million, $7.9 million and $2.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $7.6&#160;million and $2.6&#160;million for the years ended December 31, 2021 and 2020, respectively,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#x2019;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;2019 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2019 Initial Term Loan Facility, with an aggregate principal amount of $75.0 million and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the 2019 Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the 2019 Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $1.3 million, $10.0 million and $9.2 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $9.5&#160;million and $8.8&#160;million for the years ended December 31, 2021 and 2020, respectively,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i316c2f9226f948c7a4f01201f54acc48_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjE1_59d8a661-66f8-40ce-bfb3-1debdb71af8f"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i63f12ae346f44c719a6800ae9ccbebab_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzMz_4202e74a-9c7d-4b0f-bb43-b0c233be968d"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i63f12ae346f44c719a6800ae9ccbebab_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzg0_647fcb6b-cf98-4b6c-918f-dccda071a493"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA5Ng_ae708a5c-eff5-407f-9822-0b9867ce29eb"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity
      contextRef="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg4MA_f35e415f-31d7-422d-b1de-972fbbb642c6"
      unitRef="day">91</evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2b8033c2ed5c404898e4b63272e9b227_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjU4MA_16b54889-4ffb-4e63-bf0f-37e4f4259f15"
      unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4c87170725f741bb95ab4f861ab14a5f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjYwNg_fc0ff470-bf5e-4186-85cd-9cb59fbb7b8f"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i332b999bfd9a41b4b40e9a3798d29b87_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjY5Mw_795dbe1e-c801-413a-bced-8d852c71537d"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i94c23219c9604a849ec11f326a2fa715_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjcxOQ_6c3baf67-17f9-42f0-990b-25d2232a0f30"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1a618a149be24ef9872b8f1e95c9c442_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjc0Nw_31424dd8-b205-4bbe-bd32-a6cece8cf034"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i902a77068a2b40d68366da7a319b5fb5_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjg1Ng_3d571881-aaaa-412d-9bc5-b46c71937313"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjk4OA_5645d4a2-efc5-48b9-b586-868326c76de3"
      unitRef="usd">7900000</us-gaap:InterestExpenseDebt>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent
      contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzI4OQ_479962e4-103c-4a8e-b502-18f18f6290f7"
      unitRef="number">0.0300</evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent
      contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzQwOQ_bd356b62-ca31-45e2-883d-41c2f7df33cc"
      unitRef="number">0.0200</evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent
      contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzU1NQ_38927073-1140-479f-a163-5b056c6a8542"
      unitRef="number">0.0100</evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent
      contextRef="i0ad1fb852cdc456fae77b5e7da816667_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMzcwNQ_e006a534-abab-4448-ba32-f0879b4029eb"
      unitRef="number">0.0000</evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i7d73991f5a114e408f7f6580f4dd0c39_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNDgxNw_a00938fd-f2ea-414c-ba07-5760c2c01d74"
      unitRef="usd">5300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTA2Mw_4581d5ec-7668-4c86-966d-9309daae6da4"
      unitRef="usd">400000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTIyOA_85b550fd-3051-40df-a7a6-a5b2b854554a"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTI2NQ_8eb17526-22b0-4f9e-9c99-9c9bd95b1668"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ4Mw_c47c9efe-ef64-441e-8aa4-e0cbeab9f8c0"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTU1MQ_94890efc-aac7-499d-bbca-cf4ec486d636"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTY0MA_268338f7-f1f2-4ae8-a783-92c8489ea9c3"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ide70b505dfd6454e9ffca84126ff1890_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTY1NQ_fabbbc6b-8531-48f0-961a-02f8c599d674"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTczNQ_4eeb945e-dfba-4dca-80db-0d47a011f1f7"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjI5MQ_e514c13a-62bf-4061-a9f2-90a0904549db"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjYwNg_a5c0e98f-ebef-4b28-9939-5c2e481e7446"
      unitRef="usd">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNjY0Mg_6e501957-22a0-40b9-bca9-77a854e4395c"
      unitRef="usd">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3MjUy_39d70196-2e7f-4231-8b98-175a6113dc83"
      unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzA1MQ_02585592-2679-4d0d-b19e-d513f32c88d8"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNzE2Nw_3be587b1-919a-4ce1-9ba7-15bb5ba7e0d7"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODA4Mg_b84553b8-f452-4280-9c38-7325cedd320b"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODIzMQ_c4814747-7fdc-48f9-92b9-b2c1265269dc"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODMyNg_da7dd618-5b31-4209-aae8-ceb94817d30d"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i0d1f72876d42429a99ca22c58f5f1ecc_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODMzMw_ce643eed-0258-4f87-9422-391f5e6f0970"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ida946158de9644dbaf87051d7f5f3639_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODQ2NQ_e828fead-d668-4d18-a2bb-697d668623e6"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i16b8497fa1ff4ce2bf2527c494b414e6_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfODQ2OQ_e43bf67e-c4f2-4f2d-b23b-97c6cbc98f74"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:StockholdersEquity
      contextRef="i1c958236f3a54e838f8aa587bb9a8d31_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTE0OA_a793d582-e469-445a-ac9d-71caa6acc49a"
      unitRef="usd">-38100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1619fddb91d54d6f96208efd4dce37f6_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTE5Ng_c98303bb-81ae-4959-8f71-e71c87995a0b"
      unitRef="usd">1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0ae7d691d994f36bcd8595faf8c39ee_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTMzNw_bc610d39-c535-47aa-a539-8eda72e52bd7"
      unitRef="usd">-11700000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i3474707099524f5ab5cb8bcdef64f129_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfOTYxOQ_773b118c-137b-4fbf-81f1-9257ac5cec99"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAwOTk_8aac15fa-e499-44ab-946d-02fca0aa7f6b"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAxMzU_276642eb-03ab-42a3-a49b-3ff3db35cb5c"
      unitRef="usd">7900000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3NDEy_02ebdfc7-766c-420e-aede-6800b622f74a"
      unitRef="usd">2700000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM4MDA2_0aa98688-c733-4ad9-b169-1cd81eaedf10"
      unitRef="usd">7600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iee8aa6b340aa40338ddc6ab43d003623_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM4MDIw_e33a3844-a3a7-4590-84a4-2f827f1ecb32"
      unitRef="usd">2600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTAzMTY_3917e57d-c312-4288-a5dc-b4b0de24558f"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA3Mzc_5ba4b59b-a4c1-453b-88fb-b8fd2744e7e6"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA3OTI_e7639c6a-d602-415d-99f1-bde8e42106a9">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTA4NDg_8eff6f61-224b-4664-a6ff-d97dae5168e1">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTEwODY_50969b4b-ae87-433b-944d-70d1ccd62630"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="if764124a6770471488243909ab9e256d_D20220811-20220811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTEzNzM_2ff66afe-7e92-463b-b458-5ba663074561"
      unitRef="usd">92800000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i7fb6b9ecd1444687b8479680f813d784_D20220817-20220818"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTE1NjI_349908b3-e46b-41a8-98a3-723fe13bfefd"
      unitRef="shares">5394165</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8a7bc6c0f93045b9ad4a49e3466404b9_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTE2OTY_03285295-ed5e-4c1b-9d5d-dd1c44d19967"
      unitRef="usd">-10200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3d60561640304c998ba5ee229f359173_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTIzODA_0dedf027-8840-44dc-877c-4697414013c9"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2804de286fbc48f587c48f683cfa4074_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTI1MTI_18e72e3d-ed65-4eba-9a04-1e1a91f34403"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2MzE_817ea807-1a28-4c49-b038-8bbb02545a03"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2NTA_9643abc7-9720-4317-902c-9441230b68f1"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="i9cfa1982d3694ef68ad15ec8c30abe44_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM2OTE_d3e1a727-78a5-483d-b6ae-7d9a3167ea20"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM4MDQ_55f4d370-bdc9-4781-8d85-9e4b1cf3aa1c"
      unitRef="usd">-19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM4NzA_9869769e-93a7-4446-9e07-ced82ea1980e"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="id4bdf1d1399c4995a8352cfa862bc618_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTM5MDE_66b7c24d-73b8-44e0-b4ed-72ecc4905b77"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i140bd5a200d14de591a2f882386a3910_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQxMzI_37b83d25-040a-4229-8092-87c7729341aa"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i140bd5a200d14de591a2f882386a3910_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQyMDU_5fe90da1-f6a6-4a69-abb5-6ba0eff1baaa"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="i84ec033ba9234eb488e9598b782c6c15_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQyNjc_502da935-d9eb-4ec5-8724-fbfe4e6e42cc">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i0b374313017e499e85ef4cf594469720_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3MDM_3c72dfbc-b23f-4529-aeeb-b9a019553550"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3NTY_371aa5f9-905f-43f5-89d6-c13be40daefa"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTQ3OTM_512e75b7-3b95-4a86-9a8e-880267df2b38"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUwNjE_79b4c878-d374-47e2-884e-493a2dc1abe6"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i21455ed9e898487f8740230211473db0_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUwNzc_6e42df3e-a0c2-4628-84d7-e7f4f30380ce"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2a685a81d42142c896e77b4bc4ca525a_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUxNzg_d830af4d-fd24-437b-bfc2-2025747c75dc"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6c6f6a273d2b4dbda2d60fcdb292d567_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTUzMDY_efcd5ba2-e5ba-4948-a8d9-f436105f603b"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU2NDY_512e75b7-3b95-4a86-9a8e-880267df2b38"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_0b7ffc12-4692-44a7-b58a-e262592524c4"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_89cfe33d-9e5e-44d2-b469-c123497324b2"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTU3MDg_a9f1733b-a453-48ba-a1b4-a81608c78a39"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTY2MDc_2e135105-4427-4852-80b9-b18a6fb73947"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTY3MjM_9c2dc441-12e6-4c9c-b0df-074d51506418"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc2MzE_1b8f6781-e44d-4bee-be05-d98aae76a548"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc3ODA_eb30a001-8766-416f-901c-f668aaea155f"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc5OTE_11760300-877a-46f4-a4e4-3f0e3e7bc3a2"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i70f4dfb899054fdfbad69a92f3ebee35_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTc5OTg_802487ef-a54c-4b2a-8fe7-12a3e26ce12a"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i8907a8164bfa458e9c10a2dbfb757881_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTgxMjk_eb30a001-8766-416f-901c-f668aaea155f"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i465bd1d9a2fc4d5fb9b86000e4ec618c_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTgxMzM_11760300-877a-46f4-a4e4-3f0e3e7bc3a2"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquity
      contextRef="ie2a2bfbe33214fceb0357343f7b7e72b_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg4NTk_d39f4871-d43f-4bbc-a70b-36568255a755"
      unitRef="usd">-71800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bd78b743e5442379fb00d3420537154_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTg5MDc_49fc43c3-6489-423f-8291-97371eb4f66b"
      unitRef="usd">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie69ff65edc314e66af837b40573b525f_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTkwNDc_7cf3c809-11c3-4743-8e3b-1edcf0c6fc4e"
      unitRef="usd">-28100000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i278ee21fa4de4432b9d32268373e0d51_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTkzMjk_479f4fc1-fcf4-42d7-88a7-35d1279cebc0"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTk4MDk_d9e454a5-6fd9-4bd4-864c-85ae31e80462"
      unitRef="usd">1300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMTk4NDU_0258cc5f-e35a-47d9-867b-542a8b54607c"
      unitRef="usd">10000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3NjIy_4536ac5c-0c81-4fa8-b265-386d3cb94ebf"
      unitRef="usd">9200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3ODE3_57c2a74e-6b93-4bcf-ac8b-74e464de6cfa"
      unitRef="usd">9500000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9bef66f774044af386b81c078514f9bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfNTQ5NzU1ODM3ODMx_9ac0bdcd-4492-4f3b-9dbf-350049e2999b"
      unitRef="usd">8800000</us-gaap:AmortizationOfDebtDiscountPremium>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjAwMjY_d97bc4d5-c2db-4ef1-8ef9-b755dee4a159"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA0MjU_a0f57908-0940-4162-ab92-e16274ea5c65"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA0ODA_c081fe74-5c4e-4b56-8171-950f57832e6f">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA1MzY_f8a5c5cd-8d2f-47ae-b612-229db9a69517">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="idab2240b7b73471e928023fa0d76e5cd_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA3NzQ_40e113d7-bc84-4d47-9934-44f174cf8bf4"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA5NDI_9f867ba2-2a53-41c3-822e-f6b68358411d"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjA5Nzk_bbaae372-2f87-46f6-be97-f2ba0c5fa4b8"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if5650df78c4e4f098ea12cdc3e6d079f_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjEyMDI_170eadd1-ad57-4cfe-a460-a02471ffcfb8"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6aef6137413544e2a1fd7506ce233492_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjEyMTg_13cfd577-9f50-46fe-9825-0802656adf7e"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i45abd4e128e343dd9005a273c0eeaa5c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE2MzY_5f4a8584-7e92-4c5e-b8b1-8bfd3c84fc76"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE3MDA_0e82411c-af25-48bd-b2d6-c287ac9c079d"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE4MzM_ea4f249a-0d4d-4171-b476-db8b5f9e45e6"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjE5Nzc_d0caf548-8311-405c-a77e-bb3e594282b0"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1bf042bd30a44a15975073db664b70be_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIwMjA_0bcee426-9ee8-4911-ab23-e57dcb2ebb0c"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIwOTM_bb860161-f0c3-4550-94c1-4c195c85a651"
      unitRef="usd">14000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i307390bb8f1941719453c9b89db584f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIxMTk_be929d44-e1f0-48f3-a395-d3db6d297aba"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIyOTM_ead80d33-11fc-4b4a-8b8d-beff3edf6244"
      unitRef="usd">26700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjIzNTQ_0da79533-dbf0-4d8a-b7c3-ad1018f043c6"
      unitRef="usd">26300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1d0fbedf21cd4a27b3a00e2646c91847_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjI0Mzc_bce84604-605d-4976-9de2-6fe9c2ff36c2"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RleHRyZWdpb246ZGQ2NjBkYjQ4MzIzNDI1MWJlNmE0Mzk5ZDc1OTFlMzFfMjMyNzY_d93bf47d-98ec-4586-990d-ba2d6a53f392">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2022 and December 31, 2021 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMi0xLTEtMS04Mjg1OA_8308564e-a07a-4add-aaec-bb907328d0a9"
      unitRef="usd">23925000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMi0zLTEtMS04Mjg1OA_392ad586-5583-4310-b0fd-9fa0ca3e3e9d"
      unitRef="usd">89361000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMy0xLTEtMS04Mjg1OA_cf9d0462-6348-4ff6-8bcb-9a72f04a7fc3"
      unitRef="usd">356000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMy0zLTEtMS04Mjg1OA_855e5430-4c1e-4659-ad7a-406dc61949c3"
      unitRef="usd">27690000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iebd374c7c4724e05ac999f332b4ab82e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNC0xLTEtMS04Mjg1OA_25fd0ab6-9df0-4847-a07b-d0741c4db3e2"
      unitRef="usd">24281000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iadf6fc0014354fbe9758d2279614f394_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNC0zLTEtMS04Mjg1OA_1400a256-8467-4d84-836d-dcaa81d17db3"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i01455d65a30b4de88519c6a15c185622_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNS0xLTEtMS04Mjg1OA_61117fd3-5f1c-4cdd-ac31-5241502f5d6d">P1Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ib0cf52d4f07c4cfa863da185050c0ce6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNS0zLTEtMS04Mjg1OA_47d17b1b-f554-4f49-b2be-c1deeb7d2d11">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i04f5b6436bc448ddb51d297c0f42e141_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNi0xLTEtMS04Mjg1OA_45ae83ed-ad60-4e6b-a3d2-64ddff01d821"
      unitRef="usd">38000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6001ba8bbed04b7a829551c60b521a2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfNi0zLTEtMS04Mjg1OA_3c01c752-f384-4ad9-813b-07c5c0896ae5"
      unitRef="usd">195445000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfOS0xLTEtMS04Mjg1OA_9981d8c2-4ecf-4b1f-aed9-480b3e4c0e30"
      unitRef="usd">168885000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfOS0zLTEtMS04Mjg1OA_d37e67db-eadf-48be-9c8a-22c4d315f431"
      unitRef="usd">126315000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTAtMS0xLTEtODI4NTg_3ef7b516-a1f2-4ad0-b23a-6f32263d73ba"
      unitRef="usd">3615000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTAtMy0xLTEtODI4NTg_7e3dc559-f9a7-4f75-81ae-057e7e66bbb3"
      unitRef="usd">46185000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2edea02961a848e792c082a2d78f7be9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTEtMS0xLTEtODI4NTg_4379895c-55b3-4156-8a19-bdff710c50cd"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf2bca88869d4c9795e3e92b114eabad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTEtMy0xLTEtODI4NTg_18e38326-2199-4caa-9dc2-5672d423d33b"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i234e83673e324a43a7dad926ee463b1a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTItMS0xLTEtODI4NTg_c31868c9-d6b9-492f-9619-dfc4527da10d">P2Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ib1fac3a03b5b4b04893ef3a79ac28376_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTItMy0xLTEtODI4NTg_ef028bb7-4c96-4790-86db-e940d532c4be">P3Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i88b3ec5f2a0940ddba506d2e9a3d8c0a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTMtMS0xLTEtODI4NTg_c6f6b390-7f90-4226-9e1d-84e197005c2f"
      unitRef="usd">185546000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4d4776fc60e442c0948db94fbd3d4085_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83MC9mcmFnOmRkNjYwZGI0ODMyMzQyNTFiZTZhNDM5OWQ3NTkxZTMxL3RhYmxlOjI5ZmIxOWM0NWNjMTQyOGNiMzU2N2YwMGEyM2NkY2UwL3RhYmxlcmFuZ2U6MjlmYjE5YzQ1Y2MxNDI4Y2IzNTY3ZjAwYTIzY2RjZTBfMTMtMy0xLTEtODI4NTg_ae0d0dfb-03e2-4df7-8c54-c57045b1b408"
      unitRef="usd">177251000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzE_9bb2f9a0-83f9-46de-b8f9-161ffddecdb4">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of December&#160;31, 2022 and 2021, respectively. The letters of credit have current expiration dates between January 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2022, 2021 and 2020,  respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2022, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of December&#160;31, 2022, there are no outstanding amounts under this reinsurance agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers. Expense associated with the UPMC Reseller Agreement for the years ended December 31, 2022, 2021 and 2020 was $1.2&#160;million, $2.4&#160;million and $4.7&#160;million, respectively, and is in wind-down. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the reduction in the Company&#x2019;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $46.0&#160;million as of December&#160;31, 2022, which represents 85% of the deferred tax assets related to the Company&#x2019;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will assess the realizability of the TRA-related deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the TRA may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation was granted final approval at hearing on November 18, 2022. The agreed-upon settlement payment of $23.5&#160;million was funded entirely by applicable directors&#x2019; and officers&#x2019; liability insurance. As such, we did not incur a significant net loss or cash outflow as a result of the settlement of this matter. This matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#x201c;Derivative Action&#x201d;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2022, approximately 99.6% of our $215.2 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million and 117.4&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately  9.7% of our consolidated revenues for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0bb561ac225443dbaff96dea400e900b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTc1_7d8c90a0-87ae-4812-aeff-6da8092c0d01"
      unitRef="usd">13100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6788632dc8e44b589e517a3e62e51f4a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTgy_72774546-5665-47b7-81ec-745e0a944a70"
      unitRef="usd">15400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic01dda4dd7b24edd859959507bf961ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMzAx_9570455a-a07f-4b0b-99dc-e881aac5afa0"
      unitRef="usd">13100000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5f551ff8e8ba4ff3beb6c4b903203199_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMzA4_7c8f7efd-5ed3-46be-9e2a-ac591226c9c8"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <evh:LineOfCreditFacilityAutomaticExtensionPeriod
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzI_e46b63d8-49ad-4948-b88c-83beb3209e33">P1Y</evh:LineOfCreditFacilityAutomaticExtensionPeriod>
    <evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNjY_3168136d-c7f9-4c3d-9621-d3abf66ab380">P1Y</evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension>
    <evh:NumberOfCustomers
      contextRef="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjM4MQ_c75aa40f-1487-41da-9eb9-0b3075b1f08b"
      unitRef="customer">20</evh:NumberOfCustomers>
    <us-gaap:Revenues
      contextRef="ic3b979d5bdf244fcb2d0d8b9f86e5f2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjUyMw_80677b95-c19c-4b44-928d-5e4f1d7ec6d8"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8421b42e39084ee89ac6a78c380b126b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNTQ5NzU1ODI5ODkx_f503c3a1-860b-4312-b708-3b331826ed25"
      unitRef="usd">2400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ea705e860864044aca57384b2588af0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjUzMA_0ab407db-7389-4ebe-bca9-b3b5fc2ec17a"
      unitRef="usd">4700000</us-gaap:Revenues>
    <evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNjgyNw_6d7edc1b-4901-40a6-ae3f-37348d28d58f"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid>
    <evh:TaxReceivableAgreementLiability
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNzI4NA_080980f4-b5fe-43e6-abf9-ec9a08cdbd20"
      unitRef="usd">46000000</evh:TaxReceivableAgreementLiability>
    <evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfNzMzMA_4e0cccca-2fe8-472a-b416-4105a1024e9a"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="id9e0a630ce154bf89c611d1821c71553_D20220802-20220802"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTAwMjY_f5689bb5-a01e-4b55-9c93-355444337328"
      unitRef="usd">23500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE1Mjg_4bdd70be-d1c5-4994-9c75-5e01de5988f8"
      unitRef="number">0.996</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE1Mzg_265960d3-18e2-4580-882b-471486f278f8"
      unitRef="usd">215200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTE2ODk_a9efa90a-7a01-4691-b697-64b4b538364e"
      unitRef="number">0.004</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMTMxNzM_ab3a3b8b-d1bf-4da7-99db-a39969639414">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million and 117.4&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately  9.7% of our consolidated revenues for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05d330e617a348658676375fec5a5db0_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMS0xLTEtMS04Mjg1OA_50b827af-b1f9-4269-9f8e-601947a44ae5"
      unitRef="number">0.425</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic09667045f534fb08afb88b78cd4bffd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMi0zLTEtMS04Mjg1OA_fed6acba-1ee1-43ad-8c4d-a3568ce8907a"
      unitRef="number">0.464</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19460fef358144489558a7d191e376e1_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMy0xLTEtMS04Mjg1OA_3a436621-c6c9-42a2-9181-df0299033852"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34c1626a52334b328a1c7519c6d48da1_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfMy0zLTEtMS04Mjg1OA_0be70b96-1580-454f-9601-5a97b89f02c1"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f194e0613ef4a9eb4ce0f29bc3e59be_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjVhMjgyNGRjMDNhMDRiY2FiNGIyMjE0ODBlYTBlMTdmL3RhYmxlcmFuZ2U6NWEyODI0ZGMwM2EwNGJjYWI0YjIyMTQ4MGVhMGUxN2ZfNC0xLTEtMS04Mjg1OA_1d3b71ca-d773-4192-8da8-5ca35bc83872"
      unitRef="number">0.113</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i47d5358cfd784a34a9c92cf66e6fe24d_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi01LTEtMS04Mjg1OA_4179bac2-a845-4575-a110-9ccdbff61a3f"
      unitRef="number">0.224</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5a3c513620354b04ae269dff1b11efc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi03LTEtMS04Mjg1OA_b8abcd47-c513-4c2e-8d6b-a2bed5222c0b"
      unitRef="number">0.280</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0971990c3b524dc2ab01bca9e7047db0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMi05LTEtMS04NjIzNg_c5b14543-2f9b-48f1-9fc1-fe1c45b25bca"
      unitRef="number">0.223</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4b0ca95c4f8d453aa5b952029c52ede5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMy01LTEtMS04Mjg1OA_1fd038fc-761a-4478-a0bb-158fc62e91bd"
      unitRef="number">0.115</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i17f79061242845d39ce24ea7ea1e6531_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfMy03LTEtMS04Mjg1OA_a08ca2fe-255b-4076-933b-2072494f0ef8"
      unitRef="number">0.141</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i37ef3bafc332487fbfffb51f8c73921e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RhYmxlOjc3MTQ0OTBlMmYxYjRlYzU5ZWMwZDU2ZDg0YTI3NTQ5L3RhYmxlcmFuZ2U6NzcxNDQ5MGUyZjFiNGVjNTllYzBkNTZkODRhMjc1NDlfNC05LTEtMS04NjI0NQ_61b58eb0-7edc-41bb-a556-33d743419205"
      unitRef="number">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ia1b1f625f4e94de3bac6f65f975417eb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDIzNQ_8675d6a1-9249-40a7-89ac-4857801497cc"
      unitRef="usd">44800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ie780f96a5b1646b797b6c069ab760343_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDI1MA_6b8cc206-9869-4fba-aeb3-7bc3b1bd04ba"
      unitRef="usd">117400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3cc10e07863c4eb1a63ee717112c9d0b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83Ni9mcmFnOjYzZDAyNzEzYmQzMzQ2ZmM5NDM0YmU1NzdkNDEyM2Q0L3RleHRyZWdpb246NjNkMDI3MTNiZDMzNDZmYzk0MzRiZTU3N2Q0MTIzZDRfMjE5OTAyMzI3MDI2NA_c8ab690d-0e28-461a-9e1d-149b05248cd1"
      unitRef="number">0.097</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1NQ_436dcd23-da8a-48ed-84cb-a4102e5326aa">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022 and 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of December&#160;31, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfNDI2_c3c17810-ae80-48c8-85cd-d81869bcab28"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i5b43f5864a3c456d988a47acf3b9ce95_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjY2Mg_7eedcd8e-8d91-4c78-8b1f-4df1e47f0dff"
      unitRef="usd">2300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i84ffe1b4508e486a9edadc82247bd895_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjY2OQ_aa4a1e46-d706-43a5-859a-a83203ff94db"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5b43f5864a3c456d988a47acf3b9ce95_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjc0NA_84aadf10-f939-4f1f-9cd6-a944dba9718a"
      unitRef="usd">2300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i84ffe1b4508e486a9edadc82247bd895_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMjc1MQ_53062ef5-2e09-4ec1-93d2-ddacadcbaff7"
      unitRef="usd">3800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1Ng_6154824a-1b01-4bce-bfcd-a26e35871677">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of December&#160;31, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS0yLTEtMS04Mjg1OA_2cfdb297-bbaf-48cf-8039-38b8bc72a61d">P9Y1M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS00LTEtMS04Mjg1OA_6a1fe250-5f1a-41d8-af21-d3516a9b3b15"
      unitRef="usd">32409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMS02LTEtMS04Mjg1OA_823a5755-5462-42d7-acdc-1b49af911642"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi0yLTEtMS04Mjg1OA_7a1e5b4c-d72c-4652-b66b-34a8264f8085">P8Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi00LTEtMS04Mjg1OA_909941ce-5103-4b6e-af1c-fe2afd640d7d"
      unitRef="usd">38163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i20e84c1fcc7a409eb2d609e87902510a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMi02LTEtMS04Mjg1OA_9e5e3081-b8aa-4df0-b4f2-4fea8de525b8"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2f31f283eac947978662db9d2181e301_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy0yLTEtMS04Mjg1OA_35848ecf-9b0b-47e8-8889-ade9dd07eeba">P3Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2f31f283eac947978662db9d2181e301_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy00LTEtMS04Mjg1OA_5797b69e-c187-46ae-a75e-56e871cbe183"
      unitRef="usd">1697000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i2f31f283eac947978662db9d2181e301_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfMy02LTEtMS04Mjg1OA_e3b7f2c1-891f-4363-89d3-a4d48b76ba87"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC0yLTEtMS04Mjg1OA_b8922817-498b-4794-99a5-6e8c2522502c">P2Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC00LTEtMS04Mjg1OA_fddd0ac8-da23-401f-aaff-27002369e2b1"
      unitRef="usd">1295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i7d9b3ff8bd76404884b782de11442494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNC02LTEtMS04Mjg1OA_3b408e60-5ec2-45e7-8548-7763de08ca95"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS0yLTEtMS04Mjg1OA_8627841c-bbfb-4a81-961b-f78940a61f97">P0Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS00LTEtMS04Mjg1OA_51c24287-30b1-4d93-b63a-95f7bb51fb81"
      unitRef="usd">396000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia459503de1114b44a6f26fc10d288f5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNS02LTEtMS04Mjg1OA_a0714b17-f913-4445-a3b5-308788ced2ff"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi0yLTEtMS04Mjg1OA_adc6f887-d766-45bf-8a89-0ae55634acbe">P4Y4M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi00LTEtMS04Mjg1OA_e460728f-f7e5-4e11-9eac-d2bac440ff46"
      unitRef="usd">4229000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="if2b3426aba894c62ba3dd99da2cf9a73_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjUxNTQ1YzkyYTcyMDRmZTI5NjExZmIzYzI3NTAyMTNhL3RhYmxlcmFuZ2U6NTE1NDVjOTJhNzIwNGZlMjk2MTFmYjNjMjc1MDIxM2FfNi02LTEtMS04Mjg1OA_964c71b8-1280-4023-b585-c171cf6fcf8f"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RleHRyZWdpb246MDkxOGQzMTg1YjA0NGIwNjkzMjI5MGVkZGJjNDg5NTZfMzI1Nw_3ce4e0cb-1595-4908-8b8b-059ddaac813c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi01LTEtMS04Mjg1OA_116e7419-c1ea-4acb-97aa-df7771bd3518"
      unitRef="usd">8956000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi03LTEtMS04Mjg1OA_354c87d2-4b9c-417b-9d64-62e4449f8079"
      unitRef="usd">12991000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMi05LTEtMS04NjMxNw_538e8ef3-9638-4873-a1a1-08a942e79b3a"
      unitRef="usd">15848000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy01LTEtMS04NjMyNQ_910f90cd-2ec9-40e8-9f78-24dd74f2f3a0"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy03LTEtMS04NjMyNQ_2e82a0d1-f17c-44a2-9a99-9378a6f76f5a"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy05LTEtMS04NjMxNw_59681016-7b42-4140-8a97-68d64d5d1f3d"
      unitRef="usd">299000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC01LTEtMS04NjMyNQ_e030a8f7-9711-4c9b-8e82-6d56bd589b00"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC03LTEtMS04NjMyNQ_20662c04-95f1-4c73-97e7-4d609063d775"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC05LTEtMS04NjMxNw_49ea6831-ae24-453d-b0d6-fd0d1acc4a2b"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy01LTEtMS04Mjg1OA_129cc8f4-fe19-4227-b8c3-d3afe68bb367"
      unitRef="usd">5682000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfMy03LTEtMS04Mjg1OA_e21f0edf-c307-411c-8f40-63301fac9bae"
      unitRef="usd">5036000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNS05LTEtMS04NjMxNw_4147d630-ea3d-44a2-9367-ae238a5b4f7a"
      unitRef="usd">5097000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC01LTEtMS04Mjg1OA_7e376c50-17dd-4399-b195-e544e48b531f"
      unitRef="usd">14638000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNC03LTEtMS04Mjg1OA_959a5871-43f6-4564-ae64-893646346885"
      unitRef="usd">18027000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOmQ1ZDVkNmJkODQ5MjRlNDZhYzgyOWY0ZjgwNTkyMmVlL3RhYmxlcmFuZ2U6ZDVkNWQ2YmQ4NDkyNGU0NmFjODI5ZjRmODA1OTIyZWVfNi05LTEtMS04NjMzMw_d57cdb97-8e35-47a5-93de-54ba39c7e32d"
      unitRef="usd">21247000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMS0xLTEtMS04Mjg1OA_89af04f5-3ac7-441c-b3b0-390b340d2755"
      unitRef="usd">10859000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMi0xLTEtMS04Mjg1OA_e1214627-4c7c-471a-a767-26fbd7765df0"
      unitRef="usd">10595000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMy0xLTEtMS04Mjg1OA_db0543ec-7c96-4eed-9b64-46ded6ec16f2"
      unitRef="usd">10012000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNC0xLTEtMS04Mjg1OA_208354f0-260e-4148-9753-4d25adce18ae"
      unitRef="usd">8987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNS0xLTEtMS04Mjg1OA_bf1bc077-3681-44c6-96d8-2e33827e24b5"
      unitRef="usd">8685000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNi0xLTEtMS04Mjg1OA_8b975418-0f99-4230-85fe-fd3424f7d064"
      unitRef="usd">31692000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfNy0xLTEtMS04Mjg1OA_89bd6a9c-4e15-4747-b1dc-2bdb75b81ea1"
      unitRef="usd">80830000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfOS0xLTEtMS04Mjg1OA_9951b636-7155-46c3-bb36-208b587d907c"
      unitRef="usd">17698000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjY2MjJkOGVkMDE1OTQ5MThhZWJiYWMwN2QxMDA4MTgyL3RhYmxlcmFuZ2U6NjYyMmQ4ZWQwMTU5NDkxOGFlYmJhYzA3ZDEwMDgxODJfMTAtMS0xLTEtODI4NTg_0ea2e933-4dcd-4011-b93c-379b060f5a78"
      unitRef="usd">63132000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMS0xLTEtMS04Mjg1OA_c13e5e99-c6cc-46e3-9538-96699b89e3f2"
      unitRef="number">0.0636</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi0zLTEtMS04NjQwMQ_726e8442-4a57-44e2-895e-cb4717062b9c"
      unitRef="number">0.0638</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi01LTEtMS04NjQwMQ_df842ea2-ebbb-46ca-a91e-59dbf3a476f5"
      unitRef="number">0.0644</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMi0xLTEtMS04Mjg1OA_e4564a24-0d5e-4c97-81dd-f5c90066bb3f">P7Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMy0zLTEtMS04NjQwMQ_f0bd3efc-7e3b-46ec-80a9-b1017ae603d2">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV83OS9mcmFnOjA5MThkMzE4NWIwNDRiMDY5MzIyOTBlZGRiYzQ4OTU2L3RhYmxlOjcxMWIxMGI4YmQwMDQ0YzZhYmU5MDkzNTUwZDVhZjQ5L3RhYmxlcmFuZ2U6NzExYjEwYjhiZDAwNDRjNmFiZTkwOTM1NTBkNWFmNDlfMy01LTEtMS04NjQwMQ_9bb96a1c-f544-4a00-8323-e5172a916238">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzE0_0af99d93-44b4-4847-a60d-e75dda830dfc">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzEz_7089b370-0ff8-4824-aa19-52efb2b74c24">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi01LTEtMS04Mjg1OA_112f45da-4664-48a6-aee7-fbb2f80ad0c5"
      unitRef="usd">-18701000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi03LTEtMS04Mjg1OA_9177faf4-f040-4777-bc9f-6ec51ec2d38b"
      unitRef="usd">-30284000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMi05LTEtMS04NjUwNQ_5c2a3b30-13b8-4ea6-a1b7-35e3c8d59d63"
      unitRef="usd">-328172000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC01LTEtMS04Mjg1OA_c1eec9a1-c762-4774-9cd7-83bc748fe20a"
      unitRef="usd">-19164000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC01LTEtMS04Mjg1OA_f0000a12-0f69-4c7c-8dd3-db41a773de91"
      unitRef="usd">-19164000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC03LTEtMS04Mjg1OA_12bae645-15fb-4b58-bcc8-a8b92cd3f67e"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC03LTEtMS04Mjg1OA_67ab0ff4-87d0-4c6d-ae77-14166e64fbf6"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC05LTEtMS04NjUwNQ_2dba2787-d143-44cd-afd3-9a456f61ad3a"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNC05LTEtMS04NjUwNQ_fe20e9fd-47fb-4716-92c8-72b0abf9cf10"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi01LTEtMS04Mjg1OA_872d184b-3e76-485e-9889-1c2a9eeaab97"
      unitRef="shares">93699000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi01LTEtMS04Mjg1OA_d4f7bc56-ce54-4b55-afb6-d2e8092c4846"
      unitRef="shares">93699000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi03LTEtMS04Mjg1OA_6422c41e-d861-4de3-b5c0-4fe5c75c6f6a"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi03LTEtMS04Mjg1OA_e4501877-9e46-48d9-a574-409f39d2d2b8"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi05LTEtMS04NjUyNw_417b4287-8e1c-4e49-bf8b-947a2a9e0b1e"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfNi05LTEtMS04NjUyNw_b8e91cca-55e5-4b5f-b235-a6bab722af6b"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNS0xLTEtODI4NTg_03631c9b-1fca-482b-bc21-712366fde1c0"
      unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNS0xLTEtODI4NTg_8e148c6b-2b64-4487-811e-8143fd8a108e"
      unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNy0xLTEtODI4NTg_7d3d737d-bbbb-4e90-95df-f5c070e63d3f"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtNy0xLTEtODI4NTg_93c76584-0af4-496c-b18f-ac56307e8f67"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtOS0xLTEtODY1MzU_0d907ba3-3b25-426d-a58e-d63555f4328d"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTQtOS0xLTEtODY1MzU_ef2de908-b81a-4ee6-9705-f0c868576b09"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNS0xLTEtODI4NTg_13051571-1486-458a-a693-81f16ec20e3c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNS0xLTEtODI4NTg_2e81288a-b6e7-45e1-b2c8-b0e4dc95ecdf"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNy0xLTEtODI4NTg_4e315877-8fcd-418c-ade6-201b86112525"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtNy0xLTEtODI4NTg_a2cb81db-574c-4b1a-b6dd-726d8b3656e9"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtOS0xLTEtODY1MzU_1cc63df2-3264-46da-adfc-81ad817f2e33"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTUtOS0xLTEtODY1MzU_4a171798-299d-444d-b4bc-be280c334f63"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNS0xLTEtODI4NTg_e00dc34d-016a-4911-aa17-a9e3f570441a"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNS0xLTEtODI4NTg_fb2f9fff-b3ac-4ab7-bb32-74d9d56181c7"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNy0xLTEtODI4NTg_ceb7521b-3185-4e91-a71c-86273bc538c3"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtNy0xLTEtODI4NTg_d80a8583-6a89-4435-b5b4-c4527c5a3bbe"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtOS0xLTEtODY1MzU_4a6e219f-944f-4248-83bb-64d123921211"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMTYtOS0xLTEtODY1MzU_b4cdb5eb-97ee-43c1-8fa3-5ff79883d395"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RleHRyZWdpb246YzI4MDI3NjczNDIzNGZjZWE5NzhiM2IzYTJmZWMzY2VfNzEw_df284718-a138-47ab-9ca9-7cf3b2b988a8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a933c8c05464474bc7d7b13541a2e90_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi01LTEtMS04Mjg1OA_659c6118-a46d-4d73-85ed-6a9019d56125"
      unitRef="shares">1804000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if76a99b4e1234159af5825d2a6781f2e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi03LTEtMS04Mjg1OA_933cc931-161c-4a44-95de-279149ff3545"
      unitRef="shares">1807000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a31bc4994b74fc58c2b392809cd688c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMi05LTEtMS04NjQ3NA_447588cc-bf68-4e33-acf8-d14f976af99d"
      unitRef="shares">797000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf5780125dcb45fbb548a97d1af89fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy01LTEtMS04Mjg1OA_c05da682-15e0-4184-9f6b-53d394a20327"
      unitRef="shares">1769000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6dd672678d98466986c506543160641f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy03LTEtMS04Mjg1OA_7a357d64-ab6a-4657-9308-e353dfb4a362"
      unitRef="shares">2036000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03c53413574a404b9b955fd4063e9fa2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfMy05LTEtMS04NjQ3NA_785fc78d-0a24-4d82-87cd-9442d86b1b79"
      unitRef="shares">1141000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia29b0fddbc044c099c98a1f8e946e6ef_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC01LTEtMS04Mjg1OA_2e7ba648-9072-49d1-a4ac-df48ac88f12f"
      unitRef="shares">9574000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ac01085f2974bffb7e9c05372fce3ed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC03LTEtMS04Mjg1OA_5e2c480e-d390-4a7e-bced-428b187e7476"
      unitRef="shares">12602000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibd9999816186400782cf19912fe831e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNC05LTEtMS04NjQ3NA_ecbdc898-d426-4393-b4d6-71e4f64804a9"
      unitRef="shares">11206000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS01LTEtMS04Mjg1OA_45343da5-7955-40e2-8c36-10d0bc2af485"
      unitRef="shares">13147000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS03LTEtMS04Mjg1OA_5e6e45ca-8471-4bcc-b20f-a0d0453c5a46"
      unitRef="shares">16445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjc1YmRjNDQzZDk2MjQzZDc4ZmYyOTlhMzgwYmE1OGNhL3RhYmxlcmFuZ2U6NzViZGM0NDNkOTYyNDNkNzhmZjI5OWEzODBiYTU4Y2FfNS05LTEtMS04NjQ3NA_883e54d9-c82c-48bc-b738-7fea535524e0"
      unitRef="shares">13144000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg0_f39aebde-35ee-4b21-9faf-5dfef7a08c75">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2011 and 2015 Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#x201c;2011 Plan&#x201d;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#x201c;2015 Plan&#x201d;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1&#160;million of the Company&#x2019;s common stock. As of December&#160;31, 2022 and 2021, 4.8 million stock options and 3.8 million shares of restricted stock have been awarded, net of forfeitures, under the 2011 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company&#x2019;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018 and April 15, 2021, to increase the number of shares authorized to 10.5 million and 15.4 million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2022, 2.8 million of stock options, 5.5 million RSUs, 1.4 million LSUs and 0.8 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan. As of December 31, 2021, 2.8 million stock options, 4.5 million RSUs and 1.1 million LSUs and 0.3 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:393.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Period (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:283.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options vested during the years ended December 31, 2022, 2021 and 2020, was $2.6 million, $4.9 million and $3.6 million, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was $16.3 million, $20.8 million and $2.2 million, respectively. We issue new shares to satisfy option exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based stock option awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company granted approximately 0.3&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. Each of the grants is subject to market-based vesting, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $13.35 per share for a consecutive ninety day period;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $16.43 per share for a consecutive ninety day period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $19.51 per share for a consecutive ninety day period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;50% of the shares subject to the option award vested on March 1, 2019, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;50% of the shares subject to the option award vested on March 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTc_a570a6ad-3bd2-47aa-b3bf-a2a19da0786d"&gt;three&lt;/span&gt; or four-year graded service vesting period where 25% of the award vests after each year of service or a three-year graded service vesting period where 33% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:412.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:42pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we granted RSUs with a weighted-average grant date fair value of $28.23, $21.10 and $8.88, respectively, which represents the weighted-average closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $11.6&#160;million, $7.3&#160;million and $6.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leveraged Stock Unit Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020 and 2019, the Company granted 0.5&#160;million and 0.7&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. Each of the grants is or was subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 33.3%, 75% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 50%, 100% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 100%, 150% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our leveraged stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per leveraged stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leveraged Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares awarded during fiscal 2022 include 0.3&#160;million additional shares awarded for the final achievement of the 2019 leveraged stock unit awards which was certified in the first quarter of fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company granted 0.3&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwMDg1_e95feb79-e657-48b8-946d-eecdc5e29c31"&gt;two&lt;/span&gt; and three-year cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 200% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwODYz_60171b02-aaa9-4bbe-95cb-bb9bb4968182"&gt;two&lt;/span&gt; and three-year cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted  if TSR performance is in the bottom quartile and will be adjusted +10% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the two performance periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our performance based stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1st Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2nd Tranche&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per performance based stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2022, the Company granted 0.5&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. A three-year cliff vesting was approved and began on January 1, 2022. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of company value. Per the agreements, company value is calculated using a formula based on revenue growth and cumulative Adjusted EBITDA, as adjusted for any acquired business during the period. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 250% of the targeted shares are earned. If the company value falls between tiers on the sliding scale, the actual company value payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:280.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Based  Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2fb1199689b9485e9e38c8454c856583_I20130923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4OQ_648bdc3b-e773-4786-bb27-baceb0c5f844"
      unitRef="shares">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id5b21dc206e94394abb9958199abeb98_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MA_a62612f4-77c0-4fe6-b80e-7a265aacdfb1"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icb78a01fb022451a868b84564b638dc6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg2MQ_70adfd13-513f-4984-9e16-c8351ae6e76a"
      unitRef="shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1fdd473b34824a438f104a82a06cc181_I20150501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNzA_d0e8ed9f-11da-4e30-b21a-d0dde931d213"
      unitRef="shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie49a044638374607bbfbdc97696620c2_I20180613"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEzMTk_83520373-d972-4255-acb1-fe5fe1eb649b"
      unitRef="shares">10500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0e202260e1024d14b21b9a333d1e719e_I20210415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEzMjY_e5123dd8-9354-40c9-8ce3-8eccf8384124"
      unitRef="shares">15400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i65cf289eea9b494d912166499c2914fb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE1OTY_98c9e38d-0000-45b7-bc75-61e55e65ca36"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia76c5580ffe1407da7f478f22181effd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2MTc_8dd6c684-b95f-4a89-a7d5-625cac658b67"
      unitRef="shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i490fcda4c6dc4ac48114257dd334a44f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2MjY_7f02c35f-c019-4e9e-bd92-4e74fd4d4710"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie8598bae5e2d4ae6a59a8764c8bc367a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2Mzg_7bc2aef4-c7f6-4d15-bef8-4cbd966b1ff3"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i34f5c218d62449f4a45332796fafbe3e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3MzE_db5622de-a633-4c08-9198-e013f0739a79"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i454730d8be0c4135908d533cc24236ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3NDk_a116c64d-415c-40ab-b00f-2206caf6aff7"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibd4ade146df04303ae15516a0f51d6e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE3NjE_e8df2f9d-8fb2-4c3b-a4a8-9aa6b33943ab"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i168e32227da54d569993ff509ca28512_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyNjUwOA_ae835ca6-ecd6-4060-9f5e-e465ac85648e"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTYy_0e53622e-d7c9-44ba-91cc-c73036a523a3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtMS0xLTEtODI4NTg_822a6a8c-4317-422a-9727-8a4e3b4c933e"
      unitRef="usd">416000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtMy0xLTEtODI4NTg_22ae1a82-bff6-444a-b7c1-d3e54785d26a"
      unitRef="usd">1337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzMtNS0xLTEtODI4NTg_781b08be-4e6f-4695-a289-5b70e6a3833b"
      unitRef="usd">2927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtMS0xLTEtODI4NTg_a93f016b-4c50-4239-83fe-d55490d53ef4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtMy0xLTEtODI4NTg_eabd0979-a7ba-4072-84ea-1a0154b86ad2"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a4f0db782744810b86b3de6bffd9661_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzQtNS0xLTEtODI4NTg_2fd20987-66ec-4243-a0d4-80c4f543b9a3"
      unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtMS0xLTEtODI4NTg_8ceb2643-f96b-438b-a539-9b042f0bcbc4"
      unitRef="usd">17327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtMy0xLTEtODI4NTg_d672819a-ec8c-4356-b051-ae932f10a04c"
      unitRef="usd">9606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzUtNS0xLTEtODI4NTg_1673d522-bea7-4d70-97c4-18fa7eca9587"
      unitRef="usd">7763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtMS0xLTEtODI4NTg_bb6d8f73-0f6b-4583-9e71-94100f84730d"
      unitRef="usd">14308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtMy0xLTEtODI4NTg_5c81986e-0a58-4c52-a71c-ed38f78c7131"
      unitRef="usd">2471000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2688027cbefe476297d030d725212d57_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzYtNS0xLTEtODI4NTg_08a02ab6-2d64-4276-b0d3-d9b9915016f8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctMS0xLTEtODI4NTg_66dcbf62-e94c-4771-a68c-2c42e9d5d838"
      unitRef="usd">1930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctMy0xLTEtODI4NTg_e46d7ccc-fa65-4705-a3e3-2a087657b125"
      unitRef="usd">3297000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzctNS0xLTEtODI4NTg_015597bd-135c-4bc6-b31a-d901703abf07"
      unitRef="usd">3841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtMS0xLTEtODI4NTg_827297cf-a19c-489e-9f1a-3d0f5d117349"
      unitRef="usd">33981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtMy0xLTEtODI4NTg_0454cfdc-37fb-49a9-a8c2-9ffee15cb8f7"
      unitRef="usd">16711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzgtNS0xLTEtODI4NTg_ef879958-702e-4526-b5a8-8e4f26d59947"
      unitRef="usd">14606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0d7c11ea28704ab6b523786a90949ff8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTEtMS0xLTgyODU4_bc9092a4-ffb4-40c8-83f2-9e180225e3a1"
      unitRef="usd">4387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5eab875363854633ac2dc697d7c48c89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTMtMS0xLTgyODU4_7747279f-f85f-4b95-951f-142c980495e1"
      unitRef="usd">2263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15eadbd1e3724998b19a496cc3d2b5aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzExLTUtMS0xLTgyODU4_7fe27949-6e4a-490e-bb70-2e376ef93667"
      unitRef="usd">1811000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9f478bf1b114c2694835b3dc5f160fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTEtMS0xLTgyODU4_81c4aad9-f5d2-4779-b4a6-dbbaa55dbab0"
      unitRef="usd">29594000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia818a57c910f43b6b57bb34ff556565f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTMtMS0xLTgyODU4_636c2c5c-6519-4a8c-b061-0def36c36926"
      unitRef="usd">14448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c1df49b093b4a088aece5a992f943a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEyLTUtMS0xLTgyODU4_6eab48e7-8771-492e-817b-4f4e27f7d0dd"
      unitRef="usd">12795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTEtMS0xLTgyODU4_71f75e2b-3c1b-493c-bd85-6494863554af"
      unitRef="usd">33981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTMtMS0xLTgyODU4_c752727b-b578-4052-97f0-e0428124335d"
      unitRef="usd">16711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZToyZWRjZjIzYmQ5MzQ0OGJkOTFmOWIyNmEyYTMxNjE2YS90YWJsZXJhbmdlOjJlZGNmMjNiZDkzNDQ4YmQ5MWY5YjI2YTJhMzE2MTZhXzEzLTUtMS0xLTgyODU4_4f753de8-b41a-48a3-89c1-27d93d603c83"
      unitRef="usd">14606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_116b7789-ddcf-4a49-9832-00564daa3c1f"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_1341f45c-7fdd-4667-af23-659c1ea75cd1"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzIzNzk_da58b21b-c108-4450-9b17-747396f04007"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTY5_9a4f6de9-69ef-400d-bd23-e944e975c476">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:393.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Period (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i126ccd42807a4cc3b17d8951d96c7aab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzItMS0xLTEtODI4NTg_d972170e-97de-460a-91fc-062012514d80"
      unitRef="usd">74000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzItMy0xLTEtODI4NTg_5a12df33-6f27-4920-9458-8c736fb54d65">P0Y3M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzMtMS0xLTEtODI4NTg_4adde784-85dd-4da0-a42e-1987928dfb30"
      unitRef="usd">36555000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzMtMy0xLTEtODI4NTg_8f35e8c5-a04b-4933-86eb-42145c2f6f30">P1Y6M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzQtMS0xLTEtODI4NTg_400a6ff0-4cbc-44ad-aeef-a46fe0868d41"
      unitRef="usd">491000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzQtMy0xLTEtODI4NTg_9ded8b41-8d96-4674-8e00-04c2b553e02a">P0Y7M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzUtMS0xLTEtODI4NTg_069c0070-e434-42dd-8808-ba53bcc5e257"
      unitRef="usd">27629000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzUtMy0xLTEtODI4NTg_8727fd62-0f80-4fb3-9d08-f8f016dfe66c">P2Y7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpmYmU3ZjM2NTYzNzg0MDZlOTAyYWY0MzIzZTgxYzk3Zi90YWJsZXJhbmdlOmZiZTdmMzY1NjM3ODQwNmU5MDJhZjQzMjNlODFjOTdmXzYtMS0xLTEtODI4NTg_06844033-f630-4db3-9c6c-badd59a9bd97"
      unitRef="usd">64749000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNjAw_b1767286-cdb4-45a9-97f1-896fb9d2116f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzI4NzQ_7aa1a5ff-fafa-4021-82db-b79be26d5db8"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzI5NTA_d0bc8681-e8de-443d-85e0-ec035934fc38">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTk0_84493d94-284f-4378-b635-e0ae741b12de">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:283.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtMS0xLTEtODI4NTg_71cf805e-61b9-4659-8339-8fc33cd25f0e"
      unitRef="shares">2549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtMy0xLTEtODI4NTg_b33bedc1-4b25-4ff1-b352-3f22af5411ec"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtNS0xLTEtODI4NTg_2a066848-1489-4ed0-a253-7d863c8460fb">P3Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzEtNy0xLTEtODI4NTg_2f34a16f-d61f-47ae-b946-a21d8e3aef92"
      unitRef="usd">46342000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzItMS0xLTEtODI4NTg_efcbb565-5209-4711-b48a-e5b1b019aea2"
      unitRef="shares">651000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzItMy0xLTEtODI4NTg_8fb6d0df-bda6-4b91-b0b5-9b141b175327"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzMtMS0xLTEtODI4NTg_9076b025-e600-4e3e-9513-d98383345ef7"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzMtMy0xLTEtODI4NTg_bb934d71-93f5-44b4-8389-d00f1807d756"
      unitRef="usdPerShare">13.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtMS0xLTEtODI4NTg_111f0bd8-404a-449d-a500-7c45603dea32"
      unitRef="shares">1895000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtMy0xLTEtODI4NTg_d871474d-d1a1-4cdd-ab83-f4191ed1d858"
      unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtNS0xLTEtODI4NTg_42c891ef-9704-438e-8639-90e1836a85d8">P3Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzQtNy0xLTEtODI4NTg_360b082c-b5c5-47d3-b4fe-a8d857447594"
      unitRef="usd">33503000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtMS0xLTEtODI4NTg_1f3b1c5a-b3df-47f8-b041-c7ec78612cc1"
      unitRef="shares">1895000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtMy0xLTEtODI4NTg_bf7856ef-e7ea-46ef-97d3-8181e29e12eb"
      unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtNS0xLTEtODI4NTg_c59dc7ce-5386-46f4-9420-fa6d16d998b6">P3Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzYtNy0xLTEtODI4NTg_dae2e02b-c94b-454f-bcc2-c1b727277e51"
      unitRef="usd">33503000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtMS0xLTEtODI4NTg_d8fa2eaa-99aa-4670-8ef3-4f8d91b4d236"
      unitRef="shares">1841000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtMy0xLTEtODI4NTg_3fb094e3-d101-42ae-bdcd-46b4fea76799"
      unitRef="usdPerShare">10.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtNS0xLTEtODI4NTg_d20b2a53-a552-46c2-bb99-054dc45480a8">P3Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpjZThlOWRmMTFjOTc0OWJhYjA4ZTdiYmJhY2Y5OWEzZi90YWJsZXJhbmdlOmNlOGU5ZGYxMWM5NzQ5YmFiMDhlN2JiYmFjZjk5YTNmXzgtNy0xLTEtODI4NTg_78f28e46-3c7f-4b89-b1b5-7528889606b5"
      unitRef="usd">32621000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0Nzc_8fdb1fec-6e0e-4fa5-95fd-7f05f0ecb7a7"
      unitRef="usd">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0ODE_45b44365-a123-4036-869d-7e44e518d600"
      unitRef="usd">4900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ0ODg_624f1c66-3599-4f79-8ceb-b151d8ae3826"
      unitRef="usd">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1Nzg_ca178fee-824c-4636-a5fa-ff9673bd4642"
      unitRef="usd">16300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i593745b628164db9ad5c5aee03724e76_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1ODI_374182d2-3d30-416d-868c-b58dfd1fc1f0"
      unitRef="usd">20800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iff6d020cdda44b2f9fd2c9e025d87bac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ1ODk_4078ec5f-d6bf-4bbe-9f60-112ee66d0cd0"
      unitRef="usd">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzQ3NDU_5d91453a-a201-4320-873f-341e96e04bd4"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="i41135afe093644db89a3b87635fe4dc4_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzUxNTk_24f5f3ec-bdfd-4729-bd72-921dd2502434"
      unitRef="usdPerShare">13.35</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="i8ec3a6efe87f4e2c84e6ce6e8641efac_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTYz_1fde305e-4a59-4dca-8270-afe731118aa2">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="if74229af73c04802bcf5f1aad8b9d1d1_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzUzNzM_a1e5cbf3-605a-4095-ae58-6405a1d836ff"
      unitRef="usdPerShare">16.43</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="i15ad45c36cfc43c9bc1893539e98ce7f_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MDk4MjI_8b4b38b5-1054-4bbb-bedc-2e845d49d7ea">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="i1492a0e32c114c64887521b21cadd182_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU1OTE_d559b1b9-4e96-4836-96f9-3fc38bf21877"
      unitRef="usdPerShare">19.51</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="i0d882797dafa45e4973fe074ac9e136b_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MDk4MjM_b3560ab1-cbb3-47c6-9a41-dc992e49158a">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i80e040acb0b747928e36b0c44713716f_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU5MDg_81f9b16c-addb-4660-a641-f946a91818c2"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic8e9688f5f7d4228b70c0cb904a39028_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU5ODI_5e9ad0bb-56ef-4865-8271-533114ae1a66"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyMTg_add8b3aa-c4d1-4fb1-a991-1076290ca510"
      unitRef="number">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyMzY_80a6813a-0200-4835-a697-ab487ae80fb7"
      unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyNTc_95bbe795-4c6b-40b4-8eaa-5d7137c460a7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzYyODI_c7d8569f-9983-4531-a265-3e8d50512411"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzY0NTI_cc16d906-fe03-4da6-b3e9-0ae593cf9bfc"
      unitRef="usdPerShare">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg1_892d2c05-89d8-4f37-9d6c-a52a39f0a3b7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i67f870a295164c058463681d0e9d876f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtMS0xLTEtODI4NTg_9c9ae336-85c2-4d4a-8eb2-7e43d551d7f8"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i67f870a295164c058463681d0e9d876f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtMy0xLTEtODI4NTg_681a57d9-c4c3-4c8d-81fb-c7ef91547e91"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9700c8ce01d04d44baee1e0b0548ab7c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtNS0xLTEtODI4NTg_e4e6bd72-1a72-4b5d-afda-95832b54c999">P4Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i67f870a295164c058463681d0e9d876f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzEtNy0xLTEtODI4NTg_8b578ef0-91aa-4bdf-be23-355f2f2bc1eb"
      unitRef="usd">5620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItMS0xLTEtODI4NTg_f4ffb969-e284-437d-97f5-50d2dc223407"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItMy0xLTEtODI4NTg_19dae78c-d2fe-4516-94ae-ac0b9f96acb8"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItNS0xLTEtODI4NTg_9bc4bf01-ae0b-4f7c-b005-b7385267c3f0">P3Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzItNy0xLTEtODI4NTg_80bd5dde-e315-4a0e-999a-fdfc1d715621"
      unitRef="usd">5730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtMS0xLTEtODI4NTg_2d9ecad3-f4d2-48aa-ad05-7687268bfeeb"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtMy0xLTEtODI4NTg_f7df01d9-f338-4079-91ef-5c440069be78"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie99cce6b7a69498b9eb6c1137c762a54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtNS0xLTEtODI4NTg_cde58677-b60c-4a7c-91dc-7b80413f13f4">P3Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i8645daae4ccd401babc69a6cbb852628_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowZGIyZWFlMTlkNjU0ZGU0YjRkMjkyM2ZjOTAwOWUxZS90YWJsZXJhbmdlOjBkYjJlYWUxOWQ2NTRkZTRiNGQyOTIzZmM5MDA5ZTFlXzQtNy0xLTEtODI4NTg_13d1dd1e-bab8-4b71-b75c-a56e97140229"
      unitRef="usd">5730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i777ec06acf834f40a1fa728483007e42_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzY5NjE_ec3a4ef9-9d93-4f2d-a777-914d908b0524">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iba9641b95f774ba8a8d7a8d32b4cce92_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTk2_6abbec4b-ebc2-4ed9-863e-d3c028a21727">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzcxMDM_5e31371d-eefa-4232-8a80-60f1b9fe3da5"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTMxMTU_27dd9131-fd45-4258-8c7f-517d64720c8e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib5c02b94720e4106be78e0e1359efd32_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyOTc1OA_d41c57a2-5bd2-4077-b8b0-7fc93b0ba916"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i31d4a953b2504f45a7692ab718621a5b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTUz_d62939cd-49ec-48a2-86b2-7464d50b3f53">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTg3_9fd646c5-efc4-49da-9417-83a88a1d3bf6">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:412.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:42pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i27068971ef7e44f082589f349b94a0f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzEtMS0xLTEtODI4NTg_f7306dea-55a2-4177-bf41-9ba0e4e14bfe"
      unitRef="shares">2087000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i27068971ef7e44f082589f349b94a0f5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzEtMy0xLTEtODI4NTg_61a29be9-42d9-489f-952f-e35b3e07ee89"
      unitRef="usdPerShare">16.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzItMS0xLTEtODI4NTg_93fffd36-dfea-43a7-8c77-d1460bc42583"
      unitRef="shares">1130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzItMy0xLTEtODI4NTg_2a31532a-c633-4e1f-9caf-708f13b9af30"
      unitRef="usdPerShare">28.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzMtMS0xLTEtODI4NTg_6dad216f-e483-4b0d-bb6a-5464639c0da8"
      unitRef="shares">206000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzMtMy0xLTEtODI4NTg_1e47266c-62ae-48af-af6f-fd8d868c4ad5"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzQtMS0xLTEtODI4NTg_7ca005ef-5e16-410c-9018-a60a882cd3d5"
      unitRef="shares">743000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzQtMy0xLTEtODI4NTg_bf0c061c-a07c-4fcb-bb75-2c09385bd978"
      unitRef="usdPerShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzUtMS0xLTEtODI4NTg_c5512ed2-51bd-45cb-b997-c4731eb81416"
      unitRef="shares">2268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3c0c173a9b95472ba3f3c39ad704ce03_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTplMmQ3ZDc4YTdiNmY0MGQ4OTk3MjlkMThiZGZhYTViZS90YWJsZXJhbmdlOmUyZDdkNzhhN2I2ZjQwZDg5OTcyOWQxOGJkZmFhNWJlXzUtMy0xLTEtODI4NTg_a081cbaa-6130-4584-91ee-b10bc3020d7c"
      unitRef="usdPerShare">22.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MDU_2a31532a-c633-4e1f-9caf-708f13b9af30"
      unitRef="usdPerShare">28.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MDk_cac2470d-b95f-4830-ac89-8cb47d230021"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc2MTY_b1372a82-71cd-4560-8749-e9c37bdb4201"
      unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i8094224f59b643989b918aff33c1cbcf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MDQ_2225a3d0-bdd6-46d8-afd2-bcd57bf33cfa"
      unitRef="usd">11600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iee0c31a4978b44aea89a762f2613f5fe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MDg_b5fca1ed-6efd-4ae4-bbfd-1ee175e1f0c5"
      unitRef="usd">7300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i87339a0b4d8d4ea793fdd421c055d70c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc4MTU_bb69745c-7800-4d82-9944-ca95c7dc7a85"
      unitRef="usd">6100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc5MDU_937b8730-2670-4ad0-a7d3-3e6cb6cf5406"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzc5MTI_a9928074-5745-4fb3-8683-b316c438717c"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgyODA_bc61237e-dc8c-42d6-945c-f8c19ebab2e4"
      unitRef="number">0.333</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib7b0ab5656f74948a97e5dc38865cf9a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgyODQ_d012e8e6-fc9d-4c52-8a55-cce27eee94be"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgzNDc_f1088ee1-d8c3-4382-abdb-6401d665312d"
      unitRef="number">0.50</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ide6d9be0dcfc44b78c44c364621abe44_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzgzNTE_9096da89-5fff-4cf5-bc63-74224ed94aae"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MTQ_55103383-faf8-4524-b5a5-d608015916f9"
      unitRef="number">1</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9499697d4bbc45fd9a70c73a6e98b136_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0MTg_f7e1d1c7-d35c-437d-80a3-431c97cfc8b0"
      unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i36d4b61188184f9b8043474a605003cb_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0ODE_5b1cf1ad-c9b2-4ec0-9cc8-62671df4570d"
      unitRef="number">2</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i36d4b61188184f9b8043474a605003cb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzg0ODU_a79ceb73-fb8a-4691-8b31-b333462f0498"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTcw_5018227c-76f7-4a71-8f89-7892373c3d4a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our leveraged stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per leveraged stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzItMS0xLTEtODI4NTg_af918682-029d-4040-8aaa-a21ba65441d5"
      unitRef="usdPerShare">8.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzItMy0xLTEtODI4NTg_9a33b81f-efe1-4223-9e42-b0aa0d243f1b"
      unitRef="usdPerShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzQtMS0xLTEtODI4NTg_48958735-d822-48d4-93af-57a0570063b3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzQtMy0xLTEtODI4NTg_6273bda5-f907-490b-a57a-b551b967e248">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzUtMS0xLTEtODI4NTg_e8bfafdc-c947-42cd-8f22-4f9eacfa158e"
      unitRef="number">0.621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzUtMy0xLTEtODI4NTg_717ce42d-f7a1-4bfa-be9e-aa0c2fa55dab"
      unitRef="number">0.517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzYtMS0xLTEtODI4NTg_97d4c07f-3aaa-46bd-a653-6433736e900b"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzYtMy0xLTEtODI4NTg_1a9ebc57-de9e-423d-a206-5a2db4036a79"
      unitRef="number">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzctMS0xLTEtODI4NTg_32142079-9d6f-4fea-9191-3c7aa36d868d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2f0db776bba14350bc9d946590fc408d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpiMDQ4M2EwYzIwNzE0OThiODkwNjcyYzMwZTA2YWM0Yi90YWJsZXJhbmdlOmIwNDgzYTBjMjA3MTQ5OGI4OTA2NzJjMzBlMDZhYzRiXzctMy0xLTEtODI4NTg_55898d76-aee5-4397-8504-0fe5a647ed3d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTc5_69649f19-b0a9-4635-be97-47fd2efc0ad2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leveraged Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMS0xLTEtOTEwMzE_b5d0e7cc-f329-49bf-baa8-9d28673feed4"
      unitRef="shares">1084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMy0xLTEtOTEwMzE_f5972b8d-327e-4854-bc00-d9578c4ac9dc"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i3b4821e4854a4c32bfdfc72b09bfaa0c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNS0xLTEtOTEwMzE_189b04cb-fe18-4fdf-a4bc-bff2dbcb753d">P7Y8M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i6e836072148b4d08a3bb37cfb2e717b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNy0xLTEtOTEwMzE_35d4bd89-5af2-4b3e-b0c2-3d5358671532"
      unitRef="usd">17993000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzItMS0xLTEtOTEwNDA_79e53331-1532-449b-bcfb-200389730e4f"
      unitRef="shares">303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzItMy0xLTEtOTMzNDk_f8219b21-b469-44a8-99e7-e98e37268830"
      unitRef="usdPerShare">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMS0xLTEtOTEwNDA_6172f0d2-7c72-42b0-b34e-57e64e26cd42"
      unitRef="shares">867000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMy0xLTEtOTQxMDU_27cbe228-4acb-4a26-9be8-6535ebd9b389"
      unitRef="usdPerShare">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMS0xLTEtODI4NTg_5eb27080-3c82-48f3-bb24-985835e385ae"
      unitRef="shares">520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtMy0xLTEtODI4NTg_964a0274-0a4e-4c0b-9381-230e7854057c"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNS0xLTEtODI4NTg_83d500a0-350c-45d4-9aee-b71c77e8fd25">P7Y2M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzEtNy0xLTEtODI4NTg_c2219462-8c6c-4d7f-9eb5-6fb8f7569125"
      unitRef="usd">9846000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMS0xLTEtODI4NTg_ba189a28-4b2d-4377-8a51-0525abd0cb1d"
      unitRef="shares">520000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtMy0xLTEtODI4NTg_18c1f69d-460c-4b54-9b43-2092240b0e30"
      unitRef="usdPerShare">9.15</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="i23513d63acc84e1d9329774077f86588_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtNS0xLTEtODI4NTg_367f908b-e400-486e-b29e-49ad235287d9">P7Y2M26D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
      contextRef="i9bb15940b3a94d76ac5798bef87541cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTpkNzIwOGEyODRjNjc0YWQ3YWU1OThiZGY0ZTA1MzBjMC90YWJsZXJhbmdlOmQ3MjA4YTI4NGM2NzRhZDdhZTU5OGJkZjRlMDUzMGMwXzMtNy0xLTEtODI4NTg_5df42773-299d-4cf1-8857-fa199d82a08b"
      unitRef="usd">9846000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i380305502d0f40bf81987e1a5ae4ab46_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTI1NjQ_fea4f487-8889-468d-b6fd-936eb49350e2"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzk5MDk_fd1b7b07-e558-4168-9b11-897be77c92ae"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNjA1_c290f470-0db9-4dec-8f77-0d63840e3f06">P3Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNDYw_4aa9b09b-4c8f-4f92-aeac-88f9a4cd640d"
      unitRef="number">1</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned
      contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwNTc4_a888681d-cf75-492b-b7b7-70663f005d00"
      unitRef="number">2</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i35c6ecda87514d238b96bac1c28adc9f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTgz_bdba609b-7f2f-4c94-8fb9-6e72cf0aac61">P3Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile
      contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzExMDkx_89bad9d4-1f5c-4b80-a3d5-6284fdaea577"
      unitRef="number">0.10</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods
      contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzE2NDkyNjc0NTk2MjE_39709979-26e9-4c18-9581-c84f601742f5"
      unitRef="performance_period">2</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods>
    <evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTU1_efb882e0-d488-4788-ac1c-0e6dc840da01">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our performance based stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1st Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2nd Tranche&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per performance based stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzEtMS0xLTEtODI4NTg_170d4d1f-d982-4cf0-9c93-00a0bc73f45e"
      unitRef="usdPerShare">20.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1f26ba9b9cd641d5aec7f9d0359b6769_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzEtMy0xLTEtODI4NTg_7643e401-58d5-44fd-a939-f3d0d3b33bc7"
      unitRef="usdPerShare">20.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzMtMS0xLTEtODI4NTg_9c3c305a-e0e3-4764-88ca-074f8df5b68e">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzMtMy0xLTEtODI4NTg_6080b622-2118-4e38-a075-5064cd9d8ed8">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzQtMS0xLTEtODI4NTg_227c1544-e172-43c3-9a65-a33a776ba74b"
      unitRef="number">0.895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzQtMy0xLTEtODI4NTg_014f3b7f-52ae-4197-b1eb-863706726aaa"
      unitRef="number">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzUtMS0xLTEtODI4NTg_9871d1fe-a9fb-4016-acb5-906b709e6032"
      unitRef="number">0.0012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzUtMy0xLTEtODI4NTg_a114706f-b308-4214-b32b-985cea0f424e"
      unitRef="number">0.0025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9fbe3ce870b94f2da8e8ed929af3c884_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzYtMS0xLTEtODI4NTg_2bf47187-bdc0-42f0-87b1-539016ebe8d2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i552120af3cb047fbb1e4888b3f50018b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTo1N2U2N2QyODA1MDA0Y2Q2YjM1NTgzMTcyMGUxOTczZC90YWJsZXJhbmdlOjU3ZTY3ZDI4MDUwMDRjZDZiMzU1ODMxNzIwZTE5NzNkXzYtMy0xLTEtODI4NTg_2be52582-cccb-4580-9441-dfe6dcf39049"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwOTk1MTE2NDA2NjQ_a3fcd677-172f-48c4-af72-c28a52c53257"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzM4NDgyOTA3MTE1MzA_ca6d7d97-5212-4b66-b60e-36906658e39c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEwOTk1MTE2NDEwODA_4aa9b09b-4c8f-4f92-aeac-88f9a4cd640d"
      unitRef="number">1</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzU0OTc1NTgyOTc4MQ_cecbfe21-0e0e-487e-af17-473fa49c808b"
      unitRef="number">2.50</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90ZXh0cmVnaW9uOmU3ZjMwYWEyNzdlNjRlZWRiN2U1MDFlMmQ5N2Y0YzgyXzEyNTky_37b54984-0184-4a04-96d4-2baef5f62e21">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:280.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Based  Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMS0xLTEtOTQxMTI_910c4418-9569-45d5-88b2-d4fd4628b5c1"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMy0xLTEtOTQxMTI_b2b9cb36-d8b4-4878-8125-398c5cc770d4"
      unitRef="usdPerShare">20.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ide564d56628c4112b1707eb060bf579b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNS0xLTEtOTQxMTQ_cb6ee2b5-9d92-42da-84cd-4c29179004df">P9Y1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i4b9e2e62339c438aa769354df4580b08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNy0xLTEtOTQxMTQ_bf701bbe-a129-4fab-9a76-f7b7928fb5cb"
      unitRef="usd">2233000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzItMS0xLTEtOTQxMTY_4c75e03b-95b0-4620-b7ca-30a57c3ae16c"
      unitRef="shares">479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzItMy0xLTEtOTM4OTk_91128d6c-6ccc-413c-a36c-5d930ead278c"
      unitRef="usdPerShare">28.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMS0xLTEtOTQxMTY_9857d7e9-132d-4640-8b21-1134e84f4184"
      unitRef="shares">625000</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMy0xLTEtOTQxMTY_d7fb1186-41a8-494a-9352-ceac41e7429a"
      unitRef="usdPerShare">23.85</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzQtMS0xLTEtOTQxMTY_95541343-5148-40f1-b27d-8e29e685beca"
      unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzQtMy0xLTEtOTQxMTY_60d06443-f84c-4af0-aca2-2c293d0e97aa"
      unitRef="usdPerShare">25.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMS0xLTEtODI4NTg_6ef60272-3bb6-4cee-88bb-48cc4b0ff5d7"
      unitRef="shares">1396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtMy0xLTEtODI4NTg_238a34d3-8681-436e-8f30-896681a410f5"
      unitRef="usdPerShare">24.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNS0xLTEtODI4NTg_0e809f01-4adb-4850-96bb-1f7e481513a5">P8Y8M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzEtNy0xLTEtODI4NTg_d87f1917-9f5f-42c0-8535-d537d4bc099a"
      unitRef="usd">5274000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMS0xLTEtODI4NTg_2f35e3ee-5c29-4564-ab6b-435547a6d745"
      unitRef="shares">1396000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtMy0xLTEtODI4NTg_24c84252-9266-4e10-b1ce-33d4660d6156"
      unitRef="usdPerShare">24.30</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtNS0xLTEtODI4NTg_2af4d17c-9a49-4d35-bf24-f97a81252788">P8Y8M19D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
      contextRef="i2258e21bec464cc5ae9efad5062cb9c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzQvZnJhZzplN2YzMGFhMjc3ZTY0ZWVkYjdlNTAxZTJkOTdmNGM4Mi90YWJsZTowOTdkNTg1MTAzZTg0MDU5YWFjMWFmMGUxZmUzZDc5Yi90YWJsZXJhbmdlOjA5N2Q1ODUxMDNlODQwNTlhYWMxYWYwZTFmZTNkNzliXzMtNy0xLTEtODI4NTg_eab802ac-690b-4197-a7d8-a0e715186c7a"
      unitRef="usd">5274000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMjc_ce69189f-d93e-4882-844c-4a733651f31c">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An income tax expense (benefit) of $(43.4)&#160;million, $0.5&#160;million, and $(2.4)&#160;million was recognized for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss from continuing operations before income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense (benefit) (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:370.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state income taxes, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at other than U.S. rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit of net operating loss carryback provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible excess compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits (shortfalls) on stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in indefinite reinvestment assertion for domestic subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax sharing settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Start-up and organizational costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest deduction limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets - Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract fulfillment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our valuation allowance (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged (credited) to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:2.94pt"&gt;Amounts charged  to other accounts includes $17.3&#160;million charged to shareholders&#x2019; equity and $0.1&#160;million charged to discontinued operations for the year ended December 31, 2022 and $1.8&#160;million charged to discontinued operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2022, the effective tax rate was 69.9% and the corresponding tax benefit recorded was $43.4&#160;million. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded by the company in 2022 primarily relates to the $46.8&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2021, the effective tax rate was (1.6)% and the corresponding tax expense recorded was $0.5&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#x2019;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2020, the effective tax rate was 0.7% and the corresponding tax benefit recorded was $2.4&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;carrying back New Century Health&#x2019;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, did not have a significant impact on the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $186.9&#160;million of federal and $301.8&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2023, respectively, and $295.5&#160;million federal and $245.0&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#x2019;s ability to utilize NOLs and could cause U.S. federal and state income taxes to be due sooner than if no such limitations applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $2.1&#160;million and $0.3&#160;million of research and development credits for federal and state income tax purposes, respectively, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a partial valuation allowance against those credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, the President signed into law the Inflation Reduction Act of 2022 which contained provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks, both of which we expect to be immaterial to our financial results, financial position and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our unrecognized tax benefits (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:402.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - tax positions in prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - tax positions in current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in various jurisdictions in the U.S., India and the Philippines. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2022, are $0.6&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#x2019;s valuation allowance. The Company has recognized $0.3&#160;million of interest and penalties related to uncertain tax positions as a component of income tax expense for the year ended December 31, 2022. The Company recognized no interest and penalties related to uncertain tax positions for the year ended December 31, 2021. The Company has accrued interest and penalties related to uncertain tax positions of $0.4&#160;million and $0.0&#160;million as of December 31, 2022 and 2021, respectively.  The Company had recognized $1.6&#160;million of uncertain tax positions as of December&#160;31, 2022, and $0.6&#160;million as of December&#160;31, 2021. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#x2019;s tangible and intangible assets. These increases in tax basis increase our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. The Company has recorded a partial TRA liability of $46.0&#160;million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated. See Note 11 for additional discussion of the implications of the TRA.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY0_8c37efeb-8bb1-4b41-8b53-5402d8020b02"
      unitRef="usd">-43400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY4_6df29640-b7dd-4699-9b6b-d89329ccc252"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc2_fba59ebf-1562-487d-9e86-ec2882b71380"
      unitRef="usd">-2400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTc_47d7b8fc-c724-4985-ad5f-4f5c78295cd9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss from continuing operations before income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItMS0xLTEtODI4NTg_c9eb7323-ec04-4935-bea5-ab580c2e2b3b"
      unitRef="usd">-66055000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItMy0xLTEtODI4NTg_c270e189-ad68-4101-850b-362bc23d3469"
      unitRef="usd">-32719000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzItNS0xLTEtODI4NTg_1ac92609-db0c-44f0-aa89-56241d86b50d"
      unitRef="usd">-332373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtMS0xLTEtODI4NTg_6457ae3c-203c-473b-9858-81cfb1920480"
      unitRef="usd">3978000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtMy0xLTEtODI4NTg_9ccff614-d5e0-4a58-8f8d-1991073b3e88"
      unitRef="usd">2918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzMtNS0xLTEtODI4NTg_d79753ea-3b30-4cb9-b99e-b027ce1c41a0"
      unitRef="usd">1833000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtMS0xLTEtODI4NTg_05f229b1-b9dd-47cd-8692-af186686301a"
      unitRef="usd">-62077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtMy0xLTEtODI4NTg_c1228c44-3b83-45e1-9cbe-e7fd8d92ab50"
      unitRef="usd">-29801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZToyNDM4NTNkOTkzNmY0NDEzOTZlMjQ1Y2U5NmIwNGQzYy90YWJsZXJhbmdlOjI0Mzg1M2Q5OTM2ZjQ0MTM5NmUyNDVjZTk2YjA0ZDNjXzQtNS0xLTEtODI4NTg_8179bf0a-0576-4d05-90e6-9c5b560a76a3"
      unitRef="usd">-330540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgyOTc_147e636a-761f-4a84-8d33-afbe99006f84">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense (benefit) (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:370.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtMS0xLTEtODI4NTg_4a059bc6-ae58-490c-ab9b-68c45fc96dc3"
      unitRef="usd">-875000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtMy0xLTEtODI4NTg_51e0072d-f52a-4521-b0a6-a89581c6a7c3"
      unitRef="usd">-1469000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzMtNS0xLTEtODI4NTg_b2835637-769b-4296-86a3-93c41118d3c8"
      unitRef="usd">-2305000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtMS0xLTEtODI4NTg_969d93c7-3a1a-4f63-8ae5-af85e8d41b98"
      unitRef="usd">1788000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtMy0xLTEtODI4NTg_a1d9ce02-11b5-4ac9-a3ff-980ad17da323"
      unitRef="usd">1449000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzQtNS0xLTEtODI4NTg_9b73314a-2491-47f3-8f5b-d80095fd117b"
      unitRef="usd">200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtMS0xLTEtODI4NTg_a189cfcd-92db-40e9-8917-249f1d85e9c0"
      unitRef="usd">1318000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtMy0xLTEtODI4NTg_5eb3e3c0-6666-426a-84b1-a42dae3364fd"
      unitRef="usd">1027000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzUtNS0xLTEtODI4NTg_0cdbdc99-a3b5-41df-8554-244c169cd620"
      unitRef="usd">721000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtMS0xLTEtODI4NTg_25dcfe70-9ac6-4447-84b2-bbaac00b3a68"
      unitRef="usd">2231000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtMy0xLTEtODI4NTg_ea6812db-e339-42b6-bb00-8e511553b0cc"
      unitRef="usd">1007000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzYtNS0xLTEtODI4NTg_eb4d55d5-7e5b-45a3-b4a7-6b2c26c61b78"
      unitRef="usd">-1384000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtMS0xLTEtODI4NTg_08ac4198-92ea-4b61-8491-51b16248fd65"
      unitRef="usd">5055000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtMy0xLTEtODI4NTg_ed07e42f-59b6-46cf-8061-c56ee2398bce"
      unitRef="usd">-5866000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzgtNS0xLTEtODI4NTg_a1448007-3d74-4861-bca2-a46afb308327"
      unitRef="usd">-38258000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktMS0xLTEtODI4NTg_483b344f-4682-46d4-9cb1-e728e39c652e"
      unitRef="usd">-2790000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktMy0xLTEtODI4NTg_716b75df-2505-4fdb-b096-155bd030b57e"
      unitRef="usd">-4021000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzktNS0xLTEtODI4NTg_04ac7c04-b8d3-422c-a106-a766c81f3a1a"
      unitRef="usd">-9565000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTEtMS0xLTgyODU4_e7d59489-33cc-4f30-a19d-8e4547351d82"
      unitRef="usd">92000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTMtMS0xLTgyODU4_2038c9e4-dc98-4ee7-8065-6fe6195fa852"
      unitRef="usd">-493000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEwLTUtMS0xLTgyODU4_9d570c18-f67d-4d84-9ddd-176663196d30"
      unitRef="usd">-303000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTEtMS0xLTgyODU4_08f34644-5dbb-4333-a5e2-ff7ac6d9b74e"
      unitRef="usd">2357000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTMtMS0xLTgyODU4_a3b3a48f-f746-4aba-99fa-e6156ee8f2b3"
      unitRef="usd">-10380000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzExLTUtMS0xLTgyODU4_b457d323-78dc-41a5-ae74-3f47168d5348"
      unitRef="usd">-48126000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTEtMS0xLTgyODU4_29d2fad5-b6b9-4adf-b5c8-12eb432eba51"
      unitRef="usd">-47964000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTMtMS0xLTgyODU4_5ff4c168-9b78-4ba8-a872-4860fd985231"
      unitRef="usd">9856000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEyLTUtMS0xLTgyODU4_460ff2e5-6829-4111-83c8-8d7c9f455949"
      unitRef="usd">47142000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTEtMS0xLTgyODU4_70c9ed1a-b1de-4f35-b1d0-f850299d7c22"
      unitRef="usd">-43376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTMtMS0xLTgyODU4_d626588e-1e31-447a-9f02-3702ae0f2cbb"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo2ODM0NDQ1YTUzM2U0NTE2YmFkMDI1YzdjNWZhNWU4ZS90YWJsZXJhbmdlOjY4MzQ0NDVhNTMzZTQ1MTZiYWQwMjVjN2M1ZmE1ZThlXzEzLTUtMS0xLTgyODU4_29003c2e-71a9-4f2b-a2bc-2c4e2f01e2cd"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTQ_33e8d6e7-0d60-4c7d-915b-ad48e43dd69e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state income taxes, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at other than U.S. rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit of net operating loss carryback provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible excess compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits (shortfalls) on stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in indefinite reinvestment assertion for domestic subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax sharing settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItMS0xLTEtODI4NTg_f5b3f339-ef63-4c0c-ae28-294855c792c2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItMy0xLTEtODI4NTg_1b7b3724-eecc-40f5-9e48-75b050254b17"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzItNS0xLTEtODI4NTg_8aba9873-12e2-4334-9500-39d4a915f7ff"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtMS0xLTEtODI4NTg_f7418d23-c8b5-418d-846c-259ec27f154e"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtMy0xLTEtODI4NTg_564c815d-8fa1-4465-9924-e165345c7d40"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzMtNS0xLTEtODI4NTg_c3d816f9-f458-4d53-b94b-6b4503dc60be"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtMS0xLTEtODI4NTg_25876679-d9c6-4284-b15b-2bd5651166b3"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtMy0xLTEtODI4NTg_0b2257f1-1ba6-429d-a8e8-f06684dbbcbe"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzQtNS0xLTEtODI4NTg_1271c834-4df8-4f23-8b2e-bacd7d9cb6d0"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtMS0xLTEtODI4NTg_7bb8cc68-817f-4ef9-8e88-afb980c0185a"
      unitRef="number">0.773</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtMy0xLTEtODI4NTg_cab844c9-9add-4f97-9732-95559f785b6b"
      unitRef="number">-0.331</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzUtNS0xLTEtODI4NTg_6a6ee555-b115-4436-8045-1a36923ba4ee"
      unitRef="number">-0.143</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtMS0xLTEtODI4NTg_c1a6db84-ac73-4390-8a79-de444fa6d739"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtMy0xLTEtODI4NTg_0bbd7b0e-707d-4e75-9777-0d3b1d718fa5"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzYtNS0xLTEtODI4NTg_b947929f-8925-4c0e-ae5f-3ad22cbabc3f"
      unitRef="number">0.011</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctMS0xLTEtODI4NTg_e3469e08-27bd-409b-986b-5b0b50c16c5b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctMy0xLTEtODI4NTg_0bbd7141-4c76-4c8b-8fc2-daa3b3d73743"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzctNS0xLTEtODI4NTg_978768b1-3d66-4a5b-b5c8-0d6effcb0282"
      unitRef="number">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktMS0xLTEtODI4NTg_70828d55-6d63-4a9b-893e-3ef8e4cedd73"
      unitRef="number">-0.278</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktMy0xLTEtODI4NTg_5529afe8-686e-4364-bb00-064bc31ec667"
      unitRef="number">-0.101</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzktNS0xLTEtODI4NTg_5856752d-08fd-4f3c-9196-be8f6b8f5d22"
      unitRef="number">-0.003</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTEtMS0xLTgyODU4_1f895530-dd3b-42bd-91a0-b5cbd332ef22"
      unitRef="number">0.122</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTMtMS0xLTgyODU4_0bc4430d-f38f-45db-8dde-a97e57fabf45"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEwLTUtMS0xLTgyODU4_1004ec2d-b06b-47aa-a47b-fcfa434635f6"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTEtMS0xLTgyODU4_eae99a5f-1de0-43c5-b341-822ebbb06a22"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTMtMS0xLTgyODU4_47c6f67a-0eb3-4f06-a64c-dad6f848e5db"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzExLTUtMS0xLTgyODU4_d9f0a792-21dd-4b77-aefe-2bfad976d10f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTEtMS0xLTgyODU4_c7017bfc-bdc8-4fb0-9972-6e459700a693"
      unitRef="number">-0.011</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTMtMS0xLTgyODU4_45daca15-feb6-4ffd-b0b7-891a2f3f7f17"
      unitRef="number">0.002</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTUtMS0xLTgyODU4_63b26c6a-9a45-4715-bc5b-dba0c7b461a5"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTEtMS0xLTkyOTQ4_c63458b6-c982-4472-94a0-ba1a73442291"
      unitRef="number">-0.017</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTMtMS0xLTkyOTQ4_b09e0551-eb84-401c-a6b2-d23d1efc0f8d"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzEyLTUtMS0xLTkyOTQ4_c2966601-e6b0-49c4-a35c-5bc24ec6c43d"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTEtMS0xLTgyODU4_f0de1e7c-97ff-4be6-9252-f5b858018e99"
      unitRef="number">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTMtMS0xLTgyODU4_ea074938-a624-4e7d-b221-fb23899a2465"
      unitRef="number">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE0LTUtMS0xLTgyODU4_07ea0a3c-fb33-4f16-a0b1-076968696104"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTEtMS0xLTgyODU4_4d109ab1-2637-4e4b-aebc-a754f0b5e7cd"
      unitRef="number">-0.011</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTMtMS0xLTgyODU4_893d258c-4ae4-435c-b4a3-d6b1e0d1c459"
      unitRef="number">0.066</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE1LTUtMS0xLTgyODU4_3a4673ea-b64a-4e22-bbfd-6858335f2330"
      unitRef="number">-0.008</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTEtMS0xLTgyODU4_9bad426d-ca34-4c5d-81f1-86c41ffb8160"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTMtMS0xLTgyODU4_7279e5f0-7526-4b40-b4a2-22a2b1a1bece"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTUtMS0xLTgyODU4_509fdf3a-052c-4e33-8ebc-5af30d1f3195"
      unitRef="number">0.010</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTEtMS0xLTgyODU4_7b1d0fcd-0e6b-44a7-8361-3df3c8203725"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTMtMS0xLTgyODU4_d95193aa-a37b-4555-a81b-750ac99cae4a"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE3LTUtMS0xLTgyODU4_d37225ac-114d-4bd2-a85b-c93ca71f60ab"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTEtMS0xLTkyOTM4_f595c03a-affb-442b-8b48-9cad7dcc18a9"
      unitRef="number">-0.091</evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement>
    <evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTMtMS0xLTkyOTM4_a4e8cbae-78ed-458f-925b-8edfba12dd58"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement>
    <evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE2LTUtMS0xLTkyOTM4_c15f35e5-c592-40c5-b1d5-c7b70b6f28de"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTEtMS0xLTgyODU4_1e5464eb-80b5-4445-9e28-a855c52327fb"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTMtMS0xLTgyODU4_16b2c80c-5f08-4fd9-9bc9-12674b82d3bb"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE4LTUtMS0xLTgyODU4_7f3617fe-6310-466a-8b59-34ff7bd20b07"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTEtMS0xLTgyODU4_16bf0e20-f9ab-43c5-b5b3-d0cd66399149"
      unitRef="number">0.699</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTMtMS0xLTgyODU4_cb67d903-65b8-4eeb-b1ae-afac84551df3"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo4ZTlkNThiOWI3NjQ0OTE2YjI1YWFjZTM0MzdjMTFhMS90YWJsZXJhbmdlOjhlOWQ1OGI5Yjc2NDQ5MTZiMjVhYWNlMzQzN2MxMWExXzE5LTUtMS0xLTgyODU4_08a0bd5f-4362-47bc-bc90-5bc756070118"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMjM_32656467-df08-45d0-832b-a0e71cacc418">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Start-up and organizational costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest deduction limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets - Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract fulfillment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our valuation allowance (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged (credited) to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:2.94pt"&gt;Amounts charged  to other accounts includes $17.3&#160;million charged to shareholders&#x2019; equity and $0.1&#160;million charged to discontinued operations for the year ended December 31, 2022 and $1.8&#160;million charged to discontinued operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <evh:DeferredTaxAssetsStartupandOrganizationalCosts
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzMtMS0xLTEtODI4NTg_84414535-0594-4df9-a8d7-6ce77581f7fd"
      unitRef="usd">84000</evh:DeferredTaxAssetsStartupandOrganizationalCosts>
    <evh:DeferredTaxAssetsStartupandOrganizationalCosts
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzMtMy0xLTEtODI4NTg_a98d40e8-47a9-4554-8c4f-0cf088870b65"
      unitRef="usd">103000</evh:DeferredTaxAssetsStartupandOrganizationalCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzQtMS0xLTEtODI4NTg_9c7ab624-7e7d-4a49-8fd1-fb55625447f8"
      unitRef="usd">12281000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzQtMy0xLTEtODI4NTg_672e74bd-c6a8-430d-bdcf-4417da106f9c"
      unitRef="usd">18774000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzUtMS0xLTEtODI4NTg_e1a96259-bfcd-493f-bd7e-6350df048790"
      unitRef="usd">16362000</evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzUtMy0xLTEtODI4NTg_a8b9ae71-19b4-4092-af30-e7a5376ada2b"
      unitRef="usd">15968000</evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzYtMS0xLTEtODI4NTg_b16f937a-f638-49ee-859b-2cc69503dc0e"
      unitRef="usd">9326000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzYtMy0xLTEtODI4NTg_7a3fbd56-740e-4056-9b2b-79fe8b179a80"
      unitRef="usd">10345000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzctMS0xLTEtODI4NTg_9fdc3bf7-c880-46c1-8315-474d86478a7a"
      unitRef="usd">1263000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzctMy0xLTEtODI4NTg_16e166b8-c893-458f-ae05-1f6b3b264ba8"
      unitRef="usd">8714000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzgtMS0xLTEtODI4NTg_5e146b1d-3066-4e70-9fa1-d0623ea5252a"
      unitRef="usd">131317000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzgtMy0xLTEtODI4NTg_5fd43150-2068-4781-958b-9a61ff996327"
      unitRef="usd">130242000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzktMS0xLTEtODI4NTg_12c7ce07-3d2d-4adf-bce6-14c02c37b0bc"
      unitRef="usd">1828000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzktMy0xLTEtODI4NTg_bda47c49-46e6-41a6-a823-8286c1fdd7ca"
      unitRef="usd">1828000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEwLTEtMS0xLTgyODU4_6641b4e4-423f-46f1-9835-ec692b3ec06e"
      unitRef="usd">393000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEwLTMtMS0xLTgyODU4_3c5cff48-f585-48a6-9c4b-dee7ae95b3ca"
      unitRef="usd">480000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzExLTEtMS0xLTgyODU4_63a11692-f2ca-409c-b092-3b22e27174e2"
      unitRef="usd">7089000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzExLTMtMS0xLTgyODU4_d4993abe-7985-4c37-8819-2ca3be31091a"
      unitRef="usd">7795000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <evh:DeferredTaxAssetOutsideBasisDifferences
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEyLTEtMS0xLTgyODU4_58b1be46-72fe-43aa-9759-c9101c25acd9"
      unitRef="usd">650000</evh:DeferredTaxAssetOutsideBasisDifferences>
    <evh:DeferredTaxAssetOutsideBasisDifferences
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEyLTMtMS0xLTgyODU4_d954a31f-5317-4288-9f35-26391d84a5c8"
      unitRef="usd">1972000</evh:DeferredTaxAssetOutsideBasisDifferences>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEzLTEtMS0xLTgyODU4_25ded0a5-f2bb-4d33-a639-f32726e500b2"
      unitRef="usd">6677000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzEzLTMtMS0xLTgyODU4_5000a0b3-37a8-4cfb-90b3-777d89976789"
      unitRef="usd">9236000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE0LTEtMS0xLTgyODU4_28310828-5475-40a9-96bf-d2bb975c0aae"
      unitRef="usd">187270000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE0LTMtMS0xLTgyODU4_b87e6c42-91d3-4006-90bd-9a81180bb467"
      unitRef="usd">205457000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE1LTEtMS0xLTgyODU4_5ad757fd-09c8-4a58-a550-fc67d66d92e1"
      unitRef="usd">70790000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE1LTMtMS0xLTgyODU4_5ffce3cc-de66-4d6e-b972-89f4bbd7b2df"
      unitRef="usd">101345000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE2LTEtMS0xLTgyODU4_db52703d-7df1-43df-a4f5-91ec59589147"
      unitRef="usd">116480000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE2LTMtMS0xLTgyODU4_0138b5a0-a529-4a28-b4f1-79c044884562"
      unitRef="usd">104112000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE5LTEtMS0xLTgyODU4_479a60a0-20ac-499f-8892-f46f813225ae"
      unitRef="usd">11173000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzE5LTMtMS0xLTgyODU4_b64ece07-09ab-40ae-9ccb-652fb8ca6a72"
      unitRef="usd">12501000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIwLTEtMS0xLTgyODU4_37199b64-dc71-4389-9f07-041cd9fc313a"
      unitRef="usd">89784000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIwLTMtMS0xLTgyODU4_c149ed00-62cb-494d-9866-4da82eb6cb82"
      unitRef="usd">48677000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIxLTEtMS0xLTgyODU4_8daba110-57d2-4bbd-9d75-8d12f769767a"
      unitRef="usd">12696000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIxLTMtMS0xLTgyODU4_ff837b62-2835-460d-9828-534f0b6c066c"
      unitRef="usd">12284000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIyLTEtMS0xLTgyODU4_dc3398a9-6921-42de-8af6-d0f8e1c8d81c"
      unitRef="usd">4501000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIyLTMtMS0xLTgyODU4_220ae388-722a-4baa-81f7-186799b40033"
      unitRef="usd">8317000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIzLTEtMS0xLTgyODU4_33cd7401-94b9-45fc-83f4-eec745c52588"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzIzLTMtMS0xLTgyODU4_ccd53607-b2ab-475f-88f0-59d6ef46952a"
      unitRef="usd">17604000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI0LTEtMS0xLTgyODU4_a0d04977-f375-4c77-9c21-00d6aade3a64"
      unitRef="usd">2136000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI0LTMtMS0xLTgyODU4_41e7da4c-faaf-4314-9c1a-f5e050df954a"
      unitRef="usd">5387000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI1LTEtMS0xLTgyODU4_7011188c-e857-4286-9f7e-5f3e6d35f81c"
      unitRef="usd">120290000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI1LTMtMS0xLTgyODU4_3e16ae75-c8ca-4478-aa01-c1a4d56a6fdb"
      unitRef="usd">104770000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI2LTEtMS0xLTgyODU4_05157338-376c-49af-b626-6d361f9fc912"
      unitRef="usd">3810000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTo5OTM2MmYzODU4ZTg0ODE4YjkxZWRhMWQ1ZmU1MjM5ZS90YWJsZXJhbmdlOjk5MzYyZjM4NThlODQ4MThiOTFlZGExZDVmZTUyMzllXzI2LTMtMS0xLTgyODU4_a5f10afb-d4c3-4bda-b763-5e2afe7975a2"
      unitRef="usd">658000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie2c16ad239424ec88d83268977b370bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzItMS0xLTEtODI4NTg_cd2cd9ac-2d60-40a9-ad31-04c2ae461f06"
      unitRef="usd">101345000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id2f84cee7ed64c41ad902dcd77f1d4e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzItMy0xLTEtODI4NTg_41417d62-4513-4796-87f9-c7952e3f4307"
      unitRef="usd">89723000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzMtMS0xLTEtODI4NTg_46a25e3b-0d48-4865-a1f5-a3f0a4e08ba3"
      unitRef="usd">-47964000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzMtMy0xLTEtODI4NTg_bb8835c8-801f-4a59-ad97-3a65ae9f6a2d"
      unitRef="usd">9856000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia829e7f7e46b4f72ad20e60e5efc4bf7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzQtMS0xLTEtODI4NTg_4b0abb0c-5781-45d5-8b5f-1517c4fd983c"
      unitRef="usd">17409000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i1bcc31dfbdcc4eb8bfbbb9b2fdbb9eee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzQtMy0xLTEtODI4NTg_c2b98827-7fe1-4d93-aafc-e8ba1acf9fa7"
      unitRef="usd">1766000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i00a909c5b37546d18248f54d9b4a4151_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzUtMS0xLTEtODI4NTg_6cd0dd64-be88-43dd-9e6d-335cf8db8684"
      unitRef="usd">70790000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie2c16ad239424ec88d83268977b370bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTpmYTk0YWViNTY4MTg0OTJlOWZkOTlhYTRmMDhmODMwNy90YWJsZXJhbmdlOmZhOTRhZWI1NjgxODQ5MmU5ZmQ5OWFhNGYwOGY4MzA3XzUtMy0xLTEtODI4NTg_4ceccfb3-7522-4ace-baf9-faa778f2c5b7"
      unitRef="usd">101345000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2de795bc67904a5e85f0decbbd09ab32_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3Njg_8f368c56-6e7f-4f54-a3d7-a06766f4d772"
      unitRef="usd">17300000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i997feae046c54b3a9bf17e3433160784_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3ODQ_37898dac-7b8f-4c43-bb5b-296b289d1b5a"
      unitRef="usd">100000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="id31a88fa387b4e53a12f438b4b3b5bac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzk0Mg_38a7c66e-4566-4d07-90a5-22dbf49a09bd"
      unitRef="usd">1800000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNTI0Ng_d291c0ab-422a-4117-accd-1ee2ff014f69"
      unitRef="number">0.699</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNTI1Mw_33a24430-525c-4ef7-b77a-ee9e328607c9"
      unitRef="usd">-43400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0Mzc_9ca6101d-1b12-4ebc-a5e0-de3d44fa92e8"
      unitRef="usd">-46800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzEyMDY_1d683934-947d-4979-8e8f-632f39a67c65"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzEyNTY_cc9dbeb0-d751-47fd-9977-0a3b2a14f826"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDY_52419f8f-009c-446c-8535-b31d6134b23c"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2OTc_d682fa02-9cec-4dd1-b014-51c554fe2bdd"
      unitRef="usd">-2400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ief049904d28f460d998a77dd264865b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQwODg_e2dffde5-962d-45b0-92a7-ac871f03a8dd"
      unitRef="usd">186900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib8dfb8ced52c4e3cb9c781d4c11d94cc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQxMDY_4da5f3e3-59f9-401c-ab77-1ff77ac96e9c"
      unitRef="usd">301800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i84bf075d368e44968b724f9fa95b7960_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQyMzE_74d0b4d8-e18c-4364-83db-47e44671ff5f"
      unitRef="usd">295500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib816cd0b1e5246268d85139debf44ec6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQyNDY_9c358cd4-2a5d-4367-a1e3-3e7ffb0eae3a"
      unitRef="usd">245000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ic2fe137ef9b94b438227de3ce6b602f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQ5NTc_94c6b22f-4b59-4065-b979-d54f88361ff8"
      unitRef="usd">2100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i6973c687f47242d48d1ab11cc64f5795_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzQ5NjQ_592864ad-402f-4f35-b880-193c8f139968"
      unitRef="usd">300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzgzMTI_64ff1f2d-e210-466e-a2a3-7817f77d5c97">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our unrecognized tax benefits (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:402.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - tax positions in prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - tax positions in current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItMS0xLTEtODI4NTg_f62de48a-0f78-4704-8366-a2ddb49e6f74"
      unitRef="usd">609000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItMy0xLTEtODI4NTg_116901e7-6913-4f8a-a462-11c6f6739861"
      unitRef="usd">678000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie5f26637675c489a938b4dd3e4068e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzItNS0xLTEtODI4NTg_b360383a-9584-4be1-9564-118bcc97ad16"
      unitRef="usd">753000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMS0xLTEtOTMwMjE_33d09c79-a035-4134-a96f-ce1a45bcc582"
      unitRef="usd">616000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMy0xLTEtOTMwMjE_5f897e25-4472-4df7-8632-4dcc289a7a3b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtNS0xLTEtOTMwMjE_acc25e8e-0355-46b1-bbb3-7fb1b8b0efa8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMS0xLTEtOTMwMzA_a22fa7b4-1683-4ead-ab29-ba4ef0138501"
      unitRef="usd">399000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMy0xLTEtOTMwMzA_bf85df19-9fa1-43fc-b005-ad491ad294a7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtNS0xLTEtOTMwMzA_0df23f2b-68e0-44ad-84a8-9a42ef5b8d46"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMS0xLTEtODI4NTg_101223e6-7ea7-4dec-a359-83bac1871b51"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtMy0xLTEtODI4NTg_f06b02d8-cb3a-4e43-9bb7-3a283664a33d"
      unitRef="usd">69000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzMtNS0xLTEtODI4NTg_b146ebcf-7237-480b-9066-265de0357a57"
      unitRef="usd">75000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMS0xLTEtODI4NTg_fbd8657b-46f0-4e7b-b2fa-71832d47d62e"
      unitRef="usd">1624000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtMy0xLTEtODI4NTg_f3a271cf-7d9f-4f54-a81a-ec240ec9eddc"
      unitRef="usd">609000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90YWJsZTplNTFhOTRiOTY1MDU0MDBmYWU4ZWU4NjQwZTJhNjYzOS90YWJsZXJhbmdlOmU1MWE5NGI5NjUwNTQwMGZhZThlZTg2NDBlMmE2NjM5XzQtNS0xLTEtODI4NTg_221b5f34-605b-4079-9a16-50ef58291f6e"
      unitRef="usd">678000</us-gaap:UnrecognizedTaxBenefits>
    <evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU1ODA_2d8b5b81-538f-490f-87d9-8ef50a8d0d4f"
      unitRef="usd">600000</evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNzkzOA_65c34745-4086-4263-b6d4-8e427da0810f"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0Mjg_063a44b9-5e96-4bab-bfd1-1369340caf3f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU0OTc1NTgyNzk1Mg_078172bf-3a16-42f8-836c-ff8d695f2e1e"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzM4NDgyOTA3MTE3OTg_d069e9e6-2274-48a7-8518-3a0f6bc130f4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU4ODU_7ae254fb-75a7-4482-a7e6-1a7d5d5bca98"
      unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzU5Mjk_73028042-1f25-49f5-886a-c32a71e9bbc8"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzY4MTc_e18bb098-002c-40fd-9d7a-458a58e5bf27"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders>
    <evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc1Njg_560c406f-ba88-421d-b030-a120d18b478a"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4265c7d21f1d4b838581fca135d6e78c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc4NjA_09f10d0e-a8b5-40cb-ba26-bbd0b72bb735"
      unitRef="usd">79300000</us-gaap:OperatingLossCarryforwards>
    <evh:TaxReceivablesAgreementLiability
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzE2NDkyNjc0NTY0MDY_2746ce8f-d1d7-4e25-b323-26c3babfdb13"
      unitRef="usd">46000000</evh:TaxReceivablesAgreementLiability>
    <evh:TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNjIvZnJhZzo1NjE0N2Y1M2M1MjY0NWEwYjBlNzgyNmE1OTgwZDY5ZC90ZXh0cmVnaW9uOjU2MTQ3ZjUzYzUyNjQ1YTBiMGU3ODI2YTU5ODBkNjlkXzc5OTg_b5645c3f-be2e-49f3-9c63-468334069418"
      unitRef="number">0.15</evh:TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzU5Ng_fdf34090-24df-48c7-aeb5-25e038fe7ccc">Employee Benefit Plans&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $7.4&#160;million, $5.4&#160;million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in contributions to the 401(k) plan for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Total contributions for the year ended December 31, 2020, are net of $0.2&#160;million from discontinued operations.&lt;/span&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzM5MA_f795fc4c-1e33-47ed-9c6a-b0bceee2ae14"
      unitRef="usd">7400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzM5NA_c6fae005-328c-48b3-a6cb-3aefad42078a"
      unitRef="usd">5400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzQwMQ_a10f6727-1cee-4bb5-bb59-91cb872b543f"
      unitRef="usd">6200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i8a1343f8f96b4ae18337534fb232cef4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNTMvZnJhZzo5ZDQ2ZmJkMjIwMTg0YmU3YTllNzdkZDA5YWM3YTQzYS90ZXh0cmVnaW9uOjlkNDZmYmQyMjAxODRiZTdhOWU3N2RkMDlhYzdhNDNhXzU1OA_b62541ed-75cf-480e-9790-00ae3e031d26"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjE4OA_dcfcca00-e444-4212-a204-b3fb2d95f25a">Investments in Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain from these investments was approximately $4.6 million,  $13.2 million and $10.0 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $16.9 million,  $15.9 million and $192.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="ib9836acdd1fb436298594c2019552b35_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI0NA_0185b9f4-db1e-4d15-b625-175c3045d9b2"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="ife27a03e76054f2293b5ac1cb4a4010f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI1MQ_4a0c5fd9-0d7f-4bc0-9815-74260f6413d0"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="if07bcd3c52e24dc1836baafe4f759c78_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI1OA_89572e94-8085-44de-ae0a-62a9a0d9d974"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTI2NQ_2640ec05-99d3-4899-9c9a-73c6bf47d520"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="if07bcd3c52e24dc1836baafe4f759c78_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1Mg_b6e6a60a-6a55-4bd0-ae8e-e17903530b21"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="ib9836acdd1fb436298594c2019552b35_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1Mg_fbad8d22-c45a-470e-8294-5d60d29d5f8f"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="ife27a03e76054f2293b5ac1cb4a4010f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1OQ_a5625ab9-b402-46a2-aae2-b6858b00eea6"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i3411f0bebcc04f939f1a1b5d7cd63bef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTM1OQ_e8e572bd-d7de-404d-be18-7f95c266b065"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTgwOA_2b765b9d-a470-4022-9025-eb13aea49a2e"
      unitRef="usd">4600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMTg0NA_7489738b-b4dc-4057-b730-f5d564247049"
      unitRef="usd">13200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfNTQ5NzU1ODE2MTk2_99451f6a-a6c6-4fc6-bb10-813033631c08"
      unitRef="usd">10000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i08ddb5f52bed406dacf7038dcf91f94c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjEyNg_4ac3dfbb-57df-4e47-b538-e7c01ccc1384"
      unitRef="usd">16900000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i5ab25d9d5a634cb59dbe05457f809563_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfMjE2Mg_a472db18-7d6d-4aeb-bb0e-2afb9e8cca11"
      unitRef="usd">15900000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i8a8a373598344ec1894589f6195ded59_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85MS9mcmFnOmNkYWNmZGU3ZWZmNDRkNmM4YTJjMDg1YWJkYjJmMzI4L3RleHRyZWdpb246Y2RhY2ZkZTdlZmY0NGQ2YzhhMmMwODVhYmRiMmYzMjhfNTQ5NzU1ODE2MzMw_1e4d1f07-ba72-4916-8771-671cf3167f96"
      unitRef="usd">192800000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI1Nw_15bd34de-c163-4c1b-8227-2f934828741f">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#x2019;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (gain) loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.85% - 10.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI1OQ_54da63f4-9ab2-4632-b12f-550e034ec66c">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if17c85faa0f841b99a3b41d10678e6f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy0xLTEtMS04Mjg1OA_5e38d305-0235-43bf-9675-4c5143952ecb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8d6345c725b74f1185b75d72fe34dc81_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy0zLTEtMS04Mjg1OA_2fd5f22f-5b79-4c73-90ce-3e0da125f938"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy01LTEtMS04Mjg1OA_d13e1a23-6df0-4b9f-94ce-0f039674edd0"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfMy03LTEtMS04Mjg1OA_31ef5524-9071-4bd8-a0e2-eabe0b90ed8a"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if17c85faa0f841b99a3b41d10678e6f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC0xLTEtMS04Mjg1OA_9d8fcdb7-892e-4f40-bf8e-fe9198cebfc0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8d6345c725b74f1185b75d72fe34dc81_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC0zLTEtMS04Mjg1OA_355f2cd7-4ec2-4be4-aac3-83f6ae7c7f85"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC01LTEtMS04Mjg1OA_ed9ae7fd-eb61-46a9-b83a-16b2eab72e43"
      unitRef="usd">78000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i380a94d4a42d4e59aa37d27a99b46bfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjlhZTNmNTJlNDA0NDRkMDBhNmJlNDE2OTBkZTlmYzg2L3RhYmxlcmFuZ2U6OWFlM2Y1MmU0MDQ0NGQwMGE2YmU0MTY5MGRlOWZjODZfNC03LTEtMS04Mjg1OA_acc30541-c7b4-4438-867b-9157ff8f47bf"
      unitRef="usd">78000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i922ff0166d094a94bc7b6cb25be53520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy0xLTEtMS04Mjg1OA_d52f0642-3438-4a16-8c6e-d00c05bb58ca"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7077a023068e40ef90f4eafdef2ac9d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy0zLTEtMS04Mjg1OA_ebb6ee4a-799d-4b87-83e8-b50ddf8000e0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy01LTEtMS04Mjg1OA_7af22d7f-255d-4df8-a6ea-853e6a2faaaf"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfMy03LTEtMS04Mjg1OA_c7c3da13-50b5-4217-985c-d806306e1b25"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i922ff0166d094a94bc7b6cb25be53520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC0xLTEtMS04Mjg1OA_c403958b-8e98-4947-8f26-8919f33cc6ef"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7077a023068e40ef90f4eafdef2ac9d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC0zLTEtMS04Mjg1OA_37b23023-1c27-4ecf-8b6a-cb6772b2fc33"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC01LTEtMS04Mjg1OA_27170565-fd8c-4ff1-9dee-e9ead8588228"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3611ba9fb1d644eab8c3ac98b959d3c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOmM2OTQ5YzJmNGFkYTRjMDBiODNkZWY0NTFhYWYyMGRkL3RhYmxlcmFuZ2U6YzY5NDljMmY0YWRhNGMwMGI4M2RlZjQ1MWFhZjIwZGRfNC03LTEtMS04Mjg1OA_cb499fab-4f19-4358-bea1-439955b4a685"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI2MA_54f2d4dc-ae45-46a2-92a9-b4571ffe0dc8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (gain) loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMi0xLTEtMS04Mjg1OA_15e0f217-48eb-4334-b4c6-5d9c5e3af8eb"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMi0zLTEtMS04Mjg1OA_f111839d-2519-47e3-8d43-dd4ed2ab2e6a"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMy0xLTEtMS04Mjg1OA_f0db3c6c-916c-41ac-b143-2ad8b218456f"
      unitRef="usd">75000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfMy0zLTEtMS04Mjg1OA_724ebb1c-fa10-4cf0-bdcb-67735af54a8f"
      unitRef="usd">14600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNC0xLTEtMS04Mjg1OA_3194bb41-9355-410a-af36-724fcd3ae9af"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNC0zLTEtMS04Mjg1OA_cc78d3f2-49bb-4fc5-ba51-22c2302c4418"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0wLTEtMS04OTYxNQ_18d250a8-ffa3-4981-a373-91017e1f61d8">Unrealized (gain) loss, net</evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0wLTEtMS04OTYxNQ_5f68097d-06ed-44f1-b5b0-a30919dea20e">Unrealized (gain) loss, net</evh:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0xLTEtMS04Mjg1OA_c0ba3d60-2133-4c68-8cb6-496c04bcedcd"
      unitRef="usd">25700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNS0zLTEtMS04Mjg1OA_ea05268a-1103-49b5-8619-0f540d7b4cf2"
      unitRef="usd">-14100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNi0xLTEtMS04Mjg1OA_07cd59c2-5ecb-4a96-9216-6fdfb3e6770f"
      unitRef="usd">78000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjIwYzhlYjNiMGY3MzQ0MjU4Y2MyMzY3ODM3OWVjZTEzL3RhYmxlcmFuZ2U6MjBjOGViM2IwZjczNDQyNThjYzIzNjc4Mzc5ZWNlMTNfNi0zLTEtMS04Mjg1OA_c066b171-5407-4fd2-a851-7f5100023cd5"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RleHRyZWdpb246ZDcyNDU2Y2VlMDc3NDEwNWJmNDdkNTg1NjI2NTg1MWNfNTI2MQ_28931531-ccfa-4cf2-b45f-4c386b63aeaa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.85% - 10.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iad6f61726ccd42ffaccedd44ffd7e5ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfMy0xLTEtMS04Mjg1OA_2d92b1de-499f-4661-a659-8fe6f613abed"
      unitRef="usd">78000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id9511c01ee7c4db793847be4cc362076_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfMy03LTEtMS04Mjg1OA_59d6f668-1899-4344-874a-8c8d059f6d39"
      unitRef="usd">77946000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaa8ce3db74aa417989fbb9df2f38ad5b_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfNC03LTEtMS04Mjg1OC90ZXh0cmVnaW9uOmEwODM3ZTVlOGVkODRjM2RiYzg4MGFkNTU0MDA0YTgxXzE2NDkyNjc0NDE2ODc_69026719-b1a1-450f-a1c7-f1c494285944"
      unitRef="number">0.0985</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaae7be454d7b4ccca01d6d258c44d97f_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjkwNjEyNGRkZTA0MTRjOTM4Zjc2ZDBjYjgzOTkxMWI2L3RhYmxlcmFuZ2U6OTA2MTI0ZGRlMDQxNGM5MzhmNzZkMGNiODM5OTExYjZfNC03LTEtMS04Mjg1OC90ZXh0cmVnaW9uOmEwODM3ZTVlOGVkODRjM2RiYzg4MGFkNTU0MDA0YTgxXzE2NDkyNjc0NDE2OTY_98c941b3-f502-4289-b719-9303009f5753"
      unitRef="number">0.1001</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifa4b399529244e3a9a265bff227a5cba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfMy0xLTEtMS04Mjg1OA_c42b6963-54e8-4ee6-b48d-f3c67283ae5c"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i84e6659721d84a6a93639ba51c8411c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfMy03LTEtMS04Mjg1OA_6f2b1a6a-8bc3-4671-93b1-257e61424431"
      unitRef="usd">30935000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i025995168f8f42fba6c2563b6e8916a1_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV85Ny9mcmFnOmQ3MjQ1NmNlZTA3NzQxMDViZjQ3ZDU4NTYyNjU4NTFjL3RhYmxlOjQ3MzY5YmRkNDZmMTQ5MDBhOWZiNWEwNDc3MzhlYzc1L3RhYmxlcmFuZ2U6NDczNjliZGQ0NmYxNDkwMGE5ZmI1YTA0NzczOGVjNzVfNC03LTEtMS04Mjg1OA_ed2c24e1-642e-4b3c-a658-cd212b204a50"
      unitRef="number">0.0604</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90ZXh0cmVnaW9uOmEzZTJkMzcxODYyNzQwN2FiZDRjNjc1NTA2MmY3YzlhXzExNzY_0bb47c61-304a-420b-9555-4e0c4f23e656">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:367.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90ZXh0cmVnaW9uOmEzZTJkMzcxODYyNzQwN2FiZDRjNjc1NTA2MmY3YzlhXzExNzM_b0174fba-f695-47d2-b924-81803b40f37e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:367.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzItMS0xLTEtODI4NTg_e79c652c-09ae-4b5f-94f8-21570741cecb"
      unitRef="usd">8787000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzItMy0xLTEtODI4NTg_e5ed3afd-1ce7-4bc3-b592-479114452f3e"
      unitRef="usd">2719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzMtMS0xLTEtODI4NTg_812d29be-7423-41a2-94a4-7c803b56ebea"
      unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzMtMy0xLTEtODI4NTg_94e4737b-c83b-4d1b-b47b-00ae46113deb"
      unitRef="usd">15000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzQtMS0xLTEtODI4NTg_00e6391a-df63-419c-964c-2f2b3ab4d338"
      unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzQtMy0xLTEtODI4NTg_616a8a3f-eccf-4f7a-8a48-48a0b5f9bc7e"
      unitRef="usd">4877000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzctMS0xLTEtODI4NTg_5987a43d-8d25-4e08-96c4-82d62ba2a3b4"
      unitRef="usd">27000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzctMy0xLTEtODI4NTg_42998660-2a95-4290-9c52-879e2bbc230b"
      unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzgtMS0xLTEtODI4NTg_4f1d2272-f914-4576-a56c-aa6fd2d62323"
      unitRef="usd">192000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzgtMy0xLTEtODI4NTg_91678ede-c08b-4bb0-8f61-59a602758cae"
      unitRef="usd">1120000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ie38cc40fb229457c9241d55acdc35d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzktMS0xLTEtODI4NTg_ce7d3f08-d134-4e1c-bd2c-4d43fd0e9e8e"
      unitRef="usd">0</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i27fa49659d7d4d6f9e976bf660432df5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTpkZTRjMjQ5ZWM2YzY0YzRmOThmYzU1ODM1Nzc1MjY5Yy90YWJsZXJhbmdlOmRlNGMyNDllYzZjNjRjNGY5OGZjNTU4MzU3NzUyNjljXzktMy0xLTEtODI4NTg_3c17f205-b1ad-4fce-ae3d-1a009a931360"
      unitRef="usd">734000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:RevenueFromRelatedParties
      contextRef="if4619916bbd2482ab8018d375249be03_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItNS0xLTEtODI4NTg_b52a0e68-2eed-43ed-8c22-3eca18557dd9"
      unitRef="usd">154591000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i0251e2b7f89d4de890ab29fd635ae904_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItNy0xLTEtODI4NTg_cca9d69c-40ac-4859-add4-fdbb722c405f"
      unitRef="usd">45082000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i843d5fcb4df3420485390014398766dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzItOS0xLTEtODcwNDk_5863a74e-e1ad-4660-98d9-794c16188eb1"
      unitRef="usd">231755000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i48a4f5ce8e6c44d9b8740ae1f7ba19dc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtNS0xLTEtODI4NTg_7c4ab117-3a8f-4767-915b-150ea794f2d5"
      unitRef="usd">128308000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i375cbb6ae8bf4bf4af4ed3910f4e95fb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtNy0xLTEtODI4NTg_3c418c7f-703e-486c-8b4b-e825f7a314b1"
      unitRef="usd">3063000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4b7bf3dd1e1e42c38fecc74e534c3349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzUtOS0xLTEtODcwNDk_147a90fd-02e0-4c06-bba7-343d317d8267"
      unitRef="usd">2863000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0c76ef785ed6456998aa2837427805d2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtNS0xLTEtODI4NTg_42a9b210-8f9d-43e0-a58c-e298fd738487"
      unitRef="usd">1507000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i9903fd78307a4882846df7bd26ed4ca2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtNy0xLTEtODI4NTg_2a37a391-21b6-4853-9981-a7b6de1b824b"
      unitRef="usd">285000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="if2afd02fdc0d43e283e8a6be9bbf3622_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDAvZnJhZzphM2UyZDM3MTg2Mjc0MDdhYmQ0YzY3NTUwNjJmN2M5YS90YWJsZTo0M2VmNDBlNTFjOGM0ZDA2OWJlZDMxM2UzMzUwNjUzYy90YWJsZXJhbmdlOjQzZWY0MGU1MWM4YzRkMDY5YmVkMzEzZTMzNTA2NTNjXzYtOS0xLTEtODcwNDk_a0066576-a20b-4540-8f2f-b20924fd6641"
      unitRef="usd">113000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90ZXh0cmVnaW9uOjNhODc1YjkzNjE4YTRiNDU5OTA4YTVjYTg0MmQxYmIyXzE0NjQ_9c6191cb-006c-400e-bd14-8077f54a04e9">Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90ZXh0cmVnaW9uOjNhODc1YjkzNjE4YTRiNDU5OTA4YTVjYTg0MmQxYmIyXzM4NDgyOTA2OTkwMTA_fb4b42af-7e10-48f6-8583-3e4b4d33cb08">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i507c481168c24a8282e6d5446b4557e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItMS0xLTEtOTQxNDU_f227a37f-d900-4d94-9262-a29f6656fc40"
      unitRef="usd">185000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i91a9aeec0e924002bd91990917dd2807_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItMy0xLTEtOTQxNDU_cae28a25-8053-4572-9f1b-d941306ea139"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i83cb6ba27fa047439559a1ce5bdf570e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzItNS0xLTEtOTQxNDM_e749d2e8-b2ea-4f11-a6eb-0765a701f447"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i6af8d3395ca54542b8e581cd46d63e85_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtMS0xLTEtOTQxNDU_14c9f2d6-ce3b-44fe-8609-98c49874ba7c"
      unitRef="usd">2742000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4ea6990f35a04f21953a710e60c32fb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtMy0xLTEtOTQxNDU_58ce109f-85ed-44ca-b265-6b251c542617"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ia138a2f2ee96409fbd2de15262bbc9a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzMtNS0xLTEtOTQxNDM_f46c0fdf-77c5-4aa6-914d-fc8ed28a5183"
      unitRef="usd">2742000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="if4d2a17bc955412cbbed83c8fa718cf1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtMS0xLTEtOTQxNDU_fbfbacca-f7dc-4304-bdfb-69afe51e5d2a"
      unitRef="usd">4391000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icc7c08e385554e8cb407ca29ab063d05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtMy0xLTEtOTQxNDU_92469134-616e-46f0-ab51-21cbdda8d124"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i3d50a01d5910438a928adb7f868c6ed6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzQtNS0xLTEtOTQxNDM_87a65680-2dc6-4e11-b937-1186f556489a"
      unitRef="usd">5666000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtMS0xLTEtOTQxNDU_08ac7e58-ba27-432e-9bca-8656e24277fe"
      unitRef="usd">7318000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtMy0xLTEtOTQxNDU_419d9daa-842c-4dcb-95bb-7c3953fcccea"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDMvZnJhZzozYTg3NWI5MzYxOGE0YjQ1OTkwOGE1Y2E4NDJkMWJiMi90YWJsZTo0MmVkYmQwNzljMjc0NmQ1ODUzZGE1NDlmNmMzZjM2Zi90YWJsZXJhbmdlOjQyZWRiZDA3OWMyNzQ2ZDU4NTNkYTU0OWY2YzNmMzZmXzUtNS0xLTEtOTQxNDM_6251088a-1b0d-47c5-b3ba-73da0b98adb0"
      unitRef="usd">8593000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzY_20f306a3-b607-42ff-9959-5f7e9ce25170">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision for) benefit from income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on extinguishment/repayment of debt, net, goodwill impairment, gain from equity method investees, loss on disposal of assets, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs and loss from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment/repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $0.5&#160;million and $6.8&#160;million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI0Mg_87c7c719-1772-4984-9334-44786f9c73e4"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzM_4f6e6857-0e35-4917-95e1-1986c010810e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMS0xLTEtODI4NTg_ce1e114e-35f2-466e-94d4-60da51d761fa"
      unitRef="usd">408371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMy0xLTEtODI4NTg_3cf92d05-a902-4784-90ba-6f9814adc635"
      unitRef="usd">944511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16141fafab8e460196d863fb9865d30b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtNS0xLTEtODI4NTg_5f7333e2-6ddf-49fa-9e63-87f9defc6edb"
      unitRef="usd">-869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtNy0xLTEtODI4NTg_4214a764-8a2c-44a9-bd87-dfa5b75e989c"
      unitRef="usd">1352013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtOS0xLTEtODI4NTg_bb658694-e8a5-4290-9854-0f4b246272a2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzMtMTEtMS0xLTgyODU4_aa4c66db-0868-4055-964f-0b339d595934"
      unitRef="usd">1352013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMS0xLTEtODI4NTg_fc9a03f8-659e-4fec-ab51-c3171bb42c36"
      unitRef="usd">311627000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMy0xLTEtODI4NTg_48fe23fb-605d-4baf-9e8b-854611e4f226"
      unitRef="usd">598144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46413fc7149140518ad72598cb806328_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtNS0xLTEtODI4NTg_886ba342-496f-4568-93d6-b597dcbcd5cd"
      unitRef="usd">-1814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtNy0xLTEtODI4NTg_40ebb366-8c92-49c2-914d-29ae8ef32e83"
      unitRef="usd">907957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtOS0xLTEtODI4NTg_a21403d6-9325-40d7-928d-f34ae9985af6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzYtMTEtMS0xLTgyODU4_b6911f44-267b-486a-abbf-eb931509fd7e"
      unitRef="usd">907957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMS0xLTEtODc3NTU_22cb26b3-fd04-477b-af73-64ed22823787"
      unitRef="usd">385134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMy0xLTEtODc3NTU_ef406e50-a9bc-4aaa-84fc-8f7843a8cd94"
      unitRef="usd">542279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife5cf9a41dc0464dadd48964641367bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktNS0xLTEtODc3NTU_30ca2b1f-ae15-4512-b869-4991e1e0ff9d"
      unitRef="usd">-2774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i214e73201d094671bbc005a4978f6737_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktNy0xLTEtODc3NTU_bd0da357-0b48-4613-9164-6b3b7f39dd51"
      unitRef="usd">924639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktOS0xLTEtODc3NTU_dc9d42f8-983d-4333-8a4f-485b468d81c1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzktMTEtMS0xLTg3NzU1_6033bdcd-42fc-48c8-86fd-1d26fc42941b"
      unitRef="usd">924639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia1602b4347c34498a6f4ddd81dea54f3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTEtMS0xLTgyODU4_a48e4782-5b83-4f97-a977-b7ceeeed5b1e"
      unitRef="usd">57936000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie6398e6840de42ba817fc80ac4a21a97_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTMtMS0xLTgyODU4_c6d67e31-6d51-46fc-a363-2d9c475a7863"
      unitRef="usd">78639000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i0927fbf5014643e68e94b14b2c87177f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTUtMS0xLTgyODU4_3fe6099f-6117-47d2-9a39-c24c7ec48ef0"
      unitRef="usd">136575000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i239c2fcc0ebb4a7fb0870da1e7fa5d49_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTctMS0xLTgyODU4_319dab37-3312-4525-834f-9206a096d072"
      unitRef="usd">-30244000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEwLTktMS0xLTgyODU4_1c60467c-eb25-4b59-ad7b-b53bc330ddb9"
      unitRef="usd">106331000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ic29a106fde4c444b87f50fefb72b51c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTEtMS0xLTgyODU4_fba955c9-b3b8-4587-ad9b-995896c2853a"
      unitRef="usd">17063000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i558a28f3b50f44c38dc6718be1cbc981_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTMtMS0xLTgyODU4_cd5a195c-e865-4ba7-826c-fe4063239758"
      unitRef="usd">82920000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i282b2f9618d34925a993da7f8d2891e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTUtMS0xLTgyODU4_df9784bf-2517-4416-a7c7-4c97f6268cc3"
      unitRef="usd">99983000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia5e86d6a1a934317bb3fc9148a3146aa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTctMS0xLTgyODU4_5dc5366c-bf90-479b-b9ea-5f23d4871b1a"
      unitRef="usd">-33666000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzEzLTktMS0xLTgyODU4_74ccad7a-d5b5-4190-9b56-5586cf1e30a9"
      unitRef="usd">66317000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i11687dcd518740f18a90d1e6d3e63938_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTEtMS0xLTg3NzU4_85a5f94c-33e1-4293-82ee-623867f8909e"
      unitRef="usd">57731000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i49a1af18280d44fe90f675b974b196d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTMtMS0xLTg3NzU4_d18afc53-403f-4880-87f4-f3665ec48c47"
      unitRef="usd">26864000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i214e73201d094671bbc005a4978f6737_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTUtMS0xLTg3NzU4_2b1a37d8-319a-43e6-9b04-7b9c334349af"
      unitRef="usd">84595000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i15f74e3335a94d99834d66fcd9aba380_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTctMS0xLTg3NzU4_8b586d5f-6650-4dcc-9673-fa7eab4a0c10"
      unitRef="usd">-36022000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZToyYTA0ZGRiZmU1NGM0OGFhYmQ4M2RkYWM0YTMwYWVkOS90YWJsZXJhbmdlOjJhMDRkZGJmZTU0YzQ4YWFiZDgzZGRhYzRhMzBhZWQ5XzE5LTktMS0xLTg3NzU4_f75ed29a-69b9-4b1b-aaf7-7277a5ffee7a"
      unitRef="usd">48573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzMxMzU_2e8ddc46-ca57-4d82-835f-bc1104b40eb7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment/repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_10d0eefe-ba92-43ed-8ad4-cf1c38d26017"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIzLTAtMS0xLTg5NjEz_c6986d1f-b177-4a6b-bfff-2bb07e04a03e"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $0.5&#160;million and $6.8&#160;million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItNS0xLTEtODI4NTg_51025e15-83d6-4ce4-aa51-d89ac0a06d94"
      unitRef="usd">-19164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItNy0xLTEtODI4NTg_64aca2a7-e414-4ca7-9622-843c24747b75"
      unitRef="usd">-37601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzItOS0xLTEtODcxNDg_27aff77e-0448-42c6-b5ce-ddcfe3f47279"
      unitRef="usd">-334246000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtNS0xLTEtODI4NTg_77d3c87c-380e-42d6-ab8b-45ce2eb4e5a1"
      unitRef="usd">1369000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtNy0xLTEtODI4NTg_069cd645-2486-4d02-b881-4fe388de69ad"
      unitRef="usd">407000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzQtOS0xLTEtODcxNDg_69d05b00-0dda-4515-b9ea-78b7bc40039f"
      unitRef="usd">2633000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtNS0xLTEtODI4NTg_8d6db517-61b7-4e92-87e0-e9e7cf5f2ddb"
      unitRef="usd">15572000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtNy0xLTEtODI4NTg_48067f4a-85d5-4a77-94ce-d74ddcbaa634"
      unitRef="usd">25425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzUtOS0xLTEtODcxNDg_21d7471c-642f-454f-b564-a17fbf4d37ea"
      unitRef="usd">28325000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtNS0xLTEtODI4NTg_89550962-9294-4d46-934d-56dc56caf52e"
      unitRef="usd">-43376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtNy0xLTEtODI4NTg_4c614299-9048-49e0-a542-224129562f70"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzYtOS0xLTEtODcxNDg_551855ea-00e9-453f-9606-0276cb96fd78"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtNS0xLTEtODI4NTg_26ad842d-524d-4c58-966c-195b66aa1724"
      unitRef="usd">67195000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtNy0xLTEtODI4NTg_e32269d6-e83b-4ab3-9884-a22ac4f54a00"
      unitRef="usd">60037000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzgtOS0xLTEtODcxNjI_66fbc295-6d8f-4b7c-aee0-025a34b17e9d"
      unitRef="usd">60835000</us-gaap:DepreciationAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNS0xLTEtODcxOTQ_8d8ea15c-84d2-4a92-8ec5-907e46d46a5e"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNy0xLTEtODcxOTQ_bb7c0991-bf1b-473e-b45c-d3a794087690"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktOS0xLTEtODcxOTQ_d760fb58-6971-436c-8a99-766ff8a8c171"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <evh:GainOnTransferOfMembership
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNS0xLTEtODI4NTg_f761e3bb-e10b-4cfa-87c5-b5d0d81da565"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzktNy0xLTEtODI4NTg_236c09cd-e9bc-4ba6-aa00-2888ff65e146"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTktMS0xLTg3MjIz_3dbd7a8c-4ed6-486d-947d-ad1ec5c1ba33"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTUtMS0xLTk3Nzkw_fbce464d-11d3-48e6-a4b8-be22c3313308"
      unitRef="usd">45950000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTctMS0xLTk3Nzkw_64b96d99-5d64-4e48-9519-84598f6c727e"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTktMS0xLTk3Nzkw_c3ccd5dd-0198-4ea7-878f-989e48115308"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTUtMS0xLTgyODU4_77d64676-3a64-48f1-aafd-add39e6021e5"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEwLTctMS0xLTgyODU4_45f55865-2f25-4c89-9e8e-0c392e8cd80c"
      unitRef="usd">-21343000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTktMS0xLTg3MjAz_49de7963-e920-4908-952e-a23f2102f16b"
      unitRef="usd">-4789000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTUtMS0xLTg3Mzcy_6f852fa2-f6b7-4382-b607-e7145b0e89aa"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTctMS0xLTg3Mzcy_5866b5bb-9744-4f5f-833f-f163223494d9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTktMS0xLTg3Mzcy_ed4f33e0-0ea4-4097-8d67-423337295bf7"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTUtMS0xLTgyODU4_24703dc5-452b-4052-8b92-1801ef669fb4"
      unitRef="usd">4569000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzExLTctMS0xLTgyODU4_cdc1c06a-5e06-4336-8982-f9bfc9a2d283"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTktMS0xLTg3MzU2_8867d3b0-3919-4c95-998d-e062515af213"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTUtMS0xLTg3Mzkz_c34a7a7a-b896-4625-a221-c77ecabbd5ed"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTctMS0xLTg3Mzkz_d869a3b2-3c47-4d7a-9786-3ac427b77137"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTktMS0xLTg3Mzkz_1c7bede6-1bdd-4e15-a23b-367d78f610f5"
      unitRef="usd">-698000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTUtMS0xLTgyODU4_fcab6b90-4d9b-4d5b-b972-92bde3ce4ca0"
      unitRef="usd">-23522000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEyLTctMS0xLTgyODU4_2b976aa3-2361-48c3-9c39-dda5df992f15"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTktMS0xLTg3MzQ4_1965a159-07e1-4f25-89e2-d114cd1d58bc"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTUtMS0xLTgyODU4_97e35179-3c94-42e8-919d-7ad051870e46"
      unitRef="usd">57000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzEzLTctMS0xLTgyODU4_8fd983c5-302d-4649-823e-6c13a9021c58"
      unitRef="usd">-146000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTktMS0xLTg3MzQw_3cfa487b-1346-40b2-829d-0d9a0b8952a1"
      unitRef="usd">-118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTUtMS0xLTgyODU4_4b3cefd9-06ed-42d0-aa6c-ac00eb7a5d9c"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE0LTctMS0xLTgyODU4_bc15e827-ede6-4823-be16-c371bc37993e"
      unitRef="usd">7318000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTktMS0xLTg3MzQw_053c5758-b041-406b-b8ed-6f370d9d7622"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTUtMS0xLTgyODU4_43105990-320a-4324-9039-6be863668bac"
      unitRef="usd">33981000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE1LTctMS0xLTgyODU4_ba6a8a39-b673-45d1-b90b-7062a5aa78e1"
      unitRef="usd">16711000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTktMS0xLTg3MzI3_83f95b2d-3884-411a-8781-77db36ffa36a"
      unitRef="usd">14606000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTUtMS0xLTgyODU4_f0e8388b-88cf-40a2-a8bc-3e05a13330b0"
      unitRef="usd">13265000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE2LTctMS0xLTgyODU4_7bef8c77-f17f-44cf-8dc8-7d9eae3cc05e"
      unitRef="usd">198000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTktMS0xLTg3MzI3_1d952fd3-3d6b-4f93-97ca-20d0b3a1a03e"
      unitRef="usd">8986000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTUtMS0xLTgyODU4_30bb1b71-e526-4d98-a4b4-a10e191e1671"
      unitRef="usd">99000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE3LTctMS0xLTgyODU4_0dd24f84-5696-42ba-a58d-90a7f112c99a"
      unitRef="usd">476000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTktMS0xLTg3MzI3_a6e45c5a-7ad8-410c-880b-ec00c33ad6ad"
      unitRef="usd">3944000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTUtMS0xLTgyODU4_fb9a9bcd-bfa5-4bff-b688-5e5a97fae924"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE4LTctMS0xLTgyODU4_f086d0d2-e947-4b36-9436-a873e056aefd"
      unitRef="usd">6513000</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTktMS0xLTg3MjYy_2eb2cd68-ede4-455d-92a5-48bb6ff38b09"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTUtMS0xLTgyODU4_b5ecf84b-d30a-4b75-9dcf-c1a60930c17f"
      unitRef="usd">11671000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzE5LTctMS0xLTgyODU4_4c57df29-544f-4cc6-880c-3b87889fda65"
      unitRef="usd">4194000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTktMS0xLTg3MjU0_df33b606-ac43-42b1-a7e9-67443eeef99c"
      unitRef="usd">2116000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTUtMS0xLTgyODU4_3a6f70e8-795d-4d07-94b5-062a024f3f14"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIwLTctMS0xLTgyODU4_c86fd325-2fbe-480c-890f-9bea1191d6c6"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTktMS0xLTg3MjM2_3dd583db-b965-45fb-9fb8-6a58fc1fbe5b"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTUtMS0xLTgyODU4_f4c4649c-f64c-4c3f-903b-5753a040fcd2"
      unitRef="usd">106331000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIxLTctMS0xLTgyODU4_169ac10a-cf59-4670-877a-45cf9a8b4aeb"
      unitRef="usd">66317000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90YWJsZTo2NGZlNzc3OWNhYTY0NWRjYjMzMjkyM2E0ODU5ZDlkMC90YWJsZXJhbmdlOjY0ZmU3Nzc5Y2FhNjQ1ZGNiMzMyOTIzYTQ4NTlkOWQwXzIyLTktMS0xLTg3MjE0_5c4cdc93-8e85-461a-82c0-51711a2c647c"
      unitRef="usd">48573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI4NTg_3e724a0d-d187-4ffc-a50f-e2e675db99dc"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDYvZnJhZzo4N2ZjMWZlMjM1YWE0MTM0OGQ5MzNiYzE0NjkzNWQxZS90ZXh0cmVnaW9uOjg3ZmMxZmUyMzVhYTQxMzQ4ZDkzM2JjMTQ2OTM1ZDFlXzI5MTY_96f98c70-26e2-458d-af35-5bd0ae5400d6"
      unitRef="usd">-6800000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90ZXh0cmVnaW9uOmFhZWZlZGYzYmRiZTQxNWM4NjFkNjE2MTc2Y2QwNDExXzQ1MDI_76200897-ce17-4e9e-bb97-9b19cccf88f1">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90ZXh0cmVnaW9uOmFhZWZlZGYzYmRiZTQxNWM4NjFkNjE2MTc2Y2QwNDExXzQ1MDQ_10339414-d0cf-42f2-abb3-16f88924dcda">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMS0xLTEtODI4NTg_79e08f39-db5e-47d2-b251-011da96ccc8b"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMy0xLTEtODI4NTg_3d6f6637-5802-494f-aa1c-ad55dd7ef3f2"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtNS0xLTEtODI4NTg_4924d38b-6933-49d3-a9f7-92ac4dba50ac"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8657dbb0d0dd4be59bdd0f45bedbdb0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtNy0xLTEtODI4NTg_67072d3a-7b62-4edc-a2ae-c8c893027bee"
      unitRef="usd">56296000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iab33ed40dddd4e0fa7dbca93177aa44b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtOS0xLTEtODI4NTg_4efef94e-de07-49be-884a-1401096a587f"
      unitRef="usd">122532000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9ecd37c0c42545c0976d2fd1ee487164_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzMtMTEtMS0xLTgyODU4_06ab6347-ca4e-4e78-9f9e-4d69425c17f0"
      unitRef="usd">178828000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMS0xLTEtODI4NTg_62ecc223-6807-4bb9-a25f-dffdba8ce2dd"
      unitRef="usd">0</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMy0xLTEtODI4NTg_4db8b678-b9ed-4498-bbe8-73e8b0ee6617"
      unitRef="usd">605757000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtNS0xLTEtODI4NTg_f7f43e1c-dc27-4337-ab65-7a3827592d75"
      unitRef="usd">605757000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtNy0xLTEtODI4NTg_efc47aac-9659-40d3-b14c-6acfab131149"
      unitRef="usd">8632000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtOS0xLTEtODI4NTg_6beb9342-6219-4ba3-a88c-33fdf82251b6"
      unitRef="usd">449172000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzUtMTEtMS0xLTgyODU4_b9d52610-7f57-44ec-836f-627dd23541cb"
      unitRef="usd">457804000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMS0xLTEtODI4NTg_7b0eff11-cecf-4f85-8560-0f3339ca21d3"
      unitRef="usd">-8176000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMy0xLTEtODI4NTg_0b9ec8ea-0732-481e-b97d-67a4abebf2f0"
      unitRef="usd">-3336000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtNS0xLTEtODI4NTg_b499e6a5-b156-4806-a927-b269fcde0b2e"
      unitRef="usd">-11512000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtNy0xLTEtODI4NTg_c4231122-c0c5-4617-ae98-3d6ea20774fe"
      unitRef="usd">7036000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtOS0xLTEtODI4NTg_8f59d73e-5637-493a-bb97-77aa8d71f3e7"
      unitRef="usd">73000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzYtMTEtMS0xLTgyODU4_4c380011-6b68-45e2-9087-922c481e2587"
      unitRef="usd">7109000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMS0xLTEtODI4NTg_7821f9c1-418a-402c-93d2-f19848486238"
      unitRef="usd">-8176000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMy0xLTEtODI4NTg_3b2c2edd-48a7-4434-9d5c-47d25310f01a"
      unitRef="usd">602421000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctNS0xLTEtODI4NTg_2bda15f2-7779-44e0-94b0-b3493a3b093c"
      unitRef="usd">594245000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctNy0xLTEtODI4NTg_5b7c8308-3962-4768-8a57-4ea3ef367355"
      unitRef="usd">15668000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctOS0xLTEtODI4NTg_81709d9a-ef18-4009-866c-c11d4b2bfcf5"
      unitRef="usd">449245000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzctMTEtMS0xLTgyODU4_77a7aa92-9f2e-473c-be03-5e1479edfd33"
      unitRef="usd">464913000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMS0xLTEtODI4NTg_7d599dd1-8db2-4d02-b3ae-1de99dafd56a"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMy0xLTEtODI4NTg_5f8a7d94-3f98-4756-9c73-081218938c35"
      unitRef="usd">427994000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktNS0xLTEtODI4NTg_a71f2cb3-9736-4cc7-b13c-5bd3277a7dbc"
      unitRef="usd">427994000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktNy0xLTEtODI4NTg_aac16e52-eeee-4d1a-8bb2-1bbbf6ce94d1"
      unitRef="usd">20802000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktOS0xLTEtODI4NTg_11e320e5-2c78-4907-aebd-c317754c188f"
      unitRef="usd">326026000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzktMTEtMS0xLTgyODU4_daacf48b-bb71-4e75-a3f8-5653124ae56a"
      unitRef="usd">346828000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTEtMS0xLTgyODU4_5d160108-35f5-4f73-9133-af44ac00ba22"
      unitRef="usd">12911000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTMtMS0xLTgyODU4_739ab76e-97fd-4a62-91cb-0a46c4ac7eb7"
      unitRef="usd">124904000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTUtMS0xLTgyODU4_8b6cbb05-a8db-4801-b8e7-72e6fec23d53"
      unitRef="usd">137815000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTctMS0xLTgyODU4_b2a47c8b-ea04-49d9-951d-561193cf2285"
      unitRef="usd">25544000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTktMS0xLTgyODU4_2048d669-7dce-47bd-9463-46aac5e8779f"
      unitRef="usd">100075000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEwLTExLTEtMS04Mjg1OA_f9e94d59-fea7-4ab1-8dd7-372457fcdf4c"
      unitRef="usd">125619000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i265daacbff994c5b90701fef58a1c7cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTEtMS0xLTgyODU4_1e3a5669-a182-4060-ba64-03d42a0d3bce"
      unitRef="usd">12911000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i89deefbb403d4bbbbf1e4cd6325e891a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTMtMS0xLTgyODU4_7364f9d7-3e8c-4da7-a1e0-d4e9e8cb8fec"
      unitRef="usd">552898000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTUtMS0xLTgyODU4_816af749-b9ae-44e3-a83c-a26bbf19a3c2"
      unitRef="usd">565809000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="id9571070c288405895ac0648fd0b1fad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTctMS0xLTgyODU4_c6fcb5e4-1c9a-4fd3-ac39-d29da2ced792"
      unitRef="usd">46346000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i8eb54cef0efa4717bed394709a8a2e2f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTktMS0xLTgyODU4_de1cbedb-b66f-419b-b561-baa52483b178"
      unitRef="usd">426101000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzExLTExLTEtMS04Mjg1OA_c7c039dd-e2cc-43b8-9312-923755e72d11"
      unitRef="usd">472447000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i49b5f7dbfd86405d8aab5b6fb5231f95_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTEtMS0xLTgyODU4_d29e02ca-ec02-4763-869c-30e67544c714"
      unitRef="usd">4531000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i33ea7981a58e4cf1bb90015e38b89007_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTMtMS0xLTgyODU4_7e2d4673-ea18-4654-997c-94407fe0c44d"
      unitRef="usd">195199000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7de54fc5bc4847faa175a8ac09179032_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTUtMS0xLTgyODU4_58a3e2ec-58e5-4544-b22a-f6183a7f3b86"
      unitRef="usd">199730000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic2836cea2fd340c28f57a47a9edab8d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTctMS0xLTgyODU4_f2c496bd-4d01-420d-b6e6-9c41fc1c1b86"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iffb588c9720747cb8e17ec8afc367996_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTktMS0xLTgyODU4_54fcb113-51a9-4133-b26a-51070a65bd1e"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5ce8d9bb4f134dbb9349d1760a71011b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMDkvZnJhZzphYWVmZWRmM2JkYmU0MTVjODYxZDYxNjE3NmNkMDQxMS90YWJsZTpjOWRjMmRmMjQ3Y2Q0YTIxYjY1ZjZhNDc0NjMzN2U1Yi90YWJsZXJhbmdlOmM5ZGMyZGYyNDdjZDRhMjFiNjVmNmE0NzQ2MzM3ZTViXzEyLTExLTEtMS04Mjg1OA_d23be45e-6b0c-4dc6-9c40-e69cf0cd7fe0"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90ZXh0cmVnaW9uOmI5Mjc2NzEyMmM5ZjQ5NGFhYTM2MzE5NzYxYjE0ZmU5XzE3NQ_fdb2adf3-8abf-483a-bfa5-b2e82271eac2">Quarterly Results of Operations (unaudited)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,634&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,855&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,349)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,125)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,349)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90ZXh0cmVnaW9uOmI5Mjc2NzEyMmM5ZjQ5NGFhYTM2MzE5NzYxYjE0ZmU5XzE3Ng_8dbc2729-aec4-45dc-9cde-0ddbb6cda92a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,634&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,855&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,349)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,125)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,349)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,350)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMS0xLTEtODgzOTE_3a6e79bd-aa09-4e13-8f6e-d933d32bf073"
      unitRef="usd">382432000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMy0xLTEtODc3NjM_c0b03300-02db-46ff-9011-256a6bd9546c"
      unitRef="usd">352585000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNS0xLTEtODc3NjM_5bcfc47d-1975-415d-9261-5bae3181ccdf"
      unitRef="usd">319939000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNy0xLTEtODc3NjM_8e9aed0b-21d2-42ca-81a0-7b974bc26edf"
      unitRef="usd">297057000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODgzOTE_7ce73830-b483-4917-927f-dede24a24bb2"
      unitRef="usd">384310000</us-gaap:OperatingExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODgzOTE_fb3e8a56-76de-49f2-998d-4f4bcafb6d26"
      unitRef="usd">384310000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMy0xLTEtODc3Njk_717ae2a1-bcd9-4446-91ee-79665732f73b"
      unitRef="usd">339634000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNS0xLTEtODc3Njk_3ba7f107-ca92-4206-8d16-35548091a5a4"
      unitRef="usd">324572000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNy0xLTEtODc3Njk_dd1dd914-27ef-4557-ba81-425ab6cf95c5"
      unitRef="usd">299855000</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMS0xLTEtODgzOTE_5a5e5307-e0ae-4e41-9a53-11a0edad4dec"
      unitRef="usd">-11349000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMy0xLTEtODc3NzE_926bc695-6361-42ea-b6ba-bd4319a94afd"
      unitRef="usd">2123000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNS0xLTEtODc3NzE_53be3078-d3fa-4f09-8a62-6e93ea83c8c0"
      unitRef="usd">-4125000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNy0xLTEtODc3NzE_507dff5c-ba51-485f-94d0-4c72ada99ab5"
      unitRef="usd">-5350000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMS0xLTEtODgzOTE_ba022879-b660-4ceb-9da3-54f0a5e9c9fc"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMy0xLTEtODc3NzM_cb92cce9-0d8f-4a08-9c6e-13083f15a418"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNS0xLTEtODc3NzM_c0e6d8a2-e619-43b3-948a-b92a770b8b43"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNy0xLTEtODc3NzM_61af0a2f-b917-4eca-a584-2d09bb24f4fd"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODgzOTE_11819543-dd40-41a0-9947-d9ceef1a8795"
      unitRef="usd">-11349000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODgzOTE_f30114ad-fd2b-45dd-91ff-bc0ec7891981"
      unitRef="usd">-11349000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODc3NzU_8cbbf119-d495-4e04-99e0-9bbfe4c3fa1c"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODc3NzU_9857544f-6f2a-4eba-b824-a3032b197d21"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODc3NzU_4042a2b3-825e-4fcc-9d5a-b2c8d4de1c5e"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODc3NzU_6a2c2989-29d4-4970-a7cd-788f2ecb87bd"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODc3NzU_0062eb12-d078-439e-8dc7-f31e208b248c"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODc3NzU_8b897b75-2595-47c7-91e0-4413eaed4845"
      unitRef="usd">-5350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTg4Mzkz_30824775-11c9-4cb9-b2e4-8c3bb46cdbe6"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTg4Mzkz_5078b798-745c-4e64-8fb7-81b53433e8f6"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTg3Nzgy_4a797f90-ad8d-4f7a-a2b1-2ef399d617b5"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTg3Nzgy_e8639e32-7531-4707-829f-3ccf1d2b2658"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTg3Nzgy_97698986-fb41-4fe8-bb83-7dfdb78cbe10"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTg3Nzgy_b8e5c3cd-9639-4bcb-badb-865124a38f37"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTg3Nzgy_1a7993e8-f79f-477c-ba87-07dba33bc9d6"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTg3Nzgy_3b97dacc-f82f-48fe-aa7d-38200b8a9095"
      unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTk0MTU4_39148552-231a-48f9-9064-8d61b457c52c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i00104c8c47c0426591c253e73ef11658_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTk0MTU4_fc6bbd44-bf65-4b63-9c6c-d00ee9eabf32"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTg4Mzk3_2336abb8-35d5-4479-ac53-4699a06204a6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="icbe8e6dbb66546f7ab7a913b1a147954_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTg4Mzk3_883c88d9-4d81-4fc7-9749-bd84ff896f1c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTg4Mzk3_43983d77-a922-486e-984e-5f57d49b1ff8"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0da262640f774b11a75c8b33b6d01d0b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTg4Mzk3_baab50de-0913-4767-99fc-1aac5b3717ba"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTg4Mzk3_4583e65c-d770-4eac-bc25-2adf9bb9acb6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i75551e652d8b4ae194c8bdbbb0594f55_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTg4Mzk3_c1799fe6-7687-4c0b-ac6a-991d491d67e1"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:Revenues
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMS0xLTEtODI4NTg_27c2bccf-00e4-4206-951b-573e132cf499"
      unitRef="usd">248358000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtMy0xLTEtODI4NTg_163e2720-c1e2-4295-88c7-a4f85f5453c1"
      unitRef="usd">222471000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNS0xLTEtODI4NTg_8457ff99-f320-4b83-b968-f88aae0c5d78"
      unitRef="usd">222057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzMtNy0xLTEtODI4NTg_14eebbcd-dcf9-4db2-bf0a-1108759d8923"
      unitRef="usd">215071000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMS0xLTEtODI4NTg_8a9b7ccb-1530-42e9-ba5d-720b2403f2d4"
      unitRef="usd">260572000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtMy0xLTEtODI4NTg_f01bb93b-7752-41e1-9e9f-21c8bf7f0901"
      unitRef="usd">229052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNS0xLTEtODI4NTg_9fbc1778-d432-4944-8021-98fd3c570c96"
      unitRef="usd">229728000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzQtNy0xLTEtODI4NTg_c7f5e0b4-cfd2-4bbc-b031-6584c54f3f2e"
      unitRef="usd">231016000</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMS0xLTEtODI4NTg_90a2b3aa-0546-4a80-a615-57f42f497571"
      unitRef="usd">3053000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtMy0xLTEtODI4NTg_d7af5833-2fb6-4770-84a5-2f1472b8b5b8"
      unitRef="usd">-13040000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNS0xLTEtODI4NTg_29704c09-3961-409c-873a-79be4350b08a"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzUtNy0xLTEtODI4NTg_8a0fd663-3bd7-4b15-8550-848c9c9ca1f1"
      unitRef="usd">-11190000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMS0xLTEtODI4NTg_07be0ce3-d11e-4e7b-82fb-29cae14341d8"
      unitRef="usd">-8700000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtMy0xLTEtODI4NTg_b5bf83a6-4416-4adf-8a4e-1ceabd1da6ff"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNS0xLTEtODI4NTg_e9d892a3-d092-4e6f-a2a2-3df59e3325a2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzYtNy0xLTEtODI4NTg_df383bf3-a24f-43a8-a6d4-70c58122e78e"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODI4NTg_422a97f7-59c4-4568-b147-b53a3d81d944"
      unitRef="usd">-5647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMS0xLTEtODI4NTg_9047993d-e343-4279-a7bc-9ed190fd7fc3"
      unitRef="usd">-5647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODI4NTg_9f6bc839-b0d7-46f4-847e-f471e60f911b"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctMy0xLTEtODI4NTg_fbe7e817-02cd-4fd5-99f4-95c5ffdb2dcb"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODI4NTg_9d59b18f-06de-4500-8d06-443bd9411f93"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNS0xLTEtODI4NTg_e8821c57-175d-4a4b-8617-fdcf74d43b6c"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODI4NTg_114a80a4-9ea9-445c-be28-0be7844308c8"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzctNy0xLTEtODI4NTg_660bd444-36a4-4489-a0de-e8c1def0ef5f"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTgyODU4_a73a91b9-8411-4cc8-86ca-c6fa80f0fdc4"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTEtMS0xLTgyODU4_ba505c31-4563-4b37-bba7-48808f064fc6"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTgyODU4_46043a8c-b95c-4388-ae7a-25af1dd872bd"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTMtMS0xLTgyODU4_7aeb7df0-671f-40ef-89b2-2b58dd6305ef"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTgyODU4_01c3b654-62ec-483c-8d65-643784c869dc"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTUtMS0xLTgyODU4_e76ee6e4-5d27-4f5f-a775-280c123935fb"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTgyODU4_89b208fb-0a5b-4a6d-82a2-ef8c7b8b820c"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzExLTctMS0xLTgyODU4_fb5cdda1-bc71-4316-af6e-b6031c928785"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTgyODU4_2d293011-f4f0-4c9f-a72b-53f693704b2f"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i60147b063f994be48a84d5d80558ad21_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTEtMS0xLTgyODU4_61f282e8-ec9c-471a-bd84-fc91a8a8da3c"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTgyODU4_6719c36d-8fca-45a6-9cd6-8dd4440432e2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i892f30e439ed468c872cd62441fadd53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTMtMS0xLTgyODU4_8fe05706-3ece-4705-ac8b-1bcc7a523c6e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTgyODU4_5e26ccfa-0664-4af9-b13c-dcea9da08664"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id942ca2c743848b68895e7f7d2ee6c6e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTUtMS0xLTgyODU4_c0a4c8bc-f66f-4821-a5d2-47ed61cf9bde"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTgyODU4_815c058a-df92-4362-af25-ecf65981c210"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6a4783458489412fac5a73d83bb6a5fa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNzEvZnJhZzpiOTI3NjcxMjJjOWY0OTRhYWEzNjMxOTc2MWIxNGZlOS90YWJsZTo3ZjFjMzJiNTU5NTU0ODIxOTBmNmM5YzU2MTNjYzE5MC90YWJsZXJhbmdlOjdmMWMzMmI1NTk1NTQ4MjE5MGY2YzljNTYxM2NjMTkwXzEyLTctMS0xLTgyODU4_d213f7c0-f389-45b4-ac07-ce73a69c8a05"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90ZXh0cmVnaW9uOjU4ZDA2MTE0N2E1NjQwOWI4NWI2NmMzZDAxNGFkYjUxXzEzMw_65473808-c606-4c7b-af5f-579232a12d39">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of earn-outs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with debt repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for asset acquisition or business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90ZXh0cmVnaW9uOjU4ZDA2MTE0N2E1NjQwOWI4NWI2NmMzZDAxNGFkYjUxXzEzMg_f51578fd-6633-4113-8784-d9d0c6c34d49">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of earn-outs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with debt repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for asset acquisition or business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtMS0xLTEtODI4NTg_0f021507-8ca4-4eed-a161-aa75ed792fe4"
      unitRef="usd">573000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtMy0xLTEtODI4NTg_6c51c37b-8b23-4713-8c72-d62b84ac53c0"
      unitRef="usd">784000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzMtNS0xLTEtODc1MDY_90f99e1b-e8bd-496f-b26b-7fa069f6304d"
      unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODc4MDA_037eb09c-2976-4b7e-9180-0e837d692c8f"
      unitRef="usd">0</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODc4MDU_8807852f-fef4-4f93-8d22-1c46d6ab7d01"
      unitRef="usd">0</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtNS0xLTEtODc4MDU_ca599076-a07d-4b65-a8fb-3640ac371f50"
      unitRef="usd">2200000</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODc1MzQ_35bccd75-27e8-4f7c-ab4a-7db24bda0d8d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODc1MzQ_c8bce1ed-80fe-432c-851d-424b7bbe8282"
      unitRef="usd">450000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtNS0xLTEtODc1MzQ_a35cbb36-ede4-4041-bcf5-8da5c3cf387c"
      unitRef="usd">4185000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtOTQ1Mjc_d9206462-7be0-4a41-b297-5d2a69940ac8"
      unitRef="usd">450000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtOTQ1Mjc_f15fe9f8-cdfd-4507-82e7-378cb697c3fd"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtNS0xLTEtOTQ1Mjc_5f0f1c64-3971-4f6a-9e54-6d452e6cd17b"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:GainLossFromTransferOfMembership
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtODc4MTE_1121efcc-2727-49bc-9ef1-380253e17838"
      unitRef="usd">0</evh:GainLossFromTransferOfMembership>
    <evh:GainLossFromTransferOfMembership
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtODc4MTE_00575aa7-a364-42c1-9dd2-f097ae4b7715"
      unitRef="usd">-22969000</evh:GainLossFromTransferOfMembership>
    <evh:GainLossFromTransferOfMembership
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtNS0xLTEtODc4MTE_8812679f-af5e-4246-ad45-d03dce3ebd03"
      unitRef="usd">0</evh:GainLossFromTransferOfMembership>
    <us-gaap:StockIssued1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMS0xLTEtODI4NTg_92f6c486-b738-42e1-bac9-3ace9a0686f3"
      unitRef="usd">130175000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzQtMy0xLTEtODI4NTg_ade2b2c0-8a3b-4998-b985-6a4af835b282"
      unitRef="usd">56626000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzctNS0xLTEtODc3OTg_606df781-5422-4171-a8de-a89418921d85"
      unitRef="usd">0</us-gaap:StockIssued1>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzUtMS0xLTEtODI4NTg_867f4309-416a-4ee3-a67f-5f6cbb40c6af"
      unitRef="usd">101999000</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzUtMy0xLTEtODI4NTg_b555ac3a-481f-4524-b29f-a536153785f4"
      unitRef="usd">28492000</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtNS0xLTEtODc3OTg_9a14c868-8b3f-4032-a0ef-f26f40a64e03"
      unitRef="usd">0</evh:StockIssuedInConnectionWithDebtRepayment>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMS0xLTEtODc4MTk_ef16556e-037b-47fd-b1b1-70580af67f9e"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMy0xLTEtODc4MjE_ec0b53d9-5bb8-45e2-a665-6bde0a5ca6e0"
      unitRef="usd">14600000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktNS0xLTEtODc4MjM_78763a08-b754-4051-8075-fd160c3388ec"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMS0xLTEtODI4NTg_31961b86-7579-4d87-882c-a2da0ce6acb0"
      unitRef="usd">791000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzYtMy0xLTEtODI4NTg_818463ae-3689-4155-8440-e4ff8608970d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEwLTUtMS0xLTg3Nzk4_af55a515-1361-4f23-b5a1-53d9856a844c"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:OperatingLeasePayments
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtMS0xLTEtODI4NTg_bf5abc36-2640-43ea-9137-d6eb6605c15e"
      unitRef="usd">14087000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtMy0xLTEtODI4NTg_d6c33a73-418f-4656-a85b-493ff9154dac"
      unitRef="usd">13845000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzgtNS0xLTEtODc0OTA_7582e606-903c-4f31-a1e6-389e6e10123b"
      unitRef="usd">13708000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMS0xLTEtODI4NTg_79b63504-e210-449f-abbb-d9bc26906deb"
      unitRef="usd">4308000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktMy0xLTEtODI4NTg_f1920ca4-73cf-4391-9177-3a58e11b14f4"
      unitRef="usd">2583000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzktNS0xLTEtODc0OTA_05d97616-f97d-4c0d-97ee-938cfe7edba3"
      unitRef="usd">2170000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <us-gaap:InterestPaidNet
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTEtMS0xLTgyODU4_d2ea904c-b1a7-4f07-af0e-54c37c045457"
      unitRef="usd">6269000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTMtMS0xLTgyODU4_c76a453c-8fa7-4b61-a4a6-450e96741731"
      unitRef="usd">7113000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzExLTUtMS0xLTg3NDk4_c6d3bf83-5f7f-4aba-ae7a-dcb790703a83"
      unitRef="usd">13352000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTEtMS0xLTgyODU4_afe18122-675a-445f-a9da-8836a335473f"
      unitRef="usd">1397000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i31eb6c1187d448c78f5a68ed447bae27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTMtMS0xLTgyODU4_8b7183ea-9b1f-4a9e-9f0d-215b29adef03"
      unitRef="usd">551000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ia961fb7cf435462e959290d28c1600b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTIvZnJhZzo1OGQwNjExNDdhNTY0MDliODViNjZjM2QwMTRhZGI1MS90YWJsZTpmMGE4MzU5MmI0ZWM0MGY5YWMyYTc4NTkzZTI1NmZlZC90YWJsZXJhbmdlOmYwYTgzNTkyYjRlYzQwZjlhYzJhNzg1OTNlMjU2ZmVkXzEyLTUtMS0xLTg3NDk4_5f4a71ef-63b1-40c7-bf69-365e6a3d070d"
      unitRef="usd">9679000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzg5Mw_8b5e657a-4298-476d-9022-59127e54fce8">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIA Purchase and Ares Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2023 (the &#x201c;Closing Date&#x201d;), Evolent Health, Inc. (the &#x201c;Company&#x201d;) consummated the transactions (the &#x201c;Closing&#x201d;) contemplated by the previously announced Stock and Asset Purchase Agreement (the &#x201c;Magellan Purchase Agreement&#x201d;), dated November 17, 2022, by and among the Company, Evolent Health LLC (&#x201c;EVH LLC&#x201d;), Magellan Health, Inc. (&#x201c;Magellan Parent&#x201d;), and Magellan Healthcare, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, on the Closing Date, we entered into Amendment No. 1 to the Credit Agreement, dated as of August 1, 2022, by and between the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company, as the Parent, each other Guarantor party thereto, Ares, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent (the &#x201c;Existing Credit Agreement&#x201d;; the Existing Credit Agreement, as amended by Amendment No. 1, the &#x201c;Credit Agreement&#x201d;) that provided us with new secured debt financing in the form of (i) additional commitments under our existing asset-based revolving credit facility in an aggregate principal amount equal to $25.0&#160;million (the &#x201c;Priority ABL Incremental Facility&#x201d;), and (ii) additional commitments under our existing term loan facility in an aggregate principal amount equal to $240.0&#160;million (the &#x201c;Term Loan Incremental Facility&#x201d; and together with the Priority ABL Incremental Facility, the &#x201c;Acquisition Facilities&#x201d;), and effected certain amendments to the Existing Credit Agreement. On the Closing Date, we borrowed $25.0&#160;million under the Priority ABL Incremental Facility and $240.0&#160;million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable at Closing and pay transaction fees and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All loans under the Credit Agreement (including loans under the Acquisition Facilities and loans outstanding under the Existing Credit Agreement) (collectively, the &#x201c;Loans&#x201d;) will mature on the date that is the earliest of (a) the sixth anniversary of the Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. We have paid closing fees equal to 3.00% of the aggregate commitments provided in respect of the Acquisition Facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Credit Agreement may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loans under the Acquisition Facilities are subject to the same security and guarantee arrangements and affirmative and negative covenants, mandatory prepayment provisions and events of default as loans outstanding under the Existing Credit Agreement, in each case, subject to certain modifications agreed by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Magellan Purchase Agreement and at Closing, EVH LLC acquired all of the issued and outstanding shares of capital stock of National Imaging Associates, Inc. as well as certain assets held by Magellan Parent and/or certain of its subsidiaries that were used in the Magellan Specialty Health Division. At Closing, EVH LLC paid cash consideration to Magellan Parent and certain of its affiliates of approximately $386.7&#160;million (which is subject to certain post-Closing adjustments) and issued 8,474,576 shares of the Company&#x2019;s Class A Common Stock (&#x201c;Magellan Class A Shares&#x201d;) to Magellan Parent. Pursuant to Amendment No. 1 and the Securities Purchase Agreement, Ares and certain of its affiliates, who, along with certain of their affiliates, are currently lenders and agents under our Existing Credit Agreement, have provided funds used in the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pro forma financial information has not been presented for the NIA acquisition as the initial accounting for this business combination is incomplete as of the filing date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cumulative Series A Convertible Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the &#x201c;Securities Purchase Agreement&#x201d;) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company&#x2019;s newly created Series A Preferred Stock, par value $0.01 per share, at a purchase price of $960.00 per share, resulting in total gross proceeds to the Company of $168.0&#160;million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company&#x2019;s Class A common stock, par value $0.01 per share (the &#x201c;Class A Common Stock&#x201d;) and all future series of the Company&#x2019;s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company&#x2019;s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a change of control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such change of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Existing Credit Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders  (the &#x201c;Ares Registration Rights Agreement&#x201d;), which granted certain registration rights to Ares in respect of the shares of the Company&#x2019;s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Payment of Contingent Consideration&lt;/span&gt;&lt;/div&gt;Subsequent to December 31, 2022, the Company satisfied its contingent consideration obligation for the periods ended December 31, 2022. As a result, it made cash payments of $0.3&#160;million and issued 849,716 shares of its Class A Common Stock with a fair value of $26.5&#160;million. See Note 4 and Note 18 for additional information regarding the IPG acquisition and the fair value determination of the IPG earn-out consideration.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i00a3b9433a4c407da22c8da144e6159f_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4Mjk_75a688c1-430f-4773-8d00-ca243118bf6f"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i25bed0d5f05c47d3835d72e78088845d_I20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NDQ_ffde7c35-3f0a-4531-b13a-ab558ac55b56"
      unitRef="usd">240000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NjA_eca3c4b3-bbe1-43d4-a036-5875883601f5"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4NzU_2f540a85-26ae-4cba-99d3-ef5297cd0197"
      unitRef="usd">240000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity
      contextRef="ic51fa49de7744b81a659539a652a6cfb_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMTQ_6fbb1146-1077-4413-9172-64fa5aa0acb3"
      unitRef="day">91</evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i33f01c74be814b40a8b3c55316700bd3_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4OTI_553ef499-81a4-4388-ab08-184df1cf8b7e"
      unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia6d4b347f77b40ef82561500db57566f_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc4OTk_0d385b4d-23c0-4d06-ae72-e5b4d37d9846"
      unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie9a86616c8d74739ae6c3edec5552b03_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MDY_a3710d62-7910-4c8d-9ae1-4db7125e29c2"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id784014eb86c4d16a227b2b1b8318c54_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MTM_85931167-a875-45b4-8b77-bc839f513ba3"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1efeef5e73bf4654a2cf68f3a38325c6_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MjA_e3204835-8dcd-47ea-8315-d9857d56a9c8"
      unitRef="number">0.0300</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent
      contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5Mjc_a6667124-5076-4553-b5d2-d9cabf5a003c"
      unitRef="number">0.0300</evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent
      contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5MzQ_1c5e3f6d-6cac-49b5-b0fe-c3f7732c2a6c"
      unitRef="number">0.0200</evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent
      contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NDE_55301447-ed2b-4e07-bce5-d31a533e9845"
      unitRef="number">0.0100</evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent
      contextRef="ib2481dd1d18d4097b5ac505e147f59d4_D20230120-20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NDg_4f1b4a8c-a562-49c2-b24f-e8fc67264614"
      unitRef="number">0.0000</evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5Njc_b4e73fb8-918d-4af1-b9d5-b8425908c365"
      unitRef="usd">386700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5NTY_885c1a02-06e9-4752-9462-4952709e338b"
      unitRef="shares">8474576</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5ODM_e967a179-ddf0-4af7-84ab-c5e856286844"
      unitRef="shares">175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMDE_4e1567ef-fe51-4c93-87bb-b4352ca5e0d9"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i04f3fa6a087c446baded83c2feace046_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5Nzc5OTI_fa9a5c1b-cb98-4385-ad13-24999d18e44b"
      unitRef="usdPerShare">960.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3ec3c8c32864442591417ee98f9b5830_D20230120-20230120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMDg_5f24ca1a-e7b5-4cfe-8c13-96c8fd840771"
      unitRef="usd">168000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMjQ_fe0f9e5a-fc25-4a92-8988-5970901a119e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMjY_7827c95e-c8f3-4402-b95b-afa46de4e7a9"
      unitRef="usdPerShare">1000</us-gaap:PreferredStockLiquidationPreference>
    <evh:PreferredStockVariableDividendRateBasisSpread
      contextRef="ia89686cfadfc473caea4541bb62f1bb3_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMzE_69974835-2ab1-4285-9568-3b2b1efe449b"
      unitRef="number">0.0600</evh:PreferredStockVariableDividendRateBasisSpread>
    <evh:PreferredStockDividendRatePercentageAnnualIncreaseInRate
      contextRef="i86e686cc2d964acc99bb40a8e562febb_D20230120-20230120"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwMzg_f0d7e45d-b85a-40d7-8483-479543aa031d"
      unitRef="number">0.020</evh:PreferredStockDividendRatePercentageAnnualIncreaseInRate>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="i2f63204d749d4153bfe87ae223342e6f_I20230120"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNDQ_4f9bc7aa-bece-4213-8644-bba8f2e64a6d"
      unitRef="usdPerShare">40.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <evh:PreferredStockRedemptionPricePercentage
      contextRef="i4cb6fa070893484684f8ab6a16c9b50a_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNTI_4cd4eff0-dd57-4276-8105-24bf0dc4d74d"
      unitRef="number">1.6500</evh:PreferredStockRedemptionPricePercentage>
    <evh:PreferredStockRedemptionPricePercentage
      contextRef="ie9a97018288f4cc8b3674c490b0d4fa5_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwNzg_2bd20741-6c56-4a53-82f8-787a25086fa4"
      unitRef="number">1.5000</evh:PreferredStockRedemptionPricePercentage>
    <evh:PreferredStockRedemptionPricePercentage
      contextRef="i4cb6fa070893484684f8ab6a16c9b50a_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwODc_0fb8e4dd-cccc-43f9-8286-980887dbcbf5"
      unitRef="number">1.6500</evh:PreferredStockRedemptionPricePercentage>
    <evh:PreferredStockRedemptionPricePercentage
      contextRef="ibc785f8e81be428088e0d8326cda1937_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgwOTY_00b800ed-8e12-4742-82f4-afca3a2998e9"
      unitRef="number">1.5000</evh:PreferredStockRedemptionPricePercentage>
    <evh:PreferredStockRedemptionPricePercentage
      contextRef="i09af4e4b44d0499bb93e05f0108e6e4d_I20230120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzYwNDczMTM5NzgxMDU_32add0e9-3bfe-4904-b970-76a856b3933e"
      unitRef="number">1.3500</evh:PreferredStockRedemptionPricePercentage>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="i4ac1e2d763d64e7f83a06724d5407c9f_D20230101-20230223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4MzE_6db30dc7-6fb8-4354-9c5c-51355e155f54"
      unitRef="usd">300000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4NDU_e6b80d11-d5c6-46fe-bc02-aac96a2a3b55"
      unitRef="shares">849716</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i07ec7dd39f064557bb35aff603cd8f28_D20230101-20230223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8xMTUvZnJhZzoyZDM4MTJkOGRiYTg0ZTg4YjE5MTMyZDEwYzA5ODg1MS90ZXh0cmVnaW9uOjJkMzgxMmQ4ZGJhODRlODhiMTkxMzJkMTBjMDk4ODUxXzgyNDYzMzcyMzU4MTY_37693404-1ae7-4489-a11f-ae9b2e6aa71e"
      unitRef="usd">26500000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 19 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMy0xLTEtODI4NTg_a7ab14e2-e852-4a28-82e4-923e898ed186"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMTItMS0xLTEtODI4NTg_a3cb4f70-f5c5-451f-8fd4-aff7c014997d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMS0xLTEtODI4NTg_39aa7229-ba1a-4572-99b1-532cf8df9588"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0xLTEtMS04Mjg1OA_86b60d99-c8d6-497d-ba27-7a3cb86c34f3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMS0xLTEtODI4NTg_04e0ebea-21b6-4ae9-8c86-dbd3e5f28492"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMS0xLTEtODI4NTg_ddd98fb1-d23a-4be3-aab8-744f7d127716"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjUtMy0xLTEtODI4NTg_45f9c07b-e5e5-447e-82f9-2d52be38e7c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0xLTEtMS04Mjg1OA_c3ebe53a-014a-4bbc-8c9a-fd14dcb232d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjAtMy0xLTEtODI4NTg_f9d7d85b-71c0-4a04-a9c2-ce64af10d1b2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNi0zLTEtMS04Mjg1OA_95711a9c-2185-498e-8d4b-08496c3f61df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfNS0zLTEtMS04Mjg1OA_5fcaba85-8b61-4c73-b335-47364bec0a3a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RhYmxlOjUxZTVlODZmNjNiNjRlZDc4NTZlYmVjYmQxZTczOTU2L3RhYmxlcmFuZ2U6NTFlNWU4NmY2M2I2NGVkNzg1NmViZWNiZDFlNzM5NTZfMjEtMy0xLTEtODI4NTg_4565bc7d-dedc-43d8-9c79-dc74bd13b631"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yNS9mcmFnOjRiNDQyZGQzN2Q1OTQzNGQ4MDk5MDA1NmFmZTMyYzM0L3RleHRyZWdpb246NGI0NDJkZDM3ZDU5NDM0ZDgwOTkwMDU2YWZlMzJjMzRfMTkw_a60b5310-0055-411a-b851-6a1961f8b422"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTMtNS0xLTEtODQ4MTc_137d6944-89ea-4a83-8146-6b2c50d6d799"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMS0xLTEtODI4NTg_3a0b29de-1024-4bd8-b684-a6a4b745e5ff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMS0xLTEtODI4NTg_7d9bcaa2-479a-4b1e-9753-d190b0e198ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNDktMy0xLTEtODI4NTg_957bca45-438a-4b5e-bc20-ac39fb3db2ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTAtMy0xLTEtODI4NTg_942b744f-28d8-47b0-b98a-1c058b0ad719"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RhYmxlOjQyNmExYTA5YjQ1OTQ5NzE5YmRkODMzNTUxOTczN2RlL3RhYmxlcmFuZ2U6NDI2YTFhMDliNDU5NDk3MTliZGQ4MzM1NTE5NzM3ZGVfNTQtNS0xLTEtODQ4MTc_f0ec6caa-85e0-4c32-8376-495512d4a028"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8zNC9mcmFnOjdhY2UxNDMwMjhlNTQ0N2RhMzk3ZWMxZThjNTE5ZGFjL3RleHRyZWdpb246N2FjZTE0MzAyOGU1NDQ3ZGEzOTdlYzFlOGM1MTlkYWNfNTY3_d39eb2c4-5630-4ef7-a808-d882a8c0907a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $0.5&#160;million and $6.8&#160;million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy03LTEtMS04Mjg1OA_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy05LTEtMS04NjUwNQ_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNS0xLTEtODI4NTg_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjUtOS0xLTEtODQwMzI_db8fa82a-2083-4210-bed1-4f50f172fcd5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMjAtNy0xLTEtODI4NTg_202c3f80-7e49-4a50-ae59-df851071f27a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV84Mi9mcmFnOmMyODAyNzY3MzQyMzRmY2VhOTc4YjNiM2EyZmVjM2NlL3RhYmxlOjdmMTExZTBkNzY3NTQ1N2ZiZGVlMDgyZTM2OWE2NDJkL3RhYmxlcmFuZ2U6N2YxMTFlMGQ3Njc1NDU3ZmJkZWUwODJlMzY5YTY0MmRfMy01LTEtMS04Mjg1OA_8659a9aa-2429-4147-8818-0825c75e6af9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDM2_eb8c388b-635a-409e-85ff-b718ed527163"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi01LTEtMS04Mjg1OA_97335807-03b8-4397-84b4-15be2ae8d772"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMi03LTEtMS04Mjg1OA_a6e916c5-53e3-4b82-a348-30dafebe83fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNi05LTEtMS04Mzg4OA_44aace1c-2991-410e-a25d-79b335d43786"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfMy05LTEtMS04Mzg4NA_800c78c9-ad0b-4fc2-b294-e29a27bd87b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC03LTEtMS04Mjg1OA_db9afc91-44b3-4d18-9c2e-9dfd6f605e1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS01LTEtMS04Mjg1OA_1929c248-779b-46bd-b495-2b56079914bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS03LTEtMS04Mjg1OA_218e443b-1d46-44a7-8172-a7718dc3544d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNS05LTEtMS04Mzg4OA_de183f08-df47-43d0-b3c8-24557c0b0464"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RhYmxlOjdiZDlhMjdhOTVjYjQ2MThiZGE0MzNkNTY5ZWE4Y2Q4L3RhYmxlcmFuZ2U6N2JkOWEyN2E5NWNiNDYxOGJkYTQzM2Q1NjllYThjZDhfNC01LTEtMS04Mjg1OA_00490414-12e9-4cd1-a4fd-23b0fffe73a5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU1Y2M0Zjc4NWNlNTQ1OTdhMTM3Mzg3YTBkM2Y1MWU5L3NlYzplNWNjNGY3ODVjZTU0NTk3YTEzNzM4N2EwZDNmNTFlOV8yOC9mcmFnOjM5MjU2NmM2MjAzYzRmMzliN2E4ZTZjMWEzOTBmMmUyL3RleHRyZWdpb246MzkyNTY2YzYyMDNjNGYzOWI3YThlNmMxYTM5MGYyZTJfNDMz_a232b473-a0e7-48a5-9e03-8846b4d26431"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>146
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #>)6%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  WB5A6++#KP>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITU%,'1S43PI""XHWL)D=C?8M"$9:??M;>-N%]$'\)B9/]]\
M ]-B4#A$>HY#H,B.TM7DNSXI#!MQ8 X*(.&!O$GEG.CGYFZ(WO#\C'L(!C_,
MGD!6U0UX8F,-&UB 15B)0K<6%48R/,03WN**#Y^QRS"+0!UYZCE!7=8@]#(Q
M'*>NA0M@@3%%G[X+9%=BKOZ)S1T0I^24W)H:Q[$<FYR;=ZCA[>GQ):];N#ZQ
MZ9'F7\DI/@;:B//DU^;N?OL@M*QD4U2RD-=;*55UJV3SOKC^\+L(^\&ZG?O'
MQF=!W<*ON]!?4$L#!!0    ( #>)6%:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MX/,58^)P(+^@^(^(\?\ 4$L#!!0    ( #>)6%:_MJ;X.@(  +P%   8
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC91=;YLP%(;_BL6D7E6!.!_;4D!*
MFE6+E$Q1NW47TRX<. E6L<UL4]I_/W\0EDD)R@WXX[ROGV,X)VZ$?%$%@$9O
MK.0J"0JMJUD8JJP 1M1 5,#-SEY(1K29RD.H*@DD=R)6ACB*IB$CE =I[-:V
M,HU%K4O*82N1JADC\GT!I6B28!@<%Q[IH=!V(4SCBAS@"?2/:BO-+.Q<<LJ
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MWO:L6PLB7+-=K!?B\("EGQO#%XI8Y5\XE+F.!>%.:9&48%*0\+08V6MY#R>
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MMINDV#VGXZ>;E\LTP_^HJ?; 23O8LG/8NG/8PG/8RG-(F@.EN5":!Z7Y4%H
MI8506H2B==-.ZP]4Q/[ EU3I43CEV0Q3IA?FB94'YPS6[L81)5!1"TJSH32G
MWP%QH:(>E.9#:0&4%D)I$8K6C?+6LZ>(/7LO+MHCY@Z^>8&:^: T J594)JM
ML(X^69N.Z<<(2$T72O.@-!]*"Z"T$$J+4+1NWFC]@<H9?^"0(CX*IWJ<JC!>
M(;'DX"302Y1 12THS3[0.M,I^GL _FZ:&CW80YU]4)H/I0506@BE12A:-VA;
M9Y\B=O;=_-RZ/F+UP5,"J',02B-0F@6EV0JGFM^47B<(E72A- ]*\Z&T $H+
MH;0(1>LFE]8WJ(A]@S^87+@)A>,84R<Z\^4BU%'83Y1 12THS5;8(H#,M(&_
MESH];8 Z *$T'TH+H+002HM0M&YDMU9!16P5_!DKA<62@^<*4!\BE$:@- M*
MLQ76=,<L%(8JNE":!Z7Y4%H I8506H2B=1-*ZU-4Q#Y%U$)AA;7*:>SL .I#
M["-)H)(6E&9#:4Z?P^%")3THS8?2 B@MA-(B%*W[WJO67*B>,1=^6ZSB[#ZY
M7.39UZ38O?;WS!Q!3!PZ1X#2YE :@=(L*,U6.1[$,6-'AFJZ4)H'I?E06@"E
MA5!:A*)U,T9KME3%A0<Y&8.;)=A*=\J$>>(U$XL-#O]>H@0J:D%I]H'6?94>
M'=7<W9S03@)HQSPHS8?2 B@MA-(B%*T;KJU-4>U1^*]\/HV/%W]LTW+WVN6S
M0SWT3;A0VAQ*(U":!:79*EL]4#9-)BE O890F@>E^5!: *6%4%J$HG5SQ[.W
MXI[Q&HIR!S=?L!8WW3 4>GVR6'9P(N@E2J"B%I1FJQR#)ET4F+^;[!MVL:_8
MA=H'H;0 2@NAM A%ZP9N:Q]4A3:C'RD6HK+6M=&$+A8BEA\<P#TD"532@M)L
M*,V!TEPHS>MSJGRH9 "EA5!:A*)UP[QU^ZEBMY^H6(C*&M!&JFF,:=._6&)P
M*/=3)5!5"TJSH30'2G.A- ]*\WN>^P"J&D)I$8K6#>C6":B>>5=O[THA,C?F
MH4X_*&T.I1$HS5)9;]YT;-++_FVHJ .EN5":!Z7Y4%H I8506H2B==-'Z_53
MS[S"5U@IA)\R6,.9,54-E2X$K++>M9%AJ/0[+.8]>:0GS^)L-Z7O>6WQ81D<
MF.PNR*HVGM)K%%S>/LAC0S:I[QL\#G&DTJ_V]'E;&8IATI7  XZN.C7I[H4\
M'J\B!V>[$Q4YU-:;INZM*G].10X5ZDJ#TN90&H'2+"C-AM(<*,V%TCPHS8?2
M B@MA-(B%*V;=%K_FBKVK[UD:;S*OH!55:?T5ZDSL?+@G,':LSBB!"IJ06DV
ME.;T.R N5-2#TGPH+8#20B@M0M$Z4:ZUCC7MG&/MA4OC-4YY.N;EU&+QH8$.
MI1$HS8+2[#X'UX%*NE":!Z7Y4%H I8506H2B=;-!ZT;3SKG1!BQXUUAOE:;I
MM"5-K#@X!;!>+5:30#4M*,WF'#5Z,0IW)^D2T2ZT6QZ4YD-I 9060FD1BM8-
MV-:/IHG]:#<_=[&[6'WHHP(H;0ZE$2C-@M)LC76L:5,F:4 -:U":!Z7Y4%H
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M\X?WT\MOQ32Z_@;_/A:?OEU'G]]%5Y?7OT;O/GS^_3HZCWZ[GD8O_O[RS62
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M/TL+FEOP6I"MD>+D60624'6DC_#I#NMSD(2V^"+3H-R +(MU 9_-=HS?\ 5
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M^!'!!;?YEQ;$<GY$NF0RV!08LB-]&IR+W**@ 6H104%DM3.8Q/&L],?/8 9
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M5"I]C*4IUU#_P(A49K"\.,V.+?4UF),Z%\<=PK>\DY) ]B&T;%54*T(6P3L
ME)@Q<IJC"<DVIM-:%5V1/?B7CUFO16"DHB4507UQ[(2AYRY2CI&5%1&WZMJ3
M"E/>H^6Z+RG! 2H!V/P-3(+-36G+'CNS012$!1*[[.&OUAN3%T>Q0MIM,>*U
MKM!E[>T%/-JOH(B<$HAFH@P9^U/WF.3;@3:4D.^6J<:P:(HRJ0^_3_9COY(F
MR0(O!NH6^N1[Z\T<97-8/-"W06WK**V)NY-L>XRJ&N'LI=@W&$80ZZ5+/+^]
M[VIT?-5A3 T& XN/J2F(B;98-"8DX5P.[;P\QTJD=(RD?-QH>.W]Z@DK<O-R
M%X'=W!Y6< .<*+>\&/>6YME4G@P$R]37&+1R.H:&V6D[\][AK@<<[5?EN/U^
M*N^5QQF,("@./19L#1%!H72(B@J^K8!R&V@@W+>%FJ9/H3RPVT.!"_V684._
M_SB]@UG;R-3\/I0KWZ$A<4P<;%WB)%)HXAI6%/^-NP3OJ,YQ@K>=!C;1;!]:
M?(Z< D;3)#1*6YCS; LN[80,H"13/Q(VH+7<.DX9%,MII#CN@5'VQ%))_(B)
MFQT'?5]TA/Z E"[4&:"H"O/]7"W#J@GN13-P8PE""1LD-?*!>>+PIV[J"N"6
M\2"<4HG:VT.M$1PO>VF:7L59ZQ#X:"Q5/?$&)@Y'!'J*SY/ KL9,'GK0OFEE
MNMT@W_%[N'$S'8X5G*J>Q(DP=T28E$E(XDF.?H5U<*V<O0K -@S";E[8PO97
M5/KGB?A#JA%QPEW&SW<+)-QGG4O.TFHN)+NB<R"PR^BW?T''E0">ZP3E4$SA
MYPX_&9LJZG9*L(E3-5/\\.#(;1Q<  <ZN2K-S<V3-D[Q95\E2$-D7BBM#L2T
M3':2JM+2$5J15$\RP->2;EF^1^=)#HRB?[\2-:S?<?Y)ZV"0I^AG,U.#8H2>
M U)KA@-_["=Y2?OQ,=*:-E9>07=I\RLNO:]%Y_@D89!6#:?L(8RQ D^F]]['
MSEM$U=07/+_=1$F_M*[6M+[/D:WYB!D[Q'B_ IZKY8S'-$FK"$L5]FPI2B .
M]UUK6W&%+N6P[T@:V6&#*M^M))<M 0=ZSQ/*^'TKQ-Y??G$G^XI+FB**P0U;
M3P9*4TIBBYKLD 9N,'H?CO"<2G49NSW>B]6C-8\.^8PZBOJ[Y*#U>%^<_- 8
MWMO(N#H1Y>7W=%-PPX>)P]&X7$+*+Z4!WO>MP0;?)@DH0X^.SU-Z[W%JV<-$
MQ^8?;O[HT+M#3YMJ5 VV6!X=9@>P0]H%(ET_7)1$*5I76X?=M?"0=F]\LL6Z
M:>MV=>T;.LZYB[1#OP5O&8C.Q&&?R-/0)S*YP^*HC'H)P%SN[1U(0PCI#^!3
M5JU"1\AR>M4;0U@<B^BQ+!>@AUNC%M>3[GC_;RN\&_']T&;&5?$IV!2Q#[@O
ME9?W-W<&:!K)#<LEGECFHU>!;1.H'3BN.4BSVQ$@70"I&SU1_Z?TX[@#P"^7
MR)CJ +@'6B%.3AP;_*@U9MR"W<)_\O5N Y-4]/_3Y7S;K"".)"O1[2.8KO/P
MAY^O+#D2&34!'& 3 $0!5H_-4[]-J.Y.YSH_(Q0!G[FM?M^T6AG7"T6BU*4<
M<Z/W^X AZ0&W'&!+#K=MNW;5F4T\?([2;=@G[:N"N:28DVR7V?H"P>RV74W,
MC#2O:UTM/@4JQX+!88!]Z;38EI[S\]O^?4WUQ_C(\%DX,GR^<V3X-#Z)\?&;
M3AK[?NJD=+LUUW(*BW*/MPRAE7ILEB,OS!<JF0J2"&J3IA9IWVNAA\_5$XI[
MT#RJQEM(2B]>$X^-:(4GY$=3A&2N3'$-D /H568/1P-(1P5"V*,HM-U8:J7C
M8Y&AL$""(8= @$?AJ"^?OE"@H*/'5$NG='8'R.\D$,>$$YGNZ#R-G'SP [9Z
M'K200QU+2XB'HU".A4^C579T#G$@&K':W5'0'F[]&%_*X&D6D..R.N5X&&KV
M-$9PSHQS*)(7\M,M0(*"(Z[=:BH2OOX4GRPU>#(1VT(8Y,$2.&HEK:1&^VF-
MB3JL<!O.,@9R90 _._H-)9@#%E]T1ZHB:CR,:XCH/9003"!9+-^;EI(?&.<I
M%:&[>B879[1JYC33QOE"UCEL<Z]I6T,R!?>RM'B6"]_R6;+1B2/M5Y#<$B=?
MN+Y;N<FF!R:(/506JXWYPCXC<"F]B8-LB</.B K<.W\)A_:U1KO"PH!G(*(.
M4CW'L%-&C9ICHI-Y$_>7W%9VJ4),8%S4/J]Z3\F$<5%^8;GH^Z5IKYK(6YC/
M[^PN?-N]# #.V/R$:_R52^)Z)8SVT*?(B+N9)CE0%H&0.NMH(-#UAJ#IFDL
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ML#407U#9/6()H ;Y8F&@H!8"35GAT A>(5A3G]'E>*RFQQ+,E-@:^Z=$10!
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MC.;9@)GPZ2 \.-WXU_6E=GCY][>(2_21M #S*ZW=YH$$;+_?G/T?4$L#!!0
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M(Y3U"(TL\/V#+@E7;V56HH;X@*)141%S! B[UCL&3ZAH>@Z67PC; 5F'"6
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MYQD2"  ]D^=MZ;N,Q-GRO%D(F[#90SS9/ "&=8442/'HCJ#W_-RM!,N]5*H
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ME1OZ\U:!1=-X UQ?E8"]_8 '^!_B>?%_4$L#!!0    ( #>)6%:^WUI&3A4
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MW7K7AWN&F5NL6@1.B,4H=Q#N@E.[H66N!(^0X@Y=]5<P[61?+ZJRN5:,6 Y
MDF3S&*$FS\MU-*=M9 ="F-EK*"V;9WQ="-Q=%@^R'9O\$RK=I)\W,% Z4 UR
M<_#+-Y =LO9H+O_\5W+QX4TK"@!'LA:A ,<LR<JU.&-6,U3-$&H#=:P>^Q8_
ME;*;=ZH#-W4/"M@-;OJ!0$;,DX.C#U@._<!6]GD=/<BNEH&0+A2)]P.J'L4
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MV I+4?3C3BB'^L:;+7_/6AKO3<Y#ZOK*T@2\7QGCZQO:H/G >?U_4$L#!!0
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M_L"5:=TZ?=L-&I1T96Q6H8/N91Z]$8+@8ZM/6-6OLA,]Y 0N\>A/'#VD/&R
M2<];F](NW]Q=TV/V=\WV>(2[RTTXV5<28>T)O8RM;.7Q^I[Y[Q?*'<6G@A4O
MHK:"X>TX\N[NOVL/M<+#<262*.A))ZZ=@9&-ZR@X7V+'-</SL8MG3CM7?L;[
MXO @]/,@<=\,LED&]Z].,O2S= :1'\0IML,DM'EHI6;=O2T8>B>D06UF_FF&
M0!%>&Q&$H1\%*7R3AG (8[3,($S])#GM>@D<>KRF>^5%0]7:%5&8 +(5IJLT
M=J.[.NVR*T]>EG=%WE>BU@P=X+1"TV"2G7J@NL*IZQBY<<7*2AHL?5RSQEJ3
M*KL YRN)7O4=N\&N>EW\ U!+ P04    "  WB5A6]Q2&U3H1  #D00  &0
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MJDN'X 4$>% ;S51G>'S0]3<]0WQ>9TC /$6##_24 W5HPZ64?#33DSO0LSL
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M'1AZQ4:T.5/L-V[_XQP2S3MK*4,C$O ;1K:&*J;B$_*57NM<@O5\5/.).*$
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M="!<^I9(@V#K>'_':86O@?A8XO.+'"_ ^X7%&=@.&*#[H)O]!5!+ P04
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MR;@G;.SGXL";)O10"^.1S.&S1 M,E@VPOC3X+W4#WF#75,_^ U!+ P04
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MK23E8_18U;"+YS?<N*!%(&T7I&Q%'^*2/5TME5UP.!U%.)&MH[(#O,R Q6\
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MGJ+JGSE>9  \#*9.Y'KV,@B!:T#N%XR1EY8<=P,7T5 T WU-F8^2"';/VW1
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MXE!]()7 IOYXIR+E0F&\O;(5!@BY9 ZEQ>2U1Z8[+&V[,$Q,>/5>V6IXO .
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M#LY/#X*.JA_>+/A;^8GQ:&;YS[F2X(X6X/W4P*GC#SJ@_I\GWOX'4$L#!!0
M   ( #>)6%:!I%+V&RL  '.5   9    >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;,5]V9+;1I;HKR T[KFE"!15I*329BNB5+*[-6%;"I6Z_3!Q'T @2:(%
M C02J!+OU]^SY@*"J,7VS(,M%@GD<O+L6WY_T[1?[<:8+OFVK6K[PZ--U^U>
M/WEB\XW99G;6[$P-OZR:=IMU\&>[?F)WK<D*>FE;/5F<G9T_V69E_>CM]_3=
MI_;M]TW?565M/K6)[;?;K-V_,U5S\\.C^2/]XG.YWG3XQ9.WW^^RM;DRW3]W
MGUKXZXD;I2BWIK9E4R>M6?WPZ&+^^MWB!;Y 3_RK-#<V^)S@5I9-\Q7_^%#\
M\.@,5V0JDW<X1 ;_7)M+4U4X$JSC=QGTD9L37PP_Z^@_T>9A,\O,FLNF^JTL
MNLT/CUX^2@JSROJJ^]S<_,/(AI[C>'E36?I_<B//GCU*\MYVS59>AA5LRYK_
MS;X)(.[RPD)>6-"Z>2):Y?NLR]Y^WS8W28M/PVCX@;9*;\/BRAI/Y:IKX=<2
MWNO>OLML:9-FE7QJC35UER&LTN2*#PE_N"K7=;DJ\ZSNDHL\;_JZ*^MU\JFI
MRKPT-LGJ(KG<9/7:)&4=/=&6=5[N*GCF1)]^_/V3#E:-<S_)987O>(6+(RN<
M+Y)?FKK;V.3'NC!%/, 3V*[;\T+W_&XQ.>)[D\^2I_,T69PM%A/C/74P?$KC
M/3TRWAA4_OMB:;L6<.[_CNV8QWLV/AX2XFN[RW+SPZ,=GDI[;1Z]_<__F)^?
MO9E8[3.WVF=3HX^?^-@B'S#,EXU)\J:V (4BZTR1K,HZ R3(JL3"$P;(N:.7
M.GCPLMGNLGJ?9*U)8)\[^+= %,H G&T!KQF@A6Z3_'-V-4O^?G'Q:99\[-L[
MC ]H5_6%H4DR/AN:-*O@L7YIRZ+,6CBD67(!WY1U9]I<UZ*/(U;#^=4V(^YA
M:96F*H$$:6)8IU\(/#";.)GG[F2>3X(TP*,?;5<"RQ'RNK# -'>TCK&#^N.C
M)GAP? :T&X36$=#BME$8E-V>CP=/!OCS[WT)B "LJ09FC@\G70-_?06H1;-F
MP:S9:H7,&5:&1P73-RW"-MOZ([/6R&E49;8LJ[)3GH.O%*7-J\;V.#,\#4O#
MT7#R8R\Z[$/\T<^C6]4YQI;5FFM3]X:>,=] 0EH8&Z 2O("[VIFV;(H90+>Q
M$1Q:Y)4;T\)$U1YQ\M\ !P18SHR4 )5W/:P(M@8"QL+>^JJ #0/(VF35-EN8
M*QIUEGRH'<H3-N,2;J66=+"NWN*#39LFR[Y+ZJ9+$.GQ[:Y):?SKK.H=E@B<
M3YCF<$:@)]A#N:P(W/AKFJR;IK@I@=CH/)IZ?5J!+"[D]\=I>$8IK;DLC*!B
M:ZJ,IX<564!NB\#8+I$0&8MJ&0AV#EAH2_HZ=8?4FKP!$4:#!>N\!AZ0P2KC
MZ1Y[>!0)* \5G6-;YG+ <*2D"B%W:I95N99%,&$0Q[=,%ULX-I1^QU[!!1)O
MYX'S*BNWO)G@A5/4.&![;8MX(0>6 Z,LX5P:V#3\61B@W)SW@F -""=-2L"$
MLB5ZA&\/0)\")C3Y5YD&\09P670 T&U,RSP9?@!VFGT3TO,8 "RUN<&%IB'Q
M1:>YZUO :FL8BO1&SB\#S&!,6C>M8L!P82) QE5?^5UYW)+U3['=<\=VSR<9
MY,<=G3V<\Y59$XC'F.SD&.,B^W#@Q']E]2LD.@ U#(B'0F?0U"HG,X_SW2;K
M@*'N%9__GXG8$!P2",>(&=ULRGQ#/+(U7<CERIK5>3H$6,%U5E9T##0'?&/X
MA$V1)GC(,-&ZKS+2?TLXTN6>&$&^*<TJ:=R6"L!"TM:1[;?)R7_^Q\O%XNS-
MY<?WO]#'^9O'2,7X&$CG#9P2_"7X@)NQ#:"*%Q.XZ8 49B2D5&G89C $&",9
M ((V MMBYHE([XB\-:>R%V)- %3FSHQT<@0IPCT33JLR 7X _1<0KF&FNFZ-
M$VO(%Y(O+4#^'R:K@-9AS_^5U3UJS'/6*^>SY$>6;M=PO'VK0FY5MK9+?H='
M0>O N?#9--*'EN4*X,!:!BP8\.FZ;'H+2-1>$Q^2=<OB;AJWD0A$"/+YBS>@
M-O_C*GB%5"/ +4"6K !MID0UE59I@5=4I.D38H#8Z)G&X3ALOW-"K=D!+M O
M&]X]H%.;P3 ]2*S6L)9V"10"(U7)E0QCQ]=@=\BZ*E F<B2$"7)^X<CYQ20Y
M7V9VPT8)?O@1) (@P#&J?N!0R6]>;)!:N0'C#R1Y5<(S2(L(#29OD@5-6ZY+
M1%$@.L %4D4(SP"IDBU;-T"P%=$YR#D8'6<T?L88^S=-5:"N!3@$P(.)<0TP
M($*4W@36NLSJKR@;&EOJ,GYZ_^$R 1VO QMEQR2!3R$!=+ ?VZ7",[+=KFV^
MB5:P @%"+!^.UD%DN#[ A8JT8MB-0?)LOX) 7O5UP1P.3A=4[@(G\N.-3H?K
MF&+K+QT>O)P\O,\@QT'B(!FY50???:A!IG1'V?V?-7;X=:Z/MOZ[,GA4[1;W
M7/@CZ66H(385ZD-M5J$$0"4&>8/J'J@QAFK)"<K8#3P!P]G'R.=6#8IL^SH!
M*]ALEX"_:@D3*P(4T_%)AE2F@S]8NV:U []=93G*=T!XDZ&T.9D_3KY+%NGB
M_!7\^S1] ?\& Q'RA>('-*Q.N,+)XG$R/TM?@9D/K//\? &L@S0A0 E@=I9E
MI7"^DZ?P, S_XD7RXFFZ6)PG'X%SM@GQNL6;Y'GRI>E8:;XKT&'9Y^FKYR_A
MP\N7/'_?HF)^,,C\6?KLU2)Y\3P]?ZD3Y4>>G9Q0!OI.A_JUJ4^/#31?I,_.
MS_&?5[!IGK2>>'YZ8A[L.QU.P';O?^B\/YL=6_[V8!&!RI[?ADYB.:I%_>^^
M9G<=X0RAEY>]P 6O@&'^VH"Z /A"F-BWA &HY?36BE6"?)#?!74*K!=Y&7$M
M6':P-N)>4VB*<[6E_7IJ-QD)<P1T0U.'RKDR-.!XRA"S8VQ7G0WAIE[21/%F
M/+],MK G$+$D1G$!_-)\Y"6$0+S>8)4S(J00$GAJM&!1[530A"=YG"QARJ79
M9-4*9\:-UG#&)+'P]-"] ^K<*4B[IE]OG!W-8J1.5A4J#J@"!@*-+%RVGW%R
M^03BS-2DV#5LZW;HD%GCM#<;PU^I(45>)5JK*5AZ,NLC38ST/_CYND1%)".=
MND:>Y@S;_*BD&Y"88+PX"1"'2EE(:'HOLXH,0/+4BC)O^VTBZF5'A"VJI\W
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M[:PXD47 *_R"EXT+'B8D.?6%= 72^24K E3354]&B7O&IRJHW$J=9!0NQAH
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M,"^ER(?>[SQ?B\M[4F"E4MJS:YMUFVW#X5.DN PFS:I]5^8,)>6#T7%E.^>
MFB6WG&HD^B3#5OVV80V<U&NFR1K.I55G;ESEY([]3\VDF"(E7[@TGRXW^AS6
M@U[Z>M!/!_6@%T$R]RB)_143)9\?5*_J,E2C.,8NVTM="QFSMPRA(31,J\$A
MO->>5T'H2XFGE'3J@J!:PJRV?)BMXL12B&_$-<7NY[&1W6.=]6 *[QV0*?;
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MWJC*;)#ZJW1//L)AA&II. +RM6YNZD#=6BSNK&\]K+I_4I+XTL?Y+?6)F-F
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M^R]-W\F:]FS8B=PC3'.XZ=)S4TUN(!ZV@"]+;,SXE=+T1#DD1T60-]@!:^?
M.6^15H*YUL1@GEOJ_,@V9X<K;(BE!\,[L?62:=2Z9_M8&G0G8]9M]%T0M'\!
M^H>1_J"%  A@(1I9AXYY$)<A^XI]; 34$4Y'H/PJ=_X=H_T6%&5!Y, \R=)@
MEL;_'\9=^=PPZ&DWP:E:9<:4\['RS<,'C?+\2? 6$%(/KN)H>B&UL>S3@)J
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MMZ4 EJ@L ;VOI33[@Q4P_FM9_@502P,$%     @ -XE85K=N<*"A!   Z H
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M-"CIH^_EF#QR_"'O!FJFK<N^<[BELJL5[:D(I6'^T1B=Z^CH9-I62,3=FV+
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M>9JGXQ2)3ZG X;OW>1PR]&O>YD8WH=IX7<O@!;4_2X<%A3:D#06%91>V(Q#
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M%>B5:!1&H%P0>H6[>D5QE<GR> S7(J.6GFU(C[C*JW;%R-;!*Z-2'<.G!A/
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MC4P:!=Q?"*$W$W- _PZ=_@M02P,$%     @ -XE85DF$RD'3!   K0L  !D
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MTCC,LQDD833)J!VGL:LQSD:\.9,DI^BDLJ3-+#S-"2BADIA '(=)E,%G99F
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M,P*\$;".&-<362O?"R/.3U6U 45/HS8:V*5::30N+RDJ-T;AW1SES/EEM<0
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M;F"8(R)+&\55(1#3&XELO\VX$YAH$GN:52\Z#'YOS(1)8^958V9CXU]3, [
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MI*('\/ZLJLSC!4W0?FD[_Q-02P,$%     @ -XE85MNUJ$RW"   -!<  !D
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M(_=%40YF_N!<[H76K7Z0LA2"/BF#W64O:5R_P M"3C1^2I+#+#H![J4 336
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MX#<$H(K(I2P+V*0\&"BH#M*(432/UC3I+_JPS14["/4.PM-9XUY@[MI-BZ^
MW"DS6E;'=$1#:<UIM[&2</XL&OF734,:"VR4OV!9A OW0_:/;1'AF DRS 29
MEZ81>[^K4P+I? "8)^B0 >,QFFW&+LNR[0"@;ZX:S3<,$D:M.XJ!!16!C54$
M+TA"!F$\8K\_4Q@1\_=%6T%B2$-.BE_?"]#2MQ,**=CG(AI3T98K:^@2!J'R
MA%$WR/KK6_D "+T+PCQ$M_<Q7QI8&X-=7Q. JY9K:1S$U/.S'-<TC]G[SB#C
M!&F"/EA)!#3&*U1$EL0^1.1IX-* )5Z2IC!"$";LIEL8.WWP+/6"U(?/8B_"
M9//'V/22^OT@Q7U.QAN=E7H-.)Q &G _\CA.DP=QL!?@3D5XOGX$GSMT[0TV
M:;4TL*SHPX%SCZ<A14#L<Z) 6;+UL1>6Y1@](UC,JF8_1)RJY6FGAQVG>P$#
M-DF>N'B*J,C; R-;=O42<6:+B1,;67&9]>Q7O6!;77CJ)7[4VS;P.*P:8RA,
MQVQS$*0!0B5W!DIA>8JQ,4-.]XC<8<;+N&]7"4V[KD9K*M(T%XV.G=](X.\?
MDJZ*VG+$<+(0M[*A484L_4B4E*\V+BA]X9$@)'#M+=A-7<2+ZH3:CK,NY<:0
MDT\FXRT=#7O6L$59JJZQ_>^$3![Y.9TWDF0?DFBJ/3 N6O=0_>_@SW*Z7#NN
MY;/R,-G5746'2TX3U!H18IOQCH :F%BI&AFO^[K*Q)^=-(]6Q1<84\;(*JG[
MDRWN]PZVR]X95@OQC#,L8XZ>_O<RYK,C'2X;.EQV_!2["\C/#<WVZ$=_]8G?
M#YNC;>THU_&/,T]BO]L7=S@'_FT98(\)WTB#!,&):YI1%,9H82UU#$122ZV*
MBM'A+ APFU8" IPE5<42G@SE9?O['3RV)^J>2YCG7W%Y5VRT'3W<&<<N=PUE
M-ZI-Z:0_I8/_L^G%O22(#I0=BYWYWI?,M4"(TO=:&NF17.ZCYO!T^"1\Z;Z$
M[K:[[\F_(<(E,-9B"5+,8_&$M>X;K;LQ:F._BRZ4,6IMERM1("UI ]XOE3+;
M&Q(P?"B_^#]02P,$%     @ -XE85BS"1E&N!   10T  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&ULQ5?;;N,V$/V5@;=9Q(!C2_(M5P.Y[+8!-D7@
M7!9%T0=:&MM$*%)+4G&V7]\A)<MR5G'ST$5?+%(BSYP9GAF.3U=*/YDEHH67
M5$ASUEI:FQWW>B9>8LI,5V4HZ<M<Z919FNI%SV0:6>(WI:(7!<&HES(N6Y-3
M_^Y63TY5;@67>*O!Y&G*]/<+%&IUU@I;ZQ=3OEA:]Z(W.<W8 N_0/F2WFF:]
M"B7A*4K#E02-\[/6>7A\,7+K_8)'CBM3&X/S9*;4DYM<)V>MP!%"@;%U"(P>
MSWB)0C@@HO&MQ&Q5)MW&^GB-_MG[3K[,F,%+);[RQ"[/6H<M2'#.<F&G:O4;
MEOX,'5ZLA/&_L"K6CLEBG!NKTG(SS5,NBR=[*>-0VW 8O+$A*C=$GG=AR+.\
M8I9-3K5:@7:K"<T-O*M^-Y'CTAW*G=7TE=,^._G,N(9')G*$&V0FUT@1M[!_
MSV8"3?NT9\F(6]J+2\"+ C!Z S",X$9)NS3P22:8; /TB%U%,5I3O(AV(EYA
MW(5^V($HB*(=>/W*Y;['Z_^[RU?<Q$(YKPW\>3XS5I-*_FIRNH <-$.ZS#DV
M&8OQK$6I85 _8VOR\4,X"DYV$!Y4A >[T"=WE(E)+A#4',Z-06N R02^<#;C
M@EM.Y$G?4XQSK;E<P 4SW#0YL=O,_1)AK@2EJ0.Q3@!EKO*_R82ESY<JS9C\
M_O'#812.3XC&AHVHL4D+)27 +,Q=M)]]M%T24B*O:<X<3=CGDJ!5;@C$M(^!
M3AO3&>KJQ.$+/J. L'RNYWVX5Y:)K2A<DO (V0DX5E0W$M3,Y_Y^V(9?P-..
M3K9&X\-.$ 2;00%:)SUO=JW1F??9>.UB^'-=C X[8V^^'/P,%U_;<&RFZ'-!
MVD([VP:1:7E E\0K+S0*9LFT57[/]>VO7ER/W%&F[)2&^6KNI$?%U\2:SV@Y
M:>AW91$&W1WI-JS2;?CN=+M<,@JV<09JD;_<XGQ34_NFMC3EWTZ[S47$)66\
M(:%R_9Y,H\L:5DL>+^M9"[FA'6MI<9GE[F04A=&BIJMEZXB81A?BHA[\F*5T
M(WKH/^@<BT+?D+A>VA=,,!E[,(KG#!=<2J<FFF2HN4KJZ@G[G7$_@/,DX<4I
MCX<^8\)!9T0/:A&L\!>4J;2W7^QIPX.DID10J4I@?T'=2!NHLIL.2.IL]J.A
ML]!V0"$!;9-"4EB=3I6O):\=FAI5FAJ]6U-.'H5R[C%>2OXMQZ*$WO&%Y',>
M,Y+8@U0S)P%?A:_]634I:K?5=U3TVI%OGW''ORUXVFV>IL8SK_,L-44^.IVN
ME58SD6Y:#%,&WY$H(F^@K!>8-%T#56H5G.K!HDLQ3S/_6JVO]BJV3:$L'C M
M\NK-FEI)84K* I65E2?+M&*46U-NG@XDYE27!.!+1HTFB<]5MA\+&T&-.T>#
M$7SU?:++V&?ZMD!(J =1.=FFE0A'W</A'AQ &'2#<*_AJOA?PE FPG\1AG[0
M.>H/?>>U\7K4#0:PUY1GO5IKFZ)>^ ;>@-];=+G5V^H_PGG1&F^6%W\P;IBF
MXF- X)RV!MTQE6-=-.W%Q*K,-\HS9:GM]L,E_<]![1;0][FB.Z:<. /5/Z?)
M/U!+ P04    "  WB5A6!*VGQ&L#  "^!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6R=5=MNXS80_96!MEAL #6Z69&2M0TXV2U:H L82=JB*/I
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M5?G1M%66!IW?%O1G0>T4Z#Y7RAX$YZ#[5\W_ E!+ P04    "  WB5A6+W(
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M53HFQ'+P"7JN)RBI/2& 2;="4Y,T(HQ2F2/MO!1-(:.=Z+'(FCNKRL]_HO=
M105&4I^DG&LHN5-$)#P5;H"^ZP/M#LU;$S^/&$[GA))3D.E>AH/8=GV<R:/I
M=%-UIR;O>7E.D4P39W%.;1(<"/[:/KAR.*IZ5E2H+*4?'LOBT>>X&86/*79=
M(K:#*V8=<:M)A<L:D4>41EP(X@.*K,L'Q':(3@^?X-4X!,:X7N5%"64<.='5
M'O?I?G*B0X\-?N["_Y]6^7YJD&_\LQC/J*:9Z.)-<I;-$\V)+/V659N1G1_
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MZ.Y=TG6LVK1O@96R]+)HS8*><JC= II?*V5W';?!\#A<_@502P,$%     @
M-XE85G=6/5DB!   >PD  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
MG599;^,V$/XK VVQB %M=%CRD;4-Y&P#=-M@LVU1%'V@I;'%1B*U)!4G_[Y#
MTE:\J6.T?>&EF6^^N4C--E(]Z K1P%-3"ST/*F/:LRC2184-TZ>R14%?5E(U
MS-!6K2/=*F2E4VKJ*(WC4=0P+H+%S)W=J<5,=J;F N\4Z*YIF'J^P%INYD$2
M[ X^\W5E[$&TF+5LC?=H?FGO%.VB'J7D#0K-I0"%JWEPGIQ=9%;>"?S*<:/W
MUF ]64KY8#>WY3R(+2&LL3 6@='TB)=8UQ:(:'S=8@:]2:NXO]ZAWSC?R9<E
MTW@IZ]]X::IY, F@Q!7K:O-9;G[ K3^YQ2MDK=T(&R^;90$4G3:RV2H3@X8+
M/[.G;1SV%";Q&PKI5B%UO+TAQ_**&;:8*;D!9:4)S2Z<JTZ;R'%ADW)O%'WE
MI&<6]UW;UDA1-JR&2Z8KN*$\P:WP^;:!._G"EC7JP2PR9-"J1<46_,*#IV^
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M/=9N6='?$2HK0-]74IK=QAKH_[<6?P-02P,$%     @ -XE85I^0D:,^ @
M,@4  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULK511;],P$/XKEIG0
M)HTY2;>N*DFD+=4$#XAJ9?" >'"32V/-L3/;:0:_'MM)0R<ZU =>FKOS?=_=
M=[4O[J1ZU!6 0<\U%SK!E3'-G!"=5U!3?2$;$/:DE*JFQKIJ0W2C@!8>5',2
M!<&4U)0)G,8^ME1I+%O#F8"E0KJM:ZI^W@*778)#O O<LTUE7("D<4,WL +S
MT"R5]<C(4K :A&92( 5E@F_">39Q^3[A*X-.[]G(*5E+^>B<CT6" ]<0<,B-
M8Z#VLX4,.'=$MHVG@1./)1UPW]ZQWWGM5LN::L@D_\8*4R5XAE$!)6VYN9?=
M!QCT7#F^7'+M?U$WY 88Y:TVLA[ MH.:B?Y+GX<Y[ '"RU< T0"(C@5,!H"?
M'.D[\[(6U- T5K)#RF5;-F?XV7BT5<.$^Q=71ME39G$F_:PV5+!?U,_T= &&
M,J[/T#OTL%J@TY,S=(*80%\JV6HJ"AT38XLZ*,F' K=]@>B5 @O(+] D/$=1
M$$4'X-GQ\/ EG%BIH]YHU!MYOLD1>L]1)H66G!6]?"L0+15H$*8/R!+=,4%%
MSBA'*QL$>W^-1M]OUMHH>P-_')I'W\#EX0;<JYSKAN:0X,;54EO Z=LWX31X
M?V@Z_XGLQ:PFXZPF_V)/,ZHK/Y3<&?#4LBWE;@"'5/=4UY[*K8YM&LYF=I?$
M9+NOY^^T:#J-9G_2^D[)WHUVV^0351LF-.)06F!P<7V%D>I?:.\8V?A+OI;&
M/AEO5G:I@7()]KR4TNP<]V[&-9G^!E!+ P04    "  WB5A6[9C(LGD&  !;
M)@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R]6MMNVS@0_17"6Q0M
MT,:FY&N:&&A\00OL=H.FW7TH^L#(M,VM1+HD93=_OT-*D2R95NU=-B^)*,X<
M#L_0E XU5SLAOZDUI1K]2&*NKEMKK3>7[;:*UC0AZD)L*(>>I9 )T="4J[;:
M2$H6UBF)VT&GTV\GA/'6^,K>NY7C*Y'JF'%Z*Y%*DX3(AQL:B]UU"[<>;WQD
MJ[4V-]KCJPU9T3NJ/V]N);3:!<J")90K)CB2='G=>HLOYT'7.%B+OQC=J;UK
M9*9R+\0WTWB_N&YU3$0TII$V$ 3^;>F$QK%!@CB^YZ"M8DSCN'_]B#ZWDX?)
MW!-%)R+^FRWT^KHU;*$%79(TUA_%[AW-)]0S>)&(E?V+=KEMIX6B5&F1Y,X0
M0<)X]I_\R(G8<\#A$8<@=PCJ#MTC#F'N$)[JT,T=NJ<Z]'*'WJD._=RA;[G/
MR+),3XDFXRLI=D@::T S%S9=UAL(9MRLK#LMH9>!GQ[?$,44$DMT*ZFB7!.3
M[U?H+EMHIN..K3A;LHAPC=Y&D4BY9GR%;D7,(D85(GR!)FO"5Q0Q7K&0C$=L
M$X/-:_21*BU9I"D8$[6V7GOWWO,M-&#%:H5>3*DF+%8OP>WSW12]>/82/3/8
MG]8B5>"HKMH:IFXFT([R:4ZR:09'ICFET04*\2L4=(+ X3X]W1T[W&>GNW<<
M[O.3W?&HZMZ&=!<Y#XJ<!Q8O/(+GRH6]F'U/V9;$-@OO-4T4^O([^&;77UVL
M9P-UW0.97?%2;4A$KUL;L[SDEK;&SW_#_<X;5PY\@LU\@LT]@56R%1;9"IO0
M][.U3(\L_D:$<].0@0TLF'DP;<?#8;\/OYKM/K\^AYQ[ JOPVRWX[3;R.TFE
MA!4/C\F"YPA^#"Z:NP?,X&YW5&-FFEGU]ZP&O?ZP5^.O,:AS^?,$5N&O5_#7
M:^3OD] DAD>5DT6[M^S=8^4^[R*X=T"=B^!#*Q?!C5&?2[ GL K!_8+@?B/!
M'P1_?81>%X?]0PZ#;K]?X]!E-1H,:APV!G8NAY[ *AP."@X')RQ2?IS),Q?J
MX"2275:')#=&?B[)GL J) \+DH?-.^DCCY906KY,N!@<'G(S'((>JE%X:!;
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MK45B+]>4+*@T!M"_%#"WO&$&*.K)QO\"4$L#!!0    ( #>)6%8&L1[8,0,
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M    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;,5676_:,!3]*U>9-&U2VWQ
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MS1Q8Y+IQ;)Z!4!T$I7$43<]-Z:" 7D'':N9E %U'!TI+H#0&I7$43<]8":.
M%D;MK4TWV'+9_B!DP++)E:WL8 >%9EEG/# 2*?"-=A7J@: TCJ+IV2D/%-!C
MARZ<-4M3K%,;F#OF3]Q^:E"5 Z5Q%$U/3:F<@%8Y=]\S:99F6V=ICE&*I_TD
MH4H'2N,HFIZD4CH!K71LYLS2*.O@S$%*[8(__>B@S@9*XRB:OC2@<C8A/:C(
M?LXL#;0-,#37^8G]N#?&+('6R: TCJ+I 2HE$[[><*$0JFV@M 1*8U :1]'T
MR)7="='#A6B@== #*P--C+%'";12!J5Q%$U/4"F=D%[*Y^(E6:$"!TI+H#0&
MI7$438]7>9Z0]CR7S)BE$=;1FI*GOPY) JV106D<1=,#.ULAF1[O<^%\69IB
MG=G NC]1O_\(K9)!:1Q%TT-3QB:DC<WW39>EX=99F@IG%AL71*C!@=(XBJ9G
MJ0Q.2!L<Z^FR-,\Z/M/E!+-9/SZHRH'2.(JFQZ=43DBKG$LFR]((Z\0&9I4-
MW()"G0V4QE$T/3+E;,*O.!N[V;(TS3J] 6T3]Y^%D$#K9% :1]'TE?^5MHDN
MT387SI:E6;;91::QB69^;^G)!%HG@](XBJ9GIXQ-1 ^B(9_; #4RT<"J/+'7
M7PT]@5;*H#2.HNE9*=42T:KEPKFR-,4ZMH')74/?V$-K95 :1]'TW)1@B>@Q
M,[U!IE;S9FFT=9A0Z0*E,2B-HVAZY$JZ1,&KB? (*F.@M 1*8U :1]'TR)6V
MB=#3M&B@==!#Z_^8 U6AE3(HC:-H>H)GC["B'8[93M-3:&F<=7[8)UM!]0Z4
MQE$T/6:E=Z+7FZ@504T/E)9 :0Q*XRB:'KE20A%ZHA8-M [:%$3F0V<2:)T,
M2N,HFAZ@$D21U3PMB]FT--@Z2.CT+2B-06D<1=.?>:B<4DQ/W_J>1CJ&*B8H
M+8'2&)3&430]<J6B8EI%V3?2-- Z:'.FU\#],[1.!J5Q%.T0X/CLD>E;4:V[
MA]O73C>:X/"D\=.[SO%9]U>WW6/C>^\G[A7OGC\_5ICY]2Y=B]_2:IW)YCP7
MCQ(Y>1/+#D!U>-#]X453[KH'LS^435-NNQ\W0C;W5;N!_/UC639?7K05/)?5
MQVZWY_\'4$L#!!0    ( #>)6%:T<E^(\@@  -EI   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;,W=6W.;2!H&X+_2I9W:2JKB"!H=O;:JDG!&F;CB
MS.XUEMH6-1PT@&QG:W_\- <+(9J.9+\7FXM$POT] J$WM,4G<?64I']F&\9R
M\AR%<78]V.3Y]G(XS%8;%OG9QV3+8OZ3^R2-_)S?31^&V39E_KHLBL(A593)
M,/*#>+"X*I?=I(NK9)>'0<QN4I+MHLA/?WYF8?)T/5 '+PN^!P^;O%@P7%QM
M_0=VR_(_MC<IOS?<*^L@8G$6)#%)V?WUX)-ZN=24HJ <\>^ /64'MTFQ*7=)
M\F=QQUE?#Y1BC5C(5GE!^/R?1_:%A6$A\?7XJT8'^\<L"@]OO^AFN?%\8^[\
MC'U)PO\$ZWQS/9@-R)K=^[LP_YX\V:S>H''AK9(P*_\F3_5894!6NRQ/HKJ8
MKT$4Q-6__G/]1!P4<$=<0.L">EPPZBG0Z@+MU()173 ZM6!<%XQ/+9C4!9-3
M"Z9UP?34@EE=,#NU8%X7S(\+)GT[3GG9<\JICZ'N=W9G;_>6O.QNM=S?P^J%
M5;XJ=3_W%U=I\D328CSWBAOE2[NLYR_&("Y2>)NG_*<!K\L7>I"MDC@/XAU;
MDV];EOI%.#)R06ZK7)+DGGQG&7]19\7-@R'O=);[09B]YX/_N-7)N]_>D]](
M$),?FV27^?$ZNQKF?!6+!QJNZM7Y7*T.[5D=C7SE:[/)B!&OV5I0[\KK52H!
MAORYV3]!].4)^DREHLY6'XFF?B!4H52P0E_DY;=LR\N5WG)=7N[N8FFY(2__
MZJ?2E3=/WW954&Z=ONVB<OOT;1>5.Z=ONZC<?=M^]][VU"U/+U<DKV)M'W.M
M]+0>SWCFA^V,"1-958[$E<4LX#+;^BMV/>"'^8RECVRP^.<_U(GR+U$:D)B.
MQ PD9B(Q"XG92,Q!8BX2\Y#8$H2UDCG:)W,DTQ>_\YEVF&3"9%:5T[*RF$X_
M+OC_!8^'<?OE"+T[XF(TT=J#C%\RIH"9396C4=8O'?N7(YSN"%6;':VP>\I6
M>8)!4TV=MD<M!:,FRG2T']7:J^/]7AU+]VK/M.H#X3_8)AE?R.=2=S_)K1\R
M\C_R(]TQ8C,_S#>BUX'TL<[]'QJ)Z4C,0&(F$K.0F(W$'"3F(C$/B2U!6"O+
MDWV6)]*YTW?VR'B.1<&<((.)Q'0D9B Q$XE92,Q&8@X2<Y&8A\26(*P5S.D^
MF%/I05823&GAN<%$8CH2,Y"8B<0L)&8C,0>)N4C,J[#)P4QT-)II1[/:97>4
MJDZG!\-:69KMLS1[]1L$,V28D)B.Q PD9B(Q"XG92,Q!8BX2\Y#8$H2UDCG?
M)W,N/<I]2;*\^&TQK8YVY!U[7H6[+'ADQ=(UXP^Y"OSJE%:\)GZ4I'GPWVH!
MJU--RO6*<_Y[9\:V/O]ME(4_R5UQ#NZ]*/'2-3HW\4A,1V(&$C.1F(7$;"3F
M(#$7B7GSSH%Q/)N-CXZ>W4'J3!OU'#Q5I3F+ILA#&OI!E.WS)CSQ)17.#154
MTZ&: =5,J&9!-1NJ.5#-A6I>K1T&1]/FX]%1O 3#9M/Y6.W)U\%9:E6:KUL6
M\D4/'\@#BUGJA]6A;AT%<9#EQ9NK_&@H#9^4/SM\2$V':@94,Z&:!=5LJ.9
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M4WT.?*(2KQM%"L@0TKL?8G6458==#;38V"9U)33V1?8QQZ\2D,8 WV="Z,/
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M'3NU#73??K8#&0\!;=+>0.S<_?V[R^4N_347S[( 4.BUI$P.G$*IZLYU95I
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M,=GSSC4HJ#Q0^KVXN8V6$ZNHB"0D% 4$EE\[<D.2I$"2=?RH02=-FT5B]_J
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M.$O4(S]\(*6@P.!%/)'Y-SB4MIX#HDPJGI;.FD%*6?&+?Y0;<>+@AV<<4.F
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M^X2%3FL)$K+6D-Y-J(N\* Z6BAO%=_G9S(HKQ=/\<DMP3(0QT/^O.5?'&_.
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MW _46TS0<00HFBUF,XX0N,<17A3S"'4L-?6:RV\4<](I9GOMDON!>HL).H8
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M+$%B!(E1),:0&$=B H1IL?5<=8#6A>[U.PZ49*B60#4"U2A48U"-0S6!TO1
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MV"PXWHS:MF7O;]@Q9-(8,C$:\LC32&25![J#;JSN>]"1, <)<Y$P#PGSD;
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MM@T850&CM@'C*F#<-F!2!4S:!JC*[L@I)R$]]:.0_<%N?;35W>%66Q]O=7?
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MTNGOO>4NQR^>%@9G=3Z-JWIHQ1U4,Z&:U30@3:MZ:"D=5'.AFM?N#/';C5N
MVK<R];I'MRI?L711W+,_([-D$_/RIL'[K?N_"W!?W!W]9/M4O7;5ANV>>AV4
M=_T_\.4?(0AHNA"K?!*Q5]&5<C42+RPM[^M?/N')NKA1^DO">;(J'BX9G;,T
M;R!^_IHD?/<D[V#_UQ7N_@]02P,$%     @ -XE85J3(%LC[!P  7ST  !D
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MG-E-6JDO1&TUPD*SH]X(>>H6\O\F\[GF7^YF>U.#B1:BHD58:#:!S9("1?_
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MOH9N>"=32&&BJN:M#E2Y-=6G-Z6"=[/YN>&@+(0V@.OK$NZY/M -[&NJ%_\
M4$L#!!0    ( #>)6%9I4(08!@,  "H*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;+5686_:,!#]*Z>LFCJ)-2&A$#J(5&#3*K55U:[;AVFJ3'(0
MJXF=V08Z:3]^M@,9M)"U$_T"MG/W_-ZSSW9OP<6]3!$5/.09DWTG5:HX<5T9
MIY@3><0+9/K+A(N<*-T54U<6 DEBD_+,]3VO[>:$,B?JV;$K$?7X3&64X94
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M3/5C#H4)T-\GG*M5QTQ0/0^C/U!+ P04    "  WB5A6#-E%BAP$  #-%@
M&0   'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6RUF%UOXC@8A?^*E1VM6HEM
MXM=\=@"II3.S775V$)V/B]5>N,2 -4G,V$Z9_ONUDS1F1 @KE-Q OM[CX^0]
M/,3CG9#?U88QC7[&4:(FWD;K[;7OJ^6&Q51=B2U+S)F5D#'59E>N?;65C(99
M41SY$ 1]/Z8\\:;C[-A<3L<BU1%/V%PBE<8QE2^W+!*[B8>]UP,+OMYH>\"?
MCK=TS1Z9_K*=2[/GERHACUFBN$B09*N)=X.O;PFQ!=D57SG;J;UM9*?R),1W
MNW,?3KS .F(16VHK0<W7,YNQ*+)*QL>/0M0KQ[2%^]NOZN^SR9O)/%'%9B+Z
MQD.]F7A##X5L1=-(+\3N3U9,J&?UEB)2V2?:Y=?V^AY:IDJ+N"@V#F*>Y-_T
M9W$C]@J@=Z0 B@+(?.<#92[OJ*;3L10[).W51LUN9%/-JHTYGMBG\JBE.<M-
MG9X^,#,EA?Y <\GM8T&?5BN^9*@X?G''-.61ND1O$$_0YXU(%4U"-?:U&=Q*
M^,MBH-M\(#@RT!U;7B&".P@" /3E\0Y=O+G\5<8WWLL)0#D!R'3)T0DHQ5@G
M-]Q!=TPM)=]F3_R?!W,MNM<L5O]6&<Z%N]7"-@[7:DN7;.*9?E=,/C-O^OMO
MN!^\K;%-2MND3GWZ/M6I9.@C3WB<QKE[-!-QS+7I>5UY@W/%0:9HT_8\'09#
M$HS]YPHCW=)(M];(C31'UEHD'?3UIFK4VO(S[U*O--=KZ^'V6K#=+VWW:^]I
M_C0_,VD"2S.W=AM=F 2],"K5997A>LE17HDPBD6B-ZB/0OJB:KP.2J^#QAMQ
M<-"(!+K!J+H1AZ61X8F;IC632*S03+*0:W03BS31:,%^I-P<J3(R/#"">X,C
M/D:ECU&MCX6AA%0\-/UV_U U:&WYF9V% _=[';05B4*Y8>=[I,'-I^*$YK"(
M!<EC8?(Q/!4,[,B":PEP5C0*R5^R,<1]4MV3V.$"U_/BG'3@0V  @2-.'"]P
M/3#>A5Q96OS]5^68;> ".U[@UH"!VR &=LC +3#CA"8Y(QV.&[AY<.!#<N#^
M:'"D)1TY<//HP(?L #@6#L<.7 ^/>9I8;B0AIY6#ML$.<.R UM@!;; #'#N@
M!7:<T!R6J8!3J8"]MY'FF0$5S!CUJUL1'#&@>6+ (3&.O%Z XP74\^)6,MI!
ML\IWB_K2<[O*T0):HP6T00MPM( 6:'%"LUO0HON:"^B>S(6C!31/"SBD11?@
MR-][<+2 YFD!A[0X%@S'"JAGQ8=WGQ8?[JMST08GB.,$:8T3I U.$,<)T@(G
M3FA"D8O1__\711PO2/.\((>\P##J5?<CV5N1:AX8Y#0P_+W%2;O0^Y'*-4\4
MBMC*U 17 _-+*O.UTWQ'BVVV7ODDM!9QMKEA-&327F#.KX30KSMV";1<P9[^
M!U!+ P04    "  WB5A6-=EZU0X#  "="0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970X."YX;6RM5EUOFS 4_2L6JZ966LMG@'0)4A(ZK=*J5?W:P[0'!VX"
M*MC,=I)NOWZV(2P?-.E#7\ VYQS?<VWL.UA1]LPS (%>RH+PH9$)45V:)D\R
M*#&_H!40^65&68F%[+*YR2L&.-6DLC =R_+-$N?$B 9Z[)9% [H014[@EB&^
M*$O,_HRAH*NA81OK@;M\G@DU8$:#"L_A'L1C=<MDSVQ5TKP$PG-*$(/9T!C9
MEW&H\!KPE,.*;[21<C*E]%EUKM.A8:F H(!$* 4L7TN80%$H(1G&[T;3:*=4
MQ,WV6OV+]BZ]3#&'"2U^Y*G(AD9HH!1F>%&(.[KZ"HV?GM)+:,'U$ZUJ;. 8
M*%EP0<N&+",H<U*_\4N3APV"[;]"<!J"LTOP7B&X#<%]*\%K")[.3&U%YR'&
M D<#1E>(*;144PV=3,V6]G.BEOU>,/DUESP1?0.9-([.T826%25 !$=TAO0P
MNGJ1NTN^3V,0."_XF<0]WL?H].0,G:"<H(>,+C@F*1^80@:C),VDF7A<3^R\
M,K'MH!M*1,;1%4DAW18PI8O6BK.V,G8.*L:07"#7_H0<RW$Z IJ\G6YWT..W
MTZT#;MQV85RMYQY>F)^C*1=,_AV_NE)<2WC=$NK$N.053F!HR".! UN"$7W\
M8/O6YZ[TO*=8_$YB6ZGSVM1YA]2C[Q4P+'(R1X7>Q@GEHBM[M4J@5=3QN(S"
M?L\?F,O-K.R#;*??M[=1<0>J%WIAB]KRT6M]] [Z&)64B?POU@>D_"F9.L/.
MZ>Q\(4UASD%T_G>UJ+\1B[7CZ2@BWD=(T]UN_-:-?]#--1$@UUH@J$^5KM#]
MHZ$?1<3["+<[\* -/#@8^!-F.9X6<&0W!7OS]OS0V0F_ V2Y.ULN[@+U@VX3
M86LB/&CB@0I<''$0[F]BSW?#'0L=J-!R@AT/^RC'=KQ=$^;&Q54"F^L"@,L
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M0+<D0$D#E'R 6A*@I@%JTX!N&M!M&J"E 5K3@%X:T&L:H*<!>M. ?AK0;QI
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M+SHHQ42RG>DIK)F4+#/#!' ,7 NHYQNFZD8YT2^H^ECS_P!02P,$%     @
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M8F)+-4=])WM9SN>NF \Z,1^(P#>6R8T G[*(1FT 6P5718@.$=ZA041,E]?
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MS3N9$<N+L+PC:*;+DAD5LLC1S4C6K<!4@)R?4RIV';5 60G[_P!02P,$%
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M6PB:!*KR:J/<LZ5"T('8?A[N?18N^21<3- /ELB90%^3 ()-![9B+P: ? S
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M@"995'^%I6:C,O[*AY_J>O0DZPEXDD5U5:AJ 9::C=RX*G_\U),LZCTD5+4
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M?$^A5ZS$PX7(MNH,ZF,F1):HCQM*0LIR _G]*LO$X2(?H#KW//\/4$L#!!0
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M(=R]/-QN"/<N#L<3#1F]<G7T,KS>&;S&)="D4@[3;X91A]UGOB8^S#KR-./
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M %,-Y/\S2L6VH ;(+W;'_P-02P,$%     @ -XE85DJ)TP46!P  "#<  !H
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MC@>8!%DWR'JBQ<*VC*G0V(#L,,=_"I#& +_/A-#/$[-!^Y<2_P=02P,$%
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M,;:#WQ.!6P5V;?4]APP4*RJD"Q"0<^,"ZU^I'PSBX$=78\]K11J>( OH]"P
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M@-^W0NB7&_-6IWN+M_X74$L#!!0    ( #>)6%;@VIJ7M ,  "<.   :
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M;+3/A$W[G5&XRY!GDAN1R1+(-_H$FER054'%%D<W@MP+!9G<"O8WY':?+$'
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M>4B89>.A5BO03IO8W,(GTZ,I?"Y=V:=6TRDGG!V_R0NA;A%A@A+GW,*58-+
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MH]: /-+5?%9MK"K\Q#)3EN8?OUS22(O:*=#Y7"F[WC@#S9 \_@-02P,$%
M  @ -XE85L/]G$/. P  71,  !H   !X;"]W;W)K<VAE971S+W-H965T,3$S
M+GAM;+U8VV[;.!#]%4);+%I@-[I8OJ6V@"1J=P,T0!!OVX>B#XPTMHB*I$M2
M=@KLQY>4;-ER9,(.A+Q$(C5S..>00T]FLN;BA\P %'JB.9-3)U-J>>FZ,LF
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MBYJS@]+9P?\MHL&'&DP6-0T7I8:+'8JGZ;@8&X'[)E5+9#6-KK,]R)U#RJ=
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MB))=5T-)M;%J4_;UI;(T)93+C.8XU$Z OJ^4LB\;=T$S&<;_ U!+ P04
M"  WB5A6%]P8\;X#  #;$P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,38N
M>&ULQ5A=CYLX%/TK%ENM6JD=#.2#3)-([4151^I(HYF=[L.J#PZY2:P!F]HF
MF97VQZ]M& @S!(46*2\)AGN/[ST^Q">>[KEXE%L A9Z2F,F9LU4JO71=&6TA
M(?*"I\#TDS47"5%Z*#:N3 60E4U*8M?'>.0FA#)G/K7W;L5\RC,54P:W LDL
M28CX]S/$?#]S/.?YQAW=;)6YX<ZG*=G /:B']%;HD5NBK&@"3%+.D(#US/GD
M75YYH4FP$=\I[.7!-3*M+#E_-(/KU<S!IB*((5(&@NBO'5Q!'!LD7<?/ M0I
MYS2)A]?/Z%]L\[J9)9%PQ>._Z4IM9T[HH!6L21:K.[[_"D5#0X,7\5C:3[0O
M8K&#HDPJGA3)NH*$LOR;/!5$'"3X_I$$OTCP3TT(BH3 -II79MM:$$7F4\'W
M2)AHC68N+#<V6W=#F5G&>R7T4ZKSU/P+H0)])W$&Z :(S 3H-5+H@[U'+--_
M0;1E]&<&$A&V0O=TP^B:1D2'/3"^E"!V9!D#NF9IIB1ZNP!%:"S?:9 *_3VZ
M@R@3@K(->H.H1MWR3&H\.765[L-4XT9%S9_SFOTC-2\@ND"!]Q[YV/?1P_T"
MO7WSK@'FZG08KQG&U6R6E/HEI;[%#;I16M!C*&SD]I]O&@==*TCDCR9.\DD'
MS9.:M_U2IB2"F:-?9[,FX,S__,,;X8]-S/0$5N,G*/D)VM!S?G:&GZ8V\]RQ
MS36_0;OY.,083]W=8?VOH_QP?!!5*VQ0%C9H+>P;["!&05-5K8E=R>\)K-;C
ML.QQ> YQ#OODIR>P&C^CDI_1;XAS=)(X7T>UB'-<%C8^19SH/W1'Y>,'!ID2
M)$;PE.H-$58(B&!ZFT81UUOL"H1=PJ8>6J?INE0]@=48"4M&PG-(.>R3GY[
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M;@+T\S7GZGE@SG?*\[SY_U!+ P04    "  WB5A6W/]_#$0$  #6$0  &@
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M-Z%R9%Y=(E0ODI6FK5XRJ9IT\[@!D@+7 FI^Q=0NU2]Z@>8J9_H_4$L#!!0
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MHG51,%<RRM&]"/_=%?#5%@QE7+].(F,C.WR4#U$V(0IY)LJ4H <I3*W11U%
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MBGYE+>(59^5$>>2YN!H+.SY[I"MQVSEXH!N6\SA;@0MQO*/9EH)ESE)0 PK
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M\<0X9VEUN*8DHGD)$->73 2S/BD[:+8 S?X#4$L#!!0    ( #>)6%8"@#7
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M>5":#Z4%4%H(I45:VXA3=1=-POY*A@Z(FDD%]@=]B1[W'A]-[O&Y.[2B-R-
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M "F[$6R7'@*Y9T*P;7JYH40N41. _/V!,?%ZDP0HCH$-_P-02P,$%     @
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M0U.3U95@-="BM)=D"Z&U*.SCFA)@=$8 WB^%T,\#LT!S,3O]#U!+ P04
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MBD@)%>L$/NG^'D8_"\]7:&'#E_1#[F(>D:*SJ.4(=A5(KH:1[<9S. !<7)T
M)",@^1>P. &8CX!Y,#I4%FQ]9<BRU.B>&)_MV/PDG$V0<6ZX\K>X1>-VN<-A
M]L!R$"E%1^47:#'";@?8[ 1L+<!=)1X!KC[7>V&B@[]AU)4\U9U,=2>!Y^($
MSTU1Z$XA5S79(E,E,Z4ESVW)$,CK>H>^SW(!9*TZ"8;YEGD[9O-SE<Z>U8RU
M/S[4)K%!ZT/I@=NCQ_'_-I)X=GD6S\GK(\@<S-NQ4Z,'-^]?W2,S-5>6"*B<
M7GS^Q761&3IY"%"WX59SC:ZUPK1QCQ^,3W#[E=:X#WQ_3;^3[ ]02P,$%
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M5.\"T+NJWA6@=U6]*T#OJGI7@-Y5]:X O:OJ70%Z5]6[ O2N[F83@-Y5]:X
MO:OJ70%Z5]6[ O1NJG<#Z-U4[P;0NZG>#:!W4[T;0.^F>C> WDWU;@"]F^K=
M 'HW=[,@0.^F>C> WDWU;@"]N^K= 7IWU;L#].ZJ=P?HW57O#M"[J]X=H'=7
MO3M [ZYZ=X#>7?7N +V[N]D;H'=7O3M [Z%Z#X#>0_4> +V'ZCT >@_5>P#T
M'JKW .@]5.\!T'NHW@.@]U"]!T#OH7H/@-[#Q3H O2WX7 ?@MP47[ 2 X!9<
MLA, AEMPT4X *&[!93L!X+@%%^X$@.067+H3 )9;</%. &ANP>4[ >"Y!1?P
M!(+H/L!D%)@^P22([B-,1(7I,TQ$A^E#3$2)Z5-,1(OI8TQ$C>ES3$2/Z8-,
M1)'IDTQ"DVDNRC1"E6DNRS1"EVG19_4$T5V::80VTUR<:80ZTUR>:80^TUR@
M:81"TURB:1_::"[K[\=Y>5OT]]H-^$B]UY?WSF^?_WKY]TF/T"O7T_L9R^4?
M4$L#!!0    ( #>)6%:%HW]XK@(  %%'   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W;S6Z;0!2&X5NQV$:&.0,,4,79M-VV6?0&J!G'R/R)F:3.W7=P?J16
MJ=7(E?INC PSYQP8Z=E]U]\>)^M6Q[X;W";:>S]]2!*WW=N^=O$XV2$\V8US
M7_OP=[Y+IGI[J.]LHI4RR78<O!W\VB\UHIOK3W97WW=^]?D8;KMV'#;1;#L7
MK3X^+5QZ;:)ZFKIV6_OP/'D8FM^ZK)\[Q&'G:8W;MY.["@NBY,T.RY,_-WC>
M]_7!SG/;V-5M/?LO=1]6)<<N<?ZQLRX^7^*-&<?=KMW:9MS>]V%+[*;9UHW;
M6^O[+GXJ>G6^LP]?V#[]RL7]3V7.-0PK;^=Q<N'$9OO^=B]'LNQ>3Z&0G7U[
M_A5?.X;2%[^?74Z[L<U?]@Z?]\<X'T[GX9+3Y?)O_.L9O]9_YQP:,D<*F2.#
MS)%#YC"0.0K('"5DC@HRARC*(!11A4*J4$P5"JI"454HK K%5:' *A19-456
M39%54V35%%DU159-D5539-44635%5DV1-:7(FE)D32FRIA194XJL*476E")K
M2I$UI<B:4F3-*+)F%%DSBJP91=:,(FM&D36CR)I19,THLF8467.*K#E%UIPB
M:TZ1-:?(FE-DS2FRYA19<XJL.4560Y'54&0U%%D-159#D=509#4460U%5D.1
MU5!D+2BR%A19"XJL!476@B)K09&UH,A:4&0M*+(6%%E+BJPE1=:2(FM)D;6D
MR%I29"TILI8464N*K"5%UHHB:T61M:+(6E%DK2BR5A19*XJL%476BB)K19%5
M%(56411;15%P%471512%5U$47T51@!5%$584A5A1&&-!<2R,L9Q %B>1Q8ED
M<3)9G% 6)Y7%B65A<EF""68))IDEF&B68+)9@@EG"2:=)9AXEOS7?-;W<3S\
MX_:G:]S7[?#2/UF*NIN?4$L! A0#%     @ -XE85@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  W
MB5A6++#KP>T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  WB5A6F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #>)6%:RP-C6
M)@@  !TQ   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  WB5A6O[:F^#H"  "\!0  &
M@(%H$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ -XE8
M5KZKF6X*"   KR$  !@              ("!V!(  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( #>)6%9+A'U<J@(  #X'   8
M      " @1@;  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  WB5A6",>8X5\*  #!.0  &               @('X'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -XE85J"Q[6:? @  ]@4  !@
M             ("!C2@  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( #>)6%:^AX !OA   )_6   8              " @6(K  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  WB5A6#:WG2PH-  #:
M/   &               @(%6/   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ -XE85H;B)L&9 P  E <  !@              ("!EDD
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #>)6%;R9SFM
MG"(  *)Q   9              " @65-  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ -XE85D(.!_;3!0  S0T  !D
M ("!.'   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  W
MB5A6D8UJ[?D+  "+*@  &0              @(%"=@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #>)6%8@#4J-F@8  ,L1   9
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M970Q-RYX;6Q02P$"% ,4    "  WB5A6/[L 6YT8  "49P  &0
M    @(%<L   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M #>)6%:^WUI&3A4  +(\   9              " @3#)  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ -XE85D%A>0R/"   [!0  !D
M             ("!M=X  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  WB5A6LHJ0#)X$  #)"@  &0              @(%[YP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #>)6%;W%(;5.A$
M .1!   9              " @5#L  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ -XE85K5"MDB3$   ."\  !D              ("!
MP?T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  WB5A6
MC)Q*5#8#   2!P  &0              @(&+#@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( #>)6%;O1&PH1P4  -P-   9
M      " @?@1 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ -XE85E4H%,Z("@  V1T  !D              ("!=A<! 'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  WB5A6(,*I_@D%  !@"P
M&0              @($U(@$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( #>)6%;=_7PK-P4  +\+   9              " @74G 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ -XE85D"2#A^X
M"0  MQD  !D              ("!XRP! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  WB5A6NZJQ\:4)  "5&0  &0
M@('2-@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #>)
M6%:G;I(\^0,  $ *   9              " @:Y  0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ -XE85J7.8Q8;!   E0D  !D
M         ("!WD0! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  WB5A6TQLO7\$.  !(,0  &0              @($P20$ >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #>)6%:!I%+V&RL  '.5
M   9              " @2A8 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ -XE85N9U]8VE"   @1L  !D              ("!>H,!
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  WB5A6Y"N<
M?+4$  "C%   &0              @(%6C $ >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( #>)6%9 9UBIU@0  ,$,   9
M  " @4*1 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M-XE85K=N<*"A!   Z H  !D              ("!3Y8! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  WB5A6<MMV)5\#  #8!P  &0
M            @($GFP$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( #>)6%:Z]^_A70,  )0'   9              " @;V> 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ -XE85C0=$1ZL!0
M,0X  !D              ("!4:(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  WB5A6HO,U"F0#  "E!P  &0              @($T
MJ $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #>)6%84
M 204R 0  (D+   9              " @<^K 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ -XE85M4$L->1!   DPH  !D
M     ("!SK ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>)6%8$K:?$:P,  +X'   9              "
M@6O0 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ -XE8
M5B)5* @= P  MP8  !D              ("!#=0! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  WB5A6+W( @I &   O$   &0
M        @(%AUP$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( #>)6%;\Q9RG%@0   <)   9              " @2C> 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ -XE85G\QZ*<'!   * H
M !D              ("!=>(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  WB5A6=U8]62($  !["0  &0              @(&SY@$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( #>)6%:?D)&C
M/@(  #(%   9              " @0SK 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ -XE85NV8R+)Y!@  6R8  !D
M ("!@>T! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  W
MB5A6!K$>V#$#  "O"0  &0              @($Q] $ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( #>)6%8(R49O0P,  (<-   9
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M970V,BYX;6Q02P$"% ,4    "  WB5A6#9  "4<+  !Z@   &0
M    @($,% ( >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M #>)6%:T<E^(\@@  -EI   9              " @8H? @!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ -XE85A?1>DWH @  -@<  !D
M             ("!LR@" 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    "  WB5A6R*6NKWL%   :(P  &0              @('2*P( >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( #>)6%8_9MM-5@,
M &P.   9              " @80Q @!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ -XE85CE[+CK  P  \PP  !D              ("!
M$34" 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  WB5A6
M<CMK\8X#  "$$   &0              @($(.0( >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( #>)6%;1NN/^7@,  &\/   9
M      " @<T\ @!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ -XE85E025OH/ P  C@@  !D              ("!8D " 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  WB5A6:"1H%<<$  "[&@
M&0              @(&H0P( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( #>)6%;^I83ST (  "X)   9              " @:9( @!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ -XE85CW)K!Z#
M!   ZA,  !D              ("!K4L" 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    "  WB5A6SLT((.<&  #R+P  &0
M@(%G4 ( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( #>)
M6%;Y,WR*V (  ,H)   9              " @857 @!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ -XE85@L'L/<@!P  _SL  !D
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M=#@Q+GAM;%!+ 0(4 Q0    ( #>)6%:0N#"#>@8  !,]   9
M  " @5N. @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @
M-XE85MJS7RV&!0  52H  !D              ("!#)4" 'AL+W=O<FMS:&5E
M=',O<VAE970X,RYX;6Q02P$"% ,4    "  WB5A6N(BV@FL(  !I80  &0
M            @(')F@( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4
M Q0    ( #>)6%:DR!;(^P<  %\]   9              " @6NC @!X;"]W
M;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ -XE85FE0A!@& P
M*@H  !D              ("!G:L" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX
M;6Q02P$"% ,4    "  WB5A6#-E%BAP$  #-%@  &0              @(':
MK@( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( #>)6%8U
MV7K5#@,  )T)   9              " @2VS @!X;"]W;W)K<VAE971S+W-H
M965T.#@N>&UL4$L! A0#%     @ -XE85BC.FK[& @  3P@  !D
M     ("!<K8" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>)6%9&[+I^Q@0  -8?   9              "
M@>[. @!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ -XE8
M5IT%.^)X @  J 8  !D              ("!Z]," 'AL+W=O<FMS:&5E=',O
M<VAE970Y-2YX;6Q02P$"% ,4    "  WB5A6%B.'-7P#  "Y#P  &0
M        @(&:U@( >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0
M   ( #>)6%8@B69'*P,  !4+   9              " @4W: @!X;"]W;W)K
M<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ -XE85OF69;_6!   )!@
M !D              ("!K]T" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q0
M2P$"% ,4    "  WB5A6O]G3]_D'  "A0   &0              @(&\X@(
M>&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( #>)6%8OSMN;
MV0<  "%#   :              " @>SJ @!X;"]W;W)K<VAE971S+W-H965T
M,3 P+GAM;%!+ 0(4 Q0    ( #>)6%9;:TJYYP4   ,M   :
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M,3 U+GAM;%!+ 0(4 Q0    ( #>)6%:<WWB?&P,  +$(   :
M  " @301 P!X;"]W;W)K<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0    (
M #>)6%;W=1A1UP,  ,@.   :              " @8<4 P!X;"]W;W)K<VAE
M971S+W-H965T,3 W+GAM;%!+ 0(4 Q0    ( #>)6%8L;WEC;P4  (X6   :
M              " @988 P!X;"]W;W)K<VAE971S+W-H965T,3 X+GAM;%!+
M 0(4 Q0    ( #>)6%9 \-O2&04  -$3   :              " @3T> P!X
M;"]W;W)K<VAE971S+W-H965T,3 Y+GAM;%!+ 0(4 Q0    ( #>)6%;@VIJ7
MM ,  "<.   :              " @8XC P!X;"]W;W)K<VAE971S+W-H965T
M,3$P+GAM;%!+ 0(4 Q0    ( #>)6%8V;30570,  $4*   :
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M,3$U+GAM;%!+ 0(4 Q0    ( #>)6%87W!CQO@,  -L3   :
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M;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;%!+ 0(4 Q0    ( #>)6%9TV5$
M)@(  +,$   :              " @<!) P!X;"]W;W)K<VAE971S+W-H965T
M,3(P+GAM;%!+ 0(4 Q0    ( #>)6%9DV?VNV04   XD   :
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M,3(U+GAM;%!+ 0(4 Q0    ( #>)6%8IWJY#I1   );:   :
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #>)6%:%YZ[ =@,  'Y*   :
M          "  4./ P!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( #>)6%:%HW]XK@(  %%'   3              "  ?&2 P!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    "' (< 1"4  -"5 P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>461</ContextCount>
  <ElementCount>606</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>138</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossperCommonShare</Role>
      <ShortName>Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Quarterly Results of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited</Role>
      <ShortName>Quarterly Results of Operations (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossperCommonShareTables</Role>
      <ShortName>Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LossperCommonShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Compensation Related Costs, Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables</Role>
      <ShortName>Compensation Related Costs, Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeTaxes</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables</Role>
      <ShortName>Quarterly Results of Operations (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsNarrativeDetails</Role>
      <ShortName>Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails</Role>
      <ShortName>Transactions - Allocation of Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails</Role>
      <ShortName>Long-term Debt - 2022 Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails</Role>
      <ShortName>Long-term Debt - 2019 Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Loss per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Loss per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Loss per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails</Role>
      <ShortName>Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Unrecognized Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Stock-based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Leveraged Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails</Role>
      <ShortName>Stock-based Compensation - Leveraged Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Changes in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Changes In Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - Quarterly Results of Operations (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails</Role>
      <ShortName>Quarterly Results of Operations (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>0000125 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>0000126 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SubsequentEvents</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="evh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - evh-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - evh-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod, us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  evh-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="evh-20221231.htm">evh-20221231.htm</File>
    <File>a123122exhibit1028.htm</File>
    <File>a123122exhibit231.htm</File>
    <File>a123122exhibit25.htm</File>
    <File>a123122exhibit26.htm</File>
    <File>a123122exhibit27.htm</File>
    <File>a123122exhibit311.htm</File>
    <File>a123122exhibit312.htm</File>
    <File>a123122exhibit321.htm</File>
    <File>a123122exhibit322.htm</File>
    <File>a2022exhibit211.htm</File>
    <File>evh-20221231.xsd</File>
    <File>evh-20221231_cal.xml</File>
    <File>evh-20221231_def.xml</File>
    <File>evh-20221231_lab.xml</File>
    <File>evh-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>evh-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1729">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>152
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 49,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1729,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 461,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 977,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 13,
    "http://www.evolenthealth.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 19
   },
   "keyCustom": 94,
   "keyStandard": 512,
   "memberCustom": 66,
   "memberStandard": 67,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.evolenthealth.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i8094224f59b643989b918aff33c1cbcf_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iadd8541853274e7ba01ebfcb87745b09_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Leveraged Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i9b49bffd2f12447bb479f1f62dd84b3e_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6e836072148b4d08a3bb37cfb2e717b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
     "shortName": "Stock-based Compensation - Leveraged Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i23513d63acc84e1d9329774077f86588_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iec00374a180d419c962d3b3783c65443_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
     "shortName": "Stock-based Compensation - Performance-based RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i2258e21bec464cc5ae9efad5062cb9c2_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i4b9e2e62339c438aa769354df4580b08_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
     "shortName": "Stock-based Compensation - Performance-based RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "icff2543fcb6e4de2a7a5ee968897c7d3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:DeferredTaxAssetsStartupandOrganizationalCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:DeferredTaxAssetsStartupandOrganizationalCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Recently Issued Accounting Standards",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "ie2c16ad239424ec88d83268977b370bf_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
     "shortName": "Income Taxes - Changes in Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id2f84cee7ed64c41ad902dcd77f1d4e2_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Changes In Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Investments in Equity Method Investees (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i08ddb5f52bed406dacf7038dcf91f94c_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i380a94d4a42d4e59aa37d27a99b46bfe_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i380a94d4a42d4e59aa37d27a99b46bfe_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i9ecd37c0c42545c0976d2fd1ee487164_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i380a94d4a42d4e59aa37d27a99b46bfe_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id9511c01ee7c4db793847be4cc362076_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "ie38cc40fb229457c9241d55acdc35d64_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "if4619916bbd2482ab8018d375249be03_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "if4619916bbd2482ab8018d375249be03_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - Repositioning and Other Changes (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Transactions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - Segment Reporting - Additional Information (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i16141fafab8e460196d863fb9865d30b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:SharebasedCompensationIncludingOnetimeAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i9ecd37c0c42545c0976d2fd1ee487164_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i00104c8c47c0426591c253e73ef11658_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - Quarterly Results of Operations (unaudited) (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
     "shortName": "Quarterly Results of Operations (unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i00104c8c47c0426591c253e73ef11658_D20221001-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000125 - Disclosure - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000126 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.evolenthealth.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id4193ae03d1a4161bf594cb95c32108d_D20230120-20230120",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Discontinued Operations",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Credit Losses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Long-term Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.evolenthealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Loss per Common Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.evolenthealth.com/role/LossperCommonShare",
     "shortName": "Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.evolenthealth.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Investments in Equity Method Investees",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Repositioning and Other Changes",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Quarterly Results of Operations (unaudited)",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited",
     "shortName": "Quarterly Results of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Supplemental Cash Flow Information",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://www.evolenthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "menuCat": "Policies",
     "order": "34",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Transactions (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Discontinued Operations (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Revenue Recognition (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Credit Losses (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Long-term Debt (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Loss per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.evolenthealth.com/role/LossperCommonShareTables",
     "shortName": "Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Compensation Related Costs, Share Based Payments (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables",
     "shortName": "Compensation Related Costs, Share Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Related Parties (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Repositioning and Other Changes (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables",
     "shortName": "Quarterly Results of Operations (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "menuCat": "Tables",
     "order": "54",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Organization (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "evh:RightOfOffsetPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i412a52bf5efb44f883cc96e71bea4860_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i61f3c8ea96904abb8624be83844c4e56_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iec00374a180d419c962d3b3783c65443_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Recently Issued Accounting Standards (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Transactions - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
     "shortName": "Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i521ab45bcc9f4828b98cbd32c8324834_I20220801",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
     "shortName": "Transactions - Allocation of Acquisition Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id2c918a773654828be4d267be661bf92_D20220801-20220801",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i00104c8c47c0426591c253e73ef11658_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7f4faacf6f0445328725694f5418ffff_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7f4faacf6f0445328725694f5418ffff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7f4faacf6f0445328725694f5418ffff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i9eb70847d04443d8b6e7ab48773cde8d_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i32b6870c04cf45a7a22f92062187c8b9_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i32b6870c04cf45a7a22f92062187c8b9_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
     "shortName": "Long-term Debt - 2022 Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i66c493c14f1043ecacf17e09302f9e1e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i01455d65a30b4de88519c6a15c185622_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
     "shortName": "Long-term Debt - 2019 Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i3d60561640304c998ba5ee229f359173_I20191230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i140bd5a200d14de591a2f882386a3910_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i140bd5a200d14de591a2f882386a3910_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i21455ed9e898487f8740230211473db0_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i1bf042bd30a44a15975073db664b70be_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iebd374c7c4724e05ac999f332b4ab82e_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "iebd374c7c4724e05ac999f332b4ab82e_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "evh:LineOfCreditFacilityAutomaticExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "evh:NumberOfOptionsToRenewLeases",
      "reportCount": 1,
      "unitRef": "option_to_renew_lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5b43f5864a3c456d988a47acf3b9ce95_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Leases - Primary Office Leases (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i16c50e08b8ef4faba8b4dd2c8041b4ea_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Loss per Common Share - Computation of Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
     "shortName": "Loss per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Loss per Common Share - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
     "shortName": "Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id5b21dc206e94394abb9958199abeb98_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Unrecognized Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Stock-based Compensation - Stock Options (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
     "shortName": "Stock-based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "id9ff7795cc344c3b888aff5a4838a7e9_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i5ce8d9bb4f134dbb9349d1760a71011b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i6da2d2f454714c87a920027e02a6f1ba_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7de54fc5bc4847faa175a8ac09179032_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
     "shortName": "Stock-based Compensation - Performance-based Stock Option Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20221231.htm",
      "contextRef": "i7e55bd977ed745d1ba69ac28771a0759_D20160301-20160331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - evh-20221231.htm",
     "menuCat": "Cover",
     "order": "127",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - evh-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 138,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r931",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r931",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r931",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r931",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r931",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_A2022CreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Credit Facilities",
        "label": "2022 Credit Facilities [Member]",
        "terseLabel": "2022 Credit Facilities"
       }
      }
     },
     "localname": "A2022CreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "label": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "negatedTerseLabel": "IPG acquisition"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value [Abstract]",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "evh_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Earnings Per Share",
        "label": "Basic and Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Loss per common share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BrightHealthManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bright Health Management, Inc",
        "label": "Bright Health Management, Inc [Member]",
        "terseLabel": "Bright Health Management, Inc."
       }
      }
     },
     "localname": "BrightHealthManagementIncMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "label": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ChangesInTaxReceivablesAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Tax Receivables Agreement Liability",
        "label": "Changes In Tax Receivables Agreement Liability",
        "negatedTerseLabel": "Change in tax receivable agreement liability"
       }
      }
     },
     "localname": "ChangesInTaxReceivablesAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "label": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "terseLabel": "Number of days prior to any junior debt maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "terseLabel": "Prepayment penalty on or after third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodFourPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "terseLabel": "Prepayment penalty prior to first anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodOnePercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "terseLabel": "Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodThreePercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "terseLabel": "Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodTwoPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_December312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2023",
        "label": "December 31, 2023 [Member]",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "December312023Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2024",
        "label": "December 31, 2024 [Member]",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "December312024Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2025",
        "label": "December 31, 2025 [Member]",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "December312025Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DeferredFinancingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Fees",
        "label": "Deferred Financing Fees [Member]",
        "terseLabel": "Deferred Financing Fees"
       }
      }
     },
     "localname": "DeferredFinancingFeesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DeferredTaxAssetOutsideBasisDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Outside Basis Differences",
        "label": "Deferred Tax Asset, Outside Basis Differences",
        "terseLabel": "Outside basis differences"
       }
      }
     },
     "localname": "DeferredTaxAssetOutsideBasisDifferences",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Assets, Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxAssetsStartupandOrganizationalCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Start-up and Organizational Costs",
        "label": "Deferred Tax Assets, Start-up and Organizational Costs",
        "terseLabel": "Start-up and organizational costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartupandOrganizationalCosts",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period",
        "label": "Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period",
        "terseLabel": "EBITDA, goal period"
       }
      }
     },
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent",
        "terseLabel": "Benefit of net operating loss carryback provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions",
        "label": "Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions",
        "terseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception",
        "label": "Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception",
        "terseLabel": "Change in indefinite reinvestment assertion for domestic subsidiaries"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent",
        "terseLabel": "Non-deductible excess compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent",
        "terseLabel": "Return to provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Cost, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Cost, Percent",
        "terseLabel": "Nondeductible transaction costs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostPercent",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Receivable Agreement",
        "label": "Effective Income Tax Rate Reconciliation, Tax Receivable Agreement",
        "terseLabel": "Tax receivable agreement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReceivableAgreement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityComponentOfLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component of Long Term Debt",
        "label": "Equity Component of Long Term Debt [Member]",
        "terseLabel": "Equity Component of Long Term Debt"
       }
      }
     },
     "localname": "EquityComponentOfLongTermDebtMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "label": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "terseLabel": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FinitelivedTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Tax Credit Carryforward [Member]",
        "label": "Finite-lived Tax Credit Carryforward [Member]",
        "terseLabel": "Finite-lived Tax Credit Carryforward"
       }
      }
     },
     "localname": "FinitelivedTaxCreditCarryforwardMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossFromTransferOfMembership": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) from Transfer of Membership",
        "label": "Gain (Loss) from Transfer of Membership",
        "terseLabel": "Gain from transfer of membership"
       }
      }
     },
     "localname": "GainLossFromTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "Loss on discontinued operations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainLossOnRepaymentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Repayment Of Debt",
        "label": "Gain (Loss) On Repayment Of Debt",
        "terseLabel": "Loss on extinguishment/repayment of debt"
       }
      }
     },
     "localname": "GainLossOnRepaymentOfDebt",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ImplantableProviderGroupIMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implantable Provider Group (\"IMP\")",
        "label": "Implantable Provider Group (\"IMP\") [Member]",
        "terseLabel": "IPG"
       }
      }
     },
     "localname": "ImplantableProviderGroupIMPMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Services Agreement",
        "label": "Income (Loss) From Equity Method Investments, Services Agreement",
        "verboseLabel": "Revenue related to services agreements"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInTaxReceivableAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Tax Receivable Agreement",
        "label": "Increase (Decrease) In Tax Receivable Agreement",
        "terseLabel": "Change in tax receivable agreement liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxReceivableAgreement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IndefinitelivedTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-lived Tax Credit Carryforward [Member]",
        "label": "Indefinite-lived Tax Credit Carryforward [Member]",
        "terseLabel": "Indefinite-lived Tax Credit Carryforward"
       }
      }
     },
     "localname": "IndefinitelivedTaxCreditCarryforwardMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LineOfCreditFacilityAutomaticExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Automatic Extension Period",
        "label": "Line Of Credit Facility, Automatic Extension Period",
        "terseLabel": "Automatic extension period"
       }
      }
     },
     "localname": "LineOfCreditFacilityAutomaticExtensionPeriod",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "label": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "terseLabel": "Automatic extension after each period"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodBeforeEachAutomaticExtension",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NationalImagingAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Imaging Associates",
        "label": "National Imaging Associates [Member]",
        "terseLabel": "National Imaging Associates"
       }
      }
     },
     "localname": "NationalImagingAssociatesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewCenturyHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Century Health [Member]",
        "label": "New Century Health [Member]",
        "terseLabel": "New Century Health"
       }
      }
     },
     "localname": "NewCenturyHealthMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Employee Directors [Member]",
        "label": "Non-Employee Directors [Member]",
        "terseLabel": "Non-Employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Measurement Period Adjustment",
        "label": "Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Measurement Period Adjustment",
        "terseLabel": "Increase/decrease to goodwill from measurement period adjustments/business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Customers",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_NumberOfOptionsToRenewLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Renew Leases",
        "label": "Number Of Options To Renew Leases",
        "terseLabel": "Number of leases option"
       }
      }
     },
     "localname": "NumberOfOptionsToRenewLeases",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PeriodsPriortoJune2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Periods Prior to June 2015 [Member]",
        "label": "Periods Prior to June 2015 [Member]",
        "terseLabel": "Periods Prior to June 2015"
       }
      }
     },
     "localname": "PeriodsPriortoJune2015Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockDividendRatePercentageAnnualIncreaseInRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Dividend Rate, Percentage, Annual Increase In Rate",
        "label": "Preferred Stock, Dividend Rate, Percentage, Annual Increase In Rate",
        "terseLabel": "Annual increase in dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentageAnnualIncreaseInRate",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_PreferredStockRedemptionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Redemption Period",
        "label": "Preferred Stock Redemption Period [Axis]",
        "terseLabel": "Preferred Stock Redemption Period [Axis]"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodAxis",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_PreferredStockRedemptionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Redemption Period [Domain]",
        "label": "Preferred Stock Redemption Period [Domain]",
        "terseLabel": "Preferred Stock Redemption Period [Domain]"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodDomain",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockRedemptionPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption, Period Four",
        "label": "Preferred Stock, Redemption, Period Four [Member]",
        "terseLabel": "After January 20, 2025"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodFourMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockRedemptionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption, Period One",
        "label": "Preferred Stock, Redemption, Period One [Member]",
        "terseLabel": "Prior to January 20, 2025"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodOneMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockRedemptionPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption, Period Three",
        "label": "Preferred Stock, Redemption, Period Three [Member]",
        "terseLabel": "Prior to January 20, 2025"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodThreeMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockRedemptionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption, Period Two",
        "label": "Preferred Stock, Redemption, Period Two [Member]",
        "terseLabel": "After January 20, 2030"
       }
      }
     },
     "localname": "PreferredStockRedemptionPeriodTwoMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PreferredStockRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Redemption Price Percentage",
        "label": "Preferred Stock, Redemption Price Percentage",
        "terseLabel": "Redemption price percentage"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_PreferredStockVariableDividendRateBasisSpread": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Variable Dividend Rate, Basis Spread",
        "label": "Preferred Stock, Variable Dividend Rate, Basis Spread",
        "terseLabel": "Percentage of preferred dividends in arrears"
       }
      }
     },
     "localname": "PreferredStockVariableDividendRateBasisSpread",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_PremiumRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium Revenue",
        "label": "Premium Revenue [Member]",
        "terseLabel": "Premium Revenue"
       }
      }
     },
     "localname": "PremiumRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions",
        "label": "Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Price Assumptions for Performance Based Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned",
        "terseLabel": "Maximum performance achieved, percentage of targeted shares earned"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold",
        "terseLabel": "Performance goal threshold"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement",
        "terseLabel": "Change in achievement (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievement",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Change In Achievement, Weighted Average Grant Date Fair Value",
        "terseLabel": "Change in achievement (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeInAchievementWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Performance Periods",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Performance Periods",
        "terseLabel": "Number of performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile",
        "terseLabel": "Percentage adjustment of shares earned, total shareholder return in top quartile"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage",
        "terseLabel": "Award vesting rights, stock price increase, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term",
        "terseLabel": "Consecutive term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number",
        "terseLabel": "Leveraged Stock Units (in shares)",
        "verboseLabel": "Performance Based Stock Units (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold",
        "terseLabel": "Award vesting rights, share price threshold (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_SharebasedCompensationAwardSubTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Sub-Tranche One [Member]",
        "label": "Share-based Compensation Award, Sub-Tranche One [Member]",
        "terseLabel": "Vest on March 1, 2019"
       }
      }
     },
     "localname": "SharebasedCompensationAwardSubTrancheOneMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationAwardSubTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Sub-Tranche Two [Member]",
        "label": "Share-based Compensation Award, Sub-Tranche Two [Member]",
        "terseLabel": "Vest on March 1, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationAwardSubTrancheTwoMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SharebasedPaymentArrangementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Tranche Four [Member]",
        "label": "Share-based Payment Arrangement, Tranche Four [Member]",
        "terseLabel": "4th Tranche"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementTrancheFourMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 21.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderClassActionComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Class Action Complaint",
        "label": "Shareholder Class Action Complaint [Member]",
        "terseLabel": "Shareholder Class Action Complaint"
       }
      }
     },
     "localname": "ShareholderClassActionComplaintMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_StockIssuedDuringPeriodSharesEarnOuts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Earn-outs",
        "label": "Stock Issued During Period, Shares, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockIssuedDuringPeriodValueEarnOuts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Earn-outs",
        "label": "Stock Issued During Period, Value, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockIssuedInConnectionWithDebtRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued in Connection with Debt Repayment",
        "label": "Stock Issued in Connection with Debt Repayment",
        "terseLabel": "Class A common stock issued in connection with debt repayment"
       }
      }
     },
     "localname": "StockIssuedInConnectionWithDebtRepayment",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Shares",
        "label": "Stock Vested And Retired During Period, Shares",
        "negatedTerseLabel": "Share retirement (in shares)"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodShares",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Value",
        "label": "Stock Vested And Retired During Period, Value",
        "negatedTerseLabel": "Share retirement"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodValue",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Liability",
        "label": "Tax Receivable Agreement Liability",
        "terseLabel": "Tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent Of Cash Savings Not Paid To Shareholders",
        "label": "Tax Receivable Agreement, Percent Of Cash Savings Not Paid To Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings not paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentOfCashSavingsNotPaidToShareholders",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "label": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "terseLabel": "Amount of tax benefit percent"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement Liability",
        "label": "Tax Receivables Agreement Liability",
        "terseLabel": "TRA liability"
       }
      }
     },
     "localname": "TaxReceivablesAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentOfTaxSavingsToBePaid",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 18.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TwoThousandElevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eleven Equity Incentive Plan [Member]",
        "label": "Two Thousand Eleven Equity Incentive Plan [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "localname": "TwoThousandElevenEquityIncentivePlanMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]",
        "label": "Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen",
        "label": "Two Thousand Nineteen [Member]",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "TwoThousandNineteenMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UPMCResellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPMC Reseller Agreement",
        "label": "UPMC Reseller Agreement [Member]",
        "terseLabel": "UPMC Reseller Agreement"
       }
      }
     },
     "localname": "UPMCResellerAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UniversityHealthCaredbaPassportHealthPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Health Care d/b/a Passport Health Plan [Member]",
        "label": "University Health Care d/b/a Passport Health Plan [Member]",
        "terseLabel": "Passport"
       }
      }
     },
     "localname": "UniversityHealthCaredbaPassportHealthPlanMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate",
        "label": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would not impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_VitalDecisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Decisions",
        "label": "Vital Decisions [Member]",
        "terseLabel": "Vital Decisions"
       }
      }
     },
     "localname": "VitalDecisionsMember",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_WeightedAverageCommonSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Common Shares Outstanding",
        "label": "Weighted Average Common Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageCommonSharesOutstandingAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_WeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.evolenthealth.com/20221231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r886",
      "r1000",
      "r1044",
      "r1045",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r355",
      "r417",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r445",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r991",
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r355",
      "r417",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r445",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r991",
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r307",
      "r366",
      "r376",
      "r382",
      "r466",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r724",
      "r727",
      "r730",
      "r731",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r307",
      "r366",
      "r376",
      "r382",
      "r466",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r724",
      "r727",
      "r730",
      "r731",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r307",
      "r366",
      "r376",
      "r382",
      "r466",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r724",
      "r727",
      "r730",
      "r731",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r451",
      "r907",
      "r999",
      "r1058"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r618",
      "r813",
      "r853",
      "r887",
      "r888",
      "r904",
      "r917",
      "r926",
      "r993",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r618",
      "r813",
      "r853",
      "r887",
      "r888",
      "r904",
      "r917",
      "r926",
      "r993",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r451",
      "r907",
      "r999",
      "r1058"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r447",
      "r818",
      "r905",
      "r924",
      "r988",
      "r989",
      "r999",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r447",
      "r818",
      "r905",
      "r924",
      "r988",
      "r989",
      "r999",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r600",
      "r618",
      "r649",
      "r650",
      "r651",
      "r812",
      "r813",
      "r853",
      "r887",
      "r888",
      "r904",
      "r917",
      "r926",
      "r986",
      "r993",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r600",
      "r618",
      "r649",
      "r650",
      "r651",
      "r812",
      "r813",
      "r853",
      "r887",
      "r888",
      "r904",
      "r917",
      "r926",
      "r986",
      "r993",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r448",
      "r449",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r906",
      "r925",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r448",
      "r449",
      "r867",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r906",
      "r925",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r369",
      "r370",
      "r371",
      "r457",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r710",
      "r711",
      "r712",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r765",
      "r766",
      "r770",
      "r771",
      "r772",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r453",
      "r844",
      "r896"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r923"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Changes in Allowance for Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r844",
      "r871"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r145",
      "r320"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r328",
      "r846",
      "r861",
      "r865"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r923"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r962",
      "r963",
      "r964",
      "r1037"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r369",
      "r370",
      "r371",
      "r373",
      "r382",
      "r457",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r659",
      "r660",
      "r661",
      "r688",
      "r689",
      "r690",
      "r691",
      "r710",
      "r711",
      "r712",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r765",
      "r766",
      "r770",
      "r771",
      "r772",
      "r773",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r820",
      "r821",
      "r822",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of 2024 Notes, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r189",
      "r190",
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r653"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r329",
      "r455",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Charge-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r75",
      "r94",
      "r254",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r557",
      "r768",
      "r952"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r557",
      "r768",
      "r902",
      "r903",
      "r952"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of the debt discount and the issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r94",
      "r132",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r236",
      "r942",
      "r943",
      "r944"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r264",
      "r280",
      "r323",
      "r351",
      "r425",
      "r437",
      "r443",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r717",
      "r719",
      "r745",
      "r923",
      "r991",
      "r992",
      "r1047"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r316",
      "r330",
      "r351",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r717",
      "r719",
      "r745",
      "r923",
      "r991",
      "r992",
      "r1047"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r708",
      "r915",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r708",
      "r915",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r222",
      "r223",
      "r225"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r222",
      "r223"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r220",
      "r222",
      "r223",
      "r714"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r716",
      "r951"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 19.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r221",
      "r224",
      "r715"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or input ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Impact to cash and cash equivalents and restricted cash from initial consolidation"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r96",
      "r318",
      "r890"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r99",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash and Restricted Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r90",
      "r96",
      "r104"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r90",
      "r253"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r21",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows (used in) provided by investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r21",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r351",
      "r388",
      "r389",
      "r396",
      "r398",
      "r407",
      "r408",
      "r461",
      "r522",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r745",
      "r889",
      "r937",
      "r953",
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r269",
      "r286"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note $11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r516",
      "r517",
      "r873",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock",
        "verboseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r962",
      "r963",
      "r1037"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r36",
      "r923"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r332",
      "r334",
      "r341",
      "r840",
      "r847"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r249",
      "r250",
      "r451",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r249",
      "r250",
      "r451",
      "r866",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r249",
      "r250",
      "r451",
      "r872",
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r113",
      "r114",
      "r249",
      "r250",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r249",
      "r251",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r249",
      "r250",
      "r451",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r573",
      "r574",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r573",
      "r574",
      "r596"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r573",
      "r574",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r32",
      "r267",
      "r281"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r156",
      "r535",
      "r536",
      "r547",
      "r548",
      "r549",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r122",
      "r436",
      "r437",
      "r438",
      "r439",
      "r445",
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r945",
      "r946"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r472",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r956",
      "r1033",
      "r1035"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r956",
      "r1033"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r207",
      "r685",
      "r698",
      "r956"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r956",
      "r1033",
      "r1035"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion issued (in share)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r350",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r551",
      "r558",
      "r559",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r265",
      "r267",
      "r278",
      "r355",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r769",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r159",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r49",
      "r164",
      "r166",
      "r168",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r49",
      "r164",
      "r166",
      "r168",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r255",
      "r257",
      "r535",
      "r769",
      "r900",
      "r901"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r355",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r769",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r164",
      "r167",
      "r168",
      "r169",
      "r254",
      "r255",
      "r257",
      "r276",
      "r355",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r769",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r256",
      "r547",
      "r562",
      "r900",
      "r901"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Accrued deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r956",
      "r1034",
      "r1035"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r256",
      "r994"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r207",
      "r956",
      "r1034"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r207",
      "r686",
      "r697",
      "r698",
      "r956"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r33",
      "r34",
      "r266",
      "r277",
      "r679"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r667",
      "r668"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r206",
      "r956"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r956",
      "r1034",
      "r1035"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest deduction limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1031"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r200",
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state research tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r193",
      "r1031"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense",
        "terseLabel": "Contract fulfillment costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Software",
        "terseLabel": "Internally developed software costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Right-of-use assets - Operating"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r202",
      "r1032"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r94",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r94",
      "r143"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r313",
      "r952"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r420"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r595",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r623",
      "r655",
      "r656",
      "r658",
      "r663",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r6",
      "r8",
      "r12",
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "verboseLabel": "(Loss) gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r12",
      "r19",
      "r66",
      "r289"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r12",
      "r19",
      "r23",
      "r669",
      "r696",
      "r703"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r20",
      "r315"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r10",
      "r11",
      "r20",
      "r27"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r20",
      "r315"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r915",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r342",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r385",
      "r388",
      "r396",
      "r397",
      "r398",
      "r402",
      "r731",
      "r732",
      "r841",
      "r848",
      "r893"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r342",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r388",
      "r396",
      "r397",
      "r398",
      "r402",
      "r731",
      "r732",
      "r841",
      "r848",
      "r893"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r670"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r353",
      "r670",
      "r700"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r700",
      "r1029"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in state rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings at other than U.S. rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Non-deductible goodwill impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r1028",
      "r1029"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Excess tax benefits (shortfalls) on stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "U.S. state income taxes, net of U.S. federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Convertible debt extinguishment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r1029",
      "r1036"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax sharing settlement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r657"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted Average Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r1027"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r1027"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r163",
      "r307",
      "r336",
      "r337",
      "r338",
      "r363",
      "r364",
      "r365",
      "r370",
      "r379",
      "r381",
      "r406",
      "r466",
      "r572",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r730",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r798",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r126",
      "r828",
      "r830",
      "r832",
      "r834",
      "r836",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "negatedLabel": "Equity method investment impairment",
        "terseLabel": "Impairment of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r89",
      "r129",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments and Impairment of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Valuation Techniques and Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r241",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r549",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r738",
      "r809",
      "r810",
      "r811",
      "r900",
      "r901",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r737",
      "r738",
      "r740",
      "r741",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r549",
      "r602",
      "r607",
      "r738",
      "r809",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r549",
      "r602",
      "r607",
      "r738",
      "r810",
      "r900",
      "r901",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r549",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r738",
      "r811",
      "r900",
      "r901",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r742"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Unrealized (gains) losses, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r549",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r809",
      "r810",
      "r811",
      "r900",
      "r901",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r778",
      "r782",
      "r922"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r778",
      "r782",
      "r922"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r456",
      "r475",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r456",
      "r475",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r322",
      "r500"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r501",
      "r819",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r137",
      "r826"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r133",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r137",
      "r819"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r952"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets and consolidation",
        "verboseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r94",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 20.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment/repayment of debt, net",
        "negatedTerseLabel": "Loss on extinguishment/repayment of debt, net",
        "verboseLabel": "Loss on extinguishment/repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "terseLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r321",
      "r484",
      "r839",
      "r898",
      "r923",
      "r975",
      "r982"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r487",
      "r898"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r496",
      "r497",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r486",
      "r493",
      "r898"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r94",
      "r485",
      "r490",
      "r496",
      "r898"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r71",
      "r95",
      "r231",
      "r374",
      "r375",
      "r376",
      "r377",
      "r394",
      "r398"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r352",
      "r699"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r261",
      "r272",
      "r292",
      "r425",
      "r436",
      "r442",
      "r445",
      "r842",
      "r895"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r352",
      "r699"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r425",
      "r436",
      "r442",
      "r445",
      "r895"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r232",
      "r351",
      "r369",
      "r425",
      "r436",
      "r442",
      "r445",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r732",
      "r745",
      "r895",
      "r991"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r63",
      "r270",
      "r273",
      "r288",
      "r342",
      "r369",
      "r374",
      "r375",
      "r376",
      "r377",
      "r388",
      "r396",
      "r397",
      "r732",
      "r841"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations, basic (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r63",
      "r288",
      "r291",
      "r342",
      "r369",
      "r374",
      "r375",
      "r376",
      "r377",
      "r388",
      "r396",
      "r397",
      "r398",
      "r732",
      "r841",
      "r848"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r12",
      "r23",
      "r289",
      "r315",
      "r704"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss from discontinued operations, net of tax",
        "totalLabel": "Net loss",
        "verboseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r12",
      "r19",
      "r23",
      "r232"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r66",
      "r289",
      "r291",
      "r342",
      "r389",
      "r396",
      "r397",
      "r1055",
      "r1056"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r237",
      "r389",
      "r396",
      "r397"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r65",
      "r94",
      "r128",
      "r271",
      "r287",
      "r422"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Gain from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r915",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r22",
      "r24",
      "r25",
      "r26",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r502",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r671",
      "r677",
      "r684",
      "r695",
      "r701",
      "r705",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r354",
      "r380",
      "r381",
      "r423",
      "r669",
      "r696",
      "r702",
      "r849"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from (provision for) income taxes",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Total tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r335",
      "r665",
      "r666",
      "r677",
      "r678",
      "r683",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r814",
      "r951"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r951",
      "r1041"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r136",
      "r815",
      "r816",
      "r817",
      "r819",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r131",
      "r135"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r256",
      "r275",
      "r339",
      "r419",
      "r767"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r75",
      "r555",
      "r564",
      "r902",
      "r903"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r345",
      "r348",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Software Development Costs"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r417",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r74",
      "r418"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r938"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r789",
      "r922"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1042"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Primary Office Leases and Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1040"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r351",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r718",
      "r719",
      "r720",
      "r745",
      "r894",
      "r991",
      "r1047",
      "r1048"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r268",
      "r284",
      "r923",
      "r955",
      "r971",
      "r1039"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r317",
      "r351",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r718",
      "r719",
      "r720",
      "r745",
      "r923",
      "r991",
      "r1047",
      "r1048"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r293",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r845",
      "r850",
      "r852"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]",
        "terseLabel": "Claims paid related to:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedTerseLabel": "Current year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedTerseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total claims incurred"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]",
        "terseLabel": "Incurred health care costs:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r32",
      "r267",
      "r281",
      "r548",
      "r563",
      "r900",
      "r901"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r1038"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r67",
      "r95",
      "r274",
      "r290",
      "r315",
      "r331",
      "r333",
      "r338",
      "r351",
      "r369",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r394",
      "r425",
      "r436",
      "r442",
      "r445",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r732",
      "r745",
      "r895",
      "r991"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377",
      "r385",
      "r386",
      "r395",
      "r398",
      "r425",
      "r436",
      "r442",
      "r445",
      "r895"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r398"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r310",
      "r367",
      "r368",
      "r371",
      "r372",
      "r382",
      "r383",
      "r384",
      "r459",
      "r460",
      "r467",
      "r468",
      "r692",
      "r693",
      "r694",
      "r728",
      "r734",
      "r735",
      "r736",
      "r752",
      "r753",
      "r754",
      "r774",
      "r775",
      "r793",
      "r799",
      "r823",
      "r824",
      "r825",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r107",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r366",
      "r369",
      "r370",
      "r371",
      "r373",
      "r376",
      "r382",
      "r402",
      "r457",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r659",
      "r660",
      "r661",
      "r688",
      "r689",
      "r690",
      "r691",
      "r710",
      "r711",
      "r712",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r765",
      "r766",
      "r770",
      "r771",
      "r772",
      "r773",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r820",
      "r821",
      "r822",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Accrued net working capital adjustment with business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Payables Assumed",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "terseLabel": "Consideration for asset acquisition or business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r171",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Disposal of assets"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r230",
      "r572",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r425",
      "r436",
      "r442",
      "r445",
      "r895"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r783",
      "r922"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r777"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r777"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r777"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r779",
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r776"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r788",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r787",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r29",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r232",
      "r233",
      "r235"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash inflows (outflows), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "terseLabel": "Payment for contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r91",
      "r295"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total claims paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromLoansReceivable": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.",
        "label": "Payments for (Proceeds from) Loans Receivable",
        "negatedTerseLabel": "Loan for implementation funding"
       }
      }
     },
     "localname": "PaymentsForProceedsFromLoansReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r948",
      "r949"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayment of Credit Agreement including settlement of warrants"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r713"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash",
        "verboseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r78",
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r600",
      "r601",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r35",
      "r164",
      "r165",
      "r953",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r941"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r263",
      "r279",
      "r938"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r346",
      "r947"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r950"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r187"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r144",
      "r319"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r146",
      "r285",
      "r843",
      "r923"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment",
        "verboseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r343",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data [Abstract]",
        "terseLabel": "Quarterly Financial Data [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialDataAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r110",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Results of Operations (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowances"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Adjusted EBITDA to Net Loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r609",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r304",
      "r802",
      "r803",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r609",
      "r802",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r800",
      "r801",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Repayment and repurchase of 2021 Notes and financing fees",
        "terseLabel": "Repayment and repurchase of 2021 Notes and financing fees"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r96",
      "r104",
      "r262",
      "r282",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r96",
      "r104",
      "r318"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r96",
      "r104",
      "r869"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r868",
      "r870"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r868",
      "r870",
      "r941"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r868",
      "r870"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r506",
      "r509",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r505",
      "r508",
      "r511",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative Amount Incurred through December 31, 2021"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r94",
      "r510",
      "r511",
      "r987"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r505",
      "r506",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r170",
      "r283",
      "r860",
      "r865",
      "r923"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r307",
      "r363",
      "r364",
      "r365",
      "r370",
      "r379",
      "r381",
      "r466",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r730",
      "r856",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r416",
      "r417",
      "r435",
      "r440",
      "r441",
      "r447",
      "r448",
      "r451",
      "r594",
      "r595",
      "r818"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r451",
      "r968"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r599",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r585",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r70",
      "r301",
      "r524",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r340",
      "r351",
      "r416",
      "r417",
      "r435",
      "r440",
      "r441",
      "r447",
      "r448",
      "r451",
      "r461",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r529",
      "r531",
      "r533",
      "r534",
      "r745",
      "r842",
      "r991"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r786",
      "r922"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r210",
      "r211",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Purchase Price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r22",
      "r24",
      "r25",
      "r26",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the U.S. Statutory Tax Rate to our Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r184",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r130",
      "r315",
      "r351",
      "r461",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r133",
      "r136",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r133",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets",
        "verboseLabel": "Schedule of Intangible Assets Details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r898",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Activity in Claims Reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Leveraged Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Unaudited consolidated quarterly results of operations"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r104",
      "r262",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r104",
      "r262",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Costs Associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule Of Information Of Performance Based Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r620",
      "r622",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r177",
      "r179",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Option Price Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Units Information"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule Of Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r921",
      "r1030"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Changes in Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Major Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r451",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r508",
      "r513",
      "r898",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r425",
      "r428",
      "r439",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r939",
      "r940",
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period for vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "negatedTerseLabel": "Forfeited / Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Change in achievement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "terseLabel": "Number of awards issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "netLabel": "Performance Based Stock Units",
        "terseLabel": "Total RSUs",
        "verboseLabel": "Leveraged Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant-Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r920"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "terseLabel": "Number of options issued (in shares)",
        "verboseLabel": "Outstanding at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "1st Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "3rd Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "2nd Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r627",
      "r646",
      "r647",
      "r648",
      "r649",
      "r652",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "Performance-Based Stock Option Awards Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CompensationRelatedCostsShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "verboseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use software development costs",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r312",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r451",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r503",
      "r508",
      "r513",
      "r898",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r351",
      "r388",
      "r389",
      "r396",
      "r398",
      "r407",
      "r408",
      "r461",
      "r522",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r745",
      "r889",
      "r937",
      "r953",
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r55",
      "r163",
      "r307",
      "r336",
      "r337",
      "r338",
      "r363",
      "r364",
      "r365",
      "r370",
      "r379",
      "r381",
      "r406",
      "r466",
      "r572",
      "r659",
      "r660",
      "r661",
      "r690",
      "r691",
      "r730",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r798",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r406",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Class A common stock issued in connection with business combinations"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r35",
      "r36",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r163",
      "r164",
      "r170",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r35",
      "r36",
      "r163",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r163",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r36",
      "r163",
      "r170",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r55",
      "r163",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Shares issued for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r163",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r163",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r170",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r163",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r124",
      "r923",
      "r955",
      "r971",
      "r1039"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedTerseLabel": "Stockholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r764",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r764",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r764",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r764",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r806",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r851"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "verboseLabel": "Current year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r851"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares issued"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r57",
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r53",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r36",
      "r163",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Consolidation of equity method investment"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r369",
      "r370",
      "r371",
      "r373",
      "r382",
      "r457",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r659",
      "r660",
      "r661",
      "r688",
      "r689",
      "r690",
      "r691",
      "r710",
      "r711",
      "r712",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r765",
      "r766",
      "r770",
      "r771",
      "r772",
      "r773",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r820",
      "r821",
      "r822",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r505",
      "r506",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r664",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end-of-year",
        "periodStartLabel": "Balance at beginning-of-year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r672"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r675"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases - tax positions in current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases - tax positions in prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Reduction of valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation Allowance of Deferred Tax Assets"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r356",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end-of-year",
        "periodStartLabel": "Balance at beginning-of-year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged (credited) to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged (credited) to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r784",
      "r922"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r387",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r385",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossperCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/subtopic&trid=2560295",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r927": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r928": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r929": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r931": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r932": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r933": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r934": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r935": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r936": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131251-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>153
<FILENAME>0001628908-23-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-23-000029-xbrl.zip
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MD.W@2)_5IQM28SV7"*49D+EW!\LRAPYQUD\A;12_+.^#F&Y+=-F D-PS$%%
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MD,5^.&C/T3-U]>O)R=G5U?O++?'1ONCVT9XW<4/+&A@PGLU-4RZ,2%3SS&K
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MZSEO0<*"YNVJ@"#26\+N3-:>+Y>?UV1U?JT.TTV9\WK-)Y\/YVXRA7$O$S"
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MGFYYMFF/UNXF;O\3S/X%4$L#!!0    ( #>)6%:_1\4[XK8! $>>#@ 4
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M/J;^,XEO\\MBEF;PV! N@JL954Y (-[.+K%L%=DRDH]9$@0G5XDR4.&X+:G
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M=0?,^$ZMCTV\7&=RB((9L-(,^4HDT8 .YN;E8@'?X!469<3HZ2FA#51!AS-
MYSG;M*'9WN=H&,#VSH7W+S\NA=.'B/+4,%*<52%_BQ;.WO&^N:E#*7+FY[,=
MV.)F(E9&WX7-/D(5U###%_ 6$Q@YK=[.SK3]%MV8<6+'.+5F_5(4WA]I]A''
M?.8OH@+]CQ E7CH@Q-ZQ2RNPT1MU834>@Q/JO$9N5LD/4<8G4UYDI41-3:5W
MN9"'<)6MOIM[S/50]B;[V]U%CX,J='\'M9_J8'&F@9/BV^"<U\Q"*D:S9Z$K
M->YL(3(,'8!O;C^% 8*9D( I:MI%5%N=UH-C\P)7^K6ZH.UZPH+TDT55Y8)A
MA;?B4NA@7Y6SL-ZAVAM+"9#LR;4<T7S'*&MB?-->@1\$U'$S+$G_)N@7Q-Y$
MB<HL+:FA"#L<DS3]F&M>K"S,D9-0D_;!:0JJ>D$=2'*$@90Q(O_F8@X[, E]
M;N'J FSW1[9?@D1C(V_J!XK,G@@$J^1_6H[Q?%B4V2+-]9?41/8^@E5LFFUI
MW?PD)]%B[ I2U5^VH2-TR[36 (,)!,F#L1V)D@R_C<@B>7D14TW$WMC5S,^C
MG'MPT#RZW'_Z36 <,#\8@FT +*^=HPK5I,-L)DD&381XTUG"^$*!8]!H7S]9
M(DQ7([GQA,_DN%V$]LBA?UMA]U0BU)"]3=+"[4-KDN*<TL?8>@5P3'UZ"O\C
M?RF9W9&Y,YU'S-SG?K=/#6IIQ20(/8-WQ)<)4(CH8RU7.!9Z>EIMP./ THD
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MI"/Q!KJ(FNC=:*BP,WVVC@S@V2V7YK>NNUV&HH.K@1@ 7?S-!>]@@-ETUK0
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M-80(.N[?#+IVS]O?8(*#*"US[RP-A2IH4U3V[HO(85S<RHRQV6D4R@B-%8]
MQ.=$\]MAL<WHZ"<CHS':W:A+P+V+#NZC#"9I#I\B*)H=3^6[..[KV@[MTIMQ
M>[-?*SP-V?XRBQ/A1,)Z2K<;V6-4M;S]'9-V5]91ON&JY^LZOO@:L;K&K.'S
MW=C3G7)CFQN^;^K&@G&:EF 3\/Q/Y1ZO2)#I+Z9!?8CPL]N)54FX/C."5PIX
M52M42W<^JW7&4$E=%9)RX20Z(H@K+_G>%@5#H0]284W/RORZ<SM2=A_F_-('
ML/SELV0GM=42W7M0N:E,I<K&\RIHE#D@;=2[=/> LK@L'^Y8*.$E=3=,SRR5
M,:^\7"S #AGQ>]R+.%W8P/*J@K47_BFGZ&X)W6S7$QJSSB8T;$ 993=4Q!>3
M ;&8%F;3:4./%!-HNQ2V<>:SQ8< 8WCR1Q8  BL7XHZ_E?4[CH=O3AGLDH >
M430I"P7WC+*0VC#"<;U22/8X=5.A>H&3&VYD2G@(+8PM#%5\.(PD])1G0<6/
M278IY[PR+_T4N68F^?9SCG&!;&:JBM$Y=DB$>4^7*K4@$5UI]L2#2ZE<J2GY
M=*2[FEW4%@/>@W>(2UUYXF[)_48?A78_A47EGE=4SB,-7]#E_2PNTJ7,5WQ*
M#)4IOC2:DXIK-JUFB!XW0V2M(=XZIN8NL,,TW>"3[ZD3463.9_DL6A#OA#67
ML1W@UMDGV0FZ->U$5]"4N81.0TA<A\3?=#XDOI&*VVJWMC5;7'91)@I<[E<#
M6[!^WZ]N]G6;G(SVA>G01*EQK$%8JHPG"6I_?:<_'Y\F7\^M+WP3<A5NCH&.
M"(I$H2:4';5 "Y:2BQ^_EA$6JGLA5CPRJT=N1,0$,C3W>-UW;N6SS5[Y["C-
MN@BC;BUG0HTV$[L9KF3G0PZ]>$K]C,G94=Z/+W&8XE[#-RN^VB.".K6MHI01
MJ8<G.R:''!Q?Q'[0PL^I._B8YFQU+:_6Q8L-"+0QE".KQRIA805:TSB+NTQ&
MA]VY4=CUT"]\I&C*C(G"2H76279[P H+B:50RF?//539*<7=9JR&C?-#NZ4D
M/C979FH @%/TIW+^".XHYW.M78O60D#JGNZBMLV4DYFDE7$#X8K<X+HZ 5L!
M$@)&M@H8J=_!Q.)=U%XF5F>W?+ZZ>^^0'YH&PI$*XQ!QK%YK,MEWT);1E@.(
MA4=F%YN?3NE.ZV45>ZX,O+!UO?#E4-*E'RMM+77(G L-Y>!E6AEKACX%NO((
MXQ]P#Y(UV<F^.HY:X# V<^CGQH\_:T8,-9SBI)!<9N9845_D4C\II0::#K8>
M.,.TJ2@IZF>AR=GPB>2 ^]_A#6[4#62S*:X6K3L]JFDU0C]RT0-ML6FMJEMW
M^M4> 3@#IKI!N?<E.F-9E'\D5HX\=_K[:/VM'H@?NHU$&):FR>!-U>AN% Y@
M,"KN:C!JY. ZZC9"75P<)MX0^$I8B>R VM01<YWP6-0_M3 SBB*;=C--VU*S
M#8ZX3,<-/35S'37+U*'WARR<B".P&-19=2<2K*JS+!&-+FD0CF?DTS<PGD _
M+$C_1_#*IC1?J9T1<B_Y'GBAT;R<2]]_,5OF44!$*R*8)?Q//\2+&(E\CUT5
M\$C+4OC6X1Y"ZA-_*NY*TE:AP)-;N+0\MO$V,I:;QH56D_VU:JB7*>KY8Z@P
MDF=R89A(+YXJV4<A&6GF\S+1T'=I./#9Q%@=S3->0\.$#Y#E)9(&75DB;8+4
MV*) ^_THG0HQ/'+)IM#8\S'7Q&:@_95Y.I%+<1L>&_S+E)IUAI<\"-E54'_D
M]8K0U[3L*AMKQ?7LV1A9IY7A5Y^(YB#G7J<)[]2[J0;VW2"[J]U-STZ$&B"\
M'<'84Q15*HQ>HOX=H1D=^P\C)P:RWUS)"8^4>ZS1Q5S)6)*FKKWR@:RMF$E$
M"'+%H%#GG*YK1661F%D ;UTA.S(MM-.LVBZ[ZL$UN8(64N6)'B'I(UC;H.#<
MEORWS85;.RWL#>(=L->UC');0Y!.HZIJ)']);O"K%($:[%A5-[U")+IK^B5X
MX# O'<OHC"8C4OGMU+ST$*?7<?JWG8_3;V2@;,D>L:7''(@@G!$#=IU@R)1B
MAF [B*QR^)*?&JJ/05QLSZ#IK.RG@9>L2>6N.KF?&70MT:%(-B5!:%IS@2U"
MI #D'*&MSI4$"3YZ:;*J:U']*9&*D([%^_]"1"&HQ)%;0+>7DL:K#?2Q. CK
M.LG8O1:;WUY?Y88R3/2K<BI(,&<=&*'-9&U>+AU-5.%_17-O.]0ZS,/NLEB-
MT*SFPD<F)C)J?!=%Q$(&NSGQ7!CPR 4Z&P#TR#I.<(%P 0RA+RU*Y#X/G_/E
M<6AM&S:7;39YS^9FX\E-!=HGL(AW-J"T?*Z"Z0Y/P8YUA[T65H1\![D(.G[X
M-',1-/5/ ;4Q%6P*9[@V"U-03\R%;4+=>@/0FK&O(69]KSS8\3Y!K[;-;[.V
M3Q E"<,PDRDM"K."51H(RGV[.X_)<AKXT\#G)!1#2 R6UC\/K#\U]-Y!."!'
MTB*213QM@F$'H'R'T^\]M=K<M;8'^J2FX8=>9[2XV_^@=9AD0""9JM-SRG+J
M[1T$%X+N@?%2:$73<-EPHO[KM&8. =.>^2G])#&><Q^%%$?S#-&R?W>'WD%1
MZ3AIS_.H7>SL,!Y)\BR-77X.4ANMVV3CSEM51@YC(LL"1-FGB@:2&V7CT&20
M1O&1O-]N5)4N9+1*]:'2N7ZGV973+-X)=;>=V?7]X".J!"$OOPJ'D$8VWLG&
M=,G!+RLJ<B(;6;CRY'"DH/3Q*+ &HT:<:A?F6S#F7^^6$:'Y!#4J9[#H!W8Q
M=T=WG5V,CX25G6RU]9.ZSV%;'N=L&#"L<-1MZVWEY3I@L6'%KNS>J3$46$>+
MYXYA(*YVNCQ792U7V&UJ3S7#YM@2!A:)AYX(/B2_QSWRL('5 ;?>W_?V/AER
MEN;$L'46,EZ<+XT*_&:2E@FY!7M+'03T"_Z-;>BKER#\X1?33,=';[I8M.3T
MFJ!:+MT8S.KB(XL[<ZLV+%UXQ0-\MSR88@7 WLG+?2^&&4'3(8#W3^<6/-VD
MT#OO0!D15"_1 1D$DU76S8<*%*K I L_6@G<X#5F#4+#(PXK%N-B'9_L>YOW
M_B-X;$\%8T/)H'WORX)GZE/!Z=^LNL-'$G3"BL@L%*_3LY>"X 1W1-$DE>U?
M3XZ.1C!+7V>7OJX_NK<I(GN4"5&EZ-;24'N1G0K>:-USHUZA"[JG7?R_.1C#
MR5'G80S'Q[NFA3=4PV3 $>0AQU@5A9BY2GV1I;-H$LGPLSX(*?\HDCO_3B9>
M\78X H>87^8L&7/)JMY$4YR@B00^*R5>)06Y$U@GL)@A#!?6GG*RK/(IAL(*
M'D\,F+['G*H[MZ#WFZVG#F#-TQR;W=Y3/5C"D=M%%@4,U-9UIKD?8RQ.@V4)
M!V?@LCKZ9GZAN&]-G_A,3,L<01'FHVF4P>.MQA1TC$0P,[[N,.\GX=_^\N+U
MCXBDHQWGQ-SZO)@;KF75[G&[IJI>=6ZKI8R],<2GPT:H*=JR+^_U'&^H !EI
M2+!)Q95MPT((5JK;/DM/P>:Y<R ;LOVNALU.,!P-'EPV(D$CE$F1!A_-GZIA
MKP.DQ6!ZZ^([_=^BI+1JYIA&O;9%QAX)<<AZ.Q1S[J/+[[G2,E$_V43S%?$I
M]Y9;8\7L^NY9MWV4&>S]!&_E1P3 ,96B#ORKZO/$_H3JF!6*$'Z?2$A_S^?T
M$5$3@F93R$N14^$E)GU6$5P_24I)NB.27$,Q31WH7X_9JZ-"5HYI<64XGCT1
M%Q.5BS21L"N)^28&E].C?9"C)4EI3,V29644/(KB.O3\"EL85JWFXEYP[W'K
M](,O*&O5YZ6./CTF"-"(HNSS%&TX0[8RUF89'Q\CIE HHEQ::B 1\Y3VGXXN
MHN;66/I*3*O7L]NL:>"\+62EH FVU\%39<.NB4!,I8R&MR!^5PNO7%.A,??<
MPA&MS_EYFHC"STS"V3WN7;3/2KE*OU?Z,9ZNE 7)<ELQ@BP7U4Z^F%WB\'&M
M;T_7:POI4]MIWBY8F%Z2[$8C[\\49A.#C04!M*D 5]RANQ]+P+J4G'SF9Q+M
MGB%G3"FH 4LZC= ;C:D_"\8G<S:G8ZNOMW7Z6KB1?J].NX]):!QM9[5B3WH]
M39O,DKU[M(%OG\L:I^ &L'(R%H6@B@0D@4KCD/9B*;L$68[CW ]F\#,L1,$Z
MC 47!=X+N']LJ*8L;!ALX@A-UH4JE-!P(T.U[M0O8=9VTC!.GT:JTC 3]0</
M>^Y_1$/BWH<9P"=.^0W4:6@]H_).:\=(YK2?FPR<8YF@%_S%VA-M>==M>&0U
MQ@ HRI>K5BCT%W4OM<G)' ZRU:9 #NVPYO3"QR=I<F#"?>J.N.R2_"%>#C68
M)GEQW/GD19?;!SF\'D;)D%8Y8,U%)!TPG#M28MJUT?1NO@?&\0$F )S0'5H"
MMN,_DFZZC!1,23%[?SUYJ:("Y-IKKC<I":N"(*6-T#8*$3"R>&81[KK"W*TU
MN,ZJ3E?2'6NL2=+@I_LU:@)^RSJ"U0)92!QBQWCO%3F!T=P$*8E/+B 6$H89
M<[6+;I$KV[-;W.&2CIB?MRG6\.U.80V;BUC.&T!R+FW")&*7S9@(M;TFEO(X
MIL"JG'IF%&(BCY4OF55Z6L:Q1_U]^!>$SJOK.J'OGS:!^UJ?B/(DF0\D+8G>
M-K;#J?E N.^#^0473_.Y19MFY?FZMFJUAG)-X:T)J+ICYAE2Q$Q3V7JB\EB8
MJS4]R9B'TFX'SBJ&D/TC=F1D/@5C?RI,"'K#7["4D K".$&*7=$G2-,?BJF/
M''UX>'+R+!>RMIS#CDS=0$>UY%:I'WU-"1L.%6\J"V-E">FCZIBM8*?#$LA,
M'[+!A[@3H=D&9IY3RQY5[]GR#B.7#A!%@UK,V,P9>N_Z-1L7PU=RTD3#YNJG
M:FKI9\FKRU78<V3UMH[06BI)JB06DES.QXV.LZD7/T@7DG"R07LHP">>.7*G
MH>A72J2YR?U"\]NON1F>/94;CG3%2H ^F$N/HBA/?="S(9> $.E7&NI@CB17
M3J=?;DMTIW3BS6[!Y,\,&0%RS!$?AFS=3G5%.U%)L5LJI+F2XG/WP -YM@D+
M:V@M%;%BE:JPD3Z*LT0H[X9+A3A46F@JX$"79YOF<=1'9$,;.MT]TZ([<DD>
M]<<JN$BT,-;GB[20/1=P\,@+(R^CW3^231DE"8B/&<I[ 1OE3D-D?%!RA6:Y
MP'X&5'_G/Y %L&JB:&M*]Q,AZ%64!>4<LP@!5B!R(WE2MGL;FC'[Q&H#TT+T
M>31LY-K()3.5JEW4?U'9FYFLAHY.+0T G]%I4,U0+P5WQVOKWW2XMEXRI*,;
M5V\5Q=PE7G5@L.EB\93R9B)N4B;<HEY=2*)'(!J[&7SZD#C,_57>5_K2\.NH
MIZWZE*K3(/GYC;YBK:)7REHKR2:M_3AE7;3T.E+$?G/*VTCUE9<YXC8(?1C@
M V+6)"/;3QHY%MX(TT"I^C>\[U1$F$-";9*D"0Q=//BZ.8#]5#0Y-V[B;-HW
M?W45S#7E1A$;/=RBAHE]]FO.YK=@8+_=+25,?<JE24UMIK=K4=O-7=MM0[M_
ML=U49/3LUNMKFJX_U?R EUDSDB%3HC,E)YW/E&RDH[:DDN"$F1*DHG*ZY'R\
M\.$2T)'13$&B6X88-5Z5K"\O-2TAX&=YG92H;U(LQL)QX5:D'T>2-LF..8U4
MY'<]94L;Y4MS%W*GYS6O@BZG3I )L9P3P8IT-3<]9VD[[<S)>GRT6T?KK?])
M[$1\BFYGZ;)-MD4W(U0_<QK"*_Q/OH231&F(T@SO1KA[&3NAHH?_]),2'"S^
M*??'>$T&K86C,&5CIC,+EZPQJE]V_T +A$SR\#%$!D^9^(Y2&30V+EAD8N'C
M9WLX:S[1@<A4H/R&BUC0CP&E.(UBO+;P/W+M"?>MIB)N*Z1'S:O0:<GWC1<)
MWV?I O0GN#\-P%O<&R"6H/'!85E-3O+#)TN;4=YM^.10Y*G< EW-O[5O3MV)
MLU+Q"*_$#!K]8M>9UQ/XJ!!H)?S9VPW9O"/']NR0+JY/LV-()"QY;53O+UV5
M12XMO-8,(S 2]VO6>-]:)KE_B6E 159,;]LU&U,2P]$A3UK'UZ4L^#29]UJ*
M@D;*4"[V6ZA90,[=KKV[%%35U,<-X% K6L]7S6D85NCY(4@ <?P'0592 ^"5
M3B:_C,=7QB:"A\$41?F,'VGR;E.I>WFJ,S'EK@O*!OHY2N"65%]?P .9/+J_
MV_()FI*%NZ7-I,EN4$.9S"6.Q2\1-RK#D+P,*F 7EO%2-2>"(PW^H,LQ3L@L
MT3:A"2*0'E:8[4920O"">Y%5-U;MQHYHF]GOHAY4T;QY:@;D/D9M*WF4M[3/
M<N;0G IYG@81310H4B32HWP*_H7;_*,0"_PDLWO$5?I<7ES?>&!98)@$%_"/
M@Q.ZP?'1V[>LT1,$866<QU%E9G,N'+ 4<5ZH3FUQ&K!.4L"IO+DCRA/IVMYV
MVX1KSE78GHZMO@D*(*D1J2,@>8=/B,W6UAG(\R%S#O#Z9K&'WD4BE32YTDB#
MN7>Z#]K91T ?#%N!$ZCXU6A. EVT%P91;NS/,HOR,)(=:;BJ-EG9[6$J^%1
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MW"61Z^KD:G<Z^[YFJYZ^>FTKR?UUHD]LVD(F,"6''_5*I#;M&^D-I)"XMPX
MH?":-C3*&>3;5R_W9DX4LS;*;L*IR,[&P7,_G]6K)":/7-&RC4EU:]K1FCS
M*BR=J-/3K8U..TY7/P!-Z<HCJ9Q=KXZ<LTMF#_3,,X\RC=Z>-03$7,M%N5*
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M6)$57A*LJ2-3L[L !@Z5@_:7_  VU=2*G\>+:VCO!;^]2A?7</ [6^T&EL_
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M\==^G; D\3/TQ$V9W<$H3.B9*UZ0--OTW3"P%"Y>XW, 7@4H@;@1A;=RM^2
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M3K=QE3S)R_(:1J0T^/H.>.<XX])<CP$-QLDIFJS8X3UE/M=@,U!NL<06(<%
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M86<A#6%DF:GPMW%Q#14L3'7UQFWC9L,(+8B+8OKN%;<PYG$9#"QNBR FQW$
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M['"V8=<NSH*I*LKI@T4-N!9DQMVW2\51';.?C^N8O0*F<JZ1^!VRY_OOS0Q
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MW&!\R0J) *RI3Y; %93F$7I7Z]!]86X_NB5OEK24$,<^L8-C#@-O@/50=HL
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M&OAU<^8&G@<&M1[<2.4C7*H+99H*<?2D/PH\V\-T]JS.!E\Y($^;(?MF0".
MXS!-@=S&RVILQ>16*=)B4?AO2:'S#%XZC]?<'P ((P'H[283W@XJ_CJUU^IC
M@IOFU@S4,?H=S)WD%E?FE_2#P8V'0GYXTW0N"E=6?-/A2?4NYOC8ELY=!ESK
ML :036L>.+*1L/D3>=F1KQ(%5*U[#'T1<]B+W\+OCX'3NQDYL_ZQO%D['DI
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MT_.?__(O)W2EW==[Z!NW9W*WL6C8<'V]NWA.!RWV#&D3E9S'T.J=WD?C<H<
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MS[(3=M%;NIO]%3SC O:/N^&%UD?A7@K(9[P'K1[;TC,<=J;I0>^8.^<GU9[
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M-4HQG#-^6Y0C3K['#89.R,'[%#0S[V&B#L$.VDF(+]S'&(] (0X8"$ (N=<
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M'J /P2X$(J,Q(1L$+Z)M1UB?%O>S$>)LY65QB2QW3C$G2#8=3]QQ:2L<'V7
M';-^$XV(W#8 LK ;[S7#E459/,&.62(%I@\WKK1"S'O-1S@[Z':R;HP"^$O
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M#-WWSL]/L;N0_:%NB6A:&$^ES1^QG:A^?@84(-\>##ID,*1E,\5X,1_LX(.
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MG_ Q!ML6!!C^$QO##A71N4BJ7K>W&[KL(L':SU[W[-G3!UL)CO\.$K&ASN$
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M^#J$_W)70O@]&72.J6-'/SOD_W&ZB6WK^W4ZMS?+KL8OU;3^58U>BDI3=P#
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M6&IC2J54\$PA,Q)6FACJ\3YSF1OA/?^NTJDB#3;_*@YM\+>\DW *P#_ B<3
MGOK8SHQDBJI(3Q6%;FCF[7-U)C,HI<WNDKA%<C"'5K3HV[\FVZ2<DN'25P4W
MT #TR-3]<MR'I]XFG"82Z@4GL4432.GL.L1ZB[ -\WBM11][XUAE1\RE9A>W
M@[T@V"JLP&$-!QL!&)A?J^+GL!FSF7AH2(XB6HM!<]8^M%S2/*+:W;EXFYR1
M!',ZCSGENL@*+M]E13S)B(FA09<D_"JH[PX%&CN)\'>XMB''@568V3FPL7#7
MD#=CR$OK!DFBV,F1!E(%67%!:#1U"_O5ZN:(&U%*WV9AB[%Z13Y@'1ZG]W#
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MO7%,ZC$D@^QC8BK.]-"R^?0+=)"4-[$!1)/&LH>I9IH6$WIRWI&@5Y#M6Y,
MW[$.GY+HZMQEB1J@V=M6/AU7/-+RCG@0M9+F>MW5.M#(VBS/8Y7#Y C)# MN
M&3DRC2DN\EG +')OAZB/4@QPP&IX;_WCTV/_Y/3-J*L%&%T%DMQ.&PPJ?!MV
MH)7U?$RSH@"#=A6N;Y5X/PS(7)U0L1UJ$*DCO=;4JM5XSU*DW7P'[4._UG7B
M=S^N#$;OH$:_7HWFF_3FH#9;D);SL^N+&^^L2_T/W/:6I8FBNB??.XM"W[O6
M8'--R#6], 6%-US8AS#[A;?SR][UGG=Z_';D[13I+9=P<GL 2)N:Z23DZ@^J
M32+?BE'*L*>KI'K#K(P%/BNSK6($$ -&WRU7G=IHZ,@"%]J6-0<0O7Y'*B>P
M-QS$O 4Q5_F46D@Q-\L5.UWSN]; ]*-TUOROBYS1AL+-6+6=]9O^ MN [OB?
M6-T;!=N<4FV^?$JC_'!8P?EV]<7-X_9MNHV.[EK';%"P+2C86$6S+BG3I:>R
M<20X^;X79!%H("RL!8FA*F<<L._%ZCXOL7. ^P>I*I>Q-#53URG+QTHI4(S-
M8F/"GV4B7X0:QA[ZU8U3[(4D>,3;+-(+AH0U5X'5&[$'N(C26 :'1;^W%1*L
M?3:S[S&)2QGR@[$T<DG5X?.2>+O-Q."'V.@@TXT,=BWV;E+'15Z.YZE.%+=1
M+A +\[96NTJEZEK8%<<:ZXOH\Y\1+Y*(#C"IRR WB$5BVF2":!'%U4!@K"&6
M/#%' 7:Z_5DB("5^XSP7OZ@7/]MJI^K6X$3 "Y+&3TUD-]67,, 9%[Q%"?^[
M^HY*X (JALNB!9R8@TYH0R<X//%H@75)/ZP86^@E!&@F4MH,_X$"MU Q.0U.
M=P4W#E'UN--91("XL#6*7>+$9$EGAV.J.8R "%(5 +K=AHS+:CYF6&JD^* B
M0B*!K# T(AIZ Q9HM*XJ"<?CL'VOH3/'4ODAD+%-(&-%D"6$86US%]90Y$J4
M:C#5P1U+1YBI";Q@:O-!U/TZ./TJ)(J@OBPT<\4A_RIH38M32IYFDU]N7'+E
MZ%(7<,)IJD@S?NI]9,"A0TWE&CGW\4LIO)MM-$5RC%'-E^'Q4\?@EZ+4Y\U:
M1K_MK"DG^F^:L7O;33-VD=)]!Y7\5\*4X0(DE+AA(_6SG[H[:*F;E(R+:8SB
M:BB<0(#QJL&P:=FPZ20'S*9H$G@#1H.YX]ZLCDV0]$N%^.)=/,R1LRQW"&32
M$LTAVVU'-9UED1?P#_J;GE"G$X\X8"IK.8AQ"V*<AAVBMF*9E"ZF:ZSU+P7^
M#D3GX-W;-X.(M"$B<<S$*MY/L*** 3(Z2-'(4(9VL.-JL,KM":V0HF(U3FT/
M?N.B+,,.$_K3XDO1]8B)B$$59K6B/P@,D+Y+X9&)P/8/==95G?6[H<[Z^Q;Q
MMZLQGNAV<)A+$7FT;55QN$E5) 6R%'FT,YA#CBVD- .+!0$OP)C)N.73 '%)
M:208X]&<*)68!GNFBJ(1HT&;'6>_P[YE;G!I7'64LV[!RVZS-,]WL<G+I=K#
M:+3"EA=[G8.V84F)\A=8T-L+*5_E'&C+_%\CXQ2SJ/,E&'KX?(Z(OQEC_!+I
ME*(((45#FN&50;;:D*UD$N$*(4%@T3XA]JIX^8ZI%2]]MT8!9"S0&8H4:"_2
MBZKBIF:\ZG^4\9(O/_6]P_W#0Y]E#T10%_<8]&N0*M%WE/9M1B"W>MY9>0O2
MQS\X/'[N(Y')27O=%A@X)Q+OBU8SK\NR,QQ4[2B3O!NOOVY]Y;1!U1SM&,H9
MNR2!/J*4&#0@0AP#18,6EB^E=))<YO1[$"OS!US(#(\,<J(?YE%FT<D$(?A!
MS^:/NVB#-/X;I9',[FZ)HWMB:&1!&*=8JC%+L^*6$/'(#C<4OL0S /)7"E<P
MO?$RTU3;P?4?LZC@+VGJA;KC2A(GK( XE,8%L:)9W98^L[Z -=VH.@7QA*.$
M"T3JV2E3_&#0K"@FH>)!T-L0]/D2P:>\FW12W(-)T2V)-Z,R(DV^@"6>QGA8
M;DR>">P-<P.X2#Y-YYB;!0\YL%_:>^[HO=L]W_L8)>7#R.4Y$0BK#W#'ZNH/
M*?)O&1V-WW_&>]_0O;U+1)>0:B'E O=)TDR@XKCRP8'&GG@E[HA9&D838;;W
M:W.4J\@_=R93C8MNS_O2?H:,*MD<7[>)&*1<8HZ*(Z/D_"1+9WYS-<F!W_@H
M']L@+.EVR*1#JZ\DLC\,,"B.%4]^1<1M7R2F\1$A(PN]N<J*I6U'%@0-G/6,
M-!*/F5'7&&WGW+ T:_M@*G,92Y+<O:W"M+LM>I/(!Z<I\Z?EBV&L:HB)!A):
M?I*OO"YXF3KFD3YQ#89F,/=4,+]!5<?3J+FP#V5J[Y\__699#WX6F,XK+B3[
MR _T=GZ^^DB K1^I'_OO?SL^_?%C-,XP8 1?>3L?\0+NS[XI$VHG0AZ=I1%H
M>Z.;\YN/([^B2H>++PT(T,JUEW#MH,9;4.,"HML=[7US=GVS>Y[^OGN(4FC&
MY]N2%[T0?FV&RRX+B28*("_;SYSSP$Q'GJ<!LU(9;."\@A0VVXMAB,N"PO,O
ML'VE/W)HRHXZ%&E$H?MG"1X89O[A))!US*<Z+LBF15;I0/OF5^;[0M$9,DUG
MU7<DC#%I=(Z6^UX^I?*">ZQI9BX^Q'-G\!/$6%,3C37!"Q40Y;U#V$5PP"$8
M!P&;#[<E"#C.1OJQB-I33(]ZDY?4A:VO>\8?PWSS:/?6_=Y-_KGH]M3,1DF&
MG$[B][*=R!-*8]JW5\S3PYE%N/Z/-(M#[Q?FY/[LW-B>%I^#H)S31_#H&UH#
M^DY^<^848/-P7#<A(IS;1'!!R3;A FL$YT//G,HR1.*&W?[7[_;WJE#PA+2M
M?HHUN]R)@?X*=KTNS-<:P\!9FH"-%.*P,Q@VVE4A"OPT-1!%.*4\>I%E^">M
MBQ,,X4EQLJVRUPX0>GOC?2*A@'6/*XY!'1^7M2]^3MU?.17DP6\88A/4XB4W
MA5C7KP+3!6?189&A!I& FUX8U1I[=(S76 >.;V*8KGL8FV(K"/,;2NOX2_1<
M!6\'BY1-<R>[)3:[0H-K).BLPU*!/G,)LQ12#74HI@[EW?Y+J4-I2<F9L")1
M[U"I?FU#LNSP/EVW+[A"WF$%Q*[\:IM<R38$L\W!N'5Z/]$D,_'CW.;MUO4$
M^(9!#2FGIM1V9R@XP<X*TRSWI8F'&1J$F1>U$"PP&*1X@2WZP'!'0A_90*W
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MT2IE2[,UL.)6SXLFW,B]R@3P2'E?L&]]]XKZU@EE8U#6?[VL_0I+%D2(WX0
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M4X_BF'HM5,QMK_#FP0-GYI>GE'GCU3<[Q7JU#!33>-Z,C_MIC?V4II*DN<;
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ME05X+95 5XB_DRVX$WMK<_P$SO.^3M=J= .-A_24&Y5YKVG%9,K10@6XI0E
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MM,ANKC7],9DR1:Y!Z+PH>UFYY.*BM:1:P4<<T2TX];C@9@K*'L4TFCX'1>=
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M\!$ 'G"?8 ,JD/8DQ$*VIS=U (ZILLC%>PA2' _1&$HAY$0#E;T_^A[TQ31
M.8J"A:YHM%1%*FZQC%0I;1>0WUP?TKBH^0IDOXN@EB!R6,T11';IWB:,],%V
M;.;%,U/M G_;RCQ87<ME;&C2BY%,#09\))KA\TP*C5@Q;6SJY6SX1QKEUCR"
M315SG3&N6=8<I(PVIT<7@"EC F*P/Q/ &R %L17P, 0^CWR&:-OE>_8N'0#2
M!H H,J8B81D0_42YE!(+ &DDC8FCG"Q$PDW_SP3BF& >ZD@U[VHWQ."-V,'6
M$;3U9LP5+S0K9.4&CT*^"E+I(0.U4M]'V3417!M7P<CV;LX+9,2C1(/P7R=]
M5AJUHH5?D!=DA' _(!?SAYY X,4!B$50YKZ=]_8%3333=CW0OG%J!>@M_$18
M.\>ZI$P@9I2))S!SAW=9MZ^SV5XRJA/EV )A9<<)&!:%LAH0RJ@"*[2M<[K5
MFXUUK7CD\U@P[;*4?!I=FM<%VPW(\JF;H9RP\7;+Z@5G2NL\GH9D6!!V[XLD
M 'C"[RTA[9YV&VVW1?6P0&[ LRGN(^;=C:4^YS!7#]HBIK4M:$D >I_>9PRU
M"PB&T;$_>&#'.BN]]I:>7&2'+SR^T!7&N);:%'N0.V'W\PB,SUK6M9(^8P&(
M)V,;K4.K8&CWTH-,RZX9-+H]>[#=!"NJ*3%N+]UY#%5 &RI) X\DL@7F,?5=
M'F(RII%V^R2F/'#W9!@ND-/2(L(]W)]:] R=42SDE+$%]NSY0Q8DP'7GVX2S
MRZL6BNP!&)B0L3N8 0A8\(I XEKSD+N*N!Y"PEZT-7FZUN^ARU(!L*W5TF3H
M-J!0,SJ!3MRPD7;C+GMA\%8;/-MZ;^S<S:=F\[I$3N%A+@3D^KC,8\CQ$A5+
M]#Q8^BK,71:QKW(U!^M+4U?T2$!+T7/:O#(KN"VM^@1T\GL2,5+;=]L#I2Q>
M>:$)@O=H@O!XC(\U2#NQG#J:#"?-K=IF5IC0"V21Q;FK^GVZ1#17M8KJ<ZU5
MX$JUN?:!)"!NG2WA2ZM5;#XGE=/R13.*V#UI9X:T9HF^4(U(\R-P'B/T%?F$
M8<9@'[?*8%;'7U?.7SQE"2[;UI8:B@GKQS>>NTP!NS]_A'I:BL2L/N)4<'+L
MJ9,5(3:V+5Z'*GMK3 >LZ"E&[XHTA!"H0<6$3O7._W5T] OO?"G\77MF_'T)
M?&#/%C"9;/6PT2M9P[5S[[/89%P-\MJ=ZICYD(?X=E\G(VI@90C^=1+'PH9#
M60%OD7T*F\K/BHTHCS"7@)9HD/(^#!DFD,8#T_LN"V1AR'SC-IH>G#ARV3^X
MAX$<,Y76#[&?3KP_X*%L#I@QZ<V5\*5#12L32$]%*9;5.%-?M&9*\+JTN(QA
MI P+63JR<-?"/KL/VIM(%5C9-(=EII!+C6)(D=Q\<7JS%^O-<:BMQ$73V3/S
M?;K"PG$#^!"D!_?AUT@:K$/Z3!F[L";=4'99-QY6 #!;R;#^,R60F 4H<$0-
M.NY=UP\2LVC-63#HAYDZ=IEPC2B*P:-KP$Y6:]N;KUZ LEI/CV7F1_:L-Z[1
MAL3W02?X,)=CIE:[28Y[F7\CXW\\C[1+I+&FY(Z9V!TE;;>4"GBMVFO=7M_9
MZZ&]?K#XP6Z/':+!\@./LG-BED560A9<X;G!68NV8*' --/5".='QX-VQ(:M
MU_A?H=Y1 J$KR(?_1P%_OA[MYQ_"V[0+]:%RA&511SW7$ IJ<FIW)Z&IMGES
M\B<%N'DYVE+[MB#[Z[^O5=]Y#H%Y3KXX=-XEM^?];J?7(_8 V=6IBX5L!)">
M_,,STSZU]6]':8NQA(=^D_F)26.C@ F K9J=CK89,5?:V#/3L_.%U(-HZ(MV
MC]JJUA]ZKNJ[ZM;TU?G/U05^P^JLT[SHGQ7(>;=56ILYSI'W4/+\G#Y#P3].
M[=&)3=;Z.9_)V-LW]<,C;:_@^_&K*X+Z=X)-M^G&/B__/$M(="%\M8!85NOF
MO8H\3Z:/W_MULR&D->0L)!W+5;@#=!5"0C'?,_YV"EI?.7H63#8C,OQZW<9R
MS'.FMU>*>Z6X5XK[FU+<9?-3Y^*BV5V-UIYD.H\/DV?4/']&;#.EN']'VLD=
MV^).VTMCQ"6UO@!&O%8,OSR2?CNT]5J#^:X:3-G]Z1S[1WQ._@=02P,$%
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M.;0O/ IN&#?@\8;XD;$"P@4#!'FLI!U1#Q++,'-3]J9G(6VBM"VQ'^5THU4
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M@ET/],8BM[%EEN%6]C?PSE0E;N/1Z8[)^(M] ]IWT.[?GO,5,I348#*K(X+
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M5,>RYOO]%6[W:^LXA\@AO,YQ+T# Q8TD#,(<>/&*S(R4"FK0K2H!XM=W9&D
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M?OGA#R^1NT[*B"]%+>N?> M=3ELI84J /NIH_@S+*]I:<>HY4C:L?1'WOE
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M^;!-3KSETP\_SE7<'[?G75QLM:1YO[-]/F4QD>_$LKQX-13 M-@7)?=HQ!%
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MW9:MKI#;0MOY.2A$9T!L;G(YQ90+5P]5&^P^N1]/Q@=SGHZV.<V_,FO*XX&
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MGUY:]D^G"%$BS9 ]@26,S+'ZA&"#MGC67D^=RXG:R,E&3E8M)^KJ<J*6U_(
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M<-(1(&]WJM_4J^9.E7,>A0GH_-QQ$5>%:U(:AV9 X*RY[02!W1E6WV( \R9
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MS7. A0BT^WC^E$R]_^>2-O4P\>WV^Q]VWQNG!R?'I^?&R8?3LP^[_7/C_-@
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MV[C"3=[F",0LP^5:%V"OBZH2NJ4//A7;8<!Y99/VU0V"*S3%/X:X^OSV]=:
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MNY<I' $.*9T\O;G&LXSU0]@!#!M&IW)T7#7:UI,2\/._Q[(46UN$ [EG]%W
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MC7%PHPZ[>41Q(=X&T[9PZ]6HBBKFR9G"*2;.;3+EMK#FC+X.;0Y-3% @331
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M#]-=4\B'3TSS:RR]S))979U)O%OZA$H'EY&6+HVT>-]0'XLA1[\>[L\@KM0
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M\C)4,H@11ON23B@!C#&7<(;1[<&+@0/_>$U,P6<8YP7B^:9R>0APL5VQO6!
MEQ0IQ8S";L>OW S0R]I1F QN_$)AM+1)<N YH]7@R;6!M) =FJ?UPF6[#;O*
M#1- G1C9<%3 &2TGF*VF7(="*-_]Z\WKO<,7H(YA)1?X!;SX^P%1O?IY!Z/+
M?[0]>NHCG@$<)'H:MK%:Z 70=,LE L=V5_257]%@O#?SBN[2):7[&"%036%S
M0(TB:D9M<S3#X"^G/4M,3WSM@U<I1HP1Q@!_K1WBRYU<QDUKM/NL2HO=#E^#
MGBXPR?K)K03?Y0^=N39;ERX(WBD-G<ENCMV\M*4;6RPT\KO]IT<>+^#*1I/_
M:'V?Y06&02>8A74>+A.I@\H7>JF;1U\:#^F=G;1<AZ-7NPER[F0;X3VSJLK.
M/#7&&6<G2K#::W_>^4J ?:30FTI<CF#N&4%&".4(@C-)41AF7EW@JQ%CD^:U
MP 0P,\<OF*5B99BK93COMI.3JT]'E4Y0.&,.P@E@+F1 =L&XZSFO[C,(/I53
M90GB'$'?(^Q-#+-EVK31.<4;>C+/'4?HC'<567*[K;OBK</;50-H8U![BRB>
M@1'OF4 +89<F<-;@(: O&1)(EW9>_KO+$7**,;#3W)W!/](NRSGJQ9$V><A.
M(U[U=K:KI4#(P-S!$(6Y.;OEM(;GBDV41R&O &2=Y\M&0/L#4?:,&;MP9]&Q
MQI.*50-##Z$2UZ2%28_"<XK\$]Z<<L>><OU"XV1,:IFM&V.[*/MUFNI9)0@A
M+*[K(KL;$RQ1F%0*M1CF,TF7%'S'3U7DR6&-".F& ;V/6QU@"J!?_F!LI<C?
MYIS+V2YH<WTB<4Q8+\ZB$*@G+=67(IQY1]4ZN&&G6'G ]<Y4A=[ ]A"'7UTC
M)I8-:0*^JP2-8IB">OW!&/#A.06$X4>,"8XF^LXENP:M@"897N0+ B=PJ4+3
M+99:JL&E$7A!@)PLL'J!"M,HZ,+?;A%ZT@H>H@E!= WL,!)"0_<L&9++TZ0-
M8LLD#:<;O^[-[Y3#C63B2;&+E;!(\S) (LHYE8[P25]V;2@Q&=?"P%;-RIRM
MS+7 S(8;0((SNSV^^CT^\>6,D@UK>T 96#I8R5JU-4?K0^6"!- D08.YUF[G
M"%RU(X#8;((GE W7'KM63A@GKGFKZ%:E,Z<7KCV]&(G]O&3OD$!L>*$[Y8WD
M2!KOO'48Q'@<> I'>\V3+A&%W1WT:\O$.#3:3&;4Q /$KQ^ODI.W'TS59 @'
MH"&?KM0Y.$- <N'&174&GYH4:;[8'?TKW<,?/D\*.%&G>);I^L3/$V [KRGO
M->T:+!HITDZB<UJ/8J,!^$VE'P\@"4F]S?-Q3O7!!(R1K^"9)=->T9 L&)BI
MRQ'FM):@+:WV80-O)QE7:JH%GRTOIQRHP7(@+ AN$.@FV?02S'I72T0&MUSN
M<_6ZS#TN"GV6H\L>.VX;3;?='E]]0-=H[&6=GZ83W@^PX%+<IE9*6(OT;*>-
MKW0_7N.*8R($K:!)5=<=.<Q)QD&U*4/6Z*^NKJO:AV6;5=.Z!?U!'&2LJY.O
M-TB)@)^B#>6B63ZJ@["7GM,5!VE)9[O/<$VC8@AQ&6LE]A4 ^]X[0_YZ+#)+
MF6,.=E7B(T Z)EV-"I>**3<'[IMTZF8=$G)17$:_):3QI"*(H**<$OLE^FTH
M73YN2_Z$S29@41BJ>B7)&7+O?4AF9\3?;&T$Y<9'_;C,M*K%22R0?J#C(#S<
MU.W*7!,C-N4:C;SU4T%L-2S 9F 63_@C<@O"$LQ4OJ3&H@%[KTAKX<PP47[C
M?,9/PC]N>IH.9P?/N6[YHEVIT\RA,R]H2OPQ*=.%!'(I&IBY?W>,PA9I0LBF
MR0,981IW.5PT^'T;#M3;4&/&Q.F#51^")8CB!SMYN!%Y^#C/X5)!PR$7=&:.
MFX>A>J8N-K@!Q&2Z&;-^IJWJ*?!&T'W$7V-. )7-6=ZXY#2O"@X&,27DL*(B
M![=AEH"J:R?BS;+]XG,!<97>UXA3[FA5+DBK\NQ6TJKLCO[7L4X[YE@5ZDDX
MDQA0ZL"N$ I*^&G:GC$KXD9:$W/_<QEGG!@DE $;OHS/](Q? 9^T4_+7;53*
MG2XD],%O$,9S;R2@LU$3R/9369WMS:LS$SA&-8Z@ >*EL41V^-0(M+O)#/1A
MZMW%?^VQ)H,3JJM"F!$W7]()(;Z(=%8N8[^IZD4BT1_'2Z;Z)>8H:5S\X:H6
MSB+Z3 &*HFP8"-RI3"P)5Q(BU>*P$"*ES/Z+(C+!V2#SPU2$[X3G2D%%L,]H
MQM<Y([XTFLS7"?'<F4M!MG<D(0E!CDQ#P:=\@ -B7/^O7$0MVJ=[:)^N(@D:
M[;+5MT06?G=4CHU+_49)<M$G2$$\X"12NF@,FTK67L@HC6SXT_Z:;Y8V\DL\
MLO2L]+%58F>EKQ%3FYH;0EL50J&JEU3>*B'SU6"N9+::T'F AI)AFE0T5S06
M$5\[%!9%]QF98L7&":;-,.9- FYKL5PS[MZ%J!J.43=]_WDGX]<DXU8AP?V4
M"6GNO)*@1@!.Q%;/$K8:#:3=1EV]I<NV['1EZ%?!-<5CXM8RV6>AHI#@$5*"
M"D81\1IRJ*/R#.#,V$CV$N'?+;$\T7=A?I89&GU%NRV<&?=L<#!6'*'LBY4T
M-V, Y2#C_$YVKB'[BB37><W&Z!(E01$1@K&HW1ZW?U#*;+R(O$6<?H8M+MT4
M<3:RY82;&0)0\.W"%9'2B^7SDCNCQ"S7NWV_XGVG#)?$M&N7+\9=C>X([BR:
M#B &C'XG]J+0N./C;\>ZK^RKD++ ;T1R(+2J5-&^<VNOIZPTSD]H03'U&X$]
MM4R+#&XWVT6;R. 7E %M#>>$&YR<6VZE\BINI5+5X=-="^[/_WK63M4/O[[[
MA:U9 5]ME*N=E%PMF,KOR(0;+/BM *N_:WIG7'-3DXDK''</JJ+B/&1Y_#RA
M4N:^-)TY+WW8U=0AZU!KY0Y+L[ SA(OP 3LQN";*R!1;.\O6N_;,N5)[LIQ[
M\9^Y6@CMM&49C )6'+^!_3>G4] !)"W6T?/UNM( A8A07,T$&O6"]$_);3-J
M[C(01D@N(MB/X<F1;[J3EJN6%L_6SGX M0C%5C,NI4HG.=9'!T=/DE^KECJW
MP*_J?#9CLL.-**\A0OA!2/UNCZ]<(X2^E O7SBNV WFW6\I;96[<*@@+0T*>
M703A]JYM"VXS U?+#A1]'2X;1]XRI?0D@ DYT8BJB\&0R!3C!EN]RJ8R6K,:
M%TIZP$\5\J'HSM_M[56GIVE/0CN.(;)[A%5:?B&/#SF?0ZY?..4<?\AL_FZ+
MKW*+N=NO!K9ILR7ZLKDK'"K5F#(*7#W* B'!!'>SH \E4R20\^RO?N<EK*-O
MW.WP%2MHCFF%."KW1%W6^<1Y9/$I0<6*P&4S+3!U1)U9<9LF#);>*=_K5+X?
M''6B/$[>UPX<E)J:&^#>83]VQ>TMZ6_.DV\C&ATV<J96D:))YPYA'E)IBK_4
M+Q)67?L$"1X CKG0:ZOS-=17=]=/X;JZ7_!AW;(5<N7J097Z&-Q1ZEBB+"/P
M!*H<-B&TM5;)34=.;[<D^D?O804J;F^%E^A@*9)DD[ 2W&"\2IJTX _3&TA<
M<32A&[&/PV^3N)W 7:4U@-A?RKXWC"DQ/;GA/Q2/(?7/_;I#,V^4CY 07^UA
M8=Q0!"<NA26JDUYNGZP%LBYKII/<[?A5WS+@1E?:TE/X8-!_X^8+6W:<FM+*
MM_A6L6T9Q*L+L3,?;3,"!K</''EO?T:U"6RUI-J\F02$>T*09Z_!8]]D-Z++
MT@1TSBB2T+:7?=3S HL[H;MJH=NJ2C*'AB81)='-TLJGO#(2HG-J>\^RPD7[
MU#&Z6\0)X=62KYI4D'*"?O4U%39VI*47+#6]3B.;J#\&Q=X@LH58-9FFIQ4'
ME/_HLIQ"C6&X6=XL,06Q$[WKP=R&%C/HC#*F=<5N*ZPYJH^L">W8K8$D,((*
M%8JC[;Q2JM4[T+>5=MR6VHXLU10E6P-+H=3M].OLD?NNZAHNP]U/_J?JP%*5
M@"&2;A [(CPNU[2@-$R%A_O:)-+\H#PF=3[6]JO@UE0S1XA&RMU0 IJ3!.L-
MZVEOMS8<MQWB\1F$6*);D[XQA!EB^&$EVJQV',WD5NBN:-P9_M*_VKP)_E F
M#D'\G']8\1VIG9=\J;L/@U-?V(LN#&T =^[68K()=_TN4!46Q#"):E$Q,"&.
M9X*W^\EQ((S>].903N9K($B-D^?0?S5VF4_R1< 3%TUEV77S!6X*AJ2T61"[
MN0-#>S.E0RW;':*8H=>N)(:SF#=ML#OP:(!<2:X2RBB;2@J[8N5Z'-1E,+22
MATVHE9'V,@X^GLEM1)X=&UH@"7H+54(?2Z@*ENV>G.PG9-<;@1R0M2#5_<_U
M%TZ7?43'L<U;;,H%1PAV--LKJNI3_)#]Y'U!@7OR"M4I;81! XTT2M9(_=./
M\IQ?Y#D?PF#VDI.T4\Z57])RUJ4SMR]54I=7CU_8_?OQTX-O;H<V7NL,3MKX
M-Q)QSGJCJAKL4WO[.X73$R_>;?8*.BQ?:$EVM:P7K&5]?BMK66^##47K@]=W
MX(/VXFIP<BBW0XQ_:&B1//.-+K=(=58.DD38]AX>\=JL2E?[0C(/GS(OMEF_
MGOF6F@CC!C, L1=\&X?6?QOZ_"6*"*7+?QQ#@C-W"L94E)PR+7#2ML5+Q7/U
M<#%M8YM-HD+T:[C$>!26G<!]!G>ZY_$RZPJ#<RD,V%=Z;#6SK,ZU;R2TV5GE
MG^*D,H;WPMN3O<Z785?TCD83 +R162C3 2?V^S^GMV(?Z>D%')/#YY=Q*8_1
M"MIT)(XN="1NUI&$(<2.Y.&C?5H! IO-D8ZAG#GEU="M1NA8X3Z#239+2\&@
M8J9&"E#@GU*W9&U*"DEDW#"5'D -5?'7\%C\:"AE&6%_$.R?W)A*8.[$(PWJ
M8=5>/-YL%>WV_4OVW?=-P^..E$Q5R0=8<8234.02^B2J<O&JCIP4VL#=AEWM
MAH$S%Q$DC2F7;?LN2*N$I90+!1W-O4QA9*439W6)].QPT+C*4%LQ,/@4]76*
M[<NYEPN2\O>N53FK1LO[B]8CUWM7[4XTKDLTP*3,%VH7P1*'S.>@@<'(EG)6
M108%UJVY&LP&T.5ZJY-N;YK^/1$Y(4'F=AM^71N.YF&!#;2J5G 02,0!OJ9M
M6)?6.84O@EFG;4Y'OL6I.=LA/M7KYC-=Q[]YQ8\_[3;\JV]X=%-3\0>:Z;B+
MU$?3'&J_??@'WQ#S3X8#;HT_J:WEJ)<5ND\6;H&.7]FP:\2LQ0OF>UAW]L9=
MZY%^UG?<YJULN_]"I5<E/BB>/^^*CKC,6\IR\;(V?ZF1O!4,;XJA:K?"$052
M#7&G1G\LCT7/>[8&P&AM.N?YOZ;&38/(B3S*#W&D[73;]!/V;P57H8[=;Q )
MG=I^\K:J'98TCVR_ 59!Z 8S<+KCTF8DOR7+9=-VG#/^_>2G'%?,-YFA_+UW
MJ2=NP_<\_R!8N8C6<772/V3*8M.+7,0.-3U6H8;2@'RMZ6BHWRQM>&+CR$QV
M-L3<#=M#B.\/,6OW$E4^\'\'E, EPJ0:9L+& E6-O>[4(K:3MTDQV2U;U(E7
M6TY'#&X<3.)7%/B1;D,;ZV1NW;J=&XPSJQ0R?1CQT9^V+ADGM](FY/LD97?"
MV:Y^@O'YWC_@@9@.H50E81]^.,$__STM.\Q['#T:86T3_"\^=EF[98IJ'847
M\Z2G;J\"53U.FUS\B1,,]Y:8$POPBF\EV2)_DQ3*=WJ ?*S-,SZ:1E6$MO!M
MK.!%\O90L4.D,K"'-;>7$D!7_.=Q57UJ-/=74^^KC-.=/"6UFR>^<TZTU"9%
MA3!&GL;F]/NE<T"W31*/)]A.&19%+ZI+']ZO*W<93./45F;;8Q*VFKM VSWR
M90,&?4%28(.Y6N1- > *V3AP^&PJ<Z$0FQJ!W,@W*HY9L_\?>^_:',EQ9 O^
ME;)[=6=)LP2&38JB*-I^@%JBV#M#D<:F1-M/:XFJ*"#969FE? "J^?4;?OP1
M'IE9!:";+35 ?)D1&U59D?'P\,?Q<SP&H8?1(KMDN7&S^Q25#?01KJ/RGP&;
M[3R^S"7SSE>OQWA2W&LOSS[N?BKO$UI$O*<MD;O%S1[?VK_3HM9#L02<(&R3
M=E>H6AN\O$MJG;TN-_0V^-\EG91F4T;/(UC"R8>E<1W;39^P<7!8,+3XY\/B
ML^%"T7_P*!DI-?8/FKX[QJ!^@=PV<L507@:U@U]JXJ3S(9=+SIU*E$W2AMY'
M6[16EEY.]ND9:+G"77,I1;N1S2+?CTOF@[-*#RR__LBICA4.P)$C@:"8"SE+
M;G5VK6W;#)Y#:SEVU&A(R"P!5WBWI+&]DO#J2VV][3%=U#NDLS^X];G3?TF.
M2EH7F@<F>URX.S+TQR_OM 3N.Q$D[GW65]M7FD#!6G0-4,:?600^J4..P;K'
MBB^9N,7@XH* SL@5_+4]7[W0_?LR[M-H;B\,Y8Q0I:PM?CK:PX.?XTK1P$X4
MLHZ,;\;[44R(=FCG?\%3JJ9^TEV'3@\)0:^#4!L9SU4*RQ50A9#S=&?\L0D]
M7V7.RJG&^GL<07^Z ?[KD2>@C8:K*@"H.< (4S)N?7W75"RT+#TC/'Y)A,>7
MQQ$>]X=7O?CR,T-7_;IP(3,T%V9UCN::I9)52?)11T'W]S<TO<FAR*17V7%+
M9?+8UHH,[S3&$,KUR7:6>).+%<LOE\G*->&JI:: [(F.3:9-?4T",<X'P[_!
MN4#*DD6#GQ3@Q=R55_$"N8)L,^>OCM&5/HG,RC<6-]$=<2M):LHI:2Y#U<H3
MJ,AF#)1P62)[LMQ#.X ,$HM^OOINOMZ8=3#]$%J)/UBL7K;MF_A_HJ]_6'W#
MZKQTL+YI^SWMR'[U&J -SLY236BS^O33\]_^G\DVPP!I30^AC#<4>JK^%)T7
MO,AG+^ *?;H09^@+TI;"-M+4#37[DKYC_%R\3ZZGL>PB.$OYS80DWCTZ:Y-*
M^QY!^GTG0$CY^.&+>SWZ<=3D*="PZ*MT;?0VV$.R8JC3*BFTB[1IFS,Z<K=E
MO7CZ!$$&B/3\AU.#83'+ V>";GR,WM(7^&#.T2LV'G"W2I:/[AC\ES+=\72%
MYBK>G$ R,+QA4_7KL>\MH9?-LA(V#ZB^]%I0R4DYLUZ\?'EU6?$-.G1"$QU=
MH+BFFGO\X>OO->^X"O\D#OD^"+N6/PP+C&U&$WT;E"E:N3S3H<ZT6(V]R\/<
MX9E2B2^>L[Q'58J[_13B^&T@K[S:J'3WOBX;&3*B)M?=BIP6NA7&/=Y?MS1G
M"^*\(GZ@_X\NV;AU)CK!S2K.D!X5[F2PD0'T'Z<&+0=R\>!(^N]0$NAVF7 '
M[-C6]S$A8M0?L?Q*0CUF)LMQ?V1(FMLXD_%=W62DUV<HI6HE^NGJVO'J.I6]
M;JSQG1-8W6:^R=R[TBI>]+9IM ?/H7AH#U&3*]2Y\>#-H8E'<CUK3U(Q5SD%
MZ:GQBV^HBX)BIJMJG;RO35A+.^M\L]*9[?V!Y,0:S&/0]A'@^^C+G'_G3Z0C
M5DS;51-R@%?(1BC7J!YF)DE4?T:R>YR$C,NAF;;;G" DC[_*U-QCOT*)LV*^
MDV/\%<(;KN/9"+(!9#]/OU)U<VJ]N)1?0_&\I,B83NSJNQB5TN5)%V>Q^N,W
M?Z&!>^2D''29\S]_\SH.Y8KWR3;;^+?7K>;S)/WPXM/S3__/Y&,VL?)1VC[K
M4-TP%R"6\W78#W*C?U+(P,H&S<R@!*2)',1"4 _"/ZL!Y_55W+0H:/LM$5^1
MTB-\&>M0*1%! AS4%(=42'HXV<!:&FCB<^A]+P\T+]H76VX(R82M2D=I2JS?
MB8M2];.QQ+>@,C6O17RB3045=!OMQ8Z[8E7NX]/^B3I0'%X,6XIXUZUVF)2D
M 2"(UVC=KJH&P M-"K$C%%_:_XJ^Y0Y-47R-3"\K.VZ\?66CGOB4G IADTWT
M5.)"X="28HE2C6'[!\$K:#%"^Y;6<=N!MT+G%(R3NWWMFX:C;QM?-YT99^I4
M(IKN1K2DL'R&#>J8W\\13)&QG7/ZY*-TIR48$WVWZG"N/B[R0-'ZU7B_Z:_@
M!! 9MDR$XD:0 A19U,PT\'CE$V0<67\N9?DIX2.S5ZX[^)A9T$HW.$'\^R1E
MY/2OI1,[3H6#8BTN6?PO"'%259_=,HQDZ\#_\]^RF;+4$R%BI%5(Y)ZIS'1F
M/^1']-@#L#\&=@INDZK"?6*NNT-L^ 6;L ^-9337R)#>QL]?2UE.MUJ*OK_S
M+M^=G25IP^>[0!B$03PHP?X5X6D:^E><Q@.Z^*_C3#":-Z%OU*E;L]):+T>U
M+M=O,!/T$FO;G(1UF!U$;M>EW!L-C:ZXV>U?R+T^QH 4OM)PC=&<H;%RW^['
M6GUP)#/)_< =0GP<EW757X>-8T:^>,D@FHLK.J)_C#_']NU/54]WU<9<5CB0
M.+M+J=QM[G)+IVG/82DO'W=^VI$'%>/YZC4W:%-UD9(;;1=.Q&;\8)K>R[)Y
M0]HOZQC\7P;]9WHPT)@NAH",)1!6K'3$)I:];>+Z#G$FXKN ;@9NYI5,(*\^
MF=VJ&:$(0;)ZN^"Z9-G_\"5#W(@GPD:%^KZC-69@ S2^W'YRI<;<WU!6G7*C
M_'QT]\CUQ%(_B#0^HC#^X\=NF2[B(40LH%DA<D?.R(5TERC.S8YU 52LATU*
M3C!T&9SW&_\+57A>=SPQ'GXP'9)Y,_Z!N+6S ZAWF-Q^LL?:Z,+$D[GIU^5>
M'/F6XMS0H=1  #K4Q0MORA)IC9R]J;.+M#99VFB4F+R&R^.S$, Y%)V])*@H
ME"BWH7LLB(12BH7E!Z(;3LWF_'1DF/;4/P3S463\.DS.[I_!GXYQ<)GE2J/+
ME&+IH^.K=KMH3]AI!,,8$AAK;O]GU*'^-%KCIS.$0WQRE?,79D2H(@RM6X/R
M@4.V6KM %J9G39GY"BR]VMT_[E[6-=''ZY$!3:R'I8SW+$>#?$;Z]9HT]WKG
M<=YO(/Z7%V<$\7])X/5UR4*@$("+2WW5FH$N^&/(F%?),8OQ,2-$.S%4*+T+
M!P_E!OJQ)VBQ9-"CU2IA_-@HSZQWNJ-7Y1A/OW)9)&()RA)7E '1=T =6;,8
M]WR+A3<HC%-";YX"I6R<HG1+O=\7U0O!5Q"XDFG! ]^ZJJB7K?0D*[-^X-[@
MS3"=!0QZ/@]&J#&QQ)GGYM,-RU+E! O#(8OW,.(L(BM,3HT;J?Z.(A./<K?/
M.=KOFA8]:1RJ9T8"+,3I!%9D>.!!<O@+TS%9-4$3I4R')%848^3N )=J"G%K
M\U9_3<5\K,CTN83?BS<KU0+&3M/R/H_Y=TK-4X%!P]WAL.?*RJH;$1F1?W:&
M8@32H^>KGZYI;9%F2A]6=C;ZX-G0\A<T;9DHV["H:XK3!^ 2.IE"Y.6];]7/
M9N<R:.()J>CFX)QA_"S:OGTNRB+-[#DZTC[&*_15QR=G_>^)ZT:Y3FB"K[IR
M?\UAKV0!^>:OQW#&4%8?!<B%_[<&41&82'IU*3DC$&[HO*3=^099V02(QWI'
MGR->HO%?PP[Y"E$O-/U= $8DF_!,/_%>G<M//_G5TT^\!:+O;8]*/'3QO%4;
MDN:A@Q*M%4?Z<JR])4Q^&(ZX9! 0TS/4C J@\=?T-,N82DXS3-@MRDVYQ]F+
M9KN[ N@<9T]2#_;U>$D,-,KLO$JD+Y5\,E*=V%:?_)+A&'X*+31:?V;GDG_C
MT:>*0'4Q6<95DXFMR)NF"L:M=ON$8IYZRUF[*!T0#JT$N<+_47!B)\P65B!K
M& IHT<0YM1BQ'0>BH%J)I67+*]QL;I?AIE&.,PSD/M89D0]@>YL.S5/QA9E=
M&;OT\B 47EI#PF[M2JN@?/WU:W]J"E3&+9H,S4W5M>P>LE>"3!>E$&Z87L"?
M/AR[7;N)P0&>0RM$=V?9:,LR>AWKS-GMVI*\+-:(QM*97K#PE)7&76!D$W&N
MHJ/4QY<J(8X9]H/O#UL>% U^3?[M&MSB7&W-C@XFE@N'T=5?^33K_18#&4R$
M7)JD2X-S9!G<)*%,';WUUB%%O$6N+D$1;'/>3BH$Y8J4 Q/&PY]_YL='2FR3
MT"2AP@.-[>94>C_+SQ^!5>9Y MUW*0L[]Q)=564S0<SS2U233HY4^19[S@VR
M&[7Q###SSB>R@I>!@:BF(,V9*4VJ\SM=\7]D3^2.!#C +WV2!1N??VQ6A4Y\
M/4=G=#X3.@/3TN*#9BT?NDV5%CTM=-?]N:FB^:$*#Y>.J@Z8)7BEF.%^H -%
M^0YQ;RNMNRV\0!PV87SH1" VU%\I3KQMXB-<("#\\&^E!V(!T:WG7!)G63D[
M5XLUVG;E+A!Y#NU_HV[BQC9U4S[\V3F-KW/S8%3L*3DNU)?32]U4\7 6)^**
M$_'<9 (6T&A_)%!V5H0^WIU[#P&V(P91E*=<:.W2__%6 %;NY;>OA9D<GMI5
M:-9&!6! #=T"2\@BC[DU ! ]D?^C2P1-Y^F?*IH3S?K(WP5LPX_M2:T<H#J>
M=7S1W=59@WQ\YQZ+%A?E=Y^SSXLN<>=:67J8*2CB],6?B4Z/C:IR2!,:XL]M
MA77=C@ HQOG2\:;I2OFJWEHQ=%5)3,]J,:K629*+>_08;%"W.O7./%)_8OT[
M_R../9X?KMRXE[G XI@8&&T;2(^-G ^T%4@K5&T\#DB11E2=8^)P 2.E0L*I
MY[M:@$OFH2U,JGFZK8#A\H=.#\?I393YT%KZL?R: P6=D%YY#$#O>U6GN6 W
MJ4YBMG0>A*0VK_(:81KSZ)KO?F-QZKX4C0$D%*_HX.38ACQEQQ6 :AW_K;L)
M!SD,U%>%U'WVZR"TK5CH1"]VDRA/K&[8*]EN%3"MP-W49 -S*3RZ%[FEU<%0
MU@UCL7PKV#[(G*HBD"8:"P<TN0R<R-X$DT+6S27U4E_6M?V)CBUE_94QQS>2
M:X6F,D[MV$]2JGAS.2%DDOU=%)^X?&QU^D:45]U,/-V=_V,J,#IP;GIU7^N(
MTSIZ3I7IH;C#T*@#3CR%'(NE,B6L'%+H*4-+0E,5]AHJ%]+(>WR_TA:]8P@X
MDHR2Q?6A9C<.9MV-<1L>5MR)K-<WQ81:\J>Z6+S<+K[+A+X=I4\*%%)W'XYX
M&YUWA(M4B6LY<*<__(F2\(/"!CT ?HR/7;U62_(=98M@F%XU,/9Q5OX2[RY<
MGNE*YF(QQ>^KE_\O8=U^N_H>*.CX?C^,=1"XW]*?)/PD)BDR@_%5N\D9H*Q7
M?/=^=NEPI"$1_L**/>5[XV7;7'4:1J<M4[=K;)BKJJ_+1/!J 0+7R!BA'B01
MTNX'^X94]^26-PGZ;E(9ZJ4^!Z<XP6;)P2KE<DC,!OFB+=N_Y%B";&""0XA^
M/>-YX]Q!-V=/"9]$6*N.#?G_K'K,2,,,FJ,Y"$ZALM:N8A1[/L.;C-UN6I7-
M,DZA 0Z/"YS4:4!IN_M*@2X1[ZS^@A\7<OG"097C)4(-.[S>A5]P=?&9U JU
M&OQOJ@''GQ?+0NE:</J2"8P778(*GUZ+S.G>1:=@>W"-!TLV4-IS924YX8Q6
MW+;O*['CFG,&%F(<UN+W"!Z)7Y)W4P(Y(;"523Z6;9K-.J&K7W/93#JOI)1G
M6>]KELJ@]#OC.2U;+X:W[62F)\>#>D^&3%>'BW4<3"JZIA2IA'LYPT6<J [-
M$0C(TAS)MN527T87@CTNVWF)!Z3MYIBM O1F]%P^P$>$''@NG[#SD57,)P<L
M7W*SH=!N.Z-K\R#H2LX@N(-'$'8)M@AA1*>]IIPS0]-]_+<)-5%N2KY&L)Q"
ME&S>>NZG_RN-MOSRXHA[:8Q+:9%C)KZP/5]( "HGQ-F(K./A!2,"R&M&0R"#
M]Y>MU*MXEF^$X^GEM]^^^GBU'Q4U6I)E@-C1G@S%.-1,A$A!#-TAJ;&%$Y>P
MO_\58-YVP=@@F&1#_33QI1J=%;)]9([@&<;/[.1'^ V^?27% ?*ZMG%EVD(K
M>%QZ4-SL54N]0G'6J(XF#6.$++"WYE1!/,3$K2!]9'B4?)@+$ST5X7XFF,TA
M\T87OPT>5LD<>MI.K@,R,%-+4;0"R% ,O%FYXQ2L1)1.P@@/<?$^^P1I*K&Q
M_Z"&2+HP6(TNKS(J@_Q!VH;>^!*!7 5'EDF!UN5-C+8,44J&F^,R0<.G^3<8
M,H(]+KG0_O)!'NXVH5+IDV/9C768I1.+=_--'N!]_.+&]QDY<4_DQ(M?/7+B
M-&SY0_&*\2T+A-[9"=;D]3MXO<].[\3IO:<'\>P;?T#G^^NXSG&+4"X4\/B+
M?5?5Y)Y]DKSD>-*9\I*FZVL:!<6A7U=== M>MEW<RC=5%[?##^A%CJMS$=?I
M(_JPBI]]_?*'BR-LG/U"'2<>HC<A['V%1(\[-XV&IJ,^DXV5/;"0S<: ._'#
MUUGC\>KE=W]_]:>S%U^RY[@VQXZ05&B,\P/^_IL_6Q-_/+4>E4RYK?AG\+GM
MR#'B5!@(B\] ][QAK@]U=5\P2=BG-E9K%+5.T>\2I9ATW<;O?!_GADF@N.PH
MPL6#D!CR(+!G71]RL_JVS)^\#O9IC [66S5 _8>+W.6.)R^X+@BF(Z1FZ+C\
MM3H\]FE9$ ,O2!<^>5; 1).BW>IBX!H_-U7?3H!*4^GBU)U^P#70<=]'&?VI
MDEP_TI%2> I?1[(GR/#T'EEMGP(/Q\B-O/$;^* :#NOH!<*9*U6:K"S%!!G?
M3H8N\9CVIYS#IS)-PREY09HP&@N98&_[[2ZY,4,ML9YGO;V@@FJT-K*]IC;C
MY86S&&J XEH9X\RG7Q1BIP0WW7O -*\:73=7\=3M,VH+?QG%KPQ!JCS@\Z#J
M;E9QD#7NP(QC%>T8C=1"&DRU;7J4^PG!R\60INF)\;&A'@-DQ2\NZ">OJTL*
M3[D%$C]@[94(UZRXYU@$&,VGV)N6B^'R7]I&R.Y)>BHUC\>CZ$%,9]( L';-
MH!KR:8R7T<KIL)-LF5CN*;S X:1H)C,RD4FI3+_YYQ]>O;Z@7@D=*5BV*12;
MDN!S,B-NJ+S-_E/>6']M5Z]EA60GZ8YQ[*T#O\C'J6Z?%M\J?$<6&A!(7C9,
M)EY*FL[UG6G"+\N:80YD)%%]'RJL'LU(NFO8XV'8IG;7#V?M]DSDKSSD+#FH
M1"&4GH'44/1IZIJF(U$AW.^I!/ZS?]^6:PJN44A=Z.J3GCKK\(>@ 2$2[=3<
M9V2\D] ]7-[R1HJW/6I_GHL#\^6/90;+P\[+,7DX+O2+JZNV1>\97>O"Y*WK
M;MW0T1X18Q9&O1V[INJO.5D4.#U@\\A<-0"N$.B#QV68.7_6/X+(><+$Q7\:
MF\D7/]8F35P6\U]S+G/\DNNUG7^4^SC+R_J0WHJ)+V5. "^/"_6SI$FD\VI]
M'38CW8_S1ZI<L0@''WE\&M_EP6X"78>/>7EG!Q'K; >N5#5X4!C44+U-O#Z<
M8T%W).=]N$3NE\Q-7X:9%<"4,J<1_83KA5>K:,MGVP.7/1DV/=W3 XT?STXR
M88%VE#13?#>"DW28F,/[FJ&C\LEMOH!4%#Y]0!?/83ITU%C%M5.!*7$)C.9:
M#1^XW,(U.7S$E*)F30V3H>?$*L;5W<IILBP61X99!#S-_N(C9[Z)7_/;_.9/
MV1_ZR32_)X'_=7NKC6)*$[*("P-[^BXC!,&>@XU,\7CA4I+%ZN=H%Q#(EFL%
M$OXGL+]A/>*"Y'^?RKG3$@,^.SN@5F'DI"5. [$Y"@&.<W_SQAC&,8N[+#%)
MS@RP'K1)<Q*<OYT,^1/>2L[7D91TGT_W$MBU4 8[9RHT,\.;;?E;MC$RO=6^
M,+E-2^KPODC@3=XAM-"OAS*:J_^.%[G'D?:AWIXQ&W19RR=O24N@#I?<9N \
M=+F9OXZ?C-NS+JL=-B2%H4-U]J9:O[FD]@?^3?JWH8MKE!NNN(]O2O$XH+_A
M/#KZX%,&A;QJ;N@:N^+9UY,"*V#!"/;.MBO'#?0MY,(K+T=I8K6&3VC?#.V>
MD35:"EI )\45]WE?107R[6\()-[ T6EON\%W%\%+"N!@7*H;"C3IE6VX;]&
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MH_3\[(52>BI%L'%)\#4$.0)TK&L@D7[RXP*PE%V8AB)5_-<@F":\OEBI#>G
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M75PIV [#WC3DC&48@'(<KDDN5Z@TH_/90<E^T';/_'*3KCQ)@"$E.BK(W<Q
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MJS;NR$<PJW=!_'PWL4VGP<H8_(Q"MWWJSKE.+)  >?5.$9GSEE<$0H- <LL
M"2-QOIVR$R247W+#H'!4=AML>L7PW6]@\/D&:JH;>H<&9IPYRFUHY%"$G_@!
M C7.$&SD=-IKW6_[+7-5&*78<DWG*"*#L8CS);,4;)6YM[J*=P]57*U-#*R
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M%-VV:/+>F!],CI=M@L(Z>XB>3?H8K@C(S+ZQE>#<V?<!C2@6",W;8]\<W&
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M*8/(Y=2/Y2;D[ZF9'5X</UV\ET9W2)5 #,W$JZNQC!?!$(*U QG9GUB"C.]
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MF3_(/L8\X#JFTGZDSIU''!Z?.,E^[ICN8 :+- IXCIHD-0PD,%@IDT]%/[7
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M%2E105)J,+<<@=% **OD(:-3C<8)4Q,@KAG/\E77CGN#_ER-C8HZGV@0[4F
MQ>1DXN?WTDNV*S%R>4<X_RZ#BO V YM2.R?U<<?G#;4BQ!"N&R5\7;W!MDJ.
M)O(TR_L#T;%)$>*=)B69M[,Y=(51?29T25/F2 ]"M$F#KFX*JX6B%MD'O6%3
M7T R3/2BH;Z9* N8<YZ00(5&UAZ$CR)5:HDU!_ ![UL(V#KY9YQQ)#0?*Q!(
MBOD'\//4 OQ0GDE9^2,N@AJJ^QT@7CXR#X*\EH>+4<^1#$8TD.0LI1[1.]Z!
M65^1@(MQNTWOBNC'UF,I>6U>'WIM<QB F(0TG.OPZ"84(*H_F>#S'O'<#_%J
M]=>J.%)C[\")A@1+=KI0RR"FCSH<!1 ]O97]#:P-)GJI$^K0+0\*M-4P"L.L
M4#JDJJWVEQ3NO"HPHY,3N:+CW7:TH9Z1&N^*U/CM,U+CU/QPLV5\#*?>?XZ!
M FN!B.*Z4'WC0F'/3([7WB3804LBH=]RC4?#5SVX9699Y?PQ!]!2UOQD326K
M^'#ADNBM#MFAZ]H#RPT4JW$?WX5Z[L37N>H0:7=MWY^I)3B>X1:S>K*Y+;]D
M=4A6BI]:)+,T?<LICTV+*=!K_QZWD"4GC.I1YM!8[(Q@DQ? SXVA\;EUI!I2
MQP>*UB(CS\^^"V.ZV*_FC;,U(\6@08B;."?#T:A3J>%%8 <4OJ<1%. >8V8<
M]D3D0\JA>)AG],?]=5NSOH_'.;;Q>KZR?@.,8TV-!:A4RSJ8_[BP9Q6^F3QB
M'P><WK:TA?C1AOM-W^76ND::U7'#%N)%Q"D;^3XUU?$% 6,&FS_V7,QIRK)%
M@$7"WZN[D$LI+"1EM-/3:KDH&95<H.O8*W?,.20[R+[<43L!$Z"Q7XK>W# @
M!L$_.J]B(SI@H98</K&]1RHHQDB4 SH)1!,![1P5JN(0SA5#3.V3@-$I;>24
M>%Y<L;PY.DW;?9((DYUWZ<G?:*EC6]ZT7>%_V=S;^7JQE\/!SQ$(0XH/3_-K
M:6NORXIMD+F6I'LBUY+^'E5YGW!M\:J(KKF(5U7:.#C+HH,W78^L,-!K.Q/'
M;R8!:8[R=4#;#9Q4J8WZ *"K=MD<I?RX:Q2KC$2%(19$="3]$4!;4^"LS N2
MSM81<#U#.6AQ5=\WB<@@^&IM,)"7=4D"<)JUC[^[?N-1+'0T4AFZ D2$1D%+
MKK.M(: &)(IITXH#/6.^<QZ2]W3YNZZLA*=U.U*V*:OT'DG;4#H+9]AD6F;9
MI%M+F=SC5#_7=M\KI9O _$1?+$Y$([>NBHL9&.D$/,IM&08NSP+)B8:Z>F?)
M[CWNB;\+(8193G/KF6)FM+@GW.N72>L0N)]FW784+P]'G\YN6N6>2,>G$'.2
MN1!;,!QIFL25!!T%T^*O"/71E%[*?]:\1O(%IZRH[DYP?D(_DL\:#8B:#HP,
M,=@M96^)Y0.Y(S8HEZ&N @<<ET=FH^W2,YJVN7N\>'D>,3R+Q:=:Z)22,TJQ
MAANUNAR'X$\1X"UXCZ7'T>G Q5@?#,$-Q@S)3ANS$G\/BM:#2$5.5V0'-*A%
M)&A=#]1OC%P<43+9A>O'0L^<<@XP-Q=R6O0HG_K#$.0Q].X%].H:>#:S *!I
MX79YOA+&']]GEZT&OGF$X0QG("YD,-5J1"L*;<?&6" *L%F=EIO\E+;9 U*J
M7UB9:+#6DQ0MBA^QQ7&2>*27TFF$]1S8)U;^WX;759W*H\>&Y7NV SGXN\OJ
M:FQ' >NZGJ>'O"#E"I3TA:+5Q#BED>*_HE[JZ[)$7S?!A5NZ<1E#F_I#7 MI
M'$L8F)"];#C]_ZAOEU^@T7CO5 FG[9"M@WAIITEAS9Q'FH9F?)ED&Q(EX)%,
MR4*\_C2P$_>!")_ .+WUW#O4G>O0OV53ZI(P@OK,MT+5'W]LEOPO\MI8P>P&
M-46\OB?)Q]QC8W+2B(D)>US5-?<09!9JRM63,1PZ2Z Z,>!4$(8J/OYYHA!E
M/?PDDDQ"/X<K@ND8;,<?>_E\%#-T];1VI!AF!:'03S52NJ')GX3! M>-G^X)
M*+N $29S%A\T8 _6REH\H=AYZRUCK=5V]^#&IG).TAHL9E:"2;5NM!;64S9!
MU#;G,DSWWBH//@<G6(>/O2YW7[IA>GA\J+=GX9]A/0Y82W9$+(\JK(G&8*C?
MY!M1FWZ8'4AN4<>VZ&/[)0@A V?8&]!KSL$$Z5:/5E4(:X[MU.2;7"%;:QQ8
M[V17'K<U?N"%^5,0#!.= X6+97A%<S.L P?81QPER99[!N0[\AG"QB>XR6GW
M#S(X;:)$D*]Q)#?]@CC.\IE\='+;:C^:%K,<?#1%;GD-V46@CWLCW+7L""RD
M= +VH]1RH[ZWLQLCU/(RB!.*:$1T98MTC**!^W2,ZEM/:/*:Q<0H19O"I<CB
M!*&X3AU9CNIA8: 3YAYYT?2:S0DSZGNFS<V>_09YV+=4:_CS35LK/.=OWW_[
M4DTH_F/UZOO510J'L+O]U3I_+&Z0^7-^3-^QYWGUPH4?2]V]^*OA.;S!0R9X
MJ-8] 2""8)J2D9R<=WU5,))0W/G/&!7#*[@LB3<?IXM^ZRONJI)5/OD2Q?'!
M+?.OJZC>)C?F]".OA,WJ/_[WBR]^^U7"GYU\D;@5NF@@6K02%? "3KP7-7!1
MC$C<](7/UMAL"R<'4;BBK1@<4-4N-?T_ SO>%=CQ^3.PX]3\>"W?<]WK=L*2
MH7:M"],K.#M:[,M*TDVS>!1]I!Z_=+BR)W590E-"[TFU9F,)#Y^+S/)+W,"H
M>4;NG#-MMR7K3[2#8?%"D7Z5A2^!0Y"_B?Q=O)!NE$9.[ %R!7/< #7Q::BF
MA(TH":6/RLTY3!QQ3AQX&0*,2R ;C!]1YP8S"!QC*8V,"3W3:+*2.)26^SJ<
M4O*$H.S:L8VTDS85N&I)WUU^\0F[1']2[#M0/!TRGG+1CTE;1Y?):X6?='E]
M^7^^^1SIV!]^\:G=DZ?47)W583O\X8M/XRS,G\3_5"$4^\,9&<)_T_2CYO:[
MK_1E_O5#^"J;KL\^/?^<YB)C$)0E5<?73O:",Y='[:F]^8S;"3;<<]!_];QX
M[W'Q%%RM7B*8MEF3XP2P33A-#8K7'@L95&Q6+;<&.MQEF%U^LPWRO/#O<^&G
M=_ 4O^4*;LL^S('[/VIK,S@.#T\$)-A3)$IPPV ;%B$]B!/CQO.\^/^*4P]T
M1EH-@QS,W4WO-J]$[FC<2VUOYC4O;I?+0^X>?$5;XGF9W_/-G,$A+$,_"606
M@&0_QT"=\-_!(Y./$X],%U<">G,*K77^Z7K',=ZQYE#0MYYT>C-R03LNFHUM
MH?165MT40)61-2EC7L*C9,I9"SHH)WE=7$6A"SCCNU-/[V:\RR>(GH_V0OA+
MX@EOCA^EV=;SK1O3#Z%+%?8C%^EIVB)JH*# ^)" ]O?8:A82:QU!"7:XAU5Z
M-](1OHMW1Z"P'H?Y,"P(2I_@=$IJEE(OP8.T:,)DR!R*]RC&M3JFT*C,D(S*
M <+?8E:R"IYCK\P8Z5"QE(KG'EWGL@IN>(DD24:HE%Q3/TO$C18&6BQ$U-R^
MS!D5L/EE_(3;$&J&UQL2%X#GOF*HE>_[O&ME[TEI&K]5>(F^8@82#LE<+38:
M3R?D> NY ^SK!GLR")$'UB09U^5<,CE9CNS1K8%M<=9_E(/NZ+4T]H+R!6_L
M(5QU#,%>D)>LN'3_S);Q3N5%J2K#C3:<Z$+7"W #PE_"J=\L'L>B*< 1IX]3
MIE[O\/@3M'C4\S@X0I-4K'L.*_B,E1@^7J+@!0'&X^4VRRZ<J-;]=+*VJ<UF
ML[KFXH3E]$L+(.IAPOY\BHAS@L\AFBSM?*-BK9/"Q$+HZ.DD8FA7='LQ%H9\
M;^ZVE.X6HB;JA*<CB=.+J\RKIDHWJC,?FBMIMF%\@2&;O3])B. E^CT-S])(
MH6UM.'&1^3DQ%T:,FUH"RQYXVT,[)J*$M#IM#N%"(2$.+P8=HXL8 5=/GU(=
MP$2]A<Q\XOB8[,V,]S6'4Z4Z;_96"=&A%Z!"&\P&IO)O*K":3L6^W8\\$FPH
ME@PR2FT&6$A,9.NI6Z_J5$9)^;SZD#Y%Y=8W(?^<XWA(Z@<C++K)%(E6(G1^
M =YC8T]/('HPK9[GLLZ%>V5FWD@$X70!;![[O7HZ8O-V0G2?]B:#SC-!D[;I
MREM9$'P&1Y4]9KV$Y?:%1#,T"P^"K_0FDN5V0,$SX5WASZ(4%5W"MJ"/>M90
MVG&T0)MTZ^>M%W:J6=7GY_B#:Z:USIE#$P%0]J3I4]2:I![-D5E2[VLF%^=2
M/==R@UD02_./D2&$ZNU3J^2F)+-8Y>M#"'CIN[>N17<C2-,B?B"QLM#0A\J"
M4!H7ZRIGS=X)V#,9^*T,U+:!7_.T)51Q&>C ![[FE($OQ>79R3;4O9 R5QS6
MEW5<X(9[-EB4;Z03'B0%XQVYH!Z>4I.8L9=%3%SW,S=>B5N/X.S;B:53(^+]
M]%D/]KMI.C\[D@FGQCJ#NM+^#D]@INF%R1=O<NY]C]$D*(0(9MRFNY;N2.4E
MPC91=FK0?B9P^"9Z)43E+/#G%KNR[5SWL)80MET93U/<4L"BO38GM?*"Z5-<
MUH:]V:I?; 923.\L<#S..^W<18AD:.ZJ/JR.<Q6XWI3+"36/Y,_BPT2I[6KB
M7A'5ZK'E(6!PKTD,A^U0&B'H'(/&LD;B=3<B-%=?P?7W&R1"[<M2@U)6?&N2
ME5YS%Y5]B>P.W%[Q24V.%P^)6YJQ)YDVP"S+H)V @@01N/WT/;GC/-3E(7/3
MQV@-:Y^F=#M)YD8U&\FZ6 8C,X1F=F[%['2[#\NR/"/=[HET^]TSTNVT=$MO
MD>T"1XM2<WM$IP><:8<=%#\OC1;#X%9C']SQS8YBAHOR!]M1Z&ZJ&/P.:@=&
M :Z9'[J<="(?K^VA\RTN((@K-YQ:=ZYV$8_S 'M?5SMTSPS1J1:%Z022M62
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MX\&%!R0"T3R>'+ >Y!00"P#8 G4!JY>HI(0<F^7V]FC:1GZ#1E$?B57VH1-
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M8-NVU?AL"50.:9CH6B&XZ%9](^RO+%F2!VE0+BU7.EG5LZ]<" K9=TP<47#
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M&B4ERSW# B086O7';2>3T+BJM&>(/D'C:ZWWK)/2'K+G<GL])LR L@"& YX
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M_<?1>;\W7O/[VIO7_GARWAN.G^/!@][9LSSW&0?<_^HS_#U*1EXY= 8G)#5
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MBHUT3KI?O?4V7L")8@ZSXYO5L3[8L+B9]@V9Y/0RE%>,HF0)9GKA<^G-1)U
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MB<F\IA$054!_@/1C3#1U+W:2@$%./^%A"44Z$FV*@0C#UY%S/7+9=YA/@Z^
MMV;91Z>W89DK2S?2%1#KQD'K\^!\2R08Z3<D.@>.4=Q0^W(3)+@.Q6T$,[S7
MF_RA(Y/I5=PF'S+LVD39,OC L(*,( @"IX34A6CR\;:HI#71&B4WYHXKL#AC
M[$5P9I#X)U0O0AH\SDUN'TD5L"S+;K?9L(X.BI+:/L<M(H#F LK@JD\!CHF@
M:9\J\<S86"]QIW'5LBZL:+R+DBX4O_;Y<JQ&A?)HVJ=RTC079%7JL20-1@%Q
MR"2AH./&$\452&7;/ @;[-:#D>>W:25ID49<@-*X%)I4F4OSP$4([H(X00$6
M>;2U)O@XL *ZI(E3'+ZD(:44JG$ST.D@U"! ,5:J?U7&")*=8S:%6/PP+JN&
M?:]\N,)P3$^55,5\-X1^E0Q#%CVU7)H8M*9;<[2((R)"TXY.PYZ3GCF:K;^7
M>5R$L:$E"5J.'T\B$AASGAB\]$4._ V?\,N@3DDZ@:BA91V#Q?"04Q+_TFVI
M.,_+E#.[Q"UK6Q*@.,5:I7H07&Z9[BR5B-PF!<3VK;X)7T&NH(PFM\2$K6QD
M//E%O1=JI@(,V6-C))SY:&.H92^I<]"PE6 )QP1%'65C6=XB(15E >!/%IW,
MC66'(V4W'CYHA)163ZES%ZKX2AWP-)Z66 N%>Y(_'DJ3(MJ908(O>/SHZ;40
M5)PNU9Q\3+/[) IGE"K$%!T7/5O-H >L7;&9!#VE96HMH-B,:%M].^B=:A[8
MMOR+!T\R->5PD=X)CJP63C6GV[X1 P\\%'&"I"?Q/*;R,'^3J@"[A 245'#O
M&^XXK#<!(0F1XU[W) ?JG:7/-LL]_2<6C=^)3<*6MQ&Q8EVK,_8_@:,9PK+6
M"D)KI&*ZOR.-A$-*G%DK46GM&DE7HG6/HDQ5&%*"H6OT*IWG6LF0^]Y4G[$C
MH:\M/=CW$40.R/=XG00Q,_59.2 N%;XT+OZ^N[K\S05^]*+VI58P@RT0FI<\
MFD+%I8CT(EC9U.D;/ =!%43IZMH\>CBK5>@P@A1P+*0JLINE7\&VO'1 W((I
M\) 'E'L;Z-D0"<Z*J/H*?96\8@6V2Q"'WE'E 03)D$%EUBO?ZM^:1R&>DA/0
M<DY!F0ZC"7TJE67DD94[@X:)#-48:(E)KN:TD. !!.?N)%A-G2B<C=</S(31
M<4*/-:B?NI&,_5PW[;[$,<(28LD5A[*2AG)S/68TAXN2R,.E,E/-242)!BDC
M8'?#"?#106Y>=P/GN0E-3%V9$.=<O06*0H4&DE,=1/RJK$9TVNYB.ELK>0]I
MK,'A\@/TVRELK^QGK/6"*"IF]L0DLF,Q-Z!!H_]!S @2<,A3@#T-<\"CL) G
M#O>(_R#\PP0,P(O'C@[ID3B]RQ*45Y.T 2$-HQGV_$]-&.UFY9;:I*'/-@'\
M)W7:@W/KPTK&Z6W$G/7:&"!IGD=J3X>T7YB@$;U;MS(1?M4.NUN!!O]EB5ON
M$LP*? #M=CJ-68]AA>N42\^AX(=C:LW ,"V>N/H;O=3"IPD*&UV$51J>UV!:
MV-@B-Q'X! 4:GWMN7&YY6O\D'09*?FXXAK'OIS%M!8S_"M@%%S6VZ->J!%;*
M*IT6"3%@M;6)D3/H5\"_AM(JUE4GZ.J$85>=L&Y^; )X8;S#@&<:UFL/261=
M T3J;)JP9#3B3*5\EV*J-4R8:OX$C!>,U9M:G#AO:9/C,]_^G! K_]$1==HH
MK2Y:W6N)$03;6N+(LVDJUDA/8%_:F8;ZF89?LDP7$.F;E-*([%-[ 6UM7\SN
M-M L/>2>IP'@+ BM@D9&GR&O=5!W>'8Y]$Q^- RXZDLW-*Z:)AD!^I)K3%34
MM,_46F.YX2?/E#$*]E:E#6:O#[@'32L7<FFC[=""H;3-%G%AF4*I!L DIR0:
MVQ"7H'ABEIIN_4IU/)K3.MP@YXY7K-(HG^$8\KC0J4+X2?<-3LRIKOOL16UD
M-R"R1<T8HC8MBNK4FP]P, ) $NAIKNYZNXV 4"HH'*A3,G;+R'*!C2HIQ:S-
M9U0?ZA:5P\TTMXX]N9UJ\TV 4CT)#O),T FG$'I73S-K]M<BTSDCM:>EGZ?Y
M&[V,PCU))4'$-YC>XNI(U7W- X4IPZ9>,E815<9'*[]8WA10(@KEV#73FJ7/
MI1C_?XLG0B(X7%WR"R$APC[$#+ZC,>Q-'1B_QY50HH ']X?%@YUWBKX'I7,0
MMF\EXS%)"EF_+9YBH!+$ YIVK<[$)DNWVH1747=M'^MSQ 3S 0V";HF<KV6.
MX]8X/=RWA['B35[(G?-A-*?\&I=%PGYT&U6?3(J]2S/IQVB,1Y6.1F5W*[&T
ME@;0^/*E,B&X'JJP-AQ_? &@HQ3@6*N::85-R NG30)V!['#FG%U+\-L(3H1
M'FG!ZUY+8.D0OKXUCWZYG$%6 NB%27/\<GG]$R5$0N_R^B_\Y;A_ZFMW<C>B
M!M9"89@_2Q%F&HS>MREL"Q.B-CTA:)5[;] NTLU1[^[5G]2F*E?/_(5KOX?\
M*9CP(IXO$@@?29S5^5 Q\TT:)[8^EUI ZF FU8JT"+_7CKM/K F,*Q,XJ4Q@
MY$Y@IB:0'MCSKADU@4#,2OXDI:RS._X>UDBPY[!*G.)]]NO#Z$:BO-1633]2
M(5X4H#-2N:4V!P%;JX+;7+V?,:' W:$\QSSFHPUJB_D8A$(W==(HXZ;,)A\Y
M/DEZ5'W@9,GE2QI_9P$POFKR(P=U0[?9HJIA@U3-BIZ_V5*='5*FHJN4+,V]
M@* LU1S3/.,BS&^B,,3.@?KL3*4NZ 8!*Y2E'(3F\79I0E"?>C.9RN#+P';
MPKX;Z(3'=L.C^%7E/NL6;CDJ9#!LKTN;X4T\50Z0;C, 4.0\OJ-B$C6<H[CV
M[-J8X&0B_80(JV!YE@%U>*N9FL?+>15,KRJ'5O.]0!YA6)DF=Y* -Z1/?3F+
MJ7MALXW@'46]64_-..;+RN(5G:]J_*%YNZR[_08R[>>+9:E-];IXU79,^X;-
M'MJP3A0'))2A)"2MPKTJ 6Q6BFGG49EG.MK(FX)LQ_\,TB64;^H.7-J+EC]
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M<7+BCP>?1UW9[8YN=QSF[AA?G/N#DVTKCW9@=WSACM ON"[8J<5-BJ8OKJ7
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MEU0+@<9_:"2!Q;XFW1MR5[SXO;4GP RM"<#QO<\^@6W*QCQ$3,>4Z))8]WO
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MZ[G@XL*)3F-5'/"4FYU?7>Q<5%X)02)L"8!<LU[A*Y@S83K=<S2HD0>%S<O
MGS G;JY2H,VT#,M[&72\Z59$C_R@+)J6#=M+1[WF==?+"71&-(^B?-2XO%K
M%]0^FLH?5-(&%Z)C!,&T"V,\)VB*)Z@6OZ.^N#1#*8Y#5%<9/"<)1PPZSMB
ML\!0I7N5X?T[3$_'K8L==N7)[H1*0WKFE5#[; 4G?NG;C7:'\X7(Y U3)?L0
M1W\]%(R!7H#Z+I=18M$4$CP]KIV0AMQSC"D+%.;W/^BNI,,9[+N%HW8STZ-Q
M?]M<;DNA9G[B(6V(\)=FG7-:$6]1TV\Z2XZTI,=\X3$>GKW5R'SO4*X+<JM\
M9-HY"P2H>>U[$6-SM]5PF1FL93*CL+K<:>79XA?H2!=Q5VA6,6*OR8&9@%4
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M?3O.=>HTK=(UY4S8S[_H8<839IT&R:Z824QMB_/2ME;+)$J6T%H\<R7.;E/
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MKOJTYJH--?U2G%-'.19/<R=->5X-1ES;3\QF2IL-TNJ)B]*DBH5'H*'X,V3
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M48R0!=Z5"P8L&U*6]G(^0 [%4H7.&G5V*B!=@+85@Y+%W^+Y'JP$*8MZ9K%
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M(<SM=Z5CMZO&)-6CP2*ML3B*S6R.]<A<@''<I@NP(IIU >F![>XW$'RHCK?
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MF/;1:,\S'S+15[RM ;5W4\^SU=-KKP^N'+Q_@Z.,FQN$Z#H9HFBUA;M^QM>
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M>'1R<52.T^'50:DQYI9:+A?=H62,3#Q8R&J0@6!$@<? P'%I2+"(,NH:8WX
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M&BM]6)H1;9ET5A /4F@)@BD"CGL'5B1.O&8,%=W9%?36A%3SZ1W!\K*E<E=
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M% AO%5@M'7CO!085LL0O;1I=)U%L&,(K#V^"E+J:N:H\O#X>7DI2*;21B4!
M:UJ25)R!M42"D][80*--UG21AQ] K];/XTG^<=0+YY,)CL*'WFR2/VS8="_V
M7'Q]/IV=X6CVL)JW:E%$E5*54I72PY'2*@WV)E'FN?)4*A0I.\F:*<HTSY8:
M&JWY]S?8'\].<5+ZYR=XBJ/IX"T^&87Q&5XHJ<<7.NJDJ*CY=>Z-XLDGA;5W
MI:^:6=,G[OWOXTGSPFPV&?CSF?-#/!G_[O+'S*IAMYIA1[-1MU1]Y)%PFS3(
M9HUAL-FFLR;# 85US$E4/NWL&MJ1^=*5"BIA5RE5*752K:YOFEA5JQU7JXMQ
M:VV=))*6-:)8.BXH@I<Q O/2*TU02F6J6MTL*JB$O0E2ZL:@L4K8W2;LI0"W
M$=(+G_T@$9J=[H:"DS:[14:))%,2--D.$?8#:+[(![\W'$\?V,:<FA.M4JI2
MJE*J4JI2ZI*45C&K"0:KM8Z6&B<,-U8J(3'1)(@F3.+WF]79)IC;T;]EPZ 6
M?;1H$[-L#W]<L(FE)4$&YT#\7_;>=:FM9-D:?14%YSLG5D>HZ+I?W#N(H WN
MQ8X&VFV\^K/_$'4%V4)BS2D9P].?K"D)A 0V-A((J-AKMX4N\U8U1N7(S,I4
MV286W"*#"0P:"]1I%I+DN26,:1,Y7Q.O%$Q?52@7PGT*H[0:CN="N,LDW'FO
ML1?:Z(AD\@YQAA4RT2O$M->1V<BBM85PGQR4"^$^A5%:#<=Q(=PE$NZ<UY<P
MIS6+&/ED$^+6)^0(T4@'AQ7%FD:Q8H3[I!.:]0P0U8U _-UV;<_'EJUS^XFM
MZ..)BU6+D7;N14'OD\CL^E6(%1K=W2L&8Q#Z0]>-K7Q3DT\'_=-7>7CJ?K<3
M1I\\/3;[L7H]7%L!)&6<P(1S,!H)L=3X*$Q*0F!YN'/'_1K-P4<;-@IY+9"\
MV%PE'B>]E8IA)(14B$>5@+4"13X2RSPL33HG[N6R83"F"RH;M@CX/'+P^]$8
M8M7":__G,0;_!P9]E3ASW@!<&&'F#6['_2X\NWK[O\/.X+S0YF)I<Z;^D:.@
MH:,GB&'M$:>>(I>$1X124-I4JR@]T&8;DWMO8RND64BSD.84:2JC*#4X4$XM
M9Y(Z"TQ)L.3>,9$<+J2Y*J0YVRB%2TN5P"C@I!$W$A2R!IG,:0Q<:\MP:DB3
M:[G (K6%. MQ/F/B_!%_(V7..NTC]Y3S%(C+&>5!.QH(B\G1VYGS6XUP"X4N
M4Z[/^AH]-4H',#6#,0G!FL>1]3(@&#1&DY*1195)E*CYXGP_G&-:N+-P9^'.
M4;E3'9W'6)'$-?=$6&4PB#PE.&8,I%_ASM7CSME,)!M=BE@ZY+D%LS,X@HR3
M!F&?DE#,:N73VH;$LDUN:,]9V+.P9V'/GXQT2TT-Q=:#:N<L,"T]V"H6WE32
M:?H-S5[8\['8D\SF<5(B)6,&R<15%NTYP*TU<HQSDY*DRO*U#0JF)YUO<UK(
MLY!G(<^?\G=Z;*B6EFBJ*3?<.,RI8C1:1GQ(NO@[5X<RYS(Q-54*>XLD%F!P
MLI1RF,@B+Q6QEGL<-5W;T,*T.2G^SD*<A3@729P)\R!]5%2:P'&P#D!FM-+P
M)Y4"QT419^I\C0%=Q*I?.//'.5/,<&;"!K.@&:)66L0])TAC[^$_,O<Q5-$(
M=YD,73BS<&;AS$4&UT,4/'GA/-=<)6N)$E9;L$&!.S'[1HBH&)L/2YSS6>@\
M!I>D1XE2BG@T#%D?(_),8I#LV#GJGI.QV>2P_]J4L(%_0^?+QO_ ?R:7/ 8
MDX"0T_ZHP/NK*N:Z.%_B;V>=,#B>H&/J5^,;P5<_L0XN>SBX_2=3%^TC(*EZ
M<(S3ILELC"WK??\$3GT.C[:UUQ_ P0?]UNM^KWGR=A!#ZTVG9WN^8[NM=P-X
M(Y<&NBJ-,OL,5^36%+M^A=/_S5?;$$84WO.DM/! 8,(H2YAB6ED<6!(DFD/&
MUR8_.JXF=W!JCR)R5;2?D4UP@Z]L]\R>UVN_7GL.)YT>FIY/LU-A]%0V_L=5
M\+L;+O4A'RG!W]L=T3S3[?_L_[F]=]#Z]_;FGP?_;K=V]EZO/]X\N.-%O][?
M>[?_Y\[6YL'V5NO= ?RS"_?PKK7_IO5Z\]V_6V_^W/_GW0K=Q<W3^5^=7FMP
MW!_",4+]RZV7>V*K(YAWF3S%=8OK\NH;[KNBKH9LX2ZZ]K2.KR8O?@N=^K1K
MSU]U>LVU-#_Z;7ST,=_E$\QP;7.^T<?C^2XX7L>X,3K'.X?&9Q[#81W?9)".
M/F14KHMO?/[-'W_S0RG7J5C&@<FZ6LIQEWC!^-&?\'A?V<PB3/AHUMRH=+Z[
M392(N>_>($-&H'@8J_O[=#5IJ0% CZT/T5:M[5Z Y7=Z&]HU6^L>#^Y1-=GW
M.6^\=SE;ES?;F#>IWVMFY77;\8<,RQ6?(=_<B#CW.+YQN[>"YT4^4U*>Z<*?
M*;XO7:UV,<D[/HC7MCYNO>GVS^K67U7_2R=SNCMO_>M]#2]V>K^T]D]C!1(3
M]-<FZ.HOH"'C[:4G[_!P;IU!/SI3?[I*P\N]R(5,\AFW[6I-\A\KF?HC]_C(
MKN([WND/^XI7P>=[QWLKA4A^S@5\L??:G/B3-[W]3^'X WW_=6]K]VSWTW$^
M#]ZC?Q_O7GQF'__9_?KQX/C3WL&V^/C'FT]_LK^//YQ\[>Y_>GN^=[+]]</!
MIOCP*5_76[%WL2T^G/S]>7]K]V+OX/W7_0-_ <?I3GX#YQI^I._EWM8._7#P
MYGAWJ]O9VWHO]K8^L]V#;N?C'V_Y[L4NR>>"ZV4?__A/VCW'E^[?W4]'9'_S
M,& L)?<2)2PYXM%99!-/B%%B!%$\6<H64(3D9CY;Y<A7H:55NK<?H25&HI.>
M$*T"Y]HKG825.H:\5=Y&JAI:(A-:(H665H"6+F9H*5+A94PP8U7>ZBF90=9Q
MBYC&CFG)I-%\;8.IMKRAODBAI56";J&E$2U9(TERRB?.!)<T&F&:_>C:$XFQ
MTPTMX0DMX4)+*T!+4\GL[^G>VT,:I)*2&,1]BHB#G8NTR76/+!8I!8J="D!+
MC+<I7ZUF'3-RE++GXW.Y&9I736R:<'85 8R^TXVMWEBGYG?S:Y^=,[87X"OU
MH.KX'.]NWAMF[TRGU^I?.F?LI7/FU7V\,ZOBVUCI8RS1C=+@2#6!NI6>PJ^/
M;>\HYBF8;*=J?;'=8<Q5"?.R K<#4SN_K#NAF9_]WG/ILOZD7!6_#VNXLKI^
MW3]QG5XS#J\OQ^?U]/!L5E4>SX:21D.[T]L\@;$8[*=;?O)GQ[I.MS,X)V59
M7]2ROO=NS@G"<B$+'!P*BEC$=93(2N60H"$JXTC2 99URMHB!]Y6855_X=WX
M[L@0#^LT*+SPU'EAU@M!0^)&1(.BM&#N\\"049*@B$VTS%A-DUO;(*Q-]:*J
MG!9R6$%R6(!T+^3PU,EAUA= 2+1:,0J4( 3B.'IDH]<HT. DLTP[$M<V6%M+
MO$+<L,04C*<BJ[*7K 6 #YUZI*2&H//'(A]P]%Q:?BZ>!A<OHN*7XU=_V$XO
M#\E^;ZM33S90[*?-NHZ#^C(QYBHOIO#6C_!69T[LV*AC<HXBC2W-W=4,<D9S
MA%/2F'/L"&%K&US.5^,H/62>#907'R/].2@7^V1A.)\5+SQR8;B+"$#M$1?8
M(L<(1KYIT"8EH7E'M&PK/1^I*$A_-DA??-BQ+-K+!_.TV&"[9X=!X$BE4$A(
MG!!/D2!CB4(LD11-B%3D7;K2S%=O?3PHEPC.1H9)*U7]DU9L=K.W3N+@N)^C
MBE]B/8C?2/)^GCZ7!P[97'>Z7.5(O($1&947V&W&8Z<9CL;'4DR2A;'8?+)I
M%$I[80QBV!G$;; (K$Z*HC<I,A6-XA:D1UM(4\(LSQ/5"X^S%%0_-*KGHR01
M@RF9$*$F=VJG#%G+(DI@3%H7)0M$-5$2H@JLGRFL%QXA*;!^:%C/20YCD]!)
M(J,"+-8D4N248O!*:D<T25:1W..QC=F*P+K$-C:VXFD%T[^)9#1)C?:D#U=W
M,7HC?CV-O?HG5<>+\)8L7'1,#PB\[L8FJ-L+FU/C4FAL432V_WI.<YC(N(DN
MH&";O&TP4:RP 6%C7(S*4,'DVH94;6+NW72Q^$%7%]D+%QX%V0^,[%G=85WP
M3FB/@G,*<>XITC1W%I"!<"N%! +/?5G 0+EWX<*"[-5%]L*U1T'V R-[5GHD
M'Y*)'J/D'$>P?$L -;P21 E#A#-*Y(Y+I,W5*JW9)>"QL7-R:CM5%N=YHTH)
M>CRV_+C9<;(_.([5P;'M'<23TWYEJ_.K<5OU(O5/@].N]IB(W8/W=/?HT"JI
MI&86P3H%G!:H0M;F/2::"6H=YMCB11>H+[[2%<3XPH5(P?AC8?QB!N,J:1>2
M,BAR#QCW&B,C'2B2&'6,GN*06Y47C#][C"]<DMP7XT6@W OH9 [H'!,G& +J
M#HB+@$>N!TXHMU%3J0Q9V^"J3=B]TZA+@&21(&XZC"!G<VV'W/8@]NIKL9$2
M&GDP;?+NV%;Q]SP2KZ<&HO#6$D3(I<M4VD"Q2HAP$D&$!(DL#!;2UG+&"!BE
MSN7Z-6US_PVMQ66ZNEA>N 8I6'XPL3'!LL(.XZ@P3":!<Y=0BRP#L2%%:)H7
MP@#3M0TBVXH4+#]C+"]<:Q0L/YB>R $/L?OV4#/AJ>4:4:=]WMZ!D6'<YG9L
MPNH@@*%SH0G>EGB5-FN5@,?&5DRQJD!,#.S7EHN]F#J#%Q;?6(TZ7).!&"6.
M'MBOL=[L!?CW-;S9*;FB"ZR+>;"9N:O1%OM;.WSOX.A0.$J58Q%1KE2NUZN1
MT8(C&.^8O*-.:;FVP040V/P6M9(#_BRPO;RZV]_'=H'OC\'W_#I\O4I<66M0
M)-%F+V9$!ON(" 6#A,6H%0'X"KHB-6T+=E=P_T99EU< V'N7ZW(^S_8A@]$R
MP0&PA:"(<Z*0E8:C9 C!TLIH?-[$T29L10I;EA#%QG2:X:3<;QX3>%$/6K8I
ML5#"% \6IGAM3SL#> 87V1\R&HG7,! E&70Y'+8]IRVHQ2DQ%H"TA ,.LRQS
M&$4TL! \E=Y;V53GQ6*5G"/%T;GJ08N"[(=&]HSL2)HPH9Q$WH2(.( <:2\I
M,E($ICV6B8_JZV)>0AC/&-D+#V$49#\PLF=UA_!:IF0%LMQZQ*D$W>$%1C"T
M40D7M<P)4I2LV*[+$M"84Q]A$N!(G9[M^=P&)^N0LHGCX13(])#LIS>3<<B,
M5MPG"Z2QG3GI@25PE6*Y<B;'B"N:"U;9A*S!R441E#=9>K09GG>?E'3N9X/H
MA2N/@N@'0_2,Y&")!F&Q1HP'!X@&PT0+;I C)'#&K>))@^30(#GN;9@42*\N
MI!<N.0JD'PK2LUK#A$BBI 2ID/(BS34LTEZ@P!/QQF-AJ6R2IY0NG3A6"J]-
M>5S *0CT7@TR(^N-DWCB8E4?=TY+C&/I"F-2RGN_=S >@OVT>SD 99OH0AAK
M=TY6&!)M]$HB;#U#7&*&G.(244$Y!J-21"X6MD^T.#Y7..]B8<KB1Y!<#)![
MPGE&4QBK8.@<1H$D@WC@ CD#(Z:\%: VHA1>-<F/AMTG^;$ >757Y(7)B;(B
M/PB$KVN(SX>&>Z,TD8@UV[BEY\AD,&ON#(,%V2>UDBMR"5AL_-'OA[-.M]OJ
M7-8^*+&)!XM-3)[^5>&)7+.[\-1">.KME'* \VSM D\EL"\X1I28B+@F'L$R
MHY%EUDN1I&2T5)%Z"4!>>$BB 'FY0#Z_#F2GHR.*6&02!LV0/$5&2XPXQ3HJ
MSF6RI5342P#RP@,1=P%R\0#<#\U[,\LR5C282"-R1"C$0]3(.*^03($3DW=:
M*)S3G40;YL<*H;G$("Z[@<,EPM4/._5QALRO53RUYY,ZMB&Z0;O5BS\G+%Z$
M V1Y&[NS-Z3.HQ3K_=[VM5':3ULP,H7:EJ,XQ@D3EC/%@D18-3O(>$26*XIT
M\)HXYS67OFD#1,R]<Z"*AW-U ;Z\W=T%X(^D1,:E&XB$@8T>49=KPDDND9&,
M($PXYD8$ZDQH4K49OW<MRP+PU07X\K: %X _(,#?3XL3NKOE#SGS03 /XL2%
MW">'8F0P$P@X7 CN<1*>Y:Z[2L_W\7N^D0VY3E==FKP^MKVCV.KTFN)25?2Q
M\\6Z;FS9HRK&1IQT.]9UNIW!>0EY/$BRU$[/5]'6<2N._MWI'=BO?U^.S.9D
M8 JC+9+19C6)D]8;;#E*WEG$+<EE;#6#5UYX18AR3(\2+L0J>5N*[W3U-,E]
MH5U"(C^/ZADA$J.(VF.&A+08\<@SJA5&,5#&<B>PP'@)B;P 6"\TF:K ^D%A
M_>&Z_+C8/72,:T8$0P%;B3BC!%FE!+*"&"L$X03;581UB8UL-/UE6GY854T@
MY#16=M!L +?U,<B2U.V?U:U_]8>#YM4O)43R2"&29ISV^KT\+J,Z>]NC;B9%
MABR2V69E2$A&QL04HE'E;AHV(JT#1]1P+X.A3KOL.6U+4B(CSQC7RXN,? /7
M!;H_!MT9K1&H3,X":@7!%+2&$$@G;I *F K)X6--UC98"6D^9^ N+^)1@+L8
MX/IK:F)O:_LP"IXH3Q()CP/BR47D4L"(ZJ",4HH%[]<V=.D+OEJH'(4RZAS+
M&!6P;=E>N(Q>=&+=:(><:V7]?X>=NI.'K'YUJYA8A)^E'&/Y(I?0U0^S;7H/
M=P-3\BK"-IJ->8I>%E]^D767'[BUR[>\=I-1FG+=]2Z+._[3&1R_'M;PH&*U
MF0>J"-_%+<)'<\)7:4<$3AH)QFGN<TV1321W>PE2&F=2="GG!-*VN:'D2MGQ
M_"SPON3@6\'[(^)]-D70.A%!)"'.9&X/DS<K"4N1,)Z ]>V#5VYM0[25FL\@
M*FA_%FA?<DRNH/VQT/[YNL0^V#SDCG/LA4-*<I_KJ1%DK6'(R("]#490/6IN
MCXE:#;@O6V _!17S5]ZQU F3/O8C@=V_%L#+[\!8H<N_?U[2O(@\A.4%[.8)
M<#Q\DVY98W<AD&#C2FQ8K^SA7"CMS;69R;TJ+1@YT<L$EHY(R#"M$0M>1)HP
M2!F16V5)=>]M$"7Y:'5!O[QH7@']"H!^1MEH;[PF4B&GHT0<AX <YA@)J\$\
M<3P*AK.R$>;>>R,*Z%<7],N+!!;0/S+H/VW."1PK8PS&)J2E-R!PA$#.8X>P
MT )C*4#^Z+4-U69\E78/E%#-VL;$(_""6V&N4$CFEBY;>\5!LUC^FE4J%B=M
M&-' 7R&7CP:E8JTB*!!E+?9>4VDR?TDSKU2*._99('O)P9>"[ ="]HP<\5B)
M;)L@3XD'9"N,G#(<1<H==XHP)GG3G<:42,MSA?:2(RT%V@\![>TYT:&\8<QF
M+$N<W8M8(Q,B14$9:7W T89<1XFT^0T5XDI4Y;%SPT[M>8Y*EF#)@U66OCU(
M_-=H+ I?+9*O9D6&D(90[1)B-H(IDK1%,*(*F<1#"-H%EGC3FYO(TBCO&>-Z
MX86F"ZX?%M<S$@,'P3@Q%'$,Q@C'2B(=I48PG"G[/AW(C.P\H*5TRG.&]<++
M3A=8/R"L=V;DQ=&A2Y&#NN#(A91]@EXAS1RLV41HZAG#2N"U#=8&\VR%8%UB
M&HW$J(;QVF:H$M)8B9RL\<C\>34PA<,6R6%S]12B4$:"VHC"*I <$2.=C$->
M:#!,+/$TM\6DNJT,60T72?%^KF!@XU[X+A#^,0C/!C D9]BI@%@P'G&.P0)Q
M42(G<"12Y-TBN:X"Y06_3P>_*R<KRJJ\-$COSBD+$9DSBB9$N815F2D&&L-1
M%!)W&A9E'HA;V]!MC><7Y>=;<^$I*0O?/\DYAK8!;]X$$D].N_WS&%LN]F+J
ME#T@CQK6V!Z/QM^Q:P?%'+D/=\TJBF29-M8'%&P.NCI!D:,B(>E9;LW%O:&Y
M4/1*^42*J_/I13"^!>%BFRP0WS-R0_H4))8!R4 XXL9KY. EPI%KYA/6B:;&
MZ\ET0?CS1?@#J(Z"\(= ^-LY]>%EP((8CRCC!'&K$M(B)L0DX09KH8P63=H4
MN7]WJA+86"B )SN<6E7\$GO#G\N=>KI>DU6-:MQ456-"9^>%S!9)9G-R1#*A
M",B1)"(&.6($LE9Z)%20,1GM(F-K&[(M\+RY4ORCSP+I#QG?^ [2"YA_#,RS
MH0ZC4B2.(6E@L#BC#%EF#3)1^IAP8EB!]E"L;-1XIE!^R$WC9=%^()Q?;Y^Y
M]^G#86(R.LHEPBPJQ$F(R#KOD8&WO4S),1MS_,/<($#*OHU'PO'?$7[X)69@
MM'S7=DY&];!.8]5 I9>[H0*P0LM65:Y,G3M E2C(8VTDW^G5PRH/RF8O_'4U
M1+_G$=J<&J#B=5D2Y\UE8G$7HU4BIX\"YUE*D8Z@6S17F&H2/2.FR<3B3*Z0
MUZ4X5E=?KA0&6$T&F%$WRB8CO(%E$E.#N- )#![LD&!".Q&L]+G%+FNK&PIC
MW=WJ*=A?8>PO7M\4[*\@]C_,*9Y,[#@F@7!D#/%D*3+P5J8",.UL5$[FJ*IL
MDWOY*4NX9;&2)[]&_82&=9SJU?DBBV0]:NCE9I;;GXS(G_GO9K#VT_LZEH+F
M"^>SN7I9+EGNN$<$5B_$97;2^N3S!CD!IBQC+)'<IU/<4'FCM/M[-DA_*"U3
MD/YP2)]1+09+# /+4,** -*E1%HT'7D9XTG+%"AN<M7Y_ :4@O1G@_2'4BX%
MZ0^$=#^G48)7F! AD3?<(!ZI1$92AB(5!N:AY2F:)B_,L%6">HG-K&U<HJ;5
MS;"Y]\;WE^&-><@4L>N\5N+,2V&TN?XCWE)GF4>2BP",YAVRD5.4G+1"&(6I
M\5FE&'V?.'/QN*XPQA\R.:Q@_"$P/MM(46@OO'8H:0?ZQ+&<S0ZO!,,)!\,2
M#:,$4$H+QI\GQA\R:ZQ@?.D8/[JN3"[>'DHK<0K4H,!SDG=0&%E/([(Z):9B
MDHGEW(FVTBN"\1(\ 4W2-$KL]GM':!"KDU*,:_4T21ZAO7YOW+RR!(.71&=S
MO=[S@ :94, V IT)B1SAV8*QTEGA7;2YUWM;X15I!EN\J4]:EA28/PS,9QLA
M*F45H0KIQFKAS""+M4242@*#;JVWJK%:;G"G%IBO+,Q7:Q-] ?=#@/OSG"2)
M)*AD+$9!,(MX,A%I)3EB>; ))<8RFL.B1-X[F_LIQ4K,BHN2O3AH>5L?-UM7
MJE@/JHX?Y'I>^;W3JO^E$^ O=][ZUS!O9>GT?IG.^X+A^W+OH(KK5R%6:- _
M?94?6]WO=D(KW_E3),/5D#8PJJ]A /\:C]_OY^]A\*9\-9N7 U=(<9&D.)<5
M%E/@*MK<Y9TBGIN^&TX(8L)8YQ/&RNDF@BS$ @(N=P/2$W+3/BMF>,QJ8H4/
M'HD/9A602Y%(;E",F"$>;$"6&X."5@+8WX,))=<VF&ZKA94++*2PRJ2P&E&=
M0@^/0 \7FW,:BCD6A=<>E!,3>5,,:"@J'+(6J(%8QPAV8"[(-J7S_=!6S%Q8
M8L1G1025NKE]?!9.;[K]L[KUU[1\RI!J[8!\VNE] 9F5Y=/F]^73'1[.]X?Q
M5K9=A$_K/E?XM"]RB;Z#%9GA-Z]9S0P_M?!X<N6+9N]7R_K_#CMU)Q/1J J&
M&];PP[K.A<%=I]?4!2^IEP]8 _PO>][L:#WH;^:QJ>+OXQ&)]1]5ORXK^0)7
M\OG.IDYK96S@*(",0]PE RMY$(AR3SB/WFL,AC[ENDW(??H,E32L%<;TPF5\
MP?2#8OI\-GF::&LC1L+)A'C4"FF)/6*:*JL4_)?8M0UNVB"]"J2?)Z07'L#\
M/J0+:G\ M=>;E@)R#XUQ$AM+$ F:(>ZI!G4M0%UK;S@%.$M)US;8#=NRGUNB
MY$J+BC_[<,ZL)SHGI]VF%LNHE5""VX)[>&$)DJL@'-[TJ[^J/CS"4+^I^B=Y
M@.J_HX^=+_.=EE/G:PSH(E;]PE<_Q%?3[83>PO?\H<&)"DT"(BH 7^E<OUOF
M4J B6>)<$(J%M8W_[__1,)2_K5 F1<F56O4@8 'VPP+[_#JP%=:<6"80ELP
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MNJ%Z?$/-"@.\ E_-#-003K\WT<KVBN ;X7%BSR?D?1&OK;G 2" UKJV\H^2
M;!!4($MN27K- 8FK$&(^![P31W060SNW9<IYNT?#KJU:+KM&VKG=;9-O>MR)
ME_(%;BF'D^M\S&SC5)<I#:_WMW8O<QI@R<I? X5^W#]K(APC\LLW4X-8\E<V
M4;[I*=Z_'F,]L7"(Z0P,N*V1I9 9_G)%JR(:WTNS#@_JL2DR8MCQ$+3S<Y]-
M3H8/0/\"N_9'%L11%2]MN+P(7DOTA7O^7PO:'WY!QFFPZZU1(<J<17NW+.;+
M\'$GP7,8>1K@@F$E^]+I#VN 0),J4D^N>W1QMV8<C+^UV.KD.WMOYGKC#7,D
M:C]=3NT)5*_E' !@?,X[..M7H8Z]RY0#_-)(_> #WC_8H7!\MO=IF^]M'AJB
M*$XA*T@,"I**A+3D EEJF,+,J*3=VL;@K#^??C"9P=>P<1G5V_[WNZFYTOC%
MZL8A8<-)I]>I!U635MVJP2+J-NZ,9@8UF=.-)0,X'*=$-2;?96[0)"\*>*2R
M<)@AV.55'+GH7D]RC=Z-#U/?? WU:3;0NB"9<B93Z]M&RS<CT\\G9_RNB=7R
M]L3JA\Z1OM%9_-T8SXR)HIA)7 I@0J&Y9=0IXJ4G3.*$<33LT6-"/^(I_ZZ]
MM3'E$+B648CZ54X2:H3=(*]G_7HPVKQ1Q4M4YM4J:Y:1HLKK1KZ;U_"[(:P^
MDXTG<-A)N/]U_O5?L-[T<G*, ST1@"_^SDHFKV6C:#1I# ;;@I4'#EDU1L.P
MKJ><F%?+_$1^@Q4P1O8-#O"%11R7*#INSIQ[/Y7M=_,W1K+DQ2U<V=_Y^5#2
M8.&I8Z0B<8A[)9&C0B/K* G.)H])>J+^SLO26LV+J0%_XJ+CGZGTX!P'.X;/
MNN?C7$18E?,*/LXHS)P"+'34R?8TV&Y@N$XVM@V.P0*>I"@"670;4=+D',ZF
MPEXWU7.V4_:"PAH$"WZ.E\ UC%FE^66G!\*B]SE[;?):/+Z,-UL[KUNG-F\>
M[9R.F"=_*_/?H*'&2?:S/3VM^E_'_KJ<NC3*DQYOL;LQ5?<X=ILP'MQ-S%JB
M^AP'P'W C*/\+EL!$X=\HJOCW7BZ?!U/TN%R,[/-[?(OS'?-#\/@'K+);G.7
M%6TT(B3D7?C&(8-U1,I('AF!I9Z$)TJ"5U/@"C]3[^WTOL ?=]Z ^-C3_)T_
MCF'8C?OI>U/[Q7H9FW5]]U"))$P0%D46%:A0)G,:O$"4PIO!<"W]W :GE5SM
M_KYAK\;4_HW.U02^3!:Y_-[TATW4)\>?^MT<;:G@WBYB$R+)SIA)9"/'HZ:#
M'O]J=A[!-[*9_4MV+*5^#@C4KWX,+F,/U42K-B4VFBLYK>.KR8O?P$P_[=KS
M5YU>\QR:'_T&RQFLWY-R'3<4UFQ../IXK/<$Q^L8CVJK5M,U0<9R<!W?5+!H
M]"$3?)V*VS__YH^_^:'6DXM:\(')I(#K(U[P3Q2X_6Y!:S/WU1N*/HU<%X]4
MXF@NVZAQ-$S7$+A6G&89#VFJ4-==*]>L^./+B]^MW3I_Y'9?UC,C=YEJ]($+
M3C]24>G+-:[Q W7CH-E)E7U/H\!Z?C=9/]HHVLV]M^H76$?Z1=?8>S%5] C7
M6AFFO32"1VDM<UQ%&J.R3A,B[EH+^GN*XTD4ROM9/3(NE'?\:?]@!W_<>B\^
M_O/^[..GMZ"B-\7>']L\UV'XN'6$/_[Q]F+O8.?K;*&\_3]VQ>ZGO^%\73CV
M[R=[6SL7NUN?\8>#HZ^[6[]_WM_Z^_/'K5VR^PDTS+A('OS+=S\=D?W-0P>R
M4#CJD$A<(IZ<0,92C@QS'M/H@_,65H$VE?.M+Q?<G^X)EAHM1/<2B$X1[QG!
MC-*FPQ=W!GM.L!+!*BWEG2LR%Z)[0**[F"$Z26R"I4HC&:U"')XJ<I)3A)ER
M7G'&F :B8VWU1(AN(7;XD^W">66'-S&0Z92M>M 9C!,JGJ#E34N3S>^P,;4*
M$\.UDB+742<:3)5HK:51RA2"+&;GRK%Q9\[LE$R9&'E$7$J#N,,1::TQ<L%R
M![+"!\'7-@AN&U*Z:#YC,-O X1AP\TD3;H)SW$EGHH[!,9@0LIA6*PCF6=,J
MT6 )=1$Y$@'1-.0N>B8BC[65/GA#I <PD[:4JP3F6RPH\3(\F:,]0Z=5W\>Z
M'B7:C].FGZ#5Q.YC-=TPA,^/:$GB1E&#>0 -&YAV CM/C%(R!BR*LVX%B?9\
MSFJ"(53".H(8S%G$"57(,1P0D<%B;*TD3@+1@HA5:D$B=H5\<@7,E_V(I7#!
M"$6LT]QJXZ2RE(+)1)*36I!B-:T@F&>M)AI(D%1J!,9O+M'#'<JE]1#733:\
MT4R!U:18FU*Y0F!>!;_38\!S/^?[WYH]\.*%'+4>_B^7V 8%;Y33,0:;F,"*
M$F/"DNR+U/D: [J(5;^PT0^PT=[K.=,BA80#HQHTG'&(RXB1<XHBC($[@O$P
M>?5E^Z85$G'%([-H((=H ;Z<4T4X)\(PCZW&S&+GHE0+M"T*8'\$L'/F@S14
MY@I_E.&4&]P%9&/DR"=K ];1A.#6-L0*076)F6/-]:@F6W6EC8B#9K_B357R
M;\Z\7EC(\:5G)CSCY(2?:X_P?;Z>VL%2=.#"B'P^ RM*S0*,&7(X4B#RJ)!6
M'BC=8A&=9IIKLK9!9=L(O>S,A.>2A57H[KG2G?!1!^,<3X3QX)QAW 2B)+:*
M8$)*+M8J4MZL[4H898D3AG+0%W%N+% >DT@Z[Y20QA@BUS:T7D3 \*$H;QE^
ML;OL,[GM&%,W/-.)^D=WLJS85:["!I1'B=@.JUST<U8]_)1+\D5$299F&2^B
MA5A9.>ZP<LQ'0#VC(JJ8D/<R(#  .+(:C&6LJ,7*$AX-7=L@O,W-HE:.%;*'
M"[8?V@PLV%X>MN<\FM8GZR5#E'"/N,SV8;(.)>VDQHYHZ7- 5+2EOK=;\VD$
M1)^66]/?;* LPKTY;RV^++W_P_?_;(C^(=R;8\NZD/NBR'U_/KY,B)64<8JH
MLQIQZP*RCCBD+>9*"\E46ICA]J-H>>38<V&]PGH/9=X6UELJZ\V:M K+9+SW
MB#B1$!<,(\VB0$H&PX-B05&Q*)/VH5AO&?ZWGW(ASGMV%^WH?-RK?*F9EGO]
M'KI%2Y3\R\=V=L+@^+)P+#@Y_&!S,"G-LK^UP_<.C@X5A<&C,B*BN$4\I("T
M2AXI!1,\FL@TSQMD:9O+>V>'EW3,U<7U0SDZ"ZZ7A.OSZ[@&6T!$XBQRS:X/
M;3C226(4*;8F*"N\"PVNS?VW<#VAW$U"F]JH*VV7C+R<O=NMD\4G<HYKT]Y@
M,;Y8I\#B']"S62L>PE=:UHEEK!/;<_:?9TPZ'#A26C'$%=-(YS:&2FB6F%8J
MYE[RB['_%@ZIIY$V6LBUD.L*&.*%7)=/KC-&N,J5+P)8W8%A#>)::61(XDA(
M(SD!QB7,+<H(7QER;4SX7YO6!ZO<A&F\Q?2'_[FU;<3XV:%,RZ^(OL[5XWL=
MO=7I!8#>*Y2_M.B[%^OT#K=_6_T;NJ[O6*][H1>M[W3)UYXO63=-UX&_<V?Q
MNFD0,JN2IKJR^^_54Z]R-ZI1(_%,QY^&O1%1-U4?F_KJ5QUGZ_76NQA'C?H(
M'95BO[5-W^BWOG]RTAF,?_RB9Q!=Y1DT-4V:CF3?JOF9A[WJU)]1?6R;;L)9
ME/>;66"K*C<^'K=P&S4IJ^)EDS-[6RNUEO4>*'TP/;]T<Z+K\^JJ!UKK!*;7
ML+KJ73GZ$;GA1WDR7K_>J:M\X9.2K?2DS%S6S)UQF^])'[]I?KN]RAJ,OHO'
MMIOR)#@=MQUM&@)F3H-I>6KK&@V.P9@X@GEZDB=@/>[2UVNE;NXEG-N!3_4+
M3%7_)'<"[_2;DX]?A7@:>TV3[WZON<Y!YZ3Y*P$&XNBM\74VIQU=:PSK=YMZ
MY@XSSUQ.O,?L;'9+/[-L$+W@IF8Y5>$0GF52U%N4&..(D]P%P/F(@DB)!*L$
MP?I)-#7+_31'C<2:1O)-<S"8T5\ZN9UV;ET/TRMW9QGU(6YZ!M_6^W+&F3LV
M77*3[SA:@3IC[,"JDXWU!O/.=F%1BJWZ.$8XQN#8@BD_/,EP;*#7N)";)J'P
M'9BGE\"NC_MGO=9-AZP'\,]HS9I<;\J-TF9:J-W>-VW<YRPSKK@1K$^JC1IG
M;$E=R;A>4G^V9;51^Y$++FW4KKP^J]9&[0:%O^)/\+Z=U&[->7H)3^Y._=0>
MM KQHVQGO6WA+35O2A&()0<ZXY?C6QI[S^SWV_Z:&]_"7UN@V>$*.KUA#/L@
MK$9=;%^"E_X]''?W?/_ L[V3#_CCUEN\>[+-=[=V*/Q.?#S8Z^Q>?#R!:SB;
M]=+OY7NXV!%[%YY^S-[ZK;?G'PZ.SG8_?0 QTNWNTIV+O9./<+^_W]0B@DD:
M!*4<I4 U K-/(,M=0LX$G"0Q7C*QMD&T;H,F?"I5(DIAG,*)JQF?+)RX@IPX
MNY]$:^.BH1@%$R3B7EJD R$H-^ @N11\LB+7"I-MJI\,)R[$ GZ"^QS^_NGL
MP9(>7:H?/DE&FR_H8ID1*OF E,_=P**+2$<1D? :XV"QY<PLJOIAV>>PND!^
MB/2J N0% GFNII]-3#HBD->&(&XU1R:WJC&"$*:C4TRK1=7T6_[&AF^Y?)?1
M!.S&T*J8N/<?L:;+#X7'?B*(]02;C9%;FHW=*P6P=!2_]Z-Y-FOAHHS:O +.
M:/FYY?'Z&R^L .[#+)8W=%MA@G(P:"V2G@3$I>#(89#U8 D3:QUV.'JP>HEH
MDT47_;X7QIZ&V[,P;&'8AU$;A6%7A6'G/*6)$Q*X1#P)AKBA"N2($$B%P&%E
M=9YB8%@F>-OP!=<8?Q2&+;L[GF\:].KM[M@<)5/6P^Y@DLWHN_UZG%8\2FZ$
M>0^O#ZIA;/T[VN[@N!6&38)[_CAUJGK0^N_05H-8Y>]EOFU_0S<VJ?*70::Q
M^ASE64]O!!@Q:F;_*J9N](/IS.QF+JG?ZMD#V;J.8T7;[5C7Z<(@Q7KVZFW=
M9.Y/(EY3!UEOO;X2M(U8AO-5\3CV:AACN"KX.[:.+;SN]0<M%V.O94.>G'"8
MY@*JYEO=81CM=+F[?!Z=[?9OWG0A_X*1JG]IMB*<1UNU8B^?=CHIKAF-J=T.
M8B87_-=K*=O?__LN3/3PF>%_PQW#6@R,61]4-D18JYLFGYNCW1[UU>>;.:$X
MY_6^Z5=;0.F#-.Q.OO47/'I__C07Z9_/&_^T+?8/-L_S KV[M4EV-P\IC4[K
MB(&$:$+<68(LB)GF3R:D"$S%54DA;X[XJC. T_D[+%J3H6Y=S8@&>)?3HIY;
MGFZ?TZNX*E_>8#5U@\!).5V^"F.2\K:J.OGUB%/[8)0 \6;2_=+O^/Q!D\K>
M CAE7FK9R=-IF"9OC#D%+@'VA-\,>SFG'.BYTYQJE ._WOHG;V?Y'&&6##IY
M7\MH-U<^V_6#A3$&)QNSQC1^[3O#'A!Y-X:I>ZI;>5$-K>%ISOT?5@WQU_5D
M>?EBJTY_".<$([!?U>TQ)><EZ[A3PUMY=6[%KWE?3833C)8K>Q0G:YZ]X3&.
M-P3 T<8[&F'-@_7E?++UR\/  RGGTTVJRN0]"OV3$>&%QEZ #Z]VL8TO;[2W
MX,2>MVQ*>:%K;JA9O,XG6ROSV\VFH,NSC$B]ETE=C<8EC$X!=S:U+ZV*1[9J
M[ORF>[KVL.OOK T_R_U/@QJ6O$3]564K8W#^%TRB :Q/63V>YODZ6G5>[+:E
MV>7G[6%BN>.I9L@ &A"/42"8V@F!L<4\HS0)8T9.@,9ZV\RJ&PNJ84A$U#!*
M21MM W%*A>0)E@:3V>5J,AH- "Z'H@VS:S!O LUB8GSJQF*\^Q(QGFQ,POR<
M5P_C?1XC[\?4K\8*%%_]Q#HP$8>#VW\RES7_2$M1+KAP[=%-_?>XNE)]1Q&Y
M*MK/R":XV%>V>V;/Z[5?KV]\ZO30] .<O??;1^#2_)P>M1'&%#.)2P$&LM#<
M,NH4\=(3)G'".!HV.\FBU0(FE;?!.1Y2U"PIQY)0G%HC@ER[Y3S?G9RK:4I<
MPTB<8*2Q)J8,"-^O)X:"]\.3X4C(A;RYUH_WYC6+S$D?-/%%\\8Z*)1O?-SL
MHOW&N4$(#?,YAO5$@M:#RN8+1_DF6B=Q<-R')194^.C3X_Y$FN8_)Q9)/D#,
MED<7\%=?+OPC 3FV54:E!>#')^NMQUH?RLK0K QT]^PP>2<5LQ9Q32GBC,.B
M((-'$0MBC*)$<3(+6D"H%U$&)['B41.8I<X9Y8A5+%DE9U>&Z]M.Z^')"=B2
M%['^UMQQYZ-YDS=?@]65P+ILJ/K;2\FRS*F;N>Z[C^'Z8],<"X99"I(#U\'O
MF%,!PVMM);9$//A&4^#Z=3SB^ULVFOZ_M^V>E&Q=27+KQWC]]L^^=5C&US$S
M=SKL.#7E>>\"&_%RU3H&O7$&3'V7784_<>,K&ZVZ<67@A%I!71(Q.0Z+OV;>
M&QD5<=%R+?%]5H;W#0?]V4G7FYG!;?A785AEC^#37#-&$:>3_^WL?3H^_@AK
MQ.[)#LY5PCYN>5@+]C[OG>S2W2::M/MU]^#WD]F(TX>3';K_QYO/^UN?SS]\
M>GN^]\??G_<N/I_MTK?TP\4'N-:/)[L7VU]W__B8=E_C\TG$:>_BPSDH$.\%
MCE@'Q#PQB&,&%BI8:TC ZN-@!(WD8.RQ67IO?+#U35M"GW7R^R7PZWX:_#3P
MOW_C3POX6G"#,<,Z*<.=-6#U1T4-3!UAP2[4!?B/#OQW<\"WW@6PC&!22J,0
MYTPBK6- E(!28U0(P7-KJQN!?S_</\$%_\VPZG4&PRI>%VE+6O;OFG8[2Q@K
M2 V)&L>%P5H3PXFG#DQMY;%W DSNZ&FAAD>GALX4-1QLTOUW!G_\O\?8G_RG
M9_\QP_V3;0J_._MP\J:S?W#<^;CU5GRX@&O;>G.\_\\V/#NXMH/W%Q\^_>^G
M_WL!!@4.(G%FD(LA(1XX19H"S02B09>IF(CR-QD4Z)M>AV"PQ-(J4'2.,UA3
MK*)*JQ ]UI:%4.;1\YI'GP^M-1HSF:N(VZ:5C$,ZJH0,ITHE&R*A<6U#?<<P
MO4IU?PGFZ4YV@??@6H9UO#116R%^B=W^R*N879BW;\Q\248K%HJE9&S01'(:
MO?:4<#"*O-)&!5.,UL=GE//K1NO>YB$/ 'V&'2(!5A@.8X*<:NILA$#A?T1)
M( 6Q#+7Z!*W6/[-+_[B?Z\2>Y'*"\=O;LI^;K^K=53#DTH6=<@I(JXHGMM/+
M3N^KJ,?\[+C,2YV+@ZYN3LSME7=7YA+_R>5;X;2=03QI=>J<4AQ&@S+(-;,G
MZ93UX%JZY*T1MYP-,AU1@R/&;JX5:R=YBOEXHZS//.)',/+Y1SF=L-WJI)SC
MT\Z_NDP;@L_SA[GP;/;H]^M1\<NI?,NKW,7F"D9I.=](:)S)W/Q&?N/MY6N?
M0AK*M\<]CFO[9G[HYH+#7SIPY&:TQY5:QF6H)\7.^SF#%Q[1)-=U.K?IYJAI
MN\D. K:SG:JQ=W*MX)BCH_"?WBC8Z3L53"48H)P&!$?,US.(H\2D:Q<SS@R#
MJZF'N>CV:/QS[M(H'[8%E-+<A\_QU\P5ZZTW_1NN.R<VN7'%[GRYP$8PS:^N
MLKY,6SOJP0,-4Q6.YZ_%SAV_E:GZ-$_A?%U3ES-Z-E^!ND,]5>:[*==\WT,#
M<#J#RX,WL>?AR22R# M'SCF&PT[VV([R?G,6FA\7F1[G83>)7LUOZO'UYH$:
MCA*[)HD@UR+6_S][[]H<MZVLC?Z5*9V]STFJ!EHD 9! 4N4JQ7*\E(HDQY;C
MDK^H<)5&'LUHS\6R_.M/-T!R.#==+-G6A?M]ER-I."0(-+J?;G0_'<>TV=D:
M-!<Z[%@89TEACN./7XEOIR]+ZO3;SFKUAKW)_!3.,M+$]\M(6\J^>8#YR)7/
M 9CW7>EQM,G%F-UU?$0MS!G--<GSW!.6,$EDH@M"N4]9GAF?2/9(DXNKI>YL
M-YS+EW/.Y>-,*CYH4.+#NH0)J5(B B@!95$ZU+BM>ZL\[F[  KWQ)!JJ'J95
M]$/N+)BL\7 P</TY;(-J<3!V@1N[LF_CR=!\(C'S%_$"7#!+(7)GY_WA)2B@
MB?KB(J;08.<\**E8(5%=,"X!4&]D8X<(ARTDAO@&J+HF,',ER7</ =@8U3-B
M$K"NI_#C>+.S.J00P@AE>E0U1[99*:/.S_ME:LA<_ ',[K'KA)*6]/>9G</N
M!&H$ZCE^WAN'=^Z[2522L*HJ]I;HG*AQV?^DM".J&BS^4CYJ-M!@U2]Z_3X:
M8+2[$2!,QF'E0@G)^70$=L:A0;DL7ZP7&UK5;S2>ZC%@C)#F[.$&T:2/05I#
M LQ@ JL[/3_&<HRX/H.3D-$=:H;*YB]U_G2PE=7XPO_ZXV%S'K$P9S:I*^:\
M672S#@<-P(*M J;S5._PT@O9:"L%NO'L&B6C*"YDHX&TPLI5R6@@42MRB+PK
MQ?4887@U2=42HCL <PW8;!*;0\R)P=S,!<2N[.7Z!?T^&=[?UYK^@9E^;CP&
M%:31A4&?X7F:TX/W=/_@U5'A<ZZDR B7PA$F14I4FAMB,V82+1(ET\=:H%.M
M=:>YV$_7_XM6%2V0,F5[K%*].F6J)A7!8L8.,%';A'+(67UA]!KJ%-;*4KM0
M3(*6J_(GYNV9#64YB//QT:53476I"=F.6*CBRT?,#R2Z2]63$*^;<+>@W&>]
MD]"Z3\&$Q09=8/YMZ?-7732J^$'U\HN%F_ Y*!5;5OO$KC=S.G3VL'%5SM1\
M'7S'S<[^=-0H1)IO[X0SVJ@E"@\\CV$)[?H]]SE:5(USH "GH)/2[>CII-%V
MJC<X<5CO@Q8/M/=H@N&4X-0.SK%4R$PJUZ:++EA5;PN_F.#550N(;K3MP;*-
MXI+58P;K-^I-8M%2_1[!<L/0XGM4C^UA:318X/C$.+VE;8S#Q@&CXXKQH @7
MNC,?-#A\&/G#2(0;3+':R4_#(7]]31FX01DM,5JW1H&EQ8Y>W#G:X5$/ PF5
MZ]L9Q==YNCL:]P7ZQ^-Z/]YH/]39ZO-7WV:/E-J@O@[E #!0,XH'PG<\'%K$
M?IN=U^5/> 6F+1\/HCS-[W>DWHB(L4+3L_#$^'+@1L=A#*->R,:O/]*5'C<S
M/0[ >5Y##36*[!APV<5<P;?20Q!4K(XK8X-ST:DP&/>E%VNN9YG["]N^B;R;
M/=RB NN6VQ>W'*+@<WSS(>"U4$==O\;B3;MSX\<OQ[DMB\!CX.IVNJT;>^!%
M7VJ$^GE8]OCR'D,N<+?9FKT_']8UY;"GQXTXT/([8F#/A\).ZW!/E\M0?:'4
MFHTH;C52C->M'"A.68@<8G1V'$O_NZ$@M.$--*=B$1TW9N__&]]3=/@)*Q.,
MG,9XUW$\J&ZJC.:N5O6"7<Z+: ^V;_0:2OF8BP"JR9PI7+^7@CX/ZQJ_WWA:
MS\/^=38<4@SG;C=9#6+ F)U@6\1QI;'F5=ZZ]^V61;.P_0>KA+TA=MW%V+$:
M-ZQ6*3T8$8CV"QR^V?N2I0#$PKW&[ERA%:NZ]*W3=C4=1'FC,(K*B6XP,K ;
MA4I7/:&MU_V.3B?F+4PN=T,M68-X]GGZG8MAW(LCF5E.!4M)D6$FDLDT45I*
MXAC-A.)>%M(ME6(5,/<\29FU!6,\DQ:\5<-<ZHW1B5LJTHU+T(EKT-EIDJBW
M);KW4Z(K'GB)[K4EMXLBEMI$,.XR(0MF>:&5T;(0W(C<)CI?6Z)[O6C./\<(
MYK7U+&$L RUC%+,4U(BVFC+OL3KDP>*)X!;T*AQ=>8--*%:YMV[DYK $AID;
M\5V$[&"S,5Q9>R\S*UMBS\CFA$QXXP#FJB+<X)O,0Y7Z-+!B"IFU3<##T_()
M+BJ%JLC75U^#9V)@/OPZLB&<6^/J*[XS/X3@#M6V/D10L9=SP"7@%V!VS+C*
MDYC5#,=Q.E?AF1*0P&_U\>IEB2+*GJ-EF^'JBXO1% Q]E] 'CR9<B7M<%1L/
MN"X<T0]CB_6 C @B(W#>S^ A:G39/ C&&':( ]0JM)J",OB_9GZK)L9S7UP(
MMC<_@U_GY[IZPW%G>'V+U;!>,W063Z\;3PI9*C$P<HN'?+M?,6L1?C."%3Q7
M6#6RV/_[47LIM\1F.W.B=X4=OQ^[_6#TZVKC<KVQF#M@K7=^%=*K:8*&M2,?
M<DVB1L#H#2K84<C:PPTYM].;WE5U*K162*--P/.JF:M5*Y2HI=9_MSI1O!CA
M.20XCL@@/^\2-@?ML)-S,!XQTR1L]O*ZJ#>K<2PHMGEMB3&8*B:ZPIN\^G7U
M;+IQ V,:2K!KI3XOOS@9@4A$.E%P+5=E\8 N4?U+/.B+1]CA-C-;6,9WZ_C7
M<HROL5Z]$'@>+B2!18>]VSSUG0G*&&,RH)4J00E'R)6HX+<K&W*=G4 +/S25
MBWHP8SPHPT9-[WY@O^FV,!DARC1>.A+'G+(&NCB=VN-(^@%/*F/0S4#Y9WQ(
M28D5V;8:L?O-96W2 =<097IX*YW>3$@;KK9N]ZG>OZ]/6T5\0R^5B1H<(V?;
M5@C^51\]3__VX#V%<1Q)F4IFA2 9=>#4TI01+4T.MD(6A<Y]EHELT1/(G2J,
MS@IIE&'*4J&D2I*TT(Q*GXDEIW9FU'Z^F:X6_5%#D^OR:V=P?K)T-%,?QIS#
M=G/=SGE_NNH,$^T,;$N"*S\:]OMUDI.+B3'-<Q>XRYJSG+F3.4Q%63H@6'<Z
M@PY:F<]=>6?A5 =SA2,+$Z;LHZ8$98>QWF#HHX=0>5TS158>.,P'DX\!_T9K
M73MM8+["D0S:Z!EGX<CUW6<UF%3&)E ]EI<V=?XDS T\N'HE'*9:/%CJ8VX2
M9@A7A#MK"(>[2X[H6HKX^@E'^*>->U"B,]KXG;T_%W4JZ&KM1OO^;?78]_#4
M\7*)TV!Z=@&.Z=@-:C[XY)FIV;VO\'9;1SHWGA=<$9=J29C2FFB3**)H+I1@
MCG'#-EY,3F O+;&Y+\A/Q%N!+C.(_DS8&I)8YM0' !*,^#X(;J1'CGX]0$T\
M];M:DK6;7 2VY_B@^,=0*1&SL\O[=Y>SZ4TX[>B6:7>N2BOH7 RG?=N!;8W'
M*9_P/"'@[9A4;J=F%9Q=VD 1*N),+$#%Q6.Q1WXX\ UNU[66^07FA:R2F!K-
M1V[SR"T+PXV$KRKFU*QRRBI O*ZPHCJUCJ(0UA\TMYU3;H'P-48]L)H T_=7
MB4A=FG&-@-3NQ$H963B0K]^D\@3O\?DKW1F%<XJQP#BI,ULQH_,-EBY:R!#@
MP_O,?<GAP\LCPM7>56VSEL=6O[&MXT%J-,N#F"_"6>7 P3V.P?6>U.[RTK?"
MJ%9]$)_OSAH91O-E*@,PQ]-1D*C2RLU/QM)@:D<8K@N<C&N'=-R %Q42<+;<
M!&50\*:E(LV"E_D9KFGZ%QQ'A4IQ=%PFK)9!48SPK=B,]UQ)MN06UE$^>2.'
M$%]RU3"C04">YVG(DBJS3Q!%A%$%'O['X"0N>H9_8@J!^QN+@)ZM<[A_\/XH
M397A1<:)I3;!]K89TBY88IR1V*S;9EP^TJ3;V9)WMLJBPCWP3YZN6[A3NF)!
MZ]3O7OEC<W3YDYNDG(8<F85,VBK]HW;<FD4 C33<-9RBD=U6-0^MFE4)P?R6
MF<!1\YZK"58IS!T[S0CHZ^2].N"XZK4QI?2^\JF^KY9Z9TX (_?=OF_HIT75
M=8"6]-GRYV)0ZQ3<+2<3I9.<"$4]8=P51(C$DU2(7*29<H"&%X-:62ZYT(G0
MN2]83K4VU+/,>%%P:5RQ,JCUX#;YP;TR^=YF2_Q89ES.D!DW=CE>S8R[JO-B
M_)!1474F7L=_^XT?RF*SN.F-'T+GYI_#G#G"PQ(\N IE<JCB6OJ\:Y/[4D^-
M<$KF,L'HD<@SIIV@@C'#',]O8#W6VXRGSE*T=[9_\+9W>+"3[F]O?3W\^A9L
MQMO>[JD].83[?WS]/CO\:GM[K__M+[$498=\[_5?)[NG[]GN-HX7GO]ZYW(O
M^_-D]\._GSX>?#S=RW:2CQ_^14[=^3ZY+Q=YS_X!>W7X9>_U3G9X]O'D\/3M
MR=XIVJZ33[O;?_4.3_\\W?MZF'W<WF*!/Z_0)E.))33S8,,$941HR8CC-G<)
MMT(48(72Y)8$>LC,FA19;J20C%&E:6XT39SD62(4EZTD/3%)^G3D"TQ/!2#D
MO9&$P;(3D3M)P+/+N>52%X7:>)$M2](U%'J+MBN[PG8]*A-5MIN*=?D88SGI
MG=^$+NN9V"*K3)YH)@U53"LA=9::5*A4I4QF_":>3*M!OK,&>7>-!CE]#QKD
M%=_;-NSCZW^^[)V^/=U__>\)OO/'#Z]2_,['LW_XWH?=+VB+LE1X;.)#9.H9
M83[/B,X-(\J:C/F")BI'CNAEDNBK;5%F<P#R(G'&*E8X+TUA$Y6YS'JME*>M
M)#TQ2?IT1!/)?2H+ HXY)RQ+/9&:&B*M\U10[Y628(NN8VZ\DRUZ$G[4@3,G
M WC6\>6SX7&\LN>(,"[Q:'^88LX!4$ZHX<QEVB14);Q5)3]?E?065,G6$<_0
M@OB<:,/ QV%2$EDD\(\L,NIHRIU6MZ)Q?:J0],UHB*G#(\RANAB./@7AQP21
M%I;68,)G3AGX_YFP3&@ME99<,\/A_Q6ITJT&^/D:X/(ZQW:'[;Y^"\][>_+Q
MPS_9[M>WO8\PAH^O=R]V3S^QO:_@[)Z]_[I[\/X282G+I1/4I,114Q!6&$ZT
MA9\LULSE(K&I9+=O,:!I[K3/=9ZGE"5@2FC!?986*?Q5.=&:DJ<F2)^.LH1S
M(Y4C+&4I_%,PHH5 .^330NDDX99?;X<60&E-&_WD<]%VUIPGE[FZ"U2\/;^>
M>G>^QJ6DUPTG2X$IUM1IQN$Y=:K-8LI2LUBF3)5RXUFJ4>PRKB]7UHM,OAMO
MK2K3GS%'KDDJNRI-JCQDG^5YE;1..U<3ZU:EK>.I]SW3"TDZF%M73=N*+*W9
MC%=D&6J94+<DT9W/)%]!GQMX,A8)=.O7#<-8)-"]92X2YD4M'>2WI!#?+^O@
M;4G)N36P#8[75Y'@X]EF1^V!U>"9M;F4 #IT!O##.(,=CA)2)*[(G,RY+_12
MZ0Q B81:+1TSC', J86T16ZYYRE3RZ4SU>P'U;*"8[<EA;@?4@CYP$DAKB5Y
M6,QF46E*,<\EHX;I3 KGC0*$+)/4"\WH \U?69/5?MVFF=\F2WV.*AKFG\W!
M[ ;'($$AZW>T;L"8]/RYXB#K7+B0&-X)S,T$F9LO.]XAF^ 6?!#:$<PH>5>3
M+GW C""PH\%RKGUL16>,+S4;0< LX^DY9BN'[T_JJ",R88S4&+24P3+5;L?
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MXWQPQ/?-9(@GVC&#;(TGGI)$=#M_5%V.7H9>#V6)SB^1%U8D_-??.LON<>Q
MM#7+B:[_]G?#.;R2NA5!8V\<Q@)0>53YJ C&85.:@//#D;R:-6(:GX3#GUG&
M:2/#=M88J9&J7?^MZ;.&;-KZGF;VVN$3@VGS 5"'\2*Y:X,C]T:LM)O-&0[%
M9'4CO9CBCQNZK!O4[K@7,[:C8U=G J9\#@'#Q>A"Q<S!6"<7_,P)IO*7Z7EF
M.AK%(.M"NGPC_6#F-\*X*GC>[9P,+S QO>$TQD3D3B^DXZU)(!RNJ/I:F4!X
MAQ3?MIG"35.#L_6IP;<X,)+U@=&/SB=^B"'=<';%OOO95:6$&SIXN^X]\E".
M!_;?5?9_Y^+P[# [/-NYW/OPMO]Q^Q^PV^_98?;V#)[]=3?[J_=Q^S#;.]U9
MLO^'IW_T/IY^[!T"X/_X^M]/>]M;%WL')Z<?7W\\@V=^/3S[Z]/>*;S%Z5N_
M]_6?=/?X*+,@K47.2<$4V'^:>R*U3XC$IM-%+G*-B1WSIU/64Z[S0LLB+1CW
MB<Y41KD21GE?<&,7CQ,.9H?^UY]"?6OJ[_(!U?7#7&POHBF3E'O)/!.,*3P=
MD4Q[5W#%"S:OF,[4"&P+*56:6$GC^I.VU4K0L7:B?^Z+W+;^\0QKL&+A\9N2
M$;'S>C2<GC_0][N:CZT^U*D#<DWV&@PR]ETH(D?$A:BM:A;A.SMO7C</!=;Z
M6#'[<L'-XEFJ-./:&$#_(A-:"J/!TS*"9DQ05KI9(EG7%7)1M6[-!O?&C=!2
M@U';]_\.$0[ME)5+\:J1L[731;)GIG5W#SY='*56IU8@04J*=#E.6R)LDA"3
M2U98*U)N<PS$)$LNU_]6097/PWB>$2/956D8DH^^>1WZC6*/+=P;H61R6.8#
M@[T[#@1LC0XF 7_5X?6SZ=A,P3!^<B!X\3RFC+[',/1<_M9XKIX.L#U\*=#F
M#0.I4BB1O(S%;S$'.0PJIMV66Q=>)R3VE'7]"XU69F-K9/S"UL93%'\9'E-Q
M*HSQ!.BL/E("GP=/BZJ6 1TL[?6 HH?7OH9U[MR5R'N.$D]534*FL3'+:#C&
MC8^#"C\W6K6$<[O!2:PDFE:Y2_#2=;D@$KJJT600_)G'J+H.AB@>39U4E027
M/(!E,_EP*H@M=F(=K9V=ZX"4!<=L=OC0#>=&MPD7V<S(5*BBH#D/>LPQFX')
M=WF>:B^S$AR*$APN*K3EN-$*J/BR^5X'LV8YZ>.(*_T$7$F/$I]1#3"*9"+A
M@"IM2J1/#$Q.EOA44JT2P(4L3S>+Z\)*<_U *Z&)&:OS9&_UT=EBE4%,YX\W
MV#M\]PI_GC>[42FL%>:J8""TE/RY\EG23XT/AJ4MK036C5^C$FIE<I5,[F\?
MIT=:>+"W,B&<Y@5A#)P<410)\=+FW&?"&P F+S*>;_)K@MJ56EO0>&OE(I93
M_"C5U8!B\5"LAE\Q.7!_A/]%!%VU]0Z5;N6GK0"M%*"#5U^.K#0NSPQRDZ8%
MUDQ0(JG1!"!SZDU&$R'DQ@MZG4JKJ]^6ZZ%04W4;Z<XA>^*QV,.5PH:4MZ6T
MM9*U6K(.OQPECAJ593G),B<(F,64B"RCQ($WP&B6.YM3< AH<OW);)"K1:<R
M8J^0PA$:#&)U^SEBT-O(UK?YC#<5*71GP+#-"5>#@G'\%G_:]_O3";H2XU"O
M\U_ HZU4K78SMS )1#*9IE1GQ MM0&,I\+., 4?3Z=2(0B<Z!1@FBLUE3W,!
MA=U!)_UXN:E.R1Y).LA/$(ZONUM'+&<ZSY4@-M,I@07B1$AAP9QY#H:CX%ZQ
MC1<%OTXX5NH<]*K+"JA.[(,2^.G_,QPUS-]5X+TJPH\FL2P%6[PX)H0CZWZL
M)OHQ6<&K@Z[?.^GZ2F^\K*)JI&@U^Q[,*JD6N$0KEK$ZCS'4H5=68@[>;O[(
M0MYWYL39:1_T_0I0._[CLO';,SZ^0=*-3"7<,V:12!>0@R\$$2JAA,DL]2X5
M29::Q7,.7GCPRJVA29:P5#J-_(HN3R@O"B-@TR]6@_RHQ:Z;NMF=FI$G9D%4
M@6. DXT4B"TL,'7V +7,,Y<#D7K%>6[ (Y$.E+DQ1( :)Z#(-7BYWHIB20Z,
MXH9R4$P>4&9F !VDUF3(QI0CT::XJBKH(4<FL:)Y.C(G2.4; T485E1E(\<Z
MA;M*9"E%:XE%4D7IF@M @>:L.!MM0Y&.U^'N<=E;.C3)04ZY*;R9'?^ZW('X
MFAK=>.)5IU%@-36!">VK\['[K?KA=]L;G_?5Y6^]09B6\*7?YY>*PQR&G'3
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MDQ%92$I87CBBC'4DLRF5.3>><@7;>NUJ PQ!:P5+T+_<[*#57&UK.FKDP":
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MJ1H$>'-QTH/7F7MA'%( !0A1 LB =T)PA$ 7<&$OO!'Z4. P-(<*7UEZZB8
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MZ),>)DSJC#=CM> %])K*S@F\C)L"@9Q8Y_]&(5]T )7[M+0^RR.%Q'A3_P+
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M%H5 '"M /Z<=@IU-5=A<*'A9&E[C9?3[Y2<[P7DJP/>[&9R.LVSE/)+CE!8
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M'K"R^_!:@7>5%9,1N]XT;#>15#/B'1C(CGKJ*!BJX-A>&#TZK<! X"QKZ;Y
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M9XD3Q5^ EXX%&]@SMM8[5/>SUJ9R,VEXEH38H!>7>FMG+;)CM*\1-F24ZRA
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M+:D%'S\>C<"I3*19=HPYEW+95@QR69/'WWHCY$HKTB6G?]$;7T@6VY+7(WK
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M)1D+.>$^2J*<X,0)F7%AJ87]0T^9W,Q_O'C,3P.[I&3_)[6[6M"W<*:_5O5
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MD9B'*;;X'#$T*CK8G%"#VY>;"1X0<FSHA-@:()+TPO$0#(=N[[)AAH.3;MD
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M2!T9KR!"&ZY*^ JF21\Y=K1TDW;Q:!&G?(JWN_TGW(Z5VG[#/$=68A]$0 5
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M4=W]4$KJJI1"&5#QH7+(T0PK'91'S5ADH7KB1![3JU$"*::CPM=4,[XYCO4
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M$O_U$@++)*_#B6G'E!>W4-2##G MQJ\E_@?7'< *_)FV"Q0"T^O@SYUJ]MM
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M.TJ4QH0W5C#XS3-BN.?*RL(:);&3Y \K[RMDUN?J?M]NGY^8'C"$V6R\^;Y
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MZ[ZNM4?^9Z@ RW!0[9%?,QZ;5>H#+S*9JPC&<!"$@UI'=#".>-A6QWD6(R^
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M@!2-#58KI+L%ON_5T=U>"=Q[UV462TJLZ6XQW1UGN]M'IL@+"AHYD=)EA,<
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M^!/\S$8WYGNP^92S3CLK VAF7MAVJU0I>'/P6+VS; ./&^ X9>.7 \2+?.I
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M9"^G'C\A]?),77Y\#J9[CSLS4/'NYWXE=IV*F24,3+#-.1EP2,@%*Q%W!F
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MG,@ QE'GAC4=4B#)DP3&D>(U/>_6L1:C-Q.C[X<<*QV]R!SW+L?E+B*3)$:
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M%9'8_7AHL)'!:H-$2@E@/ D$YIXAE;>>(H2\UL8\=W>*3-0XO@0X;K@QTJC
MG?-<I&"LPEXQ*Z/1CC!9X_A\*2W>VOUR* 3!C&D&<I<TXH)RY(05*$BL,1&&
MR&1N4=K' ODSY:,&\M>1B4Q'&TD@7J' (#3C3 6DL<U6GGBCP QKAW.K6 WD
MRPGD3(*.2D*T)IHGD^=D,ZZXE5A@S/ST83,UD+^=TNYL?CP4COA$;$#>N#S(
MSV-DO-=(4JE(2%PH'#+OS0R _)GR40/YZ\C$WJ%5QD>GP+@[;1&7AB#M&$&.
M,0;Q4\+<Z%MDXC8@+WXY/VZ4*?[\UU/[LW':.RW.VMUN(_<^E(?8TW:O=?[K
M;++PKSK/:&+'K,2<086';5:M%1O=;N^T^JR>8+3K+PX%)F 9E4=*)H6X52!G
M"0)!I0UEBGD6N!V?2#27-06Y<+,RH?9ZC8M>MJ)Y7RUOATW;KJMFR8&6Y,F#
M3]Z'6IQA1$SS%YKMH]@+#2,B+S0]Z3$W? N9P;.&$9D%'</SJ5V-\][/XQ8_
MWBA]S@P'#YF_,Z,A3@^F=)_S-YJ+D1XPV.G^QWU7[XR8YXK:4O"-#'IJAAT=
M(XT+9_$6JW<TG:O_R3,4WE=+_WOLV']F;67=<O;2_?N-K<TO? NNN7_U^6+[
MZB/>V3UN[&Q^O]@^\9=PM8N#W0VZ_VT+[S?&^_?A^,VC*[C_DZV3/.S[B]CY
MXS/?@>.WK_X\V;KZO;FU>7"\?_6U,6UX@4V&:*DIPC37 &".D;;6(DLAD)."
M<Y()[/2:F14MYY(QJ-1H^O[0])F%Q36:+@^:CK&A&,N8TR2AF")!G%*&3.04
M.6PM#I2S1%QNJ1%T4=!T)H[Y=&+"N<;#D5SCAX=$=T^F4'W+:[Q@U+4H]-8?
M?^9J?XBO<K'^DQ;Z_JAS;HW>U.S^DV*%&6TK#2W1B/H-5F@7%HC<:(V!I_<?
M0J^3^_AK@_4 @S7)7\VU$5HQ@8*F%'$=.#+,)B24Q4)A+)G+L\N&SG]?8M8K
M[H19Z,N30&W9=.Y)'F6M<PNB<^/34ZEB+EB!DL$*<8,=LJ!OR E!G)$J4JX?
MJ',OZ)TMG '_T6Z"R#<A('IGPRH>60WXO%3@[+B6[\*=OX=K^17BT\4O*'E=
MR)ED4H[:)9N"1]YP@!SJ ](I&_QDHO7)$J$CQ*7T5JZ'5^:@?PLU^L>+AGDU
M]#P[;U9#ST) SYBWD]OQ(Z<!)64)XH!#R$43D;78TV2%"-:MK MR:[_^NX.>
M.BNS_K71_8Y2)\8AXT'1 6U\;_F9UW'I9K<?,0U7\U)^@I7\W%_("E4?0G!2
M;T(\!''W)^?1J\ ]5@FQO)'+I0O(2L&0Y(PI)J/!V&6"%#VEL;O.Z,RK]U-K
MZ8)KZ?A 5&NB\T+!"P5OB%,&6DJQ1,+2X#AFTBJSLD[7!+]'2^L<T/IFXT<C
MQ%8H+ANQ^=YFE;ZJKW!;#]&LH[#!BD[B4&K\C %=Q4Z[CLT>AT%^PE-@E'"*
ME4$FR(1XBA89L#R(>64MDWDP<ZC:+PG]K0[/ZLS0G/I&-2HM-"J->49":*.#
MDLC&*!!G1B$M,$<X16$E5S&P&I6F)HV&,ZG*OK>Q[<,IDZIFP-#8OR4FX9[/
MVMU&OO"'3LPYU!^QW_+61X21L_H-<_CZ%.NZ[6;O_/93)AI:WJA5D6!Q\V6,
M_CP>NN%G]B@BUXGV.[()[O:#;5[8R^[*/V\\U&FCA4;?X/C#W[X$PR;=T16M
M\(9IP@453"27>&#><F-#4@D3IZTA8N6:IW0CPY?VX SB"/Z?\IQ)9XP%_!6>
M29DBL7*.>T9OCOF8RNB:6Z9#S-5=<(50],IY*;;XO0E0@/[RQ^TFW-*/08MQ
M<=H.L5F1L.8VN=%VU-#HEL2MH6A4S*E5XZAU[1]QK<BW$P9Q2*<DA^T6%>%J
MGV@U#G:J;QXV,I!D>$2SD>*@$[SL<5TKINQS3WS#<0,>O),!:O0HN+VJY^^T
MG?.H,:M/;BYJM$,Y*P:,8Z^\D^%3Y[Y^,&UPX3A:'C>XHS[/=Y^4MCOHP@V]
M/'VE/*+9.&WDLZH;NAQ,IFE?#,;2E,V^U4OK3,_U3CS<WMI?<$+FG^C!%<M(
MK_"]SH]\7A%3RGRW]KQ:&)"S&U2UU3?=?+UCLW7Z+R2?E<\>OOEN95 RB>[U
MRV@7#KY@=%8TK.;8#5?G=1NG9_!U#?CX-)X?MV$E]UJA6I!;CEB=+@N@8>4-
MY>_)=PZP/KB3<G$;X:P-;Q#^?7X18_7.!E2_Y5"]DH$X7[D5!B\G T$VG#V0
MF+S":\6W6+5=WWY[U<>CBVWSG*%4='LI-7PC2]>((,:?L>,;W9COP>93SCKM
M+/Z@@WDMVZU2B>#%P6/USN#559./X,!V+F:_R*<.Y/$>)>FNC1G_A2! *&OV
M;W%7,P\UJ'#-=K#KQ:$TDIM$3*ZF-XA+)O).HD)<I4!C\M@&NA!L!Y];5>B0
M[4V)N7W.\5+H[Z$Z^*5/#)*5V1X==>)1Q4-^#D:D"W):&</N<8;:TDRU>W"K
MH;LZ.3RL$T]MHY7A81P&KL\O2\Y^+3G%'\*OT.=#R.T(8SG#-Z-;8&9 F?!H
MN@6JY0NQ(@B]8'0+]0W/TPU/3_D+/AMBAL6B$I@V@^<AA>E+^T(&77Y%O\VO
M*/O\BMSH5^3D5E%FM^HW-/*&O@XMX;]&+.'NPSJ"EO8U;0S=B\]#]V)2=F[9
M?A3+SMRQ,QK]=7,<,LJC4\X-?=)&Y'V-G4NU&3!U;I.,FDFL*.':\8"U9<XQ
MY9.C41'EV.'GJ0,M9U<>>F];]7:[54V3W>YO9CRD4((M:-S6WP[XOGWU^6+G
MCX^7.YM?3[9//'S^A>U_VR-Y6^#@#[C&[@;9NOK]9.M?X]L!7]C6R0;?W_W,
MX9IT^^KK\<%F.(;[%3M__/G] &*_K<T]N)^M"XCUKC<I=S]>;%U]/'0BX*B\
M1XE1"/N,2\A9JY$)X)\KEF(,?&6=K&(]62DQXZ;JI>"G>-?D%$O.3/$TZ'Q%
M0HHA<KX;+HK7P\W+F[B9A%'4Z8 851%Q+3AR'F,4C,BS/*PWP9=CJ?&S*^\7
M"3<?<XTGT>W-+9!,364SQS4E,8N'Y9Y1ET+R(#<8[&QNT9@Z1ORUT&+$QQ[#
MBV'$-A*PY7BMNZ3-RJ^&(MMCWA?1QF'N'4J1:,1!.I#ESB.7$@W..R5R,89:
MDWJRWF#VI>2UT_.>G9Z7C!.?PIQP+WX-,RC#!$KIVHS 6ATZSA2\QEP@)@)W
M(4_&LHFB7-Z,'/84L2"8@."1"$;!!5*KQDS.O9Q''V@FR;8%9./ZUW'6Q;PA
M:?UQ(_XHU;*N\[]K^#D3A 7)K/>:1Q(,HT8ICI5*6@JM[YD5\IK9M/'AYS7H
M/0+T/M_(EVUO;APJ$P5CC*",;HASXR#N2PZ6&3-M%,.1IY5UAI^->+,IG:UK
MZE^4JO1Y,%!3E2X/3 Q]HZVK[<WOAPG"?N,H08Y+ S"1,^HF*A2-CDQ1J37+
MP^;HM#;AY0&*1;_&>]U]_;M,(C]G@W4!\?^7I74!J^6L7< G8?O6A LHB<H=
M=10IK\ %I XCQWA$0D7)(Y4^<(A[(0">0/9?'QOOSF-F?SFU?ZF]OYL 4'M_
M,T>(H??WY2=\?DB5=Y%2C;CU#GY0B8R+&DG!1'3!. @59^3]S3%0+/HUWFLZ
M\/[:._J<Y. [KKTSSA%A.';,&AZ4M%XHHUU,6@E.O"_W5-[459RHO:M]Q:>5
MUPVZ[:.C"FN,F->9 3XQY!SER&BAP18P+6Q<61?TV?.?'J5<;YP?>';R<.X@
M\^&[R=,><4$A[JZ!>$_!N;I0;BD0<'QHD^064\41MA C<X\=,DQ#2,1P5%IP
M+)1?63=KI$Z$+D?-VY/"XKKF;6D!87O,)=(L"(PMN$0">\1%'HIC8T1.$:]4
MU"E0D6O>*)])S5OMB[P37^0E8ZVZ?FT9@&C,,_&P_(9+BK27 $1!)62B$T@F
MIY,2TI ,1&95<SE'KLE+[$G.J(J?P2.%=B\34-P(.><RNU=?H\YV7N]UEXPO
MHPQ4.3PL2FZY8?:STOE9I$#K1.<]QC?^.'Y!PULM^48K# ?QM?-'=<KS>=OC
M?;/J+-'&YLTO1P/B3"FDK2 ("RJL"]@[$F:9\IRC>+\.)I8EF'B9Q.:;P%J=
MXGRQ[?[!L GM29(&P$[FC(83'!G'&:+84 K"@F,N]JQ3G'6*<SX@H$YUOA P
MC*<ZF53)8.U0!!E#7,N(',WS:(P-($-4JV#J5&?MG;QQJO-E,>F6-.<M4%6G
M/&<*2./#'T+B5"EP34QV5WPB2&NA0(()?*"I!;":TY3GW=,79C!K86X(C/_J
M<Q!G[<I\]A6#?6IDV2]33T6CY9N]$(O')668Q@P+@6G "< B:6*TBL0*&[EU
M7-Y3KSS+,3"/[EI]""C(!06%IU-WPSUL'EWN[.8I,)_)]LF7PQ0M3UPK4&N=
M6;QU0$ZF@ R3T7'#!(XT3Z>\K3T5Q+F9)2EK;?X8)*Y[4QQA)4I.^-3(?QQI
M&!^0Q><10G>2;%<4])GTVF>M+\GO^S,?4J/3/2_^MV<[.?$*%QR1^K5B-LSS
M;Z3RY14_-,[AZ_P#0  $OY3YE@>?L9Q[\/6OO>Y"OX$[GW>S0KG,*;(Z.@:C
MFC !C_\XK M12!Z$E%1[3@AU1&$5'9: >^ <N:G$2R.^D:BA;KZ@[KO8RFVU
M@3CEL$)1"(TXD1H91\"),<I%I;RAN9SV?G@[FZI=>=\G0Y+-(T].SYKMRQBK
M#SNQF@.0>80;/V*W1,'AG)^BV6X=H8K:O^=][%8#!.#$TW8G%N58F^9E4:I9
MGMCA>_DBQ9F]K 84Y*D$)4P>MYLA=KK]T2_#B2W=M6*CN*&5.39'C9_HN!%"
M;'UX1W+P\6)K\X@<1B-2=,J@*,%]Y=J!(' 94(P^>!&I\:#0Z^<7[3[RE0MR
M)U.;\!+.M1 R$0[!N79&@E-+/-4V>)/N8&K+X=-'V\D)E>[O$21C..=WU_Z,
MW<T\"<<W*KQHA0V0B?/&5?G//]JV.47M!YF7BS:8R]AZ=[H.QYQLD$-/#3BJ
M"B,<'/@R@(%()Z7@GY)ICB-+6,(:'W=B1#E)-1X4%+YWVJM&I14;(9LW4-6/
MOW_>W=PHCN#-5W,WSO+$G/X&L(,XM94'#/UI6^"#7!9]JNFU8N"3YSE%L-1P
M_' 8D2VZS4;9+%."<_9:1N"E&F#5OWJS?3&8AC3\>[Z3:H#2S<LT,HCX8Y F
M.!/ HSAMM!JGO=,;)W<B6)?.T/VZ_8'7BL^I/\AH\BKERX#O:[7/!PY=-2:I
M!1_=.+([_AK*ZSYR&B45.E+BHN>2>P_1AXG)!H$E]<YX.CU;,1)]#-,53S''
MY8^_J\%-7[/_T1WQM+(^[H(\=3,0+_ZHR>>@[/;F_L4AM]9DKDK$O<X3; U%
M-EI00YV,Y3Y(CD.>V3>YE?N/030P3<[&9.QZ[I9MA'+(F.T<Q?-JZE=?:NW/
M":F=O-#CY) [$VF4E#'C.=/6*@GQ$0^)"XT=UM,)[EY.#K>J9QP1QXW^X\%'
MV?& <&HG[9;O)H8*D#Z62OC.)777\T,+\:[4)""?E$#<4(? 451(82G!3F 1
M,%Y9IW=)ZGG_S=X"<N5 M]L-2K+-9O=Z.EP#W+C!:+T;N%X%-_T9&'=<#YS#
M=J\<)-A?^GQ;S6:>1S<R;Q$,0PZE;*?R%<_*L83PM:-3ZJXOT>V;J_..S1*'
M\JG5;+BA@1L8M\ORU-KG[,O8SN;^U:'$1!&' 0-MGI#F7$1&>! T9YSC!L1/
MT]KG7-0UOMS>/;HZ=,%9F2V>2A0LGC<<?$[P/F54U"=LK9?DJ3[GJ/&Z:%2Z
M; ?'C+B3_7EU^1+G[?-!!JZ*#>&/Y[U.J_AE9?>OKRN_CNOMQ&6S 84CQPUG
M/]U6I=FK?%NC67FI$Y?X/XMD5J]-9?7V\Q]VTJBQW,VO]*_K-_JU?*&?6[OM
MLR_]]_"N[>G/K<WO/P^U<3:8P!%)(I>T:(PL"P))JGD*X 0*I;+G-\6<WBEQ
MO3/X?"AP:^61(Z-B1\;7EI'9 ,.J*;O@>AX/K/6M0CGRO8=G?9R;96IP5I):
M59ONI!%_KX+E*548H&A#7%[P6JUG2";=WOQ^F7=+X;[HULG'0V84-D891&4$
M@^R)!H.L"?(@H]E8<YI$WR"/2>D-Z:RDI#NK_867F6Q;RMIPJNUTD?H*YA^^
M,T<'68_RK+Z_!Z.W-ZY';=?S;G?WR&%,3FL:,0I<:\05_,BN%\)1!A @'"PF
M"S'O-J>.^H@Y,DZ]'#.=L]0YN3PJ[96C,657#KS'!TVAG8>QLQP/QGD^>NPL
MTWPPLG;&,T856["AJ(^YX5O:@^A['(I*NN?%;B=G9]_UH$\*T<*TU_ $45D*
MUM1!E>UP!'C*\V"KD>'9Z[T3A?O;W#,;B/#>I[(LT6"66WI1X.&TX$0+1A6/
MRH&_$EWR3BO%A<-F?N@GWR?Y>)N _TFWZ9?+G<T-\$,W\#[]0O=/MDC.-&WM
M^LNM/_9^[NSZJX/Q*L^3O?P=[&#S,]_:W+O8VOQZ<K!YT-BZVB,[FUL_<_7H
MP>Y'L7VU_7T:Z1@$M($'DE PF73,)XR,-PQEU@WG%8, ).9D^)I\\9F>K\T\
M]E(3KFHX778X)8E*9XTS>5N3!&&C5\D$S(1Q4LD:3M\/G(X5S2O)6>2P[D('
M@3A/X.$99E!B 0?F& -,K>#4+ J<SL1%7T"RAY$LV(>7:+&:BVN\8/Q5"ILJ
MTQ%SO<X?ATP>L7,ZBU&9"]^R:I*+S$>ML#,\T6!UU#$8:FQB7FO^4%:^I[2(
M#4W1B/H-N[Y@@<AR]IV^EL6:I. PGGF&A4411X8X&#"DM;<(*YYT2,))G0.
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M*U =)2-*C9\QH*O8:==@^SBPW9],WKG$%=$0-P>/ 6P31EHY@@0SX/%%%W4
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MQ<(X+Y&-0B-NL$?6&8>D]EPD;V3P;&U3JWF2N%<OB+4@T7-%HN5YZK^+1"_
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MT[>MAJ^EX^;DEGF<$O.E2#]I"%L6V9BKUVR!M[O V\$,UZ B^!051L9Z4$M
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MF"FZN&3LYV)T*];]E2PA.D=I]VF\*;AR7US9F2[S)XAAN6([4X K0@AD-7%
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M8H$O%OBG[M K@#(_H$RY](ATU&OLD4@X-YT)!AGG#2)4*NXT#<Q5@%+J#!=
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M:%_9UH6][*W]:^*ASIIM-#Z#TP]_^Q+4/Z=6M#Z0O(\"8YZ"2II'&JQA6)G
ME A:1,WKLQ2^$\-6#KYQ7"8:&9-8!X!DIEG4$D>X2DP^>'-]. _Q8@'&D,G3
M]X,_CF'0BGMI)+QP &]58K;5#G]\%;+]#&+[<.M?6QU_^D3/W\__/<;^[*^V
M_60&>R<?Z<[^._;YY./5P=5'N.8[ N-J[OS^$<;PEA[L?Q1[V[^>[IZT3O][
M=72U<[)SR*@4DDN%0N5E$@$CS:A#%D=%O/6>P_'9B*"FG&>QZ0[BK8+TN$C]
M 8;03'!H JZ"UG7>:6<'0H7+@'ROX17;OJQBE-0O/=#>QG#]%@S^J9E1LS.
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MQ4)(*CBLL@:HHNM4S]8]>91X\Y(^LHI:1I'L1Y?L*25$*AH5=["-I05-A.&
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M11X<"LJ)27#"8&R 6G'ID19,(,?@*"*,.YH#AO'&;/>!I7+Q.;=$X>*+VR7
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MZ@B;I@OU:5.C_)!A#-K#4R!\K;,^I!UJ1#OTY'4FC;G'=BIF9Q2*<X?C>?A
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M<V_-!>DQ1?!75_ ?E[X4P5^VX.].G?8X),H2=0C0'2.>L\ TMQH9RVE,PNG
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M\W<S=S($=G(??LNI%%X%2A()W&FFA2;)6\)$D%%I7]JO+TT.^.[)UB$VB>"
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M$;5/RUFYE9THM:9UL^Y?[8^;<QLF9NDZUOM:$"<V0-X1$_"7=]?U"=;-(84
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M/3_\WGAI3+;VHB@[S$G;G@WB+Y,??@VMP5G;7OS2ZA9#6SST*RRF(]@#Q_H
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M6F'(VM")W/ L@:".#VMP2]RNO9GK(HPPS,0@3KIT]R_#&@3;;/JRN:_F/[1
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M??]+0('5&+@'H]2?!;]Q@2# OQ>,?9E+<+J\;"<KYL7*]'9P7"R*XH<L,+
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M6<Q!*]__Z\UTMG\>OS3KEKWI(R":PQYLEMD*Z+0F]GOAE9AK _P^-F3;V1,
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M\&E?'- 70UB8V57YR^O 2=JD P-,\E9PP:G346CB Y=!LJC%FHS*YY$0\1R
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M85WR[X^UN8LKS;GX9%DB(K^[591J*$V^W*"L/H.Q7-COA:NP%BU<&G_^_QW
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MP2FBE!-JA*1)X<Q3M.SLO75@5R6I&[@!/UR$9K4!/X(X+]H[0A M1+0(XVC
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M_;MM=7*0>[<#7\/(V_9NNO+ N\6ZY1-EW<__/<3^^.^._<<,=X\.V.?C[>_
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M;.5?]M*KK ]P">@>Z]JM_N$H!G*O0 M<9Q14RQS2 W3XN-[XYS!V9C^'><P
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M!7%R;0-\CR91A2&>,4/,K1M[88BGS1 S*5UG@J"28*22 ">#1X\TDPD80X5
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M1*:=AM]4(=35)]3I7%VD@4O%4+2Y]KP4'!FC/#*<8Y4B]IR'M0UB1).8>?5
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M/"D-^D5P890E3#&M\C;,)$@T^U21M4MG+1IIZDJD[70'L4'9>N-?$R,RA]U
MD]KQP]#V!K'7/GW7ZMA.GO>M3JT#8;3WX$Z_M;O^RW(5WNG.V=NQPFOM[FVQ
MG2/_??OH/Z#(/N'=O3]!"<)Y1]O?=_<\W?YGZ_O.[Y_;NZ#P/O_W$/OCOSOV
M'S/</=X2VT>>PK5.M[,B._H@=GY_=_AI;QN4UENQ<_8)E.!;_/GXHP#EQ78^
M[*?@J V)(6U=0EPSBURR MR J"E(2;2>UD8+B&<,F]EL,$($&XR7-"K.B'#8
M8B4(]5KG+3Q^K1'!BCC)TML; C.<CW_CS]@?M@&2 (_=<W@T?AIV[#"T!C'\
M/ N.*?F^7OBG4%3/YH\?=>K5 "5!)LS!,>+")0=P4=9ZG)B,CIMSZVY1LOJ7
M/XQAV(Z[Z6:IS=KV18ONP;X.SE-%#;+1<\1%\&!GA8AP $M:^@"C;Z?G5THO
M+??8. R^+R<N\4B8B,X%)91RTZ+[&.1XM1FR=Q@;Y[C(;U%9;55WX/^=XZEW
M@:?N)3R!.AH<=H=P^]!O-N)W'\&T@^\;_<.LS> J]N?&MPB_VCYX ^UV]UO_
MU1V@5OVH#+YSP[2V,&%PVO:D'U^-?_DUM/HG;7OZJM6I7K$ZZ==CVSMH=<;6
MJIBU*BJM5W_]Z[=6&!QFUVH=U^Y5M8+VW"0>?;U>?35E+M??";;..+_V:[Q.
MKOWNILL2NH[-_2Y[\W=,B/D_+%XWFCV1A]7K%-_OJLMY5G.KJXY6?B^@DA9Y
M4$-T#_9J["TI@C)C&%80?]?M 8'%QMYA+\;&-AQ_V&^\!==H<I7X#T;T+AVJ
M)]SG*1_YUM[SBH_JF^CCL0,MD%?%7E.Z:&9(;GCK,J[UN/X%VG4TL+@,[!P'
M]C_#3BQC.M\QW;8]?SC- '=635=7<EN13,75+YX=KMM(TOVWA=U&Q.Z]][,\
MX2H^X4-MNJ?4S*FN?SB*>#ZD!N4SS6P^SPPEQ@1SKSU7'G,JA2&>"A85BXD0
M*70=TH++WK88TY^U /6?1!KRWJ&M.@W999^/WAUMG_VGM;/W4<!_>/?-%AS[
MV_'.\;;X=/:1;N_M''TZ>RNV7T^E(8_"\?8_VV?;QUL$G@_^^\"WC^"XWS_1
M3V?MHYV]3]^W*=QY[\NW_YZ-=W/D3ID'9[M[;_>9E5$9%Y"UV* <XT(ZR8B"
M82PPZA)6;&V#:=KD;+9+[OURD$]H@4:AHU5ZM[NLZG511YGCNU)PF91URAK"
M'+&$*R/X*,*N1G2$#<.%CI9 1^<]NST\X_:^QPXSAC'"-+>YD2DA@PG,D9!6
MN@ 3)SW0D:!-H6?KW1<Z*G2TFG2$@Z622HZ34MP18I7PVC'F9, D8#>B(SZF
M(UGH:!ETM//7)!T)YQ-8M $1HP3B1 1DJ"1(.!L9T<3[D/N($],T;%[;70L=
M%3I:^#92(02)4M"@';>1&/#<'!A+#@O#DQ!3ZP] )1=G;1ET-&4=Z6AL!&V!
M* D4\5S81!.+D7(&M(JG,F8ZHD8UL9@M<+4\.II3V/@)1;]&BRPZ!XU8+Z;N
M/R2D?$/X_$G3T-QC1KOC81\M82]\-$<^^C 3/%(>YDHSC!S7#'%#%)A'*L'X
MADBYI=PYNER!J!;V;G9"D8?'D(?D6-162*1DB" /B2)C=$ \@7:R"9P=*G,P
MD3<9F2UE<,4'#Z?,>>2)GAOMSCTV5FAWL3";, ._["NB;*26(.>#09QSB0R)
M$2D#$ZH838HY@!DS3<EF]PT55#V1$$]!U4)1-1GK^;+/G%6)8(6\-=FYPA+I
M0"1B0G"-#;'"<D 5Y4VA9C-A!55/)%)14+585$WIJA!("(9P1%5,B NAD+,Z
M%V41UDF?C/"Y=[DQ32UF$SH/6WSVA-?0[,1!WH[8/8Z-G]K=?O_G1NIUC\=[
M5')<X6(;Q[VHY\?+O5>/-NY2YG\.GF0?7AA^FR:0K6I:<H7_=S EK\]GY&*?
M&AS1'N9A?=_MY0\V!X->RPVK+2U[W9UN)S]IK]N&-SS8R@L_8W]06&A^+/1Q
MQC$55D3!0+='G!N*14Z0L8(AL-)P##;PD%L,$M)D_!;]Q.:Z*>.Y@729?FB!
MYA. YF4#X>SMOJ'2>6D$DDQFLR!:Y*2#'X$S8JSA-@4P$)K T/,QNE\J,.^D
M/1_NRQ;M^60A.N$9 T0%<Q&4IT:!I=Q\#QNDK:1(1L-B;LRI/<Y=% B=M>"+
M\EP41N?@&1>,/EV,3JE1@55(27CPK@6H42T2,CQ@Q+VB-EACK ,_6S29F$V\
M_+R(/5Y/QLW.[G7M78=6_[P(Q"7_NMGHQ*I0S\!^OY;-;M%R[PDVUEMFZG:2
MA=Y<FIL+'H+YVTU[]OLDMZ36]QC06>QU"ZW<B58^S3C.SL)<:65RF\U,)M$A
M$RQ# JP \*F--\F?5T)[Z(JC&XCD"734?-[P7K"O7N#]./">L!JV][TS%,37
M(!QT0MQBC8R7$1&&-4M$6$YT@?=3A?<J>OP_ GH!])T />FJY_U30-+:4A0E
M,;D%+@,W0%L$.+=*80>N(@-77<[&TN[<_K;@> 75]-S3Y45-+P/54VI:$@OF
M-DT 8Z(0C]XB*S1'-&#C'.6)YQCYZJGIEYVQMY>"8KFD,'QW#.BM2BL>=MLA
M]JIZC&^_=MNY$O"_HVT/#IL-0-QZ2>D_:DH?YNZ"YS:_VE:[#F2^KF;LKT'7
M?QE-V&^VW_(EDCD_LO,S(0="- &'DJ$0.$8\[V\RABL43"8F8C6XFX\=F7JP
MW+QIM8>#&(KD+%)R$L.$<!M0"M3E.K\!&9) :X)5[)4VQ&AR[2J/DKEZLJ&D
M L/EPG#"6OVXK[USP*P&!6X$6*LX]XB.P.+P<>2>)4O\4Q&8HN\7+BY&"R4X
M3T@F:D%<\MH?33FR##/JB%&!DNL7 )4504\]/EC8>ZEPG(P@?MSG8"-;ZAC2
M5$3$D_?(! &8I%[G=;+$B_C8^Z**V[;Z<B,M]=1H@Z@)''&C,++*!Z2T3C1Z
MIY4+>9&8T+,M=XOM_0Q6C14T+A.-4T85QI)&1R@*>=TF9R8B';Q"B9%(L7:4
MZ[O9X*L@-T7_/X+D:*>-<DH@*K+WID!H# 'OC7/"HHV!:W[M0L+;K2P<T^.8
MPVJ6?D@JL(%S>F")U<#+-1[I&L\LHU1=\55K '?SMU#T6Q/YI=RGZW).:55L
MIG*-!5_C):W0KFS%JM=JJ+7_JA1:*-=X#*J?[!9]IX:X(S%B$N1LME'Q>;/
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MFDG+0 ,IE@L,-IDI2_:>,9 7X#K, KE@]8Y8G7(0M%-$5ZMJ72X8:$U$)N&
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M"\,(Z'-DM1*( XT@T"8*.:^928*PJLX&NU(2UAO_Q-KAJ7;0^)%?5[GUYSF
MNXG% P.?5XC%5?F U^>>Y;L8W\=>3J;;@U@DXUPR<IB34<PU$T@''Q!7T2+
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M0;* 5KP81K#EP*;8U/,#V_EQ^,.( X\Z4:2'\#_=L6,?@,WKZ#Z>$]&-@C#
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MW=AE/0KM!UHSK=UCR>C2L!M%MA\;'0?V2A#8+HGCCF&'D1=;W@."HWHLO:
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MA7 Z868GD'^1(U8=S3;NB_Q#$F"4C_7M0C62]+*,>?I$JU/9KDB8P[AI^72
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M<>>IU9>%@_<]ACO6GQ;FTIO&G_17Y99TE.Y2,O0H&5I!0U4G4:VIH0;17]F
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M/E<T'.=8B_-XVP!I;H8$OL;ZFPCY-/G68&3L!@$=T!CH-5!P_+7 X0$O1NL
M3(W5.7JC\U5Q='4\YIYA@JCGLPW3ZCCN063;9L>TI@[(?.W\XN%)V+7>@IN?
M@?4XQ1Q0$)M\/BZ\1 4E"KCSM_+5E&MTCZ6<E2FS^.^WK(TL8FZW"%X@#&1
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M;TI$K\FO;)#U[X'8C^B@2$318I\HF=U&F3TZ/%,R.T=FCT@:CE/.BLZ2P<\
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M+""S1-\F)9J9336):S%6?-9YUZ=X$8F-F-.BW %C?E*X6OI@)^&09.TC;L0
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M&2GL?%TR^JY3&$H;1VE?/<_\Q.MG28HG>-T 3?UXR]]MZF,,)<95<<+#J3C
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MRHN"_NLQ]"@$S3>W?_OI_P%02P,$%     @ .(E85@_QQ3FR/P  K9D" !0
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M9!UIE[B3PH+-48+REDQ5*S-(:P3721LF^SE=[?.T;$V[6I9SX(E#"-44LSR
M%YY4K+.Y.">45_Z !V;;;7:'/5S=B@O;');M*(Z>\@EX1E:8IC56S3!ER#0+
MUM,HI53665&TMH?+)QC"8>E>@M]]<GNR=M_5>3LMO\]P 6WDHHXE$P;KM*QG
M;A8\65FT#_L<M"^*_NS5TKT#:$C^3P/YMYO\9GQXVTT)U/SJ[5F8S$D5U9CB
M1=5$=;/5)CHRM MX+1AMMD5"S,R 3=$6@=X7UWI#> S/D'R>!FQH-O4-DR46
MF?3C?^'BK*$+:?YL.JMXUGTP##S*F$&44L@XMPX<SQ&<8<)HIEG,K0,DF^ :
MDH_4@!S-1=&,)*\F\S#Y.*Z>VV*8!.G%EW1V62_"_7TZS7^,S\Y&+$I?$K/
M$B/Z%DW(A!10+Z!%GJ2+=_WBO4FR":XA>4P-2-)<% VWE8<3!]<(7$IF-,H(
M/ 3RYKA2I.]L ANX8\9PJT3KDZ/-D&U"%/MTB-*#.)I1Y8:H25LI?&!@DJTW
M5S%#K$802S%+[@+/NG68=1N]X)Z.N'>:TH8;Q(TW^VIR4LKX;!SF.'M_&6?C
M/ Y=/1>?S:9I\2YQ\?^;CB?S?]#'+[N:UN!=$<(@V*A(707E(7HF@4E=6/&R
MF-R:!7L!WH0Z_NE0YW#"ZR,58>5:LY"<%BY#8>1 *<XT.&LBH%<&!6?6Y73@
M _S=<U'?AJL:)U^-K03.A9,*BJK73$A50S Q 8VT9I4P*T3S*.2]2(84E=N3
M P\EH>XQ]<WH_>+\XFQZA?@.%Q<.[QFIR9E;'PI8S(FTO$"(-8\B^*PY(P,/
M56[,B.^"&E+DKC$YV@JDR3'ES='9RVGW\K+JXK?3LW&Z^A4G6,:+Y,'?)]4"
M?'86QN>+7,+E#_E_7RZU_5?3\"UV9=J=US(<OX89YI.N(R=C<4(W&\7$.&9#
M*X#;&J/2BN9-(2T(F8)23L5XAVKWGG<>"N^0XH>-6#A8<3?,0U[&._YK//_T
MC/!.S[_FBURMILY[D<BDJ)<M53UC)-<VAAP@12:<US1_N?F-G0UP#2E$V5CM
M-1=+RTL[W>6]BEAK+"H;#\4[6?T?@D,>+C!-6$I [T+K,_L'P0PI0-G>7&H@
M@+XSNFZL.$M;L*E'+*@+<71Q[A8]!%UDB<Q[ALTS_!Y%-*2H9&-F-!3%'7K\
M^R]W9^LUO6Y6RNO]!_KSMQ=O/KP_?7GZ]L6[DP^OZ+<G;YX_._WM[;L7__GB
MS?M7_WCQZ@V]?/'Z]/V^U;ZV?EPO!<'V&W2CFF&K(BMDF+S_%#I\/CZ[)#-[
ME(Q%Z\GOTJQF_F232)7X1'.*,GI5)-K6/OT#4/8/D*TJ#;VD];>\U7-)S[E>
M+--)?>#ULQ;/'7FEC8\%@>MD:T)<!I<, V4#C3LS(UGKNBY;@QQ2.* %A[Z-
MC/4IM8;1UW68S\>SM$2*^2O058&KNX =<L=)Z8(WZ&O&403'@P+IT42.,O#F
M"6![P!U2B*%_PO4GR9872.^64[LII2:T%2Y8#US91)YD#.!,+I!<CHK15.CF
MEX@?@;/O2.E[ODIG%()UR3(R<KE4H%Q)$!S7P*TO4O'B.;;.DKL%8$B:MQ4'
M[BZ&W6>\[:6A>\;W<MK1S$Z6-FVZ^M"%R8S\Y#K_D[QX=2V-F^C+S:J==HM?
MS.?=.%[.:ZCYP_1M6'K2)F05:79R"(ZL;A,@2"E F8QD=D>,IGDJWB$'."3M
MW1=IA\N8ACI_MH@W7@<49R-T-KF(ME;"HZ6)S('3RH$M)B4IZ$_3OE+ ;0S[
MCNG7R]EX@K,922Z.)PM)W%R]G]-/LW&^WG_7@Z7//M4?7TU.SNO1T6EYX)_<
M^,!\A%YXFAL+3(54SVD=^%H5B4N;,OG63#6_-WV@H0UK1]J#H7=7]!"IT2X3
M)XPG=7L]G9"Q>3&=+:HLGY9E5@$?:5UD0AU!<IU!D;(!+ZV")!US1C">5//\
MG$<1;;F%]%MELBG-&DJB7>D//#NK>84X(;J>T4A/\OEX,I[-*WD_X_6X1X8C
M0TU>KK?!5-/,0S &(6@=&*987//:"9LA&])98%.R]""8YLE]K\XOPKA;W/*L
M]GLAHA8>/.1ZFJC(E >?BP2'@:R8R+T3K8W;^Y$,Z;RNK0;9?^(;WJPE [AF
MC"T-7-H%R8C]U^+EB&SK4"QG8+TA5C+%P$5?P&7TDBLO;//<E4?@#.F,KBD=
M6HF@J=]P6BI+%T62L/L\3GB3O+X.EWX^P_MPLU!RTC("J35&-A+-3. N@Z#W
M942.*;2N@K\_ZB&=]35EV($%VOZP>"V\))0/B3D.6J0 JH@"H=8?%38PSB0&
MXUL?M]P#H[EK'KWEVO%Z<ELK-0OD9 %XL@ *602>1Y%R:UW[N&O^7<>P7Y-]
M7]'?MP1VGO"&I;$_X^025X=4=U-V;I9D=2;H_W,-<B56K''&@XF,$U"+9!;0
M9H \HU*>\>A:1[!W@#FDD&%K[O0MM7;IR'=.NGX-LW$:D7B5R0Q!FBRK1\K!
M"99 6R629B8;U]J@OQ?(08[F%T]:GK,9S)*;:$ HH4'94JO7);*LE4$O'->1
M'^5@_BO$(87B]N?.3H?R.\KK6$?R:W"=T38Z,H:X$F8)M\;XP1B'2:.D>6I_
MC79'L$/2SGT3K2\9-J/<K>/2D\]A?+8\*EIK871=1':5J<"YYF3E>^"B5ILI
M)9$7H#4DS[QU7&!IGBJ[-<C^M?N(\12]1 5>90M*(X)+7M.6+FU$7W1L?KOJ
M^ZB&I,/[9=;V^GTKB1U%I=\^K'V'%]7EG7Q\0?]@?C42DOODBP0>#1F-7I"/
MH&R&4K*WWA0I=>NTQF;@AZ3RC\G+0\G_"-O#<N<L7&M?*_K1%F;J<60&5VC2
M2L%D:0/3F;>.'&P)\0!; Q(KT'H!D==*U=)94C0T$\$6RZ,.,93#V_I/<VO8
MGE4[; S;R&N &P-REE5P"HJO#HKF&AR+".3;URR R%SS.DM_\HVA-2L/)?V>
MR'O?HOH5R[3#F^*L.'OQ9=X%DNAX$KJK5R2(13V9&L&:+DZE7TWFV.%L/G(A
M"\5H,E&'#(H7!='0+.MH4.>29&C>G;3'X>QS6;LF=YQ.%FE^!;O3\AN>1V+?
MI_'%J#8&R86DGH*+U1BPX!WYBC0R68R+T=S=9^^]7OWP$X:T70R%;>LWJQO)
MIEVT=='BY3><?YJN58E=Y)5^^!0F'_"<U$:=BYMC_A$RHXU#1YK#U^MZA4'(
M6 _Q2K+&BFQM\U#LUB@'E;HU-"(>2/AM$^-I_-/;9R*KQ"-RR[/E!J&X>OF)
M2S+!/.? M8@R2Y-H0^LCD_U!1$/*!!LJ]QK*M$F%DV4*[>S5Y%;O@-D]S0.,
M"8;[13-OLOU5YK)VUQ+@M&56.6FY$QOLH1L_<,L4LC^7*NM/=#V4JUM.RLUX
MBR75J;"FR958FXU:"%)QP%RL6512$^T=L/NQ#"DO;6@4:RK'GERI^W?RV2C+
MZ(W("6).M8 O,Q!=T""BMD5KEG3/YWL/ !M2EMIP^=9:PDTVRJ]7!][A1;A:
M6(RE]EP;66&M,C* <C6P@606>FD+.-KWF)(T$SQML#$^^( AU<P=&FG:2:9E
M'>_%>%8FG4 G?%89=(F<U&2,$*)F8!06S15ZK=N??-Z"L&45WC^7)=5";+TF
MS19A2];< .VM1.*(9+>IFDN>=$JAECWTK0-\WTV:/6XYWJ%2:%_I'3#>/"I1
M).8".0*:O 'E<@"'6@,Y P%);;H<^ST%^?ZAV[#B[-(Q[Y.5D)2K%4="H*E#
M#RE+QDA7)+([GFJ<?>CQZJW8NOV)YF%(T7AU$]#KK>JZ.NFH%B?W*ACP7B=0
MH2"XDFH4R3@F,A.VIRI#WT!Y8E'H!O3:3QK'*\'W[.3]?[Y\??I?+>OL??W.
MWHOI/0"_4<6\VD6P_J_ZH)]#Q37[IL7@[3?6/OD6NW%U65-7*S0^Q^7?]'IY
MW^#%E[0(W[T+<WQ1C\#G(Z64T9$A8-81E+8. B,C1'!449.AP'S[!E"''&&#
M[*H*X6TW_3PFZ?YZ]?NL-C1]26IZDNH=CC0??UZV2HTYEN)2J!VOR8P3*4)=
MCB!0(*(J/-O61O/FZ(:T^0Z8X_>4JNI#_"V3_^[#=^,5K.%#)IQ$%Z%6C5O6
M#/"9U[);RHCD(_+<.N5M<W1#2C)Z^O3<5_Q]TW,95+V-3T@6?- &;$YU^2"9
MM3;0\A'<FR*B5[:'M-0-T0WIE/GITW-?\;?+R%D,\;2L#_MTLM<$C]!P4P*W
M9(,O[@E'03]Y"<(GEXTI1>?6&1(]#&-0M52>#N&/3:B^%?=]=D\RR>9<,CA7
MG4ZO.7A#/JCC,OI,[BAGK7/4=C5[MY^'M\NSG=GR<.?%EZJU+L>S3^>+>F\S
M$@^/3'DN!:1<L[2T9Q"D88!>H$:EI6Y^G>*[H 95F:$G*GW3%K.II!I6<+BX
M ?8>)^-IMS@E]#8+00X#N,P9J)@XN.@X6(N.M$UU)-H7:;@/R:#"9@>B2@.9
MM.S9GA#S(D[X:C:[K+V;3LOKZ>3C!^S.%[A8+DIX%B#[>IPC50)OM0 FA8V:
M8>"&M=8PWT4U)(OX4!JFK:C:4>B:S!^FOXTGTVX\OUI<5K^^"#-*@AG,F7P^
M7RJMBP/'2 $&R5(*AFFN^]J@[D<TJ"3+ ^].#634B^I97)TZO5@<3;SX@ET:
MTS2,:$*-]O6^%&V=H)@Q$$(MM\!<\"5)Q.9I)-\%-:3TR2,HGOT%U5SO7/?.
M_##]$+[4.D>5U#3XE].;>AWDU$S/ZTG5LC:<";4HG JD%J4F+2ES;6TA@2OE
MA Z"B]#ZT&%7K%LF3_Y0NJI7N3;)CUPA)4CK:V39('/QSFQ6$=\S09D77C+3
M8+3+A-62L6>U(]\@*^5EK-<@-DB@W!W!EAF63YI9!Y35,4+7T:M,(\_ 3*G:
M5]=2FR:#-$4SEWB-7PXD=+W;@?1)^C^7XPYS%=CBYV41\Y%ST2?I'>A<$U[)
M3H&0A*NKGI8Z*L%]ZY3W1^ ,Z8BS)_9\4Z6RD7#ZU,;+JO?A[+2\J5?T.]I3
M/H[3LOS]R20_'R^FI#8^/BT/WK(?.5$41A,AJD4;E%C;M?,"7C K3'71K=Q=
M7S?!^!1"*:T(."AY]^!)7R^J_\0SLG]^"X2VNFR8ZM]US@QSTD:RL(.I07GO
M&#B/"*P6*HE<2F-:MZS>&-R6H9DGS<-^)=><6'>6RN)B[GU3P5)65F1!RKIV
MFRRR9G G YH[(1DJ[53K,Y4M(3Z%($Y?).M#BOWIL 4\PILO*S)<*N*1<;KX
M6.OK^46W9L; NV+ I(3TNVAY;S[XX\BVC._\4,1J*+.^5=?K:9C,OMX 'V43
M=-"FEFH4'E2HO6E48!!+H@V\]J1QK1/!-T/V%"(X!U)4^\BLEZCS+5MP=<'A
MU>3]99R-\SAT- ^UKT0IX[,QF9&SD8S,<4(-/-:B ER052A$ D^31+]C*<36
M!3;WP3ND6[2'HMZAQ-O&95U#N[(5*]2O=[X)A!!HZ_*H[=ELTN!3Y( E.4'3
MI J[<U!_O]_YO0=M>5_V*5.E_<3WHISNKP) G*8YF>39:?>\MF6K5?^JS_H.
M:1"3T_(L7(SGX6QDD4=K8@)7*^NH+! ";=&0@TPHG-.R]*FI]@(_I'NW1U!;
MAQ-\?T;_JK<ISO[>U2O!2:+5*BGPZ&A)21'!RXBU)*8PPJ0@<NN[*=_#M%&X
MEOV@EED301WC%@FSEA1RI-$R06JYD&,;O## N'*R6.W;%U+:]1;)]O.PWL'L
MM-P<12W3!]'):)-C4$KMT*-3(.^+66!6".8\5[*T/N5Y#,\3..W8ES]W%T\S
M\;3KHWO_07B()N3"!)10 BB%<6F[+#8 DS$%;+U(=D]?.&#MYD.0I(%(6MZ:
MOW/MX"2EVC9\1OO P@4O/@NBJ@'A)+&V:+)R,9/Q$)6P0<9LFE_*^RZH)Y#:
MV9HT;075(W]>G%^<3:\0KW-S5N46EXD9LB#I.9">;$Y5@H<8D8'DV?BB1-"E
M]9'4-OB&=*/H:*QJ)+Y^%51W>1N9E#D86SQMI8JHCP'!LQA!6D:NN$W&^' (
M'74'UQ-(!#V(FMI'7'WWAG<ZV=H?E7;=VJ>>A@Q1.GII1/96JL*;=P3?O3?\
MH8I@'H@L#432HYY9U:1.EUVW5C=XD>Z'!,J$ B)8\J^5%?6LGBPW7P3*(&+,
M/112W1C?$PCJ]Z]W&HFO1X*][9!XGY]C08*XZN-\,LD+Z-<GJBJ@2B61AC2U
MWUS(C'2E4X!>%BDL%RST3[5-D ZJG.;16-=<ILVJ]#[09\1Z\C2ELK6+-*T%
M;P($'EV]6BX8=[1+QSLQHQYZP/@?A!<-Y[K/C6TUVM?U]==Z^,Z'6'C(P)E:
M7,S1$(/5P+1.TC./Q??0C'0S<-N&XI\RB_J57#-B/<>+#M-X,6'T\QDNQ#')
MZS'04:FW37T@W29KDWJ--/[ /'AR%PFQS8&W/M79!-=&=/K!8M/-Y=7.-2.5
M.:NF/\Y.)[?K(JQ*ECNMHJV)B8[5BJ($R^5B(.;"41>GLF]=9O:[H#;BT+&S
MZ9N[;$U%U<2X^59-WNK\<M/X992*T#X0GNB$JATZ:QV%Q$CT)A6:,Y'2)A<T
M-GW>1OSX0:+4O<FAX6ZUM,C7ZAF3[J._G]&;8S+*D](\YEP/71:IAK(V1%"N
MGIG'&!5FWKPC_?<P;<2@'RPBW51.S=BSRH%X-CV/X\EBNI8EDS\N:O=,9C0E
MW;5HNEI6:Y%"L6Q%]6I".^QEU8\/_),;.XZ/:%F@TW7[Y5'0X(* $)D&+%$*
MS75*JK6Y=*"A;<3E'RP8/D36]-/4?62STS8:!*RW.)7W#!P&"=)G0I*%\;R'
M"\;;->+@/UCX?'<)-._%F6BXMULV1I%B1E0@<QT8:6V(DG0UO:M%$@J+:FVQ
M/PAF(W(<NY)!:W:T$4TSIEPGGX[_5;->)O,NI$7-NUO.)^;:&0(18NT]3C@0
MG!,!3'92:^E2RJV5R :P-F+/D1/?6Y.GM;0:]YI;7N >+[/LED'U^V8@QV2#
ML:0#)99:N$I!](64(]9B+S$K%;9K0;?9<S<BS(\6\NY-,#W%"%Y-9I==K8]'
MWL5;[,JT.Z^O%FEYZ];8^KDA<R8B_0^,Y30_]?#0AQBAE)B=L-(X[C?@4Q,P
M&^5-_B !\>-(L,<3F)5.K36KGEW.YK0Y=U^C^4GYC'8Q.RR",BZ#L]:0PQL$
M"Y;V[AXZ 6\%<2/R_6#A\SZEV)..>V 77Q8O,<B=8Z2!96WHIPL$I3BPG*,*
M)EB\6Q)[0U7V\#,W(LV/$B_O52 ]T6654+P6LYWD^TB^V-A'B89OHD^0"XK:
M[5I679HA"^&*171,E)THM!V.C6AU[&(R_=*J1\'U1+7;!]GOJF1."TW5$J H
MC*G"$7*4%A0K$9P0"H*(&%DHWJ+:B5F//G8C(AV[8$R_1&HGE@-WMC<B"&_0
M@E'95^U)FRW3"DSU)9#^L\W/AYMUMA?'KA73@Z746&3MVNG<"V81*OOP*4P^
MX/G%M*O=36\RDD=.!:<B.0HV(WFH(M>";[5)5>3((F>U*5!C:FV/<B.>_6#A
M[YYEV7_W4?)4Q[-I>=OAC'Z[^,[W=8J[JVEY/_XX&9=Q"I/Y]>Y.$_=V>C9.
M-&V!=O?%(=%XLO;+;CQ)XXLSO-.Y)ZQW[EE;@,]Q'L9GL]O#W:C#Z3!P-^NB
M.HSAW!+#$#JUCGCB.3 R$SW:4+=[!S&S E8KPWVF=8JM$R(:-@3;?K:^>=+Z
M;I5-8+9HFHQD.-G,G$$(@3:O$*2/:*)M7M;I,3Q#NEI_.)9]VR6GD<2:>#G7
M&.X,\(3VPJZ[(LWPCW!VB2^^7+=UN[^N[(C)4CR+$HI5!I1'0S9V3H ^.%:\
M=()O<F31 LN0;N8?GF-'D6C#GEX/KXQGRPM1(X7:&8P:HJE9(];1_'C+P ?)
M O?>F]RZ@NL&L)J/_''IC:Q3TDK%0)10@R&)0S!&@..!6Y%,YJKU+K<EQ"'I
M^M:\^JY&;RB]@RRNKQ<.1\72?XS<6C2V]AIA"D+4@: 6]$PF*4-KQW$S9'TO
ML;4Y\.1GF60B)%8L*#3U$$1ITH!&Q&R#9JGU[<7-T3V5A;4CI[9=6SN*K7\_
M>7&7+J3%=GIRMN G_3@M:ZTDZBG*[@[ME@]HYGGN,[!&+N(]*:KO,$W)Z_T7
MN:F90)/[NSA16'9'N.[DL;JY3RQ:.UZGSUR>8Z['632YU@BCR.KA#E3.!0+6
M=G%!YV*E"(6U3N7J:2@]I(YO NM>..NI#"6B$TYY8(S5*@GUP-"2>2MIX2KF
M78BVM4?:TU &U0MX" MB@SSR@U.HB8O<<B ?PN3C^.:C(T.S*S*OM2@3[8RY
M"/!.D]6)M%EQYSR_>P)TK^/<'\(AN=-#(OF >-'G=:&=Q_-J,K\>T6S$&2N,
M/"@0)C-0VGB(03G07'D4-H3(6M?BZVDH0ZK@-Z35,"0&-2^]-?):&N/HZ2'5
M]B L)@C.6T#!2E"%_L\UO\9]_>PA%?<;(N%VDE'/]RN_7G9;E5.A6> C+ZU6
MM8EKX*F:+2Y!Y()!M+Z4I%C1HG7)MFWP'7 NUFCP:NF\YY$J4=(DU'L8)+I%
ML-M%3D*D_8\)0_^%(\[./8B'%(;IC8>;70WM1<B'*^&OE41><@*M9:G=Q#@$
M[Q6$(F,HB:N,0RSA?T2KNQ]R-174,73\,K5GU8]G]HJVN(5M4W^X[@LEC9-2
MD!E#MKQ*QA'U.<T3HBF.!YV:5^UL"'_@QN_1-5Y3\0_2J5N/PKCHBHXY@N6)
M@W(N+N83?'2"#+>(WCW)0-Y!0D/A/DC/OBGY>5V$>+W>/@UF5>OZ5YQ@J;5%
MBBB9LV A&:1MM?;U]5)QR,EDY46]V,INBZ)E$*GI6 9N51U\Y30(-QV/:X/4
M8=^.?%6[YQU^QLDEJ6G&+6T8FFQ3YFI_( -.&0U<Y*RY5%&4UATW#SK @1N7
M1UMCPV?;,!?4\G;@XN[-:3P;?US663!&!;?(5T]1@:KQG>!8+9FO46%25IG6
M0;/^1S5P$_C'6CK[\VJ0ZV6E #Z$+^O3+IS/T5@/ 6N;+58ST71A8'*0S" 7
M7 ]YO=P_JA\@?/UDUDL#7AWSM'P[,_56=8R8:)/,!; (,DECK4M?^VYS)C +
M1%0R#\7]&6B;G2&MC<%S:)"[RKVCO-5HS3N1=!$*$&M_FMK1T6N>(-,R0(LT
MS'" (IW]#7!(G8B&M)Z&S[:A)VDI9TK@28#QLMJ=*8 +P0&J'!,3JO"P2=69
M0R5I#4(1+3]YW5?F_GXR.FCDG'LBLY6@BLW@BE7 ?0W(N\#<L#W$30<ZA)CF
M@%;( ?128_(-><-??O)K"1T:6:XA(^5 83TEY2I"*"2+D(.11EN!CCV59;4V
MKB%$+?^,JVA7:@URT=SIKG<][X&7J%VI+6%5[1[CZI4ARR%H6SPS@G'3^LI;
M[X,:0J3R3[)<]B?5(-?*]76[]1OIBI$GK$N&DGDMI6421._)!S%966N$U*)U
M)^Q^1S2$^.2?9)7L2:?^[VO>7PCAIJ;..YQ=$E.GY>OO=K^ZN?NSFMWB;#3<
M1A<ZEQ6XP]G?N^GEQ:O)8[4I;@IRK7618(9+*9@&DX4!996"*)2%$".:D+(.
MJ;5BV@_QWGVA=GCZJI$"-QF]RZ0'L)IR@F8L1(<U,4Y8A2HZV[I0\QYP!W7-
M\H T_:;#U($DWJYUV>: 5[D01J(S3@A(+$50M<*B4[5.@+.%9Q$+RM9U%[9'
M.01']&GQ<1?Q'H.&WZR;H@NR[#UDI26MEF+ \UI\V 6TVB.9\LV;Z[72E+W.
MU-]Q0C_5*UTG^7P\&<_F]?W/-[UZ0DB.U;*H+&92,XO:-E)($+4*B,HR2M6Z
M)W,[]$.(UQZ:O7NL[I9<Z*7+\YUFP0\4/--<"^[1@1"ZMO>4I)QBX&"-<C;(
M&&SS-N);@WSJ6T\39O8JV29'D5M,S;.S,#Z?K>9%T[PX[0-H46A>(B.+C:."
MHCQMCSD7IC<IH[CK\X<0,SP6O0XFMV,8-K4<T^RTU,O2L_?3LSQBW";#%:T!
MQ@DP3Q9<J(7Q2]92&:%R\Q3W/> .(4IW=+5W(&FWI.>WT&[7V+_W([]BF79X
MTT=Y5 LO*BD2N&QJXV1!:XOY7!T5R9U75KK6Q4,:03^&Y[+FW)GL/(:2@)68
MR>GW]9RN$ F*K+U2R/LR0W!>MFR&>[AE?G#VMHCX["C_HWC;]=CL9@<MR8K"
M/!C'+"C/.$0>/83"BC91&NN.N"&M0]W2!N\]'OFD:+JKR(_!S]5%[A5>@<P1
MU 36&5,OGF@(GBG(15I+VSBY%*WS9W='NZ4I_W]9VDCPQR3J<J)&6F0KN$80
MM1R20C(UHT&R^S(S7AD;4^[!8-H-[, L^Z?(TAVDWE.7L_O#+V]P?EKJO!AN
M#"T@<CN2K34OK*!EA :8]]Q&[YCCK>W1;?#UXN_0][XH!1,]XM[?CP2/*NE2
MP,CH0)%_2).2'12:$"4"DPI;YT#O!'10I["]T>Z>Y=BS3 ?G;I.&RKD6Q^$Z
MJPH>(4@3H/B29(Z^!NV?@KM]W.#X<1G:L]C[3\5ZVTT)Z/PJ+//%+FI9,)JN
MW?.MOO.%S9*JM@'>*'-J]<BW9[7;V^WGC@J/12H?R.D7)-:@,G@R02"9;#!H
MQ:QH7<_^,3Q[E_)[Z+N7]>&*UXPER4#%2 LI. \QUS@G2@ST2A?3VO)]'-&0
M(EK->/)-V;YV0FFV&YZD='E>Y[I>B_]Z7D@_G^$]!X</#F&4=):29@8LJWNY
M8;4LK50@O4@Q!<X5;]UMJA7V006J>F/?423=_PZXJFL<)FMUL)=9UC1C][RU
M^]ZX\Z.:[9IM!MMH/WTYGA"57X\_XWU@1EBD+J$030P15A5&?K9T&8K-C'EI
ME6>M[>/'$>VK*A_Y]J4"MUJY6J$*I+)(6MQJ<#H7\#ZC*<;RQ%KG5G\/TY#V
MU89\N:O;FHJFV=[Z"*HU9;RN=$?19B4,><2%NPA*<@D^J (\6Y&5C=HU;T.[
M/<I![9?'854+^1U[;UP'/BUW/]#7-KG94P^T8^XP!8?9/%,LM3]?J#RMO@"O
MOH"R0'872SD9FNO6#MK1-L]U(5R?)/TWANX#C0M':&WQR48HB5:5"I(F0K "
MQEO'N4Z<:'= A?@(U">TU6[#KFV48BM!'F0'OA_LR^EE-PI,T0RIFOR5/2A-
M)D.H'6ZC06.%5<4>TI![!.F0(KF#XMS68CP2Y4[*'+L%8/H'(VZ,S-(Y0&MJ
MU0A6+P#PV@Q6!'HA7,JMS[CV@#ND).C!D&]W@1Z)@6_(H/GP!YY]QM^F9#[-
M1E*Y%#Q7H% (4)DGFBM.>ELZXTPLF)NWC=\/\9!2(P;#P[W$>L3]]\,?TU'T
M!%5)#=5# Z6" V>9A^Q-PE)TEN: D:.'@0ZI+NE@B+>+$(]I[U4UK9@)*6H!
M-B9:&P8S^&(M6 PU<RU;S5L?_NV&=$B5.P?%N*W%V'_PY?5T\I%L@?/G&.?/
MII//2+AI&.]Q,IYV;Z9SG#T+77<UGGS\1SB[Q-WC+3L^J%F(I<5 &T55UAY?
MT8R4YZ9H:\CI=/6Z&2^DA KI).<*;7K*ZKO]?O9>V'<@['\]-\Y?36;S[K*>
MO?T^"4O^8UXDJUQ.YF\[/!]?GI],\N*CM8/6).'B9E-=AL8H219G B%2 "6<
MABAU!HU,\9BX\#U<UMT+\J 2Z/8AU+?W<0\GRH;7P]=!OPP)20,3UI$-O 2>
M ]!$B)H')<$Y9T#S('**QGO?^J3B(2Q#BH+T1Y@=Y_X &UWM.U(KGUU,)[5:
MV;0LWKG>G??8US;ZWG;;V/;#:+1K+9Y3E_D(K;"H521["0M9,-Z2T202E&@=
MJD(*@+4NZW/S\'TUQ3]"MZAP]W4T/I2823>!KPT<E?8(02$"^NPL+[;8YD6*
MO@$QI*C\;G*^JQ7VF^>6KE;=G18HWM7).RV_SY9&^JT348\Y"I<Y!)%HJ 0&
M@HD62BE9%)\R-K^ON"&T(6T;;:C1ATQZ(<S=BV-*8HR&*%M<%,M(O<O)U]9N
M B/W4C1OD?H(G"$%MML38Y^Y;T:&FVO8:UK,6R8#(Z-&Y-KSEW%PF!RPG'1.
MS@I76A]Y?XMB2+'D-J+?<Z8/93[^%N:7W7A^=6UUW6H#N9\!^?UO;FQ";CF4
M9D8DJ7F\+>W5HZ]6#>.?7^(H!:=XO6I%JI[(I%%5CR1"<#*[S%P(V#K8N2FV
M?;7*IL_YYG!$,U8/BQD4;VF5^81D2ZD$WM$DF2(U;WYC?5>LPS)H>^#<705V
M$*$VV]@V17L3M+8,9;!>@4U8E;$J=?M--#^..=+LG)GV+M]V&(=E* ^(<CL)
M\>!4NYV2H)*-*'4 ;F@MJ* KU)H9(Y+57-HHBCT2WP:;73(HTNTNSN,HN9J)
MQ5VR7BSNR^8Z+Z(&+&4"C3[R:$IJGU.R+<9A6?X#XMM.0CP*U9:)ID+6KF39
M0++6UCMR&KQ(-$4N<D1O.&/'LF^WRA4^5.;(X,BVO1B/P[8_IB-$IF@B/$3D
M#I1$ <&X##QG822F5&SKN-66$(>4,3(\IFTIPL$$0T9WFE"T#(?0=Q\Z(')W
M.(<.B>B2N? F$@=BO20F%00I'+#BHQ+),!U;M[4;1$CD]TF^3CW _.)+HH]>
M'S"76N5$.UIVDIF:MQS!Z2AK14Q;&#+G?.M#FYV /LE@R#9LVTJ[-1%G3R'^
M&Y C4WBL/@L$3)*4.QF407D'D9O:><=FAZUSLAZ \B3C&ONPIX5(^M\#W\^G
MZ9^1 .::C(&3V>)K?Y]T-PWUUM_?.\UDK\<UVRG;#;K1YOF"IFYZA?@>N\_C
MA.\_A0Y_O8OO3<UVFM5+T'^$+L\^3.?A;/WW];CIS73^WSC_V@UQ9$5FP3,-
M)(%ZI.5S;7BOB<8R>.?(C32M@^V]#69?)=D;L*_?M/Q'BX+"'SZ%R>G%HJ8:
MV;U*V^(2E%*K#166P*DLP KRZ9EE7,O6-L_1!CLD,V$8Z^KNSO T>-C,-NEO
MN%6-KX;F)!<9G:GUCP4HP0WMJ-J"-%)746F'K8]V#C*P(=E-?[;EM"N_^C?;
M;DIDXNQ]^H3Y\@S)X9_.9LL*FF^[Z>?QC!Y$+]8^NKO=MM_SFAEN#8?=R'*[
M7=3TV;*B*1G]7PNJWJEIBK/?QI-IC="L<L-.:K64]6^IU=_F5[_A_-.4?E-I
MNW!(1@*3"LQRT-G7OI@ND^>0$21S6EJ7E(ZMD[8..+RV5;\W@OJ<?IC-QVF4
M>+#)ZES/D%/U\PPX@Q[JS3FO7-:!M[;/]H [) MKJ/R_NTD<BAT]%;'?"/!+
M>CG^.!DA+SPY$P!U\:"XDA X.F#6,PR:,8>M XJ[HQV2??,#DWD7;AS4C+GY
M\3K<\BM.L(SW*""Z^7?W89YL,YQ6]W$ONXY /?#D461<A)@5I%K%744,$(TJ
M4&OS&1F<-*EU+M+CB/;5D-??_A)S;?3[[8!3]LQPQ4#EY$ I3<XN8P(*6?$J
M!_I5:'X?^7%(0]JX&[+EKGIJ*9AF^^DUJ/?S,$=2TJ_I']P#S4DFE;<!:,]7
MH#QB#?U[0%>,CUE&)EM70]D(V)!VR?Z9TU!(K?ESO8]^"XJC%]DJVEA=J,<Z
MM>2/Y36@$;)),@F&O"=M\P"D(25U'D#;M!!,8^O]6S A!1M<R5!JSTN%NA9J
ML0Y\K9(<$O,BMLZ7ZW?W?7"@2C&1<@'.D'PF3U/O:A$%X;SRGK':JNB(UL80
MG.;]V/' ,F@ACX;U+ H2JOP0*!:]-R+4D_6B09G(P(=@P<DB51 ZIMS:0OL.
MI"'MLWVPI*5$FM-D>5QU#W5342&1:QQ,5>#(P&E;"XTFU(M*>[E]\9/'$ UI
M8^V3) WD<3!58E7RHEX]\RD3>UG6X&L9T!0]4VB-8[)Y6_%M5,GN([YVHQX:
MN(HYHG6!ALO(&!9D%L<8')"'A3DA<LU;VYV;(1O2AMN2/0^MEH9R:KYJ;CE4
M#TX"IAQ=(*N;RTPJHR9GLX* :+(WLAB36A^";(-O2%OS(?C47&;-677M<CV$
M3<9L&#<,>*+-@G8,#H&;" &5#CH:Y,T#CILA&]+^?1#-U$Y.!ST2J)D8DS0^
M6_9.FY:Z(BZ)FE?O:&7,I\MVM^//]</UG29'!3L^LX\CA!;#;Y6?NGK6#;SZ
MQ/L.GD:Q*.F+$H!)D@<AO(>@R$X46I=@73&9M4Y2V!S=KIJ/&// 4VX+Z7I)
MG9;:1?<F_WLZ6Q9EC2']\R9%Y2UVJ3;X"X[4M"-#0%OE0"6D^<*8P$0=O6*F
M,,F^0]_^T W)ANN)@RNE.1 1[[U);SJ.-].J%R[3HGKF]8ZPO,>RGA:W&H(@
M\R+$X@%Y).O5Q0*QA PRT_Z$4J803".6;@5L2$;A0 C:GV /QLU5YLW[RS@;
MYW'HKNH %HF8(\U19(6\UM.JA7D9DD%$)DOFTDEEE96Z%1,?@3$D$W(@O&LE
MM'9YYSLNEE?G%V'<U2R=JM9Q-DH\.5N+_Z90*SBZ+&I7(QI,<JDDK6THK0]M
M6F$?4J&-GGEZ5+$?E+3TYC-RZ\9S<A%F2 _]-/(ZQ:*- .O(<U-..L+*#5AN
MC4=ZS4KK*.!N2+<LQM%OP?D!,7)/F1Z:?^]Q/C_#92:C4EYFBPQB2AZ4T0&<
M2@),X5(7[FQJ?\5P:Y1#*LTQ+-KM*LJ#4N[9IS#Y2!]8A;3H0\L6-;7+R5*.
M9V?3/VK=W9$506J;-)1<UPUF"]%E!SP%JZ/,:/,Q^+C%$#8AJ_WSD;4O$AR4
MR2>KO,B;<-ZM#X\20ZTRU^ 3R[5<."U&EC+HR"17 9UM?I#9 /8FC'5_/L:V
M%/91(T/O<'[933Y,OXEM::^<*$D"\QY!L9J+J0(#Z0/Y>\9F+OH,##V$:Q,^
M^A^#CT<7ZT'5Y_VW>Y?Q+?H'U]'9U3"X=3&S;$ (2_9,] %"\(+V R.T3-ZG
M?)C#B#T&L5$,GOT87!X&$PY*Z+N'LXNCO#']PYK-.0YGHY!M,24HT$P&<@.Y
M@AA4 $GK41L5DY:M^Z.WP+T1;7^0LZ.CR?M@-L'*]/Z=;.MN'L;5<7P[G8V7
M<R:=$-IB@2P#F3&)6W")7B:AE45)>XB)C8R 1X%LQ+D_V7%0.\D==I^_-_L)
M9Z. VI5(AC*72,N#2PZ^W@ R:(U7M41;\QL4^^#=B)(_R$G1P>5[E!#4BTE(
M\T7P8>'"21<L8T5!,/5PGTM)>+D#B;'HP+7+H?5E^]W1;L3&/^%Y4 /9'I2+
MB\S\D_R_+U?5!)1UB,%E0((*2M7.*QP]V&"5339@.,KYSUV<&_'O4+78!\2_
MO>1Y,".POHD)QY]K1\R3CQTN3@U&9)4ZS@SI:6[)AE#TD[-"D@TA54[&D^;6
MC:R_^Q%LQ*H?Y'#G@+(Z:L#Q0Q?(HT\+Y3R=W;CQR3LLI(C)7BWU&J,NX NO
MQ>)*5BDKC[[/<./]J#;BWP]R7G-DF1XT__R;<Z9 ]FJ+7HG;/Z./_/)=AM<H
MGWSMT6M/'#&72O&A %J!H+2I;4A003'&BB(-\MC7?>#;2)K?5EP?I<JQY*0U
M<$YNCL):7IQ9!)^M*8(KS7Q?]ZSNPS.D'.\&O/CNC>==1='\^M3-NGN#M#$3
M$AZR!E9[KRA-XR2]IT!JEE'41K&]7;Y;Q[%E/G6_Z5D]LF'GN>^7!2)Z[:03
MD'*M-"@"AQ"<J35NDDR85 R'9T&#L?V]F\YFHT3NM'3<0R8S U0L$J*2!D1)
MVKJ,#GE?%_EO(QFHRMN-!]^E^/:3WQ_)[\G4J5TT0K&TW%BMYF23 %>SQ)G/
M3"D?6<#6[0H;I6 =0Q'VQ)$]Y=)?F8=UQ9^D4<(Q"5@TC=B0CQ"5<9"39#HK
MYJR21S.<6AG!JW>O?:9GX6(\#V>+<N33,O\C=#AB)C$N:>"2U_W*"0;!%MJT
M5"K!UU7->UPQ6V$=HJ;=FUN/K*;^!-F'3EY#^_?I-/\Q/CM;U*^=A\G'ZK<O
M=</=UR/!2["Y7A@GSQV4)*40.;GN3!>9A)?%V+XN]N\,>D@7!0],Q+Y$VS,C
M:]NL\>3C2=?5LYEE6-P4E-)+#TZ7 "HE"]XK6CK2&^ES0*9;Y\)L#&Y(5P(/
MS+!]1=4SD^YHXI&36CHO'$1TFBR;;&JO/@;.V<"+\HZ5H^R?0[JL=]S-<BL1
M]<R>E^,)V<-WZ<VCLD[7W%B?:PUCS^OEK%33%)C)QGI_( [="V](+:\/S*3]
MQ=4SGQ9GO:.0<D9&GKB6VI/W%A-X5Z^KH&11H/!6MDYC>@3.D&[''9@OVXNC
MO^C(,E*SH&10Q% A:F>(FJJ,S$ F1%'7O3/W:.0\&"9K,+YOZZ64:;?HQS6J
M@5:67( 2& DV>Q*L=X5$(6AU)F%\\[)!6\ ;HAN[!VN^&PYJ)*@F&02/@*N-
M==_5*3\MO\^6+LPH>S1%1 ="*EM+33@(TD>PRJ QCISJ\+WCV>V?.D3OL@$_
M>I[^'A7IPR[OR(6B8L  4F9R1Y@5X$+(@#(&Q;33FO<51=P$WQ#=R#Y532M1
M]4>FI85@59'9JP(8 ED(OE@(NAHB(OD08XZV_V.*C6VU0WN)O>Y%6T]_?U2@
M'^Z&==?NGA&%KV^=S58]2==_/=(*91&L@+"U]U:.1&>E(QBFD4M&&U#JJU1S
MFQ$,T:WLDWJ'$_<A*5L+S'2?<4;X3U+J+L/9;/$WYEN>E@XQEY! %[6XAU$@
MDI<%21?4CGRNX'KW0G;$/D1O]K T;2_B?DSY]_/0S2\OPB2?=A_#9/ROQ936
MSLPSVOXQJFB,-1!B=3!D;5]@.8?:'#$Q%[)G=A=3_M&G#JGV2M^F?+OI[T]_
MO>VFY'#,K]Z>A4GMKEG[:5XL<MF5=T8D3&"L<(1/:7"U%#JWWM8FE\'(TK>&
M>A#=D JB'$('M1%3K]O@LK[:K6C&UUIKR UF'DD5RGK?QI-YZ1D'$2,J(53)
MNL=P["80AU31Y$";6BN!];)WG5[.9^-<"U",9ZO[^XDVU8A<>-I6:>@I$3"D
MGQ1'"$)(7;PTMJ0=-JT''C>HXB ];U<M9KPW!;/J_[S.UA$K(I/R<Q!ML#3R
M:""FJ( %';EG(;#8^F[P)K@&59KC +ID;]GT?^OH91AW-0<3?\,PN^P6IY;W
M7<J93MYANNRZ\>3C<AWL? =IWR<VNY'4=.B-[B>MGR>OX#T?S]+9M"(<%60T
MC=J!R*JFWII,CI-"R%(*9]"C9*U#R(\CVE>;_7HY&T^6%>+C>+*\$K^X,?B1
MA$$_5;W;70MXB>-J1(N3EHK.P#(3M418(?= B^HCH-?<!B]:9_/O '-()W<-
M6757Y?4MP/XUX'O\6%?^.[R8=A7WW>XWR]OQF%_\^NK#\Y/=]=YNSVFF[1H,
MLY&.>X/7S6+K&>^H>%8L]Q)D6'1@UK0=%N*BM H]>6^,^]:-SV\!V,<T7U;O
MF+VZ?>E]=G/K_2OEA>:UST4$X3TG7S1$\$Q+X$YI&S1/.6YR.+SQ [?4/OW>
M(ME=X.M6>3^3W<1%NUD[H9O0TIK]BF3LX<KZN[[S?-%A&J_B]R?G=14NPUYD
M$6K%=4X@52W&ZC%7DQ/!V:)S=BRP7#8@QWXHAI1)T(8P!Y1*X_;M==@O:59J
M+&M^]1O./TWSJ\EG7!5IL4J46'OGR(RU?@*O15(-^2AH4O2)YHNW=N\V C:D
M%(+].=2?3-J5;+H7S+)],JG+#WA.NWWHKKZV&!D%IPD-.F"8:Q/EG,')>MG.
M)HW>>Z5EZ_UV>Y1;IAH,??LZD+@::J&ECEPEQ7L43&.*$&)QM5<7KX$N1OMK
M"3[P8G1N71K^#H1!=6]IJ5IVG^B&$<6'-T&=27L9GVIZ<AV<"S2XVD0+4_$Y
MJUJOHGD@<2\;Q3P]%K020#-&O,?/Y+1/$B[.8_E(<.XXK_>\:W4*E;P!A\*"
MB:(4ARQKT?K>Y1T(6QZ./Q7)[S/1/=F<-2ZTK-F%^6O)KMISM)#)/$I:&\^5
M KW,PM:L(I2 TN6<@ZVWAWLU/1_'-Z33[[XLT(82:N+]KETPKZ&_+J1YI?.Z
M&GM[V:5/888G*4TO%]'!]9J3-M6:$:: #_7&ILLT-<(3;.9]M!&U<G?<F?N#
M(WOBV/*@>^@ZYN"B:4*FOX?QY'2R*-A7L#LMO^%YQ&[V:7PQXD+)I'@!8QEA
M,=:",Y),865#<$41Y_,&-'GX"8,ZTVY#@$;3V6RO>4?&;G>9YI?U-.W9I]!]
MK.F 7M?$U$2#4S5?E1'=G-20O579>&N-:VU>W(=CV]/IH2N 9G/>3/J5C74X
MIQ/:PRZN>P&<EN6A*Q\%FXAYG -CCA,C:0_SUM2F*=GZ4%F)K4,3CR,:5%N'
M=H1H*(;&1BC9+]>N\'6">]52QKK 0'$>087D(3@3@ ?!M<\Z"M&Z,N<#4+9M
MJ/!4U$.+F6^R]2_Z*L6[?94(WMEEKO6#)S@?G^-7ZV14<I"E1 6UQ1(1U0L:
MM>%@L\S2*&=0;5*3>=OG;MO+8.A$Z'WN&RJ)5<QT.>15^(S0Z%3HH1"D(L)F
MVM(B"P$,9OJ-#T)B^P#E_5@&U6F@I99H,/7-B+ (F;^93J:K*\%+4*LPJN"F
MF.@$<"LK.84"1[L61,Z,9FAR+*WI\#BB034*:$>*AF)H9V->7^O]>H:R&&9@
MRKB"'*1TU=L)BF"07ZMJN:B8H^*A=>;<_4BVK=D_]-VCX;PWL2+NU/J?C5 @
MBRYPX/0H4"XY"$J3JO+>,,-E=FJ3U)N[W[N1'-W3D>/><]=L!6^>4KA>:6G5
M2>GDO(:Q3LOWLA#Y*(; BHL2C.&U/A,C Y='!C$:0^)'YTKK+(H##6TC;CZA
M4.:0F=$T.#*K4X3DF+_X4B%>CF>?%AD"Y3G&^2C(7"LL!S*R':N5#6MO)D4
M@P]&,E6\=SW$1QX%M5':V-.)F?8CC';N\:?I6:X-NSZ/9]/NZCUVG\?U)A*C
M!VK+'8BH!*B2:)<UK !9X\9)FX5T&WO"]S]B(SD_H>!HRQGM/T=]=:V^3+MG
M9V%\7F^HO,6.7I[7T^-%,^IUE;=[EOJN3VJ6I]YDJ(UOXUR]G':_3\BNS4M(
M)Y/5#S<!D6N?AUAY66^ +7_-1RHJK5S(8#W6\GY:0/1D0!E9A&6.]$=N;6/L
M#7KO[)'+"^)9_?[:8'4AN,H%@K.ZJ_TLS"Y)ZE>O)K/+1?K#[R2L[H^.%GTW
M>U:Q3.;_C:'['G#:J!W77.AZDT2!0K00G-8U7X(9G^M6W;JPS>%&-\0;1(=9
M"=^DR0R34>WRK?8;W]MN/.TV&IV/16I7'!19&W;4X@@A& XE!LM$8BRXUJ<I
MAQK;D.XO/.G5T@^;FJV5M^%JL>_3<);V^:*7]^P^>+H$Y1/!2ZJVF(\:7-&^
M6HDNL>!YP=9DWQC<OK.P/<.6;[^MG_RJ#OFH)AH'&P,)K?9EC8%<72$5<-*#
MJ"3W1N+1#93[L0]I?^R'E7=7]E&DWFSE[H/^1BF1;BS,)0SD>7O)7.V:5]/E
M,0,*&D(0@;R^UB5S&D$?TAXU?,;N*O,-W?'K]^L?]>#[/_[M_P=02P,$%
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MI>$\1,_((Q%>)UT8!ID/FB9<"_.'9%TSO:WA6J?Q\CL@FV"C$C7C)(("%4R
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M/+FG <4]O-E!T7=Q9F^!=W 4] :FE_.];B-0O1LM,1JQ82V@EKOY72T][N'
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M@,Z1U_O:&814^WGRDH72,IO4NA_+O8!^/ NEG7XZ."Q_ ],R6;T)J(Y,DK6
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M]UG/^V9++5K'CN^ <D(6\ZYJNVDR-Y!Y%Z7KLS%)=D9V^S#_VO^S_K1*OKJ
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MI6C75=TO9IR*CL<2-Q59]R]SN(?B>?N^D76W.'SOD\?'1)3.-./*9!8@\E1
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MV7GR48<."7?UR;R?01N6459X=X"MD:[@Y14\?J._;7-FP1HP02=0NJH#!AF
M!I!ERD8Y-<3? QYU OYN;=#&[_=O^/<*T#425Y072@DH(G)054;(B<P N55!
MF&@C'W*Q\NVGGH 7]S#35&KE+"J5:7 @G*XG5=E 4#(!]SGDQ-#0C-(A8_.8
MU<KWB<OWMO%T:N5#4+U4M?)1'ANF5+V+N:=3*V=,.Z><IGDM9)J: GVE>0"1
M+2I1I.,E/V,2[*)6WH,#(ZS<I?70;21QHZ?M)!=!,PC"U:1B9<'G&C+F8(JD
M9<GEUFZ_!^)HY*M'>>>>?/4^INTA55[%,NJ:MLXQO<TN7JZXK7C@09D"F2%Q
MV]%BZ:*F<"0';8-,!D5SV?+' )W*\M_.ZAT$!C8P7;-^"*A.8<!60(>) AHZ
M;M[+ZAU6A.W@,"HI).U3>!0UY28EVNG0GH?>!ZVL$:$TO]:;D I/Q )3,V&,
ML3LP@.!\FE^LBA*N%RX5<A6+I74OH@5E$RU</#C@QFFC3%7\"XV]?P_$]#%!
M ^=L-I_<R[(=0H)7.:^,&,Y_#[/\YN)U^#R[#.?7X$),J1@IP6CA0<6,0,$O
M+8">ALT=DZE]J_+' )T"!=I9O,.;_ZX*1%Y@_BDL+F87'V[B5B^<\O4J(DN*
M? A5E8=5$IA/)3'EBF6M>; =R2D0H(&-&QX(+1>79Z^O/EV=AYHM^5,IF"Y_
MQ\5LGM^65WG^>67=NLJA#[XDK<%8K#<)F,%CEJ SDU)FHY4<U/^"'GC'__3=
M5]\/Q?+<=P9=;-Y0<FH(OIL780#",3N%/=EQB.U"'V^.H,H>KFBXA(Q :H7T
M1E>0* W%/%R"JU,HLX*%%++QPYI;'S%9'MA0' M7QGA@8HZ\RO_G:GE9)]B;
M0S,?4?KLP!1.(5'"2!$R09>URWLQ67D_*(%PWX5G ]=TH4@OOXY9C?9Q2I=M
MRPV>Y<_SQ6_X]ZNT*HBE>.KWQ?R"ODRK_?IZ@\Z]"PI7^3-!@V*U3M$61E:1
M7M2-EAPVWXS:QHP ^-SCF?Y>Z2"H6 _YOQ+\)EUF *9.!Y_;\!SFW+.C&^>=
M?-!A*[P56Y9%!B\*S7.UJY6O[31D(FR!695IQ4[8^FYL.EX\<0AZ8%J,,7T'
M.GP=[/O+<)'#(B___)S#94V^8LS<<%<+9U*IE:@4L:G:E=CE(.NHG<XNTOK<
MNMAA$+#ISTWV]^'FXM+< 5VZ"IY7#:?W'Q$O?ZE_?1//6VFB8(K7XQQZ'9+D
M$-GJYI=)[4HTMOGUR4-83B7::&+K#K*]VW#=A.<#D'4*+QY&=9@@HXWW!E!B
M#]-W6$8>02AD0&/BJK13T-[-VIJJS8#V<\E*RW)HKL<[-2F>B#"FYL08BS=.
MEMZX5GA;[@I\7J]E.B>^*N24L= >6U/TY$R18+A3!-L'$8<TJAOPJ.G#@U9>
MF?<S:>-RB&_["E 8\S/>YH49Z8T2B59 68-E%2)X3U&+(:8KY#'[S;N5!T0<
M'GS$27BXE0E[I%'>9(B\/@_+Y=NRNN)?S5V!*QZ*06!%2IJ[*/IU7-=V E&F
M+)!^W;IO_(-@3B7T:V/M#NK[=_%<DWT(HDXQWWTT!TZDV\]=F[DT;6S=(W_J
M/K(2/4.3(X1L#"%C&5R0!4I,B3.;M0BMCZ"G\O[0W+G>SA]CXFY)<RM<KVZ.
M.V@F,S9+L,HP0J0SQ"02Y$31AZ1O&6LMB7H?Q?0K_[Z^V9HSM[-A'PSC>G<@
MYG[=/_G5AP6N7H!6O8@?_. ^78F'C6.C/W'A@3F6?(A.*<=S9%Q%P7EPM+!3
MH'8V\!E].A4[JYUBF6)/)6B^D3E#4)R!=3%:X6F+8)Y[IV+KO0L%'>UT0FW2
M+22XA!)$H!%&%Y2WK6\J'L)RZ*+=W?P^N%/Q&$MW.'*NHWM;OFG5_N77\$]5
M.OQAOEC,_ZX:XN$S_>;RRUE QC%%3T$WKZGJ5D,4AL+O;$344DE66FOVC\%W
M&DSIYI$N";^?;UM>WIR75/S+FP&<14N[=9\92.56C0B(WC9E\$X60_-Y**+U
ML>23H$Z#)VUMWS GN)ZU?.V$^FOX+_[GX[QJ7*[5YC$FZQP:"N$,#5Q'HFP1
MA$H73P1&'3<9L?6TZN$G/&_W-K1>AX*_FSZ7M?B@MC6EQ4M&PQ7X4#O/T; H
M1A<!K&9:,8?2ZEX]1*\A/&]OM[!KP]3M&S@#M")=T4+J *64*MX? G@A516,
M-)$[[@IO?2+QC'0Z]Z%"6]MW2'W[SV)V21%*J6C6)^J;#:C.%$4CA64.'%6M
M1D$+SKD$M!PE9[ 4RULW[7L:U6G0H['U.V0P_((?PGF]6R$@)D3/+!@N:Q97
M2N 4X3+6%%=,,K:Y)L#MPT_#V[O9LL/5Q+8[F)1+,#QI,!YC59.6$ @):.%-
M0N91;;;:.45MWG:G N.M>L3:O)X)PVH5J@W2UZ92%*-F%>NH-&,J^NQB5W(<
MVXWE*+\^K<T[QKY32K$.P?52M7E'^6RH)NLN!I^2$(;ES'3TA,K4[A5*TU:&
M)S"%-C/6:YM4WZ/DX]/F[<*#,79NG([VIIHQG*].H.;AXO;4\EI4-&5&(6>!
M% F=PL0@LJ) >#3>9FNCW+C'W'K@\^A##AWM[>J'>0\CME;B_?9N[1J0E4DS
M'21M+7*]DRT&/&TUZA5MR60"@9M5<=NU=[=]^ EX<W^C]='/OGNM,+M-?\O:
M>2TP0"PE@Q+"@2_.@4,6>*$-1_%L@#,?>\8)^+29":=2XLT,I8[<0E959Z1$
M \Y:"CD91A>33^A;7U0?NQ+O/E'XWC:>3HEW"*J7JL0[RF/#5%AW,?=T2KR)
M$[L534TF,0LJ<P$QI@22894/RUGRUM5CQZ[$VX$#8ZS<18DW75T?!E^O2 EI
M:6,Q ?.2QABX@H!1 X6+.6@1:0T4C=U^#\31*/&.\LX])=Y]3-LY:><:D4B&
MR80.K#2$R%),XP5G(*750LJ<)&M]'W<?Q4EX>T_C]L@-_B87:#5_:>,HI!01
M$+VF:),%<(6B(I0L\YC18/."X/LH3B6NV].^'=(LOD5T3>HAF'J5@FS!<YB(
M;E]?/>KZ/0S=_;6_*7XS46C#2UUJ%"BDO6:4DD&IUTVBE.)Y\Z* R9S_1"0W
MA>_'V+?Q"<V/>!Z^4)BQ"'\_< C(60Q!($*)EH&*B<!A\1!M<(&6(E[R1EK%
M X6>3SSH $4?>_MBWLN0!ZH ^4]8+,)%Z_*/ASZU1^W'H!%L%'[8XKWQ(3'.
MLBI6A528-=P$"JNYB.%LR .:E-]=?_C;Q;O9AX]W6_':P'DFKEA>9,W#X."\
MI7^L5,Q%H8IIO:MZ'%&C<L-O/_W/B]FJ9?A9X9GBZ.1 AT!OBJ=9EO;'$F0P
MTB0A%)>M;^\>!72P>K06?'B@#+&!Z3ML,K>"^^D?"M-G2_Q],4MX^\OE]6^7
M_"PD:6-0!ISP9([B$6+F%HHW+$D=4:?F&Y-=@)X^CYJZJG&HLQ7P6C7TQZO%
M[.+#?S[.TL=-R-<CJON]5X46@5_#)?WQY9>;W?KM0G#F=,HY4+R0C/>@5$U^
MC#E"24Y'CTQH/N0^JS/,D^#@L;FSPQW+33G&S_/%._Q\M4@?P_+.&W7F H\Z
MT43-2R)XHM FA"F:K;FU(GDC4VF=!_D$I)-@5@_S]SBKV3;R]:&4*13#U@*L
MA F)MT6!]]Q!ECQ+1^LW"C7%8CAIGNS4Z]QX4Q]+UNS6X:P3Q)*,JZ699U;6
MQQHQ.PU&AEB\2DFHULFS#X(YU"EO*V</X=!HH_>3??D6V$V.YP!H?56 ML$Z
MT EP&P<.H<4>UI^8(-9+$9V@O:*NC4935!"1O@VLJ,B1U2KQYTZ,ITZ')^?%
M&*-/(QED5&;)% &*UR,#='9]9$#!LM71!BECZVK[(Y(,VM])3VL'C;'PP;2#
MA%ZU#6ZE&+3Q<7UT@A[#O'%(3*N[-MDG[R)7+HN@M#-&E5QRL#*ELT<_N8\F
MD,Q:$J0 !$M16%LUI;*W0/^E"2<J)H:UF=FYRJ'9>?"#2C7:%>:9]#2P;$'5
M^,MA*K4"T89B'3K?>HTY?DV@,7X?K DTQM(=3GZ_Q74C3? N7.)*C2__3D$\
M_2)\H$C<*N^R$1!252]:9<9DFF>SU,$*:2U/K=..AJ,[198T\T:'@.0&VT__
M?*:8#5=:!4(R%DPA#()V::IPI)57)-#)*F.*L:RY?NT6&*?!A'WMV^%H]-MA
MOIY?_(6+RQGMT==?UL#]7=5NYF<J%971%V"NUD=PK'H5%(X71R.V&0/#UD08
M#.XTZ-''%QU.3 < 75U:$= LDHLF0V&,@&(N9!B60)A L7:)&E7K;*?!X%X,
M:7;P10=)H@>!_G95K?:VK 7\O_[)\DPSJ2W/ 9C$1&%4U0@WP=<2RA*4<-G+
MUG*%XU&>.(W:>*>#BM'=]@YG-B%ZZ30@#[4?9=(0HT)PVB1>2O(\M+ZHN?O\
MT^# SA;MH$'T^V). /+R9QKYC3;2M7H6BS+:*"28[*MZ5DW[TQ@I;'(N<ZD=
M8FM?/XSF-#S?R-I=9(ON]OQ8R6,MJ[X>U]HJK@MHY)(B($'C)L*"C9(;;1UC
MS4OB'H!R&@QH8>?[[G?[]U69I_]^G)_3IRW7*]!9E":H'#@(2]LD51.>@K01
M7"HNQ:(-EM8G%O=1G(;3][3N?7_[O=ML?II3V/%_5]V"WI;;1C\K.IYA%EH%
M9"!$*13 &@E!* 72T&[("16Y#8T]_QB>T^! ,XMO.8_:O\_W-^#J\'^<+5=]
M0&_E=$5"K62LJGI5?9T;<-(I*,3:D'PR4K4.!IX$=8K$V-?V6]BQ9ZW-W1%_
M32M;[75_O,(_YC]?7>10?QG.7W\,%Q_PU?+K2>O;0G](1/\<SJ^/['-VABQ2
M*+JI3<ED<#3GA0 TQAC)5CG&C?N?!TISVN)ZWEPZN*>VT&XO6?2'!O-Z_A?2
MS'GY/IRO!_9J^>KN&#8.8\Y,<%P(EH%SET&9F"#2^@K12\ZX<EIM"JN.8MM(
M.*=+LIY^V<*MG4]6AXSACT7(M#+_&+XL?R4'?:(96 <KC5HI']$+H%RA:$U+
M!D[)3"NV5HF'!C2Z_^339\R>UMY"CIU/4(? )2(O,5U=SO["+<BCPBRE-I!5
MU;DM:26G8&HP9U+P6@=3&O#D41"G3YEV/MC"GIW/2X>MP>N%]\W%G8GRL7G2
M*71)<*178:5@KQF]"HC@D6.NAX,>]R'4KKA.EV.3>&H+[?8^R-VF]6$4IE2,
MK[I-M3 R",(4#*!,(2G+C6F>['J$NN/MKFO&6_58*BBV:GL)$93*6M5",1H-
MYP(<A?; (JVTW#G%FK<F.7;5PU&^':)Z.,;&TPG=#4'U4E4/1WELF.+=+N:>
MC@R6H13!,>!%8PVW::8T04)R66 I2J/K/0T<F^IA!PZ,L7(7U<,JR;O*[[[1
M:A.6>V$,"+0<*%:6$#D+P$I*R'E$6]JK'FZ .!H=O%'>N:=ZN(]INZ<EKPB-
M.JD0> 9F8JB=G NX+#,4&9Q!)JUMKDYRW$U&]EGH][1O]^S2.PK>0W"]U"8C
MHWPVM+G$+@:?M.L,6N9I?H-<"DUT,12:FJ*"K#-Z)[WVKO6L?^Q-1KKP8(R=
M^S0PN)-:N*KJNL):X7737\'2ZB:B!25R+?;+5=+-6A YB6"8UEH..= >\*A#
M'Q7MZI/[[0R:&;3#DK^J<*G#7:>7O)Y_^CR_J-FC*X;'% ,+*8+W.H'2*8/3
M28,4R7"G*<1IGL3U**!3"03:6;U#\< &INMW8 BH3@'!5D"'B08:.F[>R^H=
MHH+MX$IA4K-8P-**!ZHFF4=-\Y<52G&T=4%LO3>8D I/Q -3,V&,L;M)(:SR
M$:\7+F^Y9EI4<;O@:*]:4XZ+9^"8-100)<N;]R:]!V+Z&*&!<[9*(.QJV0XA
MP:N<5T8,Y[57^IN+U^'S[#*<7X,+407#,0-&K)WUF !OM ;N6=:2*VU,ZRK#
M1P&= @7:6;S#F_^NJCI<8/XI+"YF%Q]NCJI,I!@VB@#H-*MQ:\U#-@RL\E8J
M&SW7K:\(MR,Y!0(TL''#PZ'EXO+L]=6GJ_-0,R5^HCU/NM::?%M>Y?GGE77K
M*F=%(OH1M(*N7I#R!#XH!SRY0 !E#JP,X0 ]\([_Z;NOOA^*Y;GO#+K8O&&1
MZ!!\-T?B Q".V2GLR8Y#;!?Z>',$5?9P1<,E9 12[;13EB(=H0D?S9ZUNPS!
M+84"(1:]E'E0)?$1D^6!#<6Q<&6,!R;FR*O\?ZZ6EW>ZO"9I;2Y1@S-8ZC5K
MH.U5=A"9I_G5%B;BH**2?1>>#5S3A2*]_#IF-=K'*5VV+3=XJH[Q;_CWJ[0J
MAJ%XZO?%_(*^3*O]^O+ZHMXBRTP#VMH@'(VAETD:B*$6+0CI?&RM7# *X'./
M9_I[I8-B0;W7_TKPKW?R3V+J=/"Y#<]ASCT[NG'>R0<=ML);L9D4I!/* VW4
M."C'$@05/!2ADXR&B2(';8*.DA=/'((>F!9C3-^!#E\'^_XR7.2PR,L_/^=P
M6:_W&#,WIWF,T?Z?H#DK,H5M3H OC .MODK'(FE7WUHQ=A"PZ<]-]O?AYN+2
MW $=XI(?PGD5;'C_$?'RE_K7-_&\<%*4Y"R4F&A9+9(",Q436%3.HTTYE];5
M\@]A.95HHXFM.XCE;,-UD^([ %FG\.)A5(<),MIX;P E]C!]AV7D$82V(,^<
M9BWMBJ;)T=)BR0UMY9P(F%G(-K?.OYB:%$]$&%-S8HS%&Z=?;5PKO"UWY;ZN
MU[*L1+'*:?"*TZB956O=8IZMUBZ1!<1&VY*MZ5<#'C5]>-#**_-^)FT8'JQK
M">]J.E$8\S/>IH*CY$RKZ,!%6[OX" %1V@(Y\1 $4TYL=L%\H(#SP4><A(=;
MF;!'Y<1-ALAU\X35%?\Z<=2@C4$DH.!WI=H3P1L6(3@>=7:VF.;U<P^".970
MKXVU.PCDW<5SD^L] %'?9D-WT!PXD6X_=VWO);.OK?NU%KJ+K CG8LR6D!E>
M*>_ KS1:91+92$U;WTZ-?[M[?VCN7&_GCS'Q-/V#$B)STFIPH0JVE0K&"0TA
M<,1,D8@IMDO6W%'T#]K9-T^W#1ICV,.U#>)MVP;Q*=H&/8)YHVV0D%&@]$F$
MDBELUDXKK;V3J3#IN3*;;8/X!&V#;)1*6LS$*X\4!'I.-*N$D]I1A.E=8*W3
M5*=N&^0$IN"4H8@):6"!)DW') /#HW%<JH3JY;4-&N/WP6V#QECZL&V#N*2%
MU-H 4MLJ_5@U^ 1J2#Q&SGQ.'EO?.CS'MD'M6-+,&QWBD$?4PT/..0C+@269
M0"6KP.>HR;N)_,*U]ZIU$/H<M-KWX44C:W>I]GY 0SS4!.-80,J0KKM:B<0@
MYX0Z<!]C:3]9'+E6^WXSP_YV[M05Z*OZV'59*N8[5<VK58[3=E@HQQ2"B5[2
MB$6M.' :=-"9*\YH']9ZDS(4VZD0I(,G.K4$^HKS[6+V@1A]7G]Z S!%YC!Q
M#59FLD(Q!;RJR89,>*=3!=OZ$OM)4*?(D7UMWR%;[O?P997;LU[;;E:ZM2Y]
ME3Y(1E4%3>9 Q7H[YQ('(S/W*6%R/+8.*QZ&<QJ$:&7O#OD-_R*;+'^9+Y>X
M?'OQTS\U(^=JMOSX:77G5M'^@&6^P/\L9I<4"I7ZL_4*N3F2,Z,31I\EE%"3
MW#WCX#BKEP$N&Z]I.N2MVP4T W\:-#N,+SM<O&S#?J-07[1CB!+XJF=230D+
MS'L*RP/Z' K-HJT/A1Y&<QJT:63M#BV*WN'GVYESK<BRVHN9E)VFR1&,9O5V
MV <(6CA(T<BD54IJ4\FF00'K-B2GX?\&5N[0KFC;+7.QAF?, 5S=BBG#2^V5
MAO2M2498IIWML;LY,G'C=B=?XZUZU.+&GF)JQ:2#6J\$BD(G\(&&Y(NQB=N2
MK&L]+QR[N/$HWPX1-QYCX^GT;(>@>JGBQJ,\-DS8=A=S3T<&K00%JQ6.K)IO
M.FJ(M:%([<CL"W.6F]:7:L<N;MR! V.L/(FXL=:R%H4$B)@H7HG:T_"$@B15
MR4B#U*;U?<CQBAN/\LZ3XL9C3#N-N+&/3"G,&D1,1.A4"D2#M5^0+5PXI83O
M>TEZ2@O]GO:=4MQX"*Z7*FX\RF>#16UW,/B4XL8B:!:MX)!+TJ!$;:K+1&TA
M)CAJ%K(W?2>"XQ,W[L*#,79N7%US1X7WSM*45UJ\_*9@(&8;8NV26BM0%?(
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MV>G6I87;<)SR M_,_@TSFQ_"=%-C/0!5IY.1[8@.<^:QO\>>H, >YNYP3O$
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M%16A.%EJ:EBT;%"M^G%Y_9%$Z(F</L:NC=,F?U_@I]G5I^M]](U>>43+?=*
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M/:Q(C)87(BH#RRU!D85&%B1"X3+['#+RYO?W=Q[_LL. 7?W006OC&LI-6#P
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M7D1G2A !*6#VTE9=3 W!,@3MN4T&::.E6E]\#$?WLN/!3E[L<(EW%\^-?.L
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M[649>*$U6(<V>*-T]EV*3IT(_G#KXH*(><JE= "K^NCQ/.24=]]*".]"+%Q
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MO,:],#+L". ;D@O[R+H'#A *G"_&Z55]SYQ]6T=U^6P(36(@3/$UMKM U"H
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M'\&E:J*2/EFS#>!MZ$('B -Z41OP3NX[M5%M!^NVA5X&<I<VH:J"VC(K0<M
M4%.N33JRHKTQ*N5]069;QRF>C#K=7:.3,6<?=0SE8-\]>M_V7;'!1D8>(:,/
M .6K0:ZU $D>HD'CDG1#4&83UWE8-T<IM(LC?8PV3AS*<M?>^ .F3Y,QR:D&
M6+P??YPL"[Y.%O^83&-MIES/]Y4=US:RY0@ ?0:ZM)++1MR+9<PQBTE+R92V
M(MC$LV#HN$I$QK*57T=@:;3UK")OKAY$WJP!YC??(W#H+_PYG<P>!.1L ?_]
MT0=++<YE#%C' RV4XJ'6CP%3=_$<,8?^3.R>YG2*B(<2:2>SR$&81$Z:CPP<
M!D=2=4'YC-:)UB[M140\G!5_6\1*[*/H\XC&N;>-+7>FD4 M8M8UVP3)14RH
MZ&R,U62+]+_(-#>MX[\:P/[)W9,2H0>S^G8*5^F_;L;SI3*_%SA[4QZ6/EO]
M+1+X2$J54A(,!/)EF *"5X&DIIUEH<:R-L\?.@SI3\8.K>X^+YS:BG1U62<-
M>K1>@>#.U2M8#R37 $)F$TM24O(+,;Y.$^ETCC0_&\*<8035DQ=(PF/R6682
M<ZUZ6J0"[ZKCKI-)AAGDO'6WZ4NXZ#\YA0YX(-A'E2>ZW>T"\><#P9&J/>":
M]Q"]G(A"T69F:,% YK24E+,67#(%9,J>N\Q+\+UE%UW@ T'?S-E'':=Z(!#D
M3<7:KDMCTM7E$N CR<!DFGP(+IK<NA+*Y3X0[*700QX(]M%&G_%3SP<<"LD2
MCXS5UE8>%$H!444#B0D9)2KDK$>[Z)S#RL_8-&JET('")YZ./.H"]F<X>DN-
M'Q4S?(BZ3AZ.+HK@5J(&P\C!5HXC1!\*L!2,E:+4#A@OCUMMPM$'I-8>6AHZ
MF#0;P8R1P*TA2P&56MY?@TC6EF*$R'&(:.,+"2;=2Y'[!)/NH84>S*G-IXT/
M].^62\2%Y(.V&7*NK2YR;3J7,8&)26NF8BBI];OL4UA^FDS3'I360W&R;;C6
MRZ<+LIXLHJ=1G<;\::.]#I0X0O0]'$7/(%2!J9(TN90U]E%Q%6N@?@*T3M,>
MF[D0K4^BH4FQPVX9FA/[2+QQ$;)-5._&\__\$V\6LW#]VU]?,"TP_Q9FD^G-
MP\?XVUK@5@C%@P873*QUV<AR"UR!39Q,.68=&78[(OF.!C&\J=)*D]-3J&$
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MVPBZAU2ENX#I7V[FY#W-Y[<$79]\M2QE"!"MM37!@D,HQ=/QY[G+]$OK6K]
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M2F%#0BAU:ZA,^2B:V_5N_X>VADFR_KZ@I*"J5P_,;].4"0L&7YDS\!*$,E^
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MOEV $Y73*5#+7@*[IDD#?$X9BP/_.:P.K&E6?BFF_Z0\Y*](_]?4^P>36C>
ME'/8B/FGP0-'H8$+2H>$+G+D$IM<.)J;#CZXS-_.B_VBM%XS66LE,LR/VCB!
MN\7BA=P.V#O<]1XU^8$J_7I=XO9H8+[#(YZ[.C+[WLGXG'<)5.)J8F@P'R_C
MY+S]T9[,_!=SRUB1&<E.H>AH5R/UNQ$>I C.+6TUMS;I+WWB#'%>!6]7N2'B
M7XJ.O]";?/');8KFH?3MF6[A%^7@EK25I^F8.>O=2ZN3"C+E4C>B2KLJNQ7\
M.@J>5H9^+4?NSL/7UNT&ZS58(EXH;ZIF(U'2RTD!D)&S#(X<K:9OF[0^M7R-
MH>H72:0<@_.<'L\GV8$F36DO)R4!B>;8(SM)&*UH@?>?P^2]5^-8FU5NXU T
MA;9-*95EM(3/RY54Y*+Y*H*#E>N.&;F?9+]:E43HI.RSA)2Q;^(O3C5+$1&!
M[7QQEN7EB:U'/*40'JEO1=_6/8\5<,_:(])G$=;J)$31/-L+NFO&X.FJ4!O-
M3-N<#>Q=&J\KN#RTM/F=IX_\ZW<R2OB\ R5Q3DNH7I:D"[0IXE962E=UP8G3
MY^Z/6O6D?[GD9$K+7VS/_X$0ON!YOJ3O$%+<?JJ.,8JQMZ_Q:8C=CN_"7OZ/
MR/T%.11<+&:L:6-O[%6##C%?(#]/U\$Y8.A@/_B]VHNUX/VW'P),PM_NJN+?
M(/YV^Q5@?&=6($F9*/F:(/HA="#S#AMP V^G63:N8O@8^EWE"^+!=V>/>W>@
MK%[WCBI(:W_7,I6OK=E5YN8YY.H6TJUC0W&LNPWI4]UI^9 G&1]GN)Y9>.80
MU3")A!#R'-M*R8UC"(\7I.O'7VL8UQ'6&_96R0BD^VB>M]Y8-\3=M>N(9AFZ
ME WP3+"!\),0.(&+#$1"V]WG9JG(TY ?]74]1M[>M#]@ 'F!>N*1LF,UYME&
MI)[+#:5&=+;WT^?%MY;](&45AOCK";YY2S)!'M-"K"#6[Z8LT**@@\D$2KI'
MO^6D9W7'HXD5O6=QW_Q&D6W'+ITW>-OVFD_UAL(.N@NK&T&YC)U+IX _WRP)
M]\J0AX3#2'[K#^I@Q1D"Q16U*6=[M \&F3\^>>_^:*/(J%H+]\'L$J7G6:AI
MW!UDN>Z\-W66MAMRID:P^",IQ,:@L5W0ZQQ/N_[X0.J!2V+&%%K"%8^4^PY>
M0CY'(AMJK*;%C1\_3;]>H'1Z(X%R1A EPNH!A19 4CJ*KYPS0PDJ?A:&;:EN
M.B9OH#PNX[(;-2-V-\.'NK,_N7B3C%O"(R[YLCG<$886%#@N? NQP0!)21^G
MW4O#W!P/$^TY^G%.4:FP_'&9VOK=ZVDV7=:43.$.@BRF"T&YXC?'I+:36AL7
ML#\&YL \3S8@@=EN"UWP0?/E0,E39^\.M*5]8U%%I[.P+I+7>MZ^MX]:;-DP
M\T.-W#J?2CU#[OSYU7OY?#@ XHY]U!$6#%X?_)K<B@V45Z$;?0_>EK2UN'MN
M?JA+Z--(T[S2Z^R[' WZKX:L&]^Q 2$8V?.D#!B8;5YBZ-/W,+3BC%\*K9C&
MUIB6S$P/;)*,/E9>>B*$Z]2%L1I!%G^*>YX-#!D;D97DX)I=?:XE%(?J*P_0
M'1<#8&R/?WZ+OF_BXX9>CN]3<[ITW^!V,GZ>CQI'$V-F]9BC8E$\.OK;JONT
M[4TJ2JE[(T'.3S9>"0>_3<KLU4VZLC'H[ /.PAA.S5Z)U3@*3Z#^ J3/-?%L
M\J[T= 6BY%N*;^&>L/K@E;2S]WA;J2&'#FD-RC+UX)JOULY20X= 211Z<^=X
MIR#K?=UVJL63-XE"]F89$I&IT3NB][]=.+@)_S>[I-#*A$I+YVW41D-]]"9L
M$QLHK8PQV+F3X>'$U^<6&=GE04NRB'Z.?3A5'G:.#?!KX.$B'KG _%[&46S\
ML\TP+X!30!9<>,+4$93$&3;P?3M<THGF!^7$K9 ,I6H"4T"*L-+=]3_BY8L!
M/VMFP^5C&B:P\+'>4>2==N?'W72E#+FJ.ZU7;452_;>,?+3"_28?KH82V%_N
M :X5#Y<@>,'6WL/TO\\K^5O1[6^^FEP]^:1N1W4U2NA3:6V9UT=>QS8.@S08
MT]U*L89KWZ$5U@\[8/!),=PI*O?!-CX)0Z^Z9"QD%@C^$-<$%YYE"L6J(5BB
MCBA6I""1/NWQ/^#D7 /XBDX/./1:-^M:FX^_3@ZJB+<#VJL.JMRW _]EJ_#W
M> ';M7"CS6XV+1;*F9E&ZU[]0.LJ."@3M)U[T=MRC99<%V-;?]$4N5;)&WNW
MOP!_4S3[O\\H_"NZ_&*@5N2UMSH@H7'\=6I]54)<M@:'>@^E$/DOL?_?Y?QE
M+U?M :6H*F]XNMM4..J;.^^DB<:=5]R5E@UEOPK_Y_7^?S,"O\#OHC,-U9/9
MWKEFFPSEJA[)I4I7[R&)CB(%_G4.^X((-]YOBV%G<! ZO-9)RDV;JFFY_IFC
M1KI1&EE6MR/42L;#.H  V340V\;*2;'O] <E%+_3+I'MZV4N!\^>_M4G_U>A
MZV/E=P?\; -K5,2;]<N\L\F.H6>J/E[*3&^4.EEPQ"AIZ'+=Y T]H=^:B!=J
MFB(S^>ZBFK?PTNL>\*Y_91"8#_Z+%F]-[W/R5W5/435J\S]]U3UI,1Z7=^[)
MYK:Y5RC_@_*\:YL4*XF4V\MG2V.D&JSO<!_CXG50T.LE_.O"7@)+1JT*?F4#
MRS_ [V)KK-WO5E7DI36CYY,8?&E22_Z=BXGK^V@_HX/RCG]8[O6Q0OY2"WZ9
MJFW:9%5>9]YTB=GXZX?O@Y039%+VR-?R ($!?TS2X_BE ?OE6GFJ=Y&7&CF]
MX!EEM%U_Q*00</V4*?8N<T/1'Y/V]JYM_G^Y5*H>V&&,/A,84"=7Y1[JT9>Y
M_O4#SA!MCKZN_\4J_/T57-M[KG475S@%XF,O%:4T!NU<\)4MXTBY>L-RVPV]
MZC\D__[53L,:8WIK_7X.!&:^_DNR[_-A A9QL+LHL,.O<6G8=NA-CZ-#YQY5
M8]D[I;M5 ("_X_@S:>.V$^\N-0T?F_OZZ[YKP81P/&S;<P@IE-=I..8XT?K>
M%UQE5'7BK1!Z(83AHQ\D=[,H%TWV.25-&?[\4U!W,;T*HC6BGR"L19_O^V=C
M']C T<A3,?L-&A0OK Z05Z.QCSANMM9HNYY^?N+#Y?#+]$]/AI?NV(5I8),+
M6VQU9,<Z]IMWJ",ETU<5OU?$4H6'<+0A2NN\W(5MN%S(+O0 YH.(,BU1X]QB
M:FNZV$;!G*-\=_(W*V3BK'\Q!]-^VX>K=9O;L^ZVSSQ_D%N60DZ[GE.=<]_Q
MU'<;!RN$G)%5MH9'7<[?=:OKT4;_.!61P%5NN)-%E8)?S_["[19L[=#K&S"M
M&-T8I!7AKRAEXL!IGSO^#Y.1-1]U9&(@NH[?H^(K3<R+M;GOZ:*!_OAKA4N!
M_)T L.<<AZ+_!' ]D:,5ZJ$?%XY,& [V.T8Y,%9 [O!XR#@P_M7EC'+[TE+=
M_J,IB38_$(=,3-\0;V&V43)>^U,CR+0D?SRT<LZB4B^Z_;/GRXSDBN>6;V]L
MDISY].,1(\<]W7GWPW>NMH>=^NR'SWI1GV2\]E4M]!8(D\C5-VESNJ8H9E5H
M'=V(1GDY;B;8&L9-?B]?8 A#_&0Y2S$S>-JC#+W*NWCRR/HK2]Z9;_SCO"^\
MY>8\C#QS/_SJ>U;5_SM&!XH??-EGD,Z_C-8+K=RA&W+",N2#?9ME 2;VG5+U
MY4$O&SN'>\N^,R/PSY#N?Q7,HM^>X75"*4Z]WP+D\K91FGM5NS:Z7G/0K"K8
M^S>UVRGUXP761Q3/'$87XK045J:^[)O+L2=NF!4157I9BWWXF?LJ;[#/-95-
M-XR%A_ 3QBO-H(##US'M8EGPCH&./Q-'KMU)DOXF=7//7>I;WB^*=S-%>2TO
M_))HR6R@3#)] A%=M[>468"1"];X[C2]E^A.34Y[V%+X;+VDDO"J]T:YI%IQ
M]TB @0D]5F0>;_M-5KU9699JWY8V_,31W61^)4EW^TRO^I<)Q9W*J*(S=KXZ
M8\B.642SHY_S5P&U) JV60XE#[FUMAB*?RS2U)XW&74OJXKIC3X,44P/"6\.
M%]Y:1EB;$.I*DNS.39L\V[_#Q$R[/S_WN>>RA<(#5YGF8QK3Z?_OBE*>9?+K
M5MDO[F]&.FUODA [H9M("47W<I2B&J3F85NH6% U66V\I6S@68_U2NCO?'J2
M;YX-_-ZWF#' [WSC^21?$[$"-3=$QTPG, +[#3EF,8+4A8@Z-7GDR4J*0HV?
M=L<9(T)ESYSV*N9=D(!#:Z!XOO.F')58^3LHH7?J_0P)9C1K'T,/JJ5&T[Y0
MK>-K$/F,(.CQ^*R%W*%P?;DDRE3D=_KV03M;S:V3U..%4Y9:(19J0-Z][5,S
M;=NYELS'47-2;( /0&]VO+;0 #OQ*<3-,UX9*OVN?0:F13.@P#?WVMY+.(%"
MI3MLX.J^!F/Q\^O(L=I'SIWCK/O&3&8IH)T@:XI88YT Q :H5RWEH3%!VVU4
M5.SPH)'\,J.[ID?Z(K#NO,F]5O'S0,)6#5XUPI,;!KHT?N9# V^Z%D.7ZMK:
M7.MGWLL(I J3G5Y/:,IXR>Y,/)#MX#0JXLNMKJKXD/0RMFWPTBE6YD2XVD.H
MG2X6/&O*K"Q;@+:GS.7F!V.(K5(* O<;% Y0"+'N&2,6U!,/MMG./]7=2VVC
MI5Q;S!S1O;\K^&'3N8-6B.-=!Q$',,W@2P;<:Q.:L+&HLI5FG(0-=)\\T/+X
MVL!):D5YSE"9I)55\CU!7^2Q4C,9W!SM8WR=\^.E_>[GJ\Y:9GG\93_;0(I6
MQ082QRE:K-8J\+MQ:%^PYM^^!?7+SCQ5DQ'Y'?S!1/[@+XS]];<_]#G#?U/<
M7STJ^/5!PA]-6HJ&:]'6Y@7F99UGMG6[X1E?7&&]D@6J<L&WAL(_R(2W9_LV
MK(7A)SF,Q?\RUI!WKVV' (<>PF<$'_,*ZK.J5_0)-G /C5AN!N_E__:,:2VY
MYYINY8;&FC<H#O\VA=XU>^Z_[I+\U>]_O4'_/R'^ESYS\ <E63N"[4FMC:/F
M9.2=2S([R[X&24]\F;QW+U]TP]S[@_)15R]SZ$2I24377\B]C5>6-MIO5BMJ
MYECY.4%"]5"2[O[72D5$EX"DM3? N**O,4M8NNC ?I7[IZ@6_?>S2T5\LSRM
MU<77/;X5>=G-SPJ]](AGDW5&L%_+V![*M9SJSEL,ZWS/%*\AJ;U2)4=6?^3S
M$AZ5"C]-MCBL,#V^2RO?3-^_*D]W,JM=7=_);.4H=/U38&3D);L A^PQ&F,G
M&Y#$#@FH?68#@Y:TN7Z,JO=N]":H-7!36F]"<5?YO9N&(V6B7<< X*BXJ#0@
MS;EN-)QH8_UMDUJSK:GT9^K[J].ZO',]W:<2Q_;8#144%6KW6.2$77)\.%YZ
M? _>:!K*'8H4/X4Z&O1_GR*MJ0D^OSY<.?G;&J#+V0#/.>C^\V#G<<EX"MV\
MRB,Z)E#%N_\P=H_@Y1?.ABUF6Y&4]4'X?.\O>$@5W^A[IHD-K"OSNZWG^OJ8
M@4Z^WMCS.ZN7'7C.;*&)FFYD S>GRC$AY-8!-D"6GT2>(2"W51#OIQGVP(5D
M"?66N@\[ EZTIMF/4*HG&1IHV/6M5S]AE ()G'5*,[AU=1I?$1L#"I+O3/]X
MX'OY^97)-ZT^Q3BW.R\9_JBBY54>BO=XRFW,+L:)+I9\\'F.P'PGU9!.A2_A
MNY?,U#;,W):YO7 G"-\E#)U ^H)11,T[AJ)04*O5[N4Z2DZ.S[=P-A"2]>C"
M"/,!?@:53?./:;OZR+OI=,%.K4<AKNN./776D>H,%&P_]^YYG)5=&2:R/OCY
M0Q\=I^!W]>5N]Q-/#'\MHE4>'O' RW>!ES3#X_.V15(E#_B]^9%.V8E&9;_S
MOO\I!G!IK;K@E#_.!L0@[^;JJS,L":K0W5RXS[@Z:_G:+!MI<L@8/.Y:Q3)_
MM/>ES>VSW@%/JU*@;*KQJC:V-NM.P\6R9]I$EV6G@L ES5/&5GW+\6J-/QQ;
M*HMF3MH.#3=U?QIU:!/==V]]LIL!<,#B>LF#"U([])5?Z\F9.2;_55<PA8A!
M4<[YW<)(]W[N,52 M$Y3M\?$I@\\LJU7J9:TOGJ@37/B+.OG'Q2R9(FB'#0B
MJ,(-U['1MU;^#WOO =;DEC6,!D$!$1 $Z421CH"%II38:")$::$(41%ITEN
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M_##3,U&#4^X1\*-)+-%@,<?<(2,;6K>XS@]2XA6 >HH-J@L7[H!%S^ZP01-
M:.U)!FLCR16]S*6R@O>!D-[3JSE#F\+O<ZB!:#DCY!%,/D78="=M='N!=(QH
MS"DMA^?C:NO20AC-ZZD0*3,ND7?#Z\6]!>NW(2IYU")V >I.K:F][OKN2VL"
M61JJMK9F'RS?AA#/@\25R&OP6!NOWKL)#8X?;!!;D1G2R"7CIU5A[7I@8BV#
M$<]0JW88E./#V=WXW1ZD#&(JWH>[KR1_)/M&_\,4,X9GZ:8FIF>^,+VQ/(28
M<A;WB89L@WS9JTV%&K8.MX]GZ#L&OO(>AA,6U>&YGPG.?J*ZF5$CQBJ:DIK
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M(0$>!\*=,%1M"H*GBVGT6.Z-&Z%4'L(;BYOBJ&9]6>XX1@^4*#&3 '4W:B_
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M%LG3A6?TE"GYHSP!%SJ4JHVQ11C>HAFN1#:L$5I\HR$;-MR%[>@#>8&[/Y,
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M;]MMZJK5V4*0-FLA<4#Z%5=+032UGS25_='Q%J:C7R^&<.>^.(''-'OX-)(
M'SBK&$>@9!J0MZ4(PCKB9-W+FH@B00D)L[.6\6Z.XJ//MHTY=+\X?UZP5'J$
MSI^."_!AA-%IX3RFOH)$V\&!E@^:O[U:7Z]876XL4,+? 8BA-JB)Q0^<VD_F
M'0\U'=]\M>GXNBHM-=O#J7<PWLI#CP28OGH4_17GB,-/+/$FFJ^;F&1$:F%>
MG<TYLX05#GHMFOL&0/&90NNW,]S5C-2=$[>%:\-U7+D]T]Z7'^]^R7^&)\W)
M 9 +*H!-$OW<H+@CB.;0/:?Y?!6RL0&XDS.@T FZ<"GD42,C7."U2A/5!LXP
MA^=>-A^_W:HJ+)4I=;I 36V9";*8#%42PPU/L0S.UI2\[U^6X&UHO'AC(%7=
MS(NC\=G[+D#R"R_@39L^F[K:\Z.W?3I [*\)Z5)<9'+@;P:U=%D+*G7(Y#N5
M^-[ZI*JKD(VG7Z^$&FYL4<'OG.$X:%I=^![;-J3.>"#:+>&K>BD)$,CB 4-B
M14D X\CZY8S%'BAV#;JZ<VK(9R\,*.V]Z2^M**TIC5CO=(GEN*F@W5P7TQ?V
MF&;J,5G(K6V2ZN]>LC,CA#:3 )M<9!'Q@QE1RGOOG72!\ID+&L90EF26<57>
MS(<2!XL?J!^AMKK]"B"V#P_>[E6:CB#V+&WDGNN_9#W_U]H8=.I+:T6BM9[E
M2&M8]JZ<.U!X27V\*MH(L1=K>?>>%V.AB,1*<I'IM5T["4 1B>O>=S?0].^W
MM\'T!YO.6?5(/\FTY?1.OZ2O1BM?YO0; K$_@M/W+/&76_6]WL*_T7H!?'@$
MEZYY4>5]OW@*N/CCX58*(;=53:O]VPO;FVGAYB'04#59AKE<)8D_!)I1W7OS
MEZ(+_WRK+ES#"M7WV2YI5[\$YJ_ZZ5K9B6?+-NG[U$W=PB+,FZ*@IISA@/4X
M2YF6$V9?M?>-3CIMCR;Y)V]?/Y!Y!%8BQ951VY]K>I)I@TG\([\7YV+VWA(O
MIW/PE@]19VUD[L+31N@+/K+O]"'WPM?^*B]_C#?_S79IU<;2)''-0XMK)3:0
MH&OP1@TG6M[F2NL]"=\UQ$"<7')A1ATOH")N?@^=#BF52.[=@M_5[/GS>.,#
MF]A:$1-53>-<[>'Q/+5'L0<.E$YD#%16[HVO?$WY'^-]^UIS.IP&F\3>+6:[
M9AG+E[0>/??ADOYHW\X@Y'?5:+S_S!WZASOXTL8&%8U*>#?3+Q[PH32L]:3O
MBEBT[T%7UWVF!^!_3F+Y[:89C>!2<>E+<EL:=QW$4\ZIW9&_/CM%86*RUS!R
MB?J/<)SZ/,K6V!2-"+2OAJ D68:^6R*B;D_<5BQH='P;:S:81*VU-0<M[/*O
M/0'KG-$GO,-#I&1VRL*OA$M,+!TP:E>_NAO4YV(R1<N@M-WF.9]!2%FU\Y'#
MW_Q, MQ?.3S=G'Q"TZ*EM[[1PQ-N=T2_,2+\]"/8$D#GHV!-\\#(2-N(O+P<
ML_#=2\^4.0-T;YX!4+ZF#(.T])+U!R*_J_L;/[NS*Z(K1N .;;\YZ.2K ;1"
M.0E0:O:MMDF<[=5(/PDPFCG:7_NN[8^EH%W*OOV$]=//!2TRL.\K,?3G\[A]
M;44*8C:HEU*+G VZI>%*O2?$^*D21RND^_<?TKU)\1_F<?O;!RP";.$Z@HFG
M#*QCNS-&[A^\[QM=Y2Y(7II]I4J4_E,\[C<;A<[-#[G?FVI#KSTBM7O#-^<I
ML[O=['<ZL*_FT)_%XGZ"',;@X^E^+MLC)=F-?$KW!"JH(LWT'_Z.B?0C?S#!
M'R9784K9_QEZF8J6F$Y18Y\E%-Y^1MQZ./#;]$J_-WS\Q!AR"5A& OPNDTD_
MCO(G.4]^F&#W?/Y/^81NN[= P^*!']8"!Y7.]]_QRHYU+>W>+/>(NUGMP_<(
M,!OE.<4M+$3-GI>AW^\R3J=1,;"5\"775OR$1UZ>A4,FBS7M@WN> (H+^?0X
MV31K:'%7TT%"AH*%V6E3SAY>#<23'>4VI@KG8&D1%A* ZYE_UR4*(JO9!OSR
M2]2[704D8' @>S*FQ%5+=&SK?M65I?85S69YF<%#LDS:"L7") "SEX=$H8]&
MAOM]5VB1:EVN\X=XNS<8(,KEJ\=,_O$V"?Q5]SYC"9"[!="DH+G\-@,MCQI=
MY,VW(5OG<HKHHJ=.^C=DM//F0P3'YT24"J/MM+V-'WYIF%Z<MLQR&/9>V;+O
MJ#%>)2^1YZ'Y7QG-R6O)"FXT!797&[Z>@)DU&L'=W3@#BD8GC*^?*U29RA;!
MT]]^^S;UI#[#,8BF84:6U>J+>&U]+U[@KC3,SQ"G/J-X%:N"(;[A[[$ZD]!%
MN>1.G:BJSH\ZO1UU+.;4[NLIVQO)#OGG"!G$HS90IFHQ"]1:8!&=/2?L^L*N
M:OVV6?;'E(52>]T8E1Y&CM&D\XEKCQ!LF] (('T.W".UWG;N*;NKHB*1$#/B
M>/H(XXELE\YS:5H7\J,^"BDD<)P.J:J^5_%.G9 %4:\GF"N7\*XRO"J!#VPX
M:$Y;5W-/!)LR5GMYMMAK*"U E5D@0[PO?QEG4K /5ME_G7A"[S_\Y-\MN3;7
M?WA\I"CVV&\SLWA^).W^/^X?^D=UGP!#>RM+_7<?_U66G=?T(7\K<O3]\TOW
M!F HAS&$#'8@=/3T:BZ&JW%]I:C'EM/BID-/V;5PQ(B;:,IX@/V@/US]KX%2
MFVN/L9-_"902-VL^<B%B"3\[,IS42!%W]^,I!SE1L3J40F>ML>^M^E0,JU&&
MNN*K.2]9PA#_$GBWP%M+P8W/17@DN46H'0@9[!8KFWV)W!7 7\!0!^)/>F-T
M4*>A& AL==FZLOMN1_%]1,I(V/IQN8]<X"N-;JQ?66Z9O%0QO"K8;C6U*--W
M/'=-1-%<Q/UYZECJ3FF'PQ#LKJ7*<T_7U9VR^8G\3\)O0S;#Z_>G'=HGG,CL
MS4'T#\K7_.<?[?A)I$WF3ST6EX[]-R)\_B.IN2C6D2O/2("#9]_CZ%$(-CP;
MC@X==Q,7BJ&LXSU6@F$,M15?S5UQZ6(P'&N?&R%4H@QO52]BJU2IQ/@#;E91
MW3CO"5D>W#42:NGBPO5. T-J:7!5TV3@PE,0DH@G/\-U>'*>M1]<[[2U6U[-
M%8KGRO90ZI ;XS TDE&]9BX*ND@"3)5,%FRO9.]*P*UPWT>B1@A**\*X!Q!/
MX"2UNFM!>(D^+MO^II+ .)[2E(Q2E46S<":9(Y51C?SU^KJ[H43:EET$\6,R
M6CN98@E4'+@\HQ!+Y(N8Z%7&+ 2ZOE#JROER;K3FT]-ATZO1OOF.+MK*;4K?
MSC1FB_H*A9%?GCY) S])?BLMFA%_+ 3\I%;._CALIT6WIA!S<"'P?F$WZDG]
M@,?<^D+YT."-&_(4 ;R@5\>$+GD#L;F$+!\.GQ;D8>HF^^ ":]E0CUR#+TF\
MGUTT7!-N#KIZ#0_0*2KUR+I DJP,A,>^A,B>+\PJ^IX,W/8S",5G/Q10T(J6
M;;R1O!O N87$B;<L]T_ECVA@#PQVA?B C.&G^VJ!2U@E*;1]H]C"W4/!N8OK
MQXNCE"]U3H]<I3'H3QT_]UR=6_0,M8WD2E<F7@:'G +YD0 ELA^\5:>7)UFD
M1:20E#8V^49+\=[-64^+9VY41#'GVKKRJY]2D:D^QYYX;;0TVQH.)Y3"+Z!3
M9O*?D#64-?(?QBU)(%P7HQ7LF&<$4U6K?CPL-<Y+2Z5M[;Y]_KVQL9G8:>%+
M'@(QI6]E>.(VBK"G",4^)Q!U5T@ N[4 ,D?'LP[6,\-/X:K06L,*AE.(P&-?
MUD>,\5<&D@;N:SH^>(Y/?E!JQ7'ZJ$6'5>JY,\&YTYOY."'!LBS\#1+ +QAA
M1V:46?I>D;0X]WI>KL]OGRXL#]#;S)\3]!1K!3R/"$@5]%4:)SPG 1Y*!DZ6
MF)2%;&H"K_557YAA#)S@\Z9&,3[:6A-;V6'%W>([=%:^1>K8M?;3LDQ%_ 6E
MEX_PL UD;TABG3''WTS;XRZF8/UPWF_4NA=]3A,27#3=H4_.!\02V[QE>B94
M>>A.LS$+"[TZNYW?>YV,TN6@(%#Q]@?& --3]K3P:[C,M$7.J"M1)8EC8=RG
MG'(_*' "IGZ7 J&5!.!%6$X^FF15N@AG#YU>:*R1U;<%-7<(?"E^%AF5>[Q?
MZ(2K J1W$OT"9T;TNXF8U*5(4R83EWJSZ<@=^LLD@/<M$H V\@GHBS0U8>L2
MIZZ^/5Y0B<RN7O<!M_N!_V2WH_OD2.>+V\$N7(G@&_'TVH(&=J'7/Q"ZRS)S
MP;@;<#)/O/P.M)8%Z'E;A)@^BVXA''I- M1^/W_:T@#<Y/0C[KRF%Q63)1X#
M'D%\MF;<78K\=:_LKEI9XM D92VE83Y>@/>DU_@5W7'[E$7'8#L>1+73E;>[
M14>F9N2:'!YXY!E'WTD+;=$+%W6<T+:2Q+EWBT.O<JOP/3D>G6ET_:R)X?@^
M<1?S$(C6IS\ /-Z5A:A_7BWCK%*P1AP#GP%X+J\7)-M.AKO[\!%J\6(8XP\#
M1%9"$OT(;K"1#72WN+AOY09B^/KE<R8?&YQ8E5NY#",<U*9"<&&RH=R4D6$#
MQ]BSM,34A%NU[,W91504UJ,+K\OV8_O6K3"\FH8@"\C+O%BKLF'!F-%%,WM4
MYQOO76V\/F*XO;XL2LA?05'*&:_<+S[VR/F$?$HO4Z"3ROV6&V:/R^W=>C=W
M>03KZ<4TBB(F1D980R8F6 X_X_-EU64   #4)0Y(*OA)].B4>\,H^( EY[)S
MX3&9E'<WP G>+OA6^:34@BTA $626-Z>7<A/F<;GLP;JG<7M*NAY71C5H\E>
MUPXE&@BN$OO&,K Y5>\-/)_66$\V)A$U4B%1>)-)G>LA'7O^0<J/+:P-6Y5Z
MES.Y9R-!>[;^ -<>>:0B <S\100U6C78S\>DF&,=9?'X\@76S'\61$VI9]Y/
M%N:W^..J+!7R#^!65^6A;(W4JYL=:AA6+"@ &./<RQ\=I0LI0?R 9'UPA!G.
M%L-5SQGYJ-K0P]XYPSHV]V"?<H6HZDW'!LK'C/<H5DS9CIKK.2OPFS^)BN"+
M7D@3*HS7-"0!G*S*-1&G$TN*Y##E5O=$A#1''-U#-S;6;51G.Q,-#:^*4#$]
M5?4T0B.'G5'51):$6X0$)6%<@." @B"@NT2=MCDWC??D"]YE/YJ&4FK^)]++
MT+_/1J\[:KZXZ%6MW OEIJ4TMFHA-JMZ4\<HFZ)QRUY)NN (T<?O8I(Z7#4M
M>S?OR^S5/)QED@0^ZS25N>=G7>/S,NCG[Z)Z["2F\V,[:G12_PSLV]>+!KXO
ME\%+=!R9 O"<4[/;4DLQ<Q4[:#94=JAD[ZY3_A):?/\ 5OZ@U\G]%8LLZDT%
M/C]T:3U9U<\7'MZ7PQIY;XRS[]^?Z!_T"OQ-7HED6EC<Y8)>_B=KNB$RLMKO
M]15#'6QT_NV)2NVQKJON000+7$H3+[ :31C/S<L^]A%S-"@CRI)RKXZ3S=?2
M-,$9T<8^:>A_KO'U8T]N7>2?P!?V:#I[II -:N(51A,6 E=7;%T-DE2#_)45
MHB]Q[2W,:GA<20+=YW:S>>?3R5@!JF.?46E_Q@;]73+NWC,#0Z(P1C5P30'D
M;F.3U;BN<(U/9#8>,+9'%_M8@'%_DE+X1';@[I$"X1-)@:R2>V8,L+IEN&>Q
M]I"/FX=B6!/VO$EU7Z_?!-UI[AV2Y\_8Y&N&^#\9,Z2R@?L<ZNE[GLNI\6JL
MI._,2-<\E'GLM*QRVAV?+Z-]GZDU_WP9@5-OKZ%@WT*X_81B"5.F_]E$BEYT
MKSY7#B:+R:6R']9\!VS(@U$-,MV^&2-K_&7G]CWC0.@:]]-WM<L-<G*=9TTI
MJ/&L?I<"FXJ6DM%IDO2ONG/(@D+9L4\ WBJ%'(M1]QDH4Q+L61WWA?"=]+OA
M8:+BJ.?I@[B*4Q+07<^6Z- NIU?T4 NC+.V5[++<Z+)/.U[81[@:<[3JM&G:
M3.:=7674N[+NY4L">6OWO]T-HFAM=W+L[#<;>>?S*9DF7^DH_FQ(5V,T(:/1
MLZ-A*4FX]AX=V%OVT]2S/DD:>7C%JDT3D1?NAF9;B=Q5L3(]45YC*]N0=+!W
M@ 2XT2T-42ZOZ>?G]YAC?7'N"J"NZ\AE(I_88O*>]4KB;;X+RY=*\E"QAGFZ
MIUW.39H8R,B)OQF^=<O/1CWTH'Z261"LO*I>-@R$781/A+8JS?\:W+U;O\;_
M 7#LM9#U_9!(]>*L4"8'%8S=/7=2KPB5A&O?0*L)\?E>M/Z3Z7//_MI.F<@]
MQ$KR9^P"L/BOX=L?]=JGT>_#1.1/V(7E?P0)]G+*A!__H1 O@#(YU'(CBJM&
M6WAH_'J= 5:\[L\G1XP_L]N+,?Z$6^@OPTVFWRV_"=]Z<?7T=1JA-TT F^Y_
MB0K_ >W>9__82Y5NPCC\+-?/O?+S$*$F'KS$)8T_Z3, 7'>9)#^\_-H&M&,B
MC7 O^?V7 )_)GQ3(@4PQ_JR8#@ NL(L@]DYR*0%A&F2RH(QIP+ICQI(.5T1J
M5> @&,H&)<Z+I8F.][$7897%%<84XDTY!9-I7ZG+P_5Z]"@>9\UW+=/O"N.Z
MD5-I2" ),)5:!J)>(W+!=% /@E.^^'"C:PL>QE9&U(B_7:T<E!0_&FW9(Z<;
M+-"X7'L_*O4ASK[,E4=6:^!T:J^T#8U$;OIM#7OGHRZ.@P<-CEI[ O"KA*)-
M8.C%23P;(]:,\!8NOJN(OSR@0(DN:O 1[\7;HSHDZ]G.&QN"WPU5'T=)T\W?
M?N=0%<_B2M%,6T=))D%3!< B<#,), *:$FH8MYF2#1QM](RL7XO@9</Y9>&.
MF+3834CT%E?%1GF+&STPJ&YF*'S;5L<Q=5.-'S+0=Y.Z+KDTX\-71IP(M!DY
M7-8,/*Q$"VMO()[ :6)"-3 15>1E9(>=V[@<?;5[15;3-37%5)5K0MU=U+BI
M<$R#9NB^QX&L8$E<,GE)NY9-2("#]AA5/(M8'9)ABP0XAK^ &T7O]%[%O;2=
M%N<S4;WUN61%JKGT8N#0%+UB4T[INSMWJ9P4G'R79<Z>6KTN3(E:&Z+#JN,B
MW7?=X!XDP.,4O#-:<R%@"QK2G@[SFE[S=]5.MN^!G\\8;6*/7[GU0EEZMEN@
MSL_14N^F$G>AT(C4K4L'S9<F:-"F-3!7>N=Z3I.5NIOI7C5*%[@??;8S%V+-
M5 ; %W:U8?+U%]E:)!_3O\%!- O/P^8OBQ071"A.77W*\/E\AS<](3&#!.@*
M VU_@000!T'KMY4.(8:V)8E!^9ZO:1!%Q23 -TP@D7 8].,R/@00N"L/)@&2
MV1%KGU-^7&:^^X,N]1B>F'CKRNMIJ9>DIX]0F3TK'D!BW9)) *4S),#D&\/:
M?9$!T@67CI( %E8DP,8,(V&'!?'W2U9I%@K&/1U5]USKW+K$G=$,XOR"H%4Z
M_G62V=ZE7, $J!F%DC,$,+<=.A6I6'9!KZO&YP:LH:GV!&8A>*W:#)6KO+I%
MKS*=7IE( @1'WKEXD!) \8'\F]^[-NK<$!\7@C2'<BP:W7BX(?@BSE@G4TTP
MPIT$:#EEC<_/GV5,C;T;Z3%!=V 4>S@AWH1[+(UMJ4_7=O3E-NC\3&5_DD2,
M9$$[(G$$X:2Q=K@'C0B%7YX"'1O"M=17AHY8<[K6=]A<1- Q-+J(JERF?DQ+
M[6=8#-EP%2UQV#+3?_[*_'B\C4I\O]2.%%;I^+GG_&EL#R('D_UJI3\3Q?'B
MGWWXAZT<KE4V)_ T/LTZP/<\3)W7:\6A/=EZ<<\N; "'(LFS"$"80P]9&14_
MC%9ZL6T,?:<^'^5"G@6_T=9U$D 3Y\X:TN) 9#P6HI]]47=.$G.=MAWSD+!!
MJ9WVD%4T1DF(O6RII^+7RV[:VG?U!R3=^G&IVW?S$&MBS$M,XK)*C_C;SG-L
M[>S4@B4DP(\!=NQU#0@? "ZO@(CPNR0 \DKDC\OTM[XGB9V]),!",W!W4_C'
MI:BU,.5'I#78WW.@*,UJDKV691$C&5;-)F9J5<!_VUIFB$"(?K3ME^YP<>%1
M>..@!3JZA4B':T=OW,"%3VM8:N:E !X$/],8_2@'2X[@,& %W8B@R0N$]&\B
M&1<A%^?+$*QIB:_HI?L_K;+RA:L8ODCR!6CZN.$RL-/]/AQP#8S_9.'\*) !
M%GC3N( W^P&WJFN8AB/5?=3)DW4C=94,;*N1;;BJ$"=[AJ*@>;F7Q#565^U7
MK@FO3JWVA]E5"FBEC2!7QPF#B,1/&T<D5(/UY@DC"4WV+L51T&]B9+'0"X@P
M'#9,YIAHM.4;.3US$E[@ZV0#_8%Q^1V11Q!U*B2 -3UE(WW^DBE_KROB[)5V
M6T3JE: V1LHS-$/>SM\&AY,+,U:"IQ CSAKQ;1.?%I7X"H(4B>&G1[<%'><;
MA[AZ^2D_B*I1OQ,R9<:X^\%:.-\;&+8E6J";4W5OY^)SK]^R;]M>+C8WK]:(
MF8_QCI&9$2J,*B&<'OEFNI#[*RQEW?'8I (-CR#PN 82P"< ^.-24QGP:VAA
M>[R<,]>3:F7+9X9M53$Z QLW(@%^]'VPKQ#1S7_A#;_N<A<FT=9I(JH2VR,(
M>OC</(4ZO#__1U=]^_V^CG_E#?\OF;8%K+*Y#41OJN#F*$:C=;B9@C5_KT,R
M =R[S%E_X.$;_OH*P;-?1.U_X&'X'L?FO\D>.C&NX<]].*MARRC]HZ]8PPZ(
MF>[UI\HD9PQ)^U,-7U$/<+IA]EEW\L?P]Y9K_A?9Q-Y>K(FHKUS">&D89K@Q
MYZ2<&#N5?LW?G;R6!VQ!X/<V-+2%_M&'9U^TO,Y$_IC"WJR6OZ9/_Q1)$SO5
MZ*9OE;4H&OL,,.A_ABE"I=>X9%_9XTN<T#\1UO=TT5<-6L[I)4N XGP4^31W
M3G&'IY?9[-?R?:60?YHH4(2'H&R!=3[L?7 HBBM9L$&C,'9I_;;%0\?,!R?<
MY:@I:Y2O/__2ZRJXPI(W.BQ0=>]Y"GN%XC/&X*U\*IB8:ERCTIF^S0Z)>FZ/
MLGC_@@;.A=>GAS@4 SW7N>Q'(5AU,/?MT58,!+P^015Q@2'1<<Z..CFY;12W
MP(H.7&';5<9]Q89A^HC"&,7E9T.JI^A/J1G2/FGC1@.^W ZS\\GQ!@ \MA!"
M&,8>>>"1-MWUVZ=YV*M$=.?M;"IO/??0^9)\OA3K*=EYMMK9$&)#I^F45U@S
MF1BMCP</K1WY:DJ#R8MD"X*?S%R,3_.?7,J7^F86+]-RD\/IG'Q$_YL]LM8<
MV_+B7\;BC.DCZRI-RU$&ZGSA4#4KFB=8[G6:+]Q'5GRRO"^?(&;B=!I'0.$*
M9S-@R(9!)=<GF>:L_:_*F[_,WFQ36W904;4FQ#6 F=&F)Z:L?=:&[XD8)[%5
M%HW<\C21-\S(,8W8UB1H74W6[LQ4O&#!,[A4C>0;_ 56&/(*XU+0O744D6&U
M)RWC;]UJ6[J8<R:Y=8AS8\4"NTQX45R5DKXX>11J6$VDTZ2[45YIL7-.D Q/
MWI"1&5QHX'I9>UA3;_KN=4?PJMW*-][<AVYT#"OZJ69+/8IF>UA6(G(JY[B^
MH\\'):4H,;680*P^AQD@$A<_/*A! M!;S"0SX9%'D/>[@$MDN1BB5&3#&W<D
M:7KNP<PDZ_0D6IN1E3B@)$ (Q5M(1M:RP,P:E'C(<ILCTO]KKA>"!#C)!3VM
M<N^ PK>$\\G3XQ&.IH, S .=L)F<K%A6W<R._X>]]XYK:DW7AF-%0$!%I!,;
M4B*B"-+)5C9] P("2HN*2!,B'20DB@I*W5(%A B(* B17@1"CX 0Z1!*"+V3
M4$(@[5O.*>.>,S-GWO>=<[[SE3_X_9)%<F>M9]WENM9SEY=OJ[)U,:=K;^97
MQW"=L,4&.TZK$!6:+">^M2OVY2 T/6XXP4D=!04T=&*?F0[J_=S.D !=G0W:
MCRXN2:;N(1^.(_SZ#57FW2ETE@UJ'EC'"N5O.;(X7]'OL+Y)@)BQ"'$R%H<2
MW>01M.\U>2O_0,D=6[+C<#_;1]9I>@^O67>E)M.=8BIQ4649Q=$==B(A3\E!
M[D-+6\[R8GYI?/$70[I;["@"A)OP7KV,T;"\V1N9>?;-NZPT:D)ZO(?]L++'
MIO,P\:^:]&T:;$J^D4\,8(7/(),585O1;) /7=Z^HG)L<WUTMMJ0I5QPK4X"
MD7AWDJ[8RS!=<5.:OWL*;^AF5.V*J?\;1IR_D<OBIK!!BFC6%)$>@\F:&!=C
M@VP#X\(L5D*2RV:WJX(*.CA-235PI*UG0? .6*FUQIB52^Y$$(>#84YMJQO>
MQ%2O\)8.B&TJ79TP[CP?_K/"G?"W<FX-*!+5+X]4^0H[?ULLE860QHRA)NVP
MBX!S3H#2BVA@QF\53$/L.I8-\H)FP?^J)\6FI[(B(1O@HPP5-N@%:@M&Q7BL
M5+%P4O)24MMSP1L[-F/PW$6D2& R&W24?PFUG-$T% S="<)WXO',KS:C&0%8
M(_>_'2Q@K]$??__'HLPM"6Y 3PQ?Y92^C!V1%'9IF/+S_,MLON1_+"K];\:R
M5Q-?(*J^'T5L]5\SB\V2HB24K5;^F)7ABOH__(W_:=<O+'&AJ#BVR3I6_(UA
M(W]HT6,=V]Y-^L'/C].D#2X6&D0]X@K_ZY-.H/]$>OO35S[A]SU6?/D+>'U'
MGO7<5NDOAB+]5\U,WJ,3!%O1H[O]Z+)2A U+;H:!6;*NU1H51S0(_I'49R%Z
M9K_*GG4/OHYH2U2^,&M6YJV@J^,+/8!RP3[&EB+#_29-'V.%:E0GZ>K<\1X?
MVDA,!TA2\1OGBUTO6M[^?GM6=>_GALG'ZFJ0& K'"C=9OA$MN,DW3&^&"6IH
MNDZAC[=HU$F0GU5_@A&LN[6Y.\]_A*,OMA:U+MM%9WM>CCO@KP@R<Q"=P--D
ML S^W$EHL[K\,Q0?UA/UC# 7X2>GO2P2$.Z+!M^T<Q@=\X1,XPY[)P=\/>.R
MG^+PY/\%<^L>?&_RXAX9_;58=]&R>_#4DXE0/C-8"DH"Y30R2"N8',+>Q_,M
M(L^25Y_ZYG]0>OXQX::=EI%-YOY2EL-%P] ;#\>4P650%WQ$W?D^I273X2\3
MT4,2\H,3\A_<#-I=1%!ZU=YJJAR'U*:?-D RZ"2I1@PG0Y L$-NT=I!PO+3D
MMS;%-VT^,C.S@!?C+YI&OQ4"[=F1%R'7V4]Z7G(JWG8EV<Y^JI,TPY"N[:J[
MRE946T59UXR$=\Y6A1QF83X_TLU8MQW#/$?RPB3KB*_0Y)C 9XO0H:FKM72'
M%:P3';*3LA!=V>4^OS:LSN)<F5I[@3Q52@EO1?&-SF>(EK]R<N?NNS3FIJ)Z
M=%G%)1O:W!FJQSWHS9SZ.=/3^BMYNYMXJGU#>M+G\(VB2Y'5X:>?V=KZT'N\
M'8R2F+[52$_NT(N!CQ9SW&)<?<N2\=:H^@<7F^!<MB/-1:T1 D<%]_PR >*X
M:I(5P7IA('DOY/._=9;Z!Q)*P7*H!DODV<4,(9I.-D*K9]7FU*2] 6'K]ZEO
MH:,0(7Q1G'XL8Y_XT@07G0UB<>631VY0H(URHI.\*9X]L3QN)A5YV5IV@GMN
M? UY]JH9.A&T @-9DY-C43_Z2;VT'B'&QZ%+L.O>2W#Z2_Q&U0Z'$!V^4N6S
MXK*^:\M8%1A@<-'B\Q"G:5_>(J[V%-I<SETT*VO\B$O;)U[<&I*JT$3I]+8<
M8'#2//(0]G_*50LG6'[1]^,Q5*IT$EY_:U%]BZ^X58@EA&DOAF/8('<2*P?E
M@><U@N._57EL%&U4PCRV7@?+1RR.5_12H/;S63_ZR,;.'_G7),Y]?R]/L/S/
MN9[_-1_]/^A?\N</E_Y<)";X,RW+_&E3]L^9D7_^M(WEO[<>>\O]\W[R]86?
M*LG^W._A9T9F^\>W?V[X(+"1RQ"(9YDQ 9=-?XY:&.BJB\2D0R<^H==CU\!L
MT"B$#3(I]]MD\ .>)<.6#;IS'+4Y;9HXA=DY[6-*YP!NXOMW2'DS'0'6"_3L
MO/4*'^,8'! WP4<';MT" #L%\S?G6)P+=!L:CI2\'$+BV[< *Y9J7CM^U9&9
M.;-4)]$]E=0UA\ST.;4^^I638)<YM7:&B^&,.U\BG$I.Y+KIDBOI(']+5RU8
M+3](L;I WH=*W./SVPF+5H&EN^_Z[#GESLBXK\AH9J7-;Y7%ULP#)T_",@S1
M .C]'(![.!5VE"8G[+.,6-6K!9/)._S3:51!9I9VC)!4DWV3%FY%+/81ZP8;
M9!$8FW.<*64,!"_<%F9WJ<G>76F)*W+CY:8]8H$-.G / 'FH0,"F2+!=OY)L
MEH12)J9#?CF$LGX%' 0FE3B99C*W;<@8FG0N$ O)39.QRT63J-!NQ 5:^%MW
M&\+-LE1:=N/[]HNGL!4IVY?U]7<<;U_DZWRR!KO:B)!#WZXLN5#@\#3JC$.D
M)X!BT:\V -/1<H]6P845B8%?=X=)^I@\OYGC"JDP,9 S[Z_EZU23SL+6F$Z<
MQ/2#:>?8H.7<"6($M@CU5,-R"BY!:Y\DK-%_Y>-KFE0]U3O!_6$TD_,8R-J_
MIW/#^YLQTMIZ </@)U(U^EDJK*\21RD<,6P ;(%M ^_/T7^Y18,TV:0N#+R2
M71247H*\E5<)L(Z/JY1_TAC!D%K@_'U:0[OA-4(++BEBUGS-IM7BRXW%=PE6
MT<,5KDKB2@%%=.4G=43F@\(/I-J:=,[@FG89Y'IR[;E=N4\)Z81M#_]:?(L6
M)QL4"F=]FX?A!L8/].2^\*1?P3ZJ2#8F0@YWGHU"1KB?T6?6U>S[9)M^AOHK
M,YGA/O6ZK5FP&AR&+5&,"_:L2K\A-9E1-H_BQMZ)'89,;.0,AB(/N%RC\)(^
M+/K/[DXK^Q\;3?8#5, W8LO/4N=0!.C'DW(!1N[C#H8::7Y]II+C2G49UY&=
MWG=OL.O%T +IF3>FMU#'8DYH?M0F&,V8NUVBSY?,\1#)%MC(='[2=J.F%LR<
ML)K/BX+<QY$Z W&,XV>H6H,U O23@5\F!UOD"3ZX.M5!7^)G41<EN:L>I1\(
MQM<(YYR*7SS@>! =^WIB@HJI7>K"NLL_AI+[H"4L+%F>=0R_#%W!%P/LK'<9
M[+JND5;I">T/>K6*3ZQ8.^R)5VG8K1.?4GO->[+QQO7<\$R1TE%FNA)21W$F
MJ$RMTYMH$H#LS' ^]E!'HRG<*^'-XJ37L1PS;<(-_[F';E="'V8+=KIKZ7@N
M@)\>MYZO8*B 684X-NB\*6LU[R&J@0.QXADBRA+)E?@-(I7"!AU2MJ/B1O)W
M<UEGI,+8H$V J2;DH]9+ &!X$O,2N[F'#4IT ;QDT\8 ]C9VXC4;Q*5U@K9-
M!9%%:4NDPB<%@B)O??)=OMLE[;.L$=N)\,$)3*+($ZC=+V!&$91>7=?-C/^!
M!IODD?A=CGHLS0A: ?W,Z@?"O.GGD#3\1N%L)1MD.6M0(>%)K/&IT'#>MXX7
M1.B08DZ3VE40:2=FK)2RI5SZGII=_Y!6DRU0DY2,?;6+?YHAZF7-XR7WP,3O
MZ?5L6870FH^=JJJ]KC8*\01Y6UOC+I\6,-ED;2B^A8XMP]Y?X]7^@J':\3GN
MA*1DXTAV1(8Z'Q79W:HE0AN<5 ZEL#"LHRCQ,9T9ID:O9(BP#E) +Y+V_IGJ
MF>C\CN$N\UC6WA'8$_J,)R_)<&,NZ6"R\H:TK@(;5)\5SS!]PP:1(E$N,!XV
MJ$T)T.\PAG;9""#P6"2WL3L8IGAND89E<6U,H G:#3 RQD,+RO#HU? 00Q.(
M0Q7^#J*QQDEB(9%=&U8*EA7WSSN^']C"]+<S -\3RD!U2K%!E=NLJ?Q--)=*
MK,(W@#QRZ!WYV 9U70L6,7QDGM;C%8HV#EFQ'+38  L&NI_OJ-%H'6RJ?N4^
M3*\CE&86N+G;>*>%VVN.B:.U-]Y'2&.6>VD)D%W9,!?/T[:105;Z8]IGLN]=
MU/PQ^&G."NL\"_SL X0R.:H@A*Z&N$-[0N[R:(D;;*H[EV1[PA&_)K?*'2X\
MYSD!V2'B:JY81K"Z8BX?F<<2O>OT5+ D6,I'&5V"37?Z%J&=#>J!ZGVS\GC.
MZDGBX\V7']V0=\F49-AZYPH*PVPW3$[T!G\)$=5! %CA$(9Q?)"DI\;13 0A
M+#Y'?M(ZW0/3ZQ,/WN_N?6=LQ(<)*&#8.F6["3N&[$$7H9OYN&2]M K>-DA4
MY>HMXC6K1/50U<8H=38H+W!9MY*KKXB;E=YG:-J3;F(8.[-O5YL)KR=M?I/N
M;X+N!AE78FP2=A;DW^"SYS$R-$>Z%[(-)B1\DJR,0_-U^)QJO.DF"+M;Y3A_
MNO+0,O+Q((Y(AEE9PYYU17&]*OS]ZD0L+=D:QO/0X4XZQ?AP_(F<L$03#V?C
M,>]&"YIM9,!,^>(@]E5;,\,K^9Z=%$RCH?*NHU&\_@TK1&^4UMGWB568DMJ"
M663D7TQ)W1C40?:R0<=F@(!DRLAD@\9BF]B@22?LHB5@?T"$?LD\80;K2D?I
M).[$OF")H9JANQBZ=3EUE URC$^.CZ=OU.XP"CPK>K>@/!I&/S#=%I9J>F=9
M$\VHF9N=FV--RWF:JA-SR@!LP6AF_O;_UVG\J4Z#A@5"O#>MB.+#X@1<TH%]
MM :Z#@)%NY5/>SI1L<)![FUB'2</-GLHC([F/L$\$+M\TX[W\U6- LVF/:RB
M=[I7S^B=QBSJU?,=0.(S($  ?X'U0 .,<_="B1/%I\E&Q'Y)2SQ)QD/)LI=
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MGUZ)U!\[H2B\DY[&Q?$1H\',8'&ZURD-S##?(95LQFR7'KW3T5#.JFWBSUS
MJ5M(H54;.C(.C>H>O*77,5>5="'PQ8RJ;\&+#X4SU=DF5#^1D90E$3/4\:V
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MVED%BX%RU(#IOR!.4L -< G"3K7I2\6/#PK);TN#PSMDG;.SG_MIINQ9L3S
MH?ANN;IVN58M\8#@CY=;:GD_2\6FH'^(ND.',F#_*LJF(FSK%B#JW?DT4T!4
MGIJ GV9_PYI= 3*:CX]DSN758J]I704@CY&Y,>U01W,NL^8QX #P'MRO(\"H
M9_#2-*?X"/LF?^0[<@=R#7;VUQCDM3BY)DHZCB)=8>)'CUPN6OY@ZL9*U.)
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M,RG$)'![Q*7ZP5VC%,'WDYS<(G-?CKX1<]YO?= YU6GX"M?-&K^;/;GB,U+
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MH1K_8O4,ZRO%_V4F+8PP.Y.D).?AV]V\K'M<\3=3E2,QCP?G-%%Z=6>!'P]
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MR,T26(9*H-S$!7$=4&H%5>,[[9RXS$HY,[9S_-1=L/]=W/NF)1C&;P> FP<
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MU+!,; 3TO#0%INXLQ631S9&(;N+HUGV?/Z/4U5_OXV&?@ODS=?ZI>I9Q"^2
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MC><W</EAN]OG V3Q(3$?+UK$%+@4W08\@DYYO9KZ4/,R\;>50^GI2Y"NE3'
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M?%UYDXFJ 0YDOF&0QC,+U^ D?W)L BTXZX%!6#TC%>)&84FA([.9$MX1WS8
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MG;9Y/>/ZQ2C/+ET\<D7>W?32Z S/V^3B=:W?S]9BPQK%8$%BN;0I,A1!SO(
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M;IWYVQ0]?89.ZU"U/KTOOR(.7O8,;.C5:XG)7]"PD[]W.\YY(_:H!WN'U(4
M?DJQ$GLI48H X%DB2G<GM\=G_ARV#W>5W'?<%^[02J_3Z[\R:"_]$.<E:F^V
MJ>WGV<GF-"VAE63P/#$AE\>C=#M%PEIZ?,VO-V-Y]"OQ3*S(E\^6[#;)E<F5
MN?2M44ZJW9TR]ML*,CUQ42.:[HYS@WO^("^[.QHZ&^!&>8\0(^JZ'6X0R?(R
MC*<IP/!E5^!D:6P+%*>O.UG4-<P8*$0(_K&Y+.1\N[0RQ5G,UY"0&^6@Y(V$
M42%AK\ 1U&YD9@2*"#W*W3=56 2F@S#0]N]]<%9@(=I&>B+H#!0;J2WY"SSU
M (,Z>UA].QR493#*?.D7X0HC,JG2!@#W6,648K-8+(=S3W J'7O$+D2%N(T4
ML:%PEBK-N/V(@)N8F6.%?H;M)A?2B[SJ1K;//1TDT].S(U RC7<7 (;UB14+
MW#:9M9<6V2%[DCY.*FQX"[-N**DP_H4M>%#(UP'#Z<-.7H.=1/" (Q<\1"BS
MJ*@GPP&W+\1NO;Y^A^[1JC 58KQCI8N[/M=/*&%+GM?,?4)Y8?H)Z'0.I4+\
M>M'ZOMEO\^;!XZ:3N6M]%%V:"5FHXZ59D.A7Q)7V\2$JY(>@6!K+88@YUFWM
MP+1S;'<;F[F(C %O$3<P+U!/,T,MFFHBW*Y6:3_F2>5RL;,R;RV['B%G?^>Q
M6>H;SS1\FFG??K6O1>#(E,V?0[W<;=E1K/ :S$X/U\6BXZ+GEG6BA;MS!3B%
M6T5JZU2M-2=T2XL/4:=JDV7ZGMKN%(\)CWVV*<IK*A$9G!S(R647T,GY:2U[
M<.&EP/=X'SOC/2J$S*K)=+X-5@,/0EPEUAA7C6RZV(Z%S;AM<0A_OIUKO?T^
M_3N#XIGX#3B?XW3@7%$@1[HMQ\&3P"]UVW =1#L5\H>*2( ;D:8.=-_,0<<:
MI7*JMJ<1@RHE>1J!#"]D*W0>O$O2ESK,WHFO+.-YS7UR8>>GBIAHYT1'ITV/
MM%.^<">YI"5?XEG39(V8S7X9[TUW[8#Z&#J!7KR1XV-WF0+9PE%WUS0GH9X$
M6Q&4H_1G;XZZ%R,P&_)=6I2?&E9R+AY< "9_HTTJ\*86(>2"/2891&_6%(HB
MVYQP0MGCCS=<#F?$%+<)1I1/S<J6*C4D%\2/Y:X[8LUND #8QTJ*C&&]U:S<
MMBOG):-WQ[A-BJ58@!9YU%-2"<=\&XH5MI"KHEPS\C"*W\*A38K%$60//0'^
M>CQE)<S[R7\\.I_,.DBX,5IJJ$>LH(MNOC++YVJ)O.BW ZY%OGS/]KZ ?%^Y
M""^%34L6W?<H,G0&;3SJJS)3$L;D1W:\T-P2=1]W4.N)9]KF!MVWZJF03*//
MPOJ[[AY1A2](&CU2B'O>*7)=- C8WPQ$+^,RPQ!2Y.NX!-9C*Y-FSM4EWB(7
M7=_K3SM:4O)^!FXD--, IQ/1(5?CEA<@,=8(Q_^Q(SL]CCB-DZ&,).V>4E^\
M3^9A7P./48(!6Y;06_PXM<VZ!4N%[,[>&MQ8XP1C[*&S: 45LCBV[B/+H6B?
M9>98K6_9PM7^O(7KWNU5R()I_^/K+P)?#I=83ANGCO48:M3,KAW%)M\:;M=#
MB8EKJ&W8Z?H0_^+IW"5V3OO5H1W7!I('.$13/K<&SY"OT>[..$!KO!)K,*YE
M^4'ERKRYGX?(PGM-Q>\5'U4,<M[<"H)'P*J@FQOX6P1K8M>7 '%BR8*YTBW$
ME^2D%&<G$;]SX\\J+1UBEU*/"UO9+M_G.L$*'Y%  #3J 6"V>\06DI(%8KCY
MW(C<!A7"0G\A/^&C?_15$]XG[MT[=F+"FU]&+ASRL@\*/[K)?MM +T2;IS$5
M-=4TVUBIY;E6ZRF?'=HE*IH2+)2[+;@]O.^S,R0Q^'UPJK<%Q@)>)7OAD$$J
MXG[3\VT(SN9Q["+^5)U/7]FTA1OO(_%CDV8!KV-[BM?-0D[$KH6UC,^Q5^"2
MDNT7].VDU;V(MD.=:>OCF#&]T\&J&B=E3\[$7(\@TH&G'4AT?H9M0'D>$A^Y
M"'M=[*V5&?'N].,1&7_^%-BF^LR^T_>%-X+ON'4?%QW#VJ07@-_AE9F;L"^#
MB[%$H>1P6 V9=T2FLPAWLZ,^7J::OC===.N.Q?C=N'NNFN<T!' %IAWRFY+N
ML7Y^1DM>I8D@O4H])3E0DC+A,F&)$;>!2G?6LV:*Y7LA<343-C&'SGFIV9NB
M8ATH>]1,Q0(*>]?3>Z%??MX/WO7ROFD[C$7)V(V@;:K[7JV?E->5SK6Q+'B?
M88M!1VS:&>.,WGA4J.C]&#,!;+@.%NS(?!EK&WU>P'.3K[,9@I-KCV8ER^ 9
M6Z9MZO*[]S>KG$]O716:<'YS<WN\4<R0-BD\_6ZV[.\08PDFQ ;,8(AB0HR=
MLPN+GG.)I.E>4@\ZHI:F>V]\V45F"R/5) <KHO(DN2P&KOEWD'XD$S^+M<+E
M*UK[:@'!_N7\B*Q<F<JQ17DJ)-2]<I$F:KJA ^EL^O U>M ^!!%"FR@GI"\Q
M_S8GIF/$FGC'K>]T7N(5$YNZ;)(TIX"87195X-8#K?Q?*6U:[;(?K/US57^'
M1;9<*//U <GY-K*SH2X.IH^SN9X9_N&D ( !V9QD]I5UAYR$LU#!@]M?_[DV
M',(KP/W_U-7^SPKG8%O&?U8<"5"[8C>-,#=4=!->-1[=-Z5K<G_91;Z(_,\J
M?!P'_U&%CY%'G@RK*%I%MP;<-F!PS_;:L]F5!0CXK;;0BOIW!M%B^87[V51(
M-[3PT)<<M$"%E(J10[3AB1RT(/6$3F$7@T"N_%MG)0&TG?>W+LKQ(BQM*KEA
M\Q=99AK0)_<[TQT6=,E7+FBNE]AG;>.Y1WD,=KJV<Z&K/S95/<Y"4SW%8F1_
M]\:@-^<E/F/+I ]LJPZR]A :U9Z8G0>#Q]2F)_)[+]5$DE,=4$.J[(N\>D=E
M'@\>D>!'A;]59,G7\/E'"9VS,()]#2[_;273$Q<5*L2$)K4;;>*^M-.%6'3_
M$69=7.H;4'SM6 N4UR\>9%!=E.):5S/#.X3*2.A@4]WK4/@'\2J($E9IH.5.
MHU2!'ZHS.9/W5W3*AL'HTH5%V_0=];XX:'L"#'<,+CW^4ZI5Y1QQJ;4V@'0^
M*&';3Q-JUJYZY[E/W*\0LPZYG/BEALA(AS&[CW0G\<W:6M<R+C6L3E1^2;"K
M=.IQ?%$B]22V&G'BJ'1 LQR986PA7AM7,EZ2(W;,\]-ZLX#C0Z^MLY7\K7-1
M'U:XS\@C?T"G+ E=E'Q@(0_&DC^A B4+ZP8WLW%N._IC:B9B<KU]V)CPTRP5
M+66A/LDM+0/<FF@4P[,%3E-W2TY1_O=&7^],=G<^5X#=[D>4 "W7005PB@/&
M4*7[!BA#;;8X^.=-6<WT- L0PXL!ARG'07Y[QJI*H#FS;Z<&*A[EPA_[P23-
M\!M9K(W+2HCYUZZH0:B@@4=J^VCE%1VE@>N)3N5QA)BAI=QMC]^]NF^[WOJY
M"?1\W?W*=4&'=ZBA>RPQFZNH,FT9E"BYY.*;M[*ZW<KR!L8,TA']5GF/#S7F
M?6SLI=Q!-_86K?EW2^<G/]:07SB3=LQJNPL^HT6CU93'[\@N1"P:R[PL\].K
M6^K>1)^RR?C9W]?VZ6T4J) S4B3K &_H4\I7E)M$X+,GRVYT ?Q5ULP=:GXI
MJT'*[0Z?F8]U ;IZ1'::2:!Y^!C:+*'/'D6P!YS\@:V2GP$(6]GTS:.,>Y*2
MKEK?<S)TQH_/Y'(I55SMQGUM&T;\8D\044L2\5F.,SFXO5_WRZ#5WD_4Z>*^
MUF:+.;!@4(/F> &0E;06,SNW=^&3100N?&:X2RX&RDG$QK<=WJ?Y.0G;FT^T
M$J"S>B6W*8G 0A842H4$DK01,_I^4,U4BF\P2.\8.M2:,3]M>GF 6?ZRF%1N
MH+VJ%Q7RM#665"7<UE_Z(G"G'BZ<!:(NP+=VLZ%RVUK;29&_WO\6B"6?XR%P
M?<7)-J'#$6Q4B-/ZW)41H<HF?%BXE-UHE7&<>D]@GH+#$]8'=6<NR.BHC:-8
M4PDP8CVJ:IM\W=/Q QY.%K"]1PKK)5$A^+V-7P?P9IK]4SI KADTTG"Y7*[5
M#/5L5HK0K2W'*YI\!VP/N+PS0$^%:.S];D3^W*)",FS9L7:-AA&]334U\9G2
M@3,-TUINR<"]EU.ZK)CG*A,S&KT?'7W]-5QVMG>4CR_XMFS3@?_WWE>39I-X
M=).HF-B#+TR"0[\UB>M;2^FQ/A[^$\:J[#OQ:>O: SK8=8IN:MJ2@:N!KYL)
MF[ZJQI6C7C5F_[+!T=^+;K/_JSJPTL?*_D_/FV/_[Z[WORWW_;_[)#NQB28R
M[?Y1190* ='P0Z<*Y/0%LLU_JX2ZA5(;/!#'0PDL,(J".IEQC9,*X=>!@JU7
MCI*^H#P!=KB50^1Y2[4U]@$ZRL[\R$[V?U\H]YDN374I6AMQ3';^L!)5Y.]/
M4;.0+I&=41_Y/"+!R=K"9;R_?YA111$#BVB6@N:\*RM_56$I%.2:"]".>$2%
ML*)H.NNM )@W2T( #K07J8?BE"#]1FS-^$NP6%+"$<S=^'E"%JZKC4?;5GO$
M54:FF77] C+4I>KMU9U-5X$K6,G7$0];&-#UKC\5].&/B!7@Z<L9_*/)%C3C
M1$&3_+_/](4&<J+3+!2BFT*B1YWHT$>Y>$<-9B^K_$>#V12D&"$4Q8!'AO]^
M%ADI/-Q2*R#*ZI:2*-)0-PIG0XL(V%7JS+KX#/Y0@O2"3:WL15JL-LPR2^R;
M>/:U^SWI0KB1 JXFR[&.FJK-]S@6&FLO),[7Y+=Q0G&%J(5\A-#74!E*?\A:
M?7W5W=4K&8YLS&F8!C$@:!YG.7CRTK04UAF7W*G?>>-\!R^7OV \M T,>P93
MGC>$/]&'AV+D4WDBDV6<C')()&&I;KY#*>:-'['\A9KN((7&M#@%(1CY U&L
M(Y.7]K4-\TPUO06(;H E0->%5:"4K. E.+MY1:ZL1VW($YX&K9'KA(9#+R!D
M_/+;8969;8S;IXC-I$W4M.*#>G["T'0W>\[UUCN:._),Y^Y/B?O2\3__$[EJ
M@.)$+11G[KP[ IF?8E2(MHGW(4T:?%AS^+C%=^*+?LXLO8U^?E&LLC0&*Y#=
MM*^S!HWSJ_NX9"65]+ B7*] 9*1]),'H.ON57ID+<88V0R81SDGC2TN.32R#
M$<8F/J<C-(0@Q[IEQLF6N,D1F9#QDL?M<IG \9!WWN0NF-40+K8M<]JBU]F7
M=9D'MO?B(C>+[G?/ ]/)4MX.FJ4&["FESG!2PV]@07'F%W ;QE'.0@P!-NKA
M]82 G\D3T_/)DW,S)%T/PLQ<5:P3):B1%2_6E7DI0 37BTYNH4*8-EZ&H.N?
M%H-7M,5?VNV4Y S?''@'[KW_@Q,2N'CAS6E^TW7=8-A"&JPR+-+K?4Z #Z5B
M6TDA"W8X>"* \8<+6>9Q4..3I?,#Z2QW+MWN0CACX$3^>7(.W3?H/HT=1HR7
M$#\FVOS&(KI^U6WQ2.6:X(PNCXUZ[:]+>5OTJI<@)'=>6N+<Z.238EF7_'ZN
M<RD:.8^VCRZG&*1KR%WP<#465>C9CQ^^^$X+_68<O(2#@_1UI/,!=/76\!88
MQ,LRW0SVX7#[K7Z5UGC"CMUY:VZ&Z\J:+H>FM:*%7XPAD&L0K)8J@A/.^K9]
M,*7R9Z;/#'EP7,P4^399QEP!)O<\*T+L/%_B_[K$72+I6H 0#OD-^4812COA
MQ,S!2WB8"]CA7 L9?D8:EE5LJ%ZQG?V0LKWQ]_X"<!?329*DF\]^C186J!V9
M'B78](#8;3?ETF>FN!"2&= ]$D##M?+7Q53(FM<896[B?SCZ_B,)^!^Z*,)?
MP?Y;O\51B)%B""4F\9%*0:%-AXN+"Z.6N[O2ZW/"H^<&^OST(/SQW_[(*T9>
M)-ZZ1PQ?2+=%4R'A62^D9WTU:T?V3F,"BW]H\ZA=IBN;[LH8/;9SZC4-4-WP
M0$<F!]&A UH!WS1=!'C)-_%"08U:R*?3E)"M5.="O]")_XN[]XQKZMGVA^,/
M%00143I"5*HB(+TGH@("0J0W(2+2!42J& B*@H* 4J4&002D1+H4"3TB(M(E
M""$@TB51"!O2GGCN?:YX[OF=>\^YY[SYOT@^.S-[]IZR9JWO=[)FC2%F<%7T
MATEE0U-\[N>L35SR4W?4IILZF<8 72$E4GG4R+>)[BL/"5P3)TFU3?&L,SQ"
MF@!7!QGG01\?0V^<05T9\EG-&19NL&M?<;,RJ?CP[L%[Z$GZ8>H56CYR>A*,
M:R)@6N4!:36<M@]%TR.7F^3TD)@^,W]_?4AE*KYP2:CBOC8>-[I@7!8\I.L)
M9K] "3[N>?>YX;H!E>_KA[4.S&[,M?X)%-F6V)FK!.@1#69%'\Z"#WI.L9Y#
MQ!,ZA%:'?485$9]FXF[L5ZJYO%?]S H(4C6 G'YV"; @IQ(35] 4"RK[: 0_
M$#6C4_@>P[FA1;O:;S:X,;XZK+T=@O/)IN5N<:=2TQV3#HBEZ6]YYP%;E.M
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MZN& <X [20J+Y,%XR>]?W QQ.C+J1MR\7U:KA53<AU/=>WO#0"#0>:[LNJZ
M9^@'F?5NB@UQ;]%S8P)-WWO?BF1DFVQ*Y=Z',V)[V)_<?3TKHN X)2TG,7/@
M6$?OR??ST<^B$Q7CU<1+K7R,-S]7):I(/R_H:?(-*QB8O1CLFOA^$<L2FZH9
MF$H;'<R>1&'<T#Q)UM_&9^E\3)7MC6S3RGM5/Z*M19$!A,BXT#1C[X>!<TV&
MER*MHBY</BW&JCU/JL#JTQY!7=8.K-+;:"ETX?'4;E%\*YEM?#;[016,!>7U
MX_;#(/RG":ODRX!W"/1AA"!,(=F<V/[N6C.1/IN6.5RO>&[X:<_;9=H\VH^8
MWK46W:))W*B/19R8H1CW"K_>[-"^>&MC-W>J\\>2-M:[,EWO7J.%,ZS2N(1/
MF'?I.EE^SC+QZ3>U#QCR\Q3/C%@9=GWV8UWID9.D::IGCZ5#D>3Z-Y3MUOKX
M\QYEOWM,[J&M44_G7HO.!;^:B,=<'<B+$^A6J&7-H][WRQ>_(!;_Q\M')XM;
M60:K_XPT7;5(P3=_\SEA!+,),,*<9"+/&=BG3?H9>%UZ5"!F:SX_=*@'AAZ7
MRP(3I043::=YM^_O0(F7B[!@5JHT+0]R,#1QNCXQB$UB$&%8:.P:DF"OTS&7
MJJ@>>*.BJ/JH3NE03\").8T4!0[7@A]Q>.I8ID&$16*:0^+]H*J!K2+,UC8J
MFP$B^HZM1)0%K4T8=&NZW;@VH"W\M<@4Y=UXF0%J=;8&KW^V62J_E;XR,MT?
MS93-M39'CNG^>VO'ZX<0.EZRLBS$P9,;J94CD_5:HBN=8R$[ZJD?E %3?5_T
MX+;.H57>^BV,:H<JME<1^Z%I?*$Y:8)*,SDIH_8+G>R$Y]\3U0?SJY%_N_?R
MN+!<@(P4]3DK$Q9MLO]< \U!^)"2.U!+S28^X.<VZN#-7B3L'<;Y+X>]2=1'
M0[W .!8XP+3UG-"],;0&,OSGEHCV$V246$]--)[FARN81,F$3 I,)O@G?[5'
M4P]FM6VWY*AFA%"NM;KD*I8S#:H\# G0ES3'-NJX.F%<WD0Y?IG.60VO]GCI
MB?$11.TQMO(1U7H3U2P3I_=T5T*%($D^B@HOZ7RJ?3A-U#:VPKK$,.!CB=D/
MCR6I".M"GL&:%-\:J$($)Q! \WM8X;(1.R%&W_9;W!H;A_Y5;#PR:C^3WNS7
M5G(OZ')AMB"$MVKBJ[(^$6*\BPHG4?#H6:?2OYP&)]NL0)&/^"C$BH4!GH!*
M_PJT%MF)IG/#JF_1@YZ/,D#+$2,_@P>V+'[X[)\=)3@C%5.CSL^;2JC,'G'7
M+_-96:KP2KZ7]BW3H2;91[P\^(AQ!T2"%!.W#J0+WO7OP'(;=F^<@!CQ?"W/
M+Y[<LDA),OU^LVJ8DA#;][?A)B8)MEA@]&>YD<JE7#/6B85 7*L0-F:CEZVB
M#%VS);LFZ^;8HVS:Y"@0LL=P]^V1G1"]GV00JPV]1: T.3A:2SV9.<8-$Q\R
M*0I4QH7HI]];=Y3J<.(=TM;(\R39VRYN(U1'K1_+#4?SG"F.U0+E@73V>%CK
M)<8UJXBD*+14L[D^U-V]KEZR4\9\ZH,YZ[[U*]!*H%?!=_"UX;45);,ZJFL&
M)*?D&.): E7MQO6-\)-G;I8?6>R5%L]);+@E#KHEJN)-@46,0%_I?7;BHS6N
M&S8'$5?%;0,9H/@6GB&!7K>,=J8<CAND/5K?Z_&=BV7SD2'8CBE]+H3$;4XF
MA RW#(F0) ;1RNK4</%_61A65JSX\H2MS7KWE;L'V%3PYT1G3<S0HF'AN<M4
MQ<DP;_X1I;H$E>[,0KN CNI)Y/UUJL724_PNQ!DBM$M^GUWH#P(V+I 6H#]\
M]9"=5YCC8-_^WI5W%]YJ<P\?U&WCK82+ #_(IT?H+$#=YFP(];#WS O4=([]
MDH5_!4)YQ+B'$!\>8_8EX7JA6"3IR@&>6U<J=5 K<TRH*PYXD\YU08G/Z5JA
M-Y<)(9V4&WRS[:)B*;=LL$49SH'0D!#!MFXVEZC(5M^7I9$6+Y8(KOV\C12S
M#4=,<T73A/-PVXFVD0Y(:/D8+O'EZE=FDLL/#%U$C?GL70Q0_AX&*-V:.2][
MK'CGJ8=09&!HU8F\-JWZMN!R$[+=K/ (5UXC^J.C-YWC9T2+<>*WRA "+8 <
MFS1*;O]J?+O7KIFWG#7:\FK%(PBV;3^;&*Y*VYCY:*;JN.NV),0[DEJT*M-B
M=_P8/_W@Y+5K-).<B*5F+]*)TK(6%)V=.<5[N5K3!Y Q0HVA&"J3W::@V)GZ
M93>*ABF,=TV<%K5*X8424Q8O1S% ?E;D=.HA?K()+0_JN@;8PHEOM'?1F(J%
MEDQ+9X ..QBCH#T4OY^Q/;[WU(M>1]X6G.R^X3]@AVR[#IW.X+;KXD'5= M>
MO=1!/]CG?9>5=FNLC-Z/K!M;P5(L%[83'T!V(XPU)]-2;Z9MCIE[I-=Y)%5]
M8WNQ)+"9\UI<+G@N(+X#JM65*^V//?B%MXK:P<H>Z'5SRBC'MK97NL?NG8_7
M3%K)XM?;V1K3$..V6WVG9J(Z P:_UM?,?=DLD-;"I3@-!H]X^YT;\2C#_PGY
M(15LB!G%]B9WM_!$JZ8YADU:Z9YZ#X ./,\DX>.@1 OY3S;3S8GNL_(XZ)G,
M+0>/P74-L'FC_,=CL2/77*^&;E4Z7.JXJJ T5\ J-<[436+VRC(S$KU&<K >
MM2WP0::RZD15KE$C,3[R>Q>1/_K/DXJ24/ J1U7H]"4E\/85F>\5F!L16A$X
MB"*M)N)P:-RT7QOT$P=6]/C'9K/"7A?(F]G>4N0!N_S76[[/?O0VMSCL>7*#
MQ5<7RPM@2"Z$D$<M[(@+HQ$\B#-#]RNJ\_!ORM>E*<DWUZ\Y;SY)B;;^5L85
M1HNZIZ!"?[9Q42^%4-7HE]XGB:L><O!TV1 5Z+3>3A\I'3<2EGFQA1@,L9YP
M"#Q%/0#HS'+A6&88H!@(1RC[6-](L^'++E?/5 F7SQ&><!'N@TJ5*\4P+WH"
M1'01R91GE_XHB AP9DKM(U7G9Y"[V ^C)NZ6=\?>LT,\L]^^XVCR#=89[T&_
M0P)B,=3#[@3T*O?TJCOY#D"9D0VY.,2WOCC%7SN@$E-Y^TT>[:5-DD(S-LTV
MTEI01EJC%8W1!C-E\Z=[HTNHHO\M3R+K^6%?#M^DV4ZA^*G\0;52C@Q'V%SL
MUM3I]U54)UGG(G/KHL9'%LVHK*1QS^KJ!H*_/G1/;&>9=I',N<#\W)8*8Y^Z
M<-,"+)AH"06DQCHFF;#@<<2HT\&G+T(X^8 E@^_5=@&70Z@Z:^10$C]X+X0;
MX03$-=$L0I4(M9][I9[M1<HDAI&1+$Q8DA8A>!UZ ,(3*G5&@=8]@-#P]C*8
M/7)ES'4'-("+K-Y\BE NDK=[WC(GS !]P?;>OE@E;)'RYEH2)05I\=4/\ 5/
M^'5G(XXQVV@/=,TB&P)FD0*?/+)8-S-/J%5NLV1"ZS#3570M!N@Q\F[+[M #
MX_1-<D5AB5?ZDT0R(O*XU')7N-).U 3K7L.YMS) K%2=(Z/O@W)"S)!BND3:
MD_=C0[F@Q>]YXKX!'\.2=LV\5Z)62[?U\]JG:MZXV^27Z61HUS-9GV^DYO,\
M^?J[%O=[[8-!(@)Z<NA,>';FED3)%I3B]-/CMZ:H RV,#Y6:A75[GU@)>MTW
M+/LLU$M]52YU(F"W7(@<=BLX5Y]G_2@JBFI#*#=NFQ)_0VQ!BT[$"4?'FJI?
M%Q6XS7U7YP%ZX5P[O#KD3L1QS\;T>*C7JGE_9\1)TG[VZJXC*Z\\'K,TR):S
M9S^S&&G;2M"_< H^O0:<"*$>,CF,=>(@N:^,S3B4.VN;S+ %BKAQ+*1FF?S@
M^N;[);1U\E DX5,QCE=S/A%%O"W89<?/8Q-],OZDAM,)H\#%[APAI6<J9>'Y
MA:;LIC<&ZI9,9<\JAAF^><VO_/Z51MGBC!B;\\L7L[P"NNW&OJYLW=1>_8ED
M6*I: <2<%M<B&*T&YU$QOOY]M-&::2@P25P#3/E'V*RZ4P]CITW11)?I.\,(
MFZMD'/:A[_V-OIK2F/I(:5L7Y_'*AK=+VN]%=2L"R)=_;F*E]X*K51)2!KRY
M9G3.7;C/]V'>BOU5^S(#)&O.*S!EZB '9WT2U??S&-M?DB0?0_@\JTF2$NRV
M^YR4C89Q&6I13AI/)BI-Y'2O%D^I94].A"&^'4^05YZQ'^^67:+A_/%I''I(
MU5I/SV!*IJ6UW]]>B-OF7OC33,M=A;9T":;D_8Q3 B]B*E 5M1TWNBY/27ST
M#=)1]%"YD.'<*"O#LJD_]2)2T^O/\"[H[Z!=SC]%R:#!'4&VO/QVY/36D.3N
MYLHVO0DW/W88UUTB&2I^^,D9$17>K!T]9["CQB!/,SO,K^8A?Z&32WM3_TZI
MG<=4_]8#N-!T71C?Y%1+R<&'JRZ6R=J']KW-.Y#YYVBP^,]L43'+W\.0HK^B
MHF?]RJA:U3;.*XKS78-;/CA/KGQIF+MO]Y=+K"9Z;CN!E]F.9IT1^CMC_?>*
M6?WF-/5;'P#&G8V<"1GB:F'/S2H;4^]6KCA$_5L& 7J'J4&YY6D1S'YZ9HG_
M)</I!/E#"ZJ:UQY/+CW1[UZR9L=6^G*" H?_N:;^W=FPPU?,8D?-K>'WFHWS
M/BTFG0MYJ2<L7&(K(]KU6GG7T#_74ILXZL^]56$16/R1EJ->8)Z6$XAC].&Q
M6IC,ZAA^8ON>J%_ZH;,H<36VN >S>@1]_^0D0[3UWQ:>IN_4(:5W,IJ?A'X4
MJI;-[3/B+"WR[BKR?KY:.[AR:RO!(G6>A_=(.)OUW1"S;!?EG,Q&<Q.GOM(U
M-PI*G#Z$)QK /\UVX7=IF^53Y0!K9=AAU70Q &D%.38LR;<9]T/?3C+G8REW
M95717'#W 4X811W9)H1Q2?P#<8#8'P,Y@3@E-/]P=O JDMNKHU/SGHQ_V'*C
M><G^A3N\#_7:$U/Y-314UAF@6&TS J6?:Q*'6ZK43N1FB[TE6?X):.HP&S\G
MO'PZVC;E(.Q<[ 9F3.X4!CI6&L  J=6@=)H" @)N;LR]09>@R'SG:'&T)QN:
M4.MY<F[_>$=R[NC7N;FY-XVX^72$Y'_V)4O$44\FQ6WAHQZC]X[58-16U'YV
M)MTFXS"3NXB/'8A_^B5HSE3IR=U=Z#_'C#WOE2[VJY65NI1^*!NL2ID[45,Q
MB9:<K)BH&_-K>.&8,G=+A]5@UUF>*Y.?G07:U*Y5#)O;5!E1QN6Z_WS(;XC>
M^2=GG^ZT&V?!VW<W.;\\!P.\H.M_R^/G;_H!#>_Z!]R ;-1(CZGGP6P(RXB#
M]R&G?H8JIM"Y;]"M#Q200RBJB+7)V;[Q33I\S3]S43J/ZP/7(V0M\D&$!O4\
MT3T:(LL$PCJ0$T[ K"TMFQK^;!G/N@';4XW#+ZG9M/!8WPDZ;II-EIAYK#+^
MFD-(V;5=^TG!;3_J8;_I: P3_54R1\^9B;>R(&JP"@#5*<H_\#7&4O0 <81>
M@[_>T/#ZC;='5YGBZ5@QC3NNC\6OZ3?(/)99:E">U'34E[WJ"-G;='??L;N+
M^7LOS#XNT)1Q.6:+%3QZXZ(7;%(@-Q(B#WA21!!P&K-/_$SXZ>P:%(_0\X"[
M,>#W8M(3#VHYY.C8$1!0(/R8;]EQ1)0_5(^Z]++$[W"CKI!!NJ>-3/H,<AR/
MA5:&4'DQ76#B)?1>JM88%4:<G_7K6#;AFG&MOU?S,$C$X.Q8S9#0IR6P2Z3R
M)E\5[MF=>]QO2>]87GWJ3&Q@=E@<YHK\N-2,#GYU_&>8NT12?YM:+O](A(Q<
M!F$MIH5[Q"@<8TC\@/+CN>I=J^_,,Y9\/GTO9]<SJS/ S;<HCP$]$&]Z::A8
M6]@&85BEG\TSI'[/V8QOZ\"7FZRZ#2G9UH4\NWZ@5@VGU]@6X$=:V%1C"(ZJ
M;_MF,W:_&.Q6W[QSX(S6F7Z5=35R,(H!@IQF@/#/G/@I3*C2<P,09$+\SYCM
MXV^6(H_1/PPQ0//=8,JZ]*_+DU[2?X!75J%TA#,3%)U-_'7Y(O_/B[ DD, =
M:RQ8DI0A$)W+6RDTZY"C4JOKV^)?\]GU.P<R -F7:+_$ %77,$!;I!@ZC;V/
M)$^]OX[<ID&W]Y7'^IJGK?C4-W#MJ++!CFL+LPOGH>,X)!7H8( B[H-_79KH
M@<[1<IA8IO\1='/![->EY? E5K#[-'B/6K=QORB*PS;'-5!@?6.XY4.+1ZWB
M5J[IVK>UK<IE1YL=K[&KV^F<K';".%AUXG,,10O& *$$D&L?"WY=EA0_/_Y/
M=!/[AW?O@0]D,4^^ 7=!CKE'+,GV#-"OUKCM\(=VX-GUY]UQALE&W9G:[\<L
M%VV;!_E?E[PJ3-%(7%UC3C1*/:T>2>#Y#I$NN@\E"%""@T,13N&EJU#W]5S9
M+$0BN1I3IP%PT=FYF3>;DZ"M\/%YRY];_YBSG9AF0HA/6LJT#[V"4Z^4?2AI
MPZ_X[7N/C4P-(FL"*L>U8F4Y5J,#[MP668MN/E>D=ZMH237) 6YOFE60*\A3
M4'!@Z=T%L8]CN+G<H_[Z=JE#[Y[9 [90PO=S[E)J:S=_+$V$?!T:.M?>>J/^
MP+1ZMS:,G6OY86F?:7[C%[*/>LE-NPY8]&3(,-T7>35Q'-:%K(M9Y7^&8"76
M+E8:DV]M^-A."-J85CT,,=:2=IT<M_1U_+#0(-@7D=W%;,D?"6QI;$BOZ>)8
M7IY0KO]PKQI90A$OP@$IOG0*._4,D%PR-=F%O%WNA6:-J=CT3>+DO(;_0V%5
M+#D#-/UT:+"E$QUP>,;]H*OZ8EDR]\IB3<76,2DIS,2CS-I55]P\>L9:MYU^
MS$4:JYB_-)2/DL*8G_Q>KU0CP3/UT#N\YD_E!=T;_P#Y2_ZAORXS8T%_5BAO
MO_R><;O>P@N#N//8U:1'-5=(C;6_3:/?#J?,8S/-*7H2Y<R4!##!27BV_TZN
M @">B4,_PE2+/N'L>].[U2(%(*9E6_(P72K%W<>R#[0Z-[%L.DQ)H\'J/3<:
M^J1?QK<_%R&8:YIF-W4MMPS&F2K:&ZH\ZXUMM^C2"_"4>)DT"5G><-#)5,='
MH?@@0E1_8C')X.[%:YUTZX*BSZV'OK;[;^9G0HI;HU;\'U^HJ/[5&K0TT$71
M\4Z<*2#UDL-'G#\V^_V!+.PZVI7VYN#RGL$#:D?\I2[Y)[=7K2(X:,\"H8_V
M!1'>.!AE==#E!N@FM]MQ=SK)?=@/,73[SING9RL%N_41*_6:7<XD_UZEP )'
MZF%[B[)TVREJM;&=N4]M:5R*[RB/0M Q*V>2)JR HK2^0L%^K4C8_+/A*=$Y
MS-$6;'UST5RY[HD"Y5J!K("V;SGRU\2N1G Q0$<?(I?)?C3VNG]&2_YYD=/-
M_*[N<JEBQIZ'P75&B@-1W4MCOXK*J/W5,2W_-]4MH]4UJFH&>)%FJQ_:GKUA
M?9H-K4*KA'J]D2>[$+75^*R?P$/CK.4R5>X]7W%\C5=^.G_URXW3MH]WL8A'
M!"*,@$52P RY2+*$Q(7%I>5?NZI7_9FW/G'\^.7C7'F\3 T"!K!/B*I*2]S/
MEV<.F9J9Z.GIV"B7K>!&)/A?5(S9;&7/QY[.T(-?S9^'E&A)+&V,O<,NNZ&*
M/JG<VSU^UO#^S8LN'RWQOY1BA#Y5Y><["0>*1$N(F\QWYKI<,:FZS'<7YOZP
M*@&2-[: 60FA6"TB:^;O?'W]IB86VVEO>'[T^G$I%]\//07]6L*L44G/#QH*
MB$]S"7R':'2'G[7,V7_.I%NVY(1$Z5QJ*LZ^9J9FQ.E#MTF7P,4I=*7_%]3Y
MR:'U,.\YE]&=D^VW.4N+W+ZZH[=?<^'$R)< 5HH%<**9DU1$F,LM\KWWYOZ*
MYYR3YW=RVE1@1^=T9*BZ>L?>(S;Y _;FI>;Q>IHWO8S=:ER'2LP?#4^OC/:!
M[\*)UF! RJ 3_JE^AK>H4Q@O.@E@VNFRC4].-9\KQL9]^F:F>WJ*^WMS(<19
MNBW]VB/+@P'?)9"&X'KD2FT!_1.^:NTAG0TN;ESLB LOZJB_N5X[_*QWH@5Y
MWSAB]<'\M02ML1_WT1YAV&B57CQG:(QI6O^EH8HO=2TU.:H]NP<J#?1%,FP/
M&A2CQT.--=*\(V^\9(!N<8*-*Q+P,;WO:3;1U79NME)"B?CHQ+Y 9-%;91$N
M6Q*DP96 YO(<G/(2BO\</*KZ6')1*E.?[4%!D])!T(8*A4#17D)58JB'-LF.
MQ/DV)CXZHBU2X*T9A,(U&Q[93H&%A!3WQKP.NJ-F<CR:AB/L&Q=BI^*80%$5
MV:81")^ 87%KG?*Q(?9]Z5'-DD^ZCC2J+-9F;IHG[Z\\E7?HY9-H=]RY/T@W
M681HUP&5G^<2TV(C=C6'P#FA[ER<#E/G=1,MAZ_3\:'E-(+.0)*>^/9I-,>C
M'Q?WV%>V#:>@),OU9!WLG4P676ECF">S)&OGJ!(S9_<3MQMK>6K#Y28&>WN^
MW?H9)BTO%#GC(@S_Q "1=8!4TL4&!DA_U(>J0TLN,%S,FFA5=9^"I* ^08DV
MX 0P:2.$6#H=D2ZOZ^DV)39ZA76X15:89>C(V&CKGEV65PY$FL$Y-U94Y*<O
MQ?Y(_<H "1LP0!(0Z'+*">3>1S;9;^8!''3KQ'>?>NHA.&$ST<W1@%Q-RX^0
MH-H^?>59T^?>Z>?\?)X6IW4V%ZX3]63P#98 7LFA*"'VWCD.Z!#%VJ? 3_C]
M<.LT(8D&_Z'Y[)(G#-#T1>^/'F7>7]57SM^2,OM.MF>^<I<U_$[J]0C%YEON
M:KX3\@UV$;MW *T(+V2;'W(Z.U<2&&$B!(P(A T(A!2BO:SI0B3S-JY>T1F3
MVO4L [98\00#'5YGWFT7NY;_.NVX&:W8Z:K>]:"@L?&[YR:5KC<';(_[GK I
M;&S<P&P$Y *<1(=6S!\M^P%W NO=P*<%0]HZ!;KNU^TE)D]8"<]%:/S'^0PJ
MHSNQCB?^.U<4_37Z.Z_*C0\!)6H:6O6E&^KS&I99*3D3(X__#!;=VL2B$S-M
MVLI5AXR&E$M4,+S>?E]"_3JL8Y2<C(<"7+Z=?V/7#V*??A]P1-0J*E>&%V)K
M$ *()XW4K:28^]0EF52S;RPZEVBFBB316WS6'2_0M:E>1'2;S_'1P8F.63N2
M7+74.%6-T*3>EKOMTKH N="FX:Z]:RFT#!W)5"&CSPB33K.SX.[2+!\7;%AS
M:*[5&9^:!S!C8ZN%E[O:G'N/_.B156N%1X:A[ZO<1CV""M3:;F# RPHSWX']
M'2_.AMG;1VUR!]SM2)LG;1AM?<;(=;NKOW7+*-.P=%P80'Y?H^=:+BRKU"TE
M!<?/]4EUZ-^_;&7UH%/&@9#X?:NW&<.V4MNTTP*(=09;>[Y</)GV!#1V[S1W
M@OZ00VWB#'R+8X$!VMA&KA^&.X6YI?]3\/-_"5IYG\QHR2B/!*8:7XCT;A=@
MPXIYEN.P.TA!'J?\O]# [FS\\?\&PIF-W[%]$>2)_#\V[N^4LN,+MG;O#JD4
MOE 7I_X6?NK*D<S)'0NB'BS&?P8%V?YQ]+BSR-OJJFJ(TIL'.+T:N^ZS6RZ@
M+Z.KO^V_%(+_PPQK]_^&E%D;W%TIFQM\[NESW(7<HV]_.G22V=\[5D L=Q7^
MGU[PYT6NA<J]^^!X4C]M4!)Z/<6U@#5^I.GW#:+_CS1ZKT%<V?4"XL@LUOW0
MJWO395>XK==ID+:RHY+O#EV427(1O?N,E$B-X\=LM([T:=%UB<@Q7OK92*Y_
MTPQ3:IWF/'Z)E=K";.PSZSX7 $S7/<3DU2OX;5[0_WYSVS^TJ&6FQP,RLYH;
M67\:Y*$L6*L5V-)0GS:#ZRDR.U6I/U"6=-+]5/%@IV!D>\;!([Z"E6?V\)C]
MUT>4X[\MCS3SDYGV/8E 5*)C&Y#K>K='?HL([0*DT\]N0VD1*-KNT:[??_U^
MXTY*__LNZ5^[HIF?O3O^DZC\?9?T/_>\WY;7K;M^&X/_O-4I@#1$#AV,./6F
M*(ZJ4=9+P LNS ;?G[G-VUDIB@R29H#27F4_OK2='70E7"B6\+[J,Y_/O31A
M_@,>T&03KTRO#XHPVQ[EH1'E]]X?"Q\^7QRV@6TWKHSIUQHD(.1I14Y8RP;
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M5?6CXVM]=:7>\!#DZTJFB9PE%Q(W>V?E/RU]FU&AC#F)D!QK/ZP]/[\7_+"
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MN\4.^.G8T@3HE82C.S%<"+N2T%#0-1^=&?[@Y96L#$>#D0DBNK!EI^4KF'&
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M2WR$PE^<L;ZP3ZO^IL>_=:20+ S0V^/P;5H6 W3V=\'I9\<!+TPT]5^-R!;
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M310>Q@(^Q6HI_X=],2(Z,KA5J'RP<9#0M6Y>Z&%Z9:=B+:1[A&<8[UA%1SA
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MJK4]1+.@P(F+0=8DUH%VKW3MI6!>N7.A#C]EQ-L3J9U%KADYW2Z8!3OHNW,
M+98V._/_(!;\:9SY$J(?=!?%T<UIC:\R5J>=F^C47SY.TI*6(KZ=OI9H:C^M
M:"DM:?$6]V9#I,ADX#SNYFD9*3^3RK7;_CDLK1/-G]5\@B0P!A GD08]M5@.
M^>_:1G^>V!A=,#BV8$LVH3_X+G72G%Z!"N8'4-B_NJV>;R;!,T*U?EXK,+ J
MM97-/PW1R'I"M'C";UVE1=>X,"&C@W$NWE\;*F=@'L9=FJ^H\ +PH>194>F&
MNVZ:5@Q8@!+EW(J:W-G*)0SL#D7F2Z9ZFLJGKI]O;[QGNL^$3= Y\$]\B8C
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M0[9JL+B_SGXP]" IXG_$MEASF)':LB*ZCN[T'T*175+46B0_)'TWV)%U8XP
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M9XM?I0DG,+@]5N#S()SS U7@OFY]J$P7*0D9JVV0IJ':7!Q@A6J8;#GX1+C
M^"QYM^NIWY7YA;9M6>78"' K<-.3*@_O@3 ?-L8%&\>R=OI(9Q-^1D!:L G
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M%;LI&4YUIO%/P(/ \QUV4Q%@##]>K3<$N-_0&Y\1IK,>,Q#)4_'.?(@<9?9
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M^H*U],SAHVX1.CPB-T6^"NQ[6]]''QD!)Q>;3NQ=8I8(;4H>@(GXAG&;LX6
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M],H9//$I@>J+54#QL$IK/^*H6'ISVW27 W5T:"ZC9<Z9YM:=45L873&JW)\
M72!^8?7/)I2ECR9PM'\.ZPGJ"H,+/6$!9<K4T14FOS3.=JE&\T":[!(BZAL@
M!Y%!#N*6:2_3;]Y0]>N<3^BW.S;@DT.$E.S->*]C9!JKD*E+\QCTOA"ZR!IZ
M]K_%+>C#=,&'][=$%?]P\&<<T)P;A#W@X)_^R/9\ IT7.*XQ"%NT',:+-S%J
MK*?(&M@SU-Q<*V726TQ+\[UGX9X77(]4'XFVGZ00&_BM&UA%)JR+) +%@P8^
M19W%QMRB,LB9>0$TB?Z.0>G,ZY1F+=7,<;<F0D:]+,_=V!_*RF7W1O?B%_Z5
MU!VB>1\AT=J AAC43\:#39;U_6DKU05YZ:9/E<=F:VYG51LV3=7KO,]^\5H]
M2NGC)_G,$\?JYI.)V$'"0B/='HBERJQJ#-U?Q4H@G0?,_MVH(3]I--#=&#;H
M=,F)>D%)-_SZX,I#GJSCY_<R%U\AJX:LY:GFB7_TY9&C?LU3OS,4^^$4CXL]
MSVQXRYOLK^6&*K2=N>1^=22.RY0&V^0H3K[]Z#Y8<S0%^H(]6KQ_REHMI+58
MGV''U"9( P-]^A4AQ?H_78OPC>LQ0MC'[H&_KCXT%[ .<E-2?$XKI7\%QLO@
M;-,IZ+7Q^7%W8 @RX.=D0I!WO+(JKW#$!F^6Y=_])#V:*V.3YO-YJ3/^JM.T
M3LA/^P:56WA>S/7M!6.V((*AB;(%CE/3!O^-)UE=1 28/2'C#@ 5YQG@AUT2
M597JBVOPJV/)\3_4<H^)-L1DA:L9&6%!6/ISCN 2<PA4'X@<$\(JK1-.[L4O
M+EULIFEP#&CDTO7?SC)VH8C F&"K9($TZ",13VHAQ4+K22X4T(5M5I(Q\_A5
M1#*&V(VKSWQ*M]8#(J,1X!&$\/>J!J@LTG7E:.VU)WQ@*U?*J %41:U=."P?
MQ-CY?\?+M(!'CMCS-!YZCB=RP"']2V@'Y=EX<.4"-N3_B9?M0UUB=6!"PP/H
M0ZSG>\UV8-1SL"0^3X##VE*E"Y)3T,KPENIB1>#.2XA B!R&GCA3;M_6H1]H
M_NC&\X: =^"F84((>KQ'G 8=T%_$DH.*2KYY&*.L@+3P"N3&P&*3*Z31&RYA
M1S]^?AS:MZ;;G/$#NYJS16D;L6XDXI,@(NQ#RQO>R?>M)%Z&FBNJS:I]0IV\
M<R4H^UTE[*@;/&5>:%3YDLWGP:Q7KPTD05SOV",84#.,8T-X AB&.1PC$0F6
M]04@_2UWC8'"2_>O%C-]!E4]-,LH7"?<>//C7R<%'POX;L+1A5*)-$LR[+ZU
M$//H7(\>RH5FVI)!P@N%RLB][*SRRU%I;(HWR_'R >5(23X#.0R#-%*!5KH/
M1^O1F0=99= PL"![;.4P*Z?'#&78"F 51ID:M(I!'&]+83G0?B7Q)30XZNJE
MKK/^T"[9LU]*+;1!=VWQ'/RXR<IG*G#^&K7L-9E"SJR$6JM\0D%YAQ/(A9.-
MYV9,DUFKW]*408+E+3FS@5^2&2>P7V/3-%K^$P$;7W2FH_<B8,Z7'CE;JTX&
MMM1_*I'-.]?-'5NSB<[INUE_/KEQ\&77*EM =1?$LP;LC23!*HC4C_.'-K,'
M\9G4'VQA&AI[(),Q<)=<CVR6C[I0@7GJ_)0;;.AU7REK8 A/? 2ENF#2%8UH
MF(=08@'GS;<2CCD9JI]H]EYOJ[%E::1#L[^O=KX>Y- >]?<]:$!AZ5)>JBBX
M8A<4,)YID4>18I@C8>2\E(BVW[L@T;'0P\GI)D\S;0MK%YP.%U>$''_1'4\V
M<':)VZD;Q\BSIS$M.(HRPY4] :4Z@P%UW -U*KVYDNF>"TLE0)J7C"+JN.<5
MY!WK?U8_%KWQQT%\,E5)R5:@%6+RAK5 M21A,GM$V#,PJ4V="#XHF'E+O8A,
M46$%.>5Z;]:;%E<&J2ZWN\U^?$\5%<B_49NBE-TY:V5)TA< 3FFW66F0BJ#G
M'%FGX(POTYM38G>BC1&YY!-QB"?SN<''@JQR0K@?L?*LN4,Q#81-$A&QT'F:
M%E53YPE(]+=82.76U]IG1$<*5VL+F"1*>5BZ@$!$T+%A>-=>^]XZ:]8K3!@B
M#E^/[3L>0$]BE5NK+  !_7?EM+IG:I\L%RVWC BYVLHYE$<IZ814?[@K(AQC
MQY38V/-Q2V/ZSI-HUH4,(^2T>SBLWUD.2!M JTR^G(X4]"S_K/+,=A=TU^S(
MP&W#(S</:@6^Y7-DJ'!XK"TT$+)T;P0JSI9C<\BBZ.I,,R%14:^-N@M*,UF(
M+XNW+RJ5<8D;&6N.=G!5/V1\9I4[?2\]XF3I(Q(VV4J!$?K]X:AY'U:BMI)L
MGGY'([%V>O/N8FOUS25[4^'N+U/DM9Y(CL@^YOR+F16&FC#D+\=Y^Q33I\&4
MJD!B5NWZ,PZ'FSIS?S=[(0AY6"R;<<FQ]+.-(L^CZA"K/,:7%Z\LI_:G?<?,
MI]$_LHJ@Q$I8@V[=,#9IHGPMF:RM];M.!NGL!OK\7:;8?W1,[Z?UQ^=OCX$L
M+#J8M<*@>\_F6K*\S$I-W^OPBV6_7/[Y@/MPX_=,.(U!=V&]W'.J[7E)*%0H
M79<SI9OS8WN]G'%"7<>)[=9&Z GOE:=DL=>AM^:76U)>]"XYS8S>N1$?ZB"6
MR'--N]3QGQ9#%$ ,SV(:N=$?,?)-&>X^XZ 5&*#B9W<QTW/)?ZK&(77 Q0MI
ME/][ISE&[?3@6L1RN_!=;#_F 5Z(S<,\.LD61<E3S?))=4)(]+MPDW"P7;-G
M.$79/_5U3UF.P]>GN6HY3B!OZOK +H@;"?6>9=J18'S?.Z*>D_U.ZG>=C@V\
MECU6Z5LFUMMX_@?7DT&#H8-!:HD9EV[RPB=M0%+[*RN_+ZKGWZK^L5/OX^U]
MXI>?[SG2!<U)1^/ZXR!03FS5!\QU_)(ET7Q3@6J[L4J@")+EJYS4+;]%L,P&
M'.OO=;("7)YE\V84=:"F/]N[M93T<GD]?5UE0-L%S>/8 G<8VI@^;Y0Q3968
M%]\%H7'WH94G3+8W=T&R@ S9(UG&839<5_]JCDF;F$Y#I:U\K_*HUE*[Q]T;
MH*\]AI@^?VMMIC1PK R](,<QOO'#_]9[C\.<DMT5+:AU*3IUIH7"*H'BIRN7
M0\I4AV[0C#Z<_;@M>5UH5&)?0O0JEJ)-A:Y6;'ZE3K,%JAAZS%,--&@26GYC
MHR;,HJ? QPAY]:M3;C?/VUXKIW"$QE*QC  Y_(A2[]4N8_8!*", ^:BW=!!*
M/0-=NFI_W=J R>=E@A7&A*B_[0H@V2?_4QA[@U;[24D/N"QKMJ;Q):7E#IX?
M?ZV2H](>X:@>;=!@0E*'03LK#WH]32%HN4OJB'0]%9]:4QW8D7M@^L7)6_!#
M;U,-VV&CJN&OQ;G^99"=Q4-79*DUG..T'70QM.+[SQ5'I1M6;:MZYV,-+.:^
M1&^ZT<#TO1A?(TH $*-RT]VPEP WQE&4PB3S$"J8AG&=[NIV'I$;?I![N[;H
M19]FO[==3$AQX&BZL5VZ:(TD[@6N'AO7=:N<_3Z+_1$#84*CHS4>0%RHH9V?
MAK<!^P@?+\7%X;^%Q[(^>\86E6NPO?.3C[[[0Q! 7NQG\U _XHAU/,#M$;O)
MWX5'*2;=VN>:['5K=%==*B5=2P0>O@8)E(#V\X(<RH![)R;4NO).36QN%KIT
MP3OI32WV8V,#1SA",V'>?LG%\TM62?!]CSW_PC@M.K4)O ]Y\2(-G_I'K7'J
M=[@UG'+VYXFS?0BA<+6<0W<2W32P9W]RC"'Z%X[]R\-4:@&>TU0'V*HTZ>?5
M&P;?>D2HSO&_DV9,<>(_&JJZHMRC?MCN:!W*=%!V<WFV#OH+V;S(45'2@ ?G
MMS>U;@BQ@!W!-1(&G1_T&%/9628$!0YSR"B+37/%GI\I*3A:>W5<7[XDZ]KK
M)Y;G!1J,07>@LGCB*UA+:Q_T_J(YI3.:H_;6$X;P/*:QT@3?[D=[=[FBY\C+
M@K8%A_/UMYK>Z02T/A)MZ,H^&:F4IN-]ZN&4.V$(LCA-U*#H,PR89ISM>X-^
MC[9*&+16  +)AE4;'KEO+X0P+2UBTP:E\UPAQ1HM+7D4B@3H7,$U'H4R0YH^
MH(R@X%:=$ZS59O'$)$*KT\]0@@Q:4'L>R>V"5_2U-J567RYTJ'&\I6IS0^;
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MS?58,,:@:,M^#D(6*$P-KEKP"JR,Z8HLJ?'6-./<MGVDD77DS;:3;EM./(9
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M9[*SMN^M40=BT*%QK!'4_;)TETWB6/$?VO$4B@3BKQAV[ZQ\*L[7P6 (^9G
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M/[?J7M%(DZDG'2=ZQ5O5(;$\_66C8\;MC2)UG^<=%JU#_/%M@@\A:R)X"B(
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M!E*Q(L?*T!>_$LF;7)%(KY&@;0DZ1E->1&'W5!K-((-2UF7>)YPTBLB5JON
M!.[811+YL%'Y;KS8>L\7;+7@9%X.4[1E>R\ABA-8\$U+AY!X3^O-^]H14_/E
M G0XSM35Q;2")KL&9ZMB/O]@^8.&\M&_^3#))&SG."_?B,04[?03ZQX)G"@_
M,C0\]4IBY[5H[139)HF3AQ+/"46"/UBM()-]'-MJC884=!,5(EL##*+.<?0
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ME?_5>$/'%WR8]5V73_=O[=]P]0?CH^;&]9KP9(A=;IC)%([@NR^_^V+,Y9K
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MR#T2B!-3=LG'ULR7X(W+&7ZZW^3[$\D-UW4[-N^123M?C8L##J.E:37JZN>
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MG6TSE%O=!5OH</9;Z4$5JL12<\(CU90.'U"_E?\&EA<"$ &( $0 (@ 1@ A
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MI Q3(^7_.#;8+Q>([TG>];ZL'H2KU/W@2\93F'[P)NY7S0]R>($[PUPL<OU
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M%)74E>'WD[8*RTIBRRA\%_C/'TOY1'.DH_YJ[?M;$]&NR;,1&M12-T'LLSK
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M&]QV8_O1QW:W>/XA\[M[;5-=/<DUO9/791YTN>$L6L4G]KV-4\'B-)10Q(1
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M>KOCY9X]CZ#-^?:GHMA*\7Z[-I64RQ/NTE5YN*#^/"()#F).H.#2'/-$$N*
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M0H(PARQ#F11Q1F7L:#;:##L]X[#=]6,G;,^6*5UXV_&4;PP'9JB#X U@L+G
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M9#$*,@*S!!.(3'(>BP(%8REC2;(@9<HJM;MSE*FM;&T)P9^5C);GSMUH=C.
M-XR&C@AP@L>^4:V-^EVOO;Y!ZY77/[5:V';>>YS&MC;J[=K=6GVY;\I"5:%
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M#I(O+M Y5GG33ZBJM+75H^VZ"15?Y5H+G?-2_+D,491R@F$491@B%BB(>9S
MF(0HQH)@$H5N!\Z.$DSO)'HO,ECM9 :_Y$L@5HL%71?&6PD*([QC6ISKY& 4
MIS+-8D@X-X[GC$(6!P1BFB1ZIHCB;C;.@%,S2C7I0Q,S \P(?)'Y<=F5#8+Z
M.-NU=H>[UAS<M.9 :P!*%2I+P?=FSAD\K[L\^]$OL/USAN;POM#]-GVJ7]2I
MFV5RU#<IY$.Y6'XM@S]N]9S)^EPT2(,X0%$&"4%Z<Q>%Q@VJ?TR8)"DA$<+8
MNK"0]:A3H[NO:W-VJBWHO]'EEJZ?013,RD-3ER(.MHB?/M$?!,>!"6PG,RB%
M-A'4C=@E9VG!02EYC_-]>VQ="F4,@/%H!3,LL?95-,,1JL[B&;;W&K&(AJ-Z
M+XMIN%[<P_MJ%@-V>H/$7F^0JFS83\MBLRX?RZ(,";V]I\ONK=,N\YM+I+#
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M!9%J:H385LH$.+?4L@]E6S&SJ]BI!O:ZN208#FAG-_(<W7H#<^M8AO,FVJ!
M!^+A,#*-2M-!87S-XF$'[YV):GN!_GVUW#Q6-PL^WPA]+#\>+/5%/PE-I^8\
MY2A! L,,)WHC*U(.F9()S%$JD@0S*F*ON(B><DR-R+=J *L',(+V;)/=US!N
M/#P"W ,S;R^D^V277H)3N*S27E*,G4UZ"51'LD@O&N[",NF_26HR6 W5_J-<
MW_^^6#*SN3:A%'7EY6_2X%+.RR:WE6]6IFC .UJ5N^H:S[;92S4K:()0FBA8
M9%A Q#&'),X%3&A$\UA10B.O/? @4DZ-2J^%*+NCL$>TH!NKOKE=!N;<=D'X
MEHK@+ZTC:"O9E(L'+]6\ CM%@=7T:A>F]GQENU'9D^P )>6'L$?H8O1!97R;
M,O9#P'RR /X@DX5KKI$T^7TT+G!*"PK37&KN9S*'1"81E+' *"]H(3)^:7.-
M9)KIDW6OB.3RYAK)Q<TU>B T(I>^;*Z1C-1<(QFMN48RE>8:B7]SC=<?Z<<0
M[S:5N6RJKOF_-F5E]S5?]3?IGE;RZZKD<I_\O0V;,74M3"_C'_3G!RDV?%UJ
M8MM&NS"D8L85C$24091F&%*41WH_*5DN(R:+!/EP2E#IIL9"6Y&O;#JE[<J]
MIC^!V(G=1,_XT518@[H1VYN9:6 JW.H%6HI=@;W=MEK8'(>]'L&#=@;!-Q"M
MAI5M5"(>!-;7U#W,)/YEI=^MRKO[]?^2=+Z^_XTN:%W<XV;!FRV,3!$I,LJ@
MPD4.D2HX9))3B*B(L:)ID429:\'H,W--C8AK<4$M+]@+;/O1_,V]A/ YB+O)
M-#!P0U-C%V;G]XG>V+D75@Z(X4@EDSNQ#%, V1&4CM+&YT88K6BQHRKM<L2N
M'^G?\_IU-]98$<(*GD*24\.FN80$20XYR1,L36DBOQ2/(W-,C45?]KGV[VG=
MKZ'MA< ,?1=D8[B;]K6#MK'MP"%@%^LW;5O;H>*Q+M9AVM0*6<[>;U8KS1>?
MRHK3^7]+NOJXL-G_LXCPB$8R@SDU=\TX22"-])XIR2E-TC0O,N7D0NN:9&J/
M>2,GJ 4%1E*@1;5%)MP>^DY(NY_Z4$ -_-CWPLCYD7<!X<@S7TG^M[OETW_I
MC]>/N_YA_Y1W#CK*8^ZBUO8Y=WIO3Y=YN2C7\G/Y),6-WODM[NSIRV:O?]8'
MN9NU?*AFB.>"YP6"*5'<9' 22&F>PZ+@62QEFA7$:WEWF71J1%#+#*W08"_U
MMM;#GT9P8"7W##!QLH"CQSTPKD.[W@- ZN^!]\ HE"O>9<IQ??(>(!PXYWT^
MV[<%]LMQO\CUQY]-X,G6;30K*,I21C@LE"(024PAQ84T7:SUD2,C*55>I.0R
MZ=1(J?704"OT%5A(S\.($]AN_!,:PH'YYX!RKH"6&/RRDWGG^_XU9!-F=XR"
M=4]VF'+DML?N(!SV*_;X;,\B9<<[))K4>5,]@]_+'W\MMX[DA&1YJD]!G*$"
M(AIS2&.5P2PB:2JDQ%+Y=1QPGWMJ;)3H/7\CHV>A,0^\W9AH(!0')J2S)?<;
MV8$6?H#@A!Z@A:H;YC'SN+7"_"$YJ _68XC^GMF;A>F<9;XM[Y>+)[FRMVG;
MQJUU6_;]6ZI9@9C^'Q<P*DQ5^:@@$">$P8QA(C.)&(^%K^/63X2ID=B-WMV:
MO"!N9:]L E%=U>.7<@$J8\SJ]'8@E%W<O<'#H3V"LQCL1;-96UOY=QVJEPK4
M.K3>&;0<=%\  WJ9/048W0G=#Z!C/NJ>(_4L"2W^9U.MZYY6RVT0.YU_I:4^
MM[ZGC^6:SBTWL]?<_$W6L0ORNUP]E=LFUR:,]6YA1[&Q:9H[4YKC NO]7II!
MQ+,4$I$)J 21F+$$2X:]JDP/+/#4F+;='9"W6TG)/JVD!C>W&R5/R8@#$_CU
MUYOW5^#LGG77(=FT'K<]HUHZ!2S0/1+PH6I^#RWNN&7$1P+_H#+Y6//VK8#5
MSGRX5=_DDUQLY">-WW=YUXB]SS@V,7!Z09RI%.4%4QDT-<\A2E &<6QRU2@J
M$$4)B;A3;-IE8DQMN7BIA=D9-GH \WT$6TW >@G:NC15M[WK_/:RG-L:,;P]
M!F;^H4S1HPK7)4@&*\W52XB1ZW5= M1A$:^+1NM'IN^-IHMUG6G\K:S^^>YY
M5S$JRPH9F2)>!5+&C2$)Q!CED+*"I!31A'*O1(R.N:9&BR]$!4;6_O6YNB!V
MH[9 P T=L-(/,V]Z<D C$ =US30JT3BH_)I-7#[2CS):S1>:\)F9B",:LPQ!
M@N)([ZV*%#)3%8OD<4X8B6*2R]EZJ?>-;DQQ.(470>PF&N[+_L/, 7@3HS7O
MVPSF")9NE' 90@,S04NX*]"(%^[Y/ZUZH,?^R 2C/NVG%7S]D'>\LT=R#ZU*
M?KT0'\KY1N\N/M+5HES<5?H,9P][NUIH6907>80$%/H9AR@G$M*$8UAP+% J
MXZA0>/8D5VSIE.;C-JO/M[L]]X!?\F55@4>Y,EZVAV5SB>&1J^*(=C<=#(3@
MP/Q@);85Y!J9P59HH*6NG5_>!?]\0/5(! H/[E@)00X@!\H+\L.H*S_(<:3Q
M\H3\5'N1+^3YT9[GMTVU7C[(U<%VKPGLB.(\)R0S^[&<F.N4 N(LBF!>\$*S
M=8*CB'B=X;KGF]PYKA$7'!Y./ ]Q9W!V/,B%0V_HP]QIX :(D7'$)=2Q[LQL
MXQ[MW%0_.-XY?JROB]W<%_/UQI04,K=+^_K+GW?1\T(I)%6,(56QII9<II#(
M*(4HBPN>1PJE:>KG4#\_Z=3XY87,]3U<J\SX!?D+3A9P=8R'Q75P-_CED/9P
M>;MC%,S![3#ER.YL=Q .G=<>G^WI=VH:6UQS;B+'JB_+M2T,_WE)%Z8<FBQM
M>;0O<OU%Z]MX4QC+9,XHA2DIL":I"$-"(@[3F"1Q&HL\\R.I/D),C;3V2=:K
MG<"^?JL^MG#T; V,\,#TM17;DE93V5KSV%[P*T"5!G_?F:(.X;!M6H!Q*ER!
MO6(!O687P!K*K]9'A'$];Q> =.";NV0L?^_=1Z4D7Y=/\F;!]<;P!_WYC:[E
MRSO%=W(A5;F^57K2IKSPXLY\Y=[3U>J94?[/KZOE4VG"<_4QU>PK9T4:H:)
M!$I4((ABE4/&BP*F,DYQDB$JJ5-+G^%$G!J[-AJ8^_N%U/]LE0!SXS#D6S7
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M,N(9-.8PZ]0XN!':\U3N!K#77C(<;./L)>M,Z*W$=6?.7:3J.[G@]P]T-42
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M67THE?ZC/L+*:D;B-$Y4HB#5KT&$*(&4$ 3SE"*&<R&9D*Y'#<<YIT87C9B
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ML-?E"NRT 7MU1K&'>Q7_<>PR4CW_0>WC5=O_<E@[JOQ?,/AH]?XO!Z!=^3_
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M4.J(:JMLWT35-_CZN!'X?\J78N!%P:4S3G6F-<X>A_8WY@K46-A\VUVQ(+W
MF)='2KQ].],&S]Y] U7>* 7X[8QV.H_X#67R6\"%+&<?%VN]&;@60A-%]759
MZ:WS_U,^OE\*?9[@>93&DL)8F!*8.==+*^(",D(ECPK!,N&49]P]S=06O5I2
MT(AZ!6IA@986&''=UK8SR':O.N'P&G@]Z N5,TF[(7&$/BO)_W:W?/HO/4#-
MG/J'/6&>&784*G-3;4LRCN_NVXNG'3!WJWY?K/0K=XORW[95YKLZKZ?Z^)//
M-\+T^;9I/Z9,@DG1U2_\6'[\21],MJZ-CE]O5HNJ[73%L2Q(I'?F42001(G9
MHZ,D@Y)D6.:<8D:\;N"&%GAJE/127W/]WM;8!LAN=3:E%ANM0:,VV.MM=E1;
MS>NXVEKWBUSP@W]]W/;H4_I2#!UR,Y7O0X_^/>,8*5@GH('%';FGT#C@'W8G
M&FG>?LO?NTVEAZXJO5EGY<+*J)?7><F?9Q'C&5<I@JD4&"+!&,0\P3#-L@PG
M4N0H]W(NG9YJ:DO.5E+0%M5O7>C U8W1PZ U,!<?!0K48H(_FW\'\5R<AR<0
M"W9,-"I_G5?X-?,X?.)2E[?MJW3BQ&]R4_26_97+,<^0B-.D@"0W'=L5R2'!
M*M/_85)E<:88]VI8>X$L4V.=S[+N&OS"-PBVLO=U*_N;R-<K/"CP(SIU=[[:
MO:_J"MQNUOJLN:BWD+43=ZM4>W=9=X,>R5?;&_#@KE9_2=[(4]H;LM..SOY#
M]G54S$W#FZ]TI0?>Y_ U67VV-4?KY<K4CVE_9!8)RHGD%'*6$X@BH;=S$8EA
M@G.2Z7T=BK)TIAF(+=T]$1=)Y$,#;;D&=.DUDONZ "XSC.L)?S2P!S_ 6[&
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M4WOP'<L\]#<01HP7$2*0XKB *,US2,RO#!..TR0I1.Y5<VE0\XQR_7O,.%=
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M6A00$1Y!QG@*]4LI52Q%D7#J1^L\X]1V^BVA@94:U&*#G=R><=EG(>]FUD&
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MA+._I#<*[;P:FM,AG]<_NM^ZY2-;V6PNV]*^2OG=9B-F."5$Q"F4"&-;E8I
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M&G@V.A[8MK,3= UM4JE :VJ5U= Q%C36WH#6WN:.28RX^Z0WC9$?:9I\XS?
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MK1S/Z[YT\T[1CB?%K-H2V)+A8*7L9J(]UN2L+#P9\<(XN%%?.'0'YKB.HC?
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M6H6E&,M$)U[+E;/2ID8 E7)5R)XLYINUDIX)/>>A=7,6@@$V, VT>N[B?FY
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M1KT<P(O3)BNJLMX7/%*-G+X]2%[ Z&8170+.R.Q6B5:;D><0&= DY+C:P=J
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M=262JKEY5=6N4JAJI7NOEIWVY\/Y:<CTN;'6R),R,I?58C:5/*_JP)?RZG@
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MKRDXORJ,!NS(BT(K-SB :R0''=%!*_N0!KU>*'OTZAT+[:G:]KJC'JB%[Q#
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MATH!0'MUU!3BF0-:O!X2OJ_ECZ)<;YZ^J<T/L[Z6BS2/4H)B!7D>)6:5(X9
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MW>]_KA<BP0+;;G49B25$@J20"&/'")U'.,LCH81?5TN_\>=&9^9E1 %S(8X
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MVDO<Y)T?9&X[$_L<53M"WL]"X8$<F7[>!$/W2)^P6$X4\W,6TS"!/^[8](0
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M>\/9ROZU!6S \C4>:C*;UW9R?6O7^MX+ P&OMNVFC'K5WJS%?Y_$BFWU0<Z
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MGYG6,_J0Z&FW9^?ZV/1KA@&Z!?WK6H" 1NAJUZF@!U*_H$&+TQ7HD+H".ZS
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MY2)E7:*/K5/O[B5DY//$=HJ^G?QQM-0[@,Z?-=R?8OX]S*>TPK9%U3%X5>J
M2U4+^I51"GS2#)R) 27'HG8;\[,'=NZG9%SP-%#QK+F\.T#-JYPG50?A_%.8
MY'?3-^'[9!G.MQ7Y3C,C#(<@:D:520C>J01"<49N@:^SPYL'B(\0-.X>UQY#
M[:0_<H+!F\N+R]JRY@?^7@JFY?KH^-K%7$<L+BNK& >[NC>/Y&5ZJ59545P'
M%C&%G6Z1G\@[V(66<>^&3^\L#:*CSC&W69_,J1R,%\"T4Z "DD'V%(-(YS'&
M)+#L-FGH2-2-Z4$-H_T]H'6 *CH'U_59S39-.!=.\LK 8P[UAEA"8,8"=QRS
M)RLN38N)JOO2U2_@#L'$/M;L& 5UX)C]AG'Y;KI8SB]7-[-U=2K#5-1"0!:1
M1(4N@!>:0\G1FBRC;=]<^2X5X[:L&N^8X4A]=(>H&W43%GF@%SH0II 'F[!
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MV.2;*KA;;%?OFA3RBQ!NCC=93>#Y6#Y>+M/L A?_&<XO\3\F7[^=.<&\M[I
MB):V*8\6'*^5BX6;%)/+T0T5-[7A8-RRB!,C_"1J?E8@?S\)<7)>\_$+RRB"
M<\!=S<"PKLY(,!+0!.UD(%=_M]96@R#YBLR=X&I?,%P/4U@'F-R>63QR7OQ?
M6&\&:'OY0<Q^Q7\NL%R>OY\4VF1L1D4A :24,RCN$8+U'$1BW++,61;M>R ?
M3N].*'7/#J4G4^'!<*6WQMF )ZF7\_0M+/#3?)+PU?GJ&?3C?\QF^:_)^?GO
M?W_'1,Q_"7__AODRK9H<O+JHA3!G03-BU'DH01#[SGNH;A-(6K+%J^"Q>0/<
MI@SL!&G_[" ]GI([,,GOIM7-(48J3],%OL8IELGR3#"B5Y(W'T),=3HDA:M:
M*=IHD$>NA9>Q=5;0 Z3L=MK/GAWL6DC^V12T7:^A6;DAR3>SQ;)-B=L.+QBF
MZ&U?SL8I@V..*66U!=IE:T\=5IL=9 TZ"L93]M[C"2Y2>BJ#PQBET&B A8R@
M,-&"\U%!0!8#<[$XWCHAZ$67P>V#L*/+X/917@>;[$/E-R%@5AP+V%3OSF(0
M$(/EH*U,4C&G1#J!0_@,R^#VTO^.97#[**-33/U:E!&-="H6#QAKEI4)A1R)
MR,%R)DI"D:1H[<(]TS*XO52_=QG</GKHO@Q.)E$\=P)4KIU$37'@!=EZ[5/B
M)18C!7_";7L197![*76O,KA])-QE&5Q)R=G:@4,)<@1RDN0(< N1QZAB,HG=
M;GWX8LK@#@7%T7+L8#_:ITS&%XIA@_7@O+6@E"(Y&>>@.)^$$L;)U/K&[.66
MP1WC"PVEM+[Q>&].>K2^!.8+Y"#SNB&1SY*D*E0FBQL\%ZV3%%YL&=Q>4#FR
M#&X?O74 R\=*KEB()EC:/NQ*;"X5B 4%.%N80)^82_];!M<"!GN4P>VCDP[@
M]52I%?<HG J2V#'5P\P2HD<-DA7R49357+1.+GQ197#'P*RE;KJX';U;BB52
M$I8,?0A"UUSP&KJ4##IG)6PR(876?MWS+H0[!DY'2;\#4_7HQ1K&D**7) YG
MR.S&FE'H?:; RI,U5D5XUGHK?$&%<(V/1P]32T<0VR'']>H>0S(7DE0((3F*
MX6760*R1%3:%.71)*7N"AI%/D=G=\=B!&#D\*?D@A76 R2>K7M!:;G,)D'.M
MJA+)0V2:@0V>PB?%D(?6 &Q2@'3*B\BVH-BW+FD?#76 N):9_CP9B>2;4"04
MZN%T)M:#R;316*\T$OG^-!G"PY5R#'Y^?"H<CZ7WYP7Y;3+U!!?OINFR_NB,
M.V.LDQY,KCW%H];U"@:!.6:PY&RU']$'N(?B/BI$.P3VL=I]7ECF9UIJ'65F
MX )CM62V#GJ,LHZA<2J&*'CIOF!^\!+1#G&ZG^8.1^5L&<Z'0N6?F&9?IY/_
MP?PNDS8F91*N3C^V90.TI]Q8DO2[RPO,FS_9BMPZ$:)$"3E85_O .O F&TB"
M*VZ-E2JUGBPT'#=]N!RG"-3&4'^?YOE@2;P)BV_TB^J-_0@U\7AQ%K*2Q>8
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M7_Y&.^/JO-(4IISQCACG-6 L$F(,!C@6GJ2+SL;6&;-M.>C"/)\4@ZV7P>&
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M%/I!XG%J&W\F]KJ4]S&7-2R^K0.GVNGS5?ZQ.E[\Y;SZ8[G_Y/',TT(,QBG
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M3M0ROCI9(<K(O%=1-4^P[6'O3+1,O0X.F'4&5.U>';WVP#/*C,&5H%NG<[R
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M0,4^ )-#I=P14,ZBL2E)&8CQ$$%Q:8#X,,"D0BVD$3FT/H+9OKL/2!RLQ =
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MC*V/#_8@KZ<P8#@OK85N.H#=NRD]"Q?+32'BRA<(2C.,R8'TM>A,:HJ:C K
MHN/T<^2N>5W,/62,6RDZ!(R.E757?M>G.7X//U>?<!K.ES]I#4QF9(6WB^&L
M).*!EPP%=::5X,FE# E!"Y^*+";;S/9VN)Y\[;C5G<-Z6FUE_AS@].6OV9:U
MQ"*KH^W R!K]&D?2BZDFWR:K4>0H;O=H/!Q.UZ_="4[N1<'I0)D_"SC5QCM;
MYIPA,=F2@"M!:T4J Y&AAFQ*$#D;I?4NA^E[OW@G2/F7!:E#Y?X<0%7;XVQY
M8S91E"L%%&*)0EQ=B^HM!\93U-HXGT)NA:D;[]WM8)2]*$P=*O8.G.[?-J]=
M9\K@F]EBW9)!D%RL*@J,J6Q(%X"BU !".\439EUL^VOA>TG9#5#/ZJB]A="[
MP,Y-T?QS&M;=9#"O!A!=KI;+Q>3RXM5TE?2[/>Z]8M=9BD^%(9>P)(I/8RP0
MK/.0O#+,<!MS:CZ(]#B2=\/BLSJ0/Z42#\;L#YS'6:MY/+\T_+[*$%PQ5)G<
ML+TXP\!"XC$"UH-B9:2#Z-!#C5]42BI$WKH(8%?:=L/ALSC$'U0M77=DO]5B
M1WV8+?&(5NN//FZPQD"/4#UL.Z#,M.6B3I.7T8,2CK!6#QJXE#S8D"7JUJOS
M=.V M(FU'Q:CG=_20G+.0E2$=LZ-E8ZQ;'/K%N_/I1W0/GK?I1W0/J+NSN=:
M-S.)!6,]X=?>Q%KK&<'A:LY8YD&D%$PJ?>3[GK0=T%Z*?3K?=Q\I=X>3&^F+
M66",SO.:(%\S=V@1.>DS!)=K:;#/7 ^;'=YQON]>.MXUWW<?@8]>G503)=[,
MIN1O+VN+QO7F?HEUH]^DJG)>.TJ4#%HK!DH9#5XG"<5F4YBS*1;QA*>RXZMZ
M@L>A^IP-)]R1L7*#D35G*W;RBAV^[5)C<V;!&C!!)U"Z5@L'&8 8SC)EHYS:
M!2L[O*JG1+D&6&DMW)&Q\@'_6C&PH=P5Y852 HJ('%0MU'(B,PKHK K"1!OY
M+EU_?GUJ3VEM#1!PA,@Z\#[N[4G"HE*9A '"Z4*!>S80E$S ?0XY,31D^5JG
M"CV+_C['>*I'2[I#M&R6#F/:.55GV,J0"?.!/FD>0&2+2A3I>&F=R_AL^OOL
MI>'=^OOL(^X.0'-C7]QVG7&2BZ 9!.'(1B9EP>?J/.5@BB1#Z7)KO-PAHB^H
M'*+9.TU;CA%S#S@A\:]:EO_^?R_7N9+?9U/Z=K%:1XH''I0ID!G2.G(1P45-
MFVL.V@:9#(KFC7X>(Z@G+^;XS:F=[#L TBT>-FL+HY)"DF/&HZ#5P%,BUXZ<
M/!*65M:(4'3K%D#W$C*NX6FHZ%EKJ7< G9J@/9M^7L[2?V^,J JYUH.2#8YH
M0=E$1I0'!]PX;2CLKUVH&\/F#A'C0J:!8F\WYCY*RAW Y%7.DRK^</XI3/*[
MZ9OP?;(,YQMF:K9C,5*"T<*#BIGB_>A4S>OGB3LF4_OKZ,<(&C>.:@^?=M+O
M $I_U@O9*>;?PWPZF7[=^FY>..7K 7>6M(\3%[6AA9+ ?"J)*5<L:XVA^RD9
MU\]I#YX&\AX1-8OY\NS-Y<7E.6G@!_Y>"J;E)I^_O,JS[RN]U)T<?? E:0W&
M8CV?Q@P>LP2=F90R&ZWD3D72],(;V*'OKG&S*RT]E1,>[BD/(OG.D;3MHR*D
M-[HR@]+4>=X27%USS H64LC&[S9QXD@LC>D^#Z/]/:!U@"HZ!]>K_*_+Q:H6
M<GM<X2-*GQV8PFGC3AC)!R1699WQ4DQ6WN^42G.LR;I%5[^ .P03^UBS8Q34
M@6=U3?_B[6S^ ?]ZE5:)B;3K?YK/IO0QK2+A=>C+O0L*5WD$835HB'P*6QA)
M47I1PQ#9?*S.7@3V5"!]_'G3<+KI 'CU0/=Z&6V[5<HB0VTJ('7M5NEK,S*9
MB(<Z(SO3GI&P]9GW?72,>Y0PH-IGC770 8ZNA?-Y&:8YS//BG]]S6-;< L;,
M-A-%"V=2R5#K3D#59OXN!UFEY'1VD;:'UAFH.Q$V+M*.U_]MB]5<&1T@['4X
MKR4BG[\A+M_7O]ZZL5::*)CB-?ZEI9<DA\A65T=,:E>BL<T/RQ^BI:>6#L=O
M?$TDWBER-OZHD &-B1R*T8+\46MK:AP#\E&3E99E^O4)L-/#;4L;;>\ H0-$
M/W*FV:V3O5\[RVVLJ<Z)8[099"P4<&C:^YTI$@QWBMCT0<1=BNUW>%5_,#E$
MH[/AQ#MZ3?W-.ES:A-_BC8EZWBB15F5LM)94H+#4TYYK:%4IY#'[VT>=#Y3/
M/_B*<2]0!D!'*W%VL!%=76B_.0^+Q<>RNE5<3U;CBH=B$%B1DFPL^7V.UR'"
M,<J4!=*O6_<)?9"8GAH,-<P6.4KF'8#G)OV;)56B9VARA)#-:N9G!A=D@1)3
M^O_9>],FMVYD3?@7Y0SVY:,LV]V>L"V')'?'?&)@24B<+I%ZR2K;NK_^39"L
M1;62/#@\H-PQ=W1E2;=.+D\F,H%<.+-9B]#Z'N@A%9W4B Q3[_U'_V&R[@$M
MF[*%#1^OKC-*,A9CLP2K#",.=(:81(*<Z$B5])^,-5_;_H"*B;=Q#]3KH[4A
M1PNY Y@\U7-ON-58M(1$_)/)& '!&0T4A="!FXLIS9<!#9FY?Z+Y9*U;0(^3
M=W>P^3$D?/6IWCC-1#""HO0,W)%)J:02>"XLZ&!L3)YB0#'NKH9;6GIJ]#M2
MT<^"YTBI=X>>ZZ&AFV5J]33/=X;-)AL"9N5)7(DX(T<-/@0&V>J@:FL^CMQ7
M_!QU/?7\C(&P9IKI!'/;_L<UZ6?7"8GY3JOVQI3XS,DD))WA@%+613QTB@?C
M-61EM0TZ:)G&F "R#VT]E?&WPUMSK72'MC>K^8?Y(ES4/[UF2++L?%U1BH91
M=F*B!9^L!,$Q2I62][;UUO 7B>JI^&T,? W50P? ^FT[)Y)RF =CTV8Z6L>\
MXE )K^LJZPJQP$$8+:VQSNG[,Q2&[YIYFIR>:D#:@*F5[#N T5.C(JUPQNB0
M0 J>B8T4Z%!/"41.SK#$97;MP_?CYW.>?#C^,%\T7.8=0.>Q&?^R"!$5)K#:
MU NVA."UUJ"S5SIZS"2TQK Y=I_"R0?C#X',4%EW )>OQ7)G LGML?RVZHC/
M$N433A4''#,'5;*'B*H 5T6+S"/C9=SI=,\0U],EU!B97BN]G ?@?EO-$_*9
M8B87QQ&BI>15B6+ <YV(S\"5+(K)YK4?>Q/7YPC]D0%WA%YZ!MRO5_5%X$W9
MEC?<_I/US/%D"F<DN&P9*.L$1&<L<"F$D=RZQ,:]7=^'RDY'[H^"P3:JZ@",
M7ZV\U(EC2I9#UA)!>>,A2*<!T?+ --<^M[YC.'C-Z.E'[ \!T-'B[0 :C^](
MW7"B4L[>6@,$Z#I\)2,X3^>\R<H8(WV*MG7\_C0UG4[#'W1ST$;TD]>U/1S4
MO[U@VQ7NS5BP2C"2C(PBD;,T"IQ%\IB1&\&EMB'L,X+OQ0]U.JC^&(BT%VP'
MKF937_%Q>4%Z6&^/U)E-3)8L%*#P)!M+J82K.TF8<2HZ'DN\ORNO08';?2KV
MP\U9W7 /%/7A8/%;L"SP0WT0?-^N@>B930TSS;@RF06(/!50.CB(DO"/P3.1
M%0^.MSZ@GJ-G/QR=U>5V,_%WX'Z^YN5ZXO^=K3,D*8'>:PTLA4@F(APX[ARD
M)%&F5*0/K4OA7B1J/U"=U95W6T7T$/[<".@M?KY:I8]AC9M;B^^O\/WRQZM%
M#O4OP\7KCV'Q 5^M;PLFWA3ZAV13G\/%KFH'=<$H6()B!:66H;:,!HK_?&"<
M9ZD,ER]M9QF#KOUP>!;WZ).K;=+55,]Q_WKY!Y*+OWP7+K:2>+5^=9?I>Y=R
MLU"?%7PR=1ZG!R4MV:DKKJY-]2)AL4'M'=D/)V<_B)[%??Q42NK4F5ZS_'X5
M,H4?WX<OZU_FB_DG.BJDCR6;(B#[4 =IU0T:M7&9)R.,YZB%X@T@^/#+^Z'M
M+"[C3R#ZSH%%-K/&=%4GR3S"J-.(F?L(R5L#2DE6BQH+A**CM($+H4(#C#U+
MQ'Y5I6=Q[WY:A72*O-M 8QM=_+2XX\^?<^<Y2)XUK]L(:]9E;('H"H>"V3&=
MK./<-HD/#Z-K/WR>Q;7^Y&KK(%E^L03WW4?2R[K>3Y(ESHHA9K+<=/%FXDY'
M,D@*@3,%%S)[&U5J/6SC, KW@^=9/1^,J*(. /B/,%^L?UZNU[A^L_CAKSJU
MYFJ^_ECYVKV1)%2<U;AV,P! .6TA9J? 1C*GI'51S0>\O$C4?C [BR>(<131
M^F9Y_%VYW+\F&N>7KSZL<--2W&IK[I,_>*S]N?MQ,NXF76&TR5&PNCRF8L4*
MJ(VV@$DYGHW+THQ1776:3;HIEV!XTF \QNIB)46D)H$6WB1D'M7]J[O&!3S]
M;M(]1._[;-(]1-0=G&:/[/_T3!A6Y[O;('V]X\[@LXJ5(<V8BCZ[."I8^MRD
M>Y!B7]ZD>XB4N\/)G=5^AN7,=/1$O:DYA-(0,D]@BM7,>FV3:CU[\RE:>L+,
MX3K>=Y/N(0*?^(KAI\7\<AXN:@7:S\NP^#&D^<7\\LOUZLZ46;&\0(IUASDF
M!I$5!<*C\39;&Z5^(6YY\2,]0>)8'2['$.C4>W._CO=V#%B9---!@G.YSC:I
ME=0J8AUU4C*)3.#].=&/;\I][(?WU/S>  G#!=C'ENT-&SL<SV_FI&7MO!88
M()922^J% U^< X<L\,*E+I[M 83GOM%3<WH#/#039P>QQJ.[/C-#J2.WD%7=
M2U.B 6<MA5\,HXO))VP^X><\]N8.B4L'2[I#M.P,*7$2@"+,F\0LJ,QK]6E*
M(!G6?6@Y2][Z$NYL]N8>I.']]N8>(NX.0/,.TQ5]]<[ UH3D;%E,P+PDF02N
M(&#40(%3#EI$\LJMIQ$\(*(OJ!RCV0=[<X>(N0.<U)OJ-V5[K.XX$,DPF="!
ME88XL'1">\$92&FUD#(GR5H/L7Q(Q;3'T A(&2CH#J#R5>SU9>-GM7$47(D(
MB%Y3W,4"N$+A.$J6><QHL/E#T$,J>@ITAT<L Z7<'4ZNATV;*+2AU)W\H*+4
MG<+T*"6#8EV,HI3B>?-9IX_0,?&TTX&Z?18J1PAZ\@*=B_"%#L]5^/.)"Q_.
M8@@"$4JLS;XQ$3-8/$0;7" GR<O]AMDG*FY>^%!/L#A&C\NQA-J!.WGJ9=U9
M[13+ I029#DR9PB*3L\J'RL\QVAZFHA[TAVE[9YRCI-W=["Y,YO5>N]"H:A+
MQD!!7! 27$()(A ;T05%!C<J;GJ?B'N0HO>=B'N(U#M S]UH_<9]AK]J">QW
MR]5J^6=MQ0N?Z6\NO\P",HXI>A":_+4B^4$4AIQV-B)JJ20KK5MI#Z&OIQN]
M-B@;33L=(.\M?KX9:W@]W:+RN[YF>!:M#.@SY8G*;=J)R90L'>+>R6(XG>%%
MM"[D>9&HGG*P-AAKJX>)(^W;29F_A/_@OS\N:^'TMN$38[+.H0$7# E*1S*/
M4M_Q=?%D+*CC?30]&F(__86>HJ-AT&@HR0X<S?4LP]_"/->QEW1 RVBX A_J
ME"\2 X0L EC-M&(.I=5CS8S<D=#GA-HA3F2(C#N R!X%R*YH(74 2DAK[VT(
MX(54M0K91.ZX*[SU77&;2O"3M^T/@5%;/0PM!&\"K7^OYI<4PY5*_Y:$^T-W
M9HKBM<(R!XZ*4H:(%IQS">C03<Y@*9:WGI;V,E5]SK0= J[&FNC ;?U,.+VH
M2PF)<!.B9Q8,EW4)>$K@%/%AK"FNF&2L:%T6?O/Q/D?4#DJ[CI)K,T",W7#R
M[[!:A47K;I.G?NHXK29[\3!NGXGWH<2D/1AF)"B>.%!@@\"5DD9JM#F.L7&J
M?9_);C?=3J1O5F_G'S[N[E=-4<76U"]A0C*E0A&=YPZRY%DZQ24*U9C'IZF9
M_A9Q( J>6/8X5/ =G$2/<K*MG$\RQJ ,\,S*]MV/8C4-1H9(Z6)*0K7N07F2
MF"Y60 [6]CX@.ECTO6)H]TAHO131"0=:!\HG4Z2('^D_ RLJ<F3UYO,4*.KB
M<;V-PO>!T1'2[P%(#Y>C&I59JG-D% ^4-J*CP#XF2>*)5D<;I(RMKY([W4 [
M7,$OKZ(]1-H]X.4QR=QF$L8&SG/Q8'F1-0>@$]Y;^L5*Q5P4JIC6]:3/4S3M
M.]<IC['CE- KI'Y?S#>#,F:%9X4AD;G5O97*>[VU#QF,-$D(DE3KE_EG">K0
M,1VI^7U =90:>L74#W_A*LUW0X-N_G*]^]LUGX4D[28F<,*3^(I'<L/<0O&&
M):DCZN9C<XXBM$.G-B(&FZIMZ@[0QQC\#5?S9?[^:C5??/CWQWGZ>)_%G03J
MN?&J$"&_A$OZQY=?KE^=;VYV9DZGG$/)D(SW=*K4^UB*)* D5]>.,:'Y/BV$
M(Y,Y;6' "/CM3;4=>.#K-_$?EZO;<6VWUCMS@4>=Z$#A)?FZ/RJ 8XI.%6ZM
M2-[(5%K?PK] TK0U"2-ZU9:J.)N+>]*^_G5YB>M6\Z'N_;BQID(]1_6X=_0A
M*9E+]& 4JQE)RA3B.09!DYX32SJ6\YT%912F5(RO?9\U?@V"^ IU4WDBOBTW
MIOFEV+G,@CI$[_O,@CI$U!T<5(_V"@L1E,I:U7.6&.%<@,,8@46G)'=.L>8E
M+$?WW9]T'M1!RMVG[_X027>(ENM+0892!#(:7C39D*,CU)L@(;DLL!2ET8V-
MEQZNVX=K>+^^^T/$W0%HMF-*-N?Z=9>OL-P+8T!@72B7A83(60!64D+.(]K2
M^I[T 1%]0>48S3[HNQ\BY@YP\L@P-=1)A< S,!,#J*0+N"PS%!F<02:M;7[]
M>>18PI..?QER# V4<G<XN3-'R:-EGHP&<BED/3$4PGM4D'5&[Z37WK5V*V<S
MEO @'>\[EO 0@?<Q>NS..N5-GGF%->>\GJ1FR=>*:$&).A8VU2WRUEH0.8E@
MF-9:[K-98X]/]02/8_7Y<!!9,^%VX&3>D3HV-X_;A94W:T[7&VN**0864@3O
M=0*E:]*HDP8IDN%.TV'=?-#4LP3UU&LV_(AJ)_L.@'2/AYVEE<*D9K& )0<,
M2F*"J,DDK%"*HZW^N75@\R@ATSJBAHI>MI9Z!]#9ULMLMN?NG*BW7#,MZEM?
M<!318X10/ /'K*&#/=D'ZQ@;%2?=(6):R#10[*-52<=*N0.8O,IY7L4?+FI/
MW4^+U^'S_#)<[)@)407#,0-&K/.HF:"44FO@GF4MN=+&N,:0>9:@:;.I]O!I
M)_T.H/2VOKLL,/\05HOYXL/U18*)%,=%$0"=9C5VLQ"D86"5MU+9Z+EN_7SP
M."73QCGMP=- WA.B9KVZG+V^^G1U$>IFO!\H9TB[)_\WY55>?M[HI9[D5B2"
M.K%2T"E0C"?P03G@R05B2.; ]NJCI@_>P0[]URUN]J6EI];[XR/E423?.9)V
MYJ:==LK2D2PT\4'F5N<X$5NET(G-HI<R[]5+-1!+4X;/XVC_ &@=H8K.P?4J
M_[^K]>6=J?I)6IM+U%";>>NS3:#D(SN(S)--VL)$W*N=;:C+ND=7OX [!A.'
M>+,A"NH@LKJEOQ8B_8I_ODJI3@&C4_^WU7)!OTV;3'B]>S2TR#+3@+8ND4%C
MR'"E@1BBUD)(YYLWC!Y$8$]C28;?-XVGFPZ 5U\7;\WH.L!,03JA/%"0R4$Y
MEB"HX*$(G60T3!39>K#-8W1,>Y4PHMJ7C770 8YNA?/N,BQR6.7U[Y]SN*QW
M_(R9ZZL3QBCI(59<77REF*-\MS .Y/R5CD52*M.ZBFXOPJ9%VG#]W_=8S971
M <*^"Q=UO,J[CXB7/]=_?1W&"B=%2<Y"B8E\>Y$44ZB8P*)R'FW*N83&H'J*
MEIX&*0T_^)I(O%/D7%?4%.29$_RU*[J.NB2/S0V%ITX$S"QDFUN_U#U-S;1>
MJ(VV]X#0$:*?N#K@WLW>[7C+.UM,LA+%*J?!U^% BED%#E,!GJW6+I'$Q+WQ
M%(]6!^SQJ?Y@<HQ&E^.)=_(A_=M/_CA?D*3H$*X#H'9LH.1,J^C 15L[582
M*&V!G'@(@BDG[K> /S&>_\E/3/N ,@(Z6HFS@X/HYD%[U\^T>57<UE\9M#&(
M!!3VE9H^1/"&10B.1YV=+:9Y2?V3Q/0TL*]AM<@@F7< GKOT7[\M">=BS)8X
M,)NE;0Z\IX,ZRB2RD9J2A)':_^]0T4F-R##U/MYJ?:RL>T#+PV$J"9$Y:36X
M4$@@I1+OA(80.&*FX]64UNL_.AU=<[1>7YY8<XB0.X#)4T,O9=8R^Q3 )U^?
MAG2&F+T%^O]*L$@GK>>-L3)D5<R)AH*V+J\_3M[=P>;.TA**[9AGTA/U9%*J
MCO#9A.G&&AN*=>C\N)VDO:^*.4C1^ZZ*.43JW:'G>N+[6SK(-Z=Y_@U7J>KJ
M ]F:5=YE0Q:6ZA*<S<+''#)DJ8,5TEJ>6L?%^U/74^?/& AKIID.,'?-RP]_
M?<;%&C<CX(5D+)A"-(M"DBH<(3 *&'6RRIAB+..M:Q\?(:.GXOPV*!HJZP[@
M\K58[K2N;'^[)NV\K3KB,Y6*RN@+,$?<*8YUA0 K4!Q)R&8,#%N#:&_B>JIF
M&\-!M=++>0!N,^*+&,LBN6@R%,:(,<R%!,D2"!,BG?91HVJ]%W9OXGHJ_#@9
MX([02\^ ^_6J)K)ORO96_O:?K&>:26UY#L!J%;/:9,DF>$@QEJ"$RUZ.,:?^
M,"I[>H(=&8)M--4!%N^^]\QL0O32:4!.%*N4-,2H$)PVB9>2/ ^M-P7<_7Y/
MM]]M\'.T=(]&!@$T+EN-RELMB>2\_I%D=;UB9[?"B449;1023/9UA5/=R*QK
M-Q9S+G.I'6)KI#Q-34_W5&UPTTCR'?B7KY\0-QN:UG6Y'-?:*JX+:.1UY88@
M.9%Y@(V2&VT=8\W[M)\@92_T^'-"3PN9=P"=S5/!Q^4%*6"]/6=G49J@<N @
M+"6PJ@[3#=)&<*FX%(LV6-J_U=ZG8K_;379.B!DHZJ%+^MZWJX7]M*0 [7\V
MVGA3;NH6-B8PPRRT"LA B+)YEI00A%(@#>6K3JC(;>MJQ>?HV0]'9W5-WDS\
M';B?KWFYGE%9+_UO=NB*A%K)6!?+U37QW("33D$A0PG))R-5ZR#H1:+V ]59
MW8RW5<3D%6IW!70[]GASD_']%;Y?_GBUR*'^9;AX_3$L/N"K]>W=_YM"_Y!L
MZG.XV#U Y>P,";! ;78 )8,C%QT"D$AB)-'F&.\]%S]1UM:6KOUP>!9WZY.K
M;=)D\#GN7R__0'+QE^_"Q582K]:O[C)][Z)N9H+C0K ,G+L,RL0$D8()B%YR
MQI73ZOZ&TX.P>B Y^T'T+.[HIU)2]\A\OPJ9 I#OPY?U+_/%_!,=%CI8:11/
M8 K9FW*% ELM&3@E,P4F6B6^SRRYP[^\'][.XHK^!*+O])R^YHZL9HWIJK9%
M/\)H5)BEU :RJMN+2Q(08S(UWC4I>*V#*0TP]BP1^\'M+*[C3ZN03I%W&VIL
MXXN?%G<\^G,.W2ET27 DJROUQE!O1N@C>.28Z[6SQR%@/):N_?!Y%M?]DZOM
MG+:?\+;;3_AIMI\\0_6XVT\H2W \"@WT&PDJU92A7MJBYE:KR(V.K2^M3K?]
MI%C#27)UKT\L%&OR4M\QD/[3)",LT\ZVKHL_E^TGA^A]G^TGAXBZ@]NW1S<V
M>(=),>F@CI !A<F!#\2-+\8F;DNRKK4MG,?VDX.4N\_VDT,DW2%:KD<>*>%X
ME8B7=6JVCII264HZ:G&0+\Q9;EJ7Q)_-]I.#-+S?]I-#Q-T!:!ZNY=!:UO$;
M@3QM(I\;M2=Q" 5)JI*1A*)-ZZ:^\]A^<I!F7]Q^<HB8.\#)(SL;?&2*,DH-
M(B8RGE3H<#98+S)LX<(I)?P8*^EZWWXRY!@:*.7N<')G>8.@W"U:P8'2-@U*
MU*=T)NH%&*5WFH7LS;AHZ7C[R4$ZWG?[R2$"GWKQ\FU-Z1U'F3<+.OCUJ(68
M;8CU4;-.H5+( W@6&;E/9V-AB3SHO3Z'QY<GO_RIGN!QK#Z7XPFWXTTY:L>.
MHI/4!EE'!)FZS$42.[RX.L#,F%B21S9T4X[J8=I)<ZRT%FYW!]+M%:>-4DF+
M&:+T%,TQS\'[VH$OM2-+\"ZPUKLJAG28GW0[3KL0YCAY=P>;.[W.3F *3AE0
M'HGZ8"*)13(P/!K'I4JH_MX=Y@<I>M\.\T.DWAUZGNUCYA)MM#: U+:6;=4:
M&($:$H^1,Y_)GXX;%Y]?AWD[A#733 >8>Z9=(N2<@[ <6*)S6R6KP.=(Z09+
M&0O7WJO65SH#&U5.7A,W!%.-)-\!AIYLF@AUU0O% E*&M!NV(!*#G!/JP'V\
MLX6^@T:5DY>K#?-(PV7>!73BY>WK_2Z%P'SGIF-SDO-91J$<4P@F>DD2$G7G
ME-.@@\Y<<>9L\S%@^]+69_OXT..NN5:Z0]N;U?P#6<]%_=-KAE*DC"5Q#59F
MDEHQ!;RJBS^8\$ZGRMP8)0//$M5G;W@[? W50P? ^BU\V;2P;\_OZ]-\V[M3
MEU GHVK5''.@8AU$[1('(S/W*6%R/+8.HYXFI\]&\4%Q5"/9=P"C?X3Y8OWS
M<KW&]9O%#W_550A7\_7'RMZ6N^^P+%?X[]7\DD+%4O]L2^=]SF=&)XP^2RBA
M+LGRC(/CK,[]<]EX36Z;M^ZO:D9\GSWI0R ZC5X[ /1CO%YW\13M&*($OFG&
MKWL\ O.>4IZ /H="WK[U3>K3U/39R#X$<HTDWP&&WN+G&P^_?6G8Y,@F9:?)
MB8/1K Y1]P&"%@Y2-#)IE9*2K2.UQRGIM*=]"'@:B/QLRJH??^A\'5:K+V1
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MVJ!YN(9?@,P1XI[XL/K]MU]>DVGAQ06N7GU8X::=Z7H=) J3JF<V+G*23,E
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M!T&C(&F(R#M S[_":EZO3FX=K$I&D 4(*$$P4-HF<$4JX$'8DJQA.:O&F'E
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MCCO ^3,#5X250:D FZ=4Q7,!1_\-+#@=M&39Y-;N=-C$F_,JP#@()_M/R3E
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M[PE6=I8J9=0F.P]!QQJ\)@E!, FH=4+.M,N^]4BF9PF:-MMMIO;]X'2$#CH
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M%TIW:ADM =*+H1RCAIT<?OB+SL?Y&M?7HMB\V_ZTN%S-%^MYV@AE5I17UF,
M(6,=Q2@]!)X5!(HKD[0V^FAZR3 .X*OSB=2=9AYC >>\7_)?I<OY'_/++R,^
MZ-__Q G?]9_EKH_G?9&S*LQ%*"$:4+9VG,;Z5*I=8<6F:'/KULR)G_<'&O"=
M[<IOEQ<7/RY7]2]G0CDF4=8DJ2Y_58*L-3D),K%D=>":B];OI>-P<M8/_X>@
M><2UV\<"XQL(C!XN'R\A1^.*@.*T H6!=,(V:\B%8HJ3:MC)WVQ'V4??WV5K
M0V2.OJ/^$)@<;2>?-R'7N\NPNFQC+?6L_VF]OL+\_=7JYDYYP_KZ;H'?==B7
M9[E8(X5#2+@I*-49/!H*\"*:X)AE@K6N_SV<RC.]11T1[^,J^G! ^RV@%_BA
MGHOON_'_).R"\TLZP&\RG)F4&9%5P3LM0,D8P8=(EAZ345B<M8)U=@(\PL:9
MWJCV>P8,A<JW8S0/3T/,!I-T"G2N*[(P"'""._!:Q!RS%(&U3LNF"9KZNVCM
MUV"&P61@T/3#(G=A*]L;Z%>+^E:#=:;'^V7]HX>R459HRO@X).])-C8YB)CJ
M W]1J"V%F<W7$9R*MVG#LS/.T4<!SS>0M3\AEUTP6RO5KN42,O%O+$3#*#=S
M.8$W/E3WAQB+05^Z*9HZD+=IX[MOSZB&@><;,*H[7N7?6(MJ2$C;D6C72>)O
MJWG"&EV477018W&HF ,;+>6,5A8ZRC.#7#0+R@@?66\OAH=S.6U<>,:&-C*@
M_CXF-PN&<^.1@\RU[)K5Z5K2(V2I?3$\:R5[.\;V9.V;N:D>!>'3&.1!<.OG
M;OOHUH:G2AV>E5%$):+2C-)I[6N5:8;(28]<&$'_(\T(]^(GY?";N5/OPC*G
M ]\Y'),O2>>1J]=GY<-"#ES)&O44DH\T"IP/ GA1P5I#.7(:I1+ZA#Q^,]?[
M9V&>8P+P' RT46#A4PC"2P9:VKJHT^#VN81[PY#K3'EVQU5'@\WQ'!X/NC#'
M">#VMWEN>%9BRDNT//DZDXN35DEB(>I4$X$8O#,B6-^9@0[C>-KB\#.^W#DA
MT+Z! _+.Y?+S'JN4S!-JD)C)JW+.(;@D0+H2C&/".MO;A>J>K.UE:.:_AG82
MZ$R\]^8>'V^Q#D@AC_%ZN=C(^RI<O,?5IQOQDY] ::4%(^MR@50?8BB*!EL'
MI&4FF77W[EH>75!RX&?W0JS]AA [MFIZ\>,#^@F?/MZ>DI28&688RSI#LH%1
M+N@RQ%0L2*E+TLCJE4UGO:A'L#G-1?[HD&W<CSHV?KX!$SLXL'Q*<GQF$9WR
MQE;54OZG:[F9JY&FLD*J@%;+45HYNN!^FOO[<S/(B=#V#=CITW'ITR+27(G@
M(H6G$LF5.6; Y\+!2B11212<]W84'L'F-%?SYV9Y8^-GXASGU8</JTW=_M>]
M\C>B+W2&\Z $H#0>E*( /5CNP6GI;!U%P97<(Z=YX3-[0=%]8SE,2]'WXJC;
MW);?F]L@9792^0C(+9D3$W4:J>(@K/*$LE+0=/P<<\24CU'RCZ9P&^^E9(#N
MOP$C>#G.>T*-,UF,C]+1H6B* N5] (^JSI_V6!^8- LG+_09B]GI<H:>C>@T
MV.G%R-J$=%\+@L\R16PI.P;.VUI+[SBICI(CQS!;5K(P(?4;^=_C9KH ?W0S
MF5[[9S@@ZLX"[\W?W1VIM-F2U7I<U-X?''MXU'&<]S%*BLQ!B+KRCXG:C)KH
M%Z>RI8R2RR"C0JY:%PE^*YNB(K+D9*:###D%C\6394<ZYB2WA7.+BB38VIO_
M=U/4@9@=;U/4(>KO(*SY>H$,-]P:'@-P6:]I:Q5U9#P#)B^+]-*2?!MC]YO<
M%'40")[=%'6(1CJ T_&">V8[#-9:C=IH8R4C&5#V#;$FYD$(F9(W3IY^J\F9
M;XHZ"%:GV!1UB(X[P/F=V&[#ZGJW<JAH$UU4#G*L;=&1T?&#Y =X]%BXL4KH
MUC6B3Y#2>?/@Z!A9ME=8![A[1RK<R._U15BOZ:"J.<7&HK/S)H7,@64AZM!N
M$HYP :Q'[J(P.F'SMIZGB/E6-CH-.<;;:*H#R-VE?V>(+C"1#"I(7A$'16L(
M:!Q$FY,*2J+/K5NN'U(QL8-KH]YE4UGW@);EIT_+Q8:/5SL7JY,I&+V#5#BY
M6#3D8IT(H$DJRKN<@V^=$#^D8EJT#-7K?9@,$_+1,/D#5W'9""B[#44;DT'+
M"YD% \OK%:@L)(L@$0J7V>>0D8?6;ZUW/C]QMV@7I]6QVNC X^Q(WYF50*>0
M90]6646)35(0'"MD##&@ER:JT+J*ZBL"IO4S1ZOQ<3@<(=,. /&$'6T,A6R)
M[.W- G=N,SK.F8\66"H95,!(*049CC6.2>4]'>8G:H9_C+PNP'0,"/:[,1BL
MD;, V_L_ESO6,&89?1;$"ZL.6E%D&.@7%XPU&9F,+)X<;#?D39NTG1)LQVGD
M/,!&N,&;]=<QZ&@Y<8,!E"5)^B)D?1Z1=0&VM7BB"K;'"9PV[CHIX([4RL1E
MND\4/53&WEW%!YZ;7+7WGBO@: K)$ ME-#E"\!R5%9BEN]=1\FC5[F%?G7:V
MQ' 0C2SG<T#0K3O.@F)63_EK1),HB:4HP&M9&2T2A7'DJ7,K!!UV[HTVY>"$
M"#I.SOT>>X>L":00,@A*?.K,(?*ZC*DZN%:!)K<;E&)&JM)+H>H-U1//S>GB
M8N+$NC]GM.]*#?]!__#R9A+7/U;+]7K&C+-DUW73@:,CP\1:;6@L\*P%^15M
ME>]M!<4C;'3^I-D8B8T+M8?"HL](XI;]^$0![N:7W2G[MK;2;4O(-G-!:ER^
M_KB\R#/KBC$L25(%CW3PUD<;$SA$:;/W]?(\[=-Q-BZ59SIU=!C^.U-^[V;P
M5!WZ(Y*HCU%;2:SF'S[@ZC5Y"4Q7E_,_L':4SAR*'.I,?W2,D[8BI1@D(0@I
M9:VSBN[^_<%Q-M&.Y#.=^WD" YD(%KV$4VU$0T=GJH#Z@+.4ZAUU\8 ^"2"/
M4<"AM?7XU %1<J[R& %5:T;.=#1GPY!J4FCT8A_'Z.#',%]M&ZS6ZZM/VR#S
M[7S]GQ]76'N<D+!T^39<XDP)EP6Z *DP2\<K2W2RR@)6:9^,(8]Q^FGP0YF:
M]M*H![OI!C+?F@U=-]+^:WE!/^9B?OEE(Q)92&/1*C!<UUO?8B&X'(%%Y7BV
MT0C=S>+5_=F:=O+EMV1'#6#3BR4=<R0_)Y+M?!PO;528$DBG*,NS/$,0B"!3
M"E)Y$;+I9N#9B]Q,.W^S![N9'B2]F$MK#_+]_(]YQD7>^ ^#$7U1 ;Q,",K5
M=4>.2] ^NY*MUR6.,IM@3*:F'?S4@_%T YESMJ%'+];OC6O;_.7W))4;Z<V$
M+Y;E("&AK05N-H(KU>,$HRDU#!Y3-T^1Q[&XEWWY_]K7R>'T#5C;P_7.-G.;
M?4R0O4JUAL^#MZH *K3.(0K->WO;/&X).&?_-9D1,-%%-\Q0$>R]#-T)BQBM
MA<PH"U0F:(@L,$@B*R-E,4;UMD1C7][V,Z+_U@><$$'?UH'S[(H1Z6TRA0G
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MA90Z!5O]SP5>^:&>[*_&(J&VI$)50@CU?))+F;FV(H?6X_B?)6I<J]5$]#O
MZ7 YC'VAX;]?$Q\O%]__8_UT<&6'<TI*:@O(#%;[7BBB"0E<$MH$HE^YLLME
M]N!O[P\21XAOWI27(Z)AN5A-/E1KO%80NKR9S>38:8F97#Q'SI[*"BCLI&][
MQ9S9Z>& ?NL-,T)?_3 AMS[PI4R&/N2>.ISS/<#E:@*[55[PDB!%+D!%ER *
MD8$K%;,.,0N[4]7D+H 9TXP<(:R[XCZ <R,+_)_3V?3KY=>KQ1]T1&[1@[1T
M;N4M'3YE\MV=%84,)1U_IW?99T1^ZT-'%OHA(INWX-_8@@]_W2!<1*,Y,Q9D
M<!2E89V,XGT&DV.QQHC@^4ZS0I\3_,T/'2<EUTSP!_.O@\#CY@X^QR5W$36D
MQ!P%Z-Y4@^> R2@Y,DU':_W\M>]BR^%*?[N(9@^51C] NEH-(WUDD;0@Q7IW
M!J+;(SG'0FK'H\J!N=;O^YTNMMQ+C$\OMMR#IQT XA$]>G"-HM*U;<DXT*60
MZ=610<RNK@!UL6!0X5Y/YT^[V'(?$!RQV'(?B9P%V'[LDPI1>F$EW<OH)1GH
M4G=VTF4?;.(A^VB=.=&0P.X76PX*ML,D<AY@N[%"$;D@W]$6H$"@-H%)#DYS
M"TRXXD4AYU*=?FEOKXLMAP7<@5+I%W+[=*:5D%5-<@+%,1212CILD!@AZYR2
M-=9R.4C3^5%4CSQQNXN@X,2R/V>TWUQUL1E)N1F2[+P.8"+=,$HR!=XD <02
MIA+G0OEN%CH\0'_G)76-L=<*^L<"X>R5X -N7L#P(R[^G":\8@)+WJL29=W9
M6D>&$SN<"1&**=DJH5'Q$VUU/^X@9[]=;CRU: &-7O3CD#D/3^Y#HK"63HL6
M"E/D%Z:Z9+)(I @844A5-,-!;HO6!SG[Y7)'Z\>HT.A%/PZ1P1LR#ZOO;V?+
MU>)R[=J^6WW!Q:<O8;;M+?YC/OMSW5[\87YQ\=M\4?_1I&3#C-,9D#L&BND$
M,28&1BFTPG)?[NXD'>]B.>B$9[]\;I0;9W@P_1RJMAUG'#(O6N8".7L!J@@-
MT7,#Q!/NI32&Y6[FB.Y[N#.-=$Z \-,KXP%P.U@/OZW]SX^KL%AUKHVWMUU,
M0A364^ ()0L**(/AX!E'D%D+%QGF++O9Y;#GV<XTO'I)NG@$V%[TE4A2*TC1
M:[YFC2P^<Q4-9/2>W''+(%# "B34F(4PI$2#[,H[S?'.-))[2:IX'.3VUT:_
MT<;9>CQ3W?77O5)NQDU=LR<K*4NMLM<F2B#1:7"L!$BH9=2R!"8&63A^@K.=
M:1CXDM3Q"+#]#+IXUXG/27(C,H/"==UPR"(XFRTH<NIC=JB8[&:)TB Q8W_S
M8E^2-AX#MR-CQC>S?"ZZ^.QJQ)N"]F1VM(\1DD,.BAL/7F0D[Z*@#<BC3-W,
MN!V&!6>JUV>3;!T,CB\Z]-R=?1,T7DO-R!5Q2$Y)8'7O7"(D"!V,XH6%?(:7
M;IMENN><PQU.<3HT GNA^*?+_S[//D72U]YS2(7"$U5=MZ"8@%QB=,4X%?+Y
MA,%#K-4^YPSR"[ $0^+Y13L"VX3@):'Z>:YY8SQRQ@"UHX (T8#/G(&3601;
M.)9\=NGIG4[^XC/7+\ $#(;D%ZW_MS.0SS-.H$43&8<H*!!4JB@(,1I(/)+L
M,]HB3M1R=OK#O_B$^0NP D/B^44;@CUBJ9*Y+#H&L*X.AC#,@D_T971HI)(R
MVG0^-J!Q1J"_3-Y/I?X#H?C%9_=OF\U/\U6X^,$I[@)CL4205E&P5(($AUE!
MD3D%-(Q9?C[584^==.0>S9>:JV\&KC-<TO4[;@S0@#NZGOB(H5=T[7JZ/C9T
M!>.D#$:0AZ<S75E%0E3:@K')2Q&E**SURN27LJ$K,6^%B@E2$KPN *PC+30#
MF80H='\6H9OWQ/R]H6M/S ZWH6L?\7<0)=U>W%.8+<I[";F(6E5%UZ//KH /
M03(E?+&V==;R16[HV@L$3V[HVD<B'<#I<,8]L8VGI&1L-@PL4Y6;BH'+*H*)
M$5E148AP\F$.9[ZA:R]8G6)#USXR'GG"^@.>W.\?_W6U\$))\L1=1(J5,P-E
MHZ-@7QF((9(QB+*0B_J,[_KLAW1><#&X_.=#".-@5!$!<3[ 9%:+R'+T'C"Q
MVH=7U=,S11&J*"H1PYQN/;MIW\FL9[ QZYBK^%!I=' 1WQZQYLG*VQS(*_:Y
M9@YXA&BC!E-$MDF0EKC6X^@ZG<RZEQB?G,RZ#T\[ ,0C>O3@'%")45@,!E)(
M=#134[V%:Z #:\4"ESR?:&I<[Y-9]P+!$9-9]Y'(68#MQAQ0IWEBC .+=>F8
MR'2T1(?,R64O$U-)G:A>KO?)K,."[3")G ?8;LP U=)G"G(XV$+>IA)8\T6&
M+@"'Q%N/RIL3U6CW/YEU8, =*)61P[][&<@;ONCV9+_-+Q?;@Q5;<C+:@"O"
M@(K>@M/"0V ^1Z9]X/;.VJ4'P\&]/G3<XIOC(30LESNP6&LMJ$_L:Y=46H)W
MIAO=)>= :45!:B";2T&PLS87SW3KZ8RW"'@I&R6/3KH>))&>X'252ZF[RRUR
M")K5;;Z($$,BO1 )9?1%8F[] G6'A Y2G8<)\S%8',#9D:\I<N<^?9E?+L,L
M_S&=X0IQ=G77)NU,(:HSIX!">:$@A$AG"JB2\R4K$7>XDA[]@$Z$?XC(YJWY
MUX%U:% K8X3-JF@)TI&+1H>4X QWY)T5F:.)7)5NJAA_WVN*_!DLH#SF6CNQ
M[,\9[?N.YE+K%;!> W+BAG*&7$[/"VA!8K$E8#JC!I\#YL#UU\][(&;'FNVV
M#X"Z"7F/'JV\?J9[OY@F?#M+"Z1_<&/8LHE,Q(0)-&.,7#7FP:&RI DENYAE
M\'=;9Y\)E@<E]TR;78]3DU[AT,O5TX8M-Y@0;0BZU#=K8];S=!P$+U-]S([>
M16^YV&EO][[W3.N#G&E?:,-+951H]*(?7;2T2X,YJ)H2X$F32^T"A!(X^% 0
M$V/:B&ZV XTRHJ&_SLSS<N[:0K 7W3W$@%V?^-5R>?EUPZLW?WW#M)FK^)5/
M)-DJG9T#BF5U3<M(",8Z,)P'[H0*V@_R(#?(:<ZT\7'D6ZXM2+HHY#M8%$_Q
MXK_F%_1K+L@2?2!C,I'.J,2D@,AL+>(EUS@Z%X$GR10/A7[4S5Z(W8]U]IV%
MHUQ0 \&FEZNG%4L^3)?_\]L"*=HD LFM7C-$(4,?38:DZL(++Q%<*)XN9)-%
M+D7G?O:K['JHG;3(_JU%)X#,2].A*[/RZ_3/:<997C,$#5?"U8J=ND)0U77.
M,6I+XF*%9V8#EZ5G'7KH4#OID/M;ATX F9?1SOXJK8@!J^\G:&N_^U$CM+<_
M>=H^VMR%PLAEY,"4L*!"<A 82F!<L*!%-JS\W>;^\+,T.I>$(X8Q5>IL6(S@
M UV(LOBZ)0PQVN8YM+_;W/?$['!M[ON(OP,'Z';W:]*\IA RW3P4!I$OI\%I
MZZ!(7T3@0;G2NAWJ1;:Y[P6")]O<]Y%(!W :I 569VV*T0*8I3^4BX8B=+;V
MUDJ4R$I1)W>AS[S-?2]8G:+-?1\9=]WF;GS,63(*>WDIH'0)$')5_8"HHJ2P
MV._2U_"SM;GO)?^=V]SW$<9Y9\=OQ+9%*\-#@NBUJDUJI99/,3!9QBQ,+);S
M4UO+-C6I9]!4?\S%?V+9GX.WT'9C6'+2KX<#,E$T*,8S.!0<R$@$IKQ( <]G
M <5#)^S\7FB,W],/A#T43.=]M>R]\TXH\B%3K+*3Q!I3LZN2*2@A,LVU+LR<
M3Q71(2L6^U.Q$V!\M!6+^\#MIUO+--%<&)YLH4B/[*HJQH$G+P30&<<32\KT
M\_XT1#M&?W7F+TD7CP#;"[\4[ZQE5E%G[QF#5"BJ54HE"%%F$#;$Q+DNL;3N
M93_5V<ZT@/TEJ>$18/L9=X#KX+@1!2%'(T %9Z"V* -F(740RJOFTWS[<E#[
M*V-_2=IX#-Q>_):0PS;%9.8XUN5JL53'PN8"(8<")A0=8]'%VO-9'S+<#O#^
MG-VSR>T,!L>?(\_Z?&,/P[H044G2M$BV.EE-5I "!).3%L;:R/CY>,!_[P _
M@>)T: 3V0O%/EVS:86<J1BM5ME!DB:"DUA"1>R!G+?O(<N!GM ;L[QW@+\X2
M#(GG%^T([+LSU2(/,A0RG"$5BMPD!\>< ,18YU^NW\O/QA ,L0/XG!-F+\ 0
M#(GG%VT(]O"E2.Q2NRP@)Q'KVL8$+HD",B5O$Z+G^GR<@<81P3EGZ%Z ^@^$
MXA>?W7MWN5JNPBQ/9Y_O<.X#UCI/^O[K^6S=KW$9+NH(@^4D*X8I!@[*V3K"
M@(*K6(,KS1)74265L'7305<,.%-WH/?,WM!0[.46O]=QN,-<D6>9]^KSY\7Z
M?>\M<6@Z6T[3VMC=X.D$!=<BH0.I12V[R0J"S &$5TQ3V"/\W0'^XXVG:7#>
M,[VU&VKI.0#M7.>![AB/O)KEZ_$_\_JMZ^9'G3RS1B)@J@O]6(X0*Y-,,,YR
M=$+>K;EL.R'TV .<_WRH ]3K?"#SL^G5]<N]JEN=+!13G0+K/$23/!2*]1U3
MS%AC>]2J,6N5SPC48ZKA 0C[V93P^=A;!49BM8G893VH@&1^8V 0"GD,43C%
M[Y:%]*&?G;X5_:VZ(^#R)]?JQX-Q--RRP#AX6=>DU5'.@3,* T14.7(FI-QE
M87BW!QPG[_.WCH^'TA>KZH]$\8_P=J*B1*NM FDC\4RA(A08"4G[9 JBT%R,
MJMG[G6><U-#?BGPR#)[AD+WWN"CSQ=<P2QM6?OCXKV7KZ7I/?<;08_5V/E\?
M\_0X,]F8I,&[^D@HF:=;PB3P-C"K=,1D6Y>[O)1Y>IX9HS2QKO@Z4L.0HCJ1
M%'%2H]$V%G*V6[\S_#U/;T_,#C=/;Q_Q=_ D=V?,5G"Y%">!Z.1UQ2K1;;,
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M #/FQ76$L.Z*^P#.C2SP?TYGTZ^77[>$VU0\!@R@R9(1X3Y!W;9%;B!Q)9C
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MX_ D(;W,I#RQI]!..&?JTGY:!+HQUHO>7\^7U]=$*%ES1ZJ81"T)(DY#=+X
M+VAC\-EE]MPC<7NJ>AEYV8$WVT!L9W*[7VGHFQD==YT;7#\Q*J84XY:TTOG:
MFUH*A#JKG7$==416BF[]B'XXM;T,T1PQMWN$^,[4LG[ U>5B]FE^+_4GK L2
ME08GE2 7O+XWBN@!191&I^23D /:UL?HV@VD9_.X-KKHS@"V5\/>/E[&Y31/
MP^)[#1N_U1]-4$6KI34@<M50(1@$.C4DS9G5SD0;=QD_?"09NX'R;%[%3BV8
M,[GCZ9L?<;6ZP,V<)[+]15@T=9YRJ:L(* ZT=2Z\S(;+E(IF8Y2#W:9R-V2>
MS5/7B<1U!D;QTX/#P2<Y26UUKFU<W-25WQJ"KFLABTC226$X9XWLX<,4[ :X
MLWE_.J$XSL0*KAL=7N7_OKR:=Y>,8]8K#I9^(2A,$;QWN-X-;H4IWKC6[4V'
MT+D;,,_FD>ED(NL6E@\N];;9VBPT ZZUI+ MUR$\18"UW% LEV3&T]2Y'KYT
M_84\_QPMGG/I9[E7#Q9F^6H5S+31&HH=/V.0?I5#SG>"_A2.R$1D")D7@A*7
M#**JC78Q<($V"E9:;ZX<L#_E'I/_P-7U44THO'CFP!<;23F]JUX$!_J^],E9
M16%^XZ,^14^_'27[8.+9O<2'2F#DX.'>.3ZNPF)U^8VT]MWB<YA-_V\MJG!1
M,_++"1/6)*4C"%XW7223P2LKP%M,+AGC1=FE3G._3^UC3LSQDIZ?A.T=>&#W
M3O>/^3S_>WIQL=GQ&6:?:UYR\Z,)#ZS$5&O\4>;- [E714.L:Y55<5R(UC[8
M/O3U,0RF&?@&%U%O]NQ'Z3*&)7Z8?OZR>E?^M=P<;2*R*L454B?TM3J#97!*
M""@E<2>#(P]SEV>+_3ZUCVDNP]JS=FSOT9Y5?V+[O>O7E24N_EQO,5YO+PX7
MR^T6XQO.[X0[&S#97)M&U_U,"B(=&81DM998JQB&&A!X+.U]#($9W@Z>0K3G
M >F;E9=T]JNERF\H%IU_QUL_GF2KK1$B K-)@1+((::$P"EHUZ8XZ57KRH6V
M)QBWQV=,> \EYAY!?K^/J<P7_PZ+O)PHR7-4M4/:.^*RK^UW/"O0/-D8C+<B
M#QXU/T[>N&TZIX-G(P'UB+WKVN!;Q[JN$_:&%:5)H:2M=<+21SJ>9) D,IWH
MRZ);C_#?D\1QVVY.:B);":I''+Y?S$G)5M_?7X1975-5%U-]6S\_1G0QI)RA
M1%%?NIV%X&NS6S%*9>:#&SYQ^"AUX_;"G Y];<33(?"N-J/=U*J)-BB+R1$L
MDAXIPV)EG0*9,T/!*!+T0TT"?HJN<3M83@:VHT726;+GW>5J.<VU;VRZO)HC
MDB@V2\SGD@H#<A*JZ\ H-G,&*\]$<%$&'79I9-WQXT;N.CE)?J<%ISNT4<MU
M[<,$L[("LP:GL( *O')).S LQ9P%IQ^U[AU]F)*1FT-.Z/?OS?<>T?./!44M
MD^PCTCWMP19=&ZRB!9<S_>$XV4YCM9*M-\D^3,G('1HG?+O8F^\=#62^/L4#
M@X$L11I,)H3$I 25:J\>W4AT%S-O;9+<:AP:2@<.=1JNJ>)TN#I2(N.W\S[%
MLHE*.K.H$I"2U/*'6"#4%4UUWHEU.2056_>3/T3'R-T0IT/3OCSORT;=>.NX
MR2'TW)LB U@6-2CF%#@Z!$2E0];$)I8'M% /$]7O.-!&%4<-9-&7^W2K0/#V
MZT3X-B4T3_\/\\=Y65&$BI.$O@AA%" S"903'*(Q'%24T=@0;&J^:_)06KLI
M76H!F9T V5A^W>+TB7J9>_4SP91@E(E@9'VZ*,%",.2C(O&7\9B<D0-FN0XC
MNINZIY,A=RB)=@OA6IHSG7U^M5C4=O9-KT<NR8?H.-ADZC(EQ<%Y\GTXTADI
M*O?6#%BA\C1QW=1-G0R2QTJH6^C=N24FO.1D&$9@6NK:^6; !U'?>I40THG,
M^6DLY!W"NJEZ&NO^WDLRW<+MM^F,HO>[FH3(D=40+,68*O,2N+J96 GT*?A"
M@?Y0BU%W(*^;BJ230>]X*74+P$U^VTJ1/'.2="G51LK*+<\B)%X+ITJI-2PG
M =SNCPNGJ"DZ&<#VET)'@+K.*]RL.E7,)Z-# FF\!46!4UVN;H%EG9ET*-U@
M54,/T=--B=" D#I:#MWF]2:>"1\29Q#KY N%-D 0N+:W+H48LH@#UJ#MBZ-1
MIC:US^#MQ?6CGQ1.V^R\&91&(<S]EY0FC<X[_/Y!FISW/=<)&IRS<<(BMU""
M7#]5,'#"$3"98(DQ[I@_HP;GQ^N /]61*9.LO<LE2M#.DBM8K(40R>@:*0MW
MJ.IY&Y_V&9+Z;7/>!QEW359+.73@2]U7U]K5<]7@\XE^RZN_IA1R2)2* E]
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MT5TU=26H0HS33K/6B=)]Z-L-7>><CV\HGU&3J UZ?2C =-$+!L+F=0;,0<"
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MY=-Z(AA+N\V _=__]4 ;))E__OE/VS_4_T1R:O_\I_\'4$L! A0#%     @
M-XE85HD'<6JT0   NK8! !8              ( !     &$Q,C,Q,C)E>&AI
M8FET,3 R."YH=&U02P$"% ,4    "  WB5A6)W\(?R@#  !N"   %0
M        @ 'H0   83$R,S$R,F5X:&EB:70R,S$N:'1M4$L! A0#%     @
M-XE85K]'Q3OBM@$ 1YX. !0              ( !0T0  &$Q,C,Q,C)E>&AI
M8FET,C4N:'1M4$L! A0#%     @ -XE85HHIPO;(!P  VC4  !0
M     ( !5_L! &$Q,C,Q,C)E>&AI8FET,C8N:'1M4$L! A0#%     @ -XE8
M5M56T"=F"@  'T@  !0              ( !40," &$Q,C,Q,C)E>&AI8FET
M,C<N:'1M4$L! A0#%     @ -XE85@^<M+A'"   ,2P  !4
M ( !Z0T" &$Q,C,Q,C)E>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( #>)6%95
M!;T4/P@  "TL   5              "  6,6 @!A,3(S,3(R97AH:6)I=#,Q
M,BYH=&U02P$"% ,4    "  WB5A6-!KF+N,$  !C%0  %0
M@ '5'@( 83$R,S$R,F5X:&EB:70S,C$N:'1M4$L! A0#%     @ -XE85N :
MW%C4!   -Q4  !4              ( !ZR," &$Q,C,Q,C)E>&AI8FET,S(R
M+FAT;5!+ 0(4 Q0    ( #>)6%:ME:GQ/P0  (4L   3              "
M ?(H @!A,C R,F5X:&EB:70R,3$N:'1M4$L! A0#%     @ .(E85E1>LU^7
MV@4 Z7H[ !               ( !8BT" &5V:"TR,#(R,3(S,2YH=&U02P$"
M% ,4    "  XB5A6?\H@:X@C   ;J@$ $               @ $G" @ 979H
M+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( #B)6%8/\<4YLC\  *V9 @ 4
M          "  =TK" !E=F@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M #B)6%:>'/GJM>   &9P"@ 4              "  <%K" !E=F@M,C R,C$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( #B)6%8J\R*)E&$" $PN P 3
M      "  :A,"0!E=F@M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @ .(E8
M5C;N;Y=,X@$ O2D4 !0              ( !;:X+ &5V:"TR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ .(E85OI?,T>E50$ E?L/ !0
M ( !ZY - &5V:"TR,#(R,3(S,5]P<F4N>&UL4$L%!@     1 !$ 7P0  ,+F
$#@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
